PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Allen, MD; Bigler, ED; Larsen, J; Goodrich-Hunsaker, NJ; Hopkins, RO				Allen, Mark D.; Bigler, Erin D.; Larsen, James; Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.			Functional neuroimaging evidence for high cognitive effort on the Word Memory Test in the absence of external incentives	BRAIN INJURY			English	Article						fMRI; word memory test; neuropsychological assessment; symptom validity testing; malingering	TRAUMATIC BRAIN-INJURY; INVOLVEMENT; RETRIEVAL; ATTENTION; ANTERIOR; TBI	Primary objective: This study presents data from a functional neuroimaging experiment which brings into question whether poor performance on the Word Memory Test (WMT) can be construed as straightforward evidence for 'poor effort' in the context of cognitive assessment, as asserted in a recent report in this journal. Methods and procedures: Functional magnetic resonance image (fMRI) data were acquired from four participants without brain injury who engaged in the delayed recognition (DR) portion of Green's WMT protocol. Outcomes and results: Compared to a simple perceptual identification control task, this study found a highly reliable activation pattern across all participants which was restricted almost exclusively to cortical areas most commonly associated with task difficulty, memory load, concentration and other forms of cognitive effort These areas include dorsolateral prefrontal cortex, anterior insula, superior parietal cortex and the dorsal anterior cingulate. Conclusions: These findings demonstrate that the WMT activates numerous cortical regions that are critical for cognitive effort. Given the extensive neural network necessary to perform the WMT, this study raises important questions about what WMT 'failure' truly means in patients with traumatic brain injury, who have increased likelihood of disruption within this neural network of vision, language, attention, effort and working memory.	[Allen, Mark D.; Bigler, Erin D.; Larsen, James; Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Allen, Mark D.; Bigler, Erin D.; Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Hopkins, Ramona O.] LDS Hosp, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT USA		Allen, MD (corresponding author), Brigham Young Univ, Dept Psychol, 1022 SWKT, Provo, UT 84602 USA.	m_allen@byu.edu					Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Buckner RL, 1998, NEUROIMAGE, V7, P151, DOI 10.1006/nimg.1998.0327; Cowell RA, 2006, J NEUROSCI, V26, P12186, DOI 10.1523/JNEUROSCI.2818-06.2006; Dockree PM, 2006, BRAIN, V129, P128, DOI 10.1093/brain/awh664; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick RI, 2007, ASSESSMENT, V14, P3, DOI 10.1177/1073191106292009; Gorissen M, 2005, SCHIZOPHR RES, V78, P199, DOI 10.1016/j.schres.2005.02.016; GREEN P, 2003, MANUAL WORLD MEMORY; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Herrmann M, 2001, HUM BRAIN MAPP, V13, P94, DOI 10.1002/hbm.1027; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; OKEEFE FM, 2006, J INT NEUROPSYCH SOC, V13, P38; Ranganath C, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0005.2000; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sarter M, 2006, BRAIN RES REV, V51, P145, DOI 10.1016/j.brainresrev.2005.11.002; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245	21	34	34	1	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1425	1428		10.1080/02699050701769819			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200011	18066945				2022-02-06	
J	Ballweg, JA; Wernovsky, G; Ittenbach, RF; Bernbaum, J; Gerdes, M; Gallagher, PR; Dominguez, TE; Zackai, E; Clancy, RR; Nicolson, SC; Spray, TL; Gaynor, JW				Ballweg, Jean A.; Wernovsky, Gil; Ittenbach, Richard F.; Bernbaum, Judy; Gerdes, Marsha; Gallagher, Paul R.; Dominguez, Troy E.; Zackai, Elaine; Clancy, Robert R.; Nicolson, Susan C.; Spray, Thomas L.; Gaynor, J. William			Hyperglycemia after infant cardiac surgery does not adversely impact neurodevelopmental outcome	ANNALS OF THORACIC SURGERY			English	Article; Proceedings Paper	43rd Annual Meeting of the Society-of-Thoracic-Surgeons	JAN 29-31, 2007	San Diego, CA	Soc Thorac Surg			ACUTE MYOCARDIAL-INFARCTION; HYPOTHERMIC CARDIOPULMONARY BYPASS; CIRCULATORY ARREST; HEART-SURGERY; STRESS HYPERGLYCEMIA; DIABETIC-PATIENTS; BLOOD-GLUCOSE; MORTALITY; CHILDREN; FLOW	Background. Hyperglycemia has been associated with worse outcome after traumatic brain injury and cardiac surgery in adults. It is not known whether postoperative hyperglycemia results in worse neurodevelopmental outcome after infant cardiac surgery. Methods. Secondary analysis of postoperative glucose levels was performed in infants younger than 6 months of age enrolled in a prospective study of genetic polymorphisms and neurodevelopmental outcomes who were undergoing repair of two- ventricle cardiac defects. Neurodevelopmental outcomes at 1 year of age were assessed with the Bayley Scales of Infant Development-II, yielding two indices: Mental Developmental Index and Psychomotor Developmental Index. Results. Surgical repair was performed in 247 infants with 1 in-hospital and 3 late deaths. Neurodevelopmental evaluation was performed in 188 of 243 (77%) survivors. Glucose levels at cardiac intensive care unit admission and during the first 48 postoperative hours were available for 180 of 188 patients. Mean admission glucose was 328 +/- 106 mg/ dL; maximum glucose was 340 +/- 109 mg/dL. At least one glucose was greater than 200 mg/dL in 160 of 180 patients, and 49 of 180 patients (27%) had a glucose greater than 400 mg/dL. Only 1 patient had a glucose less than 50 mg/dL. Female sex (p = 0.02), but no other patient or operative variable, was associated with higher glucose levels. Mean Mental Developmental Index and Psychomotor Developmental Index were 90.6 +/- 14.9 and 81.6 +/- 17.2, respectively. Hyperglycemia was not associated with lower Mental Developmental Index and Psychomotor Developmental Index scores for the entire cohort or for neonates alone. Conclusions. Hyperglycemia is common early after infant cardiac surgery, but is not associated with worse neurodevelopmental outcome at 1 year of age.	Childrens Hosp, Div Pediat Cardiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Psychol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Genet, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Cardiothorac Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Cardiothorac Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Cardiac Ctr, Div Biostat & Data Management Core, Philadelphia, PA 19104 USA		Ballweg, JA (corresponding author), Childrens Hosp, Div Pediat Cardiol, 34th & Civic Ctr Blvd,Suite 6121, Philadelphia, PA 19104 USA.	ballweg@email.chop.edu	Ittenbach, Richard F/Q-1806-2015; Carvalho, Lidiane/P-8446-2019; gaynor, J william/E-5194-2013	Carvalho, Lidiane/0000-0002-2290-329X; gaynor, J william/0000-0001-7955-5604	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071834] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL071834-01A1, HL071834, R01 HL071834-05, R01 HL071834-03, R01 HL071834, R01 HL071834-02, R01 HL071834-04] Funding Source: Medline		Aouifi A, 1997, J CARDIOTHOR VASC AN, V11, P411, DOI 10.1016/S1053-0770(97)90046-X; Bellinger DC, 1999, CIRCULATION, V100, P526, DOI 10.1161/01.CIR.100.5.526; Bellinger DC, 2003, J THORAC CARDIOV SUR, V126, P1385, DOI 10.1016/S0022-5223(03)00711-6; BELLINGER DC, 1995, NEW ENGL J MED, V332, P549, DOI 10.1056/NEJM199503023320901; Bellinger DC, 2001, J THORAC CARDIOV SUR, V121, P374, DOI 10.1067/mtc.2001.111206; CALLAHAN DJ, 1990, PEDIATR RES, V27, P186, DOI 10.1203/00006450-199002000-00020; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; de Ferranti S, 2004, ANESTHESIOLOGY, V100, P1345, DOI 10.1097/00000542-200406000-00005; Doenst T, 2005, J THORAC CARDIOV SUR, V130, P1144, DOI 10.1016/j.jtcvs.2005.05.049; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; Foo K, 2003, HEART, V89, P512, DOI 10.1136/heart.89.5.512; Galli KK, 2004, J THORAC CARDIOV SUR, V127, P692, DOI 10.1016/j.jtcvs.2003.09.053; Gaynor JW, 2003, J THORAC CARDIOV SUR, V126, P1736, DOI 10.1016/S0022-5223(03)01188-7; GAYNOR JW, 2007, IN PRESS J THORAC CA; Guvener M, 2002, ENDOCR J, V49, P531, DOI 10.1507/endocrj.49.531; HATTORI H, 1990, ANN NEUROL, V28, P122, DOI 10.1002/ana.410280203; HOLLINGSHEAD A, 1975, FACTOR INDEX SOCIAL; Jonas RA, 2003, J THORAC CARDIOV SUR, V126, P1765, DOI 10.1016/j.jtcvs.2003.04.003; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; Licht DJ, 2004, J THORAC CARDIOV SUR, V128, P841, DOI 10.1016/j.jtcvs.2004.07.022; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Newburger JW, 2003, J PEDIATR-US, V143, P67, DOI 10.1016/S0022-3476(03)00183-5; Nicolson S C, 1992, J Cardiothorac Vasc Anesth, V6, P316, DOI 10.1016/1053-0770(92)90148-Z; Ouattara A, 2005, ANESTHESIOLOGY, V103, P687, DOI 10.1097/00000542-200510000-00006; Quinn DW, 2006, J THORAC CARDIOV SUR, V131, P34, DOI 10.1016/j.jtcvs.2005.05.057; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; SCHURR A, 1987, BRAIN RES, V421, P135, DOI 10.1016/0006-8993(87)91283-2; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANNUCCI RC, 1992, BIOL NEONATE, V62, P215; Wahab NN, 2002, J AM COLL CARDIOL, V40, P1748, DOI 10.1016/S0735-1097(02)02483-X; Williams LS, 2002, NEUROLOGY, V59, P67, DOI 10.1212/WNL.59.1.67; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Yates AR, 2006, PEDIATR CRIT CARE ME, V7, P351, DOI 10.1097/01.PCC.0000227755.96700.98	37	34	36	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0003-4975	1552-6259		ANN THORAC SURG	Ann. Thorac. Surg.	DEC	2007	84	6					2052	2058		10.1016/j.athoracsur.2007.06.099			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cardiovascular System & Cardiology; Respiratory System; Surgery	234PP	WOS:000251176300035	18036934				2022-02-06	
J	Chen, M; Regan, RF				Chen, Mai; Regan, Raymond F.			Time course of increased heme oxygenase activity and expression after experimental intracerebral hemorrhage: correlation with oxidative injury	JOURNAL OF NEUROCHEMISTRY			English	Article						free radical; hemoglobin toxicity; iron; oxidative stress; stroke	VASCULAR ENDOTHELIAL-CELLS; TRAUMATIC BRAIN-INJURY; COMPLEMENT ACTIVATION; HEMOGLOBIN TOXICITY; CARBON-MONOXIDE; IN-VITRO; TIN-MESOPORPHYRIN; RAT-BRAIN; INDUCTION; PROTECTS	Heme oxygenase (HO) activity in tissue adjacent to an intracerebral hematoma may modulate cellular vulnerability to heme-mediated oxidative injury. Although HO-1 is induced after experimental intracerebral hemorrhage (ICH), the time course of this induction, its effect on tissue HO activity, and its association with oxidative injury markers has not been defined. We therefore quantified HO activity, HO-1 expression, tissue heme content, and protein carbonylation for 8 days after injection of autologous blood into the mouse striatum. Increased striatal HO-1 protein was observed within 24 h, peaked on day 5 at a level that was 10-fold greater than baseline, and returned to baseline by day 8; HO-2 expression was not altered. HO activity increased by only 1.6-fold at its peak on day 5, and had also returned to baseline by day 8. A significant increase in protein carbonylation was observed at 3-5 days, which also was markedly attenuated by 8 days, concomitant with a return of tissue heme to near-normal levels. These results suggest that the increase in HO activity in tissue surrounding an experimental ICH is considerably less than would be predicted based on an analysis of HO-1 expression per se. As HO-1 expression is temporally associated with increased tissue heme and increased protein carbonylation, it may be more useful as a marker of heme-mediated oxidative stress in ICH models, rather than as an index of HO activity.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA		Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg Rm 239, Philadelphia, PA 19107 USA.	raymond.regan@jefferson.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050662, R01NS042273] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS50662, NS42273] Funding Source: Medline		BALLA G, 1992, J BIOL CHEM, V267, P18148; Basuroy S, 2006, AM J PHYSIOL-CELL PH, V291, pC897, DOI 10.1152/ajpcell.00032.2006; Benvenisti-Zarom L, 2005, NEUROPHARMACOLOGY, V49, P687, DOI 10.1016/j.neuropharm.2005.04.023; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Botros FT, 2005, KIDNEY INT, V68, P2745, DOI 10.1111/j.1523-1755.2005.00745.x; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen JJ, 2005, CURR NEUROVASC RES, V2, P121, DOI 10.2174/1567202053586767; Cichon G, 2001, GENE THER, V8, P1794, DOI 10.1038/sj.gt.3301611; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Gong Y, 2006, ACTA NEUROCHIR SUPPL, V96, P232; HEINSEN H, 1994, ACTA NEUROPATHOL, V88, P320, DOI 10.1007/BF00310376; Hori R, 2002, J BIOL CHEM, V277, P10712, DOI 10.1074/jbc.M107749200; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Kreiser D, 2003, PEDIATR RES, V54, P172, DOI 10.1203/01.PDR.0000072516.83498.07; KUROSS SA, 1988, BLOOD, V71, P876; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Munoz AM, 2005, J CHEM NEUROANAT, V29, P113, DOI 10.1016/j.jchemneu.2004.10.001; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Ono S, 2002, J NEUROSURG, V96, P1094, DOI 10.3171/jns.2002.96.6.1094; Opatrny K, 2007, ARTIF ORGANS, V31, P200, DOI 10.1111/j.1525-1594.2007.00365.x; Parfenova H, 2006, AM J PHYSIOL-CELL PH, V290, pC1399, DOI 10.1152/ajpcell.00386.2005; Qu Y, 2005, J CEREBR BLOOD F MET, V25, P1466, DOI 10.1038/sj.jcbfm.9600143; Qu Y, 2007, J NEUROSURG, V106, P428, DOI 10.3171/jns.2007.106.3.428; Quan S, 2004, KIDNEY INT, V65, P1628, DOI 10.1111/j.1523-1755.2004.00562.x; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Ren H, 2007, J NEUROCHEM, V100, P532, DOI 10.1111/j.1471-4159.2006.04230.x; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Salinas M, 2004, FEBS LETT, V578, P90, DOI 10.1016/j.febslet.2004.10.077; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P51, DOI 10.1111/j.1365-2990.1980.tb00204.x; Teng ZP, 2004, NEUROBIOL DIS, V17, P179, DOI 10.1016/j.nbd.2004.07.009; Tolosano E, 2002, DNA CELL BIOL, V21, P297, DOI 10.1089/104454902753759717; TRAKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732, DOI 10.1016/0003-9861(88)90503-6; TYRRELL RM, 1993, CARCINOGENESIS, V14, P761, DOI 10.1093/carcin/14.4.761; Vreman HJ, 2000, PLACENTA, V21, P337, DOI 10.1053/plac.1999.0495; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Wagner KR, 2004, ANN NY ACAD SCI, V1012, P237, DOI 10.1196/annals.1306.020; Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Yang SX, 2006, J CEREBR BLOOD F MET, V26, P1490, DOI 10.1038/sj.jcbfm.9600305; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	63	34	37	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2007	103	5					2015	2021		10.1111/j.1471-4159.2007.04885.x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	231YN	WOS:000250985200029	17760860				2022-02-06	
J	Walker, R; Cole, JE; Logan, TK; Corrigan, JD				Walker, Robert; Cole, Jennifer E.; Logan, T. K.; Corrigan, John D.			Screening substance abuse treatment clients for traumatic brain injury: Prevalence and characteristics	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; substance abuse; screening	DEPRESSION FOLLOWING MILD; MAJOR DEPRESSION; SPINAL-CORD; HEAD-INJURY; POPULATION	Objectives: To examine clinical characteristics of clients in state-funded substance abuse treatment who report traumatic brain injury with loss of consciousness (TBI-LOC). Participants: Adult clients (N = 7784) entering state-funded substance abuse treatment in a rural state during a 12-month period. Measurement tools: Substance use and mental health problems were measured using the federal Substance Abuse and Mental Health Services Administration (SAMHSA) adaptation of the Addiction Severity index (ASI). A brain injury screening question was used to determine the number of TBI-LOCs in a client's lifetime. Design: Cross-sectional study of intake characteristics as part of a state-mandated treatment outcome study. Results: Almost one-third (31.7%) of substance abuse treatment clients reported 1 or more TBI-LOCs. The clients reporting 2 or more TBI-LOCs were more likely than clients with none or 1 TBI-LOC to have serious mental health problems (ie, depression, anxiety, hallucinations, and suicidal thoughts and attempts), trouble controlling violent behavior, trouble concentrating or remembering, and more months of use of most substances. When depression and anxiety were held constant, and controlling for race and gender, clients with TBI-LOC had more months of marijuana and tranquilizer use. Conclusions: Findings suggest that treatment providers may need to be attentive to the complex conditions that co-occur with TBI-LOC. Future research should examine whether there are differences in treatment outcome for clients reporting TBI-LOC.	Univ Kentucky, Coll Med, Ctr Drug & Alcohol Res, Lexington, KY 40506 USA; Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40506 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Walker, R (corresponding author), Univ Kentucky, Coll Med, Ctr Drug & Alcohol Res, Lexington, KY 40506 USA.		Cole, Jennifer E/Y-6388-2019; Corrigan, John D./E-2921-2011; Logan, TK o/O-7061-2018				Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Corrigan J.D., 2005, REHABILITATION TRAUM, P133; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dodge R, 2005, J SUBST ABUSE TREAT, V28, P189, DOI 10.1016/j.jsat.2004.12.005; EHRMAN RN, 1994, J CONSULT CLIN PSYCH, V62, P843, DOI 10.1037/0022-006X.62.4.843; Fals-Stewart W, 2000, J CONSULT CLIN PSYCH, V68, P134, DOI 10.1037/0022-006X.68.1.134; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levy DT, 2004, MED SCI MONITOR, V10, pCR17; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Mulvey KP, 2005, AM J EVAL, V26, P587, DOI 10.1177/1098214005281320; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017	23	34	34	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2007	22	6					360	367		10.1097/01.HTR.0000300231.90619.50			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	234RN	WOS:000251181500006	18025968				2022-02-06	
J	Pappas, E				Pappas, Evangelos			Boxing, wrestling, and martial arts related injuries treated in emergency departments in the United States, 2002-2005	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						combat sports injuries; sports injuries; emergency department visits; complex sample design	OSTEOARTHRITIS; PREVALENCE; AMATEUR; SPORTS; KARATE	The incidence of injury in combat sports has not been adequately reported although it is important to identify the nature and frequency of injuries prior to the implementation of prevention programs. This study compared injury rates treated in Hospital Emergency Departments between different combat sports of boxing, wrestling, and martial arts. A secondary objective described anatomic region and diagnosis of these injuries. Data were obtained on all boxing, wrestling, and martial arts-related injuries that were in the National Electronic Injury Surveillance System database and resulted in Emergency Department visits between 2002 and 2005. Pearson's chi-square statistics were calculated to compare injury rates for each activity accounting for complex sample design. Martial arts had lower injury rates compared to boxing and wrestling for all diagnoses (p < 0.001). Boxing had lower injury rates compared to wrestling for strains/sprains and dislocations. Boxing and wrestling had similar injury rates for concussions. Injury prevention efforts should consider the distribution of injuries and concentrate on preventing strains/sprains in wrestling, concussions in boxing and wrestling, and fractures for all three activities. The findings of the present study do not provide evidence that combat sports have alarmingly high rates of injuries resulting in emergency department visits.	Long Isl Univ, Div Phys Therapy, Brooklyn, NY 11201 USA		Pappas, E (corresponding author), Long Isl Univ, Div Phys Therapy, 1 Univ Pl,Brooklyn Campus, Brooklyn, NY 11201 USA.	evangelos.pappas@liu.edu	Pappas, Evangelos/A-4467-2008	Pappas, Evangelos/0000-0002-8340-0303			Arriaza R, 2005, KNEE SURG SPORT TR A, V13, P603, DOI 10.1007/s00167-004-0593-6; BIRRER RB, 1988, AM J SPORT MED, V16, P408, DOI 10.1177/036354658801600418; Bledsoe GH, 2006, J SPORT SCI MED, V5, P136; IOANNOU S, 1984, CAN MED ASSOC J, V131, P10; Jarrett GJ, 1998, AM J SPORT MED, V26, P674, DOI 10.1177/03635465980260051301; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LUNDBERG GD, 1983, JAMA-J AM MED ASSOC, V249, P250, DOI 10.1001/jama.1983.03330260068037; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pasque CB, 2000, AM J SPORT MED, V28, P509, DOI 10.1177/03635465000280041101; Porter M, 1996, CLIN J SPORT MED, V6, P97, DOI 10.1097/00042752-199604000-00006; Roos H, 1998, ARTHRITIS RHEUM, V41, P687, DOI 10.1002/1529-0131(199804)41:4<687::AID-ART16>3.0.CO;2-2; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; TENVERGERT EM, 1992, J SPORT MED PHYS FIT, V32, P214; von Porat A, 2004, ANN RHEUM DIS, V63, P269, DOI 10.1136/ard.2003.008136; Zazryn T, 2006, BRIT J SPORT MED, V40, P670, DOI 10.1136/bjsm.2006.025924; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321; Zetaruk MN, 2005, BRIT J SPORT MED, V39, P29, DOI 10.1136/bjsm.2003.010322	17	34	34	0	9	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	OCT	2007	6				2		58	61					4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	215DS	WOS:000249789100011	24198705				2022-02-06	
J	Lim, JH; Gibbons, HM; O'Carroll, SJ; Narayan, PJ; Faull, RLM; Dragunow, M				Lim, Joanne H.; Gibbons, Hannah M.; O'Carroll, Simon J.; Narayan, Pritika J.; Faull, Richard L. M.; Dragunow, Michael			Extracellular signal-regulated kinase involvement in human astrocyte migration	BRAIN RESEARCH			English	Article						glial scar; astrocyte	FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; ASTROGLIAL ACTIVATION; REACTIVE GLIOSIS; CELL-MIGRATION; ERK/MAP KINASE; GLIAL SCAR; RAT-BRAIN; IN-VITRO; GLUTAMINE-SYNTHETASE	Glial scar formation occurs after virtually any injury to the brain. The migration of astrocytes into regions of brain injury underlies the formation of the glial scar. The exact role of the glial scar has yet to be elucidated, although it is likely to impair brain recovery. Understanding astrocyte migration is fundamental to understanding the formation of the glial scar. We have used human astrocytes (NT2A cells), derived from human NT2/D1 precursor cells to study astrocyte migration using an in vitro scratch wound model. Time-lapse microscopy and bromodeoxyuridine labeling revealed that the astrocytes migrated rather than proliferated across the scratch. Time course immunocytochemical studies showed that scratching human astrocytes induced the activation (phosphorylation) of ERK 1/2 at 10 min after scratch. The MEK 1/2 inhibitor U0126 inhibited both the ERK 1/2 phosphorylation and the migration of the astrocytes across the wound after scratch. Thus, the migration of human astrocytes after injury is partly initiated by activation of the MEK-ERK signalling pathway. (c) 2007 Elsevier B.V. All rights reserved.	Univ Auckland, Fac Med & Hlth Sci, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Dept Anat & Radiol, Auckland 1, New Zealand		Dragunow, M (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Pharmacol & Clin Pharmacol, Private Bag 92019, Auckland 1, New Zealand.	m.dragunow@auckland.ac.nz		Faull, Richard/0000-0003-3385-9498; Narayan, Pritika/0000-0002-8713-1470			Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1984, LAB INVEST, V50, P147; Bani-Yaghoub M, 1999, NEUROREPORT, V10, P3843, DOI 10.1097/00001756-199912160-00022; BEACH TG, 1989, GLIA, V2, P420, DOI 10.1002/glia.440020605; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Colodner KJ, 2005, J NEUROPATH EXP NEUR, V64, P163, DOI 10.1093/jnen/64.2.163; DELACOURTE A, 1990, NEUROLOGY, V40, P33, DOI 10.1212/WNL.40.1.33; DELAMONTE SM, 1987, NEUROLOGY, V37, P562, DOI 10.1212/WNL.37.4.562; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Entschladen F, 2005, EXP CELL RES, V307, P418, DOI 10.1016/j.yexcr.2005.03.029; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GOLDMAN JE, 1978, J CELL BIOL, V78, P426, DOI 10.1083/jcb.78.2.426; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holley JE, 2003, NEUROPATH APPL NEURO, V29, P434, DOI 10.1046/j.1365-2990.2003.00491.x; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kornyei Z, 2000, J NEUROSCI RES, V61, P421, DOI 10.1002/1097-4547(20000815)61:4<421::AID-JNR8>3.0.CO;2-4; Lind CRP, 2006, NEUROSCIENCE, V141, P1925, DOI 10.1016/j.neuroscience.2006.05.038; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MILLER RH, 1984, J NEUROSCI, V4, P585; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; ONG WY, 1993, J NEUROCYTOL, V22, P893, DOI 10.1007/BF01186359; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Sandhu JK, 2002, J NEUROSCI RES, V68, P604, DOI 10.1002/jnr.10236; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Vis JC, 1998, CELL BIOL INT, V22, P837, DOI 10.1006/cbir.1998.0388; Walz W, 1998, NEUROSCI LETT, V257, P127, DOI 10.1016/S0304-3940(98)00813-1; Wang John Q., 2003, Current Neuropharmacology, V1, P1, DOI 10.2174/1570159033360548; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webster B, 2006, J NEUROPATH EXP NEUR, V65, P142, DOI 10.1097/01.jnen.0000199599.63204.6f; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3; ZLOTNIK I, 1968, BRIT J EXP PATHOL, V49, P555	52	34	39	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	2007	1164						1	13		10.1016/j.brainres.2007.06.020			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	208LX	WOS:000249321900001	17644078				2022-02-06	
J	Bouras, T; Stranjalis, G; Korfias, S; Andrianakis, I; Pitaridis, M; Sakas, DE				Bouras, Triantafyllos; Stranjalis, George; Korfias, Stefanos; Andrianakis, Ilias; Pitaridis, Marianos; Sakas, Damianos E.			Head injury mortality in a geriatric population: Differentiating an "Edge" age group with better potential for benefit than older poor-prognosis patients	JOURNAL OF NEUROTRAUMA			English	Article						age; geriatric population; head injury; mortality; outcome; traumatic brain injury	TRAUMATIC BRAIN INJURY; GLASGOW COMA SCALE; PREDICTION; FUTURE; WORSE; SCORE	A comparison of outcomes between different modes of head-injury treatment in the elderly has important bearing on questions of cost-effectiveness and medical ethics. Here, we have examined rates of mortality in elderly head-trauma victims to determine whether it is valid to differentiate an "edge" age group of younger elderly patients, 65 -74 years of age, from older elderly patients, considering possible benefit from intensive treatment and surgical intervention. We collected data from 1926 cases of head trauma and separated them into three age groups: 14-64 years, 65 -74 years, and 75 years or older. We then compared these groups with respect to cause of injury, severity of injury, and whether or not treatment included either admission to an Intensive Care Unit (ICU) or surgical intervention. We found that road traffic accidents were the major cause of head injury in the younger age group, whereas in the elderly falls predominated. Mortality was higher in the elderly in all the head injury severity subgroups. Young subjects with a Glasgow Coma Scale (GCS) score of less than or equal to 8 tended to benefit from ICU treatment whereas patients 75 and over did not, regardless of their severity of injury. For these patients who were in the 65-74 age group, the data suggested that some benefit was likely. Patients 75 and older were significantly less likely to survive surgical intervention than younger patients. We conclude that it is valid to treat patients in the age group 65-74 years as a separate group from those patients 75 and older. Patients in this younger subset of the elderly may benefit from ICU treatment or surgical intervention. However, the patients in our older subset of elderly patients clearly did not, and they had a significantly higher risk of surgical mortality.	Univ Athens, Evangelismos Hosp, Dept Neurosurg, Athens, Greece; Univ Athens, Evangelismos Hosp, Intens Care Unit, Athens, Greece		Bouras, T (corresponding author), Univ Athens, Evangelismos Hosp, Dept Neurosurg, Athens, Greece.	trbouras@yahoo.gr					AMACHER AL, 1987, NEUROSURGERY, V20, P954; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Demetriades D, 2001, J TRAUMA, V51, P754, DOI 10.1097/00005373-200110000-00022; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Grant PT, 2000, INJURY, V31, P519, DOI 10.1016/S0020-1383(00)00038-3; Helling TS, 1999, J TRAUMA, V46, P453, DOI 10.1097/00005373-199903000-00019; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Maurice-Williams RS, 1999, BRIT J NEUROSURG, V13, P5, DOI 10.1080/02688699944104; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nagurney J T, 1998, J Emerg Med, V16, P709, DOI 10.1016/S0736-4679(98)00083-3; STRANG I, 1978, INJURY, V10, P154; Stranjalis G, 1998, J NEUROSURG, V88, P782, DOI 10.3171/jns.1998.88.4.0782; STRANJALIS G, 2000, J RESTOR NEUROSCI NE, V6, P24; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; ZWIMPFER TJ, 1993, CRIT CARE CLIN, V9, P727, DOI 10.1016/S0749-0704(18)30166-0	25	34	39	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1355	1361		10.1089/neu.2005.370			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500007	17711397				2022-02-06	
J	Gallagher, CN; Hutchinson, PJ; Pickard, JD				Gallagher, Clare N.; Hutchinson, Peter J.; Pickard, John D.			Neuroimaging in trauma	CURRENT OPINION IN NEUROLOGY			English	Article						computed tomography; imaging; MRI; PET; trauma	DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; CT HEAD RULE; NEW-ORLEANS CRITERIA; BRAIN-INJURY; CORPUS-CALLOSUM; FIBER TRACKING; ISCHEMIA; DAMAGE; STEM	Purpose of review Developments in imaging following traumatic brain injury are outlined. Numerous techniques have evolved over the past several years giving us more information about the injury and prognosis for recovery. Some of these techniques are in clinical use while others are used primarily in research but have the potential to become clinically useful. Recent findings Computed tomography (CT) scanning is the primary imaging technique for acute brain injury, giving rapid information and being part of a general trauma work up in the emergency situation. It has supplanted plain films in the immediate management of brain injury. Following stabilization, MRI is the method of choice for evaluating the full extent of brain injury. Information on diffuse axonal injury is obtained by several MRI sequences. Diffusion tensor imaging is able to show long tract damage and relates to prognosis. There are several techniques which are best suited to research in brain injury, including single photon emission CT, PET and xenon CT. Summary CT and MRI are now the imaging techniques for acute and subacute brain injury, respectively. Diffusion tensor imaging is being developed to provide more information on structural damage in brain injury. There are several research techniques available for brain injury, particularly relating to cerebral blood flow and metabolism.	Univ Cambridge, Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge, England; Univ Calgary, Calgary, AB, Canada		Gallagher, CN (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Acad Neurosurg, Hills Rd, Cambridge, England.	galclare@gmail.com			MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390, G0600986, G0601025] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G0601025, G9439390] Funding Source: Medline		Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Bradley PG, 2004, CLINICAL MR NEUROIMAGING: DIFFUSION, PERFUSION AND SPECTROSCOPY, P626, DOI 10.1017/CBO9780511544958.040; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; Gean AD, 1994, IMAGING HEAD TRAUMA; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Hassan Z, 2005, EMERG MED J, V22, P845, DOI 10.1136/emj.2004.021717; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Lee Bruce, 2005, NeuroRx, V2, P372; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Menon DK, 2006, CURR OPIN CRIT CARE, V12, P85, DOI 10.1097/01.ccx.0000216572.19062.8f; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Pickard JD, 2005, ACT NEUR S, V95, P459; Poon WS, 2005, ACT NEUR S, V95, P9; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; Teasdale E, 2005, HEAD INJURY PATHOPHY, P169; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yen K, 2006, AM J NEURORADIOL, V27, P70	46	34	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	AUG	2007	20	4					403	409		10.1097/WCO.0b013e32821b987b			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	195NL	WOS:000248418800005	17620874				2022-02-06	
J	Wagner, AK; Postal, BA; Darrah, SD; Chen, X; Khan, AS				Wagner, Amy K.; Postal, Brett A.; Darrah, Shaun D.; Chen, Xiangbai; Khan, Amina S.			Deficits in novelty exploration after controlled cortical impact	JOURNAL OF NEUROTRAUMA			English	Article						exploratory behavior; novelty; open field; traumatic brain injury; Y-maze	TRAUMATIC BRAIN-INJURY; WATER MAZE PERFORMANCE; CHRONIC METHYLPHENIDATE TREATMENT; SENSATION-SEEKING TRAIT; ENVIRONMENTAL ENRICHMENT; MODERATE HYPOTHERMIA; NUCLEUS-ACCUMBENS; MOTIVATIONAL DEFICITS; COGNITIVE DEFICITS; PREFRONTAL CORTEX	Experimental models of traumatic brain injury (TBI) have been utilized to characterize the behavioral derangements associated with brain trauma. Several studies exist characterizing motor function in the controlled cortical impact (CCI) injury model of TBI, but less research has focused on how CCI affects exploratory behavior. The goal of this study was to characterize deficits in three novelty exploration tasks after the CCI. Under anesthesia, 37 adult male Sprague Dawley rats received CCI (2.7 mm and 2.9 mm; 4 m/sec) over the right parietal cortex or sham surgery. For days 1-6 post-surgery, the beam balance and beam walking tasks were used to assess motor deficits. The Open Field, Y-Maze, and Free Choice Novelty (FCN) tasks were used to measure exploratory deficits from days 7-14 post-surgery. Injured rats displayed a significant, but transient, deficit on each motor task (p < 0.0001). Open Field results showed that injured rats had lower activity levels than shams (p < 0.0001), displayed less habituation to the task, and had more anxiety related behaviors ( thigmotaxis) across days (p < 0.0001). Y-maze results suggest that injured rats spent less time in the novel arm versus the familiar arms when compared to shams (p < 0.0001). For FCN, injured rats were less active (p < 0.05) and spent less time and had fewer interactions with objects in the novel environment compared to shams (p < 0.05). These results suggest that several ethological factors contribute to exploratory deficits after CCI and can be effectively characterized with the behavioral tasks described. Future work will utilize these tasks to evaluate the neural substrates underlying exploratory deficits after TBI.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15260 USA.	wagnerak@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER		Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cannon CM, 2004, PHYSIOL BEHAV, V81, P741, DOI 10.1016/j.physbeh.2004.04.020; Chen Q, 2006, P NATL ACAD SCI USA, V103, P3881, DOI 10.1073/pnas.0505407103; Choleris E, 2001, NEUROSCI BIOBEHAV R, V25, P235, DOI 10.1016/S0149-7634(01)00011-2; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Daenen EWPM, 2001, BRAIN RES, V918, P153, DOI 10.1016/S0006-8993(01)02987-0; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; De Leonibus E, 2003, EUR J NEUROSCI, V18, P2365, DOI 10.1046/j.1460-9568.2003.02939.x; DELLU F, 1993, PERS INDIV DIFFER, V15, P411, DOI 10.1016/0191-8869(93)90069-F; Dellu F, 1997, NEUROBIOL LEARN MEM, V67, P112, DOI 10.1006/nlme.1997.3746; Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305; Dellu F, 2000, NEUROBIOL LEARN MEM, V73, P31, DOI 10.1006/nlme.1999.3919; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hughes RN, 1997, BEHAV PROCESS, V41, P213, DOI 10.1016/S0376-6357(97)00055-7; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maurer N, 2001, EXPERT OPIN BIOL TH, V1, P923, DOI 10.1517/14712598.1.6.923; Maurice T, 2001, BRAIN RES, V898, P113, DOI 10.1016/S0006-8993(01)02152-7; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Mele A, 2004, BEHAV PHARMACOL, V15, P423, DOI 10.1097/00008877-200409000-00017; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; OADES R, 1985, PSYCHOPHARMACOLOGY, V85, P123, DOI 10.1007/BF00427335; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pogorelov VM, 2005, NEUROPSYCHOPHARMACOL, V30, P1818, DOI 10.1038/sj.npp.1300724; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X; REBEC GV, 1984, NEUROSCI BIOBEHAV R, V8, P153, DOI 10.1016/0149-7634(84)90030-7; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; Rossetti ZL, 2005, J NEUROSCI, V25, P2322, DOI 10.1523/JNEUROSCI.3038-04.2005; Roy V, 2004, BEHAV BRAIN RES, V154, P439, DOI 10.1016/j.bbr.2004.03.010; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sutcliffe JS, 2007, BEHAV BRAIN RES, V177, P117, DOI 10.1016/j.bbr.2006.10.029; TIPPER SP, 1989, J EXP CHILD PSYCHOL, V48, P353, DOI 10.1016/0022-0965(89)90047-7; Vallee M, 1997, J NEUROSCI, V17, P2626; van der Meulen JAJ, 2007, CEREB CORTEX, V17, P1444, DOI 10.1093/cercor/bhl057; Viggiano D, 2003, NEUROSCI BIOBEHAV R, V27, P683, DOI 10.1016/j.neubiorev.2003.08.011; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wang H, 2005, NEUROSCI BIOBEHAV R, V29, P1361, DOI 10.1016/j.neubiorev.2005.05.008; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982	78	34	34	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1308	1320		10.1089/neu.2007.0274			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500002	17711392				2022-02-06	
J	Henry, JD; Phillips, LH; Crawford, JR; Kliegel, M; Theodorou, G; Summers, F				Henry, Julie D.; Phillips, Louise H.; Crawford, John R.; Kliegel, Matthias; Theodorou, Georgia; Summers, Fiona			Traumatic brain injury and prospective memory: Influence of task complexity	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							VERBAL FLUENCY PERFORMANCE; EVENT; INTENTIONS; DEFICITS; AGE	A quantitative review indicated that prospective memory impairment is a consistent feature of traumatic brain injury (TBI). However, evidence also suggests that manipulations that increase demands on controlled attentional processes moderate the magnitude of observed deficits. A total of 16 TBI participants were compared with 15 matched controls on a task in which the number of prospective target events was manipulated. This manipulation was of interest because two competing models make different predictions as to its effect on controlled attentional processes. In the context of Smith and Bayen's (2004) preparatory attentional processes and memory processes (PAM) model increasing the number of target events should increase requirements for controlled attentional processing. In contrast, McDaniel and Einstein's (2000) multiprocess framework assumes that distinct target events presented in focal awareness of the processing activities required for the ongoing task are likely to depend on automatic processes. This latter model therefore leads to the prediction that increasing the number of target events should not increase demands upon controlled attentional processes. Consistent with McDaniel and Einstein's (2000) multiprocess framework, TBI patients were significantly and comparably impaired on the one- and the four-target-event conditions relative to controls. Further, TBI deficits could not be attributed to increased difficulty with the retrospective component of the prospective memory task. The practical and theoretical implications of these results are discussed.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Aberdeen, Dept Neurosurg, Aberdeen, Scotland; Univ Zurich, Zurich, Switzerland		Henry, JD (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	julie.henry@unsw.edu.au	Crawford, John R/A-4165-2008; Phillips, Louise H/A-7952-2008	Crawford, John R/0000-0003-3403-3428; Phillips, Louise H/0000-0003-1005-8567; Henry, Julie/0000-0002-2081-3717; Kliegel, Matthias/0000-0002-2001-2522; Phillips, Louise/0000-0002-0988-3028			Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cherry KE, 2001, MEMORY, V9, P177, DOI 10.1080/09658210143000092; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cohen J, 1977, STAT POWER ANAL BEHA; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; Crawford J.R, 2005, EFFECTIVENESS REHABI, P233, DOI DOI 10.1093/ACPROF:OSO/9780198526544.003.0019; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; Einstein GO, 2000, PSYCHOL AGING, V15, P671, DOI 10.1037//0882-7974.15.4.671; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1991, HDB NEUROPSYCOLOGY, V6, P183; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McDaniel MA, 2004, J EXP PSYCHOL LEARN, V30, P605, DOI 10.1037/0278-7393.30.3.605; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McQueen, 2003, BRAIN IMPAIR, V4, P135, DOI [10.1375/brim.4.2.135.270, DOI 10.1375/BRIM.4.2.135.27024]; Nelson H.E., 1982, NATL ADULT READING T; Neulinger K., 2002, BRAIN IMPAIR, V3, P1, DOI [10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith RE, 2004, J EXP PSYCHOL LEARN, V30, P756, DOI 10.1037/0278-7393.30.4.756; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81	32	34	35	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	2007	29	5					457	466		10.1080/13803390600762717			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	185RJ	WOS:000247727800001	17564911				2022-02-06	
J	Rodgers, ML; Strode, AD; Norell, DM; Short, RA; Dyck, DG; Becker, B				Rodgers, Martina L.; Strode, Anne D.; Norell, Diane M.; Short, Robert A.; Dyck, Dennis G.; Becker, Bruce			Adapting multiple-family group treatment for brain and spinal cord injury intervention development and preliminary outcomes	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						family psychoeducation; family support program; traumatic brain injury; spinal cord injury	QUALITY-OF-LIFE; CAREGIVER BURDEN; SCHIZOPHRENIA; IMPACT; SATISFACTION; MANAGEMENT; SURVIVORS; PATIENT; TBI	Objective: There is a need for interventions that assist in managing the multiple adjustments of persons with spinal cord and brain injuries and their families. The purpose of the present field-initiated development project was to adapt a family psychoeducation model, multiple-family group treatment (MFGT), for persons with brain and spinal cord injury and their families. Design: The experiences of survivors and caregivers in MFGT were evaluated using quantitative and qualitative methods. Twenty-seven survivors and 28 caregivers participated in MFGT for 12-18 mos. Reliable and valid quantitative measures were used to assess a variety of target outcomes. Additionally, semistructured interviews and focus groups were conducted with participants. Results: Survivors reported a decrease in depressive symptoms and anger expression toward others as well as an Increase in life satisfaction. Caregivers reported a significant reduction in burden. The themes derived from the qualitative analysis addressed the normalization of the caregiving experience, importance of socialization, improvement in a variety of coping skills, and education about the injuries. Conclusions: The findings support the adaptation of MFGT for brain and spinal cord injuries.	Washington State Univ, Washington Inst Mental Illness Res & Training, Spokane, WA 99210 USA; Washington State Univ, Dept Psychol, Spokane, WA 99210 USA; St Lukes Rehabil Inst, Spokane, WA USA		Dyck, DG (corresponding author), Washington State Univ, Washington Inst Mental Illness Res & Training, POB 1495, Spokane, WA 99210 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [H133G RR 020006] Funding Source: Medline		ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Cohen S., 1985, SOCIAL SUPPORT THEOR, P73, DOI [10.1007/978-94-009-5115-0_5, DOI 10.1007/978-94-009-5115-0_5]; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dyck DG, 1999, PSYCHOSOM MED, V61, P411, DOI 10.1097/00006842-199907000-00001; Dyck DG, 2000, PSYCHIAT SERV, V51, P513, DOI 10.1176/appi.ps.51.4.513; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Folzer SM, 2001, AM J ORTHOPSYCHIAT, V71, P245, DOI 10.1037/0002-9432.71.2.245; Gonzalez S, 2002, MULTIFAMILY GROUPS T, P315; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LEHMAN AF, 1988, EVAL PROGRAM PLANN, V11, P51, DOI 10.1016/0149-7189(88)90033-X; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCDONELL MG, 2006, FAM PROCESS, V33, P147; McFarlane W. R., 1991, MULTIPLE FAMILY PSYC; McFarlane WR, 1996, PSYCHIAT SERV, V47, P744; McFarlane WR, 2003, J MARITAL FAM THER, V29, P223, DOI 10.1111/j.1752-0606.2003.tb01202.x; MCFARLANE WR, 1995, FAM PROCESS, V34, P127, DOI 10.1111/j.1545-5300.1995.00127.x; MCFARLANE WR, 1994, NEW DIRECTIONS MENTA, V62, P13, DOI DOI 10.1002/YD.23319946204; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Prigatano GP, 2003, INT REV PSYCHIATR, V15, P371, DOI 10.1080/09540260310001606755; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROHRER K, 1980, ARCH PHYS MED REHAB, V61, P225; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; SATIN W, 1989, J PEDIATR PSYCHOL, V14, P259, DOI 10.1093/jpepsy/14.2.259; Seale C., 2004, QUALITATIVE RES PRAC; Smith Michele S, 2002, Rehabil Nurs, V27, P209; SPIELBERGER CD, 1985, ANGER HOSTILITY CARD, P6; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; Sullivan J, 1990, Crit Care Nurs Clin North Am, V2, P407; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; *US CDCP, 2000, EP TRAUM BRAIN INJ U; VITALIANO PP, 1985, MULTIVAR BEHAV RES, V20, P3, DOI 10.1207/s15327906mbr2001_1; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; WELLER DJ, 1977, SOC WORK HEALTH CARE, V3, P7, DOI 10.1300/J010v03n01_02; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	49	34	34	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	2007	86	6					482	492		10.1097/PHM.0b013e31805c00a1			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	172UJ	WOS:000246829600009	17515688				2022-02-06	
J	Stalnacke, BM; Elgh, E; Sojka, P				Stalnacke, Britt-Marie; Elgh, Eva; Sojka, Peter			One-year follow-up of mild traumatic brain injury: Cognition, disability and life satisfaction of patients seeking consultation	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; head trauma; brain concussion; post-concussion symptoms; life satisfaction; neuropsychological tests	POST-CONCUSSION SYMPTOMS; NEURON-SPECIFIC ENOLASE; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; WESTERN SWEDEN; SERUM-LEVELS; CHRONIC PAIN; ACUTE-PHASE; TASK; QUESTIONNAIRE	Objective: To investigate cognitive function, symptoms, disabilities and life satisfaction of patients with mild traumatic brain injury who accepted consultation one year post-trauma. Design: Prospective study. Patients: Sixty-nine patients (16 accepted the consultation offered, 53 declined). Methods: At follow-up, the patients answered questionnaires about symptoms, disabilities (RHFUQ) and life satisfaction (LiSat-11). The patients who underwent consultation and their healthy control subjects were administered a neuropsychological evaluation. Results: In the group undergoing consultation, the number of cognitive tests with outcomes below cut-off limits (-1.5 SD) was statistically significantly higher compared with a control group (21 tests in 11 patients vs 8 tests in 7 control subjects; p = 0.025). The number of patients with one or more disability was statistically significantly higher among patients with consultation than without (94% and 34%, respectively; p < 0.001). Total RHFUQ score was statistically significantly higher for the group with consultation than without (5.9 +/- 3.7 and 1.1 +/- 2.3, respectively p < 0.001). The group with consultation exhibited a lower level of life satisfaction (41.5 +/- 10.4 vs 45.8 +/- 13.8 for the non-consulting group; p = 0.057). Conclusion: The high frequency of occurrence of disabilities and lower cognitive functioning, together with the lower level of life satisfaction, appear to characterize patients choosing consultation 1 year post-injury. This highlights the importance of offering consultation for persons suffering mild head injuries.	Dept Community Med & Rehabil, Umea, Sweden; Dept Rehabil Med, Umea, Sweden; Dept Geriatr, Umea, Sweden		Sojka, P (corresponding author), Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se					Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fugl-Meye KS., 1991, CLIN REHABIL, V5, P25, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105]; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Levander S., 1988, AUTOMATED PSYCHOL TE; Lezak M, 2004, NEUROPSYCHOLOGICAL A, P158; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; REITAN RM, 1992, J CLIN PSYCHOL, V48, P521, DOI 10.1002/1097-4679(199207)48:4<521::AID-JCLP2270480414>3.0.CO;2-C; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Skell RL, 2000, BRAIN INJURY, V14, P705; SMITH JR, 1986, MANUAL CWT SERIAL CO; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207	33	34	34	0	3	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2007	39	5					405	411		10.2340/16501977-0057			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	174SF	WOS:000246962400011	17549333	gold, Green Submitted			2022-02-06	
J	Gopcevic, A; Mazul-Sunko, B; Marout, J; Sekulic, A; Antoljak, N; Siranovic, M; Ivanec, Z; Margaritoni, M; Bekavac-Beslin, M; Zarkovic, N				Gopcevic, Aleksandar; Mazul-Sunko, Branka; Marout, Jasminka; Sekulic, Ante; Antoljak, Natasa; Siranovic, Mladen; Ivanec, Zeljko; Margaritoni, Marko; Bekavac-Beslin, Miroslav; Zarkovic, Neven			Plasma interleukin-8 as a potential predictor of mortality in adult patients with severe traumatic brain injury	TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						traumatic brain injury (TBI); coma; mortality; inflammation; Interleukin-8 (IL-8)	CEREBROSPINAL-FLUID; HEAD-INJURY; BARRIER DYSFUNCTION; MICE DEFICIENT; CARDIAC-ARREST; TNF-ALPHA; ASTROCYTES; EXPRESSION; CHEMOKINES; MEDIATORS	Because of complex pathophysiology and severe consequences, traumatic brain injuries (TBI) are an important medical problem. Pathophysiology of TBI includes local and systemic stress response, in which interleukin-8 (IL-8) is considered as a key mediator of neuroinflammation. However, prognostic relevance of IL-8 measurement in adult patients with severe TBI is not certain. Therefore, IL-8 was determined in blood samples from central venous and jugular bulb catheter and in cerebrospinal fluid of twenty patients with isolated TBI at admission to Intensive Care Unit. None of the patients had history of stroke, dementia, autoimmune diseases, acute infection or medication with anti-inflammatory drugs. Ten patients died due to traumatic brain injury, while the other ten recovered well. While there was no significant difference of IL-8 levels in cerebrospinal fluid between survivors and nonsurvivors, central venous plasma level of IL-8 was significantly lower in survivors (71.00 +/- 14.17 pg/ml), than in nonsurvivors (111.26 +/- 16.9 pg/ml). Receiver Operating Characteristic (ROC) analysis revealed significant prognostic value for IL-8 in the blood as well as for the age of patients, Glasgow Coma Scale (GCS) and Acute Physiologic and Chronic Health Evaluation (APACHE II). These findings suggest that the central venous plasma values of IL-8 at admission might be an early predictive marker in patients with severe TBI, comparative to standard clinical prognostic markers such as APACHE II and GCS.	Rudjer Boskovic Inst, Dept Mol Med, HR-1000 Zagreb, Croatia; Univ Zagreb, Sestre Milosrdnice Univ Hosp, Dept Anesthesiol & Intens Care, Zagreb 41000, Croatia; Univ Zagreb, Sestre Milosrdnice Univ Hosp, Lab Endocrinol, Zagreb 41000, Croatia; Univ Zagreb, Dept Anesthesiol, Zagreb 41000, Croatia; Univ Zagreb, Univ Hosp, Div Neuroanesthesia & Neurointens Care, Zagreb, Croatia; Univ Zagreb, Inst Publ Hlth, Zagreb, Croatia; Univ Dubrovnik, Gen Hosp, Dubrovnik, Croatia; Univ Zagreb, Sestre Milosrdnice Univ Hosp, Dept Surg, Zagreb 41000, Croatia		Zarkovic, N (corresponding author), Rudjer Boskovic Inst, Dept Mol Med, Bijenicka 54, HR-1000 Zagreb, Croatia.	zarkovic@irb.hr	Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Chuang D, 2005, ANZ J SURG, V75, P813, DOI 10.1111/j.1445-2197.2005.03530.x; Croitoru-Lamoury J, 2003, GLIA, V41, P354, DOI 10.1002/glia.10181; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; Emir M, 2005, TOHOKU J EXP MED, V207, P119, DOI 10.1620/tjem.207.119; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hoch RC, 1996, J LAB CLIN MED, V128, P134, DOI 10.1016/S0022-2143(96)90005-0; IMAI Y, 2003, JAMA-J AM MED ASSOC, V9, P2104; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KUSHI H, 2003, CRIT CARE MED S, V31, P363; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; MASTROIANNI CM, 1994, PEDIATR INFECT DIS J, V13, P1008; MASTROIANNI CM, 1998, CLIN EXP IMMUNOL, V22, P724; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; Mimasaka S, 2002, TOHOKU J EXP MED, V197, P145, DOI 10.1620/tjem.197.145; Minami K, 2004, TOHOKU J EXP MED, V203, P129, DOI 10.1620/tjem.203.129; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nikolic-Heitzler V, 2006, TOHOKU J EXP MED, V210, P247, DOI 10.1620/tjem.210.247; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Pratschke J, 2000, ANN SURG, V232, P263, DOI 10.1097/00000658-200008000-00017; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schlag G, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P3; SMITH WB, 1991, IMMUNOLOGY, V72, P65; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stoeck K, 2006, J NEUROIMMUNOL, V172, P175, DOI 10.1016/j.jneuroim.2005.10.008; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Wildburger R, 2000, WIEN KLIN WOCHENSCHR, V112, P798; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X	38	34	37	0	4	TOHOKU UNIV MEDICAL PRESS	SENDAI	2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN	0040-8727	1349-3329		TOHOKU J EXP MED	Tohoku J. Exp. Med.	APR	2007	211	4					387	393		10.1620/tjem.211.387			7	Medicine, General & Internal; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Research & Experimental Medicine	156JO	WOS:000245644200010	17409679	Bronze			2022-02-06	
J	Ko, K; Segan, S				Ko, Kathryn; Segan, Scott			In situ hinge craniectomy	NEUROSURGERY			English	Article						brain injury; craniectomy; hinge	DECOMPRESSIVE CRANIECTOMY	OBJECTIVE: To describe an optional method for performing decompressive craniectomy using in situ hinge craniectomy technique in patients with traumatic brain injury and stroke. METHODS: Sixteen patients underwent surgery for treatment of presenting pathology followed by the placement of hinge craniectomy. The technique is detailed. RESULTS: Six patients with traumatic head injury and 10 with stroke underwent treatment of their primary pathologies with subsequent hinge craniectomy. Of these patients, more than half underwent refixation of the hinge in a minor procedure after recovery. No patient had complications related to this technique and none required further cranial decompression. In patients with intracranial pressure monitoring, all displayed values in the normal range. CONCLUSION: In this limited study, in situ hinge craniectomy proved useful in the treatment of patients experiencing stroke or traumatic brain injury. This procedure has the potential to eliminate the additional second incision to explant the bone flap or the refrigeration storage of the bone flap. Also, the second operation to restore the cranial contour by reimplanting the bone flap or by the creation of a cranioplasty with artificial material would not be necessary.	Cornell Univ, Weill Med Coll, Dept Neurosurg, New York, NY 10021 USA; St Barnabas Hosp, Stroke Ctr, Div Neurol, Bronx, NY USA		Ko, K (corresponding author), Cherokee Stn, POB 20398, New York, NY 10021 USA.	k@gyrus.cc					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Raposio E, 1998, ANN PLAS SURG, V41, P17, DOI 10.1097/00000637-199807000-00004; Traxler H, 2002, CLIN ANAT, V15, P173, DOI 10.1002/ca.10022; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110	6	34	34	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2007	60	4		S			255	258		10.1227/01.NEU.0000255380.64969.81			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	155VR	WOS:000245607100015	17415161				2022-02-06	
J	Krakau, K; Hansson, A; Karlsson, T; de Boussard, CN; Tengvar, C; Borg, J				Krakau, Karolina; Hansson, Annette; Karlsson, Torbjorn; de Boussard, Catharina Nygren; Tengvar, Christer; Borg, Jorgen			Nutritional treatment of patients with severe traumatic brain injury during the first six months after injury	NUTRITION			English	Article						traumatic brain injury; parenteral nutrition; enteral nutrition; oral feeding; level of independence; malnutrition	SEVERE HEAD-INJURY; ENERGY-EXPENDITURE; NITROGEN-EXCRETION; ENTERAL NUTRITION; METABOLIC CHANGES; ESPEN GUIDELINES; SECONDARY; INSULT; REHABILITATION; REQUIREMENTS	Objective: This study explored current nutritional treatment policies and nutritional outcome in patients with severe traumatic brain injury. Methods: We performed a retrospective, structured survey of the medical records of 64 patients up to 6 months after injury or until the patients were independent in nutritional administration. Results: Enteral nutrition was administered to 86% of patients. Fourteen patients (22%) had a gastrostomy; after 6 months four were still in use. At 6 months, 92% of patients received all food orally and 84% had gained nutritional independence. Energy intake was equal to the calculated basal metabolic rate throughout the first month after injury and increased by 21% during the second month. Sixty-eight percent exhibited signs of malnourishment with weight losses of 10-29%. Conclusion: This study suggests that most patients with severe traumatic brain injury regain their nutritional independence within the first 6 months after injury, but also that most develop signs of malnutrition. (c) 2007 Elsevier Inc. All rights reserved.	Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden; Danderyd Hosp, Dept Rehabil Med Stockholm, Stockholm, Sweden; Karolinska Univ Hosp, Dept Neurosurg Intens Care, Stockholm, Sweden; Univ Uppsala Hosp, Dept Surg Sci Anesthesiol & Intens Care, Uppsala, Sweden; Cent Hosp Vasteras, Dept Rehabil Med, Vasteras, Sweden		Krakau, K (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden.	karolina.krakau@ds.se		Borg, Jorgen/0000-0002-2372-7478			Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1053/apmr.2000.0810176; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; *BRAIN TRAUMA FDN, 2000, NUTR J NEUROTRAUMA, V17, P539; BRANSON R D, 1990, Respiratory Care, V35, P640; Bruder N, 1998, CRIT CARE MED, V26, P568, DOI 10.1097/00003246-199803000-00033; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; BRUDER N, 1991, CRIT CARE MED, V19, P43, DOI 10.1097/00003246-199101000-00013; CHARLIN V, 1993, REV MED CHILE, V121, P626; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Denes Z, 2004, DISABIL REHABIL, V26, P1163, DOI 10.1080/09638280412331270380; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; DOLCE G, 2002, POST TRAUMATIC VEGET, P22; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; Formisano R, 2004, BRAIN INJURY, V18, P103, DOI 10.1080/0269905031000149470; FUGAZZA G, 1998, EUROPA MEDICOPHYSICA, V34, P125; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; HARRIS JA, 1919, BIOMETRIC STUDY BASA, P223; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Klodell CT, 2000, AM J SURG, V179, P168, DOI 10.1016/S0002-9610(00)00297-X; Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Loser C, 2005, CLIN NUTR, V24, P848, DOI 10.1016/j.clnu.2005.06.013; McCall M, 2003, JPEN-PARENTER ENTER, V27, P27, DOI 10.1177/014860710302700127; Minard G, 2000, JPEN-PARENTER ENTER, V24, P145, DOI 10.1177/0148607100024003145; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; Ott L, 1999, J NEUROTRAUM, V16, P233, DOI 10.1089/neu.1999.16.233; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Stechmiller J, 1994, J Neurosci Nurs, V26, P224; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; THOMSON MA, 2000, P NUTR SOC LOND, V60, pA83; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Yanagawa T, 2002, COCHRANE DB SYST REV; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010	50	34	40	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0899-9007	1873-1244		NUTRITION	Nutrition	APR	2007	23	4					308	317		10.1016/j.nut.2007.01.010			10	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	159ES	WOS:000245848800005	17369022				2022-02-06	
J	Maroon, JC; El-Kadi, H; Abla, AA; Wecht, DA; Bost, J; Norwig, J; Bream, T				Maroon, Joseph C.; El-Kadi, Hikmat; Abla, Adnan A.; Wecht, Daniel A.; Bost, Jeffrey; Norwig, John; Bream, Tim			Cervical neurapraxia in elite athletes: evaluation and surgical treatment - Report of five cases	JOURNAL OF NEUROSURGERY-SPINE			English	Article						neurapraxia; spinal concussion; spinal stenosis; transient spinal cord injury; quadriplegia	SPINE INTERBODY FUSION; FINITE-ELEMENT MODEL; CREST BONE-GRAFT; FOOTBALL PLAYERS; MANAGEMENT GUIDELINES; DISC DEGENERATION; STENOSIS; STABILITY; ADJACENT; CORD	Object. Neurapraxia, transient posttraumtic paralysis of the motor and/or sensory tracts in the spinal cord, may be a career-ending event in an athlete. Management, rehabilitation, and return-to-play decisions remain controversial. Methods. Five elite football players were evaluated after experiencing episodes of neurapraxia. All patients experienced bilateral paresthesias-three in all four extremities and two in the upper extremities-lasting a few minutes to more than 24 hours. Transient motor deficits occurred in two individuals but caused no permanent sequelae. Neuroimaging confirmed the presence of herniated discs, focal cord compression, and no parenchymal changes in all cases. All patients underwent anterior cervical microdiscectomy and fusion, and cervical plates were placed in four. After aggressive rehabilitation and confirmation of fusion ranging from 9 weeks to 8 months postoperatively, the players were allowed to return to active play. Two of the players developed recurrent career-ending disc herniations, one above and the other below the fusion level. One player required repeated spinal cord decompression. Conclusions. Neurologically intact athletes with focal cord compression due to a single-level herniated disc may safely return to football after undergoing decompressive surgery and confirmation of fusion. It appears, however, that there may be an increased chance of repeated herniation above or below a fused level.	Univ Pittsburgh, Presbyterian Hosp, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Pittsburgh Steelers Football Org, Pittsburgh, PA USA; Chicago Bears Football Org, Chicago, IL USA		Maroon, JC (corresponding author), Univ Pittsburgh, Presbyterian Hosp, Sch Med, Dept Neurosurg, Suite C-500,200 Lothrop St, Pittsburgh, PA 15213 USA.	maroonjc@upme.edu					Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086-199608000-00037; Bailes JE, 2005, J NEUROSURG-SPINE, V2, P11, DOI 10.3171/spi.2005.2.1.0011; BUCKWALTER JA, 1995, SPINE, V20, P1307, DOI 10.1097/00007632-199506000-00022; Cantu RC, 1998, CLIN SPORT MED, V17, P137, DOI 10.1016/S0278-5919(05)70068-5; CANTU RC, 1993, MED SCI SPORT EXER, V25, P316; Dai LY, 1998, SPINE, V23, P1734, DOI 10.1097/00007632-199808150-00005; DiAngelo DJ, 2000, SPINE, V25, P783, DOI 10.1097/00007632-200004010-00005; Eck JC, 2002, SPINE, V27, P2431, DOI 10.1097/00007632-200211150-00003; Goulet JA, 1997, CLIN ORTHOP RELAT R, P76; HASHIMOTO I, 1977, J NEUROSURG, V47, P912, DOI 10.3171/jns.1977.47.6.0912; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009; Kandziora F, 2001, SPINE, V26, P1850, DOI 10.1097/00007632-200109010-00007; Kettler A, 2001, J NEUROSURG, V94, P97, DOI 10.3171/spi.2001.94.1.0097; Kumaresan S, 1997, BIO-MED MATER ENG, V7, P221; Lopez-Espina CG, 2006, SPINE, V31, P972, DOI 10.1097/01.brs.0000215205.66437.c3; Maiman DJ, 1999, BIO-MED MATER ENG, V9, P27; MAROON JC, 1991, CLIN NEUR, V37, P612; MAROON JC, 1977, JAMA-J AM MED ASSOC, V238, P2049; MEYER SA, 1994, AM J SPORT MED, V22, P158, DOI 10.1177/036354659402200202; MUELLER FO, 2005, ANN SURVEY FOOTBALL; Natarajan RN, 2000, SPINE, V25, P955, DOI 10.1097/00007632-200004150-00010; Phillips W C Jr, 1986, Del Med J, V58, P559; Pitzen TR, 2002, J NEUROSURG, V97, P128, DOI 10.3171/spi.2002.97.1.0128; ROBERTSON WC, 1979, JAMA-J AM MED ASSOC, V241, P1480, DOI 10.1001/jama.241.14.1480; SALLIS RE, 1992, PHYSICIAN SPORTSMED, V20, P47, DOI 10.1080/00913847.1992.11947521; Smith M G, 1993, J Ky Med Assoc, V91, P273; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; Torg JS, 1997, J NEUROSURG, V87, P843, DOI 10.3171/jns.1997.87.6.0843; Torg JS, 1997, MED SCI SPORT EXER, V29, pS256, DOI 10.1097/00005768-199707001-00008; Vaccaro Alexander R, 2002, Spine J, V2, P351; WATKINS RG, 1996, SPINE SPORTS, P157	32	34	35	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	APR	2007	6	4					356	363		10.3171/spi.2007.6.4.13			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	152DV	WOS:000245341900014	17436927				2022-02-06	
J	Tranel, D; Hathaway-Nepple, J; Anderson, SW				Tranel, Daniel; Hathaway-Nepple, Julie; Anderson, Steven W.			Impaired behavior on real-world tasks following damage to the ventromedial prefrontal cortex	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SORTING TEST-PERFORMANCE; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE DAMAGE; STRATEGY APPLICATION; ECOLOGICAL VALIDITY; EXECUTIVE FUNCTION; SIMPLIFIED VERSION; GOAL MANAGEMENT; DEFICITS; LESIONS	Patients with damage to the ventromedial prefrontal cortices (VMPC) commonly manifest blatant behavioral navigation defects in the real world, but it has been difficult to measure these impairments in the clinic or laboratory. Using a set of "strategy application" tasks, which were designed by Shallice and Burgess (1991) to be ecologically valid for detecting executive dysfunction, we investigated the hypothesis that VMPC damage would be associated with defective performance on such tasks, whereas damage outside the VMPC region would not. A group of 9 patients with bilateral VMPC damage was contrasted with comparison groups of participants with (a) prefrontal brain damage outside the VMPC region (n = 8); (b) nonprefrontal brain damage (n = 17); and (c) no brain damage (n=20). We found support for the hypothesis: VMPC patients had more impaired performances on the strategy application tasks, especially on a Multiple Errands Test that required patients to execute a series of unstructured tasks in a real-world setting (shopping mall). The results are consistent with the notion that efficacious behavioral navigation is dependent on the VMPC region. However, the strategy application tasks were relatively time consuming and effortful, and their diagnostic yield over and above conventional executive functioning tests may not be sufficient to warrant their inclusion in standard clinical assessment.	Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, Iowa City, IA 52242 USA		Tranel, D (corresponding author), Univ Iowa Hosp & Clin, Dept Neurol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	daniel-tranel@uiowa.edu		Anderson, Steven/0000-0002-7364-1680; Tranel, Daniel/0000-0002-1338-1389	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA022549, R01 DA022549-02] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS019632, P01 NS19632, NS19632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS019632, P01NS019632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA022549] Funding Source: NIH RePORTER		Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; ANDERSON SW, 2002, HDB NEUROPSYCHOLOGY, V7, P145; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Damasio A., 1994, DESCARTES ERROR EMOT; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; Damasio H, 2004, COGNITION, V92, P179, DOI 10.1016/j.cognition.2002.07.001; Damasio H, 2000, HDB NEUROPSYCHOLOGY, P77; Denburg NL, 2005, NEUROPSYCHOLOGIA, V43, P1099, DOI 10.1016/j.neuropsychologia.2004.09.012; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fellows LK, 2005, CEREB CORTEX, V15, P58, DOI 10.1093/cercor/bhh108; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; Goel V, 2000, COGN NEUROPSYCHOL, V17, P415, DOI 10.1080/026432900410775; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.7.1120-1122; Jelicic M, 2001, INT J NEUROSCI, V110, P73, DOI 10.3109/00207450108994222; Kafer K L, 1997, J Int Neuropsychol Soc, V3, P108; Kliegel M, 2000, MEM COGNITION, V28, P1041, DOI 10.3758/BF03209352; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, IN PRESS J CLIN EXPT; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shuren JE, 2002, ARCH NEUROL-CHICAGO, V59, P916, DOI 10.1001/archneur.59.6.916; Stout JC, 2004, PSYCHON B REV, V11, P742, DOI 10.3758/BF03196629; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; TRANEL D, IN PRESS HDB CLIN NE; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Yechiam E, 2005, PSYCHOL SCI, V16, P973, DOI 10.1111/j.1467-9280.2005.01646.x	49	34	34	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2007	29	3					319	332		10.1080/13803390600701376			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	165XG	WOS:000246340000009	17454352	Green Accepted			2022-02-06	
J	Berger, C; Xia, F; Kohrmann, M; Schwab, S				Berger, Christian; Xia, Feng; Koehrmann, Martin; Schwab, Stefan			Hypothermia in acute stroke - Slow versus fast rewarming - An experimental study in rats	EXPERIMENTAL NEUROLOGY			English	Article						hypothermia; glutamate; middle cerebral artery; stroke; brain edema; inflammation	CEREBRAL-ARTERY OCCLUSION; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; FOREBRAIN ISCHEMIA; THERAPEUTIC HYPOTHERMIA; NEURONAL DAMAGE; CYCLOSPORINE-A; FOCAL MODEL	The rewarming phase after therapeutic hypothermia in cerebral ischemia appears crucial as rapid rewarming may lead to rebound phenomena and enhance deleterious ischemic effects. We hypothesized that slow and controlled rewarming after moderate hypothermia is superior to fast rewarming in rats subjected to 90 min temporary middle cerebral artery occlusion (tMCAO). Two experiments were designed: (i) 34 rats were randomly assigned to either normothermic treatment, to hypothermia (33 degrees C) with rapid rewarming within 20 min, or to hypothermia with slow rewarming within 2 h after 4 h of hypothermia starting 2 h after tMCAO. Infarct size, neuroscore, myeloperoxidase and aquaporin 4 (AQP4) positive cells were assessed on day 5 after tMCAO. (ii) In 15 rats, striatal cerebral microdialysis was performed from 1.5 h before until 8 h after tMCAO. Total infarct volume was largest in the normothermic group (89.9 +/- 16.9 mm(3)) followed by the fast rewarming group (69.2 +/- 12.6 mm(3)), and a significantly smaller infarct volume in the slow rewarming group (41.1 +/- 6.6 mm(3), p < 0.05). Neurological functions improved in both hypothermia groups at day 5 after tMCAO (Neuroscore median 2.5 in normothermia vs. 1.5 in both hypothermia groups) though without any difference between slowly and fast rewarmed animals. Periinfarct expression of AQP4 was less prominent in slowly rewarmed animals as was the count of MPO-positive cells in subcortical regions. Glutamate release was significantly higher at 4 distinct time points in the control group. Slow rewarming after a period of hypothermia is superior to fast rewarming. It may blunt deleterious rebound effects such as overexpression of AQP4, sustain anti-inflammatory mechanisms and thereby preserve the neuroprotection delivered by hypothermia. (c) 2006 Elsevier Inc. All rights reserved.	Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany		Berger, C (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	christian.berger@urz.uni-heidelberg.de					Aoki A, 2002, NEUROL RES, V24, P271, DOI 10.1179/016164102101199909; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Berger C, 2002, STROKE, V33, P519, DOI 10.1161/hs0102.100878; BLAIR E, 1956, CIRCULATION, V13, P909, DOI 10.1161/01.CIR.13.6.909; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Fujisawa H, 1999, J NEUROTRAUM, V16, P1083, DOI 10.1089/neu.1999.16.1083; Inamasu J, 2001, NEUROL RES, V23, P105, DOI 10.1179/016164101101198217; Ishikawa M, 1999, STROKE, V30, P1679, DOI 10.1161/01.STR.30.8.1679; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kloss CUA, 2002, NEUROL RES, V24, P713, DOI 10.1179/016164102101200636; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; MARSH DC, 1991, HEPATOLOGY, V13, P500, DOI 10.1002/hep.1840130318; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Ooboshi H, 2000, BRAIN RES, V884, P23, DOI 10.1016/S0006-8993(00)02861-4; POPOVIC V, 1959, ANN NY ACAD SCI, V80, P320, DOI 10.1111/j.1749-6632.1959.tb49212.x; Schabitz WR, 2001, STROKE, V32, P1226, DOI 10.1161/01.STR.32.5.1226; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; Steiner T, 2001, STROKE, V32, P2833, DOI 10.1161/hs1201.99511; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Wakiyama S, 1997, BRIT J SURG, V84, P459; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; ZHANG RL, 1995, BRAIN RES, V682, P182, DOI 10.1016/0006-8993(95)00346-R	45	34	36	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2007	204	1					131	137		10.1016/j.expneurol.2006.10.002			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	148PC	WOS:000245086100014	17112513				2022-02-06	
J	Qu, Y; Chen-Roetling, J; Benvenisti-Zarom, L; Regan, RF				Qu, Yan; Chen-Roetling, Jing; Benvenisti-Zarom, Luna; Regan, Raymond F.			Attenuation of oxidative injury after induction of experimental intracerebral hemorrhage in heme oxygenase-2 knockout mice	JOURNAL OF NEUROSURGERY			English	Article						stroke; intracerebral hemorrhage; free radical; hemoglobin; iron; lipid peroxidation; mouse	TRAUMATIC BRAIN-INJURY; HEME OXYGENASE-1 HO-1; RAT-BRAIN; SUBARACHNOID HEMORRHAGE; HEMOGLOBIN TOXICITY; LIPID-PEROXIDATION; TIN-MESOPORPHYRIN; CARBON-MONOXIDE; CELL INJURY; NEURONS	Object. Experimental evidence suggests that hemoglobin degradation products contribute to cellular injury after intracerebal hemorrhage (ICH). Hemoglobin breakdown is catalyzed in part by the heme oxygenase (HO) enzymes. In the present study, the authors tested the hypothesis that HO-2 gene deletion is cytoprotective in an experimental ICH model. Methods. After anesthesia was induced with isoflurane, 3- to 6-month-old HO-2 knockout and wild-type mice were stereotactically injected with 15 mu l autologous blood and a group of control mice were injected with an equal volume of sterile saline. Striatal protein and lipid oxidation were quantified 72 hours later using carbonyl and malondialdehyde assays. Cell viability was determined by performing a 3(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay. Following blood injection, the investigators found a 3.4-fold increase in protein carbortylation compared with that in the contralateral striatum in wild-type mice; in knockout mice, the investigators found a twofold increase. The mean malondialdehyde concentration in injected striata was increased twofold in wild-type mice at this time, compared with 1.5-fold in knockout mice. Cell viability, as determined by NITT reduction, was reduced in injected striata to 38 +/- 4% of that in the contralateral striata in wild-type mice, compared with 66 +/- 5% in HO-2 knockout mice. Baseline striatal HO-1 protein expression was similar in wild-type and HO-2 knockout mice, but was induced more rapidly in the former after blood injection. Conclusions. Deletion of HO-2 attenuates oxidative cell injury after whole-blood injection into the mouse striatum. Therapies that specifically target HO-2 may improve outcome after ICH.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA		Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg,Room 329, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042273] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042273] Funding Source: NIH RePORTER		Arthur AS, 1997, NEUROSURGERY, V41, P1385, DOI 10.1097/00006123-199712000-00028; Balla J, 2005, MOL NUTR FOOD RES, V49, P1030, DOI 10.1002/mnfr.200500076; Blumenthal SB, 2005, FASEB J, V19, P1272, DOI 10.1096/fj.04-3259com; Chang EF, 2003, J NEUROSCI, V23, P3689; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Grundemar L, 1997, TRENDS PHARMACOL SCI, V18, P193, DOI 10.1016/S0165-6147(97)01065-1; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HEINSEN H, 1994, ACTA NEUROPATHOL, V88, P320, DOI 10.1007/BF00310376; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Kress GJ, 2002, J NEUROSCI, V22, P5848; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Munoz AM, 2005, J CHEM NEUROANAT, V29, P113, DOI 10.1016/j.jchemneu.2004.10.001; Murrell M. T., 1997, Society for Neuroscience Abstracts, V23, P849; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; Ono S, 2001, ACT NEUR S, V77, P93; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Qu Y, 2005, J CEREBR BLOOD F MET, V25, P1466, DOI 10.1038/sj.jcbfm.9600143; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P51, DOI 10.1111/j.1365-2990.1980.tb00204.x; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; WEBER CM, 1994, J NEUROCHEM, V63, P953; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Yamauchi T, 2004, J NEUROTRAUM, V21, P1017, DOI 10.1089/0897715041651042	39	34	35	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2007	106	3					428	435		10.3171/jns.2007.106.3.428			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	145KV	WOS:000244864700010	17367065				2022-02-06	
J	Sherman, TE; Rapport, LJ; Hanks, RA; Ryan, KA; Keenan, PA; Khan, O; Lisak, RP				Sherman, T. E.; Rapport, L. J.; Hanks, R. A.; Ryan, K. A.; Keenan, P. A.; Khan, O.; Lisak, R. P.			Predictors of well-being among significant others of persons with multiple sclerosis	MULTIPLE SCLEROSIS			English	Article						anosognosia; awareness of deficit; caregiver; multiple sclerosis; neurobehavioral; significant other; social support; subjective well-being	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; SOCIAL SUPPORT; SHORT-FORM; CAREGIVERS; AWARENESS; IMPAIRMENT; SYMPTOMS; INDIVIDUALS; DYSFUNCTION	Objective To examine patient and significant other characteristics as predictors of significant other well-being. Methods A total of 74 persons with multiple sclerosis (MS) and their significant others participated. Executive functioning was measured using neuropsychological tests. Awareness of cognitive deficit was measured as the discrepancy between the patient's reports of their abilities and objective test results. Awareness of functional deficit was measured as the discrepancy between the patient's and significant other's reports of the patient's functional abilities. Patient neurobehavioral disturbance was measured using a significant-other rated questionnaire. Significant other perceived social support and well-being (ie, psychological distress, life satisfaction, and general health status) were assessed using questionnaires filled out by the significant other. Results Executive dysfunction, neurobehavioral disturbance, and lack of awareness of functional deficits in patients were associated with poor well-being outcomes; whereas, lack of awareness of cognitive deficits was only weakly related to well-being. Social support was associated with positive well-being outcomes. Conclusions Diminished insight regarding functional limitations may increase significant others' supervisory burden as patients attempt activities independently, whereas lack of awareness of cognitive deficits may not be directly associated with behavior-relevant impairments that significant others find distressing. Social support appears to be a powerful aid in diffusing the distress among significant others of MS patients.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Sci Oriented Solut, Kennesaw, GA 30144 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA		Sherman, TE (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA.	tsherman@dmc.org		Rapport, Lisa/0000-0001-8014-9523			Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Aronson KJ, 1997, NEUROLOGY, V48, P74, DOI 10.1212/WNL.48.1.74; BEATTY WW, 1988, ARCH NEUROL-CHICAGO, V45, P611, DOI 10.1001/archneur.1988.00520300029013; BEATTY WW, 1991, J CLIN EXP NEUROPSYC, V13, P309, DOI 10.1080/01688639108401046; Benson D.F., 1986, FRONTAL LOBES; BENTON A L, 1978, Archives of Neurology, V35, P364; BOYLE EA, 1991, ARCH NEUROL-CHICAGO, V48, P1150, DOI 10.1001/archneur.1991.00530230058022; Carone DA, 2005, J INT NEUROPSYCH SOC, V11, P574, DOI 10.1017/S135561770505068X; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Cottrell SS, 1926, J NEUROL PSYCHOPATHO, V7, P1; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; DEBETTIGNIES BH, 1990, J CLIN EXP NEUROPSYC, V12, P355, DOI 10.1080/01688639008400980; Delis D.C., 2000, CVLT 2 CALIFORNIA VE; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR., 1993, NATL COMPUTER SYSTEM; DEsposito M, 1996, NEUROPSYCHOLOGY, V10, P51, DOI 10.1037/0894-4105.10.1.51; DesRosier M B, 1992, Rehabil Nurs, V17, P87; DIENER E, 1984, J PERS SOC PSYCHOL, V47, P1105, DOI 10.1037/0022-3514.47.5.1105; Diener E., 2002, HDB POSITIVE PSYCHOL, V2, P63; ELSASS P, 1983, ACTA NEUROL SCAND, V68, P257, DOI 10.1111/j.1600-0404.1983.tb04835.x; ERGH T, 2004, P 32 ANN M INT NEUR; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Fidell L.S., 2000, USING MULTIVARIATE S; Good D M, 1995, J Neurosci Nurs, V27, P305; Goverover Y, 2005, MULT SCLER J, V11, P203, DOI 10.1191/1352458505ms1153oa; GRANT I, 1989, CURR PROB N, V10, P17; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; HEATON RK, 1993, WISCONSIN CORD SORTI; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hobart J, 2001, BRAIN, V124, P962, DOI 10.1093/brain/124.5.962; Hoogervorst ELJ, 2001, NEUROLOGY, V56, P934, DOI 10.1212/WNL.56.7.934; JUDGE T, 1990, THESIS U ILLINOIS; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; KNIGHT RG, 1992, NEUROPSYCHOLOGY DEGE; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Long KA., 1993, FAM COMMUNITY HEALTH, V16, P46, DOI 10.1097/00003727-199304000-00009; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McKeown LP, 2003, CLIN REHABIL, V17, P234, DOI 10.1191/0269215503cr618oa; Mohr DC, 2001, J CLIN PSYCHOL, V57, P479, DOI 10.1002/jclp.1042; MOHR DC, 1998, CLIN HDB HLTH PSYCHO, P313; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; O'Brien M T, 1993, J Community Health Nurs, V10, P123, DOI 10.1207/s15327655jchn1003_1; O'Brien R A, 1995, Sch Inq Nurs Pract, V9, P323; PAKENHAM KI, 2001, PSYCHOL HLTH MED, V0006, P00013, DOI DOI 10.1080/13548500125141; Paul RH, 1998, MULT SCLER, V4, P433, DOI 10.1177/135245859800400506; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Pozzilli C, 2004, MULT SCLER, V10, P442, DOI 10.1191/1352458504ms1046oa; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Provinciali L, 1999, ACTA NEUROL SCAND, V100, P156; *PSYCH CORP, 1997, WAIS 3 WMS 3 TECHN M; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1984, BRAIN COGNITION, V3, P94, DOI 10.1016/0278-2626(84)90010-1; SARASON IG, 1985, PSYCHOSOM MED, V47, P156, DOI 10.1097/00006842-198503000-00007; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SMTIH A, 1973, SYMBOL DIGIT MODALIT; Spilker B., 1996, QUALITY LIFE PHARMAC, P337; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Sugar C, 1943, J NERV MENT DIS, V98, P267, DOI 10.1097/00005053-194309000-00004; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Thornton AE, 2002, J INT NEUROPSYCH SOC, V8, P395, DOI 10.1017/S1355617702813200; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Winegarden BJ, 1998, CLIN NEUROPSYCHOL, V12, P311, DOI 10.1076/clin.12.3.311.1992; Zakzanis KK, 2000, ARCH CLIN NEUROPSYCH, V15, P115, DOI 10.1016/S0887-6177(98)00157-7; Zivadinov R, 1999, J NEUROL SCI, V168, P127, DOI 10.1016/S0022-510X(99)00189-6	76	34	34	1	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1352-4585			MULT SCLER	Mult. Scler.	MAR	2007	13	2					238	249		10.1177/1352458506070754			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	158LK	WOS:000245792800014	17439890				2022-02-06	
J	Demakis, GJ; Hammond, F; Knotts, A; Cooper, DB; Clement, P; Kennedy, J; Sawyer, T				Demakis, George J.; Hammond, Flora; Knotts, Allison; Cooper, Douglas B.; Clement, Pamelia; Kennedy, Jan; Sawyer, Tom			The Personality Assessment Inventory in individuals with traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Personality Assessment Inventory; Traumatic Brain Injury; psychometric research	HEAD-INJURY; MMPI-2; SCALE; VALIDITY	This study examined the Personality Assessment Inventory (PAI) in 95 individuals who had suffered a traumatic brain injury (TBI). Participants were recruited from a rehabilitation hospital (n=60) and a military hospital (n=35); despite differences in demographics and injury characteristics groups did not differ on any of the clinical scales and were thus combined. In the combined group, the highest mean clinical scale elevations were on Somatic Complaints, Depression, and Borderline Features and the most common configural profiles, based on cluster analysis, were Cluster I (no prominent elevations), Cluster 6 (social isolation and confused thinking), and Cluster 2 (depression and withdrawal). Factor analysis indicated a robust three-factor solution that accounted for 74.86 percent of the variance and was similar to findings from the psychiatric and non-psychiatric populations in the standardization sample. The above findings are compared with the previous literature on psychopathology in TBI, particularly in regards to the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), as well as previous psychometric research on the PAI. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ N Carolina, Charlotte, NC 28223 USA; Charlotte Inst Rehabil, Charlotte, NC USA; Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA; Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA		Demakis, GJ (corresponding author), Univ N Carolina, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	gdemakis@email.uncc.edu					Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Caperton JD, 2004, PSYCHOL ASSESSMENT, V16, P187, DOI 10.1037/1040-3590.16.2.187; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; Cureton E, 1983, FACTOR ANAL APPL APP; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; DEISINGER JA, 1995, ASSESSMENT, V0002, P00173, DOI DOI 10.1177/107319119500200207; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Kellogg SH, 2002, J PERS ASSESS, V79, P73, DOI 10.1207/S15327752JPA7901_05; KOSCHAT MA, 1991, PSYCHOMETRIKA, V56, P229, DOI 10.1007/BF02294460; Lally SJ, 2003, PROF PSYCHOL-RES PR, V34, P491, DOI 10.1037/0735-7028.34.5.491; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Morey, 1991, PERSONALITY ASSESSME; Morey LC, 1998, ASSESSMENT, V5, P203, DOI 10.1177/107319119800500301; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; Parker JD, 1999, PSYCHOL ASSESSMENT, V11, P507, DOI 10.1037/1040-3590.11.4.507; Piotrowski C, 2000, PSYCHOL REP, V86, P65, DOI 10.2466/PR0.86.1.65-66; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Ruiz MA, 2002, ASSESSMENT, V9, P261, DOI 10.1177/1073191102009003005; Tasca GA, 2002, J PERS ASSESS, V79, P337, DOI 10.1207/S15327752JPA7902_14; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	22	34	34	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					123	130		10.1016/j.acn.2006.09.004			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	144RV	WOS:000244814700014	17182214	Bronze			2022-02-06	
J	Fletcher, AE; Khalid, S; Mallonee, S				Fletcher, Amy E.; Khalid, Sumera; Mallonee, Sue			The epidemiology of severe traumatic brain injury among persons 65 years of age and older in Oklahoma, 1992-2003	BRAIN INJURY			English	Article						traumatic brain injury; injury epidemiology; elderly injury; injury surveillance	FALLS; MORTALITY	Primary objective: To describe the epidemiology of traumatic brain injury ( TBI) among persons 65 years of age and older in Oklahoma from 1992 - 2003. Research design: Descriptive epidemiology of data collected through active statewide surveillance on TBI inpatient hospitalizations and fatalities. Methods and procedures: Data collected from hospital medical records and the Office of the Chief Medical Examiner. TBI was defined by ICD- 9- CM codes for skull fracture 800.0 - 801.9, 803.0 - 804.9, concussion or other intracranial injury 850.0 - 854.1 and head injury, unspecified 959.01; all cases included a description of TBI. Main outcome and results: TBI rates increased 79% for the study population; however, case- fatality rates decreased from 32% in 1992 to 18% in 2003. The TBI rate increase was observed among all elderly age groups, both genders and all races. Unintentional injuries nearly doubled while both assault and self- inflicted injuries decreased. Fall- related TBI increased by 126%, while MVC- related TBI increased by 17%. Survivors were hospitalized for an average of 6.8 days and over half required post- acute care. Conclusions: The increased TBI rate and decreased case- fatality rate among elderly persons means potentially more persons living with TBI disability. TBI prevention efforts among the elderly must be expanded, especially for fall- related TBI.	Oklahoma Dept Hlth, Oklahoma City, OK 73117 USA		Fletcher, AE (corresponding author), Oklahoma Dept Hlth, 1000 NE 10th St, Oklahoma City, OK 73117 USA.	amyt@health.ok.gov					Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P276; *CDCP NAT CTR HLTH, 2004, US CENS POP BRIDG RA; *CDCP NAT CTR INJ, 2006, WEB BAS INJ STAT QUE; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cox E, 2001, WMJ, V100, P39; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fuller GF, 2000, AM FAM PHYSICIAN, V61, P2159; Goleburn CR, 2001, J CLIN GEROPSYCHOL, V7, P161; Gunnell D, 2003, SOC SCI MED, V57, P595, DOI 10.1016/S0277-9536(02)00408-2; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 2000, ARCH INTERN MED, V160, P2145, DOI 10.1001/archinte.160.14.2145; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lin Julie T, 2005, Phys Med Rehabil Clin N Am, V16, P109, DOI 10.1016/j.pmr.2004.06.005; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Schootman M, 2000, J TRAUMA, V48, P70, DOI 10.1097/00005373-200001000-00012; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Stevens JA, 2001, JAMA-J AM MED ASSOC, V286, P2665, DOI 10.1001/jama.286.21.2665; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; WENDLING T, 2004, SUMMARY REPORTABLE I; 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X	33	34	37	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	7					691	699		10.1080/02699050701426873			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400005	17653943				2022-02-06	
J	Goddeau, RP; Silverman, SB; Sims, JR				Goddeau, Richard P., Jr.; Silverman, Scott B.; Sims, John R.			Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia	NEUROCRITICAL CARE			English	Article						dexmedetomidine; sympathetic storming; paroxysmal autonomic instability with dystonia; diencephalic seizure; dysautonomia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DIENCEPHALIC SEIZURES; SYMPATHETIC STORM; DYSAUTONOMIA; STIMULATION; LABETALOL; INFUSION	Introduction A 38-year-old man with severe head trauma complicated by paroxysmal severe intracranial pressure elevation associated with tachypnea, tachycardia, diaphoresis, and extensor posturing was diagnosed as suffering from paroxysmal autonomic instability with dystonia (PAID). These events were unresponsive to standard medical therapy, which included morphine, fentanyl, labetalol, lorazepam, metoprolol, and clonidine. Methods A trial treatment with dexmedetomidine dine, a central acting alpha2-agonist, to control symptoms of PAID was initiated 12 days after injury. PAID-related events subsided during the 72-h infusion protocol of 0.2-0.7 mcg/kg/h. No further events were noted after termination of the 72-h infusion. Conclusions Dexmedetomidine may be a novel pharmacologic agent to aid in abrogating PAID.	Massachusetts Gen Hosp East, Dept Neurol & Radiol, Div Neurocrit Care & Stroke, Boston, MA 02129 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA; Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, Div Neucrit Care & Stroke, Boston, MA USA		Sims, JR (corresponding author), Massachusetts Gen Hosp East, Dept Neurol & Radiol, Div Neurocrit Care & Stroke, CNY149 Rm6403, Boston, MA 02129 USA.	jsims@partners.org					Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Bernath O, 2001, J NEUROL NEUROSUR PS, V70, P818, DOI 10.1136/jnnp.70.6.818; Bicer C, 2006, EUR J ANAESTH, V23, P149, DOI 10.1017/S0265021505002061; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Diamond AL, 2005, NEUROCRIT CARE, V2, P288, DOI 10.1385/NCC:2:3:288; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Eltorai I M, 1997, J Spinal Cord Med, V20, P361; Feld J, 2007, J CLIN ANESTH, V19, P30, DOI 10.1016/j.jclinane.2006.05.019; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Goh KYC, 1999, PEDIATR NEUROL, V21, P742, DOI 10.1016/S0887-8994(99)00069-7; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Hogue CW, 2002, ANESTHESIOLOGY, V97, P592, DOI 10.1097/00000542-200209000-00012; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Oppenheimer SM, 1996, CLIN AUTON RES, V6, P131, DOI 10.1007/BF02281899; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Swissa M, 2004, J AM COLL CARDIOL, V43, P858, DOI 10.1016/j.jacc.2003.07.053; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Watt JA, 1999, J NEUROSCI, V19, P1586; Zhou SM, 2004, J CARDIOVASC ELECTR, V15, P430, DOI 10.1046/j.1540-8167.2004.03517.x	23	34	35	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care		2007	7	3					217	220		10.1007/s12028-007-0066-0			4	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	237SO	WOS:000251396900006	17603760				2022-02-06	
J	Pickett, TC; Radfar-Baublitz, LS; McDonald, SD; Walker, WC; Cifu, DX				Pickett, Treven C.; Radfar-Baublitz, Laleh S.; McDonald, Scott D.; Walker, William C.; Cifu, David X.			Objectively assessing balance deficits after TBI: Role of computerized posturography	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						assessment; balance; computerized posturography; mobility; posttraumatic amnesia; postural instability; rehabilitation; traumatic brain injury; vestibular dysfunction; visual cues	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; MULTICENTER ANALYSIS; POSTURAL STABILITY; REHABILITATION; CONCUSSION; STRENGTH; GAIT; SWAY	Balance impairment, or postural instability, is a common source of residual physical disability after severe traumatic brain injury (TBI). Standardized functional measures such as the Functional Independence Measure (FIM) do not specifically assess balance. Furthermore, no agreement exists as to the optimal way to objectively measure balance problems in the TBI population. Technological advances have led to force-plate balance measurement known as computerized posturography testing (CPT). Published CPT data for severe TBI are lacking, and the feasibility of using CPT during rehabilitation has not been described. This study described CPT findings in 21 ambulatory patients with severe TBI who were undergoing inpatient rehabilitation at a Defense and Veterans Brain Injury Center. Results demonstrated the utility of CPT in detecting and quantifying postural instability. Comparisons with the normative database indicate that the sample had a high degree of balance impairment despite some participants having reached the ceiling of the FIM ambulation scale at discharge from the acute rehabilitation setting. The quantitative CPT measures are a promising way to characterize postural instability in severe TBI populations.	[Pickett, Treven C.; McDonald, Scott D.; Cifu, David X.] Vet Adm Med Ctr, Hunter Holmes McGuire Dept, Polytrauma Rehabil Ctr, Mental Hlth Serv Line, Richmond, VA 23249 USA; [Pickett, Treven C.; Walker, William C.; Cifu, David X.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Pickett, Treven C.; Radfar-Baublitz, Laleh S.; Walker, William C.; Cifu, David X.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA		Pickett, TC (corresponding author), Vet Adm Med Ctr, Hunter Holmes McGuire Dept, Polytrauma Rehabil Ctr, Mental Hlth Serv Line, 1201 Broad Rock Blvd,116B, Richmond, VA 23249 USA.	Treven.Pickett@va.gov	Walker, William C/N-3162-2014	Cifu, David/0000-0003-1600-9387			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERG K, 1992, CAN J PUBLIC HLTH, V83, P7; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Black FO, 2001, CURR OPIN OTOLARYNGO, V9, P314, DOI DOI 10.1097/00020840-200110000-00011; CHOI SC, 1996, NEUROTRAUMA, P779; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hillier SL, 1997, BRAIN INJURY, V11, P661; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Nallegowda M, 2004, AM J PHYS MED REHAB, V83, P898, DOI 10.1097/01.PHM.0000146505.18244.43; *NEUROCOM INT INC, 1993, OBJ QUANT BAL MOB; NeuroCom International Inc, 1993, BAL MAST OP MAN; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SALAZAR AM, 1999, BRAIN INJ SOURCE, V3, P8; TEASDALE G, 1974, LANCET, V2, P81; Whyte J., 1998, REHABILITATION MED P; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; [No title captured]	28	34	35	2	10	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					983	989		10.1682/JRRD.2007.01.0001			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	253NL	WOS:000252524800011	18075955	Bronze			2022-02-06	
S	Sharma, HS; Patnaik, R; Patnaik, S; Mohanty, S; Sharma, A; Vannemreddy, P		Slikker, W; Andrew, RJ; Trembly, B		Sharma, H. S.; Patnaik, R.; Patnaik, S.; Mohanty, S.; Sharma, A.; Vannemreddy, P.			Antibodies to serotonin attenuate closed head injury induced blood-brain barrier disruption and brain pathology	NEUROPROTECTIVE AGENTS: EIGHTH INTERNATIONAL NEUROPROTECTION SOCIETY MEETING	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	8th International Conference on Neuroprotective Agents	SEP 18-20, 2006	Mackinac Isl, MI	Int Neuroprotect Soc		closed head injury; serotonin; brain edema; blood-brain barrier; brain damage; antibodies to serotonin; neuroprotection	RAT SPINAL-CORD; TERM IMMOBILIZATION STRESS; EXPERIMENTAL ANIMAL-MODELS; INDUCED EDEMA FORMATION; TOPICAL APPLICATION; NITRIC-OXIDE; CELL CHANGES; MICROVASCULAR PERMEABILITY; YOUNG-RATS; TRAUMA	Closed head injury (CHI) often results in profound brain swelling and instant death of the victims due to compression of the vital centers. However, the neurochemical basis of edema formation in CHI is still obscure. Previous studies from our laboratory show that blockade of serotonin synthesis prior to CHI in a rat model attenuates brain edema, indicating a prominent role for serotonin in head injury. Thus, neutralization of endogenous serotonin activity and/or blocking of its receptors will induce neuroprotection in CHI. Since serotonin has more than 14 receptors and selective serotonin antagonists are still not available, we used serotonin antiserum to neutralize its in vivo effects before or after CHI in a rat model. CHI was produced by an impact of 0.224 N on the right parietal skull bone under Equithesin anesthesia by dropping a weight of 114.6g from a height of 20 cm through a guide tube. This concussive brain injury resulted in blood-brain barrier (131313) disruption, brain edema formation, and volume swelling at 5 h that were most pronounced in the contralateral cerebral hemisphere. The plasma and brain serotonin levels were increased several-fold at this time. Intracere-broventricular administration of serotonin antiserum (1:20, monoclonal) into the left lateral cerebral ventricle (30 mu L in PBS) 30 min before or 30 min (but not 60 min) after CHI significantly attenuated BBB disruption, brain edema formation, volume swelling, and brain pathology. The plasma and brain serotonin levels continued to remain high. These observations are the first to suggest that antiserum to serotonin when administered into the CSF during the early phase of CHI are capable of inducing neuroprotection.	[Sharma, H. S.; Sharma, A.; Vannemreddy, P.] Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care, Uppsala, Sweden; [Patnaik, R.] Banaras Hindu Univ, Dept Biomed Engn, Varanasi 221005, Uttar Pradesh, India; [Patnaik, S.] Banaras Hindu Univ, Dept Pharm, Inst Technol, Varanasi 221005, Uttar Pradesh, India; [Mohanty, S.] Banaras Hindu Univ, Inst Med Sci, Dept Neurosurg, Varanasi 221005, Uttar Pradesh, India		Sharma, HS (corresponding author), Frodingsgatan 12 28, SE-75421 Uppsala, Sweden.	Sharma@surgsci.uu.se	Patnaik, Ranjana/D-1469-2017; Patnaik, Ranjana/AAZ-4440-2020; Sharma, Aruna/D-4430-2011	Patnaik, Ranjana/0000-0002-8131-177X; Patnaik, Ranjana/0000-0002-8131-177X; 			Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; DEY P K, 1984, Indian Journal of Physiology and Pharmacology, V28, P177; DEY PK, 1983, INDIAN J MED RES, V77, P554; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; Gong Y, 2006, ACTA NEUROCHIR SUPPL, V96, P232; Kroesen BJ, 1998, ADV DRUG DELIVER REV, V31, P105, DOI 10.1016/S0169-409X(97)00096-3; Lesch KP, 2005, HANDB EXP PHARM, V169, P71; MILLER T, 1994, CSN INJURY DATA CHIL; MOHANTY S, 1985, BRAIN OEDEMA, P25; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; RAPOPORT SI, 1976, BLOOD BRAIN BARRIER, P1; RUAN JS, 1994, THESIS WAYNE STATE U, P1; SALZMAN SK, 1994, J PHARMACOL EXP THER, V269, P322; SALZMAN SK, 1991, ANN NEUROL, V30, P533, DOI 10.1002/ana.410300405; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P309; Sharma H. S., 2000, CURRENT DRUGS, P28; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Sharma HS, 1996, ADV BEHAV BIOL, V46, P117; SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R; SHARMA HS, 1990, BRAIN RES, V517, P215, DOI 10.1016/0006-8993(90)91029-G; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2003, ACT NEUR S, V86, P407; Sharma HS, 2002, AMINO ACIDS, V23, P261, DOI 10.1007/s00726-001-0137-z; Sharma HS, 1995, PROG BRAIN RES, V104, P401; SHARMA HS, 1989, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1988, P317; SHARMA HS, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P147; Sharma HS, 1995, NEW CONCEPTS OF A BLOOD-BRAIN BARRIER, P75; Sharma HS, 1997, ACT NEUR S, V70, P155; Sharma HS, 2000, ACT NEUR S, V76, P91; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1994, ACTA NEUROCHIR, P65; SHARMA HS, 1988, NEUROSCI RES, V5, P224, DOI 10.1016/0168-0102(88)90051-X; Sharma HS, 1996, BEHAV BRAIN RES, V72, P189; Sharma HS, 1999, ACTA U UPSAL, V830, P1; Sharma HS, 1982, THESIS BANARAS HINDU, P1; SHARMA HS, 2005, SOLICITED CONTRIBU S, V23, P1; SHATTIL SJ, 1992, IMMUNOMETHODS, V1, P53; TAUB R, 1989, J BIOL CHEM, V264, P259; TEITLER M, 1994, CRIT REV NEUROBIOL, V8, P175; THURMAN DJ, 1994, TRAUMATIC BRAIN INJU; Vannemreddy P, 2006, ACTA NEUROCHIR SUPPL, V96, P151; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; Westman, 2004, BLOOD SPINAL CORD BR, P117	50	34	36	1	12	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-685-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2007	1122						295	312		10.1196/annals.1403.022			18	Multidisciplinary Sciences; Neurosciences; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BHD20	WOS:000252267100022	18077582				2022-02-06	
J	Sundstrom, A; Nilsson, LG; Cruts, M; Adolfsson, R; Van Broeckhoven, C; Nyberg, L				Sundstroem, A.; Nilsson, L.-G.; Cruts, M.; Adolfsson, R.; Van Broeckhoven, C.; Nyberg, L.			Fatigue before and after mild traumatic brain injury: Pre-post-injury comparisons in relation to Apolipoprotein E	BRAIN INJURY			English	Article						mild head injury; fatigue; Apolipoprotein E; pre-injury	HEAD-INJURY; PATIENT COMPLAINTS; PROSPECTIVE COHORT; FOOTBALL PLAYERS; E POLYMORPHISM; APOE GENOTYPE; E EPSILON-4; RECOVERY; CONCUSSION; ASSOCIATION	Primary objective: To assess the incidence of fatigue for persons following a mild traumatic brain injury (MTBI) and to evaluate the relationship between fatigue and APOE genotype. As fatigue is often found to be influenced by anxiety, depression and sleep disturbance, these factors were also measured. Methods and procedures: Thirty-one persons who sustained a MTBI were drawn from a population-based longitudinal study. Each person who sustained a MTBI was matched by age, gender, education and APOE genotype with two non-head injury controls. Self-reported pre- and post-injury incidence of fatigue, anxiety, depression and sleep disturbance was compared within-group and between groups. Results: For the MTBI group, incidence of fatigue was almost twice as common post- than pre-injury, whereas there was no corresponding change in a non-injured control group. Within the MTBI-group, post-injury fatigue was particularly common for carriers of the APOE epsilon 4 allele. Conclusions: Fatigue is common sequela after a MTBI and especially pronounced for carriers of the APOE epsilon 4 allele.	Umea Univ, Dept Psychol, S-90187 Umea, Sweden; Stockholm Univ, Dept Psychol, Stockholm, Sweden; Univ Antwerp VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; Umea Univ, Dept Radiat Sci Diagnost Radiol, S-90187 Umea, Sweden; Umea Univ, Physiol Sect, S-90187 Umea, Sweden		Sundstrom, A (corresponding author), Umea Univ, Dept Psychol, S-90187 Umea, Sweden.	anna.sundstrom@psy.umu.se	Van Broeckhoven, Christine/G-8362-2017; Nyberg, Lars/C-2514-2009; Nyberg, Lars/M-5986-2019; Cruts, Marc/J-6161-2013; Van Broeckhoven, Christine/M-7853-2019	Van Broeckhoven, Christine/0000-0003-0183-7665; Nyberg, Lars/0000-0002-3367-1746; Nyberg, Lars/0000-0002-3367-1746; Cruts, Marc/0000-0002-1338-992X; Van Broeckhoven, Christine/0000-0003-0183-7665; Adolfsson, Rolf/0000-0001-9785-8473			Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corwin Elizabeth J, 2002, Biol Res Nurs, V3, P222, DOI 10.1177/109980040200300407; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; EVENS RW, 1992, NEUROL CLIN, V10, P815; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gerberding J.L., 2003, C MILD TRAUM BRAIN I; GROOT MH, 2003, ARCH PHYS MED REHAB, V84, P1714; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Loge JH, 1998, J PSYCHOSOM RES, V45, P53, DOI 10.1016/S0022-3999(97)00291-2; LOGE JH, 2003, EUROPEAN J PALLI S14, V10; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V412, P611; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Nilsson LG, 1997, AGING NEUROPSYCHOL C, V4, P1, DOI 10.1080/13825589708256633; Nilsson LG, 2004, AGING NEUROPSYCHOL C, V11, P134, DOI 10.1080/13825580490511026; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; van der Linden G, 1999, PSYCHOL MED, V29, P863, DOI 10.1017/S0033291799008697; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Werf SP, 2001, EUR NEUROL, V45, P28, DOI 10.1159/000052085; WENHAM PR, 1991, CLIN CHEM, V37, P241; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	45	34	35	1	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1049	1054		10.1080/02699050701630367			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600007	17891567				2022-02-06	
J	Turner-Stokes, L				Turner-Stokes, Lynne			Cost-efficiency of longer-stay rehabilitation programmes: Can they provide value for money?	BRAIN INJURY			English	Article						rehabilitation; outcome measurement; dependency; cost-efficiency; brain injury	TRAUMATIC BRAIN-INJURY; NEEDS-ASSESSMENT NPCNA; INPATIENT REHABILITATION; CARE NEEDS; PREDICTION; DEPENDENCY; OUTCOMES; STROKE; SCORE	Purpose: To examine the cost-efficiency of longer stay rehabilitation in patients with complex neurological disabilities. Methods: Longitudinal cohort analysis of consecutive admissions to a specialized in-patient rehabilitation unit. Selection criteria: patients who were highly dependent on admission (NPDS >= 25) and had a length of stay> 125 days. Serial changes in dependency and care costs were measured by the Northwick Park Dependency and Care Needs Assessment (NPDS/ NPCNA), which provides a generic estimation of dependency, care hours and weekly cost of continuing care in the community. Results: Of 410 admissions over 5 years, 51 met the case-selection criteria - mean age 39 +/- 17 years, male: female ratio 2:1. The mean length of stay (LOS) was 184 +/- 56 days (max 312). Between 4 months and discharge ( mean 58 +/- 56 days later) significant changes were seen in dependency ( t = 4.8, p< 0.0001) and care costs ( t = 2.0, p< 0.05). The mean additional cost of rehabilitation beyond 4 months ( pound 16 766 +/- 17 334) would be offset by the mean weekly savings in cost of care within 36 months. The two cases who stayed> 300 days are presented in more detail. Conclusions: The additional investment in longer-stay rehabilitation in this group of complex patients was offset relatively quickly by long-term savings in the cost of care.	Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, Harrow HA1 3UJ, Middx, England; Kings Coll London, Sch Med, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England		Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, Watford Rd, Harrow HA1 3UJ, Middx, England.	lynne.turner-stokes@dial.pipex.com	Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462			Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; HEDRICK WP, 1995, BRAIN INJURY, V9, P563, DOI 10.3109/02699059509008215; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Nyein K, 1999, CLIN REHABIL, V13, P482, DOI 10.1191/026921599674590637; Nyein K, 1999, CLIN REHABIL, V13, P56, DOI 10.1191/026921599701532135; Rusconi S, 2003, DISABIL REHABIL, V25, P1281, DOI 10.1080/09638280310001608582; SLADE A, 1999, CLIN REHABIL, V13, P80; Stineman MG, 1997, STROKE, V28, P550, DOI 10.1161/01.STR.28.3.550; Turner-Stokes L, 2006, J NEUROL NEUROSUR PS, V77, P634, DOI 10.1136/jnnp.2005.073411; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 1999, CLIN REHABIL, V13, P253, DOI 10.1191/026921599677787870; Turner-Stokes L, 1998, CLIN REHABIL, V12, P304, DOI 10.1191/026921598669173600; TURNERSTOKES L, 2007, IN PRESS CLIN MED; TURNERSTOKES L, 2005, COCHRANE DATABASE SY; TURNERSTOKES L, 1999, CLIN REHABILITATIO S, V13	18	34	38	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1015	1021		10.1080/02699050701591445			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600003	17891563				2022-02-06	
J	Durham, SR; Liu, KC; Selden, NR				Durham, Susan R.; Liu, Kenneth C.; Selden, Nathan R.			Utility of serial computed tomography imaging in pediatric patients with head trauma	JOURNAL OF NEUROSURGERY			English	Article						brain injury; trauma; computed tomography; pediatric neurosurgery	BRAIN-INJURY; CT; CHILDREN; SCAN	Object. The purpose of this study was to evaluate the risk of progression of traumatic intracranial lesions in children by comparing initial and subsequent computed tomography (CT) scans. Reserving repeated CT imaging for patients who harbor higher-risk lesions may reduce overall radiation exposure, the need for sedative agents, and cost. Methods. The authors performed a retrospective cohort study in 268 patients younger than 18 years of age who underwent repeated CT scanning within 24 hours of their initial CT scanning procedure. The risk of progression between the initial and repeated CT scanning sessions and the need for delayed neurosurgical intervention were, determined for each lesion type. In 54 patients (20.1%) the normal findings on the initial CT study did not change on subsequent imaging. In 61 (28.5%) of the 214 patients in whom abnormal findings were present on the initial scan, progression was demonstrated. Patients with epidural hematoma (EDH; odds ratio [OR] 12.29), subdural hematoma (SDH; OR 3.18), cerebral edema (OR 9.34), and intraparenchymal hemorrhage (IPH; OR 18.3) were found to be at a significantly increased risk for progression and to require delayed neurosurgical intervention (OR 11.91). No significantly increased risk was found for patients with subarachnoid hemorrhage (SAH), intraventricular hemorrhage (IVH), diffuse axonal injury (DAI), or skull fracture. Conclusions. Repeated CT imaging in children with high-risk lesions such as EDH, SDH, cerebral edema, and IPH is recommended. However, in children with low-risk lesions, such as SAH, IVH, DAI, and isolated skull fractures but no sign of clinical deterioration, repeated imaging may be less likely to alter the clinical management scheme. The limited benefits of undertaking repeated imaging in these patients should be weighed against the risks of radiation exposure, sedation, intrahospital transportation, and patient monitoring.	Oregon Hlth & Sci Univ, Doernbecher Childrens HOsp, Div Pediat Neurosurg, Dept Neurol Surg, Portland, OR 97201 USA; Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Dept Surg Pediat Neurosurg, Lebanon, NH USA		Durham, SR (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03766 USA.	srd@hitchcock.org		Selden, Nathan/0000-0001-6108-9721			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS5; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Donnelly LF, 2001, PEDIATR RADIOL, V31, P388, DOI 10.1007/s002470100479; ELSNER H, 1990, J NEUROSURG, V72, P813, DOI 10.3171/jns.1990.72.5.0813; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; HURST JM, 1992, J TRAUMA, V33, P582, DOI 10.1097/00005373-199210000-00015; JAIMOVICH R, 1992, PEDIATR NEUROSURG, V17, P25, DOI 10.1159/000120562; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Paterson A, 2001, AM J ROENTGENOL, V176, P297, DOI 10.2214/ajr.176.2.1760297; POON WS, 1992, NEUROSURGERY, V30, P681; Schuster R, 2005, AM SURGEON, V71, P701; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; VANE DW, 1995, J TRAUMA, V38, P867, DOI 10.1097/00005373-199506000-00006	19	34	34	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2006	105	5		S			365	369		10.3171/ped.2006.105.5.365			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	102HC	WOS:000241800600007	17328259				2022-02-06	
J	Sury, MD; Frese-Schaper, M; Muhlemann, MK; Schulthess, FT; Blasig, IE; Tauber, MG; Shaw, SG; Christen, S				Sury, Matthias D.; Frese-Schaper, Manuela; Muhlemann, Miranda K.; Schulthess, Fabienne T.; Blasig, Ingolf E.; Tauber, Martin G.; Shaw, Sidney G.; Christen, Stephan			Evidence that N-acetylcysteine inhibits TNF-alpha-induced cerebrovascular endothelin-1 upregulation via inhibition of mitogen- and stress-activated protein kinase	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						nuclear factor kappa B; reactive oxygen species; cerebral blood flow; nitric oxide	FACTOR-KAPPA-B; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; BACTERIAL-MENINGITIS; TRANSCRIPTIONAL ACTIVITY; INDUCED PHOSPHORYLATION; CEREBROSPINAL-FLUID; OXIDATIVE STRESS	N-Acetylcysteine (NAC) is neuroprotective in animal models of acute brain injury such as caused by bacterial meningitis. However, the mechanism(s) by which NAC exerts neuroprotection is unclear. Gene expression of endothelia-1 (ET-1), which contributes to cerebral blood flow decline in acute brain injury, is partially regulated by reactive oxygen species, and thus a potential target of NAC. We therefore examined the effect of NAC on tumor necrosis factor (TNF)-alpha-induced ET-1 production in cerebrovascular endothelial cells. NAC dose dependently inhibited TNF-alpha-induced preproET-1 mRNA upregulation and ET-1 protein secretion, while upregulation of inducible nitric oxide synthase (iNOS) was unaffected. Intriguingly, NAC had no effect on the initial activation (i.e., 11513 degradation, nuclear p65 translocation, and Ser536 phosphorylation) of NF-kappa B by TNF-alpha. However, transient inhibition of NF-kappa B DNA binding suggested that NAC may inhibit ET-1 upregulation by inhibiting (a) parallel pathway(s) necessary for full transcriptional activation of NF-kappa B-mediated ET-1 gene expression. Similar to NAC, the MEK1/2 inhibitor U0126, the p38 inhibitor SB203580, and the protein kinase inhibitor H-89 selectively inhibited ET-1 upregulation without affecting nuclear p65 translocation, suggesting that NAC inhibits ET-1 upregulation via inhibition of mitogen- and stress-activated protein kinase (MSK). Supporting this notion, cotreatment with NAC inhibited the TNF-alpha-induced rise in MSK1 and MSK2 kinase activity, while siRNA knock-down experiments showed that MSK2 is the predominant isoform involved in TNF-alpha-induced ET-1 upregulation. (c) 2006 Elsevier Inc. All rights reserved.	Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland; Inst Mol Pharmacol, Berlin, Germany; Univ Bern, Dept Clin Res, CH-3012 Bern, Switzerland		Christen, S (corresponding author), Univ Bern, Inst Infect Dis, Friedbuehlstr 51, CH-3010 Bern, Switzerland.	stephan.christen@ifik.unibe.ch	Christen, Stephan/B-8602-2009; Kummer, Juerg/B-3322-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033997] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS33997] Funding Source: Medline		Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Auer M, 2000, J INFECT DIS, V182, P347, DOI 10.1086/315658; Bedford H, 2001, BRIT MED J, V323, P533, DOI 10.1136/bmj.323.7312.533; Blasig IE, 2001, MICROVASC RES, V62, P114, DOI 10.1006/mvre.2001.2318; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Christen S, 2001, FREE RADICAL BIO MED, V31, P754, DOI 10.1016/S0891-5849(01)00642-6; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Faraci FM, 1998, PHYSIOL REV, V78, P53, DOI 10.1152/physrev.1998.78.1.53; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Koedel U, 1997, NEUROSCI LETT, V225, P33, DOI 10.1016/S0304-3940(97)00177-8; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Leib SL, 1998, J INFECT DIS, V177, P692, DOI 10.1086/514226; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; Merkelbach S, 2000, ACTA NEUROL SCAND, V102, P118, DOI 10.1034/j.1600-0404.2000.102002118.x; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Modanlou HD, 1996, CAN J PHYSIOL PHARM, V74, P368, DOI 10.1139/cjpp-74-4-368; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ohkita M, 2002, JPN J PHARMACOL, V88, P197, DOI 10.1254/jjp.88.197; Ohkita M, 2002, JPN J PHARMACOL, V89, P81, DOI 10.1254/jjp.89.81; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; PFISTER HW, 1992, STROKE, V23, P1798, DOI 10.1161/01.STR.23.12.1798; Pfister LA, 2000, ANN NEUROL, V47, P329, DOI 10.1002/1531-8249(200003)47:3<329::AID-ANA8>3.0.CO;2-R; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Rossi GP, 2001, INT REV CYTOL, V209, P241; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Schaper M, 2002, J NEUROPATH EXP NEUR, V61, P605, DOI 10.1093/jnen/61.7.605; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schubert SY, 2002, FASEB J, V16, P1931, DOI 10.1096/fj.02-0147fje; Shaw SG, 2000, ANAL BIOCHEM, V278, P143, DOI 10.1006/abio.1999.4451; Sibson NR, 2002, BRAIN, V125, P2446, DOI 10.1093/brain/awf256; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TUREEN J, 1995, J CLIN INVEST, V95, P1086, DOI 10.1172/JCI117755; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Woods M, 2003, MOL PHARMACOL, V64, P923, DOI 10.1124/mol.64.4.923; Xu J, 1997, BIOCHEM BIOPH RES CO, V235, P394, DOI 10.1006/bbrc.1997.6800; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	57	34	35	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	NOV 1	2006	41	9					1372	1383		10.1016/j.freeradbiomed.2006.07.016			12	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	097CM	WOS:000241424000003	17023264				2022-02-06	
J	Bigler, ED; Ryser, DK; Gandhi, P; Kimball, J; Wilde, EA				Bigler, Erin D.; Ryser, David K.; Gandhi, Partha; Kimball, Jordan; Wilde, Elisabeth A.			Day-of-injury computerized tomography, rehabilitation status, and development of cerebral atrophy in persons with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; computerized tomography; magnetic resonance imaging; disability rating scale; FIM; rehabilitation outcome	SEVERE HEAD-INJURY; PROGNOSTIC VALUE; AXONAL INJURY; STEM LESIONS; COMA; MRI; CT; CLASSIFICATION; PREDICTION; SCAN	Objective: To compare day-of-injury (DOI) computerized tomography (CT) findings with acute injury severity markers, disability at acute hospital admission and discharge from inpatient rehabilitation, injury severity markers, and degree of postacute cerebral atrophy on magnetic resonance imaging (MRI). Design: Retrospective chart review of 240 consecutive traumatic brain injury (TBI) admissions (mean age 31.7 +/- 15.8 yrs) with moderate-to-severe initial brain injury. All DOI CT abnormalities were qualitatively rated. Disability was assessed using the Disability Rating Scale (DRS) and the FIM measure. In a representative subset, cerebral atrophy was determined by the ventricle-to-brain ratio (VBR) method and quantified from MRI scans 25 or more days postinjury. Results: CT classification resulted in nonsignificant differences in DRS and FIM ratings at the time of discharge from the rehabilitation unit, except in brainstem injury subjects who had significantly higher DRS and lower FIM scores at rehabilitation discharge. At 25 or more days postinjury, presence of any DOI CT abnormality was associated with larger VBR. Increased VBR, as an index of cerebral atrophy, was associated with worse rehabilitation discharge DRS and FIM ratings. Conclusions: Other than brainstem injury, DOI CT findings relate poorly to rehabilitation outcome. Presence of DOI CT abnormalities were associated with the development of cerebral atrophy, which was associated with poorer rehabilitation discharge DRS and FIM scores.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; LDS Hosp, Neuro Specialty Rehabil Unit, Salt Lake City, UT USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 Spencer W Kimball Tower, Provo, UT 84602 USA.						Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BOWEN JM, 1997, DEV MED CHILD NEUROL, P39; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DUNCAN PW, 1990, REHABILITATION ADULT; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; *FIM, 1990, UN DAT SET MED REHB; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gean AD, 1994, IMAGING HEAD TRAUMA; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hamilton BB, 1987, REHABILITATION OUTCO; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Herzog T, 1996, RES METHODS SOCIAL S; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN JR, 1989, AM STATISTICIAN, V43; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Wedekind C, 2002, MUSCLE NERVE, V26, P270, DOI 10.1002/mus.10187; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	61	34	34	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	2006	85	10					793	806		10.1097/01.phm.0000237873.26250.e1			14	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	089JD	WOS:000240875700002	16998426				2022-02-06	
J	Hessen, E; Nestvold, K; Sundet, K				Hessen, Erik; Nestvold, Knut; Sundet, Kjetil			Neuropsychological function in a group of patients 25 years after sustaining minor head injuries as children and adolescents	SCANDINAVIAN JOURNAL OF PSYCHOLOGY			English	Article						mild head injury; cognitive deficits; neuropsychological impairment	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; MILD; CHILDHOOD	Previous studies suggest that neuropsychological impairment following mild to moderate pediatric head injury may become persistent and interrupt the normal course of intellectual development. In this study 45 subjects were assessed with a standardized neuropsychological test battery 25 years after sustaining mild to moderate head injury as children. Although the group scores in the normal range, significant relations between head injury severity and current neuropsychological function were found. The most important predictor of poor outcome was length of PTA at injury, EEG pathology, and loss of consciousness at injury. No significant influence of pre- and post-injury risk factors on current neuropsychological function was evident. The findings support the view that complicated mild and moderate paediatric head injury may heighten the risk of developing subtle neuropsychological problems later in life.	Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway; Univ Oslo, Inst Psychol, Oslo, Norway		Hessen, E (corresponding author), Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway.	erik.hessen@nevropsykologi.no					Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2000, BRAIN INJURY, V14, P679; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; ENGVIK H, 1978, WECHSLER ADULT INTEL; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; GIMSE R, 1995, WECHSLER MEMORY SCAL; GULDBRANDSEN GB, 1984, J CLIN NEUROPSYCHOLO, V6, P257; Heaton RK, 1991, COMPREHENSIVE NORMS; Horowitz I, 1983, Int Rehabil Med, V5, P32; *HOUS COMM SEL COM, 2001, 3 REP HEAD INJ REH; JENNETT B, 1975, LANCET, V1, P480; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1989, PSYCHIAT MED, V7, P11; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MASSAGLI TL, 1996, ARCH PHYS MED REHAB, V77, P25; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, P134; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Reitan RM, 1985, HALSTEADREITAN NEURO; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; *STAT NORW, 2001, LEV ED PERS 16 YEARS; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Winogron H W, 1984, J Clin Neuropsychol, V6, P267; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	37	34	34	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0036-5564			SCAND J PSYCHOL	Scand. J. Psychol.	AUG	2006	47	4					245	251		10.1111/j.1467-9450.2006.00514.x			7	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	061SU	WOS:000238893700002	16869857				2022-02-06	
J	Weir, N; Doig, EJ; Fleming, JM; Wiemers, A; Zemljic, C				Weir, Nicole; Doig, Emmah J.; Fleming, Jennifer M.; Wiemers, Anna; Zemljic, Collette			Objective and behavioural assessment of the emergence from post-traumatic amnesia (PTA)	BRAIN INJURY			English	Article						post-traumatic amnesia; traumatic brain injury; behaviour	CLOSED-HEAD INJURY; TRAUMATIC BRAIN-INJURY; PRACTICAL SCALE; INCONTINENCE; DURATION	Primary objective: To determine the profile of resolution of typical PTA behaviours and describe new learning and improvements in self-care during PTA. Research design: Prospective longitudinal study monitoring PTA status, functional learning and behaviours on a daily basis. Methods and procedures: Participants were 69 inpatients with traumatic brain injury who were in PTA. PTA was assessed using the Westmead or Oxford PTA assessments. Functional learning capability was assessed using a routine set of daily tasks and behaviour was assessed using an observational checklist. Data was analysed using descriptive statistics. Main outcomes and results: Challenging behaviours that are typically associated with PTA, such as agitation, aggression and wandering resolved in the early stages of PTA and incidence rates of these behaviours were less than 20%. Independence in self-care and bowel and bladder continence emerged later during resolution of PTA. New learning in functional situations was demonstrated by patients in PTA. Conclusions: It is feasible to begin active rehabilitation focused on functional skills-based learning with patients in the later stages of PTA. Formal assessment of typically observed behaviours during PTA may complement memory-based PTA assessments in determining emergence from PTA.	Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld, Australia		Weir, N (corresponding author), Princess Alexandra Hosp, Occupat Therapy Dept, Ipswich Rd,Woolloongabba, Brisbane, Qld 4102, Australia.	nicole_weir@health.qld.gov.au	Fleming, Jennifer M/B-4436-2011; Doig, Emmah/AAG-6674-2021	Doig, Emmah/0000-0002-7020-053X			Ahmed S, 2000, BRAIN INJURY, V14, P765; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; CHAPPARO C, 2001, OT AUSTR 21 NAT C BR; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Foxx-Orenstein A, 2003, ARCH PHYS MED REHAB, V84, P231, DOI 10.1053/apmr.2003.50095; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GEFFEN G, 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; *RANCH LOS AM MED, 1980, LEV COGN FUNCT; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tate RL, 2001, J HEAD TRAUMA REHAB, V16, P525, DOI 10.1097/00001199-200112000-00002; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; TEASDALE G, 1974, LANCET, V2, P81; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412	24	34	34	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2006	20	9					927	935		10.1080/02699050600832684			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100005	17062424				2022-02-06	
J	Bouillon, L; Mazer, B; Gelinas, I				Bouillon, Louise; Mazer, Barbara; Gelinas, Isabelle			Validity of the Cognitive Behavioral Driver's Inventory in predicting driving outcome	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	6th National Workshop on Driver Rehabilitation Specialists	MAY 28, 2004	Edmonton, CANADA	Jewish Rehabilitat Hosp Fdn			BRAIN-DAMAGE; STROKE; FITNESS; INJURY; SKILLS	OBJECTIVE. This study seeks to (a) compare Cognitive Behavioral Driver's Inventory (CBDI) scores for clients who passed and failed a driving evaluation and for diagnostic groups (left cerebrovascular accident [CVA], right CVA, traumatic brain injury [TBI], and cognitive decline); (b) determine sensitivity, specificity, and positive and negative predictive values of the CBDI; (c) compare validity of the CBDI with other tools; and (d) identity factors associated with outcome. PARTICIPANTS. This historical cohort study included clients with neurological conditions who completed a driving evaluation. MEASURES. CBDI, Motor-Free Visual Perception Test (MVPT), Bells test, and driving results were extracted from the charts. RESULTS. Mean CBDI (p < 0.0001) and MVPT (p < 0.0001) scores were significantly worse for those failing compared to passing the driving evaluation, Sensitivity of the CBDI was 62%, specificity was 81%, positive predictive values were 73%, and negative predictive values were 71%. Results varied according to diagnostic group. CONCLUSIONS. The CBDI is not sufficiently predictive of outcome to replace a driving evaluation, and is predictive only for clients with R-CVA and TBI. Evaluation of driving should vary according to diagnosis.	Jewish Rehabil Hosp, CRIR, Laval, PQ H7V 1R2, Canada; McGill Univ, Sch Phys & Occupat Therapy, CRIR, Jewish Rehabil Hosp, Montreal, PQ H7V 1R2, Canada		Bouillon, L (corresponding author), Jewish Rehabil Hosp, CRIR, 3205 Pl Alton, Laval, PQ H7V 1R2, Canada.	barbara.mazer@mcgill.ca					Antrim J. M., 1989, COGNITIVE REHABILITA, V7, P16; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; BOUSKA MJ, 1982, MANUAL APPL MOTOR FR; BRACY OL, 1985, COGNITIVE REHABILITA, V4, P10; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; Engum ES, 1990, MANUAL COGNITIVE BEH; ENGUM ES, 1988, COGNITIVE REHABILITA, V6, P12; Engum ES, 1990, COGNITIVE REHABILITA, V8, P20; Fisk GD, 1997, ARCH PHYS MED REHAB, V78, P1338, DOI 10.1016/S0003-9993(97)90307-5; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GREEN RC, 1994, ARCH NEUROL-CHICAGO, V51, P779, DOI 10.1001/archneur.1994.00540200055017; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Klavora P, 2000, ARCH PHYS MED REHAB, V81, P701, DOI 10.1016/S0003-9993(00)90096-0; Korner-Bitensky N, 2000, AM J PHYS MED REHAB, V79, P253, DOI 10.1097/00002060-200005000-00007; Korner-Bitensky N, 1994, Can J Occup Ther, V61, P141; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; LAMBERT EW, 1990, COGNITIVE REHABILITA, V8, P34; Liddle J., 2003, BRIT J OCCUPATIONAL, V66, P125, DOI DOI 10.1177/030802260306600307; Lincoln N., 1992, CLIN REHABIL, V6, P275, DOI DOI 10.1177/026921559200600402; Lister R, 1999, BRIT J OCCUPATIONAL, V62, P514; Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Michon J. A., 1985, HUMAN BEHAV TRAFFIC, P485, DOI [DOI 10.1007/978-1-4613-2173-6_19, 10.1007/978-1-4613-2173-6_19]; Owsley C, 1993, Clin Geriatr Med, V9, P389; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; Reitan R, 1986, TRAIL MAKING TEST MA; Simms B., 1985, BR J OCCUP THER, V48, P363; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	31	34	34	1	2	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JUL-AUG	2006	60	4					420	427		10.5014/ajot.60.4.420			8	Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Rehabilitation	065RN	WOS:000239177100008	16915872				2022-02-06	
J	Olga, NK; Murashov, AK; Hoane, MR				Olga, N. Kokiko; Murashov, Alexander K.; Hoane, Michael R.			Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						recovery of function; traumatic brain injury; SERM; neuroprotection; rat	ESTROGEN-RECEPTOR MODULATORS; OVARIECTOMIZED FEMALE; POSTMENOPAUSAL WOMEN; GENDER-DIFFERENCES; NMDA ANTAGONISTS; SEX-DIFFERENCES; UNITED-STATES; ESTRADIOL; RECOVERY; PROGESTERONE	Hormonal differences between males and females have surfaced as a crucial component in the search for effective treatments after experimental models of traumatic brain injury (TBI). Recent findings have shown that selective estrogen receptor modulators (SERMs) may have therapeutic benefit. The present study examined the effects of raloxifene, a SERM, on functional recovery after bilateral cortical contusion injury (bCCI) or sham procedure. Male rats received injections of raloxifene (3.0 mg/kg, i.p.) or vehicle (1.0 ml/kg, i.p.) 15 min, 24, 48, 72, and 96 h after bCCl or sham procedure. Rats were tested on both sensorimotor (bilateral tactile removal and locomotor placing tests) and cognitive tests (reference and working memory in the Morris water maze). Raloxifene-treated animals showed a significant reduction in the initial magnitude of the deficit and facilitated the rate of recovery for the bilateral tactile removal test, compared to vehicle-treated animals. The raloxifene-treated animals also showed a significant improvement in the acquisition of working memory compared to vehicle-treated animals. However, raloxifene did not significantly improve the acquisition of reference memory or locomotor placing ability. Raloxifene treatment also did not result in a significant reduction in the size of the lesion cavity. Thus, the task-dependent improvements seen following raloxifene treatment do not appear to be the result of cortical neuroprotection. However, these results suggest that raloxifene improves functional outcome following bCCI and may present an interesting avenue for future research. (c) 2006 Elsevier B.V. All rights reserved.	So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA; E Carolina Univ, Sch Med, Dept Physiol, Greenville, NC 27858 USA		Olga, NK (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA.	kokikoon@vcu.edu; murashoval@mail.ecu.edu; mhoane@siu.edu	Murashov, Alexander/ABB-2151-2020; Murashov, Alexander K/F-2241-2011	Murashov, Alexander/0000-0002-8912-5891; Murashov, Alexander K/0000-0002-8912-5891; Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Arteaga E, 2003, MENOPAUSE, V10, P142, DOI 10.1097/00042192-200310020-00005; Behl C, 2002, J STEROID BIOCHEM, V83, P195, DOI 10.1016/S0960-0760(02)00271-6; BIRGE SJ, 1994, CLIN GERIATR MED, V10, P589, DOI 10.1016/S0749-0690(18)30318-5; BROWN TJ, 1988, ENDOCRINOLOGY, V123, P1761, DOI 10.1210/endo-123-4-1761; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Cyr M, 2001, BRAIN RES REV, V37, P153, DOI 10.1016/S0165-0173(01)00115-1; Cyr M, 2001, NEUROPSYCHOPHARMACOL, V25, P242, DOI 10.1016/S0893-133X(01)00233-0; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FERRIS DC, 1995, NEUROREPORT, V6, P1485, DOI 10.1097/00001756-199507310-00005; Galanopoulou AS, 2003, NEUROSCI LETT, V342, P201, DOI 10.1016/S0304-3940(03)00282-9; Gibbs RB, 2004, PSYCHONEUROENDOCRINO, V29, P741, DOI 10.1016/S0306-4530(03)00118-5; Goekoop R, 2005, NEUROIMAGE, V25, P63, DOI 10.1016/j.neuroimage.2004.11.012; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HAMPSON E, 1990, PSYCHONEUROENDOCRINO, V15, P97, DOI 10.1016/0306-4530(90)90018-5; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Lacreuse A, 2002, NEUROBIOL AGING, V23, P589, DOI 10.1016/S0197-4580(02)00002-7; Littleton-Kearney MT, 2002, CNS DRUG REV, V8, P309; McMurray R, 2003, BRAIN RES, V980, P140, DOI 10.1016/S0006-8993(03)02984-6; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P412, DOI 10.1016/S0002-9378(97)70207-2; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; O'Neill K, 2004, EXP NEUROL, V185, P63, DOI 10.1016/j.expneurol.2003.09.005; Ozgonul M, 2003, ENDOCR RES, V29, P183, DOI 10.1081/ERC-120022299; Purdie DW, 1999, BRIT J CLIN PHARMACO, V48, P785; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schmidt R, 1996, J AM GERIATR SOC, V44, P1307, DOI 10.1111/j.1532-5415.1996.tb01400.x; Scott JA, 1999, AM FAM PHYSICIAN, V60, P1131; Sherwin BB, 1996, OBSTET GYNECOL, V87, pS20, DOI 10.1016/0029-7844(95)00431-9; SMITH SS, 1989, BRAIN RES, V503, P354, DOI 10.1016/0006-8993(89)91691-0; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Tsang KL, 2000, NEUROLOGY, V54, P2292, DOI 10.1212/WNL.54.12.2292; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207	49	34	34	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 30	2006	170	2					233	240		10.1016/j.bbr.2006.02.026			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	051RX	WOS:000238179500008	16580743				2022-02-06	
J	Kesting, MR; Holzle, F; Pox, C; Thurmuller, P; Wolff, KD				Kesting, Marco Rainer; Hoelzle, Frank; Pox, Christian; Thurmueller, Petra; Wolff, Klaus-Dietrich			Animal bite injuries to the head: 132 cases	BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY			English	Article						animal bites; primary wound closure; wound infection; antibiotic prophylaxis	DOG BITES; WOUNDS; FACE; RECONSTRUCTION; ANTIBIOTICS; CHILDREN; NECK	We made a retrospective study of the casenotes of 132 patients with bite injuries who were treated in the departments of craniomaxillofacial surgery in Berlin and Bochum university hospitals. Dogs caused most of the injuries (n = 121, 92%) and the lips were most commonly involved. Nearly half the patients had superficial injuries. More than 70% of the patients presented to the clinic within 6 h after the bite, and developed fewer wound infections than the patients who presented late. A total of 71 patients were given antibiotics for prophylaxis. Patients who were given amoxycillin with clavulanic acid developed no Wound infections. Surgical management included cleansing and primary Closure of the wound. Infected wounds were closed primarily after insertion of a drain. Wound cultures showed mainly streptococcus. We Concluded that antibiotic prophylaxis is essential for several indications and the antibiotic of first choice is amoxycillin-clavulanic acid. Primary wound closure is an approved principle even in infected wounds. (C) 2005 The British Association of Oral and Maxillofacial surgeons. Published by Elsevier Ltd. All rights reserved.	Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Dept Oral & Maxillofacial Plast Surg, D-44892 Bochum, Germany; Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Dept Med, D-44892 Bochum, Germany		Kesting, MR (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Dept Oral & Maxillofacial Plast Surg, Schornau 23-25, D-44892 Bochum, Germany.	marco.kesting@ruhr-uni-bochum.de					Burt JD, 2000, PLAST RECONSTR SURG, V105, P2440, DOI 10.1097/00006534-200006000-00021; CALLAHAM M, 1980, ANN EMERG MED, V9, P410, DOI 10.1016/S0196-0644(80)80153-3; Correira Kristine, 2003, JAAPA, V16, P28; DIRE DJ, 1992, PEDIATR EMERG CARE, V8, P194, DOI 10.1097/00006565-199208000-00005; DIRE DJ, 1992, ANN EMERG MED, V21, P1008; Ebinger T, 2002, CHIRURG, V73, P601, DOI 10.1007/s00104-002-0430-8; GILBERT DN, 2002, SANFORD GUIDE ANTIMI; GOLDSTEIN EJC, 1992, CLIN INFECT DIS, V14, P633, DOI 10.1093/clinids/14.3.633; Goldstein EJC, 1999, CURR CLIN TOPICS INF, V19, P99; Holm M, 2000, SCAND J INFECT DIS, V32, P181, DOI 10.1080/003655400750045303; Javaid M, 1998, J ROY SOC MED, V91, P414, DOI 10.1177/014107689809100804; Kountakis S E, 1998, Ear Nose Throat J, V77, P216; LACKMANN GM, 1992, J CRANIO MAXILL SURG, V20, P81, DOI 10.1016/S1010-5182(05)80472-X; Lengele BG, 2004, INT J ORAL MAX SURG, V33, P396, DOI 10.1016/j.ijom.2003.11.004; LIEBANA J, 2004, MED ORAL PATOL ORA S, V9, P75; Liebana Jose, 2004, Med Oral Patol Oral Cir Bucal, V9 Suppl, P82; Matter HC, 1998, EUR J EPIDEMIOL, V14, P483, DOI 10.1023/A:1007460213308; Metzger R, 2002, MMW Fortschr Med, V144, P46; Mitchell RB, 2003, LARYNGOSCOPE, V113, P492, DOI 10.1097/00005537-200303000-00018; Scheithauer MO, 1997, HNO, V45, P891, DOI 10.1007/s001060050170; Smith PF, 2000, J CLIN PHARM THER, V25, P85; Talan DA, 1999, NEW ENGL J MED, V340, P85, DOI 10.1056/NEJM199901143400202; Tu AH, 2002, PLAST RECONSTR SURG, V109, P1259, DOI 10.1097/00006534-200204010-00008; Wolff KD, 1998, J ORAL MAXIL SURG, V56, P838, DOI 10.1016/S0278-2391(98)90009-X	24	34	35	0	7	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0266-4356	1532-1940		BRIT J ORAL MAX SURG	Br. J. Oral Maxillofac. Surg.	JUN	2006	44	3					235	239		10.1016/j.bjoms.2005.06.015			5	Dentistry, Oral Surgery & Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine; Surgery	050CE	WOS:000238064300018	16055237				2022-02-06	
J	Busnello, JV; Leke, R; Oses, JP; Feier, G; Bruch, RS; Quevedo, J; Kapczinski, F; Souza, DO; Portela, LVC				Busnello, Joao Vicente; Leke, Renata; Oses, Jean Pierre; Feier, Gustavo; Bruch, Ricardo S.; Quevedo, Joao; Kapczinski, Flavio; Souza, Diogo O.; Portela, Luis Valmor Cruz			Acute and chronic electroconvulsive shock in rats: Effects on peripheral markers of neuronal injury and glial activity	LIFE SCIENCES			English	Article						NSE; S100B; lactate; electroconvulsive shock; electroconvulsive therapy	TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; CEREBROSPINAL-FLUID; INDUCED SEIZURES; S100B PROTEIN; ENOLASE; THERAPY; SERUM; ASTROCYTES; DAMAGE	Electroconvulsive therapy is considered one of the most effective treatments of major depression, but controversy still exists on whether it may be brain damaging. The aim of this work was to evaluate the cerebrospinal fluid (CSF) levels of neuron specific enolase (NSE), protein S100B and lactate of rats submitted to acute and chronic models of ECS. Rats were submitted to either one shock (acute) or a series of eight shocks, applied one at even, 48 h (chronic). CSF samples were collected at 0, 3, 6, 12, 24, 48 and 72 h after the shock in the acute model and at these same time intervals after the last shock in the chronic model. Both models did not produce significant alterations in the levels of NSE. S100B levels were significantly increased at 6 h in the chronic model (p < 0.0001). There was a significant increase in the levels of lactate at 0 h in both models (p < 0.001). These results support the proposition that ECS does not produce neural damage, and suggest that the alterations in the levels of S100B and lactate may reflect an astrocytic activity of a protective nature. (c) 2005 Elsevier Inc. All rights reserved.	Univ Fed Rio Grande Sul, Dept Bioquim, Inst Ciencias Basicas Saude, BR-90035003 Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Ctr Pesquisa, Lab Psiquiatria Expt, BR-90035000 Porto Alegre, RS, Brazil; Univ Fed Rio Grande Sul, BR-90035000 Porto Alegre, RS, Brazil; Univ Extremo Sul Catarinense, Programa Pos Grad Ciencias Saude, Lab Neurociencias, BR-88806000 Criciuma, SC, Brazil; FUC, Inst Cardiol Rio Grande Sul, BR-90620001 Porto Alegre, RS, Brazil		Busnello, JV (corresponding author), Univ Fed Rio Grande Sul, Dept Bioquim, Inst Ciencias Basicas Saude, Ramiro Barcelos,2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.	joaovi@terra.com.br	Kapczinski, Flavio/J-5803-2014; de Quevedo, Joao Luciano/E-5491-2013; Souza, Diogo O/J-8894-2014; de Quevedo, Joao Luciano/N-1407-2019; Kapczinski, Flavio/D-3175-2013; Oses, Jean Pierre/E-2534-2013	de Quevedo, Joao Luciano/0000-0003-3114-6611; Souza, Diogo O/0000-0002-4322-0404; de Quevedo, Joao Luciano/0000-0003-3114-6611; Kapczinski, Flavio/0000-0001-8738-856X; Portela, Luis Valmor/0000-0001-6113-8466; Oses, Jean Pierre/0000-0002-2012-273X			Agelink MW, 2001, J NEUROL NEUROSUR PS, V71, P394, DOI 10.1136/jnnp.71.3.394; Berrouschot J, 1997, J NEUROL SCI, V150, P173, DOI 10.1016/S0022-510X(97)00086-5; Bouzier-Sore AK, 2003, BIOCHIMIE, V85, P841, DOI 10.1016/j.biochi.2003.08.003; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Carney S, 2003, LANCET, V361, P799; Deitmer JW, 2001, RESP PHYSIOL, V129, P71, DOI 10.1016/S0034-5687(01)00283-3; DEVANAND DP, 1994, AM J PSYCHIAT, V151, P957; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; FILLENZ M, 2005, EPUB ROLE LACATE BRA; FINK M, 2005, PSYCHOBIOLOGY ELECTR; Haglid KG, 1997, BRAIN RES, V753, P196, DOI 10.1016/S0006-8993(96)01463-1; Heizmann CW, 2004, CLIN CHEM, V50, P249, DOI 10.1373/clinchem.2003.027367; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; INGVAR M, 1983, ACTA NEUROL SCAND, V68, P129, DOI 10.1111/j.1600-0404.1983.tb05339.x; KAISER E, 1989, CLIN CHIM ACTA, V183, P13, DOI 10.1016/0009-8981(89)90268-4; Kogel D, 2004, NEUROSCIENCE, V127, P913, DOI 10.1016/j.neuroscience.2004.06.013; Koppal T, 2001, NEUROCHEM INT, V39, P401, DOI 10.1016/S0197-0186(01)00047-X; KRAGH J, 1993, BIOL PSYCHIAT, V33, P794, DOI 10.1016/0006-3223(93)90020-E; Kulpa J, 2002, CLIN CHEM, V48, P1931; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; LINDEFORS N, 1995, NEUROSCIENCE, V65, P661, DOI 10.1016/0306-4522(94)00550-O; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Manev H, 2003, J AFFECT DISORDERS, V75, P59, DOI 10.1016/S0165-0327(02)00044-7; Manev R, 2001, EUR J PHARMACOL, V420, pR1, DOI 10.1016/S0014-2999(01)00989-X; Ongur D, 2004, HARVARD REV PSYCHIAT, V12, P253, DOI 10.1080/10673220490886185; Pellerin L, 2005, MOL NEUROBIOL, V32, P59, DOI 10.1385/MN:32:1:059; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Portela LVC, 2002, CLIN CHEM, V48, P950; Portela LVC, 2002, BRAIN RES, V950, P74, DOI 10.1016/S0006-8993(02)02987-6; Rabinowicz AL, 1996, EPILEPSIA, V37, P122, DOI 10.1111/j.1528-1157.1996.tb00002.x; RASMUSSEN CV, 1994, NEUROCHEM RES, V19, P1527, DOI 10.1007/BF00969001; Sterling P, 2000, NATURE, V403, P242, DOI 10.1038/35002188; TORRE ER, 1993, BRAIN RES, V631, P256, DOI 10.1016/0006-8993(93)91543-2; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wong ML, 2001, NAT REV NEUROSCI, V2, P343, DOI 10.1038/35072566; Zachrisson OCG, 2000, PSYCHIAT RES, V96, P157, DOI 10.1016/S0165-1781(00)00202-X; Zetterstrom TSC, 1998, MOL BRAIN RES, V57, P106, DOI 10.1016/S0169-328X(98)00077-1	40	34	35	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAY 22	2006	78	26					3013	3017		10.1016/j.lfs.2005.11.028			5	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	045NR	WOS:000237749300005	16413036				2022-02-06	
J	Rickards, H				Rickards, H			Depression in neurological disorders: an update	CURRENT OPINION IN PSYCHIATRY			English	Article						brain injury; depression; epilepsy; multiple sclerosis; Parkinson's disease	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; MAJOR DEPRESSION; EPILEPSY; INVENTORY; SYMPTOMS; VALIDITY; SCALE	Purpose of review Depressions are a heterogeneous group of conditions that contribute significantly to impairments in quality of life, independent of the severity of neurological illness. Depression may predate neurological signs and symptoms in the evolution of neurodegenerative disorders, and there is some evidence that depressive illness itself may be a risk factor in the aetiology of some dementias. This review aims to summarize the relevant current literature on diagnosis, aetiology and treatment of depression in neurology. Recent findings Diagnosing depression in neurological conditions can be particularly difficult because of communication difficulties and changes in emotional expression as a result of the underlying neurological disease. Rating scales loaded towards somatic symptoms can show poor validity for screening or rating of severity in this setting. The evidence for the treatment of depression in neurological disease is scant, and often the treatment advice is based on consensus views of clinicians. Nevertheless, there have been some clinical trials, which are reported. Summary Depression is common in neurology. It is underrecognized and undertreated. Recent research has allowed us to define depression more clearly in this setting. Trials of treatment are urgently needed, especially as depression is a significant factor in quality of life and may affect prognosis.	Queen Elizabeth Psychiat Hosp, Dept Neuropsychiat, Birmingham B15 2QZ, W Midlands, England		Rickards, H (corresponding author), Queen Elizabeth Psychiat Hosp, Dept Neuropsychiat, Mindelsohn Way, Birmingham B15 2QZ, W Midlands, England.	hugh.rickards@bsmht.nhs.uk					Al-Adawi S, 2004, J NEUROPSYCH CLIN N, V16, P435, DOI 10.1176/appi.neuropsych.16.4.435; Arnett P, 2005, MULT SCLER J, V11, P328, DOI 10.1191/1352458505ms1162oa; Chou KL, 2005, PARKINSONISM RELAT D, V11, P403, DOI 10.1016/j.parkreldis.2005.04.005; Chwastiak L, 2002, AM J PSYCHIAT, V159, P1862, DOI 10.1176/appi.ajp.159.11.1862; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Ertan FS, 2005, J NEUROL NEUROSUR PS, V76, P1445, DOI 10.1136/jnnp.2004.057984; Ettinger A, 2004, NEUROLOGY, V63, P1008, DOI 10.1212/01.WNL.0000138430.11829.61; Feinstein A, 2004, NEUROLOGY, V62, P586, DOI 10.1212/01.WNL.0000110316.12086.0C; Gilliam FG, 2005, CURR OPIN NEUROL, V18, P129, DOI 10.1097/01.wco.0000162853.29650.ec; Gold R, 2005, EUR J NEUROL, V12, P649, DOI 10.1111/j.1468-1331.2005.01083.x; Hart S, 2005, QUAL LIFE RES, V14, P695, DOI 10.1007/s11136-004-1364-z; Jones JE, 2005, J NEUROPSYCH CLIN N, V17, P172, DOI 10.1176/appi.neuropsych.17.2.172; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kuhn KU, 2003, EPILEPSY BEHAV, V4, P674, DOI 10.1016/S1525-5050(03)00211-7; Leentjens AFG, 2000, MOVEMENT DISORD, V15, P1221, DOI 10.1002/1531-8257(200011)15:6<1221::AID-MDS1024>3.0.CO;2-H; Leentjens AFG, 2003, J NEUROPSYCH CLIN N, V15, P74, DOI 10.1176/appi.neuropsych.15.1.74; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Lincoln NB, 2003, STROKE, V34, P111, DOI 10.1161/01.STR.0000044167.44670.55; Loring DW, 2004, EPILEPSY BEHAV, V5, P976, DOI 10.1016/j.yebeh.2004.08.019; Menza M, 2004, J NEUROPSYCH CLIN N, V16, P315, DOI 10.1176/appi.neuropsych.16.3.315; Mergl R, 2005, J NEUROL NEUROSUR PS, V76, P138, DOI 10.1136/jnnp.2004.037127; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Moran PJ, 2005, J BEHAV MED, V28, P35, DOI 10.1007/s10865-005-2561-0; Patten SB, 2003, NEUROLOGY, V61, P1524, DOI 10.1212/01.WNL.0000095964.34294.B4; Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; RUPANG P, 2005, PSYCHOSOMATICS, V46, P131; Shabnam GN., 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003465; Specchio LM, 2004, CLIN NEUROPHARMACOL, V27, P133, DOI 10.1097/00002826-200405000-00009; Thapar A, 2005, J PSYCHOSOM RES, V59, P269, DOI 10.1016/j.jpsychores.2005.04.001; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P1273, DOI 10.1136/jnnp.2004.050096; Veazey C, 2005, J NEUROPSYCH CLIN N, V17, P310, DOI 10.1176/appi.neuropsych.17.3.310; Weintraub D, 2005, J NUCL MED, V46, P227	35	34	38	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0951-7367	1473-6578		CURR OPIN PSYCHIATR	Curr. Opin. Psychiatr.	MAY	2006	19	3					294	298		10.1097/01.yco.0000218601.17722.5b			5	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	035YX	WOS:000237038800010	16612216				2022-02-06	
J	Tamas, A; Zsombok, A; Farkas, O; Reglodi, D; Pal, J; Buki, A; Lengvari, I; Povlishock, JT; Doczi, T				Tamas, Andrea; Zsombok, Andrea; Farkas, Orsolya; Reglodi, Dora; Pal, Jozsef; Buki, Andras; Lengvari, Istvan; Povlishock, John T.; Doczi, Tamas			Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid precursor protein; corticospinal tract; neuroprotection; PACAP; traumatic brain injury	VASOACTIVE-INTESTINAL-PEPTIDE; PERCUSSION BRAIN-INJURY; CEREBELLAR GRANULE NEURONS; FOCAL CEREBRAL-ISCHEMIA; FREE-RADICAL PRODUCTION; CYCLOSPORINE-A; HIPPOCAMPAL-NEURONS; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; NEUROTROPHIC FACTOR	Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system. Numerous studies have shown its neuroprotective effects both in vitro and in vivo. Previously,, it has been demonstrated that PACAP reduces brain damage in rat models of global and focal cerebral ischemia. Based on the protective effects of PACAP in cerebral ischemia and the presence of common pathogenic mechanisms in cerebral ischemia and traumatic brain injury (TBI), the aim of the present study was to investigate the possible protective effect of PACAP administered 30 min or 1 h postinjury in a rat model of diffuse axonal injury. Adult Wistar male rats were subjected to impact acceleration, and PACAP was administered intracerebroventricularly 30 min (n = 4), and 1 h after the injury (n = 5). Control animals received the same volume of vehicle at both time-points (n = 5). Two hours after the injury, brains were processed for immunohistochemical localization of damaged axonal profiles displaying either beta-amyloid precursor protein (beta-APP) or RMO-14 immunoreactivity, both considered markers of specific features of traumatic axonal injury. Our results show that treatment with PACAP (100 mu g) 30 min or 1 h after the induction of TBI resulted in a significant reduction of the density of beta-APP-immunopositive axon profiles in the corticospinal tract (CSpT). There was no significant difference between the density of beta-APP-immunopositive axons in the medial longitudinal fascicle (MLF). PACAP treatment did not result in significantly different number of RMO-14-immunopositive axonal profiles in either brain areas 2 hours post-injury compared to normal animals. While the results of this study highlighted the complexity of the pathogenesis and manifestation of diffuse axonal injury, they also indicate that PACAP should be considered a potential therapeutic agent in TBI.	Univ Pecs, Dept Anat, Fac Med, Hungarian Acad Sci,Neurohumoral Regulat Res Grp, Pecs, Hungary; Univ Pecs, Dept Neurosurg, Fac Med, Pecs, Hungary; Univ Pecs, Cent Lab Anim Res, Fac Med, Pecs, Hungary; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; Univ Pecs, Dept Neurosurg, Fac Med, Hungarian Acad Sci,Clin Neurosci Res Grp, Pecs, Hungary		Tamas, A (corresponding author), Univ Pecs, Dept Anat, Fac Med, Hungarian Acad Sci,Neurohumoral Regulat Res Grp, Pecs, Hungary.	andrea.tamas@aok.pte.hu	Pal, Jozsef/C-4073-2009; Doczi, Tamas/C-5750-2009; Buki, Andras/B-1960-2010; Pal, Jozsef/I-3416-2013	Pal, Jozsef/0000-0001-6468-6409	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [1-R03-TW0131302A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R03TW001313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; BULLOCK JA, 1993, AMATEUR ENTOMOLOGI A, V11, P1; Canonico PL, 1996, ANN NY ACAD SCI, V805, P470; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIRNAGL U, 1990, BRAIN RES, V527, P62, DOI 10.1016/0006-8993(90)91060-T; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Figiel M, 2000, J NEUROSCI, V20, P3596, DOI 10.1523/JNEUROSCI.20-10-03596.2000; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frechilla D, 2001, NEUROREPORT, V12, P919, DOI 10.1097/00001756-200104170-00011; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Katahira M., 2003, Regulatory Peptides, V115, P49; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Kim WK, 2000, J NEUROSCI, V20, P3622, DOI 10.1523/JNEUROSCI.20-10-03622.2000; Kimura H, 2003, LARYNGOSCOPE, V113, P1000, DOI 10.1097/00005537-200306000-00016; Kinhult J, 2001, PEPTIDES, V22, P2151, DOI 10.1016/S0196-9781(01)00568-X; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; LEE VMY, 1987, J NEUROSCI, V7, P3474; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; OHTAKI H, 2003, REGUL PEPTIDES, V15, P53; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 2001, HEAD TRAUMA BASIC PR; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SEKI T, 2003, REGUL PEPTIDES, V115, P55; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, J NEUROCHEM, V83, P1272, DOI 10.1046/j.1471-4159.2002.01242.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZAMBONI L, 1967, J CELL BIOL, V35, pA148	79	34	35	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2006	23	5					686	695		10.1089/neu.2006.23.686			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	042LJ	WOS:000237529200007	16689670				2022-02-06	
J	Boran, BO; Boran, P; Barut, N; Akgun, C; Celikoglu, E; Bozbuga, M				Boran, Burak O.; Boran, Perran; Barut, Nehir; Akgun, Cem; Celikoglu, Erhan; Bozbuga, Mustafa			Evaluation of mild head injury in a pediatric population	PEDIATRIC NEUROSURGERY			English	Article						head injury, mild; linear skull fracture	TRAUMATIC BRAIN-INJURY; COMA SCALE SCORE; COMPUTED-TOMOGRAPHY; GUIDELINES; MANAGEMENT; EMERGENCY; ADMISSION; CRITERIA	Approximately 5 million children present to emergency departments, seeking care for head injuries, each year, and 80% of these children are classified as cases of mild head injury. Due to the huge number of patients and low frequency of intracranial lesions in this group, obtaining a computed tomography scan for each and every patient is a significant economic problem. This study was conducted to identify the clinical parameters and the radiographic findings that may be associated with intracranial lesions in children with mild head injury. 421 patients, with a Glasgow Coma Scale score of 15 and without any focal neurological deficit, were studied. Intracranial lesion was noted in 37 cases (8.8%). Sensitivity of a plain radiogram was 43.2%, and specificity was 93%. An intracranial pathology was demonstrated in 28.9% of the patients with a linear skull fracture. The only clinical parameters associated with an increase in the frequency of detection of intracranial lesions were posttraumatic seizures and loss of consciousness. Age, sex, headache, vomiting and scalp lacerations were not associated with a higher frequency. Even when patients with a history of loss of consciousness or posttraumatic seizure were subtracted from the study group, intracranial lesions were noted in 4.1% of the cases, and in 1.8% neurosurgical intervention was required. Computed tomography is the gold standard in the evaluation of pediatric patients with mild head trauma, and every child who has experienced a head injury should undergo a cranial computed tomography evaluation, even if he or she appears in perfect health. Copyright (c) 2006 S. Karger AG, Basel.	Dr Lutfi Kirdar Kartal Res & Training Hosp, Neurosurg Clin 2, TR-34720 Istanbul, Turkey; Dr Lutfi Kirdar Kartal Res & Training Hosp, Clin Pediat 2, Istanbul, Turkey		Boran, BO (corresponding author), Dr Lutfi Kirdar Kartal Res & Training Hosp, Neurosurg Clin 2, Ortac Apt 13-12, TR-34720 Istanbul, Turkey.	burakoboran@hotmail.com	Boran, Perran/AAS-4469-2020	Boran, Perran/0000-0002-9885-7656			Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Duhaime AC, 1999, PRINCIPLES AND PRACTICE OF PEDIATRIC NEUROSURGERY, P799; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Hsiang JNK, 1997, J NEUROSURG, V72, P189; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; KAUFMAN BA, 1996, PEDIATR NEUROSURG, V25, P204; Lapierre F, 1998, NEUROCHIRURGIE, V44, P55; Luerssen TG, 1999, PRINCIPLES AND PRACTICE OF PEDIATRIC NEUROSURGERY, P813; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SERVADEI F, 2004, YOUMANS NEUROLOGICAL, P5065; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5	26	34	35	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2006	42	4					203	207		10.1159/000092355			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	120CH	WOS:000243060700001	16714859				2022-02-06	
J	Jankowitz, BT; Adelson, PD				Jankowitz, Brian T.; Adelson, P. David			Pediatric traumatic brain injury: Past, present and future	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; treatment guidelines	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; YOUNG-CHILDREN; DEXAMETHASONE THERAPY; INTRACRANIAL-PRESSURE; QUINOLINIC ACID; COMA SCALE; INFANTS; SEVERITY; SURVIVAL	Traumatic brain injury (TBI) is the leading cause of death and disability in children. Evidence-based guidelines for the management of this population are available; however, the data highlight significant deficiencies with few treatment standards or guidelines. Considering the limited availability of resources, it is necessary to define realistic goals. Attention should be given to injury prevention, developing standardized pediatric admission and outcome evaluations, increasing the utility and spectrum of physiological and biochemical testing, and defining the evolving role of imaging in TBI. Copyright (c) 2006 S. Karger AG, Basel.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA		Adelson, PD (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.	David.Adelson@chp.edu	Adelson, David/W-2083-2019				Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ARJAMAA O, 1992, ACTA PHYSIOL SCAND, V144, P113, DOI 10.1111/j.1748-1716.1992.tb09275.x; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Centers for Disease Control and Prevention and National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Falk AC, 2005, CHILD NERV SYST, V21, P430, DOI 10.1007/s00381-005-1142-4; FANCONI S, 1988, INTENS CARE MED, V14, P163; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; Han Yong Y, 2003, Pediatr Crit Care Med, V4, P21, DOI 10.1097/00130478-200301000-00004; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Hulka F, 1997, J TRAUMA, V42, P514, DOI 10.1097/00005373-199703000-00020; *IMPACT, BEST APPR CONC MAN; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1996, PEDIATR NEUROSURG, V25, P309, DOI 10.1159/000121145; KASSELL NF, 1980, NEUROSURGERY, V7, P598, DOI 10.1227/00006123-198012000-00011; Kim PK, 2005, WORLD J SURG, V29, P1557, DOI 10.1007/s00268-005-0106-x; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsubara Kosuke, 2005, Nihon Hoshasen Gijutsu Gakkai Zasshi, V61, P1581; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MOSS GS, 1988, AM J SURG, V155, P425, DOI 10.1016/S0002-9610(88)80106-5; Msall ME., 1993, PHYS MED REH CLIN N, V4, P517; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PHILLIPS R, 1987, J NEUROSURG, V67, P846, DOI 10.3171/jns.1987.67.6.0846; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; RODGERS GB, 1993, BICYCLE BICYCLE HELM; ROEBER DE, 2002, COMMUNICATION   0305; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEPAS JJ, 1989, J PEDIATR SURG, V24, P156, DOI 10.1016/S0022-3468(89)80237-4; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; Westbrook A, 1997, Nurs Crit Care, V2, P72; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YOUNG B, 1983, CHILD BRAIN, V10, P185; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731	69	34	35	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					264	275		10.1159/000094153			12	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600004	16943650				2022-02-06	
J	Sumpter, RE; McMillan, TM				Sumpter, RE; McMillan, TM			Errors in self-report of post-traumatic stress disorder after severe traumatic brain injury	BRAIN INJURY			English	Article						PTSD; brain injury; self-report; assessment	SCALE	Assessing PTSD by questionnaire can lead to false positive diagnosis after severe traumatic brain injury. Sumpter and McMillan, reported quantitative data on 34 people with severe TBI; 59% were PTSD 'cases' by questionnaire assessment, but only 3% using a structured interview. The present paper describes ways in which these individuals made errors on questionnaires. Some did not follow questionnaire instructions because of inattention and concrete thinking or instead reported effects of brain injury. Symptom overlap between TBI and PTSD, including insomnia, irritability and impaired concentration can cause errors. Brain injury can also provoke curiosity about loss of memory (during coma, retrograde and post-traumatic amnesia), decreased participation, social withdrawal and difficulty adjusting to injury that may be mistaken for fear-associated PTSD symptoms. Assessment of PTSD by questionnaire can lead to erroneous conclusions and factors related to brain injury must be carefully considered when investigating PTSD.	Univ Glasgow, Fac Med, Gartnavel Royal Hosp, Glasgow G12 OXH, Lanark, Scotland		McMillan, TM (corresponding author), Univ Glasgow, Fac Med, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 OXH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baddeley A., 1992, SPEED CAPACITY LANGU; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050118030; NELSON HE, 1991, NATL ADULT READINT T; ODDY M, 2003, NEUROLOGICAL REHABIL, P453; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	17	34	34	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					93	99		10.1080/02699050500394090			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000010	16403704				2022-02-06	
J	Whyte, J; Grieb-Neff, P; Gantz, C; Polansky, M				Whyte, John; Grieb-Neff, Patricia; Gantz, Christopher; Polansky, Marcia			Measuring sustained attention after traumatic brain injury: Differences in key findings from the sustained attention to response task (SART)	NEUROPSYCHOLOGIA			English	Article						brain injuries; attention; vigilance; sustained attention to response task (SART)	HEAD-INJURY; METHYLPHENIDATE; DEFICITS; FAILURES; MOOD	Clinical reports after traumatic brain injury (TBI) suggest frequent difficulties with sustained attention, but their objective measurement has proved difficult. In 1997, Robertson and colleagues reported on a new sustained attention assessment tool, the sustained attention to response task (SART). Individuals with TBI were reported to produce more errors of commission on the SART than control participants, and both groups showed a relationship between SART errors and everyday lapses of attention as measured by the cognitive failures questionnaire (CFQ). Although few direct replications of these findings have been reported, the SART has been used widely as a measure of sustained attention in TBI, in normal controls, and in various other clinical samples. As part of a program of research on attention in TBI, we administered the SART and the CFQ to a sample of 34 survivors of moderate to severe TBI and to 35 control participants. CFQ scores reported by significant others showed clear group differences in everyday lapses of attention. Despite this, group differences in SART errors of commission were small and non-significant, and the correlations between SART errors and CFQ scores were small within both groups. Further analyses excluding participants with invalid score profiles, or restricting the analysis to the first performance of the SART failed to alter the results. These findings suggest that more research is needed to establish the validity of the SART as a measure of sustained attention after TBI, and to determine under what circumstances the original findings hold. (c) 2006 Elsevier Ltd. All rights reserved.	Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA; Drexel Univ, Dept Biostat, Philadelphia, PA 19104 USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor St,Suite 213, Philadelphia, PA 19141 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Bellgrove MA, 2005, NEUROPSYCHOLOGIA, V43, P1847, DOI 10.1016/j.neuropsychologia.2005.03.011; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Broun T., 1910, Bulletin of the New Zealand Institute Wellington, V1; BUCHTEL HA, 1987, ATTENTION VIGILANCE; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Cohen J., 1988, T TEST MEANS; Dale MT, 2003, BRIT J ANAESTH, V90, p824P; David AS, 2002, PSYCHOL MED, V32, P1357, DOI 10.1017/S0033291702006359; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Hull L, 2003, PERS INDIV DIFFER, V35, P1211, DOI 10.1016/S0191-8869(02)00329-X; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MELAMED S, 1985, SCAND J REHABIL MED, P16; PARASURAMAN R, 1984, SUSTAINED ATTENTION; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Thompson JP, 2002, EUR J ANAESTH, V19, P585, DOI 10.1017/S0265021502000947; Wallace JC, 2003, J BUS PSYCHOL, V17, P503, DOI 10.1023/A:1023452218225; WALLACE JC, 2001, N AM J PSYCHOL, V3, P481; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	29	34	34	1	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	10					2007	2014		10.1016/j.neuropsychologia.2006.02.012			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	068VS	WOS:000239403200039	16682059	Green Submitted			2022-02-06	
J	Yi, JH; Hoover, R; McIntosh, TK; Hazell, AS				Yi, JH; Hoover, R; McIntosh, TK; Hazell, AS			Early, transient increase in complexin I and complexin II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine	JOURNAL OF NEUROTRAUMA			English	Article						antioxidant; complexin; excitoxicity; fluid-percussion, neurotransmitter; traumatic brain injury	NEUROTRANSMITTER RELEASE; SNARE COMPLEX; VESICLE EXOCYTOSIS; AMINO-ACIDS; 2 ISOFORMS; RAT; MODEL; EXPRESSION; PROTEINS; DEPLETION	Alteration of excitatory neurotransmission is a key feature of traumatic brain injury (TBI) in which extracellular glutamate levels rise. Although increased synaptic release of glutamate occurs at the injury site, the precise mechanism is unclear. Complexin I and complexin II constitute a family of cytosolic proteins involved in the regulation of neurotransmitter release, competing with the chaperone protein alpha-SNAP (soluble N-ethylmaleimide-sensitive factor-attachment protein) for binding to the synaptic vesicle protein synaptobrevin as well as the synaptic membrane proteins SNAP-25 and syntaxin, which together form the SNAP receptor (SNARE) complex. Complexin I is predominantly a marker of axosomatic (inhibitory) synapses, whereas complexin II mainly labels axodendritic and axospinous synapses, the majority of which are excitatory. In order to examine the role of these proteins in TBI, we have studied levels of both complexins in the injured hemisphere by immunoblotting over a time period ranging from 6 h to 7 days following lateral fluid-percussion brain injury in the rat. Transient increases in the levels of complexin I and complexin II proteins were detected in the injured cerebral cortex 6 h following TBI. This increase was followed by a decrease of complexin I in the injured cortex and hippocampus, and a decrease in both complexins in the injured thalamus region at day 3 and day 7 post-injury. The early, transient increase in the injured cortex was completely blocked by N-acetylcysteine (NAC) administered 5 min following trauma, suggesting an involvement of oxidative stress. Neuronal loss was also reduced in the injured hemisphere with post-TBI NAC treatment. Our findings suggest a dysregulation of both inhibitory and excitatory neurotransmission following traumatic injury that is responsive to antioxidant treatment. These alterations in complexin levels may also play an important role in neuronal cell loss following TBI, and thus contribute to the pathophysiology of cerebral damage following brain injury.	Univ Montreal, Hop St Luc, Dept Med, Montreal, PQ, Canada; Univ Penn, Dept Neurosurg, Philadelphia, PA USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Hazell, AS (corresponding author), Univ Montreal, Hop St Luc, Dept Med, Montreal, PQ, Canada.	alan.stewart.hazell@umontreal.ca	Sanjuan, Miguel AF/B-7709-2011	Sanjuan, Miguel AF/0000-0003-3515-0837	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-R01-40978, NS-P50-08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER		Abderrahmani A, 2004, J CELL SCI, V117, P2239, DOI 10.1242/jcs.01041; Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Eastwood SL, 2001, BRAIN RES BULL, V55, P569, DOI 10.1016/S0361-9230(01)00530-5; Eastwood SL, 2001, NEUROSCIENCE, V105, P219, DOI 10.1016/S0306-4522(01)00141-5; Edwardson JM, 2003, J BIOL CHEM, V278, P30849, DOI 10.1074/jbc.M304615200; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Freeman W, 2004, BRAIN RES BULL, V63, P33, DOI 10.1016/j.brainresbull.2003.12.003; Hazell AS, 2001, J NEUROCHEM, V78, P560, DOI 10.1046/j.1471-4159.2001.00436.x; Ishizuka T, 1999, NEUROSCIENCE, V88, P295, DOI 10.1016/S0306-4522(98)00223-1; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Morton AJ, 2001, J NEUROCHEM, V76, P166, DOI 10.1046/j.1471-4159.2001.00059.x; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Peters A, 1996, J NEUROCYTOL, V25, P687, DOI 10.1007/BF02284835; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Sawada K, 2002, MOL PSYCHIATR, V7, P484, DOI 10.1038/sj.mp.4000978; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yamada M, 1999, NEUROSCIENCE, V93, P7, DOI 10.1016/S0306-4522(99)00104-9; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099	32	34	36	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2006	23	1					86	96		10.1089/neu.2006.23.86			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	009GP	WOS:000235100100007	16430375				2022-02-06	
J	Hernandez, AV; Steyerberg, EW; Taylor, GS; Marmarou, A; Habbema, JDF; Maas, AIR				Hernandez, AV; Steyerberg, EW; Taylor, GS; Marmarou, A; Habbema, JDF; Maas, AIR			Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic brain injury: A systematic review	NEUROSURGERY			English	Article						acute traumatic brain injury; CONSORT; covanate adjustment; randomized clinical trials; reporting; subgroup analysis; systematic review	SEVERE HEAD-INJURY; NEUROPROTECTIVE AGENTS; MULTICENTER TRIAL; SAMPLE-SIZE; OUTCOMES; EPIDEMIOLOGY; HYPOTHERMIA; INCREASES; MORTALITY; MANNITOL	OBJECTIVE: Few randomized clinical trials (RCTs) in the field of traumatic brain injury (TBI) have shown a significant treatment benefit. We critically reviewed the use of two types of secondary analyses, covariate adjustment and subgroup analysis, which are common in TBI trials. METHODS: We performed a systematic, review of therapeutic phase III RCTs, including adult patients with acute, moderate-to-severe TBI. Glasgow Outcome Scale (GOS) at >= 3 months as outcome, and >= 50 patients per arm were required. We compared the actual reporting of covariate adjustment and subgroup analyses with the Consolidated Standards of Reporting Trials (CONSORT) recommendations. Likewise, we reviewed six protocols of large multicenter RCTs and compared planned and reported subgroups. RESULTS: We identified 18 RCTs (n = 6439). Sixteen trials used GOS at 6 months as outcome. Five RCTs reported covariate adjustment. The number of covariates was limited (<= 5), most frequently including age. Many covariates were outcome predicus tors. Four RCTs reported only adjusted treatment effects as the main efficacy parameter. Eleven RCTs reported subgroup analyses. Several subgroup factors (<= 7, mainly outcome predictors) and outcomes (<= 4) were included. The highest total number of subgroups was 15, and only three RCTs completely pre-specified subgroups. Notably, 10 of 11 RCTs performed inappropriate separate subgroup analyses. Of 11 RCTs, 5 gave subgroups the same emphasis as the overall effect. Reported subgroup analyses were insufficiently described, and clearly differed from those planned in the protocol. CONCLUSION: The reported covariate adjustment and subgroup analyses from TBI trials had several methodological shortcomings. Appropriate performance and reporting of covariate adjustment and subgroup analysis should be considerably improved in future TBI trials because interpretation of treatment benefits may be misleading otherwise.	Univ Rotterdam, Med Ctr, Erasmus MC, Dept Publ Hlth,Ctr Clin Decis Sci, Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Div Commun Hlth Sci, Edinburgh, Midlothian, Scotland; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA USA; Univ Rotterdam, Erasmus MC, Dept Neurol Surg, Rotterdam, Netherlands		Hernandez, AV (corresponding author), Univ Rotterdam, Med Ctr, Erasmus MC, Dept Publ Hlth,Ctr Clin Decis Sci, Rotterdam, Netherlands.	a.hernandez@erasmusmc.nl	Hernandez, Adrian V./ABD-4616-2021; Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Hernandez, Adrian V./0000-0002-9999-4003; Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS-042691-001A] Funding Source: Medline		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; BULLOCK MR, 2002, NEUROSURG FOCUS; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Choi S C, 1998, J Biopharm Stat, V8, P367, DOI 10.1080/10543409808835246; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cook DI, 2004, MED J AUSTRALIA, V180, P289, DOI 10.5694/j.1326-5377.2004.tb05928.x; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; *CPMP, 2003, CPMPEWP286399 EMEA; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; HERNANDEZ AV, 2004, 9 BIANN C EUR SOC ME; HUKKELHOVEN CW, 2000, BRIT MED J, P321; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Lu Li-quan, 2003, Chin J Traumatol, V6, P302; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Masson F, 2000, ANN FR ANESTH, V19, P261; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Moye LA, 2001, CONTROL CLIN TRIALS, V22, P605, DOI 10.1016/S0197-2456(01)00180-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; Simes RJ, 2004, MED J AUSTRALIA, V180, P467, DOI 10.5694/j.1326-5377.2004.tb06027.x; Vranos G, 2004, NEUROSURGERY, V55, P18, DOI 10.1227/01.NEU.0000126873.00845.A7; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	51	34	35	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2005	57	6					1244	1253		10.1227/01.NEU.0000186039.57548.96			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	991PQ	WOS:000233826300050	16331173				2022-02-06	
J	Inoue, Y; Shiozaki, T; Tasaki, O; Hayakata, T; Ikegawa, H; Yoshiya, K; Fujinaka, T; Tanaka, H; Shimazu, T; Sugimoto, H				Inoue, Y; Shiozaki, T; Tasaki, O; Hayakata, T; Ikegawa, H; Yoshiya, K; Fujinaka, T; Tanaka, H; Shimazu, T; Sugimoto, H			Changes in cerebral blood flow from the acute to the chronic phase of severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; neurological outcome; severe head injury; xenon-CT	MILD HYPOTHERMIA THERAPY; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; METABOLISM; PRESSURE; ISCHEMIA; COMA; VASOSPASM; TRAUMA; SCALE	We studied cerebral blood flow (CBF) in the transition from the acute to the chronic phase of severe head injury in order to determine patterns of change in relation to neurological outcome. We measured CBF with stable xenon-enhanced computed tomography (Xe-CT) in 20 consecutive patieints at 1, 2, 3, 4, and 6 weeks after severe head injury, and analyzed the relation between the pattern of change in CBF and neurological outcome at 6 months after injury. CBF values were significantly lower in the brain-injured patients than in 14 healthy volunteers, except at 3 weeks after injury, when CBF increased in the patients to a value that did not differ significantly from that in the normal volunteers. We therefore focused on the change in CBF at 3 weeks after injury. We separated the 20 brain-injured patients into two subgroups, of which the first (subgroup A) consisted of nine patients whose CBF had returned to normal by week 3 post-injury, while the second (subgroup B) consisted of 11 patients whose CBF was subnormal at week 3 post-injury. CBF was significantly higher in subgroup A than in subgroup B at 2 weeks post-injury (P < 0.05). CBF in subgroup B remained significantly lower than that in subgroup A throughout the study period. At 6 months post-injury, subgroup A had a significantly better neurological outcome than did subgroup B (p < 0.05). We conclude that patients whose CBF returns to normal at 2-3 weeks following severe traumatic brain injury after being abnormally low in the acute phase of injury can be expected to achieve a good neurological outcome.	Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neurosurg, Suita, Osaka 5650871, Japan		Inoue, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Acute Crit Med, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan.	yinoue@hp-emerg.med.osaka-u.ac.jp					BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CORTE FD, 1997, ACTA NEUROCHIR, V139, P639; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; GUR D, 1982, STROKE, V13, P750, DOI 10.1161/01.STR.13.6.750; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SAWADA Y, 1982, ANESTHESIOLOGY, V56, P53, DOI 10.1097/00000542-198201000-00013; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SEGAWA H, 1983, STROKE, V14, P356, DOI 10.1161/01.STR.14.3.356; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; TEASDALE G, 1974, LANCET, V2, P81	23	34	35	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1411	1418		10.1089/neu.2005.22.1411			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500004	16379579				2022-02-06	
J	Karhunen, H; Jolkkonen, J; Sivenius, J; Pitkanen, A				Karhunen, H; Jolkkonen, J; Sivenius, J; Pitkanen, A			Epileptogenesis after experimental focal cerebral ischemia	NEUROCHEMICAL RESEARCH			English	Article						animal models; brain ischemia; epilepsy; seizures	QUALITY-OF-LIFE; ARTERY OCCLUSION; BLOOD-FLOW; NONCONVULSIVE SEIZURES; STATUS EPILEPTICUS; BRAIN INFARCTION; GENE-EXPRESSION; TIME-COURSE; RAT MODEL; STROKE	Cerebrovascular diseases are one of the most common causes of epilepsy in adults, and the incidence of stroke-induced epileptogenesis is increasing as the population ages. The mechanisms that lead to stroke-induced epileptogenesis in a subpopulation of patients, however, are still poorly understood. Recent advances in inducing epileptogenesis in rodent focal ischemia models have provided tools that can be used to identify the risk factors and neurobiologic changes leading to development of epilepsy after stroke. Here we summarize data from models in which epileptogenesis has been studied after focal ischemia; photothrombosis, middle cerebral artery (MCA) occlusion with filament, and endothelin-1-induced MCA occlusion. Analysis of the data indicates that neurobiologic changes occurring during stroke-induced epileptogenesis share some similarities to those induced by status epilepticus or traumatic brain injury.	Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Neurosci & Neurol, FIN-70211 Kuopio, Finland; Brain Res & Rehabil Ctr Neuron, Kuopio, Finland; Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitka-nen@uku.fi					ARMON C, 1991, CLIN NEUROPHARMACOL, V14, P17, DOI 10.1097/00002826-199102000-00002; Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; Bernard C, 2004, SCIENCE, V305, P532, DOI 10.1126/science.1097065; BEZVENYUK Z, 2003, 3 SOC NEUR; Bidmon HJ, 1998, NEUROSCIENCE, V82, P397; Biernaskie J, 2001, MAGNET RESON MED, V46, P827, DOI 10.1002/mrm.1263; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Bogaert L, 2000, BRAIN RES, V887, P266, DOI 10.1016/S0006-8993(00)02959-0; BOGOUSSLAVSKY J, 1992, ARCH NEUROL-CHICAGO, V49, P385, DOI 10.1001/archneur.1992.00530280073025; Brewster AL, 2005, NEUROBIOL DIS, V19, P200, DOI 10.1016/j.nbd.2004.12.015; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; BuchkremerRatzmann I, 1996, STROKE, V27, P1105, DOI 10.1161/01.STR.27.6.1105; BuchkremerRatzmann I, 1997, NEUROREPORT, V8, P519, DOI 10.1097/00001756-199701200-00028; Burn J, 1997, BRIT MED J, V315, P1582, DOI 10.1136/bmj.315.7122.1582; Cheung CM, 2003, J NEUROL, V250, P839, DOI 10.1007/s00415-003-1091-3; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P184, DOI 10.1038/jcbfm.1986.31; Dihne M, 2002, STROKE, V33, P3006, DOI 10.1161/01.STR.0000039406.64644.CB; Dittmar M, 2003, STROKE, V34, P2252, DOI 10.1161/01.STR.0000083625.54851.9A; Ellerkmann RK, 2003, NEUROSCIENCE, V119, P323, DOI 10.1016/S0306-4522(03)00168-4; Engel J, 2001, EPILEPSIA, V42, P3, DOI 10.1046/j.1528-1157.2001.0420s6003.x; Frahm C, 2004, NEUROSCIENCE, V127, P341, DOI 10.1016/j.neuroscience.2004.05.027; Frontczak-Baniewicz M, 2001, NEUROENDOCRINOL LETT, V22, P87; Fuxe K, 1997, NEUROREPORT, V8, P2623, DOI 10.1097/00001756-199707280-00040; Gartshore G, 1996, NEUROSCI LETT, V202, P209, DOI 10.1016/0304-3940(95)12236-2; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Gregersen R, 2001, EXP BRAIN RES, V138, P384, DOI 10.1007/s002210100715; GROME JJ, 1988, J CEREBR BLOOD F MET, V8, P89, DOI 10.1038/jcbfm.1988.11; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HUNTER AJ, 1995, TRENDS PHARMACOL SCI, V16, P123, DOI 10.1016/S0165-6147(00)88999-3; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Jolkkonen J, 2003, BEHAV BRAIN RES, V138, P187, DOI 10.1016/S0166-4328(02)00241-3; Jonkman EJ, 1998, ACTA NEUROL SCAND, V98, P169, DOI 10.1111/j.1600-0404.1998.tb07289.x; Jutila L, 2002, ADV TECH STAND NEUR, V27, P3; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; KELLY KM, IN PRESS ANIMAL MODE; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; KOTILA M, 1992, EPILEPSIA, V33, P495, DOI 10.1111/j.1528-1157.1992.tb01698.x; KUDO M, 1982, STROKE, V13, P505, DOI 10.1161/01.STR.13.4.505; KUGE Y, 1995, STROKE, V26, P1655, DOI 10.1161/01.STR.26.9.1655; Labovitz DL, 2001, NEUROLOGY, V57, P200, DOI 10.1212/WNL.57.2.200; Leidy NK, 1999, NEUROLOGY, V53, P162, DOI 10.1212/WNL.53.1.162; Li GL, 2000, APMIS, V108, P98; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Liu JP, 2002, EPILEPSY RES, V52, P85, DOI 10.1016/S0920-1211(02)00194-8; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Lukasiuk K, 2004, NEUROCHEM RES, V29, P1169, DOI 10.1023/B:NERE.0000023604.91584.6c; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Miyake K, 2002, BRAIN RES, V935, P24, DOI 10.1016/S0006-8993(02)02420-4; Moyanova S, 1998, ARCH PHYSIOL BIOCHEM, V106, P384, DOI 10.1076/apab.106.5.384.4362; MULLER TB, 1995, STROKE, V26, P1453, DOI 10.1161/01.STR.26.8.1453; Neumann-Haefelin T, 1998, NEUROSCIENCE, V87, P871, DOI 10.1016/S0306-4522(98)00124-9; Nilsson T, 1997, NEUROSURGERY, V40, P346, DOI 10.1097/00006123-199702000-00023; Paolucci S, 1997, EPILEPSIA, V38, P266, DOI 10.1111/j.1528-1157.1997.tb01115.x; PITKANEN A, IN PRESS ANIMAL MODE; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reith J, 1997, STROKE, V28, P1585, DOI 10.1161/01.STR.28.8.1585; ROBINSON MJ, 1991, J CARDIOVASC PHARM, V17, pS354, DOI 10.1097/00005344-199100177-00101; RYGLEWICZ D, 1990, ACTA NEUROL SCAND, V81, P488; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Schroeter M, 1999, NEUROSCIENCE, V89, P1367, DOI 10.1016/S0306-4522(98)00398-4; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; SHARKEY J, 1993, J CEREBR BLOOD F MET, V13, P865, DOI 10.1038/jcbfm.1993.108; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Silverman IE, 2002, ARCH NEUROL-CHICAGO, V59, P195, DOI 10.1001/archneur.59.2.195; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; STROEMER RP, 1993, NEUROSCI LETT, V162, P51, DOI 10.1016/0304-3940(93)90557-2; Su H, 2002, J NEUROSCI, V22, P3645; Sutula TP, 2004, EPILEPSY RES, V60, P161, DOI 10.1016/j.eplepsyres.2004.07.001; Vernino S, 2003, STROKE, V34, P1828, DOI 10.1161/01.STR.0000080534.98416.A0; Wang CX, 2001, J NEUROSCI METH, V109, P147, DOI 10.1016/S0165-0270(01)00408-3; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Williams AJ, 2002, BRAIN RES, V932, P45, DOI 10.1016/S0006-8993(02)02275-8; Williams AJ, 2001, J PHARMACOL EXP THER, V299, P48; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Witte O W, 1999, Adv Neurol, V81, P25; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	83	34	37	0	7	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	DEC	2005	30	12					1529	1542		10.1007/s11064-005-8831-y			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	994TN	WOS:000234054200009	16362772				2022-02-06	
J	Marin-Caballos, A; Murillo-Cabezas, F; Cayuela-Dominguez, A; Dominguez-Roldan, JM; Rincon-Ferrari, MD; Valencia-Anguita, J; Flores-Cordero, JM; Munoz-Sanchez, MA				Marin-Caballos, A; Murillo-Cabezas, F; Cayuela-Dominguez, A; Dominguez-Roldan, JM; Rincon-Ferrari, MD; Valencia-Anguita, J; Flores-Cordero, JM; Munoz-Sanchez, MA			Cerebral perfusion pressure and risk of brain hypoxia in severe head injury: a prospective observational study	CRITICAL CARE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; TISSUE OXYGEN; NOREPINEPHRINE; AUGMENTATION; DOPAMINE; TENSION; BLOOD; PO2	Introduction Higher and lower cerebral perfusion pressure (CPP) thresholds have been proposed to improve brain tissue oxygen pressure (PtiO(2)) and outcome. We study the distribution of hypoxic PtiO(2) samples at different CPP thresholds, using prospective multimodality monitoring in patients with severe traumatic brain injury. Methods This is a prospective observational study of 22 severely head injured patients admitted to a neurosurgical critical care unit from whom multimodality data was collected during standard management directed at improving intracranial pressure, CPP and PtiO(2). Local PtiO(2) was continuously measured in uninjured areas and snapshot samples were collected hourly and analyzed in relation to simultaneous CPP. Other variables that influence tissue oxygen availability, mainly arterial oxygen saturation, end tidal carbon dioxide, body temperature and effective hemoglobin, were also monitored to keep them stable in order to avoid non-ischemic hypoxia. Results Our main results indicate that half of PtiO(2) samples were at risk of hypoxia ( defined by a PtiO(2) equal to or less than 15 mmHg) when CPP was below 60 mmHg, and that this percentage decreased to 25% and 10% when CPP was between 60 and 70 mmHg and above 70 mmHg, respectively ( p < 0.01). Conclusion Our study indicates that the risk of brain tissue hypoxia in severely head injured patients could be really high when CPP is below the normally recommended threshold of 60 mmHg, is still elevated when CPP is slightly over it, but decreases at CPP values above it.	Hosp Univ Virgen Rocio, Serv Cuidados Crit & Urgencias, Seville 41013, Spain; Hosp Univ Virgen Rocio, Unidad Apoyo Invest, Seville 41013, Spain; Hosp Univ Virgen Rocio, Serv Neurocirugia, Seville 41013, Spain		Marin-Caballos, A (corresponding author), Hosp Univ Virgen Rocio, Serv Cuidados Crit & Urgencias, Avda Manuel Siurot S-N, Seville 41013, Spain.	antmarin@terra.es	Murillo-Cabezas, Francisco/AAO-3348-2021; IBIS, NEUROCRITICOS/C-1805-2016; Dominguez-Roldan, Jose-Maria/M-1728-2016	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478			BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Bruzzone P, 1998, ACT NEUR S, V71, P111; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Schneider GH, 1998, ACT NEUR S, V71, P62; SIGGAARDANDERSEN O, 1995, CRIT CARE MED, V23, P1284, DOI 10.1097/00003246-199507000-00020; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Stocchetti N, 1998, ACT NEUR S, V71, P162; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; UPDATE NOTICE GUIDEL; MANAGEMENT PROGNOS 1	27	34	36	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	DEC	2005	9	6					R670	R676		10.1186/cc3822			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014XR	WOS:000235514400014	16356218	Green Published, gold			2022-02-06	
J	Marmarou, A; Guy, M; Murphey, L; Roy, F; Layani, L; Combal, JP; Marquer, C				Marmarou, A; Guy, M; Murphey, L; Roy, F; Layani, L; Combal, JP; Marquer, C		Amer Brain Injury Consortium	A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B-2 receptor antagonist anatibant (LF16-0687Ms) in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						anatibant; bradykinin; clinical trial; LF16-0687 Ms; pharmacokinetics	KALLIKREIN-KININ SYSTEM; HEAD-INJURY; CLINICAL-TRIALS; LF 16-0687MS; EDEMA; PLASMA; MEDIATOR; INHIBITION; METABOLITE; HUMANS	Traumatic brain injury (TBI) mortality and morbidity remains a public health challenge. Because experimental studies support an important role of bradykinin (BK) in the neurological deterioration that follows TBI, a double-blind, randomized, placebo-controlled study of Anatibant (LF16-0687Ms), a selective and potent antagonist of the BK B-2 receptor, was conducted in severe (Glasgow Coma Scale [GCS] < 8) TBI patients (n = 25) at six sites in the United States. At 8-12 h after injury (9.9 +/- 2.8 h), patients received a single subcutaneous injection of Anatibant (3.75 mg or 22.5 mg, n = 10 each) or placebo (n = 5). The primary objective was to investigate the pharmacokinetics of Anatibant; general safety, local tolerability, levels of the bradykinin metabolite BK1-5 in plasma and cerebrospinal fluid (CSF), intracranial pressure (ICP), and cerebral perfusion pressure were also assessed. We observed a dose-proportionality of the pharmacokinetics, C-max, and AUC of Anatibant. V-d/F, Cl/F, and t(1/2) were independent on the dose and protein binding was > 97.7%. Anatibant, administered as single subcutaneous injections of 3.75 g and 22.5 mg, was well tolerated in severe TBI patients with no unexpected clinical adverse events or biological abnormalities observed. Interestingly, plasma and CSF levels of BK1-5 were significantly and markedly increased after trauma (e.g., 34,700 +/- 35,300 fmol/mL in plasma vs. 34.9 +/- 5.6 fmol/mL previously reported for normal volunteers), supporting the use of Anatibant as a treatment of secondary brain damage. To address this issue, a dose-response trial that would investigate the effects of Anatibant on the incidence of raised ICP and on functional outcome in severe TBI patients is needed.	Labs Fournier SA, F-21121 Daix, France; ABIC Tech Ctr, Richmond, VA USA; Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA		Guy, M (corresponding author), Labs Fournier SA, 50 Rue Dijon, F-21121 Daix, France.	m.guy@fr.fournierpharma.com					BETZ AL, 1992, NEUROSURGERY SCI BAS, P353; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; FESSLER RD, 1993, ANN EMERG MED, V22, P998, DOI 10.1016/S0196-0644(05)82741-6; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HELLAL F, 2003, NSS 2003 BIL; Kaplan R P, 1987, Adv Dermatol, V2, P19; KASUYA H, 1988, ACTA NEUROCHIR, V91, P120, DOI 10.1007/BF01424566; Kenworthy KE, 1999, BRIT J CLIN PHARMACO, V48, P716; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; Maas AIR, 2004, ACT NEUR S, V89, P113; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Murphey LJ, 2000, J PHARMACOL EXP THER, V294, P263; Murphey LJ, 2004, J PHARMACOL EXP THER, V308, P1046, DOI 10.1124/jpet.103.059337; Murphey LJ, 2001, ANAL BIOCHEM, V292, P87, DOI 10.1006/abio.2001.5073; MURR R, 1993, ACTA NEUROCHIR, P11; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Phillis J. W., 1993, REGULATION CEREBRAL, P315; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pretorius M, 2004, CLIN PHARMACOL THER, V76, P379, DOI 10.1016/j.clpt.2004.06.004; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Schilling L, 1997, KIDNEY INT, pS69; Schulz J, 2000, ACT NEUR S, V76, P137; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; SUGIMOTO K, AM J PHYSL, V274, pR1556; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505; 2002, CDC REPORT, V51, P1	47	34	35	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1444	1455		10.1089/neu.2005.22.1444			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500007	16379582				2022-02-06	
J	Fonseca, AH; Ochsner, MG; Bromberg, WJ; Gantt, D				Fonseca, AH; Ochsner, MG; Bromberg, WJ; Gantt, D			All-terrain vehicle injuries: Are they dangerous? A 6-year experience at a level I trauma center after legislative regulations expired	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Meeting of the Southeastern-Surgical-Congress	FEB 11-15, 2005	New Orleans, LA	SE Surg Congress			CHILDREN	All-terrain vehicles (ATVs) have increased in popularity and sales since 1971. This rise in popularity led to an increase in injuries resulting in voluntary industry rider safety regulations in 1988, which expired without renewal in 1998. Our purpose was twofold, to determine the incidence and severity of ATV injuries in our patient population and what, if any impact the safety regulations had. To further characterize the risk of ATV use, we compared them to a vehicle generally recognized as dangerous, the motorcycle (MC). Our trauma registry was reviewed from January 1998 through August 2004 for ATV or MC injured. Data collected included age, gender, mortality, Injury Severity Score (ISS), helmet use, and injury distribution. These were compared to our data from the decade of regulation. There were 352 MC and 221 ATV patients. ATV injured demonstrated a higher proportion of pediatric and female patients (P < 0.001 and P < 0.01, respectively), a decrease in helmet use (8.6% vs 64.7%, P < 0.001), and increased closed head injuries (CHI) (54.2% vs 44.9%, P < 0.05) compared with MC injured. ISS and mortality were similar. The average number of patients from 1988 to 1998 was 6.9/yr compared to 31.6/yr (P < 0.001) during 1998-2004 with equal ISS. Our data show that there has been a dramatic and progressive increase in the number of ATV crashes since expiration of industry regulations. ATVs are as dangerous as MCs based on patient ISS and mortality. There are significantly more children and women injured on ATVs. The lower rate of helmet use in ATVs may account for the significantly greater incidence of CHI. These data mandate the need for injury prevention efforts for ATV riders, in particular children, through increased public awareness and new legislation.	Mem Hlth Univ Med Ctr, Dept Surg Educ, Savannah, GA USA		Fonseca, AH (corresponding author), 1105 E 50th St, Savannah, GA 31404 USA.						Acosta JA, 2003, J TRAUMA, V55, P282, DOI 10.1097/01.TA.0000080525.77566.ED; Branas CC, 2001, ACCIDENT ANAL PREV, V33, P641, DOI 10.1016/S0001-4575(00)00078-6; Brown RL, 2002, J PEDIATR SURG, V37, P375, DOI 10.1053/jpsu.2002.30826; HARGARTEN SW, 1991, AM J EMERG MED, V9, P149, DOI 10.1016/0735-6757(91)90178-M; KYLE SB, 1998, REPORT 1997 INJURY S; Lynch JM, 1998, J PEDIATR SURG, V33, P329, DOI 10.1016/S0022-3468(98)90456-0; Moore MJ, 1997, INT REV LAW ECON, V17, P379, DOI 10.1016/S0144-8188(97)00022-7; Murphy N, 2004, J TRAUMA, V56, P1185, DOI 10.1097/01.TA.0000123038.94864.E2; RODGERS GB, 1990, ACCIDENT ANAL PREV, V22, P47, DOI 10.1016/0001-4575(90)90006-7; Rodgers GB, 1999, ACCIDENT ANAL PREV, V31, P409, DOI 10.1016/S0001-4575(98)00080-3; Ross RT, 1999, AM SURGEON, V65, P870; Upperman JS, 2003, J PEDIATR SURG, V38, P1284, DOI 10.1016/S0022-3468(03)00383-X; *US CONS PROD SAF, 1998, ALLT VEH EXP INJ DEA; *US CONS PROD SAF, 2002, ANN REP ATV DEATH IN	14	34	34	0	0	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	NOV	2005	71	11					937	940					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	985SH	WOS:000233398200013	16372612				2022-02-06	
J	Pegg, PO; Auerbach, SM; Seel, RT; Buenaver, LF; Kiesler, DJ; Plybon, LE				Pegg, PO; Auerbach, SM; Seel, RT; Buenaver, LF; Kiesler, DJ; Plybon, LE			The impact of patient-centered information on patients' treatment satisfaction and outcomes in traumatic brain injury rehabilitation	REHABILITATION PSYCHOLOGY			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; OWN HEALTH-CARE; DECISION-MAKING; INTERPERSONAL IMPACTS; STRESS MANAGEMENT; RESEARCH ISSUES; INTERVENTIONS; CIRCUMPLEX; ADJUSTMENT; MEDICINE	Objective: To evaluate the effects on patients with traumatic brain injury (TBI) of detailed, personalized information about their injuries, acute care treatment, and rehabilitation progress. Participants: Twenty-eight former or present military personnel (mean age = 30 years) with moderate to severe TBI (mean of 29 days spent in intensive care before admission to TBI unit). Design: Two (personalized information vs. general information) X 2 (high- vs. low-patient preference for health care information) factorial design. Interpersonal behavior of patients, information providers, and health care staff were measured by the Impact Message Inventory. Outcome Measures: Rehabilitation Intensity of Therapy Scale, Functional Independence Measure, Treatment Satisfaction Questionnaire. Results: Patients given personalized information exerted greater effort in physical therapy, made greater improvement in functional independence, and were more satisfied with rehabilitation treatment. Patient preference for information and ratings of interpersonal behavior were largely unrelated to patient outcomes. Conclusion: Cognitively impaired TBI patients can benefit from interventions designed to enhance their sense of control and personal involvement in their own care.	Western Kentucky Univ, Dept Psychol, Bowling Green, KY 42101 USA; Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA		Pegg, PO (corresponding author), Western Kentucky Univ, Dept Psychol, 1 Big Red Way, Bowling Green, KY 42101 USA.	phil.pegg@wku.edu					AUERBACH SM, 1983, J PERS SOC PSYCHOL, V44, P1284, DOI 10.1037/0022-3514.44.6.1284; Auerbach SM, 2004, J BEHAV MED, V27, P11, DOI 10.1023/B:JOBM.0000013641.64651.16; AUERBACH SM, 1989, J CONSULT CLIN PSYCH, V57, P388, DOI 10.1037/0022-006X.57.3.388; Auerbach SM, 2002, J HEALTH PSYCHOL, V7, P393, DOI 10.1177/1359105302007004328; Auerbach SM, 2002, J BEHAV MED, V25, P17, DOI 10.1023/A:1013585617303; Auerbach SM, 2001, J HEALTH PSYCHOL, V6, P191, DOI 10.1177/135910530100600208; Auerbach SM, 2000, ANN BEHAV MED, V22, P246, DOI 10.1007/BF02895120; AVERILL JR, 1973, PSYCHOL BULL, V80, P286, DOI 10.1037/h0034845; Baltes M. M., 1986, PSYCHOL CONTROL AGIN; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Cromwell R. L., 1977, ACUTE MYOCARDIAL INF; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Elliott TR, 2002, REHABIL PSYCHOL, V47, P131, DOI 10.1037//0090-5550.47.2.131; Ford S, 1995, EUR J CANCER, V31A, P2264, DOI 10.1016/0959-8049(95)00336-3; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hogbin B., 1992, PSYCHO-ONCOLOGY, V1, P147, DOI [10.1002/pon.2960010304, DOI 10.1002/PON.2960010304]; Kaplan RM, 1999, ANN BEHAV MED, V21, P3, DOI 10.1007/BF02895027; Kiesler D.J., 1996, CONT INTERPERSONAL T; Kiesler DJ, 2003, SOC SCI MED, V57, P1707, DOI 10.1016/S0277-9536(02)00558-0; KIESLER DJ, 1983, PSYCHOL REV, V90, P185, DOI 10.1037/0033-295X.90.3.185; Kiesler DJ., 1993, IMPACT MESSAGE INVEN; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Lazure L L, 1995, Am J Crit Care, V4, P157; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARTELLI MF, 1987, J CONSULT CLIN PSYCH, V55, P201, DOI 10.1037/0022-006X.55.2.201; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; MERZ JF, 1990, J LEGAL MED, V11, P321, DOI 10.1080/01947649009510831; MEYER TJ, 1995, HEALTH PSYCHOL, V14, P101, DOI 10.1037/0278-6133.14.2.101; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PEGG PO, 2001, TREATMENT SATISFACTI; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schmidt JA, 1999, J COUNS PSYCHOL, V46, P325, DOI 10.1037/0022-0167.46.3.325; Seel R. T., 2001, REHABILITATION INTEN; SIMINOFF L A, 1989, Annals of Behavioral Medicine, V11, P108, DOI 10.1207/s15324796abm1103_3; STEWART M, 1989, COMMUNICATING MED PA; SULS J, 1989, J CONSULT CLIN PSYCH, V57, P372, DOI 10.1037/0022-006X.57.3.372; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *UN DAT SYST MED R, 1997, FIM INSTR	42	34	34	0	6	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2005	50	4					366	374		10.1037/0090-5550.50.4.366			9	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	990KL	WOS:000233741700006					2022-02-06	
J	Holsti, M; Kadish, HA; Sill, BL; Firth, SD; Nelson, DS				Holsti, M; Kadish, HA; Sill, BL; Firth, SD; Nelson, DS			Pediatric closed head injuries treated in an observation unit	PEDIATRIC EMERGENCY CARE			English	Article; Proceedings Paper	Research Forum of the American-College-of-Emergency-Physicians	OCT 12-13, 2003	Boston, MA	Amer Coll Emergency Physicians		observation unit; closed head injuries		Background: Closed head injury (CHI) is common in childhood and frequently results in hospital admission for observation and treatment. Observation units (OUs) have shown significant benefits for patients and physicians. At our institution, a level 1 pediatric trauma center, patients with CHI are often admitted to an OU for up to 24 hours of observation and treatment. Study Objectives: To describe characteristics of patients with a CHI admitted to a pediatric OU and to identify demographic, historical, clinical, and radiographic factors associated with the need for unplanned inpatient admission (UIA) after OU management. Methods: Retrospective cohort review of all OU admissions for CHI at Primary Children's Medical Center (PCMC) from August 1999 through July 2001. Data collected included age, gender, mechanism of injury, presenting symptoms, physical examination findings, head computed tomography (CT) results, diagnosis, length of stay, outcome of the injury, and need for UIA. Results: During the study period, 827 patients were seen in the ED for CHI. Two hundred eighty-five patients (34%) were admitted to the OU, 273 (33%) were admitted to an inpatient service, and 269 (33%) were discharged home. OU patients had a median age of 5.2 years, ranging from 2 weeks to 17 years. Sixty-one percent were male. The median admission length of stay was 13 hours. Common mechanisms of injury included: falls (60%), motor vehicle accidents (12%), bicycle accidents (10%), impacts from objects (9%), autopedestrian accidents (4.6%), and snow-related accidents (4.6%). Presenting symptoms in the ED included vomiting (39%), loss of consciousness (26%), amnesia to event (19%), persistent amnesia (5%), and seizures (4%). Physical examination findings noted in the ED included altered mental status (45%), facial abnormalities (43%), scalp abnormalities (38%), and neurologic deficits (9%). Two hundred eighty patients (98%) admitted to the OU had a head CT performed. Skull fractures were present in 109 patients (39%) and intracranial pathology (ie, epidural hematoma, subdural hematoma, or intraparenchymal contusion) was present in 38 patients (13%). Only 13 patients (5%) required admission to an inpatient service from the OU for the following reasons: continued need for intravenous (IV) fluids (n = 5), venous thrombosis (n = 2), persistent CSF leakage (n = 3), decreased level of consciousness (n = 1), pain management (n = 1), and clearing of the patient's cervical spine (n = 1). No patient deteriorated or required neurosurgery. Patients with basilar skull fractures, a head laceration (scalp or facial), and patients that needed IV fluids in the ED were more likely to need inpatient admission after a 24-hour observation stay. Logistic regression analysis identified basilar skull fractures (OR 11.61), face/scalp lacerations (OR 7.52), and the need for ED IV fluid administration (OR 4.26) to be associated with UIA. Most children with these findings were successfully discharged within 24 hours, however. Age, sex, loss of consciousness, seizure, vomiting, arnnesia, altered mental status, neurologic deficits, intracranial pathology, and skull fractures (aside from basilar skull fractures) were not related to UIA. Conclusion: The vast majority (96%) of pediatric OU patients with CHI such as small intracranial hematomas, skull fractures, and concussions were discharged safely within 24 hours without serious comp 1 i cations. The presence of a basilar skull fracture, head laceration, and the need for ED IV fluids were associated with increased risk ofUIA. OU admission is an efficient and effective management setting for children with stable intracranial pathology, skull fractures, and concussions.	Univ Utah, Sch Med, Div Pediat Emergency Med, Dept Pediat,Primary Childrens Med Ctr, Salt Lake City, UT 84158 USA; Univ Utah, Primary Childrens Med Ctr, Dept Pediat, Salt Lake City, UT 84158 USA		Holsti, M (corresponding author), Univ Utah, Sch Med, Div Pediat Emergency Med, Dept Pediat,Primary Childrens Med Ctr, POB 581289, Salt Lake City, UT 84158 USA.	maija.holsti@hsc.utah.edu					DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; OCHOAGOMEZ J, 2000, EUR J EMERG MED, V7, P257; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Scribano PV, 2001, PEDIATR EMERG CARE, V17, P321, DOI 10.1097/00006565-200110000-00001	5	34	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	OCT	2005	21	10					639	644		10.1097/01.pec.0000181426.25342.a9			6	Emergency Medicine; Pediatrics	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	975MY	WOS:000232667800001	16215464				2022-02-06	
J	Tweedy, SM; Trost, SG				Tweedy, SM; Trost, SG			Validity of accelerometry for measurement of activity in people with brain injury	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						activity monitors; health promotion; physical activity; rehabilitation; stroke; traumatic brain injury	COMPUTER-SCIENCE; VALIDATION; INC.	Purpose: To evaluate the validity of a uniaxial accelerometer (MTI Actigraph) for measuring physical activity in people with acquired brain injury (ABI) using portable indirect calorimetry (Cosmed K4b(2)) as a criterion measure. Methods: Fourteen people with ABI and related gait pattern impairment (age 32 +/- 8 yr) wore an MTI Actigraph that measured activity (counts(.)min-(1)) and a Cosmed K4b(2) that measured oxygen consumption (mL(.)kg(-1.)min(-1)) during four activities: quiet sitting (QS) and comfortable paced (CP), brisk paced (BP), and fast paced (FP) walking. MET levels were predicted from Actigraph counts using a published equation and compared with Cosmed measures. Predicted METs for each of the 56 activity bouts (14 participants X 4 bouts) were classified (light, moderate, vigorous, or very vigorous intensity) and compared with Cosmed-based classifications. Results: Repeated-measures ANOVA indicated that walking condition intensities were significantly different (P < 0.05) and the Actigraph detected the differences. Overall correlation between measured and predicted METs was positive, moderate, and significant (r = 0.74). Mean predicted METs were not significantly different from measured for CP and BP, but for FP walking, predicted METs were significantly less than measured (P < 0.05). The Actigraph correctly classified intensity for 76.8% of all activity bouts and 91.5% of light- and moderate-intensity bouts. Conclusions: Actigraph counts provide a valid index of activity across the intensities investigated in this study. For light to moderate activity, Actigraph-based estimates of METs are acceptable for group-level analysis and are a valid means of classifying activity intensity. The Actigraph significantly underestimated higher intensity activity, although, in practice, this limitation will have minimal impact on activity measurement of most community-dwelling people with ABI.	Univ Queensland, Sch Human Movement Studies, Brisbane, Qld 4072, Australia; Kansas State Univ, Dept Kinesiol, Manhattan, KS 66506 USA; Kansas State Univ, Commun Hlth Inst, Manhattan, KS 66506 USA		Tweedy, SM (corresponding author), Univ Queensland, Sch Human Movement Studies, Brisbane, Qld 4072, Australia.	seant@hms.uq.edu.au	Tweedy, Sean M/E-8448-2011; Trost, Stewart G/B-5948-2012	Tweedy, Sean M/0000-0002-2011-3382; Trost, Stewart G/0000-0001-9587-3944			*AM COLL SPORTS ME, 2000, ACSMS GUID EX TEST P, P22; Bauman A, 1999, J Sci Med Sport, V2, P30, DOI 10.1016/S1440-2440(99)80182-0; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boyd R, 1999, DEV MED CHILD NEUROL, V41, P676, DOI 10.1017/S0012162299001395; *DEP HLTH FAM SERV, 1998, DEV ACT AUSTR FRAM A, P1; *EUR HEART NETW, 1999, PHYS ACT CARD DIS PR, P21; FORTUNE N, 1999, DEFINITION INCIDENCE; Freedson PS, 1998, MED SCI SPORT EXER, V30, P777, DOI 10.1097/00005768-199805000-00021; Gonzalez EG, 2001, DOWNEY DARLINGS PHYS, P417; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; HASKELL WL, 1998, EXERCISE HLTH CONNEC, P301; HOFFER MM, 1973, J BONE JOINT SURG AM, VA 55, P137, DOI 10.2106/00004623-197355010-00014; LUCIA A, 1993, INT J SPORTS MED, V14, P380, DOI 10.1055/s-2007-1021196; McLaughlin JE, 2001, INT J SPORTS MED, V22, P280, DOI 10.1055/s-2001-13816; MELANSON EL, 1995, MED SCI SPORT EXER, V27, P934; Nichols JF, 2000, RES Q EXERCISE SPORT, V71, P36, DOI 10.1080/02701367.2000.10608878; SALLIS JF, 1999, PHYSICAL ACTIVITY BE, P5; Trost SG, 1998, MED SCI SPORT EXER, V30, P629, DOI 10.1097/00005768-199804000-00023; US Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; US Department of Health and Human Services, 2002, PROGR BRIEF E BYRN M, P2; Vinet A, 1996, SPINAL CORD, V34, P288, DOI 10.1038/sc.1996.52; Welk GJ, 2000, MED SCI SPORT EXER, V32, pS489, DOI 10.1097/00005768-200009001-00008; *WHO, 2004, FOOD NUTR BULL, V25, P292	23	34	34	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2005	37	9					1474	1480		10.1249/01.mss.0000177584.43330.ae			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	967FY	WOS:000232078100004	16177597				2022-02-06	
J	Kane, RL; Short, P; Sipes, W; Flynn, CF				Kane, RL; Short, P; Sipes, W; Flynn, CF			Development and validation of the spaceflight cognitive assessment tool for windows (WinSCAT)	AVIATION SPACE AND ENVIRONMENTAL MEDICINE			English	Article; Proceedings Paper	Workshop on New Directions in Spaceflight Behavioral Health	DEC 02-03, 2003	Davis, CA			spaceflight; behavioral health; cognitive assessment; psychometrics	INDUCED ALLERGIC RHINITIS; BRAIN INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; MENTAL PERFORMANCE; DIPHENHYDRAMINE; CONCUSSION; VIGILANCE; TESTS	The Spaceflight Cognitive Assessment Tool for Windows (WinSCAT) was developed by an integrated product team as a tool to support medical operations at NASA Johnson Space Center and as way to monitor the neurocognitive status of space crews. It is based on 20 yr of experience in performance and cognitive testing within the U.S. Department of Defense. As a result, WinSCAT development has benefited from diverse efforts supporting its technical reliability and validation. The rationale, background, and development of WinSCAT are described, research supporting its use is summarized, and recommendations are made for its continued development.	Univ Maryland, Sch Med, VA Med Ctr, Baltimore, MD 21201 USA; Baltimore Educ & Res Fdn, Baltimore, MD USA; Wyle Labs, Houston, TX USA; NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA		Kane, RL (corresponding author), Univ Maryland, Sch Med, VA Med Ctr, 10 N Greene St, Baltimore, MD 21201 USA.	robert.kane@med.va.gov					Anger WK, 1996, NEUROTOXICOL TERATOL, V18, P347, DOI 10.1016/0892-0362(96)00079-7; BANDERET LE, 2002, MID S AM PSYCH ASS A; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2003, ARCH CLIN NEUROPSYCH, V18, P740; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Eddy DR, 1998, ACTA ASTRONAUT, V43, P193, DOI 10.1016/S0094-5765(98)00154-4; Farmer K, 2000, HEADACHE, V40, P657, DOI 10.1046/j.1526-4610.2000.040008657.x; FRENCH J, 1999, SENSITIVITY SCAT SLE; GAMACHE G, 1998, NCRFTR9801; Holliday SL, 2003, LUPUS, V12, P697, DOI 10.1191/0961203303lu442oa; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane R. L., 1997, NEUROPSYCHOLOGY HDB; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KANE RL, 1997, CONT APPROACHES NEUR; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; LAW WA, 2003, J INT NEUROPSYCH SOC, V9, P248; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; LOWE M, 1920, IN PRESS ACCELERATED; LOWE M, 1998, 1301 NEDU TR; LOWE M, 2000, UNDERSEA HYPERBAR M, V27, P15; LOWE M, 1999, UNDERSEA HYPERB ME S, V26, P17; Manzey D, 1998, ERGONOMICS, V41, P537, DOI 10.1080/001401398186991; Manzey D, 2000, AVIAT SPACE ENVIR MD, V71, pA69; RETZLAFF P, 1999, MS80665 NASA LB JOHN; RIKKEN G, 2000, ANN M EUR AC ALL CLI; ROEBUCKSPENCER T, 2004, ANN M AM PSYCH ASS 2; SARABIA S, 2004, ANN M AM COLL CLIN P; STARBUCK VN, 1995, NEUROPSY NEUROPSY BE, V8, P189; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; WARDEN DL, 2003, M AM AC NEUR 2003 AP, V60, pA302; Wilken JA, 2003, ANN ALLERG ASTHMA IM, V91, P375, DOI 10.1016/S1081-1206(10)61685-7; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa; Wilken JA, 2002, ANN ALLERG ASTHMA IM, V89, P372, DOI 10.1016/S1081-1206(10)62038-8	34	34	36	2	12	AEROSPACE MEDICAL ASSOC	ALEXANDRIA	320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA	0095-6562			AVIAT SPACE ENVIR MD	Aviat. Space Environ. Med.	JUN	2005	76	6		S			B183	B191					9	Public, Environmental & Occupational Health; Medicine, General & Internal; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine; Sport Sciences	933GJ	WOS:000229616600024	15943211				2022-02-06	
J	Takeda, T; Ishigami, K; Hoshina, S; Ogawa, T; Handa, J; Nakajima, K; Shimada, A; Nakajima, T; Regner, CW				Takeda, T; Ishigami, K; Hoshina, S; Ogawa, T; Handa, J; Nakajima, K; Shimada, A; Nakajima, T; Regner, CW			Can mouthguards prevent mandibular bone fractures and concussions? A laboratory study with an artificial skull model	DENTAL TRAUMATOLOGY			English	Article						mouthguard; distortion; acceleration; concussions; mandibular bone fractures	AMERICAN FOOTBALL; MOUTH PROTECTORS; DENTAL INJURIES; ABSORPTION; BASKETBALL; PLAYERS; SPORTS; SHOCK	Some sports' accidents are responsible for inflicting traumatic brain injuries and mandibular bone fractures when impacts occur to the chin. It is often thought that mouthguards can prevent many of these injuries. However, such assertions may be insufficient without adequate research. It is therefore necessary to establish a systematic method of investigation to solve this problem. In the present laboratory study, tests were performed using pendulum impact equipment and an artificial skull model connected to strain gages and accelerometers to simulate and measure the surface distortions related to bone deformation or fractures and the acceleration of the head related to concussions. As impacts, direct blows to the mandibular undersurface were applied. As a result, wearing a mouthguard decreased (P < 0.01) the distortion to the mandibular bone and the acceleration of the head significantly compared with not wearing a mouthguard (54.7%: to the mandible - measured at a total of three different points, 18.5%: to the head measured at a total of three different points). Within the limits of this study, the following conclusions were drawn: The present measuring system in this study was able to evaluate the distortion to the mandibular and the acceleration of the head from the direct blow to the mandibular undersurface. Mouthguards can reduce distortion to the mandibular and the acceleration of the head from the same blow. So mouthguards might have the possibility to prevent mandibular bone fractures and concussions. However, further well-designed and exhaustive studies are vital to show that mouthguards reduce the incidence of concussions and mandibular bone fractures.	Tokyo Dent Coll, Dept Sports Dent, Mihama Ku, Chiba 2618502, Japan; Tokyo Natl Coll Technol, Tokyo, Japan		Takeda, T (corresponding author), Tokyo Dent Coll, Dept Sports Dent, Mihama Ku, 1-2-2 Masago, Chiba 2618502, Japan.	takedat@attglobal.net					*C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CHAPMAN PJ, 1985, AUST DENT J, V30, P364, DOI 10.1111/j.1834-7819.1985.tb02533.x; de Wet F A, 1981, J Dent Assoc S Afr, V36, P249; de Wet FA, 1999, J PROSTHET DENT, V82, P301, DOI 10.1016/S0022-3913(99)70084-3; DORNEY B, 1994, PHILLIP J, V9, P311; GARON MW, 1986, J AM DENT ASSOC, V112, P663, DOI 10.14219/jada.archive.1986.0063; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; ISHIKAWA G, 1982, DENT PATHOLOGY, P344; KAWAMATA T, 2002, J JAPN SOC CLIN SPOR, V19, P637; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KUMAZAWA Y, 1992, KANAGAWA SHIGAKU, V26, P412; KURITA H, 1994, J JPN STOMATOL SOC, V43, P270; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; MARROW RM, 1986, DENT SCH Q U TEXAS, V2, P11; MASESTRELLODEMO.MG, 1989, J DENT CHILD, V1, P36; MCNUTT T, 1989, Pediatric Dentistry, V11, P209; MORROW RM, 1991, ATHLETIC TRAINING, V26, P344; Morton J G, 1979, N Z Dent J, V75, P151; PICCININNI P, 2001, BRIT J SPORT MED, V35, P375; POWERS J M, 1984, Journal of the American Dental Association, V109, P84; SANE J, 1988, AM J SPORT MED, V16, P647, DOI 10.1177/036354658801600616; Satoh T, 1990, J JPN SOC BIOMECHANI, V14, P68; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; SUEI Y, 1993, J JPN STOMATOL SOC, V42, P739; SUMIYOSHI S, 1996, NIHON KOUKUU GEKA GA, V42, P1192; Taguchi Y, 2002, J JAPN SOC CLIN SPOR, V19, P609; Takeda T, 2004, DENT TRAUMATOL, V20, P150, DOI 10.1111/j.1600-4469.2004.00247.x; Takeda T, 2004, DENT TRAUMATOL, V20, P29, DOI 10.1111/j.1600-4469.2004.00220.x; Takeda T, 2004, DENT TRAUMATOL, V20, P12, DOI 10.1111/j.1600-4469.2004.00210.x; TAKEDA T, 1995, J JPN SOC CLIN SPORT, V12, P569; TAKEDA T, 1996, J JPN SOC CLIN SPORT, V13, P1152; TANAKA N, 1992, J STOMATOL SOC JPN, V59, P571; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Woodmansey K F, 1999, Gen Dent, V47, P64	38	34	36	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	JUN	2005	21	3					134	140		10.1111/j.1600-9657.2005.00320.x			7	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	924FF	WOS:000228963600004	15876323				2022-02-06	
J	Hellmich, HL; Capra, B; Eidson, K; Garcia, J; Kennedy, D; Uchida, T; Parsley, M; Cowart, J; DeWitt, DS; Prough, DS				Hellmich, HL; Capra, B; Eidson, K; Garcia, J; Kennedy, D; Uchida, T; Parsley, M; Cowart, J; DeWitt, DS; Prough, DS			Dose-dependent neuronal injury after traumatic brain injury	BRAIN RESEARCH			English	Article						Fluoro-Jade; laser capture microdissection; injured neuron; gene expression	LATERAL FLUID PERCUSSION; FLUORO-JADE; CLINICAL-TRIALS; CELL-DEATH; NEUROPROTECTION; DEFICITS; HIPPOCAMPUS; MECHANISMS; EXPRESSION; ISCHEMIA	The Fluoro-Jade (FJ) stain reliably identifies degenerating neurons after multiple mechanisms of brain injury. We modified the FJ staining protocol to quickly stain frozen hippocampal rat brain sections and to permit systematic counts of stained, injured neurons at 4 and 24 h after mild, moderate or severe fluid percussion traumatic brain injury (TBI). In adjacent sections, laser capture microdissection was used to collect uninjured (FJ negative) CA3 hippocampal neurons to assess the effect of injury severity on mRNA levels of selected genes. Rats were anesthetized, intubated, mechanically ventilated and randomized to sham, mild (1.2 atm), moderate (2.0 atm) or severe (2.3 atm) TBI. Four or 24 h post-TBI, ten frozen sections (10 mu m thick, every 15th section) were collected from the hippocampus of each rat, stained with FJ and counterstained with cresyl violet. Fluoro-Jade-positive neurons were counted in hippocampal subfields CA1, CA3 and the dentate gyrus/ dentate hilus. At both 4 and 24 h post-TBI, numbers of FJ-positive neurons in all hippocampal regions increased dose-dependently in mildly and moderately injured rats but were not significantly more numerous after severe injury. Although analysis of variance demonstrated no overall difference in expression of mRNA levels for heat shock protein 70, bcl-2, caspase 3, caspase 9 and interleukin-1 beta in uninjured CA3 neurons at all injury levels, post hoc analysis suggested that TBI induces increases in neuroprotective gene expression that offset concomitant increases in deleterious gene expression. (c) 2005 Elsevier B.V. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA		Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu; bacapra@utmb.edu; caeidson@utmb.edu; jmgarcia@utmb.edu; drkenned@utmb.edu; tuchida@utmb.edu; maparsle@utmb.edu; jccowart@utmb.edu; ddewitt@utmb.edu; dsprough@utmb.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS042849-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER		Amano T, 2002, NEUROL RES, V24, P809, DOI 10.1179/016164102101200771; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bota M, 2003, NAT NEUROSCI, V6, P795, DOI 10.1038/nn1096; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Butler TL, 2003, BRAIN RES BULL, V59, P339, DOI 10.1016/S0361-9230(02)00926-7; Carlson NG, 1999, J IMMUNOL, V163, P3963; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HEILMICH HL, 2005, IN PRESS ANESTHESIOL; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Lee JS, 2004, J NEUROTRAUM, V21, P549, DOI 10.1089/089771504774129883; Leung CHW, 2003, BRAIN RES, V984, P182, DOI 10.1016/S0006-8993(03)03129-9; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; Myhrer T, 2003, BRAIN RES, V967, P293, DOI 10.1016/S0006-8993(03)02232-7; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; SAS, 1999, SAS STAT US GUID VER, V10th; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Ye XM, 2001, BRAIN RES PROTOC, V8, P104, DOI 10.1016/S1385-299X(01)00086-1; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5	50	34	34	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 24	2005	1044	2					144	154		10.1016/j.brainres.2005.02.054			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	931CH	WOS:000229462900002	15885213				2022-02-06	
J	Rutland-Brown, W; Wallace, LJD; Faul, MD; Langlois, JA				Rutland-Brown, W; Wallace, LJD; Faul, MD; Langlois, JA			Traumatic brain injury hospitalizations among American Indians/Alaska natives	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						accidents; alcohol drinking; craniocerebral trauma; hospitalization; North American Indians; seat belts; traumatic brain injury; wounds and injury	DRINKING DRIVERS; BELT USE; ALCOHOL; PATTERNS; CHILDREN; CRASHES; LAWS	Objectives: To compare the incidence of nonfatal traumatic brain injury (TBI) hospitalization among American Indians/Alaska Natives (AI/AN) with that of other race groups and to assess alcohol and protective equipment (PE) use among those who sustained TBI related to a motor vehicle (MV) incident. Methods: Data were obtained from 13 states funded by the Centers for Disease Control and Prevention to conduct TBI surveillance from 1997 to 1999. Rates by race and by cause were calculated for the 13 states combined. Blood alcohol concentration (BAC) levels and PE use were compared between AI/AN and "other" races in a subgroup of these states. Results: Although not significantly different, AI/AN had the highest overall age-adjusted TBI hospitalization rate (71.5 per 100,000). Rates were significantly higher among AI/AN than among whites for ages 20 to 44 years (78.5 per 100,000 vs 54.7 per 100,000, P < .0001). MV incidents were the leading cause of TBI (40.1% of cases) among AI/AN, and AI/AN injured in MV incidents had higher BAC levels (65.7% >= 0.08 g/dL vs 31.6% >= 0.08 g/dL, P < .0001) and lower PE use (22.0% vs 40.4%, P < .0001) than the "other" race group. Conclusion: AI/AN have high rates of TBI hospitalization compared with other races. High BAC levels and low use of PE in MV incidents appear to be associated with the higher rates in this population.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA		Rutland-Brown, W (corresponding author), 4770 Buford Highway,NE,MS F-41, Atlanta, GA 30341 USA.	wfr7@cdc.gov		Faul, Mark/0000-0002-7683-0348			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Blackmer J, 1999, BRAIN INJURY, V13, P627; Campos-Outcalt D, 2003, INJURY PREV, V9, P251, DOI 10.1136/ip.9.3.251; *CDCP NAT CTR HLTH, 1999, TRAUM BRAIN INJ US; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P303; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Dee TS, 1998, ACCIDENT ANAL PREV, V30, P1, DOI 10.1016/S0001-4575(97)00056-0; FOSS RD, 1994, AM J PUBLIC HEALTH, V84, P1732, DOI 10.2105/AJPH.84.11.1732; Lange JE, 1998, AM J PUBLIC HEALTH, V88, P1718, DOI 10.2105/AJPH.88.11.1718; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levy DT, 2004, MED SCI MONITOR, V10, pCR17; MAY PA, 1992, AM INDIAN ALASKA NAT, V4, P5; MAY PA, 1995, IHS PRIM CARE PROVID, V20, P37; McDonald AJ, 2004, ARCH INTERN MED, V164, P531, DOI 10.1001/archinte.164.5.531; Phelan KJ, 2002, INJURY PREV, V8, P216, DOI 10.1136/ip.8.3.216; Quinlan K P, 1998, Inj Prev, V4, P276; Quinlan KP, 2000, JAMA-J AM MED ASSOC, V283, P2249, DOI 10.1001/jama.283.17.2249; Sallee D, 2000, Alaska Med, V42, P37; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; Valent F, 2002, J TRAUMA, V52, P745, DOI 10.1097/00005373-200204000-00023; VOAS R, 1999, ETHNICITY ALCOHOL RE; Voas RB, 2002, ADDICTION, V97, P1439, DOI 10.1046/j.1360-0443.2002.t01-2-00267.x	22	34	35	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					205	214		10.1097/00001199-200505000-00004			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500004	15908821				2022-02-06	
J	Besson, VC; Zsengeller, Z; Plotkine, M; Szabo, C; Marchand-Verrecchia, C				Besson, VC; Zsengeller, Z; Plotkine, M; Szabo, C; Marchand-Verrecchia, C			Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat	BRAIN RESEARCH			English	Article						inhibitors; neurological deficit; neuroprotection; poly(ADP-ribose) polymerase; rat; traumatic brain injury	ADP-RIBOSE POLYMERASE; DNA STRAND BREAKS; POTENT INHIBITOR; CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CELL-DEATH; SYNTHETASE; ACTIVATION; IMPROVES; PARP	Traumatic brain injury produces peroxynitrite, a powerful oxidant which triggers DNA strand breaks, leading to the activation of poly(ADP-ribose)polymerase-1 (PARP-1). We previously demonstrated that 3-aminobenzamide, a PARP inhibitor, is neuroprotective in a model of traumatic brain injury induced by fluid percussion in rat, suggesting that PARP-1 could be a therapeutic target. In order to confirm this hypothesis, we investigated the effects of PJ34 and INO-1001, two PARP inhibitors from structural classes other than benzamide, on the post-traumatic consequences. Pre- and post-treatments with PJ34 (30 mg/kg/day) and INO-1001 (10 mg/kg/day) decrease the neurological deficit at 3 days post-injury and this deficit is still reduced at 7 days. These neurological recovery-promoting effects are associated with the inhibition of PARP-1 activation caused by trauma, as demonstrated by abolishment of immunostaining of poly(ADP-ribose). Thus, the present work strengthens strongly the concept that PARP-1 inhibition may be a suitable approach for the treatment of brain trauma. (c) 2005 Elsevier B.V. All rights reserved.	Univ Paris 05, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, F-75006 Paris, France; Inotek Pharmaceut Corp, Beverly, MA 01915 USA		Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, 4 Ave Observ, F-75006 Paris, France.	catherine.marchand@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; Szabo, Csaba/ABG-2644-2021; besson, valerie C/L-7388-2017; Szabo, Csaba/D-1882-2013; BESSON, VALERIE/AAZ-9989-2020	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; besson, valerie C/0000-0002-1491-2380; BESSON, VALERIE/0000-0002-1491-2380; Zsengeller, Zsuzsanna/0000-0002-4540-5728	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS037985] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS037985] Funding Source: NIH RePORTER		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; ARNE JC, 1999, J BIOL CHEM, V274, P17860; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faro R, 2002, ANN THORAC SURG, V73, P575, DOI 10.1016/S0003-4975(01)03329-X; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Goldfarb RD, 2002, CRIT CARE MED, V30, P974, DOI 10.1097/00003246-200205000-00004; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Ivanyi Z, 2003, SHOCK, V19, P415, DOI 10.1097/01.shk.0000048904.46342.22; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Khan TA, 2003, J AM COLL SURGEONS, V197, P270, DOI 10.1016/S1072-7515(03)00538-6; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Komjati K, 2004, INT J MOL MED, V13, P373; Lacza Z, 2003, INT J MOL MED, V12, P153; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mabley JG, 2001, INFLAMM RES, V50, P561, DOI 10.1007/PL00000234; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mesenge C, 1999, J CEREB BLOOD FLOW M, V19, pS390; Pacher P, 2002, BIOCHEM PHARMACOL, V64, P1785, DOI 10.1016/S0006-2952(02)01421-1; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shimoda K, 2003, AM J PHYSIOL-LUNG C, V285, pL240, DOI 10.1152/ajplung.00319.2002; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002	43	34	36	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 18	2005	1041	2					149	156		10.1016/j.brainres.2005.01.096			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	921UM	WOS:000228790800005	15829224				2022-02-06	
J	Colak, A; Karaoglan, A; Barut, S; Kokturk, S; Akyildiz, AI; Tasyurekli, M				Colak, A; Karaoglan, A; Barut, S; Kokturk, S; Akyildiz, AI; Tasyurekli, M			Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury	JOURNAL OF NEUROSURGERY-SPINE			English	Article						z-LEHD-fmk; apoptosis; caspase-9; programmed cell death; spinal cord injury; rat	APOPTOTIC CELL-DEATH; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; CYTOCHROME-C; BRAIN-INJURY; MITOCHONDRIA; EXPRESSION; NECROSIS; ICE; INTERLEUKIN-1-BETA	Object. Apoptosis is considered one of the most significant mechanisms in the pathogenesis of neuronal damage after spinal cord injury (SCI). This form of cell death occurs via mediators known as caspases. The aim of this study was to evaluate the neuroprotective effect of the caspase-9 inhibitor, z-LEHD-fmk, in a rat model of spinal cord trauma. Methods. Fifty-four Wistar albino rats were studied in the following three groups of 18 animals each: sham-operated controls (Group 1); trauma-only controls (Group 2); and trauma combined with z-LEND-fmk-treated animals (0.8 mu M/kg; Group 3). Spinal cord injury was produced at the thoracic level by using the weight-drop technique. Responses to SCI and the efficacy of z-LEHD-fmk treatment were determined on the basis of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling staining and light and electron microscopy findings in cord tissue at 24 hours and 7 days posttrauma. Six rats from each group were also assessed for functional recovery at 3 and 7 days after SCI. This was conducted using the inclined-plane technique and a modified version of the Tarlov motor grading scale. At 24 hours postinjury, light microscopic examination of Group 2 tissue samples showed hemorrhage, edema, necrosis, polymorphonuclear leukocyte infiltration, and vascular thrombi. Those obtained in Group 3 rats at this stage showed similar features. At 24 hours postinjury, the mean apoptotic cell count in Group 2 was significantly higher than that in Group 3 (90.25 +/- 2.6 and 50.5 +/- 1.9, respectively; p < 0.05). At 7 days postinjury, the corresponding mean apoptotic cell counts were 49 +/- 2.1 and 17.7 +/- 2.6, also a significant difference (p < 0.05). Electron microscopy findings confirmed the occurrence of programmed cell death in different cell types in the spinal cord and showed that z-LEHD-fmk treatment protected neurons, glia, myelin, axons, and intracellular organelles. Conclusions. Examination of the findings in this rat model of SCI revealed that apoptosis occurs not only in neurons and astrocytes but also in oligodendrocytes and microglia. Furthermore, immediate treatment with the caspase-9 inhibitor z-LEHD-fmk blocked apoptosis effectively and was associated with better functional outcome. More in-depth research of the role of programmed cell death in spinal cord trauma and further study of the ways in which caspases are involved in this process may lead to new strategies for treating SCI.	Taksim Educ & Res Hosp, Neurosurg Clin, Istanbul, Turkey; Taksim Educ & Res Hosp, Pathol Clin, Istanbul, Turkey; Istanbul Univ, Dept Histol & Embryol, Cerrahpasa Med Sch, Istanbul, Turkey		Colak, A (corresponding author), Terakki Caddesi,47-7, Istanbul, Turkey.	drahmetcolak@yahoo.com	Kokturk, Sibel/I-4296-2014; Kokturk, Sibel/H-5559-2019	Kokturk, Sibel/0000-0001-5636-3300; Kokturk, Sibel/0000-0001-5636-3300			Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Bresnahan J. C., 1996, Society for Neuroscience Abstracts, V22, P1185; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh K, 1996, NEUROSCI LETT, V216, P9; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Mouw G, 2002, METAB BRAIN DIS, V17, P143, DOI 10.1023/A:1019921904378; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; RINK A, 1995, AM J PATHOL, V147, P1575; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rudel T, 1999, HERZ, V24, P236, DOI 10.1007/BF03044967; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Sugawara T, 2002, FASEB J, V16, P1997, DOI 10.1096/fj.02-0251fje; Tarlov I.M., 1957, SPINAL CORD COMPRESS; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	46	34	36	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	MAR	2005	2	3					327	334		10.3171/spi.2005.2.3.0327			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	917IW	WOS:000228455300013	15796358				2022-02-06	
J	Church, AJ; Andrew, RD				Church, AJ; Andrew, RD			Spreading depression expands traumatic injury in neocortical brain slices	JOURNAL OF NEUROTRAUMA			English	Article						anoxic depolarization; cortical spreading depression; ischemia; migraine aura; neocortex; peri-infarct depolarization; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; SEVERE HEAD-INJURY; CENTRAL NERVOUS-SYSTEM; ANOXIC DEPOLARIZATION; EXTRACELLULAR POTASSIUM; MODERATE HYPOTHERMIA; HIPPOCAMPAL SLICE; IN-VITRO; MILD HYPOTHERMIA; ARTERY OCCLUSION	Traumatic brain injury (TBI) is particularly common in young people, generating healthcare costs that can span decades. The cellular processes activated in the first minutes following injury are poorly understood, and the 3-4 h following trauma are crucial for reducing. subsequent injury. Spreading depression (SD) is a profound inactivation of neurons and glia lasting 1-2 min that arises focally and migrates outward across gray matter. In the hours following focal stroke, the metabolic stress of energy reduction and recurring SD-like events (peri-infarct depolarizations, PIDs) interact to promote neuronal injury. Similar recurring depolarizations might evolve immediately following TBI and exacerbate neuronal damage peripheral to the impact site. To test this possibility and examine if certain drugs might limit damage by inhibiting what we term traumatic spreading depression (tSD), we developed a technique whereby a small weight was dropped onto a live slice of rat neocortex while imaging changes in light transmittance (LT). Imaging revealed a propagating front of increased LT arising at the border of the impact site. Traumatic SD significantly expanded the region of ensuing damage. Both tSD and subsequent damage were blocked by the NMDA receptor antagonist MK-801 (100 muM) or the sigma-1 receptor (sigma(1)R) ligands dextromethorphan (30 muM) or BD-1063 (100 muM). Co-application of the sigma(1)R antagonist (+)3-PPP with DM reversed the block as did lowering temperature from 35degreesC to 32degreesC. This study provides evidence that an event similar to peri-infarct depolarization can arise from an injury site in neocortex within seconds following impact and act to expand the region of acute neuronal damage.	Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Queens Univ, Ctr Neurosci Studies, Kingston, ON K7L 3N6, Canada		Andrew, RD (corresponding author), Queens Univ, Dept Anat & Cell Biol, Botterell Hall, Kingston, ON K7L 3N6, Canada.	andrewd@post.queensu.ca					Anderson TR, 2002, J NEUROPHYSIOL, V88, P2713, DOI 10.1152/jn.00321.2002; ANDERSON TR, 2005, J NEUROPHYSIOL; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Ba AM, 2002, J NEUROPHYSIOL, V88, P2726, DOI 10.1152/jn.00729.2001; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; BALESTRINO M, 1995, J NEUROSCI METH, V59, P99, DOI 10.1016/0165-0270(94)00199-Q; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BURES J, 1975, EPILEPSIA, V16, P111, DOI 10.1111/j.1528-1157.1975.tb04727.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1995, J NEUROSURG ANESTH, V7, P152, DOI 10.1097/00008506-199504000-00023; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Footitt DR, 1998, BRAIN RES, V781, P339, DOI 10.1016/S0006-8993(97)01359-0; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GOETZ CG, 1999, TXB CLIN NEUROLOGY, P810; GORDON N, 1989, DEV MED CHILD NEUROL, V31, P682; HAAS DC, 1988, J NEUROSURG, V68, P181, DOI 10.3171/jns.1988.68.2.0181; HAAS DC, 1975, ARCH NEUROL-CHICAGO, V32, P727, DOI 10.1001/archneur.1975.00490530049003; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hartings JA, 2003, J NEUROSCI, V23, P11602; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; Jarvis CR, 1999, NEUROIMAGE, V10, P357, DOI 10.1006/nimg.1999.0473; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Joshi I, 2001, J NEUROPHYSIOL, V85, P414, DOI 10.1152/jn.2001.85.1.414; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.053; Koistinaho J, 1999, STROKE, V30, P114, DOI 10.1161/01.STR.30.1.114; Koroleva VI, 1998, BRAIN RES, V786, P104, DOI 10.1016/S0006-8993(97)01448-0; Largo C, 1997, J NEUROPHYSIOL, V78, P295, DOI 10.1152/jn.1997.78.1.295; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Martins-Ferreira H, 2000, BRAIN RES REV, V32, P215, DOI 10.1016/S0165-0173(99)00083-1; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MCINTYRE LA, 2003, JAMA-J AM MED ASSOC, V289, P3007; MCLACHLAN RS, 1994, BRAIN RES, V666, P133, DOI 10.1016/0006-8993(94)90295-X; MEDEN P, 1994, BRAIN RES, V647, P131, DOI 10.1016/0006-8993(94)91407-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Mitsikostas DD, 2001, BRAIN RES REV, V35, P20, DOI 10.1016/S0165-0173(00)00048-5; Nallet H, 1999, BRAIN RES, V842, P148, DOI 10.1016/S0006-8993(99)01859-4; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NELLGARD B, 1992, ACTA PHYSIOL SCAND, V146, P497, DOI 10.1111/j.1748-1716.1992.tb09451.x; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Obeidat AS, 2000, J CEREBR BLOOD F MET, V20, P412, DOI 10.1097/00004647-200002000-00024; Obrenovitch TP, 1996, J CEREBR BLOOD F MET, V16, P923, DOI 10.1097/00004647-199609000-00016; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OKA H, 1977, BRAIN, V100, P287, DOI 10.1093/brain/100.2.287; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; REID KH, 1988, J PHARMACOL METHOD, V19, P1, DOI 10.1016/0160-5402(88)90040-X; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Sakas DE, 1997, NEUROSURGERY, V41, P661, DOI 10.1097/00006123-199709000-00031; Sakas DE, 1997, MED HYPOTHESES, V48, P431, DOI 10.1016/S0306-9877(97)90042-6; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; SOMJEN GG, 1990, STROKE, V21, P179; SOMJEN GG, 1992, CAN J PHYSIOL PHARM, V70, pS248, DOI 10.1139/y92-268; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tanaka E, 1999, J NEUROPHYSIOL, V81, P1872, DOI 10.1152/jn.1999.81.4.1872; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Walz W, 1997, NEUROSCI BIOBEHAV R, V21, P135, DOI 10.1016/S0149-7634(96)00003-6; Whittemore ER, 1997, J PHARMACOL EXP THER, V282, P326; Yenari MA, 2000, BRAIN RES, V885, P208, DOI 10.1016/S0006-8993(00)02942-5; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	78	34	37	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					277	290		10.1089/neu.2005.22.277			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400007	15716633				2022-02-06	
J	Thompson, HJ; Hoover, RC; Tkacs, NC; Saatman, KE; McIntosh, TK				Thompson, HJ; Hoover, RC; Tkacs, NC; Saatman, KE; McIntosh, TK			Development of posttraumatic hyperthermia after traumatic brain injury in rats is associated with increased periventricular inflammation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						circadian rhythm; head injury; inflammatory response; model development; thermoregulation	CLOSED-HEAD INJURY; FLUID-PERCUSSION INJURY; NEURONAL CELL-DEATH; ADULT-RAT; MODERATE HYPOTHERMIA; MESSENGER-RNA; FEVER; TEMPERATURE; PROTEIN; EXPRESSION	Posttraumatic hyperthermia (PTH) is a noninfectious elevation in body temperature that negatively influences outcome after traumatic brain injury (TBI). We sought to (1) characterize a clinically relevant model and (2) investigate potential cellular mechanisms of PTH. In study 1, body temperature patterns were analyzed for 1 week in male rats after severe lateral fluid percussion (FP) brain injury (n = 75) or sham injury (n = 17). After injury, 27% of surviving animals experienced PTH, while 69% experienced acute hypothermia with a slow return to baseline. A profound blunting or loss of circadian rhythmicity (CR) that persisted up to 5 days after injury was experienced by 75% of brain-injured animals. At 2 and 7 days after injury, patterns of cell loss and inflammation were assessed in selected brain thermoregulatory and circadian centers. Significant cell loss was not observed, but PTH was associated with inflammatory changes in the hypothalamic paraventricular nucleus (PVN) by one week after injury. In brain-injured animals with altered CR, reactive astrocytes were bilaterally localized in the suprachiasmatic nucleus (SCN) and the PVN. Occasional IL-1beta+/ED-1 + macrophages/microglia were observed in the PVN and SCN exclusively in brain-injured animals developing PTH. In animals with PTH there was a significant positive correlation (r = 0.788, P < 0.01) between the degree of postinjury hyperthermia and the total number of cells positive for inflammatory markers within selected thermoregulatory and circadian nuclei. In study 11, a separate group of animals underwent the same injury and temperature monitoring paradigm as in study 1, but had additional physiologic data obtained, including vital signs, arterial blood gases, white blood cell counts, and C-reactive protein levels. All parameters remained within normal ranges after injury. These data suggest that PTH and the alteration in CR of temperature may be due, in part, to acute reactive astrocytosis and inflammation in hypothalamic centers responsible for both thermoregulation and CR.	Univ Penn, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; VA Med Ctr, Philadelphia, PA USA		McIntosh, TK (corresponding author), 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	tkm53@comcast.net			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 043126, NS 08803] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31 NR007694, NR 07694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, T32NS043126, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR007694] Funding Source: NIH RePORTER		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Armstrong William E., 1995, P377; Behr R, 1997, ANN NY ACAD SCI, V813, P722, DOI 10.1111/j.1749-6632.1997.tb51774.x; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cermakian N, 2003, BRAIN RES REV, V42, P204, DOI 10.1016/S0165-0173(03)00171-1; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHILDERS MK, 1994, BRAIN INJURY, V8, P335, DOI 10.3109/02699059409150984; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT DR, 2002, 32 ANN M SOC NEUR; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNHA BA, 1988, HEART LUNG, V17, P608; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Elmquist JK, 1996, J COMP NEUROL, V371, P85, DOI 10.1002/(SICI)1096-9861(19960715)371:1<85::AID-CNE5>3.0.CO;2-H; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GUILIAN D, 1988, J NEUROSCI, V8, P2485; GUILIAN D, 1985, SCIENCE, V228, P497; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kozak W, 1998, ANN NY ACAD SCI, V856, P33, DOI 10.1111/j.1749-6632.1998.tb08310.x; Lausberg G, 1971, Cah Anesthesiol, V19, P315; LITTLE RA, 1985, BRIT MED BULL, V41, P226, DOI 10.1093/oxfordjournals.bmb.a072055; LITTLE RA, 1981, BRIT J SURG, V68, P221, DOI 10.1002/bjs.1800680402; LOESCH A, 1983, AUST J EXP BIOL MED, V61, P545, DOI 10.1038/icb.1983.52; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; PAXINOS G, 1990, STEREOTACTIC ATLAS R; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Powers JH, 1996, INFECT DIS CLIN N AM, V10, P45, DOI 10.1016/S0891-5520(05)70285-3; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REFINETTI R, 1999, CIRCADIAN PHYSL; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; RUDY TA, 1977, J PHYSIOL-LONDON, V272, P721, DOI 10.1113/jphysiol.1977.sp012069; RUDY TA, 1980, THERMOREGULATORY MEC, P75; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Saper CB, 1998, ANN NY ACAD SCI, V856, P90, DOI 10.1111/j.1749-6632.1998.tb08317.x; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Segatore M, 1992, J Neurosci Nurs, V24, P104; Simerly Richard B., 1995, P353; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Thompson HJ, 2003, J NEUROL NEUROSUR PS, V74, P614, DOI 10.1136/jnnp.74.5.614; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; WHYTE J, 1993, AM J PHYS MED REHAB, V72, P281, DOI 10.1097/00002060-199310000-00006; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	74	34	36	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2005	25	2					163	176		10.1038/sj.jcbfm.9600008			14	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	893SS	WOS:000226740100003	15647747	Bronze			2022-02-06	
J	Moon, C; Ahn, M; Kim, S; Jin, JK; Sim, KB; Kim, HM; Lee, MY; Shin, T				Moon, C; Ahn, M; Kim, S; Jin, JK; Sim, KB; Kim, HM; Lee, MY; Shin, T			Temporal patterns of the embryonic intermediate filaments nestin and vimentin expression in the cerebral cortex of adult rats after cryoinjury	BRAIN RESEARCH			English	Article						brain injury; cryoinjury; nestin; vimentin; regeneration	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; SPINAL-CORD; ASTROCYTES; CELLS; ENCEPHALOMYELITIS; DIFFERENTIATION; MACROPHAGES	The expression of two embryonic intermediate filaments, nestin and vimentin, in the rat brain at days 0 (control), 1, 4, 7 and 14 post-cryoinjury was studied to elucidate their roles in brain injury. Western blot analysis showed that both nestin and vimentin expressions in the ipsilateral cerebral cortex were significantly increased at 4 and 7 days post-cryoinjury, and were decreased at day 14 after cryoinjury. Immumohistochemistry showed that there were few nestin- and vimentin-positive cells in the cerebral cortex in normal controls. On days 4 and 7 post-injury, abundant glial cells in the periphery of the lesion were immunostained for nestin and/or vimentin; only vimentin was detected in the majority of inflammatory cells in the core lesion. These findings suggest that nestin and vimentin contribute to the repair of brain injury through the migration of activated cells and the formation of a glial sear. (C) 2004 Elsevier B.V. All rights reserved.	Jeju Natl Univ, Dept Vet Med, Cheju 690756, South Korea; Hallym Univ, Ilsong Inst Life Sci, Anyang 431060, South Korea; Jeju Natl Univ, Dept Neurosurg, Coll Med, Cheju 690756, South Korea; Kyung Hee Univ, Dept Pharmacol, Coll Oriental Med, Seoul 130701, South Korea; Catholic Univ Korea, Dept Anat, Coll Med, Seoul 137701, South Korea		Shin, T (corresponding author), Jeju Natl Univ, Dept Vet Med, Cheju 690756, South Korea.	shint@cheju.ac.kr		SHIN, Taekyun/0000-0002-9851-4354			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Baldwin SA, 1996, GLIA, V16, P266; CAIN H, 1983, VIRCHOWS ARCH B, V42, P65, DOI 10.1007/BF02890371; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; Calza L, 2002, P NATL ACAD SCI USA, V99, P3258, DOI 10.1073/pnas.052704499; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Moon C, 2000, NEUROSCI LETT, V289, P41, DOI 10.1016/S0304-3940(00)01253-2; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shin Tae-kyun, 2003, J Vet Sci, V4, P9; Soares HD, 1995, J NEUROSCI, V15, P8223; Sun D, 2000, J NEUROPATH EXP NEUR, V59, P1031, DOI 10.1093/jnen/59.12.1031; TSURU A, 1990, J CELL BIOL, V110, P1655, DOI 10.1083/jcb.110.5.1655; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6	18	34	35	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 3	2004	1028	2					238	242		10.1016/j.brainres.2004.09.022			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	872LS	WOS:000225209300014	15527750				2022-02-06	
J	Chuah, YML; Maybery, MT; Fox, AM				Chuah, YML; Maybery, MT; Fox, AM			The long-term effects of mild head injury on short-term memory for visual form, spatial location, and their conjunction in well-functioning university students	BRAIN AND COGNITION			English	Article						mild head injury; short-term memory; visual span; spatial span; visuospatial span; nonverbal memory	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; PARKINSONS-DISEASE; OBJECT; PERFORMANCE; SYMPTOMS; TASK	Research has suggested the presence of subtle long-term cognitive changes in otherwise well-functioning individuals who have previously sustained a mild head injury (MHI). This paper investigated the long-term effects of MHI on visual, spatial, and visual-spatial short-term memory in well-functioning university students. Sixteen students who reported having sustained a MHI were compared to 16 controls on tests of short-term memory (STM) for abstract polygons in haphazardly arranged locations. The three tests differed only in the requirements for recall (shapes for the visual task, locations for the spatial task, and the shapes in their respective locations for the visual-spatial task). MHI participants were selectively impaired on spatial memory, suggesting that tasks of spatial STM may be more sensitive, compared to tasks of visual STM, to the subtle long-term cognitive changes that may be present after a MHI. (C) 2004 Elsevier Inc. All rights reserved.	Univ Western Australia, Sch Psychol, Crawley, WA 6009, Australia		Chuah, YML (corresponding author), Univ Western Australia, Sch Psychol, 35 Stirling Highway, Crawley, WA 6009, Australia.	pcmcyml@nus.edu.sg	Fox, Allison M/H-9218-2014; Maybery, Murray/H-5390-2014	Fox, Allison M/0000-0001-5189-6271; Maybery, Murray/0000-0002-3760-1382			BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Chalfonte BL, 1996, MEM COGNITION, V24, P403, DOI 10.3758/BF03200930; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FOX GA, 1991, ADV APPL RES, P165; FRENCHAM KA, IN PRESS J CLIN EXPT; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HULME C, 1991, J MEM LANG, V30, P685, DOI 10.1016/0749-596X(91)90032-F; Jastak S., 1984, WRAT R WIDE RANGE AC; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin H.S., 1989, MILD HEAD INJURY; Luciana M, 1997, J COGNITIVE NEUROSCI, V9, P330, DOI 10.1162/jocn.1997.9.3.330; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; NHMRC-Australia, 2001, AUSTR ALC GUID HLTH; Owen AM, 1996, P NATL ACAD SCI USA, V93, P9212, DOI 10.1073/pnas.93.17.9212; Postle BR, 1997, NEUROPSYCHOLOGIA, V35, P1413, DOI 10.1016/S0028-3932(97)00054-7; Postle BR, 1997, NEUROPSYCHOLOGY, V11, P171, DOI 10.1037/0894-4105.11.2.171; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; SMITH EE, 1995, J COGNITIVE NEUROSCI, V7, P337, DOI 10.1162/jocn.1995.7.3.337; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; TRESCH MC, 1993, NEUROPSYCHOLOGIA, V31, P211, DOI 10.1016/0028-3932(93)90085-E; Wilson JTL, 1989, NEUROPSYCHOLOGY, V3, P255, DOI 10.1037//0894-4105.3.4.255	35	34	34	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	DEC	2004	56	3					304	312		10.1016/j.bandc.2004.08.002			9	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	872LT	WOS:000225209400004	15522768				2022-02-06	
J	Koh, JO; Watkinson, EJ; Yoon, YJ				Koh, JO; Watkinson, EJ; Yoon, YJ			Video analysis of head blows leading to concussion in competition Taekwondo	BRAIN INJURY			English	Article							KICKS	Primary objectives: To analyse the situational and contextual factors surrounding concussions and head blows in Taekwondo. Methods and procedures: Prospective design. Direct observation, subject inter-view and videotape recording used. A total of 2328 competitors participated in the 2001 tournament, South Korea. All matches were recorded on videotape. All recipients of head blows were interviewed by athletic therapists and the researcher immediately after the match. The videotapes of concussions and head blows were analysed. Results: A total of 1009 head blows including concussions were analysed. Head blows and concussions were most evident when the attacker was situated in a closed stance and received a single roundhouse kick. The most frequent anatomical site of the head impact was the temporal region. Conclusions: The frequency of head blows and concussions is high in Taekwondo. Development of blocking skills, safety education, rigorous enforcement of the competition rules and improvement of head-gear are recommended.	Yonsei Univ, Dept Sports & Leisure Studies, Seoul 120749, South Korea; Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB, Canada		Koh, JO (corresponding author), Yonsei Univ, Dept Sports & Leisure Studies, 134 Shinchon Dong, Seoul 120749, South Korea.	kohjaeok@hotmail.com		Koh, Jae Ok/0000-0002-3639-0739			CHUANG TY, 1992, J BIOMECH ENG-T ASME, V114, P346, DOI 10.1115/1.2891394; Giza CC, 2001, J ATHL TRAINING, V36, P228; GORDIS L, 2000, EPIDEMIOLOGY, P77; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; SERINA ER, 1991, J BIOMECH, V24, P951, DOI 10.1016/0021-9290(91)90173-K; ZEMPER ED, 1994, AM SOC TEST MATER, V1229, P116, DOI 10.1520/STP12808S	12	34	34	0	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2004	18	12					1287	1296		10.1080/02699050410001719907			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	871BW	WOS:000225105300009	15666571				2022-02-06	
J	Meyers, JE; Rohling, ML				Meyers, JE; Rohling, ML			Validation of the Meyers Short Battery on mild TBI patients	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						neuropsychology; validity; reliability; short battery	HEAD-INJURY; WAIS-R; INDEX	This manuscript reports the results of two studies focusing on patients with mild Traumatic Brain Injury (TBI). The first assesses the validity of the Meyers Short Battery (MSB) of neuropsychological tests. The second study reports on the reliability of the MSB. The groups consisted of normal controls, depressed, chronic pain patients, and patients with mild TBI. Validity was assessed using a discriminant function analysis comparing the non-TBI participants with the TBI participants, which showed a 96.1% correct classification rate. When patients were assessed at least 6 months post-injury and re-assessment 12-14 months later, an overall reliability of r = .86 was obtained. This indicates that the MSB has adequate psychometric properties for clinical use. The results are consistent with previous published research indicating, that the MSB is sensitive not only to the presence of mild TBI but also to the degree of cognitive impairment based on loss of consciousness. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Ctr Neurosci Orthoped & Spine, Dakota Dunes, SD USA; Univ S Alabama, Moville, AL USA		Meyers, JE (corresponding author), Ctr Neurosci Orthoped & Spine, Dakota Dunes, SD USA.	jmeyers@mstar.net					BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Benton A.L., 1983, CONTRIBUTIONS NEUROP; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; Meyer-Abich KM, 2000, FORSCH KOMP KLAS NAT, V7, P154, DOI 10.1159/000021332; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/09084280152829084; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Meyers JE., 1995, REY COMPLEX FIGURE T; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O, 1991, COMPENDIUM NEUROPSYC; Tabachnick B. G., 1989, USING MULTIVARIATE S; Volbrecht ME, 2000, ARCH CLIN NEUROPSYCH, V15, P251, DOI 10.1016/S0887-6177(99)00016-5; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M	22	34	34	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2004	19	5					637	651		10.1016/j.acn.2003.08.007			15	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	845PT	WOS:000223257500003	15271408	Bronze			2022-02-06	
J	Goforth, PB; Ellis, EF; Satin, LS				Goforth, PB; Ellis, EF; Satin, LS			Mechanical injury modulates AMPA receptor kinetics via an NMDA receptor-dependent pathway	JOURNAL OF NEUROTRAUMA			English	Article						AMPA; CaMKII; desensitization; glutamate; NMDA; traumatic brain injury	PROTEIN-KINASE-II; TRAUMATIC BRAIN-INJURY; STRETCH-INDUCED INJURY; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; SILENT SYNAPSES; CALCIUM; RAT; DESENSITIZATION; ACTIVATION	Alterations in glutamatergic transmission are thought to contribute to secondary neuronal damage following traumatic brain injury. Using an in vitro cell injury model, we previously demonstrated an apparent reduction in AMPA receptor desensitization and resultant potentiation of AMPA-evoked currents after stretch injury of cultured neonatal rat cortical neurons. In the present study, we sought to further characterize injury-induced enhancement of AMPA current and elucidate the mechanisms responsible for this pathological process. Using the patch-clamp technique, agonist-activated currents were recorded from control and injured neurons. Potentiation of AMPA-mediated currents occurred quickly, within 15-30 min following injury, and persisted for at least 24 h. Stretch-injury slowed the activation and desensitization of AMPA mediated currents recorded from excised outside-out patches. The co-application of 100 muM AMPA and 20 AM thiocyanate enhanced AMPA receptor desensitization in control neurons and restored desensitization in injured neurons. The potentiation of AMPA-elicited current was prevented by the NMDA receptor antagonist D-APV (20 muM) or the CaMKII inhibitor KN93 (10 muM). These results suggest that mechanical injury initiates a biochemical cascade that involves NMDA receptor and CaMKII activation and produces a long-lasting reduction of AMPA receptor desensitization, which may contribute to the pathophysiology of traumatic brain injury.	Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Dept Physiol & Med Endocrinol, Richmond, VA 23298 USA		Satin, LS (corresponding author), Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, POB 980524, Richmond, VA 23298 USA.	lsatin@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214, 5 T32 NS 07288-13] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS027214] Funding Source: NIH RePORTER		Aguayo LG, 1998, PFLUG ARCH EUR J PHY, V435, P382, DOI 10.1007/s004240050527; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; ARAI A, 1995, NEUROSCIENCE, V66, P815, DOI 10.1016/0306-4522(94)00616-D; ARMSTRONG D, 1988, CALCIUM ION CHANNEL, P220; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BOWIE D, 1993, BRIT J PHARMACOL, V109, P779, DOI 10.1111/j.1476-5381.1993.tb13642.x; BULLOCK R, 1997, HEAD INJURY PATHOPHY, P120; Churn SB, 1995, ADV NEUROIMMUNOL, V5, P241, DOI 10.1016/0960-5428(95)00016-U; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Davies G., 1982, CURR PSYCHOL, V2, P235, DOI [https://doi.org/10.1007/BF03186766, DOI 10.1007/BF03186766, DOI 10.1007/BF02684516]; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; EVANS RH, 1982, BRIT J PHARMACOL, V75, P65, DOI 10.1111/j.1476-5381.1982.tb08758.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093; HALL RA, 1993, BRAIN RES, V628, P345, DOI 10.1016/0006-8993(93)90978-V; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY PT, 1991, MOL NEUROBIOL, V5, P153, DOI 10.1007/BF02935544; KELLY PT, 1987, METHOD ENZYMOL, V139, P690; KESSLER M, 1986, MOL PHARM, V49, P123; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; LIAO D, 2000, NATURE, V405, P955; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; NIELSEN EO, 1988, EUR J PHARMACOL, V157, P197, DOI 10.1016/0014-2999(88)90383-4; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OBENOVITCH TP, 1997, J NEUROTRAUM, V14, P677; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OLSEN RW, 1987, BRAIN RES, V402, P243, DOI 10.1016/0006-8993(87)90030-8; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; Pickard L, 2001, NEUROPHARMACOLOGY, V41, P700, DOI 10.1016/S0028-3908(01)00127-7; Rammes G, 1999, PFLUG ARCH EUR J PHY, V437, P191, DOI 10.1007/s004240050768; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Soderling TR, 1996, NEUROCHEM INT, V28, P359, DOI 10.1016/0197-0186(95)00098-4; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; WANG LY, 1994, J PHYSIOL-LONDON, V475, P431, DOI 10.1113/jphysiol.1994.sp020083; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	72	34	36	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					719	732		10.1089/0897715041269704			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600008	15253800				2022-02-06	
J	Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V				Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V			S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients	NEUROLOGICAL RESEARCH			English	Article						S-100 protein; severe head injury; subarachnoid hemorrhage; neurocritical care; secondary brain damage	SEVERE HEAD-INJURY; NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; ACUTE STROKE; NEUROBIOCHEMICAL MARKERS; SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; CARDIAC-SURGERY; S100B PROTEIN; SERIAL S-100	There is growing evidence that S-100B protein measured by a simple blood test can be used as a novel biochemical marker of brain cell damage. The objective of our study was to investigate the potential of S-100B measurements to diagnose an acute neurological complication in the analgo-sedated and intubated intensive care patient and the impact on patient management. Serum S-100B levels were serially investigated in 246 neurocritical care patients. Venous blood samples for S-100B determination were obtained as soon as possible after admission and every 24 hours thereafter, for the duration of the stay at the neurocritical care unit. Blood samples were taken every morning as part of the routine laboratory investigation for analysis of S-100B using the immunoluminometric assay (AB Sangtec Medical, Bromma, Sweden) and a fully automated LIAISON(R) system (Byk-Sangtec-Diagnostica, Dietzenbach, Germany) with a short time to result. The primary endpoint of our study was the occurrence of a severe neurological complication. Patients were admitted to the neurosurgical intensive care unit after routine major intracranial surgery in 116 cases (47%) and after a neurological or neurosurgical emergency in 130 cases (53%). Of the latter group, 79 patients (.32%) underwent emergency surgery for evacuation or decompression of a space-occupying lesion before ICU admission. A severe neurological complication was defined as a new infarction, new hemorrhage or a newly developed progressive disease despite maximum therapy with a radiologically confirmed increase of mass lesion and midline shift. In 33 patients (13%) a complication with neurological deterioration occurred. All patients showed pathologically increased serum S-100B values (mean 2.00 mug/l, standard deviation 2.67 mug/l, range 0.31-9.66 mug/l). Twenty-eight of these patients (85%) showed S-100B increases >0.5 mug/l. In five cases (16 %), the increase in S-100B was the first sign of neurological complication and prompted emergency computed tomography scanning. In another two ;cases, increasing S-100B values changed management decision towards a surgical intervention. The major finding of our study was the influence of serial S-100B measurement on actual management of the patient in 27% of cases with neurological complications.	Univ Frankfurt, Dept Neurosurg, Neuroctr, D-60528 Frankfurt, Germany		Raabe, A (corresponding author), Univ Frankfurt, Dept Neurosurg, Neuroctr, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	A.Raabe@em.uni-frankfurt.de					Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bertsch T, 2001, CLIN CHEM LAB MED, V39, P319, DOI 10.1515/CCLM.2001.050; Bottiger BW, 2001, CIRCULATION, V103, P2694; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 2001, ANN THORAC SURG, V71, P1433, DOI 10.1016/S0003-4975(00)02612-6; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McKeating EG, 1998, ACT NEUR S, V71, P117; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	37	34	34	0	0	MANEY PUBLISHING	LEEDS	HUDSON RD, LEEDS LS9 7DL, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	JUN	2004	26	4					440	445		10.1179/016164104225015958			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	829CP	WOS:000222021400015	15198874				2022-02-06	
J	DeKosky, ST; Taffe, KM; Abrahamson, EE; Dixon, CE; Kochanek, PM; Ikonomovic, MD				DeKosky, ST; Taffe, KM; Abrahamson, EE; Dixon, CE; Kochanek, PM; Ikonomovic, MD			Time course analysis of hippocampal nerve growth factor and antioxidant enzyme activity following lateral controlled cortical impact brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						catalase; free radical; glutathione peroxidase; hippocampus; nerve growth factor; reactive oxygen species; superoxide dismutase; traumatic brain injury	GLUTATHIONE-PEROXIDASE ACTIVITY; NGF RESTORES DECREASE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; RADICAL GENERATION; CEREBRAL-ISCHEMIA; TEMPORAL PROFILES; OXIDATIVE DAMAGE; HEAD-INJURY; CATALASE	Gradual secondary injury processes, including the release of toxic reactive oxygen species, are important components of the pathogenesis of traumatic brain injury (TBI). The extent of oxidative stress is determined in part by the effectiveness of the antioxidant response, involving the enzymes glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). Since nerve growth factor (NGF) may be involved in the initiation of antioxidant activity, we employed a controlled cortical impact injury model in rats to produce secondary hippocampal damage and determined the subsequent time course of changes in NGF production and GPx, CAT, and SOD activity in this brain region. Hippocampal NGF production showed a rapid increase with a biphasic response after TBI. NGF protein was increased at 6 h, plateaued at 12 h, declined by 7 days, and exhibited a second rise at 14 days after injury. Similar to NGF, hippocampal GPx activity also showed a biphasic response, increasing by 12 h, declining at 24 h, and exhibiting a second peak at 7 days. In contrast, increased CAT activity occured steadily from 1 day through 7 days after injury. SOD activity was decreased at 6 h after injury, and continued to decline through 14 days. The initial rise in NGF preceded that of CAT, and coincided with an increase in GPX and a drop in SOD activity. These data demonstrate a complex temporal spectrum of antioxidant enzyme activation following secondary brain injury in the hippocampus, and suggest a selective regulatory role for NGF in this response.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA		DeKosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 3471 5th Ave,Ste 811, Pittsburgh, PA 15213 USA.	DekoskyST@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318, NS07391] Funding Source: Medline		AEBI H, 1984, METHOD ENZYMOL, V105, P121; ASHTON D, 1989, BRAIN RES, V487, P368, DOI 10.1016/0006-8993(89)90842-1; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CRISTIANO F, 1995, MECH AGEING DEV, V80, P93, DOI 10.1016/0047-6374(94)01561-Y; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FRIM DM, 1994, EXP NEUROL, V128, P172, DOI 10.1006/exnr.1994.1125; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Islekel S, 1999, RES EXP MED, V199, P167, DOI 10.1007/s004330050121; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; JENNER P, 1992, ANN NEUROL, V32, pS82, DOI 10.1002/ana.410320714; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM YS, 1991, J NEUROSCI RES, V29, P100, DOI 10.1002/jnr.490290111; KITAGAWA K, 1990, NEUROSCIENCE, V35, P551, DOI 10.1016/0306-4522(90)90328-2; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P135, DOI 10.1038/jcbfm.1993.16; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Mayo JC, 2003, FREE RADICAL RES, V37, P543, DOI 10.1080/1071576031000083206; MICHOWIZ SD, 1990, STROKE, V21, P1613, DOI 10.1161/01.STR.21.11.1613; Namba K, 2001, J NEUROSURG ANESTH, V13, P131, DOI 10.1097/00008506-200104000-00010; NISTICO G, 1991, NEUROSCI LETT, V130, P117, DOI 10.1016/0304-3940(91)90241-K; NISTICO G, 1992, FREE RADICAL BIO MED, V12, P177, DOI 10.1016/0891-5849(92)90024-B; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Povlishock J T, 1992, Hum Cell, V5, P345; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; Salvemini D, 2003, CRIT CARE MED, V31, pS29, DOI 10.1097/00003246-200301001-00005; Sampath D, 1997, NEUROCHEM RES, V22, P351, DOI 10.1023/A:1027387105882; SAMPATH D, 1994, J NEUROCHEM, V62, P2476; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Takeuchi A, 2000, J NEUROBIOL, V45, P39, DOI 10.1002/1097-4695(200010)45:1<39::AID-NEU4>3.0.CO;2-A; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	50	34	34	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					491	500		10.1089/089771504774129838			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900001	15165358				2022-02-06	
J	Prabhakaran, P; Reddy, AT; Oakes, WJ; King, WD; Winkler, MK; Givens, TG				Prabhakaran, P; Reddy, AT; Oakes, WJ; King, WD; Winkler, MK; Givens, TG			A pilot trial comparing cerebral perfusion pressure-targeted therapy to intracranial pressure-targeted therapy in children with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain injury; trauma; cerebral edema; Glasgow Coma Scale; Glasgow Outcome Scale; intracranial pressure; cerebral perfusion pressure	SEVERE HEAD-INJURY; COMA DATA-BANK; BLOOD-FLOW; PRACTICAL SCALE; HYPERTENSION; HYPOTENSION; MANAGEMENT; INSULTS; ADULT	Object. The authors sought to compare cerebral perfusion pressure (CPP)- with intracranial pressure (ICP)-targeted therapy in children with severe traumatic brain injury (TBI). Methods. A randomized controlled trial was developed to assess CPP and ICP therapies in 17 children (range 15 months-15 years of age) with poststabilization Glasgow Coma Scale (GCS) scores of less than or equal to 8 who were admitted to a pediatric intensive care unit at a Level I trauma center. Goals in the ICP group were to maintain ICP lower than 20 mm Hg and CPP higher than 50 mm Hg. In the CPP group, goals were to maintain CPP higher than 70 mm Hg for patients at least 2 years old and higher than 60 mm Hg for patients younger than 2 years of age. The study outcomes were death or functional outcome at 1 year postinjury. The median GCS scores in the CPP group (12 patients) and the ICP group (five patients) were 6 and 7, respectively. In the CPP group, two patients died, one was lost to follow up, four were unimpaired, and five had mild impairment. In the ICP group, all patients survived one was lost to follow up, two had mild impairment, and two had hemiparesis and moderate impairment. There were four unimpaired survivors in the CPP arm compared with none in the ICP arm (p = 0.08). Conclusions. The CPP method appears to be safe, although this feasibility study does not establish that the CPP therapy is superior to ICP therapy.	Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA		Reddy, AT (corresponding author), 1600 7th Ave S,ACC 512, Birmingham, AL 35233 USA.	areddy@peds.uab.edu					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BOREL CO, 1987, AM J PHYSIOL, V253, pH1342; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Davis RJ, 1992, TXB PEDIAT INTENSIVE, P805; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ELADAWY Y, 1989, INTRACRANIAL PRESSUR, V7, P829; FEIN JM, 1983, J NEUROSURG, V59, P51, DOI 10.3171/jns.1983.59.1.0051; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; JENNETT B, 1975, LANCET, V1, P480; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; KONTOS HA, 1978, AM J PHYSIOL, V234, P371; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosner M., 1986, INTRACRANIAL PRESSUR, P137, DOI [10.1007/978-3-642-70971-5_25, DOI 10.1007/978-3-642-70971-5_25]; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; Rosner Michael J., 1993, P57; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P414; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; TEASDALE G, 1974, LANCET, V2, P81; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; 2000, J NEUROTRAUMA, V17, P513	39	34	35	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2004	100	5		S			454	459		10.3171/ped.2004.100.5.0454			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	819MT	WOS:000221319700010	15287454				2022-02-06	
J	Jin, C; Schachar, R				Jin, C; Schachar, R			Methylphenidate treatment of attention-deficit/hyperactivity disorder secondary to traumatic brain injury: A critical appraisal of treatment studies	CNS SPECTRUMS			English	Article								Objective: Are stimulants effective in treating attention-deficit/hyperactivity disorder secondary to traumatic brain injury (ADHD/TBI)? The authors reviewed and examined the current knowledge on efficacy of stimulant treatment ADHD/TBI. Method: A systematic review of the literature using a quality assessment scale to assess the quality of randomized clinical trials was undertaken. We identified all studies in which stimulants had been administered to individuals with ADHD/TBI. Information was extracted on study characteristics, interventions, and outcomes. A meta,analysis was not performed because of the limited number of studies with strict research design and the heterogeneity of outcome measures. Seven studies involving 118 subjects, 41 of whom were children and adolescents, were identified. Results: Of the seven identified studies, one was a chart review, one used a single-blind, placebo-controlled crossover design, and five were double-blind, placebo-controlled crossovers. These studies used >50 subjective and objective tests to measure behavioral and cognitive outcomes. Methylphenidate (MPH) effects on behavior (hyperactivity, impulsivity) were evident but were not as robust as those typically observed with MPH in primary ADHD. The effect of MPH on cognition was less apparent. More favorable outcome was associated with initiation of treatment soon after head injury, although this factor was not systematically studied, and trials with relativly long durations. Studies with negative MPH response reported neither improvement in behavioral nor cognitive symptoms. Conclusion: There is only modest evidence to support the efficacy of MPH in the treatment of ADHD/TBI. While MPH might still be a promising treatment for ADHD/TBI, there is need for rigorous treatment outcome research among representative samples of ADHD/TBI individuals. CNS Spectr. 2004;9(3):217-226	Univ Toronto, Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; N Shore Univ Hosp, Dept Psychiat, Div Child & Adolescent Psychiat, Manhasset, NY 11030 USA; NYU, Sch Med, Dept Psychiat, New York, NY USA		Schachar, R (corresponding author), Univ Toronto, Hosp Sick Children, Dept Psychiat, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	atm@sickkids.on.ca		Schachar, Russell/0000-0002-2015-4395			Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; [Anonymous], 1999, JAMA-J AM MED ASSOC, V10, P974; Biederman J, 1996, ARCH GEN PSYCHIAT, V53, P437; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Coull JT, 1998, PROG NEUROBIOL, V55, P343, DOI 10.1016/S0301-0082(98)00011-2; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FRANCES A, 1985, HOSP COMMUNITY PSYCH, V36, P711; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GUALTIERI CT, 1988, BRAIN INJURY, V4, P273; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; Handen BL, 1999, J AM ACAD CHILD PSY, V38, P805, DOI 10.1097/00004583-199907000-00009; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jadad AR, 1999, CAN J PSYCHIAT, V44, P1025, DOI 10.1177/070674379904401009; Justice AC, 1998, JAMA-J AM MED ASSOC, V280, P240, DOI 10.1001/jama.280.3.240; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kube DA, 2002, CLIN PEDIATR, V41, P461, DOI 10.1177/000992280204100702; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LPPER S, 1976, J NERV MENT DIS, V5, P366; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; MAHALICK DM, 1996, TRAUMA, V38, P39; Max JE, 1998, BRAIN INJURY, V12, P31; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Mehta MA, 2000, J NEUROSCI, V20; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; PARY R, 2002, ANN CLIN PSYCHIAT, V2, P105; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; SALAZAR AM, 2000, JAMA-J AM MED ASSOC, V23, P3075; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Seeman P, 1998, MOL PSYCHIATR, V3, P386, DOI 10.1038/sj.mp.4000421; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; STERN JM, 1978, SCAND J REHABIL MED, V10, P7; TANNOCK R, 1995, J AM ACAD CHILD PSY, V34, P886, DOI 10.1097/00004583-199507000-00012; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Weinberg R M, 1987, Brain Inj, V1, P57, DOI 10.3109/02699058709034445; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Worzniak M, 1997, J FAM PRACTICE, V44, P495; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962	52	34	34	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1092-8529	2165-6509		CNS SPECTRUMS	CNS Spectr.	MAR	2004	9	3					217	226		10.1017/S1092852900009019			10	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	895VB	WOS:000226890800008	14999162				2022-02-06	
J	Paschen, W; Yatsiv, I; Shoham, S; Shohami, E				Paschen, W; Yatsiv, I; Shoham, S; Shohami, E			Brain trauma induces X-box protein 1 processing indicative of activation of the endoplasmic reticulum unfolded protein response	JOURNAL OF NEUROCHEMISTRY			English	Article						brain trauma; endoplasmic reticulum; heat-shock protein 70; growth arrest and DNA damage-inducible gene; 153; glucose-regulated proteins; unfolded protein response; X-box protein 1 processing	CLOSED-HEAD INJURY; NITRIC-OXIDE SYNTHASE; XBP1 MESSENGER-RNA; CEREBRAL-ISCHEMIA; TRANSCRIPTION FACTOR; STRESS-RESPONSE; TRANSLATIONAL CONTROL; CELL INJURY; ER STRESS; RAT-BRAIN	Brain trauma was induced in mice using a closed head injury (CHI) model. At 1, 6 or,24 h after trauma, brains were dissected into the cortex, striatum and hippocampus. Changes in levels of processed X-box protein 1 (xbp1), glucose-regulated protein 78 (grp78), growth arrest and DNA damage-inducible gene 153 (gadd153) and heat-shock protein 70 (hsp70) mRNA, indicating impaired endoplasmic reticulum (ER) and cytoplasmic functioning, were evaluated by quantitative PCR. In the cortex, processed xbp1 mRNA levels rose to 2000% of control 1 h after CHI, and stayed high throughout the experiments. In the hippocampus and striatum, processed xbp1 mRNA levels rose in a delayed fashion, peaking at 6 h (1000% of control) and 24 h after, CHI (1500% of control) respectively. Levels of grp78 mRNA were only slightly increased in the cortex 24 h after CHI (150% of control), and were unchanged or transiently decreased in the hippocampus and striatum. Levels of gadd153 mRNA did not change significantly after trauma. A transient rise in hsp70 mRNA levels was observed-only in the cortex, peaking at 1 h after CHI (600% of control). Processing of xbp1 mRNA is a sign of activation of the unfolded protein response indicative of ER dysfunction. The results suggest that brain trauma induces ER dysfunction, which spreads from the ipsilateral cortex to the hippocampus and striatum., These observations may have clinical implications and should therefore be considered for future investigations on therapeutic intervention of brain injury caused by contusion-induced neurotrauma.	Max Planck Inst Neurol Res, Dept Expt Neurol, Lab Mol Neurol, D-50931 Cologne, Germany; Hebrew Univ Jerusalem, Hadassah Med Ctr, Pediat Intens Care Unit, Jerusalem, Israel; Res Dept Herzog Hosp, Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Paschen, W (corresponding author), Max Planck Inst Neurol Res, Dept Expt Neurol, Lab Mol Neurol, Gleueler Str 50, D-50931 Cologne, Germany.	paschen@mpin-koeln.mpg.de					Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; Anwaar I, 1999, ANGIOLOGY, V50, P1, DOI 10.1177/000331979905000101; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gissel C, 1997, J NEUROCHEM, V69, P2538; GOSH TK, 1991, J BIOL CHEM, V266, P24690; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; KUZNETSOV G, 1992, J BIOL CHEM, V265, P3932; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LONGO FM, 1993, J NEUROSCI RES, V36, P325, DOI 10.1002/jnr.490360310; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; Miyoshi K, 2000, MOL BRAIN RES, V85, P68, DOI 10.1016/S0169-328X(00)00243-6; PARFETT CLJ, 1989, GENE, V82, P291, DOI 10.1016/0378-1119(89)90054-1; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Paschen W, 2003, J CEREBR BLOOD F MET, V23, P449, DOI 10.1097/01.WCB.0000054216.21675.AC; Paschen W, 1996, MED HYPOTHESES, V47, P283, DOI 10.1016/S0306-9877(96)90068-7; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; WILETTE RN, 1993, LIFE SCI, V52, P35; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	58	34	36	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2004	88	4					983	992		10.1046/j.1471-4159.2003.02218.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	774UK	WOS:000189003500023	14756820	Bronze			2022-02-06	
J	Ueda, Y; Suehiro, E; Wei, EP; Kontos, HA; Povlishock, JT				Ueda, Y; Suehiro, E; Wei, EP; Kontos, HA; Povlishock, JT			Uncomplicated rapid posthypothermic rewarming alters cerebrovascular responsiveness	STROKE			English	Article						cerebrovascular circulation; hypothermia; rewarming; rats	PIAL ARTERIOLES; POSTTRAUMATIC HYPOTHERMIA; POTASSIUM CHANNELS; VASODILATION; TEMPERATURE; OPENERS; VESSELS; INJURY	Background and Purpose - Recently, we focused on the cerebrovascular protective effects of moderate hypothermia after traumatic brain injury, noting that the efficacy of posttraumatic hypothermia is related to the rate of posthypothermic rewarming. In the current communication, we revisit the use of hypothermia with varying degrees of rewarming to ascertain whether, in the normal cerebral vasculature, varying rates of rewarming can differentially affect cerebrovascular responsiveness. Methods - Pentobarbital-anesthetized rats equipped with a cranial window were randomized to 3 groups. In 1 group, a 1-hour period of hypothermia ( 32 degreesC) followed by slow rewarming ( over 90 minutes) was used. In the remaining 2 groups, either a 1- or 2-hour period of hypothermia was followed by rapid rewarming ( within 30 minutes). Vasoreactivity to hypercapnia and acetylcholine was assessed before, during, and after hypothermia. Additionally, the vascular responses to sodium nitroprusside ( SNP) and pinacidil, a K-ATP channel opener, were also examined. Results - Hypothermia itself generated modest vasodilation and reduced vasoreactivity to all utilized agents. The slow rewarming group showed restoration of normal vascular responsivity. In contrast, hypothermia followed by rapid rewarming was associated with continued impaired responsiveness to acetylcholine and arterial hypercapnia. These abnormalities persisted even with the use of more prolonged (2-hour) hypothermia. Furthermore, posthypothermic rapid rewarming impaired the dilator responses of SNP and pinacidil. Conclusions - Posthypothermic rapid rewarming caused cerebral vascular abnormalities, including a diminished response to acetylcholine, hypercapnia, pinacidil, and SNP. Our data with acetylcholine and SNP suggest that rapid rewarming most likely causes abnormality at both the vascular smooth muscle and endothelial levels.	Virginia Commonwealth Univ, VCU Hlth Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, VCU Hlth Ctr, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu	Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Horiuchi T, 2001, STROKE, V32, P218, DOI 10.1161/01.STR.32.1.218; Inoue S, 2001, CRIT CARE MED, V29, P2162, DOI 10.1097/00003246-200111000-00019; Irikura K, 1998, J CEREBR BLOOD F MET, V18, P1294, DOI 10.1097/00004647-199812000-00003; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Mustafa S, 2002, STROKE, V33, P256, DOI 10.1161/hs0102.101545; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; OGURA K, 1991, J NEUROSURG, V75, P433, DOI 10.3171/jns.1991.75.3.0433; Polderman KH, 2001, J NEUROSURG, V94, P853; Rosenblum WI, 2001, EUR J PHARMACOL, V430, P101, DOI 10.1016/S0014-2999(01)01361-9; Sagher O, 1997, J NEUROSURG, V87, P431, DOI 10.3171/jns.1997.87.3.0431; Saito W, 1998, J CARDIOVASC PHARM, V31, P327, DOI 10.1097/00005344-199802000-00021; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	20	34	34	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2004	35	2					601	606		10.1161/01.STR.0000113693.56783.73			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	769VB	WOS:000188669500062	14739414	Bronze			2022-02-06	
J	Patrick, PD; Buck, ML; Conaway, MR; Blackman, JA				Patrick, PD; Buck, ML; Conaway, MR; Blackman, JA			The use of dopamine enhancing medications with children in low response states following brain injury	BRAIN INJURY			English	Article							FRONTAL-LOBE DYSFUNCTION; VEGETATIVE STATE; AMANTADINE	Primary objective: The study examines the possible relationship between dopamine-enhancing medications and improvement of arousal and awareness in children during persistent low response states (Rancho Los Amigos Levels I, II and III). Research design: A retrospective review was conducted of 10 children enrolled in an existing clinical protocol. The Kluge Children's Rehabilitation Center (KCRC) low response protocol provides a double baseline serial measure (A, A, B, B, B) design. Scores on the Western NeuroSensory Stimulation Profile (WNSSP) are the dependent variable. Methods and procedures: Ten children, mean age of 13.7 years low response state (30 days or more) who were treated with dopamine agonists. Co-morbid or iatrogenic influences were addressed or ruled out. Seven children had traumatic brain injury, one cerebral vascular accident, one anoxia and one encephalitis. Experimental intervention: On average, dopamine medications were started 52.9 days post-event. Main outcomes and results: Paired t-test of WNSSP scores before medications and on medications were significant at p=0.03 (paired t-test). Also, the distributions of the slopes (rates of change of WNSSP scores over time) were significantly different in the pre-medication and medication phases (Paired T-test, p=0.02). Random coefficient model comparison of individuals during pre- and medication phase response variability on WNSSP yielded F-test at p=0.02. Conclusions: These results suggest a promising relationship between acceleration of recovery for some children in a low response state and administration of dopamine-enhancing medications.	Univ Virginia, Childrens Med Ctr, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, Charlottesville, VA 22903 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA		Patrick, PD (corresponding author), Univ Virginia, Childrens Med Ctr, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, 2270 Ivy Rd, Charlottesville, VA 22903 USA.	pdp2n@virginia.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039631] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD39631] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Ansell BJ, 1989, W NEUROSENSORY STIMU; BACHMAN DL, 1992, J HEAD TRAUMA REHAB, V7, P50; BALL WS, 1990, CURR OPIN RADIOL, V2, P877; Cantais E, 2001, INTENS CARE MED, V27, P1511, DOI 10.1007/s001340101039; CROWDER MJ, 1990, ANAL REPEATED MEASUR; Di Rocco C, 1974, J Neurosurg Sci, V18, P169; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; GAULTIERI CT, 1989, CLIN NEUROPHARMACOL, V4, P258; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Hagen C, 1979, LEVELS COGNITIVE FUN; HAYES RI, 1992, J HEAD TRAUMA REHAB, V77, P16; HAYES RI, 1989, MILD HEAD INJURY; HORVATH TB, 1974, J NEUROL NEUROSUR PS, V37, P416, DOI 10.1136/jnnp.37.4.416; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Maj J, 1997, EUR J PHARMACOL, V324, P31, DOI 10.1016/S0014-2999(97)00066-6; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; PLUM F, 1991, CEREBRAL CORTEX; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; Schneider WN, 1999, BRAIN INJURY, V13, P863; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; WOLF AP, 1995, BRAIN INJURY, V9, P487, DOI 10.3109/02699059509008208; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	40	34	37	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2003	17	6					497	506		10.1080/0269905031000070279			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	672GG	WOS:000182512400004	12745705				2022-02-06	
J	Feeney, CJ; Pennefather, PS; Gyulkhandanyan, AV				Feeney, CJ; Pennefather, PS; Gyulkhandanyan, AV			A cuvette-based fluorometric analysis of mitochondrial membrane potential measured in cultured astrocyte monolayers	JOURNAL OF NEUROSCIENCE METHODS			English	Article						astrocyte; mitochondrial membrane potential (Delta psi(M)); plasma membrane potential; potentiometric fluorescent dyes JC-1, Rh123, TMRM; protonophore FCCP; azide; hydrogen peroxide	DEPOLARIZATION; NEURONS; INJURY; CELLS	Mitochondrial membrane potential (Deltapsi(M)) plays a key role in coordinating mitochondrial function and cell biology in general. In astrocytes, Deltapsi(M) is an important indicator of the health of these brain cells and their response to traumatic and hypoxic injury. We have shown previously how fluorescent signals can be measured from cells attached to a coverslip in a standard cuvette with a fluorometer and modulated using a cuvette perfusion system (Pflugers Arch-Eur. J. Physiol. 421 (1992) 400). Here we report on how this method can be employed to characterize the actions of a number of potentiometric fluorescent cationic dyes, including JC-1, Rh123 and TMRM, for their ability to monitor Deltapsi(M) in primary cultures of intact astrocytes. All dyes detected the reversible depolarization produced by brief exposure to the mitochondrial uncoupler protonophore FCCP, which short circuits and dissipates Deltapsi(M). Qualitatively similar responses were measured after treatment with either azide, an inhibitor of complex IV in the mitochondrial respiratory chain, or the oxidant H2O2, Cell depolarization with high potassium modified the responses to FCCP. The time courses of these responses differed in a manner dependent on the particular dye used and in a way that correlated with expected permeation rate. The merits and pitfalls of these different potentiometric dyes for monitoring Deltapsi(M) are discussed. (C) 2003 Elsevier Science B.V. All rights reserved.	Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada		Pennefather, PS (corresponding author), Univ Toronto, Inst Med Sci, 100 Coll St, Toronto, ON M5S 1A8, Canada.	p.pennefather@utoronto.ca					BUNTING JR, 1992, BIOPHYS CHEM, V42, P163, DOI 10.1016/0301-4622(92)85006-P; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; LLORIS J, 1998, P NATL ACAD SCI USA, V95, P6803; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; SCHLICHTER LC, 1992, PFLUG ARCH EUR J PHY, V421, P400, DOI 10.1007/BF00374232; Toescu EC, 2000, PFLUG ARCH EUR J PHY, V440, P941, DOI 10.1007/s004240000390; Ward MW, 2000, J NEUROSCI, V20, P7208; White RJ, 1996, J NEUROSCI, V16, P5688; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	23	34	34	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAY 30	2003	125	1-2					13	25		10.1016/S0165-0270(03)00027-X			13	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	687EJ	WOS:000183362900003	12763226				2022-02-06	
J	Foster, M; Tilse, C				Foster, M; Tilse, C			Referral to rehabilitation following traumatic brain injury: a model for understanding inequities in access	SOCIAL SCIENCE & MEDICINE			English	Article						brain injury; social problems theory; rehabilitation	HEALTH-CARE; HEAD-INJURY; CHILDREN; SERVICES; STROKE; DISABILITY; CENTERS; PEOPLE	Identifying inequities in access to health care requires critical scrutiny of the patterns and processes of care decisions. This paper describes a conceptual model. derived from social problems theory. which is proposed as a useful framework for explaining patterns of post-acute care referral and in particular, individual variations in referral to rehabilitation after traumatic brain injury (TBI). The model is based on three main components: (1) characteristics of the individual with TBI, (2) activities of health care professionals and the processes of referral. and (3) the contexts of care. The central argument is that access to rehabilitation following TBI is a dynamic phenomenon concerning the interpretations and negotiations of health care professionals. which in turn are shaped by the organisational and broader health care contexts. The model developed in this paper provides opportunity to develop a complex analysis of post-acute care referral based on patient factors, contextual factors and decision-making processes. It is anticipated that this framework will have utility in other areas examining and understanding patterns of access to health care. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Queensland, CONROD, Ctr Natl Res Disabil & Rehabil Med, Herston, Qld 4006, Australia; Univ Queensland, Sch Social Work & Social Policy, Brisbane, Qld 4072, Australia		Foster, M (corresponding author), Univ Queensland, CONROD, Ctr Natl Res Disabil & Rehabil Med, Herston, Qld 4006, Australia.		Tilse, Cheryl/A-1266-2008; Tilse, Cheryl/AAH-2155-2019	Tilse, Cheryl/0000-0001-5596-9132; 			Banja J, 1999, BRAIN INJURY, V13, P745, DOI 10.1080/026990599121142; BARTON L, 1996, DISABILITY SOC EMERG, P3; BATAVIA AI, 1993, HEALTH AFFAIR, V12, P40, DOI 10.1377/hlthaff.12.1.40; BENTOVIN D, 1994, AUSTR CASEMIX B, V6, P11; BEST J, 1987, SOC PROBL, V34, P101, DOI 10.1525/sp.1987.34.2.03a00010; Best J., 1993, CONSTRUCTIONIST CONT; BEST J, 1995, IMAGES ISSUES TYPIFY, P3; BONITA R, 1987, AGE AGEING, V16, P29; CAPLAN AL, 1987, ETHICAL POLICY ISSUE, P1; Cavestri R, 1997, ITAL J NEUROL SCI, V18, P9, DOI 10.1007/BF02106224; CLARK JA, 1991, SOC SCI MED, V32, P853, DOI 10.1016/0277-9536(91)90241-4; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Duckett S, 1995, J Qual Clin Pract, V15, P133; Foster M, 2000, BRAIN INJURY, V14, P1035; FOSTER M, 2001, THESIS U QUEENSLAND; GILES GM, 1994, AM J OCCUP THER, V48, P199, DOI 10.5014/ajot.48.3.199; GREENWALD CG, 1993, FRONT FOOD FOOD INGR, V1, P7; GRIFFIN D, 1993, ARCH PHYSICAL MED RE, V74, P1087; GRIFFITHS L, 1993, SOCIOL REV, V41, P415, DOI 10.1111/j.1467-954X.1993.tb00072.x; GRIFFITHS L, 1994, QUALITATIVE HLTH RES, V4, P385; GRIMMER K, 1996, J QUALITY CLIN PRACT, V16, P4; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HARRISON S, 1995, BRIT MED BULL, V51, P885, DOI 10.1093/oxfordjournals.bmb.a073003; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Holstein JA, 1993, RECONSIDERING SOCIAL, P151; Hughes D, 1997, SOC SCI MED, V44, P589, DOI 10.1016/S0277-9536(96)00207-9; HUNTER DJ, 1995, BRIT MED BULL, V51, P876, DOI 10.1093/oxfordjournals.bmb.a073002; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MANNING N, 1985, SOCIAL PROBLEMS WELF, P1; Marks D, 1997, DISABIL REHABIL, V19, P85, DOI 10.3109/09638289709166831; MECHANIC D, 1992, U PENN LAW REV, V140, P1713, DOI 10.2307/3312429; Mechanic David, 1989, PAINFUL CHOICES RES; MELVIN JL, 1988, ARCH PHYS MED REHAB, V69, P163; Miller G., 1993, RECONSIDERING SOCIAL, P25; Miller Gale, 1993, RECONSIDERING SOCIAL, P5; MUNFORD R, 1997, HUMAN SERVICES PARTN, P17; Nocella L., 1998, SOCIOLOGY SOCIAL PRO; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Pain K, 1998, J REHABIL, V64, P5; Patford J., 1999, AUSTR SOCIAL WORK, V52, P3, DOI 10.1080/03124079908414103; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Reitan TC, 1998, SOC SERV REV, V72, P285, DOI 10.1086/515760; Rubington E., 1995, STUDY SOCIAL PROBLEM; SAX S, 1990, HEALTH CARE CHOICES; SCHNEIDER JW, 1985, ANNU REV SOCIOL, V11, P209; Spector Malcom, 1987, CONSTRUCTING SOCIAL; SUSMAN J, 1994, SOC SCI MED, V38, P15, DOI 10.1016/0277-9536(94)90295-X; Unsworth C A, 1997, Pediatr Rehabil, V1, P207; UNSWORTH CA, 1995, ARCH PHYS MED REHAB, V76, P331, DOI 10.1016/S0003-9993(95)80658-X; WILLIAMS S, 1995, AUSTR OCCUPATIONAL T, V42, P143; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	55	34	34	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	MAY	2003	56	10					2201	2210	PII S0277-9536(02)00236-8	10.1016/S0277-9536(02)00236-8			10	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Biomedical Social Sciences	668VF	WOS:000182313300016	12697208				2022-02-06	
J	Hough, MS; Barrow, I				Hough, MS; Barrow, I			Descriptive discourse abilities of traumatic brain-injured adults	APHASIOLOGY			English	Article							CLOSED HEAD-INJURY; NARRATIVE DISCOURSE; ADOLESCENTS; CHILDREN; COHESION	Background: Studies examining the discourse abilities of adults who have suffered traumatic brain injuries (TBI) have revealed that although these individuals display relatively normal language skills on traditional aphasia tests, they demonstrate varying levels of impairment in the coherence, cohesion, and informational content of their extended verbal output. Discourse studies with the TBI population have varied relative to the type of discourse task as well as the level or approach of analysis. One approach to discourse analysis has involved examination of the cognitive functions distinguishing macrostructural and microstructural discourse processing. Macrostructural analyses are global analyses focused at the level of the entire text, dealing with large supra-sentential discourse units. Microstructural analyses are concerned with smaller structural elements in a text and the relations between these elements; the focus is at the local level of the word or sentence. Aims: In the current investigation, three analyses were undertaken to examine descriptive discourse production of five high-functioning TBI adults (three males, two females) who had suffered brain injury as the result of motor vehicle accidents. The first analysis, thematic coherence, is a macrostructural analysis, whereas the other two analyses, cohesion and lexical errors, are microstructural analyses. Methods & Procedures: Two topics, family description and work experience, were used to elicit discourse; performance was compared between the language samples. Each participant's performance was reviewed individually and findings were compared to the mean performance of a group of 15 normal functioning young adults. For thematic coherence, global and local coherence were evaluated and scored separately on different 5-point rating scales. Cohesion analysis involved identification of three types of cohesive ties (closed-class appropriate, open-class appropriate, incomplete cohesion) with scores computed as proportions of total spoken words. Lexical error production included identification of verbal paraphasias and indefinite terms, also computed as proportions of total words spoken. Outcomes & Results: The results revealed that mean coherence ratings for each TBI participant were consistently lower than those observed for the control group, regardless of coherence type (local, global) or discourse topic (family, work). Furthermore, the TBI participants demonstrated greater difficulty with global than local coherence and showed more performance variability among participants in global as compared to local coherence. However, all five TBI adults displayed minimal deficits in lexical production and cohesion. Conclusions: Overall, the findings revealed dissociation of microlinguistic and macrolinguistic cognitive functions in the TBI participants, thus providing support for the distinction between and independent organisation of microstructural and macrostructural discourse components.	E Carolina Univ, Greenville, NC 27858 USA; Hampton Univ, Hampton, VA 23668 USA		Hough, MS (corresponding author), E Carolina Univ, Greenville, NC 27858 USA.						American Speech-Language-Hearing Association (ASHA), 1997, GUID AUD SCREEN; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Cherney L. R., 1998, ANAL DISCOURSE COMMU; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1994, DISCOURSE ANAL APPL; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Fayol M., 1993, NARRATIVE DISCOURSE; GLOSSER G, 1988, J SPEECH HEAR DISORD, V53, P115, DOI 10.1044/jshd.5302.115; GLOSSER G, 1993, NARRATIVE DISCOURSE; Glosser G., 1992, J GERONTOL B-PSYCHOL, V47, P266; Glosser G., 1990, BRAIN LANG, V40, P67; Glosser G., 1992, J CLIN EXPT NEUROPSY, V14, P40; Goodglass H, 1983, ASSESSMENT APHASIA R; HAGEN C, 1984, LANGUAGE DISORDERS A; HAGEN C, 1979, INTERVENTION STRATEG; Halliday M. A. K., 1989, LANGUAGE CONTEXT TEX; Halliday M. K., 1976, COHESION ENGLISH; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HODGES T, 1998, THESIS CAROLINA U; LOBAN WD, 1963, LANGUAGE ELEMENTARY; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Myers P.S., 1999, RIGHT HEMISPHERE DAM; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; PIERCE RS, 1990, COGNITIVE LANGUAGE A; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Van Dijk TA., 1983, STRATEGIES DISCOURSE; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; YLVISAKER M, 1994, LANGUAGE INTERVENTIO	32	34	35	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology		2003	17	2					183	191		10.1080/02687030244000608			9	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	641UK	WOS:000180765100007					2022-02-06	
J	Williams, WH; Evans, JJ; Needham, P; Wilson, BA				Williams, WH; Evans, JJ; Needham, P; Wilson, BA			Neurological, cognitive and attributional predictors of posttraumatic stress symptoms after traumatic brain injury	JOURNAL OF TRAUMATIC STRESS			English	Article						PTSD; brain injury; predictors; insight and attributions	EVENT SCALE; DISORDER; IMPACT; MEMORY	We investigated the relationship between the reporting of symptoms of posttraumatic stress disorder (PTSD) in a community sample of 66 survivors of severe traumatic brain injury (TBI) and measures of injury severity, memory, insight, and index-event attributions. Correlational analyses revealed that reporting of PTSD symptoms was related to level of insight and not associated with the severity of survivors' injury, educational background, premorbid or current IQ, or memory impairment. The severity of PTSD symptoms was also associated with external attributions to others of causality for the event.	Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England; Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, England; Cognit & Brain Sci Unit, Cambridge, England		Williams, WH (corresponding author), Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England.			williams, huw/0000-0003-0670-2620			Baddeley A., 1992, SPEED CAPACITY LANGU; Brewin C. R., 1984, J SOC CLIN PSYCHOL, V2, P156, DOI [10.1521/jscp.1984.2.2.156, DOI 10.1521/JSCP.1984.2.2.156]; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Cummings J. L., 1995, NEUROPSYCHIATRY BEHA; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; KING NS, 1997, J NEUROL NEUROSUR PS, V62, P8; Lishman WA, 1998, ORGANIC PSYCHIAT; Markowitsch HJ, 1998, NEUROCASE, V4, P429, DOI 10.1080/13554799808410636; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Raven J.C., 1947, RAVENS PROGR MATRICE; Robertson I., 1994, TEST EVERYDAY ATTENT; Rothbaum B, 2000, J TRAUMA STRESS, V13, P558; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Warrington E., 1983, GRADED NAMING TEST; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; [No title captured]; [No title captured]	26	34	34	0	6	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0894-9867			J TRAUMA STRESS	J. Trauma Stress	OCT	2002	15	5					397	400	UNSP 0894-9867/02/1000-0397/1	10.1023/A:1020185325026			4	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	593AK	WOS:000177968900007	12392227				2022-02-06	
J	Niess, C; Grauel, U; Toennes, SW; Bratzke, H				Niess, C; Grauel, U; Toennes, SW; Bratzke, H			Incidence of axonal injury in human brain tissue	ACTA NEUROPATHOLOGICA			English	Article						diffuse axonal injury; beta-amyloid precursor protein; drug intoxication; traumatic brain	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; NERVE-FIBERS; DAMAGE; NEUROPATHOLOGY; DIAGNOSIS; DISEASE; TRAUMA; MILD	Diffuse axonal injury (DAI) is considered to be the morphological correlate of traumatic brain injury as seen in acceleration/deceleration trauma and is believed to be the main cause for a poor clinical outcome in the absence of detectable intracranial lesions. To estimate the overall incidence of DAI, and since most changes are only seen microscopically to rule out whether there is a high number of undetected cases, 450 non-selected human brains were examined. Samples from two brain areas (pons and cerebrum) were immunostained for P-amyloidprecursor-protein (PAPP), and axonal damage was assessed microscopically. Axonal injury was detected in 12% of all cases, but only one third had a history of traumatic brain injury. The majority of the positive cases were associated with drug intoxication, chiefly due to opiates. PAPP staining was positive in both pons and cerebrum to a much higher extent in intoxication than in trauma cases; the latter showing axonal damage mainly in the pons area. This may reflect a more generalized pathomechanism in the intoxication group as compared to more biomechanical mechanisms in the trauma group. The findings also show that various causes may produce diffuse axonal injury and suggest that traumatic brain injury is not the only and probably not even the main cause of the observed neuropathological changes. A correlation between axonal damage and age-related processes could not be shown.	Goethe Univ Frankfurt, Zentrum Rechtsmed, D-60596 Frankfurt, Germany		Niess, C (corresponding author), Goethe Univ Frankfurt, Zentrum Rechtsmed, Kennedyallee 104, D-60596 Frankfurt, Germany.	niess@em.uni-frankfurt.de					Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Imajo T, 1996, AM J FOREN MED PATH, V17, P324, DOI 10.1097/00000433-199612000-00010; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OBREJA C, 2000, NEUROBIOL AGING, V2, P148; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Oehmichen M, 1996, ACTA NEUROPATHOL, V91, P642, DOI 10.1007/s004010050478; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Walter GF, 1999, CRIT REV NEUROSURG, V9, P367, DOI 10.1007/s003290050157	33	34	37	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUL	2002	104	1					79	84		10.1007/s00401-002-0525-9			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	569AP	WOS:000176577400012	12070668				2022-02-06	
J	Taubenfeld, SM; Stevens, KA; Pollonini, G; Ruggiero, J; Alberini, CM				Taubenfeld, SM; Stevens, KA; Pollonini, G; Ruggiero, J; Alberini, CM			Profound molecular changes following hippocampal slice preparation: loss of AMPA receptor subunits and uncoupled mRNA/protein expression	JOURNAL OF NEUROCHEMISTRY			English	Article						hippocampus; glutamate receptor; neurotrophin; slice; transcription factor	IMMEDIATE-EARLY GENES; LONG-TERM POTENTIATION; CONDITIONED TASTE-AVERSION; TRAUMATIC BRAIN INJURY; HEAT-SHOCK-PROTEIN; C-FOS; MESSENGER-RNA; SYNAPTIC TRANSMISSION; ANTISENSE OLIGONUCLEOTIDE; PROTOONCOGENE EXPRESSION	The acute hippocampal slice preparation is a convenient, in vitro model widely used to study the biological basis of synaptic plasticity. Although slices may preserve their electrophysiological properties for several hours, profound molecular changes in response to the injury caused by the slicing procedure are likely to occur. To determine the magnitude and duration of these changes we examined the post-slicing expression kinetics of three classes of genes known to be implicated in long-term synaptic plasticity: glutamate AMPA receptors (GluR), transcription factors and neurotrophins. Slicing resulted in a striking loss of GluR1 and GluR3, but not of GluR2 proteins suggesting that rapid changes in the composition of major neurotransmitter receptors may occur. Slicing caused a significant induction of the transcription factors c-fos , zif268 , CCAAT enhancer binding protein (C/EBP ) beta and delta mRNAs and of the neurotrophin brain-derived neurothophic factor (BDNF ) mRNA. In contrast, there was no augmentation, and sometimes a decline, in the levels of the corresponding proteins. These data reveal that significant discrepancies exist between the slice preparation and the intact hippocampus in terms of the metabolism of molecular components known to be involved in synaptic plasticity.	Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA		Alberini, CM (corresponding author), Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218,1 Gustave L Levy Pl, New York, NY 10029 USA.						AITKEN PG, 1995, J NEUROSCI METH, V59, P139, DOI 10.1016/0165-0270(94)00204-T; Akaneya Y, 1997, J NEUROSCI, V17, P6707; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Berardi N, 1999, J NEUROBIOL, V41, P119, DOI 10.1002/(SICI)1097-4695(199910)41:1<119::AID-NEU15>3.3.CO;2-E; Cammarota M, 1998, EUR J NEUROSCI, V10, P2669, DOI 10.1046/j.1460-9568.1998.00254.x; Castren E, 1998, PROG BRAIN RES, V117, P57; Chaudhuri A, 1997, NEUROREPORT, V8, pR5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK GD, 1987, NEUROSCIENCE, V21, P665, DOI 10.1016/0306-4522(87)90027-3; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DJURICIC B, 1994, METAB BRAIN DIS, V9, P377, DOI 10.1007/BF02098884; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; FEIG S, 1993, J NEUROSCI, V13, P1010; Gall CM, 1998, NEUROBIOL LEARN MEM, V70, P14, DOI 10.1006/nlme.1998.3835; Hasegawa K, 1998, BRAIN RES, V785, P262, DOI 10.1016/S0006-8993(97)01410-8; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; HOSSMANN KA, 1993, RESUSCITATION, V26, P225, DOI 10.1016/0300-9572(93)90143-E; Hossmann KA, 1999, ADV EXP MED BIOL, V474, P155; Houpt TA, 1996, LEARN MEMORY, V3, P25, DOI 10.1101/lm.3.1.25; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; KACZMAREK L, 1993, J NEUROSCI RES, V34, P377, DOI 10.1002/jnr.490340402; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kennis JHH, 1997, EXP NEUROL, V147, P18, DOI 10.1006/exnr.1997.6576; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kjoller C, 2000, NEUROCHEM INT, V37, P7, DOI 10.1016/S0197-0186(00)00008-5; Lamprecht R, 1996, LEARN MEMORY, V3, P31, DOI 10.1101/lm.3.1.31; Lessmann V, 1998, GEN PHARMACOL-VASC S, V31, P667; Linnarsson S, 1997, EUR J NEUROSCI, V9, P2581, DOI 10.1111/j.1460-9568.1997.tb01687.x; LIPTON P, 1979, J PHYSIOL-LONDON, V287, P427, DOI 10.1113/jphysiol.1979.sp012668; Lipton P, 1999, METHODS, V18, P127, DOI 10.1006/meth.1999.0766; Lynch G, 1998, NEUROBIOL LEARN MEM, V70, P82, DOI 10.1006/nlme.1998.3840; Ma YL, 1998, NEUROSCIENCE, V82, P957; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; Monje ML, 2000, BRAIN RES, V857, P172, DOI 10.1016/S0006-8993(99)02404-X; Montag-Sallaz M, 1999, J NEUROBIOL, V38, P234, DOI 10.1002/(SICI)1097-4695(19990205)38:2<234::AID-NEU6>3.0.CO;2-G; Montkowski A, 1997, NEUROREPORT, V8, P779, DOI 10.1097/00001756-199702100-00040; MORLEY P, 1994, BRAIN PATHOL, V4, P37; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; NIKOLAEV E, 1991, BRAIN RES, V560, P346, DOI 10.1016/0006-8993(91)91257-2; NOWAK TS, 1993, PROG BRAIN RES, V96, P195; Oorschot DE, 2000, EXP NEUROL, V161, P227, DOI 10.1006/exnr.1999.7248; Paschen W, 1999, ACT NEUR S, V73, P1; Radulovic J, 1998, J NEUROSCI, V18, P7452; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raley-Susman KM, 1998, BRAIN RES, V782, P281, DOI 10.1016/S0006-8993(97)01329-2; RALEYSUSMAN KM, 1995, BRAIN RES, V694, P94, DOI 10.1016/0006-8993(95)00770-Q; Riedel G, 1996, PROG NEURO-PSYCHOPH, V20, P761, DOI 10.1016/0278-5846(96)00058-9; SCHLINGENSIEPEN R, 1994, NEUROREPORT, V30, P101; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; SHARP FR, 1993, STROKE S, V24, P172; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Siklos L, 1997, NEUROSCIENCE, V79, P1013, DOI 10.1016/S0306-4522(97)00031-6; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TAKEMOTO O, 1995, STROKE, V26, P1639, DOI 10.1161/01.STR.26.9.1639; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; Tischmeyer W, 1999, CELL MOL LIFE SCI, V55, P564, DOI 10.1007/s000180050315; Tomimoto H, 1999, ACTA NEUROPATHOL, V97, P22, DOI 10.1007/s004010050951; VORNOV JJ, 1991, J NEUROCHEM, V56, P996, DOI 10.1111/j.1471-4159.1991.tb02020.x; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Wan HM, 1999, J NEUROSCI, V19, P1142; Watson PL, 1997, BRAIN RES, V775, P134, DOI 10.1016/S0006-8993(97)00893-7; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; Zhang Y, 1999, BRAIN RES, V832, P112, DOI 10.1016/S0006-8993(99)01459-6; ZHOU QH, 1995, J NEUROSCI METH, V59, P85, DOI 10.1016/0165-0270(94)00197-O; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	74	34	34	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	2002	81	6					1348	1360		10.1046/j.1471-4159.2002.00936.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Neurosciences & Neurology	559ZN	WOS:000176056700020	12068082				2022-02-06	
J	Gellrich, NC; Schimming, R; Zerfowski, M; Eysel, UT				Gellrich, NC; Schimming, R; Zerfowski, M; Eysel, UT			Quantification of histological changes after calibrated crush of the intraorbital optic nerve in rats	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							RETINAL GANGLION-CELLS; FETAL BRAIN GRAFTS; ADULT-RATS; INJURY; FIBERS; CAT; LESIONS; TECTUM; BLOCK	Background: Traumatic optic nerve lesions (TONL) are probable but unpredictable consequence after severe midface or skull base trauma. Based on a previously described rat model, the authors developed a new model in order to simulate optic nerve crush during trauma on the optic canal. Methods: To achieve a calibrated TONL, a microinjuring device was designed that made it possible, to assess the correlation between a defined trauma and the neuronal degeneration in the rat retinal ganglion cell (RGC) layer. This device is based on a small dynamometer mounted onto a conventional micromanipulator. The supraorbital approach was chosen to expose the extracranial optic nerve. Results: In this rat model (n=100, Wistar strain) the parameters of "force' and "time" could be precisely monitored during the experiment. The decrease in he mean number of retinal neurons (N) according to the pressure exerted (2-30 cN.mm(-2)) on the optic nerve was linear for 1, 6, and 15 minutes of injuring time; the decrease in N for varying injuring forces also appears to be nearly linear. Conclusion: The results show that this model provides a reliable method for studying quantitatively the anatomical effects of TONL on the RGC layer and the optic nerve itself, and may allow the design of treatment strategies following TONL.	Univ Hosp Freiburg, Dept Oral & Maxillofacial Surg, D-79106 Freiburg, Germany; Univ Tubingen Hosp, Dept Oral & Maxillofacial Surg, Tubingen, Germany; Ruhr Univ Bochum, Dept Neurophysiol, Bochum, Germany		Gellrich, NC (corresponding author), Univ Hosp Freiburg, Dept Oral & Maxillofacial Surg, Hugstetterstr 55, D-79106 Freiburg, Germany.			Eysel, Ulf/0000-0001-6087-957X			BAHR M, 1992, J COMP NEUROL, V320, P370, DOI 10.1002/cne.903200308; BERRY M, 1986, BRAIN RES S, V13, P18; BLAUGRUND E, 1992, EXP NEUROL, V118, P105, DOI 10.1016/0014-4886(92)90027-N; BURKE W, 1986, J PHYSIOL-LONDON, V376, P461, DOI 10.1113/jphysiol.1986.sp016164; BURKE W, 1985, J PHYSIOL-LONDON, V364, P81, DOI 10.1113/jphysiol.1985.sp015731; COTTEE LJ, 1991, EUR J NEUROSCI, V3, P1245, DOI 10.1111/j.1460-9568.1991.tb00058.x; CRESPO D, 1985, DEV BRAIN RES, V19, P129, DOI 10.1016/0165-3806(85)90238-X; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; EYSEL UT, 1978, PFLUG ARCH EUR J PHY, V375, P251, DOI 10.1007/BF00582438; FORRESTER J, 1967, NATURE, V214, P245, DOI 10.1038/214245a0; FUKUDA Y, 1982, EXP NEUROL, V75, P525, DOI 10.1016/0014-4886(82)90181-9; Gellrich N C, 1999, Mund Kiefer Gesichtschir, V3, P176, DOI 10.1007/s100060050128; Gellrich N C, 1996, Fortschr Kiefer Gesichtschir, V41, P1; GELLRICH NC, 1994, INT J ORAL MAX SURG, V23, P403, DOI 10.1016/S0901-5027(05)80030-X; GREHN F, 1987, CHIBRET INT J OPHTHA, V5, P17; HOLLANDER H, 1968, Brain Research, V10, P120, DOI 10.1016/0006-8993(68)90117-0; LINDEN R, 1987, J COMP NEUROL, V258, P138, DOI 10.1002/cne.902580111; MATSUZAKI H, 1982, JPN J OPHTHALMOL, V26, P447; MCKERRACHER L, 1992, J NEUROBIOL, V23, P568, DOI 10.1002/neu.480230510; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; OWUSUYAW V, 1992, BRAIN RES, V576, P220, DOI 10.1016/0006-8993(92)90684-2; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PERRY VH, 1983, J COMP NEUROL, V219, P356, DOI 10.1002/cne.902190309; POTTS RA, 1982, DEV BRAIN RES, V3, P481, DOI 10.1016/0165-3806(82)90013-X; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SIEVERS J, 1989, J COMP NEUROL, V281, P467, DOI 10.1002/cne.902810310	26	34	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161			BRIT J OPHTHALMOL	Br. J. Ophthalmol.	FEB	2002	86	2					233	237		10.1136/bjo.86.2.233			5	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	519QN	WOS:000173737100024	11815353	Green Published, Bronze			2022-02-06	
J	Romano, J; Beni-Adani, L; Nissenbaum, OL; Brenneman, DE; Shohami, E; Gozes, I				Romano, J; Beni-Adani, L; Nissenbaum, OL; Brenneman, DE; Shohami, E; Gozes, I			A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury - Gene atlas array analysis	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						NAP; Mac-1; atlas array; head trauma; ADNP; VIP	TRAUMATIC BRAIN INJURY; VASOACTIVE-INTESTINAL-PEPTIDE; CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; RAT-BRAIN; INFLAMMATORY RESPONSE; MONOCLONAL-ANTIBODIES; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; TNF-ALPHA	The femtomolar-acting eight-amino-acid peptide (NAP), derived from activity-dependent neuroprotective protein (ADNP), provides long-term protection against the deleterious effects of closed head injury (CHI) in mice. Fifteen minutes after injury, mice were divided into two groups, control and NAP-treated and a single subcutaneous injection of NAP or vehicle was administered. A third group served as sham-treated (not subjected to head trauma). Each mouse was assessed for its clinical function, using neurological severity score, at various time intervals following CHI, up to 30-45 d. Total cerebral cortex RNA was prepared from the site of injury of CHI mice, and from parallel regions in peptide-treated and sham brains. RNA was then reversed transcribed to yield radioactive cDNA preparations that were hybridized to Atlas array membranes containing 1200 cDNAs spots. Comparison of sham-treated individual mice showed differential expression levels of at least 15 mRNA species. Furthermore, results indicated that one of the genes that did not change among individuals but specifically increased after CHI and decreased after NAP treatment was the cell surface glycoprotein Mac-1 (CD11B antigen). Thus, Mac-1 is suggested as a marker for the long-term outcome of head injury and as a potential target for NAP protective actions.	Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, IL-69978 Tel Aviv, Israel; NICHHD, Sect Dev & Mol Pharmacol, LDN, NIH, Bethesda, MD 20892 USA; Hebrew Univ Jerusalem, Sch Pharm, IL-91120 Jerusalem, Israel		Gozes, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [Z01HD000047] Funding Source: NIH RePORTER		ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CORIA F, 1994, REV NEUROSCIENCE, V5, P275; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Engel S, 1996, Acta Neurochir Suppl, V66, P89; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; Gozes I, 1999, CURR MED CHEM, V6, P1019; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Walzog B, 1999, FASEB J, V13, P1855, DOI 10.1096/fasebj.13.13.1855; Whalen MJ, 1999, CRIT CARE MED, V27, P1014, DOI 10.1097/00003246-199905000-00049; WHALEN MJ, 1998, CRIT CARE MED, V25, pA85; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1	41	34	35	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696			J MOL NEUROSCI	J. Mol. Neurosci.	FEB-APR	2002	18	1-2					37	45		10.1385/JMN:18:1-2:37			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	533FR	WOS:000174519200005	11931348				2022-02-06	
J	Thatcher, RW; Biver, C; Gomez, JF; North, D; Curtin, R; Walker, RA; Salazar, A				Thatcher, RW; Biver, C; Gomez, JF; North, D; Curtin, R; Walker, RA; Salazar, A			Estimation of the EEG power spectrum using MRI T-2 relaxation time in traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						traumatic brain injury; magnetic resonance imaging T-2 relaxation time; entropy; qEEG	CLOSED-HEAD INJURY; BIOPHYSICAL LINKAGE; ALZHEIMERS-DISEASE; TISSUE; MECHANISMS; MILD; SEGMENTATION; CONCUSSION; FREQUENCY; SEQUENCES	Objectives: To study the relationship between magnetic resonance imaging (MRI) T-2 relaxation time and the power spectrum of the electroencephalogram (EEG) in long-term follow up of traumatic brain injury. Methods: Nineteen channel quantitative electroencephalograms or qEEG, tests of cognitive function and quantitative MRI T-2 relaxation times (qMRI) were measured in 18 mild to severe closed head injured outpatients 2 months to 4.6 years after injury and 11 normal controls. MRI T-2 and the Laplacian of T-2 were then correlated with the power spectrum of the scalp electrical potentials and current source densities of the qEEG. Results: qEEG and qMRI T-2 were related by a frequency tuning with maxima in the alpha (8-12 Hz) and the lower EEG frequencies (0.5-5 Hz), which varied as a function of spatial location. The Laplacian of T2 acted like a spatial-temporal 'lens' by increasing the spatial-temporal resolution of correlation between 3-dimensional T-2 and the ear referenced alert but resting spontaneous qEEG. Conclusions: The severity of traumatic brain injury can be modeled by a linear transfer function that relates the molecular qMRI to qEEG resonant frequencies. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Bay Pines Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA; Univ S Florida, Coll Med, Dept Neurol, Tampa, FL USA; Univ S Florida, Coll Med, Dept Radiol, Tampa, FL USA; Def & Vet Head Injury Program, Washington, DC 20307 USA		Thatcher, RW (corresponding author), Bay Pines Vet Adm Med Ctr, Res & Dev Serv 151, Bldg 23,Room 117, Bay Pines, FL 33744 USA.						ADVANI SH, 1982, HUMAN BODY DYNAMICS, P3; BARTH J, 1983, NEUROSURGERY, V13, P520; Bendat J. S., 1980, ENG APPL CORRELATION; BENSAID AM, 1994, P SPIE MED IMAGING, P454; BEZDEK JC, 1993, MED PHYS, V20, P1033, DOI 10.1118/1.597000; BLOCH F, 1946, PHYS REV, V70, P460, DOI 10.1103/PhysRev.70.460; BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535; CHAITIN G, 1987, ALGORITHMIC INFORMAT; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; CRONWALL D, 1980, LANCET, V11, P605; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DARWIN RH, 1986, RADIOLOGY, V160, P375, DOI 10.1148/radiology.160.2.3726116; DASILVA FHL, 1995, DYNAMICS ELECT ACTIV; DASILVA FL, 1987, ELECTROENCEPHALOGRAP; DAWANT BM, 1993, IEEE T MED IMAGING, V12, P770, DOI 10.1109/42.251128; DECERTAINES JD, 1993, MAGN RESON IMAGING, V11, P841, DOI 10.1016/0730-725X(93)90201-N; DIXON RL, 1982, MED PHYS, V9, P807, DOI 10.1118/1.595189; FEYNMAN R, 1963, FEYNMAN LECT PHYSICS, V1; FEYNMAN RP, 1963, FEYNMAN LECT PHYSICS, V2; Freeman W.J., 1975, MASS ACTION NERVOUS; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; HICKEY DS, 1986, BRIT J RADIOL, V59, P565, DOI 10.1259/0007-1285-59-702-565; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; KIRSCH SJ, 1992, NEUROSCI LETT, V134, P187, DOI 10.1016/0304-3940(92)90513-7; KJOS BO, 1985, AM J ROENTGENOL, V144, P1165, DOI 10.2214/ajr.144.6.1165; KOENIG SH, 1991, MAGNET RESON MED, V20, P285, DOI 10.1002/mrm.1910200210; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Laakso MP, 1996, NEUROBIOL AGING, V17, P535, DOI 10.1016/0197-4580(96)00036-X; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; Makeig S, 1996, ADV NEUR IN, V8, P145; Malmivuo J, 1995, BIOELECTROMAGNETISM; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; MILLS CM, 1984, RADIOLOGY, V150, P87, DOI 10.1148/radiology.150.1.6689792; MiotNoirault E, 1997, J NEUROSCI METH, V72, P5, DOI 10.1016/S0165-0270(96)00148-3; NARAYANA PA, 1988, MAGN RESON IMAGING, V6, P271, DOI 10.1016/0730-725X(88)90401-8; Nicholis G., 1989, EXPLORING COMPLEXITY; Nunez P, 1981, ELECT FIELDS BRAIN; Nunez P.L., 1995, NEOCORTICAL DYNAMICS; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; Otnes RK, 1972, DIGITAL TIME SERIES; PASCUALMARQUI RD, 1988, INT J NEUROSCI, V43, P237, DOI 10.3109/00207458808986175; PASCUALMARQUI RD, 1999, NEUROIMAGE, V9, pS204; Press WH, 1994, NUMERICAL RECIPES C; PURPURA DP, 1959, INT REV NEUROBIOLOGY, V1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 2000, NEUROIMAGE, V9, pS110; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; TILLMAN S, 1997, PSYCHIAT RES-NEUROIM, V75, P173; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Egren L., 1996, CLIN ELECTROENCEPHAL, V27, P164; VANROTTERDAM A, 1982, B MATH BIOL, V44, P283, DOI 10.1016/S0092-8240(82)80070-0; von Bierbrauer A., 1993, EEG EMG Z ELEKTROENZ, V23, P151; Wehrli F. W, 1992, MAGNETIC RESONANCE I, P3; Whittall KP, 1997, MAGNET RESON MED, V37, P34, DOI 10.1002/mrm.1910370107; [No title captured]; [No title captured]	70	34	34	0	5	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	SEP	2001	112	9					1729	1745		10.1016/S1388-2457(01)00609-5			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466ZQ	WOS:000170676400019	11514257				2022-02-06	
J	Nakahara, M; Ericson, K; Bellander, BM				Nakahara, M; Ericson, K; Bellander, BM			Diffusion-weighted MR and apparent diffusion coefficient in the evaluation of severe brain injury	ACTA RADIOLOGICA			English	Article						brain death; severe brain injury; MR imaging; diffusion, apparent diffusion coefficient	CEREBRAL-ISCHEMIA; WHITE-MATTER; T2-WEIGHTED MRI; WATER DIFFUSION; STROKE; DEATH; TEMPERATURE; EDEMA; RATS; CATS	Purpose: To study apparent diffusion coefficient (ADC) maps in severely brain-injured patients. Material and Methods. Four deeply comatose patients with severe brain injury were investigated with single-shot, diffusion-weighted, spin-echo echoplanar imaging. The tetrahedral diffusion gradient configuration and four iterations of a set of b-values tone time of 0 mm(2)/s, and four times of 1000 mm(2)/s) were used to create isotropic ADC maps with high signal-to-noise ratio. ADC values of gray and white matter were compared among patients and 4 reference subjects. Results. One patient was diagnosed as clinically brain dead after the MR examination. The patient's ADC values of gray and white matter were significantly lower than these of 3 other brain-injured patients. In addition the ADC value of white matter was significantly lower than that of gray matter. Conclusion: The patient with fatal outcome shortly after MR examination differed significantly from other patients with severe brain injury but non-fatal outcome, with regard to ADC values in gray and white matter. This might indicate a prognostic value of ADC maps in the evaluation of traumatic brain injury.	Nippon Med Sch, Dept Radiol, Bunkyo Ku, Tokyo 1138603, Japan; Karolinska Hosp, Dept Neuroradiol, S-10401 Stockholm, Sweden; Karolinska Hosp, Dept Neurosurg, S-10401 Stockholm, Sweden		Nakahara, M (corresponding author), Nippon Med Sch, Dept Radiol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.						BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; Falini A, 1998, AM J NEURORADIOL, V19, P648; Grohn OHJ, 1998, J CEREBR BLOOD F MET, V18, P911; HASEGAWA Y, 1994, J CEREBR BLOOD F MET, V14, P383, DOI 10.1038/jcbfm.1994.49; HOSSMANN KA, 1994, J CEREBR BLOOD F MET, V14, P723, DOI 10.1038/jcbfm.1994.93; Ishii K, 1996, AM J NEURORADIOL, V17, P731; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kumada K, 2000, No To Shinkei, V52, P719; Kuroiwa T, 1998, STROKE, V29, P859, DOI 10.1161/01.STR.29.4.859; LEBIHAN D, 1989, RADIOLOGY, V171, P853, DOI 10.1148/radiology.171.3.2717764; LEE DH, 1995, CAN ASSOC RADIOL J, V46, P174; LINK J, 1994, FORENSIC SCI INT, V69, P195, DOI 10.1016/0379-0738(94)90384-0; Lovblad KO, 2000, STROKE, V31, P539, DOI 10.1161/01.STR.31.2.539; MELLERGARD P, 1995, SURG NEUROL, V43, P91, DOI 10.1016/0090-3019(95)80049-M; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; Miyabe M, 1996, J CEREBR BLOOD F MET, V16, P881, DOI 10.1097/00004647-199609000-00012; Miyasaka N, 2000, RADIOLOGY, V215, P199, DOI 10.1148/radiology.215.1.r00ap24199; MORI S, 1995, MAGNET RESON MED, V33, P41, DOI 10.1002/mrm.1910330107; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Mukherjee P, 2000, RADIOLOGY, V215, P211, DOI 10.1148/radiology.215.1.r00ap29211; Nagesh V, 1998, STROKE, V29, P1778, DOI 10.1161/01.STR.29.9.1778; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; ROUSSEL SA, 1995, J CEREBR BLOOD F MET, V15, P578, DOI 10.1038/jcbfm.1995.71; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Ulug AM, 1997, STROKE, V28, P483, DOI 10.1161/01.STR.28.3.483	28	34	36	0	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0284-1851			ACTA RADIOL	Acta Radiol.	JUL	2001	42	4					365	369		10.1080/028418501127346990			5	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	454ZN	WOS:000170001800004	11442459				2022-02-06	
J	van Reekum, R; Streiner, DL; Conn, DK				van Reekum, R; Streiner, DL; Conn, DK			Applying Bradford Hill's criteria for causation to neuropsychiatry: Challenges and opportunities	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; PSYCHIATRIC-DISORDERS; ALZHEIMERS-DISEASE; DEPRESSION; STROKE; RISK	Establishing an argument of causation is an important research activity with major clinical and scientific implications. Sir Austin Bradford Hill proposed criteria to establish such an argument. These criteria include the strength of the association, consistency, specificity, temporal sequence, biological gradient, biologic rationale, coherence, experimental evidence, and analogous evidence. These criteria are reviewed with the goal of facilitating an increase in rigor for establishing arguments of causation in neuropsychiatry. The challenges and opportunities related to these criteria in neuropsychiatry are reviewed, as are two important arguments for causation: one for poststroke depression and one for brain injury as a cause of psychiatric disorders.	Baycrest Ctr Geriatr Care, Dept Psychiat, Toronto, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Univ Toronto, Div Geriatr Psychiat, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada		van Reekum, R (corresponding author), Baycrest Ctr Geriatr Care, Dept Psychiat, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Streiner, David/E-6563-2011	Streiner, David/0000-0003-0610-6271			Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dep. Clin. Epidemiol. Biostat. McMaster Univ., 1981, CAN MED ASSOC J, V124, P985; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; HILL AB, 1965, P ROY SOC MED, V58, P293; House A, 1996, J NEUROPSYCH CLIN N, V8, P453; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Lyketsos CG, 1998, J NEUROPSYCH CLIN N, V10, P103, DOI 10.1176/jnp.10.1.103; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MORRIS PLP, 1992, AUST NZ J PSYCHIAT, V26, P208, DOI 10.3109/00048679209072029; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; STARKSTEIN SE, 1988, BRAIN, V111, P375, DOI 10.1093/brain/111.2.375; Streiner DS, 1989, PDQ EPIDEMIOLOGY; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; van Reekum R, 1999, J PSYCHIATR NEUROSCI, V24, P413; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	19	34	34	0	1	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2001	13	3					318	325		10.1176/appi.neuropsych.13.3.318			8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	462RP	WOS:000170433800002	11514637				2022-02-06	
J	Soto-Ares, G; Vinchon, M; Delmaire, C; Abecidan, E; Dhellemes, P; Pruvo, JP				Soto-Ares, G; Vinchon, M; Delmaire, C; Abecidan, E; Dhellemes, P; Pruvo, JP			Cerebellar atrophy after severe traumatic head injury in children	CHILDS NERVOUS SYSTEM			English	Article						traumatic brain injury; children; cerebellar atrophy; cerebellum; magnetic resonance imaging	BRAIN INJURY; MRI; ACTIVATION; TOMOGRAPHY; COGNITION; DEFICITS; LESIONS; SYSTEM; SCALE; MILD	Objects: The purpose of this study was to describe late neuropathological MRI findings in pediatric severe head injury and to explore the relationship between these lesions and cognitive sequelae. Methods: Thirteen infants with severe head trauma (Glasgow 6) were included in this investigation. Clinical examination, a battery of tests designed to assess neurophysiological status, and MRI investigations of the brain were obtained in periods ranging between 8 and 20 months after the accident. Hemosiderin deposits, encephalomalacia, and cerebellar atrophy were the most frequent traumatic sequelae. The lesions were located in frontal lobes, the basal ganglia, and the cerebellum. Six patients had cerebellar atrophy associated with frontal or temporal postraumatic lesions. Cerebellar clinical dysfunction was observed in only 3 of these patients. Performance on tests evaluating frontal lobe functions was depressed in 5 of them. Conclusions: Late MRI after severe head trauma in our pediatric population showed unexpected cerebellar atrophy. Its correlation with prefrontal dysfunction is difficult to confirm because of its association with other parenchymal post-traumatic lesions. Further research involving a larger sample of patients with brain injury of varying severity is in progress, to investigate whether cerebellar atrophy could be a consequence of severe head trauma.	CHRU Lille, Hop Roger Salengro, Dept Neuroradiol, F-59037 Lille, France; CHRU Lille, Hop Roger Salengro, Dept Pediat Neurosurg, F-59037 Lille, France		Soto-Ares, G (corresponding author), CHRU Lille, Hop Roger Salengro, Dept Neuroradiol, F-59037 Lille, France.			Vinchon, Matthieu/0000-0002-9122-6165			Alavi A, 1997, J NUCL MED, V38, P1717; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Ciesielski KT, 1997, NEUROPSYCHOLOGIA, V35, P643, DOI 10.1016/S0028-3932(96)00119-4; DAUM I, 1997, INT REV NEUROBIOL, V41, P445; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GUPTA N, 1994, AM J ROENTGENOL, V163, P750, DOI 10.2214/ajr.163.3.8079896; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HUSSEIN M, 1998, CLIN NUCL MED, V28, P309; Ito H, 1997, Ann Nucl Med, V11, P167; Ivry R B, 1992, Curr Opin Neurobiol, V2, P212, DOI 10.1016/0959-4388(92)90015-D; Jancke L, 1999, NEUROIMAGE, V9, P497, DOI 10.1006/nimg.1998.0426; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PARADISO S, 1998, NEUROPSYCHIATRY NEUR, V10, P1; Parsons LM, 1997, LEARN MEMORY, V4, P49, DOI 10.1101/lm.4.1.49; Pasquier F, 1996, EUR NEUROL, V36, P268, DOI 10.1159/000117270; Peeters RR, 1999, EUR J NEUROSCI, V11, P2720, DOI 10.1046/j.1460-9568.1999.00687.x; Rollins NK, 1995, PEDIATR RADIOL, V25, pS20; Tamada T, 1999, NEUROREPORT, V10, P325, DOI 10.1097/00001756-199902050-00022; TEASDALE G, 1974, LANCET, V2, P81; Townsend J, 1999, J NEUROSCI, V19, P5632; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VERTICHEL P, 1993, REV NEUROL, V149, P8; VERTICHEL P, 1993, REV NEUROL, V149, P491; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	35	34	34	0	6	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	APR	2001	17	4-5					263	269		10.1007/s003810000411			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	434AX	WOS:000168793900013	11398947				2022-02-06	
J	Kotchoubey, B; Lang, S; Baales, R; Herb, E; Maurer, P; Mezger, G; Schmalohr, D; Bostanov, V; Birbaumer, N				Kotchoubey, B; Lang, S; Baales, R; Herb, E; Maurer, P; Mezger, G; Schmalohr, D; Bostanov, V; Birbaumer, N			Brain potentials in human patients with extremely severe diffuse brain damage	NEUROSCIENCE LETTERS			English	Article						apallic syndrome; stimulus complexity; event-related potentials; P3	PERSISTENT VEGETATIVE STATE; COMPLEX TONES; PITCH; DIAGNOSIS	To test higher cortical functions of neurological patients, oddball tasks are often used in which a frequent and a rare stimulus are randomly presented and a P3 brain wave is recorded to the rare stimulus. We examined 33 patients with extremely severe brain injury. Three oddball conditions were used: with two sine tones IST), with two complex tones (CT) and with vowels 'o' and 'i'. Across all patients, CT elicited P3 more often than ST, and the occurrence of the P3 after vowels was intermediate. However, among patients who showed a distinct P3 wave, its amplitude in the subgroup with traumatic brain injury was larger to vowels than to CT. In patients with non-traumatic etiology, CT and vowels elicited a P3 of a nearly equal amplitude. Stimuli of sufficient complexity should be used when the P3 technique is applied for assessment of cortical functions in severely impaired patients. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72074 Tubingen, Germany; Rehabil Ctr Godeshohe, Bonn, Germany; Clin Karlsbad Langensteinbach, Karlsbad, Germany; Hosp Neurorehabil, Neresheim, Germany; Rehabil Clin Wangen in Allgau, Wangen In Allgau, Germany; Hagau Jugendwerk, Gailingen, Germany; Univ Padua, Dept Gen Psychol, Padua, Italy		Kotchoubey, B (corresponding author), Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Gartenstr 29, D-72074 Tubingen, Germany.	boris.kotchoubey@uni-tuebingen.de		Bostanov, Vladimir/0000-0002-2946-0786; Birbaumer, Niels/0000-0002-6786-5127			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Cariani PA, 1996, J NEUROPHYSIOL, V76, P1717, DOI 10.1152/jn.1996.76.3.1717; Celesia GG, 1997, THEOR MED, V18, P221, DOI 10.1023/A:1005709410296; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; COLES MGH, 1990, TUTORIALS PSYCHOPHYS, P413; DALLEORE G, 1987, APALLIC SYNDROME; Donchin E., 1986, PSYCHOPHYSIOL SYST P, P244; Fishman YI, 1998, BRAIN RES, V786, P18, DOI 10.1016/S0006-8993(97)01423-6; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Jones SJ, 2000, BRAIN, V123, P1007, DOI 10.1093/brain/123.5.1007; KENNARD C, 1995, J NEUROL NEUROSUR PS, V59, P347, DOI 10.1136/jnnp.59.4.347; MAROSI M, 1993, LANCET, V341, P1473, DOI 10.1016/0140-6736(93)90914-3; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Tervaniemi M, 2000, NEUROSCI LETT, V279, P29, DOI 10.1016/S0304-3940(99)00941-6; Tervaniemi M, 2000, NEUROSCI LETT, V290, P66, DOI 10.1016/S0304-3940(00)01290-8; Vihla M, 2000, P NATL ACAD SCI USA, V97, P10590, DOI 10.1073/pnas.180317297; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; WLTZKE W, 1996, NEUROL REHAB, V2, P68	19	34	36	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 23	2001	301	1					37	40		10.1016/S0304-3940(01)01600-7			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	411NB	WOS:000167505200010	11239711				2022-02-06	
J	Mautes, AEM; Thome, D; Steudel, WI; Nacimiento, AC; Yang, Y; Shohami, E				Mautes, AEM; Thome, D; Steudel, WI; Nacimiento, AC; Yang, Y; Shohami, E			Changes in regional energy metabolism after closed head injury in the rat	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						regional; ATP; glucose; lactate; closed head injury (CHI); rat	EXPERIMENTAL BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; TNF-ALPHA; IMPAIRED MITOCHONDRIAL; GLUCOSE-UTILIZATION; EXPRESSION; INTERLEUKIN-6; DYSFUNCTION	We examined in the present investigation regional ATP, glucose, and lactate content in the cortical and subcortical structures, in a rat model of closed head injury (CHI). In serial tissue sections bioluminescence imaging of ATP, glucose, and lactate was performed at 4 h, 12 h and 24 h (n 4/5 per time point with) after the induction of CHI or sham surgery. Bioluminescence images were analyzed by computer-assisted densitometry, at the lesion site, in remote cortical areas, and in the subcortical structures (thalamus and caudate nucleus). ATP content was significantly decreased at the lesion site after 4 h and in the remote cortex at 12 h post-injury. At 12 h, the ATP content reached baseline levels on the ipsilateral side and at 24 h also at remote lateral parietal sites. In the contralateral cortex, ATP increased transiently above the baseline at 12 h. No significant changes in ATP were found in the thalamus and caudate nucleus. Cortical glucose and lactate contents could not be discerned over time. Following CHI there is an acute and progressive, yet transient, ischemic cortical profile, which is not reflected in subcortical areas.	Univ Saarland, Sch Med, Neurosurg Res Lab, Homburg, Germany; Univ Saarland, Sch Med, Dept Neurosurg, Homburg, Germany; Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Jerusalem, Israel		Mautes, AEM (corresponding author), Univ Saarland, Sch Med, Neurosurg Res Lab, Homburg, Germany.						Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Mautes A. E., 2000, EUR J TRAUMA, V26, P122; MeierRuge WA, 1997, ANN NY ACAD SCI, V826, P229, DOI 10.1111/j.1749-6632.1997.tb48474.x; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pierce JES, 1996, J NEUROSCI, V16, P1083; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU NC, 1995, MOL PHARMACOL, V48, P550	28	34	34	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	FEB	2001	16	1					33	39		10.1385/JMN:16:1:33			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	429NW	WOS:000168524700004	11345518				2022-02-06	
J	Kroppenstedt, SN; Stover, JF; Unterberg, AW				Kroppenstedt, SN; Stover, JF; Unterberg, AW			Effects of dopamine on posttraumatic cerebral blood flow, brain edema, and cerebrospinal fluid glutamate and hypoxanthine concentrations	CRITICAL CARE MEDICINE			English	Article						blood pressure elevation; brain edema; cerebral blood flow; cerebrospinal fluid; controlled cortical impact; dopamine; excitotoxicity; laser-Doppler; traumatic brain injury	CONTROLLED CORTICAL IMPACT; HEAD-INJURED PATIENTS; AMINO-ACIDS; INTRAVENOUS-INFUSION; L-ARGININE; RATS; RELEASE; AUTOREGULATION; ISOFLURANE; PERFUSION	Objectives: Dopamine is often used in the treatment of traumatic brain injury to maintain cerebral perfusion pressure. However, it remains unclear whether dopamine contributes to secondary brain injury caused by vasoconstriction and resulting diminished cerebral perfusion. The present study investigated the effects of dopamine in different concentrations on posttraumatic cortical cerebral blood flow (CBF), brain edema formation, and cerebrospinal fluid concentrations of glutamate and hypoxanthine. Design: Randomized, placebo-controlled trial. Setting: Animal laboratory. Subjects: Eighteen male Sprague-Dawley rats subjected to a focal cortical brain injury. Interventions: Four hours after controlled cortical impact, rats were randomized to receive physiologic saline solution (n = 6), 10-42 mug/kg/min dopamine (n = 6), or 40-50 mug/kg/min dopamine (n = 6), for 3 hrs. Cortical GBF was measured over both hemispheres by using laser-Doppler flowmetry before trauma and before, during, and after the infusion period. At 8 hrs after trauma, brains were removed to determine hemispheric swelling and water content. Cisternal cerebrospinal fluid was sampled to measure glutamate and hypoxanthine. Measurements and Main Results: After trauma, cortical CBF was significantly decreased by 46% within the vicinity of the cortical contusion in all rats. Infusion of saline and 10-12 mug/kg/min dopamine did not change mean arterial blood pressure (MABP) or cortical CBF. However, infusion of 40-50 mug/kg/min dopamine, which elevated MABP from 89 to 120 mm Hg, significantly increased posttraumatic CBF within and around the contusion by 35%. Over the nontraumatized hemisphere, CBF remained unchanged. Hemispheric swelling, water content, cerebrospinal fluid glutamate, and hypoxanthine levels were not affected by dopamine in the given dosages. Conclusions: Under the present study design, there was no evidence for a dopamine-mediated vasoconstriction, because posttraumatic cortical GBF was increased by dopamine-induced elevation of MABP, However, the increase in CBF did not significantly affect edema formation or cerebrospinal fluid glutamate and hypoxanthine levels.	Humboldt Univ, Dept Neurosurg, Charite Virchow Med Ctr, D-13353 Berlin, Germany		Kroppenstedt, SN (corresponding author), Humboldt Univ, Dept Neurosurg, Charite Virchow Med Ctr, Augustenburger Pl 1, D-13353 Berlin, Germany.						ALTURA BM, 1980, BRIT J PHARMACOL, V69, P543, DOI 10.1111/j.1476-5381.1980.tb07900.x; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P103, DOI 10.1111/j.1399-6576.1995.tb04285.x; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt D S, 1995, New Horiz, V3, P376; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; GARNETT ES, 1980, AM J PHYSIOL, V238, pR318, DOI 10.1152/ajpregu.1980.238.5.R318; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; GRANDE PO, 1998, PATHOPHYSIOLOGICAL P, P123; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HARKNESS RA, 1988, J CHROMATOGR-BIOMED, V429, P255, DOI 10.1016/S0378-4347(00)83873-6; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KEMPSKI O, 1995, INT J MICROCIRC, V15, P37, DOI 10.1159/000178947; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Maeda T, 1997, ACT NEUR S, V70, P102; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUELLER RA, 1988, CELL MOL NEUROBIOL, V8, P235, DOI 10.1007/BF00711249; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Noh JS, 1999, EXP NEUROL, V159, P217, DOI 10.1006/exnr.1999.7144; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; RAMANI R, 1991, J CEREBR BLOOD F MET, V11, P388, DOI 10.1038/jcbfm.1991.79; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; Talmor D, 1998, ANESTH ANALG, V87, P574, DOI 10.1097/00000539-199809000-00014; UNGERSBOCK K, 1993, STROKE, V24, P563, DOI 10.1161/01.STR.24.4.563; VONESSEN C, 1981, STROKE, V12, P331, DOI 10.1161/01.STR.12.3.331; VONESSEN C, 1980, SURG NEUROL, V13, P181; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zauner A, 1996, ACT NEUR S, V67, P40	53	34	35	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2000	28	12					3792	3798		10.1097/00003246-200012000-00004			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388NB	WOS:000166186200003	11153616				2022-02-06	
J	Arroyos-Jurado, E; Paulsen, JS; Merrell, KW; Lindgren, SD; Max, JE				Arroyos-Jurado, E; Paulsen, JS; Merrell, KW; Lindgren, SD; Max, JE			Traumatic brain injury in school-age children academic and social outcome	JOURNAL OF SCHOOL PSYCHOLOGY			English	Article						traumatic brain injury; neuropsychology; academic achievement; social behavior; children and adolescents	COGNITIVE SEQUELAE; PERFORMANCE; RESERVE; SCALE; COMA	School-aged children with a traumatic blain injury (TBI) require extraordinary effort and energy from individuals in their school, home, and community. The purpose of this study was to examine the academic, behavioral, and social outcomes of a cohort of children and adolescents following TBI. A comprehensive assessment of cognitive functioning, achievement, and adaptive behavior was administered to 43 school-aged children 2 pars after their TBI. Premorbid functioning for each participant was obtained from state-mandated test scores assessed prior to the TBI. The predictive utility of premorbid functioning, TBI severity, and age at injury were examined. Findings revealed that premorbid functions were significant predictors of reading and spelling achievement and adaptive functioning. Severity of injury was predictive of adaptive functioning. Implications of findings include program development, reintegration into school, and educating parents and teachers. (C) 2000 Society for the Study of School Psychology. Published by Elsevier Science Ltd.	Univ Iowa, Iowa City, IA 52242 USA		Paulsen, JS (corresponding author), Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.		Paulsen, Jane/AAQ-2932-2020	Paulsen, Jane/0000-0002-0983-228X			ALBERTS MS, 1991, COGNITIVE REHABILITA, P95; Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Begali V., 1992, HEAD INJURY CHILDREN; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Clark E., 1997, CHILDHOOD TRAUMATIC, P191; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; DEATON AV, 1987, J LEARN DISABIL, V20, P581, DOI 10.1177/002221948702001003; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Geerlings MI, 1999, PSYCHOL MED, V29, P1219, DOI 10.1017/S0033291799008867; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; HARRISON PL, 1989, 10 MENTAL MEASUREMEN, P903; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; HOOVER H, 1993, IOWA TEST BASIC SKIL; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kehle T. J., 1997, CHILDHOOD TRAUMATIC, P135; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Lehr E, 1990, PSYCHOL MANAGEMENT T; Max JE, 1998, BRAIN INJURY, V12, P31; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Savage R. C., 1994, ED DIMENSIONS ACQUIR; SEGATORE M, 1992, HEART LUNG, V21, P548; Slater E.J., 1989, J ADOLESCENT RES, V4, P371; *SPSS INC, 1993, SPSS WIND PROF STAT; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224; Wilkinson, 1984, WIDE RANGE ACHIEVEME	39	34	34	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4405			J SCHOOL PSYCHOL	J. Sch. Psychol.	NOV-DEC	2000	38	6					571	587		10.1016/S0022-4405(00)00053-4			17	Psychology, Educational	Social Science Citation Index (SSCI)	Psychology	387HC	WOS:000166116300004					2022-02-06	
J	Klonoff, PS; Lamb, DG; Henderson, SW				Klonoff, PS; Lamb, DG; Henderson, SW			Milieu-based neurorehabilitation in patients with traumatic brain injury: Outcome at up to 11 years postdischarge	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	18th Annual Meeting of the National-Academy-of-Neuropsychology	NOV, 1998	WASHTINGTON, D.C.	Natl Acad Neuropsychol		brain injuries; rehabilitation; employment; treatment outcome	FOLLOW-UP; REHABILITATION; STABILITY	Objective: To examine the rate of productivity and competitive activity in participants with traumatic brain injury (TBI) at a milieu-based day treatment neurorehabilitation program. Design: Follow-up data in a cross-sectional design sought from all admissions from May 1986 to May 1998 at 3 months and at year 1, 3, 5, 7, 9, and 11. Setting: Outpatient milieu-based interdisciplinary day treatment program. Patients: One hundred twelve participants with TBI, representing 78.9% of TBI patients successfully discharged from the program. Interventions: Milieu-based interdisciplinary neurorehabilitation (mean length of treatment, 6.2mo). Main Outcome Measures: Productivity, defined as gainful employment, school, and/or volunteer work, and competitive activity, defined as work for pay or enrollment in school. Results: 88.4% of patients were productive up to 11 years after discharge, with 76.8% engaged in competitive activity and with no decline in productivity seen over time from discharge. Conclusions: A large majority of patients suffering from TBI are able to return to work or a productive life situation after milieu-based neurorehabilitation. Level of outcome did not significantly decline over an 11 year follow-up interval.	Barrow Neurol Inst, Catholic Healthcare W, Phoenix, AZ 85013 USA; Adult Day Hosp Neurol Rehabil, Phoenix, AZ USA		Klonoff, PS (corresponding author), Barrow Neurol Inst, St Josephs Hosp & Med Ctr, ADHNR, 222 W Thomas Rd,Ste 115, Phoenix, AZ 85013 USA.						Ashley MJ, 1997, BRAIN INJURY, V11, P677; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAMES P, 1995, BRAIN INJURY, V10, P631; Evans RW, 1997, ARCH PHYS MED REHAB, V78, pS17, DOI 10.1016/S0003-9993(97)90151-9; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, BRAIN INJURY, V13, P417; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Hillier SL, 1997, BRAIN INJURY, V11, P661; Klonoff P S, 1997, Appl Neuropsychol, V4, P107, DOI 10.1207/s15324826an0402_3; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; KLONOFF PS, 1997, CLIN NEUROPSYCHOLOGY, P219; Klonoff PS, 2000, INT HDB NEUROPSYCHOL, P195; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; Wall JR, 1998, BRAIN INJURY, V12, P215	18	34	35	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2000	81	11					1535	1537		10.1053/apmr.2000.9177			3	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	369YT	WOS:000165095900016	11083362				2022-02-06	
J	Grundy, PL; Patel, N; Harbuz, MS; Lightman, SL; Sharples, PM				Grundy, PL; Patel, N; Harbuz, MS; Lightman, SL; Sharples, PM			Glucocorticoids modulate BDNF mRNA expression in the rat hippocampus after traumatic brain injury	NEUROREPORT			English	Article						adrenalectomy; BDNF; fluid percussion; glucocorticoids; hippocampus; traumatic brain injury	NEUROTROPHIC FACTOR EXPRESSION; FLUID-PERCUSSION MODEL; MESSENGER-RNAS; HEAD-INJURY; STRESS; CORTICOSTERONE; ISCHEMIA; NEURONS; DEATH	Brain-derived neurotrophic factor (BDNF) expression in rat hippocampus is increased after experimental traumatic brain injury (TBI) and may be neuroprotective. Glucocorticoids are important regulators of brain neurotrophin levels and are often prescribed following TBI. The effect of adrenalectomy (ADX) on the expression of BDNF mRNA in the hippocampus after TBI has not been investigated to date. We used fluid percussion injury (FPI) and in situ hybridization to evaluate the expression of BDNF mRNA in the hippocampus 4 h after TBI in adrenal-intact or adrenalectomized rats (with or without corticosterone replacement). FPI and ADX independently increased expression of BDNF mRNA. In animals undergoing FPI, prior ADX caused further elevation of BDNF mRNA and this upregulation was prevented by corticosterone replacement in ADX rats. These findings suggest that glucocorticoids are involved in the modulation of the BDNF mRNA response to TBI. NeuroReport 11:3381-3384 (C) 2000 Lippincott Williams & Wilkins.	Frenchay Hosp, Dept Neurosurg, Acad Ctr, Bristol BS16 1LE, Avon, England; Univ Bristol, Div Child Hlth, Bristol BS2 8HW, Avon, England; Univ Bristol, Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England		Grundy, PL (corresponding author), Frenchay Hosp, Dept Neurosurg, Acad Ctr, Room 1, Bristol BS16 1LE, Avon, England.			Lightman, Stafford/0000-0002-8546-9646			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BENGZON J, 1993, NEUROSCIENCE, V53, P433, DOI 10.1016/0306-4522(93)90207-V; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Chao HM, 1998, ENDOCRINOLOGY, V139, P3112, DOI 10.1210/en.139.7.3112; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; JACOBSON L, 1989, ENDOCRINOLOGY, V124, P2144, DOI 10.1210/endo-124-5-2144; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LAUTERBORN J, 1995, NEUROSCIENCE, V68, P363, DOI 10.1016/0306-4522(95)00150-H; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McEwen BS, 1995, VITAM HORM, V51, P371, DOI 10.1016/S0083-6729(08)61045-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Pringle AK, 1996, NEUROSCI LETT, V211, P203, DOI 10.1016/0304-3940(96)12745-2; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; WHITELEY T, 1999, THESIS U NEWCASTLE U	24	34	40	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	OCT 20	2000	11	15					3381	3384		10.1097/00001756-200010200-00023			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	366MY	WOS:000090010200018	11059906				2022-02-06	
J	Chua, KSG; Kong, KH				Chua, KSG; Kong, KH			Alcohol neurolysis of the sciatic nerve in the treatment of hemiplegic knee flexor spasticity: Clinical outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						ethyl alcohol; hemiplegia; muscle spasticity; rehabilitation; sciatic nerve	BOTULINUM TOXIN	Objective: To study clinical outcomes after 50% to 100% alcohol neurolysis of the sciatic nerve in the treatment of chronic hemiplegic knee flexor spasticity. Design: Case series using a convenience sample. Setting: Rehabilitation teaching hospital. Patients: Eight patients (mean age, 55.1 +/- 12.1 yr; mean duration to block, 4.4 +/- 3.7 mo) with chronic hemiplegia and severe spasticity (modified Ashworth scale [MAS] score < 2) secondary to cerebrovascular accidents (n = 5) and traumatic brain injuries (n = 3). Two patients were ambulant, 6 were wheelchair-bound. Interventions: Fifty percent to 100% alcohol neurolysis of the sciatic nerve using repetitive electric stimulation to localize the sciatic nerve. Main Outcome Measures: MAS score, gain in knee range of motion (ROM), and visual inspection of gait at 0, 1, and 6 months postneurolysis. Nonparametric tests were used in statistical analysis. Results: The mean preinjection MAS score was 2.8 +/- 0.7, which improved to 1.4 +/- 0.7 at 1 month (p = .005), and 1.8 +/- 0.9 (p = .01) and 1.9 +/- 1.1 (p = .02) at 3 and 6 months postinjection, respectively. The mean gain in knee ROM was 34.4 degrees +/- 15.7 degrees at 1 month postinjection and was maintained at 6 months postinjection. Improvements in gait were noted in both ambulant patients, and improved positioning in 3 of 6 wheel-chair-bound patients. The incidence of dysesthetic pain was 0%. Conclusion: Fifty percent to 100% alcohol neurolysis of the sciatic nerve is a safe and effective method for treatment of hemiplegic knee flexor spasticity, with therapeutic effects lasting 6 months.	Tan Tock Seng Hosp, Rehabil Ctr, Dept Rehabil Med, Singapore 569766, Singapore		Chua, KSG (corresponding author), Tan Tock Seng Hosp, Rehabil Ctr, Dept Rehabil Med, 17 Ang Mo Kio Ave 9, Singapore 569766, Singapore.						AWAD EA, 1972, ARCH PHYS MED REHAB, V53, P554; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; CARPENTER EB, 1980, DEV MED CHILD NEUROL, V22, P497; DENGLER R, 1992, J NEUROL, V239, P375; GLENN MB, 1990, PRACTICAL MANAGEMENT, P27; HALPERN DANIEL, 1966, ARCH PHYS MED REHABIL, V47, P659; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; KHALILI AA, 1967, JAMA-J AM MED ASSOC, V200, P1166; Kong KH, 1999, ARCH PHYS MED REHAB, V80, P1234, DOI 10.1016/S0003-9993(99)90021-7; Kong KH, 1999, INT J REHABIL RES, V22, P327, DOI 10.1097/00004356-199912000-00011; Lance J.W., 1980, SPASTICITY DISORDERE, P485; MAY O, 1912, BRIT MED J, V31, P465; O'Hanlan J T, 1969, Va Med Mon (1918), V96, P429; Pelissier J, 1993, Cah Anesthesiol, V41, P139; Petrillo C R, 1988, Int Disabil Stud, V10, P97; SHIN DY, 1996, PHYSIATRIC PROCEDURE, P150; TARDIEU G, 1968, DEV MED CHILD NEUROL, V10, P555	17	34	39	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2000	81	10					1432	1435		10.1053/apmr.2000.9395			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	360WA	WOS:000089689300017	11030512				2022-02-06	
J	Dolinak, D; Smith, C; Graham, DI				Dolinak, D; Smith, C; Graham, DI			Hypoglycaemia is a cause of axonal injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						axonal injury; human hypoglycaemia; raised intracranial pressure	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; INTRACRANIAL-PRESSURE; VEGETATIVE STATE; BRAIN-DAMAGE; BETA-APP; NEUROPATHOLOGY; HYPOGLYCEMIA; DIAGNOSIS	Axonal injury as demonstrated immunohistochemically is increasingly being recognized at post-mortem in patients who have been unconscious, and in some cases the cause of the coma may not be immediately apparent. Considerations include microscopical diffuse traumatic axonal injury and axonal injury associated with a range of metabolic encephalopathies. In this study, extensive neurohistological examination was undertaken in 13 patients in whom coma was attributed to hypoglycaemia and in whom neurohistological examination had revealed varying degrees of widely distributed neuronal necrosis: in five of these cases there was also evidence that the intracranial pressure had been high with internal hernation. It is concluded that a significant amount of axonal injury found in these 13 cases can be attributed to hypoglycaemia per se although the amount and distribution of the axonal damage is altered in the presence of raised intracranial pressure. However, in some cases axonal damage is seen in the absence of an elevated intracranial pressure and in one case its distribution closely mimicked that seen in microscopical diffuse traumatic axonal injury. This further demonstrates that not all axonal pathology is traumatic, and that adequate sampling and care in interpretation of A beta-PP staining is required in forensic practice.	Univ Glasgow, S Glasgow Univ Hosp NHS Trust, Dept Neuropathol, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland		Graham, DI (corresponding author), Univ Glasgow, S Glasgow Univ Hosp NHS Trust, Dept Neuropathol, Inst Neurol Sci, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.						ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; AUER RN, 1989, CLIN NEUROPATHOL, V8, P63; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brierly J, 1984, GREENFIELDS NEUROPAT, P125; DOLINAK D, 2000, IN PRESS ACTA NEUROP; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; PILZ P, 1994, BRAIN PATHOL, V4, P485; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; [No title captured]	23	34	36	0	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	OCT	2000	26	5					448	453		10.1046/j.1365-2990.2000.00273.x			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	361RB	WOS:000089735900007	11054185				2022-02-06	
J	Kesler, SR; Adams, HF; Bigler, ED				Kesler, SR; Adams, HF; Bigler, ED			SPECT, MR and quantitative MR imaging: correlates with neuropsychological and psychological outcome in traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; MILD	This study examined the relative effectiveness of magnetic resonance (MR) imaging, single photon emission tomography (SPECT) and quantitative magnetic resonance (QMR) imaging in detecting brain abnormalities in 52 traumatically brain injured patients. The relationship between brain abnormalities and neuropsychological and psychological testing results was also investigated. Sixty-two per cent of patients had abnormal clinical MR findings, 57% had abnormal SPECT and 51% had abnormal QMR. Each neuroimaging modality detected brain abnormalities that the other two did not. Neuropsychological and psychological testing indicated significant memory impairments and subjective emotional distress even several years post-injury. Memory and intellectual impairments modestly but significantly correlated with the number of brain abnormalities indicated by all three imaging studies combined, as well as those detected individually by QMR and MR. SPECT abnormalities alone were not correlated with intellectual and memory outcome. Psychological distress was also related to the number of MR abnormalities, with most brain abnormalities being in the frontal areas.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.						ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1996, NEUROIMAGING, V2, P261; *BIOM IM RES, 1993, AN 6 0; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; DEROGATIS LR, 1994, S CHECKL 90 ADM SCOR; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 1999, BRAIN INJURY, V13, P229, DOI 10.1080/026990599121601; Gean AD, 1994, IMAGING HEAD TRAUMA; GRAY BG, 1992, J NUCL MED, V33, P52; Hopkins RO, 1997, NEUROPSYCHOL REV, V7, P87, DOI 10.1023/B:NERV.0000005946.46506.a9; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JONES RD, 1996, HEAD INJURY POSTCONC; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Laatsch L, 1997, BRAIN INJURY, V11, P851; Levin H.S., 1989, MILD HEAD INJURY; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MASDEU J, 1992, J NEUROIMAGING, V4, P177; Orrison William W. Jr., 1996, P71; Primus EA, 1997, BRAIN INJURY, V11, P577; PRITCHARD D, 1992, FORENSIC REPORTS, V5, P287; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Reynolds C.R., 1994, TEST MEMORY LEARNING; RIZZO M, 1996, HEAD INJURY POSTCONC; ROSENTHAL M, 1993, H133A2001693 NAT I D; Septien L., 1993, Encephale, V19, P249; Umile EM, 1998, BRAIN INJURY, V12, P577; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WILSON J T L, 1990, Brain Injury, V4, P349	35	34	35	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2000	14	10					851	857					7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	364QG	WOS:000089902900001	11076132				2022-02-06	
J	Angstwurm, K; Reuss, S; Freyer, D; Arnold, G; Dirnagl, U; Schumann, RR; Weber, JR				Angstwurm, K; Reuss, S; Freyer, D; Arnold, G; Dirnagl, U; Schumann, RR; Weber, JR			Induced hypothermia in experimental pneumococcal meningitis	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain edema; cerebral blood flow; intracranial hypertension; laser Doppler flowmetry	ACUTE BACTERIAL-MENINGITIS; CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; CARDIOPULMONARY BYPASS; MILD HYPOTHERMIA; NITRIC-OXIDE; BLOOD-FLOW; RAT; RABBITS	Pneumococcal meningitis resulting from Streptococcus pneumoniae has a death rate of 28% in adults. In severe bead injury and stroke, inflammatory changes and intracranial hypertension are improved by induced hypothermia, which also is neuroprotective. We hypothesized that moderate hypother- mia ameliorates inflammatory changes in experimental pneumococcal meningitis. Wistar rats were cooled systemically, and meningitis was induced by pneumococcal cell wall components. The increase of regional cerebral blood flow in the meningitis animals was blocked by hypothermia at 6 hours. The reduction of intracranial pressure correlated with temperature. The influx of leukocytes into the cerebrospinal fluid and levels of tumor necrosis factor alpha in the cerebrospinal fluid were decreased. Cooling the animals 2 hours after meningitis induction to 30.5 degrees C was also protective. We conclude that hypothermia is a new adjuvant approach to reduce meningitis-induced changes, in particular intracranial pressure, in the early phase of the disease.	Humboldt Univ, Klinikum Charite, Dept Neurol, D-10098 Berlin, Germany; Humboldt Univ, Klinikum Charite, Inst Microbiol & Hyg, D-10098 Berlin, Germany		Weber, JR (corresponding author), Humboldt Univ, Klinikum Charite, Dept Neurol, Clara Zetkin Str 94, D-10098 Berlin, Germany.			Dirnagl, Ulrich/0000-0003-0755-6119			BALCH HH, 1955, SURGERY, V38, P1036; BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CROUGHWELL N, 1992, J THORAC CARDIOV SUR, V103, P549; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREELEY WJ, 1993, ANN THORAC SURG, V56, P1464, DOI 10.1016/0003-4975(93)90731-V; Haddix TL, 1996, J SURG RES, V64, P176, DOI 10.1006/jsre.1996.0325; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; KOEDEL U, 1995, ANN NEUROL, V37, P313, DOI 10.1002/ana.410370307; LEDEIST F, 1995, CIRCULATION, V92, P354, DOI 10.1161/01.CIR.92.9.354; Luhm J, 1998, EUR J BIOCHEM, V256, P325, DOI 10.1046/j.1432-1327.1998.2560325.x; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCCREDIE DA, 1992, J PEDIATR, V61, P653; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Schwab M, 1998, ACTA NEUROBIOL EXP, V58, P29; SESSLER DI, 1995, J NEUROSURG ANESTH, V7, P38, DOI 10.1097/00008506-199501000-00008; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; TUREEN JH, 1990, J CLIN INVEST, V85, P577, DOI 10.1172/JCI114475; Weber JR, 1995, J NEUROIMMUNOL, V63, P63	28	34	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2000	20	5					834	838		10.1097/00004647-200005000-00010			5	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	312WM	WOS:000086967000010	10826534	Bronze			2022-02-06	
J	Wang, XK; Feuerstein, GZ				Wang, XK; Feuerstein, GZ			Role of immune and inflammatory mediators in CNS injury	DRUG NEWS & PERSPECTIVES			English	Article							FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE SYNTHASE; INTERLEUKIN-1 RECEPTOR ANTAGONIST; MESSENGER-RNA EXPRESSION; CLOSED-HEAD INJURY; GENE-EXPRESSION; RAT-BRAIN; TNF-ALPHA; ARTERY OCCLUSION	Accumulating evidence has shown that the central nervous system can mount a well-defined inflammatory reaction to a variety of insults including trauma, ischemia, transplantation, viral infection, and immune and neurodegenerative disorders. In this review, we summarize the evidence that in brain ischemia and trauma, inflammatory reaction figures prominently in mediation of brain injury. The inflammatory condition consists of inflammatory cells (first neutrophils, followed by monocytes/macrophages) and mediators (cytokines, chemokines and adhesion molecules). De novo up-regulation of various inflammatory mediators has been observed and their roles in brain injury have been extensively studied. In addition, recent evidence emerges on specific signal pathways in brain injury. Taken together, targeting specific inflammatory mediators involved in brain injury may provide novel therapeutic opportunities for CNS injury such as stroke and neurotrauma. (C) 2000 Prous Science. All rights reserved.	Dupont Merck Pharmaceut Co, Expt Stn, Dept Cardiovasc Sci, Wilmington, DE 19880 USA								Baron M, 1997, POINT VET, V28, P1; Barone F. C., 1999, Society for Neuroscience Abstracts, V25, P1060; BARONE FC, 1992, NEUROSCI BIOBEHAV R, V16, P219, DOI 10.1016/S0149-7634(05)80182-4; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BUTTINI M, 1995, NEUROSCIENCE, V65, P523, DOI 10.1016/0306-4522(94)00525-A; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/S0304-3940(96)13116-5; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1998, CEREBROVASC DIS, P507; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; GARCIA JH, 1994, AM J PATHOL, V144, P188; GARCIA JH, 1974, J NEUROPATH EXP NEUR, V33, P408, DOI 10.1097/00005072-197407000-00007; GOLDBLUM SE, 1990, AM J PHYSIOL, V258, pL57, DOI 10.1152/ajplung.1990.258.2.L57; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grandati M, 1997, BRIT J PHARMACOL, V122, P625, DOI 10.1038/sj.bjp.0701427; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Haring HP, 1996, J NEUROPATH EXP NEUR, V55, P236, DOI 10.1097/00005072-199602000-00012; Hayward NJ, 1996, EXP NEUROL, V139, P188, DOI 10.1006/exnr.1996.0093; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Jiang N, 1995, ANN NEUROL, V38, P935, DOI 10.1002/ana.410380615; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; Nagayama M, 1998, J CEREBR BLOOD F MET, V18, P1107, DOI 10.1097/00004647-199810000-00007; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nogawa S, 1997, J NEUROSCI, V17, P2746; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Planas AM, 1995, NEUROSCI LETT, V200, P187, DOI 10.1016/0304-3940(95)12108-G; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Salvemini D, 1996, METHOD ENZYMOL, V269, P12; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIREN AL, 1992, STROKE, V23, P1643, DOI 10.1161/01.STR.23.11.1643; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Vuorte J, 1999, J IMMUNOL, V162, P2353; WANG XK, 1995, STROKE, V26, P1665, DOI 10.1161/01.STR.26.9.1665; WANG XK, 1995, BRAIN RES BULL, V36, P607, DOI 10.1016/0361-9230(94)00243-T; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; Wang XK, 1998, J NEUROSCI, V18, P2075; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; Zhang RL, 1999, NEUROLOGY, V52, P273, DOI 10.1212/WNL.52.2.273; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; Zhao X., 1999, Society for Neuroscience Abstracts, V25, P793	81	34	36	0	2	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	0214-0934	2013-0139		DRUG NEWS PERSPECT	Drug News Perspect.	APR	2000	13	3					133	140		10.1358/dnp.2000.13.3.657283			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	336RJ	WOS:000088316500001	12937603				2022-02-06	
J	Lee, JY; Park, J; Kim, YH; Kim, DH; Kim, CG; Koh, JY				Lee, JY; Park, J; Kim, YH; Kim, DH; Kim, CG; Koh, JY			Induction by synaptic zinc of heat shock protein-70 in hippocampus after kainate seizures	EXPERIMENTAL NEUROLOGY			English	Article						calcium; NMDA; TFL; cell culture; brain injury; neuronal death	TRAUMATIC BRAIN INJURY; HSP-70 MESSENGER-RNA; KAINIC ACID; RAT-BRAIN; CORTICAL-NEURONS; FOCAL ISCHEMIA; INDUCED DEATH; C-FOS; EXPRESSION; HSP70	Following seizures, heat shock protein (HSP)-70 is induced in various brain regions, Since zinc that can induce HSP-70 in various cell systems is enriched in certain glutamatergic terminals and translocates to postsynaptic neurons with seizures, we examined the possibility that HSP-70 induction in the epileptic brain is mediated by synaptic zinc. Adult rats were injected intraperitoneally with kainate to induce seizures. Seizures were halted 3 h after the kainate administration by the injection of phenytoin. Staining of brain sections with zinc-specific fluorescent dye Tn at 24 h after the kainate injection revealed a one-to one correlation between dense Tn fluorescence and acidophilic neuronal degeneration in the hippocampus. Subsequent staining with anti-HSP-70 antibody, however, revealed that more numerous neurons than degenerating neurons exhibited HSP-70 immunoreactivity, Most of the HSP-70(C) neurons were not stained with acid fuchsin but exhibited mild zinc fluorescence in the cytoplasm, Intraventricular injection of CaEDTA attenuated neuronal death as well. as the HSP-70 induction in a dose-dependent manner. Supporting the specificity of zinc rather than calcium as the inducer of HSP-70 in neurons, exposure to zinc but not to a calcium ionophore or excitotoxins increased expression of HSP-70 mRNA and protein in cultured cortical neurons. The present results suggest that not only selective neuronal death, but also HSP-70 induction in neurons after seizures, is mediated by the translocation of endogenous synaptic zinc. (C) 2000 Academic Press.	Univ Ulsan, Coll Med, Natl Creat Res Initiat, Ctr Study CNS Zinc, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Neurol, Seoul 138736, South Korea; Hanyang Univ, Coll Nat Sci, Dept Biol, Seoul 133791, South Korea		Koh, JY (corresponding author), Univ Ulsan, Coll Med, Natl Creat Res Initiat, Ctr Study CNS Zinc, Seoul 138736, South Korea.		Koh, Jae-Young/C-9014-2011; Kim, Yang-Hee/N-7614-2013; Lee, Joo-Yong/F-4545-2014	Koh, Jae-Young/0000-0002-4318-495X; Kim, Yang-Hee/0000-0002-0595-8547; Kim, Chul Geun/0000-0002-5848-3338			Armstrong JN, 1996, NEUROSCIENCE, V74, P685, DOI 10.1016/0306-4522(96)00164-9; Budde T, 1997, NEUROSCIENCE, V79, P347, DOI 10.1016/S0306-4522(96)00695-1; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; Detre JA, 1997, J NEUROL SCI, V148, P163, DOI 10.1016/S0022-510X(97)05368-9; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; FERRER I, 1995, BRAIN RES, V692, P41, DOI 10.1016/0006-8993(95)00527-W; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; FREDREICKSON CJ, 1987, BRAIN RES, V446, P383; Gaspary H, 1995, MOL BRAIN RES, V34, P327, DOI 10.1016/0169-328X(95)00195-X; Hasegawa K, 1998, BRAIN RES, V785, P262, DOI 10.1016/S0006-8993(97)01410-8; Hashimoto K, 1998, BRAIN RES, V804, P212, DOI 10.1016/S0006-8993(98)00708-2; HATAYAMA T, 1992, MOL CELL BIOCHEM, V112, P143; Hu RQ, 1998, BRAIN RES, V810, P229, DOI 10.1016/S0006-8993(98)00863-4; Iwata A, 1997, J NEUROTRAUM, V14, P201, DOI 10.1089/neu.1997.14.201; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lees GJ, 1998, BRAIN RES, V799, P108, DOI 10.1016/S0006-8993(98)00483-1; Noga M, 1997, NEUROREPORT, V8, P1239, DOI 10.1097/00001756-199703240-00036; Okimura Y, 1996, J NEUROTRAUM, V13, P385, DOI 10.1089/neu.1996.13.385; Parat MO, 1998, BIOL TRACE ELEM RES, V65, P261, DOI 10.1007/BF02789101; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; ROWENSTEIN DH, 1991, NEURON, V7, P1053; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sharp FR, 1998, ANN NEUROL, V44, P581, DOI 10.1002/ana.410440402; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Suh S. W., 1996, Society for Neuroscience Abstracts, V22, P2101; Tomimoto H, 1999, ACTA NEUROPATHOL, V97, P22, DOI 10.1007/s004010050951; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Yin HZ, 1995, NEUROREPORT, V6, P2553, DOI 10.1097/00001756-199512150-00025; Zhang X, 1996, EUR J NEUROSCI, V8, P1432, DOI 10.1111/j.1460-9568.1996.tb01605.x; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x	36	34	36	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2000	161	2					433	441		10.1006/exnr.1999.7297			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	290FW	WOS:000085666500001	10686065				2022-02-06	
J	Hoffman, N; Donders, J; Thompson, EH				Hoffman, N; Donders, J; Thompson, EH			Novel learning abilities after traumatic head injury in children	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						novel learning; head injury; children	CATEGORY TEST; BRAIN INJURY; WISC-III; SEVERITY	The cognitive abilities of 69 children with traumatic head injury (THI) were evaluated with the California Verbal Learning Test-Children's Version (CVLT-C; Delis, Kramer, Kaplan, & Ober, 1994), the Children's Category Test (CCT; Boll, 1993), and the Wechsler Intelligence Scale for Children-Third Edition (WISC-III; Wechsler, 1991). Compared to children with mild to moderate injuries, children with severe THI demonstrated statistically significant impairments on the CVLT-C Total T-score as well as the WISC-III Processing Speed index, but findings for the CCT were less robust. Longer length of coma and male gender were associated with relatively poorer performance on the CVLT-C. Children with sever-e THI demonstrated difficulties with both capacity and speed of information processing, which could not be accounted for by attentional or general verbal knowledge factors, it is concluded that the combination of the CVLT-C and the WISC-III is useful in the evaluation of cognitive sequelae of THI bnl that findings from the CCT must be considered with some caution in this population. (C) 1999 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BOLL T, 1993, CHILDRENS CATEGORY T; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Cohen J., 1977, STAT POWER BEHAV SCI; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 1996, ARCH CLIN NEUROPSYCH, V11, P131, DOI 10.1016/0887-6177(95)00005-4; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 1998, J INT NEUROPSYCH SOC, V4, P242, DOI 10.1017/S1355617798002422; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; DONDERS J, IN PRESS DEV NEUROPS; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Reitan R. M., 1992, NEUROPSYCHOLOGICAL E; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Ylvisaker M., 1994, ED DIMENSIONS ACQUIR, P69	26	34	34	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2000	15	1					47	58		10.1016/S0887-6177(98)00156-5			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	265XN	WOS:000084271600006	14590567	Bronze			2022-02-06	
J	Cirak, B; Rousan, N; Kocak, A; Palaoglu, O; Palaoglu, S; Kilic, K				Cirak, B; Rousan, N; Kocak, A; Palaoglu, O; Palaoglu, S; Kilic, K			Melatonin as a free radical scavenger in experimental head trauma	PEDIATRIC NEUROSURGERY			English	Article; Proceedings Paper	European Congress on Neurotrauma	OCT, 1998	MAGDEBURG, GERMANY	Bundesministerium Fur Bild Forsch		experimental head trauma; free radical; lipid peroxidation; malondealdehyde; melatonin	CENTRAL-NERVOUS-SYSTEM; OXYGEN FREE-RADICALS; SPINAL-CORD INJURY; BRAIN INJURY; PINEAL-GLAND; EDEMA; RATS; ACID	Head trauma causes two kinds of injury in the neural tissue. One is the primary injury which occurs at the time of impact. The other one is a secondary injury and is a progressive process. Free radicals are produced during oxidative reactions formed after trauma. They have been thought to be responsible in the mechanism of the secondary injury. Some studies have been conducted to demonstrate the role of free oxygen radicals in neuronal injury. The alterations in the free radical level during the early posttraumatic period and the effect of a free radical scavenger on these alterations have not been studied as a whole. We aimed to demonstrate the free oxygen radical level changes in the early posttraumatic period and the effect of melatonin, which is a potent free radical scavenger, on the early posttraumatic free radical level. A two-staged experimental head trauma study was designed. In stage one, post-traumatic free radical level changes were determined. In the second stage, the effect of melatonin on the free radical level changes in the post-traumatic period was studied. Two main groups of rats each divided into four subgroups were studied. Rats in one of the main groups underwent severe head trauma, and malondealdehyde (MDA) levels were measured in the contused cerebral tissue at different time points. Rats in the other main group also underwent the same type of trauma, and melatonin was injected intraperitoneally at different time points after trauma. The MDA level alteration in the tissue was determined after the injection of melatonin. The MDA level increased rapidly in the early posttraumatic period. But in time, it decreased in the groups with only trauma. In the melatonin-treated group, the MDA level decreased after the injection of melatonin, when injected in the early posttraumatic period, compared to the control and trauma groups. However, melatonin increased MDA to a higher level than in the groups with only trauma and the control group when injected later than 2 h after trauma. The MDA level increases in the very early posttraumatic period of cerebral trauma and decreases in time. Melatonin, which is the most potent endogenous free radical scavenger, when injected intraperitoneally to the cerebral traumatized rats in the very early posttraumatic period, causes a significant decrease in the MDA level. But, melatonin, when injected more than 2 h after trauma, increases the MDA level in experimental cerebral trauma in rats. Copyright (C) 2000 S. Karger AG, Basel.	100 Yil Univ, Tip Fak Arastirma Hastanesi, Sch Med, Dept Neurosurg, TR-65300 Van, Turkey; Ankara Univ, Sch Med, Dept Pharmacol, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Neurosurg, Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, Ankara, Turkey; Inonu Univ, Sch Med, Dept Neurosurg, Malatya, Turkey		Cirak, B (corresponding author), 100 Yil Univ, Tip Fak Arastirma Hastanesi, Sch Med, Dept Neurosurg, Beyin Cerrahisi, TR-65300 Van, Turkey.						ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; AVOLIO AEC, 1992, NEUROSURGERY, V31, P557, DOI 10.1227/00006123-199209000-00019; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BULLOCK R, 1993, SCHWEIZ MED WSCHR, V123, P449; CADET JL, 1988, INT J NEUROSCI, V40, P13, DOI 10.3109/00207458808985722; ERLICH SS, 1985, J NEUROSURG, V63, P321, DOI 10.3171/jns.1985.63.3.0321; FADEN AI, 1987, CLIN NEUROPHARMACOL, V10, P193, DOI 10.1097/00002826-198706000-00001; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HINDER RA, 1991, ARCH SURG-CHICAGO, V126, P104; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; KAPPERS JA, 1976, ACTA NEUROCHIR, V34, P109, DOI 10.1007/BF01405867; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; LERNER AB, 1960, J BIOL CHEM, V235, P1992; MAESTRONI GJM, 1993, J PINEAL RES, V14, P1, DOI 10.1111/j.1600-079X.1993.tb00478.x; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V129, P181, DOI 10.1111/j.1748-1716.1987.tb08057.x; PALAOGLU S, 1994, ACTA NEUROCHIR, V128, P8, DOI 10.1007/BF01400646; PIERREFICHE G, 1993, RES COMMUN CHEM PATH, V80, P211; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; PRYOR WA, 1986, ANN NY ACAD SCI, V393, P1; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; REITER RJ, 1994, ANN NY ACAD SCI, V12, P1; TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; [No title captured]	33	34	34	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	DEC	1999	31	6					298	301		10.1159/000028879			4	Clinical Neurology; Pediatrics; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	292NV	WOS:000085802600003	10702729				2022-02-06	
J	Oehmichen, M; Theuerkauf, I; Meissner, C				Oehmichen, M; Theuerkauf, I; Meissner, C			Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI	ACTA NEUROPATHOLOGICA			English	Article						trauma; axonal injury; microglia; immunohistochemical double labeling	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; BRAIN INJURY; DIAGNOSIS; MILD	The aim of the present study was to determine whether axonal injury (AI) induces a microglial reaction within 15 days after brain trauma. In 40 selected cases of confirmed Al, the topographical relation of Al and microglial reaction was assessed using an immunohistochemical double-labeling technique for simultaneous demonstration of AI using beta-amyloid precursor protein (beta-APP) antibody and of microglia using CD68 antibody. Although traumatic injury was usually followed by a moderate early diffuse rise in the number of CD68-reactive cells in the white matter, increases in macrophages in areas of Al accumulation were only sporadic and did not occur until after 4 days. At survival intervals of 5-15 days a moderate microglial reaction in regions of beta-APP-positive injured axons was detected, at maximum, in half of the case material. During this interval AI-associated satellitosis-like clusters or stars described by other authors after a survival time of more than 7 weeks were an isolated phenomenon. The prolonged microglial reaction as well as the reduction of beta-APP-positive Al during longer survival periods supports the hypothesis that AI is not primarily chemotactically attractive and that the damage to a portion of beta-APP-stained axons may be partly reversible. Most cases clearly require a prolonged interval of more than 15 days before initiation of the final scavenger reaction. For forensic purposes the increase in the number of microglial cells within the region of AI accumulation after a survival time of more than 5 days and the multiple and distinct demonstration of star-like microglial reactions within the white matter after survival times exceeding 7 weeks may provide valuable postmortem information on the timing of a traumatic event.	Univ Lubeck, Inst Forens Med, D-23562 Lubeck, Germany		Oehmichen, M (corresponding author), Univ Lubeck, Inst Forens Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.	tychsenl@rmed.mu-luebeck.de					ADAMS H, 1988, INTRO NEUROPATHOLOGY; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BAZZAZ AA, 1995, NEUROPATHOL APPL NEU, V21, P447; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graeber MB, 1997, RES LEG MED, V17, P239; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; Lassmann H, 1997, RES LEG MED, V17, P253; MAZWELL WL, 1997, J NEUROTRAUM, V7, P419; MERZ H, 1995, LAB INVEST, V73, P149; Meyermann R, 1997, RES LEG MED, V17, P261; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Oehmichen M, 1997, RES LEG MED, V17, P19; Oehmichen M., 1996, WOUND HEALING PROCES; OEHMICHEN M, 1999, IN PRESS INT J LEGAL; OEHMICHEN M, 1978, MONONUCLEAR PHAGOCYT; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Povlishock JT, 1997, RES LEG MED, V17, P175; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; [No title captured]	29	34	35	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	1999	97	5					491	494		10.1007/s004010051018			4	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	189TU	WOS:000079922900008	10334486				2022-02-06	
J	Bouillon, B; Raum, M; Fach, H; Buchheister, B; Lefering, R; Menzel, J; Klug, N				Bouillon, B; Raum, M; Fach, H; Buchheister, B; Lefering, R; Menzel, J; Klug, N			The incidence and outcome of severe brain trauma - Design and first results of an epidemiological study in an urban area	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain trauma; head injury; incidence; epidemiology; outcome	SEVERE HEAD-INJURY; SCORE	Epidemiological data on the incidence, the prehospital and hospital care and the outcome of traumatic brain injury in Germany are scarce. It is therefore difficult to estimate the importance of this injury with respect to magnitude as well as effectiveness and efficiency of therapeutic concepts. We therefore planned a study that was supposed to provide population based epidemiological data in the field of severe brain trauma from the site of the accident until discharge from hospital. All 90,000 prehospital emergencies that were cared for by emergency physicians in Cologne from January 1990 until December 1996 were screened for identification of severe brain trauma. Their clinical course was reviewed using standard records and patients were included if they had their accident within the city of Cologne and fullfilled the final inclusion criteria of GCS less than or equal to 8 or AIS(Head) greater than or equal to 3. 650 eligible patients were identified of whom 530 had complete datasets (follow-up 80 %). Univariate statistical analysis was performed for all relevant variables. The main study endpoints were incidence and outcome of severe brain trauma. The annual incidence of severe brain trauma in Cologne (1 mio. inhabitants) was 93. The average age was 39 years and 71 % of the patients were male. The average prehospital GCS was 6.8, the average prehospital Trauma Score was 8.3 points. 49 % of the study population suffered from multiple injuries. The overall mortality rate was 46,6 %. 60 % of deaths occurred within the prehospital setting. The incidence of severe brain trauma in Cologne in this study was significantly lower compared to what could be expected from the literature. The overall mortality was high, especially the high prehospital death rate is striking.	Univ Cologne, Dept Surg 2, D-51109 Cologne, Germany; Univ Cologne, Inst Med Stat Informat & Epidemiol, D-5000 Cologne 41, Germany; Univ Cologne, Dept Surg 2, Biol & Expt Div, D-51109 Cologne, Germany; Neurosurg Clin, Cologne, Germany; Univ Cologne, Dept Gen Neurosurg, D-5000 Cologne 41, Germany		Bouillon, B (corresponding author), Univ Cologne, Dept Surg 2, Ostmerheimer Str 200, D-51109 Cologne, Germany.						Baethmann A, 1998, Curr Opin Anaesthesiol, V11, P193, DOI 10.1097/00001503-199804000-00013; BAETHMANN A, 1996, ACTA NEUROCHIR S, V66; BOUILLON B, 1990, THEOR SURG, V5, P36; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HARTWIG E, 1993, UNFALLCHIRURG, V96, P264; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; Moecke H., 1994, Intensivmedizin und Notfallmedizin, V31, P96; Prough DS, 1997, J TRAUMA, V42, pS10, DOI 10.1097/00005373-199705001-00003; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; TEASDALE G, 1974, LANCET, V2, P81; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	17	34	34	0	1	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					85	92					8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	183XN	WOS:000079579700002					2022-02-06	
J	Delmonico, RL; Hanley-Peterson, P; Englander, J				Delmonico, RL; Hanley-Peterson, P; Englander, J			Group psychotherapy for persons with traumatic brain injury: Management of frustration and substance abuse	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anger; frustration; group psychotherapy; substance abuse; traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION; ANGER	Residual emotional and behavioral difficulties in individuals who have sustained a traumatic brain injury (TBI) have been well documented in the literature. The issues are complex, interdependent, and often include substance abuse, depression, anxiety, chronic suicidal or homicidal ideation, poor impulse control, and significant degrees of frustration and anger. Often, preexisting psychological conditions and poor coping strategies are exacerbated by the trauma. Emotional and behavioral difficulties can interfere with the neurorehabilitation process at all levels. In acute rehabilitation, these issues have traditionally been addressed on an individual basis. However, in postacute settings, an interpersonal group format can be effectively implemented. The majority of individuals with TBI have minimal funding for longterm cognitive and behavioral remediation; often the only avenue available is support groups. This article will describe group psychotherapy models used with individuals with acute or postacute TBI within a comprehensive rehabilitation center. Interdisciplinary treatment of frustration and substance abuse and a continuum of care will be emphasized. Education, social support, skills development, interpersonal process, and cognitive-behavioral approaches will also be discussed. The psychotherapy groups focus on treatment of substance abuse and frustration management through education, social support, and development of interpersonal skills. Practical considerations of running such groups are presented.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Psychol Serv, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Speech Pathol Serv, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Recreat Serv, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Traumat Brain Injury Project, San Jose, CA 95128 USA		Delmonico, RL (corresponding author), Kaiser Fdn, Rehabil Ctr, 975 Sereno Dr, Vallejo, CA 94589 USA.						Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; BENYISHAY Y, 1979, NYU REHABIL MONOGR, V60, P39; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; CHEMTOB CM, 1997, J CONSULT CLIN PSYCH, V65, P1841; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; KLONOFF PS, 1993, B MENNINGER CLIN, V57, P227; KREUTZER J S, 1990, Brain Injury, V4, P1, DOI 10.3109/02699059009026142; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Lakin P, 1989, NEUROPSYCHOLOGICAL T; LIRA FT, 1983, INT J CLIN NEUROPSYC, V5, P159; MacKinley W. W., 1988, J HEAD TRAUMA REHAB, V3, P64; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Novaco R. W., 1997, LEGAL CRIMINOL PSYCH, V2, P77, DOI [DOI 10.1111/J.2044-8333.1997.TB00334.X, 10.1111/j.2044-8333.1997.tb00334]; NOVACO RW, 1977, J CONSULT CLIN PSYCH, V45, P600, DOI 10.1037/0022-006X.45.4.600; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPARADEO FR, 1992, NEUROREHABILITATION, V2, P65; SPARADEO FR, 1995, ADV MED PSYCHOTHER, V8, P101; SPARADEO FR, 1992, HDB ASSESSING TREATI; SPIELBERGER CD, 1991, STATE TRAIT ANGER EX; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; WILLIAMS J, 1991, HEAD INJURY FAMILY M; Yalom I.D., 1975, THEORY PRACTICE GROU	25	34	38	0	13	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1998	13	6					10	22		10.1097/00001199-199812000-00004			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	141KF	WOS:000077142300004	9885315				2022-02-06	
J	Mori, K; Maeda, M; Miyazaki, M; Iwase, H				Mori, K; Maeda, M; Miyazaki, M; Iwase, H			Effects of mild (33 degrees C) and moderate (29 degrees C) hypothermia on cerebral blood flow and metabolism, lactate, and extracellular glutamate in experimental head injury	NEUROLOGICAL RESEARCH			English	Article						head injury; hypothermia; cerebral blood flow; cerebral metabolism; glutamate	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; ISCHEMIA; RAT; MICRODIALYSIS; HIPPOCAMPUS; TEMPERATURE; RELEASE; DAMAGE; ACCUMULATION	The effects of mild (33 degrees C) and moderate (29 degrees C) hypothermia were investigated to determine which temperature was more effective against compression-induced cerebral ischemia. Eighteen cats were anesthetized. The animals were divided into three groups according to deep-brain temperature (control, 37 degrees C; mild hypothermia, 33 degrees C;and moderate hypothermia, 29 degrees C). Intracranial pressure (ICP) and cerebral blood flow (CBF) were monitored, the latter by hydrogen clearance. Arteriovenous oxygen difference (AVDO(2)) and cerebral venous oxygen saturation (ScvO(2)) were measured in blood samples from the superior sagittal sinus. The cerebral metabolic rate of oxygen (CMRO2) and the cerebral metabolic rate of lactate (CMR lactate) were calculated. Extracellular glutamate was measured by microdialysis. ICP was increased by inflation of an epidural balloon until CBF became zero, and this ischemia was maintained for 5 min, after which the balloon was quickly deflated All parameters were recorded over 6 h. Evans blue was injected to examine vascular permeability changes. CBF was decreased by 56% by mild hypothermia and by 77% by moderate hypothermia. Mild hypothermia had a coupled metabolic suppression whereas moderate hypothermia significantly increased AVDO(2) and decreased ScvO(2), producing a low CBF/CMRO2 (relative ischemia). After balloon deflation, all three groups showed reactive hyperemia, which was significantly reduced by mild and moderate hypothermia. CBF then decreased to 50% of pre-inflation values and ScvO(2) decreased (post-ischemic hypoperfusion). CBF/CMRO2, ScvO(2), and AVDO(2) did not differ significantly between the three groups. After balloon deflation, all three groups showed increased CMR lactate, which was significantly reduced by mild and moderate hypothermia. Extracellular glutamate increased:in control animals (3.8+/-1.72 mu M), an effect most effectively suppressed in the mild hypothermia group (1.0+/-0.46 mu M). Damaged tissue volumes as indicated by Evans blue dye extravasation were 729+/-89 mm(3) in control, 247+/-56 mm3 in mild hypothermia, and 267+/-35 mm(3) in moderate hypothermia animals. These data suggest that mild hypothermia (33 degrees C) might be the optimal brain temperature to treat compression-related cerebral ischemia.	Juntendo Univ, Dept Neurosurg, Izunagaoka Hosp, Shizuoka 41022, Japan; Juntendo Univ, Casualty Ctr, Izunagaoka Hosp, Shizuoka 41022, Japan		Mori, K (corresponding author), Juntendo Univ, Dept Neurosurg, Izunagaoka Hosp, 1129 Nagaoka, Shizuoka 41022, Japan.						AUKLAND K, 1964, CIRC RES, V14, P164, DOI 10.1161/01.RES.14.2.164; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BOELS PJ, 1985, EXPERIENTIA, V41, P1374, DOI 10.1007/BF01949995; BULLOCK R, 1992, BRIT J CLIN PHARMACO, V34, P396, DOI 10.1111/j.1365-2125.1992.tb05648.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P177; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1992, ACTA PHYSIOL SCAND, V146, P543, DOI 10.1111/j.1748-1716.1992.tb09462.x; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HAIKALA H, 1986, BRAIN RES, V375, P313, DOI 10.1016/0006-8993(86)90751-1; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; Huang FP, 1998, NEUROL RES, V20, P57; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; LEVY DE, 1979, NEUROLOGY, V29, P1245, DOI 10.1212/WNL.29.9_Part_1.1245; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARTINS E, 1988, J CEREBR BLOOD F MET, V8, P531, DOI 10.1038/jcbfm.1988.93; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; MITANI A, 1992, NEUROSCIENCE, V48, P307, DOI 10.1016/0306-4522(92)90492-K; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; NEMOTO EM, 1978, CRIT CARE MED, V6, P203, DOI 10.1097/00003246-197807000-00002; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAKAMOTO N, 1986, BRAIN RES, V364, P373; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SNYDER JV, 1975, STROKE, V6, P21, DOI 10.1161/01.STR.6.1.21; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P617, DOI 10.1038/jcbfm.1991.112; YABUKI A, 1991, Neurologia Medico-Chirurgica, V31, P568, DOI 10.2176/nmc.31.568; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919	43	34	42	0	0	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	DEC	1998	20	8					719	726					8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	146MG	WOS:000077432400009	9864737				2022-02-06	
J	Ribotta, MGY; Privat, A				Ribotta, MGY; Privat, A			Biological interventions for spinal cord injury	CURRENT OPINION IN NEUROLOGY			English	Article							TRAUMATIC NEURONAL INJURY; CENTRAL-NERVOUS-SYSTEM; CORTICAL CELL-CULTURE; D-ASPARTATE RECEPTORS; ADULT-RATS; GLUTAMATE NEUROTOXICITY; LOCOMOTOR RECOVERY; BRAIN INJURY; ANTAGONISTS; GENE	Spinal cord injury is frequently followed by the loss of supraspinal control of sensory, autonomus and motor functions at sublesional level. To enhance recovery in patients with spinal cord injuries, three fundamental strategies have been developed in experimental models. These strategies involve three different time points for postlesional intervention in the spinal cord. Neuroprotection soon after injury uses pharmacological tools to reduce the progressive secondary injury processes that follow during the first week after the initial lesion occurs, in order to limit tissue damage. A second strategy, which is initiated shortly after the lesion occurs, aims at promoting axonal regeneration by acting pharmacologically on inhibitors or barriers of regeneration, or by the application of cell or gene therapy as a source of neurotrophic factors or as a bridge or support to enhance the regeneration of lesioned axons. Finally, a mid-term substitutive strategy is the management of the sublesional spinal cord by sensorimotor stimulation or the supply of missing key afferents, such as monoaminergic systems. These three strategies are reviewed. Only a combination of these different approaches can provide an optimal basis for potential therapeutic interventions aimed at functional recovery after spinal cord injury. Curr Opin Neurol 11:647-654 (C) 1998 Lippincott Williams & Wilkins.	Univ Montpellier 2, INSERM, U336, F-34095 Montpellier, France		Ribotta, MGY (corresponding author), Univ Montpellier 2, INSERM, U336, Pl E Bataillon,BP 106, F-34095 Montpellier, France.	u336@univ-montp2.ir					Akesson E, 1998, EXP NEUROL, V149, P262, DOI 10.1006/exnr.1997.6668; Alonso G, 1997, J COMP NEUROL, V384, P181; BARBEAU H, 1994, CURR OPIN NEUROL, V7, P517, DOI 10.1097/00019052-199412000-00008; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; Bjugn R, 1997, EXP NEUROL, V148, P179, DOI 10.1006/exnr.1997.6610; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Bregman BS, 1998, EXP NEUROL, V149, P13, DOI 10.1006/exnr.1997.6669; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; Brook GA, 1998, ACTA NEUROPATHOL, V95, P378, DOI 10.1007/s004010050814; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chau C, 1998, J NEUROPHYSIOL, V79, P392, DOI 10.1152/jn.1998.79.1.392; Chauvet N, 1998, EXP NEUROL, V151, P1, DOI 10.1006/exnr.1998.6784; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; CHOI DW, 1987, J NEUROSCI, V7, P357; Cot C, 1998, INT J DEV NEUROSCI, V16, P9, DOI 10.1016/S0736-5748(97)00048-8; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Diener PS, 1998, J NEUROSCI, V18, P779; DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700; EIDELBERG E, 1989, BRAIN RES BULL, V22, P39, DOI 10.1016/0361-9230(89)90125-1; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Felici F, 1997, SPINAL CORD, V35, P383, DOI 10.1038/sj.sc.3100403; FeraboliLohnherr D, 1997, EXP BRAIN RES, V113, P443, DOI 10.1007/PL00005597; FERNAUDESPINOSA I, 1993, GLIA, V8, P277, DOI 10.1002/glia.440080408; Finiels F, 1995, NEUROREPORT, V7, P373, DOI 10.1097/00001756-199512290-00088; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.3.CO;2-6; Gerin C, 1998, BRAIN RES, V794, P169, DOI 10.1016/S0006-8993(98)00278-9; Grill R, 1997, J NEUROSCI, V17, P5560; Grill RJ, 1997, EXP NEUROL, V148, P444, DOI 10.1006/exnr.1997.6704; Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693; Holtmaat AJGD, 1998, BRAIN RES REV, V26, P43, DOI 10.1016/S0165-0173(97)00044-1; Hughes S, 1997, DEV BRAIN RES, V102, P13, DOI 10.1016/S0165-3806(97)00072-2; Iadecola C, 1997, J NEUROSCI, V17, P9157; Kanellopoulos GK, 1997, ANN THORAC SURG, V64, P1279, DOI 10.1016/S0003-4975(97)00903-X; Keirstead HS, 1998, EXP NEUROL, V151, P303, DOI 10.1006/exnr.1998.6806; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LEVALLOIS C, 1994, INT J DEV NEUROSCI, V12, P547, DOI 10.1016/0736-5748(94)90062-0; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Li Y, 1997, EXP NEUROL, V145, P397, DOI 10.1006/exnr.1997.6502; Liu S, 1997, J NEUROSCI RES, V49, P425, DOI 10.1002/(SICI)1097-4547(19970815)49:4<425::AID-JNR4>3.0.CO;2-A; Lu YM, 1996, J NEUROSCI, V16, P5457; LUNDBERG A, 1966, MUSCULAR AFFERENTS M, P275; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; Muir GD, 1997, TRENDS NEUROSCI, V20, P72, DOI 10.1016/S0166-2236(96)10068-0; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Olney J. W., 1978, NEUROTOXICITY EXCITA, P95; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; PRIVAT A, 1988, PROG BRAIN RES, V78, P155; Privat A, 1997, REV NEUROL-FRANCE, V153, P515; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; REGAN RF, 1995, BRAIN RES, V682, P144, DOI 10.1016/0006-8993(95)00330-S; RIBOTTA MGY, 1995, J NEUROSCI RES, V41, P79, DOI 10.1002/jnr.490410110; Ribotta MGY, 1997, J NEUROSCI RES, V48, P281; Ribotta MGY, 1997, ADV EXP MED BIOL, V429, P121; RIBOTTA MGY, 1998, IN PRESS ANN NY ACAD; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RONDOUIN G, 1988, NEUROSCI LETT, V91, P199, DOI 10.1016/0304-3940(88)90768-9; ROSSIGNOL S, 1966, HDB PHYSL 12, P173; Rossignol Serge, 1994, Current Opinion in Neurobiology, V4, P894, DOI 10.1016/0959-4388(94)90139-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHSTEIN JD, 1995, J NEUROCHEM, V65, P643; Steward O, 1997, EXP NEUROL, V148, P100, DOI 10.1006/exnr.1997.6613; Sundstrom E, 1997, EXP NEUROL, V148, P407, DOI 10.1006/exnr.1997.6691; Taoka Y, 1998, J NEUROSCI, V18, P1393; Tello J.F., 1911, TRAB LAB INVEST BIOL, V9, P123; Teng YD, 1998, EUR J NEUROSCI, V10, P798, DOI 10.1046/j.1460-9568.1998.00100.x; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Tuszynski MH, 1998, CELL TRANSPLANT, V7, P187, DOI 10.1016/S0963-6897(97)00166-8; Vanek P, 1998, EUR J NEUROSCI, V10, P45, DOI 10.1046/j.1460-9568.1998.00018.x; Watanabe M, 1998, J NEUROTRAUM, V15, P285, DOI 10.1089/neu.1998.15.285; Wickelgren I, 1998, SCIENCE, V279, P319, DOI 10.1126/science.279.5349.319; WICTORIN K, 1992, NEUROREPORT, V3, P1045, DOI 10.1097/00001756-199212000-00003; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; YAKOVLEFF A, 1995, EXP BRAIN RES, V106, P69; Zompa EA, 1997, J NEUROTRAUM, V14, P479, DOI 10.1089/neu.1997.14.479	80	34	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	1998	11	6					647	654		10.1097/00019052-199812000-00007			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	148EC	WOS:000077490900007	9870132				2022-02-06	
J	Sohlberg, MM; Mateer, CA; Penkman, L; Glang, A; Todis, B				Sohlberg, MM; Mateer, CA; Penkman, L; Glang, A; Todis, B			Awareness intervention: Who needs it?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness deficit; behavior modification; brain injury; intervention	TRAUMATIC BRAIN INJURY; HEAD-INJURY; DEFICITS; DYSFUNCTION; UNAWARENESS; ADULTS	It is widely accepted that awareness deficits present challenges to recovery and should be addressed as part of rehabilitation programming. Response to awareness intervention is commonly inferred from measurements that rely on reports by subjects and significant others. This article describes the findings from a pilot study that examined the relationship among a variety of awareness indicators in three individuals with brain damage over a 9-month period. Results suggest a dissociation between behavioral and perceptual indices of awareness. Changes in behavioral indicators of awareness selected by caregivers were not related to changes in self- or caregiver ratings. nle clinical and research implications of the findings are discussed.	Univ Oregon, Eugene, OR 97403 USA; Univ Victoria, Dept Psychol, Victoria, BC, Canada; Western Oregon Univ, Teaching Res Div, Monmouth, OR USA		Sohlberg, MM (corresponding author), Univ Oregon, 5270, Eugene, OR 97403 USA.						ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CAVELLO MM, 1992, BRAIN INJURY, V6, P327; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; DeLuca J., 1992, NEUROREHABILITATION, V2, P23, DOI [https://doi.org/10.3233/NRE-1992-2305, DOI 10.3233/NRE-1992-2305]; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Herbert CM, 1989, CLIN REHABIL, V3, P125; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Langer KG., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [DOI 10.1080/09602019208401395, 10.1080/09602019208401395]; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1986, AWARENESS DEFICIT BR; PRIGATANO GP, 1991, AWARENESS DEFICITS A; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; SOHLBERG MM, 1994, TRAINING USE COMPENS; SOHLBERG MM, IN PRESS APHASIOLOGY; Sohlberg MM, 1996, PICTURE THIS STRATEG; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	28	34	35	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					62	78		10.1097/00001199-199810000-00008			17	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600008	9753536				2022-02-06	
J	Hux, D; Bond, V; Skinner, S; Belau, D; Sanger, D				Hux, D; Bond, V; Skinner, S; Belau, D; Sanger, D			Parental report of occurrences and consequences of traumatic brain injury among delinquent and non-delinquent youth	BRAIN INJURY			English	Article							FLUID-PERCUSSION INJURY; MINOR HEAD-INJURY; EPIDEMIOLOGY; POPULATION; ATTENTION; CHILDREN; SEQUELAE; COUNTY	Completed questionnaires from parents of youths attending a public middle school or high school and parents of youths admitted to an institution for juvenile delinquents provided information about incidents of traumatic brain injury (TBI) in their children. Results revealed that approximately 40% of the non-delinquent youth and 50% of the delinquent youth had sustained one or more TBIs during their childhood or youth. The majority of injuries appeared to be mild and had no permanent consequences. However, the parents of more than one-third of the delinquent youth with TBI histories reported long-term effects on academic performance, behaviour and emotional control, activity level, and/or interactions with friends and family members; parental reports of long-term effects occurred significantly less frequently among the non-delinquent youth. The most common causes of TBI differed between the two adolescent populations. Non-delinquent youth sustained TBIs most frequently from blows to the head during; sporting events, and delinquent youth sustained TBIs with approximately equal frequency from sporting events, falls, motor vehicle accidents, and fights.	Univ Nebraska, Barkley Mem Ctr 318E, Dept Special Educ & Commun Disorders, Lincoln, NE 68588 USA; Youth Rehabil & Treatment Ctr, Geneva, NE USA		Hux, D (corresponding author), Univ Nebraska, Barkley Mem Ctr 318E, Dept Special Educ & Commun Disorders, Lincoln, NE 68588 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BARNES J, 1978, J IRISH MED ASSOC, V71, P19; Bond M. R., 1990, REHABILITATION ADULT, P179; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1990, REHABILITATION ADULT, P163; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Caveness W F, 1979, Adv Neurol, V22, P1; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GORDON N, 1993, BRAIN DEV-JPN, V15, P169, DOI 10.1016/0387-7604(93)90060-L; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HURT J, 1992, J CLIN PSYCHOL, V48, P120, DOI 10.1002/1097-4679(199201)48:1<120::AID-JCLP2270480117>3.0.CO;2-5; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KANDEL E, 1991, CRIMINOLOGY, V29, P519, DOI 10.1111/j.1745-9125.1991.tb01077.x; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MILLER JD, 1985, LANCET, V1, P1141; OSTROV E, 1972, J YOUTH ADOLESCENCE, V1, P179, DOI 10.1007/BF01537072; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosen CD, 1986, HEAD TRAUMA ED REINT; ROSENBAUM JL, 1989, CRIME DELINQUENCY, V35, P31, DOI 10.1177/0011128789035001003; Sanger D. D., 1997, AM J SPEECH-LANG PAT, V6, P70; STRICKER LJ, 1988, J APPL SOC PSYCHOL, V18, P423, DOI 10.1111/j.1559-1816.1988.tb00026.x; Szekeres S. F., 1987, COMMUNITY REENTRY HE COMMUNITY REENTRY HE, P87; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; VIRKKUNEN M, 1977, DIS NERV SYST, V38, P907; VIRKKUNEN M, 1976, ACTA PSYCHIAT SCAND, V53, P168, DOI 10.1111/j.1600-0447.1976.tb00072.x; 1992, FED REG, V57, P44794; [No title captured]	41	34	34	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1998	12	8					667	681					15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800004	9724838				2022-02-06	
J	Pell, M; Flynn, WJ; Seibel, RW				Pell, M; Flynn, WJ; Seibel, RW			Is colostomy always necessary in the treatment of open pelvic fractures?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	11th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 14-17, 1998	SANIBEL, FLORIDA	E Assoc Surg Trauma		open pelvic fractures; fecal diversion; colostomy	INJURY; MANAGEMENT; CLOSURE	Background: Wound management in open pelvic fractures has used fecal diversion, debridement, and closure by secondary intention to prevent pelvic sepsis. Colostomy care and takedown adds to the morbidity and resource utilization of this approach, We reviewed our experience to determine if a selective approach to fecal diversion based on wound location was possible. Methods: Retrospective analysis of patients admitted to a Level I trauma center during an 8-year period, Fractures were classified as open if the fracture was in continuity with the wound. Wounds were classified as perineal if they involved the rectum, ischiorectal fossa, or genitalia, and as nonperineal if they involved the pubis anteriorly, iliac crest, or anterior thigh, Pelvic sepsis was defined as cellulitis, fasciitis, or infection of a pelvic hematoma. Diversion consisted of loop or end colostomy, Results: Eighteen patients with open fractures were identified. Four died from closed head injury and blood loss, The remaining 14 were treated as follows. Five patients with perineal wounds had diversion of their fecal stream. Their Injury Severity Score was 34 +/- 8.3 and their Revised Trauma Score was 7.69 +/- 0,15, No patient developed pelvic sepsis, Nine patients with nonperineal wounds did not undergo diversion, Their Injury Severity Score was 28.6 +/- 5.3 and their Revised Trauma Score was 7.36 +/- 0,45, No patients developed pelvic sepsis in the nondiverted group. Conclusion: No patients with anterior wounds and an intact fecal stream developed pelvic sepsis. Colostomy may not be necessary in all patients with open pelvic fracture, Protocols using fecal diversion based on wound location appear to be safe and may decrease resource utilization and subsequent morbidity related to colostomy closure.	SUNY Buffalo, Erie Cty Med Ctr & Labs, Dept Surg, Buffalo, NY 14215 USA		Flynn, WJ (corresponding author), SUNY Buffalo, Erie Cty Med Ctr & Labs, Dept Surg, Buffalo, NY 14215 USA.						AGNEW SG, 1994, ORTHOP CLIN N AM, V25, P715; DAVIDSON BS, 1993, J TRAUMA, V35, P36, DOI 10.1097/00005373-199307000-00006; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; FLINT L, 1990, ANN SURG, V211, P730; GRUEN GS, 1994, J TRAUMA, V36, P706, DOI 10.1097/00005373-199405000-00019; Khoury DA, 1996, DIS COLON RECTUM, V39, P605, DOI 10.1007/BF02056935; KUDSK KA, 1990, J TRAUMA, V30, P1155, DOI 10.1097/00005373-199009000-00012; KUSMINSKY RE, 1982, DIS COLON RECTUM, V25, P787, DOI 10.1007/BF02553312; MAULL KI, 1977, J TRAUMA, V17, P685, DOI 10.1097/00005373-197709000-00005; MILESKI W, 1991, SURG GYNECOL OBSTET, V171, P17; PORTER JA, 1989, DIS COLON RECTUM, V32, P299, DOI 10.1007/BF02553484; RICHARDSON JD, 1982, J TRAUMA, V22, P533, DOI 10.1097/00005373-198207000-00002; ROTHENBERGER D, 1978, J TRAUMA, V18, P184, DOI 10.1097/00005373-197803000-00006; SINNOTT R, 1992, AM J SURG, V163, P283, DOI 10.1016/0002-9610(92)90003-A; TRUNKEY DD, 1974, J TRAUMA, V14, P912, DOI 10.1097/00005373-197411000-00002; WONG RW, 1994, J SURG RES, V57, P289, DOI 10.1006/jsre.1994.1147	16	34	37	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	1998	45	2					371	373		10.1097/00005373-199808000-00029			3	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	109VL	WOS:000075344500039	9715198				2022-02-06	
J	Togher, L; Hand, L				Togher, L; Hand, L			Use of politeness markers with different communication partners: an investigation of five subjects with traumatic brain injury	APHASIOLOGY			English	Article; Proceedings Paper	27th Clinical Aphasiology Conference	JUN, 1997	BIGFORK, MONTANA				LANGUAGE; SKILLS	Politeness is a complex interpersonal phenomenon which has received considerable attention by linguists over recent years. This paper presents preliminary work which examines some methodological and theoretical issues related to the concept of politeness using the systemic functional approach. Results are presented for five traumatically brain injured subjects and five matched controls during telephone interactions with four different interlocutors. The results indicate that TBI subjects are able to access a wide variety of politeness strategies; however, their ability to manipulate these across the four different tenor relationships is impaired when compared with control subjects. The richness of this approach in highlighting the unique features of communication disorders following traumatic brain injury and new ways to approach their management is discussed.	Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, Lidcombe, NSW 2141, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Liverpool Are Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, POB 170, Lidcombe, NSW 2141, Australia.		Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Austin JL., 1962, DO THINGS WORDS, V2; BERRY M, 1981, STUDIES DISCOURSE AN, P120; Brown P., 1978, QUESTIONS POLITENESS, P56; Cole Morgan, 1975, SYNTAX SEMANTICS, V3, P59, DOI DOI 10.1017/CBO9780511609213.004; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; FERGUSON A, 1992, J NEUROLINGUIST, V7, P277, DOI 10.1016/0911-6044(92)90019-S; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Grice H. P., 1975, SYNTAX SEMANTICS, P41; Halliday M., 2004, INTRO FUNCTIONAL GRA; Halliday M. A. K., 1978, LANGUAGE SOCIAL SEMI; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Halliday M. A. K., 1970, NEW HORIZONS LINGUIS, P140; Halliday Michael Alexander Kirkwood, 1989, LANGUAGE CONTEXT TEX; Hartley L. L, 1995, COGNITIVE COMMUNICAT; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Lakoff R., 1974, BERKLEY STUDIES SYNT, V1, P1; Levinson, 1987, POLITENESS SOME UNIV; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Poynton C., 1985, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Stubbs Michael, 1983, DISCOURSE ANAL SOCIO; TANNEN D, 1981, DISCOURSE PROCESS, V4, P221, DOI 10.1080/01638538109544517; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; ULICHNY P, 1989, DISCOURSE PROCESS, V12, P309, DOI 10.1080/01638538909544733; VENTOLA E, 1987, STRUCTURE SOCIAL INT	33	34	35	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	JUL-AUG	1998	12	7-8					755	770		10.1080/02687039808249571			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	ZU108	WOS:000074162800020		Green Submitted			2022-02-06	
J	Yeates, KO; Taylor, HG				Yeates, KO; Taylor, HG			Predicting premorbid neuropsychological functioning following pediatric traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	24th Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 1996	CHICAGO, ILLINOIS	Int Neuropsychol Soc, US PHS, Natl Inst Aging, Alzheimers Dis Cooperat Study			DEMOGRAPHIC-VARIABLES; HEAD-INJURY; WAIS-R; INTELLIGENCE; IQ; VALIDATION; SEVERITY; INDEX; SCALE	This study examined the prediction of premorbid neuropsychological functioning using data from an ongoing prospective study of traumatic brain injuries (TBI) in children ages 6 to 12 years. Prediction equations were derived based on 80 children with orthopedic injuries (OI), who served as a comparison group for the children with TBI. Collectively, parent ratings of premorbid school performance, maternal ethnicity, family socioeconomic status, and children's word recognition skill predicted from 13% to 45% of the variance in three measures of neuropsychological functioning. The regression equations were used to compute predicted scores among 109 children with TBI. Actual scores fell significantly below predicted scores among children with TBI, and the magnitude of the deficits was correlated with injury severity. Premorbid neuropsychological functioning can be predicted in children with TBI, but with less precision than would be desirable for clinical purposes.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA		Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.		Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		Achenbach TM, 1991, MANUAL CHILD BEHAV C; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BRYAN J, 1992, J CLIN EXPT NEUROPSY, V14, P64; CHRISTENSEN H, 1991, PSYCHOL ASSESSMENT, V3, P147; Delis D, 1994, MANUAL CALIFORNIA VE; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FINKELSTEIN NW, 1980, AM J MENT DEF, V84, P546; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; HART S, 1986, BRIT J CLIN PSYCHOL, V25, P119, DOI 10.1111/j.2044-8260.1986.tb00680.x; JENNETT B, 1975, LANCET, V1, P480; KAREKEN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P147, DOI 10.1016/0887-6177(94)E0012-E; KARZMARK P, 1985, J CLIN EXP NEUROPSYC, V7, P412, DOI 10.1080/01688638508401273; KLESGES RC, 1987, INT J CLIN NEUROPSYC, V9, P1; KLESGES RC, 1980, J CONSULT CLIN PSYCH, V49, P141; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Psychological Corporation, 1992, WECHSL IND ACH TEST; RAMEY CT, 1978, AM J MENT DEF, V82, P525; REYNOLDS CR, 1979, CLIN NEUROPSYCHOLOGY, V1, P36; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; SILVERSTEIN AB, 1987, J CLIN PSYCHOL, V43, P493, DOI 10.1002/1097-4679(198709)43:5<493::AID-JCLP2270430511>3.0.CO;2-V; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P18, DOI 10.1080/13854049008401493; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P64, DOI 10.1080/13854049008401497; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; WILLSHIRE D, 1991, J CLIN EXP NEUROPSYC, V13, P204, DOI 10.1080/01688639108401038; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; [No title captured]; [No title captured]	38	34	35	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1997	19	6					825	837		10.1080/01688639708403763			13	Psychology, Clinical; Clinical Neurology; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	ZA276	WOS:000072347100004	9524877				2022-02-06	
J	Pike, BR; Hamm, RJ				Pike, BR; Hamm, RJ			Activating the posttraumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						M-1 agonist; M-2 antagonist; Morris water maze; muscarinic; rats; spatial memory; treatment	CLOSED-HEAD-INJURY; FLUID-PERCUSSION INJURY; MUSCARINIC RECEPTORS; RATS; SCOPOLAMINE; DEFICITS; ADAPTATIONS; ANTAGONIST; BASAL; MOTOR	Cognitive impairment after traumatic brain injury (TBI) is correlated with decreased cholinergic markers of neuronal viability. The purpose of this experiment was to test the hypothesis that pharmacological activation of the muscarinic cholinergic system during the recovery period after TBI will improve cognitive performance. LU 25-109-T is a partial muscarinic M-1 agonist that also acts as an antagonist at presynaptic M-2 autoreceptors (thus, increasing ACh release). Injured rats were injected subcutaneously daily for 15 days with either 0.0, 3.6, or 15 mu mol/kg of LU 25-109-T beginning 24 h after a receiving a moderate (2.1 +/- 0.1 arm) level of central fluid percussion brain injury. Cognitive performance was assessed on days 11-15 postinjury in a Morris water maze (MWM). Injured rats treated with 15 mu mol/kg, but not those treated with 3.6 mu mol/kg, showed a significant improvement (P < 0.01) in MWM performance as compared with injured vehicle-treated rats. This result supports the hypotheses that a decrease in posttraumatic cholinergic neurotransmission contributes to TBI-induced cognitive deficits and that increasing cholinergic tone during the recovery period following TBI will improve cognitive performance. (C) 1997 Elsevier Science Inc.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		BECKER RE, 1988, DRUG DEVELOP RES, V12, P163, DOI 10.1002/ddr.430120302; BENBARAK J, 1981, EUR J PHARMACOL, V74, P73, DOI 10.1016/0014-2999(81)90325-3; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUYUKUYSAL RL, 1989, BRAIN RES, V482, P371; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; Dixon C. E., 1995, Society for Neuroscience Abstracts, V21, P762; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doods Henri N., 1995, Drugs of the Future, V20, P157; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAYES RL, 1988, J NEUROTRAUM, V5, P287; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Liu S. J., 1993, Society for Neuroscience Abstracts, V19, P1881; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARKS MJ, 1981, J PHARMACOL EXP THER, V218, P337; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEIER E, 1995, LIFE SCI, V56, P1006, DOI 10.1016/0024-3205(95)93724-S; MEIER E, IN PRESS DRUG DEV RE; Moltzen Ejner K., 1995, Drugs of the Future, V20, P37; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PEDIGO NW, 1988, PSYCHOPHARMACOLOGY, V95, P497; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; SARTER M, 1990, PSYCHOPHARMACOLOGY, V101, P1, DOI 10.1007/BF02253710; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Sinson G., 1995, Society for Neuroscience Abstracts, V21, P2121; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Taylor Palmer, 1994, P231	41	34	34	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	AUG	1997	57	4					785	791		10.1016/S0091-3057(96)00453-4			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	XN588	WOS:A1997XN58800021	9259007				2022-02-06	
J	Pieter, W; Zemper, ED				Pieter, W; Zemper, ED			Injury rates in children participating in taekwondo competition	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						taekwondo; boys; girls; martial sports; Junior Olympic; injuries	CONCUSSION; PREVENTION; ATHLETE; SPORTS	Objective: To report rates of injuries sustained during Junior taekwondo competitions. Design: Prospective, Materials and Methods: Data were collected with simple check-off forms that describe the athlete, nature, site, circumstances, and severity of the injury at three major taekwondo tournaments involving a total of 3,341 boys and 917 girls, Main Results: No difference was found between boys (58.34/1,000 athlete-exposures) and girls (56.57/1,000 athlete-exposures) in total injury rate (p > 0.05), Collapsed over gender, significant differences (p = 0.013) in injury rates of body parts were found with the lower extremities (21.83/1,000 athlete-exposures) ranked first, Unblocked attacks are the major cause of injury in both boys and girls. Conclusions: Coaches are advised to work on the blocking skills of their Junior taekwondo athletes, No head contact for children in taekwondo competition should also be considered.	EXERCISE RES ASSOCIATES OREGON,EUGENE,OR		Pieter, W (corresponding author), UNIV N LONDON,SCH HLTH & SPORTS SCI,166-220 HOLLOWAY RD,LONDON N7 8DB,ENGLAND.						BROEKHOFF J, 1995, P 1992 OLYMP SCI C, V5, P258; Caine D., 1990, PEDIAT EXERC SCI, V2, P209, DOI [10.1123/pes.2.3.209, DOI 10.1123/PES.2.3.209]; CAINE D, 1990, CAHPER J, V56, P24; CAINE DJ, 1987, PHYSICIAN SPORTSMED, V15, P67, DOI 10.1080/00913847.1987.11709303; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; GOLDBERG B, 1989, PHYSICIAN SPORTSMED, V17, P174, DOI 10.1080/00913847.1989.11709740; GOLDBERG B, 1984, PHYSICIAN SPORTSMED, V12, P122; JORRITSMA LSM, 1987, RAPPORT COMMISSIE VE; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KOZAR B, 1988, CHILDREN SPORT, P119; Kurland Harvey L, 1980, Phys Sportsmed, V8, P80, DOI 10.1080/00913847.1980.11948652; LORISH TR, 1992, AM J SPORT MED, V20, P199, DOI 10.1177/036354659202000218; MAFFULLI N, 1990, SPORTS MED, V9, P229, DOI 10.2165/00007256-199009040-00004; Malina R.M., 1991, GROWTH MATURATION PH; MARTIN RK, 1987, AM J SPORT MED, V15, P603, DOI 10.1177/036354658701500614; McCarroll JR., 1984, PHYS SPORTS MED, V12, P113, DOI [10.1080/00913847.1984.11701775, DOI 10.1080/00913847.1984.11701775]; MCLATCHIE GR, 1994, CLIN PRACTICE SPORTS, V5, P609; MICHELI LJ, 1986, EXERCISE SPORTS SCI, P359; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pappas A M, 1983, Phys Sportsmed, V11, P140, DOI 10.1080/00913847.1983.11708566; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1995, ICHPER SD 38 WORLD C; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; PIETER W, 1995, TAEKWONDO TECHNIK TR; POIRIER T, 1990, THESIS U PARIS VAL M; RETTIG AC, 1989, AM J SPORT MED, V17, P567, DOI 10.1177/036354658901700420; Ryan A J, 1983, Phys Sportsmed, V11, P49, DOI 10.1080/00913847.1983.11708702; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; TANNER JM, 1990, FETUS MAN PHYSICAL G; WESTERHOF B, 1995, 1995 ICHPER SD 38 WO, pP23; WILKINS KE, 1980, AM J SPORT MED, V8, P377, DOI 10.1177/036354658000800517; Zemper E D, 1989, Br J Sports Med, V23, P161; Zemper E. D., 1991, INT C EXP SPORTS MED; ZEMPER ED, 1993, PRIMARY CARE SPORTS, P63	35	34	35	1	8	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	1997	43	1					89	95		10.1097/00005373-199707000-00020			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	XN917	WOS:A1997XN91700025	9253914				2022-02-06	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Magnesium sulphate improves neurologic outcome following severe closed head injury in rats	NEUROSCIENCE LETTERS			English	Article						diffuse axonal injury; trauma; magnesium; brain	TRAUMATIC BRAIN INJURY; NEURONS; RECEPTORS; MG-2+	While recent evidence suggests that brain intracellular free magnesium concentration declines following severe diffuse traumatic brain injury. no studies have examined whether magnesium administration following such injury can improve subsequent neurologic outcome. The present study shows that MgSO4 administered as a bolus at 30 min following severe closed head injury in rats significantly improves posttraumatic neurologic outcome as assessed by both rotarod and angleboard tests. Moreover, this improvement in outcome was evident with both intravenous and intramuscular drug administration. We conclude that parenteral administration of magnesium sulphate may be neuroprotective following severe closed head injury of a diffuse nature. (C) 1997 Elsevier Science Ireland Ltd.	JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA				Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			Bara M., 1984, MAGNESIUM, V3, P212; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	23	34	35	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 13	1997	228	3					175	178		10.1016/S0304-3940(97)00394-7			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XJ901	WOS:A1997XJ90100009	9218636				2022-02-06	
J	Chiu, WT; Yeh, KH; Li, YC; Gan, YH; Chen, HY; Hung, CC				Chiu, WT; Yeh, KH; Li, YC; Gan, YH; Chen, HY; Hung, CC			Traumatic brain injury registry in Taiwan	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; helmet use; Registry	HELMET USE LAWS; HEAD TRAUMA; POPULATION; FATALITIES; REPEAL	This project was designed to examine the epidemiology of traumatic brain injury (TBI) in Taiwan. A total of 58,563 cases of TBI was collected from 114 hospitals in Taiwan during the period July 1, 1988-June 30, 1994. Traffic accident was the major cause of TBI (69.4%), followed by falls and assaults. Motorcyclists accounted for the vast majority of TBI cases among traffic accident victims (64.5%). The Glasgow Coma Scale was used in assessing the severity. 41,646 cases (79.5%) were considered mild, 4,637 cases (8.9%) moderate, and 6,078 cases (11.6%) severe. Skull x-ray showed fracture in 7,663 cases (14.6%). Intracranial hemorrhage was identified in 28.6% of patients receiving CT scanning. Craniotomy was performed in 5,226 cases (9%). The outcome of TBI was determined by the Glasgow Outcome Scale. Death occurred in 2,621 cases (5.4%), vegetative state in 429 cases (0.9%), severe disability in 1,293 cases (2.6%1, moderate disability in 1,890 cases (3.9%), and good recovery in 42,596 cases (87.2%). The severity and outcome were worse than those of Western reports. In order to alleviate this problem, a helmet use persuasion program was conducted by the Police Department in Taipei City from January to lune, 1994. Results of this program showed a significant reduction of TBI-related hospitalization, severity and fatality during this period of intervention. This study points out the seriousness of TBI in Taiwan and suggests some approaches and priorities for prevention.	NATL TAIWAN UNIV,TAIPEI 10764,TAIWAN		Chiu, WT (corresponding author), TAIPEI MED COLL,TAIPEI,TAIWAN.			Li, Yu-Chuan (Jack)/0000-0001-6497-4232; Chen, Shawn Hsiang-Yin/0000-0001-5535-7152			Anderson DW, 1980, J NEUROSURG S, V53, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ANNEGERS JF, 1979, CENTRAL NERVOUS SYST; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; FRANKOWSKI RF, 1985, ADV PSYCHOSOM MED, V16, P153; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNET B, 1981, BRIT MED J, V282, P153; JENNET B, 1980, CLIN NEUROEPIDEMIOLO, P356; JENNETT B, 1975, LANCET, V1, P480; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; KRAUS JF, 1980, J NEUROSURG, V53, P803; MCHUGH TP, 1985, JSC MED ASS, V6, P588; McSwain N.E., 1984, IMPACT REENACTMENT M; MCSWAIN NE, 1980, SURG GYNECOL OBSTET, V151, P215; MCSWAIN NE, 1990, J TRAUMA, V30, P1189, DOI 10.1097/00005373-199010000-00002; Mounce N, 1992, REINSTATED COMPREHEN; MURDOCK MA, 1991, WESTERN J MED, V155, P370; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Nygren A, 1986, Acta Neurochir Suppl (Wien), V36, P10; PARKISON D, 1985, CAN J SURG, V28, P78; RUSSO PK, 1978, NEW ENGL J MED, V299, P1074, DOI 10.1056/NEJM197811092991915; Servadei F, 1985, J Neurosurg Sci, V29, P297; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; WATSON GS, 1981, AM J PUBLIC HEALTH, V71, P297, DOI 10.2105/AJPH.71.3.297; WATSON GS, 1980, AM J PUBLIC HEALTH, V70, P579, DOI 10.2105/AJPH.70.6.579; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	33	34	34	0	3	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897	0161-6412			NEUROL RES	Neurol. Res.	JUN	1997	19	3					261	264		10.1080/01616412.1997.11740811			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XC468	WOS:A1997XC46800010	9192378				2022-02-06	
J	Springer, JA; Farmer, JE; Bouman, DE				Springer, JA; Farmer, JE; Bouman, DE			Common misconceptions about traumatic brain injury among family members of rehabilitation patients	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY	Objective: To investigate misconceptions about traumatic brain injury (TBI) held by family members early in the recovery process and to compare family responses to those reported by the general public. Design: Descriptive survey. Setting: Rehabilitation hospital. Participants: 51 family members and close friends (eg, fiances) of patients with acquired brain injury who were admitted for rehabilitation. Convenience sample. Interventions: None. Main Outcome Measure: A 40-item questionnaire assessing knowledge about TBI, adapted from previously published interview surveys of the general public. Results: Family members endorsed common misconceptions about TBI, especially in the areas of unconsciousness, amnesia, and recovery. Compared to previous surveys of the general public, they showed: (1) better understanding of the immediate significance of brain injury and its negative impact on cognition and (2) more misconceptions on items assessing beliefs about the patient's potential long-term outcome and future vulnerability. Conclusions: Some misconceptions held by family members may be detrimental to the rehabilitation process and should be addressed through improved family education. Other misconceptions may be related to optimistic appraisal strategies that help families cope. The self-report TBI questionnaire can be used to clarify family educational needs and may also sensitize professionals to family coping issues. More research is needed to determine the impact of family knowledge and beliefs about TBI on the recovery process.	UNIV MISSOURI, SCH MED, DEPT PHYS MED & REHABIL, COLUMBIA, MO USA; UNIV CINCINNATI, MED CTR, DEPT PHYS MED & REHABIL, CINCINNATI, OH 45267 USA; DRAKE CTR INC, DEPT PSYCHOL, TRAUMAT BRAIN INJURY PROGRAM, CINCINNATI, OH USA		Springer, JA (corresponding author), MED COLL WISCONSIN, DEPT NEUROL, MCW CLIN FROEDTERT, 9200 W WISCONSIN AVE, MILWAUKEE, WI 53226 USA.						Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MERRITT KL, 1990, PSYCHOL REP, V67, P129, DOI 10.2466/PR0.67.5.129-130; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SANGER MS, 1993, J DEV BEHAV PEDIATR, V14, P88; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TAYLOR SE, 1989, J SOC CLIN PSYCHOL, V8, P114, DOI 10.1521/jscp.1989.8.2.114; TAYLOR SE, 1990, AM PSYCHOL, V45, P40, DOI 10.1037/0003-066X.45.1.40; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHYTE J, 1994, J HEAD TRAUMA REHAB, V9, pR6, DOI 10.1097/00001199-199409000-00002; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	14	34	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1997	12	3					41	50		10.1097/00001199-199706000-00005			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	XC699	WOS:A1997XC69900005					2022-02-06	
J	Deshpande, AA; Millis, SR; Zafonte, RD; Hammond, FM; Wood, DL				Deshpande, AA; Millis, SR; Zafonte, RD; Hammond, FM; Wood, DL			Risk factors for acute care transfer among traumatic brain injury patients	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; YATES CONTINUITY CORRECTION; 2X2 CONTINGENCY-TABLES; REHABILITATION; MANAGEMENT; COMPLICATIONS; HYPONATREMIA; REASONS	Objective: Acute inpatient traumatic brain injury (TBI) rehabilitation has seen a jump in complexity of medical patient care over the past several years, often necessitating transfer back to an acute care facility. The purpose of this study was to determine the association between selected clinical variables and transfer from inpatient rehabilitation to an acute care facility. Design: A retrospective review of cases from 1992 to 1994. Setting: A TBI unit in a freestanding rehabilitation hospital. Patients: Twenty-two patients were identified as having received acute care transfer. This group was compared with 78 patients, admitted in the same interval, who did not require acute care transfer. The variables evaluated included recent surgery, pneumonia, fracture, intracranial blood, tracheostomy use, percutaneous feeding tube use, deep venous thrombosis, focal neurological examination, following simple commands, serum sodium level of <135mmol/L, serum white blood cell count of >11,000 cells/mu L, and serum hemoglobin level of <10.0g/dL. Analysis: Chi-square analysis was performed on the association between acute care transfer and the noted variables. Results: History of pneumonia (p<.03) and history of recent surgery (p<.02) were both associated with acute care transfer, and serum hemoglobin of <10.0g/dL had a trend towards association (p<.10). Conclusion: Physiatrists caring for the TBI patient may warrant more acute observation of individuals with these parameters to prevent the problems necessitating acute care transfer. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	REHABIL INST MICHIGAN,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202								Atchison James W., 1993, Brain Injury, V7, P347, DOI 10.3109/02699059309034961; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CITTAPIETROLUNGO TJ, 1993, ARCH PHYS MED REHAB, V74, P905; Cohen J., 2013, STAT POWER ANAL BEHA; CONOVER WJ, 1974, J AM STAT ASSOC, V69, P374, DOI 10.2307/2285661; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; HAIG AJ, 1990, J OCCUP ENVIRON MED, V32, P241, DOI 10.1097/00043764-199003000-00011; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KEIL MK, 1994, ARCH PHYS MED REHAB, V75, P116; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; MANTEL N, 1974, J AM STAT ASSOC, V69, P378, DOI 10.2307/2285663; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NORUSIS MJ, 1993, SPSS WINDOWS 6 0; POWELL JN, 1994, J HEAD TRAUMA REHABI, V9, P57; SEIGLER EL, 1994, ARCH INTERN MED, V154, P2185; SIVAKUMAR V, 1994, NEUROSURGERY, V34, P269, DOI 10.1227/00006123-199402000-00010; WOO P, 1989, LARYNGOSCOPE, V99, P725; [No title captured]	25	34	34	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1997	78	4					350	352		10.1016/S0003-9993(97)90224-0			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	WT595	WOS:A1997WT59500004	9111452				2022-02-06	
J	Williams, IM; Ponsford, JL; Gibson, KL; Mulhall, LE; Curran, CA; Abel, LA				Williams, IM; Ponsford, JL; Gibson, KL; Mulhall, LE; Curran, CA; Abel, LA			Cerebral control of saccades and neuropsychological test results after head injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						brain injury; saccades; neuropsychology	CORTICAL CONTROL; SUPERIOR COLLICULUS; DIRECTED SACCADES; GUIDED SACCADES; EYE-MOVEMENTS; DISEASE	Abnormalities in the control of saccades have been described in patients with cerebral pathology(1,2). We assessed control of visually guided, reflexive and volitional saccades in 16 patients suffering severe traumatic brain injury and 12 controls and related the results to deficits on neuropsychological tests of speed of information processing and goal directed behaviour. All saccadic latencies were prolonged, Suppression of inappropriate saccades nas impaired on volitional saccade tests which proved to be more sensitive in identifying impairment of goal directed behaviour than the neuropsychological test results. Patients' self-paced saccade rate was lower than controls' and correlated with performance on several visually mediated neuropsychological test results. Patients' visually guided, reflexive saccades were hypometric; this hypometria correlated with both visual and non-visual neuropsychological test results and with post-traumatic amnesia duration. Hypometria in reflexive saccades may reflect diffuse brain injury. Re-examination after 12 months revealed that the control of volitional saccades improved but there was no improvement in the visually guided reflexive saccade measures. The volitional saccade tests may be useful in documenting both impairment and subsequent recovery.	MONASH UNIV, ALFRED HOSP, DEPT MED, NEUROOPHTHALMOL LAB, MELBOURNE, VIC 3181, AUSTRALIA; BETHESDA HOSP, MELBOURNE, VIC, AUSTRALIA; INDIANA UNIV, DEPT OPHTHALMOL, INDIANAPOLIS, IN 46204 USA				Abel, Larry/D-9915-2012	Abel, Larry/0000-0002-2393-0644			ABEL LA, 1984, NEURO-OPHTHALMOLOGY, V4, P21, DOI 10.3109/01658108409019492; ADAMS JH, 1990, HDB CLIN NEUROLOGY, V57, P43; Benton A., 1976, MULTILINGUAL APHASIA; BROWN JW, 1985, HDB CLIN NEUROLOGY, V1, P23; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; DEJONG JD, 1971, EXP NEUROL, V32, P58, DOI 10.1016/0014-4886(71)90165-8; Deng S.-Y., 1986, ADAPTIVE PROCESSES V, P201; FLETCHER WA, 1986, ANN NEUROL, V20, P464, DOI 10.1002/ana.410200405; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GUITTON D, 1985, EXP BRAIN RES, V58, P455; HEYWOOD S, 1975, BASIC MECHANISMS OCU, P561; HOTSON JR, 1982, NEUROLOGY, V32, P31, DOI 10.1212/WNL.32.1.31; KEATING EG, 1986, BEHAV BRAIN RES, V22, P191, DOI 10.1016/0166-4328(86)90064-1; LASKER AG, 1987, NEUROLOGY, V37, P364, DOI 10.1212/WNL.37.3.364; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Milner B., 1964, FRONTAL GRANULAR COR; OHTSUKA K, 1991, NEUROSCI RES, V10, P290, DOI 10.1016/0168-0102(91)90086-E; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; PIERROTDESEILLIGNY C, 1991, EXP BRAIN RES, V83, P607; PIERROTDESEILLIGNY C, 1991, NEURO-OPHTHALMOLOGY, V11, P63, DOI 10.3109/01658109108997298; PIERROTDESEILLIGNY C, 1991, J NEUROL NEUROSUR PS, V54, P1106, DOI 10.1136/jnnp.54.12.1106; POSNER MI, 1984, J NEUROSCI, V4, P1863; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHARPE JA, 1982, NEUROLOGY, V32, P57, DOI 10.1212/WNL.32.1.57; SHARPE JA, 1986, ADAPTIVE PROCESSES V, P239; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith, 1973, SYMBOL DIGIT MODALIT; TEDESCHI G, 1983, PSYCHOPHARMACOLOGY, V79, P190, DOI 10.1007/BF00427810; TEDESCHI G, 1989, EUR J CLIN PHARMACOL, V37, P513, DOI 10.1007/BF00558133; Tusa R J, 1989, Bull Soc Belge Ophtalmol, V237, P67; WURTZ RH, 1986, PROGR BRAIN RES OCUL, V64, P190	33	34	34	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	1997	4	2					186	196		10.1016/S0967-5868(97)90072-2			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WQ637	WOS:A1997WQ63700015	18638954				2022-02-06	
J	BakerPrice, LA; Persinger, MA				BakerPrice, LA; Persinger, MA			Weak, but complex pulsed magnetic fields may reduce depression following traumatic brain injury	PERCEPTUAL AND MOTOR SKILLS			English	Article							CLINICAL POPULATIONS; NORMATIVE DATA; EPILEPSY; PHENOMENOLOGY; STIMULATION; INDEXES; SENSE	Many patients who display psychological depression following a traumatic brain injury do not respond completely to antidepressant drugs. We hypothesized that this type of depression is strongly correlated with subclinical, complex partial seizure-activity within the hippocampal-amygdaloid region that continues for months to years after apparent neurological and behavioral ''recovery.'' Four depressed patients who had sustained traumatic brain injuries and who exhibited mild to moderate brain impairment according to standardized tests received 30 min. of weak (1 mu T) burst-firing magnetic fields across the temporal lobes once per week for 5 weeks. There was a significant improvement of depression and reduction of phobias while physical symptoms and other complaints were not changed.	LAURENTIAN UNIV,DEPT PSYCHOL,CLIN NEUROPSYCHOL LAB,SUDBURY,ON P3E 2C6,CANADA								BANCAUD J, 1994, BRAIN, V117, P71, DOI 10.1093/brain/117.1.71; Beck AT, 1987, BECK DEPRESSION INVE; BUREAU YRJ, 1995, ELECTRO MAGNETOBIOL, V14, P1, DOI 10.3109/15368379509028464; DEROGATIS LR, 1994, S CHECK LIST 90 R MI; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; GILLIS C, 1993, PERCEPT MOTOR SKILL, V76, P168, DOI 10.2466/pms.1993.76.1.168; JACOBSON JI, 1994, PANMINERVA MED, V36, P201; JOFFE TR, 1994, ANTICONVULSANTS MOOD; JOHN ER, 1990, MACHINERY OF THE MIND, P27; PERSINGER MA, 1995, PERCEPT MOTOR SKILL, V80, P1011, DOI 10.2466/pms.1995.80.3.1011; Persinger MA, 1995, PERCEPT MOTOR SKILL, V81, P1283, DOI 10.2466/pms.1995.81.3f.1283; PERSINGER MA, 1994, INT J NEUROSCI, V79, P191, DOI 10.3109/00207459408986080; PERSINGER MA, 1993, J CLIN PSYCHOL, V49, P33, DOI 10.1002/1097-4679(199301)49:1<33::AID-JCLP2270490106>3.0.CO;2-H; PERSINGER MA, 1994, PSYCHOL REP, V75, P1059, DOI 10.2466/pr0.1994.75.3.1059; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; PERSINGER MA, 1993, HEALING SUFFERING DE, P227; RICHARDS PM, 1993, INT J NEUROSCI, V71, P71, DOI 10.3109/00207459309000594; Richards PM, 1996, ELECTRO MAGNETOBIOL, V15, P141, DOI 10.3109/15368379609009830; ROBERTS RJ, 1992, EPILEPSY RES, V13, P167, DOI 10.1016/0920-1211(92)90073-3; ROBERTSON MM, 1987, EPILEPSIA, V28, P364, DOI 10.1111/j.1528-1157.1987.tb03659.x; RUTTAN LA, 1990, J BIOELECTRICITY, V9, P33, DOI 10.3109/15368379009027758; SANDYK R, 1994, INT J NEUROSCI, V77, P203, DOI 10.3109/00207459408986032; SANDYK R, 1995, INT J NEUROSCI, V81, P199, DOI 10.3109/00207459509004887; SANDYK R, 1994, INT J NEUROSCI, V75, P213, DOI 10.3109/00207459408986305; TILLER SG, 1994, INT J NEUROSCI, V79, P157, DOI 10.3109/00207459408986076; WAHLER HJ, 1973, WAHLER PHYSICAL SYMP; ZYSS T, 1994, MED HYPOTHESES, V43, P69, DOI 10.1016/0306-9877(94)90052-3	27	34	34	0	0	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	OCT	1996	83	2					491	498		10.2466/pms.1996.83.2.491			8	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	VL128	WOS:A1996VL12800023	8902023				2022-02-06	
J	High, WM; Hall, KM; Rosenthal, M; Mann, N; Zafonte, R; Cifu, DX; Boake, C; Bartha, M; Ivanhoe, C; Yablon, S; Newton, CN; Sherer, M; Silver, B; Lehmkuhl, LD				High, WM; Hall, KM; Rosenthal, M; Mann, N; Zafonte, R; Cifu, DX; Boake, C; Bartha, M; Ivanhoe, C; Yablon, S; Newton, CN; Sherer, M; Silver, B; Lehmkuhl, LD			Factors affecting hospital length of stay and charges following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed head injury; duration of impaired consciousness; Functional Independence Measure; length of stay	FUNCTIONAL INDEPENDENCE MEASURE; HEAD-INJURY; INPATIENT REHABILITATION; MILD; PREDICTION; COMA	Objective: To examine the effect of initial severity of traumatic brain injury (TBI), level of functional independence at admission to rehabilitation, medical complications, mechanism of injury, and payer source on hospital length of stay (LOS) and charges. Design: Cohort analysis. Setting: Inpatient rehabilitation. Patients: 525 subjects from the National Institute on Disability and Rehabilitation Research TBI Model Systems National Data Base with relatively mild to severe TBI, an average Glasgow Coma Scale (GCS) score of 8.5 (SD=3.9), and average duration of impaired consciousness (DIC) of 15.1 days (SD=40.6). Intervention: Inpatient rehabilitation. Main Outcome Measures: Hospital LOS, hospital charges. Results: Persons with lower initial GCS scores generally reached the rehabilitation setting later and stayed longer than persons with higher initial GCS scores. Within each GCS level, lower initial Functional independence Measure (FIM) scores were associated with longer acute care and rehabilitation LOS. For persons admitted to rehabilitation with relatively high or medium FIM scores, greater severity of injury resulted in relatively modest increases in rehabilitation LOS. In contrast, low admission FIM scores were associated with much longer rehabilitation LOS for patients with severe injuries, compared with those with relatively mild injuries. Initial GCS score, DIC, admission FIM, and acute LOS accounted for 48% (adjusted R(2)) of the variance in rehabilitation LOS and 42% of the variance in rehabilitation hospital charges. Of the medical complications examined, only neurologic complications and intracranial operations added significantly to the model, explaining an additional 2% of the variance In rehabilitation LOS. The effect of payer source on LOS is complicated by age as well as by severity and mechanism of injury. Conclusions: Age, severity of injury, and medical complications are powerful predictors of rehabilitation LOS and hospital charges. Other factors, such as functional independence at rehabilitation admission and length of acute hospitalization, explain additional variance. None of these factors in isolation is able to sufficiently predict rehabilitation LOS or charges. Multidimensional analysis of these factors is necessary to plan or administer the delivery of brain injury services.	BAYLOR COLL MED,HOUSTON,TX 77030; SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128; WAYNE STATE UNIV,DETROIT,MI; REHABIL INST MICHIGAN,DETROIT,MI; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA					Cifu, David/0000-0003-1600-9387			Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; CIFU DX, IN PRESS ARCH PHYS M; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LONG WB, 1994, ARCH PHYS MED REHAB, V75, P144; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; SEIGEL JH, 1991, CRIT CARE MED, V19, P1252; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS RJL, 1994, J ROY SOC MED, V87, P83; [No title captured]	24	34	34	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					85	96		10.1097/00001199-199610000-00008			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300008					2022-02-06	
J	Rossi, C; Sullivan, SJ				Rossi, C; Sullivan, SJ			Motor fitness in children and adolescents with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; RECOVERY; RELIABILITY	Objective: This study examined the test-retest reliability of selected motor fitness test items among children with severe traumatic brain injury. Design: A cohort study consisting of two testing session, one week apart. Setting: All subjects were recruited from among the former clients of a pediatric rehabilitation center. Subjects: A convenience sample of 19 subjects, 13 boys and 6 girls aged 8 to 17 years, volunteered to participate, All participants had a diagnosis of a severe traumatic brain injury ((X) over bar +/- SD = 5.88 +/- 1.71 on the Glascow Coma Scale), had completed a program of physical rehabilitation. and were evaluated at 4.16 +/- 2.61 years after their injury. Main Outcome Measures: Performance on twelve motor fitness test items (including flexibility, agility, muscular strength. cardiorespiratory endurance, power, muscular endurance. and coordination) was measured at each of two structured evaluation sessions. Results: No differences (t tests, p less than or equal to.05) were found between the performances on the two testing sessions for any of the variables. The test-retest reliability was established via the intraclass correlation (ICC) and ranged from .84 to .98, indicating ''almost perfect'' agreement. Conclusion: The data indicate that these motor fitness testing protocols are reliable and applicable to traumatic brain injured children in a clinical setting and can thus be used by therapists to plan future interventions to improve the fitness of this clientele. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	CONCORDIA UNIV,DEPT EXERCISE SCI,MONTREAL,PQ,CANADA; UNIV MONTREAL,FAC MED,ECOLE READAPTAT,MONTREAL,PQ H3C 3J7,CANADA; INST READAPTAT MONTREAL,CTR RECH,MONTREAL,PQ,CANADA								*AM ALL HLTH PHYS, 1980, TECHNICAL MANUAL HLT; AYRES AJ, 1976, INTERPRETING SO CALI; BARROW HM, 1989, PRACTICAL MEASUREMEN, P99; BLASKEY J, 1984, PEDIAT NEUROLOGIC PH, P213; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Bruininks, 1978, BRUININKS OSERETSKY; CASEY R, 1986, PEDIATRICS, V78, P497; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; CURETON TK, 1964, CHILD DEV PUBLICATIO; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FLEISHMAN EA, 1964, STRUCTURE MEASUREMEN, P58; GLENCROSS DJ, 1966, RES QUART, V37, P353, DOI 10.1080/10671188.1966.10614761; GRUBER JJ, 1964, TESTS MEASUREMENTS L; HALEY S M, 1991, Physical and Occupational Therapy in Pediatrics, V11, P1; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; JACKSON AS, 1967, RES QUART, V40, P708; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAFFE MB, 1985, HEAD INJURY REHABILI, P167; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON RB, 1980, DEV MED CHILD NEUROL, V22, P3; Kirkendall D., 1987, MEASUREMENT EVALUATI; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEGER L, 1992, CAN J APPL SPT SCI, V9, P64; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LIU NYS, 1992, RES Q EXERCISE SPORT, V63, P360, DOI 10.1080/02701367.1992.10608757; Pate R.R., 1983, PHYSICIAN SPORTSMED, V11, P77, DOI [10.1080/00913847.1983.11708509, DOI 10.1080/00913847.1983.11708509]; PATE RR, 1991, J SCHOOL HEALTH, V61, P231, DOI 10.1111/j.1746-1561.1991.tb06021.x; PERRIN JC, 1985, PEDIAT REHABILITATIO, P254; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; SAFRIT MJ, 1981, EVALUATION PHYSICAL; SHICK J, 1970, RES QUART, V41, P88, DOI 10.1080/10671188.1970.10614951; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SHUMWAYCOOK A, 1992, PHYS MED REHABIL CLI, V3, P355; VITALE AE, IN PRESS BRAIN INJ; WINNICK JP, 1985, PHYSICAL FITNESS TES; [No title captured]	41	34	34	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1996	77	10					1062	1065		10.1016/S0003-9993(96)90069-6			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	VL132	WOS:A1996VL13200012	8857887				2022-02-06	
J	Petty, MA; Poulet, P; Haas, A; Namer, IJ; Wagner, J				Petty, MA; Poulet, P; Haas, A; Namer, IJ; Wagner, J			Reduction of traumatic brain injury-induced cerebral oedema by a free radical scavenger	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						head injury; edema; antioxidant free radical scavenger; magnetic resonance imaging	ARACHIDONIC-ACID METABOLISM; EXPERIMENTAL HEAD-INJURY; SUPEROXIDE-DISMUTASE; 21-AMINOSTEROID U74006F; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; EDEMA; RAT; TISSUE; MICE	Oxygen derived free radicals have been proposed to be in part responsible for the cerebral oedema resulting from head injury. In the present study the effects of free radical suppression with MDL 74,180 (2,3-dihydro-2,2,4,6,7-pentamethyl-3 -(4-methylpiperazino)-methyl-1-benzofuran-5-ol dihydrochloride), an alpha-tocopherol analogue free radical scavenger, on the development of cerebral oedema resulting from head injury has been assessed. Fluid percussion head injury in rats caused a regional oedema 48 h after injury. Infusion of MDL 74,180 for 2 h after the injury significantly attenuated oedema development in a dose-related manner, Using magnetic resonance imaging, cerebral oedema development was monitored in head injured mice, Oedema was apparent 4 h after head injury and was greatest in the vicinity of the olfactory bulb and surrounding the ventricles. Treatment with MDL 74,180 (1-10 mu g/kg intravenously, administered 3-5 min after the injury) significantly reduced the oedema development. MDL 74,180 is a potential treatment for the oedema caused as a result of head injury.	FAC MED,INST BIOL PHYS,STRASBOURG,FRANCE		Petty, MA (corresponding author), MARION MERRELL,16 RUE ANKARA,F-67080 STRASBOURG,FRANCE.		Poulet, Patrick/AAD-1438-2020; Poulet, Patrick/AAG-7783-2021; Poulet, Patrick/A-2001-2012; NAMER, Izzie-Jacques/AAS-7224-2020	NAMER, Izzie-Jacques/0000-0003-1822-7759; Poulet, Patrick/0000-0001-7998-9672			Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; Bolkenius FN, 1996, EUR J PHARMACOL, V298, P37, DOI 10.1016/0014-2999(95)00768-7; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1989, J NEUROTRAUM, V6, P144; IKEDA Y, 1989, Neurological Research, V11, P213; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MILLER JD, 1993, 2 INT NEUR S; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; WEI E, 1981, CIRC RES, V49, P95; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166	29	34	36	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	JUN 27	1996	307	2					149	155		10.1016/0014-2999(96)00235-X			7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	UY106	WOS:A1996UY10600004	8832216				2022-02-06	
J	Novack, TA; Caldwell, SG; Duke, LW; Bergquist, TF; Gage, RJ				Novack, TA; Caldwell, SG; Duke, LW; Bergquist, TF; Gage, RJ			Focused versus unstructured intervention for attention deficits after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; PROGRAM	Objective: To examine the effectiveness of focused versus unstructured cognitive remediation to address attention deficits following traumatic brain injury (TBT). Based on previous reports on postacute TBI subjects, it was hypothesized that focused intervention would yield superior results. Design: Intervention study with pre- and posttreatment data collection. Setting: Acute rehabilitation hospital. Patients: Sixty-one consecutive patients with severe TBI referred for cognitive remediation were randomly assigned to focused or unstructured remediation of attention deficits. From this sample, 22 pairs were selected, matched for age, education, time postonset of injury, and number of remediation sessions. Interventions: Structured, hierarchical interventions were presented to the focused group. The unstructured group participated in nonsequential, nonhierarchical activities. The average number of sessions was 20. Main Outcome Measures: Digit Span, Mental Control, Simple and Choice Reaction Time, Functional Independence Measure, selected neuropsychological tests. Results: No significant group differences were detected in attentional skills, functional skills, or general cognitive abilities. Conclusions: Progress in attentional skills during acute rehabilitation after TBI is similar with focused and unstructured cognitive remediation.	UNIV ALABAMA,DEPT REHABIL MED,BIRMINGHAM,AL; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294; CARLE CLIN ASSOC,URBANA,IL; PALMYRA REG REHAB CTR,DEPT PSYCHOL NEUROPSYCHOL,ALBANY,GA								ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Benton A., 1978, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Carter LT, 1980, THINKING SKILLS WORK; DAVIES A, 1968, J CLIN PSYCHOL, V24, P96; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; DUKE LW, 1992, HDB HEAD TRAUMA ACUT; Gansler D A, 1991, Arch Clin Neuropsychol, V6, P335, DOI 10.1016/0887-6177(91)90010-7; Golden CJ, 1978, STROOP COLOR WORD TE; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hamilton BB, 1987, REHABILITATION OUTCO; HARNADEK A, 1979, BASIC THINKING SKILL; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KILPATRICK K, 1977, THERAPY GUIDE ADULT; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POSNER MI, 1987, NEUROPSYCHOLOGICAL R; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Wechsler D, 1987, MEMORY SCALE REVISED; Wilkinson, 1984, WIDE RANGE ACHIEVEME	21	34	35	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					52	60		10.1097/00001199-199606000-00008			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400008					2022-02-06	
J	Suuronen, P; Lehtonen, E; Tschernij, V; Larsson, PO				Suuronen, P; Lehtonen, E; Tschernij, V; Larsson, PO			Skin injury and mortality of Baltic cod escaping from trawl codends equipped with exit windows	ARCHIVE OF FISHERY AND MARINE RESEARCH			English	Article								Skin injury and mortality of Baltic cod (Gadus morhua L.) escaping from trawl codends equipped with two different types of 95 mm exit window were investigated between May and June 1994 in the southern Baltic Sea (ICES Subdivision 25). Fish escaping through the end of an open codend extension (i.e. the trawl was towed without the codend) were also studied. Escaping fish were collected in a small mesh cage that was released from the codend cover, closed and then slowly towed to the cage site. In total, nine valid hauls were completed, and 261 cod (24 to 50 cm long) were held in cages for a period of 10 to 14 days. Only two escapees (34 and 36 cm) died during the experiment; both fish died during the first caging day. The degree of skin injury of fish was examined after cagings. Scale loss was the predominant visible skin injury; the main area of injury for most specimens was the posterior half of the body. Other skin injuries included lesions around the flank and snout, and dark 'net marks' behind the head. Scale loss was observed in 29 of 109 (27 %) cod that had escaped through exit windows codends. The average injured area was 2.5 % of the total skin area. For the open codend escapees, 48 of 139 (35 %) fish examined exhibited scale loss, and the average injured area was 2.3 % of the total skin area. No clear relationship existed between the degree of skin injury and fish size. Most of the observed skin injuries were probably caused by mechanical abrasion while fish were inside the trawl.	SWEDISH BOARD FISHERIES,BALT SEA RES STN,S-37137 KARLSKRONA,SWEDEN; INST MARINE RES,LYSEKIL,SWEDEN		Suuronen, P (corresponding author), FINNISH GAME & FISHERIES RES INST,POB 202,FIN-00151 HELSINKI,FINLAND.						CHAMBERS J, 1992, STAT MODELS S PACIFI, V15; CHOPIN FS, 1995, FISH RES, V21, P315, DOI 10.1016/0165-7836(94)00301-C; Hastie T. J., 1990, GEN ADDITIVE MODELS; HAY DE, 1986, FISH RES, V4, P191, DOI 10.1016/0165-7836(86)90002-0; HILDEN M, 1996, IN PRESS ECOL EC; JACOBSEN JA, 1992, INT COUNC EXPLOR SEA, V29; JONSSON E, 1994, INT COUNC EXPLOR SEA, V16; LARSSON PO, 1988, INT COUNC EXPLOR SEA, V57; LOCKWOOD SJ, 1983, FISH RES, V2, P129, DOI 10.1016/0165-7836(83)90114-5; LOWRY N, 1994, INT COUNC EXPLOR SEA, V29; LOWRY N, 1995, INT COUNC EXPLOR SEA, V5; MAIN J, 1991, 1891 SCOTT FISH; MAIN J, 1981, 23 SCOTT FISH; MARTEINSSON JE, 1991, SKADER PA FISK SOM S; NETZEL J, 1989, INT COUNC EXPLOR SEA, V54; OTTERLIND G, 1960, INT COUNC EXPLOR SEA, V204; ROALD SV, 1980, INT COUNC EXPLOR SEA, V34; Robinson W. E., 1993, NA26FD003901 NOAA; Sangster GI, 1996, FISH RES, V25, P323, DOI 10.1016/0165-7836(95)00430-0; SANGSTER GI, 1992, INT COUNC EXPLOR SEA, V30; SOLDAL A, 1994, TEMA NORD, V521, P37; SOLDAL AV, 1993, ICES MAR SC, V196, P122; SOLDAL AV, 1993, INT COUNC EXPL SEA W; SOLDAL AV, 1991, INT COUNC EXPLOR SEA, V44; SPARHOLD H, 1995, P C BALT FISH WARN G, P43; Suuronen P, 1996, ICES J MAR SCI, V53, P691, DOI 10.1006/jmsc.1996.0088; Thurow F., 1993, International Council for the Exploration of the Sea Cooperative Research Report, V186, P20; THUROW F, 1976, INT COUNC EXPLOR SEA, V4; ZAFERMAN ML, 1989, INT COUNC EXPLOR SEA, V18; 1991, INT COUNC EXPLOR SEA, V16; [No title captured]; 1994, INT COUNC EXPLOR SEA, V17; 1995, INT COUNC EXPLOR SEA, V18	33	34	35	0	5	GUSTAV FISCHER VERLAG	JENA	VILLENGANG 2, D-07745 JENA, GERMANY	0944-1921			ARCH FISH MAR RES	Arch. Fish. Mar. Res.		1996	44	3					165	178					14	Fisheries	Science Citation Index Expanded (SCI-EXPANDED)	Fisheries	WG934	WOS:A1996WG93400001					2022-02-06	
J	FELDMAN, Z; ZACHARI, S; REICHENTHAL, E; ARTRU, AA; SHAPIRA, Y				FELDMAN, Z; ZACHARI, S; REICHENTHAL, E; ARTRU, AA; SHAPIRA, Y			BRAIN EDEMA AND NEUROLOGICAL STATUS WITH RAPID INFUSION OF LACTATED RINGERS OR 5-PERCENT DEXTROSE SOLUTION FOLLOWING HEAD TRAUMA	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; BRAIN EDEMA; NEUROLOGICAL OUTCOME; RINGERS SOLUTION; DEXTROSE; RAT	HYPERTONIC SALINE 7.5-PERCENT; HEMORRHAGIC-SHOCK; CEREBRAL HEMODYNAMICS; COLLOID SOLUTIONS; RESUSCITATION; INJURY; FLUID; HYPERGLYCEMIA; RAT; METABOLISM	Rapid infusion of 0.25 ml/g of 0.98 saline over 30 minutes has been shown to have no effect on electrolyte balance, neurological severity score (NSS), or brain edema, following closed head trauma (CHT). Rapid infusion of the same volume of 5% dextrose solution decreased blood sodium concentration, increased edema, and decreased NSS following CHT. In the present study the authors examined the effect of rapid infusion (30 minutes) of smaller volumes of 5% dextrose (0.08 ml/g and 0.16 ml/g) and of 0.25 ml/g lactated Ringer's solution on blood electrolyte concentrations, plasma osmolality, brain edema, and NSS. The purposes of this study were to determine whether rapid infusion of a large volume of lactated Ringer's solution could be given after CHT without increasing mortality or brain edema or producing electrolyte disturbances, and whether small volumes of 5% dextrose could be infused with few or none of the deleterious effects expected from large volumes of 5% dextrose. One hundred eighteen mts, which survived halothone anesthesia and CHT, were randomly assigned to one of 15 experimental groups. Fluids were administered beginning 1 hour after scalp incision or CHT. The NSS, extent of edema, blood electrolyte concentrations, and plasma osmolality in the groups treated with lactated Ringer's solution were not significantly different from those values in the nontreated groups. In addition, the mortality rate after CHT was not increased by administration of lactated Ringer's solution. The groups treated with 5% dextrose solution showed a significantly higher mortality rate, but the NSSs of the surviving rats were not different from controls. None of the groups treated with 0.16 ml/g 5% dextrose solution survived 24 hours. Although blood glucose concentration increased to 1126 +/- 102 g% (mean +/- standard deviation) and 1568 +/- 283 g% and blood sodium concentration decreased to 110.4 +/- 4.6 mEq/L and 91.0 +/- 5.2 mEq/L in the groups treated with 0.08 ml/g and 0.16 ml/g of 5% dextrose solution, respectively, plasma osmolality was normal and no significant difference could be found between the brain tissue specific gravity of animals in the nontreated and 5% dextrose treatment groups. It is concluded that in the CHT model used in this study, the large volume of lactated Ringer's solution did not affect blood electrolyte concentration, neurological outcome, or formation of brain edema, whereas smaller volumes of 5% dextrose solution increased blood glucose and decreased blood sodium concentrations, did not affect plasma osmolality, and had a deleterious effect on neurological outcome.	BEN GURION UNIV NEGEV,SOROKA MED CTR,DEPT NEUROSURG,IL-84105 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,SOROKA MED CTR,DEPT ANESTHESIOL,IL-84105 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,IL-84105 BEER SHEVA,ISRAEL; WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA					Feldman, Zeev/0000-0002-9719-3894			BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; COLLINS WF, 1974, PRINCIPLES SURGERY, P1631; DOMINO KB, 1989, ASA ANN REFRESHER CO, V115; DRUMMOND JC, 1992, ASA ANN REFRESHER CO, V116; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GUNNAR W, 1988, SURGERY, V103, P398; KRAMER GC, 1986, SURGERY, V100, P239; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MCCORNISH PB, 1971, ANESTHESIA NEUROLOGI, P304; PETERS RM, 1986, SURG GYNECOL OBSTET, V163, P219; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; POOLE GV, 1986, CRIT CARE MED, V14, P629, DOI 10.1097/00003246-198607000-00009; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHENKIN HA, 1976, J NEUROSURG, V45, P432, DOI 10.3171/jns.1976.45.4.0432; THOMAS LM, 1973, NEUROLOGICAL SURGERY, P956; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; WARNER DS, 1988, ANESTHESIOLOGY, V68, P86, DOI 10.1097/00000542-198801000-00014; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	29	34	35	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	1995	83	6					1060	1066		10.3171/jns.1995.83.6.1060			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	TG914	WOS:A1995TG91400017	7490621				2022-02-06	
J	KEMP, PM; HOUSTON, AS; MACLEOD, MA; PETHYBRIDGE, RJ				KEMP, PM; HOUSTON, AS; MACLEOD, MA; PETHYBRIDGE, RJ			CEREBRAL PERFUSION AND PSYCHOMETRIC TESTING IN MILITARY AMATEUR BOXERS AND CONTROLS	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						BOXING; PSYCHOMETRICS; SPECT	CHRONIC BRAIN-DAMAGE; CLOSED-HEAD-INJURY; ALZHEIMERS-DISEASE; BOXING LEAD; COMPUTED-TOMOGRAPHY; BLOOD-FLOW; TECHNETIUM-99M-HMPAO SPECT; CT; AFTERMATH; DEMENTIA	The objective was to compare two neurophysiological variables in active amateur boxers with non-boxing sportsmen. 41 boxers and 27 controls were given psychometric tests: 34 boxers and 34 controls underwent technetium-99m hexamethylpropyleneamineoxime single photon emission computerised tomography (Tc99m HMPAO SPECT) cerebral perfusion scans. The controls performed better at most aspects of the psychometric tests. Boxers who had fought fewer bouts had a tendency to perform better at psychometric tests than those boxers who had fought more bouts. Tc-99m HMPAO SPECT cerebral perfusion scanning showed that controls had less aberrations in cerebral perfusion than the boxers. In conclusion, significant differences were shown in two neurophysiological variables between young amateur sportsmen who box and those who do not. The long term effects of these findings remain unknown.	INST NAVAL MED,DEPT MED,GOSPORT PO12 2DL,HANTS,ENGLAND		KEMP, PM (corresponding author), ROYAL NAVAL HOSP,DEPT NUCL MED,GOSPORT,HANTS,ENGLAND.						AINSWORTH ME, 1965, THESIS U MANCHESTER; AZARI NP, 1993, J CEREBR BLOOD F MET, V13, P438, DOI 10.1038/jcbfm.1993.58; BARBER DC, 1992, PHYS MED BIOL, V37, P1485, DOI 10.1088/0031-9155/37/7/002; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CLARK C, 1985, J CEREBR BLOOD F MET, V5, P142, DOI 10.1038/jcbfm.1985.18; CLARK CM, 1991, J CEREBR BLOOD F MET, V11, pA96, DOI 10.1038/jcbfm.1991.44; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; FAZEKAS F, 1989, J NUCL MED, V30, P1607; GEMMELL HG, 1990, J NUCL MED, V31, P1595; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GRONWALL D, 1975, LANCET, V2, P995; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HOUSTON AS, 1994, J NUCL MED, V35, P239; HOUSTON AS, 1992, IEE C PUBL, V354, P369; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; KASTE M, 1982, LANCET, V2, P1186; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MCKEITH IG, 1993, BRIT J PSYCHIAT, V163, P597, DOI 10.1192/bjp.163.5.597; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MESSA C, 1994, J NUCL MED, V35, P210; MONTALDI D, 1990, J NEUROL NEUROSUR PS, V53, P33, DOI 10.1136/jnnp.53.1.33; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROPER SN, 1991, J NUCL MED, V32, P1684; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SMITH M, 1988, USERS MANUAL ESSEX C; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; TEASDALE G, 1986, CLOSED HEAD INJURY P; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TURNAGE JJ, 1992, ERGONOMICS, V35, P1271, DOI 10.1080/00140139208967393; UNTERHARNSCHEID.FJ, 1975, HDB CLIN NEUROLOGY, V23, P527; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267	43	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	1995	59	4					368	374		10.1136/jnnp.59.4.368			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	RX450	WOS:A1995RX45000006	7561914	Green Published, Bronze			2022-02-06	
J	UNSAL, A; SEGALOWITZ, SJ				UNSAL, A; SEGALOWITZ, SJ			SOURCES OF P300 ATTENUATION AFTER HEAD-INJURY - SINGLE-TRIAL AMPLITUDE, LATENCY JITTER, AND EEG POWER	PSYCHOPHYSIOLOGY			English	Article						P300; LATENCY JITTER; SINGLE-TRIAL ANALYSIS; TRAUMATIC BRAIN INJURY	VARIABILITY; RECOGNITION; PERFORMANCE; POTENTIALS; INTENSITY; TIME	Single trial amplitude, latency jitter, and electroencephalographic (EEG) power were examined as sources of the group difference in averaged P300 amplitude among 15 traumatically brain injured and 20 control individuals in an auditory oddball paradigm. Mean amplitude of the individual trials was highly correlated with the amplitude of the averaged P300, with little additional unique variance attributable to latency jitter or EEC power. The group difference in P300 amplitude was also explained by the mean amplitude of the single trials. These results support the robustness of the event-related potential averaging technique within the paradigm used.	BROCK UNIV,DEPT PSYCHOL,ST CATHARINES,ON L2S 3A1,CANADA		UNSAL, A (corresponding author), MCMASTER UNIV,MED CTR,DEPT PSYCHIAT,HAMILTON,ON L8N 3Z5,CANADA.						Campbell K., 1986, ELECTROENCEPHALOGR S, V38, P486; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Deacon-Elliott D., 1987, COGNITIVE REHABILITA, V5, P12; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DUNCANJOHNSON CC, 1979, PSYCHOPHYSIOLOGY, V16, P53, DOI 10.1111/j.1469-8986.1979.tb01440.x; Fabiani M., 1987, ADV PSYCHOPHYSIOLOGY, V2, P1; FEIN G, 1989, ELECTROEN CLIN NEURO, V72, P384, DOI 10.1016/0013-4694(89)90044-8; FORD JM, 1994, BIOL PSYCHIAT, V35, P96, DOI 10.1016/0006-3223(94)91198-3; Isreal J B, 1980, Prog Brain Res, V54, P416, DOI 10.1016/S0079-6123(08)61653-2; JASIUKAITIS P, 1988, PSYCHOPHYSIOLOGY, V25, P157, DOI 10.1111/j.1469-8986.1988.tb00979.x; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; MCCARTHY G, 1983, SCIENCE, V211, P77; MICHALEWSKI HJ, 1986, ELECTROEN CLIN NEURO, V65, P59, DOI 10.1016/0168-5597(86)90037-7; OLBRICH HM, 1986, FORTSCHR NEUROL PSYC, V54, P182, DOI 10.1055/s-2007-1001863; PAPANICOLAOU AC, 1985, PSYCHOPHYSIOLOGY, V22, P326, DOI 10.1111/j.1469-8986.1985.tb01608.x; PARASURAMAN R, 1982, PERCEPT PSYCHOPHYS, V31, P1, DOI 10.3758/BF03206196; Pedhazur E. J., 1982, MULTIPLE REGRESSION; PICTON TW, 1988, HDB ELECTROENCEPHALO, P361; ROTH WT, 1984, PSYCHOPHYSIOLOGY, V21, P466, DOI 10.1111/j.1469-8986.1984.tb00228.x; RUCHKIN DS, 1978, MULTIDISCIPLINARY PE; RUCHKIN DS, 1988, HUMAN EVENT RELATED, V3, P7; SEGALOWITZ NS, 1993, APPL PSYCHOLINGUIST, V14, P369, DOI 10.1017/S0142716400010845; SEGALOWITZ SJ, 1994, UNPUB SPEED VARIABIL; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742	24	34	35	0	0	SOC PSYCHOPHYSIOL RES	WASHINGTON	1010 VERMONT AVE NW SUITE 1100, WASHINGTON, DC 20005	0048-5772			PSYCHOPHYSIOLOGY	Psychophysiology	MAY	1995	32	3					249	256		10.1111/j.1469-8986.1995.tb02953.x			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	QV891	WOS:A1995QV89100006	7784533				2022-02-06	
J	HARTL, R; SCHURER, L; GOETZ, C; BERGER, S; ROHRICH, F; BAETHMANN, A				HARTL, R; SCHURER, L; GOETZ, C; BERGER, S; ROHRICH, F; BAETHMANN, A			THE EFFECT OF HYPERTONIC FLUID RESUSCITATION ON BRAIN EDEMA IN RABBITS SUBJECTED TO BRAIN INJURY AND HEMORRHAGIC-SHOCK	SHOCK			English	Article							SMALL-VOLUME RESUSCITATION; CEREBRAL WATER-CONTENT; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; HYPERONCOTIC SOLUTIONS; HYDROCEPHALIC RABBITS; SALINE RESUSCITATION; DOGS; HYPERTENSION	Small-volume resuscitation with 7.2% NaCl/10% dextran 60 (HHS) restores cardiovascular stability faster than all other therapeutic modalities currently known. This study was undertaken to elucidate the effects of HHS on the brain, specifically on the formation of posttraumatic brain edema, HHS was administered to anesthetized albino rabbits with or without a focal cryogenic brain lesion and hemorrhagic shock. Specific gravity of small tissue samples was determined 4 h after injury and values were topographically assembled to form a color-coded map of both hemispheres, allowing for a high resolution mapping of brain edema. Cerebral blood flow on the side of the lesion, as assessed by the H-2 clearance method, increased transiently after injury but remained unchanged from baseline during shock and after infusion of HHS, indicating intact cerebrovascular autoregulation. The cryogenic lesion without subsequent HHS infusion resulted in significant brain edema formation in grey and white matter of the exposed hemisphere, In injured animals resuscitation with HHS led to a global reduction of brain water content in both hemispheres, We conclude that small-volume resuscitation with HHS does not worsen posttraumatic brain edema. To the contrary, our results show that it decreases cerebral water content even in regions close to the injury. This makes it worthwhile to investigate the benefits of HHS for the treatment of intracranial hypertension.	UNIV HEIDELBERG, KLINIKUM MANNHEIM, DEPT NEUROSURG, HEIDELBERG, GERMANY; UNIV MAINZ, DEPT PEDIAT SURG, MAINZ, GERMANY; ZENT KLIN BAD BERKA, DEPT NEUROSURG, BAD BERKA, GERMANY; UNIV MUNICH, INST SURG RES, MUNICH, GERMANY; UNIV MUNICH, DEPT NEUROSURG, MUNICH, GERMANY		HARTL, R (corresponding author), CORNELL UNIV, COLL MED,DEPT SURG,DIV NEUROSURG, AITKEN NEUROSURG LAB,1300 YORK AVE, ROOM LC 807, NEW YORK, NY 10021 USA.						AUKLAND K, 1965, ACTA NEUROL SCAND, VS 41, P42; BATTISTELLA F, 1992, CIRC SHOCK, V37, P16; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BERGER S, 1993, ZBL CHIR, V118, P237; BERGER S, IN PRESS NEUROSURGER; DELBIGIO MR, 1987, PEDIATR NEUROSCI, V13, P72, DOI 10.1159/000120304; GO KG, 1972, J NEUROL SCI, V16, P209, DOI 10.1016/0022-510X(72)90090-1; Groger U, 1990, Adv Neurol, V52, P215; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HERRMANN HD, 1972, EXP NEUROL, V34, P115, DOI 10.1016/0014-4886(72)90192-6; KITA H, 1994, ACTA NEUROCHIR, P452; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOROSUE K, 1990, J NEUROSURG, V73, P576, DOI 10.3171/jns.1990.73.4.0576; KRAMER GC, 1986, SURGERY, V100, P239; KREIMEIER U, 1988, EUR SURG RES, V20, P277, DOI 10.1159/000128773; KREIMEIER U, 1990, J SURG RES, V49, P493, DOI 10.1016/0022-4804(90)90174-Z; KREIMEIER U, 1993, CURR OPIN ANESTHESIO, V6, P400; KUROIWA T, 1985, ACTA NEUROPATHOL, V66, P3, DOI 10.1007/BF00698288; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P549; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629, DOI 10.1152/ajpheart.1988.255.3.H629; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MURR R, 1992, CURR OPIN ANAESTH, V5, P285; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; PERTOFT H, 1978, ANAL BIOCHEM, V88, P271, DOI 10.1016/0003-2697(78)90419-0; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PRIST R, 1992, CIRC SHOCK, V36, P13; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; PROUGH DS, 1991, CRIT CARE MED, V19, P364, DOI 10.1097/00003246-199103000-00015; PROUGH DS, 1991, ANESTH ANALG, V73, P736; SCHURER L, 1992, EUR SURG RES, V24, P1, DOI 10.1159/000129183; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; TAMAKI N, 1990, J NEUROSURG, V73, P274, DOI 10.3171/jns.1990.73.2.0274; TENGVAR C, 1982, ACTA NEUROPATHOL, V57, P143, DOI 10.1007/BF00685382; THEODORSSONNORHEIM E, 1986, COMPUT METH PROG BIO, V23, P57, DOI 10.1016/0169-2607(86)90081-7; VELASCO IT, 1989, CRIT CARE MED, V17, P261, DOI 10.1097/00003246-198903000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WISNER DH, 1992, J TRAUMA, V32, P351, DOI 10.1097/00005373-199203000-00013; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	42	34	34	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	APR	1995	3	4					274	279					6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	QT198	WOS:A1995QT19800005	7541301				2022-02-06	
J	EWINGCOBBS, L; THOMPSON, NM; MINER, ME; FLETCHER, JM				EWINGCOBBS, L; THOMPSON, NM; MINER, ME; FLETCHER, JM			GUNSHOT WOUNDS TO THE BRAIN IN CHILDREN AND ADOLESCENTS - AGE AND NEUROBEHAVIORAL DEVELOPMENT	NEUROSURGERY			English	Article						ADOLESCENTS; BRAIN INJURY; CHILDREN; GUNSHOT WOUNDS; NEUROPSYCHOLOGICAL ASSESSMENT; OUTCOME	CLOSED HEAD-INJURY; CIVILIAN PRACTICE; EXPERIENCE; MANAGEMENT; MEMORY; SCALE; COMA	NEUROBEHAVIORAL OUTCOME AFTER craniocerebral gunshot wounds was evaluated in a prospective, 3-year, longitudinal follow-up of a consecutive case series of 13 children and adolescents. The younger group was composed of seven children, ages 1.5 to 4 years, and the older group contained six children, ages 5 to 14. Outcome measures included the Glasgow Outcome Scale and neuropsychological assessment of intelligence, language, motor, memory, attention, academic achievement, and adaptive behavior. Glasgow Outcome Scale scores at baseline indicated moderate and severe disabilities in 69 and 23%, respectively. At the 3-year follow-up, 85% had moderate disabilities but only 8% were severely disabled. Significant and persistent neurobehavioral deficits varied with developmental level at the time of cerebral insult. Intellectual functioning was clearly more impaired in children younger than 5 years of age at the time of injury than in older children. Cognitive and motor factors were most closely related to deficits in the younger group. Disability in older children and adolescents was associated with impaired attention, adaptive behavior, and behavioral disturbance. Disabilities appear to be at least as severe in our sample after cerebral gunshot wounds as in our studies of severe pediatric closed-head injury. At the time of follow-up, younger children sustaining gunshot wounds had slightly lower intelligence quotient scores and similar receptive language, expressive language, and gross motor scores compared with children with severe closed-head injury. The older gunshot wound patients were significantly more impaired than patients with severe closed-head injuries on measures of adaptive behavior and attention. Our findings suggest that early brain injury may not be associated with a more favorable prognosis than comparable injuries in older children and that the type of deficits observed vary with developmental level at the time of injury.	UNIV TEXAS,HLTH SCI CTR,DEPT PSYCHIAT,SAN ANTONIO,TX 78284; OHIO STATE UNIV,COLL MED,DIV NEUROL SURG,COLUMBUS,OH 43210		EWINGCOBBS, L (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PEDIAT,6431 FANNIN,MSB 7142,HOUSTON,TX 77030, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [27597, 21889] Funding Source: Medline		BARLOW B, 1982, J PEDIATR SURG, V17, P927, DOI 10.1016/S0022-3468(82)80469-7; BASTIA HC, 1898, TREATISE APHASIA OTH; Bayley N., 1969, MANUAL BAYLEY SCALES; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DUNN LM, 1970, PEABODY INDIVIDUAL A; Dunn LM., 1981, PEABODY PICTURE VOCA; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HEDRICK DL, 1974, SEQUENCED INVENTORY; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; Jastak S., 1978, WIDE RANGE ACHIEVEME; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LILLARD PL, 1978, SURG NEUROL, V9, P79; McCarthy, 1972, MCCARTHY SCALES CHIL; MINER ME, 1990, NEUROSURGERY, V26, P20, DOI 10.1227/00006123-199001000-00002; MINER ME, 1986, NEUROSURGERY, V19, P952, DOI 10.1227/00006123-198612000-00009; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; SAINTJAMESROBER.I, 1979, ADV CHILD DEV BEHAV, V14, P253; SARNAIK AP, 1989, J TRAUMA, V29, P1434, DOI 10.1097/00005373-198910000-00023; SHERMAN WD, 1980, WESTERN J MED, V132, P99; SMITH A, 1984, EARLY BRAIN DAMAGE, V1, P299; Spreen O., 1969, NEUROSENSORY CTR COM; TEASDALE G, 1974, LANCET, V2, P81; Terman L. M., 1972, STANFORD BINET INTEL; TEUBER H, 1962, Dev Med Child Neurol, V4, P3; Wechsler D., 1974, WECHSLER INTELLIGENC; [No title captured]	39	34	35	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1994	35	2					225	233		10.1227/00006123-199408000-00007			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	PA207	WOS:A1994PA20700021	7969829				2022-02-06	
J	LEE, MW; DEPPE, SA; SIPPERLY, ME; BARRETTE, RR; THOMPSON, DR				LEE, MW; DEPPE, SA; SIPPERLY, ME; BARRETTE, RR; THOMPSON, DR			THE EFFICACY OF BARBITURATE COMA IN THE MANAGEMENT OF UNCONTROLLED INTRACRANIAL HYPERTENSION FOLLOWING NEUROSURGICAL TRAUMA	JOURNAL OF NEUROTRAUMA			English	Article							SEVERE HEAD-INJURY; PRESSURE; THERAPY	The purpose of this study was to evaluate the role of barbiturate therapy as an adjunctive treatment for control of intracranial hypertension when conventional methods failed. To this end, a retrospective chart review was conducted on 21 neurosurgical trauma patients with uncontrolled intracranial pressure (ICP) admitted to a trauma/intensive care unit. In this patient population, the overall mortality was 48%. Control of ICP was achieved in 67% of patients. The survival of patients experiencing ICP control with barbiturate coma was better than those patients who failed therapy (71% vs 14%,p = 0.021). Thus, in a subgroup of neurosurgical trauma patients who are refractory to conventional management of elevated ICP, barbiturates appear to improve survival, suggesting that this therapy has an important role in the management of neurotrauma patients.	MERCY HOSP, DEPT MED, DIV CRIT CARE MED, TRAUMA INTENS CARE UNIT, PITTSBURGH, PA 15219 USA; MERCY HOSP, DEPT SURG, DIV GEN SURG, PITTSBURGH, PA USA; MERCY HOSP, DEPT SURG, DIV TRAUMA SERV, PITTSBURGH, PA USA								BOWERS SA, 1980, NEUROSURGERY, V6, P237; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; HOFF JT, 1977, ACTA NEUROL SCAND, V56, P158; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1980, NEUROSURGERY, V7, P593, DOI 10.1227/00006123-198012000-00010; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PAPPAS TN, 1981, AM J HOSP PHARM, V38, P494, DOI 10.1093/ajhp/38.4.494; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SMITH AL, 1977, ANESTHESIOLOGY, V47, P285, DOI 10.1097/00000542-197709000-00010; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014	14	34	34	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					325	331		10.1089/neu.1994.11.325			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100008	7996586				2022-02-06	
J	BOHNEN, N; TWIJNSTRA, A; JOLLES, J				BOHNEN, N; TWIJNSTRA, A; JOLLES, J			PERSISTENCE OF POSTCONCUSSIONAL SYMPTOMS IN UNCOMPLICATED, MILDLY HEAD-INJURED PATIENTS - A PROSPECTIVE COHORT STUDY	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						MHI; POSTCONCUSSIONAL SYMPTOMS; STROOP COLOR WORD TEST; LIGHT, SOUND	SEQUELAE; CONCUSSION	We report the follow-up of 41 nonhospitalized subjects with uncomplicated mild head injury (MHI) and no premorbid compromising condition. At 3 months after the trauma 22 patients still complained of at least 1 postconcussional symptom (PCS) and 10 patients had 3 or more PCS. At 6 months 12 patients complained of at least 1 PCS, whereas 9 patients still had 3 symptoms or more. Patients with persistent PCS complained more of emotional symptoms. Results obtained with objective tests indicated that this group was characterized by a decreased performance on the Stroop Color Word Interference Test and a reduced tolerance to light and sound stimuli in comparison with patients with only few or no PCS. Persistent neurobehavioral deficits were correlated with scores on a postconcussive/cognitive rating scale, but not with scores on an emotional/vegetative scale. Although most patients may substantially recover after MHI, about 1 in 4 patients may persist with a residue of neurobehavioral deficits. Patients with persistent PCS should be evaluated in a multidiagnostic and objective way in order to gain a better understanding of the nature and origin of the subjective symptoms.	UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS				Bohnen, Nicolaas/A-1312-2007				Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JONSSON CO, 1967, ACTA NEUROL SCAND, V43, P158, DOI 10.1111/j.1600-0404.1967.tb05725.x; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NOVICK MR, 1966, J MATH PSYCHOL, V3, P1, DOI 10.1016/0022-2496(66)90002-2; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; VERHAGE R, 1964, THESIS NETHERLANDS; [No title captured]; 1985, SAS USERS GUIDE STAT	24	34	35	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	JUL	1993	6	3					193	200					8	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	LK298	WOS:A1993LK29800010					2022-02-06	
J	PERSINGER, MA				PERSINGER, MA			PERSONALITY CHANGES FOLLOWING BRAIN INJURY AS A GRIEF RESPONSE TO THE LOSS OF SENSE OF SELF - PHENOMENOLOGICAL THEMES AS INDEXES OF LOCAL LABILITY AND NEUROCOGNITIVE STRUCTURING AS PSYCHOTHERAPY	PSYCHOLOGICAL REPORTS			English	Article							SIGNS	Both theoretical and empirical observations suggest that significant alterations in self-concept should occur following most closed head injuries because of diffuse synaptic modification within the temporofrontal regions; this loss of the sense of self should evoke a grief-like response sequence and should encourage paranormal/religious experiences during the subsequent months to years. The marked consistency between phenomenological' experiences and the results of neuropsychological assessments of 56 adults who had sustained brain injuries supported this hypothesis. Subsequent reports by these patients indicated that clinical translation of posttraumatic experiences into rational neurobehavioral terms and interventions tailored for the individual's specific pattern of brain ''dysfunction'' may facilitate adaptation during the grieving period.			PERSINGER, MA (corresponding author), LAURENTIAN UNIV,DEPT PSYCHOL,BEHAV NEUROSCI LAB,SUDBURY P3E 2C6,ONTARIO,CANADA.						BUREAU YRJ, 1992, INT J BIOMETEOROL, V36, P226, DOI 10.1007/BF02726403; ELLIS A, 1989, WHY SOME THERAPIES D; Lachar D., 1974, MMPI CLIN ASSESSMENT; Levin H.S., 1989, MILD HEAD INJURY; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; MISSAGHI B, 1992, PHARMACOL BIOCHEM BE, V43, P1081, DOI 10.1016/0091-3057(92)90485-X; PERSINGER MA, 1993, PERCEPT MOTOR SKILL, V76, P915, DOI 10.2466/pms.1993.76.3.915; PERSINGER MA, 1992, PERCEPT MOTOR SKILL, V75, P568, DOI 10.2466/PMS.75.5.568-570; PERSINGER MA, 1985, PERCEPT MOTOR SKILL, V60, P827, DOI 10.2466/pms.1985.60.3.827; PERSINGER MA, 1987, J GEN PSYCHOL, V114, P179, DOI 10.1080/00221309.1987.9711068; PERSINGER MA, 1993, J CLIN PSYCHOL, V49, P33, DOI 10.1002/1097-4679(199301)49:1<33::AID-JCLP2270490106>3.0.CO;2-H; PERSINGER MA, 1993, IN PRESS PHYSL BEHAV; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; RANDO TA, 1984, GRIEF DYING DEATH; Roberts RJ, 1990, NEUROPSYCHOLOGY, V4, P65; ROSS J, 1987, PERCEPT MOTOR SKILL, V64, P828, DOI 10.2466/pms.1987.64.3.828; Skinner B. F., 1957, VERBAL BEHAVIOR; TUCKER IF, 1970, ADJUSTMENT MODELS ME	18	34	35	0	9	PSYCHOLOGICAL REPORTS	MISSOULA	P O BOX 9229, MISSOULA, MT 59807	0033-2941			PSYCHOL REP	Psychol. Rep.	JUN	1993	72	3	2				1059	1068		10.2466/pr0.1993.72.3c.1059			10	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	LH985	WOS:A1993LH98500001	8337306				2022-02-06	
J	POPOVICH, PG; STREIT, WJ; STOKES, BT				POPOVICH, PG; STREIT, WJ; STOKES, BT			DIFFERENTIAL EXPRESSION OF MHC CLASS-II ANTIGEN IN THE CONTUSED RAT SPINAL-CORD	JOURNAL OF NEUROTRAUMA			English	Article							CENTRAL NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HISTOCOMPATIBILITY COMPLEX ANTIGENS; INTERFERON-LIKE IMMUNOREACTIVITY; MICROGLIAL CELLS; IA-ANTIGEN; IMMUNOHISTOCHEMICAL ANALYSIS; UNMYELINATED AXONS; INJURY; BRAIN	Following contusion injury to the dorsal surface of thoracic rat spinal cord, major histocompatibility complex (MHC) class II (Ia) antigen expression by microglia was evaluated throughout the developing lesion. Past investigations of various central nervous system (CNS) lesions have examined short-term or acute sequelae of post-traumatic Ia expression. This report demonstrates that in animals allowed to recover for 18 (sub-chronic) and 45 (chronic) days post-injury, MHC class II antigen is expressed differently at rostral and caudal extents of the lesion as compared with the lesion's epicenter. Following contusion injury to the thoracic spinal cord, sub-chronically injured animals demonstrated Ia-positive microglial staining throughout the white matter rostral and caudal to the epicenter of the lesion, whereas Ia-positive microglia and/or perivascular cells are localized within the gray matter adjacent to it. MHC class II immunoreactivity is down-regulated on microglia at chronic survival times but clusters of Ia-positive macrophages are prominent in regions of maximal degeneration at the epicenter of the lesion. Our findings support the theory that two distinct populations of macrophages participate in resolving traumatic injury. One population is the parenchymal CNS microglia and the other is presumably exudate macrophages derived from the blood. Furthermore, the immunocompetence of these cells as measured by MHC expression may be differentially regulated. This hypothesis is based on differences in Ia-positive staining observed between microglia and macrophages over time concomitant with differences in the spatial distribution of these cell types.	OHIO STATE UNIV,COLL MED,DEPT PHYSIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT SURG,COLUMBUS,OH 43210; UNIV FLORIDA,COLL MED,DEPT NEUROSCI,GAINESVILLE,FL 32611				Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS10165] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS010165] Funding Source: NIH RePORTER		AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; DALLMAN MJ, 1984, EUR J IMMUNOL, V14, P260, DOI 10.1002/eji.1830140311; de Sousa BN, 1979, DEV NEUROSCI, V2, P115; DICKSON DW, 1991, LAB INVEST, V64, P135; FUKOMOTO T, 1982, EUR J IMMUNOL, V12, P237; GEHRMANN J, 1991, RESTOR NEUROL NEUROS, V2, P181, DOI 10.3233/RNN-1991-245605; GEHRMANN J, 1992, J CEREB BLOOD FLOW M, V12, P527; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, TRENDS NEUROSCI, V13, P366, DOI 10.1016/0166-2236(90)90020-B; KAWAMATA T, 1992, AM J PATHOL, V140, P691; KIEFER R, 1990, NEUROSCIENCE, V37, P725, DOI 10.1016/0306-4522(90)90103-B; KONNO H, 1989, J NEUROIMMUNOL, V25, P151, DOI 10.1016/0165-5728(89)90132-X; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LANGFORD LA, 1981, SCIENCE, V211, P176, DOI 10.1126/science.7444459; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MATSUMOTO Y, 1986, J NEUROIMMUNOL, V12, P265; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; MILLIGAN CE, 1991, J COMP NEUROL, V314, P136, DOI 10.1002/cne.903140113; MORIOKA T, 1992, GLIA, V6, P75, DOI 10.1002/glia.440060110; OLSSON T, 1989, J NEUROSCI, V9, P3870; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; SMETANKA AM, 1990, BRAIN RES, V521, P343, DOI 10.1016/0006-8993(90)91564-W; SOBEL RA, 1988, J NEUROPATH EXP NEUR, V47, P19, DOI 10.1097/00005072-198801000-00003; STOKES BT, 1992, EXP NEUROL, V116, P1, DOI 10.1016/0014-4886(92)90171-L; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; TOOYAMA I, 1990, BRAIN RES, V523, P273, DOI 10.1016/0006-8993(90)91496-4; VASS K, 1986, ACTA NEUROPATHOL, V70, P149, DOI 10.1007/BF00691433; WAKEFIELD CL, 1975, EXP NEUROL, V48, P637, DOI 10.1016/0014-4886(75)90020-5; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WOODROOFE MN, 1986, J NEUROL SCI, V74, P135, DOI 10.1016/0022-510X(86)90100-0	39	34	36	1	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SPR	1993	10	1					37	46		10.1089/neu.1993.10.37			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	LC106	WOS:A1993LC10600004	8320731				2022-02-06	
J	HOWARD, MA; BELL, BA; UTTLEY, D				HOWARD, MA; BELL, BA; UTTLEY, D			THE PATHOPHYSIOLOGY OF INFANT SUBDURAL HEMATOMAS	BRITISH JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; INFANT; SHAKEN BABY SYNDROME; SUBDURAL HEMATOMA	PERMANENT BRAIN-DAMAGE; MENTAL-RETARDATION; CHILD-ABUSE; HEMATOMA; SHAKEN; INJURIES; SHAKING	The widely accepted theories concerning the pathophysiology of infant subdural haematoma (SDH) were formulated in the pre-computed tomographic (CT) scan era. Violent shaking is considered to be a crucial cause of SDH in non-accidentally injured infants. This theory has been re-examined in a clinical and CT scan review, and our findings have been correlated with results of recent head injury research. A retrospective review was conducted of all head injured infants (up to 18 months old) treated at Atkinson Morley's Hospital over a recent 20-year period (n = 100). Twenty-eight infants with a SDH were identified. CT scans were reviewed and each SDH greater than 0.5 cm thick was morphometrically analysed. Seventeen infants were Caucasian, 10 were non-Caucasian and one was of mixed race. A race-dependent pattern of SDH pathophysiology was noted, with non-Caucasian infants with a head injury more likely to have a SDH than Caucasian infants (67 v 21% p < 0.01). All had a history of, or radiographic and clinical findings most consistent with, an impact injury, and non-Caucasian infants were significantly more likely to have a normal scalp examination despite the impact injury (p < 0.05) and to have developed the SDH after a relatively trivial fall (p < 0.01). They were also more likely to have a large ( > 0.5 cm thick) SDH (p < 0.05), and to suffer post-traumatic seizures (p < 0.05). Our findings do not support shaking as the only cause of infant SDH formation and also suggest that non-accidental injury is a less common cause of SDH than it is believed to be.	ATKINSON MORLEYS HOSP,COPSE HILL,WIMBLEDON,LONDON SW20 0NE,ENGLAND					Howard, Matthew/0000-0003-3935-8889			ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; GUTIERREZ FA, 1975, CHILD BRAIN, V1, P269; HAHN YS, 1983, CHILD BRAIN, V10, P229; Hendrick E B, 1964, Clin Neurosurg, V11, P46; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; IVAN LP, 1983, CAN MED ASSOC J, V128, P281; MCCLELLAND CQ, 1980, CHILD BRAIN, V7, P225; REKATE HL, 1985, J NEUROSURG, V62, P316; SPORACIO RR, 1971, NY STATE J MED, V71, P212	16	34	35	0	6	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.		1993	7	4					355	365		10.3109/02688699309103489			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	LT994	WOS:A1993LT99400003	8216905				2022-02-06	
J	WRATHALL, JR; BOUZOUKIS, J; CHOINIERE, D				WRATHALL, JR; BOUZOUKIS, J; CHOINIERE, D			EFFECT OF KYNURENATE ON FUNCTIONAL DEFICITS RESULTING FROM TRAUMATIC SPINAL-CORD INJURY	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						SPINAL CORD CONTUSION; NMDA RECEPTOR ANTAGONISTS; NON-NMDA RECEPTOR ANTAGONISTS; EXCITATORY AMINO ACIDS	EXCITATORY AMINO-ACIDS; NMDA RECEPTOR ANTAGONISTS; BLOOD-FLOW; RAT-BRAIN; GLUTAMATE; CONTUSION; ISCHEMIA; INHIBITION; BLOCKADE; CALCIUM	The potential role of excitatory amino acid (EAA) receptors in spinal cord trauma was examined in a standardized rat model of contusive injury. EAA antagonists were administered in a split-dose protocol with half given 5 min prior to and the remainder 15 min after contusion produced at the T8 vertebral level. Hindlimb function was assessed using a battery of tests of reflex and more complex behaviors at 1 day after injury and weekly thereafter through 4-8 weeks. Functional deficits were compared for groups administered intravenous MK 801 (1 mg/kg), dextromethorphan (10 mg/kg) and kynurenate (300 mg/kg) or the vehicle, saline, alone. In addition, possible effect of the drugs themselves on hindlimb function were assessed in uninjured controls. None of the drugs produced more than transient effect on uninjured rats. In contused rats, only kynurenate produced significant reductions in functional deficits as compared to saline controls. Significant improvement of hindlimb function was also observed when the thoracic cord was locally perfused with kynurenate via intrathecal cannulas and when kynurenate was directly infused into the contusive injury site by stereotaxic microinjection. Using the latter route of administration, a dose-dependent effect of kynurenate (100, 200 and 400 nmol) on the ability of contused rats to use their hindlimbs in locomotion was demonstrated. The highest dose also resulted in a significant reduction in overall functional deficits from 1 week through 1 month and at 2 months after injury. Our results support the hypothesis that EAA receptors at or near the injury site are involved in producing a proportion of the overall functional deficits stemming from traumatic injury. In addition, the efficacy of the broad spectrum antagonist of EAA receptors, kynurenate, and the absence of effect of the NMDA receptor antagonists, MK 801 or dextromethorphan, suggests than non-NMDA receptors may play a hitherto unappreciated role in secondary injury after spinal cord contusion.	GEORGETOWN UNIV, DEPT ANAT & CELL BIOL, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS028130] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS28130] Funding Source: Medline		ANDINE P, 1988, NEUROSCI LETT, V90, P208, DOI 10.1016/0304-3940(88)90813-0; BALENTINE JD, 1977, ANN NEUROL, V2, P520, DOI 10.1002/ana.410020612; BIRCH PJ, 1988, EUR J PHARMACOL, V151, P313, DOI 10.1016/0014-2999(88)90814-X; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; COLLINS WF, 1979, NEURAL TRAUMA, P273; DANYSZ W, 1989, NEUROSCI LETT, V96, P340, DOI 10.1016/0304-3940(89)90402-3; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FERKANY JW, 1988, EUR J PHARMACOL, V151, P151, DOI 10.1016/0014-2999(88)90707-8; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; HEADLEY PM, 1990, TRENDS PHARMACOL SCI, V11, P205, DOI 10.1016/0165-6147(90)90116-P; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HOOVLER D W, 1987, Society for Neuroscience Abstracts, V13, P1500; HOOVLER DW, 1991, ACTA NEUROPATHOL, V81, P303, DOI 10.1007/BF00305872; JAHR CE, 1986, J PHYSIOL-LONDON, V370, P515, DOI 10.1113/jphysiol.1986.sp015948; JENSEN AM, 1991, J NEUROSCI, V11, P1674; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; Kochhar A, 1991, J NEUROTRAUM, V8, P175, DOI 10.1089/neu.1991.8.175; LAPIN IP, 1986, J NEURAL TRANSM, V65, P177, DOI 10.1007/BF01249080; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; MARTINEZARIZALA A, 1990, EXP NEUROL, V108, P232, DOI 10.1016/0014-4886(90)90128-F; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MORONI F, 1988, J NEUROCHEM, V51, P177, DOI 10.1111/j.1471-4159.1988.tb04852.x; MORONI F, 1988, NEUROSCI LETT, V94, P145, DOI 10.1016/0304-3940(88)90285-6; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; NELLGARD B, 1992, J CEREBR BLOOD F MET, V12, P2, DOI 10.1038/jcbfm.1992.2; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Olney J, 1978, KAINIC ACID TOOL NEU, P95; PANJABI MM, 1988, SPINE, V13, P1365, DOI 10.1097/00007632-198812000-00007; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; RAINES A, 1988, Journal of Neurotrauma, V5, P151, DOI 10.1089/neu.1988.5.151; RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SIMON RP, 1986, NEUROSCI LETT, V71, P361, DOI 10.1016/0304-3940(86)90648-8; TURSKI WA, 1988, BRAIN RES, V454, P164, DOI 10.1016/0006-8993(88)90815-3; URCA G, 1990, BRAIN RES, V529, P7, DOI 10.1016/0006-8993(90)90805-L; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; WRATHALL JR, IN PRESS BRAIN RES; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667	46	34	34	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 6	1992	218	2-3					273	281		10.1016/0014-2999(92)90179-8			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	JH152	WOS:A1992JH15200011	1425945				2022-02-06	
J	DITUNNO, JF				DITUNNO, JF			FUNCTIONAL ASSESSMENT MEASURES IN CNS TRAUMA	JOURNAL OF NEUROTRAUMA			English	Article							SPINAL-CORD INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; QUADRIPLEGIA; INDEPENDENCE; SENSITIVITY; RELIABILITY; RECOVERY	How effectively the survivor of CNS trauma can function in society is the ultimate clinical outcome. Many victims of spinal cord injury (SCI) and traumatic brain injury (TBI) are frequently left with permanent impairment. Measurements of impairment, and the direct relationship to the functional loss and resultant disability, should be the gold standard for determining the effectiveness of interventions. The primary impairments in SCI are motor and sensory loss while those in TBI are neurobehavioral disorders. Classifications for impairment are reasonably well defined in SCI and several approaches are gaining wide acceptance. We hope that internationally agreed upon standards will be forthcoming within the year. The functional independence measure (FIM), which was developed in the past 6-7 years, will be added to the standards. It shows good reliability for SCI as an overall assessment and some of the specific categories of self-care and mobility. An extension of the FIM is needed for more precise measurement of function in quadriplegic subjects. Classification of impairment in TBI has been more difficult. While the Glasgow Outcome Scale has gained international acceptance for almost 10 years, it has limitations in gradations from the moderate disability to the good recovery groups. The Disability Rating Scale (DRS) has shown good reliability, better precision than the Glasgow Outcome Scale, and greater reliability than other measures. An extension of the FIM, called the functional assessment measure (FAM), and the DRS are currently being tested by regional TBI centers in the United States. Functional assessment measures should be available within the next several years.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT REHABIL MED,PHILADELPHIA,PA 19107								[Anonymous], 1980, INT CLASSIFICATION I; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHENG LL, 1991, AM J PARAPLEGIA SOC, V14, P94; COLE TM, 1990, REPORT TASK FORCE ME, P30; CROZIER KS, 1991, ARCH PHYS MED REHAB, V72, P119; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DEMAGONE D, 1991, J AM PARAPLEGIA SOC, V14, P95; DILLER L, 1989, TRAUMATIC BRAIN INJU, V2; DITUNNO JF, 1991, IN PRESS ARCH PHYS M; FUHRER MJ, 1991, J AM PARAPLEGIA SOC, V14, P64; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRESHAM GE, 1986, PARAPLEGIA, V24, P38, DOI 10.1038/sc.1986.7; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HAMILTON BB, 1990, SPINAL CORD INJURY M, P49; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HERBISON GJ, 1990, REPORT TASK FORCE ME, P43; HUSSEY RW, 1973, ARCH PHYS MED REHAB, V54, P544; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; NAGAI SZ, 1982, LIMITATIONS FUNCTION; POPE AM, 1991, DISABILITY AM NATION; POTVIN AR, 1985, QUANTITATIVE EXAMINA, V2; POTVIN AR, 1985, QUANTITATIVE EXAMINA, V1; ROGERS JC, 1980, ARCH PHYS MED REHAB, V61, P316; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; WALKER MD, 1991, NEW ENGL J MED, V324, P1885, DOI 10.1056/NEJM199106273242608; WELCH RD, 1986, ARCH PHYS MED REHAB, V67, P235; WHITENECK GG, 1988, 14TH AM SPIN INJ ASS, P48; YARKONY G, 1988, ARCH PHYS MED REHAB, V69, P73; 1989, STANDARDS NEUROLOGIC	32	34	34	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S301	S305					5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600029	1588620				2022-02-06	
J	JANECZKO, K				JANECZKO, K			THE PROLIFERATIVE RESPONSE OF S-100 PROTEIN-POSITIVE GLIAL-CELLS TO INJURY IN THE NEONATAL RAT-BRAIN	BRAIN RESEARCH			English	Article						BRAIN INJURY; REACTIVE ASTROCYTE PROLIFERATION; NEWBORN RAT; S-100 PROTEIN IMMUNOCYTOCHEMISTRY; AUTORADIOGRAPHY	FIBRILLARY ACIDIC PROTEIN; CORPUS-CALLOSUM; MOUSE-BRAIN; ASTROCYTES; LOCALIZATION; CORTEX; IMMUNOFLUORESCENCE; HIPPOCAMPUS; ANTIBODIES; APPEARANCE	Astroglial proliferative response to unilateral injury of the cerebral hemisphere was studied in newborn rats using [H-3]thymidine autoradiography combined with immunocytochemical staining for S-100 protein as an astroglial marker. The animals received [H-3]thymidine at different intervals following injury and the distribution of double-labeled cells was recorded 4 h after each [H-3]thymidine injection. The reactive proliferation of all cells within the investigated areas was detectable as early as about 2 h after injury. However, the quantitative increase in astroglial mitotic rate could be first detected on day 1 following the injury and the reactive changes were observed until day 8. They were regarded as evidence for the ability of astroglia to proliferate in response to injury in the neonatal brain. Since the astroglial divisions occurred mainly at the lesion site, the post-traumatic gliosis could be considered not only a result of astrocyte migration towards the lesion but also an effect of local mitotic activity.			JANECZKO, K (corresponding author), JAGIELLONIAN UNIV,INST ZOOL,DEPT NEUROANAT,KARASIA 6,PL-30060 KRAKOW,POLAND.			Janeczko, Krzysztof/0000-0002-9544-918X			Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BLAKEMORE WF, 1971, J NEUROL SCI, V12, P319, DOI 10.1016/0022-510X(71)90066-9; BOYES BE, 1986, NEUROSCIENCE, V17, P857, DOI 10.1016/0306-4522(86)90050-3; CAVANAGH JB, 1970, J ANAT, V106, P471; COCCHIA D, 1981, CELL TISSUE RES, V214, P529; DUFFY PE, 1983, ASTROCYTES NORMAL RE; FERRER I, 1980, ACTA NEUROPATHOL, V50, P69, DOI 10.1007/BF00688538; FOG R, 1983, J HIRNFORSCH, V24, P341; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GOMEZ LA, 1990, INT J DEV NEUROSCI, V8, P55; HAAN EA, 1982, P NATL ACAD SCI-BIOL, V79, P7585, DOI 10.1073/pnas.79.23.7585; HELPAP B, 1976, VIRCHOWS ARCH B, V22, P151; Jacobson M, 1978, DEV NEUROBIOLOGY; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; JANECZKO K, 1985, FOLIA BIOL, V33, P121; KORR H, 1986, ASTROCYTES CELL BIOL, V3, P77; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MOORE IE, 1987, NEUROPATHOL APPL NEU, P219; MORI S, 1972, BRAIN RES, V46, P177, DOI 10.1016/0006-8993(72)90014-5; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; RAPPORT MM, 1974, T AM SOC NEUROCHEM, V5, P58; ROESSMANN U, 1986, ACTA NEUROPATHOL, V70, P302, DOI 10.1007/BF00686088; SCHMIDTKASTNER R, 1990, J CHEM NEUROANAT, V3, P179; SUMI SM, 1968, ACTA NEUROPATHOL, V10, P324, DOI 10.1007/BF00690707; TUCKETT F, 1986, J EMBRYOL EXP MORPH, V94, P95; ZHOU HF, 1990, J COMP NEUROL, V292, P320, DOI 10.1002/cne.902920213; ZUCKERMAN JE, 1970, J NEUROCHEM, V17, P247, DOI 10.1111/j.1471-4159.1970.tb02207.x	31	34	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 8	1991	564	1					86	90		10.1016/0006-8993(91)91355-5			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GR945	WOS:A1991GR94500012	1777824				2022-02-06	
J	YUAN, XQ; WADE, CE; CLIFFORD, CB				YUAN, XQ; WADE, CE; CLIFFORD, CB			SUPPRESSION BY TRAUMATIC BRAIN INJURY OF SPONTANEOUS HEMODYNAMIC RECOVERY FROM HEMORRHAGIC-SHOCK IN RATS	JOURNAL OF NEUROSURGERY			English	Article						BRAIN INJURY; FLUID-PERCUSSION INJURY; HEMORRHAGIC SHOCK; CATECHOLAMINE; ALDOSTERONE; RAT	FLUID-PERCUSSION MODEL; HEAD-INJURY; LACTIC-ACIDOSIS; ANGIOTENSIN-II; MORTALITY; ACTH; TRH	The effects of brain trauma on cardiovascular and endocrine responses to hemorrhage were investigated. Forty anesthetized rats were randomly assigned to one of four groups of 10 rats each: a control group (Group C); a group with induction of hemorrhage at 16.2 ml/kg/10 min (Group H); a group with fluid-percussion brain injury at a peak pressure of 1.7 atm and an impulse duration of 25 msec (Group T); and a group receiving hemorrhagic shock following brain trauma (Group TH). Group C and T rats showed no significant alterations in cardiovascular function. At the end of hemorrhage there were no significant differences between Groups TH and H in the nadirs of mean arterial blood pressure (MABP) (mean values +/- standard error of the mean: 42 +/- 2 vs. 40 +/- 4 mm Hg) and stroke volume index (SVI) (0.61 +/- 0.11 vs. 0.66 +/- 0.10 ml/bt/kg); however, 1 hour post-hemorrhage recovery was blunted in Group TH compared to Group H (MABP 56 +/- 4 vs. 65 +/- 3 mm Hg; cardiac index 182 +/- 15 vs. 220 +/- 15 ml/min/kg; and SVI 0.71 +/- 0.06 vs. 0.81 +/- 0.06 ml/bt/kg). Since the two groups showed no significant differences in heart rate, preload (central venous pressure), and afterload (systemic vascular resistance), the reduced cardiac index recovery in Group TH is believed due to the attenuation of cardiac contractile performance. The Group TH preparation potentiated hormonal responses to hemorrhage with significantly higher epinephrine and aldosterone levels than in Group H. Brain trauma enhanced the norepinephrine response to hemorrhage, even at an injury level that by itself did not result in an increase in this hormone. Group TH rats also had significantly lower blood pH and HCO3 levels. The data suggest that brain trauma suppresses MABP and cardiac index recovery after hemorrhage mainly by inhibiting cardiac contractile performance, probably due to high catecholamine levels and severe metabolic acidosis.	LETTERMAN ARMY INST RES,DIV MIL TRAUMA RES,SAN FRANCISCO,CA 94129								Altman PL, 1974, BIOL DATA BOOK, VIII; BERNTON EW, 1985, ANN EMERG MED, V14, P729, DOI 10.1016/S0196-0644(85)80047-0; CHEN V, 1990, AM J PHYSIOL, V258, pH101, DOI 10.1152/ajpheart.1990.258.1.H101; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; CRUICKSHANK JM, 1988, POSTGRAD MED, P140; DAVIES AO, 1984, J CLIN ENDOCR METAB, V59, P398, DOI 10.1210/jcem-59-3-398; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GUYTON AC, 1986, TXB MED PHYSL, P206; HINDMAN BJ, 1990, ANESTHESIOLOGY, V72, P1064, DOI 10.1097/00000542-199006000-00018; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1986, ANN EMERG MED, V15, P1462, DOI 10.1016/S0196-0644(86)80944-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1986, CIRC SHOCK, V18, P241; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; NEWFIELD P, 1980, CRIT CARE MED, V8, P254, DOI 10.1097/00003246-198004000-00123; PILATI CF, 1990, P SOC EXP BIOL MED, V193, P225; POPP AJ, 1982, J SURG RES, V32, P416, DOI 10.1016/0022-4804(82)90121-4; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; RAFF H, 1985, AM J PHYSIOL, V249, pR611, DOI 10.1152/ajpregu.1985.249.5.R611; RAFF H, 1986, AM J PHYSIOL, V250, pR240, DOI 10.1152/ajpregu.1986.250.2.R240; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SALTER G, 1977, ANN SURG, V181, P1; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; STENING WA, 1986, AUST NZ J SURG, V56, P549, DOI 10.1111/j.1445-2197.1986.tb07098.x; WADE CE, 1986, AM J PHYSIOL, V250, pR287, DOI 10.1152/ajpregu.1986.250.2.R287; WADE CE, 1980, J APPL PHYSIOL, V49, P930, DOI 10.1152/jappl.1980.49.6.930; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; [No title captured]; [No title captured]	34	34	35	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1991	75	3					408	414		10.3171/jns.1991.75.3.0408			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GC311	WOS:A1991GC31100013	1651379				2022-02-06	
J	GALLETTI, P; DEROSA, M; COTTICELLI, MG; MORANA, A; VACCARO, R; ZAPPIA, V				GALLETTI, P; DEROSA, M; COTTICELLI, MG; MORANA, A; VACCARO, R; ZAPPIA, V			BIOCHEMICAL RATIONALE FOR THE USE OF CDPCHOLINE IN TRAUMATIC BRAIN INJURY - PHARMACOKINETICS OF THE ORALLY-ADMINISTERED DRUG	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	MEETING ON PHARMACOLOGY OF TRAUMATIC BRAIN INJURY	JUN 22-23, 1990	TOLEDO, SPAIN	WORLD FEDERAT NEUROL			CDP-CHOLINE; ISCHEMIA; BIOSYNTHESIS; METABOLISM	A pharmacokinetic analysis of CDPcholine has been carried out treating either rats or dogs by oral administration with the double labelled molecule. [methyl-C-14, 5-H-3]CDPcholine represents a useful tool to test the structural integrity of this compound during the transmembrane transport and to follow the metabolic fate of cytidine and choline fragments. Furthermore, the identification of the labelled metabolites of the exogenously administered CDPcholine in the various organs allows us to draw interferences about its pharmacological mechanism(s). These studies appear of great interest in view of the extensive therapeutic use of the molecule in the treatment of several CNS pathologies including traumatic brain injury. The results of this work can be summarized as follows. (a) The molecule is rapidly cleaved at the level of the pyrophosphate bridge and a fast uptake of the hydrolytic products occurs. (b) The metabolism of the molecule is characterized by a differential utilization of the two moieties by the various organs. Liver is the most active organ in utilizing CDPcholine with a preferential uptake of the choline fragment. (c) The [H-3]cytidine moiety, in all the organs examined, appears to be incorporated into the nucleic acid fraction via the cytidine nucleotide pool. The [C-14]choline moiety is in part converted into betaine, which in turn acts as methyl donor to homocysteine, yielding [C-14]methionine, subsequently incorporated into proteins. The time-dependent increase in the labelling of phospholipids is indicative of a recycling of choline methyl groups via CDPcholine and/or S-adenosylmethionine. (d) The uptake of CDPcholine by the brain is relatively low; however, a good metabolic utilization of the drug can be observed. The salvage of the choline moiety in de novo phospholipid biosynthesis is indeed highly operative in this organ.			GALLETTI, P (corresponding author), NAPLES UNIV,SCH MED 1,DEPT BIOCHEM MACROMOLECULES,VIA COSTANTINOPOLI 16,I-80138 NAPLES,ITALY.		Morana, Alessandra/AAX-8200-2020	De Rosa, Mario/0000-0002-2976-0818; MORANA, ALESSANDRA/0000-0003-3189-2526			ALBERGHINA M, 1981, J NEUROSCI RES, V6, P421, DOI 10.1002/jnr.490060316; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BOISMARE F, 1978, PHARMACOLOGY, V17, P15, DOI 10.1159/000136830; DEROSA M, 1985, NOVEL BIOCH PHARM CL, P139; DORMAN RV, 1982, PHOSPHOLIPIDS NERVOU, P132; FINKELSTEIN JD, 1980, TRANSMETHYLATION, P49; FIORAVANTI M, 1983, CEREBRAL PATHOLOGY O, P343; GALLETTI P, 1985, BIOCHEM PHARMACOL, V34, P4121, DOI 10.1016/0006-2952(85)90204-7; KAKIHANA M, 1988, STROKE, V19, P917; KENNEDY EP, 1957, FED PROC, V16, P847; KHORANA HG, 1954, J AM CHEM SOC, V76, P3617; LOEB C, 1985, NOVEL BIOCH PHARM CL, P339; MCMURRAY WC, 1972, ANNU REV BIOCHEM, V41, P129, DOI 10.1146/annurev.bi.41.070172.001021; MILLER LL, 1951, J EXP MED, V94, P431, DOI 10.1084/jem.94.5.431; PECKER J, 1980, LOUEST MED, V33, P1075; RIGOULET M, 1979, J NEUROCHEM, V32, P535, DOI 10.1111/j.1471-4159.1979.tb00381.x; ROMEO G, 1981, B SOC ITAL BIOL SPER, V62, P1175; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X	19	34	34	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL	1991	103			S			S19	S25					7	Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GF379	WOS:A1991GF37900004	1940961				2022-02-06	
J	AISEN, ML; HOLZER, M; ROSEN, M; DIETZ, M; MCDOWELL, F				AISEN, ML; HOLZER, M; ROSEN, M; DIETZ, M; MCDOWELL, F			GLUTETHIMIDE TREATMENT OF DISABLING ACTION TREMOR IN PATIENTS WITH MULTIPLE-SCLEROSIS AND TRAUMATIC BRAIN INJURY	ARCHIVES OF NEUROLOGY			English	Article								Glutethimide has been used to control essential tremor. Its efficacy in the treatment of disabling cerebellar and rubral tremor was assessed in an open study of six patients with multiple sclerosis and two patients with traumatic brain injury. Functional and quantitative tremor severity was assessed before treatment and 7 to 14 days after a stable dose was achieved. Six of eight patients exhibited visible functional benefit from treatment with glutethimide; abstract testing results correlated well with functional status in most cases. Four patients chose to continue to receive medication. Controlled trials of glutethimide to compare its efficacy with that of other medications used in the treatment of action tremor are indicated.	ROCKY MT MULTIPLE SCLEROSIS CTR,DENVER,CO; MIT,CAMBRIDGE,MA 02139		AISEN, ML (corresponding author), BURKE REHABIL CTR,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.						ADELSTEIN BD, 1987, NEUROLOGY S, V37, P356; ADELSTEIN BD, 1984, 6TH P ANN IEEE EMB C, P47; BARUZZI A, 1983, NEUROLOGY, V33, P296, DOI 10.1212/WNL.33.3.296; BERINGHAUSE S, 1988, THESIS MIT; COHEN H, 1960, N Y State J Med, V60, P280; FAHN S, 1988, PARKINSON DIS MOVEME, P255; FEELY M, 1981, BRIT MED J, V282, P740, DOI 10.1136/bmj.282.6265.740-b; GROWDON JH, 1975, NEUROLOGY, V25, P259, DOI 10.1212/WNL.25.3.259; MCDOWELL FH, 1989, MOVEMENT DISORD, V4, P75, DOI 10.1002/mds.870040110; SADWIN A, 1958, AM J PSYCHIAT, V115, P469; STEPHEN CR, 1960, ANESTHESIOLOGY, V21, P482, DOI 10.1097/00000542-196009000-00004; TURRIAN H., 1958, HELVETICA PHYSIOL ET PHARMACOL ACTA, V16, P208	12	34	34	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	MAY	1991	48	5					513	515		10.1001/archneur.1991.00530170077023			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FK271	WOS:A1991FK27100013	2021365				2022-02-06	
J	Cheng, CLY; Povlishock, JT				Cheng, Charles L. Y.; Povlishock, John T.			The Effect of Traumatic Brain Injury on the Visual System: A Morphologic Characterization of Reactive Axonal Change	JOURNAL OF NEUROTRAUMA			English	Article							MINOR HEAD-INJURY; LATERAL GENICULATE-NUCLEUS; HORSERADISH-PEROXIDASE; CAT; DEGENERATION	Reactive axonal changes following fluid-percussion brain injury were studied in the highly organized afferent pathways of the cat visual system. The visual system offers several features advantageous to the study of traumatic brain injury. Specifically, as the retinal cells of origin of the optic nerve and tract are isolated from the employed fluid-percussion injury, concomitant traumatically induced somatic change is not a confounding variable. Additionally, the existence of axons of varying diameters and topographic localization within the visual pathways allows the relationship between both fiber size and distribution and their predilection for traumatically induced change to be considered. Since the visual pathway is a highly organized sensory pathway, data obtained in this system can be compared with similar studies previously conducted in motor systems. In these experiments, 20 adult cats were subjected to brain injury and killed at posttraumatic survival periods ranging from 2 to 60 days. Six cats received intravitreous injections of horseradish peroxidase (HRP) to aid in the recognition of axonal change. At the designated survival time, all animals were perfused with aldehydes. The visual system from optic chiasm to lateral geniculate was sectioned and prepared for routine light (LM) and electron microscopic (TEM) study. Animals injected with HRP were processed for the LM and TEM visualization of HRP reaction products. By the second posttraumatic day, reactive axonal swellings were observed in the optic tracts as they entered the medial intralaminar nuclei of the lateral geniculate bodies. Proximal segments of the reactive axons showed enlargement and lobulation, whereas the distal segments underwent wallerian degeneration. Over a 2 week posttraumatic course, some axonal swellings persisted unchanged, some degenerated, and others initiated regenerative sprouting. With continued survival, however, all the reactive swellings manifested only progressive degenerative change. These reactive axonal changes appeared to constitute a primary response to the traumatic episode and occurred without concomitant damage to either the related brain parenchyma or its intrinsic vasculature. Although these findings replicate many of those previously described in motor pathways, new conceptual information has been provided. These studies preclude concomitant somal damage as a confounding variable and suggest that large-caliber axons are susceptible to the shear and tensile forces of traumatic brain injury.	[Povlishock, John T.] Virginia Commonwealth Univ, Med Coll Virginia, MCV Stn, Dept Anat, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, MCV Stn, Dept Anat, Box 709, Richmond, VA 23298 USA.				NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 20193]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER	This work was supported by NIH Grant NS 20193.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; GENNARELLI JA, 1982, ANN NEUROL, V12, P564; GUILLERY RW, 1980, J COMP NEUROL, V194, P117, DOI 10.1002/cne.901940107; GUILLERY RW, 1970, J COMP NEUROL, V138, P339, DOI 10.1002/cne.901380307; GUILLERY RW, 1982, J NEUROSCI, V2, P714; ITAYA SK, 1982, BRAIN RES, V236, P199, DOI 10.1016/0006-8993(82)90046-4; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; LAEMLE LK, 1975, BRAIN RES, V100, P650, DOI 10.1016/0006-8993(75)90164-X; LASEK RJ, 1981, POSTTRAUMATIC PERIPH; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MESULAM MM, 1980, NEUROSCIENCE, V5, P1277, DOI 10.1016/0306-4522(80)90200-6; MESULAM MM, 1978, J HISTOCHEM CYTOCHEM, V26, P206; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBSON JA, 1983, J COMP NEUROL, V216, P89, DOI 10.1002/cne.902160108; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Tomlinson B, 1970, J CLIN PATHOL S4, V23, P154	25	34	34	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma		1988	5	1					47	60		10.1089/neu.1988.5.47			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V22HC	WOS:000208265300004	3193463				2022-02-06	
J	PARKINSON, D; WEST, M; PATHIRAJA, T				PARKINSON, D; WEST, M; PATHIRAJA, T			CONCUSSION - COMPARISON OF HUMANS AND RATS	NEUROSURGERY			English	Article											PARKINSON, D (corresponding author), UNIV MANITOBA,FAC MED,NEUROL SURG SECT,WINNIPEG R3E OW3,MANITOBA,CANADA.							0	34	35	1	5	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery		1978	3	2					176	180		10.1227/00006123-197809000-00008			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FT423	WOS:A1978FT42300008	703936				2022-02-06	
J	Hawryluk, GWJ; Rubiano, AM; Totten, AM; O'Reilly, C; Ullman, JS; Bratton, SL; Chesnut, R; Harris, OA; Kissoon, N; Shutter, L; Tasker, RC; Vavilala, MS; Wilberger, J; Wright, DW; Lumba-Brown, A; Ghajar, J				Hawryluk, Gregory W. J.; Rubiano, Andres M.; Totten, Annette M.; O'Reilly, Cindy; Ullman, Jamie S.; Bratton, Susan L.; Chesnut, Randall; Harris, Odette A.; Kissoon, Niranjan; Shutter, Lori; Tasker, Robert C.; Vavilala, Monica S.; Wilberger, Jack; Wright, David W.; Lumba-Brown, Angela; Ghajar, Jamshid			Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations	NEUROSURGERY			English	Article						Traumatic brain injury; Head injury; Guideline; Fourth edition; Brain Trauma Foundation; Severe; Decompressive craniectomy; Craniectomy; Decompression; Surgery	INTRACRANIAL HYPERTENSION; TRIAL	When the fourth edition of the Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury were finalized in late 2016, it was known that the results of the RESCUEicp (Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension) randomized controlled trial of decompressive craniectomy would be public after the guidelines were released. The guideline authors decided to proceed with publication but to update the decompressive craniectomy recommendations later in the spirit of "living guidelines," whereby topics are updated more frequently, and between new editions, when important new evidence is published. The update to the decompressive craniectomy chapter presented here integrates the findings of the RESCUEicp study as well as the recently published 12-mo outcome data from the DECRA (Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury) trial. Incorporation of these publications into the body of evidence led to the generation of 3 new level-IIA recommendations; a fourth previously presented level-IIA recommendation remains valid and has been restated. To increase the utility of the recommendations, we added a new section entitled incorporating the Evidence into Practice. This summary of expert opinion provides important context and addresses key issues for practitioners, which are intended to help the clinician utilize the available evidence and these recommendations. The full guideline can be found at: https://braintraurna.org/guidelines/guidelines-for-the-management-of-severe-tbi-4th-ed#/.	[Hawryluk, Gregory W. J.] Univ Manitoba, GB1 Hlth Sci Ctr, Sect Neurosurg, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada; [Rubiano, Andres M.] Univ El Bosque, INUB MEDITECH Res Grp, Bogota, Colombia; [Rubiano, Andres M.] Valle Salud Clin, Cali, Colombia; [Totten, Annette M.; O'Reilly, Cindy] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Ullman, Jamie S.] Zucker Sch Med Hofstra Northwell, Hempstead, NY USA; [Bratton, Susan L.] Univ Utah, Salt Lake City, UT USA; [Chesnut, Randall; Vavilala, Monica S.] Univ Washington, Seattle, WA 98195 USA; [Harris, Odette A.; Lumba-Brown, Angela; Ghajar, Jamshid] Stanford Univ, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, Vancouver, BC, Canada; [Shutter, Lori] Univ Pittsburgh, Pittsburgh, PA USA; [Tasker, Robert C.] Harvard Med Sch, Boston, MA 02115 USA; [Tasker, Robert C.] Boston Childrens Hosp, Boston, MA USA; [Wilberger, Jack] Drexel Univ, Pittsburgh, PA USA; [Wright, David W.] Emory Univ, Atlanta, GA 30322 USA		Hawryluk, GWJ (corresponding author), Univ Manitoba, GB1 Hlth Sci Ctr, Sect Neurosurg, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	ghawryluk@hsc.mb.ca	Shutter, Lori A/G-2957-2013	Kissoon, Niranjan/0000-0001-8847-9973; Hawryluk, Gregory/0000-0002-5604-7057; Totten, Annette/0000-0002-9100-8678; Tasker, Robert/0000-0003-3647-8113	US Army Contracting Command, Aberdeen ProvingGround, Natick ContractingDivision [W911 QY-14-C-0086]	This material is based upon work supported by (1) the US Army Contracting Command, Aberdeen ProvingGround, Natick ContractingDivision, through a contract awarded to Stanford University (W911 QY-14-C-0086). Any opinions, findings, and conclusions, or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, or Stanford University. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. This material is based upon work supported by (1) the US Army Contracting Command, Aberdeen ProvingGround, Natick ContractingDivision, through a contract awarded to Stanford University (W911 QY-14-C-0086). Any opinions, findings, and conclusions, or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, or Stanford University. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut R, 2020, INTENS CARE MED, V46, P919, DOI 10.1007/s00134-019-05900-x; Clark DJ, 2013, ACTA NEUROCHIR, V155, P1329, DOI 10.1007/s00701-013-1748-3; Cooper DJ, 2020, J NEUROTRAUM, V37, P810, DOI 10.1089/neu.2019.6869; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dunn LT, 2002, J NEUROL NEUROSUR PS, V73, pI23; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Hawryluk GWJ, 2019, INTENS CARE MED, V45, DOI 10.1007/s00134-019-05805-9; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchinson PJ, 2019, ACTA NEUROCHIR, V161, P1261, DOI 10.1007/s00701-019-03936-y; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kolias AG, 2013, BRIT J NEUROSURG, V27, P330, DOI 10.3109/02688697.2013.779365; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marion DW, 2006, NEUROSURGERY, V58, P655; Monro A., 1783, OBSERVATIONS STRUCTU; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Tsoucalas G, 2017, WORLD NEUROSURG, V103, P501, DOI 10.1016/j.wneu.2017.04.022; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	20	33	36	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2020	87	3					427	434		10.1093/neuros/nyaa278			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	OW8HM	WOS:000593120600044	32761068	hybrid, Green Published			2022-02-06	
J	McLean, SA; Ressler, K; Koenen, KC; Neylan, T; Germine, L; Jovanovic, T; Clifford, GD; Zeng, DL; An, XM; Linnstaedt, S; Beaudoin, F; House, S; Bollen, KA; Musey, P; Hendry, P; Jones, CW; Lewandowski, C; Swor, R; Datner, E; Mohiuddin, K; Stevens, JS; Storrow, A; Kurz, MC; McGrath, ME; Fermann, GJ; Hudak, LA; Gentile, N; Chang, AM; Peak, DA; Pascual, JL; Seamon, MJ; Sergot, P; Peacock, WF; Diercks, D; Sanchez, LD; Rathlev, N; Domeier, R; Haran, JP; Pearson, C; Murty, VP; Insel, TR; Dagum, P; Onnela, JP; Bruce, SE; Gaynes, BN; Joormann, J; Miller, MW; Pietrzak, RH; Buysse, DJ; Pizzagalli, DA; Rauch, SL; Harte, SE; Young, LJ; Barch, DM; Lebois, LAM; van Rooij, SJH; Luna, B; Smoller, JW; Dougherty, RF; Pace, TWW; Binder, E; Sheridan, JF; Elliott, JM; Basu, A; Fromer, M; Parlikar, T; Zaslavsky, AM; Kessler, R				McLean, Samuel A.; Ressler, Kerry; Koenen, Karestan Chase; Neylan, Thomas; Germine, Laura; Jovanovic, Tanja; Clifford, Gari D.; Zeng, Donglin; An, Xinming; Linnstaedt, Sarah; Beaudoin, Francesca; House, Stacey; Bollen, Kenneth A.; Musey, Paul; Hendry, Phyllis; Jones, Christopher W.; Lewandowski, Christopher; Swor, Robert; Datner, Elizabeth; Mohiuddin, Kamran; Stevens, Jennifer S.; Storrow, Alan; Kurz, Michael Christopher; McGrath, Meghan E.; Fermann, Gregory J.; Hudak, Lauren A.; Gentile, Nina; Chang, Anna Marie; Peak, David A.; Pascual, Jose L.; Seamon, Mark J.; Sergot, Paulina; Peacock, W. Frank; Diercks, Deborah; Sanchez, Leon D.; Rathlev, Niels; Domeier, Robert; Haran, John Patrick; Pearson, Claire; Murty, Vishnu P.; Insel, Thomas R.; Dagum, Paul; Onnela, Jukka-Pekka; Bruce, Steven E.; Gaynes, Bradley N.; Joormann, Jutta; Miller, Mark W.; Pietrzak, Robert H.; Buysse, Daniel J.; Pizzagalli, Diego A.; Rauch, Scott L.; Harte, Steven E.; Young, Larry J.; Barch, Deanna M.; Lebois, Lauren A. M.; van Rooij, Sanne J. H.; Luna, Beatriz; Smoller, Jordan W.; Dougherty, Robert F.; Pace, Thaddeus W. W.; Binder, Elisabeth; Sheridan, John F.; Elliott, James M.; Basu, Archana; Fromer, Menachem; Parlikar, Tushar; Zaslavsky, Alan M.; Kessler, Ronald			The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure	MOLECULAR PSYCHIATRY			English	Article							MAXIMUM-LIKELIHOOD-ESTIMATION; STRUCTURAL EQUATION MODELS; MOTOR-VEHICLE COLLISION; POSTTRAUMATIC-STRESS; WIDESPREAD PAIN; DISORDER; US; INJURY; PREDICTORS; SYMPTOMS	Adverse posttraumatic neuropsychiatric sequelae (APNS) are common among civilian trauma survivors and military veterans. These APNS, as traditionally classified, include posttraumatic stress, postconcussion syndrome, depression, and regional or widespread pain. Traditional classifications have come to hamper scientific progress because they artificially fragment APNS into siloed, syndromic diagnoses unmoored to discrete components of brain functioning and studied in isolation. These limitations in classification and ontology slow the discovery of pathophysiologic mechanisms, biobehavioral markers, risk prediction tools, and preventive/treatment interventions. Progress in overcoming these limitations has been challenging because such progress would require studies that both evaluate a broad spectrum of posttraumatic sequelae (to overcome fragmentation) and also perform in-depth biobehavioral evaluation (to index sequelae to domains of brain function). This article summarizes the methods of the Advancing Understanding of RecOvery afteR traumA (AURORA) Study. AURORA conducts a large-scale (n = 5000 target sample) in-depth assessment of APNS development using a state-of-the-art battery of self-report, neurocognitive, physiologic, digital phenotyping, psychophysical, neuroimaging, and genomic assessments, beginning in the early aftermath of trauma and continuing for 1 year. The goals of AURORA are to achieve improved phenotypes, prediction tools, and understanding of molecular mechanisms to inform the future development and testing of preventive and treatment interventions.	[McLean, Samuel A.; An, Xinming; Linnstaedt, Sarah] UNC Sch Med, Inst Trauma Recovery, Dept Anesthesiol, Chapel Hill, NC 27599 USA; [Ressler, Kerry; Germine, Laura; Pizzagalli, Diego A.; Rauch, Scott L.; Lebois, Lauren A. M.] McLean Hosp, Dept Psychiat, Boston, MA USA; [Koenen, Karestan Chase; Basu, Archana] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Neylan, Thomas] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Jovanovic, Tanja] Wayne State Univ, Dept Psychiat & Behav Neurosci, Sch Med, Detroit, MI 48207 USA; [Clifford, Gari D.] Emory Univ, Sch Med, Dept Biomed Informat, Atlanta, GA USA; [Zeng, Donglin] UNC Gillings Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA; [Beaudoin, Francesca] Brown Univ, Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA; [House, Stacey] Washington Univ, Sch Med, Dept Emergency Med, St Louis, MO USA; [Bollen, Kenneth A.] Univ N Carolina, Dept Stat & Operat Res, Chapel Hill, NC 27515 USA; [Musey, Paul] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN 46202 USA; [Hendry, Phyllis] Univ Florida, Coll Med, Dept Emergency Med, Jacksonville, FL USA; [Jones, Christopher W.] Cooper Univ Hlth Care, Dept Emergency Med, Camden, NJ USA; [Lewandowski, Christopher] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA; [Swor, Robert] William Beaumont Sch Med, Dept Emergency Med, Royal Oak, MI USA; [Datner, Elizabeth] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Mohiuddin, Kamran] Einstein Hlth Med Ctr, Dept Emergency Med, Philadelphia, PA USA; [Stevens, Jennifer S.; Young, Larry J.; van Rooij, Sanne J. H.; Binder, Elisabeth] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA; [Storrow, Alan] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN USA; [Kurz, Michael Christopher] Univ Alabama Birmingham, Sch Med, Dept Emergency Med, Birmingham, AL USA; [McGrath, Meghan E.] Boston Univ, Med Ctr, Dept Emergency Med, Boston, MA USA; [Fermann, Gregory J.] Univ Cincinnati, Med Ctr, Dept Emergency Med, Cincinnati, OH 45267 USA; [Hudak, Lauren A.] Emory Univ Hosp, Dept Emergency Med, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Gentile, Nina] Temple Univ, Lewis Katz Sch Med, Dept Emergency Med, Philadelphia, PA 19122 USA; [Chang, Anna Marie] Thomas Jefferson Univ Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA; [Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Pascual, Jose L.; Seamon, Mark J.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Sergot, Paulina] Univ Texas Houston, McGovern Med Sch, Dept Emergency Med, Houston, TX USA; [Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; [Diercks, Deborah] UT Southwestern Med Ctr, Dept Emergency Med, Dallas, TX USA; [Sanchez, Leon D.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Rathlev, Niels] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA; [Domeier, Robert] St Joseph Mercy Ann Arbor Hosp, Dept Emergency Med, Ypsilanti, MI USA; [Haran, John Patrick] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA USA; [Pearson, Claire] Wayne State Univ, Sch Med, Dept Emergency Med, Detroit, MI USA; [Murty, Vishnu P.] Temple Univ, Dept Psychol, Coll Liberal Arts, Philadelphia, PA 19122 USA; [Insel, Thomas R.; Dagum, Paul; Dougherty, Robert F.] Mindstrong Hlth, Mountain View, CA USA; [Onnela, Jukka-Pekka] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Bruce, Steven E.] Univ Missouri, Dept Psychol Sci, St Louis, MO 63121 USA; [Gaynes, Bradley N.] UNC Sch Med, Dept Psychiat, Chapel Hill, NC USA; [Joormann, Jutta] Yale Univ, Dept Psychol, New Haven, CT USA; [Miller, Mark W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Pietrzak, Robert H.] Yale Sch Med, Dept Psychiat, West Haven, CT USA; [Buysse, Daniel J.; Luna, Beatriz] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Harte, Steven E.] Univ Michigan, Dept Anesthesiol, Sch Med, Ann Arbor, MI 48109 USA; [Barch, Deanna M.] Washington Univ, Sch Med, Dept Psychol & Brain Sci, St Louis, MO USA; [Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Pace, Thaddeus W. W.] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ USA; [Sheridan, John F.] Ohio State Univ, Coll Dent, Sch Med, Columbus, OH 43210 USA; [Elliott, James M.] Northwestern Univ, Feinberg Sch Med, Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA; [Fromer, Menachem; Parlikar, Tushar] Verily Life Sci, San Francisco, CA USA; [Zaslavsky, Alan M.; Kessler, Ronald] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA		McLean, SA (corresponding author), UNC Sch Med, Inst Trauma Recovery, Dept Anesthesiol, Chapel Hill, NC 27599 USA.	Samuel_McLean@med.unc.edu	Lebois, Lauren/AAB-3224-2021; Sanchez, Leon/R-7681-2019; Buysse, Daniel/AAJ-1608-2021; Seamon, Mark/AAM-4713-2021; Facility, Biospecimen Processing/AAC-7837-2022; Stevens, Jennifer/T-4290-2018	Lebois, Lauren/0000-0001-5816-9181; Sanchez, Leon/0000-0002-8807-0913; Buysse, Daniel/0000-0002-3288-1864; Stevens, Jennifer/0000-0003-4674-0314; Germine, Laura/0000-0001-8690-8412; Linnstaedt, Sarah/0000-0001-5295-7072; Clifford, Gari/0000-0002-5709-201X; Sergot, Paulina/0000-0003-0796-8009; McLean, Samuel/0000-0001-9482-3582	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH110925]; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); One Mind Foundation; Mayday Fund	Funding for the study was provided by NIMH U01MH110925, the US Army Medical Research and Material Command, The One Mind Foundation, and The Mayday Fund. Verily Life Sciences and Mindstrong Health provided some of the hardware and software used to perform study assessments.	Alarcon LH, 2012, J TRAUMA ACUTE CARE, V72, P629, DOI 10.1097/TA.0b013e31824416aa; American College of Emergency Physicians (ACEP), 2017, ER VIS INCR HIGH REC; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bollen KA, 1995, SOCIOL METHODOL, V25, P223, DOI 10.2307/271068; BOLLEN KA, 1987, SOCIOL METHOD RES, V15, P375, DOI 10.1177/0049124187015004002; Boscarino JA, 2006, ANN EPIDEMIOL, V16, P248, DOI 10.1016/j.annepidem.2005.03.009; CHERNOW B, 1987, ARCH INTERN MED, V147, P1273, DOI 10.1001/archinte.147.7.1273; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Elklit A, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.24221; Freeman D, 2013, PSYCHOL MED, V43, P2673, DOI 10.1017/S003329171300038X; Giannoudis PV, 2007, SPINE, V32, P776, DOI 10.1097/01.brs.0000259223.77957.76; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Hastie T, 2009, ELEMENTS STAT LEARNI, V2nd, DOI 10.1007/978-0-387-84858-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu JM, 2016, PAIN, V157, P438, DOI 10.1097/j.pain.0000000000000388; JAKSCHIK BA, 1974, J CLIN INVEST, V54, P842, DOI 10.1172/JCI107824; Jenewein J, 2009, J PSYCHOSOM RES, V66, P119, DOI 10.1016/j.jpsychores.2008.07.011; Kessler RC, 2016, MOL PSYCHIATR, V21, P1366, DOI 10.1038/mp.2015.198; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kessler RC, 2015, JAMA PSYCHIAT, V72, P49, DOI 10.1001/jamapsychiatry.2014.1754; Kessler RC, 2014, WORLD PSYCHIATRY, V13, P265, DOI 10.1002/wps.20150; Klein A, 2000, PSYCHOMETRIKA, V65, P457, DOI 10.1007/BF02296338; Klein AG, 2007, MULTIVAR BEHAV RES, V42, P647, DOI 10.1080/00273170701710205; Koenen KC, RO1 IDENTIFYING RISK, P2014; LEFER AM, 1969, AM J PHYSIOL, V216, P314, DOI 10.1152/ajplegacy.1969.216.2.314; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2009, J REHABIL RES DEV, V46, P697702; MacKinnon DP., 2008, ERLBAUM, DOI [DOI 10.1007/978-1-4842-0043-8_5, DOI 10.4324/9780203809556]; McLean SA, 2014, PAIN, V155, P309, DOI 10.1016/j.pain.2013.10.016; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Hospital Ambulatory Medical Care Survey, 2011, 2011 EM DEP SUMM TAB; Roberts AL, 2011, PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; SPATHSCHWALBE E, 1991, BIOL PSYCHIAT, V29, P575, DOI 10.1016/0006-3223(91)90093-2; Sterling M, 2011, PAIN, V152, P1272, DOI 10.1016/j.pain.2011.01.056; UDELSMAN R, 1987, J SURG RES, V43, P539, DOI 10.1016/0022-4804(87)90128-4; Ulirsch JC, 2014, EUR J PAIN, V18, P559, DOI 10.1002/j.1532-2149.2013.00395.x; Ulirsch JC, 2014, PAIN, V155, P2116, DOI 10.1016/j.pain.2014.07.025; Vanderhaeghen M, 2007, AIP CONF PROC, V904, P25; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; World Health Organization, 1993, ICD 10 CLASS MENT BE; Wynne-Jones G, 2006, J RHEUMATOL, V33, P968; Zatzick DF, 2003, PSYCHOSOMATICS, V44, P479, DOI 10.1176/appi.psy.44.6.479; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	45	33	33	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	FEB	2020	25	2					283	296		10.1038/s41380-019-0581-3			14	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	KH7UM	WOS:000510855100005	31745239	Green Submitted, Green Accepted			2022-02-06	
J	Liu, L; Chen, B; Liu, K; Gao, JB; Ye, YC; Wang, Z; Qin, N; Wilson, DA; Tu, YF; Peng, F				Liu, Lu; Chen, Bin; Liu, Kun; Gao, Junbin; Ye, Yicheng; Wang, Zhen; Qin, Ni; Wilson, Daniela A.; Tu, Yingfeng; Peng, Fei			Wireless Manipulation of Magnetic/Piezoelectric Micromotors for Precise Neural Stem-Like Cell Stimulation	ADVANCED FUNCTIONAL MATERIALS			English	Article						magnetic control; micromotor; neuronal regeneration; precise stimulation; wireless ultrasound	DEEP BRAIN-STIMULATION; DIFFERENTIATION; GROWTH; ENHANCEMENT; ACTIVATION; DELIVERY; SYSTEMS; ENERGY; DEVICE; CAMP	Precise neural electrical stimulation, which is a means of promoting neuronal regeneration, is a promising solution for patients with neurotrauma and neurodegenerative diseases. In this study, wirelessly controllable targeted motion and precise stimulation at the single-cell level using S.platensis@Fe3O4@tBaTiO(3) micromotors are successfully demonstrated for the first time. A highly versatile and multifunctional biohybrid soft micromotor is fabricated via the integration of S.platensis with magnetic Fe3O4 nanoparticles and piezoelectric BaTiO3 nanoparticles. The results show that this micromotor system can achieve navigation in a highly controllable manner under a low-strength rotating magnetic field. The as-developed system can achieve single-cell targeted motion and then precisely induce the differentiation of the targeted neural stem-like cell by converting ultrasonic energy to an electrical signal in situ owing to the piezoelectric effect. This new approach toward the high-precision stimulation of neural stem-like cells opens up new applications for micromotors and has excellent potential for precise neuronal regenerative therapies.	[Liu, Lu; Chen, Bin; Liu, Kun; Gao, Junbin; Ye, Yicheng; Tu, Yingfeng] Southern Med Univ, Guangdong Prov Key Lab New Drug Screening, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China; [Liu, Lu; Wang, Zhen; Qin, Ni; Peng, Fei] Sun Yat Sen Univ, Sch Mat Sci & Engn, Guangzhou 510275, Guangdong, Peoples R China; [Wilson, Daniela A.] Radboud Univ Nijmegen, Inst Mol & Mat, NL-6525 AJ Nijmegen, Netherlands		Tu, YF (corresponding author), Southern Med Univ, Guangdong Prov Key Lab New Drug Screening, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China.; Peng, F (corresponding author), Sun Yat Sen Univ, Sch Mat Sci & Engn, Guangzhou 510275, Guangdong, Peoples R China.	tuyingfeng1@smu.edu.cn; pengf26@mail.sysu.edu.cn	Wilson, Daniela A./A-8119-2010; Liu, Kun/Y-9393-2018; Tu, Yingfeng/B-7661-2016	Wilson, Daniela A./0000-0002-8796-2274; Liu, Kun/0000-0002-7276-7935; Tu, Yingfeng/0000-0003-2605-0172	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21805318, 51973241, 31800835]; Guangdong Provincial Science FoundationNational Natural Science Foundation of Guangdong Province [2018B030306007, 2018A030313521]; Chinese 1000-Talent Young Program; Pearl Youth Scholar Funded Scheme	This work was supported by the National Natural Science Foundation of China (Grant Nos. 21805318, 51973241, and 31800835) and the Guangdong Provincial Science Foundation (Grant Nos. 2018B030306007 and 2018A030313521). The authors are grateful for the support from the Chinese 1000-Talent Young Program and Pearl Youth Scholar Funded Scheme.	Albert GC, 2009, NEUROSCI BIOBEHAV R, V33, P1042, DOI 10.1016/j.neubiorev.2009.04.006; Balazs AC, 2018, ACCOUNTS CHEM RES, V51, P2979, DOI 10.1021/acs.accounts.8b00511; BELAY A, 1993, J APPL PHYCOL, V5, P235, DOI 10.1007/BF00004024; Brooks AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08423-7; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; Chang XC, 2019, ACS APPL MATER INTER, V11, P28507, DOI 10.1021/acsami.9b08159; Chen DZ, 2012, INT J NANOMED, V7, P4973, DOI 10.2147/IJN.S35140; Chen MC, 2010, AM J PHYSIOL-CELL PH, V299, pC516, DOI 10.1152/ajpcell.00534.2009; Choi H, 2018, ACS APPL MATER INTER, V10, P2338, DOI 10.1021/acsami.7b16595; Ciofani G, 2010, ACS NANO, V4, P6267, DOI 10.1021/nn101985a; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; de Avila BEF, 2017, ACS NANO, V11, P5367, DOI 10.1021/acsnano.7b01926; de Haas R, 2012, J NEUROSCI METH, V209, P113, DOI 10.1016/j.jneumeth.2012.05.028; Dubey AK, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5414-6; Esch T, 1999, J NEUROSCI, V19, P6417; Fu SZ, 2017, NANOSCALE, V9, P9026, DOI 10.1039/c7nr01168g; Gao W, 2014, NANOSCALE, V6, P10486, DOI 10.1039/c4nr03124e; Gao W, 2013, NANOSCALE, V5, P4696, DOI 10.1039/c3nr01458d; Garcia-Gradilla V, 2013, ACS NANO, V7, P9232, DOI 10.1021/nn403851v; Genchi GG, 2016, ADV HEALTHC MATER, V5, P1808, DOI 10.1002/adhm.201600245; Goud KY, 2019, ACS SENSORS, V4, P2196, DOI 10.1021/acssensors.9b01127; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; Halls ML, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004143; Hoop M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03992-3; Hu XH, 2018, SMALL, V14, DOI 10.1002/smll.201800504; Huang C, 2010, GLIA, V58, P1415, DOI 10.1002/glia.21017; Iacovacci V, 2019, SMALL, V15, DOI 10.1002/smll.201900709; Jang B, 2017, ACS NANO, V11, P6146, DOI 10.1021/acsnano.7b02177; Jeon S, 2019, SCI ROBOT, V4, DOI 10.1126/scirobotics.aav4317; Jurado-Sanchez B, 2015, CHEM COMMUN, V51, P14088, DOI 10.1039/c5cc04726a; Kagan D, 2012, ANGEW CHEM INT EDIT, V51, P7519, DOI 10.1002/anie.201201902; Kagan D, 2010, SMALL, V6, P2741, DOI 10.1002/smll.201001257; Katuri J, 2017, ACCOUNTS CHEM RES, V50, P2, DOI 10.1021/acs.accounts.6b00386; Khan Z, 2005, CURR PHARM BIOTECHNO, V6, P373, DOI 10.2174/138920105774370607; Kim Y, 2019, SCI ROBOT, V4, DOI 10.1126/scirobotics.aax7329; Kong L, 2019, ANAL CHEM, V91, P5660, DOI 10.1021/acs.analchem.8b05464; Kong L, 2018, ACS APPL MATER INTER, V10, P22427, DOI 10.1021/acsami.8b05776; Lee H, 2018, BIOMED MICRODEVICES, V20, P1, DOI 10.1007/s10544-018-0344-y; Lee K, 2016, ANGEW CHEM INT EDIT, V55, P7384, DOI 10.1002/anie.201601211; Lee S, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700985; Levi-Montalcini R., 1997, NEUROREPORT, V3, P352; Li H, 2018, MICROMACHINES-BASEL, V9, DOI 10.3390/mi9040182; Li H, 2016, J MICROENCAPSUL, V33, P712, DOI 10.1080/02652048.2016.1234514; Li JX, 2017, SCI ROBOT, V2, DOI 10.1126/scirobotics.aam6431; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Maric T, 2019, ACS APPL MATER INTER, V11, P31832, DOI 10.1021/acsami.9b08332; Marino A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24697-1; Marino A, 2015, ACS NANO, V9, P7678, DOI 10.1021/acsnano.5b03162; Mojon DS, 2015, EYE, V29, P225, DOI 10.1038/eye.2014.281; Moo JGS, 2016, ACS SENSORS, V1, P949, DOI 10.1021/acssensors.6b00314; Moo JGS, 2015, CHEM-EUR J, V21, P58, DOI 10.1002/chem.201405011; Ni SB, 2017, SOFT MATTER, V13, P4252, DOI 10.1039/c7sm00443e; Pantazis P, 2010, P NATL ACAD SCI USA, V107, P14535, DOI 10.1073/pnas.1004748107; Parran DK, 2003, DEV BRAIN RES, V141, P71, DOI 10.1016/S0165-3806(02)00644-2; Peng F, 2017, ADV MATER, V29, DOI 10.1002/adma.201604996; Royo-Gascon N, 2013, ANN BIOMED ENG, V41, P112, DOI 10.1007/s10439-012-0628-y; Safdar M, 2018, ADV MATER, V30, DOI 10.1002/adma.201703660; Srivastava SK, 2016, ADV MATER, V28, P832, DOI 10.1002/adma.201504327; Tu YF, 2019, ANGEW CHEM INT EDIT, V58, P8687, DOI 10.1002/anie.201900917; Valls-Sole J, 2008, CLIN NEUROPHYSIOL, V119, P1219, DOI 10.1016/j.clinph.2007.12.020; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Wang ET, 2010, CHIN J TRAUMATOL, V13, P55, DOI 10.3760/cma.j.issn.1008-1275.2010.01.011; Wang H, 2016, CHEM-US, V1, P473, DOI 10.1016/j.chempr.2016.08.009; Wang W, 2019, J AM CHEM SOC, V141, P6601, DOI 10.1021/jacs.8b13882; Wang XP, 2019, ADV MATER, V31, DOI 10.1002/adma.201901592; Wang XD, 2007, NANO LETT, V7, P2475, DOI 10.1021/nl0712567; Wang Y, 2018, ANGEW CHEM INT EDIT, V57, P13110, DOI 10.1002/anie.201807033; Wu J, 2018, NANO ENERGY, V45, P44, DOI 10.1016/j.nanoen.2017.12.034; Wu MX, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201606039; Xi W, 2013, NANOSCALE, V5, P1294, DOI 10.1039/c2nr32798h; Xie YZ, 2017, BIOSENS BIOELECTRON, V87, P31, DOI 10.1016/j.bios.2016.07.104; Xu TL, 2017, ADV MATER, V29, DOI 10.1002/adma.201603250; Xu TQ, 2019, SCI ROBOT, V4, DOI 10.1126/scirobotics.aav4494; Xuan MJ, 2018, ANGEW CHEM INT EDIT, V57, P12463, DOI 10.1002/anie.201806759; Yamamoto D, 2019, J CHEM PHYS, V150, DOI 10.1063/1.5055830; Yan XH, 2017, SCI ROBOT, V2, DOI 10.1126/scirobotics.aaq1155; Yan XH, 2015, ADV FUNCT MATER, V25, P5333, DOI 10.1002/adfm.201502248; Zhang SF, 2009, PHARM RES-DORDR, V26, P1561, DOI 10.1007/s11095-009-9897-z	79	33	33	45	178	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1616-301X	1616-3028		ADV FUNCT MATER	Adv. Funct. Mater.	MAR	2020	30	11							1910108	10.1002/adfm.201910108		JAN 2020	8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	KV0UQ	WOS:000508487300001					2022-02-06	
J	Krizman, J; Kraus, N				Krizman, Jennifer; Kraus, Nina			Analyzing the FFR: A tutorial for decoding the richness of auditory function	HEARING RESEARCH			English	Article							FREQUENCY-FOLLOWING-RESPONSE; HUMAN BRAIN-STEM; MUSICAL EXPERIENCE; NEURAL REPRESENTATION; SPEECH-PERCEPTION; PHASE-LOCKING; PITCH; CHILDREN; HEARING; SOUND	The frequency-following response, or FFR, is a neurophysiological response to sound that precisely reflects the ongoing dynamics of sound. It can be used to study the integrity and malleability of neural encoding of sound across the lifespan. Sound processing in the brain can be impaired with pathology and enhanced through expertise. The FFR can index linguistic deprivation, autism, concussion, and reading impairment, and can reflect the impact of enrichment with short-term training, bilingualism, and musicianship. Because of this vast potential, interest in the FFR has grown considerably in the decade since our first tutorial. Despite its widespread adoption, there remains a gap in the current knowledge of its analytical potential. This tutorial aims to bridge this gap. Using recording methods we have employed for the last 20 + years, we have explored many analysis strategies. In this tutorial, we review what we have learned and what we think constitutes the most effective ways of capturing what the FFR can tell us. The tutorial covers FFR components (timing, fundamental frequency, harmonics) and factors that influence FFR (stimulus polarity, response averaging, and stimulus presentation/recording jitter). The spotlight is on FFR analyses, including ways to analyze FFR timing (peaks, autocorrelation, phase consistency, cross-phaseogram), magnitude (RMS, SNR, FFT), and fidelity (stimulus-response correlations, response-to-response correlations and response consistency). The wealth of information contained within an FFR recording brings us closer to understanding how the brain reconstructs our sonic world. (C) 2019 Elsevier B.V. All rights reserved.	[Krizman, Jennifer; Kraus, Nina] Northwestern Univ, Dept Commun Sci & Disorders, Auditory Neurosci Lab, Evanston, IL 60208 USA; [Kraus, Nina] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA		Kraus, N (corresponding author), Northwestern Univ, 2240 Campus Dr, Evanston, IL 60208 USA.	nkraus@northwestern.edu			National Science FoundationNational Science Foundation (NSF) [BCS-1430400]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD069414]; National Association of Music Merchants; Dana Foundation; Knowles Hearing Center, Northwestern University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069414] Funding Source: NIH RePORTER	The authors thank everyone in the Auditory Neuroscience Laboratory, past and present, for their help with data collection and processing. The authors also thank Trent Nicol and Travis White-Schwoch for their comments on an earlier version of the manuscript. This work was supported by the National Science Foundation (BCS-1430400), National Institutes of Health (R01 HD069414), the National Association of Music Merchants, the Dana Foundation, and the Knowles Hearing Center, Northwestern University. The authors declare no conflicts of interest.	Aiken SJ, 2008, HEARING RES, V245, P35, DOI 10.1016/j.heares.2008.08.004; Akhoun I, 2008, CLIN NEUROPHYSIOL, V119, P922, DOI 10.1016/j.clinph.2007.12.010; Anderson S, 2013, J ACOUST SOC AM, V133, P3030, DOI 10.1121/1.4799804; Anderson S, 2013, P NATL ACAD SCI USA, V110, P4357, DOI 10.1073/pnas.1213555110; Anderson S, 2010, HEARING RES, V270, P151, DOI 10.1016/j.heares.2010.08.001; Anderson S, 2010, J NEUROSCI, V30, P4922, DOI 10.1523/JNEUROSCI.0107-10.2010; Assaneo MF, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao3842; Ayala YA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16774-8; Banai K, 2009, CEREB CORTEX, V19, P2699, DOI 10.1093/cercor/bhp024; Bidelman GM, 2018, NEUROIMAGE, V175, P56, DOI 10.1016/j.neuroimage.2018.03.060; Bidelman GM, 2015, HEARING RES, V323, P68, DOI 10.1016/j.heares.2015.01.011; BinKhamis G, 2019, EAR HEARING, V40, P659, DOI 10.1097/AUD.0000000000000648; Bonacina S, 2018, ANN NY ACAD SCI, V1423, P338, DOI 10.1111/nyas.13704; Carcagno S, 2011, JARO-J ASSOC RES OTO, V12, P89, DOI 10.1007/s10162-010-0236-1; Chandrasekaran B, 2010, PSYCHOPHYSIOLOGY, V47, P236, DOI 10.1111/j.1469-8986.2009.00928.x; Chen JR, 2019, AUTISM RES, V12, P1022, DOI 10.1002/aur.2110; Coffey EBJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11070; Etard O, 2019, NEUROIMAGE, V200, P1, DOI 10.1016/j.neuroimage.2019.06.029; Forte AE, 2017, ELIFE, V6, DOI 10.7554/eLife.27203; Galbraith GC, 1998, NEUROREPORT, V9, P1889, DOI 10.1097/00001756-199806010-00041; Galbraith GC, 1995, NEUROREPORT, V6, P2363, DOI 10.1097/00001756-199511270-00021; Galbraith GC, 1997, ELECTROEN CLIN NEURO, V102, P46, DOI 10.1016/S0013-4694(96)96006-X; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Gama N, 2017, J NEUROSCI METH, V280, P47, DOI 10.1016/j.jneumeth.2017.01.016; GORGA MP, 1988, J SPEECH HEAR RES, V31, P87, DOI 10.1044/jshr.3101.87; Greenberg S., 1998, P 11 INT S HEAR, P257; GREENWOOD D, 1961, J ACOUST SOC AM, V33, P1344, DOI 10.1121/1.1908437; Hornickel J, 2013, J NEUROSCI, V33, P3500, DOI 10.1523/JNEUROSCI.4205-12.2013; Hornickel J, 2012, HEARING RES, V284, P52, DOI 10.1016/j.heares.2011.12.005; Hornickel J, 2009, P NATL ACAD SCI USA, V106, P13022, DOI 10.1073/pnas.0901123106; Jeng FC, 2011, EAR HEARING, V32, P699, DOI 10.1097/AUD.0b013e31821cc0df; John MS, 2000, HEARING RES, V141, P57, DOI 10.1016/S0378-5955(99)00209-9; Johnson KL, 2008, CLIN NEUROPHYSIOL, V119, P2623, DOI 10.1016/j.clinph.2008.07.277; Kachlicka M, 2019, BRAIN LANG, V192, P15, DOI 10.1016/j.bandl.2019.02.004; KIMBERLEY BP, 1993, J ACOUST SOC AM, V94, P1343, DOI 10.1121/1.408162; King C, 2002, NEUROSCI LETT, V319, P111, DOI 10.1016/S0304-3940(01)02556-3; Kraus N., 2016, SCI REP, V97, pe11; Kraus N., 2016, MAKING SENSE SOUND B; Kraus N, 2017, SPRINGER HANDB AUDIT, V61, P1, DOI 10.1007/978-3-319-47944-6_1; Kraus N, 2017, NEUROSCIENTIST, V23, P287, DOI 10.1177/1073858416653593; Kraus N, 2017, NEUROSCI LETT, V646, P21, DOI 10.1016/j.neulet.2017.03.008; Kraus N, 2015, TRENDS COGN SCI, V19, P642, DOI 10.1016/j.tics.2015.08.017; Kraus N, 2010, NAT REV NEUROSCI, V11, P599, DOI 10.1038/nrn2882; Krishnan A, 2005, COGNITIVE BRAIN RES, V25, P161, DOI 10.1016/j.cogbrainres.2005.05.004; Krishnan A, 2004, HEARING RES, V189, P1, DOI 10.1016/S0378-5955(03)00402-7; Krishnan A, 2002, HEARING RES, V166, P192, DOI 10.1016/S0378-5955(02)00327-1; Krishnan A, 2009, BRAIN LANG, V110, P135, DOI 10.1016/j.bandl.2009.03.005; Krizman J, 2019, HEARING RES, V380, P166, DOI 10.1016/j.heares.2019.07.002; Krizman J, 2016, DEVELOPMENTAL SCI, V19, P881, DOI 10.1111/desc.12347; Krizman J, 2015, NEUROSCI LETT, V585, P48, DOI 10.1016/j.neulet.2014.11.011; Krizman J, 2014, BRAIN LANG, V128, P34, DOI 10.1016/j.bandl.2013.11.006; Krizman J, 2012, P NATL ACAD SCI USA, V109, P7877, DOI 10.1073/pnas.1201575109; Krizman J, 2012, CLIN NEUROPHYSIOL, V123, P590, DOI 10.1016/j.clinph.2011.07.037; Krizman J, 2010, AUDIOL NEURO-OTOL, V15, P332, DOI 10.1159/000289572; Kumar V, 2013, 2013 ACM/IEEE INTERNATIONAL CONFERENCE ON INFORMATION PROCESSING IN SENSOR NETWORKS (IPSN), P3, DOI 10.1109/IPSN.2013.6917551; Kuwada Shigeyuki, 2002, J Am Acad Audiol, V13, P188; Liu LF, 2006, J NEUROPHYSIOL, V95, P1926, DOI 10.1152/jn.00497.2005; Lyon R. F., 1982, Proceedings of ICASSP 82. IEEE International Conference on Acoustics, Speech and Signal Processing, P1282; Maggu AR, 2018, INTERSPEECH, P1437, DOI 10.21437/Interspeech.2018-2130; Malmierca M.S., 2015, ANATOMY PHYSL MAMMAL, P155; Malmierca MS, 2019, NEUROIMAGE, V184, P889, DOI 10.1016/j.neuroimage.2018.10.012; Malmierca MS, 2011, AUDITORY CORTEX, P189, DOI 10.1007/978-1-4419-0074-6_9; Mansour Y, 2019, HEARING RES, V377, P234, DOI 10.1016/j.heares.2019.04.004; Marmel F, 2013, JARO-J ASSOC RES OTO, V14, P757, DOI 10.1007/s10162-013-0402-3; Musacchia G., 2019, J PERINATOL, DOI [10.1038/541372-019-0421-y, DOI 10.1038/541372-019-0421-Y]; Musacchia G, 2007, P NATL ACAD SCI USA, V104, P15894, DOI 10.1073/pnas.0701498104; Neef NE, 2017, DEV COGN NEUROS-NETH, V24, P63, DOI 10.1016/j.dcn.2017.01.008; Nishida T, 2018, 2018 IEEE INTERNATIONAL CONFERENCE ON AGENTS (ICA), P126, DOI 10.1109/AGENTS.2018.8460069; Omote A, 2017, CORTEX, V93, P146, DOI 10.1016/j.cortex.2017.05.005; Otto-Meyer S, 2018, EXP BRAIN RES, V236, P733, DOI 10.1007/s00221-017-5164-4; PALMER AR, 1986, HEARING RES, V24, P1, DOI 10.1016/0378-5955(86)90002-X; Parbery-Clark A, 2013, J NEUROSCI, V33, P16741, DOI 10.1523/JNEUROSCI.5700-12.2013; Parbery-Clark A, 2009, J NEUROSCI, V29, P14100, DOI 10.1523/JNEUROSCI.3256-09.2009; Ribas-Prats T, 2019, HEARING RES, V371, P28, DOI 10.1016/j.heares.2018.11.001; Roque L, 2019, J SPEECH LANG HEAR R, V62, P1099, DOI 10.1044/2018_JSLHR-H-ASCC7-18-0076; RUGGERO MA, 1987, J NEUROPHYSIOL, V58, P379, DOI 10.1152/jn.1987.58.2.379; Ruggles D, 2012, CURR BIOL, V22, P1417, DOI 10.1016/j.cub.2012.05.025; Russo N, 2004, CLIN NEUROPHYSIOL, V115, P2021, DOI 10.1016/j.clinph.2004.04.003; Russo NM, 2008, CLIN NEUROPHYSIOL, V119, P1720, DOI 10.1016/j.clinph.2008.01.108; Sanfins MD, 2018, J INT ADV OTOL, V14, P100, DOI 10.5152/iao.2018.3574; Selinger L, 2016, J NEUROSCI, V36, P10782, DOI 10.1523/JNEUROSCI.1595-16.2016; Skoe E., 2010, PLOS ONE, V243, P104; Skoe E., 2013, NEUROSCIENCE; Skoe E, 2017, NEUROSCIENCE, V349, P278, DOI 10.1016/j.neuroscience.2017.02.049; Skoe E, 2015, CEREB CORTEX, V25, P1415, DOI 10.1093/cercor/bht311; Skoe E, 2013, J NEUROSCI, V33, P17221, DOI 10.1523/JNEUROSCI.2102-13.2013; Skoe E, 2011, J NEUROSCI METH, V196, P308, DOI 10.1016/j.jneumeth.2011.01.020; Skoe E, 2010, EAR HEARING, V31, P302, DOI 10.1097/AUD.0b013e3181cdb272; SOHMER H, 1977, ELECTROEN CLIN NEURO, V42, P656, DOI 10.1016/0013-4694(77)90282-6; Song JH, 2008, J COGNITIVE NEUROSCI, V20, P1892, DOI 10.1162/jocn.2008.20131; Song JH, 2011, CLIN NEUROPHYSIOL, V122, P346, DOI 10.1016/j.clinph.2010.07.009; Strait DL, 2014, CEREB CORTEX, V24, P2512, DOI 10.1093/cercor/bht103; Strait DL, 2009, EUR J NEUROSCI, V29, P661, DOI 10.1111/j.1460-9568.2009.06617.x; Tichko P, 2017, HEARING RES, V348, P1, DOI 10.1016/j.heares.2017.01.014; Tierney A., 2015, P NATL ACAD SCI USA; Tierney A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00855; Tierney A, 2013, J NEUROSCI, V33, P14981, DOI 10.1523/JNEUROSCI.0612-13.2013; Warrier CM, 2011, HEARING RES, V282, P108, DOI 10.1016/j.heares.2011.09.001; Werff KRV, 2017, EAR HEARING, V38, pE200, DOI 10.1097/AUD.0000000000000411; White-Schwoch T, 2019, J NEUROPHYSIOL, V122, P844, DOI 10.1152/jn.00112.2019; White-Schwoch T, 2017, CEREB CORTEX, V27, P5095, DOI 10.1093/cercor/bhw293; White-Schwoch T, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002196; Wong PCM, 2007, NAT NEUROSCI, V10, P420, DOI 10.1038/nn1872; Zhao TC, 2019, BRAIN LANG, V194, P77, DOI 10.1016/j.bandl.2019.05.002; Zhu L, 2013, J ACOUST SOC AM, V134, P384, DOI 10.1121/1.4807498	105	33	33	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-5955	1878-5891		HEARING RES	Hear. Res.	OCT	2019	382								107779	10.1016/j.heares.2019.107779			16	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	JF2KL	WOS:000491214200003	31505395	Bronze, Green Accepted			2022-02-06	
J	Izzy, S; Liu, Q; Fang, Z; Lule, S; Wu, LM; Chung, JY; Sarro-Schwartz, A; Brown-Whalen, A; Perner, C; Hickman, SE; Kaplan, DL; Patsopoulos, NA; El Khoury, J; Whalen, MJ				Izzy, Saef; Liu, Qiong; Fang, Zhou; Lule, Sevda; Wu, Limin; Chung, Joon Yong; Sarro-Schwartz, Aliyah; Brown-Whalen, Alexander; Perner, Caroline; Hickman, Suzanne E.; Kaplan, David L.; Patsopoulos, Nikolaos A.; El Khoury, Joseph; Whalen, Michael J.			Time-Dependent Changes in Microglia Transcriptional Networks Following Traumatic Brain Injury	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						traumatic brain injury; microglia; transcriptome; neurodegeneration; mice; neuroimmunology; neuroinflammation	CONTROLLED CORTICAL IMPACT; INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; CD40 LIGAND; CELL-DEATH; EXPRESSION; HYPOXIA; NEUROINFLAMMATION; ACTIVATION; MECHANISM	The neuroinflammatory response to traumatic brain injury (TBI) is critical to both neurotoxicity and neuroprotection, and has been proposed as a potentially modifiable driver of secondary injury in animal and human studies. Attempts to broadly target immune activation have been unsuccessful in improving outcomes, in part because the precise cellular and molecular mechanisms driving injury and outcome at acute, subacute, and chronic time points after TBI remain poorly defined. Microglia play a critical role in neuroinflammation and their persistent activation may contribute to long-term functional deficits. Activated microglia are characterized by morphological transformation and transcriptomic changes associated with specific inflammatory states. We analyzed the temporal course of changes in inflammatory genes of microglia isolated from injured brains at 2, 14, and 60 days after controlled cortical impact (CCI) in mice, a well-established model of focal cerebral contusion. We identified a time dependent, injury-associated change in the microglial gene expression profile toward a reduced ability to sense tissue damage, perform housekeeping, and maintain homeostasis in the early stages following CCI, with recovery and transition to a specialized inflammatory state over time. This later state starts at 14 days post-injury and is characterized by a biphasic pattern of IFN gamma, IL-4, and IL-10 gene expression changes, with concurrent proinflammatory and anti-inflammatory gene changes. Our transcriptomic data sets are an important step to understand microglial role in TBI pathogenesis at the molecular level and identify common pathways that affect outcome. More studies to evaluate gene expression at the single cell level and focusing on subacute and chronic timepoint are warranted.	[Izzy, Saef; Sarro-Schwartz, Aliyah] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Izzy, Saef; Brown-Whalen, Alexander; Perner, Caroline; Hickman, Suzanne E.; El Khoury, Joseph] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02115 USA; [Izzy, Saef; Lule, Sevda; Wu, Limin; Chung, Joon Yong; Brown-Whalen, Alexander; Perner, Caroline; Hickman, Suzanne E.; El Khoury, Joseph; Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Charlestown, MA USA; [Izzy, Saef; Fang, Zhou; Sarro-Schwartz, Aliyah; Perner, Caroline; Hickman, Suzanne E.; Patsopoulos, Nikolaos A.; El Khoury, Joseph; Whalen, Michael J.] Harvard Med Sch, Boston, MA 02115 USA; [Liu, Qiong] Fudan Univ, Sch Basic Med Sci, Dept Anat Histol & Embryol, Shanghai, Peoples R China; [Liu, Qiong] Shanghai Key Lab Med Imaging Comp & Comp Assisted, Shanghai, Peoples R China; [Fang, Zhou; Patsopoulos, Nikolaos A.] Brigham & Womens Hosp, Dept Neurol, Syst Biol & Comp Sci Program, Ann Romney Ctr Neurol Dis, Boston, MA USA; [Fang, Zhou; Patsopoulos, Nikolaos A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; [Fang, Zhou; Patsopoulos, Nikolaos A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; [Fang, Zhou; Patsopoulos, Nikolaos A.] Broad Inst Harvard, Cambridge, MA USA; [Patsopoulos, Nikolaos A.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02115 USA; [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA		El Khoury, J (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02115 USA.; El Khoury, J; Whalen, MJ (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Charlestown, MA USA.; El Khoury, J; Whalen, MJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Whalen, MJ (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02115 USA.	jelkhoury@mgh.harvard.edu; MWHALEN@mgh.harvard.edu	; Lule, Sevda/N-8229-2017	Chung, Joon Yong/0000-0002-3980-2065; Lule, Sevda/0000-0001-7066-6471; Perner, Caroline/0000-0002-0851-1759	National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [1RF1AG051506, R01NS092847-01]; National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [31871029]	This work was supported by the National Institute on Aging (NIA) Grant 1RF1AG051506 (to JK), the R01NS092847-01 (to DK), and National Natural Science Fund of China 31871029 (to QL).	Aarts SABM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01791; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Alawieh A, 2018, J NEUROSCI, V38, P2519, DOI 10.1523/JNEUROSCI.2197-17.2018; Almeida-Suhett CP, 2014, J NEUROTRAUM, V31, P683, DOI 10.1089/neu.2013.3029; Arneson D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06222-0; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bizet AA, 2011, BBA-MOL CELL RES, V1813, P742, DOI 10.1016/j.bbamcr.2011.01.028; Block F, 1997, NEUROREPORT, V8, P3829, DOI 10.1097/00001756-199712010-00033; Brait VH, 2019, CIRC RES, V124, P279, DOI 10.1161/CIRCRESAHA.118.313818; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Calingasan NY, 2002, NEUROBIOL AGING, V23, P31, DOI 10.1016/S0197-4580(01)00246-9; Carbonell WS, 2005, J NEUROSCI, V25, P7040, DOI 10.1523/JNEUROSCI.5171-04.2005; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Chung JY, 2019, J NEUROTRAUM, V36, P370, DOI 10.1089/neu.2018.5659; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clarkson BDS, 2014, J EXP MED, V211, P595, DOI 10.1084/jem.20131377; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hammad A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1066-z; Hanamsagar R, 2017, GLIA, V65, P1504, DOI 10.1002/glia.23176; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Hickman S, 2018, NAT NEUROSCI, V21, P1359, DOI 10.1038/s41593-018-0242-x; Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Higashida T, 2011, CURR NEUROVASC RES, V8, P44, DOI 10.2174/156720211794520251; Hirbec HE, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00227; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Huang RQ, 2010, NEUROSCI LETT, V473, P22, DOI 10.1016/j.neulet.2010.02.011; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jing J, 2013, J IMMUNOL, V190, P6360, DOI 10.4049/jimmunol.1202942; Joy MT, 2019, CELL, V176, P1143, DOI 10.1016/j.cell.2019.01.044; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laporte V, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-3; Lipponen A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31570; Liu YWY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1173-x; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Moran LB, 2007, J NEUROIMMUNOL, V183, P1, DOI 10.1016/j.jneuroim.2006.10.023; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Nishihara T, 2011, EXP NEUROL, V229, P507, DOI 10.1016/j.expneurol.2011.04.006; O'Neil SM, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0636-8; Oflazoglu E, 2009, ADV EXP MED BIOL, V647, P174, DOI 10.1007/978-0-387-89520-8_12; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a020560; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Saber M, 2017, J NEUROTRAUM, V34, P423, DOI 10.1089/neu.2016.4401; Samal BB, 2015, J MOL NEUROSCI, V57, P282, DOI 10.1007/s12031-015-0626-2; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Smith DE, 2009, IMMUNITY, V30, P817, DOI 10.1016/j.immuni.2009.03.020; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Spencer NG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162497; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Szmydynger-Chodobska J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167677; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Takeuchi H, 2006, NEUROBIOL DIS, V22, P33, DOI 10.1016/j.nbd.2005.09.014; Tan J, 2002, NAT NEUROSCI, V5, P1288, DOI 10.1038/nn968; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; von Bernhardi R, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00426; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Waggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188; Wang H, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw677; Wang WY, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.49; White TE, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2412-0; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wong YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020216; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027798; Zhang M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02751	98	33	33	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	AUG 8	2019	13								307	10.3389/fncel.2019.00307			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IO2YK	WOS:000479247500001	31440141	gold, Green Published			2022-02-06	
J	Kochanek, PM; Tasker, RC; Carney, N; Totten, AM; Adelson, PD; Selden, NR; Davis-O'Reilly, C; Hart, EL; Bell, MJ; Bratton, SL; Grant, GA; Kissoon, N; Reuter-Rice, KE; Vavilala, MS; Wainwright, MS				Kochanek, Patrick M.; Tasker, Robert C.; Carney, Nancy; Totten, Annette M.; Adelson, P. David; Selden, Nathan R.; Davis-O'Reilly, Cynthia; Hart, Erica L.; Bell, Michael J.; Bratton, Susan L.; Grant, Gerald A.; Kissoon, Niranjan; Reuter-Rice, Karin E.; Vavilala, Monica S.; Wainwright, Mark S.			Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary	NEUROSURGERY			English	Article						Critical care; Evidence-based medicine; Head injury; Guidelines; Pediatrics; Systematic review; Traumatic brain injury	EARLY DECOMPRESSIVE CRANIECTOMY; COMMON DATA ELEMENTS; REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL PERFUSION-PRESSURE; THERAPEUTIC HYPOTHERMIA; HYPERTONIC SALINE; HEAD-INJURY; CENTER EXPERIENCE; SINGLE-CENTER; CHILDREN	The purpose of this work is to identify and synthesize research produced since the second edition of these Guidelines was published and incorporate new results into revised evidence-based recommendations for the treatment of severe traumatic brain injury in pediatric patients. This document provides an overview of our process, lists the new research added, and includes the revised recommendations. Recommendations are only provided when there is supporting evidence. This update includes 22 recommendations, 9 are new or revised from previous editions. New recommendations on neuroimaging, hyperosmolar therapy, analgesics and sedatives, seizure prophylaxis, temperature control/hypothermia, and nutrition are provided. None are level I, 3 are level II, and 19 are level III. The Clinical Investigators responsible for these Guidelines also created a companion algorithm that supplements the recommendations with expert consensus where evidence is not available and organizes possible interventions into first and second tier utilization. The complete guideline document and supplemental appendices are available electronically (https://doi.org/10.1097/PCC.0000000000001735). The online documents contain summaries and evaluations of all the studies considered, including those from prior editions, and more detailed information on our methodology. New level II and level III evidence-based recommendations and an algorithm provide additional guidance for the development of local protocols to treat pediatric patients with severe traumatic brain injury. Our intention is to identify and institute a sustainable process to update these Guidelines as new evidence becomes available.	[Kochanek, Patrick M.] Univ Pittsburgh, Dept Anesthesiol Pediat Bioengn & Clin & Translat, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med,Sch Med,Safar Ctr Resuscitat R, Pittsburgh, PA USA; [Tasker, Robert C.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Dept Neurol, Boston, MA USA; [Tasker, Robert C.] Harvard Med Sch, Boston, MA 02115 USA; [Carney, Nancy; Totten, Annette M.; Davis-O'Reilly, Cynthia; Hart, Erica L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Pacific Northwest Evidence Based Practice Ctr, Portland, OR 97201 USA; [Adelson, P. David] Childrens Hosp, BARROW Neurol Inst Phoenix, Dept Pediat Neurosurg, Phoenix, AZ USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Bell, Michael J.] Childrens Natl Med Ctr, Dept Crit Care Med, Washington, DC 20010 USA; [Bratton, Susan L.] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, Child & Family Res Inst, British Columbias Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Reuter-Rice, Karin E.] Duke Univ, Sch Nursing, Div Pediat Crit Care Med, Dept Pediat,Sch Med, Durham, NC USA; [Vavilala, Monica S.] Univ Washington, Dept Pediat, Dept Anesthesiol & Pain Med, HIPRC, Seattle, WA 98195 USA; [Wainwright, Mark S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA		Kochanek, PM (corresponding author), UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, John G Rangos Res Ctr, 6th Floor,4401 Penn Ave, Pittsburgh, PA 15224 USA.	kochanekpm@ccm.upmc.edu	Kissoon, Niranjan/AAC-6140-2021	Reuter-Rice, Karin/0000-0003-1501-8994; Kissoon, Niranjan/0000-0001-8847-9973; Totten, Annette/0000-0002-9100-8678	U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911QY-14-C-0086]; Brain Trauma Foundation; Society of Critical Care Medicine; Stanford UniversityStanford University; Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Sage Therapeutics	Supported, in part, by the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to StanfordUniversity (W911QY-14-C-0086) and a subcontract awarded toOregon Health & Science University. Prior editions were supported, in part, by funding from multiple sources through the Brain Trauma Foundation. Dr Kochanek received funding from the Society of Critical Care Medicine (Editor-in-Chief of Pediatric Critical Care Medicine), from serving as an expert witness on cases in pediatric critical care. DrsCarney and Totten's, MsDavis-O'Reilly's, and MsHart's institutions received funding from Stanford University. Dr Selden disclosed that he has stock options (current $ 0 value) in Cerebrotech for scientific advisory board service (this device is not clinically available and is not referenced in the work). Dr Reuter-Rice received funding from textbook royalties and curriculum content, and she received support for article research from Robert Wood Johnson Foundation funding 2013-2016. Dr Wainwright received funding from Sage Therapeutics. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Bata SC, 2014, ANZ J SURG, V84, P438, DOI 10.1111/ans.12582; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bell MJ, 2017, CHILD NERV SYST, V33, P1663, DOI 10.1007/s00381-017-3530-y; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chin KH, 2015, PEDIATR CRIT CARE ME, V16, P352, DOI 10.1097/PCC.0000000000000344; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Crompton E, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002565; Crompton EM, 2017, CRIT CARE MED, V45, P575, DOI 10.1097/CCM.0000000000002205; Csokay A, 2012, CHILD NERV SYST, V28, P441, DOI 10.1007/s00381-011-1661-0; de Andrade AF, 2011, ARQ NEURO-PSIQUIAT, V69, P79, DOI 10.1590/S0004-282X2011000100016; Desgranges FP, 2014, CHILD NERV SYST, V30, P1393, DOI 10.1007/s00381-014-2417-4; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Ferguson NM, 2016, PEDIATR CRIT CARE ME, V17, P444, DOI 10.1097/PCC.0000000000000709; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2010, NEUROCRIT CARE, V12, P430, DOI 10.1007/s12028-010-9344-3; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, pS1, DOI 10.1097/PCC.0000000000001735; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kurz JE, 2016, PEDIATR CRIT CARE ME, V17, P649, DOI 10.1097/PCC.0000000000000765; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mhanna MJ, 2015, J NEUROSURG-PEDIATR, V16, P508, DOI 10.3171/2014.10.PEDS14117; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piper BJ, 2015, ANAESTH INTENS CARE, V43, P204, DOI 10.1177/0310057X1504300210; Prasad GL, 2015, BRAIN INJURY, V29, P1717, DOI 10.3109/02699052.2015.1075146; Roumeliotis N, 2016, CHILD NERV SYST, V32, P2363, DOI 10.1007/s00381-016-3231-y; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Taha AA, 2011, J NEUROSCI NURS, V43, P291, DOI 10.1097/JNN.0b013e318234e9b2; Tasker RC, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002526; Tasker RC, 2017, PEDIATR CRIT CARE ME, V18, P355, DOI 10.1097/PCC.0000000000001098; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Webster DL, 2015, J CRIT CARE, V30, P1267, DOI 10.1016/j.jcrc.2015.07.022; Welch TP, 2016, CRIT CARE MED, V44, P809, DOI 10.1097/CCM.0000000000001558	63	33	35	1	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2019	84	6					1169	1178		10.1093/neuros/nyz051			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	IC8QQ	WOS:000471247000028	30822776	Bronze			2022-02-06	
J	Callcut, RA; Kornblith, LZ; Conroy, AS; Robles, AJ; Meizoso, JP; Namias, N; Meyer, DE; Haymaker, A; Truitt, MS; Agrawal, V; Haan, JM; Lightwine, KL; Porter, JM; San Roman, JL; Biffl, WL; Hayashi, MS; Sise, MJ; Badiee, J; Recinos, G; Inaba, K; Schroeppel, TJ; Callaghan, E; Dunn, JA; Godin, S; McIntyre, RC; Peltz, ED; O'Neill, PJ; Diven, CF; Scifres, AM; Switzer, EE; West, MA; Storrs, S; Cullinane, DC; Cordova, JF; Moore, EE; Moore, HB; Privette, AR; Eriksson, EA; Cohen, MJ; Manning, RJ; Gutierrez, T; Deramo, P; Dunne, CE; Wong, MD; Krell, RV; Cross, AM; Butler, C; Moore, C; Rumford, R				Callcut, Rachael A.; Kornblith, Lucy Z.; Conroy, Amanda S.; Robles, Anamaria J.; Meizoso, Jonathan P.; Namias, Nicholas; Meyer, David E.; Haymaker, Amanda; Truitt, Michael S.; Agrawal, Vaidehi; Haan, James M.; Lightwine, Kelly L.; Porter, John M.; San Roman, Janika L.; Biffl, Walter L.; Hayashi, Michael S.; Sise, Michael J.; Badiee, Jayraan; Recinos, Gustavo; Inaba, Kenji; Schroeppel, Thomas J.; Callaghan, Emma; Dunn, Julie A.; Godin, Samuel; McIntyre, Robert C.; Peltz, Erik D.; O'Neill, Patrick J.; Diven, Conrad F.; Scifres, Aaron M.; Switzer, Emily E.; West, Michaela A.; Storrs, Sarah; Cullinane, Daniel C.; Cordova, John F.; Moore, Ernest E.; Moore, Hunter B.; Privette, Alicia R.; Eriksson, Evert A.; Cohen, Mitchell Jay; Manning, Ronald J.; Gutierrez, Tim; Deramo, Paul; Dunne, Casey E.; Wong, Monica D.; Krell, Regina V.; Cross, Alisa M.; Butler, Cressilee; Moore, Cindy; Rumford, Richelle		Western Trauma Assoc Multictr	The why and how our trauma patients die: A prospective Multicenter Western Trauma Association study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	48th Annual Meeting of the Western-Trauma-Association (WTA)	FEB 15-MAR 03, 2018	Whistler, CANADA	Western Trauma Assoc		Hemorrhage; cause of death; exsanguination	BLOOD-CELL TRANSFUSION; PREHOSPITAL DEATHS; MORTALITY; IMPACT	BACKGROUND: Historically, hemorrhage has been attributed as the leading cause (40%) of early death. However, a rigorous, real-time classification of the cause of death (COD) has not been performed. This study sought to prospectively adjudicate and classify COD to determine the epidemiology of trauma mortality. METHODS: Eighteen trauma centers prospectively enrolled all adult trauma patients at the time of death during December 2015 to August 2017. Immediately following death, attending providers adjudicated the primary and contributing secondary COD using standardized definitions. Data were confirmed by autopsies, if performed. RESULTS: One thousand five hundred thirty-six patients were enrolled with a median age of 55 years (interquartile range, 32-75 years), 74.5% were male. Penetrating mechanism (n = 412) patients were younger (32 vs. 64, p < 0.0001) and more likely to be male (86.7% vs. 69.9%, p < 0.0001). Falls were the most common mechanism of injury (26.6%), with gunshot wounds second (24.3%). The most common overall primary COD was traumatic brain injury (TBI) (45%), followed by exsanguination (23%). Traumatic brain injury was nonsurvivable in 82.2% of cases. Blunt patients were more likely to have TBI (47.8% vs. 37.4%, p < 0.0001) and penetrating patients exsanguination (51.7% vs. 12.5%, p < 0.0001) as the primary COD. Exsanguination was the predominant prehospital (44.7%) and early COD (39.1%) with TBI as the most common later. Penetrating mechanism patients died earlier with 80.1% on day 0 (vs. 38.5%, p < 0.0001). Most deaths were deemed disease-related (69.3%), rather than by limitation of further aggressive care (30.7%). Hemorrhage was a contributing cause to 38.8% of deaths that occurred due to withdrawal of care. CONCLUSION: Exsanguination remains the predominant early primary COD with TBI accounting for most deaths at later time points. Timing and primary COD vary significantly by mechanism. Contemporaneous adjudication of COD is essential to elucidate the true understanding of patient outcome, center performance, and future research. Copyright (c) 2019 Wolters Kluwer Health, Inc. All rights reserved.	[Callcut, Rachael A.; Kornblith, Lucy Z.; Conroy, Amanda S.; Robles, Anamaria J.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94143 USA; [Meizoso, Jonathan P.; Namias, Nicholas; Manning, Ronald J.] Univ Miami, Jackson Mem Hosp, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Meyer, David E.; Haymaker, Amanda] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Surg, Houston, TX 77030 USA; [Truitt, Michael S.; Agrawal, Vaidehi; Gutierrez, Tim; Deramo, Paul] Methodist Dallas Med Ctr, Div Trauma & Acute Care, Dallas, TX USA; [Haan, James M.; Lightwine, Kelly L.] Univ Kansas, Sch Med, Dept Trauma, Via Christi Hlth,Wichita Campus, Wichita, KS 67214 USA; [Porter, John M.; San Roman, Janika L.] Cooper Univ Hosp, Div Trauma, Camden, NJ USA; [Biffl, Walter L.] Scripps Mem Hosp La Jolla, Dept Surg, La Jolla, CA USA; [Hayashi, Michael S.] Univ Hawaii, Queens Med Ctr, Dept Surg, Honolulu, HI 96822 USA; [Sise, Michael J.; Badiee, Jayraan; Dunne, Casey E.] Scripps Mercy Hosp, Trauma Serv, San Diego, CA USA; [Recinos, Gustavo; Inaba, Kenji; Dunne, Casey E.] Los Angeles Cty Univ Southern Calif Med Ctr, Div Surg Crit Care & Trauma, Los Angeles, CA USA; [Schroeppel, Thomas J.; Callaghan, Emma] Univ Colorado Hlth, Dept Surg, Mem Hosp, Colorado Springs, CO USA; [Dunn, Julie A.; Godin, Samuel] Univ Colorado Hlth North, Med Ctr Rockies, Dept Surg, Loveland, CO USA; [McIntyre, Robert C.; Peltz, Erik D.; Krell, Regina V.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO USA; [O'Neill, Patrick J.; Diven, Conrad F.; Cross, Alisa M.] Abrazo Med Grp, Dept Trauma & Gen Surg, Abrazo West Campus, Goodyear, AZ USA; [Scifres, Aaron M.; Switzer, Emily E.; Butler, Cressilee; Moore, Cindy; Rumford, Richelle] Univ Oklahoma, Dept Surg, Oklahoma City, OK USA; [West, Michaela A.; Storrs, Sarah] North Mem Hlth Hosp, Div Trauma & Emergency Acute Care Surg, Robbinsdale, MN USA; [Cullinane, Daniel C.; Cordova, John F.] Marshfield Clin Fdn Med Res & Educ, Dept Surg, Marshfield, WI USA; [Moore, Ernest E.; Moore, Hunter B.] Univ Colorado, Denver Hlth Med Ctr, Dept Surg, Denver, CO 80202 USA; [Privette, Alicia R.; Eriksson, Evert A.] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA; [Cohen, Mitchell Jay] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; [Cohen, Mitchell Jay] Univ Colorado, Med Ctr, Aurora, CO USA		Callcut, RA (corresponding author), Zuckerberg San Francisco Gen Hosp, Dept Surg, Ward 3A,1001 Potrero Ave, San Francisco, CA 94110 USA.	Rachael.Callcut@ucsf.edu	INABA, KENJI/AAC-8532-2020; Meizoso, Jonathan/AAF-5777-2019; Agrawal, Vaidehi/B-8282-2019; Wong, Monica D/D-9016-2017; Callcut, Rachael/ABE-1484-2021	Meizoso, Jonathan/0000-0002-6616-6682; Agrawal, Vaidehi/0000-0002-1958-630X; Wong, Monica D/0000-0001-7041-9518; Schroeppel, Thomas/0000-0001-9164-5004; Hayashi, Michael/0000-0001-9743-4945; West, Michaela A/0000-0002-6598-4114; Meyer, David/0000-0002-3816-0160	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01ES026834]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K01ES026834] Funding Source: NIH RePORTER	Dr. Callcut is supported by NIH K01ES026834.	Brown JB, 2015, J AM COLL SURGEONS, V220, P797, DOI 10.1016/j.jamcollsurg.2015.01.006; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Cripps MW, 2013, J TRAUMA ACUTE CARE, V75, pS255, DOI 10.1097/TA.0b013e31829a24b4; Davis JS, 2014, J TRAUMA ACUTE CARE, V77, P213, DOI 10.1097/TA.0000000000000292; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; Fox EE, 2017, SHOCK, V47, P567, DOI 10.1097/SHK.0000000000000788; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Nardi G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0817-9; Oliver GJ, 2017, INJURY, V48, P985, DOI 10.1016/j.injury.2017.02.026; Oyeniyi BT, 2017, INJURY, V48, P5, DOI 10.1016/j.injury.2016.10.037; Pang JM, 2008, INJURY, V39, P102, DOI 10.1016/j.injury.2007.05.022; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Powell EK, 2016, J TRAUMA ACUTE CARE, V81, P458, DOI 10.1097/TA.0000000000001078; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Trunkey D, 1988, SCI AM, V4, pb22; Valdez C, 2016, J SURG RES, V200, P604, DOI 10.1016/j.jss.2015.08.031; Weireter LJ, 2014, AM SURGEON, V80, P764	19	33	34	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2019	86	5					864	870		10.1097/TA.0000000000002205			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	HW6KW	WOS:000466799900015	30633095	Green Accepted			2022-02-06	
J	Yauger, YJ; Bermudez, S; Moritz, KE; Glaser, E; Stoica, B; Byrnes, KR				Yauger, Young J.; Bermudez, Sara; Moritz, Kasey E.; Glaser, Ethan; Stoica, Bogdan; Byrnes, Kimberly R.			Iron accentuated reactive oxygen species release by NADPH oxidase in activated microglia contributes to oxidative stress in vitro	JOURNAL OF NEUROINFLAMMATION			English	Article						BV2; Iron sulfate; Neuronal toxicity; Microglial polarization; Neuroinflammation	TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; ACCUMULATION; EXPRESSION; SUSCEPTIBILITY; NEUROTOXICITY; DEFEROXAMINE; INFLAMMATION; SPECIFICITY; INVOLVEMENT	Background: Excessive iron contributes to oxidative stress after central nervous system injury. NADPH oxidase (NOX) enzymes are upregulated in microglia after pro-inflammatory activation and contribute to oxidative stress. The relationship between iron, microglia, NOX, and oxidative stress is currently unclear. Methods: We evaluated the effects of iron on lipopolysaccharide (LPS)-activated microglia and its secondary effect within neuronal co-cultures. Further, NOX2 and four specific inhibitors were tested to evaluate the relationship with the reactive oxygen species (ROS)-producing enzymes. Results: An iron dose-dependent increase in ROS production among microglia treated with LPS was identified. Interestingly, despite this increase in ROS, inflammatory polarization alterations were not detected among the microglia after exposure to iron and LPS. Co-culture experimentation between primary neurons and exposed microglia (iron and LPS) significantly reduced neuronal cell number at 24 h, suggesting a profound neurotoxic effect despite the lack of a change in polarization phenotype. NOX2 and NOX4 inhibition significantly reduced ROS production among microglia exposed to iron and LPS and reduced neuronal damage and death in response to microglial co-culture. Conclusions: In conclusion, iron significantly increased ROS production and neurotoxicity without exacerbating LP-activated microglia phenotype in vitro, suggesting that iron contributes to microglia-related oxidative stress, and this may be a viable therapeutic target for injury or neurodegeneration. Further, this study highlights both NOX2 and NOX4 as potential therapeutic targets in the treatment of iron-induced microglia-related inflammation and neurotoxicity.	[Yauger, Young J.; Moritz, Kasey E.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Neurosci Grad Program, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Bermudez, Sara; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Glaser, Ethan; Stoica, Bogdan] Univ Maryland, Sch Med, Dept Anesthesiol, 655 W Baltimore St,Room 6-015, Baltimore, MD 21201 USA; [Glaser, Ethan; Stoica, Bogdan] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, 655 W Baltimore St,Room 6-015, Baltimore, MD 21201 USA		Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Neurosci Grad Program, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	kimberly.byrnes@usuhs.edu		Byrnes, Kimberly/0000-0002-7501-7734	Tri Service Nursing Research Program (TSNRP) [HU0001-15-1-TS16]	This research was completely funded by the Tri Service Nursing Research Program (TSNRP) grant number HU0001-15-1-TS16.	Aguirre P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144848; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chenais B, 2002, J NEUROCHEM, V81, P615, DOI 10.1046/j.1471-4159.2002.00864.x; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Das A, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0644-1; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z; Ghosh M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0463-9; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Haleagrahara N, 2013, J TOXICOL SCI, V38, P25, DOI 10.2131/jts.38.25; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2016, J BIOENERG BIOMEMBR, V48, P169, DOI 10.1007/s10863-015-9600-5; Iles KE, 2002, IMMUNOL RES, V26, P95, DOI 10.1385/IR:26:1-3:095; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Ke Y, 2007, PROG NEUROBIOL, V83, P149, DOI 10.1016/j.pneurobio.2007.07.009; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Lazarus RC, 2015, FREE RADICAL BIO MED, V78, P89, DOI 10.1016/j.freeradbiomed.2014.10.507; Li YP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0740-2; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Mehhase J, 2006, BBA-MOL CELL RES, V1763, P854, DOI 10.1016/j.bbamcr.2006.04.012; Nakamura T, 2005, BRAIN RES, V1039, P30, DOI 10.1016/j.brainres.2005.01.036; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; Nishio S, 1997, ACT NEUR S, V70, P84; Piga R, 2007, NEUROTOXICOLOGY, V28, P67, DOI 10.1016/j.neuro.2006.07.006; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Song N, 2007, J NEUROSCI RES, V85, P3118, DOI 10.1002/jnr.21430; Stansley B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-115; Sung YM, 2016, PAK J PHARM SCI, V29, P1087; Tamashiro TT, 2012, JOVE-J VIS EXP, DOI 10.3791/3814; Urrutia P, 2013, J NEUROCHEM, V126, P541, DOI 10.1111/jnc.12244; von Leden RE, 2017, J NEUROTRAUM, V34, P755, DOI 10.1089/neu.2016.4486; Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703; Wang QS, 2014, GLIA, V62, P2034, DOI 10.1002/glia.22724; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; You LH, 2015, NEUROSCIENCE, V284, P234, DOI 10.1016/j.neuroscience.2014.09.071; Zhang GX, 2016, NEUROCHEM RES, V41, P2948, DOI 10.1007/s11064-016-2013-y; Zhang LJ, 2013, NEUROL SCI, V34, P639, DOI 10.1007/s10072-012-1090-1; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhu YQ, 2017, PARKINSONISM RELAT D, V36, P76, DOI 10.1016/j.parkreldis.2017.01.003; Zucca FA, 2017, PROG NEUROBIOL, V155, P96, DOI 10.1016/j.pneurobio.2015.09.012	47	33	34	3	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 18	2019	16								41	10.1186/s12974-019-1430-7			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	HM1IC	WOS:000459202900004	30777083	Green Published, gold			2022-02-06	
J	Balan, I; Beattie, MC; O'Buckley, TK; Aurelian, L; Morrow, AL				Balan, Irina; Beattie, Matthew C.; O'Buckley, Todd K.; Aurelian, Laure; Morrow, A. Leslie			Endogenous Neurosteroid (3 alpha,5 alpha)3-Hydroxypregnan-20-one Inhibits Toll-like-4 Receptor Activation and Pro-inflammatory Signaling in Macrophages and Brain	SCIENTIFIC REPORTS			English	Article							CORTICOTROPIN-RELEASING-FACTOR; STEROID-HORMONE METABOLITES; OF-CONCEPT TRIAL; NEUROACTIVE STEROIDS; PROGESTERONE METABOLITE; ETHANOL-CONSUMPTION; NEGATIVE SYMPTOMS; ALCOHOL-DRINKING; GENE-EXPRESSION; GROWTH-FACTOR	The endogenous neurosteroid (3 alpha,5 alpha)3-hydroxypregnan-20-one (3 alpha,5 alpha-THP, allopregnanolone) has protective activity in animal models of alcoholism, depression, traumatic brain injury, schizophrenia, multiple sclerosis, and Alzheimer's disease that is poorly understood. Because these conditions involve proinflammatory signaling through toll-like receptors (TLRs), we examined the effects of 3 alpha,5 alpha-THP, and pregnenolone on TLR4 activation in both the periphery and the central nervous system (CNS). We used monocytes/macrophages (RAW264.7) as a model of peripheral immune signaling and studied innately activated TLR4 in the ventral tegmental area (VTA) of selectively bred alcohol-preferring (P) rats. LPS activated the TLR4 pathway in RAW264.7 cells as evidenced by increased levels of p-TAK1, TRAF6, NF-kappa B p50, phospho-NF-kappa B-p65, pCREB, HMGB1, and inflammatory mediators, including MCP-1 and TNF alpha. Both 3 alpha,5 alpha-THP and pregnenolone (0.5-1.0 mu M) substantially (similar to 80%) inhibited these effects, indicating pronounced inhibition of TLR4 signaling. The mechanism of inhibition appears to involve blockade of TLR4/MD-2 protein interactions in RAW246.7 cells. In VTA, 3 alpha,5 alpha-THP (15 mg/kg, IP) administration reduced TRAF6 (similar to 20%), CRF (similar to 30%), and MCP-1 (similar to 20%) levels, as well as TLR4 binding to GABAA receptor a2 subunits (similar to 60%) and MyD88 (similar to 40%). The data suggest that inhibition of proinflammatory neuroimmune signaling underlies protective effects of 3 alpha,5 alpha-THP in immune cells and brain, apparently involving blocking of protein-protein interactions that initiate TLR4-dependent signaling. Inhibition of pro-inflammatory TLR4 activation represents a new mechanism of 3 alpha,5 alpha-THP action in the periphery and the brain.	[Balan, Irina; Aurelian, Laure] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA; [Beattie, Matthew C.; O'Buckley, Todd K.; Morrow, A. Leslie] Univ N Carolina, Dept Psychiat & Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27515 USA		Aurelian, L (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA.; Morrow, AL (corresponding author), Univ N Carolina, Dept Psychiat & Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27515 USA.	LAurelian@som.umaryland.edu; morrow@med.unc.edu		Balan, Irina/0000-0002-2299-6115; O'Buckley, Todd/0000-0001-8723-734X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01-AA020935, R01-AA024095, R01-AA021261]; Bowles Ctr for Alcohol Studies; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U24AA015512, R01AA024095] Funding Source: NIH RePORTER	This work was supported by NIH grants U01-AA020935, R01-AA024095 (ALM), R01-AA021261 (LA) and the Bowles Ctr for Alcohol Studies (ALM).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alfonso-Loeches S, 2016, NEUROCHEM RES, V41, P193, DOI 10.1007/s11064-015-1760-5; Alfonso-Loeches S, 2010, J NEUROSCI, V30, P8285, DOI 10.1523/JNEUROSCI.0976-10.2010; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Aurelian L, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.72; Balan I, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8040072; Balan I, 2018, BRAIN BEHAV IMMUN, V69, P139, DOI 10.1016/j.bbi.2017.11.008; Beattie MC, 2017, ADDICT BIOL, V22, P318, DOI 10.1111/adb.12326; Bhattacharya A, 2016, PSYCHOPHARMACOLOGY, V233, P1623, DOI 10.1007/s00213-016-4214-0; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P11, DOI 10.2174/156720506775697160; Bsibsi M, 2010, J IMMUNOL, V184, P6929, DOI 10.4049/jimmunol.0902419; Carlson SL, 2013, J PHARMACOL EXP THER, V345, P317, DOI 10.1124/jpet.112.201954; Chandrashekaran IR, 2018, FEBS LETT, V592, P179, DOI 10.1002/1873-3468.12953; Chattopadhyay S, 2014, CYTOKINE GROWTH F R, V25, P533, DOI 10.1016/j.cytogfr.2014.06.002; Cochet F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112318; Cook JB, 2014, J NEUROSCI, V34, P5824, DOI 10.1523/JNEUROSCI.4733-13.2014; CRAWLEY JN, 1986, BRAIN RES, V398, P382, DOI 10.1016/0006-8993(86)91500-3; Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003; Crews FT, 2017, NEUROPHARMACOLOGY, V122, P56, DOI 10.1016/j.neuropharm.2017.01.031; Crews FT, 2017, PSYCHOPHARMACOLOGY, V234, P1483, DOI 10.1007/s00213-017-4560-6; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dedic N, 2018, CURR MOL PHARMACOL, V11, P4, DOI 10.2174/1874467210666170302104053; DEVAUD LL, 1995, ALCOHOL CLIN EXP RES, V19, P350, DOI 10.1111/j.1530-0277.1995.tb01514.x; Faraz M, 2018, J BIOL CHEM, V293, P3421, DOI 10.1074/jbc.M117.807487; Fox HC, 2013, PSYCHONEUROENDOCRINO, V38, P1532, DOI 10.1016/j.psyneuen.2012.12.022; Fu HQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106331; Gondre-Lewis MC, 2016, STRESS, V19, P235, DOI 10.3109/10253890.2016.1160280; HARRISON NL, 1987, J PHARMACOL EXP THER, V241, P346; Quadros IMH, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00134; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Irwin RW, 2014, PROG NEUROBIOL, V113, P40, DOI 10.1016/j.pneurobio.2013.08.004; June HL, 2015, NEUROPSYCHOPHARMACOL, V40, P1549, DOI 10.1038/npp.2015.4; Kanes S, 2017, LANCET, V390, P480, DOI 10.1016/S0140-6736(17)31264-3; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Kim SJ, 2017, BMB REP, V50, P55, DOI 10.5483/BMBRep.2017.50.2.011; Kokate TG, 1996, NEUROPHARMACOLOGY, V35, P1049, DOI 10.1016/S0028-3908(96)00021-4; Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024; Lacagnina MJ, 2017, NEUROPSYCHOPHARMACOL, V42, P156, DOI 10.1038/npp.2016.121; Laing JM, 2010, J NEUROCHEM, V112, P662, DOI 10.1111/j.1471-4159.2009.06475.x; Lawrimore CJ, 2017, ALCOHOL CLIN EXP RES, V41, P939, DOI 10.1111/acer.13368; Leclercq S, 2012, BRAIN BEHAV IMMUN, V26, P911, DOI 10.1016/j.bbi.2012.04.001; Lee JW, 2017, J CHROMATOGR B, V1065, P14, DOI 10.1016/j.jchromb.2017.09.002; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Liu JA, 2011, P NATL ACAD SCI USA, V108, P4465, DOI 10.1073/pnas.1019020108; Lowery-Gionta EG, 2012, J NEUROSCI, V32, P3405, DOI 10.1523/JNEUROSCI.6256-11.2012; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Maroso M, 2011, J INTERN MED, V270, P319, DOI 10.1111/j.1365-2796.2011.02431.x; Maroso M, 2011, NEUROTHERAPEUTICS, V8, P304, DOI 10.1007/s13311-011-0039-z; Marx CE, 2007, BIOL PSYCHIAT, V61, p13S; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Mayfield J, 2017, NEUROPSYCHOPHARMACOL, V42, P376, DOI 10.1038/npp.2016.177; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; Milivojevic V, 2016, PSYCHONEUROENDOCRINO, V65, P44, DOI 10.1016/j.psyneuen.2015.12.008; Morita N, 2017, FEBS LETT, V591, P1732, DOI 10.1002/1873-3468.12693; Morrow AL, 2007, PHARMACOL THERAPEUT, V116, P1, DOI 10.1016/j.pharmthera.2007.04.003; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; Morrow AL, 2001, BRAIN RES REV, V37, P98, DOI 10.1016/S0165-0173(01)00127-8; Noorbakhsh F, 2014, FRONT CELL NEUROSCI, V8, P1, DOI 10.3389/fncel.2014.00134; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; OWENS MJ, 1992, BRAIN RES, V573, P353, DOI 10.1016/0006-8993(92)90788-B; Pandey SC, 2012, BRIT J PHARMACOL, V165, P1316, DOI 10.1111/j.1476-5381.2011.01695.x; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pascual M, 2017, ADDICT BIOL, V22, P1829, DOI 10.1111/adb.12461; Pascual M, 2011, BRAIN BEHAV IMMUN, V25, pS80, DOI 10.1016/j.bbi.2011.02.012; Patchev V.K., 1996, BRAIN SOURCE TARGET, P93; Patchev VK, 1996, NEUROPSYCHOPHARMACOL, V15, P533, DOI 10.1016/S0893-133X(96)00096-6; PATCHEV VK, 1994, NEUROSCIENCE, V62, P265, DOI 10.1016/0306-4522(94)90330-1; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Phillips TJ, 2015, GENES BRAIN BEHAV, V14, P98, DOI 10.1111/gbb.12189; Porcu P, 2014, PSYCHOPHARMACOLOGY, V231, P3257, DOI 10.1007/s00213-014-3564-8; Porcu P, 2010, ALCOHOL CLIN EXP RES, V34, P432, DOI 10.1111/j.1530-0277.2009.01123.x; Poulopoulos A, 2009, NEURON, V63, P628, DOI 10.1016/j.neuron.2009.08.023; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Qin LY, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-10; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Sanada T, 2008, J BIOL CHEM, V283, P33858, DOI 10.1074/jbc.M806923200; Sato S, 2016, MICROBIOL IMMUNOL, V60, P382, DOI 10.1111/1348-0421.12381; Sawle P, 2005, BRIT J PHARMACOL, V145, P800, DOI 10.1038/sj.bjp.0706241; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; Silva E, 2007, INTENS CARE MED, V33, P1829, DOI 10.1007/s00134-007-0748-2; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; Thomson CA, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-73; Tsatsanis C, 2006, J IMMUNOL, V176, P1869, DOI 10.4049/jimmunol.176.3.1869; VanDoren MJ, 2000, J NEUROSCI, V20, P1982; Vartanian KB, 2010, TRANSL STROKE RES, V1, P252, DOI 10.1007/s12975-010-0033-5; Walter TJ, 2017, ALCOHOL CLIN EXP RES, V41, P2066, DOI 10.1111/acer.13511; Whitman BA, 2013, ALCOHOL CLIN EXP RES, V37, P2086, DOI 10.1111/acer.12189; Winkler Z, 2017, BEHAV BRAIN RES, V334, P119, DOI 10.1016/j.bbr.2017.07.023; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107	100	33	34	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 4	2019	9								1220	10.1038/s41598-018-37409-6			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK0UA	WOS:000457616300109	30718548	Green Published, gold			2022-02-06	
J	Sosa, MAG; De Gasperi, R; Garcia, GSP; Perez, GM; Searcy, C; Vargas, D; Spencer, A; Janssen, PL; Tschiffely, AE; McCarron, RM; Ache, B; Manoharan, R; Janssen, WG; Tappan, SJ; Hanson, RW; Gandy, S; Hof, PR; Ahlers, ST; Elder, GA				Sosa, Miguel A. Gama; De Gasperi, Rita; Garcia, Georgina S. Perez; Perez, Gissel M.; Searcy, Courtney; Vargas, Danielle; Spencer, Alicia; Janssen, Pierce L.; Tschiffely, Anna E.; McCarron, Richard M.; Ache, Benjamin; Manoharan, Rajaram; Janssen, William G.; Tappan, Susan J.; Hanson, Russell W.; Gandy, Sam; Hof, Patrick R.; Ahlers, Stephen T.; Elder, Gregory A.			Low-level blast exposure disrupts gliovascular and neurovascular connections and induces a chronic vascular pathology in rat brain	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Animal model; Blast; Brain; Chronic; Gliovascular; Neurovascular; Rat; Vascular pathology	DISORDER-RELATED TRAITS; BLOOD-VESSELS; INJURY MODEL; STRESS; PRESSURE; WAVE; INFLAMMATION; MEMBRANES; BIOMARKER; DISEASE	Much concern exists over the role of blast-induced traumatic brain injury (TBI) in the chronic cognitive and mental health problems that develop in veterans and active duty military personnel. The brain vasculature is particularly sensitive to blast injury. The aim of this study was to characterize the evolving molecular and histologic alterations in the neurovascular unit induced by three repetitive low-energy blast exposures (3x74.5kPa) in a rat model mimicking human mild TBI or subclinical blast exposure. High-resolution two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry of purified brain vascular fractions from blast-exposed animals 6weeks post-exposure showed decreased levels of vascular-associated glial fibrillary acidic protein (GFAP) and several neuronal intermediate filament proteins (-internexin and the low, middle, and high molecular weight neurofilament subunits). Loss of these proteins suggested that blast exposure disrupts gliovascular and neurovascular interactions. Electron microscopy confirmed blast-induced effects on perivascular astrocytes including swelling and degeneration of astrocytic endfeet in the brain cortical vasculature. Because the astrocyte is a major sensor of neuronal activity and regulator of cerebral blood flow, structural disruption of gliovascular integrity within the neurovascular unit should impair cerebral autoregulation. Disrupted neurovascular connections to pial and parenchymal blood vessels might also affect brain circulation. Blast exposures also induced structural and functional alterations in the arterial smooth muscle layer. Interestingly, by 8months after blast exposure, GFAP and neuronal intermediate filament expression had recovered to control levels in isolated brain vascular fractions. However, despite this recovery, a widespread vascular pathology was still apparent at 10months after blast exposure histologically and on micro-computed tomography scanning. Thus, low-level blast exposure disrupts gliovascular and neurovascular connections while inducing a chronic vascular pathology.	[Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Searcy, Courtney; Vargas, Danielle; Spencer, Alicia; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Garcia, Georgina S. Perez; Janssen, Pierce L.; Janssen, William G.; Gandy, Sam; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [De Gasperi, Rita; Garcia, Georgina S. Perez; Perez, Gissel M.; Searcy, Courtney; Vargas, Danielle; Spencer, Alicia; Gandy, Sam] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Garcia, Georgina S. Perez; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave Levy Pl, New York, NY 10029 USA; [Janssen, Pierce L.; Janssen, William G.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Tschiffely, Anna E.; McCarron, Richard M.; Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [McCarron, Richard M.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20914 USA; [Ache, Benjamin; Manoharan, Rajaram] Micro Photon Inc, 1550 Pond Rd, Allentown, PA 18104 USA; [Tappan, Susan J.] MBF Biosci, 185 Allen Brook Lane, Williston, VT 05495 USA; [Hanson, Russell W.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Gandy, Sam; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Gandy, Sam; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA; [Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA		Sosa, MAG (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Sosa, MAG (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA.; Sosa, MAG (corresponding author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.	miguel.gama-sosa@mssm.edu		Vargas, Danielle/0000-0003-4409-9391	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service AwardsUS Department of Veterans Affairs [1 I01RX000996, 1 I01RX000684, 1 I21 RX002069-01, 1 I21 RX002876-01]; Department of DefenseUnited States Department of Defense [0000B999.0000.000.A1503]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 AG005138]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44MH099721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000996, I01RX002660, I21RX002069, I01RX000684, I21RX002876] Funding Source: NIH RePORTER	We thank Dr. Virginia Lee for generously providing the rat anti-GFAP antibody. We thank Timothy Tetreault for assistance with automatic quantification of vasculature. Work described in this paper was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1 I01RX000996, 1 I01RX000684, 1 I21 RX002069-01 and 1 I21 RX002876-01; by Department of Defense work unit number 0000B999.0000.000.A1503 and by NIH grant P50 AG005138. PLJ was a Carolyn L. Kuckein Student Research Fellow of the Alpha Omega Alpha Honor Medical Society. MAGS, RDG, GMP, GE, AET, SG and STA are employees of the U.S. government. This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, Department of Veterans Affairs, nor the U.S. Government.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Balaban C, 2016, J NEUROSCI METH, V272, P56, DOI 10.1016/j.jneumeth.2016.02.001; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bir C, 2012, MAGN RESON IMAGING, V30, P527, DOI 10.1016/j.mri.2011.12.003; Boulay AC, 2015, JOVE-J VIS EXP, DOI 10.3791/53208; BUSIJA DW, 1984, REV PHYSIOL BIOCH P, V101, P161, DOI 10.1007/BFb0027696; CAMPAGNE MV, 1991, J HISTOCHEM CYTOCHEM, V39, P1267, DOI 10.1177/39.9.1833448; Carr W, 2016, MIL MED, V181, P28, DOI 10.7205/MILMED-D-15-00137; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen HJ, 2015, CHIN J TRAUMATOL, V18, P267, DOI 10.1016/j.cjtee.2015.11.006; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Chun HB, 2011, J CEREBR BLOOD F MET, V31, P2267, DOI 10.1038/jcbfm.2011.104; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; dela Paz NG, 2009, CELL TISSUE RES, V335, P5, DOI 10.1007/s00441-008-0706-5; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Franciosi S, 2007, J NEUROSCI METH, V163, P76, DOI 10.1016/j.jneumeth.2007.02.020; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Hald ES, 2014, TRANSL STROKE RES, V5, P385, DOI 10.1007/s12975-013-0300-3; Hamel E, 2006, J APPL PHYSIOL, V100, P1059, DOI 10.1152/japplphysiol.00954.2005; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Iadecola C, 2017, NEURON, V96, P17, DOI 10.1016/j.neuron.2017.07.030; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Li BC, 2014, NEUROL RES, V36, P974, DOI 10.1179/1743132813Y.0000000314; Logsdon AF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29341-6; Logsdon AF, 2017, ARCH NEUROSCI, V4, DOI 10.5812/archneurosci.44254; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Ma Y, 2014, NEUROCHEM RES, V39, P1809, DOI 10.1007/s11064-014-1395-y; Mackie AR, 2011, TEX HEART I J, V38, P474; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; Pasquinelli G, 2007, STEM CELLS, V25, P1627, DOI 10.1634/stemcells.2006-0731; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Perez-Garcia G, 2019, NEUROPHARMACOLOGY, V145, P220, DOI 10.1016/j.neuropharm.2018.09.023; Perez-Garcia G, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0357-17.2018; Perez-Garcia G, 2018, BEHAV BRAIN RES, V340, P117, DOI 10.1016/j.bbr.2016.09.061; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Rajkowska G, 2013, BIOL PSYCHIAT, V73, P613, DOI 10.1016/j.biopsych.2012.09.024; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Rodriguez UA, 2018, J NEUROTRAUM, V35, P375, DOI 10.1089/neu.2017.5256; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sajja Venkata Siva Sai S, 2012, Biomed Sci Instrum, V48, P374; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Searcy JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089970; Sharrock AE, 2019, INJURY, V50, P125, DOI 10.1016/j.injury.2018.06.037; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sosa MAG, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0483-z; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Stenmark KR, 2013, ANNU REV PHYSIOL, V75, P23, DOI 10.1146/annurev-physiol-030212-183802; Stokum JA, 2017, BEHAV BRAIN RES, V333, P43, DOI 10.1016/j.bbr.2017.06.038; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tchantchou F, 2018, J NEUROTRAUM, V35, P1192, DOI 10.1089/neu.2017.5401; Toklu HZ, 2015, J CEREBR BLOOD F MET, V35, P1950, DOI 10.1038/jcbfm.2015.151; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Wang JM, 2016, CHIN J TRAUMATOL, V19, P125, DOI 10.1016/j.cjtee.2016.03.001; Wang Y, 2017, J NEUROTRAUM, V34, P952, DOI 10.1089/neu.2016.4465; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zhang YM, 2014, NEUROCHEM RES, V39, P950, DOI 10.1007/s11064-014-1292-4	93	33	33	2	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.	JAN 9	2019	7								6	10.1186/s40478-018-0647-5			20	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HG9II	WOS:000455320300002	30626447	gold, Green Published			2022-02-06	
J	Valera, EM; Cao, AH; Pasternak, O; Shenton, ME; Kubicki, M; Makris, N; Adra, N				Valera, Eve M.; Cao, Aihua; Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek; Makris, Nikos; Adra, Noor			White Matter Correlates of Mild Traumatic Brain Injuries in Women Subjected to Intimate-Partner Violence: A Preliminary Study	JOURNAL OF NEUROTRAUMA			English	Article						corona radiata; diffusion tensor imaging; domestic violence; intimate-partner violence; mild traumatic brain injury	FREE-WATER ELIMINATION; TOPOGRAPHIC PARCELLATION; SALIENCE NETWORK; IN-VIVO; DIFFUSION; CONCUSSION; MULTISITE; PREVALENCE; INTEGRITY; FASCICLE	A large proportion (range of 44-75%) of women who experience intimate-partner violence (IPV) have been shown to sustain repetitive mild traumatic brain injuries (mTBIs) from their abusers. Further, despite requests for research on TBI-related health outcomes, there are currently only a handful of studies addressing this issue and only one prior imaging study that has investigated the neural correlates of IPV-related TBIs. In response, we examined specific regions of white matter microstructure in 20 women with histories of IPV. Subjects were imaged on a 3-Tesla Siemens Magnetom TrioTim scanner using diffusion magnetic resonance imaging. We investigated the association between a score reflecting number and recency of IPV-related mTBIs and fractional anisotropy (FA) in the posterior and superior corona radiata as well as the posterior thalamic radiation, brain regions shown previously to be involved in mTBI. We also investigated the association between several cognitive measures, namely learning, memory, and cognitive flexibility, and FA in the white matter regions of interest. We report a negative correlation between the brain injury score and FA in regions of the posterior and superior corona radiata. We failed to find an association between our cognitive measures and FA in these regions, but the interpretation of these results remains inconclusive due to possible power issues. Overall, these data build upon the small but growing literature demonstrating potential consequences of mTBIs for women experiencing IPV, and further underscore the urgent need for larger and more comprehensive studies in this area.	[Valera, Eve M.; Cao, Aihua; Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek; Makris, Nikos; Adra, Noor] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Valera, Eve M.; Cao, Aihua; Kubicki, Marek; Makris, Nikos; Adra, Noor] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA; [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek; Makris, Nikos] Harvard Med Sch, Dept Radiol, Boston, MA USA; [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA; [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek] Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA; [Makris, Nikos] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA; [Adra, Noor] Wellesley Coll, Wellesley, MA 02181 USA		Valera, EM (corresponding author), Massachusetts Gen Hosp, Psychiat, Room 2660,149 Thirteenth St, Charlestown, MA 02129 USA.	eve_valera@hms.harvard.edu	Shenton, Martha/V-8780-2019	Adra, Noor/0000-0001-7214-6293	Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR14075, P41 EB015896]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR023043, 1S10RR023401]; VA Merit AwardUS Department of Veterans Affairs [I01 RX00928]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401131]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2015M572049]; China State Scholarship Fund;  [NIH R21AT008865];  [NIH R01 AG042512];  [NIH R01 MH102377];  [NIH R01 MH112748];  [NIH K24 MH110807];  [NIH P41 EB015902];  [NIH R01MH111917];  [R01MH112748]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT008865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902, P41EB015896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH110807, R01MH111917, R01MH112748, R01MH102377] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042512] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000928] Funding Source: NIH RePORTER	We thank all of the women who participated in this study. We thank Brittany LeBlanc for data management assistance, Drs. Michael Alexander, Margaret O'Connor, and Gregory Sorensen for helpful advice in developing this project. This work was supported by a Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health (EMV), and grants provided to the Athinoula A. Martinos Center for Biomedical Imaging, NCRR P41RR14075 and P41 EB015896. This work also involved the use of instrumentation supported by the National Institutes of Health (NIH) Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers 1S10RR023043 and 1S10RR023401. The study was also supported by the following grants: NIH R21AT008865, NIH R01 AG042512, NIH R01 MH102377, NIH R01 MH112748, NIH K24 MH110807 to MK; NIH P41 EB015902 to OP; NIH R01MH111917 and R01MH112748 to NM; VA Merit Award I01 RX00928 to MS; and National Natural Science Foundation of China, grant 81401131, China Postdoctoral Science Foundation, grant 2015M572049, and China State Scholarship Fund to AC.	Albi A, 2017, HUM BRAIN MAPP, V38, P12, DOI 10.1002/hbm.23350; [Anonymous], 2011, NATL INTIMATE PARTNE; Army Individual Test Battery, 1944, MAN DIR SCOR; Averill C.L., 2017, CHRONIC STRESS, P1; Baumgartner C., 2012, UNIFIED TRACTOGRAPHY; Bernstein DP, 1997, J AM ACAD CHILD PSY, V36, P340, DOI 10.1097/00004583-199703000-00012; BERNSTEIN DP, 1994, AM J PSYCHIAT, V151, P1132, DOI 10.1176/ajp.151.8.1132; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Campbell JC, 2003, AM J PUBLIC HEALTH, V93, P1089, DOI 10.2105/AJPH.93.7.1089; Catalano S., 2013, INTIMATE PARTNER VIO; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Committee on Mild Traumatic Brain Injury and American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P48; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Defense & Veterans Brain Injury Center, 2017, DOD WORLDW NUMB TBI; Delis D.C., 2000, CVLT 2 CALIFORNIA VE; Devries KM, 2013, SCIENCE, V340, P1527, DOI 10.1126/science.1240937; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Finkbeiner NWB, 2016, CAN J PSYCHIAT, V61, P270, DOI 10.1177/0706743716644953; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Jahanshad N, 2013, NEUROIMAGE, V81, P455, DOI 10.1016/j.neuroimage.2013.04.061; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Kircanski K, 2018, JAMA PSYCHIAT, V75, P631, DOI 10.1001/jamapsychiatry.2018.0468; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lipsky S, 2007, PSYCHIAT SERV, V58, P822, DOI 10.1176/appi.ps.58.6.822; Makris N, 1999, NEUROIMAGE, V9, P18, DOI 10.1006/nimg.1998.0384; Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186; Makris N, 2007, NEUROIMAGE, V37, P1100, DOI 10.1016/j.neuroimage.2007.05.042; MARSHALL LL, 1992, J FAM VIOLENCE, V7, P103, DOI 10.1007/BF00978700; McAllister T, 2017, J ATHL TRAINING, V52, P309, DOI 10.4085/1062-6050-52.1.14; Metzler-Baddeley C, 2012, NEUROIMAGE, V59, P1394, DOI 10.1016/j.neuroimage.2011.08.043; Meyer JW, 1999, NEUROIMAGE, V9, P1, DOI 10.1006/nimg.1998.0383; Mori S, 2005, MRI ATLAS HUMAN WHIT; Murray CE, 2016, TRAUMA VIOLENCE ABUS, V17, P298, DOI 10.1177/1524838015584364; Murrough JW, 2016, HUM BRAIN MAPP, V37, P3214, DOI 10.1002/hbm.23235; National Center for Injury Prevention and Control, 2003, COSTS INTIMATE PARTN; National Football League, 2018, NFL REL INJ DAT 2017; Pasternak O, 2012, LECT NOTES COMPUT SC, V7511, P305, DOI 10.1007/978-3-642-33418-4_38; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Plichta SB, 2001, WOMEN HEALTH ISS, V11, P244, DOI 10.1016/S1049-3867(01)00085-8; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; St Ivany A, 2016, FAM COMMUNITY HEALTH, V39, P129, DOI 10.1097/FCH.0000000000000094; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; United States Census Bureau, 2011, AGE SEX COMPOSITION; Valera E., 2016, TRAUMA BRAIN IMAGING, V11, P1664, DOI DOI 10.1007/s11682-016-9643-1; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilkinson G, 1993, WRAT3 WIDE RANGE ACH; Wilson M, 1994, Juristat, V14, P1; Wrocklage KM, 2017, EUR NEUROPSYCHOPHARM, V27, P515, DOI 10.1016/j.euroneuro.2017.02.010; Zieman G, 2017, J NEUROTRAUM, V34, P876, DOI 10.1089/neu.2016.4579	55	33	33	2	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2019	36	5					661	668		10.1089/neu.2018.5734		OCT 2018	8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	HR2BG	WOS:000446466800001	29873292	Green Published			2022-02-06	
J	George, MJ; Prabhakara, K; Toledano-Furman, NE; Wang, YW; Gill, BS; Wade, CE; Olson, SD; Cox, CS				George, Mitchell J.; Prabhakara, Karthik; Toledano-Furman, Naama E.; Wang, Yao-Wei; Gill, Brijesh S.; Wade, Charles E.; Olson, Scott D.; Cox, Charles S., Jr.			Clinical Cellular Therapeutics Accelerate Clot Formation	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Tissue factor; Coagulation; Clinical cellular therapeutics	MESENCHYMAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; BONE-MARROW; PROCOAGULANT ACTIVITY; PROGENITOR CELLS; ANTICOAGULANT; THERAPY; THROMBELASTOGRAPHY; DELIVERY; BLOOD	Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi-potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence-activated cell sorting (FACS) separated samples into high- and low-TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High-TF expressing cells decreased clotting time more than low-TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion.	[George, Mitchell J.; Wang, Yao-Wei; Gill, Brijesh S.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, McGovern Med Sch, Houston, TX 77030 USA; [George, Mitchell J.; Prabhakara, Karthik; Toledano-Furman, Naama E.; Olson, Scott D.; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, McGovern Med Sch, 6431 Fannin St,MSB 5-246, Houston, TX 77030 USA		Cox, CS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, McGovern Med Sch, 6431 Fannin St,MSB 5-246, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Olson, Scott/0000-0001-8032-3755	Glassell Family Stem Cell Research Program; NIH T32United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM008792-14]; Cellvation Inc.; Athersys Inc.; Hope Biosciences; CBR Inc.; Biostage Inc.; Athersys; Hope Bio; GenzymeSanofi-AventisGenzyme Corporation; Biostage; CBR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This study was supported by the Glassell Family Stem Cell Research Program. M.G. was supported by the NIH T32 grant GM008792-14. C.S.C. has sponsored research and scientific advisory board positions with Cellvation Inc., Athersys Inc., Hope Biosciences, CBR Inc., and Biostage Inc. Dr S.D.O. has sponsored research with Athersys, Hope Bio, and Biostage Inc. B.S.G. discloses consulting relationship with Cellvation, Inc. S.D.O. discloses research funding through sponsored research agreements with Hope Bio, CBR, and Athersys with recent funding from Genzyme and Biostage. All other authors declare no potential financial conflict.	Aranda P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007809; Baygan A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00795; Boozer Sherry, 2009, J Stem Cells, V4, P17, DOI jsc.2009.4.1.17; Burrows GG, 2013, STEM CELL TRANSL MED, V2, P745, DOI 10.5966/sctm.2013-0031; Christy BA, 2017, J TRAUMA ACUTE CARE, V83, pS164, DOI 10.1097/TA.0000000000001485; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Elliott A, 2015, INT J STROKE, V10, P194, DOI 10.1111/j.1747-4949.2012.00919.x; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gleeson BM, 2015, STEM CELLS, V33, P2726, DOI 10.1002/stem.2050; Hincker A, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0549-2; Hogan NM, 2013, BIOCHEM BIOPH RES CO, V435, P574, DOI 10.1016/j.bbrc.2013.05.013; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Katori N, 2005, ANESTH ANALG, V100, P1781, DOI 10.1213/01.ANE.0000149902.73689.64; Kota DJ, 2017, STEM CELLS, V35, P1416, DOI 10.1002/stem.2603; Levi M, 1997, EUR J CLIN INVEST, V27, P3, DOI 10.1046/j.1365-2362.1997.570614.x; Liao L, 2017, THERANOSTICS, V7, P106, DOI 10.7150/thno.16911; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Moll G, 2015, STEM CELLS DEV, V24, P2269, DOI 10.1089/scd.2015.0120; Moll G, 2014, STEM CELLS, V32, P2430, DOI 10.1002/stem.1729; Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111; Moll G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021703; Park MS, 2017, J TRAUMA ACUTE CARE, V83, P381, DOI 10.1097/TA.0000000000001466; Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171; Roobrouck VD, 2011, STEM CELLS, V29, P871, DOI 10.1002/stem.633; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; Stephenne X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042819; Taylor F B Jr, 1994, Prog Clin Biol Res, V388, P175; Van Haren RM, 2013, J TRAUMA ACUTE CARE, V75, P37, DOI 10.1097/TA.0b013e3182984911; Van PY, 2009, J TRAUMA, V66, P1509, DOI 10.1097/TA.0b013e3181a51e33; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Weiss Daniel J, 2011, Proc Am Thorac Soc, V8, P223, DOI 10.1513/pats.201012-071DW	32	33	34	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	OCT	2018	7	10					731	739		10.1002/sctm.18-0015			9	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	GW8MF	WOS:000447232200006	30070065	Green Published, gold			2022-02-06	
J	Miao, HS; Li, RM; Han, C; Lu, XZ; Zhang, H				Miao, Hongsheng; Li, Runming; Han, Cong; Lu, Xiuzhen; Zhang, Hang			Minocycline promotes posthemorrhagic neurogenesis via M2 microglia polarization via upregulation of the TrkB/BDNF pathway in rats	JOURNAL OF NEUROPHYSIOLOGY			English	Article						ICH; microglial polarization; minocycline; neurogenesis; TrkB/BDNF pathway	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; CANNABINOID RECEPTOR 2; INTRAVENTRICULAR HEMORRHAGE; EXPERIMENTAL STROKE; NEUROTROPHIC FACTOR; M1/M2 POLARIZATION; ACTIVATION; INFLAMMATION; MODEL	Intracerebral hemorrhage (ICH) is a devastating disease worldwide with increasing mortality. The present study investigated whether minocycline was neuroprotective and induced M2 microglial polarization via upregulation of the TrkB/BDNF pathway after ICH. ICH was induced via injection of autologous blood into 150 Sprague-Dawley rats. A selective TrkB antagonist [N2-2-2-oxoazepan-3-yl amino] carbonyl phenyl benzo (b) thiophene-2-carboxamide (ANA 12)] and agonist [N-[2-(5-hydroxy-1H-indol-3-yl) ethyl]2-oxopiperidine-3-carboxamide (HIOC)] were used to investigate the mechanism of minocycline-induced neuroprotection. Minocycline improved ICH-induced neurological deficits and reduced M1 microglia marker protein (CD68, CD16) expression as well as M2 microglial polarization (CD206 and arginase 1 protein). Minocycline administration enhanced microglia-neuron cross talk and promoted the proliferation of neuronal progenitor cells, such as DCX- and Tuj-1-positive cells, 24 h after ICH. Minocycline also increased M2 microglia-derived brain-derived neurotrophic factors (BDNF) and the upstream TrkB pathway. ANA 12 reversed the neuroprotective effects of minocycline. HIOC exhibited the same effects as minocycline and accelerated neurogenesis after ICH. This study demonstrated for the first time that minocycline promoted M2 microglia polarization via upregulation of the TrkB/BDNF pathway and promoted neurogenesis after ICH. This study contributes to our understanding of the therapeutic potential of minocycline in ICH. NEW & NOTEWORTHY The present study gives several novel points: 1) Minocycline promotes neurogenesis after intracerebral hemorrhage in rats. 2) Minocycline induces activated M1 microglia into M2 neurotrophic phenotype. 3) M2 microglia secreting BDNF remodel the damaged neurocircuit.	[Miao, Hongsheng; Han, Cong; Lu, Xiuzhen] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China; [Li, Runming; Zhang, Hang] 205 Hosp Peoples Liberat Army China, Dept Neurosurg, Jingzhou, Peoples R China		Miao, HS (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Gen Hosp, 650 Xinsongjiang Rd, Shanghai 210620, Peoples R China.	miaohongsheng1973@yeah.net			National Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81601356]	This work was supported by the National Science Foundation of China (NSFC, no. 81601356).	Ahn SY, 2013, STROKE, V44, P497, DOI 10.1161/STROKEAHA.112.679092; Alam MA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00094; Baker RG, 2011, CELL METAB, V13, P11, DOI 10.1016/j.cmet.2010.12.008; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; CASH E, 1993, CELL IMMUNOL, V147, P129, DOI 10.1006/cimm.1993.1053; Chang JJ, 2017, EUR J NEUROL, V24, P1384, DOI 10.1111/ene.13403; Chen QW, 2015, STROKE, V46, P2902, DOI 10.1161/STROKEAHA.115.009713; Daly LT, 2016, PLAST RECONSTR SURG, V138, p856E, DOI 10.1097/PRS.0000000000002633; Dang G, 2017, TRANSL STROKE RES, V8, P174, DOI 10.1007/s12975-016-0505-3; Deonarine K, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-11; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Fagan SC, 2011, TRANSL STROKE RES, V2, P202, DOI 10.1007/s12975-011-0072-6; Fouda AY, 2017, STROKE, V48, P2885, DOI 10.1161/STROKEAHA.117.018658; Gemma C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00229; Gustafsson E, 2003, STROKE, V34, P2710, DOI 10.1161/01.STR.0000096025.35225.36; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hahn JN, 2016, J IMMUNOL, V197, P3850, DOI 10.4049/jimmunol.1600436; Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hess David C, 2010, Rev Neurol Dis, V7 Suppl 1, pS7; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Huang WC, 2010, ANAT CELL BIOL, V43, P325, DOI 10.5115/acb.2010.43.4.325; Jiang B, 2017, TRANSL STROKE RES, V8, P183, DOI 10.1007/s12975-016-0506-2; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim KH, 2013, J EXP NEUROSCI, V7, P85, DOI 10.4137/JEN.S11269; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Lan X, 2017, BRAIN BEHAV IMMUN, V61, P326, DOI 10.1016/j.bbi.2016.12.012; Lei CY, 2015, STROKE, V46, P500, DOI 10.1161/STROKEAHA.114.006825; Li L, 2015, TRANSL STROKE RES, V6, P467, DOI 10.1007/s12975-015-0425-7; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Pang T, 1820, BIOCHIM BIOPHYS ACTA, P503; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Perego C, 2016, NEUROBIOL DIS, V96, P284, DOI 10.1016/j.nbd.2016.09.017; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Quirie A, 2013, EUR J NEUROSCI, V37, P1193, DOI 10.1111/ejn.12111; Shi W, 2011, ACTA NEUROCHIR SUPPL, V110, P61, DOI 10.1007/978-3-7091-0356-2_12; Soliman S, 2015, TRANSL STROKE RES, V6, P309, DOI 10.1007/s12975-015-0408-8; Strahan JA, 2017, DEV NEUROBIOL, V77, P753, DOI 10.1002/dneu.22457; Tang J, 2016, MOL NEUROBIOL, V53, P1935, DOI 10.1007/s12035-015-9154-x; Tang JJ, 2015, NEUROBIOL DIS, V78, P126, DOI 10.1016/j.nbd.2015.01.009; Tao YH, 2016, BRAIN BEHAV IMMUN, V58, P118, DOI 10.1016/j.bbi.2016.05.020; Wan S, 2016, TRANSL STROKE RES, V7, P478, DOI 10.1007/s12975-016-0472-8; Zhao F, 2011, STROKE, V42, P3587, DOI 10.1161/STROKEAHA.111.623926; Zhao H, 2015, TRANSL STROKE RES, V6, P407, DOI 10.1007/s12975-015-0428-4	50	33	40	2	23	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	SEP	2018	120	3					1307	1317		10.1152/jn.00234.2018			11	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	GX3UY	WOS:000447653800002	29790836	Bronze			2022-02-06	
J	Katz, BP; Kudela, M; Harezlak, J; McCrea, M; McAllister, T; Broglio, SP				Katz, Barry P.; Kudela, Maria; Harezlak, Jaroslaw; McCrea, Michael; McAllister, Thomas; Broglio, Steven P.		CARE Consortium Investigators	Baseline Performance of NCAA Athletes on a Concussion Assessment Battery: A Report from the CARE Consortium	SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE FUNCTION; STANDARDIZED ASSESSMENT; FOOTBALL PLAYERS; SPORT; STATEMENT; SYMPTOMS; POSITION; HISTORY; RELIABILITY	Background Sport-related concussion and repetitive head impact exposure in contact sports continue to receive increased attention in public and medical spheres. The Concussion Assessment, Research and Education (CARE) Consortium, a multicenter cooperative, was established to study the natural history of concussion in National Collegiate Athletic Association (NCAA) collegiate student-athletes across 29 colleges and universities in the United States. The purpose of this investigation is to provide normative data from the CARE Consortium and evaluate for differences between sport categories. Methods NCAA student-athletes were evaluated annually for general demographics and sport-specific characteristics before the start of the competitive season. We collected demographic and medical history information and evaluated each student-athlete's neurocognitive function, neurological status, postural stability, and self-reported symptoms. Sports were categorized by the amount of contact typically associated with the sport (i. e., contact, limited contact, non-contact). Comparisons between the three sport categories for the evaluated variables were made using linear or zero inflated negative binomial regression models adjusted for gender, concussion history, and household income. Results Over a 2-year period (August 2014-July 2016), 15,681 NCAA athletes completed preseason evaluations. Overall, 53% of the athletes were in the contact sport group, 31% were in the limited contact group and 17% were in the non-contact group. After adjusting for covariates, there were statistically significant differences found between athlete groups, although the differences and effect sizes were small and not clinically significant. The contact sport group had better scores on Immediate Post- Concussion Assessment Testing (ImPACT similar to) visual and verbal memory, Sport Concussion Assessment Tool (SCAT) symptom checklist, and Brief Symptom Inventory-18 (BSI-18), but slower ImPACT reaction time and worse scores on Standardized Assessment of Concussion (SAC). Further, the data indicate that some ImPACT score distributions were noticeably different from those presented in the technical manual. Conclusions In this large, racially and socio-economically diverse cohort of male and female college athletes, we found no evidence that student-athletes participating in contact sports have clinically meaningful deficits in preseason cognitive and balance testing. They also did not report significantly more symptoms of psychological distress when compared with student-athletes in non-contact or limited contact sports. In addition, the data suggest potential limitations when using published ImPACT norms when evaluating injured athletes.	[Katz, Barry P.] Indiana Univ, Indiana Univ Sch Med, Dept Biostat, 410 West Tenth St, Indianapolis, IN 46260 USA; [Katz, Barry P.; Kudela, Maria] Richard M Fairbanks Sch Publ Hlth, Dept Biostat, Indianapolis, IN 46202 USA; [Harezlak, Jaroslaw] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Broglio, Steven P.] Univ Michigan, Univ Michigan Injury Ctr, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA		Katz, BP (corresponding author), Indiana Univ, Indiana Univ Sch Med, Dept Biostat, 410 West Tenth St, Indianapolis, IN 46260 USA.; Katz, BP (corresponding author), Richard M Fairbanks Sch Publ Hlth, Dept Biostat, Indianapolis, IN 46202 USA.	bkatz@iu.edu	Harezlak, Jaroslaw/P-8557-2014	Harezlak, Jaroslaw/0000-0002-3070-7686; Cameron, Kenneth/0000-0002-6276-4482	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DoD)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; Department of DefenseUnited States Department of Defense	Contributing investigators include Scott Anderson, ATC (University of Oklahoma); Jeffrey Bazarian, MD, MPH (University of Rochester); Christopher Todd Bullers, MD (Wake Forest University); Christopher Giza, MD (University of California-Los Angeles); Kevin Guskiewicz, PhD, ATC (University of North Carolina); Jessica Dysart Myles, PhD, ATC (University of North Georgia); Patrick O'Donnell, MHA (United States Coast Guard Academy); Steven J. Svoboda, MD (United States Military Academy); and Ryan Tierney, PhD, ATC (Temple University). The authors would also like to thank Jody Harland, Janetta Matesan, Larry Riggen, and Shi Zhao (Indiana University); Ashley and Ellie Rettmann (University of Michigan); Melissa Koschnitzke (Medical College of Wisconsin); Michael Jarrett, Vibeke Brinck and Bianca Byrne (Quesgen); Thomas Dompier, Melissa Niceley Baker, and Sara Dalton (Datalys Center for Sports Injury Research and Prevention); and the research and medical staff at each of the participating sites. This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DoD). The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014, is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (DHP funds).	Barr WB, 2001, J ATHL TRAINING, V36, P297; Broglio SP, 2017, SPORTS MED; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cameron KL, 2012, J NEUROTRAUM, V29, P1313, DOI 10.1089/neu.2011.2168; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; ImPACT Applications Inc, IMPACT VERS 2 0 CLIN, P1; ImPACT Applications Inc, 2011, IMM POSTC ASS TEST I, P1; Kaplan GA, 2001, INT J EPIDEMIOL, V30, P256, DOI 10.1093/ije/30.2.256; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Loeys T, 2012, BRIT J MATH STAT PSY, V65, P163, DOI 10.1111/j.2044-8317.2011.02031.x; Matheson GO, 2011, CLIN J SPORT MED, V21, P25, DOI 10.1097/JSM.0b013e3182095f92; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Ulfarsson T, 2014, BRAIN INJURY, V28, P328, DOI 10.3109/02699052.2013.865274; Zimmer A, 2013, J ATHL TRAINING, V48, P659, DOI 10.4085/1062-6050-48.5.06	36	33	33	0	10	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	AUG	2018	48	8					1971	1985		10.1007/s40279-018-0875-7			15	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	HF7XO	WOS:000454455500014	29498030	Green Submitted			2022-02-06	
J	Rehman, SU; Ahmad, A; Yoon, GH; Khan, M; Abid, MN; Kim, MO				Rehman, Shafiq Ur; Ahmad, Ashfaq; Yoon, Gwang-Ho; Khan, Mehtab; Abid, Muhammad Noman; Kim, Myeong Ok			Inhibition of c-Jun N-Terminal Kinase Protects Against Brain Damage and Improves Learning and Memory After Traumatic Brain Injury in Adult Mice	CEREBRAL CORTEX			English	Article						amyloidogenic and nonamyloidogeneic pathway; neurodegeneration; oxidative stress; SP600125; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; JNK PATHWAY; MOUSE MODEL; IN-VITRO; CANNABINOID RECEPTORS; TAU PHOSPHORYLATION; THERAPEUTIC TARGET	Traumatic brain injury (TBI) is a global risk factor that leads to long-term cognitive impairments. To date, the disease remains without effective therapeutics because of the multifactorial nature of the disease. Here, we demonstrated that activation of the c-Jun N-terminal kinase (JNK) is involved in multiple pathological features of TBI. Therefore, we investigated the disease-modifying therapeutic potential of JNK-specific inhibitor (SP600125) in TBI mice. Treating 2 different models of TBI mice with SP600125 for 7 days dramatically inhibited activated JNK, resulting in marked reductions of amyloid precursor protein (APP) expression level and in amyloid beta production and hyperphosphorylated tau and regulation of the abnormal expression of secretases. Furthermore, SP600125 strongly inhibited inflammatory responses, blood-brain barrier breakdown, apoptotic neurodegeneration, and synaptic protein loss, regulated prosurvival processes and improved motor function and behavioral outcomes in TBI mice. More interestingly, we found that SP600125 treatment ameliorated amyloidogenic APP processing and promoted the nonamyloidogenic pathway in TBI mouse brains. Our findings strongly suggest that active JNK is critically involved in disease development after TBI and that inhibition of JNK with SP600125 is highly efficient for slowing disease progression by reducing multiple pathological features in TBI mouse brains and regulating cognitive dysfunction.	[Rehman, Shafiq Ur; Ahmad, Ashfaq; Yoon, Gwang-Ho; Khan, Mehtab; Abid, Muhammad Noman; Kim, Myeong Ok] Gyeongsang Natl Univ, Coll Nat Sci, Dept Biol & Appl Life Sci BK21, Jinju 660701, South Korea		Kim, MO (corresponding author), Gyeongsang Natl Univ, Coll Nat Sci, Dept Biol & Appl Life Sci BK21, Jinju 660701, South Korea.	mokim@gnu.ac.kr	Kim, Myeong Ok/AAS-1488-2021; Bin Abid, Noman/AAP-2032-2021	Kim, Myeong Ok/0000-0003-4317-1072; Bin Abid, Noman/0000-0001-6929-8878	National Research Foundation of Korea - Ministry of Science, ICT & Future Planning [2016M3C7A1904391]	This research work was supported by the Brain Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1904391).	Abeti R, 2012, NEUROCHEM RES, V37, P2589, DOI 10.1007/s11064-012-0895-x; Ahmad A, 2017, MOL NEUROBIOL, V54, P2269, DOI 10.1007/s12035-016-9795-4; Ahn JH, 2016, BMB REP, V49, P376, DOI 10.5483/BMBRep.2016.49.7.246; Ando K, 2016, BIOCHEM BIOPH RES CO, V478, P929, DOI 10.1016/j.bbrc.2016.08.053; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bachstetter AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0289-5; Badshah H, 2016, J NEUROIMMUNE PHARM, V11, P48, DOI 10.1007/s11481-015-9623-z; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Braithwaite SP, 2010, NEUROBIOL DIS, V39, P311, DOI 10.1016/j.nbd.2010.04.015; Chambers JW, 2013, J BIOL CHEM, V288, P1079, DOI 10.1074/jbc.M112.421354; Chang CP, 2016, MOL NEUROBIOL, V53, P7329, DOI 10.1007/s12035-015-9623-2; Chen CY, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0092271, 10.1371/journal.pone.0108021, 10.1371/journal.pone.0106248]; Chen D, 2012, ACTA NEUROCHIR, V154, P1469, DOI 10.1007/s00701-012-1328-y; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Desai AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085237; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Graczyk PP, 2013, FUTURE MED CHEM, V5, P539, DOI [10.4155/FMC.13.34, 10.4155/fmc.13.34]; Guglielmotto M, 2011, J ALZHEIMERS DIS, V27, P871, DOI 10.3233/JAD-2011-110884; Han D, 2016, BRAIN BEHAV IMMUN, V51, P56, DOI 10.1016/j.bbi.2015.07.025; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kabadi SV, 2015, J CEREBR BLOOD F MET, V35, P2010, DOI 10.1038/jcbfm.2015.165; Kawai N, 2013, BRAIN INJURY, V27, P1026, DOI 10.3109/02699052.2013.794963; Kim BJ, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0093-4; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Ma QL, 2009, J NEUROSCI, V29, P9078, DOI 10.1523/JNEUROSCI.1071-09.2009; Mehan S, 2011, J MOL NEUROSCI, V43, P376, DOI 10.1007/s12031-010-9454-6; Merlo L, 2014, J NEUROTRAUM, V31, P1375, DOI 10.1089/neu.2014.3385; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Ploia C, 2011, J ALZHEIMERS DIS, V26, P315, DOI 10.3233/JAD-2011-110320; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Ramin M, 2011, BEHAV BRAIN RES, V217, P424, DOI 10.1016/j.bbr.2010.11.017; Rehman SU, 2017, MOL NEUROBIOL, V54, P255, DOI 10.1007/s12035-015-9604-5; Repici M, 2006, ADV EXP MED BIOL, V588, P145; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; Thakur A, 2007, J NEUROSCI RES, V85, P1668, DOI 10.1002/jnr.21298; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vogel J, 2009, NEUROPHARMACOLOGY, V57, P539, DOI 10.1016/j.neuropharm.2009.07.021; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wang C, 2011, NEUROSCI LETT, V491, P127, DOI 10.1016/j.neulet.2011.01.022; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Yang ST, 2015, J NEUROL SCI, V349, P99, DOI 10.1016/j.jns.2014.12.032; Yang WJ, 2017, ACTA NEUROL SCAND, V135, P622, DOI 10.1111/ane.12644; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Zhang J, 2015, J CEREBR BLOOD F MET, V35, P443, DOI 10.1038/jcbfm.2014.216; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144; Zhou Q, 2015, ANN NEUROL, V77, P637, DOI 10.1002/ana.24361; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	72	33	35	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	AUG	2018	28	8					2854	2872		10.1093/cercor/bhx164			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GP6DH	WOS:000440966600016	29088310	Bronze			2022-02-06	
J	Hoshi, Y; Okabe, K; Shibasaki, K; Funatsu, T; Matsuki, N; Ikegaya, Y; Koyama, R				Hoshi, Yutaka; Okabe, Kohki; Shibasaki, Koji; Funatsu, Takashi; Matsuki, Norio; Ikegaya, Yuji; Koyama, Ryuta			Ischemic Brain Injury Leads to Brain Edema via Hyperthermia-Induced TRPV4 Activation	JOURNAL OF NEUROSCIENCE			English	Article						brain edema; hyperthermia; ischemia; TRPV4	TARGETED TEMPERATURE MANAGEMENT; FOCAL CEREBRAL-ISCHEMIA; NEURONAL EXCITABILITY; CELL-VOLUME; ION-CHANNEL; HYPOTHERMIA; ASTROCYTES; PERMEABILITY; MODULATION; INDUCTION	Brain edema is characterized by an increase in net brain water content, which results in an increase in brain volume. Although brain edema is associated with a high fatality rate, the cellular and molecular processes of edema remain largely unclear. Here, we developed an in vitro model of ischemic stroke-induced edema in which male mouse brain slices were treated with oxygen-glucose deprivation (OGD) to mimic ischemia. We continuously measured the cross-sectional area of the brain slice for 150 min under macroscopic microscopy, finding that OGD induces swelling of brain slices. OGD-induced swelling was prevented by pharmacologically blocking or genetically knocking out the transient receptor potential vanilloid 4 (TRPV4), a member of the thermosensitive TRP channel family. Because TRPV4 is activated at around body temperature and its activation is enhanced by heating, we next elevated the temperature of the perfusate in the recording chamber, finding that hyperthermia induces swelling via TRPV4 activation. Furthermore, using the temperature-dependent fluorescence lifetime of a fluorescent-thermosensitive probe, we confirmed that OGD treatment increases the temperature of brain slices through the activation of glutamate receptors. Finally, we found that brain edema following traumatic brain injury was suppressed in TRPV4-deficient male mice in vivo. Thus, our study proposes a novel mechanism: hyperthermia activates TRPV4 and induces brain edema after ischemia.	[Hoshi, Yutaka; Matsuki, Norio; Ikegaya, Yuji; Koyama, Ryuta] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Chem Pharmacol, Tokyo 1130033, Japan; [Okabe, Kohki; Funatsu, Takashi] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Bioanalyt Chem, Tokyo 1130033, Japan; [Okabe, Kohki] JST, PRESTO, Kawaguchi, Saitama 3320012, Japan; [Shibasaki, Koji] Gunma Univ, Grad Sch Med, Dept Mol & Cellular Neurobiol, Maebashi, Gunma 3718514, Japan; [Ikegaya, Yuji] Natl Inst Informat & Commun Technol, Ctr Informat & Neural Networks, Suita, Osaka 5650871, Japan		Koyama, R (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Chem Pharmacol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	rkoyama@mol.f.u-tokyo.ac.jp	Shibasaki, Koji/U-8674-2018; Funatsu, Takashi/Q-1404-2015	Shibasaki, Koji/0000-0003-2330-1749; Funatsu, Takashi/0000-0002-9656-8308; Ikegaya, Yuji/0000-0003-2260-8191	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [17H03988, 15H0300]; Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17H05738, 15H05931, 15H05934]; Brain Science Foundation	This work was supported in part by Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (B) 17H03988 to R.K. and 15H0300 to K.S., Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research on Innovation Area "Dynamic Regulation of Brain Function by Scrap & Build System" 17H05738 to R.K. and "Thermal Biology" 15H05931 to K.O. and 15H05934 to K.S., and the Brain Science Foundation to R.K.	ABE K, 1988, J CEREBR BLOOD F MET, V8, P436, DOI 10.1038/jcbfm.1988.81; Adeva MM, 2012, NEUROCHEM INT, V61, P166, DOI 10.1016/j.neuint.2012.05.007; Aiyagari V, 2002, NEUROLOGIST, V8, P152, DOI 10.1097/00127893-200205000-00002; Bardutzky J, 2007, STROKE, V38, P3084, DOI 10.1161/STROKEAHA.107.490193; Belkacemi T, 2017, GLIA, V65, P1535, DOI 10.1002/glia.23180; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Bernal W, 2013, J HEPATOL, V59, P74, DOI 10.1016/j.jhep.2013.02.010; BETZ AL, 1994, J CEREBR BLOOD F MET, V14, P29, DOI 10.1038/jcbfm.1994.5; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Butenko O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039959; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843; Everaerts W, 2010, PROG BIOPHYS MOL BIO, V103, P2, DOI 10.1016/j.pbiomolbio.2009.10.002; Fenton RA, 2010, CELL MOL LIFE SCI, V67, P829, DOI 10.1007/s00018-009-0218-9; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; Pascual MG, 2011, NEUROREHABILITATION, V29, P353, DOI 10.3233/NRE-2011-0712; Gota C, 2009, J AM CHEM SOC, V131, P2766, DOI 10.1021/ja807714j; Guler AD, 2002, J NEUROSCI, V22, P6408; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hayashi T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117677; Heinrich C, 2014, STEM CELL REP, V3, P1000, DOI 10.1016/j.stemcr.2014.10.007; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Hirayama Y, 2015, J NEUROSCI, V35, P3794, DOI 10.1523/JNEUROSCI.4218-14.2015; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; Honkaniemi J, 1996, J CEREBR BLOOD F MET, V16, P557, DOI 10.1097/00004647-199607000-00005; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Jie PH, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00141; Jo AO, 2015, J NEUROSCI, V35, P13525, DOI 10.1523/JNEUROSCI.1987-15.2015; Kauer JA, 2009, TRENDS NEUROSCI, V32, P215, DOI 10.1016/j.tins.2008.12.006; Khan M, 2017, NEURAL REGEN RES, V12, P696, DOI 10.4103/1673-5374.206632; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Lipski J, 2006, BRAIN RES, V1077, P187, DOI 10.1016/j.brainres.2006.01.016; Lu KT, 2017, J NEUROCHEM, V140, P718, DOI 10.1111/jnc.13920; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206; MOSER EI, 1994, J NEUROSCI, V14, P4458; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Okabe K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1714; Paczynski RP, 2000, STROKE, V31, P1702, DOI 10.1161/01.STR.31.7.1702; Polderman KH, 2015, THER HYPOTHERMIA TEM, V5, P73, DOI 10.1089/ther.2014.0031; Rakers C, 2017, GLIA, V65, P1550, DOI 10.1002/glia.23183; RITCHIE JM, 1957, J PHYSIOL-LONDON, V136, P80, DOI 10.1113/jphysiol.1957.sp005744; Rungta RL, 2015, CELL, V161, P610, DOI 10.1016/j.cell.2015.03.029; Ryskamp DA, 2014, J NEUROSCI, V34, P15689, DOI 10.1523/JNEUROSCI.2540-14.2014; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; SCHIFF SJ, 1985, BRAIN RES, V345, P279, DOI 10.1016/0006-8993(85)91004-2; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Shen J, 2019, J CEREBR BLOOD F MET, V39, P1501, DOI 10.1177/0271678X18769515; Shibasaki K, 2007, J NEUROSCI, V27, P1566, DOI 10.1523/JNEUROSCI.4284-06.2007; Shibasaki K, 2016, J ANESTH, V30, P1014, DOI 10.1007/s00540-016-2225-y; Shibasaki K, 2015, PFLUG ARCH EUR J PHY, V467, P2495, DOI 10.1007/s00424-015-1726-0; Shibasaki K, 2014, J BIOL CHEM, V289, P14470, DOI 10.1074/jbc.M114.557132; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Takayama Y, 2014, FASEB J, V28, P2238, DOI 10.1096/fj.13-243436; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; Tucker B, 2017, J EMERG MED, V53, P18, DOI 10.1016/j.jemermed.2017.02.010; Vardjan N, 2016, ADRENERGIC ACTIVATIO, P1034; Veenith TV, 2016, JAMA NEUROL, V73, P542, DOI 10.1001/jamaneurol.2016.0091; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; White JPM, 2016, PHYSIOL REV, V96, P911, DOI 10.1152/physrev.00016.2015	71	33	34	2	16	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 20	2018	38	25					5700	5709		10.1523/JNEUROSCI.2888-17.2018			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GK1NB	WOS:000435883500005	29793978	Green Published, Bronze			2022-02-06	
J	Chenoweth, JA; Gaona, SD; Faul, M; Holmes, JF; Nishijima, DK				Chenoweth, James A.; Gaona, Samuel D.; Faul, Mark; Holmes, James F.; Nishijima, Daniel K.		Sacramento County Prehosp Res Co	Incidence of Delayed Intracranial Hemorrhage in Older Patients After Blunt Head Trauma	JAMA SURGERY			English	Article							PRESCRIPTION ANTIPLATELET AGENTS; BRAIN-INJURY; PREINJURY ANTICOAGULANTS; CLOPIDOGREL USE; WARFARIN; MANAGEMENT; GUIDELINE; RISK	IMPORTANCE Current guidelines conflict on the management of older adults who have blunt head trauma taking anticoagulant and antiplatelet medications. This is partially due to the limited data comparing patients who are taking these medications with those who are not. OBJECTIVE To investigate the incidence of delayed traumatic intracranial hemorrhage in older adults with head trauma, including those taking anticoagulant and antiplatelet medications. DESIGN, SETTING, AND PARTICIPANTS This prospective observational cohort study included patients 55 years and older who had blunt head trauma and were transported via emergency medical services between August 1, 2015, and September 30, 2016. The setting was a multicenter study conducted at 11 hospitals in northern California. Patients were excluded if they had traumatic intracranial hemorrhage on the initial cranial computed tomographic scan, did not have a cranial computed tomographic scan performed at the initial emergency department visit, refused consent for a follow-up telephone call, or did not have reliable means of follow-up. MAIN OUTCOME AND MEASURE The primary outcome of this study Was the incidence of delayed traumatic intracranial hemorrhage within 14 days of injury. RESULTS Among 859 patients enrolled in the study, the median age was 75 years (interquartile range, 64-85 years), and 389 (45.3%) were male. A total of 343 patients (39.9%) were taking an anticoagulant or antiplatelet medication. Three patients (0.3%; 95% CI, 0.1%-1.0%) had a delayed traumatic intracranial hemorrhage. Of the 3 patients, 1of 75 patients (1.3%; 95% CI, 0.0%-7.2%) who were taking warfarin sodium alone and 2 of 516 patients (0.4%; 95% CI, 0.1%14%) who were not taking any anticoagulant or antiplatelet medication had a delayed traumatic intracranial hemorrhage. Thirty-nine patients (4.5%; 95% CI, 3.2%-6.2%) were lost to follow-up. CONCLUSIONS AND RELEVANCE Overall, the incidence of delayed intracranial hemorrhage in older adults who have blunt head trauma is low, including patients taking an anticoagulant or antiplatelet medication. These findings suggest that routine observation and serial cranial computed tomography may not be necessary in these patients.	[Chenoweth, James A.; Gaona, Samuel D.; Holmes, James F.; Nishijima, Daniel K.] Univ Calif Davis, Sch Med, Dept Emergency Med, 4150 V St,Patient Support Serv Bldg Ste 2100, Sacramento, CA 95817 USA; [Faul, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA		Chenoweth, JA (corresponding author), Univ Calif Davis, Sch Med, Dept Emergency Med, 4150 V St,Patient Support Serv Bldg Ste 2100, Sacramento, CA 95817 USA.	jachenoweth@ucdavis.edu	Chenoweth, James/AAN-9965-2021; Chenoweth, James/AAP-4537-2021	Chenoweth, James/0000-0001-9537-0116; Faul, Mark/0000-0002-7683-0348	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE002177]; Mentored Clinical Research Training Program Award from the National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR000002, KL2TR000134]	This work was funded by grant U01CE002177 from the Centers for Disease Control and Prevention. Dr Nishijima was supported through a Mentored Clinical Research Training Program Award (grant UL1TR000002 and linked award KL2TR000134) from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health	Quintero-Gonzalez JA, 2010, INVEST CLIN, V51, P269; American College of Surgeons Trauma Quality Improvement Program, ACS TQIP BEST PRACT; Barnes GD, 2015, AM J MED, V128, P1300, DOI 10.1016/j.amjmed.2015.05.044; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Chung Pearl, 2015, J Med Case Rep, V9, P173, DOI 10.1186/s13256-015-0652-2; Desai NR, 2014, AM J MED, V127, P1075, DOI 10.1016/j.amjmed.2014.05.013; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; Menditto VG, 2012, ANN EMERG MED, V59, P451, DOI 10.1016/j.annemergmed.2011.12.003; Miller J, 2015, J TRAUMA ACUTE CARE, V79, P310, DOI 10.1097/TA.0000000000000725; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Ostini R, 2008, PHARMACOEPIDEM DR S, V17, P1077, DOI 10.1002/pds.1638; Peck KA, 2014, J TRAUMA ACUTE CARE, V76, P431, DOI 10.1097/TA.0000000000000107; Peck KA, 2011, J TRAUMA, V71, P1600, DOI 10.1097/TA.0b013e31823b9ce1; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	19	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JUN	2018	153	6					570	575		10.1001/jamasurg.2017.6159			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	GJ8PU	WOS:000435653000019	29450470	Bronze, Green Published			2022-02-06	
J	Gellerfors, M; Fevang, E; Backman, A; Kruger, A; Mikkelsen, S; Nurmi, J; Rognas, L; Sandstrom, E; Skallsjo, G; Svensen, C; Gryth, D; Lossius, HM				Gellerfors, M.; Fevang, E.; Backman, A.; Kruger, A.; Mikkelsen, S.; Nurmi, J.; Rognas, L.; Sandstrom, E.; Skallsjo, G.; Svensen, C.; Gryth, D.; Lossius, H. M.			Pre-hospital advanced airway management by anaesthetist and nurse anaesthetist critical care teams: a prospective observational study of 2028 pre-hospital tracheal intubations	BRITISH JOURNAL OF ANAESTHESIA			English	Article						airway management; emergency medical services; intubation; intratracheal	RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; EMERGENCY MEDICAL-SERVICES; CLINICAL-PRACTICE; ADVERSE EVENTS; PHYSICIAN; MULTICENTER; HYPOTENSION; GUIDELINES; STATEMENT	Background: Pre-hospital tracheal intubation success and complication rates vary considerably among provider categories. The purpose of this study was to estimate the success and complication rates of pre-hospital tracheal intubation performed by physician anaesthetist or nurse anaesthetist pre-hospital critical care teams. Methods: Data were prospectively collected from critical care teams staffed with a physician anaesthetist or a nurse anaesthetist according to the Utstein template for pre-hospital advanced airway management. The patients served by six ambulance helicopters and six rapid response vehicles in Denmark, Finland, Norway, and Sweden from May 2015 to November 2016 were included. Results: The critical care teams attended to 32 007 patients; 2028 (6.3%) required pre-hospital tracheal intubation. The overall success rate of pre-hospital tracheal intubation was 98.7% with a median intubation time of 25 s and an on-scene time of 25 min. The majority (67.0%) of the patients' tracheas were intubated by providers who had performed >2500 tracheal intubations. The success rate of tracheal intubation on the first attempt was 84.5%, and 95.9% of intubations were completed after two attempts. Complications related to pre-hospital tracheal intubation were recorded in 10.9% of the patients. Intubations after rapid sequence induction had a higher success rate compared with intubations without rapid sequence induction (99.4% vs 98.1%; P=0.02). Physicians had a higher tracheal intubation success rate than nurses (99.0% vs 97.6%; P=0.03). Conclusions: When performed by experienced physician anaesthetists and nurse anaesthetists, pre-hospital tracheal intubation was completed rapidly with high success rates and a low incidence of complications.	[Gellerfors, M.; Svensen, C.] Karolinska Inst, Dept Clin Sci & Educ, Sect Anaesthesiol & Intens Care, Stockholm, Sweden; [Gellerfors, M.] Swedish Air Ambulance SLA, Mora, Sweden; [Gellerfors, M.; Svensen, C.] Soder Sjukhuset, Dept Anaesthesiol & Intens Care, Stockholm, Sweden; [Gellerfors, M.] Swedish Armed Forces, SAE Medevac Helicopter, Linkoping, Sweden; [Fevang, E.; Kruger, A.; Lossius, H. M.] Norwegian Air Ambulance Fdn, Dept Res & Dev, Drobak, Norway; [Fevang, E.] Stavanger Univ Hosp, Dept Anaesthesiol & Intens Care, Stavanger, Norway; [Backman, A.] Karolinska Inst, Ctr Resuscitat Sci, Stockholm, Sweden; [Kruger, A.] Norwegian Univ Sci & Technol, Dept Emergency Med & Prehosp Serv, St Olavs Univ Hosp, Trondheim, Norway; [Mikkelsen, S.] Odense Univ Hosp, Mobile Emergency Care Unit, Dept Anaesthesiol & Intens Care Med, Odense, Denmark; [Nurmi, J.] Helsinki Univ Hosp, Dept Emergency Med & Serv, Helsinki, Finland; [Nurmi, J.] Univ Helsinki, Dept Emergency Med, Helsinki, Finland; [Rognas, L.] Cent Denmark Reg, Prehosp Crit Care Serv Aarhus, Dept Prehosp Crit Care Serv, Pregosp Emergency Med Serv, Aarhus, Denmark; [Sandstrom, E.] Reg Jamtland Harjedalen, Helicopter Emergency Med Serv, Ostersund, Sweden; [Skallsjo, G.] Vastra Gotalandsreg, Helicopter Emergency Med Serv, Gothenburg, Sweden; [Gryth, D.] Karolinska Inst, Sect Anaesthesiol & Intens Care Med, Dept Physiol & Pharmacol, Stockholm, Sweden; [Gryth, D.] Karolinska Univ Hosp, Perioperat Med & Intens Care, Stockholm, Sweden; [Lossius, H. M.] Univ Stavanger, Dept Hlth Sci, Stavanger, Norway		Gellerfors, M (corresponding author), Karolinska Inst, Dept Clin Sci & Educ, Sect Anaesthesiol & Intens Care, Stockholm, Sweden.; Gellerfors, M (corresponding author), Swedish Air Ambulance SLA, Mora, Sweden.; Gellerfors, M (corresponding author), Soder Sjukhuset, Dept Anaesthesiol & Intens Care, Stockholm, Sweden.; Gellerfors, M (corresponding author), Swedish Armed Forces, SAE Medevac Helicopter, Linkoping, Sweden.	mikael.gellerfors@ki.se	Mikkelsen, Soren/R-1890-2019; Rognas, Leif/AAI-9373-2020; Rognas, Leif/AAF-6182-2020	Mikkelsen, Soren/0000-0002-5187-7027; Rognas, Leif/0000-0002-2542-565X; 	Swedish Medical Association; ALF-Grant Stockholm County Council; Laerdahl Foundation	Swedish Medical Association, ALF-Grant Stockholm County Council, and the Laerdahl Foundation.	Adnet F, 1998, ANN EMERG MED, V32, P454, DOI 10.1016/S0196-0644(98)70175-1; Bossers SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141034; Bowles TM, 2011, BRIT J ANAESTH, V107, P687, DOI 10.1093/bja/aer251; Breckwoldt J, 2012, RESUSCITATION, V83, P434, DOI 10.1016/j.resuscitation.2011.10.011; Chesters A, 2014, EMERG MED J, V31, P65, DOI 10.1136/emermed-2012-201846; Crewdson K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1603-7; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Haltmeier T, 2017, EUR J TRAUMA EMERG S, V43, P731, DOI 10.1007/s00068-016-0718-x; Harris T, 2011, EMERG MED J, V28, P225, DOI 10.1136/emj.2009.088302; Heffner AC, 2012, J CRIT CARE, V27, P587, DOI 10.1016/j.jcrc.2012.04.022; Helm M, 2013, ACTA ANAESTH SCAND, V57, P199, DOI 10.1111/aas.12032; Hossfeld B, 2016, EUR J ANAESTH, V33, P881, DOI 10.1097/EJA.0000000000000533; Jensen AG, 2010, ACTA ANAESTH SCAND, V54, P922, DOI 10.1111/j.1399-6576.2010.02277.x; Kruger AJ, 2013, ACTA ANAESTH SCAND, V57, P1175, DOI 10.1111/aas.12181; Lansom Joshua D, 2016, Air Med J, V35, P295, DOI 10.1016/j.amj.2016.04.019; Lecky F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001429.pub2; Lin CC, 2008, AM J EMERG MED, V26, P845, DOI 10.1016/j.ajem.2007.11.027; Lockey D, 2014, BRIT J ANAESTH, V113, P220, DOI 10.1093/bja/aeu227; Lockey DJ, 2017, ANAESTHESIA, V72, P379, DOI 10.1111/anae.13779; Lossius HM, 2002, ACTA ANAESTH SCAND, V46, P771, DOI 10.1034/j.1399-6576.2002.460703.x; Newton A, 2008, J TRAUMA, V64, P487, DOI 10.1097/TA.0b013e31802e7476; Pakkanen T, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0256-x; Rehn M, 2016, ACTA ANAESTH SCAND, V60, P852, DOI 10.1111/aas.12746; ROGNAS L, 2013, SCAND J TRAUMA RESUS, V21; Sollid SJM, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-58; Soti A, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-014-0081-z; Sunde GA, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0136-9; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; von Vopelius-Feldt J, 2013, EUR J EMERG MED, V20, P382, DOI 10.1097/MEJ.0b013e32835b08b7	29	33	33	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAY	2018	120	5					1103	1109		10.1016/j.bja.2017.12.036			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	GN4SU	WOS:000439023600067	29661387	Green Published, hybrid, Green Accepted			2022-02-06	
J	Wang, Q; Zhang, S; Liu, TT; Wang, HH; Liu, KL; Wang, QJ; Zeng, WW				Wang, Qi; Zhang, Shan; Liu, Tingting; Wang, Huanhuan; Liu, Kaili; Wang, Qiujun; Zeng, Wenwen			Sarm1/Myd88-5 Regulates Neuronal Intrinsic Immune Response to Traumatic Axonal Injuries	CELL REPORTS			English	Article							CENTRAL-NERVOUS-SYSTEM; WALLERIAN DEGENERATION; DEATH PATHWAY; BRAIN-INJURY; ACTIVATION; SARM1; PAIN; INFECTION; CNS	Traumatic injuries can trigger inflammatory reactions, leading to profound neuropathological consequences. However, the immune capacity of neurons, distinct from that of immune cells or glial cells, in response to traumatic insults remains to be fully characterized. In this study, we demonstrate that neurons can detect, cell autonomously, distant axonal damage, resulting in rapid production of a specific collection of cytokines and chemokines. This neuronal immune response appears spatially and temporally separated from injury-induced axon degeneration. We then identify through the genetic screen that this immune response is regulated by TIR-domain adaptor Sarm1/Myd88-5. We further show that Sarm1 functions through the downstream Jnk-c-Jun signal, and blockage of this Sarm1-Jnk-c-Jun pathway effectively abolishes the recruitment of immune cells to injury-afflicted neural tissues. We therefore uncover the key function of the Sarm1 signaling pathway, independent of its known role in axon degeneration, in the neuronal intrinsic immune response to traumatic axonal injuries.	[Wang, Qi; Liu, Tingting; Liu, Kaili; Zeng, Wenwen] Tsinghua Univ, Ctr Life Sci, Beijing 100084, Peoples R China; [Zhang, Shan; Zeng, Wenwen] Tsinghua Univ, Inst Immunol, Beijing 100084, Peoples R China; [Zhang, Shan; Zeng, Wenwen] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China; [Zeng, Wenwen] Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China; [Wang, Qiujun] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Wang, Qi; Liu, Tingting] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China; [Wang, Huanhuan] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China		Zeng, WW (corresponding author), Tsinghua Univ, Ctr Life Sci, Beijing 100084, Peoples R China.; Zeng, WW (corresponding author), Tsinghua Univ, Inst Immunol, Beijing 100084, Peoples R China.; Zeng, WW (corresponding author), Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.; Zeng, WW (corresponding author), Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.	wenwenzeng@tsinghua.edu.cn	Zeng, Wenwen/D-7276-2017	Zeng, Wenwen/0000-0001-8544-3318; Wang, Qi/0000-0002-9239-1998	National Key R&D Program of China [2017YFA0505800]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31770936, 91742106]; Beijing Natural Science FoundationBeijing Natural Science Foundation [5172016]; Thousand-Talent Young Investigator Program; Center for Life Sciences; Institute for Immunology; School of Medicine at Tsinghua University	This work was supported by the National Key R&D Program of China (2017YFA0505800), the National Natural Science Foundation of China (31770936 and 91742106 to W.Z.), the Beijing Natural Science Foundation (5172016 to W.Z.), and the Thousand-Talent Young Investigator Program (to W.Z.). The Zeng laboratory was also supported by the Center for Life Sciences, the Institute for Immunology, and the School of Medicine at Tsinghua University.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Belle M, 2014, CELL REP, V9, P1191, DOI 10.1016/j.celrep.2014.10.037; Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Ghosh AS, 2011, J CELL BIOL, V194, P751, DOI 10.1083/jcb.201103153; Grace PM, 2014, NAT REV IMMUNOL, V14, P217, DOI 10.1038/nri3621; Guan ZH, 2016, NAT NEUROSCI, V19, P94, DOI 10.1038/nn.4189; Hou YJ, 2013, J IMMUNOL, V191, P875, DOI 10.4049/jimmunol.1300374; Kim YH, 2007, J EXP MED, V204, P2063, DOI 10.1084/jem.20070868; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Lewis AE, 2013, DEV BIOL, V379, P229, DOI 10.1016/j.ydbio.2013.04.026; Limatola C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00229; Lin CW, 2014, INNATE IMMUN-LONDON, V20, P161, DOI 10.1177/1753425913485877; Mukherjee P, 2013, IMMUNITY, V38, P705, DOI 10.1016/j.immuni.2013.02.013; MURPHY PG, 1995, J NEUROSCI, V15, P5130; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Old EA, 2012, CURR OPIN PHARMACOL, V12, P67, DOI 10.1016/j.coph.2011.10.015; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Panneerselvam P, 2015, INT REV IMMUNOL, V34, P432, DOI 10.3109/08830185.2015.1065826; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Renier N, 2016, CELL, V165, P1789, DOI 10.1016/j.cell.2016.05.007; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Schreiber RC, 2001, NEUROREPORT, V12, P601, DOI 10.1097/00001756-200103050-00034; SMITH ML, 1972, ANAT REC, V172, P581, DOI 10.1002/ar.1091720311; Szretter KJ, 2009, J VIROL, V83, P9329, DOI 10.1128/JVI.00836-09; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053	33	33	33	2	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	APR 17	2018	23	3					716	724		10.1016/j.celrep.2018.03.071			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	GD3EC	WOS:000430384900007	29669278	gold			2022-02-06	
J	Vasterling, JJ; Aslan, M; Lee, LO; Proctor, SP; Ko, J; Jacob, S; Concato, J				Vasterling, Jennifer J.; Aslan, Mihaela; Lee, Lewina O.; Proctor, Susan P.; Ko, John; Jacob, Shawna; Concato, John			Longitudinal Associations among Posttraumatic Stress Disorder Symptoms, Traumatic Brain Injury, and Neurocognitive Functioning in Army Soldiers Deployed to the Iraq War	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive function; Posttraumatic stress disorders; Military personnel; Veterans; Traumatic brain injury; War exposure	NEUROPSYCHOLOGICAL OUTCOMES; MILITARY DEPLOYMENT; COGNITIVE SEQUELAE; PTSD SYMPTOMS; MENTAL-HEALTH; BLAST; RISK; MEMORY; VETERANS; PERFORMANCE	Objectives: Military deployment is associated with increased risk of adverse emotional and cognitive outcomes. Longitudinal associations involving posttraumatic stress disorder (PTSD), relatively mild traumatic brain injury (TBI), and neurocognitive compromise are poorly understood, especially with regard to long-term outcomes, and rigorous research is necessary to better understand the corresponding relationships. The objective of this study was to examine short-term and long-term (>5 years) longitudinal associations among PTSD, neurocognitive performance, and TBI following military deployment. Methods: In this prospective study, N=315 U.S. Army soldiers were assessed at military installations before (2003-2005) and after (2004-2006) an index deployment to the Iraq War, and again an average of 7.6 years later (2010-2014) as a nationally dispersed cohort of active duty soldiers, reservists, and veterans. Thus, the study design allowed for two measurement intervals over which to examine changes. All assessments included the PTSD Checklist, civilian version, and individually-administered performance-based neurocognitive tests. TBI history was derived from clinical interview. Results: Autoregressive analyses indicated that visual reproduction scores were inversely related to subsequent PTSD symptom severity at subsequent assessments. Conversely, increases in PTSD symptom severity over each measurement interval were associated with poorer verbal and/or visual recall at the end of each interval, and less efficient reaction time at post-deployment. TBI, primarily mild in this sample, was associated with adverse PTSD symptom outcomes at both post-deployment and long-term follow-up. Conclusions: These results suggest longitudinal relationships among PTSD symptoms, TBI, and neurocognitive decrements may contribute to sustained emotional and neurocognitive symptoms over time.	[Vasterling, Jennifer J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Vasterling, Jennifer J.; Jacob, Shawna] VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA; [Vasterling, Jennifer J.; Lee, Lewina O.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Aslan, Mihaela; Ko, John; Concato, John] VA Cooperat Studies Program, Clin Epidemiol Res Ctr, West Haven, CT USA; [Aslan, Mihaela; Concato, John] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; [Lee, Lewina O.; Proctor, Susan P.] VA Boston Hlth Care Syst, Res Serv, Boston, MA 02130 USA; [Proctor, Susan P.] US Army Res Inst Environm Med, Natick, MA USA; [Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA		Vasterling, JJ (corresponding author), VA Boston Healthcare Syst, Psychol 116B, 150 S Huntington Ave, Boston, MA 02130 USA.	jennifer.vasterling@va.gov		/0000-0002-1652-8198	Department of Veterans Affairs (VA) Cooperative Studies Program (CSP)US Department of Veterans Affairs [566]; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD 17-03-0020]; VA Clinical Sciences Research and Development; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG048221] Funding Source: NIH RePORTER	Funding was provided by the Department of Veterans Affairs (VA) Cooperative Studies Program (CSP#566). Support for previous collection of archived data used in this study's longitudinal analyses was provided by the U.S. Army Medical Research and Materiel Command (DAMD 17-03-0020) and VA Clinical Sciences Research and Development. The funding agency (VA) provided general guidance and policies for conducting human subjects research. The manuscript underwent administrative review at the U.S. Army Research Institute of Environmental Medicine. The views expressed in this article are those of the authors and do not reflect official policy or position of the U.S. Army, Department of Defense, VA, or U.S. government. The authors have no conflicts of interest to declare. We appreciate the support of the Defense Manpower Data Center in obtaining military service status data. We also thank the VACSP#566 team, including Drs. Helen MacDonald and Christopher Harte for their leadership of clinical data collection, Patricia Crutchfield and Joseph Turner for their organizational and administrative support, Drs. Matthew Jakupcak, Brian Marx, and Miles McFall for their roles as site investigators, our dedicated team of study psychologists, Drs. Grant Huang and Theresa Gleason for their support of the study, and the VACSP#566 Executive Committee for their on-going guidance. Finally, we are grateful to the Soldiers and military veterans who comprise the Neurocognition Deployment Health Study cohort for volunteering their time to participate in the study, and also for their military service.	Alosco ML, 2016, J HEAD TRAUMA REHAB, V31, P360, DOI 10.1097/HTR.0000000000000201; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armistead-Jehle P, 2017, PHYS MED REH CLIN N, V28, P323, DOI 10.1016/j.pmr.2016.12.008; Arnsten AFT, 2015, NEUROBIOL STRESS, V1, P89, DOI 10.1016/j.ynstr.2014.10.002; Aslan M, 2013, J INVEST MED, V61, P569, DOI [10.231/JIM.0b013e31828407ff, 10.2310/JIM.0b013e31828407ff]; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bleiberg, 2002, ANAM 2001 USERS MANU; Brewin CR, 2010, PSYCHOL REV, V117, P210, DOI 10.1037/a0018113; Bryant RA, 2015, BRIT J PSYCHIAT, V206, P417, DOI 10.1192/bjp.bp.114.145516; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Clark AL, 2016, BRAIN INJURY, V30, P864, DOI 10.3109/02699052.2016.1144894; Eekhout I, 2016, LANCET PSYCHIAT, V3, P58, DOI 10.1016/S2215-0366(15)00368-5; Gilbertson MW, 2007, BIOL PSYCHIAT, V62, P513, DOI 10.1016/j.biopsych.2006.12.023; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmes EA, 2005, EMOTION, V5, P489, DOI 10.1037/1528-3542.5.4.489; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kelley AM, 2012, J PSYCHIATR RES, V46, P582, DOI 10.1016/j.jpsychires.2012.01.017; Letz R, 1996, NEUROTOXICOL TERATOL, V18, P365, DOI 10.1016/0892-0362(96)00041-4; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2017, J NEUROTRAUM, V34, P2206, DOI 10.1089/neu.2016.4434; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Ramchand R, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0575-z; Regasa LE, 2016, J HEAD TRAUMA REHAB, V31, pE28, DOI 10.1097/HTR.0000000000000155; Rubin DC, 2003, MEM COGNITION, V31, P877, DOI 10.3758/BF03196442; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Sundin J, 2014, BRIT J PSYCHIAT, V204, P202, DOI 10.1192/bjp.bp.113.129569; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2016, AM J EPIDEMIOL, V184, P796, DOI 10.1093/aje/kww151; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2006, MIL MED, V171, P253, DOI 10.7205/MILMED.171.3.253; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wingenfeld K, 2011, CNS NEUROSCI THER, V17, P714, DOI 10.1111/j.1755-5949.2010.00207.x; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	53	33	33	2	26	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	APR	2018	24	4					311	323		10.1017/S1355617717001059			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	GA1JR	WOS:000428072200001	29199924	Green Accepted			2022-02-06	
J	Laksari, K; Kurt, M; Babaee, H; Kleiven, S; Camarillo, D				Laksari, Kaveh; Kurt, Mehmet; Babaee, Hessam; Kleiven, Svein; Camarillo, David			Mechanistic Insights into Human Brain Impact Dynamics through Modal Analysis	PHYSICAL REVIEW LETTERS			English	Article							HEAD IMPACT; UNREPORTED CONCUSSION; CEREBRAL CONCUSSION; SHEAR-WAVES; INJURY; DEFORMATION; MODEL; ACCELERATION; DECOMPOSITION; EPIDEMIOLOGY	Although concussion is one of the greatest health challenges today, our physical understanding of the cause of injury is limited. In this Letter, we simulated football head impacts in a finite element model and extracted the most dominant modal behavior of the brain's deformation. We showed that the brain's deformation is most sensitive in low frequency regimes close to 30 Hz, and discovered that for most subconcussive head impacts, the dynamics of brain deformation is dominated by a single global mode. In this Letter, we show the existence of localized modes and multimodal behavior in the brain as a hyperviscoelastic medium. This dynamical phenomenon leads to strain concentration patterns, particularly in deep brain regions, which is consistent with reported concussion pathology.	[Laksari, Kaveh] Univ Arizona, Dept Bioemed Engn, Tucson, AZ USA; [Kurt, Mehmet] Stevens Inst Technol, Dept Mech Engn, Hoboken, NJ 07030 USA; [Babaee, Hessam] Univ Pittsburgh, Dept Mech Engn & Mat Sci, Pittsburgh, PA 15261 USA; [Kleiven, Svein] KTH Royal Inst Technol, Div Neuron Engn, S-11428 Huddinge, Sweden; [Camarillo, David] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA		Kurt, M (corresponding author), Stevens Inst Technol, Dept Mech Engn, Hoboken, NJ 07030 USA.	mkurt@stevens.edu	Kurt, Mehmet/AAX-3303-2021	Kurt, Mehmet/0000-0002-5618-0296; Babaee, Hessameddin/0000-0002-6318-2265	Child Health Research Institute through the Thrasher Early Career Award; Lucile Packard Foundation for Children's Health through the Thrasher Early Career Award; Stanford CTSA through the Thrasher Early Career Award [UL1 TR001085]; Thrasher Research Foundation through the Thrasher Early Career Award; National Institutes of Health (NIH) National Institute of Bio-medical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]	This research was supported by Child Health Research Institute, Lucile Packard Foundation for Children's Health, Stanford CTSA (UL1 TR001085) and Thrasher Research Foundation, who funded this work through the Thrasher Early Career Award. This study was also partially supported by the National Institutes of Health (NIH) (Grant No. 3R21EB01761101S1) National Institute of Bio-medical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1. We also thank Dr. Andrew Knutsen and Dr. Philip Bayly for sharing the MRI data.	Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Chen KK, 2012, J NONLINEAR SCI, V22, P887, DOI 10.1007/s00332-012-9130-9; Clayton EH, 2012, J R SOC INTERFACE, V9, P2899, DOI 10.1098/rsif.2012.0325; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Costa M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.198102; Cramer MS, 2003, J ACOUST SOC AM, V114, P1821, DOI 10.1121/1.1610460; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Garrick JG, 2005, CLIN J SPORT MED, V15, P385, DOI 10.1097/01.jsm.0000181438.48892.1b; Giammarinaro B, 2018, PHYS REV APPL, V9, DOI 10.1103/PhysRevApplied.9.014011; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giordano C., 2014, 2014220002 SAE; Grilli M, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.174501; Grilli M, 2012, J FLUID MECH, V700, P16, DOI 10.1017/jfm.2012.37; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Holbourn AHS, 1944, J NEUROSURG, V1, P190, DOI 10.3171/jns.1944.1.3.0190; Holbourn AHS, 1943, LANCET, V2, P438; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jayaprakash KR, 2013, J NONLINEAR SCI, V23, P363, DOI 10.1007/s00332-012-9155-0; Jayaprakash KR, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.036606; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kerschen G, 2009, MECH SYST SIGNAL PR, V23, P170, DOI 10.1016/j.ymssp.2008.04.002; Kerschen G, 2005, NONLINEAR DYNAM, V41, P147, DOI 10.1007/s11071-005-2803-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Knutsen AK, 2014, J BIOMECH, V47, P3475, DOI 10.1016/j.jbiomech.2014.09.010; KORNHAUSER M, 1954, J APPL MECH-T ASME, V21, P371; Kornhauser M., 1961, IMPACT ACCELERATION, P333; Kraitchman DL, 2003, CIRCULATION, V107, P2025, DOI 10.1161/01.CIR.0000062684.47526.47; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Kurt M, 2015, J SOUND VIB, V357, P331, DOI 10.1016/j.jsv.2015.07.012; Kurt M, 2012, ARCH APPL MECH, V82, P1461, DOI 10.1007/s00419-012-0678-5; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Laksari K., 2013, J MECH BEHAVIOR OF B, V32, P132; Laksari K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0331; Laksari K, 2015, BIOMECH MODEL MECHAN, V14, P459, DOI 10.1007/s10237-014-0616-2; Laksari K, 2012, J BIOMECH, V45, P642, DOI 10.1016/j.jbiomech.2011.12.023; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Massouros PG, 2014, INT J SOLIDS STRUCT, V51, P305, DOI 10.1016/j.ijsolstr.2013.09.022; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PELLMAN EJ, 2003, NEUROSURGERY, V53, P796; Pesheck E, 2001, NONLINEAR DYNAM, V25, P183, DOI 10.1023/A:1012910918498; Rowley CW, 2009, J FLUID MECH, V641, P115, DOI 10.1017/S0022112009992059; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Schmid PJ, 2010, J FLUID MECH, V656, P5, DOI 10.1017/S0022112010001217; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Vakakis A. F., 2008, NONLINEAR TARGETED E, V156; Versace J., 1971, 710881 SAE; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wu LC, 2016, J BIOMECH, V49, P2918, DOI 10.1016/j.jbiomech.2016.07.004; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhao W, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0091; Zou H, 2007, INT J CRASHWORTHINES, V12, P341, DOI 10.1080/13588260701433024	69	33	33	1	11	AMER PHYSICAL SOC	COLLEGE PK	ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA	0031-9007	1079-7114		PHYS REV LETT	Phys. Rev. Lett.	MAR 30	2018	120	13							138101	10.1103/PhysRevLett.120.138101			7	Physics, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Physics	GB1AR	WOS:000428783300021	29694192	Green Published, hybrid			2022-02-06	
J	Attwood, MJ; Roberts, SP; Trewartha, G; England, ME; Stokes, KA				Attwood, Matthew J.; Roberts, Simon P.; Trewartha, Grant; England, Mike E.; Stokes, Keith A.			Efficacy of a movement control injury prevention programme in adult men's community rugby union: a cluster randomised controlled trial	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CONTROL EXERCISE PROGRAM; FIFA 11+; KNEE OSTEOARTHRITIS; FOOTBALL INJURIES; SOCCER PLAYERS; FEMALE SOCCER; WARM-UP; RATES; EPIDEMIOLOGY; PREVALENCE	Background Exercise programmes aimed at reducing injury have been shown to be efficacious for some non-collision sports, but evidence in adult men's collision sports such as rugby union is lacking. Objective To evaluate the efficacy of a movement control injury prevention exercise programme for reducing match injuries in adult men's community rugby union players. Methods 856 clubs were invited to participate in this prospective cluster randomised (single-blind) controlled trial where clubs were the unit of randomisation. 81 volunteered and were randomly assigned (intervention/control). A 42-week exercise programme was followed throughout the season. The control programme reflected 'normal practice' exercises, whereas the intervention focused on proprioception, balance, cutting, landing and resistance exercises. Outcome measures were match injury incidence and burden for: (1) all >= 8 days time-loss injuries and (2) targeted (lower limb, shoulder, head and neck, excluding fractures and lacerations) >= 8 days time-loss injuries. Results Poisson regression identified no clear effects on overall injury outcomes. A likely beneficial difference in targeted injury incidence (rate ratio (RR), 90% CI=0.6, 0.4 to 1.0) was identified, with a 40% reduction in lower-limb incidence (RR, 90% CI=0.6, 0.4 to 1.0) and a 60% reduction in concussion incidence (RR, 90% CI=0.4, 0.2 to 0.7) in the intervention group. Comparison between arms for clubs with highest compliance (>= median compliance) demonstrated very likely beneficial 60% reductions in targeted injury incidence (RR, 90% CI=0.4, 0.2 to 0.8) and targeted injury burden (RR, 90% CI=0.4, 0.2 to 0.7). Conclusions The movement control injury prevention programme resulted in likely beneficial reductions in lower-limb injuries and concussion. Higher intervention compliance was associated with reduced targeted injury incidence and burden.	[Attwood, Matthew J.; Roberts, Simon P.; Trewartha, Grant; Stokes, Keith A.] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [Attwood, Matthew J.] Cardiff Metropolitan Univ, Sch Sport & Hlth Sci, Cardiff, S Glam, Wales; [England, Mike E.] Rugby Football Union, London, England		Stokes, KA (corresponding author), Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England.	k.stokes@bath.ac.uk	Attwood, Matthew J/N-2057-2019; Stokes, Keith/C-2605-2009	Attwood, Matthew J/0000-0002-3911-1897; Stokes, Keith/0000-0002-5049-2838	Rugby Football Union; Private Physiotherapy Education Fund	This research is funded by the Rugby Football Union and the Private Physiotherapy Education Fund.	Bizzini M, 2015, BRIT J SPORT MED, V49, P577, DOI 10.1136/bjsports-2015-094765; Burger N, 2017, AM J SPORT MED, V45, P278, DOI 10.1177/0363546516677548; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Crichton J, 2012, BRIT J SPORT MED, V46, P538, DOI 10.1136/bjsports-2011-090688; Dempsey AR., 2015, 33 INT C BIOM SPORTS; Falese L, 2016, RES SPORTS MED, V24, P426, DOI 10.1080/15438627.2016.1239105; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Finch CF, 2016, INJURY PREV, V22, P123, DOI 10.1136/injuryprev-2015-041667; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Geary K, 2014, CLIN J SPORT MED, V24, P502, DOI 10.1097/JSM.0000000000000071; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Grimmer KA, 2000, J ADOLESCENT HEALTH, V27, P266, DOI 10.1016/S1054-139X(00)00120-8; Grooms DR, 2013, J ATHL TRAINING, V48, P782, DOI 10.4085/1062-6050-48.4.08; Hagglund M, 2013, BRIT J SPORT MED, V47, P974, DOI 10.1136/bjsports-2013-092644; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Headey J, 2007, AM J SPORT MED, V35, P1537, DOI 10.1177/0363546507300691; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hislop MD, 2017, BRIT J SPORT MED, V51, P1140, DOI 10.1136/bjsports-2016-097434; Hopkins WG, 2016, SPORTS MED, V46, P1563, DOI 10.1007/s40279-016-0517-x; Hume PA, 2017, SPORTS MED, V47, P1209, DOI 10.1007/s40279-016-0608-8; Jeffreys I., 2006, UKSCA J, V6, P15; LaBella CR, 2011, ARCH PEDIAT ADOL MED, V165, P1033, DOI 10.1001/archpediatrics.2011.168; Lohmander LS, 2004, ARTHRITIS RHEUM-US, V50, P3145, DOI 10.1002/art.20589; Longo UG, 2012, AM J SPORT MED, V40, P996, DOI 10.1177/0363546512438761; Maffulli N, 2010, BRIT J SPORT MED, V44, P21, DOI 10.1136/bjsm.2009.069526; McCullagh P., 1989, GEN LINEAR MODELS 2, V2; McKay CD, 2016, BRIT J SPORT MED, V50, P382, DOI 10.1136/bjsports-2015-095192; McNoe BM, 2010, AM J SPORT MED, V38, P2542, DOI 10.1177/0363546510377415; O'Brien J, 2014, SPORTS MED, V44, P1305, DOI 10.1007/s40279-014-0208-4; Petersen J, 2011, AM J SPORT MED, V39, P2296, DOI 10.1177/0363546511419277; Rae K, 2005, BRIT J SPORT MED, V39, P907, DOI 10.1136/bjsm.2004.017517; RFU, 2011, RECR RET PLAY 2011; Roberts SP, 2017, AM J SPORT MED, V45, P480, DOI 10.1177/0363546516668296; Roberts SP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003998; Salaffi F, 2005, AGING CLIN EXP RES, V17, P255; Soligard T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2469; Steffen K, 2013, BRIT J SPORT MED, V47, P794, DOI 10.1136/bjsports-2012-091886; Tucker R, 2017, BRIT J SPORT MED, V51; Williams S., 2016, BMJ OPEN SPORT EXERC, V2; Williams S, 2016, BRIT J SPORT MED, V50, P651, DOI 10.1136/bjsports-2015-094798	40	33	33	1	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAR	2018	52	6					368	+		10.1136/bjsports-2017-098005			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	FZ2IO	WOS:000427401500007	29055883	Green Published, hybrid			2022-02-06	
S	Coleman, LG; Crews, FT		Grant, KA; Lovinger, DM		Coleman, Leon G., Jr.; Crews, Fulton T.			Innate Immune Signaling and Alcohol Use Disorders	NEUROPHARMACOLOGY OF ALCOHOL	Handbook of Experimental Pharmacology		English	Article; Book Chapter						Addiction; Alcohol; Neuroimmune; Treatment	NF-KAPPA-B; INTERMITTENT ETHANOL EXPOSURE; NEURO-IMMUNOLOGICAL FACTORS; TRAUMATIC BRAIN-INJURY; TOLL-LIKE RECEPTOR-3; MICROGLIAL ACTIVATION; NUCLEAR-FACTOR; TNF-ALPHA; INDUCED NEUROINFLAMMATION; INFLAMMATORY MEDIATORS	Innate immune signaling is an important feature in the pathology of alcohol use disorders. Alcohol abuse causes persistent innate immune activation in the brain. This is seen in postmortem human alcoholic brain specimens, as well as in primate and rodent models of alcohol consumption. Further, in vitro models of alcohol exposure in neurons and glia also demonstrate innate immune activation. The activation of the innate immune system seems to be important in the development of alcohol use pathology, as anti-immune therapies reduce pathology and ethanol self-administration in rodent models. Further, innate immune activation has been identified in each of the stages of addiction: binge/ intoxication, withdrawal/negative affect, and preoccupation/craving. This suggests that innate immune activation may play a role both in the development and maintenance of alcoholic pathology. In this chapter, we discuss the known contributions of innate immune signaling in the pathology of alcohol use disorders, and present potential therapeutic interventions that may be beneficial for alcohol use disorders.	[Coleman, Leon G., Jr.; Crews, Fulton T.] Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; [Coleman, Leon G., Jr.; Crews, Fulton T.] Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA		Coleman, LG (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA.; Coleman, LG (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.	leon_coleman@med.unc.edu; fulton_crews@med.unc.edu	Crews, Fulton/None	Crews, Fulton/0000-0003-2393-4976; Coleman, Leon/0000-0003-1693-3799	National Institute on Alcohol Abuse and Alcoholism through the Neurobiology of Adolescent Drinking in Adulthood (NADIA) consortium [AA020024, AA020023]; Bowles Center for Alcohol Studies [AA011605]; NCCU [AA019767]; UNC [AA019767]; K08 award program [AA024829]; Monkey Alcohol and Tissue Research Resource [MATRR-R24 AA019431]	We thank the National Institute on Alcohol Abuse and Alcoholism for its support through the Neurobiology of Adolescent Drinking in Adulthood (NADIA) consortium (AA020024, AA020023), the Bowles Center for Alcohol Studies (AA011605), the U54 collaborative partnership between NCCU and UNC (AA019767), the K08 award program (AA024829), and the Monkey Alcohol and Tissue Research Resource (MATRR-R24 AA019431).	Agrawal RG, 2011, BRAIN BEHAV IMMUN, V25, pS165, DOI 10.1016/j.bbi.2011.03.002; Alfonso-Loeches S, 2010, J NEUROSCI, V30, P8285, DOI 10.1523/JNEUROSCI.0976-10.2010; Aloe L, 1999, BRAIN RES, V840, P125, DOI 10.1016/S0006-8993(99)01748-5; Arezoomandan R, 2016, CAN J PHYSIOL PHARM, V94, P257, DOI 10.1139/cjpp-2015-0209; Attarzadeh-Yazdi G, 2014, PROG NEURO-PSYCHOPH, V53, P142, DOI 10.1016/j.pnpbp.2014.04.008; Bachtell R, 2015, CNS NEUROL DISORD-DR, V14, P692, DOI 10.2174/1871527314666150529132503; Badanich KA, 2011, BEHAV NEUROSCI, V125, P879, DOI 10.1037/a0025922; Bai LY, 2014, NEUROSCI BULL, V30, P936, DOI 10.1007/s12264-014-1483-7; Bajo M, 2015, BRAIN BEHAV IMMUN, V45, P189, DOI 10.1016/j.bbi.2014.11.011; Bajo M, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00049; Ballester J, 2017, EXPERT REV CLIN PHAR, V10, P305, DOI 10.1080/17512433.2017.1268916; Banks WA, 1995, NEUROIMMUNOMODULAT, V2, P241, DOI 10.1159/000097202; BANKS WA, 1994, NEUROSCI LETT, V179, P53, DOI 10.1016/0304-3940(94)90933-4; Barbierato M, 2013, CNS NEUROL DISORD-DR, V12, P608; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bell RL, 2015, ADDICT BIOL, V20, P38, DOI 10.1111/adb.12106; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Bhattacharya A, 2017, CURR TOP BEHAV NEURO, V31, P339, DOI 10.1007/7854_2016_43; Bhattacharya A, 2016, PSYCHOPHARMACOLOGY, V233, P1623, DOI 10.1007/s00213-016-4214-0; Bi W, 2011, BRAIN RES, V1395, P12, DOI 10.1016/j.brainres.2011.04.019; Bian C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118842; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Blanc L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081593; Blanco AM, 2005, J IMMUNOL, V175, P6893, DOI 10.4049/jimmunol.175.10.6893; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Blednov YA, 2005, BEHAV BRAIN RES, V165, P110, DOI 10.1016/j.bbr.2005.06.026; Blednov YA, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00129; Blednov YA, 2012, ADDICT BIOL, V17, P108, DOI 10.1111/j.1369-1600.2010.00284.x; Borner C, 2012, MOL PHARMACOL, V81, P587, DOI 10.1124/mol.111.076620; Bose S, 2013, ARCH PHARM RES, V36, P1039, DOI 10.1007/s12272-013-0161-z; Breese GR, 2008, NEUROPSYCHOPHARMACOL, V33, P867, DOI 10.1038/sj.npp.1301468; Breese GR, 2005, PSYCHOPHARMACOLOGY, V178, P367, DOI 10.1007/s00213-004-2016-2; Brombacher TM, 2017, J IMMUNOL, V198, P2681, DOI 10.4049/jimmunol.1601546; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Bsibsi M, 2010, J IMMUNOL, V184, P6929, DOI 10.4049/jimmunol.0902419; Buwitt-Beckmann U, 2006, J BIOL CHEM, V281, P9049, DOI 10.1074/jbc.M512525200; Calu DJ, 2007, CEREB CORTEX, V17, P1342, DOI 10.1093/cercor/bhl045; Cameron JS, 2007, J NEUROSCI, V27, P13033, DOI 10.1523/JNEUROSCI.4290-06.2007; Caraci F, 2015, SCI REP-UK, V5, DOI 10.1038/srep11252; Chen G, 2012, AUTOPHAGY, V8, P1577, DOI 10.4161/auto.21376; Coleman LG, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0799-4; Coleman LG, 2011, ALCOHOL CLIN EXP RES, V35, P671, DOI 10.1111/j.1530-0277.2010.01385.x; Cozzoli DK, 2016, NEUROPHARMACOLOGY, V105, P164, DOI 10.1016/j.neuropharm.2016.01.010; Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003; Crews F, 2006, ALCOHOL CLIN EXP RES, V30, P1938, DOI 10.1111/j.1530-0277.2006.00239.x; Crews FT, 2017, NEUROPHARMACOLOGY, V122, P56, DOI 10.1016/j.neuropharm.2017.01.031; Crews FT, 2016, PHARMACOL REV, V68, P1074, DOI 10.1124/pr.115.012138; Crews FT, 2016, PSYCHOPHARMACOLOGY, V233, P1543, DOI 10.1007/s00213-015-3906-1; Crews FT, 2015, ALCOHOL RES-CURR REV, V37, P331; Crews FT, 2014, INT REV NEUROBIOL, V118, P315, DOI 10.1016/B978-0-12-801284-0.00010-5; Crews FT, 2013, BIOL PSYCHIAT, V73, P602, DOI 10.1016/j.biopsych.2012.09.030; Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018; Cui CH, 2015, ALCOHOL, V49, P435, DOI 10.1016/j.alcohol.2015.04.006; Cui CH, 2014, INT REV NEUROBIOL, V118, P1, DOI 10.1016/B978-0-12-801284-0.00001-4; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Davis RL, 2004, NEUROSCI LETT, V371, P128, DOI 10.1016/j.neulet.2004.08.051; Dawson DA, 2008, ALCOHOL CLIN EXP RES, V32, P2149, DOI 10.1111/j.1530-0277.2008.00806.x; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Di Castro MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep34633; Drew PD, 2015, ALCOHOL CLIN EXP RES, V39, P445, DOI 10.1111/acer.12639; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fernandez-Lizarbe S, 2013, J NEUROCHEM, V126, P261, DOI 10.1111/jnc.12276; Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590; Fortier CB, 2008, NEUROPSYCHOLOGY, V22, P196, DOI 10.1037/0894-4105.22.2.196; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Frank MG, 2016, BRAIN BEHAV IMMUN, V51, P99, DOI 10.1016/j.bbi.2015.08.001; FRANKE H, 1995, ACTA HISTOCHEM, V97, P263, DOI 10.1016/S0065-1281(11)80187-X; Freeman K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-97; GEORGE FR, 1989, ANN NY ACAD SCI, V559, P382; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gorina R, 2011, GLIA, V59, P242, DOI 10.1002/glia.21094; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; Grant BF, 1998, J SUBST ABUSE, V10, P163, DOI 10.1016/S0899-3289(99)80131-X; Guo ML, 2015, AUTOPHAGY, V11, P995, DOI 10.1080/15548627.2015.1052205; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Hashioka S, 2015, CNS NEUROL DISORD-DR, V14, P251, DOI 10.2174/1871527314666150217122305; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Heberlein A, 2014, ALCOHOL, V48, P671, DOI 10.1016/j.alcohol.2014.08.003; Hoeffel G, 2015, IMMUNITY, V42, P665, DOI 10.1016/j.immuni.2015.03.011; Hu W, 2011, PSYCHOPHARMACOLOGY, V218, P331, DOI 10.1007/s00213-011-2290-8; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Irwin MR, 2009, BIOL PSYCHIAT, V66, P191, DOI 10.1016/j.biopsych.2008.12.004; Izquierdo A, 2016, NEUROSCIENCE, DOI DOI 10.1016/J.NEUR0SCIENCE.2016.03.021.[EPUB; Jackson AC, 2006, J NEUROVIROL, V12, P229, DOI 10.1080/13550280600848399; Jacobsen JHW, 2018, BRAIN BEHAV IMMUN, V67, P181, DOI 10.1016/j.bbi.2017.08.021; Jacobsen JHW, 2016, CURR OPIN PHARMACOL, V26, P131, DOI 10.1016/j.coph.2015.10.010; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Janko C, 2014, ANTIOXID REDOX SIGN, V20, P1075, DOI 10.1089/ars.2013.5179; Jensen CJ, 2013, J NEUROIMMUNE PHARM, V8, P824, DOI 10.1007/s11481-013-9480-6; Serramia MJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17887; Jimenez JL, 2001, J PHARMACOL EXP THER, V299, P753; Jokisch D, 2014, ALCOHOL CLIN EXP RES, V38, P1947, DOI 10.1111/acer.12460; June HL, 2015, NEUROPSYCHOPHARMACOL, V40, P1549, DOI 10.1038/npp.2015.4; Kaltschmidt B, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00069; Kane CJM, 2011, BRAIN BEHAV IMMUN, V25, pS137, DOI 10.1016/j.bbi.2011.02.016; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khairova RA, 2009, INT J NEUROPSYCHOPH, V12, P561, DOI 10.1017/S1461145709009924; Khakh BS, 2015, NAT NEUROSCI, V18, P942, DOI 10.1038/nn.4043; Kim C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2534; Knapp DJ, 1999, ALCOHOL CLIN EXP RES, V23, P633, DOI 10.1097/00000374-199904001-00010; Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Kreisel T, 2014, MOL PSYCHIATR, V19, P699, DOI 10.1038/mp.2013.155; Lawrimore CJ, 2017, ALCOHOL CLIN EXP RES, V41, P939, DOI 10.1111/acer.13368; Leclercq S, 2014, BIOL PSYCHIAT, V76, P725, DOI 10.1016/j.biopsych.2014.02.003; Lee M, 2013, NEUROSCIENCE, V229, P164, DOI 10.1016/j.neuroscience.2012.10.033; Lehmann SM, 2012, J IMMUNOL, V189, P1448, DOI 10.4049/jimmunol.1201078; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Lewohl JM, 2011, ALCOHOL CLIN EXP RES, V35, P1928, DOI 10.1111/j.1530-0277.2011.01544.x; Liang YL, 2014, BRAIN RES, V1590, P75, DOI 10.1016/j.brainres.2014.09.020; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lim SW, 2017, NEUROCRIT CARE, V26, P122, DOI 10.1007/s12028-016-0290-6; Lippai D, 2013, J LEUKOCYTE BIOL, V94, P171, DOI 10.1189/jlb.1212659; Liu JA, 2011, P NATL ACAD SCI USA, V108, P4465, DOI 10.1073/pnas.1019020108; Loftis JM, 2014, INT REV NEUROBIOL, V118, P165, DOI 10.1016/B978-0-12-801284-0.00007-5; Ma YH, 2006, J CELL BIOL, V175, P209, DOI 10.1083/jcb.200606016; Madrigal JLM, 2002, BRAIN RES, V938, P87, DOI 10.1016/S0006-8993(02)02467-8; Mao XRR, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-16; Marciniak E, 2015, SCI REP-UK, V5, DOI 10.1038/srep15862; Maroso M, 2011, J INTERN MED, V270, P319, DOI 10.1111/j.1365-2796.2011.02431.x; Marshall SA, 2017, J NEUROIMMUNE PHARM, V12, P249, DOI 10.1007/s11481-016-9709-2; Marshall SA, 2016, BRAIN BEHAV IMMUN, V51, P258, DOI 10.1016/j.bbi.2015.09.006; Marshall SA, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6020016; Mayfield J, 2013, CURR OPIN NEUROBIOL, V23, P513, DOI 10.1016/j.conb.2013.01.024; McCarthy GM, 2017, ADDICT BIOL; Montesinos J, 2017, ALCOHOL CLIN EXP RES, V41, P1257, DOI 10.1111/acer.13416; Montesinos J, 2016, ALCOHOL CLIN EXP RES, V40, P2260, DOI 10.1111/acer.13208; Montesinos J, 2015, BRAIN BEHAV IMMUN, V45, P233, DOI 10.1016/j.bbi.2014.11.015; Most Dana, 2014, Handb Clin Neurol, V125, P89, DOI 10.1016/B978-0-444-62619-6.00006-9; Muller MM, 2006, P NATL ACAD SCI USA, V103, P14250, DOI 10.1073/pnas.0606668103; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Narayanan KB, 2015, APOPTOSIS, V20, P196, DOI 10.1007/s10495-014-1073-1; Neupane SP, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00655; Northcutt AL, 2015, MOL PSYCHIATR, V20, P1525, DOI 10.1038/mp.2014.177; Nunez YO, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-725; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okun E, 2010, P NATL ACAD SCI USA, V107, P15625, DOI 10.1073/pnas.1005807107; Okvist A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000930; Park CK, 2014, NEURON, V82, P47, DOI 10.1016/j.neuron.2014.02.011; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pascual M, 2007, EUR J NEUROSCI, V25, P541, DOI 10.1111/j.1460-9568.2006.05298.x; Pascual M, 2011, BRAIN BEHAV IMMUN, V25, pS80, DOI 10.1016/j.bbi.2011.02.012; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Periyasamy P, 2017, MOL NEUROBIOL; Periyasamy P, 2016, AUTOPHAGY, V12, P1310, DOI 10.1080/15548627.2016.1183844; Pla A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153097; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Prieto GA, 2017, CYTOKINE GROWTH F R, V34, P27, DOI 10.1016/j.cytogfr.2017.03.005; Prieto GA, 2015, P NATL ACAD SCI USA, V112, pE5078, DOI 10.1073/pnas.1514486112; Qin LY, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-10; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Qin LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-130; Qin LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-5; Ray LA, 2014, INT REV NEUROBIOL, V118, P381, DOI 10.1016/B978-0-12-801284-0.00012-9; Reissner KJ, 2010, BEHAV PHARMACOL, V21, P514, DOI 10.1097/FBP.0b013e32833d41b2; Ripley TL, 2015, PSYCHOPHARMACOLOGY, V232, P3431, DOI 10.1007/s00213-015-3995-x; Rostene W, 2007, NAT REV NEUROSCI, V8, P895, DOI 10.1038/nrn2255; Rubio-Araiz A, 2017, ADDICT BIOL, V22, P1103, DOI 10.1111/adb.12376; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Schoenbaum G, 2004, EUR J NEUROSCI, V19, P1997, DOI 10.1111/j.1460-9568.2004.03274.x; Sheng JP, 2015, IMMUNITY, V43, P382, DOI 10.1016/j.immuni.2015.07.016; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Stalnaker TA, 2009, NEUROPHARMACOLOGY, V56, P63, DOI 10.1016/j.neuropharm.2008.07.019; Storer PD, 2005, J NEUROIMMUNOL, V161, P113, DOI 10.1016/j.jneuroim.2004.12.015; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sugimura T, 2015, NEUROSCI RES, V96, P37, DOI 10.1016/j.neures.2015.02.005; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Theberge FR, 2013, BIOL PSYCHIAT, V73, P729, DOI 10.1016/j.biopsych.2012.12.019; Townshend JM, 2003, NEUROPSYCHOLOGIA, V41, P773, DOI 10.1016/S0028-3932(02)00284-1; Tynan RJ, 2010, BRAIN BEHAV IMMUN, V24, P1058, DOI 10.1016/j.bbi.2010.02.001; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Valenta JP, 2016, ALCOHOL CLIN EXP RES, V40, P187, DOI 10.1111/acer.12928; Valles SL, 2004, BRAIN PATHOL, V14, P365; Vetreno R P, 2014, Handb Clin Neurol, V125, P477, DOI 10.1016/B978-0-444-62619-6.00027-6; Vetreno RP, 2012, NEUROSCIENCE, V226, P475, DOI 10.1016/j.neuroscience.2012.08.046; Vetreno RP, 2013, NEUROBIOL DIS, V59, P52, DOI 10.1016/j.nbd.2013.07.002; Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480; Wagley Y, 2013, BBA-MOL CELL RES, V1833, P1476, DOI 10.1016/j.bbamcr.2013.02.017; Walter TJ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0856-z; Wang X, 2016, BRIT J PHARMACOL, V173, P856, DOI 10.1111/bph.13394; Wang XH, 2013, FASEB J, V27, P2713, DOI 10.1096/fj.12-222992; Ward RJ, 1996, FEBS LETT, V389, P119, DOI 10.1016/0014-5793(96)00545-5; Ward RJ, 2009, J NEUROCHEM, V111, P1119, DOI 10.1111/j.1471-4159.2009.06389.x; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Weissenborn R, 2003, PSYCHOPHARMACOLOGY, V165, P306, DOI 10.1007/s00213-002-1281-1; Whitman BA, 2013, ALCOHOL CLIN EXP RES, V37, P2086, DOI 10.1111/acer.12189; Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450-11.2011; Worley MJ, 2016, DRUG ALCOHOL DEPEN, V162, P245, DOI 10.1016/j.drugalcdep.2016.02.036; Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512; Yelamanchili SV, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005032; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3; Zhu CB, 2010, NEUROPSYCHOPHARMACOL, V35, P2510, DOI 10.1038/npp.2010.116; Zou J, 2006, CELL MOL NEUROBIOL, V26, P385, DOI 10.1007/s10571-006-9045-9; Zou J, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00077; Zou J, 2010, ALCOHOL CLIN EXP RES, V34, P777, DOI 10.1111/j.1530-0277.2010.01150.x; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	203	33	35	2	3	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	0171-2004		978-3-319-96523-9; 978-3-319-96522-2	HANDB EXP PHARMACOL	Handb. Exp. Pharmacol.		2018	248						369	396		10.1007/164_2018_92	10.1007/978-3-319-96523-9		28	Neurosciences; Pharmacology & Pharmacy	Book Citation Index – Science (BKCI-S)	Neurosciences & Neurology; Pharmacology & Pharmacy	BQ3HJ	WOS:000584899800015	29500721	Green Accepted			2022-02-06	
J	Loftis, KL; Price, J; Gillich, PJ				Loftis, Kathryn L.; Price, Janet; Gillich, Patrick J.			Evolution of the Abbreviated Injury Scale: 1990-2015	TRAFFIC INJURY PREVENTION			English	Article						AIS; injury coding; versions	SEVERITY SCORE	Objective: Although the Abbreviated Injury Scale (AIS) was initially developed in the mid-1960s for tracking injury in automotive and aircraft crashes, it has grown to become an internationally recognized scoring system for a variety of traumatic injuries. This shift in focus and advances in organized medical care, combined with feedback from field use and outcome analysis, have resulted in several AIS updates and revisions. This article demonstrates how AIS codes and severities have changed over the last 25 years and investigates the effects of those changes. Methods: Data from each version and update of the AIS dictionary (AIS 1990, AIS 1998, AIS 2005, AIS 2008, and AIS 2015) were analyzed for changes and shifts in injury descriptions, severities, and code counts. Results: The number of AIS codes has increased to improve coding specificity and reliability for a growing number of injury types. There has also been a shift in severities, mainly within the moderate (AIS 2) to severe (AIS 4) range. AIS 1990 was the first version to utilize the 6-digit predot identifier, to add modifiers for pediatric injury, and to substantially expand brain injury codes. AIS 1998 added coding rules and guidelines throughout the dictionary and integrated the Organ Injury Scale scores. The AIS 2005 dictionary added over 400 codes and made significant changes throughout. Fewer changes were made in the AIS 2008 update. AIS 2015 includes descriptions for tissue injuries with loss of soft tissue that do not qualify as amputations, a need identified in military injury analysis. Conclusions: Each updated version of AIS reflects improving medical care and new advances in understanding, measuring, and documenting injury. AIS changes over time reflect its international and cross-domain utilization for describing injury severity and set the standard for how the world now studies traumatic injury.	[Loftis, Kathryn L.] US RDECOM, Survivabil Lethal Anal Directorate, Bldg 4501,6509 Wayberry Rd, Aberdeen Proving Ground, MD 21005 USA; [Gillich, Patrick J.] US Army Res Lab, Weap & Mat Res Directorate, Aberdeen Proving Ground, MD USA		Loftis, KL (corresponding author), US RDECOM, Survivabil Lethal Anal Directorate, Bldg 4501,6509 Wayberry Rd, Aberdeen Proving Ground, MD 21005 USA.	kathryn.l.loftis2.civ@mail.mil					[Anonymous], 1998, ABBR INJ SCAL 1990 U; Association for the Advancement of Automotive Medicine, 2007, ABBR INJ SCAL 2005 R; Association for the Advancement of Automotive Medicine, 2016, ABBR INJ SCAL 2015 R; Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005 U; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barnes J, 2009, Ann Adv Automot Med, V53, P83; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Loftis KL, 2016, TRAFFIC INJ PREV, V17, P1, DOI 10.1080/15389588.2016.1191069; Loftis KL, 2014, ASS ADV AUT MED ANN; Salottolo K, 2009, INJURY, V40, P999, DOI 10.1016/j.injury.2009.05.013; Skaga NO, 2007, INJURY, V38, P84, DOI 10.1016/j.injury.2006.04.123	13	33	35	2	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2018	19			2			S109	S113		10.1080/15389588.2018.1512747			5	Public, Environmental & Occupational Health; Transportation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Transportation	HQ5UO	WOS:000462478300017	30543458				2022-02-06	
J	Mohamed, AZ; Cumming, P; Srour, H; Gunasena, T; Uchida, A; Haller, CN; Nasrallah, F				Mohamed, Abdalla Z.; Cumming, Paul; Srour, Hussein; Gunasena, Tamara; Uchida, Aya; Haller, Courtney Nicole; Nasrallah, Fatima		Dept Def Alzheimers Dis	Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Post-traumatic stress disorder; Alzheimer's disease; Amyloid; PET; Department of Defense Alzheimer's Disease; Neuroimaging Initiative (DOD-ADNI)	PRECLINICAL ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; FLORBETAPIR-PET; BETA; DEMENTIA; RISK; METAANALYSIS; VETERANS; TAU; ASSOCIATION	Introduction: Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are risk factors for early onset of Alzheimer's disease (AD) and may accelerate the progression rate of AD pathology. As amyloid-beta (A beta) plaques are a hallmark of AD pathology, we hypothesized that TBI and PTSD might increase A beta accumulation in the brain. Methods: We examined PET and neuropsychological data from Vietnam War veterans compiled by the US Department of Defense Alzheimer's Disease Neuroimaging Initiative, to examine the spatial distribution of A beta in male veterans' who had experienced a TBI and/or developed PTSD. Subjects were classified into controls, TBI only, PTSD only, and TBI with PTSD (TBI_PTSD) groups and data were analyzed using both voxel-based and ROI-based approaches. Results: Compared to controls, all three clinical groups showed a pattern of mainly increased referenced standard uptake values (SUVR) for the amyloid tracer [F-18]-AV45 PET, with rank order PTSD > TBI_PTSD > TBI > Control, and same rank order was seen in the deficits of cognitive functions. SUVR increase was observed in widespread cortical regions of the PTSD group; in white matter of the TBI_PTSD group; and cerebellum and precuneus area of the TBI group, in contrast with controls. The [F-18]-AV45 SUVR correlated negatively with cerebrospinal fluid (CSF) amyloid levels and positively with the CSF tau concentrations. Conclusion: These results suggest that both TBI and PTSD are substantial risk factors for cognition decline and increased A beta deposition resembling that in AD. In addition, both PTSD and TBI_PTSD have a different pathways of A beta accumulation.	[Mohamed, Abdalla Z.; Srour, Hussein; Nasrallah, Fatima] Univ Queensland, Queensland Brain Inst, Bldg 79,Upland Rd, Brisbane, Qld 4072, Australia; [Cumming, Paul] Queensland Univ Technol, Sch Psychol & Counselling, Brisbane, Qld 4059, Australia; [Cumming, Paul] Queensland Univ Technol, IHBI, Brisbane, Qld 4059, Australia; [Cumming, Paul] QIMR Berghofer Inst, Brisbane, Qld 4006, Australia; [Gunasena, Tamara; Uchida, Aya; Haller, Courtney Nicole] Univ Queensland, Sch Med, Brisbane, Qld 4072, Australia		Nasrallah, F (corresponding author), Univ Queensland, Queensland Brain Inst, Bldg 79,Upland Rd, Brisbane, Qld 4072, Australia.	f.nasrallah@uq.edu.au	Mohaned, Abdalla/AAL-8721-2020; Mohamed, Abdalla/ABG-8718-2021; Mohaned, Abdalla/ABF-9320-2021; Nasrallah, Fatima/N-3398-2016	Mohaned, Abdalla/0000-0003-4499-672X; Mohaned, Abdalla/0000-0003-4499-672X; Cumming, Paul/0000-0002-0257-9621; Nasrallah, Fatima/0000-0002-7385-9559	Motor Accident Insurance Commission (MAIC), The Queensland Government, Australia [2014000857]; Wesley Hospital Medical Research Foundation, Brisbane, Australia; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; DOD-ADNI (Department of Defense)United States Department of Defense [W81XWH-12-2-0012]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); AbbVieAbbVie; Alzheimer's AssociationAlzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; BiogenBiogen; Bristol-Myers Squibb CompanyBristol-Myers Squibb; CereSpir, Inc.; CogstateCogState Limited; Eisai Inc.Eisai Co Ltd; Elan Pharmaceuticals, Inc.; Eli Lilly and CompanyEli Lilly; EuroImmun; F. Hoffmann-La Roche LtdHoffmann-La Roche; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904] Funding Source: NIH RePORTER	This research was supported by Motor Accident Insurance Commission (MAIC), The Queensland Government, Australia (grant number: 2014000857). In addition, PC acknowledges grant support from the Wesley Hospital Medical Research Foundation (2016-19), Brisbane, Australia.; Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD-ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.	Aisen PS, 2010, ALZHEIMERS DEMENT, V6, P239, DOI 10.1016/j.jalz.2010.03.006; Alway Y, 2016, DEPRESS ANXIETY, V33, P19, DOI 10.1002/da.22396; Amen DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129659; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Andersson J. L. R., 2007, NONLINEAR REGISTRATI, V22; Apostolova LG, 2010, NEUROBIOL AGING, V31, P1284, DOI 10.1016/j.neurobiolaging.2010.05.003; Balan S, 2013, DRUG ALCOHOL DEPEN, V133, P228, DOI 10.1016/j.drugalcdep.2013.04.030; Bendlin BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037720; Block SR, 2017, COGN AFFECT BEHAV NE, V17, P422, DOI 10.3758/s13415-016-0488-2; Byun BH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006441; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chetelat G, 2013, NEUROIMAGE-CLIN, V2, P356, DOI 10.1016/j.nicl.2013.02.006; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Cohen BE, 2013, J CLIN PSYCHIAT, V74, P1063, DOI 10.4088/JCP.12m08291; Csernansky JG, 2006, AM J PSYCHIAT, V163, P2164, DOI 10.1176/appi.ajp.163.12.2164; Devi L, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-34; Farias ST, 2008, NEUROPSYCHOLOGY, V22, P531, DOI 10.1037/0894-4105.22.4.531; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Grabner G., 2006, SYMMETRIC ATLASING M, P58; Greenberg MS, 2014, ALZHEIMERS DEMENT, V10, pS155, DOI 10.1016/j.jalz.2014.04.008; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hefter D, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00022; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0399-z; Isamah N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013642; Ito K, 2012, J PHARMACOKINET PHAR, V39, P601, DOI 10.1007/s10928-012-9271-3; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson KA, 2013, ALZHEIMERS DEMENT, V9, pE1, DOI [10.1016/j.jalz.2013.06.001, 10.1016/j.jalz.2013.01.002, 10.1016/j.jalz.2012.10.007]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Justice NJ, 2015, J NEUROSCI, V35, P2612, DOI 10.1523/JNEUROSCI.3333-14.2015; Kempuraj D, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00703; Kerbler GM, 2015, NEUROIMAGE-CLIN, V7, P105, DOI 10.1016/j.nicl.2014.11.015; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Landau SM, 2012, ANN NEUROL, V72, P578, DOI 10.1002/ana.23650; Lebois LAM, 2016, EXP NEUROL, V284, P141, DOI 10.1016/j.expneurol.2016.04.019; Lepage C, 2018, BRAIN IMAGING BEHAV, V12, P870, DOI 10.1007/s11682-017-9744-5; Li Wei, 2017, Alzheimers Dement (Amst), V6, P196, DOI 10.1016/j.dadm.2017.01.008; Lindauer RJL, 2005, PSYCHOL MED, V35, P1421, DOI 10.1017/S0033291705005246; Liu G, 2015, CURR ALZHEIMER RES, V12, P648, DOI 10.2174/1567205011666141107153634; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Marmar CR, 2015, JAMA PSYCHIAT, V72, P875, DOI 10.1001/jamapsychiatry.2015.0803; Masters CL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006262; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Morris E, 2016, EUR J NUCL MED MOL I, V43, P374, DOI 10.1007/s00259-015-3228-x; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris MC, 2012, CLIN PSYCHOL REV, V32, P301, DOI 10.1016/j.cpr.2012.02.002; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nemmi F., 2014, EUR J NUCL MED MOL I, V1408-1418; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rothman SM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.005; Ruigrok ANV, 2014, NEUROSCI BIOBEHAV R, V39, P34, DOI 10.1016/j.neubiorev.2013.12.004; Saint-Aubert L, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-43; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sekiguchi A, 2013, MOL PSYCHIATR, V18, P618, DOI 10.1038/mp.2012.51; Skinner J, 2012, BRAIN IMAGING BEHAV, V6, P489, DOI 10.1007/s11682-012-9166-3; Spreen O., 1998, COMPENDIUM NEUROPSYC, P75; Toledo JB, 2013, ACTA NEUROPATHOL, V126, P683, DOI 10.1007/s00401-013-1148-z; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Tsolaki M, 2009, HELL J NUCL MED, V12, P41; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; van Rooij S. J. H., 2015, PSYCHOL MED, V1-10; Vlassenko AG, 2012, BBA-MOL BASIS DIS, V1822, P370, DOI 10.1016/j.bbadis.2011.11.005; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Weiner Michael W, 2017, Alzheimers Dement (N Y), V3, P177, DOI 10.1016/j.trci.2017.02.005; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Xue C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120270; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	82	33	33	2	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2018	19						716	726		10.1016/j.nicl.2018.05.016			11	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	GQ7PL	WOS:000441936300073	30009128	gold, Green Published			2022-02-06	
J	Heitzer, M; Kaiser, S; Kanagaratnam, M; Zendedel, A; Hartmann, P; Beyer, C; Johann, S				Heitzer, Marius; Kaiser, Sarah; Kanagaratnam, Mithila; Zendedel, Adib; Hartmann, Philipp; Beyer, Cordian; Johann, Sonja			Administration of 17 beta-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice	MOLECULAR NEUROBIOLOGY			English	Article						Estrogen; Amyotrophic lateral sclerosis; Spinal cord; NLRP3; Interleukin 1 beta; Caspase 1	AMYOTROPHIC-LATERAL-SCLEROSIS; PROTEINASE-INHIBITOR 9; ESTROGEN-RECEPTOR MODULATORS; TRANSGENIC-MOUSE MODEL; TRAUMATIC BRAIN-INJURY; SUPEROXIDE-DISMUTASE 1; SKELETAL-MUSCLE; NLRP3 INFLAMMASOME; SPINAL-CORD; SEX STEROIDS	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease manifested by the progressive loss of upper and lower motoneurons. The pathomechanism of ALS is complex and not yet fully understood. Neuroinflammation is believed to significantly contribute to disease progression. Inflammasome activation was recently shown in the spinal cord of human sporadic ALS patients and in the SOD1(G93A) mouse model for ALS. In the present study, we investigated the neuroprotective and anti-inflammatory effects of 17 beta-estradiol (E2) treatment in pre-symptomatic and symptomatic male SOD1(G93A) mice. Symptomatic mice with E2 substitution exhibited improved motor performance correlating with an increased survival of motoneurons in the lumbar spinal cord. Expression of NLRP3 inflammasome proteins and levels of activated caspase 1 and mature interleukin 1 beta were significantly reduced in SOD1(G93A) mice supplemented with E2.	[Heitzer, Marius; Kaiser, Sarah; Kanagaratnam, Mithila; Zendedel, Adib; Hartmann, Philipp; Beyer, Cordian; Johann, Sonja] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Wendlingweg 2, D-52074 Aachen, Germany; [Zendedel, Adib] Guilan Univ Med Sci, Fac Med, Dept Anat Sci, Rasht, Iran; [Beyer, Cordian] JARA BRAIN, D-52074 Aachen, Germany		Johann, S (corresponding author), Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Wendlingweg 2, D-52074 Aachen, Germany.	sjohann@ukaachen.de			Medical Faculty of the RWTH Aachen University (START)	We would like to thank U. Zahn (Institute of Neuroanatomy) for the technical support. This work was supported by a research grant from the Medical Faculty of the RWTH Aachen University (START, SJ).	Acaz-Fonseca E, 2016, PROG NEUROBIOL, V144, P5, DOI 10.1016/j.pneurobio.2016.06.002; Alves CJ, 2011, BRAIN RES, V1394, P90, DOI 10.1016/j.brainres.2011.02.060; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Apolloni S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0658-8; Arevalo MA, 2012, J NEUROENDOCRINOL, V24, P183, DOI 10.1111/j.1365-2826.2011.02156.x; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001; Astiz M, 2014, NEUROTOX RES, V25, P271, DOI 10.1007/s12640-013-9417-0; Ben Haim Lucile, 2015, Front Cell Neurosci, V9, P278, DOI 10.3389/fncel.2015.00278; Blasco H, 2012, AMYOTROPH LATERAL SC, V13, P585, DOI 10.3109/17482968.2012.706303; Boileau C, 2002, ARTHRITIS RHEUM, V46, P2637, DOI 10.1002/art.10518; Boland R, 2008, STEROIDS, V73, P859, DOI 10.1016/j.steroids.2007.12.027; Brites D, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00117; Cario-Toumaniantz C, 1998, J PHYSIOL-LONDON, V508, P659, DOI 10.1111/j.1469-7793.1998.659bp.x; Cervetto C, 2013, TOXICOLOGY, V311, P69, DOI 10.1016/j.tox.2013.04.004; Chakrabarti M, 2014, BRAIN RES BULL, V109, P22, DOI 10.1016/j.brainresbull.2014.09.004; Charlier TD, 2013, J EXP NEUROSCI, V7, P31, DOI 10.4137/JEN.S11268; Chen JY, 2015, MOL MED REP, V12, P1733, DOI 10.3892/mmr.2015.3601; Chen S, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-28; Chiappetta O, 2007, INT REV NEUROBIOL, V82, P357, DOI 10.1016/S0074-7742(07)82019-8; Cho J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061186; Choi CI, 2008, J NEUROL SCI, V268, P40, DOI 10.1016/j.jns.2007.10.024; Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; de Jong S, 2013, J NEUROL, V260, P507, DOI 10.1007/s00415-012-6665-5; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Dubyak GR, 2012, CELL MICROBIOL, V14, P1697, DOI 10.1111/cmi.12001; Enns DL, 2010, SPORTS MED, V40, P41, DOI 10.2165/11319760-000000000-00000; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Foster HL, 1983, MOUSE BIOMEDICAL RES, P138; Gargiulo-Monachelli GM, 2014, HORM METAB RES, V46, P433, DOI 10.1055/s-0034-1371891; Gravel M, 2016, J NEUROSCI, V36, P1031, DOI 10.1523/JNEUROSCI.0854-15.2016; Groeneveld GJ, 2004, BRAIN RES, V1021, P128, DOI 10.1016/j.brainres.2004.06.024; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Habib P, 2014, J MOL NEUROSCI, V52, P277, DOI 10.1007/s12031-013-0137-y; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Haisenleder DJ, 2011, ENDOCRINOLOGY, V152, P4443, DOI 10.1210/en.2011-1501; Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5; Ilieva H, 2009, J CELL BIOL, V187, P761, DOI 10.1083/jcb.200908164; Johann S, 2011, J NEUROENDOCRINOL, V23, P839, DOI 10.1111/j.1365-2826.2011.02192.x; Johann S, 2010, J NEUROENDOCRINOL, V22, P926, DOI 10.1111/j.1365-2826.2010.02006.x; Johann S, 2015, GLIA, V63, P2260, DOI 10.1002/glia.22891; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Kadhim H, 2016, MED HYPOTHESES, V86, P14, DOI 10.1016/j.mehy.2015.11.022; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Kim HJ, 2012, BRAIN, V135, P2865, DOI 10.1093/brain/aws208; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Kipp M, 2016, NEUROSCI BIOBEHAV R, V67, P125, DOI 10.1016/j.neubiorev.2015.11.016; Kitajima Y, 2016, J ENDOCRINOL, V229, P267, DOI 10.1530/JOE-15-0476; Knippenberg S, 2010, BEHAV BRAIN RES, V213, P82, DOI 10.1016/j.bbr.2010.04.042; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Lammerding L, 2016, NEUROENDOCRINOLOGY, V103, P460, DOI 10.1159/000439435; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Logroscino G, 2010, J NEUROL NEUROSUR PS, V81, P385, DOI 10.1136/jnnp.2009.183525; Loram LC, 2012, PSYCHONEUROENDOCRINO, V37, P1688, DOI 10.1016/j.psyneuen.2012.02.018; Lowe DA, 2010, EXERC SPORT SCI REV, V38, P61, DOI 10.1097/JES.0b013e3181d496bc; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; McCombe PA, 2010, GENDER MED, V7, P557, DOI 10.1016/j.genm.2010.11.010; McDowell ML, 2011, NEUROCHEM INT, V59, P175, DOI 10.1016/j.neuint.2011.04.011; Mead RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023244; Meissner F, 2010, P NATL ACAD SCI USA, V107, P13046, DOI 10.1073/pnas.1002396107; Moisse K, 2006, BBA-MOL BASIS DIS, V1762, P1083, DOI 10.1016/j.bbadis.2006.03.001; Mor G, 1999, J NEUROBIOL, V40, P484, DOI 10.1002/(SICI)1097-4695(19990915)40:4<484::AID-NEU6>3.0.CO;2-C; Patel P, 2015, NEUROTHERAPEUTICS, V12, P217, DOI 10.1007/s13311-014-0311-0; Philips T, 2014, EXP NEUROL, V262, P111, DOI 10.1016/j.expneurol.2014.05.015; Philips T, 2011, LANCET NEUROL, V10, P253, DOI 10.1016/S1474-4422(11)70015-1; Platania P, 2005, NEUROBIOL DIS, V20, P461, DOI 10.1016/j.nbd.2005.03.025; Pollanen E, 2010, GROWTH HORM IGF RES, V20, P372, DOI 10.1016/j.ghir.2010.07.003; Popat RA, 2006, NEUROEPIDEMIOLOGY, V27, P117, DOI 10.1159/000095550; Poppe L, 2014, EXP NEUROL, V262, P138, DOI 10.1016/j.expneurol.2014.07.001; Pozzi S, 2006, ANN NY ACAD SCI, V1089, P302, DOI 10.1196/annals.1386.035; Rizzo F, 2014, CELL MOL LIFE SCI, V71, P999, DOI 10.1007/s00018-013-1480-4; Rocha MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073846; Saito T, 2009, CIRC RES, V105, P343, DOI 10.1161/CIRCRESAHA.108.190041; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Scott S, 2008, AMYOTROPH LATERAL SC, V9, P4, DOI 10.1080/17482960701856300; Slowik A, 2015, J STEROID BIOCHEM, V153, P135, DOI 10.1016/j.jsbmb.2015.02.013; Sperlagh B, 2014, TRENDS PHARMACOL SCI, V35, P537, DOI 10.1016/j.tips.2014.08.002; Sunyach C, 2012, NEUROPHARMACOLOGY, V62, P2346, DOI 10.1016/j.neuropharm.2012.02.013; Tanaka K, 2008, EXP NEUROL, V211, P378, DOI 10.1016/j.expneurol.2008.02.004; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Thundyil J, 2015, AGEING RES REV, V24, P17, DOI 10.1016/j.arr.2014.11.003; Turner MR, 2013, AMYOTROPH LAT SCL FR, V14, P19, DOI 10.3109/21678421.2013.778554; Vaccari JPD, 2016, J NEUROCHEM, V136, P492, DOI 10.1111/jnc.13404; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Valles SL, 2010, BRAIN RES, V1312, P138, DOI 10.1016/j.brainres.2009.11.044; van der Burgh R, 2016, ONCOTARGET, V7, P19265, DOI 10.18632/oncotarget.8086; Velders M, 2012, FASEB J, V26, P1909, DOI 10.1096/fj.11-194779; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wei Q, 2015, LAB INVEST, V95, P804, DOI 10.1038/labinvest.2015.63; Xu YJ, 2016, BRAIN BEHAV IMMUN, V56, P175, DOI 10.1016/j.bbi.2016.02.022; Ye L, 2013, J NEUROCHEM, V125, P897, DOI 10.1111/jnc.12263; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535; Zhao JJ, 2013, ARTHRITIS RHEUM-US, V65, P3176, DOI 10.1002/art.38174; Zhao TZ, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.449	102	33	33	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	DEC	2017	54	10					8429	8443		10.1007/s12035-016-0322-4			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FM8MF	WOS:000415341900071	27957680				2022-02-06	
J	Wang, J; Ma, MW; Dhandapani, KM; Brann, DW				Wang, Jing; Ma, Merry W.; Dhandapani, Krishnan M.; Brann, Darrell W.			Regulatory role of NADPH oxidase 2 in the polarization dynamics and neurotoxicity of microglia/macrophages after traumatic brain injury	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						NADPH oxidase; NOX2; Microglia; Traumatic brain injury; Inflammation; Oxidative stress; NF-kappa B	NF-KAPPA-B; NEURAL STEM-CELLS; NLRP3 INFLAMMASOME; GANGLIOSIDE GD3; ACTIVATION; EXPRESSION; NEURODEGENERATION; NEURONS; CLONING; DAMAGE	Traumatic brain injury (TBI) is a leading cause of death and disability. Secondary injuries that develop after the initial trauma contribute to long-lasting neurophysiological deficits. Polarization of microglia/macrophages toward a pro-inflammatory (M1) phenotype may increase the progression of secondary injury following TBI; however, the regulatory and functional mechanisms underlying these changes remain poorly defined. In the present study, we showed elevated expression of NADPH oxidase 2 (NOX2) and activation of nuclear factorkappa B (NF-kappa B) predominantly in microglia/macrophages at 4-and 7-days after controlled cortical impact in mice. Delayed inhibition of NOX2, beginning one day after TBI, reduced reactive oxygen species production of myeloid cells and protected neurons from oxidative damage. Moreover, delayed NOX inhibition or global genetic NOX2 knockout suppressed the M1 "pro-inflammatory" profile of microglia/macrophages and simultaneously increased the M2 "anti-inflammatory" profile in the injured brain. These changes were associated with marked down-regulation of the classical NF-kappa B pathway in microglia/macrophages and reduced production of pro-inflammatory cytokines, tumor necrosis factor-alpha and interleukin-1 beta, after TBI. Finally, we demonstrated that wildtype microglia/macrophages isolated from the ipsilateral cortex at 7 days post-TBI were neurotoxic to co-cultured primary neurons, whereas this neurotoxicity was largely attenuated in microglia/macrophages from NOX2-KO mice. Taken together, our study shows a direct link between NOX2 and the NF-kappa B pathway in microglia/ macrophages after TBI, and it provides a novel mechanism by which NOX2 activation leads to the enhanced inflammatory response and neuronal damage after brain injury. Our data also supports the therapeutic potential of targeting NOX2, which may provide efficacy with an extended therapeutic window after TBI.	[Wang, Jing; Ma, Merry W.; Dhandapani, Krishnan M.; Brann, Darrell W.] Charlie Norwood Med Ctr, One Freedom Way, Augusta, GA 30904 USA; [Wang, Jing; Ma, Merry W.; Brann, Darrell W.] Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, 1120 15th St,CA 4004, Augusta, GA 30912 USA; [Dhandapani, Krishnan M.] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA		Brann, DW (corresponding author), Augusta Univ, Dept Neurosci & Regenerat Med, 1120 15th St,CA-4004, Augusta, GA 30912 USA.	dbrann@augusta.edu		Dhandapani, Krishnan/0000-0001-7044-1117	VA Merit Review Award from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development ServiceUS Department of Veterans Affairs [5l101BX001117]	This research was supported by a VA Merit Review Award (5l101BX001117) from the United States Department of Veteran's Affairs, Biomedical Laboratory Research and Development Service.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Braun M, 2017, J IMMUNOL, V198, P3615, DOI 10.4049/jimmunol.1601948; Brewer GJ, 1996, NEUROREPORT, V7, P1509, DOI 10.1097/00001756-199606170-00014; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Correa Fernando G, 2013, Methods Mol Biol, V1041, P215, DOI 10.1007/978-1-62703-520-0_20; Dasuri K, 2013, FREE RADICAL BIO MED, V62, P170, DOI 10.1016/j.freeradbiomed.2012.09.016; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Frakes AE, 2014, NEURON, V81, P1009, DOI 10.1016/j.neuron.2014.01.013; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2; Hu X, 2015, J MAT PHY, V56, P1; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lukiw WJ, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt150; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Ma MW, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0150-7; Maraldi T, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/271602; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Sheng WS, 2013, NEUROCHEM RES, V38, P2148, DOI 10.1007/s11064-013-1123-z; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wallisch J. S., 2017, NEUROCRIT CARE; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2014, J NEUROSCI, V34, P13790, DOI 10.1523/JNEUROSCI.2275-14.2014; Wang J, 2013, P NATL ACAD SCI USA, V110, P19137, DOI 10.1073/pnas.1307224110; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; You WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060290; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	48	33	35	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC	2017	113						119	131		10.1016/j.freeradbiomed.2017.09.017			13	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	FN2FP	WOS:000415806800011	28942245				2022-02-06	
J	Kroshus, E; Rivara, FP; Whitlock, KB; Herring, SA; Chrisman, SPD				Kroshus, Emily; Rivara, Frederick P.; Whitlock, Kathryn B.; Herring, Stanley A.; Chrisman, Sara P. D.			Disparities in Athletic Trainer Staffing in Secondary School Sport: Implications for Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; health disparities; athletic trainer; high school	TRAUMATIC BRAIN-INJURY; PROLONGED RECOVERY; EPIDEMIOLOGY; MANAGEMENT; STATEMENT; BENCHMARK; EDUCATION	Objective: First, to assess whether teams at schools with an athletic trainer (AT) on staff had a higher number of diagnosed concussions than teams without medical personnel present. Second, to assess whether the variability in employment of a certified AT by Washington state high schools is patterned by socioeconomic and demographic characteristics. Design: Cross-sectional survey. Setting: Washington state public high schools. Participants: Stratified random sample of football and soccer coaches (n = 270 teams, 144 schools). Independent Variables: Presence of an AT and school characteristics (percentage of students qualifying for free or reduced price lunch, rural location, enrollment). Results: Football and boys' soccer teams at schools with an AT had a significantly greater number of athletes with diagnosed concussions compared to teams at schools without an AT (P < 0.05). There was no difference in number of athletes with diagnosed concussions by AT staffing for girls' soccer. Schools with an AT on staff were significantly more likely than schools without an AT to be in an urban location (P < 0.001), to have an enrollment of 1000 students or more (P < 0.001), and to have a smaller proportion of students eligible for school lunch (P = 0.005). Conclusions: The present study provides empirical support for the benefit of ATs in diagnosing concussions in high school sport and underscores the challenges to AT staffing in lower resource settings. These findings cause us to critically reflect on the threshold for medical oversight in contact and collision sport from the perspective of risk prevention, and the extent to which disparities in this medical oversight are acceptable in the public school setting. Clinical Relevance: Strategies for increasing AT staffing in high school sports settings should be explored given their demonstrated benefit in diagnosing concussions.	[Kroshus, Emily; Rivara, Frederick P.; Whitlock, Kathryn B.; Chrisman, Sara P. D.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA; [Kroshus, Emily; Rivara, Frederick P.; Whitlock, Kathryn B.; Chrisman, Sara P. D.] Univ Washington, Dept Pediat, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA; [Rivara, Frederick P.; Whitlock, Kathryn B.; Chrisman, Sara P. D.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98121 USA		Kroshus, E (corresponding author), Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA.; Kroshus, E (corresponding author), Univ Washington, Dept Pediat, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA.	ekroshus@u.washington.edu		Chrisman, Sara/0000-0001-5373-7223	Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Public Health Law Research (PHLR) program	Data used in this study were funded by the Robert Wood Johnson Foundation, Public Health Law Research (PHLR) program.	Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Casa DJ, 2013, J ATHL TRAINING, V48, P546, DOI 10.4085/1062-6050-48.4.12; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Comstock RD, 2016, INJURY PEDIAT ADOLES, P51; Condron DJ, 2003, SOCIOL EDUC, V76, P18, DOI 10.2307/3090259; Courson R, 2014, J ATHL TRAINING, V49, P128, DOI 10.4085/1062-6050-49.1.06; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; LaBella CR, 2013, CLIN J SPORT MED, V23, P149; Leachman Michael, 2014, MOST STATES STILL FU; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mazerolle SM, 2015, J ATHL TRAINING, V50, P1059, DOI 10.4085/1062-6050-50.10.01; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; Meehan WP, 2013, PEDIATR EMERG CARE, V29, P624, DOI 10.1097/PEC.0b013e31828e9cea; Office of the Superintendent of Public Instruction, WASH STAT REP CARD 2; Posey-Maddox L, 2013, AM J EDUC, V119, P235, DOI 10.1086/668754; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; United States Department of Agriculture-Economic Research Service (USDA-ERS), RUR POV WELL BEING; VanEenwyk J., 2009, GUIDELINES USING RUR; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	27	33	33	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2017	27	6					542	547		10.1097/JSM.0000000000000409			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	FN2KO	WOS:000415821300008	28742604				2022-02-06	
J	Medcalf, RL				Medcalf, R. L.			Fibrinolysis: from blood to the brain	JOURNAL OF THROMBOSIS AND HAEMOSTASIS			English	Article; Proceedings Paper	26th Congress of the International-Society-on-Thrombosis-and-Haemostasis (ISTH)	JUL 08-13, 2017	Berlin, GERMANY	Int Soc Thrombosis & Haemostasis		blood brain barrier; fibrinolysis; plasminogen; plasminogen activators; stroke; traumatic brain injury	TISSUE-PLASMINOGEN-ACTIVATOR; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; ACUTE ISCHEMIC-STROKE; TRANEXAMIC ACID; T-PA; INTRACRANIAL HEMORRHAGE; PROTEOLYTIC ACTIVITY; THERAPEUTIC WINDOW; LATE-PHASE	We all know about classical fibrinolysis, how plasminogen activation by either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA) promotes fibrin breakdown, and how this process was harnessed for the therapeutic removal of blood clots. While this is still perfectly true and still applicable to thromboembolic conditions today, another dimension to this system came to light over two decades ago that implicated the plasminogen activating system in a context far removed from the dissolution of blood clots. This unsuspected area related to brain biology where t-PA was linked to a plethora of activities in the CNS, some of which do not necessarily require plasmin generation. Indeed, t-PA either directly or via plasmin, has been shown to not only have key roles in modulating astrocytes, neurons, microglia, and pericytes, but also to have profound effects in a number of CNS conditions, including ischaemic stroke, severe traumatic brain injury and also in neurodegenerative disorders. While compelling insights have been obtained from various animal models, the clinical relevance of aberrant expression of these components in the CNS, although strongly implied, are only just emerging. This review will cover these areas and will also discuss how the use of thrombolytic agents and anti-fibrinolytic drugs may potentially have impacts outside of their clinical intention, particularly in the CNS.	[Medcalf, R. L.] Monash Univ, Australian Ctr Blood Dis, Level 6,Burnet Bldg,89 Commercial Rd, Melbourne, Vic 3004, Australia		Medcalf, RL (corresponding author), Monash Univ, Australian Ctr Blood Dis, Level 6,Burnet Bldg,89 Commercial Rd, Melbourne, Vic 3004, Australia.	robert.medcalf@monash.edu	Medcalf, Robert L/E-9632-2011	Medcalf, Robert/0000-0001-6885-3892			Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; ASTRUP T, 1947, NATURE, V159, P681, DOI 10.1038/159681b0; ASTRUP T, 1953, P SOC EXP BIOL MED, V84, P605, DOI 10.3181/00379727-84-20727; ASTRUP T, 1956, BLOOD, V11, P781, DOI 10.1182/blood.V11.9.781.781; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Bardehle S, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00354; Baron A, 2010, CELL DEATH DIFFER, V17, P860, DOI 10.1038/cdd.2009.172; Barthel D, 2012, J BIOL CHEM, V287, P18831, DOI 10.1074/jbc.M111.323287; Basham ME, 2001, J NEUROCHEM, V77, P318, DOI 10.1046/j.1471-4159.2001.t01-1-00239.x; Benchenane K, 2007, J CELL SCI, V120, P578, DOI 10.1242/jcs.03354; Bier OG, 1932, CR SOC BIOL, V110, P129; BIGGS R, 1947, LANCET, V252, P402; Borg RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131216; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Calabresi P, 2000, EUR J NEUROSCI, V12, P1002, DOI 10.1046/j.1460-9568.2000.00991.x; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; Centonze D, 2002, EUR J NEUROSCI, V16, P713, DOI 10.1046/j.1460-9568.2002.02106.x; Chatterjee S, 2014, JAMA-J AM MED ASSOC, V311, P2414, DOI 10.1001/jama.2014.5990; Cops EJ, 2013, EXP NEUROL, V249, P8, DOI 10.1016/j.expneurol.2013.08.001; Das R, 2014, BLOOD, V124, P679, DOI 10.1182/blood-2014-01-549659; Dastre A., 1893, ARCH PHYSL NORM PATH, V5, P661; Diebel LN, 2017, J TRAUMA ACUTE CARE, V82, P1080, DOI 10.1097/TA.0000000000001445; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Draxler DF, 2017, SEMIN THROMB HEMOST, V43, P143, DOI 10.1055/s-0036-1586227; Draxler DF, 2015, TRANSFUS MED REV, V29, P102, DOI 10.1016/j.tmrv.2014.09.006; FANTL P, 1948, AUST J EXP BIOL MED, V26, P521, DOI 10.1038/icb.1948.54; FANTL P, 1950, BRIT J EXP PATHOL, V31, P131; Fredriksson L, 2017, SEMIN THROMB HEMOST, V43, P154, DOI 10.1055/s-0036-1586229; Gaberel T, 2013, NEUROPHARMACOLOGY, V67, P267, DOI 10.1016/j.neuropharm.2012.11.023; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Grummisch JA, 2016, MOL CELL NEUROSCI, V74, P25, DOI 10.1016/j.mcn.2016.03.005; Gurwitz JH, 1998, ANN INTERN MED, V129, P597, DOI 10.7326/0003-4819-129-8-199810150-00002; Haile WB, 2012, J CEREBR BLOOD F MET, V32, P57, DOI 10.1038/jcbfm.2011.106; Hao ZF, 2006, BLOOD, V108, P200, DOI 10.1182/blood-2005-12-4884; Hijazi N, 2015, BLOOD, V125, P2558, DOI 10.1182/blood-2014-08-588442; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Hultman K, 2014, J THROMB HAEMOST, V12, P701, DOI 10.1111/jth.12553; Ishiguro M, 2012, NEUROSCIENCE, V220, P302, DOI 10.1016/j.neuroscience.2012.06.015; Jimenez JJ, 2007, CRIT CARE, V11, DOI 10.1186/cc6173; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; KONDO M, 1976, GASTROENTEROLOGY, V71, P631; KRYSTOSEK A, 1981, P NATL ACAD SCI-BIOL, V78, P7810, DOI 10.1073/pnas.78.12.7810; Kvajo M, 2004, J NEUROSCI, V24, P9734, DOI 10.1523/JNEUROSCI.3306-04.2004; Later AFL, 2013, CYTOKINE, V61, P438, DOI 10.1016/j.cyto.2012.10.033; Later AFL, 2013, J THORAC CARDIOV SUR, V145, P1611, DOI 10.1016/j.jtcvs.2012.11.042; Lei H, 2008, INVEST OPHTH VIS SCI, V49, P42, DOI 10.1167/iovs.07-0776; Li JX, 2006, J NEUROSCI, V26, P7839, DOI 10.1523/JNEUROSCI.1624-06.2006; Li JX, 2013, P NATL ACAD SCI USA, V110, pE2410, DOI 10.1073/pnas.1305010110; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Lu WQ, 2002, DEVELOPMENT, V129, P2043; MACFARLANE RG, 1946, LANCET, V251, P562; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P79, DOI 10.1097/00001721-199003000-00011; Machovich R, 1997, ARCH BIOCHEM BIOPHYS, V344, P343, DOI 10.1006/abbi.1997.0221; Macrez R, 2011, STROKE, V42, P2315, DOI 10.1161/STROKEAHA.110.606293; Macrez R, 2010, STROKE, V41, P2950, DOI 10.1161/STROKEAHA.110.592360; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Marcos-Contreras OA, 2016, BLOOD, V128, P2423, DOI 10.1182/blood-2016-03-705384; MARKUS G, 1979, J BIOL CHEM, V254, P1211; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Matys T, 2003, NAT MED, V9, P371, DOI 10.1038/nm0403-371; Medcalf RL, 2015, BLOOD, V125, P2457, DOI 10.1182/blood-2015-02-629808; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Niego B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177332; Niego B, 2014, J CEREBR BLOOD F MET, V34, P1283, DOI 10.1038/jcbfm.2014.99; Niego B, 2012, BLOOD, V119, P4752, DOI 10.1182/blood-2011-07-369512; Noel M, 2011, P NATL ACAD SCI USA, V108, P5069, DOI 10.1073/pnas.1017608108; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PLOW EF, 1975, J CLIN INVEST, V56, P30, DOI 10.1172/JCI108076; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Reust DL, 2010, ANESTH ANALG, V110, P694, DOI 10.1213/ANE.0b013e3181c7eb27; Robinson SD, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00404; Rodier M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092416; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; Samson AL, 2008, J NEUROCHEM, V107, P1091, DOI 10.1111/j.1471-4159.2008.05687.x; Samson AL, 2012, CELL REP, V2, P889, DOI 10.1016/j.celrep.2012.08.026; Samson AL, 2009, BLOOD, V114, P1937, DOI 10.1182/blood-2009-02-203448; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shaw MA, 2017, J NEUROSCI, V37, P3776, DOI 10.1523/JNEUROSCI.2932-15.2017; Shibuya M, 2005, J NEUROL SCI, V238, P31, DOI 10.1016/j.jns.2005.06.003; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Silva MMCG, 2012, J THROMB HAEMOST, V10, P2354, DOI 10.1111/j.1538-7836.2012.04925.x; Simao F, 2017, BLOOD, V129, P2280, DOI 10.1182/blood-2016-09-740670; SOREQ H, 1981, BRAIN RES, V216, P361, DOI 10.1016/0006-8993(81)90138-4; Stanley D, 2016, NAT MED, V22, P1277, DOI 10.1038/nm.4194; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Su EJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00385; Suzuki Y, 2007, J THROMB HAEMOST, V5, P1732, DOI 10.1111/j.1538-7836.2007.02628.x; Suzuki Y, 2009, BLOOD, V114, P3352, DOI 10.1182/blood-2009-02-203919; Syrovets T, 2012, J LEUKOCYTE BIOL, V92, P509, DOI 10.1189/jlb.0212056; Tait RC, 1996, THROMB HAEMOSTASIS, V76, P1004; TAKASHIMA S, 1969, BRIT J EXP PATHOL, V50, P533; THEURING F, 1995, FIBRINOLYSIS, V9, P277, DOI 10.1016/S0268-9499(95)80016-6; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; TOVI D, 1973, ACTA NEUROL SCAND, V49, P152; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Turner RJ, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00056; Vermeij JD, 2016, CEREBROVASC DIS, V42, P361, DOI 10.1159/000446160; VONKAULLA KN, 1953, P SOC EXP BIOL MED, V83, P692; Wahlgren N, 2017, J INTERN MED, V281, P273, DOI 10.1111/joim.12576; Walsh M, 2017, SEMIN THROMB HEMOST, V43, P200, DOI 10.1055/s-0036-1597900; Westendorp WF, 2015, LANCET, V385, P1519, DOI 10.1016/S0140-6736(14)62456-9; Witting PK, 2008, THROMB RES, V122, P674, DOI 10.1016/j.thromres.2007.12.013; Wu F, 2012, J NEUROSCI, V32, P9848, DOI 10.1523/JNEUROSCI.1241-12.2012; Wu XW, 2017, SHOCK, V47, P500, DOI 10.1097/SHK.0000000000000758; Yao Y, 2011, J CELL SCI, V124, P1486, DOI 10.1242/jcs.082834; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Yepes M, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3339/fncel.2015.00304, 10.3389/fncel.2015.00304]; Yu H, 2001, EUR J NEUROSCI, V14, P799, DOI 10.1046/j.0953-816x.2001.01700.x; ZANKER KS, 1978, J NEUROL SCI, V38, P67, DOI 10.1016/0022-510X(78)90246-0; Zeng B, 2002, THROMB HAEMOSTASIS, V88, P805, DOI 10.1055/s-0037-1613306; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zhao XJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180822; ZISAPEL N, 1982, BRAIN RES, V248, P129, DOI 10.1016/0006-8993(82)91154-4	120	33	36	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1538-7933	1538-7836		J THROMB HAEMOST	J. Thromb. Haemost.	NOV	2017	15	11					2089	2098		10.1111/jth.13849			10	Hematology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Hematology; Cardiovascular System & Cardiology	FL7YI	WOS:000414466400003	28925023	hybrid			2022-02-06	
J	Kuo, BJ; Vaca, SD; Vissoci, JRN; Staton, CA; Xu, L; Muhumuza, M; Ssenyonjo, H; Mukasa, J; Kiryabwire, J; Nanjula, L; Muhumuza, C; Rice, HE; Grant, GA; Haglund, MM				Kuo, Benjamin J.; Vaca, Silvia D.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Xu, Linda; Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel; Nanjula, Lydia; Muhumuza, Christine; Rice, Henry E.; Grant, Gerald A.; Haglund, Michael M.			A prospective neurosurgical registry evaluating the clinical care of traumatic brain injury patients presenting to Mulago National Referral Hospital in Uganda	PLOS ONE			English	Article							LOW-INCOME; BURDEN; IMPACT; OUTCOMES	Background Traumatic Brain Injury (TBI) is disproportionally concentrated in low-and middle-income countries (LMICs), with the odds of dying from TBI in Uganda more than 4 times higher than in high income countries (HICs). The objectives of this study are to describe the processes of care and determine risk factors predictive of poor outcomes for TBI patients presenting to Mulago National Referral Hospital (MNRH), Kampala, Uganda. Methods We used a prospective neurosurgical registry based on Research Electronic Data Capture (REDCap) to systematically collect variables spanning 8 categories. Univariate and multivariate analysis were conducted to determine significant predictors of mortality. Results 563 TBI patients were enrolled from 1 June-30 November 2016. 102 patients (18%) received surgery, 29 patients (5.1%) intended for surgery failed to receive it, and 251 patients (45%) received non-operative management. Overall mortality was 9.6%, which ranged from 4.7% for mild and moderate TBI to 55% for severe TBI patients with GCS 3-5. Within each TBI severity category, mortality differed by management pathway. Variables predictive of mortality were TBI severity, more than one intracranial bleed, failure to receive surgery, high dependency unit admission, ventilator support outside of surgery, and hospital arrival delayed by more than 4 hours. Conclusions The overall mortality rate of 9.6% in Uganda for TBI is high, and likely underestimates the true TBI mortality. Furthermore, the wide-ranging mortality (3-82%), high ICU fatality, and negative impact of care delays suggest shortcomings with the current triaging practices. Lack of surgical intervention when needed was highly predictive of mortality in TBI patients. Further research into the determinants of surgical interventions, quality of step-up care, and prolonged care delays are needed to better understand the complex interplay of variables that affect patient outcome. These insights guide the development of future interventions and resource allocation to improve patient outcomes.	[Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Haglund, Michael M.] Duke Univ, Div Global Neurosurg & Neurol, Durham, NC 27708 USA; [Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Rice, Henry E.; Haglund, Michael M.] Duke Univ, Global Hlth Inst, Durham, NC 27708 USA; [Kuo, Benjamin J.] Duke Natl Univ Singapore, Med Sch, Singapore, Singapore; [Vaca, Silvia D.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Vaca, Silvia D.; Xu, Linda; Grant, Gerald A.] Stanford Ctr Innovat Global Hlth, Palo Alto, CA USA; [Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke Univ, Med Ctr, Dept Emergency Med, Durham, NC USA; [Xu, Linda; Grant, Gerald A.] Stanford Univ, Med Ctr, Dept Neurosurg, Palo Alto, CA 94304 USA; [Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel; Nanjula, Lydia] Mulago Hosp, Dept Neurosurg, Kampala, Uganda; [Muhumuza, Christine] Makerere Univ, Sch Publ Hlth, Kampala, Uganda; [Rice, Henry E.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Haglund, Michael M.] Duke Univ, Dept Neurosurg, Med Ctr, Durham, NC 27708 USA		Haglund, MM (corresponding author), Duke Univ, Div Global Neurosurg & Neurol, Durham, NC 27708 USA.; Haglund, MM (corresponding author), Duke Univ, Global Hlth Inst, Durham, NC 27708 USA.; Haglund, MM (corresponding author), Duke Univ, Dept Neurosurg, Med Ctr, Durham, NC 27708 USA.	michael.haglund@dm.duke.edu		Staton, Catherine/0000-0002-6468-2894	Duke Department of Neurosurgery; Duke Division of Global Neurosurgery and Neurology; Duke Global Health Institute; Duke-NUS Medical School; Stanford Medical Scholars Program; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [K01TW010000] Funding Source: NIH RePORTER	Funding was provided by the Duke Department of Neurosurgery, Duke Division of Global Neurosurgery and Neurology, Duke Global Health Institute, Duke-NUS Medical School, and Stanford Medical Scholars Program. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelgadir J, 2017, WORLD NEUROSURG, V101, P651, DOI 10.1016/j.wneu.2017.02.048; Bhalla K, 2009, INJURY PREV, V15, P150, DOI 10.1136/ip.2008.020826; Bhalla K, 2009, PLOS MED, V6, P22, DOI 10.1371/journal.pmed.1000001; CDC, 2016, TRAUMATIC BRAIN INJU; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Demyttenaere SV, 2009, CAN J SURG, V52, pE146; Di Saverio S, 2014, LANGENBECK ARCH SURG, V399, P109, DOI 10.1007/s00423-013-1143-9; Gagne M, 2017, J TRAUMA ACUTE CARE, V82, P374, DOI 10.1097/TA.0000000000001319; Gupta D, 2016, WORLD NEUROSURG, V89, P169, DOI 10.1016/j.wneu.2015.12.097; Hofman K, 2005, AM J PUBLIC HEALTH, V95, P13, DOI 10.2105/AJPH.2004.039354; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jayaraman S, 2011, WORLD J SURG, V35, P505, DOI 10.1007/s00268-010-0871-z; Kim YJ, 2011, J EMERG NURS, V37, P328, DOI 10.1016/j.jen.2010.04.017; Krishnamoorthy V, 2015, J INTENSIVE CARE, P1; Kwizera Arthur, 2012, BMC Res Notes, V5, P475, DOI 10.1186/1756-0500-5-475; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Mwita CC, 2016, J NEUROSCI RURAL PRA, V7, P97, DOI 10.4103/0976-3147.165390; Opondo EA, 2009, ANN AFRICAN SURG, P1; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Staton CA, 2015, INT J INJ CONTROL SA, P1; Tobi KU, 2016, SOUTH AFR J ANAESTH, V22, P135, DOI 10.1080/22201181.2016.1206293; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Ubos. Uganda National Household Survey 2009/ 2010, 2010, UGAUBOSUBOS2012V01, P222; World Health Organization, 2015, INJURY PREV, P318	25	33	33	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2017	12	10							e0182285	10.1371/journal.pone.0182285			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL2ZD	WOS:000414088900001	29088217	Green Published, Green Submitted, gold			2022-02-06	
J	Salman, SD; Leman, Z; Sultan, MTH; Ishak, MR; Cardona, F				Salman, Suhad D.; Leman, Z.; Sultan, M. T. H.; Ishak, M. R.; Cardona, F.			Effect of kenaf fibers on trauma penetration depth and ballistic impact resistance for laminated composites	TEXTILE RESEARCH JOURNAL			English	Article						ballistic; trauma; aramid; kenaf; helmets	PERFORMANCE; PERFORATION; BEHAVIOR; ARMOR; THICKNESS; POLYMER; HELMET	Combat helmets have been utilized to provide protection against a variety of ballistic threats, by reducing traumatic head injuries and fatalities. Nevertheless, head protection from injury is critical to function and for survivability. Soldiers and civilians incur Traumatic Brain Injury (TBI) most commonly from exposure to homemade bombs or improvised explosive devices. Although the Personal Armor System for Ground Troops (PASGT) helmet is expensive, environmental issues are some technical advantages that encourage using natural/synthetic hybrid laminated composites. The effects of different configuration patterns of kenaf fibers on the Backface Signature and energy absorbed by a military helmet (PASGT) were investigated. The ballistic behaviors of the 19 layers of aramid composite and plain woven kenaf composite were compared to hybrid laminated composites. The ballistic impact tests were performed using a 9 mm full metal jacket bullet and fragment simulating projectiles at various impact velocities, using a powder gun on fabricated square panels and helmets. The results showed the positive effect of hybridization in terms of energy absorbed (i.e. penetration), Backface Signature and damage mechanisms for ballistic impact and NIJ (National Institute of Justice) tests. Hybridization of plain woven kenaf/Kevlar laminated composites will open new avenues to reduce the dependency on the ballistic resistance component (Kevlar) in the helmet shell.	[Salman, Suhad D.; Leman, Z.] Univ Putra Malaysia, Dept Mech & Mfg Engn, Serdang, Selangor, Malaysia; [Salman, Suhad D.] Univ Mustansiriyah, Mat Engn Dept, Baghdad, Iraq; [Sultan, M. T. H.; Ishak, M. R.; Cardona, F.] Univ Putra Malaysia, AMRC, Serdang, Selangor, Malaysia; [Ishak, M. R.] Univ Putra Malaysia, Lab Biocomposites Technol, Inst Trop Forestry & Forest Prod INTROP, Serdang, Selangor, Malaysia		Salman, SD (corresponding author), Univ Putra Malaysia, Dept Mech & Mfg Engn, Fac Engn, Serdang 43400, Selangor, Malaysia.	suhaddawood2007@yahoo.com	Salman, Suhad Dawood/C-9059-2016; Leman, Zulkiflle/AAE-5267-2020; Sultan, M.T.H./H-2338-2019	Salman, Suhad Dawood/0000-0001-6091-8145; Leman, Zulkiflle/0000-0002-3273-6675; 	UPM [GP-IPS/2014/9438714]; UPM under GP-IPB [9415402]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by UPM under GP-IPS/2014/9438714 and UPM under GP-IPB grant, 9415402.	Ahmad MR, 2008, MATER DESIGN, V29, P1353, DOI 10.1016/j.matdes.2007.06.007; Ali A, 2011, POLYM-PLAST TECHNOL, V50, P622, DOI 10.1080/03602559.2010.551381; [Anonymous], MLH44099A DEP DEF TE; [Anonymous], 1985, 010801 NIJ US DEP JU; [Anonymous], MILSTD662F DEP DEF T; [Anonymous], 1981, 010601 NIJ US DEP JU; Babu M.G., 2006, LAT AM J SOLIDS STRU, V3, P21; Boccaccini AR, 2005, COMPOS SCI TECHNOL, V65, P325, DOI 10.1016/j.compscitech.2004.08.002; Carey ME, 2000, NEUROSURGERY, V47, P678, DOI 10.1097/00006123-200009000-00031; Cheeseman BA, 2003, COMPOS STRUCT, V61, P161, DOI 10.1016/S0263-8223(03)00029-1; Findik F, 2003, COMPOS STRUCT, V61, P187, DOI 10.1016/S0263-8223(03)00065-5; Findik F, 2002, SCI ENG COMPOS MATER, V10, P287; Freitas CJ, 2014, INT J MED SCI, V11, P409, DOI 10.7150/ijms.8079; Gellert EP, 2000, INT J IMPACT ENG, V24, P445, DOI 10.1016/S0734-743X(99)00175-X; Greenhalgh ES, 2013, COMPOS PART A-APPL S, V44, P51, DOI 10.1016/j.compositesa.2012.08.012; Lee BL, 2001, J COMPOS MATER, V35, P1605, DOI 10.1106/YRBH-JGT9-U6PT-L555; Muhi RJ, 2009, COMPOS PART B-ENG, V40, P798, DOI 10.1016/j.compositesb.2009.08.002; Pandya KS, 2015, INT J DAMAGE MECH, V24, P471, DOI 10.1177/1056789514531440; Park JL, 2013, TEXT RES J, V83, P471, DOI 10.1177/0040517512444337; Radif ZS, 2011, PERTANIKA J SCI TECH, V19, P339; Rahner CP, 2012, THESIS; Randjbaran E, 2014, SCI WORLD J, DOI 10.1155/2014/413753; Rashid AHA, 2011, ADV MATER RES-SWITZ, V277, P36, DOI [10.4028/www.scientific.net/AMR.277J6, 10.4028/www.scientific.net/AMR.277.36]; Risby MS, 2008, DEFENCE SCI J, V58, P248, DOI 10.14429/dsj.58.1645; Sabet AR, 2009, POLYM COMPOSITE, V30, P1497, DOI 10.1002/pc.20720; Salman SD., 2015, CARBON, V3, P119; Salman SD, 2015, INT J POLYM SCI, V2015, DOI 10.1155/2015/894565; Salman SD, 2015, BIORESOURCES, V10, P8580; Sayer M, 2010, J APPL POLYM SCI, V118, P580, DOI 10.1002/app.32437; Spagnuolo D.M, 2005, DEV HYBRID THERMOPLA; Sultan MTH, 2012, ADV MATER RES-SWITZ, V399-401, P2318, DOI 10.4028/www.scientific.net/AMR.399-401.2318; Tan VBC, 2005, INT J IMPACT ENG, V31, P793, DOI 10.1016/j.ijimpeng.2004.04.003; Tarim N, 2002, COMPOS STRUCT, V56, P13, DOI 10.1016/S0263-8223(01)00177-5; Tham CY, 2008, INT J IMPACT ENG, V35, P304, DOI 10.1016/j.ijimpeng.2007.03.008; *US DEP JUST, 2000, 010104 NIJ US DEP JU; Wambua P, 2007, COMPOS STRUCT, V77, P232, DOI 10.1016/j.compstruct.2005.07.006; Yetkin SH, 2013, POLYM-PLAST TECHNOL, V52, P433, DOI 10.1080/03602559.2012.748802; Zhang DT, 2014, MATER DESIGN, V54, P315, DOI 10.1016/j.matdes.2013.08.074	38	33	33	3	20	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0040-5175	1746-7748		TEXT RES J	Text. Res. J.	OCT	2017	87	17					2051	2065		10.1177/0040517516663155			15	Materials Science, Textiles	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	FL7LL	WOS:000414429100001					2022-02-06	
J	Gao, HB; Han, ZL; Huang, S; Bai, RJ; Ge, XT; Chen, FL; Lei, P				Gao, Huabin; Han, Zhaoli; Huang, Shan; Bai, Ruojing; Ge, Xintong; Chen, Fanglian; Lei, Ping			Intermittent hypoxia caused cognitive dysfunction relate to miRNAs dysregulation in hippocampus	BEHAVIOURAL BRAIN RESEARCH			English	Article						Obstructive sleep apnea; Cognition; microRNA; Intermittent hypoxia; Hippocampus	TRAUMATIC BRAIN-INJURY; OBSTRUCTIVE SLEEP-APNEA; EXPRESSION; MICRORNA; METASTASIS; MIR-21	Intermittent hypoxia (IH) is a characteristic pathophysiological change of obstructive sleep apnea (OSA), a commonly diagnosed chronic sleep disorder. With the process of OSA, patients will suffer from the nervous system damage and appear to multiple cognitive dysfunction. The mechanism that how IH causes cognitive impairment is still unknown. Both control and experimental rats were placed in conditions absence and presence of intermittent hypoxia (IH) for 8 h a day for a week, two weeks and four weeks, and then followed by behavioral assessments with Morris Water Maze (MVVM) test. The results showed that the escape latency of the tested animals to IH significantly increased the escape latency on the last four training days in comparison to the control group. Consistent with this, the expressions of apoptosis/anti-apoptosis proteins were both changed in the hippocampus. Then we utilized the miRNA microarray assay to investigate the level of miRNA expression in rat hippocampus which suffered from intermittent hypoxia. It is noteworthy that the expressions of miR-26b and miR-207 were consistently dysregulated in all the experimental groups post IH. And we utilized qRT-PCR methods to verify the microarray results. Our results showed that microarray based analysis of microRNA expression in rat hippocampus after IH has shown that some microRNAs such as miR-26b and miR-207 could be involved in the OSA-induced cognitive impairments.	[Gao, Huabin; Huang, Shan; Ge, Xintong; Chen, Fanglian] Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, Tianjin 300052, Peoples R China; [Han, Zhaoli; Bai, Ruojing; Lei, Ping] Tianjin Med Univ, Gen Hosp, Tianjin Inst Geriatr, Tianjin 300052, Peoples R China		Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Geriatr Inst, Dept Geriatr, Tianjin 300052, Peoples R China.	leiping1974@163.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Clinical Key Subject Construction Project of NHFPC Fund; National Natural Science Funds Fund [81471252]; Tianjin Municipal Science and Technology Commission natural fund project [13JCYBJC23700]; Natural Science Foundation for the YouthNational Natural Science Foundation of China (NSFC) [81501055]	This work was supported by National Clinical Key Subject Construction Project of NHFPC Fund, The National Natural Science Funds Fund (81471252) and Tianjin Municipal Science and Technology Commission natural fund project (13JCYBJC23700)and Natural Science Foundation for the Youth (81501055).	Botling J, 2009, DIAGN MOL PATHOL, V18, P44, DOI 10.1097/PDM.0b013e3181857e92; Chen CYA, 2016, NUCLEIC ACIDS RES, V44, P3772, DOI 10.1093/nar/gkw205; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Dempsey JA, 2010, PHYSIOL REV, V90, P47, DOI 10.1152/physrev.00043.2008; Dewan NA, 2015, CHEST, V147, P266, DOI 10.1378/chest.14-0500; Duan GQ, 2015, TUMOR BIOL, V36, P6201, DOI 10.1007/s13277-015-3305-6; Gao J, 2011, ONCOL LETT, V2, P1019, DOI 10.3892/ol.2011.413; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Goldbart A, 2003, NEUROSCIENCE, V122, P585, DOI 10.1016/j.neuroscience.2003.08.054; Guimbellot JS, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-15; Huang JC, 2007, NAT METHODS, V4, P1045, DOI 10.1038/nmeth1130; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lam CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117990; Lavie L, 2015, SLEEP MED REV, V20, P27, DOI 10.1016/j.smrv.2014.07.003; Li DM, 2016, BIOCHEM BIOPH RES CO, V472, P465, DOI 10.1016/j.bbrc.2016.01.163; Li L, 2013, NEUROMOL MED, V15, P593, DOI 10.1007/s12017-013-8244-z; Montalban E, 2014, NEUROMOL MED, V16, P415, DOI 10.1007/s12017-014-8292-z; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Pickering C, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-97; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Row BW, 2007, ADV EXP MED BIOL, V618, P51; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Tao J, 2015, NEUROSCIENCE, V305, P1, DOI 10.1016/j.neuroscience.2015.07.064; Tsai MM, 2016, ONCOTARGET, V7, P39511, DOI 10.18632/oncotarget.8629; Wang Y., 2016, TUMOUR BIOL J INT SO; Wang Y, 2016, ONCOTARGET, V7, P24383, DOI 10.18632/oncotarget.8328; Wei N, 2016, MOL NEUROBIOL, V53, P6809, DOI 10.1007/s12035-015-9605-4; Zhao YN, 2016, MOL MED REP, V13, P137, DOI 10.3892/mmr.2015.4505	31	33	34	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	SEP 29	2017	335						80	87		10.1016/j.bbr.2017.06.025			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	FI5OQ	WOS:000412034100010	28647595				2022-02-06	
J	Arbogast, KB; Curry, AE; Metzger, KB; Kessler, RS; Bell, JM; Haarbauer-Krupa, J; Zonfrillo, MR; Breiding, MJ; Master, CL				Arbogast, Kristy B.; Curry, Allison E.; Metzger, Kristina B.; Kessler, Ronni S.; Bell, Jeneita M.; Haarbauer-Krupa, Juliet; Zonfrillo, Mark R.; Breiding, Matthew J.; Master, Christina L.			Improving Primary Care Provider Practices in Youth Concussion Management	CLINICAL PEDIATRICS			English	Article						primary care; electronic health record; clinical decision support; traumatic brain injury	CLINICAL DECISION-SUPPORT; TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; ELECTRONIC HEALTH RECORD; SYSTEM; KNOWLEDGE; DIAGNOSIS; SPORTS; TRENDS; RECOMMENDATIONS	Primary care providers are increasingly providing youth concussion care but report insufficient time and training, limiting adoption of best practices. We implemented a primary care-based intervention including an electronic health record-based clinical decision support tool (SmartSet) and in-person training. We evaluated consequent improvement in 2 key concussion management practices: (1) performance of a vestibular oculomotor examination and (2) discussion of return-to-learn/return-to-play (RTL/RTP) guidelines. Data were included from 7284 primary care patients aged 0 to 17 years with initial concussion visits between July 2010 and June 2014. We compared proportions of visits pre- and post-intervention in which the examination was performed or RTL/RTP guidelines provided. Examinations and RTL/RTP were documented for 1.8% and 19.0% of visits pre-intervention, respectively, compared with 71.1% and 72.9% post-intervention. A total of 95% of post-intervention examinations were documented within the SmartSet. An electronic clinical decision support tool, plus in-person training, may be key to changing primary care provider behavior around concussion care.	[Arbogast, Kristy B.; Curry, Allison E.; Metzger, Kristina B.; Kessler, Ronni S.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 2716 South St,Room 13471, Philadelphia, PA 19146 USA; [Arbogast, Kristy B.; Curry, Allison E.; Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Bell, Jeneita M.; Haarbauer-Krupa, Juliet; Breiding, Matthew J.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Zonfrillo, Mark R.] Brown Univ, Hasbro Childrens Hosp, Providence, RI 02912 USA; [Zonfrillo, Mark R.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Master, Christina L.] Grad Hosp Philadelphia, Sport Med & Performance Ctr, Philadelphia, PA 19146 USA		Arbogast, KB (corresponding author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 2716 South St,Room 13471, Philadelphia, PA 19146 USA.	arbogast@email.chop.edu	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Curry, Allison/0000-0001-7076-3538; Master, Christina/0000-0002-6717-4270; Arbogast, Kristy/0000-0002-1694-4562	US Department of Health and Human Services (DHHS); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Children's Hospital of Philadelphia	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by an intergovernmental personnel act agreement between the US Department of Health and Human Services (DHHS), Centers for Disease Control and Prevention (CDC), and the Children's Hospital of Philadelphia.	Anand V, 2012, PEDIATRICS, V129, pE1275, DOI 10.1542/peds.2011-2875; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Ballard DW, 2013, ACAD EMERG MED, V20, P352, DOI 10.1111/acem.12109; Bauer NS, 2014, J AM MED INFORM ASSN, V21, P146, DOI 10.1136/amiajnl-2013-001851; Bright TJ, 2012, ANN INTERN MED, V157, P29, DOI 10.7326/0003-4819-157-1-201207030-00450; Bryan Cathy, 2008, Inform Prim Care, V16, P79; Carl RL, 2014, CLIN PEDIATR, V53, P689, DOI 10.1177/0009922814526979; Carroll AE, 2013, PEDIATRICS, V132, pE623, DOI 10.1542/peds.2013-0933; Carroll AE, 2013, J AM MED INFORM ASSN, V20, P311, DOI 10.1136/amiajnl-2011-000682; Carroll AE, 2012, PEDIAT ALLER IMM PUL, V25, P168, DOI 10.1089/ped.2012.0143; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Cresswell Kathrin, 2012, Inform Prim Care, V20, P115; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Ip IK, 2015, AM J EMERG MED, V33, P320, DOI 10.1016/j.ajem.2014.11.005; Kaye AJ, 2010, J TRAUMA, V68, P1396, DOI 10.1097/TA.0b013e3181cf7d1b; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P458, DOI 10.1097/PEC.0000000000000161; Kitson AL, 2009, J ADV NURS, V65, P217, DOI 10.1111/j.1365-2648.2008.04864.x; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Krist AH, 2015, J AM BOARD FAM MED, V28, P299, DOI 10.3122/jabfm.2015.03.150097; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; Master CL, 2012, PEDIATR ANN, V41, pE174, DOI 10.3928/00904481-20120827-08; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Melnick Edward R, 2015, EGEMS (Wash DC), V3, P1136, DOI 10.13063/2327-9214.1136; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; National Conference of State Legislatures, 2015, TRAUM BRAIN INJ LEG; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Prober CG, 2013, ACAD MED, V88, P1407, DOI 10.1097/ACM.0b013e3182a368bd; Rattay KT, 2009, PEDIATRICS, V123, pS100, DOI 10.1542/peds.2008-1755J; Reisner A, 2015, CLIN PEDIATR, V54, P1031, DOI 10.1177/0009922815573468; Schwartz L, 2014, AM FED MED RES E REG; Taylor AM, 2015, J PEDIATR-US, V167, P738, DOI 10.1016/j.jpeds.2015.05.036; Zazove P, 2015, J AM BOARD FAM MED, V28, P334, DOI 10.3122/jabfm.2015.03.140149; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431; Zuckerman AE, 2009, PEDIATR CLIN N AM, V56, P965, DOI 10.1016/j.pcl.2009.05.018	39	33	34	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	AUG	2017	56	9					854	865		10.1177/0009922817709555			12	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	FB1OX	WOS:000405914200007	28521519	Green Accepted			2022-02-06	
J	Bhagya, VR; Srikumar, BN; Veena, J; Rao, BSS				Bhagya, Venkanna Rao; Srikumar, Bettadapura N.; Veena, Jayagopalan; Rao, Byrathnahalli S. Shankaranarayana			Short-term exposure to enriched environment rescues chronic stress-induced impaired hippocampal synaptic plasticity, anxiety, and memory deficits	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						chronic stress; environmental enrichment; hippocampus; synaptic plasticity; working memory	TRAUMATIC BRAIN-INJURY; CA3 DENDRITIC ATROPHY; RESTRAINT STRESS; COGNITIVE FUNCTION; DENTATE GYRUS; SPATIAL MEMORY; PSYCHOSOCIAL STRESS; NEUROTROPHIC FACTOR; PREFRONTAL CORTEX; RATS	Exposure to prolonged stress results in structural and functional alterations in the hippocampus including reduced long-term potentiation (LTP), neurogenesis, spatial learning and working memory impairments, and enhanced anxiety-like behavior. On the other hand, enriched environment (EE) has beneficial effects on hippocampal structure and function, such as improved memory, increased hippocampal neurogenesis, and progressive synaptic plasticity. It is unclear whether exposure to short-term EE for 10 days can overcome restraint stress-induced cognitive deficits and impaired hippocampal plasticity. Consequently, the present study explored the beneficial effects of short-term EE on chronic stress-induced impaired LTP, working memory, and anxiety-like behavior. Male Wistar rats were subjected to chronic restraint stress (6hr/day) over a period of 21 days, and then they were exposed to EE (6hr/day) for 10 days. Restraint stress reduced hippocampal CA1-LTP, increased anxiety-like symptoms in elevated plus maze, and impaired working memory in T-maze task. Remarkably, EE facilitated hippocampal LTP, improved working memory performance, and completely overcame the effect of chronic stress on anxiety behavior. In conclusion, exposure to EE can bring out positive effects on synaptic plasticity in the hippocampus and thereby elicit its beneficial effects on cognitive functions. (c) 2016 Wiley Periodicals, Inc.	[Bhagya, Venkanna Rao; Srikumar, Bettadapura N.; Veena, Jayagopalan; Rao, Byrathnahalli S. Shankaranarayana] NIMHANS, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India		Bhagya, VR (corresponding author), NIMHANS, Dept Neurophysiol, Hosur Rd,PB 2900, Bengaluru 560029, India.	bhagyapkumar@gmail.com	Rao, Bhagya Venkanna/AAY-7370-2020	Rao, Bhagya Venkanna/0000-0003-0664-0335; Shankaranarayana Rao, BS/0000-0002-8323-8211			Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Anuradha H, 2008, J NEURAL TRANSM, V115, P35, DOI 10.1007/s00702-007-0821-6; Artola A, 2006, EUR J NEUROSCI, V23, P261, DOI 10.1111/j.1460-9568.2005.04552.x; Ashokan A, 2016, PSYCHONEUROENDOCRINO, V69, P189, DOI 10.1016/j.psyneuen.2016.04.009; Beauquis J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013993; Benaroya-Milshtein N, 2004, EUR J NEUROSCI, V20, P1341, DOI 10.1111/j.1460-9568.2004.03587.x; Bhagya V, 2016, INDIAN J PHARMACOL, V48, P687, DOI 10.4103/0253-7613.194853; Bhagya V, 2015, J NEUROSCI RES, V93, P104, DOI 10.1002/jnr.23473; Bhagya V, 2011, PSYCHOPHARMACOLOGY, V214, P477, DOI 10.1007/s00213-010-2054-x; Bindu B, 2007, NEUROSCIENCE, V144, P412, DOI 10.1016/j.neuroscience.2006.09.057; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Burrows EL, 2015, NEUROPSYCHOPHARMACOL, V40, P1947, DOI 10.1038/npp.2015.44; Buschler A, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00085; Chapillon P, 1999, BEHAV GENET, V29, P41, DOI 10.1023/A:1021437905913; Chiba S, 2012, PROG NEURO-PSYCHOPH, V39, P112, DOI 10.1016/j.pnpbp.2012.05.018; Conrad CD, 1999, BEHAV NEUROSCI, V113, P902, DOI 10.1037/0735-7044.113.5.902; Cordner ZA, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.127; Cui MH, 2006, NEUROSCI LETT, V404, P208, DOI 10.1016/j.neulet.2006.05.048; Czeh B, 2002, BIOL PSYCHIAT, V52, P1057, DOI 10.1016/S0006-3223(02)01457-9; Diamond DM, 2004, EUR NEUROPSYCHOPHARM, V14, pS491, DOI 10.1016/j.euroneuro.2004.09.003; Duffy SN, 2001, LEARN MEMORY, V8, P26, DOI 10.1101/lm.36301; Fares RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053888; Fox C, 2006, BEHAV BRAIN RES, V175, P1, DOI 10.1016/j.bbr.2006.08.016; Furuie H, 2013, BEHAV PHARMACOL, V24, P678, DOI 10.1097/FBP.0000000000000003; Garcia R, 1997, NEUROSCI LETT, V233, P41, DOI 10.1016/S0304-3940(97)00621-6; Gerges NZ, 2004, HIPPOCAMPUS, V14, P402, DOI 10.1002/hipo.10193; Gerges NZ, 2001, BRAIN RES, V922, P250, DOI 10.1016/S0006-8993(01)03181-X; Gould E, 1997, J NEUROSCI, V17, P2492; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Han B, 2016, J ALZHEIMERS DIS, V53, P1539, DOI 10.3233/JAD-160189; Hellemans KGC, 2004, DEV BRAIN RES, V150, P103, DOI 10.1016/j.devbrainres.2004.03.003; Henn FA, 2005, NEUROSCI BIOBEHAV R, V29, P799, DOI 10.1016/j.neubiorev.2005.03.019; Huang FL, 2006, J NEUROSCI, V26, P6230, DOI 10.1523/JNEUROSCI.1182-06.2006; Irvine GI, 2006, HIPPOCAMPUS, V16, P149, DOI 10.1002/hipo.20142; Joels M, 2004, STRESS, V7, P221, DOI 10.1080/10253890500070005; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; Kempermann G, 2000, Prog Brain Res, V127, P35; Kleen JK, 2006, BEHAV NEUROSCI, V120, P842, DOI 10.1037/0735-7044.120.4.842; Krugers HJ, 2006, EUR J NEUROSCI, V23, P3051, DOI 10.1111/j.1460-9568.2006.04842.x; Liu LX, 2016, BEHAV BRAIN RES, V305, P148, DOI 10.1016/j.bbr.2016.03.005; Mahati K, 2016, NEUROBIOL LEARN MEM, V134, P379, DOI 10.1016/j.nlm.2016.08.017; Malchow B, 2015, SCHIZOPHRENIA BULL, V41, P847, DOI 10.1093/schbul/sbv020; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; McKittrick CR, 2000, SYNAPSE, V36, P85, DOI 10.1002/(SICI)1098-2396(200005)36:2<85::AID-SYN1>3.0.CO;2-Y; McLaughlin KJ, 2007, BRAIN RES, V1161, P56, DOI 10.1016/j.brainres.2007.05.042; Mora F, 2007, BRAIN RES REV, V55, P78, DOI 10.1016/j.brainresrev.2007.03.011; Morley-Fletcher S, 2003, EUR J NEUROSCI, V18, P3367, DOI 10.1111/j.1460-9568.2003.03070.x; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Nowakowska E, 2014, PHARMACOL REP, V66, P404, DOI 10.1016/j.pharep.2013.12.008; Pang TYC, 2013, NEUROPHARMACOLOGY, V64, P515, DOI 10.1016/j.neuropharm.2012.06.029; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pham K, 2003, EUR J NEUROSCI, V17, P879, DOI 10.1046/j.1460-9568.2003.02513.x; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Piazza F, 2014, METAB BRAIN DIS, V29, P93, DOI 10.1007/s11011-013-9467-2; Ramkumar K, 2008, NEUROCHEM RES, V33, P1651, DOI 10.1007/s11064-007-9511-x; Sarris J, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-107; Shors TJ, 1997, SYNAPSE, V26, P209, DOI 10.1002/(SICI)1098-2396(199707)26:3<209::AID-SYN2>3.0.CO;2-B; Sousa N, 2000, NEUROSCIENCE, V97, P253, DOI 10.1016/S0306-4522(00)00050-6; Srikumar BN, 2007, PSYCHOPHARMACOLOGY, V193, P363, DOI 10.1007/s00213-007-0801-4; Srikumar BN, 2006, NEUROSCIENCE, V143, P679, DOI 10.1016/j.neuroscience.2006.08.041; Sunanda, 2000, NEUROCHEM RES, V25, P1547, DOI 10.1023/A:1026606201069; Tang YP, 2001, NEUROPHARMACOLOGY, V41, P779, DOI 10.1016/S0028-3908(01)00122-8; Teather LA, 2002, EUR J NEUROSCI, V16, P2405, DOI 10.1046/j.1460-9568.2002.02416.x; Then FS, 2015, NEUROLOGY, V84, P2169, DOI 10.1212/WNL.0000000000001605; Valero J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016832; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Veena J, 2011, PSYCHOPHARMACOLOGY, V217, P239, DOI 10.1007/s00213-011-2279-3; Veena J, 2009, NEUROSCI LETT, V455, P178, DOI 10.1016/j.neulet.2009.03.059; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; Vouimba RM, 2004, EUR J NEUROSCI, V19, P1887, DOI 10.1111/j.1460-9568.2004.03294.x; Vyas A, 2002, J NEUROSCI, V22, P6810; White JH, 2015, DISABIL REHABIL, V37, P593, DOI 10.3109/09638288.2014.935876; Wright RL, 2008, BEHAV BRAIN RES, V187, P41, DOI 10.1016/j.bbr.2007.08.025; Yang JL, 2007, NEUROBIOL LEARN MEM, V87, P257, DOI 10.1016/j.nlm.2006.09.001; Yu LL, 2016, WORLD NEUROSURG, V86, P173, DOI 10.1016/j.wneu.2015.09.071	76	33	37	5	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG	2017	95	8					1602	1610		10.1002/jnr.23992			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX7OU	WOS:000403438300008	27862185				2022-02-06	
J	Seal, KH; Bertenthal, D; Barnes, DE; Byers, AL; Strigo, I; Yaffe, K				Seal, Karen H.; Bertenthal, Daniel.; Barnes, Deborah E.; Byers, Amy L.; Strigo, Irina; Yaffe, Kristine		Chronic Effects Neurotrauma Consor	Association of Traumatic Brain Injury With Chronic Pain in Iraq and Afghanistan Veterans: Effect of Comorbid Mental Health Conditions	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Military Health Scientific Research Symposium	AUG 15-18, 2016	Kissimmee, FL			Chronic pain; Depression; Rehabilitation; Veterans	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; ENDURING FREEDOM; PERSISTENT PAIN; US VETERANS; POLYTRAUMA; PTSD; WAR; PREVALENCE; REHABILITATION	Objective: To characterize the association between traumatic brain injury (TBI) and chronic pain and pain disability in the context of comorbid conditions, posttraumatic stress disorder (PTSD), and depression to better inform care of combat veterans. Design: Retrospective cohort study. Setting: Medical centers and community clinics. Participants: Combat veterans (N = 116,913) who received Veterans Affairs care between October 1, 2007 and March 31, 2015, completed a Comprehensive Traumatic Brain Injury Evaluation, and received a criterion standard diagnosis of TBI (none, mild, or moderate to severe). Interventions: Not applicable. Main Outcome Measures: Chronic pain defined as >= 2 of the same pain diagnoses >= 90 days apart and pain disability defined as self-reported pain causing moderate to very severe interference with daily functioning. Results: Fifty-seven percent received >= 1 chronic pain diagnosis. Compared to those with no TBI, PTSD, or depression, there was an independent risk for chronic pain in veterans with mild TBI, which was higher in veterans with moderate to severe TBI. The risk of chronic pain was additive and highest when all 3 conditions-TBI, depression, and PTSD-were copresent (adjusted relative risk, 1.53 and 1.62 [95% confidence interval, 1.50-1.66] for mild and moderate or severe TBI, respectively, plus other diagnoses). The relation of pain disability to TBI, PTSD, and depression followed a similar additive pattern. Conclusions: In combat veterans, chronic pain and pain disability are most commonly associated with TBI in conjunction with PTSD, depression, or both. Integrated models of care that simultaneously address pain in conjunction with TBI, PTSD, and depression will likely be the most clinically effective. Published by Elsevier Inc.	[Seal, Karen H.; Bertenthal, Daniel.; Barnes, Deborah E.; Byers, Amy L.; Strigo, Irina; Yaffe, Kristine] San Francisco VA Hlth Care Syst, San Francisco, CA USA; [Seal, Karen H.; Barnes, Deborah E.; Byers, Amy L.; Strigo, Irina; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA		Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Med, 4150 Clement St,Box 111A-1, San Francisco, CA 94121 USA.; Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Psychiat, 4150 Clement St,Box 111A-1, San Francisco, CA 94121 USA.	Karen.Seal@ucsf.edu	strigo, irina A/L-9882-2016	strigo, irina A/0000-0002-8799-716X	Veterans Health Administration Clinical Sciences Research and Development [101 CX001246]; Department of DefenseUnited States Department of Defense [W81XWH-13-2-0095]	Supported by the Veterans Health Administration Clinical Sciences Research and Development (grant no. 101 CX001246) and by the Department of Defense (grant no. W81XWH-13-2-0095). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Asmundson Gordon J G, 2002, Pain Res Manag, V7, P7; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Bosco MA, 2013, HEADACHE, V53, P1518, DOI 10.1111/head.12172; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Centers for Disease Control and Prevention, 2016, CDC GUID PRESCR OP C; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Cummings P, 2009, STATA J, V9, P175, DOI 10.1177/1536867X0900900201; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Higgins DM, 2014, PAIN MED, V15, P782, DOI 10.1111/pme.12388; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaramillo CA, 2016, HEADACHE, V56, P528, DOI 10.1111/head.12726; Krebs EE, 2009, J GEN INTERN MED, V24, P733, DOI 10.1007/s11606-009-0981-1; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Seal KH, 2016, J REHABIL RES DEV, V53, P185, DOI 10.1682/JRRD.2014.12.0301; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Stojanovic MP, 2016, PAIN MED, V17, P2017, DOI 10.1093/pm/pnw042; Stratton KJ, 2014, J REHABIL RES DEV, V51, P1189, DOI 10.1682/JRRD.2014.04.0111; Strigo IA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.116; Sullivan-Singh SJ, 2014, ARCH PHYS MED REHAB, V95, P1100, DOI 10.1016/j.apmr.2014.02.001; Tan G, 2009, PAIN MED, V10, P1237, DOI 10.1111/j.1526-4637.2009.00712.x; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558	38	33	34	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2017	98	8					1636	1645		10.1016/j.apmr.2017.03.026			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	FD1OF	WOS:000407305900017	28455190				2022-02-06	
J	Vargas, E; Barrett, DW; Saucedo, CL; Huang, LD; Abraham, JA; Tanaka, H; Haley, AP; Gonzalez-Lima, F				Vargas, Enrique; Barrett, Douglas W.; Saucedo, Celeste L.; Huang, Li-Da; Abraham, Jacob A.; Tanaka, Hirofumi; Haley, Andreana P.; Gonzalez-Lima, F.			Beneficial neurocognitive effects of transcranial laser in older adults	LASERS IN MEDICAL SCIENCE			English	Article						Brain photobiomodulation; Infrared laser; Attention; Memory; EEG; fMRI	CYTOCHROME-C-OXIDASE; NEAR-INFRARED LIGHT; COGNITIVE ENHANCEMENT; STIMULATION; PHOTOBIOMODULATION; THERAPY; OXYGENATION; HUMANS; MEMORY	Transcranial infrared laser stimulation (TILS) at 1064 nm, 250 mW/cm(2) has been proven safe and effective for increasing neurocognitive functions in young adults in controlled studies using photobiomodulation of the right prefrontal cortex. The objective of this pilot study was to determine whether there is any effect from TILS on neurocognitive function in older adults with subjective memory complaint at risk for cognitive decline (e.g., increased carotid artery intima-media thickness or mild traumatic brain injury). We investigated the cognitive effects of TILS in older adults (ages 49-90, n = 12) using prefrontal cortex measures of attention (psychomotor vigilance task (PVT)) and memory (delayed match to sample (DMS)), carotid artery intima-media thickness (measured by ultrasound), and evaluated the potential neural mechanisms mediating the cognitive effects of TILS using exploratory brain studies of electroencephalography (EEG, n = 6) and functional magnetic resonance imaging (fMRI, n = 6). Cognitive performance, age, and carotid artery intima-media thickness were highly correlated, but all participants improved in all cognitive measures after TILS treatments. Baseline vs. chronic (five weekly sessions, 8 min each) comparisons of mean cognitive scores all showed improvements, significant for PVT reaction time (p < 0.001), PVT lapses (p < 0.001), and DMS correct responses (p < 0.05). The neural studies also showed for the first time that TILS increases resting-state EEG alpha, beta, and gamma power and promotes more efficient prefrontal blood-oxygen-level-dependent (BOLD)-fMRI response. Importantly, no adverse effects were found. These preliminary findings support the use of TILS for larger randomized clinical trials with this non-invasive approach to augment neurocognitive function in older people to combat aging-related and vascular disease-related cognitive decline.	[Vargas, Enrique; Barrett, Douglas W.; Saucedo, Celeste L.; Haley, Andreana P.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Vargas, Enrique; Barrett, Douglas W.; Saucedo, Celeste L.; Haley, Andreana P.; Gonzalez-Lima, F.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Huang, Li-Da; Abraham, Jacob A.] Univ Texas Austin, Dept Elect Engn, Austin, TX 78712 USA; [Tanaka, Hirofumi] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA		Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.; Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA.	gonzalezlima@utexas.edu	Abraham, Jacob/ABD-1017-2020	Abraham, Jacob/0000-0002-5336-5631; Gonzalez-Lima, Francisco/0000-0001-9856-0775	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21 AG055772]; Darrell K. Royal Research Fund for Alzheimer's Disease; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG050898] Funding Source: NIH RePORTER	This study was supported in part by grants from the National Institute on Aging (R21 AG055772) and the Darrell K. Royal Research Fund for Alzheimer's Disease.	Anders JJ, 2015, PHOTOMED LASER SURG, V33, P183, DOI 10.1089/pho.2015.9848; Anders JJ, 2014, LASER SURG MED, V46, P34, DOI 10.1002/lsm.22212; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Basar E, 2013, INT J PSYCHOPHYSIOL, V90, P99, DOI 10.1016/j.ijpsycho.2013.07.005; Blanco N. J., 2015, J NEUROPSYCHOL; Blanco NJ, 2017, NEUROBIOL LEARN MEM, V139, P69, DOI 10.1016/j.nlm.2016.12.016; Disner SG, 2016, BRAIN STIMUL, V9, P780, DOI 10.1016/j.brs.2016.05.009; Gonzales MM, 2014, INT J OBESITY, V38, P1193, DOI 10.1038/ijo.2014.5; Gonzalez-Lima F, 2014, BIOCHEM PHARMACOL, V88, P584, DOI 10.1016/j.bcp.2013.11.010; Gonzalez-Lima F, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00036; Haley AP, 2007, J NEUROIMAGING, V17, P227, DOI 10.1111/j.1552-6569.2007.00110.x; Hamblin MR, 2016, BBA CLIN, V6, P113, DOI 10.1016/j.bbacli.2016.09.002; Hwang J, 2016, LASER MED SCI, V31, P1151, DOI 10.1007/s10103-016-1962-3; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Naeser MA, 2016, PHOTOMED LASER SURG, V34, P610, DOI 10.1089/pho.2015.4037; Nguyen-Thanh HT, 2009, AM J CARDIOL, V104, P1383, DOI 10.1016/j.amjcard.2009.07.005; Palva S, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00204; Rojas J.C., 2017, HDB LOW LEVEL LASER, P1057; Rojas JC, 2013, BIOCHEM PHARMACOL, V86, P447, DOI 10.1016/j.bcp.2013.06.012; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Tanaka M, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-48; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Wang X, 2017, J CEREB BLO IN PRESS; Wang XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep30540; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200	29	33	37	2	30	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-8921	1435-604X		LASER MED SCI	Lasers Med. Sci.	JUL	2017	32	5					1153	1162		10.1007/s10103-017-2221-y			10	Engineering, Biomedical; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Surgery	EX8AS	WOS:000403471600022	28466195	Green Accepted			2022-02-06	
J	Salehpour, F; Rasta, SH				Salehpour, Farzad; Rasta, Seyed Hossein			The potential of transcranial photobiomodulation therapy for treatment of major depressive disorder	REVIEWS IN THE NEUROSCIENCES			English	Article						cerebral blood flow; depression; near-infrared; photobiomodulation; pulsed light; prefrontal cortex	DIRECT-CURRENT STIMULATION; INFRARED-LASER THERAPY; TRAUMATIC BRAIN-INJURY; LEVEL LIGHT THERAPY; CEREBRAL-BLOOD-FLOW; PREFRONTAL CORTEX; MOUSE MODEL; OPTICAL-PROPERTIES; MITOCHONDRIAL; METAANALYSIS	Major depressive disorder is a common debilitating mood disorder that affects quality of life. Prefrontal cortex abnormalities, an imbalance in neurotransmitters, neuroinflammation, and mitochondrial dysfunction are the major factors in the etiology of major depressive disorder. Despite the efficacy of pharmacotherapy in the treatment of major depressive disorder, 30%-40% of patients do not respond to antidepressants. Given this, exploring the alternative therapies for treatment or prevention of major depressive disorder has aroused interest among scientists. Transcranial photobiomodulation therapy is the use of low-power lasers and light-emitting diodes in the far-red to near-infrared optical region for stimulation of neuronal activities. This non-invasive modality improves the metabolic capacity of neurons due to more oxygen consumption and ATP production. Beneficial effects of transcranial photobiomodulation therapy in the wide range of neurological and psychological disorders have been already shown. In this review, we focus on some issues relating to the application of photobiomodulation therapy for major depressive disorder. There is some evidence that transcranial photobiomodulation therapy using near-infrared light on 10-Hz pulsed mode appears to be a hopeful technique for treatment of major depressive disorder. However, further studies are necessary to find the safety of this method and to determine its effective treatment protocol.	[Salehpour, Farzad; Rasta, Seyed Hossein] Tabriz Univ Med Sci, Dept Med Phys, Attar Neyshapouri St,Azadi Ave, Tabriz 5166614766, Iran; [Rasta, Seyed Hossein] Tabriz Univ Med Sci, Dept Med Bioengn, Tabriz 5166614766, Iran; [Rasta, Seyed Hossein] Univ Aberdeen, Sch Med Sci, Aberdeen AB24 5DT, Scotland; [Salehpour, Farzad] Tabriz Univ Med Sci, Neurosci Res Ctr NSRC, Tabriz 5166614766, Iran		Rasta, SH (corresponding author), Tabriz Univ Med Sci, Dept Med Phys, Attar Neyshapouri St,Azadi Ave, Tabriz 5166614766, Iran.; Rasta, SH (corresponding author), Tabriz Univ Med Sci, Dept Med Bioengn, Tabriz 5166614766, Iran.; Rasta, SH (corresponding author), Univ Aberdeen, Sch Med Sci, Aberdeen AB24 5DT, Scotland.	s.h.rasta@abdn.ac.uk	Rasta, Seyed Hossein/L-6626-2017	Rasta, Seyed Hossein/0000-0003-0351-5176; salehpour, farzad/0000-0002-7070-8835			Abdo A, 2007, P ANN INT IEEE EMBS, P1723, DOI 10.1109/IEMBS.2007.4352642; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Antunes F, 2004, P NATL ACAD SCI USA, V101, P16774, DOI 10.1073/pnas.0405368101; BARKER AT, 1985, LANCET, V1, P1106; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; BEAUVOIT B, 1994, BIOPHYS J, V67, P2501, DOI 10.1016/S0006-3495(94)80740-4; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Berlim MT, 2013, J PSYCHIATR RES, V47, P1, DOI 10.1016/j.jpsychires.2012.09.025; Blanco NJ, 2017, J NEUROPSYCHOL, V11, P14, DOI 10.1111/jnp.12074; Bradford A, 2005, J PHOTOCH PHOTOBIO B, V81, P9, DOI 10.1016/j.jphotobiol.2005.05.005; Brambilla P, 2005, PHARMACOPSYCHIATRY, V38, P69, DOI 10.1055/s-2005-837806; Brunoni AR, 2016, BRIT J PSYCHIAT, V208, P522, DOI 10.1192/bjp.bp.115.164715; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carney S, 2003, LANCET, V361, P799; Cassano Paolo, 2015, Psychiatry J, V2015, P352979, DOI 10.1155/2015/352979; Cassano P, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.3.031404; Chen ACH, 2011, PHOTOMED LASER SURG, V29, P383, DOI 10.1089/pho.2010.2837; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Cusin C, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-14; de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Disner SG, 2016, BRAIN STIMUL, V9, P780, DOI 10.1016/j.brs.2016.05.009; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Duggett N.A., 2014, BIOL MED, V6, P1; Elhwuegi AS, 2004, PROG NEURO-PSYCHOPH, V28, P435, DOI 10.1016/j.pnpbp.2003.11.018; Fahim C, 2004, BRAIN COGNITION, V54, P161; Gawryluk JW, 2011, INT J NEUROPSYCHOPH, V14, P123, DOI 10.1017/S1461145710000805; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Hamblin M.R., 2006, BIOMED OPT, V6140; Hamblin M.R., 2008, BIOMED OPT, V6846; Hamblin MR, 2016, BBA CLIN, V6, P113, DOI 10.1016/j.bbacli.2016.09.002; Hamon M, 2013, PROG NEURO-PSYCHOPH, V45, P54, DOI 10.1016/j.pnpbp.2013.04.009; Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950; Henderson TA, 2015, NEUROPSYCH DIS TREAT, V11, P2191, DOI 10.2147/NDT.S78182; Hennessy M, 2017, J OPTICS-UK, V19, DOI 10.1088/2040-8986/19/1/013003; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Huang ZG, 2016, MATH PROBL ENG, V2016, DOI 10.1155/2016/5087237; Hwang J, 2016, LASER MED SCI, P1; Iaccarino HF, 2016, NATURE, V540, P230, DOI 10.1038/nature20587; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Iosifescu DV, 2008, BIOL PSYCHIAT, V63, P1127, DOI 10.1016/j.biopsych.2007.11.020; Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031-9155/58/11/R37; Jagdeo JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047460; Johnstone DM, 2014, NEUROSCIENCE, V274, P93, DOI 10.1016/j.neuroscience.2014.05.023; Kalu UG, 2012, PSYCHOL MED, V42, P1791, DOI 10.1017/S0033291711003059; Karu T, 2000, PROC SPIE, V4159, P1, DOI 10.1117/12.405918; KARU TI, 1990, PHOTOCHEM PHOTOBIOL, V52, P1089, DOI 10.1111/j.1751-1097.1990.tb08450.x; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127580; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lee BH, 2007, J AFFECT DISORDERS, V101, P239, DOI 10.1016/j.jad.2006.11.005; Litscher D, 2013, INT J PHOTOENERGY, V2013, DOI 10.1155/2013/575798; Mechan AO, 2011, BRIT J NUTR, V105, P1150, DOI 10.1017/S0007114510004940; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Mohammed H.S., 2016, LASER MED SCI, V31, P1; Morries LD, 2015, NEUROPSYCH DIS TREAT, V11, P2159, DOI 10.2147/NDT.S65809; Muili KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030655; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; O'Reardon JP, 1998, PSYCHIAT ANN, V28, P633, DOI 10.3928/0048-5713-19981101-08; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Passarella S, 1989, J Photochem Photobiol B, V3, P642, DOI 10.1016/1011-1344(89)80090-9; Passarella S, 2014, J PHOTOCH PHOTOBIO B, V140, P344, DOI 10.1016/j.jphotobiol.2014.07.021; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Petrie S.R., 2016, QUAL PRIM CARE, V24, P33; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Rasta SH, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116005; Rezin GT, 2008, NEUROCHEM INT, V53, P395, DOI 10.1016/j.neuint.2008.09.012; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Salehpour F, 2016, LASER SURG MED, V48, P695, DOI 10.1002/lsm.22542; Salehpour F, 2016, LASER SURG MED, V48, P455; Salgado ASI, 2015, LASER MED SCI, V30, P339, DOI 10.1007/s10103-014-1669-2; Santana-Blank L, 2016, PHOTOMED LASER SURG, V34, P93, DOI 10.1089/pho.2015.4015; Santana-Blank L, 2010, PHOTOMED LASER SURG, V28, pS41, DOI 10.1089/pho.2009.2647; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Shumake J, 2003, Behav Cogn Neurosci Rev, V2, P198, DOI 10.1177/1534582303259057; Smith K.C., 2007, PHOTOCHEM PHOTOBIOL, V83, P1539; Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910; Souery D, 1999, EUR NEUROPSYCHOPHARM, V9, P83, DOI 10.1016/S0924-977X(98)00004-2; Stahl SM, 2009, STAHLS ILLUSTRATED A; Szundi I, 2001, BIOCHEMISTRY-US, V40, P2332, DOI 10.1021/bi002220v; Taddeucci A, 1996, J Biomed Opt, V1, P117, DOI 10.1117/12.227816; Tagliari B, 2010, METAB BRAIN DIS, V25, P169, DOI 10.1007/s11011-010-9194-x; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063; Uccelli A, 2011, BEST PRACT RES CL HA, V24, P59, DOI 10.1016/j.beha.2011.01.004; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Videbech P, 2000, ACTA PSYCHIAT SCAND, V101, P11, DOI 10.1034/j.1600-0447.2000.101001011.x; Weiner RD, 2000, ARCH GEN PSYCHIAT, V57, P591, DOI 10.1001/archpsyc.57.6.591; Wu XJ, 2012, LASER SURG MED, V44, P227, DOI 10.1002/lsm.22004; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547; Zunszain Patricia A, 2013, Curr Top Behav Neurosci, V14, P135, DOI 10.1007/7854_2012_211	103	33	33	5	20	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	JUN	2017	28	4					441	453		10.1515/revneuro-2016-0087			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EW6MD	WOS:000402623700009	28231069				2022-02-06	
J	Keselman, P; Yu, EY; Zhou, XYY; Goodwill, PW; Chandrasekharan, P; Ferguson, RM; Khandhar, AP; Kemp, SJ; Krishnan, KM; Zheng, B; Conolly, SM				Keselman, Paul; Yu, Elaine Y.; Zhou, Xinyi Y.; Goodwill, Patrick W.; Chandrasekharan, Prashant; Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Krishnan, Kannan M.; Zheng, Bo; Conolly, Steven M.			Tracking short-term biodistribution and long-term clearance of SPIO tracers in magnetic particle imaging	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						SPIO biodistribuition; SPIO tracking; SPIO clearance	CELLS IN-VIVO; DRUG-DELIVERY; NANOPARTICLES; TOXICITY; CONTRAST; THERAPY; MPI; MR	Magnetic particle imaging ( MPI) is an emerging tracer-based medical imaging modality that images non-radioactive, kidney-safe superparamagnetic iron oxide (SPIO) tracers. MPI offers quantitative, high-contrast and high-SNR images, so MPI has exceptional promise for applications such as cell tracking, angiography, brain perfusion, cancer detection, traumatic brain injury and pulmonary imaging. In assessing MPI's utility for applications mentioned above, it is important to be able to assess tracer short-term biodistribution as well as long-term clearance from the body. Here, we describe the biodistribution and clearance for two commonly used tracers in MPI: Ferucarbotran (Meito Sangyo Co., Japan) and LS-oo8 (LodeSpin Labs, Seattle, WA). We successfully demonstrate that 3D MPI is able to quantitatively assess short-term biodistribution, as well as long-term tracking and clearance of these tracers in vivo.	[Keselman, Paul; Yu, Elaine Y.; Zhou, Xinyi Y.; Chandrasekharan, Prashant; Zheng, Bo; Conolly, Steven M.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Conolly, Steven M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA; [Goodwill, Patrick W.] Magnet Insight Inc, Newark, CA 94560 USA; [Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Krishnan, Kannan M.] LodeSpin Labs, POB 95632, Seattle, WA 98145 USA; [Krishnan, Kannan M.] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA		Keselman, P (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.	pkeselma@berkeley.edu	Chandrasekharan, Prashant/C-5174-2011; Goodwill, Patrick/AAB-8825-2022; Chandrasekharan, Prashant/I-2196-2019	Chandrasekharan, Prashant/0000-0002-6139-1979; Goodwill, Patrick/0000-0003-4240-1956; Khandhar, Amit/0000-0003-4049-1855	Keck FoundationW.M. Keck Foundation [009323]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EB019458, 1R24MH106053, 2R42EB013520-02A1]; UC DiscoveryUniversity of California System; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB019458, R42EB013520, R01EB013689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R24MH106053] Funding Source: NIH RePORTER	We are grateful for funding support from the Keck Foundation Grant 009323, NIH 1R01EB019458, NIH 1R24MH106053, NIH 2R42EB013520-02A1, and the UC Discovery Grant.	Abdollah MRA, 2014, FARADAY DISCUSS, V175, P41, DOI 10.1039/c4fd00114a; Ahrens ET, 2013, NAT REV IMMUNOL, V13, P755, DOI 10.1038/nri3531; Antonelli A, 2016, NANOMEDICINE, V11, P0216; Antonelli A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078542; Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330; Chehade M, 2016, TOMOGRAPHY, V2, P158, DOI 10.18383/j.tom.2016.00160; Dutz S, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/45/452001; Ferguson RM, 2015, IEEE T MED IMAGING, V34, P1077, DOI 10.1109/TMI.2014.2375065; Ferguson RM, 2011, MED PHYS, V38, P1619, DOI 10.1118/1.3554646; Ferguson RM, 2013, BIOMED ENG-BIOMED TE, V58, P493, DOI 10.1515/bmt-2012-0058; Gleich B, 2005, NATURE, V435, P1214, DOI 10.1038/nature03808; Goodwill P W, 2015, 5 INT WORKSH MAGN PA, P1; Goodwill PW, 2011, IEEE T MED IMAGING, V30, P1581, DOI 10.1109/TMI.2011.2125982; Goodwill PW, 2010, IEEE T MED IMAGING, V29, P1851, DOI 10.1109/TMI.2010.2052284; Goodwill PW, 2012, ADV MATER, V24, P3870, DOI 10.1002/adma.201200221; Gu L, 2012, ACS NANO, V6, P4947, DOI 10.1021/nn300456z; Hensley D, 2015, 5 INT WORKSH MAGN PA, P1; Hergt R, 2006, J PHYS-CONDENS MAT, V18, pS2919, DOI 10.1088/0953-8984/18/38/S26; Janib SM, 2010, ADV DRUG DELIVER REV, V62, P1052, DOI 10.1016/j.addr.2010.08.004; Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/nnm.11.19, 10.2217/NNM.11.19]; Kemp SJ, 2016, RSC ADV, V6, P77452, DOI 10.1039/c6ra12072e; Konkle J J, 2014, 2014 4 INT WORKSH MA, P1; Lawaczeck R, 1997, ACTA RADIOL, V38, P584, DOI 10.1080/02841859709174391; Li SH, 2012, BIOCONJUGATE CHEM, V23, P1322, DOI 10.1021/bc300175d; Lu K, 2015, 2015 5 INT WORKSH MA, P1; Lu K, 2013, IEEE T MED IMAGING, V32, P1565, DOI 10.1109/TMI.2013.2257177; Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002; Mahmoudi M, 2012, CHEM REV, V112, P2323, DOI 10.1021/cr2002596; Nguyen PK, 2014, CELL STEM CELL, V14, P431, DOI 10.1016/j.stem.2014.03.009; OCallaghan C, 1997, THORAX, V52, pS31, DOI 10.1136/thx.52.2008.S31; Orendorff R, 2016, PHYS MED BIOL; Park K., 2013, CANC TARGETED DRUG D; Rahmer J, 2015, PHYS MED BIOL, V60, P1775, DOI 10.1088/0031-9155/60/5/1775; Rahmer J, 2013, PHYS MED BIOL, V58, P3965, DOI 10.1088/0031-9155/58/12/3965; Ruangwattanapaisarn N, 2015, PEDIATR RADIOL, V45, P831, DOI 10.1007/s00247-014-3226-3; Saritas EU, 2013, J MAGN RESON, V229, P116, DOI 10.1016/j.jmr.2012.11.029; Shinkai M, 2002, PHYS MED BI IN PRESS; Wang Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep07774; Wang YXJ, 2011, QUANT IMAGING MED SU, V1, P35, DOI 10.3978/j.issn.2223-4292.2011.08.03; Yu E, 2016, NANOLETT IN PRESS; Zheng B, 2016, THERANOSTICS, V6, P291, DOI 10.7150/thno.13728; Zheng B, 2015, SCI REP-UK, V5, DOI 10.1038/srep14055; Zhou X, 2016, PHYS MED BI IN PRESS	43	33	35	3	25	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	MAY 7	2017	62	9					3440	3453		10.1088/1361-6560/aa5f48			14	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Radiology, Nuclear Medicine & Medical Imaging	ES0JL	WOS:000399212500003	28177301	Green Accepted			2022-02-06	
J	Hespanhol, LC; van Mechelen, W; Verhagen, E				Hespanhol Junior, Luiz Carlos; van Mechelen, Willem; Verhagen, Evert			Health and Economic Burden of Running-Related Injuries in Dutch Trailrunners: A Prospective Cohort Study	SPORTS MEDICINE			English	Article							COST-EFFECTIVENESS; SPORTS INJURIES; ANKLE SPRAINS; PROGRAM; PREVENTION; RUNNERS; ADULTS; INTERVENTIONS; MORTALITY	Background Trailrunning is becoming very popular. However, the risk and burden of running-related injuries (RRI) in trailrunning is not well established. Objective To investigate the prevalence, injury rate, severity, nature, and economic burden of RRIs in Dutch trailrunners. Methods This prospective cohort study included 228 trailrunners aged 18 years or over (range 23-67), and was conducted between October 2013 and December 2014. After completing the baseline questionnaire, the Oslo Sports Trauma Research Center Questionnaire on Health Problems was administered every 2 weeks to collect data on RRIs. Participants who reported RRIs were asked about healthcare utilization (direct costs) and absenteeism from paid work (indirect costs). RRI was defined as disorders of the musculoskeletal system or concussions experienced or sustained during participation in running. Results The mean prevalence of RRIs measured over time was 22.4 % [95 % confidence interval (CI) 20.9-24.0], and the injury rate was 10.7 RRIs per 1000 h of running (95 % CI 9.4-12.1). The prevalence was higher for overuse (17.7 %; 95 % CI 15.9-19.5) than for acute (4.1 %; 95 % CI 3.3-5.0) RRIs. Also, the injury rate was higher for overuse (8.1; 95 % CI 6.9-9.3) than for acute (2.7; 95 % CI 2.0-3.4) RRIs. The median of the severity score was 35.0 [25-75 %, interquartile range (IQR) 22.0-55.7], and the median of the duration of RRIs was 2.0 weeks (IQR 2.0-6.0) during the study. The total economic burden of RRIs was estimated at (sic)172.22 (95 % CI 117.10-271.74) per RRI, and (sic)1849.49 (95 % CI 1180.62-3058.91) per 1000 h of running. An RRI was estimated to have a direct cost of (sic)60.92 (95 % CI 45.11-94.90) and an indirect cost of (sic)111.30 (95 % CI 61.02-192.75). Conclusions The health and economic burden of RRIs presented in this study are significant for trailrunners and for society. Therefore, efforts should be made in order to prevent RRIs in trailrunners.	[Hespanhol Junior, Luiz Carlos; van Mechelen, Willem; Verhagen, Evert] Vrije Univ Amsterdam, Med Ctr, Amsterdam Collaborat Hlth & Safety Sports, Dept Publ & Occupat Hlth, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands; [Hespanhol Junior, Luiz Carlos; van Mechelen, Willem; Verhagen, Evert] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands; [van Mechelen, Willem] Univ Queensland, Fac Hlth & Behav Sci, Sch Human Movement & Nutr Sci, Brisbane, Qld, Australia; [van Mechelen, Willem; Verhagen, Evert] Univ Cape Town, Fac Hlth Sci, Dept Human Biol, UCT MRC Res Unit Exercise Sci & Sports Med ESSM, Cape Town, South Africa; [van Mechelen, Willem] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Dublin, Ireland; [Verhagen, Evert] Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia		Hespanhol, LC (corresponding author), Vrije Univ Amsterdam, Med Ctr, Amsterdam Collaborat Hlth & Safety Sports, Dept Publ & Occupat Hlth, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.; Hespanhol, LC (corresponding author), Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	l.hespanhol@outlook.com	Verhagen, Evert/A-1502-2013; Hespanhol, Luiz/H-8636-2013	Verhagen, Evert/0000-0001-9227-8234; Hespanhol, Luiz/0000-0003-1774-4746; van Mechelen, Willem/0000-0001-7136-6382	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [0763/12-8]; Ministry of Education of Brazil	Luiz Carlos Hespanhol Junior is a PhD candidate supported by CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior), process number 0763/12-8, Ministry of Education of Brazil. The authors wish to thank MudSweatTrails and Marc Weening for their assistance during the recruitment, and all trailrunners who participated in this study.	Bahr R, 2009, BRIT J SPORT MED, V43, P966, DOI 10.1136/bjsm.2009.066936; Chakravarty EF, 2008, ARCH INTERN MED, V168, P1638, DOI 10.1001/archinte.168.15.1638; Chaudhary MA, 1996, STAT MED, V15, P1447; Clarsen B, 2014, BRIT J SPORT MED, V48, P754, DOI 10.1136/bjsports-2012-092087; Clarsen B, 2013, BRIT J SPORT MED, V47, P495, DOI 10.1136/bjsports-2012-091524; Codogno JS, 2015, INT J PUBLIC HEALTH, V63, P309, DOI 10.1007/s00038-015-0657-z; Coon JT, 2011, ENVIRON SCI TECHNOL, V45, P1761, DOI 10.1021/es102947t; Cumps E, 2008, BRIT J SPORT MED, V42, P767, DOI 10.1136/bjsm.2007.037937; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Efron B., 1986, STAT SCI, V1, P54, DOI 10.1214/ss/1177013815; Frew EJ, 2014, BRIT J SPORT MED, V48, P207, DOI 10.1136/bjsports-2012-091202; Fuller CW, 2007, CLIN J SPORT MED, V17, P197, DOI 10.1097/JSM.0b013e3180471b89; Gabbett TJ, 2016, BRIT J SPORT MED, V50, P273, DOI 10.1136/bjsports-2015-095788; Hagberg LA, 2006, SCAND J PUBLIC HEALT, V34, P641, DOI 10.1080/14034940600627853; HATZIANDREU EI, 1988, AM J PUBLIC HEALTH, V78, P1417, DOI 10.2105/AJPH.78.11.1417; Hespanhol LC, 2016, SCAND J MED SCI SPOR, V26, P1091, DOI 10.1111/sms.12541; Hespanhol LC, 2016, J SCI MED SPORT, V19, P800, DOI 10.1016/j.jsams.2015.12.004; Hespanhol LC, 2015, BRAZ J PHYS THER, V19, P369, DOI 10.1590/bjpt-rbf.2014.0110; Hespanhol LC, 2015, SPORTS MED, V45, P1455, DOI 10.1007/s40279-015-0359-y; Hoffman MD, 2011, INT J SPORT PHYSIOL, V6, P25, DOI 10.1123/ijspp.6.1.25; Hupperets MDW, 2010, AM J SPORT MED, V38, P2194, DOI 10.1177/0363546510373470; Janssen KW, 2014, AM J SPORT MED, V42, P1534, DOI 10.1177/0363546514529642; King DA, 2009, BRIT J SPORT MED, V43, P595, DOI 10.1136/bjsm.2009.061481; Kluitenberg B, 2016, J SCI MED SPORT, V19, P470, DOI 10.1016/j.jsams.2015.07.003; Kluitenberg B, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-685; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Lee DC, 2014, J AM COLL CARDIOL, V64, P472, DOI 10.1016/j.jacc.2014.04.058; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lopes AD, 2012, SPORTS MED, V42, P891, DOI [10.2165/11631170-000000000-00000, 10.1007/BF03262301]; Nielsen RO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099877; Ottesen L, 2010, SCAND J MED SCI SPOR, V20, P118, DOI 10.1111/j.1600-0838.2010.01123.x; Pluim BM, 2016, SCAND J MED SCI SPOR, V26, P564, DOI 10.1111/sms.12471; Rae K, 2007, CLIN J SPORT MED, V17, P201, DOI 10.1097/JSM.0b013e318059b536; Schmikli SL, 2009, CLIN J SPORT MED, V19, P101, DOI 10.1097/JSM.0b013e31819b9ca3; Stamatakis E, 2008, BRIT J SPORT MED, V42, P901, DOI 10.1136/bjsm.2008.048082; Twisk JWR, 2013, APPLIED LONGITUDINAL DATA ANALYSIS FOR EPIDEMIOLOGY: A PRACTICAL GUIDE, 2ND EDITION, P237; van Dongen JM, 2014, J OCCUP ENVIRON MED, V56, P563, DOI 10.1097/JOM.0000000000000165; van Roijen LH, 2010, COLL ZORGVERZEKERING; vanMechelen W, 1997, SPORTS MED, V24, P176, DOI 10.2165/00007256-199724030-00006; Verhagen EALM, 2005, BRIT J SPORT MED, V39, P111, DOI 10.1136/bjsm.2003.011031; Videbaek S, 2015, SPORTS MED, V45, P1017, DOI 10.1007/s40279-015-0333-8; Scheer BV, 2011, CLIN J SPORT MED, V21, P444, DOI 10.1097/JSM.0b013e318225b0df; World Health Organization ( WHO), 2009, GLOB HLTH RISKS MORT; Yamato TP, 2015, J ORTHOP SPORT PHYS, V45, P366, DOI 10.2519/jospt.2015.5750	44	33	34	2	17	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	FEB	2017	47	2					367	377		10.1007/s40279-016-0551-8			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EJ6LY	WOS:000393332100012	27222128	Green Published, hybrid			2022-02-06	
J	Wang, ZF; Pan, ZY; Xu, CS; Li, ZQ				Wang, Ze-Fen; Pan, Zhi-Yong; Xu, Cheng-Shi; Li, Zhi-Qiang			Activation of G-protein coupled estrogen receptor 1 improves early-onset cognitive impairment via PI3K/Akt pathway in rats with traumatic brain injury	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Traumatic brain injury; GPER; Apoptosis; Tau; Hippocampus	CONTROLLED CORTICAL IMPACT; GLOBAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; BLUNT HEAD-INJURY; HIPPOCAMPUS; MICE; GPR30; NEURODEGENERATION; NEUROPROTECTION; PATHOLOGY	Previous studies experimentally reveal that G-protein coupled estrogen receptor 1(GPER) has neuroprotection against ischemic injury. However, its effect on traumatic brain injury (TBI) is less well established. Cognitive impairment following human TBI is a common clinical observation, and TBI is considered as a risk factor for Alzheimer's disease (AD). This study aimed to observe the possible protective effect of GPER on early-onset cognitive impairment after a single TBI and investigate the cellular mechanism underlying its actions. We found that selective GPER agonist G-1 significantly reduced hippocampal CAl neuronal loss and improved cognitive impairment in TBI rats. Although previous studies have shown that AD-like tau pathology occurs many years after both repetitive and single TBI, accumulation of hyperphosphorylated tau was not observed within days (detected at 24 h and 7d) after TBI. Furthermore, tau phosphorylation was not altered by G-1 treatment. It was found that G-1 administration caused an increase in p-Akt level. However, the neuroprotective effects of G-1 on spatial cognition and neuronal death were attenuated by PI3K/Akt inhibitor LY294002. These findings indicate that GPER agonist G-1 had protection on cognitive function via activation of PI3K/Akt signaling. Early onset cognitive impairment following a single TBI was closely associated with acute hippocampal neuronal loss rather than tau pathology. This study suggests that early activation of GPER might be a promising therapeutic strategy for improvement of TBI-induced cognitive outcomes. (C) 2016 Elsevier Inc. All rights reserved.	[Wang, Ze-Fen; Li, Zhi-Qiang] Wuhan Univ, Sch Med, Cerebral Vasc Dis Ctr, Wuhan, Hubei, Peoples R China; [Pan, Zhi-Yong; Xu, Cheng-Shi; Li, Zhi-Qiang] Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan 430071, Hubei, Peoples R China; [Wang, Ze-Fen] Wuhan Univ, Sch Basic Med Sci, Dept Physiol, Wuhan, Hubei, Peoples R China		Li, ZQ (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan 430071, Hubei, Peoples R China.	lizhigiang@whu.edu.cn			Translational Medical Research Fund of Wuhan University School of Medicine; Innovation Seed Fund of Wuhan University School of Medicine [266078]	This study is supported by Translational Medical Research Fund of Wuhan University School of Medicine and Innovation Seed Fund of Wuhan University School of Medicine (266078). We thank Leyuan Jack Chen from School of Medicine, Texas Tech University Health Sciences Center, for proofreading the manuscript.	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017; Brotfain E, 2016, CURR NEUROPHARMACOL, V14, P641, DOI 10.2174/1570159X14666160309123554; Chakrabarti M, 2016, REV NEUROSCIENCE, V27, P271, DOI 10.1515/revneuro-2015-0032; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Djordjevic J, 2016, CURR ALZHEIMER RES, V13, P730, DOI 10.2174/1567205013666160222110320; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hazell GGJ, 2009, J ENDOCRINOL, V202, P223, DOI 10.1677/JOE-09-0066; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill J.L., 2016, J NEUROCHEM; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jin-qiu Z., 2013, WORLD C ENG 2013 WCE, V3, P3, DOI DOI 10.3892/01.2012.991; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kosaka Y, 2012, TRANSL STROKE RES, V3, P500, DOI 10.1007/s12975-012-0211-8; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; lqbal K., 2009, ACTA NEUROPATHOL, V118, P53; Lu D, 2016, BIOCHEM BIOPH RES CO, V477, P209, DOI 10.1016/j.bbrc.2016.06.044; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Nag S, 2014, NEUROSCIENCE, V267, P122, DOI 10.1016/j.neuroscience.2014.02.040; Otto C, 2009, BIOL REPROD, V80, P34, DOI 10.1095/biolreprod.108.071175; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Su SH, 2016, BEHAV BRAIN RES, V313, P334, DOI 10.1016/j.bbr.2016.07.009; Wei YA, 2012, ONCOL REP, V27, P504, DOI 10.3892/or.2011.1536; Xu CS, 2015, J NEUROCHEM, V134, P566, DOI 10.1111/jnc.13134; Zhao TZ, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.449; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	37	33	34	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	JAN 22	2017	482	4					948	953		10.1016/j.bbrc.2016.11.138			6	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	EK1XB	WOS:000393720000065	27908726				2022-02-06	
J	Abu Hamdeh, S; Marklund, N; Lannsjo, M; Howells, T; Raininko, R; Wikstrom, J; Enblad, P				Abu Hamdeh, Sami; Marklund, Niklas; Lannsjo, Marianne; Howells, Tim; Raininko, Raili; Wikstrom, Johan; Enblad, Per			Extended Anatomical Grading in Diffuse Axonal Injury Using MRI: Hemorrhagic Lesions in the Substantia Nigra and Mesencephalic Tegmentum Indicate Poor Long-Term Outcome	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; head trauma; MRI; susceptibility weighted imaging	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; VEGETATIVE STATE; PROGNOSTIC VALUE; STEM LESIONS; INTRACEREBRAL HEMORRHAGE; WHITE-MATTER; CLASSIFICATION; NEUROPATHOLOGY; EPIDEMIOLOGY	Clinical outcome after traumatic diffuse axonal injury (DAI) is difficult to predict. In this study, three magnetic resonance imaging (MRI) sequences were used to quantify the anatomical distribution of lesions, to grade DAI according to the Adams grading system, and to evaluate the value of lesion localization in combination with clinical prognostic factors to improve outcome prediction. Thirty patients (mean 31.2 years +/- 14.3 standard deviation) with severe DAI (Glasgow Motor Score [GMS] < 6) examined with MRI within 1 week post-injury were included. Diffusion-weighted (DW), T2*-weighted gradient echo and susceptibility-weighted (SWI) sequences were used. Extended Glasgow outcome score was assessed after 6 months. Number of DW lesions in the thalamus, basal ganglia, and internal capsule and number of SWI lesions in the mesencephalon correlated significantly with outcome in univariate analysis. Age, GMS at admission, GMS at discharge, and low proportion of good monitoring time with cerebral perfusion pressure < 60mm Hg correlated significantly with outcome in univariate analysis. Multivariate analysis revealed an independent relation with poor outcome for age (p = 0.005) and lesions in the mesencephalic region corresponding to substantia nigra and tegmentum on SWI (p = 0.008). We conclude that higher age and lesions in substantia nigra and mesencephalic tegmentum indicate poor long-term outcome in DAI. We propose an extended MRI classification system based on four stages (stage I-hemispheric lesions, stage II-corpus callosum lesions, stage III-brainstem lesions, and stage IV-substantia nigra or mesencephalic tegmentum lesions); all are subdivided by age (>=/<= 30 years).	[Abu Hamdeh, Sami; Marklund, Niklas; Howells, Tim; Enblad, Per] Uppsala Univ, Neurosurg, Dept Neurosci, Uppsala, Sweden; [Lannsjo, Marianne] Uppsala Univ, Rehabil Med, Dept Neurosci, Uppsala, Sweden; [Lannsjo, Marianne] Uppsala Univ, Cty Council Gavleborg, Gavle Hosp, Ctr Res & Dev, Gavle, Sweden; [Raininko, Raili; Wikstrom, Johan] Uppsala Univ, Dept Radiol, Uppsala, Sweden		Abu Hamdeh, S (corresponding author), Univ Uppsala Hosp, Neurosurg, Dept Neurosci, S-75185 Uppsala, Sweden.	sami.abu.hamdeh@neuro.uu.se	/ABC-6294-2021	Marklund, Niklas/0000-0002-9797-5626; Wikstrom, Johan/0000-0002-9481-6857			Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1994, RADIOLOGY, V191, P1; Graham DI, 2005, NEUROPSYCHOL REHABIL, V15, P198, DOI 10.1080/09602010443000452; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Howells T. P., 1995, Journal of Neurotrauma, V12, P471; Howells T, 2012, INTENS CARE MED, V38, P1061, DOI 10.1007/s00134-012-2571-7; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Lansberg MG, 2001, AM J NEURORADIOL, V22, P637; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; Moen KG, 2016, J NEUROSCI RES, V94, P623, DOI 10.1002/jnr.23728; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ripoll MA, 2003, ACTA RADIOL, V44, P199, DOI 10.1034/j.1600-0455.2003.00038.x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Skoglund K, 2012, CRIT CARE MED, V40, P216, DOI 10.1097/CCM.0b013e31822d7dbd; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	50	33	35	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					341	352		10.1089/neu.2016.4426			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800009	27356857	Green Submitted, Bronze, Green Published			2022-02-06	
J	Brickell, TA; Lippa, SM; French, LM; Kennedy, JE; Bailie, JM; Lange, RT				Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Kennedy, Jan E.; Bailie, Jason M.; Lange, Rael T.			Female Service Members and Symptom Reporting after Combat and Non-Combat-Related Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						gender; military; TBI	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MENTAL-HEALTH DIAGNOSES; POST-CONCUSSION SYNDROME; OPERATION IRAQI FREEDOM; MILITARY SEXUAL TRAUMA; COMPLAINT BASE RATES; GENDER-DIFFERENCES; AFGHANISTAN VETERANS; HEAD-INJURY	Females are often excluded from military-related mild traumatic brain injury (mTBI) research because of its relatively low prevalence in this population. The purpose of this study was to focus on outcome from mTBI in female service members, compared with males. Participants were 172 United States military service members selected from a larger sample that had sustained an mTBI, and were evaluated within 24 months of injury (Age: mean =28.9, SD=8.1) at one of six military medical centers. Eighty-six women were matched to 86 men on nine key variables: TBI severity, mechanism of injury, bodily injury severity, days post-injury, age, number of deployments, theater where wounded, branch of service, and rank. Participants completed the Neurobehavioral Symptom Inventory (NSI) and the Posttraumatic Stress Disorder Checklist (PCL-C). There were no meaningful gender differences across all demographic and injury-related variables (p > 0.05). There were significant group differences and medium effect sizes for the NSI total score and all four NSI cluster scores. Symptoms most affected related to nausea, sensitivity to light, change in taste/smell, change in appetite, fatigue, and poor sleep. There were significant group differences and small-medium effect sizes for the PCL-C total score and two of the three PCL-C cluster scores. Symptoms most affected related to poor concentration, trouble remembering a stressful event, and disturbing memories/thoughts/images. Females consistently experienced more symptoms than males. As females become more active in combat-related deployments, it is critical that future studies place more emphasis on this important military population.	[Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Kennedy, Jan E.; Bailie, Jason M.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.; Lange, Rael T.] Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Kennedy, Jan E.] San Antonio Mil Med Ctr, San Antonio, TX USA; [Bailie, Jason M.] Naval Hosp Camp Pendleton, San Diego, CA USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada		Lange, RT (corresponding author), Natl Intrepid Ctr Excellence, Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	rael.lange@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Amara J, 2014, WOMEN HEALTH ISS, V24, pE171, DOI 10.1016/j.whi.2013.12.004; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baker DG, 2009, MIL MED, V174, P773; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Burrelli D.F., 2013, WOMEN COMBAT ISSUES; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crum-Cianflone NF, 2014, EPIDEMIOL REV, V36, P5, DOI 10.1093/epirev/mxt005; Department of Defense, 2014, 2013 DEM PROF MIL CO; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Dutra L, 2011, J TRAUMA DISSOCIATIO, V12, P25, DOI 10.1080/15299732.2010.496141; Eisen SV, 2012, AM J PUBLIC HEALTH, V102, pS66, DOI 10.2105/AJPH.2011.300609; Evans CT, 2013, PM&R, V5, P210, DOI 10.1016/j.pmrj.2012.12.004; Farace E, 2000, Neurosurg Focus, V8, pe6; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Fox AB, 2016, PSYCHOL TRAUMA-US, V8, P135, DOI 10.1037/tra0000033; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Haskell SG, 2010, J WOMENS HEALTH, V19, P267, DOI 10.1089/jwh.2008.1262; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2010, RET HOM IR AFGH PREL; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Iverson KM, 2013, J WOMENS HEALTH, V22, P267, DOI 10.1089/jwh.2012.3755; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luxton DD, 2010, DEPRESS ANXIETY, V27, P1027, DOI 10.1002/da.20730; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Maguen S, 2012, J PSYCHIATR RES, V46, P311, DOI 10.1016/j.jpsychires.2011.11.007; Maguen S, 2012, WOMEN HEALTH ISS, V22, pE61, DOI 10.1016/j.whi.2011.07.010; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Mattocks KM, 2012, SOC SCI MED, V74, P537, DOI 10.1016/j.socscimed.2011.10.039; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moon Cronk T., 2016, OFFICIALS DESCRIBE P; Mulrine A., 2013, 8 OTHER NATIONS THAT; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peterson AL, 2011, J CLIN PSYCHOL MED S, V18, P164, DOI 10.1007/s10880-011-9238-3; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Renshaw KD, 2009, ANXIETY STRESS COPIN, V22, P101, DOI 10.1080/10615800802354000; Rona RJ, 2007, INT J EPIDEMIOL, V36, P319, DOI 10.1093/ije/dyl273; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Skopp NA, 2011, J TRAUMA STRESS, V24, P277, DOI 10.1002/jts.20632; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; Street AE, 2013, J GEN INTERN MED, V28, pS556, DOI 10.1007/s11606-013-2333-4; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vogt D, 2011, J ABNORM PSYCHOL, V120, P797, DOI 10.1037/a0023452; Vogt DS, 2005, J TRAUMA STRESS, V18, P271; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Wojcik BE, 2009, MIL MED, V174, P1010, DOI 10.7205/MILMED-D-01-6108; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Zinzow HM, 2007, TRAUMA VIOLENCE ABUS, V8, P384, DOI 10.1177/1524838007307295; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	96	33	33	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					300	312		10.1089/neu.2016.4403			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800005	27368356				2022-02-06	
J	Bishop, S; Dech, R; Baker, T; Butz, M; Aravinthan, K; Neary, JP				Bishop, Scott; Dech, Ryan; Baker, Taylor; Butz, Matthew; Aravinthan, Kaishan; Neary, J. Patrick			Parasympathetic baroreflexes and heart rate variability during acute stage of sport concussion recovery	BRAIN INJURY			English	Article						Concussion; heart rate variability; baroreflexes; autonomic nervous system	TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR PRESSURE REACTIVITY; DYNAMIC CEREBRAL AUTOREGULATION; POTASSIUM CHANNELS; CO2 REACTIVITY; BLOOD-PRESSURE; EXERCISE; FLOW; EPIDEMIOLOGY; NEUROPHYSIOLOGY	Primary objective: To assess and compare the parasympathetic state of individuals in healthy vs concussion groups, by measuring cardiovascular metrics under resting and baroreflex conditions using a squat-stand manoeuvre.Research design: This was a retrospective mixed-method study, with participants who sustained a medically diagnosed sport concussion (n = 12), being tested within 72-hours post-injury.Methods and procedures: Participant's heart rate (Electrocardiogram, ECG) and blood pressure (finger plethysmography) data was collected during rest and during 10-second squat-stands (10SS, 0.05 Hz). Blood pressure and heart rate standard deviation data was analysed in the 0-5 seconds and 6-10 seconds periods of squatting and standing. Resting and baroreflex ECG data were analysed via Fourier Transformations for %Low Frequency and %High Frequency (%LF and %HF).Results: The control group alleviated more pressure and had a significantly higher standard deviation of heart rate during the 6-10 seconds of squatting (p < 0.05). Overall heart rate standard deviation in the concussion group was significantly lower than healthy controls when standing (p < 0.05). There were no differences in %LF and % HF between groups or between rest and 10SS.Conclusion: This study provides preliminary evidence that autonomic function is dysregulated following mTBI within the initial 72 hours of injury.	[Bishop, Scott; Dech, Ryan; Baker, Taylor; Aravinthan, Kaishan; Neary, J. Patrick] Univ Regina, Fac Kinesiol & Hlth Studies, 3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada; [Butz, Matthew] Univ Saskatchewan, Coll Med, Saskatoon, SK, Canada		Neary, JP (corresponding author), Univ Regina, Fac Kinesiol & Hlth Studies, 3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada.	patrick.neary@uregina.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Saskatchewan Health Research Foundation	The authors report no conflicts of interest. Funding was provided by the Canadian Institutes of Health Research (JPN) and the Saskatchewan Health Research Foundation (JPN).	Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bishop S.A., 2015, CURR RES CONCUSSION, V2, P49; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Blake T, 2015, BRIT J SPORT MED, V48, P569; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Chang C, 2013, NEUROIMAGE, V68, P93, DOI 10.1016/j.neuroimage.2012.11.038; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Del Coso J, 2009, EUR J APPL PHYSIOL, V107, P83, DOI 10.1007/s00421-009-1101-y; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; Edwards MR, 2002, MED SCI SPORT EXER, V34, P1207, DOI 10.1097/00005768-200207000-00024; Erlichman JS, 2009, J NEUROPHYSIOL, V102, P1577, DOI 10.1152/jn.00381.2009; Falvo M, 2012, FASEB J, V26, P1091; Faraci FM, 1996, CLIN EXP PHARMACOL P, V23, P1091, DOI 10.1111/j.1440-1681.1996.tb01175.x; Filosa JA, 2007, EXP PHYSIOL, V92, P641, DOI 10.1113/expphysiol.2006.036368; Folino AF, 2007, PROG CARDIOVASC DIS, V50, P49, DOI 10.1016/j.pcad.2007.01.001; Franke WD, 2006, GERONTOLOGY, V52, P282, DOI 10.1159/000094609; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz MB, 2009, BRIT J SPORT MED, V43, P508, DOI 10.1136/bjsm.2008.051748; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Huckstepp RTR, 2011, J PHYSIOL-LONDON, V589, P5561, DOI 10.1113/jphysiol.2011.214759; Jackson WF, 2005, MICROCIRCULATION, V12, P113, DOI 10.1080/10739680590896072; Jha NK, 2015, CURRENT RES CONCUSSI, V3, P2; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Koch A, 2005, CLIN AUTON RES, V15, P83, DOI 10.1007/s10286-005-0249-8; La Fountaine MF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00013; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Marieb E., 2007, HUMAN ANATOMY PHYSL; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1526, DOI 10.1152/ajpheart.00979.2004; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1461, DOI 10.1152/ajpheart.00948.2004; Ogoh S, 2009, J APPL PHYSIOL, V107, P1370, DOI 10.1152/japplphysiol.00573.2009; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ott MM, 2011, J NEUROPHYSIOL, V105, P2960, DOI 10.1152/jn.00262.2010; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; del Paso GAR, 2013, PSYCHOPHYSIOLOGY, V50, P477, DOI 10.1111/psyp.12027; Ryan ML, 2011, J TRAUMA, V70, P1371, DOI 10.1097/TA.0b013e31821858e6; Ryan ML, 2011, ANESTHESIOL RES PRAC, V2011, DOI 10.1155/2011/416590; Schmidt E, 2015, FLUIDS BARRIERS CNS, V12, pO56; Shaffer F, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01040; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smirl JD, 2015, J APPL PHYSIOL, V119, P487, DOI 10.1152/japplphysiol.00264.2015; Spyer KM, 2009, PHILOS T R SOC B, V364, P2603, DOI 10.1098/rstb.2009.0082; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Taylor AG, 2010, EXPLORE-NY, V6, P29, DOI 10.1016/j.explore.2009.10.004; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Tzeng YC, 2010, J APPL PHYSIOL, V108, P1162, DOI 10.1152/japplphysiol.01390.2009; Wells EM, 2016, J CHILD NEUROL, V31, P86, DOI 10.1177/0883073815570152; Willie CK, 2009, APPL ASPECTS ULTRASO, P1; Zweifel C, 2014, MED ENG PHYS, V36, P638, DOI 10.1016/j.medengphy.2014.03.002; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	67	33	33	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	2					247	259		10.1080/02699052.2016.1226385			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EM2RO	WOS:000395163500013	28045562				2022-02-06	
J	Chen, T; Dai, SH; Jiang, ZQ; Luo, P; Jiang, XF; Fei, Z; Gui, SB; Qi, YL				Chen, Tao; Dai, Shu-Hui; Jiang, Zhi-Quan; Luo, Peng; Jiang, Xiao-Fan; Fei, Zhou; Gui, Song-Bai; Qi, Yi-Long			The AMPAR Antagonist Perampanel Attenuates Traumatic Brain Injury Through Anti-Oxidative and Anti-Inflammatory Activity	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						AMPA receptor; Perampanel; TBI; Oxidative stress; Inflammation	GLUTAMATE RECEPTORS; DOUBLE-BLIND; ISCHEMIA; MICE; RAT; INFLAMMATION; EXPRESSION; MODEL; PHOSPHORYLATION; NEUROPROTECTION	Perampanel is a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPAR) antagonist, approved in over 35 countries as an adjunctive therapy for the treatment of seizures. Recently, it was found to exert protective effects against ischemic neuronal injury in vitro. In the present study, we investigated the potential protective effects of perampanel in a traumatic brain injury (TBI) model in rats. Oral administration with perampanel at a dose of 5 mg/kg exerted no major organ-related toxicities. We found that perampanel significantly attenuated TBI-induced brain edema, brain contusion volume, and gross motor dysfunction. The results of Morris water maze test demonstrated that perampanel treatment also improved cognitive function after TBI. These neuroprotective effects were accompanied by reduced neuronal apoptosis, as evidenced by decreased TUNEL-positive cells in brain sections. Moreover, perampanel markedly inhibited lipid peroxidation and obviously preserved the endogenous antioxidant system after TBI. In addition, enzyme-linked immunosorbent assay (ELISA) was performed at 4 and 24 h after TBI to evaluate the expression of inflammatory cytokines. The results showed that perampanel suppressed the expression of pro-inflammatory cytokines TNF-alpha and IL-1 beta, whereas increased the levels of anti-inflammatory cytokines IL-10 and TGF-beta 1. These data show that the orally active AMPAR antagonist perampanel affords protection against TBI-induced neuronal damage and neurological dysfunction through anti-oxidative and anti-inflammatory activity.	[Chen, Tao; Qi, Yi-Long] PLA, Dept Neurosurg, Hosp 123, Bengbu 233010, Anhui, Peoples R China; [Gui, Song-Bai] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Chen, Tao; Dai, Shu-Hui; Luo, Peng; Jiang, Xiao-Fan; Fei, Zhou] Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Xijing Hosp, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China; [Jiang, Zhi-Quan] Bengbu Med Coll, Dept Neurosurg, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China		Qi, YL (corresponding author), PLA, Dept Neurosurg, Hosp 123, Bengbu 233010, Anhui, Peoples R China.; Gui, SB (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China.	guisb_tiantan@126.com; qiyl_PLA123@126.com		Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371447, 81301037]	This work was supported by the National Natural Science Foundation of China (Nos. 81371447 and 81301037).	Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bolton C, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/mi/2006/93684; Calabresi P, 2003, NEUROBIOL DIS, V12, P82, DOI 10.1016/S0969-9961(02)00016-5; Ceolin L, 2012, NEUROCHEM INT, V61, P517, DOI 10.1016/j.neuint.2012.02.035; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chang J, 2015, EXP NEUROL, V273, P225, DOI 10.1016/j.expneurol.2015.08.020; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durand D, 2008, NEUROPHARMACOLOGY, V55, P577, DOI 10.1016/j.neuropharm.2008.06.022; Frenkel D, 2003, J IMMUNOL, V171, P6549, DOI 10.4049/jimmunol.171.12.6549; Grossman SA, 2009, J CLIN ONCOL, V27, P4155, DOI 10.1200/JCO.2008.21.6895; Hanada T, 2011, EPILEPSIA, V52, P1331, DOI 10.1111/j.1528-1167.2011.03109.x; Henley Jeremy M, 1800, Dialogues Clin Neurosci, V15, P11; Hibi S, 2012, J MED CHEM, V55, P10584, DOI 10.1021/jm301268u; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jiang XF, 2013, J SURG RES, V184, pE27, DOI 10.1016/j.jss.2013.03.067; Koeglsperger T, 2013, GLIA, V61, P985, DOI 10.1002/glia.22490; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Pang L, 2001, STROKE, V32, P544, DOI 10.1161/01.STR.32.2.544; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Seeburg PH, 2001, BRAIN RES, V907, P233, DOI 10.1016/S0006-8993(01)02445-3; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; Simma N, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0075-5; Smith S E, 1993, Funct Neurol, V8, P43; Spaethling J, 2012, NEUROBIOL DIS, V46, P646, DOI 10.1016/j.nbd.2012.03.003; Stone TW, 2002, EUR J PHARMACOL, V447, P285, DOI 10.1016/S0014-2999(02)01851-4; Turetsky D, 2005, J NEUROSCI, V25, P7438, DOI 10.1523/JNEUROSCI.1108-05.2005; Walters MR, 2005, CEREBROVASC DIS, V20, P304, DOI 10.1159/000087929; Weiser T, 2005, CNS NEUROL DISORD-DR, V4, P153, DOI 10.2174/1568007053544129; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	33	33	1	10	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2017	37	1					43	52		10.1007/s10571-016-0341-8			10	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	EI3QU	WOS:000392407200006	26883519				2022-02-06	
J	Erdodi, L; Roth, R				Erdodi, Laszlo; Roth, Robert			Low scores on BDAE Complex Ideational Material are associated with invalid performance in adults without aphasia	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Aphasia examination; aphasia screening; Boston Diagnostic Complex Ideational Material; embedded validity indicators; performance validity assessment; receptive language	TRAUMATIC BRAIN-INJURY; PRIMARY PROGRESSIVE APHASIA; LEARNING TEST-II; ALZHEIMERS-DISEASE; DIGIT SPAN; CLASSIFICATION ACCURACY; LANGUAGE IMPAIRMENT; INCOMPLETE EFFORT; EFFORT INDICATORS; RESPONSE BIAS	Complex Ideational Material (CIM) is a sentence comprehension task designed to detect pathognomonic errors in receptive language. Nevertheless, patients with apparently intact language functioning occasionally score in the impaired range. If these instances reflect poor test taking effort, CIM has potential as a performance validity test (PVT). Indeed, in 68 adults medically referred for neuropsychological assessment, CIM was a reliable marker of psychometrically defined invalid responding. A raw score <= 9 or T-score <= 29 achieved acceptable combinations of sensitivity (.34-.40) and specificity (.82-.90) against two reference PVTs, and produced a zero overall false positive rate when scores on all available PVTs were considered. More conservative cutoffs (<= 8/<= 23) with higher specificity (.95-1.00) but lower sensitivity (.14-.17) may be warranted in patients with longstanding, documented neurological deficits. Overall, results indicate that in the absence of overt aphasia, poor performance on CIM is more likely to reflect invalid responding than true language impairment. The implications of the clinical interpretation of CIM are discussed.	[Erdodi, Laszlo] Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Roth, Robert] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA		Erdodi, L (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; BLONDER LX, 1989, BRAIN COGNITION, V9, P244, DOI 10.1016/0278-2626(89)90034-1; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; BOROD J C, 1980, Journal of Clinical Neuropsychology, V2, P209, DOI 10.1080/01688638008403793; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Chapman SB, 1997, APHASIOLOGY, V11, P337, DOI 10.1080/02687039708248475; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P850, DOI 10.1080/13854046.2012.686631; Drummond SS, 2004, BRAIN INJURY, V18, P41, DOI 10.1080/0269905031000149461; Eaton KP, 2008, NEUROIMAGE, V41, P311, DOI 10.1016/j.neuroimage.2008.02.033; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; GERMANI MJ, 1995, APHASIOLOGY, V9, P1, DOI 10.1080/02687039508248685; Giovannetti T, 2008, J INT NEUROPSYCH SOC, V14, P542, DOI 10.1017/S1355617708080715; Goodglass H., 1972, BOSTON DIAGNOSTIC AP; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Heaton R. K., 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Kuljic-Obradovic DC, 2003, EUR J NEUROL, V10, P445, DOI 10.1046/j.1468-1331.2003.00604.x; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Mapstone M, 2003, NEUROPSYCHOLOGIA, V41, P1396, DOI 10.1016/S0028-3932(03)00043-5; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; PAYNEJOHNSON JC, 1986, J COMMUN DISORD, V19, P237, DOI 10.1016/0021-9924(86)90030-4; Pearson, 2009, ADV CLIN SOLUTIONS W; Rogalski E, 2007, COGN BEHAV NEUROL, V20, P38, DOI 10.1097/WNN.0b013e31802e3bae; Rosso C, 2015, NEUROREHAB NEURAL RE, V29, P287, DOI 10.1177/1545968314543926; Saykin A J, 1995, Appl Neuropsychol, V2, P79, DOI 10.1207/s15324826an0202_5; SAYKIN AJ, 1995, EPILEPSIA, V36, P1071, DOI 10.1111/j.1528-1157.1995.tb00464.x; Seniow J, 2009, J NEUROL SCI, V283, P214, DOI 10.1016/j.jns.2009.02.336; Siedlecki KL, 2008, NEUROPSYCHOLOGY, V22, P400, DOI 10.1037/0894-4105.22.3.400; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Tombaugh T.N., 1996, TEST MEMORY MALINGER; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; Vuorinen E, 2000, ALZ DIS ASSOC DIS, V14, P81, DOI 10.1097/00002093-200004000-00005; WALLACE GL, 1991, ARCH PHYS MED REHAB, V72, P674; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wicklund AH, 2004, J CLIN EXP NEUROPSYC, V26, P347, DOI 10.1080/13803390490510077; Wilde MC, 2006, CLIN NEUROPSYCHOL, V20, P702, DOI 10.1080/13854040500246901; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	53	33	33	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2017	24	3					264	274		10.1080/23279095.2016.1154856			11	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	ES5VJ	WOS:000399613800006	27101354				2022-02-06	
J	De Simoni, S; Grover, PJ; Jenkins, PO; Honeyfield, L; Quest, RA; Ross, E; Scott, G; Wilson, MH; Majewska, P; Waldman, AD; Patel, MC; Sharp, DJ				De Simoni, Sara; Grover, Patrick J.; Jenkins, Peter O.; Honeyfield, Lesley; Quest, Rebecca A.; Ross, Ewan; Scott, Gregory; Wilson, Mark H.; Majewska, Paulina; Waldman, Adam D.; Patel, Maneesh C.; Sharp, David J.			Disconnection between the default mode network and medial temporal lobes in post-traumatic amnesia	BRAIN			English	Article						post-traumatic amnesia; traumatic brain injury; functional connectivity; default mode network; memory	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; FUNCTIONAL CONNECTIVITY; ALZHEIMERS-DISEASE; POSTEROMEDIAL CORTEX; POSTERIOR CINGULATE; MEMORY PERFORMANCE; SALIENCE NETWORK; EPISODIC MEMORY; WORKING-MEMORY	Post-traumatic amnesia is very common immediately after traumatic brain injury. It is characterized by a confused, agitated state and a pronounced inability to encode new memories and sustain attention. Clinically, post-traumatic amnesia is an important predictor of functional outcome. However, despite its prevalence and functional importance, the pathophysiology of post-traumatic amnesia is not understood. Memory processing relies on limbic structures such as the hippocampus, parahippocampus and parts of the cingulate cortex. These structures are connected within an intrinsic connectivity network, the default mode network. Interactions within the default mode network can be assessed using resting state functional magnetic resonance imaging, which can be acquired in confused patients unable to perform tasks in the scanner. Here we used this approach to test the hypothesis that the mnemonic symptoms of post-traumatic amnesia are caused by functional disconnection within the default mode network. We assessed whether the hippocampus and parahippocampus showed evidence of transient disconnection from cortical brain regions involved in memory processing. Nineteen patients with traumatic brain injury were classified into post-traumatic amnesia and traumatic brain injury control groups, based on their performance on a paired associates learning task. Cognitive function was also assessed with a detailed neuropsychological test battery. Functional interactions between brain regions were investigated using resting-state functional magnetic resonance imaging. Together with impairments in associative memory, patients in post-traumatic amnesia demonstrated impairments in information processing speed and spatial working memory. Patients in post-traumatic amnesia showed abnormal functional connectivity between the parahippocampal gyrus and posterior cingulate cortex. The strength of this functional connection correlated with both associative memory and information processing speed and normalized when these functions improved. We have previously shown abnormally high posterior cingulate cortex connectivity in the chronic phase after traumatic brain injury, and this abnormality was also observed in patients with post-traumatic amnesia. Patients with post-traumatic amnesia showed evidence of widespread traumatic axonal injury measured using diffusion magnetic resonance imaging. This change was more marked within the cingulum bundle, the tract connecting the parahippocampal gyrus to the posterior cingulate cortex. These findings provide novel insights into the pathophysiology of post-traumatic amnesia and evidence that memory impairment acutely after traumatic brain injury results from altered parahippocampal functional connectivity, perhaps secondary to the effects of axonal injury on white matter tracts connecting limbic structures involved in memory processing.	[De Simoni, Sara; Grover, Patrick J.; Jenkins, Peter O.; Ross, Ewan; Scott, Gregory; Majewska, Paulina; Sharp, David J.] Imperial Coll London, Hammersmith Hosp, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London, England; [Honeyfield, Lesley; Quest, Rebecca A.; Waldman, Adam D.; Patel, Maneesh C.] Charing Cross Hosp, Dept Imaging, London, England; [Wilson, Mark H.] Imperial Coll, St Marys Hosp, Traumat Brain Injury Ctr, London, England		Sharp, DJ (corresponding author), Imperial Coll London, Dept Med, Div Brain Sci, C3NL, Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Lang, Steven/AAE-8102-2021; Sharp, David J/A-2119-2013	Lang, Steven/0000-0003-1669-9146; Wilson, Mark/0000-0002-2346-4911; Quest, Rebecca/0000-0002-0457-8665; Scott, Gregory/0000-0001-8063-5871; Waldman, Adam D/0000-0003-4398-6431	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIHR-RP-011-048]; Guarantors of Brain Clinical Fellowship; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; Medical Research Council through Clinician Scientist Fellowship; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	D.J.S. is funded by a National Institute of Health Research Professorship (NIHR-RP-011-048). P.O.J. is funded by Guarantors of Brain Clinical Fellowship. The research was also supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre and the Medical Research Council through a Clinician Scientist Fellowship awarded to D.J.S.	Ahmed S, 2000, BRAIN INJURY, V14, P765; Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Andrews-Hanna JR, 2014, ANN NY ACAD SCI, V1316, P29, DOI 10.1111/nyas.12360; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Crespo-Garcia M, 2010, NEUROIMAGE, V50, P1258, DOI 10.1016/j.neuroimage.2010.01.018; Daselaar SM, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.013.2009; Duzel E, 2010, CURR OPIN NEUROBIOL, V20, P143, DOI 10.1016/j.conb.2010.01.004; Dunn CJ, 2014, NEUROIMAGE-CLIN, V4, P473, DOI 10.1016/j.nicl.2014.02.010; Eastvold AD, 2013, J HEAD TRAUMA REHAB, V28, P48, DOI 10.1097/HTR.0b013e31823c9317; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Girardeau G, 2011, CURR OPIN NEUROBIOL, V21, P452, DOI 10.1016/j.conb.2011.02.005; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; Hayes SM, 2012, J NEUROSCI, V32, P14622, DOI 10.1523/JNEUROSCI.0700-12.2012; Huijbers W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017463; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Jones DK, 2013, NEUROPSYCHOLOGIA, V51, P67, DOI 10.1016/j.neuropsychologia.2012.11.018; Kim H, 2010, NEUROIMAGE, V49, P1045, DOI 10.1016/j.neuroimage.2009.07.058; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konigs M, 2012, J NEUROL NEUROSUR PS, V83, P1048, DOI 10.1136/jnnp-2012-302635; Leech R, 2011, J NEUROSCI, V31, P3217, DOI 10.1523/JNEUROSCI.5626-10.2011; Logothetis NK, 2012, NATURE, V491, P547, DOI 10.1038/nature11618; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marshman LAG, 2013, J CLIN NEUROSCI, V20, P1475, DOI 10.1016/j.jocn.2012.11.022; Metting Z, 2010, J NEUROTRAUM, V27, P2183, DOI 10.1089/neu.2010.1395; Nyhus E, 2010, NEUROSCI BIOBEHAV R, V34, P1023, DOI 10.1016/j.neubiorev.2009.12.014; Parvizi J, 2006, P NATL ACAD SCI USA, V103, P1563, DOI 10.1073/pnas.0507729103; Poch C, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00036; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ranganath C, 2005, HIPPOCAMPUS, V15, P997, DOI 10.1002/hipo.20141; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Schaie K Warner, 2010, ISSBD Bull, V57, P24; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Swainson R, 2001, DEMENT GERIATR COGN, V12, P265, DOI 10.1159/000051269; Tittle A, 2011, BRAIN INJURY, V25, P933, DOI 10.3109/02699052.2011.597042; van Duinkerken E, 2009, DIABETES, V58, P2335, DOI 10.2337/db09-0425; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wang L, 2010, NEUROIMAGE, V51, P910, DOI 10.1016/j.neuroimage.2010.02.046; Ward AM, 2014, HUM BRAIN MAPP, V35, P1061, DOI 10.1002/hbm.22234; Wise RG, 2006, J MAGN RESON IMAGING, V23, P862, DOI 10.1002/jmri.20584; Zhang Y, 2007, NEUROLOGY, V68, P13, DOI 10.1212/01.wnl.0000250326.77323.01; Zhou YX, 2008, ALZHEIMERS DEMENT, V4, P265, DOI 10.1016/j.jalz.2008.04.006	56	33	33	1	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2016	139		12				3137	3150		10.1093/brain/aww241			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EI7US	WOS:000392709800016	27797805	Green Submitted, Green Published, hybrid			2022-02-06	
J	Wang, JS; Su, BS; Zhu, HB; Chen, C; Zhao, G				Wang, Jiansheng; Su, Baishan; Zhu, Hongbin; Chen, Chao; Zhao, Gang			Protective effect of geraniol inhibits inflammatory response, oxidative stress and apoptosis in traumatic injury of the spinal cord through modulation of NF-kappa B and p38 MAPK	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						geraniol; traumatic injury of the spinal cord; nuclear factor-kappa B; p38 mitogen-activated protein kinase	DNA OXIDATION; BRAIN-INJURY; RECOVERY; RATS; EXPRESSION; PROTEIN; KINASE	Geraniol is a type of monoterpenoid with a rose scent and a slightly sweet flavor. It is found in the volatile oil of various plants, and has anti-inflammatory and anti-oxidant effects. The present study aimed to investigate the protective effect of geraniol in inhibiting the inflammatory response, oxidative stress and apoptosis in traumatic spinal cord injury (SCI), as well as to analyze the mechanism underlying its effect. Adult male Sprague-Dawley rats were induced to traumatic SCI through a surgical procedure and were defined as the SCI model group. SCI or normal rats were then administered 250 mg/kg/day geraniol for 4 weeks. The Basso, Beattie and Bresnahan (BBB) test and the spinal cord water content were used to analyze the effect of geraniol against traumatic SCI in rats. The inflammatory response, oxidative stress, and caspase-9 and-3 activities were measured using commercial ELISA kits. In addition, the associated mechanism was analyzed, using western blot analysis to determine the protein expression levels of nuclear factor (NF)-KB and p38 mitogen-activated protein kinase (MAPK). The results of the present study demonstrated that BBB scores were significantly increased and the spinal cord water content was significantly inhibited in SCI rats after 3 weeks of geraniol treatment. Furthermore, the inflammatory response, oxidative stress, and the caspase-9 and-3 activities were significantly suppressed upon treatment with geraniol. Finally, the mechanism of geraniol against traumatic SCI downregulated the NF-icB and p38 MAPK pathways in SCI rats. Therefore, the protective effect of geraniol is suggested to inhibit the inflammatory response, oxidative stress and apoptosis in traumatic SCI through the modulation of NF-KB and p38 MAPK.	[Wang, Jiansheng; Su, Baishan; Zhu, Hongbin; Chen, Chao; Zhao, Gang] Second Hosp Tangshan, Dept Orthoped, 21 Jianshen North Rd, Tangshan 063000, Hebei, Peoples R China		Zhao, G (corresponding author), Second Hosp Tangshan, Dept Orthoped, 21 Jianshen North Rd, Tangshan 063000, Hebei, Peoples R China.	ts13717517534@163.com					Leite MCA, 2015, MED MYCOL, V53, P275, DOI 10.1093/mmy/myu078; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Chaudhary SC, 2013, J APPL TOXICOL, V33, P828, DOI 10.1002/jat.2739; Emon ST, 2011, TURK NEUROSURG, V21, P197, DOI 10.5137/1019-5149.JTN.3523-10.2; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105944; Hagvall L, 2007, CHEM RES TOXICOL, V20, P807, DOI 10.1021/tx700017v; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Khan AQ, 2013, EXP MOL PATHOL, V94, P419, DOI 10.1016/j.yexmp.2013.01.006; Kim JH, 2012, CELL MOL BIOL, V58, P1780, DOI 10.1170/209; Knechtle B, 2003, EUR J APPL PHYSIOL, V90, P614, DOI 10.1007/s00421-003-0920-5; Kuo CY, 2015, INT J ENV RES PUB HE, V12, P4116, DOI 10.3390/ijerph120404116; Lapczynski A, 2008, FOOD CHEM TOXICOL, V46, pS160, DOI 10.1016/j.fct.2008.06.048; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lin B, 2014, EXP THER MED, V7, P66, DOI 10.3892/etm.2013.1371; Marcuzzi A, 2011, IN VIVO, V25, P87; Merlini V, 2011, NAT PROD COMMUN, V6, P465; Prasad SN, 2014, J NEUROSCI RES, V92, P1205, DOI 10.1002/jnr.23393; PRICE S, 1977, NEUROSCI LETT, V4, P49, DOI 10.1016/0304-3940(77)90123-9; Raha S, 2016, LIFE SCI; Reichenfelser W, 2012, J REHABIL MED, V44, P444, DOI 10.2340/16501977-0979; Rodriguez-Barrera R, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/827517; Su YW, 2010, PLANTA MED, V76, P1666, DOI 10.1055/s-0030-1249947; Tan JW, 2014, INT J CLIN EXP PATHO, V7, P1911; Tederko P, 2013, SPINAL CORD, V51, P802, DOI 10.1038/sc.2013.105; Turbes C C, 1997, Biomed Sci Instrum, V34, P351; Vinothkumar V, 2012, MOL CELL BIOCHEM, V369, P17, DOI 10.1007/s11010-012-1364-1; Vuckovic A, 2014, J PAIN, V15, P645, DOI 10.1016/j.jpain.2014.02.005; Weeks DL, 2011, ARCH PHYS MED REHAB, V92, P683, DOI 10.1016/j.apmr.2010.12.026; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yao AH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/591298; Yarar-Fisher C, 2016, AM J PHYSIOL-ENDOC M, V310, pE754, DOI 10.1152/ajpendo.00240.2015; Zhang XS, 2015, MOL MED REP, V11, P4262, DOI 10.3892/mmr.2015.3330; Zuo DC, 2013, WORLD J GASTROENTERO, V19, P1210, DOI 10.3748/wjg.v19.i8.1210	34	33	35	0	4	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	DEC	2016	12	6	A				3607	3613		10.3892/etm.2016.3850			7	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	EG5IB	WOS:000391076400021	28105094	Green Published, gold			2022-02-06	
J	Adrian, H; Marten, K; Salla, N; Lasse, V				Adrian, Harel; Marten, Kvist; Salla, Nuutinen; Lasse, Valimaa			Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids	ENEURO			English	Article						biomarker; diagnostics; TBI; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; C-TERMINAL HYDROLASE-L1; SERUM S100B LEVELS; CEREBROSPINAL-FLUID; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; CLEAVED-TAU; HEAD-INJURY; SCANDINAVIAN GUIDELINES	Traumatic brain injuries (TBIs) are caused by a hit to the head or a sudden acceleration/ deceleration movement of the head. Mild TBIs (mTBIs) and concussions are difficult to diagnose. Imaging techniques often fail to find alterations in the brain, and computed tomography exposes the patient to radiation. Brain-specific biomolecules that are released upon cellular damage serve as another means of diagnosing TBI and assessing the severity of injury. These biomarkers can be detected from samples of body fluids using laboratory tests. Dozens of TBI biomarkers have been studied, and research related to them is increasing. We reviewed the recent literature and selected 12 biomarkers relevant to rapid and accurate diagnostics of TBI for further evaluation. The objective was especially to get a view of the temporal profiles of the biomarkers' rise and decline after a TBI event. Most biomarkers are rapidly elevated after injury, and they serve as diagnostics tools for some days. Some biomarkers are elevated for months after injury, although the literature on long-term biomarkers is scarce. Clinical utilization of TBI biomarkers is still at a very early phase despite years of active research.	[Adrian, Harel; Marten, Kvist; Salla, Nuutinen; Lasse, Valimaa] Medicortex Finland Oy, Itainen Pitkakatu 4 B, Turku 20520, Finland		Adrian, H (corresponding author), Medicortex Finland Oy, Itainen Pitkakatu 4 B, Turku 20520, Finland.	adrian.harel@medicortex.fi					Stocchero CMA, 2014, APPL PHYSIOL NUTR ME, V39, P340, DOI 10.1139/apnm-2013-0308; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Asadollahi S, 2016, BRAIN INJURY, V30, P172, DOI 10.3109/02699052.2015.1091504; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BOCK E, 1975, SCAND J IMMUNOL, P31; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brandner S, 2013, J NEUROTRAUM, V30, P1205, DOI 10.1089/neu.2012.2621; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buki A, 2000, J NEUROSCI, V20, P2825; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; De Matteis MA, 2000, J CELL SCI, V113, P2331; Delouche A, 2016, EUR J RADIOL, V85, P25, DOI 10.1016/j.ejrad.2015.11.004; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Erickson JA, 2011, CLIN CHIM ACTA, V412, P2122, DOI 10.1016/j.cca.2011.07.020; FASSBENDER K, 1994, J NEUROL SCI, V122, P135, DOI 10.1016/0022-510X(94)90289-5; Faul M, 2010, TRAUMATIC BRAIN INJU; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gebhardt C, 2016, J DTSCH DERMATOL GES, V14, P158, DOI 10.1111/ddg.12727; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Graham MR, 2015, INT J IMMUNOPATH PH, V28, P539, DOI 10.1177/0394632015577045; Hallen M, 2008, CLIN CHEM LAB MED, V46, P1025, DOI 10.1515/CCLM.2008.190; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iliff Jeffrey J, 2012, Sci Transl Med, V4, p147ra111, DOI 10.1126/scitranslmed.3003748; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; KASANTIKUL V, 1989, J SURG ONCOL, V41, P22, DOI 10.1002/jso.2930410109; Kobeissy F. H, 2015, BRAIN NEUROTRAUMA MO; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lee JY, 2015, J KOREAN NEUROSURG S, V58, P93, DOI 10.3340/jkns.2015.58.2.93; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; MICHETTI F, 1980, J NEUROL SCI, V44, P259, DOI 10.1016/0022-510X(80)90133-1; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MOORE IE, 1987, NEUROPATH APPL NEURO, V13, P219, DOI 10.1111/j.1365-2990.1987.tb00185.x; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403; Oliver J, 2015, J EXP NEUROSCI, V9, P67, DOI 10.4137/JEN.S27921; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ottens AK, 2014, J NEUROTRAUM, V31, P782, DOI 10.1089/neu.2013.3116; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Papa L, 2015, ACAD EMERG MED, V22, P1274, DOI 10.1111/acem.12795; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Pearn ML, 2016, CELL MOL NEUROBIOL A, DOI [10.1007/s10571-016-0400-1, DOI 10.1007/S10571-016-0400-1.]; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Raad M, 2014, NEUROSCIENCE, V281, P16, DOI 10.1016/j.neuroscience.2014.08.045; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; RIDER CC, 1975, BIOCHEM BIOPH RES CO, V66, P814, DOI 10.1016/0006-291X(75)90582-3; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shibahashi K, 2016, J NEUROTRAUM, V33, P1826, DOI 10.1089/neu.2015.4237; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Simic G, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010006; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sorci G, 1999, CELL CALCIUM, V25, P93, DOI 10.1054/ceca.1998.0012; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Studer M, 2015, BRAIN INJURY, V29, P1667, DOI 10.3109/02699052.2015.1075250; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Tharp WG, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-290; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; THOMAS D G T, 1978, Lancet, V1, P113; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; TROJANOWSKI JQ, 1986, J NEUROSCI, V6, P650; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Unden L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0533-y; Vajtr D, 2012, Soud Lek, V57, P7; Vivekanandan S, 2011, BIOCHEM BIOPH RES CO, V411, P312, DOI [10.1016/j.bbrc.2011.06.133, 10.13018/BMR17764]; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WITMAN GB, 1976, P NATL ACAD SCI USA, V73, P4070, DOI 10.1073/pnas.73.11.4070; Wolf H, 2016, BRAIN INJURY, V30, P1220, DOI 10.3109/02699052.2016.1170883; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	151	33	33	2	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	NOV-DEC	2016	3	6							0294-16.2016	10.1523/ENEURO.0294-16.2016			13	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	EH7CQ	WOS:000391930900026	28032118	Green Published, gold			2022-02-06	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Cranioplasty: morbidity and failure	BRITISH JOURNAL OF NEUROSURGERY			English	Article						Complications; cranioplasty; decompressive craniectomy; outcome	MIDDLE CEREBRAL-ARTERY; DEATH FOLLOWING CRANIOPLASTY; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; AUTOLOGOUS BONE; RISK-FACTORS; COMPLICATION; HEMICRANIECTOMY; RESORPTION	Objective: Cranioplasty is a technically straightforward procedure; however, it is becoming increasingly apparent that it is associated with relatively high morbidity and a significant failure rate due to either infection or autologous bone flap resorption. The aim of this study was to determine which factors influenced the incidence of cranioplasty complications and failure. Methods: A retrospective analysis was undertaken of all patients who had a cranioplasty at the two major trauma hospitals in Western Australia between the start of 2004 and the middle of 2015. Results: Five hundred and twelve had a cranioplasty after craniectomy for a variety of different indications. Sixty-three patients developed a postoperative intracranial collection following cranioplasty (12.3%, 95% confidence interval [Cl] 9.7-15.4), however only 19 required surgical evacuation. One hundred and twenty-one patients had seizures following cranioplasty (23.6%, 95% Cl 20.2-27.5) Nine patients died within six months following cranioplasty. Forty-two patients (8.2%, 95% Cl 6.1-10.9) developed cranioplasty infection that necessitated removal of the implant. However a change in clinical management of these patients had led to no infections for the past three years. Amongst 330 patients who had autologous cranioplasty, clinically significant bone resorption occurred in 69 patients (20.9%, 95% Cl 16.9-25.6). Conclusion: One key finding in this study is the reduction in infection rate that can occur when a single senior clinician performs the procedure and there is strict adherence to aseptic technique. This may result in a significant reduction in morbidity.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA, Australia; [Ho, Kwok M.] Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA 6150, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.; Honeybul, S (corresponding author), Royal Perth Hosp, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004	WA Health and Raine Medical Research Foundation through the Raine Clinical Research Fellowship	K.M.H. is funded by WA Health and Raine Medical Research Foundation through the Raine Clinical Research Fellowship.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; Day RE, 2012, BRIT J ORAL MAX SURG, V50, P376, DOI 10.1016/j.bjoms.2011.05.001; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2016, J NEUROSURG, V18, P1; Honeybul S, 2016, J NEUROSURG-PEDIATR, V17, P701, DOI 10.3171/2015.11.PEDS15556; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PROLO D.J, 1996, NEUROSURGERY, V2nd, P2783; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Schuss P, 2013, J NEUROTRAUM, V30, P91, DOI 10.1089/neu.2012.2542; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Stieglitz LH, 2015, ACTA NEUROCHIR, V157, P275, DOI 10.1007/s00701-014-2310-7; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sultan SM, 2011, PLAST RECONSTR SURG, V127, P1855, DOI 10.1097/PRS.0b013e31820e89a5; Sviri GE, 2015, J NEUROSURG, V123, P1188, DOI 10.3171/2014.11.JNS141152; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	40	33	34	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2016	30	5					523	528		10.1080/02688697.2016.1187259			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DW7IX	WOS:000383825500005	27215939				2022-02-06	
J	Padayachy, LC; Padayachy, V; Galal, U; Pollock, T; Fieggen, AG				Padayachy, Llewellyn C.; Padayachy, Vaishali; Galal, Ushma; Pollock, Travis; Fieggen, A. Graham			The relationship between transorbital ultrasound measurement of the optic nerve sheath diameter (ONSD) and invasively measured ICP in children.	CHILDS NERVOUS SYSTEM			English	Article						Non-invasive; ICP monitoring; Optic nerve sheath diameter; Ultrasound	RAISED INTRACRANIAL-PRESSURE; TRAUMATIC-BRAIN-INJURY; SONOGRAPHIC EVALUATION; NONINVASIVE METHODS; ULTRASONOGRAPHY	Purpose To analyse the diagnostic accuracy of age-related optic nerve sheath diameter (ONSD) cut-off values in children for detecting raised intracranial pressure (ICP) and to assess the benefit of using patency of the anterior fontanelle in describing a different set of cut-off values. Methods The ONSD measurement was performed prior to invasive ICP measurement in children under general anesthesia. The diagnostic accuracy of the ONSD measurement was compared to ICP at thresholds of 20, 15, 10, and 5 mmHg. This was further analysed in children above and below the age of 1 year, with a subgroup analysis of age at 4 years, and assessment of the anterior fontanelle (AF) as a reliable physiological marker in part II of this study. Results Data from 174 children were analysed. In children <= 1 year old, the ONSD measurement with the best diagnostic accuracy for detecting ICP >= 20 mmHg was 5.16 mm, compared to 5.75 mm in children > 1 year old (p < 0.001). In addition, patency of the anterior fontanelle (AF) was found to be a useful clinical marker for defining different ONSD cutoff values at ICP thresholds of 20, 15, 10 and 5 mmHg. Conclusion Transorbital ultrasound measurement of the ONSD is a reliable non-invasive marker of ICP particularly at higher thresholds of 20 and 15 mmHg. Patency of the AF is a useful clinical marker for defining different ONSD cut-off values in children.	[Padayachy, Llewellyn C.; Fieggen, A. Graham] Univ Cape Town, Red Cross War Mem Childrens Hosp, Fac Hlth Sci, Paediat Neurosurg Unit,Div Neurosurg, Cape Town, South Africa; [Padayachy, Vaishali] Univ Cape Town, Red Cross War Mem Childrens Hosp, Trauma Unit, Cape Town, South Africa; [Galal, Ushma] Univ Cape Town, Dept Stat Sci, Cape Town, South Africa; [Pollock, Travis] Univ Cape Town, Red Cross War Mem Childrens Hosp, Paediat Opthalmol Unit, Cape Town, South Africa		Padayachy, LC (corresponding author), Univ Cape Town, Red Cross War Mem Childrens Hosp, Fac Hlth Sci, Paediat Neurosurg Unit,Div Neurosurg, Cape Town, South Africa.	llewesp@yahoo.com	Fieggen, Anthony Graham/AAT-6510-2021; Padayachy, Llewellyn/AAD-3821-2019	Fieggen, Anthony Graham/0000-0001-6541-8377; 			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Ballantyne J, 1999, CLIN RADIOL, V54, P740, DOI 10.1016/S0009-9260(99)91176-5; Beare NAV, 2008, TROP MED INT HEALTH, V13, P1400, DOI 10.1111/j.1365-3156.2008.02153.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bruce BB, 2014, J NEURO-OPHTHALMOL, V34, P288, DOI 10.1097/WNO.0000000000000153; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Geeraerts T, 2008, CRIT CARE, V12, DOI [10.1186/cc6893, 10.1186/cc7006]; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Hansen HC, 2011, ACTA OPHTHALMOL, V89, pE528, DOI 10.1111/j.1755-3768.2011.02159.x; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Kristiansson H, 2013, J NEUROSURG ANESTH, V25, P372, DOI 10.1097/ANA.0b013e31829795ce; Malayeri AA, 2005, J ULTRAS MED, V24, P143, DOI 10.7863/jum.2005.24.2.143; McAuley D, 2009, CHILD NERV SYST, V25, P87, DOI 10.1007/s00381-008-0713-6; Moretti R, 2011, ACTA ANAESTH SCAND, V55, P644, DOI 10.1111/j.1399-6576.2011.02432.x; Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Padayachy L, 2016, NEUROSURGERY, V79, P100, DOI 10.1227/NEU.0000000000001200; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Rosenberg JB, 2011, NEUROCRIT CARE, V15, P599, DOI 10.1007/s12028-011-9545-4; Steinborn M, 2015, ULTRASCHALL MED, V36, P54, DOI 10.1055/s-0034-1385012; Steinborn M, 2011, ULTRASCHALL MED, V32, P608, DOI 10.1055/s-0029-1245822; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; Wiegand C, 2007, DEV MED CHILD NEUROL, V49, P935, DOI 10.1111/j.1469-8749.2007.00935.x	24	33	35	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	OCT	2016	32	10					1779	1785		10.1007/s00381-016-3068-4			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	DY1UG	WOS:000384879300004	27659820				2022-02-06	
J	Kimbrel, NA; DeBeer, BB; Meyer, EC; Gulliver, SB; Morissette, SB				Kimbrel, Nathan A.; DeBeer, Bryann B.; Meyer, Eric C.; Gulliver, Suzy B.; Morissette, Sandra B.			Nonsuicidal self-injury and suicide attempts in Iraq/Afghanistan war veterans	PSYCHIATRY RESEARCH			English	Article						Nonsuicidal self-injury; Suicide; Suicide attempts; Suicidal ideation; PTSD; Depression; Veterans	POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; ACQUIRED CAPABILITY; WARZONE EXPERIENCES; MILITARY PERSONNEL; ERA VETERANS; RISK-FACTORS; IDEATION; PTSD; COMBAT	The present study examined the association between history of nonsuicidal self-injury (NSSI) and history of suicide attempts (SA) among 292 Iraq/Afghanistan veterans, half of whom carried a lifetime diagnosis of posttraumatic stress disorder (PTSD). Consistent with hypotheses, veterans who reported a history of NSSI were significantly more likely to report a history of SA than veterans without a history of NSSI. In addition, logistic regression demonstrated that NSSI remained a significant predictor of SA even after a wide range of covariates (i.e., combat exposure, traumatic brain injury, PTSD, depression, alcohol dependence) were considered. Taken together, these findings suggest that clinicians working with veterans should include NSSI history as part of their standard risk assessment battery. Published by Elsevier Ireland Ltd.	[Kimbrel, Nathan A.] Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA; [Kimbrel, Nathan A.] VA Midatlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA; [Kimbrel, Nathan A.] Duke Univ, Med Ctr, Durham, NC USA; [DeBeer, Bryann B.; Meyer, Eric C.] VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX USA; [DeBeer, Bryann B.; Meyer, Eric C.] Cent Texas Vet Hlth Care Syst, Temple, DC USA; [DeBeer, Bryann B.; Meyer, Eric C.] Texas A&M Univ, Hlth Sci Ctr, College Stn, TX USA; [Gulliver, Suzy B.] Baylor Scott & White Healthcare Syst, Warriors Res Inst, Waco, DC USA; [Morissette, Sandra B.] Univ Texas San Antonio, San Antonio, TX USA		Kimbrel, NA (corresponding author), Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.	Nathan.Kimbrel@va.gov	Kimbrel, Nathan/P-3109-2016; Gulliver, Suzy/X-9776-2019	Kimbrel, Nathan/0000-0001-7218-1005; Gulliver, Suzy Bird/0000-0002-6476-9447	Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) Office of Research and Development (ORD) [I01RX000304]; VA VISN 17 Center of Excellence for Research on Returning War Veterans; Central Texas Veterans Health Care System; VA Mid-Atlantic Mental Illness Research, Education, and Clinical Center; Research & Development and Mental Health Services of the Durham VA Medical Center; Clinical Science Research and Development Service of the VA ORD [IK2 CX000525]; Veterans AffairsUS Department of Veterans Affairs [I01RX000304, IK2CX000525] Funding Source: NIH RePORTER	This work was supported by a Merit Award (I01RX000304) to Dr. Morissette from the Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) Office of Research and Development (ORD), the VA VISN 17 Center of Excellence for Research on Returning War Veterans, the Central Texas Veterans Health Care System, the VA Mid-Atlantic Mental Illness Research, Education, and Clinical Center, and the Research & Development and Mental Health Services of the Durham VA Medical Center. Dr. Kimbrel was supported by a Career Development Award (IK2 CX000525) from the Clinical Science Research and Development Service of the VA ORD. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.	Asarnow JR, 2011, J AM ACAD CHILD PSY, V50, P772, DOI 10.1016/j.jaac.2011.04.003; Bentley KH, 2015, CLIN PSYCHOL REV, V37, P72, DOI 10.1016/j.cpr.2015.02.006; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blosnich JR, 2012, AM J PUBLIC HEALTH, V102, pS44, DOI 10.2105/AJPH.2011.300565; Briere J, 1998, AM J ORTHOPSYCHIAT, V68, P609, DOI 10.1037/h0080369; Bryan C., 2014, J CLIN PSYCHOL, P1; Bryan CJ, 2015, COMPR PSYCHIAT, V59, P1, DOI 10.1016/j.comppsych.2014.07.009; Bryan CJ, 2013, J CLIN PSYCHOL, V69, P64, DOI 10.1002/jclp.21932; Bryan CJ, 2011, SUICIDE LIFE-THREAT, V41, P126, DOI 10.1111/j.1943-278X.2011.00023.x; Bryan CJ, 2010, J CLIN PSYCHOL, V66, P1044, DOI 10.1002/jclp.20703; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; Chapman AL, 2006, BEHAV RES THER, V44, P371, DOI 10.1016/j.brat.2005.03.005; Crosby AE, 2011, SELF DIRECTED VIOLEN; DeBeer BB, 2014, PSYCHIAT RES, V216, P357, DOI 10.1016/j.psychres.2014.02.010; First MS, 1994, COMMUNICATION; Gerberding JLBS, 2003, REP C MILD TRAUM BRA; Gratz KL, 2014, PSYCHOL MED, V44, P2099, DOI 10.1017/S0033291713002134; Hamza CA, 2012, CLIN PSYCHOL REV, V32, P482, DOI 10.1016/j.cpr.2012.05.003; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kimbrel NA, 2015, PSYCHIAT RES, V227, P360, DOI 10.1016/j.psychres.2015.03.026; Kimbrel NA, 2015, PSYCHIAT RES, V226, P78, DOI 10.1016/j.psychres.2014.12.007; Kimbrel NA, 2014, PSYCHIAT RES, V220, P1118, DOI 10.1016/j.psychres.2014.08.053; Kimbrel NA, 2014, PSYCHIAT RES, V220, P397, DOI 10.1016/j.psychres.2014.07.064; Kimbrel NA, 2014, J TRAUMA STRESS, V27, P474, DOI 10.1002/jts.21932; Klonsky ED, 2011, PSYCHOL MED, V41, P1981, DOI 10.1017/S0033291710002497; Klonsky ED, 2013, J ABNORM PSYCHOL, V122, P231, DOI 10.1037/a0030278; Linehan MM., 1993, COGNITIVE BEHAV TREA; Maguen S, 2012, DEPRESS ANXIETY, V29, P918, DOI 10.1002/da.21954; Miller D., 1994, WOMEN WHO HURT THEMS; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Nock MK, 2006, PSYCHIAT RES, V144, P65, DOI 10.1016/j.psychres.2006.05.010; Nock MK, 2006, J ABNORM PSYCHOL, V115, P616, DOI 10.1037/0021-843X.115.3.616; Pinder RJ, 2012, INT J SOC PSYCHIATR, V58, P433, DOI 10.1177/0020764011408534; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Remafedi G, 1998, AM J PUBLIC HEALTH, V88, P57, DOI 10.2105/AJPH.88.1.57; Sacks MB, 2008, J PSYCHIATR RES, V42, P487, DOI 10.1016/j.jpsychires.2007.05.001; Selby EA, 2010, CLIN PSYCHOL REV, V30, P298, DOI 10.1016/j.cpr.2009.12.004; Silverman MM, 2007, SUICIDE LIFE-THREAT, V37, P248, DOI 10.1521/suli.2007.37.3.248; Suyemoto KL, 1998, CLIN PSYCHOL REV, V18, P531, DOI 10.1016/S0272-7358(97)00105-0; US Department of Veterans Affairs, 2013, SUICIDE DATA REPORT; Vasterling J.J., 2008, COMMUNICATION	45	33	33	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	SEP 30	2016	243						232	237		10.1016/j.psychres.2016.06.039			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	DW7EA	WOS:000383812800038	27419652	Green Accepted, Bronze			2022-02-06	
J	Cashion, AK; Gill, J; Hawes, R; Henderson, WA; Saligan, L				Cashion, Ann K.; Gill, Jessica; Hawes, Rebecca; Henderson, Wendy A.; Saligan, Leorey			National Institutes of Health Symptom Science Model sheds light on patient symptoms	NURSING OUTLOOK			English	Article						Biomarkers; Genotype; Model; Phenotype; Research; Symptom science	TRAUMATIC BRAIN-INJURY; MILITARY PERSONNEL; RADIATION-THERAPY; DIFFERENTIAL EXPRESSION; SLEEP DISTURBANCE; FATIGUE; ASSOCIATION; DEPRESSION; INSOMNIA; GENES	Since the establishment of the nursing profession, identifying and alleviating the subjective symptoms experienced by patients has been at the core of nursing practice. In supporting the scientific foundation for clinical practice, nursing science has maintained a consistent commitment to prevent, manage, and eliminate symptoms. Scientists from the intramural research program at the National Institute of Nursing Research (NINR), a component of the National Institutes of Health, developed a National Institutes of Health Symptom Science Model (NIH-SSM) to guide symptom science research programs engaged in the use of emerging "omic" methods such as the genotyping of symptom phenotypes. The NIH-SSM was developed based on the NINR intramural research program's success in designing and implementing methods for examining identified symptoms or symptom clusters. The NIH-SSM identifies the research process of characterizing symptom phenotypes, identifying and testing biomarkers, and ultimately developing clinical interventions in cancer-related fatigue, gastrointestinal disorders, and traumatic brain injuries. The purpose of this article was to demonstrate how scientists can apply the NIH-SSM, leading the broader scientific community in advancing personalized and precise clinical interventions.	[Cashion, Ann K.; Gill, Jessica; Henderson, Wendy A.; Saligan, Leorey] NINR, Div Intramural Res, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA; [Hawes, Rebecca] NINR, Div Sci Policy & Publ Liaison, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA		Cashion, AK (corresponding author), Natl Inst Nursing, Dept Hlth & Human Serv, 3 Ctr Dr,Rm 5E26, Bethesda, MD 20892 USA.	Ann.cashion@nih.gov	Gill, Gill M/Q-2020-2017; Henderson, Wendy A./F-1171-2018; Saligan, Leorey/M-7101-2015	Henderson, Wendy A./0000-0003-3924-7118; Saligan, Leorey/0000-0001-9481-7836	Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health [s ZIA-NR000018, ZIA-NR000019, ZIA-NR000027, ZIA-NR000030]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000019, ZIANR000018, ZIANR000030, ZIANR000027] Funding Source: NIH RePORTER	Drs. A.K.C., J.G., W.A.H., and L.S. gratefully acknowledge the scientific contributions of the individuals in their labs and members of their research teams. This research was supported by the Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health (Grant #s ZIA-NR000018, ZIA-NR000019, ZIA-NR000027, ZIA-NR000030).	Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889; Alosco M. L., 2015, J HEAD TRAUMA REHABI; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bower JE, 2009, CLIN CANCER RES, V15, P5534, DOI 10.1158/1078-0432.CCR-08-2584; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Cashion AK, 2015, NURS OUTLOOK, V63, P484, DOI 10.1016/j.outlook.2015.03.001; Corwin EJ, 2014, NURS OUTLOOK, V62, P346, DOI 10.1016/j.outlook.2014.06.006; Dodd M, 2001, J ADV NURS, V33, P668, DOI 10.1046/j.1365-2648.2001.01697.x; Drossman D., 2006, ROME 3 FUNCTIONAL GA; FERRER CF, 1995, AVIAT SPACE ENVIR MD, V66, P571; Fourie NH, 2014, EXP MOL PATHOL, V96, P422, DOI 10.1016/j.yexmp.2014.04.009; Gill J, 2014, PSYCHIAT RES, V216, P116, DOI 10.1016/j.psychres.2014.01.046; Gill JM, 2015, BIOL RES NURS, V17, P384, DOI 10.1177/1099800415575343; Goodan M., 2004, CANC SYMPTOM MANAGEM, P3; Grundmann O, 2010, J GASTROEN HEPATOL, V25, P691, DOI 10.1111/j.1440-1746.2009.06120.x; Guardado P, 2016, J ANXIETY DISORD, V38, P9, DOI 10.1016/j.janxdis.2015.12.004; Heinzelmann M, 2014, SLEEP MED, V15, P1565, DOI 10.1016/j.sleep.2014.08.004; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Henderson W. A., 2015, GASTROENTEROLOGY NUR; Henderson WA, 2012, TRANSL BEHAV MED, V2, P1, DOI 10.1007/s13142-012-0116-9; Henderson Wendy A, 2012, World J Gastrointest Pathophysiol, V3, P102, DOI 10.4291/wjgp.v3.i6.102; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hsiao CP, 2013, INT J MOL SCI, V14, P16943, DOI 10.3390/ijms140816943; Hsiao CP, 2013, CANCER NURS, V36, P189, DOI 10.1097/NCC.0b013e318263f514; Kurz K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036956; Livingston WS, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00059; Lukkahatai N, 2014, J PAIN SYMPTOM MANAG, V47, P748, DOI 10.1016/j.jpainsymman.2013.05.016; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Miller NL, 2010, SLEEP, V33, P1623, DOI 10.1093/sleep/33.12.1623; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Patel KV, 2015, ANN PHARMACOTHER, V49, P477, DOI 10.1177/1060028015570467; Pertl MM, 2014, J HEALTH PSYCHOL, V19, P699, DOI 10.1177/1359105313477675; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Ryan JL, 2007, ONCOLOGIST, V12, P22, DOI 10.1634/theoncologist.12-S1-22; Saligan LN, 2013, BRAIN BEHAV IMMUN, V27, P63, DOI 10.1016/j.bbi.2012.09.009; Saligan LN, 2012, BRAIN BEHAV IMMUN, V26, P830, DOI 10.1016/j.bbi.2012.05.004; Saligan L. N., 2015, WORLD J BIOL PSYCHIA, V27, P1; Saligan LN, 2014, CANCER INFORM, V13, P141, DOI 10.4137/CIN.S19745; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Seugnet L, 2009, J NEUROSCI, V29, P7148, DOI 10.1523/JNEUROSCI.5629-08.2009; U. S. Army Medical Command, 2011, JOINT MENT HLTH ADV; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845; Xiao CH, 2010, EUR J ONCOL NURS, V14, P417, DOI 10.1016/j.ejon.2010.05.011; Yellen SB, 1997, J PAIN SYMPTOM MANAG, V13, P63, DOI 10.1016/S0885-3924(96)00274-6; Yost KJ, 2011, J CLIN EPIDEMIOL, V64, P507, DOI 10.1016/j.jclinepi.2010.11.018	45	33	33	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0029-6554	1528-3968		NURS OUTLOOK	Nurs. Outlook	SEP-OCT	2016	64	5			SI		499	506		10.1016/j.outlook.2016.05.008			8	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	DW6CE	WOS:000383733200013	27349632	Green Accepted			2022-02-06	
J	Phang, I; Zoumprouli, A; Saadoun, S; Papadopoulos, MC				Phang, Isaac; Zoumprouli, Argyro; Saadoun, Samira; Papadopoulos, Marios C.			Safety profile and probe placement accuracy of intraspinal pressure monitoring for traumatic spinal cord injury: Injured Spinal Cord Pressure Evaluation study	JOURNAL OF NEUROSURGERY-SPINE			English	Article						critical care; monitoring; paralysis; perfusion pressure; spinal cord injury; trauma	PERFUSION-PRESSURE; MANAGEMENT; DEVICE; INDEX	OBJECTIVE A novel technique for monitoring intraspinal pressure and spinal cord perfusion pressure in patients with traumatic spinal cord injury was recently described. This is analogous to monitoring intracranial pressure and cerebral perfusion pressure in patients with traumatic brain injury. Because intraspinal pressure monitoring is a new technique, its safety profile and impact on early patient care and long-term outcome after traumatic spinal cord injury are unknown. The object of this study is to review all patients who had intraspinal pressure monitoring to date at the authors' institution in order to define the accuracy of intraspinal pressure probe placement and the safety of the technique. METHODS At the end of surgery to fix spinal fractures, a pressure probe was inserted intradurally to monitor intraspinal pressure at the injury site. Postoperatively, CT scanning was performed within 48 hours and MRI at 2 weeks and 6 months. Neurointensive care management and complications were reviewed. The American Spinal Injury Association Impairment Scale (AIS) grade was determined on admission and at 2 to 4 weeks and 12 to 18 months postoperation. RESULTS To date, 42 patients with severe traumatic spinal cord injuries (AIS Grades A-C) had undergone intraspinal pressure monitoring. Monitoring started within 72 hours of injury and continued for up to a week. Based on postoperative CT and MRI, the probe position was acceptable in all patients, i.e., the probe was located at the site of maximum spinal cord swelling. Complications were probe displacement in 1 of 42 patients (2.4%), CSF leakage that required wound resuturing in 3 of 42 patients (7.1%), and asymptomatic pseudomeningocele that was diagnosed in 8 of 42 patients (19.0%). Pseudomeningocele was diagnosed on MRI and resolved within 6 months in all patients. Based on the MRI and neurological examination results, there were no serious probe-related complications such as meningitis, wound infection, hematoma, wound breakdown, or neurological deterioration. Within 2 weeks postoperatively, 75% of patients were extubated and 25% underwent tracheostomy. Norepinephrine was used to support blood pressure without complications. Overall, the mean intraspinal pressure was around 20 mm Hg, and the mean spinal cord perfusion pressure was around 70 mm Hg. In laminectomized patients, the intraspinal pressure was significantly higher in the supine than lateral position by up to 18 mm Hg after thoracic laminectomy and 8 mm Hg after cervical laminectomy. At 12 to 18 months, 11.4% of patients had improved by 1 AIS grade and 14.3% by at least 2 AIS grades. CONCLUSIONS These data suggest that after traumatic spinal cord injury intradural placement of the pressure probe is accurate and intraspinal pressure monitoring is safe for up to a week. In patients with spinal cord injury who had laminectomy, the supine position should be avoided in order to prevent rises in intraspinal pressure.	[Phang, Isaac; Saadoun, Samira; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, London, England; [Zoumprouli, Argyro] St George Hosp, Neurointens Care Unit, London, England		Papadopoulos, MC (corresponding author), St George Hosp, Dept Neurosurg, Atkinson Morley Wing, London SW17 0QT, England.	mpapadop@sgul.ac.uk		Zoumprouli, Argyro/0000-0003-0890-690X; Papadopoulos, Marios/0000-0001-9174-4176; Saadoun, Samira/0000-0002-5480-5678	Wings for Life Spinal Cord Research Foundation; Fletcher Fund/Neurosciences Research Foundation; London Deanery	We thank the neurosurgeons at St. George's Hospital, King's College Hospital, and Hurstwood Park Neurological Centre for help with patient recruitment. We also thank the neuroanesthesia, operating room, and NICU staff at St. George's Hospital for help with data collection. This study was supported by Wings for Life Spinal Cord Research Foundation (M.C.P. and S.S.), Fletcher Fund/Neurosciences Research Foundation (M.C.P.), and London Deanery (I.P.).	Ackerman P, 2010, SPINAL CORD, V48, P380, DOI 10.1038/sc.2009.140; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Bekar A, 2009, J CLIN NEUROSCI, V16, P236, DOI 10.1016/j.jocn.2008.02.008; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Call MS, 2011, J TRAUMA, V71, P1673, DOI 10.1097/TA.0b013e31821e87c2; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Como JJ, 2005, J TRAUMA, V59, P912, DOI 10.1097/01.ta.0000187660.03742.a6; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Czosnyka Marek, 1800, Neurosurg Focus, V22, pE10; Ditunno JF, 2000, SPINAL CORD, V38, P234, DOI 10.1038/sj.sc.3100993; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; Hunter JD, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3325; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Koskinen LOD, 2013, ACTA NEUROCHIR, V155, P2141, DOI 10.1007/s00701-013-1856-0; Krogh K, 2006, SPINAL CORD, V44, P625, DOI 10.1038/sj.sc.3101887; Papadopoulos MC, 2015, NEUROSURGERY, V77, pE500, DOI 10.1227/NEU.0000000000000862; Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6; Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Varsos GV, 2015, J NEUROSURG-SPINE, V23, P763, DOI 10.3171/2015.3.SPINE14870; Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	27	33	34	1	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	SEP	2016	25	3					398	405		10.3171/2016.1.SPINE151317			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DT8YR	WOS:000381782200016	27129044	Bronze, Green Accepted			2022-02-06	
J	Riesberg, LA; Weed, SA; McDonald, TL; Eckerson, JM; Drescher, KM				Riesberg, Lisa A.; Weed, Stephanie A.; McDonald, Thomas L.; Eckerson, Joan M.; Drescher, Kristen M.			Beyond muscles: The untapped potential of creatine	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Creatine; Immune response; Immunomodulation; Neuroprotection	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; INTERLEUKIN-1-BETA CONVERTING-ENZYME; ALLERGIC LUNG INFLAMMATION; TRANSGENIC ANIMAL-MODEL; CYTOCHROME-C RELEASE; NEURONAL CELL-DEATH; L-DOPA TREATMENT; NF-KAPPA-B; HUNTINGTONS-DISEASE	Creatine is widely used by both elite and recreational athletes as an ergogenic aid to enhance anaerobic exercise performance. Older individuals also use creatine to prevent sarcopenia and, accordingly, may have therapeutic benefits for muscle wasting diseases. Although the effect of creatine on the musculoskeletal system has been extensively studied, less attention has been paid to its potential effects on other physiological systems. Because there is a significant pool of creatine in the brain, the utility of creatine supplementation has been examined in vitro as well as in vivo in both animal models of neurological disorders and in humans. While the data are preliminary, there is evidence to suggest that individuals with certain neurological conditions may benefit from exogenous creatine supplementation if treatment protocols can be optimized. A small number of studies that have examined the impact of creatine on the immune system have shown an alteration in soluble mediator production and the expression of molecules involved in recognizing infections, specifically toll-like receptors. Future investigations evaluating the total impact of creatine supplementation are required to better understand the benefits and risks of creatine use, particularly since there is increasing evidence that creatine may have a regulatory impact on the immune system. (C) 2016 Elsevier B.V. All rights reserved.	[Riesberg, Lisa A.; Weed, Stephanie A.; Drescher, Kristen M.] Creighton Univ, Dept Med Microbiol & Immunol, 2500 Calif Plaza, Omaha, NE 68178 USA; [McDonald, Thomas L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, 986495 Nebraska Med Ctr, Omaha, NE 68198 USA; [Eckerson, Joan M.] Creighton Univ, Dept Exercise Sci & Prehlth Profess, 2500 Calif Plaza, Omaha, NE 68178 USA		Drescher, KM (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, 2500 Calif Plaza,Criss 2,Room 424, Omaha, NE 68178 USA.	kristendrescher@creighton.edu			National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 C06 RR17417-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR017417] Funding Source: NIH RePORTER	This work was performed in a facility supported by Grant Number 1 C06 RR17417-01 from the National Center for Research Resources (KMD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Alam Q., 2015, CURR PHARM DESIGN; Andersson M, 1999, NEUROBIOL DIS, V6, P461, DOI 10.1006/nbdi.1999.0259; Andreassen OA, 2001, NEUROBIOL DIS, V8, P479, DOI 10.1006/nbdi.2001.0406; Andreassen OA, 2001, J NEUROCHEM, V77, P383, DOI 10.1046/j.1471-4159.2001.00188.x; Andres RH, 2005, CELL TRANSPLANT, V14, P537, DOI 10.3727/000000005783982756; Andres RH, 2005, NEUROSCIENCE, V133, P701, DOI 10.1016/j.neuroscience.2005.03.004; Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; [Anonymous], 1996, J STRENGTH COND RES; ARBORELIUS M, 1984, EUR J RESPIR DIS, V65, P25; avada B.S., 2015, INFLAMM RES; Azeredo R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139967; BALSOM PD, 1994, SPORTS MED, V18, P268, DOI 10.2165/00007256-199418040-00005; Bamberger M., 1998, SPORTS ILLUSTRATED, V88, P58; Bassit RA, 2008, AMINO ACIDS, V35, P425, DOI 10.1007/s00726-007-0582-4; Beal MF, 2011, AMINO ACIDS, V40, P1305, DOI 10.1007/s00726-011-0851-0; Bemben MG, 2010, J NUTR HEALTH AGING, V14, P155, DOI 10.1007/s12603-009-0124-8; Bemben MG, 2005, SPORTS MED, V35, P107, DOI 10.2165/00007256-200535020-00002; Bender A, 2006, NEUROLOGY, V67, P1262, DOI 10.1212/01.wnl.0000238518.34389.12; Bender A, 2005, J NEUROL, V252, P36, DOI 10.1007/s00415-005-0595-4; Bender A, 2008, NUTR RES, V28, P172, DOI 10.1016/j.nutres.2008.01.001; Beraud D., 2012, PARKINSONISM RELAT D, V18S1, pS17; Berjaoui S, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/573784; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Bian MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039953; Borthakur A, 2012, BBA-MOL BASIS DIS, V1822, P1300, DOI 10.1016/j.bbadis.2012.05.001; Bosco C, 1997, INT J SPORTS MED, V18, P369, DOI 10.1055/s-2007-972648; Braissant O, 2001, MOL BRAIN RES, V86, P193, DOI 10.1016/S0169-328X(00)00269-2; Brasier AR, 2006, CARDIOVASC TOXICOL, V6, P111, DOI 10.1385/CT:6:2:111; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Buki A, 2000, J NEUROSCI, V20, P2825; Burke DG, 2008, INT J SPORT NUTR EXE, V18, P389, DOI 10.1123/ijsnem.18.4.389; Burns RD, 2004, J AM DIET ASSOC, V104, P246, DOI 10.1016/j.jada.2003.11.013; Calfee R, 2006, PEDIATRICS, V117, pE577, DOI 10.1542/peds.2005-1429; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cenci MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00242; Choudhary M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474616; Chu WM, 2013, CANCER LETT, V328, P222, DOI 10.1016/j.canlet.2012.10.014; Chung YC, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370526; Dawson B, 1995, Aust J Sci Med Sport, V27, P56; Dean ED, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039227; Dedeoglu A, 2003, J NEUROCHEM, V85, P1359, DOI 10.1046/j.1471-4159.2003.01706.x; Degraaf AJ, 2014, AM J RESP CELL MOL, V51, P242, DOI 10.1165/rcmb.2013-0495OC; DELANGHE J, 1989, CLIN CHEM, V35, P1802; Demant TW, 1999, SPORTS MED, V28, P49, DOI 10.2165/00007256-199928010-00005; DHAWAN BN, 1973, BRIT J PHARMACOL, V49, P64, DOI 10.1111/j.1476-5381.1973.tb08268.x; Dolder M, 2003, J BIOL CHEM, V278, P17760, DOI 10.1074/jbc.M208705200; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Eddouks M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/142087; Elm JJ, 2012, MOVEMENT DISORD, V27, P1513, DOI 10.1002/mds.25175; Fanelli A, 2007, MED SCI SPORT EXER, V39, P1474, DOI 10.1249/mss.0b013e3180d099ad; Ferger B, 1999, J NEUROCHEM, V73, P1329, DOI 10.1046/j.1471-4159.1999.0731329.x; Ferrante Robert J., 2000, Journal of Neuroscience, V20, P4389; Ferreira SC, 2010, INT J SPORTS MED, V31, P906, DOI 10.1055/s-0030-1267160; Field ML, 1996, CARDIOVASC RES, V31, P174, DOI 10.1016/0008-6363(95)00225-1; Fifel K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086240; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GAI WP, 1994, J NEUROL NEUROSUR PS, V57, P1039, DOI 10.1136/jnnp.57.9.1039; Garcia-Delgado M, 2001, J AM SOC NEPHROL, V12, P1819, DOI 10.1681/ASN.V1291819; Gastin PB, 2001, SPORTS MED, V31, P725, DOI 10.2165/00007256-200131100-00003; Gerecke KM, 2010, BRAIN RES, V1341, P72, DOI 10.1016/j.brainres.2010.01.053; Gerlach M, 2011, J NEURAL TRANSM, V118, P1659, DOI 10.1007/s00702-011-0728-0; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Goodall Emily F., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010854; GREENE JG, 1993, J NEUROCHEM, V61, P1151, DOI 10.1111/j.1471-4159.1993.tb03634.x; Greenhaff PL, 1997, J NUTR BIOCHEM, V8, P610, DOI 10.1016/S0955-2863(97)00116-2; Grindstaff PD, 1997, INT J SPORT NUTR, V7, P330, DOI 10.1123/ijsn.7.4.330; Groeneveld GJ, 2003, ANN NEUROL, V53, P437, DOI 10.1002/ana.10554; Guan J, 2000, BRAIN RES, V859, P286, DOI 10.1016/S0006-8993(00)01988-0; Guay J, 2004, J BIOL CHEM, V279, P24866, DOI 10.1074/jbc.M403106200; Gufford Brandon T., 2013, Journal of Dietary Supplements, V10, P241, DOI 10.3109/19390211.2013.822453; Gufford Brandon T., 2010, Journal of Dietary Supplements, V7, P240, DOI 10.3109/19390211.2010.491507; Guidi C, 2008, BBA-GEN SUBJECTS, V1780, P16, DOI 10.1016/j.bbagen.2007.09.018; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; HARRIS RC, 1992, CLIN SCI, V83, P367, DOI 10.1042/cs0830367; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; HENRIKSEN JM, 1983, ACTA PAEDIATR SCAND, V72, P31, DOI 10.1111/j.1651-2227.1983.tb09659.x; Hersch S. M., 1997, MOVEMENT DISORDERS N, P503; Hultman E, 1996, J APPL PHYSIOL, V81, P232; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Ikonomidou C, 1996, CRIT REV NEUROBIOL, V10, P239; Jing X., 2015, NEUROCHEM RES; Juhn MS, 1998, CLIN J SPORT MED, V8, P298, DOI 10.1097/00042752-199810000-00007; Kadoguchi N, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-79; Kaithwas Gaurav, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P185, DOI 10.1016/S2221-1691(12)60039-2; Kaithwas Gaurav, 2010, Inflammopharmacology, V18, P127, DOI 10.1007/s10787-010-0033-9; Karimian J, 2011, J RES MED SCI, V16, P1347; Khalaf H, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-26; Khanna N.K., 1976, INDIAN J PHARM, V8, P227; KHANNA NK, 1978, ARCH INT PHARMACOD T, V231, P340; Kieburtz K, 2008, CLIN NEUROPHARMACOL, V31, P141, DOI 10.1097/WNF.0b013e3181342f32; Kieburtz K, 2015, JAMA-J AM MED ASSOC, V313, P584, DOI 10.1001/jama.2015.120; Kim SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027566; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Klivenyi P, 2003, J MOL NEUROSCI, V21, P191, DOI 10.1385/JMN:21:3:191; Kochanek Kenneth D, 2014, NCHS Data Brief, P1; Koenig KA, 2014, BRAIN CONNECT, V4, P535, DOI 10.1089/brain.2014.0271; Kowal SL, 2013, MOVEMENT DISORD, V28, P311, DOI 10.1002/mds.25292; Kreider R., 1998, J EXERC PHYSL ONLINE, V1, P7; Kreider RB, 2003, MOL CELL BIOCHEM, V244, P89, DOI 10.1023/A:1022465203458; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164; Le Floc'h N, 2004, LIVEST PROD SCI, V87, P37, DOI 10.1016/j.livprodsci.2003.09.005; LEES P, 1985, EQUINE VET J, V17, P83, DOI 10.1111/j.2042-3306.1985.tb02056.x; Lefavi R. G., 1998, J STRENGTH COND RES, V12, P275; Leland KM, 2011, INT IMMUNOPHARMACOL, V11, P1341, DOI 10.1016/j.intimp.2011.04.018; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LI TM, 1988, J NEUROL NEUROSUR PS, V51, P778, DOI 10.1136/jnnp.51.6.778; Lyck R, 2015, CURR OPIN HEMATOL, V22, P53, DOI 10.1097/MOH.0000000000000103; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Macedo S B, 2004, Homeopathy, V93, P84, DOI 10.1016/j.homp.2004.02.006; MACKAY RJ, 1983, AM J VET RES, V44, P774; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; MADAN B R, 1979, Indian Journal of Physiology and Pharmacology, V23, P1; Mandrioli J, 2003, NEUROLOGY, V60, P683, DOI 10.1212/01.WNL.0000048208.54755.78; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin LJ, 2014, NEUROBIOL AGING, V35, P1132, DOI 10.1016/j.neurobiolaging.2013.11.008; Martin LJ, 2011, J BIOENERG BIOMEMBR, V43, P569, DOI 10.1007/s10863-011-9395-y; Martin LJ, 2009, EXP NEUROL, V218, P333, DOI 10.1016/j.expneurol.2009.02.015; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mason M A, 2001, Iowa Orthop J, V21, P43; Matsui JT, 2015, HUM BRAIN MAPP, V36, P3717, DOI 10.1002/hbm.22835; Matsumoto I, 1999, THORAX, V54, P196, DOI 10.1136/thx.54.3.196; Matthews RT, 1998, J NEUROSCI, V18, P156; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; McCormack AL, 2008, J NEUROPATH EXP NEUR, V67, P793, DOI 10.1097/NEN.0b013e318180f0bd; McGuine TA, 2001, CLIN J SPORT MED, V11, P247, DOI 10.1097/00042752-200110000-00007; McGuine Timothy A, 2002, WMJ, V101, P25; McNair ND, 1999, NURS CLIN N AM, V34, P637; Metzl JD, 2001, PEDIATRICS, V108, P421, DOI 10.1542/peds.108.2.421; Mihic S, 2000, MED SCI SPORT EXER, V32, P291, DOI 10.1097/00005768-200002000-00007; MING L, 1995, J TOXICOL-CLIN TOXIC, V33, P363, DOI 10.3109/15563659509028924; Moldoveanu AI, 2001, SPORTS MED, V31, P115, DOI 10.2165/00007256-200131020-00004; Montal M, 1998, BBA-BIOENERGETICS, V1366, P113, DOI 10.1016/S0005-2728(98)00124-8; Mosley RL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009381; MOUATTPRIGENT A, 1994, BRAIN RES, V668, P62, DOI 10.1016/0006-8993(94)90511-8; Nasrallah F, 2010, PEDIATR NEUROL, V42, P163, DOI 10.1016/j.pediatrneurol.2009.07.015; Necas J, 2013, VET MED-CZECH, V58, P187, DOI 10.17221/6758-VETMED; Neves M, 2011, APPL PHYSIOL NUTR ME, V36, P419, DOI [10.1139/H11-014, 10.1139/h11-014]; NICKERSON BG, 1983, PEDIATRICS, V71, P147; Nomura A, 2003, BRIT J PHARMACOL, V139, P715, DOI 10.1038/sj.bjp.0705316; Nony PA, 1999, METAB BRAIN DIS, V14, P83, DOI 10.1023/A:1020753629477; Orsenigo MN, 2005, J MEMBRANE BIOL, V207, P183, DOI 10.1007/s00232-005-0813-0; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; Parashos SA, 2014, JAMA NEUROL, V71, P710, DOI 10.1001/jamaneurol.2014.391; Pavelko KD, 2003, J NEUROSCI, V23, P481, DOI 10.1523/JNEUROSCI.23-02-00481.2003; Pearlman JP, 2006, NUTR REV, V64, P80, DOI [10.1301/nmr.2006.feb.80-88, 10.1111/j.1753-4887.2006.tb00191.x]; Pedersen BK, 2000, BRIT J SPORT MED, V34, P246, DOI 10.1136/bjsm.34.4.246; Cunha MP, 2014, ASN NEURO, V6, DOI 10.1177/1759091414554945; Peral MJ, 2002, J PHYSIOL-LONDON, V545, P133, DOI 10.1113/jphysiol.2002.026377; Poortmans JR, 2000, SPORTS MED, V30, P155, DOI 10.2165/00007256-200030030-00002; Przedborski Serge, 2003, Curr Neurol Neurosci Rep, V3, P70, DOI 10.1007/s11910-003-0041-x; Quintanilla RA, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-45; Ram F S F, 2005, Cochrane Database Syst Rev, pCD001116; Ravina B, 2006, NEUROLOGY, V66, P664; Rawson ES, 2011, AMINO ACIDS, V40, P1349, DOI 10.1007/s00726-011-0855-9; Razonable RR, 2005, ANTIMICROB AGENTS CH, V49, P3546, DOI 10.1128/AAC.49.8.3546-3549.2005; ROSA MD, 1971, J PHARM PHARMACOL, V23, P297, DOI 10.1111/j.2042-7158.1971.tb08661.x; Rosas HD, 2014, NEUROLOGY, V82, P850, DOI 10.1212/WNL.0000000000000187; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosenfeld J, 2008, AMYOTROPH LATERAL SC, V9, P266, DOI 10.1080/17482960802028890; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Rub U, 2002, J NEUROL S3, V249, DOI DOI 10.1007/S00415-002-1301-4; Ryu H, 2005, PHARMACOL THERAPEUT, V108, P193, DOI 10.1016/j.pharmthera.2005.04.008; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Sakellaris G, 2008, ACTA PAEDIATR, V97, P31, DOI 10.1111/j.1651-2227.2007.00529.x; SAKS VA, 1991, AM J PHYSIOL, V261, P30, DOI 10.1152/ajplung.1991.261.4.L30; Salama M, 2012, CNS NEUROL DISORD-DR, V11, P836, DOI 10.2174/1871527311201070836; Santos RVT, 2004, LIFE SCI, V75, P1917, DOI 10.1016/j.lfs.2003.11.036; SCHIATTI P, 1970, Bollettino Chimico Farmaceutico, V109, P33; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schulze A, 2003, MOL CELL BIOCHEM, V244, P143, DOI 10.1023/A:1022443503883; Sestili P, 2006, FREE RADICAL BIO MED, V40, P837, DOI 10.1016/j.freeradbiomed.2005.10.035; Sestito S. E., 2015, PHARMACOL RES S, VS1043-6618, P30004; Sgambato-Faure V, 2005, J NEUROPATH EXP NEUR, V64, P936, DOI 10.1097/01.jnen.0000186922.42592.b7; Shefner JM, 2004, NEUROLOGY, V63, P1656, DOI 10.1212/01.WNL.0000142992.81995.F0; Shomrat A, 2000, EUR J APPL PHYSIOL, V82, P321, DOI 10.1007/s004210000222; Siddique T, 1996, CLIN NEUROSCI, V3, P338; Silva LA, 2013, J SPORT SCI, V31, P1164, DOI 10.1080/02640414.2013.773403; Simon DK, 2015, CLIN NEUROPHARMACOL, V38, P163, DOI 10.1097/WNF.0000000000000102; Smith J, 2000, MAYO CLIN PROC, V75, P1257, DOI 10.4065/75.12.1257; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Snow RJ, 2001, MOL CELL BIOCHEM, V224, P169, DOI 10.1023/A:1011908606819; Speer O, 2004, MOL CELL BIOCHEM, V256, P407, DOI 10.1023/B:MCBI.0000009886.98508.e7; Stackler-Ipsiroglu S., 2012, INBORN METABOLIC DIS, P240; Stavrovskaya IG, 2005, FREE RADICAL BIO MED, V38, P687, DOI 10.1016/j.freeradbiomed.2004.11.032; Stefanis L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009399; Stefanova N, 2004, NEUROBIOL DIS, V15, P630, DOI 10.1016/j.nbd.2003.11.025; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZENTAGOTHAI K, 1987, PEDIATR PULM, V3, P166, DOI 10.1002/ppul.1950030310; Tabrez S, 2012, CNS NEUROL DISORD-DR, V11, P395, DOI 10.2174/187152712800792785; Tabrizi SJ, 2012, LANCET NEUROL, V11, P42, DOI 10.1016/S1474-4422(11)70263-0; Tabrizi SJ, 2003, NEUROLOGY, V61, P141, DOI 10.1212/01.WNL.0000070186.97463.A7; Taes YEC, 2008, NEPHROL DIAL TRANSPL, V23, P1330, DOI 10.1093/ndt/gfm793; Terjung RL, 2000, MED SCI SPORT EXER, V32, P706, DOI 10.1097/00005768-200003000-00024; Tian LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132064; Tibbs RE, 1998, ANAT REC, V253, P167; TILZ GP, 1993, IMMUNOBIOLOGY, V188, P194, DOI 10.1016/S0171-2985(11)80497-3; Valastro B, 2009, BEHAV BRAIN RES, V197, P90, DOI 10.1016/j.bbr.2008.08.004; Valayannopoulos V, 2012, J INHERIT METAB DIS, V35, P151, DOI 10.1007/s10545-011-9358-9; van der Brug MP, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8280; Veech RL, 2012, IUBMB LIFE, V64, P203, DOI 10.1002/iub.590; Verbessem P, 2003, NEUROLOGY, V61, P925, DOI 10.1212/01.WNL.0000090629.40891.4B; Vieira RP, 2009, INT J SPORTS MED, V30, P684, DOI 10.1055/s-0029-1224176; Vieira RP, 2007, AM J RESP CELL MOL, V37, P660, DOI 10.1165/rcmb.2007-0108OC; Vieira RP, 2007, AM J RESP CRIT CARE, V176, P871, DOI 10.1164/rccm.200610-1567OC; Volek JS, 1999, MED SCI SPORT EXER, V31, P1147, DOI 10.1097/00005768-199908000-00011; Vuckovic MG, 2008, NEUROBIOL DIS, V32, P319, DOI 10.1016/j.nbd.2008.07.015; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; Weiler JM, 2000, J ALLERGY CLIN IMMUN, V106, P267, DOI 10.1067/mai.2000.108605; Westin JE, 2001, EUR J NEUROSCI, V14, P1171, DOI 10.1046/j.0953-816x.2001.01743.x; White RJ, 1996, J NEUROSCI, V16, P5688; Williams JK, 2015, NEUROPSYCHOLOGY, V29, P255, DOI 10.1037/neu0000102; Wolinsky, 1999, ENERGY YIELDING MACR, P213; Worms PA, 2001, J NEUROL SCI, V191, P3, DOI 10.1016/S0022-510X(01)00630-X; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu Z, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-2; Yang LC, 2009, J NEUROCHEM, V109, P1427, DOI 10.1111/j.1471-4159.2009.06074.x; Yar RA, 2015, BRAIN RES, V1595, P92, DOI 10.1016/j.brainres.2014.11.017; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zhu S, 2004, J NEUROSCI, V24, P5909, DOI 10.1523/JNEUROSCI.1278-04.2004	237	33	34	1	63	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	AUG	2016	37				SI		31	42		10.1016/j.intimp.2015.12.034			12	Immunology; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Pharmacology & Pharmacy	DQ3LE	WOS:000379103000006	26778152	Green Accepted			2022-02-06	
J	Li, W; Risacher, SL; McAllister, TW; Saykin, AJ				Li, Wei; Risacher, Shannon L.; McAllister, Thomas W.; Saykin, Andrew J.			Traumatic brain injury and age at onset of cognitive impairment in older adults	JOURNAL OF NEUROLOGY			English	Article						Alzheimer's disease; Dementia; MCI; Traumatic brain injury; Age at onset	ALZHEIMERS-DISEASE; HEAD-INJURY; DEMENTIA; RISK; CORE; PROTEIN; UPDATE; MILD	There is a deficiency of knowledge regarding how traumatic brain injury (TBI) is associated with age at onset (AAO) of cognitive impairment in older adults. Participants with a TBI history were identified from the Alzheimer's disease neuroimaging initiative (ADNI 1/GO/2) medical history database. Using an analysis of covariance (ANCOVA) model, the AAO was compared between those with and without TBI, and potential confounding factors were controlled. The AAO was also compared between those with mild TBI (mTBI) and moderate or severe TBI (sTBI). Lastly, the effects of mTBI were analyzed on the AAO of participants with clinical diagnoses of either mild cognitive impairment (MCI) or Alzheimer's disease (AD). The AAO for a TBI group was 68.2 +/- 1.1 years [95 % confidence interval (CI) 66.2-70.3, n = 62], which was significantly earlier than the AAO for the non-TBI group of 70.9 +/- 0.2 years (95 % CI 70.5-71.4, n = 1197) (p = 0.013). Participants with mTBI history showed an AAO of 68.5 +/- 1.1 years (n = 56), which was significantly earlier than the AAO for the non-TBI group (p = 0.032). Participants with both MCI and mTBI showed an AAO of 66.5 +/- 1.3 years (95 % CI 63.9-69.1, n = 45), compared to 70.6 +/- 0.3 years for the non-TBI MCI group (95 % CI 70.1-71.1, n = 935) (p = 0.016). As a conclusion, a history of TBI may accelerate the AAO of cognitive impairment by two or more years. These results were consistent with reports of TBI as a significant risk factor for cognitive decline in older adults, and TBI is associated with an earlier AAO found in patients with MCI or AD.	[Li, Wei] Indiana Univ Purdue Univ, Sch Hlth & Rehabil Sci, 2039 N Capitol Ave, Indianapolis, IN 46202 USA; [Risacher, Shannon L.; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indiana Alzheimer Dis Ctr, 355 W 16th St,Suite 4100, Indianapolis, IN 46202 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, 355 W 16th St,Suite 4800, Indianapolis, IN 46202 USA		Li, W (corresponding author), Indiana Univ Purdue Univ, Sch Hlth & Rehabil Sci, 2039 N Capitol Ave, Indianapolis, IN 46202 USA.	wl23@iu.edu	Risacher, Shannon/AAI-2141-2019; Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG19771, K01 AG049050]; Indiana Alzheimer Disease Center; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG049050, R01AG019771, P30AG010133, U01AG024904] Funding Source: NIH RePORTER	Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). Analyses in the present report were supported by NIA R01 AG19771 (to AJS), NIA K01 AG049050 (SLR), and funding from Indiana Alzheimer Disease Center.	Almeida OP, 2015, INT J GERIATR PSYCH, V30, P1215, DOI 10.1002/gps.4276; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Bruce DG, 2001, DIABETES RES CLIN PR, V53, P165, DOI 10.1016/S0168-8227(01)00266-2; Cheng PY, 2012, J DIABETES COMPLICAT, V26, P382, DOI 10.1016/j.jdiacomp.2012.06.003; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Deutsch MB, 2015, DEMENT GERIATR COGN, V39, P143, DOI 10.1159/000369787; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jack CR, 2010, ALZHEIMERS DEMENT, V6, P212, DOI 10.1016/j.jalz.2010.03.004; Jagust WJ, 2010, ALZHEIMERS DEMENT, V6, P221, DOI 10.1016/j.jalz.2010.03.003; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kloppenborg RP, 2008, EUR J PHARMACOL, V585, P97, DOI 10.1016/j.ejphar.2008.02.049; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; PISHKIN V, 1985, ALCOHOL CLIN EXP RES, V9, P400, DOI 10.1111/j.1530-0277.1985.tb05571.x; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Saykin AJ, 2010, ALZHEIMERS DEMENT, V6, P265, DOI 10.1016/j.jalz.2010.03.013; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Trojanowski JQ, 2010, ALZHEIMERS DEMENT, V6, P230, DOI 10.1016/j.jalz.2010.03.008; Wang HK, 2015, NEUROSCIENCE, V300, P94, DOI 10.1016/j.neuroscience.2015.05.013; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007	34	33	35	0	9	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	JUL	2016	263	7					1280	1285		10.1007/s00415-016-8093-4			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DQ4PH	WOS:000379185300003	27007484	Green Accepted, Green Submitted			2022-02-06	
J	Trefan, L; Houston, R; Pearson, G; Edwards, R; Hyde, P; Maconochie, I; Parslow, RC; Kemp, A				Trefan, L.; Houston, R.; Pearson, G.; Edwards, R.; Hyde, P.; Maconochie, I.; Parslow, R. C.; Kemp, A.			Epidemiology of children with head injury: a national overview	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							TRAUMATIC BRAIN-INJURY; REGION	Background The National Confidential Enquiry describes the epidemiology of children admitted to hospital with head injury. Method Children (< 15 years old) who died or were admitted for > 4 h with head injury were identified from 216 UK hospitals (1 September 2009 to 28 February 2010). Data were collected using standard proformas and entered on to a database. A descriptive analysis of the causal mechanisms, child demographics, neurological impairment, CT findings, and outcome at 72 h are provided. Results Details of 5700 children, median age 4 years (range 0-14.9 years), were analysed; 1093 (19.2%) were < 1 year old, 3500 (61.4%) were boys. There was a significant association of head injury with social deprivation 39.7/100 000 (95% CI 37.0 to 42.6) in the least deprived first quintile vs. 55.1 (95% CI 52.1 to 58.2) in the most deprived fifth quintile (p< 0.01). Twenty-four children died (0.4%). Most children were admitted for one night or less; 4522 (79%) had a Glasgow Coma Scale score of 15 or were Alert (on AVPU (Alert, Voice, Pain, Unresponsive)). The most common causes of head injury were falls (3537 (62.1%); children < 5 years), sports-related incidents (783 (13.7%); median age 12.4 years), or motor vehicle accidents (MVAs) (401 (7.1%); primary-school-aged children). CT scans were performed in 1734 (30.4%) children; 536 (30.9%) were abnormal (skull fracture and/or intracranial injury or abnormality): 269 (7.6%) were falls, 82 (10.5%) sports related and 100 (25%). A total of 357 (6.2%) children were referred to social care because of child protection concerns (median age 9 months (range 0-14.9 years)). Conclusions The data described highlight priorities for targeted age-specific head injury prevention and have the potential to provide a baseline to evaluate the effects of regional trauma networks (2012) and National Institute of Health and Care Excellence (NICE) head injury guidelines (2014), which were revised after the study was completed.	[Trefan, L.; Kemp, A.] Cardiff Univ, Sch Med, Coll Biomed & Life Sci, Cardiff CF14 4XY, S Glam, Wales; [Houston, R.] Kids Co, London, England; [Pearson, G.] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Edwards, R.] Bristol Hosp Children, Dept Neurosurg, Bristol, Avon, England; [Hyde, P.] Southampton Childrens Hosp, Paediat Intens Care Unit, Southampton, Hants, England; [Maconochie, I.] Imperial Coll NHS Healthcare Trust, London, England; [Parslow, R. C.] Univ Leeds, Sch Med, Leeds Inst Cardiovasc & Metab Med, Leeds LS2 9JT, W Yorkshire, England		Kemp, A (corresponding author), Cardiff Univ, Sch Med, Coll Biomed & Life Sci, Cardiff CF14 4XY, S Glam, Wales.	KempAM@cf.ac.uk	Parslow, Roger/AAV-1477-2020	Edwards, Richard/0000-0001-8415-2180; Maconochie, Ian/0000-0001-6319-8550; Parslow, Roger/0000-0002-3945-5294	Health Quality Improvement Partnership [504835]	Health Quality Improvement Partnership, grant number 504835.	Advanced Life Support Group, 1997, ADV PED LIF SUPP PRA; Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Arbogast KB, 2013, PEDIAT INJURY BIOMEC, P33; Burrows P, 2015, ARCH DIS CHILD, V100, P1032, DOI 10.1136/archdischild-2014-307119; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; Crandall JR, 2013, PEDIAT INJURY BIOMEC, P33; Department for Transport, 2012, REP ROAD CAS GREAT B; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hawley C, 2013, INJURY, V44, P1855, DOI 10.1016/j.injury.2013.07.021; Houston R, 2012, EMERG MED J, V29, P309, DOI 10.1136/emj.2011.112110; IBM Corp Released, 2011, IBM SPSS STAT WIND V; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kendrick D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005014.pub2; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Laflamme L, 2010, INT J PEDIAT, V2010, DOI 10.1155/2010/819687; Mackay CA, 2000, PREHOSPITAL IMMEDIAT, V4, P17; McNarry AF, 2004, ANAESTHESIA, V59, P34, DOI 10.1111/j.1365-2044.2004.03526.x; National Health Service, 2012, MAJ TRAUM CTR; NICE, 2014, HEAD INJ TRIAG ASS I; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Public Health England, 2014, RED UN INJ HOM CHILD; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	32	33	33	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	JUN	2016	101	6					527	532		10.1136/archdischild-2015-308424			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	DN3BJ	WOS:000376936900007	26998632	Green Published, hybrid			2022-02-06	
J	Iorio-Morin, C; Blanchard, J; Richer, M; Mathieu, D				Iorio-Morin, Christian; Blanchard, Jocelyn; Richer, Maxime; Mathieu, David			Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial	TRIALS			English	Article						Tranexamic acid; Cyklokapron; Conservative management; Medical management; Traumatic; Non-traumatic; Chronic subdural hematoma	TRAUMATIC BRAIN-INJURY; RECURRENCE; MANAGEMENT; RESOLUTION; ETIZOLAM	Background: Chronic subdural hematoma (CSDH) is one of the most frequent reason for cranial neurosurgical consultation. There is no widely accepted medical treatment for this condition. Herein, we present the protocol for the Tranexamic Acid (TXA) in Chronic Subdural Hematomas (TRACS) trial aiming at determining whether TXA can increase the rate of CSDH resolution following conservative management, lower the number of required surgical procedures and decrease the rate of CSDH recurrence following surgical evacuation. Methods: TRACS is a multicenter, double-blind, randomized, parallel-design, placebo-controlled, phase IIB study designed to provide preliminary efficacy data as well as feasibility, safety and incidence data required to plan a larger definitive phase III trial. Consecutive patients presenting with a diagnosis of chronic subdural hematoma will be screened for eligibility. Exclusion criteria include: specific risk factors for thromboembolic disease, anticoagulant use or contraindication to TXA. A total of 130 patients will be randomized to receive either 750 mg of TXA daily or placebo until complete radiological resolution of the CSDH or for a maximum of 20 weeks. CSDH volume will be measured on serial computed tomography (CT) scanning. Cognitive function tests, quality of life questionnaires as well as functional autonomy assessments will be performed at enrollment, at 10 weeks following randomization and at 3 months following treatment cessation. During the treatment period, patients will undergo standard CSDH management with surgery being performed at the discretion of the treating physician. If surgery is performed, the CSDH and its outer membrane will be sampled for in vitro analysis. The primary outcome is the rate of CSDH resolution by 20 weeks without intervening unplanned surgical procedure. Secondary outcomes include: CSDH volume, incidence of surgical evacuation procedures, CSDH recurrence, cognitive functions, functional autonomy, quality of life, incidence of complications and length of hospital stay. Planned subgroup analyses will be performed for conservatively versus surgically managed subjects and highly versus poorly vascularized CSDH. Discussion: CSDH is a frequent morbidity for which an effective medical treatment has yet to be discovered. The TRACS trial will be the first prospective study of TXA for CSDH.	[Iorio-Morin, Christian; Blanchard, Jocelyn; Mathieu, David] Univ Sherbrooke, Ctr Hosp, Dept Surg, Div Neurosurg, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada; [Richer, Maxime] Univ Sherbrooke, Ctr Hosp, Dept Pathol, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada; [Mathieu, David] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ J1H 5N4, Canada		Iorio-Morin, C (corresponding author), Univ Sherbrooke, Ctr Hosp, Dept Surg, Div Neurosurg, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	christian.iorio-morin@usherbrooke.ca	Iorio-Morin, Christian/I-8696-2019	Iorio-Morin, Christian/0000-0003-2995-7255	Fonds de recherche du Quebec - Sante (FRQS)Fonds de la Recherche en Sante du Quebec	CI-M receives an MD-PhD scholarship from the Fonds de recherche du Quebec - Sante (FRQS). The other authors receive no funding relative to the TRACS trial. Funding for the study is detailed in the Financial support section.	Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Devlin NJ, 2013, EUR J HEALTH ECON, V14, pS1, DOI 10.1007/s10198-013-0502-3; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Henry DA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub4; Hirashima Y, 2005, NEUROL MED-CHIR, V45, P621, DOI 10.2176/nmc.45.621; Hirashima Y, 2002, NEUROL MED-CHIR, V42, P53, DOI 10.2176/nmc.42.53; HIRASIMA Y, 1994, ACTA NEUROCHIR, V129, P20, DOI 10.1007/BF01400868; Horikoshi T, 1998, NEUROL MED-CHIR, V38, P527, DOI 10.2176/nmc.38.527; Ismail Z, 2013, CAN GERIATR J, V16, P54, DOI 10.5770/cgj.16.81; Kageyama H, 2013, J NEUROSURG, V119, P332, DOI 10.3171/2013.3.JNS122162; Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054; KUDO H, 1992, Neurologia Medico-Chirurgica, V32, P207, DOI 10.2176/nmc.32.207; LABADIE EL, 1975, NEUROLOGY, V25, P669, DOI 10.1212/WNL.25.7.669; Levy JH, 2010, ANESTH ANALG, V110, P1271, DOI 10.1213/ANE.0b013e3181d7ac98; Lim Dong-Jun, 1995, Journal of Korean Medical Science, V10, P373; Oh HJ, 2010, J KOREAN NEUROSURG S, V48, P518, DOI 10.3340/jkns.2010.48.6.518; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Sambasivan M, 1997, SURG NEUROL, V47, P418, DOI 10.1016/S0090-3019(97)00188-2; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stanisic M, 2012, ACTA NEUROCHIR, V154, P113, DOI 10.1007/s00701-011-1203-2; Vujkovac B, 2000, NEPHROL DIAL TRANSPL, V15, P107, DOI 10.1093/ndt/15.1.107; Weigel R, 2007, NEUROSURGERY, V61, P788, DOI 10.1227/01.NEU.0000298907.56012.E8; Wellington K, 2003, DRUGS, V63, P1417, DOI 10.2165/00003495-200363130-00008; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yang M, 2014, J AM MED DIR ASSOC, V15	27	33	35	1	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	MAY 5	2016	17								235	10.1186/s13063-016-1358-5			11	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	DL0SD	WOS:000375342000001	27150916	Green Published, gold			2022-02-06	
J	Agrawal, R; Noble, E; Vergnes, L; Ying, Z; Reue, K; Gomez-Pinilla, F				Agrawal, Rahul; Noble, Emily; Vergnes, Laurent; Ying, Zhe; Reue, Karen; Gomez-Pinilla, Fernando			Dietary fructose aggravates the pathobiology of traumatic brain injury by influencing energy homeostasis and plasticity	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Cognition; energy homeostasis; metabolic syndrome; mitochondria; plasticity; traumatic brain injury	MITOCHONDRIAL TRANSCRIPTION FACTOR; METABOLIC SYNDROME; NEUROLOGICAL DISORDERS; SIGNALING PATHWAY; COPY NUMBER; MEMORY; PGC-1-ALPHA; DAMAGE; EPIDEMIOLOGY; DYSFUNCTION	Fructose consumption has been on the rise for the last two decades and is starting to be recognized as being responsible for metabolic diseases. Metabolic disorders pose a particular threat for brain conditions characterized by energy dysfunction, such as traumatic brain injury. Traumatic brain injury patients experience sudden abnormalities in the control of brain metabolism and cognitive function, which may worsen the prospect of brain plasticity and function. The mechanisms involved are poorly understood. Here we report that fructose consumption disrupts hippocampal energy homeostasis as evidenced by a decline in functional mitochondria bioenergetics (oxygen consumption rate and cytochrome C oxidase activity) and an aggravation of the effects of traumatic brain injury on molecular systems engaged in cell energy homeostasis (sirtuin 1, peroxisome proliferator-activated receptor gamma coactivator-1alpha) and synaptic plasticity (brain-derived neurotrophic factor, tropomyosin receptor kinase B, cyclic adenosine monophosphate response element binding, synaptophysin signaling). Fructose also worsened the effects of traumatic brain injury on spatial memory, which disruption was associated with a decrease in hippocampal insulin receptor signaling. Additionally, fructose consumption and traumatic brain injury promoted plasma membrane lipid peroxidation, measured by elevated protein and phenotypic expression of 4-hydroxynonenal. These data imply that high fructose consumption exacerbates the pathology of brain trauma by further disrupting energy metabolism and brain plasticity, highlighting the impact of diet on the resilience to neurological disorders.	[Agrawal, Rahul; Noble, Emily; Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr South, Los Angeles, CA 90095 USA; [Vergnes, Laurent; Reue, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, 621 Charles E Young Dr South, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, 621 Charles E Young Dr South, Los Angeles, CA 90095 USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 621 Charles E Young Dr South, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu		Noble, Emily/0000-0002-7483-031X; vergnes, laurent/0000-0002-8804-589X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS050465]; NIH NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR026744]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL028481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Institutes of Health Grant NS050465 (F.G-P.), and instrument grant NIH NCRR S10RR026744 (K.R.).	Agrawal R, 2012, J PHYSIOL-LONDON, V590, P2485, DOI 10.1113/jphysiol.2012.230078; Alonso M, 2002, CELL MOL NEUROBIOL, V22, P663, DOI 10.1023/A:1021848706159; Angelucci F, 2005, MOL PSYCHIATR, V10, P345, DOI 10.1038/sj.mp.4001637; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Chen SD, 2011, INT J MOL SCI, V12, P7199, DOI 10.3390/ijms12107199; Chen TJ, 2009, J NEUROSCI RES, V87, P2297, DOI 10.1002/jnr.22057; Cheng AW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2238; Cheng ZY, 2010, TRENDS ENDOCRIN MET, V21, P589, DOI 10.1016/j.tem.2010.06.005; Cowie CC, 2009, DIABETES CARE, V32, P287, DOI 10.2337/dc08-1296; Creavin ST, 2012, J ALZHEIMERS DIS, V28, P931, DOI 10.3233/JAD-2011-111550; Dwivedi Y, 2009, NEUROPSYCH DIS TREAT, V5, P433; Eakins James, 2009, J Diabetes Sci Technol, V3, P1373; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Farooqui AA, 2012, CELL MOL LIFE SCI, V69, P741, DOI 10.1007/s00018-011-0840-1; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Glantz LA, 2007, NEUROSCIENCE, V149, P582, DOI 10.1016/j.neuroscience.2007.06.036; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Grasselli G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020791; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Gutierrez J, 2006, CIRC RES, V99, P924, DOI 10.1161/01.RES.0000248212.86638.e9; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Lee CC, 2005, J BIOL CHEM, V280, P18543, DOI 10.1074/jbc.M414112200; Ley EJ, 2011, J TRAUMA, V70, P1141, DOI 10.1097/TA.0b013e3182146d66; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mattson MP, 2008, NEURON, V60, P748, DOI 10.1016/j.neuron.2008.10.010; Mowery NT, 2009, J TRAUMA, V66, P145, DOI 10.1097/TA.0b013e3181938c5e; Nistico R, 2012, NEUROMOL MED, V14, P262, DOI 10.1007/s12017-012-8184-z; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Padwal RS, 2014, CAN J CARDIOL, V30, P467, DOI 10.1016/j.cjca.2013.11.004; Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Schirmer L, 2013, BRAIN PATHOL, V23, P2, DOI 10.1111/j.1750-3639.2012.00608.x; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Szendroedi J, 2012, NAT REV ENDOCRINOL, V8, P92, DOI 10.1038/nrendo.2011.138; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Ventura-Clapier R, 2008, CARDIOVASC RES, V79, P208, DOI 10.1093/cvr/cvn098; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073	50	33	33	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2016	36	5					941	953		10.1177/0271678X15606719			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	DK9OX	WOS:000375261800009	26661172	Green Published, Bronze			2022-02-06	
J	Pogoda, TK; Stolzmann, KL; Iverson, KM; Baker, E; Krengel, M; Lew, HL; Amara, JH; Meterko, M				Pogoda, Terri K.; Stolzmann, Kelly L.; Iverson, Katherine M.; Baker, Errol; Krengel, Maxine; Lew, Henry L.; Amara, Jomana H.; Meterko, Mark			Associations Between Traumatic Brain Injury, Suspected Psychiatric Conditions, and Unemployment in Operation Enduring Freedom/Operation Iraqi Freedom Veterans	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; employment; neurobehavioral symptoms; posttraumatic stress disorder; substance use disorder; traumatic brain injury; unemployment; veterans	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; AFGHANISTAN WAR VETERANS; SUBSTANCE USE DISORDERS; MENTAL-HEALTH PROBLEMS; CLOSED-HEAD-INJURY; DISABILITY COMPENSATION; EMPLOYMENT STATUS; COMBAT VETERANS; FOLLOW-UP	Objective: To examine the relations among demographic characteristics, traumatic brain injury (TBI) history, suspected psychiatric conditions, current neurobehavioral health symptoms, and employment status in Veterans evaluated for TBI in the Department of Veterans Affairs. Study Design: Retrospective cross-sectional database review of comprehensive TBI evaluations documented between October 2007 and June 2009. Participants: Operation Enduring Freedom/Operation Iraqi Freedom Veterans (n=11 683) who completed a comprehensive TBI evaluation. Main Measures: Veterans Affairs clinicians use the comprehensive TBI evaluations to obtain information about TBI-related experiences, current neurobehavioral symptoms, and to identify suspected psychiatric conditions. Results: Approximately one-third of Veterans in this sample were unemployed, and of these, the majority were looking for work. After simultaneously adjusting for health and deployment-related variables, significant factors associated with unemployment included one or more suspected psychiatric conditions (eg, posttraumatic stress disorder, anxiety, depression), neurobehavioral symptom severity (ie, affective, cognitive, vestibular), former active duty status, injury etiology, age, lower education, and marital status. The associations of these factors with employment status varied by deployment-related TBI severity. Conclusions: Simultaneously addressing health-related, educational, and/or vocational needs may fill a critical gap for helping Veterans readjust to civilian life and achieve their academic and vocational potential.	[Pogoda, Terri K.; Stolzmann, Kelly L.; Iverson, Katherine M.; Baker, Errol; Meterko, Mark] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA; [Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA; [Krengel, Maxine] VA Boston Healthcare Syst, Res & Dev Serv, Boston, MA USA; [Pogoda, Terri K.; Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02130 USA; [Iverson, Katherine M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02130 USA; [Krengel, Maxine] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02130 USA; [Lew, Henry L.] Virginia Commonwealth Univ, Def & Vet Brain Injury Ctr, Dept Phys Med & Rehabil, Richmond, VA USA; [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Commun Sci & Disorders, Honolulu, HI 96822 USA; [Amara, Jomana H.] Naval Postgrad Sch, Def Resources Management Inst, Monterey, CA USA		Pogoda, TK (corresponding author), Ctr Healthcare Org & Implementat Res, 150 South Huntington Ave 152M, Boston, MA 02130 USA.; Pogoda, TK (corresponding author), Boston Univ, Sch Publ Hlth, VA Boston Healthcare Syst, 150 South Huntington Ave 152M, Boston, MA 02130 USA.	terri.pogoda@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780	Office of Research and Development, Health Services Research & Development (HSR&D) Service, Department of Veterans Affairs [SDR 08-405]; HSR&D Career Development Award [CDA-2, 10-029]	This paper is based on work supported by the Office of Research and Development, Health Services Research & Development (HSR&D) Service, Department of Veterans Affairs, through SDR 08-405. Dr. Iverson's contribution to this manuscript was supported by a HSR&D Career Development Award (CDA-2; 10-029). The opinions expressed in this article are the authors' and do not reflect those of the Department of Veterans Affairs, the Veterans Health Administration, Health Services Research and Development Service, the Defense and Veterans Brain Injury Center, or the Department of Defense. Some of the findings were presented at the 2014 Academy Health Annual Research Meeting, San Diego, California.	Adler DA, 2011, PSYCHIAT SERV, V62, P39, DOI 10.1176/ps.62.1.pss6201_0039; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI [10.1089/neu.2008.0849, 10.1089/neu.2008-0849]; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen SI, 2013, WORK, V44, P213, DOI 10.3233/WOR-2012-1417; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Council NR, 2013, RET HOM IR AFGH ASS; Daggett VS, 2013, J REHABIL RES DEV, V50, P327, DOI 10.1682/JRRD.2011.09.0168; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; [Department of Veterans Affairs VHA Veterans Health Administration], 2010, SCREEN EV POSS TRAUM; Department of Veterans Affairs VHA, 2011, VHA HDB; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Drew D, 2001, PSYCHIATR SERV, V52, P1479, DOI 10.1176/appi.ps.52.11.1479; Elbogen EB, 2012, MIL MED, V177, P669, DOI 10.7205/MILMED-D-11-00388; Epidemiology Program P-DHG Office of Public Health Veterans Health Administration Department of Veterans Affairs, 2014, AN VA HLTH CAR UT OP, P1; Fortier CB, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000008; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Greenberg GA, 2007, MIL MED, V172, P162, DOI 10.7205/MILMED.172.2.162; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kleylamp M, 2013, SOC SCI RES, V42, P836, DOI 10.1016/j.ssresearch.2012.12.017; Kulka RA, 1990, TRAUMA VIETNAM WAR G; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee-Ryan FM, 2005, J APPL PSYCHOL, V90, P53, DOI 10.1037/0021-9010.90.1.53; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Nazareth I, 2006, J PSYCHOSOM RES, V60, P395, DOI 10.1016/j.jpsychores.2005.07.011; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Olson-Madden JH, 2012, J HEAD TRAUMA REHAB, V27, P370, DOI 10.1097/HTR.0b013e318268d496; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pogoda TK, 2014, J REHABIL RES DEV, V51, P363, DOI 10.1682/JRRD.2013.05.0115; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Resnick SG, 2008, J REHABIL RES DEV, V45, P427, DOI 10.1682/JRRD.2007.06.0093; ROSS CE, 1995, J HEALTH SOC BEHAV, V36, P230, DOI 10.2307/2137340; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Smith Mark W, 2005, Ment Health Serv Res, V7, P89, DOI 10.1007/s11020-005-3780-2; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tsai J, 2013, J OCCUP REHABIL, V23, P504, DOI 10.1007/s10926-013-9419-z; U.S. General Accounting Office, 2008, GAO08276; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wong ES, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-96; Zivin K, 2011, PSYCHIAT SERV, V62, P35, DOI 10.1176/ps.62.1.pss6201_0035	84	33	33	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2016	31	3					191	203		10.1097/HTR.0000000000000092			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DR3FK	WOS:000379787800011	25310289				2022-02-06	
J	Turkstra, LS; Norman, R; Whyte, J; Dijkers, MP; Hart, T				Turkstra, Lyn S.; Norman, Rocio; Whyte, John; Dijkers, Marcel P.; Hart, Tessa			Knowing What We're Doing: Why Specification of Treatment Methods Is Critical for Evidence-Based Practice in Speech-Language Pathology	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TREATMENT TAXONOMY; SOCIAL-SKILLS; REHABILITATION TREATMENTS; THERAPY; DISORDERS; CHILDREN; SERIES; TRIAL	Purpose: The purpose of this clinical focus article is to describe the conceptual framework of the multidisciplinary rehabilitation treatment taxonomy (RTT) and illustrate its potential use in speech-language pathology (SLP) clinical practice and research. Method: The method used was a critical discussion. Results: Current methods of defining and classifying SLP and other rehabilitation interventions maintain the "black box" of rehabilitation by referring to hours or days of therapy or using problem-oriented labels (e.g., naming treatment) to describe treatments, none of which reveal what is actually done to effect desired changes in patient functioning. The RTT framework uses treatment targets, ingredients, and mechanisms of action defined by treatment theory to specify SLP and other rehabilitation interventions with greater precision than current methods of treatment labeling and classification. It also makes a distinction between the target of treatment at which ingredients are directed and broader aims of treatment, which may be downstream effects explained instead by enablement/disablement theory. Conclusion: Future application of the RTT conceptual scheme to SLP intervention may enhance clinical practice, research, and knowledge translation as well as training and program evaluation efforts.	[Turkstra, Lyn S.; Norman, Rocio] Univ Wisconsin, Madison, WI 53706 USA; [Whyte, John; Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Dijkers, Marcel P.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA		Turkstra, LS (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	lyn.turkstra@wisc.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921; Whyte, John/0000-0002-4381-1474	Patient-Centered Outcomes Research Institute AwardPatient-Centered Outcomes Research Institute - PCORI [ME-1403-14083]; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133A080053]; National Institute on Child Health and Human Development, National Center for Medical Rehabilitation Research [R01 HD071089]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD071089] Funding Source: NIH RePORTER	This work was partially supported through a Patient-Centered Outcomes Research Institute Award (ME-1403-14083) and National Institute on Disability and Rehabilitation Research (now National Institute on Disability, Independent Living, and Rehabilitation Research) Cooperative Agreement H133A080053 and a Diversity Supplement to Grant R01 HD071089 from the National Institute on Child Health and Human Development, National Center for Medical Rehabilitation Research, to Rocio Norman. All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the National Institute on Disability and Rehabilitation Research, National Institute on Child Health and Human Development, and the Patient-Centered Outcomes Research Institute or its Board of Governors or Methodology Committee.	Beaulieu CL, 2015, ARCH PHYS MED REHAB, V96, pS222, DOI 10.1016/j.apmr.2014.10.028; Boyle M., 1995, AM J SPEECH-LANG PAT, P94, DOI DOI 10.1044/1058-0360.0404.94; Dijkers MP, 2014, ARCH PHYS MED REHAB, V95, pS1, DOI 10.1016/j.apmr.2013.09.023; Dijkers MP, 2014, ARCH PHYS MED REHAB, V95, pS6, DOI 10.1016/j.apmr.2013.03.032; Dijkers MP, 2014, ARCH PHYS MED REHAB, V95, pS45, DOI 10.1016/j.apmr.2013.05.033; Edmonds LA, 2014, AM J SPEECH-LANG PAT, V23, P312, DOI 10.1044/2014_AJSLP-13-0098; Fletcher-Watson S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008785.pub2; Gordan W, 2009, J SPINAL CORD MED, V32, P307, DOI 10.1080/10790268.2009.11760784; Granholm E, 2014, J CONSULT CLIN PSYCH, V82, P1173, DOI 10.1037/a0037098; Hart T, 2014, ARCH PHYS MED REHAB, V95, pS33, DOI 10.1016/j.apmr.2013.05.032; Hatfield B, 2005, ARCH PHYS MED REHAB, V86, pS61, DOI 10.1016/j.apmr.2005.08.111; Johnson ML, 2014, AM J SPEECH-LANG PAT, V23, P60, DOI 10.1044/1058-0360(2013/12-0168); Kasari C, 2012, J CHILD PSYCHOL PSYC, V53, P431, DOI 10.1111/j.1469-7610.2011.02493.x; KEITH RA, 1993, IMPROVING ASSESSMENT IN REHABILITATION AND HEALTH, P33; Llorens R, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0029-1; Meulenbroek P, 2016, J VOCAT REHABIL, V44, P15, DOI 10.3233/JVR-150777; Naeini TS, 2013, IRAN RED CRESCENT ME, V15, DOI 10.5812/ircmj.5426; Sohlberg M. M., 2011, OPTIMIZING INSTRUCTI; Van Stan JH, 2015, AM J SPEECH-LANG PAT, V24, P101, DOI 10.1044/2015_AJSLP-14-0030; Wambaugh JL, 2013, AM J SPEECH-LANG PAT, V22, pS334, DOI 10.1044/1058-0360(2013/12-0070); Whyte J, 2014, ARCH PHYS MED REHAB, V95, pS24, DOI 10.1016/j.apmr.2013.05.034; Whyte J, 2012, ARCH PHYS MED REHAB, V93, pS101, DOI 10.1016/j.apmr.2011.11.040; Wong C, 2015, J AUTISM DEV DISORD, V45, P1951, DOI 10.1007/s10803-014-2351-z; World Health Organization, 2007, INT CLASS FUNCT DIS	24	33	33	0	8	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY	2016	25	2								10.1044/2015_AJSLP-15-0060			8	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	DO6AE	WOS:000377863600006	27145191	Green Published			2022-02-06	
J	Galho, AR; Cordeiro, MF; Ribeiro, SA; Marques, MS; Antunes, MFD; Luz, DC; Hadrich, G; Muccillo-Baisch, AL; Barros, DM; Lima, JV; Dora, CL; Horn, AP				Galho, A. R.; Cordeiro, M. F.; Ribeiro, S. A.; Marques, M. S.; Antunes, M. F. D.; Luz, D. C.; Haedrich, G.; Muccillo-Baisch, A. L.; Barros, D. M.; Lima, J. V.; Dora, C. L.; Horn, A. P.			Protective role of free and quercetin-loaded nanoemulsion against damage induced by intracerebral haemorrhage in rats	NANOTECHNOLOGY			English	Article						quercetin; nanoemulsion; intracerebral haemorrhage; locomotor activity; antioxidant	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; SUBARACHNOID HEMORRHAGE; STROKE; COLLAGENASE; MODEL; CORTEX; EDEMA; BIOAVAILABILITY	Intracerebral haemorrhage (ICH) is a worldwide public health problem. Experimental studies have shown that oxidative stress plays an important role in the pathogenesis of ICH and could represent a target for its treatment. However, the blood-brain barrier is an obstacle to be overcome, as it hampers the administration of compounds to the central nervous system. In this study, we compared the effects of a quercetin-loaded nanoemulsion (QU-N) with the free form of the drug (QU-SP) in a collagenase-induced ICH rat model. Quercetin (QU) is a polyphenol that has an antioxidant effect in vitro, but due to its high lipophilicity, it has low bioavailability in vivo. In this study, animals submitted or not to ICH were treated with a single intraperitoneal QU dose (free or nanoemulsion) of 30 mg kg(-1). Motor assessment was evaluated by the open field, foot fault and beam walking behavioural tests. 72 h after surgery the haematoma size was evaluated and biochemical measurements were performed. Animals treated with QU-N had a significant improvement in the beam walking and open field tests. Also, QU-N was able to reduce the size of the haematoma, preserving the activity of glutathione S-transferase (GST), increasing GSH content, and the total antioxidant capacity. QU-SP recovered locomotor activity and increased the GSH content and the total antioxidant capacity. Thus, it can be observed that QU presented antioxidant activity in both formulations, but the incorporation into nanoemulsions increased its antioxidant effect, which was reflected in the improvement of the motor skills and in the haematoma size decrement. These results suggest that the nanoemulsion containing QU developed in this study could be promising for future studies on treatments for ICH.	[Galho, A. R.; Cordeiro, M. F.; Marques, M. S.; Antunes, M. F. D.; Luz, D. C.; Barros, D. M.; Lima, J. V.; Horn, A. P.] Univ Fed Rio Grande FURG, Programa Posgrad Ciencias Fisiol Anim Comparada, BR-96210900 Rio Grande, RS, Brazil; [Ribeiro, S. A.] Univ Fed Rio Grande FURG, Inst Ciencias Biol, Histol Lab, BR-96210900 Rio Grande, RS, Brazil; [Haedrich, G.; Muccillo-Baisch, A. L.; Dora, C. L.] Univ Fed Rio Grande FURG, Programa Posgrad Ciencias Saude, BR-96203900 Rio Grande, RS, Brazil; [Muccillo-Baisch, A. L.; Dora, C. L.] Univ Fed Rio Grande FURG, Lab Nanotecnol Aplicada Saude, BR-96203900 Rio Grande, RS, Brazil		Horn, AP (corresponding author), Univ Fed Rio Grande FURG, Programa Posgrad Ciencias Fisiol Anim Comparada, BR-96210900 Rio Grande, RS, Brazil.	anapaulahorn@pq.cnpq.br	Hadrich, Gabriela/AAM-7861-2020; Dora, Cristiana Lima/AAF-9520-2021; Horn, Ana P/N-3770-2018; Cordeiro, Marcos F/N-4080-2017; Hadrich, Gabriela/AAT-1051-2021	Cordeiro, Marcos F/0000-0002-2100-1614; Hadrich, Gabriela/0000-0002-2360-8882; Ventura-Lima, Juliane/0000-0002-1670-2037	PROCAD/CNPq [552457/2011-6]; PRONEM/FAPERGS [11/2037-9]	This work was supported by grants from PROCAD/CNPq (grant no. 552457/2011-6) and PRONEM/FAPERGS (grant no. 11/2037-9). Aline Ribeiro Galho was a fellow from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). The authors would like to thank Andressa Bernardi for critically reviewing the manuscript. The authors declare that they have no conflicts of interest.	Ahmad A, 2011, NEUROCHEM RES, V36, P1360, DOI 10.1007/s11064-011-0458-6; Amado LL, 2009, SCI TOTAL ENVIRON, V407, P2115, DOI 10.1016/j.scitotenv.2008.11.038; Andaluz N, 2002, NEUROSURG CLIN N AM, V13, P385, DOI 10.1016/S1042-3680(02)00006-2; Anderson CS, 2009, CURR OPIN CRIT CARE, V15, P93, DOI 10.1097/MCC.0b013e328325d12c; Artwohl J, 2006, J AM ASSOC LAB ANIM, V45, P98; Beray-Berthat V, 2010, J NEUROSCI METH, V191, P180, DOI 10.1016/j.jneumeth.2010.06.025; Chan ST, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/580626; Cordeiro MF, 2015, WORLD J STEM CELLS, V7, P618, DOI 10.4252/wjsc.v7.i3.618; Dong YS, 2014, INT J MED SCI, V11, P282, DOI 10.7150/ijms.7634; Dora CL, 2012, J BIOMED NANOTECHNOL, V8, P202, DOI 10.1166/jbn.2012.1380; Dora CL, 2011, LAT AM J PHARM, V30, P289; Durrieu V, 2004, J APPL POLYM SCI, V94, P700, DOI 10.1002/app.20933; Fang R, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-19; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Goldstein BL, 2012, J NEUROSCI, V32, P2027, DOI 10.1523/JNEUROSCI.5349-11.2012; Habig W H, 1981, Methods Enzymol, V77, P398; Hadrich G, 2015, DRUG DEV IND PHARM, P1; Hadrich G, 2015, PHARM RES, V33, P1; Haleagrahara N, 2013, J TOXICOL SCI, V38, P25, DOI 10.2131/jts.38.25; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Jonsson AC, 2008, STROKE, V39, P918, DOI 10.1161/STROKEAHA.107.497602; Jover R, 2006, HEPATOLOGY, V43, P1257, DOI 10.1002/hep.21180; Kilic E, 2008, J PINEAL RES, V45, P142, DOI 10.1111/j.1600-079X.2008.00568.x; Kim M, 2007, BBA-GEN SUBJECTS, V1770, P1627, DOI 10.1016/j.bbagen.2007.08.003; Liao YR, 2015, LIFE SCI, V137, P89, DOI 10.1016/j.lfs.2015.07.015; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Lu W, 2016, TRENDS FOOD SCI TECH, V47, P1, DOI 10.1016/j.tifs.2015.10.015; Ma QY, 2011, ACTA NEUROCHIR SUPPL, V111, P3, DOI 10.1007/978-3-7091-0693-8_1; MacLellan CL, 2009, BEHAV BRAIN RES, V198, P321, DOI 10.1016/j.bbr.2008.11.004; Maldonado MA, 2008, NEUROREHAB NEURAL RE, V22, P250, DOI 10.1177/1545968307308551; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Murota Kaeko, 2007, J Med Invest, V54, P370, DOI 10.2152/jmi.54.370; Nakamura T, 2005, BRAIN RES, V1039, P30, DOI 10.1016/j.brainres.2005.01.036; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Oakes KD, 2003, AQUAT TOXICOL, V63, P447, DOI 10.1016/S0166-445X(02)00204-7; Porritt MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041090; Prakash T, 2011, INDIAN J PHARMACOL, V43, P676, DOI 10.4103/0253-7613.89825; Rivera F, 2004, NEUROTOX RES, V6, P543, DOI 10.1007/BF03033450; Rogerio AP, 2010, PHARMACOL RES, V61, P288, DOI 10.1016/j.phrs.2009.10.005; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Savard C, 2009, COMPARATIVE MED, V59, P444; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Schwingel TE, 2014, N-S ARCH PHARMACOL, V387, P837, DOI 10.1007/s00210-014-0994-0; Senes M, 2007, ANN CLIN BIOCHEM, V44, P43, DOI 10.1258/000456307779596057; Shang H, 2013, FREE RADICAL RES, V47, P368, DOI 10.3109/10715762.2013.778403; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shimizu H, 2004, STROKE, V35, P2072, DOI 10.1161/01.STR.0000138022.86509.2d; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Ting YW, 2014, J FUNCT FOODS, V7, P112, DOI 10.1016/j.jff.2013.12.010; Torri C, 1997, MOL CHEM NEUROPATHOL, V30, P15, DOI 10.1007/BF02815147; Turner RJ, 2012, NEUROSCIENCE, V220, P1, DOI 10.1016/j.neuroscience.2012.06.047; Vianna MRM, 2001, BRAZ J MED BIOL RES, V34, P233, DOI 10.1590/S0100-879X2001000200011; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; White CC, 2003, ANAL BIOCHEM, V318, P175, DOI 10.1016/S0003-2697(03)00143-X; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yousef MI, 2010, FOOD CHEM TOXICOL, V48, P3246, DOI 10.1016/j.fct.2010.08.034; Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068; Zar J.H., 1999, BIOSTAT ANAL, V4; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhao LR, 2007, STROKE, V38, P2804, DOI 10.1161/STROKEAHA.107.486217	62	33	33	2	21	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0957-4484	1361-6528		NANOTECHNOLOGY	Nanotechnology	APR 29	2016	27	17							175101	10.1088/0957-4484/27/17/175101			13	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Materials Science; Physics	DH5AO	WOS:000372797400004	26965041				2022-02-06	
J	Fidan, E; Lewis, J; Kline, AE; Garman, RH; Alexander, H; Cheng, JP; Bondi, CO; Clark, RSB; Dezfulian, C; Kochanek, PM; Kagan, VE; Bayir, H				Fidan, Emin; Lewis, Jesse; Kline, Anthony E.; Garman, Robert H.; Alexander, Henry; Cheng, Jeffrey P.; Bondi, Corina O.; Clark, Robert S. B.; Dezfulian, Cameron; Kochanek, Patrick M.; Kagan, Valerian E.; Bayir, Huelya			Repetitive Mild Traumatic Brain Injury in the Developing Brain: Effects on Long-Term Functional Outcome and Neuropathology	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; development; head injury; microglia	CLOSED-HEAD INJURY; POSTTRAUMATIC-STRESS-DISORDER; FLUID PERCUSSION INJURY; DYNAMIC STRETCH INJURY; AXONAL INJURY; HIGH-SCHOOL; COGNITIVE IMPAIRMENT; NORMOBARIC HYPEROXIA; SODIUM-CHANNELS; RAT HIPPOCAMPUS	Although accumulating evidence suggests that repetitive mild TBI (rmTBI) may cause long-term cognitive dysfunction in adults, whether rmTBI causes similar deficits in the immature brain is unknown. Here we used an experimental model of rmTBI in the immature brain to answer this question. Post-natal day (PND) 18 rats were subjected to either one, two, or three mild TBIs (mTBI) or an equivalent number of sham insults 24 h apart. After one or two mTBIs or sham insults, histology was evaluated at 7 days. After three mTBIs or sham insults, motor (d1-5), cognitive (d11-92), and histological (d21-92) outcome was evaluated. At 7 days, silver degeneration staining revealed axonal argyrophilia in the external capsule and corpus callosum after a single mTBI, with a second impact increasing axonal injury. Iba-1 immunohistochemistry showed amoeboid shaped microglia within the amygdalae bilaterally after mTBI. After three mTBI, there were no differences in beam balance, Morris water maze, and elevated plus maze performance versus sham. The rmTBI rats, however, showed impairment in novel object recognition and fear conditioning. Axonal silver staining was observed only in the external capsule on d21. Iba-1 staining did not reveal activated microglia on d21 or d92. In conclusion, mTBI results in traumatic axonal injury and microglial activation in the immature brain with repeated impact exacerbating axonal injury. The rmTBI in the immature brain leads to long-term associative learning deficit in adulthood. Defining the mechanisms damage from rmTBI in the developing brain could be vital for identification of therapies for children.	[Fidan, Emin; Lewis, Jesse; Kline, Anthony E.; Alexander, Henry; Cheng, Jeffrey P.; Bondi, Corina O.; Clark, Robert S. B.; Dezfulian, Cameron; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15224 USA; [Kline, Anthony E.; Cheng, Jeffrey P.; Bondi, Corina O.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15224 USA; [Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15224 USA; [Garman, Robert H.] Vet Pathol Inc, Murrysville, PA USA; [Clark, Robert S. B.; Dezfulian, Cameron; Kochanek, Patrick M.; Bayir, Huelya] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA		Bayir, H (corresponding author), Univ Pittsburgh, Dept Crit Care Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	bayihx@ccm.upmc.edu		Bondi, Corina/0000-0002-5733-4912; Kagan, Valerian E./0000-0002-7245-1885	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD069620, HD069620] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS076511, NS076511, R01 NS061817, NS060005, R01 NS084604, NS084604, R01 NS060005, NS061817, NS084967] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U19AIO68021] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005, R01NS076511, R01NS084604, R01NS084967, R01NS061817] Funding Source: NIH RePORTER		Ahn ES, 2008, J NEUROSURG, V108, P124, DOI 10.3171/JNS/2008/108/01/0124; Anderson V, 2012, J HEAD TRAUMA REHAB, V27, P199, DOI 10.1097/HTR.0b013e31821a9d2b; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Dunkley C, 2011, EPILEPSY RES, V93, P96, DOI 10.1016/j.eplepsyres.2010.11.002; Eder C, 1998, J NEUROSCI, V18, P7127; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Ellis EF, 2007, J NEUROCHEM, V101, P1463, DOI 10.1111/j.1471-4159.2007.04515.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; IZUMI Y, 1995, SYNAPSE, V20, P19, DOI 10.1002/syn.890200104; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412, DOI 10.1152/jn.1993.70.4.1412; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kochanek PM, 2010, JAMA-J AM MED ASSOC, V303, P2190, DOI 10.1001/jama.2010.715; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Landers MS, 2012, DEV NEUROSCI-BASEL, V34, P101, DOI 10.1159/000336732; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Liaury K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-56; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; O'Brien N, 2006, BEHAV BRAIN RES, V170, P156, DOI 10.1016/j.bbr.2006.02.008; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Paxinos G, 1998, CHEMOARCHITECTONIC A; Perlson E, 2010, TRENDS NEUROSCI, V33, P335, DOI 10.1016/j.tins.2010.03.006; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Puccio AM, 2009, J NEUROTRAUM, V26, P1241, DOI [10.1089/neu.2008.0624, 10.1089/neu.2008-0624]; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Shechner T, 2014, BIOL PSYCHOL, V100, P1, DOI 10.1016/j.biopsycho.2014.04.001; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 1999, J NEUROSCI, V19, P4263; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Veenith TV, 2014, J CEREBR BLOOD F MET, V34, P1622, DOI 10.1038/jcbfm.2014.123; Walson KH, 2011, CRIT CARE MED, V39, P335, DOI 10.1097/CCM.0b013e3181ffda0e; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	89	33	35	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2016	33	7					641	651		10.1089/neu.2015.3958			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DI6QK	WOS:000373624700003	26214116	Green Published			2022-02-06	
J	Raj, R; Mikkonen, ED; Kivisaari, R; Skrifvars, MB; Korja, M; Siironen, J				Raj, Rahul; Mikkonen, Era D.; Kivisaari, Riku; Skrifvars, Markus B.; Korja, Miikka; Siironen, Jari			Mortality in Elderly Patients Operated for an Acute Subdural Hematoma: A Surgical Case Series	WORLD NEUROSURGERY			English	Article						Acute subdural hematoma; Craniotomy; Elderly; Mortality; Prognosis; Prognostic factors; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; EPIDEMIOLOGY; COMA; AGE	BACKGROUND: Surgery for elderly patients with acute subdural hematomas (ASDH) is controversial, because postoperative mortality rates are reported to be high and long-term outcomes unknown. Thus, we aimed to describe midterm and long-term mortality rates of elderly patients operated for an ASDH. METHODS: We reviewed all consecutive >= 75-year-old patients operated on for an ASDH between 2009 and 2012. We recorded data on preadmission functional status (independent or dependent) and use of antithrombotic medication. Patients were followed up a median of 4.2 years (range, 2.5-6.4 years). RESULTS: Forty-four patients were included. The majority of the patients (70%) were independent and taking antithrombotic medication (77%). Independent patients had a 1-year mortality of 42%, compared to 69% for dependent patients; 56% of patients taking antithrombotics and 30% of those without antithrombotics died within the first postoperative year. All patients with an admission Glasgow coma scale score of 3-8 died within the first postoperative year, if they used antithrombotics or were dependent before the injury. Of all 1-year survivors, 77% were alive at the end of follow-up. CONCLUSION: In this first surgical case series of 75-year-old or older patients with ASDH, the overall mortality rate appears to be relatively low, especially for preoperatively conscious and independent patients without antithrombotic medication. Patients alive at 1-year after surgery had a life expectancy comparable to their age-matched peers. The prognosis seems to be detrimental for preoperatively unconscious patients who were functionally dependent or used antithrombotic medication before the injury.	[Raj, Rahul; Mikkonen, Era D.; Kivisaari, Riku; Korja, Miikka; Siironen, Jari] Univ Helsinki, Dept Neurosurg, Helsinki, Finland; [Skrifvars, Markus B.] Univ Helsinki, Div Intens Care, Helsinki, Finland; Helsinki Univ Hosp, Helsinki, Finland		Raj, R (corresponding author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.	rahul.br.raj@icloud.com	Raj, Rahul/K-7693-2012; Korja, Miikka/E-4292-2016	Raj, Rahul/0000-0003-4243-9591; Korja, Miikka/0000-0002-4463-6954; Mikkonen, Era Daniel/0000-0003-1379-0235	Finska Lakaresallskapet, Medicinska Understodsforeningen Liv och Halsa; Maud Kuistila Memorial foundation	The study was funded by grants from Finska Lakaresallskapet, Medicinska Understodsforeningen Liv och Halsa, and the Maud Kuistila Memorial foundation.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Hanif S, 2009, Ir Med J, V102, P255; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P191, DOI 10.1007/BF01808958; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; Herou E, 2015, WORLD NEUROSURG, V83, P996, DOI 10.1016/j.wneu.2015.02.023; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taussky P, 2012, WORLD NEUROSURG, V78, P306, DOI 10.1016/j.wneu.2011.10.030; TEASDALE G, 1974, LANCET, V2, P81	27	33	34	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	APR	2016	88						592	597		10.1016/j.wneu.2015.10.095			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DK1CI	WOS:000374649700077	26548818	Green Published			2022-02-06	
J	Bramlett, HM; Dietrich, WD; Dixon, CE; Shear, DA; Schmid, KE; Mondello, S; Wang, KKW; Hayes, RL; Povlishock, JT; Tortella, FC; Kochanek, PM				Bramlett, Helen M.; Dietrich, W. Dalton; Dixon, C. Edward; Shear, Deborah A.; Schmid, Kara E.; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						penetrating ballistic-like brain injury; fluid percussion; biomarker; neuroprotection; rat; controlled cortical impact; therapy	RECOMBINANT-HUMAN-ERYTHROPOIETIN; CORTICAL IMPACT INJURY; FUNCTIONAL RECOVERY; MODEL; MICE; GENE; RATS; NEUROPROTECTION; HYPOTHERMIA; EXPRESSION	Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested given at 15 min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments. There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the 5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI, whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24-4 h delta UCH-L1 levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its further investigation in OBTT.	[Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Shear, Deborah A.; Schmid, Kara E.; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bian XX, 2010, NEUROL MED-CHIR, V50, P361, DOI 10.2176/nmc.50.361; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Jin W, 2011, J TRAUMA, V71, P680, DOI 10.1097/TA.0b013e3181f6b984; Jin W, 2011, ANN CLIN LAB SCI, V41, P25; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liao ZB, 2009, NEUROL INDIA, V57, P722, DOI 10.4103/0028-3886.59466; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Ozisik PA, 2007, SURG NEUROL, V68, P547, DOI 10.1016/j.surneu.2007.01.030; Ozturk E, 2008, PROG NEURO-PSYCHOPH, V32, P81, DOI 10.1016/j.pnpbp.2007.07.016; Ponce Lucido L, 2013, Pathophysiology, V20, P31, DOI 10.1016/j.pathophys.2012.02.005; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	48	33	34	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					538	552		10.1089/neu.2015.4116			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800004	26670694	Green Submitted			2022-02-06	
J	Wang, D; Li, T; Wei, HJ; Wang, Y; Yang, GL; Tian, Y; Zhao, ZL; Wang, L; Yu, SP; Zhang, YQ; Chen, JL; Jiang, RC; Zhang, JN				Wang, Dong; Li, Tuo; Wei, Huijie; Wang, Yi; Yang, Guili; Tian, Ye; Zhao, Zilong; Wang, Liang; Yu, Shengping; Zhang, Yongqiang; Chen, Jieli; Jiang, Rongcai; Zhang, Jian Ning			Atorvastatin enhances angiogenesis to reduce subdural hematoma in a rat model	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Subdural hematoma; Atorvastatin; Angiogenesis; Rat model	ENDOTHELIAL PROGENITOR CELLS; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR; ANGIOPOIETIN-1 AND-2; STATINS; LEAKAGE; VEGF; NEUROGENESIS; INHIBITORS; PERICYTES	Background and purpose: Statins are active in reducing plasma lipids, suppressing inflammation and promoting angiogenesis. Because angiogenesis is critical for the absorbance of subdural hematoma (SDH), we hypothesize that atorvastatin promotes angiogenesis to enhance hematoma absorption. Methods: SDH was induced in adult Wistar rats and treated with 3 mg/kg, 8 mg/kg of atorvastatin, or vehicle saline daily for 7 days. The treated rats were examined for the level of CD34+/CD133+ endothelial progenitor cells (EPCs) in the circulation by flow cytometry, hematoma volumes by magnetic resonance imaging (MRI), and changes in cognitive functions. We also examined angiogenesis in the hematoma wall by transmission electronic microscopy and immunohistochemistry for the expression of vascular endothelial growth factor (VEGF), matrix metalloprotease 9 (MMP 9) and angiopoietin. Results: SDH volume was significantly reduced and neurological deficits improved in rats receiving the low dose atorvastatin compared to those receiving either the high dose of atorvastatin or saline. Consistent with these outcome measures, the low dose atorvastatin increased the expression of angiopoient-1 and VEGF and reduced MMP9 expression in the connective tissue of the SDH wall, resulting in an increased vascular density and enhanced vascular maturation. Conclusions: The low-dose atorvastatin is effective in reducing SDH and improving neurological deficits in a rat model, primarily by promoting angiogenesis and vascular maturation. (C) 2016 Published by Elsevier B.V.	[Wang, Dong; Li, Tuo; Wei, Huijie; Wang, Yi; Tian, Ye; Zhao, Zilong; Zhang, Jian Ning] Tianjin Med Univ, Gen Hosp, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg,Tianjin Neurol Inst, Tianjin, Peoples R China; [Yang, Guili; Yu, Shengping; Zhang, Yongqiang; Jiang, Rongcai] Tianjin Neurol Inst, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg, Tianjin, Peoples R China; [Wang, Liang] Tianjin 5th Ctr Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg,Tianjin Neurol Inst, Tianjin, Peoples R China.; Jiang, RC (corresponding author), Tianjin Neurol Inst, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg, Tianjin, Peoples R China.	54454241@qq.com; lt19880619@sina.com; huijiewei@126.com; sinuosiwo@sina.com; yangguili1985@163.com; yetian1986@gmail.com; ZilongZ@BloodWorksNW.org; 757171007@qq.com; yshpvip@sina.com; friskyzyq@163.com; jieli@neuro.hfh.edu; jiang116216@163.com; jianningzhang@hotmail.com	Zhao, Zilong/AAZ-2196-2020	Wang, Dong/0000-0002-5245-3074	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100920, 81200907, 81501069, 81271359, 81502171]; science and technology grant of Tianjin Health Bureau [2014KZ020]; Tianjin Research Program of Application Foundation and Advanced Technology [14ZCZDSY00179]	We are grateful to Fanglian Chen, Weiyun Cui, Lei Zhou and Liu Li from the Tianjin Neurological Institute for their assistance with the experiments and data analyses. This work was supported by the National Natural Science Foundation of China (grant 81100920, 81200907, 81501069, 81271359 and 81502171), the science and technology grant of Tianjin Health Bureau (2014KZ020) and the Tianjin Research Program of Application Foundation and Advanced Technology (grant 14ZCZDSY00179).	Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Ahmad SA, 2001, CANCER RES, V61, P1255; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Brudno Y, 2013, BIOMATERIALS, V34, P9201, DOI 10.1016/j.biomaterials.2013.08.007; Chauvet S, 2013, CELL MOL LIFE SCI, V70, P1685, DOI 10.1007/s00018-013-1278-4; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Dulak J, 2005, ENDOTHELIUM-J ENDOTH, V12, P233, DOI 10.1080/10623320500476559; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hohenstein A, 2005, J NEUROTRAUM, V22, P518, DOI 10.1089/neu.2005.22.518; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Karabiyikoglu M, 2005, NEUROSURGERY, V57, P565, DOI 10.1227/01.NEU.0000170435.47739.AE; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lam CF, 2008, ANESTH ANALG, V107, P686, DOI 10.1213/ane.0b013e31817e6719; Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012; Li T, 2014, J NEUROL SCI, V341, P88, DOI 10.1016/j.jns.2014.04.009; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298; Naduk-Kik J, 2008, POSTEP HIG MED DOSW, V62, P442; Nagy JA, 2002, COLD SPRING HARB SYM, V67, P227, DOI 10.1101/sqb.2002.67.227; Qin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061831; Ribatti D, 2011, INT J DEV BIOL, V55, P261, DOI 10.1387/ijdb.103167dr; Sata M, 2002, CIRCULATION, V106, pE47, DOI 10.1161/01.CIR.0000030081.54465.2D; Sun TFD, 2005, BRIT J NEUROSURG, V19, P327, DOI 10.1080/02688690500305332; Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Wang D, 2014, J NEUROL SCI, V336, P237, DOI 10.1016/j.jns.2013.11.005; Wang D, 2010, J NEUROTRAUM, V27, P1489, DOI 10.1089/neu.2009.1057; WATANABE S, 1972, J NEUROSURG, V37, P552, DOI 10.3171/jns.1972.37.5.0552; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Xu Y, 2011, NEUROSCIENCE, V181, P292, DOI 10.1016/j.neuroscience.2011.02.051; Yan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067949; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306-4522(02)00175-6	40	33	40	1	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	MAR 15	2016	362						91	99		10.1016/j.jns.2016.01.017			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DH1PW	WOS:000372558400017	26944125				2022-02-06	
J	Fu, TS; Jing, R; McFaull, SR; Cusimano, MD				Fu, Terence S.; Jing, Rowan; McFaull, Steven R.; Cusimano, Michael D.			Health & Economic Burden of Traumatic Brain Injury in the Emergency Department	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article						Concussion; cost of illness; epidemiology; prevention; traumatic brain injury	UNITED-STATES; CARE; TRENDS; POPULATION; ONTARIO; VISITS; COSTS; US; PROGRAM; TBI	Objective: To evaluate epidemiological patterns and lifetime costs of traumatic brain injury (TBI) identified in the emergency department (ED) within a publicly insured population in Ontario, Canada, in 2009. Methods: A nationally representative, population-based database was used to identify TBI cases presenting to Ontario EDs between April 2009 and March 2010. We calculated unit costs for medical treatment and productivity loss, and multiplied these by corresponding incidence estimates to determine the lifetime costs of identified TBI cases across age group, sex, and mechanism of injury. Results: In 2009, there were more than 133,000 ED visits for TBI in Ontario, resulting in a conservative estimate of $945 million in lifetime costs. Lifetime cost estimates ranged from $279 million to $1.22 billion depending on the diagnostic criteria used to define TBI. Peak rates of TBI occurred among young children (ages 0-4 year) and the elderly (ages 85+ years). Males experienced a 53% greater rate of TBI and incurred two-fold higher costs compared with females. Falls, sports/bicyclist-related injuries, and motor vehicle crashes represented 47%, 12%, and 10% of TBI presenting to ED, respectively, and accounted for a significant proportion of costs. Conclusions: This study revealed an enormous health and economic burden associated with TBI identified in the ED setting. Our findings underscore the importance of ongoing surveillance and prevention efforts targeted to vulnerable populations. More research is needed to fully appreciate the burden of TBI across a variety of health care settings.	[Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] St Michaels Hosp, Dept Surg, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] Univ Toronto, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Injury Prevent Res Off, Toronto, ON, Canada; [McFaull, Steven R.] Publ Hlth Agcy Canada, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada		Cusimano, MD (corresponding author), St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off, Dept Surg,Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019		Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research #TIR-103946 and the Ontario Neurotrauma Foundation.	[Anonymous], 1999, JAMA, V282, P974; Berkowitz M, 1987, PERMANENT DISABILITY; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; Canadian Institute for Health Information (CIHI), 2011, NAT HLTH EXP TRENDS; Canadian Institute of Health Information (CIHI), 2008, DAT QUAL STUD EM DEP, VII; Canadian Institute of Health Information (CIHI), 2006, HEAD INJ CAN DEC CHA; Centers for Disease Control and Prevention, 2010, EXT CAUS INJ MORT MA; Chen A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-76; CIHI, 2007, BURD NEUR DIS DIS IN; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2010, CAN J PUBLIC HEALTH, V101, pS58, DOI 10.1007/BF03403848; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cusimano MD, 2008, INJURY PREV, V14, P113, DOI 10.1136/ip.2007.017533; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058868; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Dutton RP, 2011, J TRAUMA, V70, P554, DOI 10.1097/TA.0b013e31820d1062; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fingerhut LA, 2006, INJURY PREV, V12, P24, DOI 10.1136/ip.2005.009076; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Haddix AC, 2003, PREVENTION EFFECTIVE; Hanson HR, 2013, PEDIATRICS, V132, pE859, DOI 10.1542/peds.2013-1704; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Khan S, 2002, BRAIN INJURY, V16, P537, DOI 10.1080/02699050110119862; Lawrence BA, 2011, MED WORK LOSS COST E; Lawrence BA, 2000, INJURY CONTROL SAFET, V7, P97; Mahyr C, 2014, COSTS ASS DEATH INVE; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Mayhew D.R., 2005, BEST PRACTICES GRADU; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Miller T.R., 1995, DATABOOK NONFATAL IN; Miller TR ZE, 2009, NEUROTRAUMA CRITICAL, P445; Ministry of Health and Long-Term Care Health Data Branch, DAT QUAL REV EM TOT; Ministry of Health and Long-Term Care Health Data Branch, AMB SERV BILL; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; Simniceanu A, 2014, TRAFFIC INJ PREV, V15, P734, DOI 10.1080/15389588.2013.867483; Statistics Canada, 2014, TABL 326 0021 CONS P; Statistics Canada, 2013, LIF TABL CAN PROV TE; Statistics Canada, 2013, TABL 202 0407 INC IN; Thurman DJ., 1995, STANDARDS SURVEILLAN; US Department of Health and Human Services, 2010, TRAUMATIC BRAIN INJU; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; W.H. Organization, 2006, NEUR DIS PUBL HLTH C	51	33	33	1	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAR	2016	43	2					238	247		10.1017/cjn.2015.320			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DH5GS	WOS:000372814900003	26842131	Bronze			2022-02-06	
J	Hehar, H; Mychasiuk, R				Hehar, Harleen; Mychasiuk, Richelle			The use of telomere length as a predictive biomarker for injury prognosis in juvenile rats following a concussion/mild traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Programming; Caloric restriction; Exercise; High fat diet; Recovery	OXIDATIVE STRESS; CALORIC RESTRICTION; PROFESSIONAL FOOTBALL; GENE-EXPRESSION; OBESITY; EXERCISE; DISEASE; GENERATION; CORTEX; DAMAGE	Telomeres were originally believed to be passive players in cellular replication, but recent research has highlighted their more active role in epigenetic patterning and promotion of cellular growth and survival. Furthermore, literature demonstrates that telomere length (TL) is responsive to environmental manipulations such as prenatal stress and dietary programming. As the search for a prognostic biomarker of concussion has had limited success, this study sought to examine whether or not telomere length (TL) could be an efficacious predictor of symptom severity in juvenile rats following concussion. Rats from four distinct experimental groups (caloric restriction (CR), high fat diet (HFD), exercise (EX), and standard controls (STD)) received a mild traumatic brain injury (mTBI)/concussion and were then subjected to a behavioural test battery. The test battery was scored and the animals were categorized as poor, average, or good, based on their performance on the 6 tests examined. Skin cells (from ear notch samples) were taken 17 days post-injury and DNA was extracted for telomere length analysis. Ear notch skin cell TL was highly correlated with brain tissue TL for a given individual. Animals in the CR and EX cohorts had significantly longer telomeres, while animals in the HFD cohort had significantly shorter telomeres, when compared to controls. The mTBI/concussion reduced TL in all cohorts except the EX group. A significant linear relationship was found between TL and performance on the behavioural test battery, whereby shorter telomeres were associated with poorer performance and longer telomeres with better performance. As performance on the test battery is linked to symptom severity, this study found TL to be a reasonable tool for concussion prognosis. Future studies with human populations should examine the validity of TL in peripheral cells, as a predictor of concussion pathology. (C) 2015 Elsevier Inc. All rights reserved.	[Hehar, Harleen; Mychasiuk, Richelle] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Fdn, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Fdn, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB, Canada.	rmmychas@ucalgary.ca			Canadian Institute for Health ResearchCanadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute; Markin USRP for Health and Wellness	The authors would like to thank Irene Ma, Rose Tobias, Dr. Michael Esser, and Dr. Cam Teskey for their organizational and research support. They would also like to thank the Canadian Institute for Health Research, the Alberta Children's Hospital Research Institute, and the Markin USRP for Health and Wellness for their financial contributions.	Abdullah AI, 2012, MOL NEUROBIOL, V45, P586, DOI 10.1007/s12035-012-8277-6; Bale TL, 2010, BIOL PSYCHIAT, V68, P314, DOI 10.1016/j.biopsych.2010.05.028; Barker DJP, 2004, J AM COLL NUTR, V23, p588S, DOI 10.1080/07315724.2004.10719428; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blasco MA, 2004, CARCINOGENESIS, V25, P1083, DOI 10.1093/carcin/bgh185; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Eitan E, 2014, TRENDS NEUROSCI, V37, P256, DOI 10.1016/j.tins.2014.02.010; Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225; Entringer S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003580; Entringer S, 2011, P NATL ACAD SCI USA, V108, pE513, DOI 10.1073/pnas.1107759108; Ferezou-Viala J, 2007, AM J PHYSIOL-REG I, V293, pR1056, DOI 10.1152/ajpregu.00117.2007; Gaillard R, 2014, HYPERTENSION, V63, P683, DOI 10.1161/HYPERTENSIONAHA.113.02671; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Gilley D, 2008, MECH AGEING DEV, V129, P27, DOI 10.1016/j.mad.2007.10.010; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Guan JZ, 2008, J GERONTOL A-BIOL, V63, P467, DOI 10.1093/gerona/63.5.467; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; LaRocca TJ, 2010, MECH AGEING DEV, V131, P165, DOI 10.1016/j.mad.2009.12.009; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Lukens JN, 2009, ALZHEIMERS DEMENT, V5, P463, DOI 10.1016/j.jalz.2009.05.666; Mychasiuk R, 2015, NEUROSCIENCE, V288, P145, DOI 10.1016/j.neuroscience.2014.12.034; Mychasiuk R, 2014, JOVE, V8; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; Noeman SA, 2011, DIABETOL METAB SYNDR, V3, DOI 10.1186/1758-5996-3-17; O'Sullivan RJ, 2010, NAT STRUCT MOL BIOL, V17, P1218, DOI 10.1038/nsmb.1897; Pedram M, 2006, MOL CELL BIOL, V26, P1865, DOI 10.1128/MCB.26.5.1865-1878.2006; Proctor CJ, 2002, MECH AGEING DEV, V123, P351, DOI 10.1016/S0047-6374(01)00380-3; Puterman E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010837; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Roberts CK, 2002, CIRCULATION, V106, P2530, DOI 10.1161/01.CIR.0000040584.91836.0D; Robin JD, 2014, GENE DEV, V28, P2464, DOI 10.1101/gad.251041.114; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Seckl JR, 2007, NAT CLIN PRACT ENDOC, V3, P479, DOI 10.1038/ncpendmet0515; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796; Tzanetakou IP, 2012, AGEING RES REV, V11, P220, DOI 10.1016/j.arr.2011.12.003; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang Z., 2010, METHOD MOL BIOL, V662	63	33	34	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAR	2016	87						11	18		10.1016/j.nbd.2015.12.007			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DC1HP	WOS:000368967700002	26709201				2022-02-06	
J	Przekwas, A; Somayaji, MR; Gupta, RK				Przekwas, Andrzej; Somayaji, Mahadevabharath R.; Gupta, Raj K.			Synaptic Mechanisms of Blast-Induced Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						synapse; TBI; neuro-axonal; blast wave injury; mechanobiology; DAI	IN-VITRO; ADHESION; DEFORMATION; STRESS; BIOMECHANICS; SYNAPSES; PROTEINS; NEUREXIN; MODELS; DISPLACEMENT	Blast wave-induced traumatic brain injury (TBI) is one of the most common injuries to military personnel. Brain tissue compression/tension due to blast-induced cranial deformations and shear waves due to head rotation may generate diffuse micro-damage to neuro-axonal structures and trigger a cascade of neurobiological events culminating in cognitive and neurodegenerative disorders. Although diffuse axonal injury is regarded as a signature wound of mild TBI (mTBI), blast loads may also cause synaptic injury wherein neuronal synapses are stretched and sheared. This synaptic injury may result in temporary disconnect of the neural circuitry and transient loss in neuronal communication. We hypothesize that mTBI symptoms such as loss of consciousness or dizziness, which start immediately after the insult, could be attributed to synaptic injury. Although empirical evidence is beginning to emerge; the detailed mechanisms underlying synaptic injury are still elusive. Coordinated in vitro-in vivo experiments and mathematical modeling studies can shed light into the synaptic injury mechanisms and their role in the potentiation of mTBI symptoms.	[Przekwas, Andrzej; Somayaji, Mahadevabharath R.] CFD Res Corp, Computat Med & Biol Div, Huntsville, AL USA; [Gupta, Raj K.] US Army Med Res & Mat Command, Dept Def Blast Injury Res Program Coordinating Of, Ft Detrick, MD USA		Przekwas, A (corresponding author), CFD Res Corp, Computat Med & Biol Div, Huntsville, AL USA.	andrzej.przekwas@cfdrc.com	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	Department of Defense Congressionally Directed Medical Research Programs (CDMRP)United States Department of Defense [W81XWH-11-2-0057]	The authors (AJP and MRS) would like to express their appreciation to the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) under contract W81XWH-11-2-0057 for supporting this work. The authors acknowledge Dr. Vincent Harrand, CFDRC and Prof. Beverly Rzigalinski, Virginia Tech, for reviewing the manuscript.	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Berezin V, 2014, CELL ADHESION MOL IM; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bourgeron T, 2015, NAT REV NEUROSCI, V16, P551, DOI 10.1038/nrn3992; Brennaman LH, 2010, ADV EXP MED BIOL, V663, P299, DOI 10.1007/978-1-4419-1170-4_19; Brockett AT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124859; Calabrese B, 2006, PHYSIOLOGY, V21, P38, DOI 10.1152/physiol.00042.2005; Castaneda P, 2015, J NEUROSCI RES, V93, P1476, DOI 10.1002/jnr.23602; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Ferenc MT, 2009, SHOCKWAVES CAUSE SYN; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Fields RD, 2015, NAT REV NEUROSCI, V16, P756, DOI 10.1038/nrn4023; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Froemke RC, 2015, ANNU REV NEUROSCI, V38, P195, DOI 10.1146/annurev-neuro-071714-034002; Fujita Y, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00338; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Herculano-Houzel S, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.031.2009; High Brigit, 2015, Front Synaptic Neurosci, V7, P9, DOI 10.3389/fnsyn.2015.00009; Ho VM, 2011, SCIENCE, V334, P623, DOI 10.1126/science.1209236; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Kay KR, 2013, NAT PROTOC, V8, P1366, DOI 10.1038/nprot.2013.078; King A. I, 2003, IS HEAD INJURY CAUSE; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Leckband D, 2010, ANNU REV CHEM BIOMOL, V1, P365, DOI 10.1146/annurev-chembioeng-073009-100931; Levinson JN, 2005, NEURON, V48, P171, DOI 10.1016/j.neuron.2005.09.017; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Manibog K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4941; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Maruthamuthu V, 2009, BIOPHYS J, V96, P3005, DOI 10.1016/j.bpj.2008.12.3936; McEwen BS, 2015, NAT NEUROSCI, V18, P1353, DOI 10.1038/nn.4086; Merlo L, 2014, J NEUROTRAUM, V31, P1375, DOI 10.1089/neu.2014.3385; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mikulska K, 2012, CHEM PHYS LETT, V521, P134, DOI 10.1016/j.cplett.2011.11.033; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Mueller JK, 2014, PHYS BIOL, V11, DOI 10.1088/1478-3975/11/5/051001; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Park K, 2013, FUTUR NEUROL, V8, P555, DOI 10.2217/FNL.13.35; Popoli M, 2014, SYNAPTIC STRESS PATH; Post A, 2014, J NEUROSURG, V120, P453, DOI 10.3171/2013.10.JNS131101; Proctor DT, 2015, GLIA, V63, P2023, DOI 10.1002/glia.22875; Ramakers GJA, 2002, TRENDS NEUROSCI, V25, P191, DOI 10.1016/S0166-2236(00)02118-4; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sandi C, 2004, NAT REV NEUROSCI, V5, P917, DOI 10.1038/nrn1555; Savtchenko LP, 2007, P NATL ACAD SCI USA, V104, P1823, DOI 10.1073/pnas.0606636104; Sindi IA, 2014, NEUROBIOL AGING, V35, P746, DOI 10.1016/j.neurobiolaging.2013.09.032; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Sotomayor M, 2008, BIOPHYS J, V94, P4621, DOI 10.1529/biophysj.107.125591; Stemper BD, 2014, PROG NEUROL SURG, V28, P14, DOI 10.1159/000358748; Stenfelt S, 2005, J ACOUST SOC AM, V118, P2373, DOI 10.1121/1.2005847; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tan X.G., 2012, P ASME 2012 INT MECH, P829; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tao CL, 2012, NEUROSCI BULL, V28, P321, DOI 10.1007/s12264-012-1249-z; Turrigiano G, 2011, ANNU REV NEUROSCI, V34, P89, DOI 10.1146/annurev-neuro-060909-153238; Tyler WJ, 2012, NAT REV NEUROSCI, V13, P867, DOI 10.1038/nrn3383; Uhl GR, 2014, NEUROPSYCHOPHARMACOL, V39, P235, DOI 10.1038/npp.2013.240; Weaver JB, 2012, PHYS MED BIOL, V57, P7275, DOI 10.1088/0031-9155/57/22/7275; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Xi XF, 2001, J ACOUST SOC AM, V109, P1226, DOI 10.1121/1.1349183; Zander NE, 2015, J NEUROSCI RES, V93, P1353, DOI 10.1002/jnr.23594; Zhu C, 2014, ANN BIOMED ENG, V42, P388, DOI 10.1007/s10439-013-0904-5; Zou H, 2007, J BIOMECH, V40, P1183, DOI 10.1016/j.jbiomech.2006.06.018	90	33	34	0	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 21	2016	7								2	10.3389/fneur.2016.00002			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE2BD	WOS:000370430300001	26834697	Green Published, gold			2022-02-06	
J	Cao, F; Jiang, Y; Wu, Y; Zhong, JJ; Liu, JS; Qin, XH; Chen, LG; Vitek, MP; Li, FQ; Xu, L; Sun, XC				Cao, Fang; Jiang, Yong; Wu, Yue; Zhong, Jianjun; Liu, Jieshi; Qin, Xinghu; Chen, Ligang; Vitek, Michael P.; Li, Fengqiao; Xu, Lu; Sun, Xiaochuan			Apolipoprotein E-Mimetic COG1410 Reduces Acute Vasogenic Edema following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; blood-brain barrier; COG1410; controlled cortical impact injury; traumatic brain injury; vasogenic edema	CLOSED-HEAD INJURY; E-BASED PEPTIDE; IMPROVES COGNITIVE PERFORMANCE; SYSTEM INFLAMMATORY RESPONSE; E-DEFICIENT MICE; SUBARACHNOID HEMORRHAGE; MICROGLIAL ACTIVATION; BARRIER PERMEABILITY; CEREBRAL EDEMA; MURINE MODEL	The degree of post-traumatic brain edema and dysfunction of the blood-brain barrier (BBB) influences the neurofunctional outcome after a traumatic brain injury (TBI). Previous studies have demonstrated that the administration of apolipoprotein E-mimetic peptide COG1410 reduces the brain water content after subarachnoid hemorrhage, intra-cerebral hemorrhage, and focal brain ischemia. However, the effects of COG1410 on vasogenic edema following TBI are not known. The current study evaluated the effects of 1mg/kg daily COG1410 versus saline administered intravenously after a controlled cortical impact (CCI) injury on BBB dysfunction and vasogenic edema at an acute stage in mice. The results demonstrated that treatment with COG1410 suppressed the activity of matrix metalloproteinase-9, reduced the disruption of the BBB and Evans Blue dye extravasation, reduced the TBI lesion volume and vasogenic edema, and decreased the functional deficits compared with mice treated with vehicle, at an acute stage after CCI. These findings suggest that COG1410 is a promising preclinical therapeutic agent for the treatment of traumatic brain injury.	[Cao, Fang; Wu, Yue; Zhong, Jianjun; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Jiang, Yong; Liu, Jieshi; Qin, Xinghu; Chen, Ligang] Luzhou Med Coll, Affiliated Hosp, Dept Neurosurg, Luzhou, Peoples R China; [Vitek, Michael P.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Li, Fengqiao] Cognosci Inc, Res Triangle Pk, NC USA; [Xu, Lu] Chongqing Med Univ, Chongqing Key Lab Biochem & Mol Pharmacol, Chongqing 400016, Peoples R China		Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	jiangy0122@qq.com; sunxch1445@qq.com		Wu, Yue/0000-0002-9073-5988; Vitek, Michael/0000-0001-8140-8048; sun, xiao chuan/0000-0001-6992-332X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371319, 81371378, 81000528]; Program for New Century Excellent Talents in UniversityProgram for New Century Excellent Talents in University (NCET) [NCET-12-1057]; Foundation for outstanding youth academic technology leaders of Sichuan province [2014JQ0022]	This work was supported by the National Natural Science Foundation of China (81371319, 81371378 & 81000528), the Program for New Century Excellent Talents in University (NCET-12-1057), and the Foundation for outstanding youth academic technology leaders of Sichuan province (2014JQ0022). We thank Cognosci Inc. for providing COG1410.	Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Cao F, 2012, NEURAL REGEN RES, V7, P119, DOI 10.3969/j.issn.1673-5374.2012.02.007; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guo ZD, 2011, ACTA NEUROCHIR SUPPL, V110, P71, DOI 10.1007/978-3-7091-0353-1_13; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Kaufman NA, 2010, BEHAV BRAIN RES, V214, P395, DOI 10.1016/j.bbr.2010.06.017; Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25; Kim GW, 2003, J NEUROSCI, V23, P8733; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Mace BE, 2007, NEUROL RES, V29, P243, DOI 10.1179/016164107X158974; Marmarou A, 2003, ACT NEUR S, V86, P7; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Qiao M, 2001, STROKE, V32, P958, DOI 10.1161/01.STR.32.4.958; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang H, 2013, EXP NEUROL, V241, P67, DOI 10.1016/j.expneurol.2012.11.027; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Wei XE, 2011, J TRAUMA, V71, P1645, DOI 10.1097/TA.0b013e31823498eb; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003	46	33	37	2	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2016	33	2					175	182		10.1089/neu.2015.3887			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DA7PH	WOS:000367995800003	26192010	Green Published			2022-02-06	
J	Berger, M; Nadler, JW; Friedman, A; McDonagh, DL; Bennett, ER; Cooter, M; Qi, WJ; Laskowitz, DT; Ponnusamy, V; Newman, MF; Shaw, LM; Warner, DS; Mathew, JP; James, ML				Berger, Miles; Nadler, Jacob W.; Friedman, Allan; McDonagh, David L.; Bennett, Ellen R.; Cooter, Mary; Qi, Wenjing; Laskowitz, Daniel T.; Ponnusamy, Vikram; Newman, Mark F.; Shaw, Leslie M.; Warner, David S.; Mathew, Joseph P.; James, Michael L.		MAD-PIA Investigators	The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Amyloid-beta; anesthesia; cerebrospinal fluid; isoflurane; propofol; surgery; tau protein	NEUROIMAGING INITIATIVE SUBJECTS; TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E; TOTAL TAU; BIOMARKERS; SURGERY; BETA; ASSOCIATION; PROTEIN; RISK	Background: Preclinical studies have found differential effects of isoflurane and propofol on the Alzheimer's disease (AD)-associated markers tau, phosphorylated tau (p-tau) and amyloid-beta (A beta). Objective: We asked whether isoflurane and propofol have differential effects on the tau/A beta ratio (the primary outcome), and individual AD biomarkers. We also examined whether genetic/intraoperative factors influenced perioperative changes in AD biomarkers. Methods: Patients undergoing neurosurgical/otolaryngology procedures requiring lumbar cerebrospinal fluid (CSF) drain placement were prospectively randomized to receive isoflurane (n = 21) or propofol (n = 18) for anesthetic maintenance. We measured perioperative CSF sample AD markers, performed genotyping assays, and examined intraoperative data from the electronic anesthesia record. A repeated measures ANOVA was used to examine changes in AD markers by anesthetic type over time. Results: The CSF tau/A beta ratio did not differ between isoflurane-versus propofol-treated patients (p = 1.000). CSF tau/A beta ratio and tau levels increased 10 and 24 h after drain placement (p = 2.002x10(-6) and p = 1.985x10(-6), respectively), mean CSF p-tau levels decreased (p = 0.005), and A beta levels did not change (p = 0.152). There was no interaction between anesthetic treatment and time for any of these biomarkers. None of the examined genetic polymorphisms, including ApoE4, were associated with tau increase (n = 9 polymorphisms, p > 0.05 for all associations). Conclusion: Neurosurgery/otolaryngology procedures are associated with an increase in the CSF tau/A beta ratio, and this increase was not influenced by anesthetic type. The increased CSF tau/A beta ratio was largely driven by increases in tau levels. Future work should determine the functional/prognostic significance of these perioperative CSF tau elevations.	[Berger, Miles; Cooter, Mary; Laskowitz, Daniel T.; Newman, Mark F.; Warner, David S.; Mathew, Joseph P.; James, Michael L.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Nadler, Jacob W.] Univ Rochester, Postanesthesia Care Unit, Rochester, NY USA; [Nadler, Jacob W.] Univ Rochester, Dept Anesthesiol, Rochester, NY USA; [Friedman, Allan; Bennett, Ellen R.; Warner, David S.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27710 USA; [McDonagh, David L.] Univ Texas Dallas, Dept Anesthesiol & Pain Management, Neurol Surg Neurol & Neurotherapeut, Dallas, TX 75230 USA; [Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC 27710 USA; [Qi, Wenjing] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA; [Laskowitz, Daniel T.; Warner, David S.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [Ponnusamy, Vikram] Duke Univ, Coll Arts & Sci, Durham, NC 27710 USA; [Newman, Mark F.] Duke Univ, Med Ctr, Private Diagnost Clin, Durham, NC 27710 USA; [Shaw, Leslie M.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA		Berger, M (corresponding author), Duke Univ, Med Ctr, Room 4317, Durham, NC 27710 USA.	miles.berger@duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210; Berger, Miles/0000-0002-2386-5061; Li, Yi-Ju/0000-0001-6996-4834; Sampson, John/0000-0002-0104-7658	Department of Anesthesiology, Duke University Medical Center; NIH T32 grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM08600]; International Anesthesia Research Society Mentored Research Award; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG050918]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K76AG057022, R03AG050918] Funding Source: NIH RePORTER	This work was supported by the Department of Anesthesiology, Duke University Medical Center. MB also acknowledges support from NIH T32 grant #GM08600, an International Anesthesia Research Society Mentored Research Award, and NIH R03 #AG050918.	Anacker C, 2013, NEUROPSYCHOPHARMACOL, V38, P872, DOI 10.1038/npp.2012.253; Anckarsater R, 2014, J NEURAL TRANSM, V121, P649, DOI 10.1007/s00702-013-1156-0; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Berger M, 2014, J CARDIOTHOR VASC AN, V28, P1609, DOI 10.1053/j.jvca.2014.04.014; Cabaleiro-Lago C, 2010, ACS CHEM NEUROSCI, V1, P279, DOI 10.1021/cn900027u; Carrillo MC, 2013, ALZHEIMERS DEMENT, V9, P137, DOI 10.1016/j.jalz.2012.11.003; Chen SY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-21; Collins FS, 2014, NATURE, V505, P612, DOI 10.1038/505612a; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Hampel H, 1999, BRAIN RES, V823, P104, DOI 10.1016/S0006-8993(99)01146-4; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Karch CM, 2014, NEURON, V83, P11, DOI 10.1016/j.neuron.2014.05.041; Kim S, 2011, NEUROLOGY, V76, P69, DOI 10.1212/WNL.0b013e318204a397; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; Mattsson N, 2013, ALZHEIMERS DEMENT, V9, P251, DOI 10.1016/j.jalz.2013.01.010; Mulder C, 2010, CLIN CHEM, V56, P248, DOI 10.1373/clinchem.2009.130518; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Palotas A, 2010, J ALZHEIMERS DIS, V21, P1153, DOI 10.3233/JAD-2010-100702; Papon MA, 2011, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00272; Perret-Liaudet A, 2012, J ALZHEIMERS DIS, V31, P13, DOI 10.3233/JAD-2012-120361; Pica-Mendez AM, 2010, CLIN CHIM ACTA, V411, P1833, DOI 10.1016/j.cca.2010.07.019; Pomara N, 2011, NEUROCHEM RES, V36, P1124, DOI 10.1007/s11064-011-0459-5; Reinsfelt B, 2012, ANN THORAC SURG, V94, P549, DOI 10.1016/j.athoracsur.2012.04.044; Roses AD, 2013, ALZHEIMERS DEMENT, V9, P132, DOI 10.1016/j.jalz.2012.10.009; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Sotiropoulos I, 2008, J NEUROCHEM, V107, P385, DOI 10.1111/j.1471-4159.2008.05613.x; Su X, 2012, MOL MED, V18, P1481, DOI 10.2119/molmed.2012.00351; Tang JXX, 2011, ANESTHESIOLOGY, V115, P727, DOI 10.1097/ALN.0b013e31822e9306; Terrando N, 2015, ANESTH ANALG, V120, P649, DOI 10.1213/ANE.0000000000000624; Trojanowski JQ, 2010, ALZHEIMERS DEMENT, V6, P230, DOI 10.1016/j.jalz.2010.03.008; Vanderstichele H, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt142; Vanderstichele H, 2012, ALZHEIMERS DEMENT, V8, P65, DOI 10.1016/j.jalz.2011.07.004; Xie ZC, 2007, J NEUROSCI, V27, P1247, DOI 10.1523/JNEUROSCI.5320-06.2007; Xie ZC, 2008, ANN NEUROL, V64, P618, DOI 10.1002/ana.21548; Ye XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052887; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhang B, 2013, ANESTHESIOLOGY, V119, P52, DOI 10.1097/ALN.0b013e31828ce55d; Zhang YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027019; Zhang YongJie, 2012, Mycology - An International Journal on Fungal Biology, V3, P2; Zschocke J, 2013, CNS NEUROL DISORD-DR, V12, P1194	44	33	34	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	52	4					1299	1310		10.3233/JAD-151190			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DP9BQ	WOS:000378792100013	27079717	Green Submitted, Green Accepted			2022-02-06	
J	Karve, IP; Zhang, M; Habgood, M; Frugier, T; Brody, KM; Sashindranath, M; Ek, CJ; Chappaz, S; Kile, B; Wright, D; Wang, H; Johnston, L; Daglas, M; Ates, RC; Medcalf, RL; Taylor, JM; Crack, PJ				Karve, Ila P.; Zhang, Moses; Habgood, Mark; Frugier, Tony; Brody, Kate M.; Sashindranath, Maithili; Ek, C. Joakim; Chappaz, Stephane; Kile, Ben T.; Wright, David; Wang, Hong; Johnston, Leigh; Daglas, Maria; Ates, Robert C.; Medcalf, Robert L.; Taylor, Juliet M.; Crack, Peter J.			Ablation of Type-1 IFN Signaling in Hematopoietic Cells Confers Protection Following Traumatic Brain Injury	ENEURO			English	Article						neuroinflammation; traumatic brain injury; type-1 interferon	PROINFLAMMATORY CYTOKINE; INFLAMMATORY RESPONSE; POSITIVE FEEDBACK; INTERFERON-ALPHA; WHITE-MATTER; SPINAL-CORD; ACTIVATION; EXPRESSION; ASTROCYTES; MOUSE	Type-1 interferons (IFNs) are pleiotropic cytokines that signal through the type-1 IFN receptor (IFNAR1). Recent literature has implicated the type-1 IFNs in disorders of the CNS. In this study, we have investigated the role of type-1 IFNs in neuroinflammation following traumatic brain injury (TBI). Using a controlled cortical impact model, TBI was induced in 8-to 10-week-old male C57BL/6J WT and IFNAR1(-/-) mice and brains were excised to study infarct volume, inflammatory mediator release via quantitative PCR analysis and immune cell profile via immunohistochemistry. IFNAR1(-/-) mice displayed smaller infarcts compared with WT mice after TBI. IFNAR1(-/-) mice exhibited an altered anti-inflammatory environment compared with WT mice, with significantly reduced levels of the proinflammatory mediators TNF alpha, IL-1 beta and IL-6, an up-regulation of the anti-inflammatory mediator IL-10 and an increased activation of resident and peripheral immune cells after TBI. WT mice injected intravenously with an anti-IFNAR1 blocking monoclonal antibody (MAR1) 1 h before, 30 min after or 30 min and 2 d after TBI displayed significantly improved histological and behavioral outcome. Bone marrow chimeras demonstrated that the hematopoietic cells are a peripheral source of type-1 IFNs that drives neuroinflammation and a worsened TBI outcome. Type-1 IFN mRNA levels were confirmed to be significantly altered in human postmortem TBI brains. Together, these data demonstrate that type-1 IFN signaling is a critical pathway in the progression of neuroinflammation and presents a viable therapeutic target for the treatment of TBI.	[Karve, Ila P.; Zhang, Moses; Habgood, Mark; Frugier, Tony; Brody, Kate M.; Ek, C. Joakim; Ates, Robert C.; Taylor, Juliet M.; Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia; [Sashindranath, Maithili; Daglas, Maria; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Chappaz, Stephane; Kile, Ben T.] Walter & Eliza Hall Inst Med Res, ACRF Chem Biol Div, Parkville, Vic 3052, Australia; [Wright, David; Wang, Hong; Johnston, Leigh] Florey Inst Neurosci & Mental Hlth, Florey Imaging, Parkville, Vic 3052, Australia		Crack, PJ (corresponding author), Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia.	pcrack@unimelb.edu.au	Johnston, Leigh A/D-7102-2014; Sashindranath, Maithili/AAI-7408-2021; Medcalf, Robert L/E-9632-2011; Crack, Peter/ABE-2065-2020; Kile, Benjamin T/F-6593-2011	Johnston, Leigh A/0000-0002-5032-4674; Sashindranath, Maithili/0000-0002-9712-4784; Crack, Peter/0000-0002-5030-0330; Kile, Benjamin T/0000-0002-8836-8947; Frugier, Tony/0000-0002-1275-5158; Daglas, Maria/0000-0002-9356-4061; Chappaz, Stephane/0000-0003-0574-7544; Brody, Kate/0000-0003-0884-8893; Wright, David/0000-0002-7535-8651	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [628391, 1044714]; Australian Research CouncilAustralian Research Council; Rebecca Cooper Foundation	This work was supported by National Health and Medical Research Council of Australia Project Grant 628391 (PJC) and Project Grant 1044714 (PJC, JMT), an Australian Research Council Future Fellowship (PJC) and the Rebecca Cooper Foundation.	Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Crack PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-37; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dai PH, 2011, J VIROL, V85, P10814, DOI 10.1128/JVI.00104-11; de Weerd NA, 2007, J BIOL CHEM, V282, P20053, DOI 10.1074/jbc.R700006200; Downes CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057948; Field R, 2010, BRAIN BEHAV IMMUN, V24, P996, DOI 10.1016/j.bbi.2010.04.004; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fukuda S, 1996, HUM MUTAT, V7, P123, DOI 10.1002/(SICI)1098-1004(1996)7:2<123::AID-HUMU6>3.0.CO;2-D; Gough DJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000361; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Henry T, 2007, J EXP MED, V204, P987, DOI 10.1084/jem.20062665; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Khorooshi R, 2010, J IMMUNOL, V185, P1258, DOI 10.4049/jimmunol.0901753; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Li P, 2011, BLOOD, V117, P2847, DOI 10.1182/blood-2010-07-294272; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Mikita J, 2011, MULT SCLER J, V17, P2, DOI 10.1177/1352458510379243; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Paintlia MK, 2013, J BIOL CHEM, V288, P3831, DOI 10.1074/jbc.M112.405654; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089; Terai K, 2001, BRAIN RES, V900, P48, DOI 10.1016/S0006-8993(01)02202-8; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang RG, 2011, GLIA, V59, P946, DOI 10.1002/glia.21167; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	49	33	33	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	JAN-FEB	2016	3	1							0128-15.2016	10.1523/ENEURO.0128-15.2016			18	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	EH7AS	WOS:000391925700016	27022620	Green Published, gold			2022-02-06	
J	Kelly, KM; Miller, ER; Lepsveridze, E; Kharlamov, EA; Mchedlishvili, Z				Kelly, Kevin M.; Miller, Eric R.; Lepsveridze, Eka; Kharlamov, Elena A.; Mchedlishvili, Zakaria			Posttraumatic seizures and epilepsy in adult rats after controlled cortical impact	EPILEPSY RESEARCH			English	Article						Traumatic brain injury; Video-EEG monitoring; Mossy fiber sprouting	TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; DENTATE GYRUS; SYNAPTIC REORGANIZATION; FUNCTIONAL-CHANGES; MODEL; HIPPOCAMPUS; EPILEPTOGENESIS; POPULATION; PATTERNS	Posttraumatic epilepsy (PTE) has been modeled with different techniques of experimental traumatic brain injury (TBI) using mice and rats at various ages. We hypothesized that the technique of controlled cortical impact (CCI) could be used to establish a model of PTE in young adult rats. A total of 156 male Sprague-Dawley rats of 2-3 months of age (128 CCI-injured and 28 controls) was used for monitoring and/or anatomical studies. Provoked class 3-5 seizures were recorded by video monitoring in 7/57 (12.3%) animals in the week immediately following CCI of the right parietal cortex; none of the 7 animals demonstrated subsequent spontaneous convulsive seizures. Monitoring with video and/or video-EEG was performed on 128 animals at various time points 8-619 days beyond one week following CCI during which 26 (20.3%) demonstrated nonconvulsive or convulsive epileptic seizures. Nonconvulsive epileptic seizures of >10 s were demonstrated in 7/40 (17.5%) animals implanted with 2 or 3 depth electrodes and usually characterized by an initial change in behavior (head raising or animal alerting) followed by motor arrest during an ictal discharge that consisted of high-amplitude spikes or spike-waves with frequencies ranging between 1 and 2 Hz. Class 3-5 epileptic seizures were recorded by video monitoring in 17/88 (19%) and by video-EEG in 2/40 (5%) CCI-injured animals. Ninety of 156 (58%) animals (79 CCI-injured, 13 controls) underwent transcardial perfusion for gross and microscopic studies. CCI caused severe brain tissue loss and cavitation of the ipsilateral cerebral hemisphere associated with cell loss in the hippocampal CA1 and CA3 regions, hilus, and dentate granule cells, and thalamus. All Timm-stained CCI-injured brains demonstrated ipsilateral hippocampal mossy fiber sprouting in the inner molecular layer. These results indicate that the CCI model of TBI in adult rats can be used to study the structure-function relationships that underlie epileptogenesis and PTE. (C) 2015 Elsevier B.V. All rights reserved.	[Kelly, Kevin M.; Miller, Eric R.; Kharlamov, Elena A.; Mchedlishvili, Zakaria] Allegheny Hlth Network Res Inst, Ctr Neurosci Res, Pittsburgh, PA USA; [Kelly, Kevin M.; Kharlamov, Elena A.; Mchedlishvili, Zakaria] Allegheny Gen Hosp, Dept Neurol, Pittsburgh, PA 15212 USA; [Kelly, Kevin M.; Kharlamov, Elena A.; Mchedlishvili, Zakaria] Dept Neurol, Philadelphia, PA USA; [Kelly, Kevin M.] Drexel Univ, Dept Neurobiol & Anat, Coll Med, Philadelphia, PA 19104 USA; [Lepsveridze, Eka] Ilia State Univ, Fac Nat Sci & Engn, Tbilisi, Georgia		Kelly, KM (corresponding author), Allegheny Gen Hosp, 940 South Tower,320 E North Ave, Pittsburgh, PA 15212 USA.	kelly@wpahs.org; emiller@wpahs.org; eka_lepsveridze@iliauni.edu.ge; zmchedlishvili@sentientmedical.com	Lepsveridze, Eka/ABC-5582-2021		Health Research Formula Fund [RFA 01-07-26]; Pennsylvania Department of Health; Epilepsy Foundation	The authors would like to thank Bo Lu, M.D., who provided technical support for the animal studies, and to Teresa Hentosz for clerical support in the preparation of the manuscript. The study was supported by Health Research Formula Fund RFA 01-07-26, Pennsylvania Department of Health, and a Research Grant from the Epilepsy Foundation to ZM.	BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Belousov AB, 2012, NEUROSCI LETT, V524, P16, DOI 10.1016/j.neulet.2012.06.065; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; BUZSAKI G, 1990, NEUROSCIENCE, V38, P323, DOI 10.1016/0306-4522(90)90031-X; COENEN AML, 1992, EPILEPSY RES, V12, P75, DOI 10.1016/0920-1211(92)90029-S; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2013, EXPERT REV NEUROTHER, V13, P615, DOI [10.1586/ern.13.54, 10.1586/ERN.13.54]; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M, 2010, TRAUMATIC BRAIN INJU, P1; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; JUCKER M, 1994, NEUROSCIENCE, V60, P875, DOI 10.1016/0306-4522(94)90269-0; Kelly Kevin M, 2004, Epilepsy Curr, V4, P176, DOI 10.1111/j.1535-7597.2004.04503.x; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418, DOI 10.1152/jn.1998.79.1.418; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; TAUCK DL, 1985, J NEUROSCI, V5, P1016; VANLUIJTELAAR ELJM, 1986, NEUROSCI LETT, V70, P393, DOI 10.1016/0304-3940(86)90586-0; VERGNES M, 1982, NEUROSCI LETT, V33, P97, DOI 10.1016/0304-3940(82)90136-7; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Williams PA, 2007, NEUROSCIENCE, V149, P943, DOI 10.1016/j.neuroscience.2007.07.067; Willmore LJ, 2009, NEUROCHEM RES, V34, P688, DOI 10.1007/s11064-008-9841-3; Willoughby J.O., 1992, LAB ANIM SCI, V12, P75; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yu WH, 2002, NEUROBIOL AGING, V23, P105, DOI 10.1016/S0197-4580(01)00258-5; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	65	33	33	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	NOV	2015	117						104	116		10.1016/j.eplepsyres.2015.09.009			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY2ID	WOS:000366231100018	26432760				2022-02-06	
J	Zhao, QC; Hu, JX; Xiang, J; Gu, YM; Jin, PS; Hua, F; Zhang, ZS; Liu, YH; Zan, K; Zhang, ZH; Zu, J; Yang, XX; Shi, HJ; Zhu, JN; Xu, Y; Cui, GY; Ye, XC				Zhao, Qiuchen; Hu, Jinxia; Xiang, Jie; Gu, Yuming; Jin, Peisheng; Hua, Fang; Zhang, Zunsheng; Liu, Yonghai; Zan, Kun; Zhang, Zuohui; Zu, Jie; Yang, Xinxin; Shi, Hongjuan; Zhu, Jienan; Xu, Yun; Cui, Guiyun; Ye, Xinchun			Intranasal administration of human umbilical cord mesenchymal stem cells-conditioned medium enhances vascular remodeling after stroke	BRAIN RESEARCH			English	Article						Intranasal administration; Human umbilical cord mesenchymal stem cells; Conditioned medium; Angiopoietin; Vascular remodeling	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MYOCARDIAL-INFARCTION; IN-VITRO; ANGIOGENESIS; EXPRESSION; ANGIOPOIETIN-1; PROMOTE; ACTIVATION; RECOVERY	Stem cell-based treatments have been reported to be a potential strategy for stroke. However, tumorigenic potential and low survival rates of transplanted cells could attenuate the efficacy of the stem cell-based treatments. The application of stem cell-condition medium (CM) may be a practicable approach to conquer these limitations. In this study, we investigated whether intranasal administration of human umbilical cord mesenchymal stem cells (hUCMSCs)-CM has the therapeutic effects in rats after stroke. Adult male rats were subjected to middle cerebral artery occlusion (MCAo) and were treated by intranasal routine with or without hUCMSCs-CM (1 ml/kg/d), starting 24 h after MCAo and daily for 14 days. Neurological functional tests, blood brain barrier (BBB) leakage, were measured. Angiogenesis and angiogenic factor expression were measured by immunohistochemistry, and Western blot, respectively. hUCMSCs-CM treatment of stroke by intranasal routine starting 24 h after MCAo in rats significantly enhances BBB functional integrity and promotes functional outcome but does not decrease lesion volume compared to rats in DMEM/F12 medium control group and saline control group. Treatment of ischemic rats with hUCMSCs-CM by intranasal routine also significantly decreases the levels of Ang2 and increases the levels of both Ang1 and Tie2 in the ischemic brain. To take together, increased expression of Ang1 and Tie2 and decreased expression of Ang2, induced by hUCMSCs-CM treatment, contribute to vascular remodeling in the ischemic brain which plays an important role in functional outcome after stroke. (c) 2015 Elsevier B.V. All rights reserved.	[Zhao, Qiuchen; Xu, Yun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurol, Nanjing 210008, Jiangsu, Peoples R China; [Hu, Jinxia; Hua, Fang; Zhang, Zunsheng; Liu, Yonghai; Zan, Kun; Zhang, Zuohui; Zu, Jie; Yang, Xinxin; Shi, Hongjuan; Zhu, Jienan; Cui, Guiyun; Ye, Xinchun] Xuzhou Med Coll, Affiliated Hosp, Dept Neurol, Xuzhou, Jiangsu, Peoples R China; [Xiang, Jie] Xuzhou Med Coll, Affiliated Hosp, Dept Rehabil Med, Xuzhou, Jiangsu, Peoples R China; [Gu, Yuming] Xuzhou Med Coll, Affiliated Hosp, Dept Intervent Radiol, Xuzhou, Jiangsu, Peoples R China; [Jin, Peisheng] Xuzhou Med Coll, Affiliated Hosp, Dept Plast Surg, Xuzhou, Jiangsu, Peoples R China		Xu, Y (corresponding author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurol, Nanjing 210008, Jiangsu, Peoples R China.	xinchunye@gmail.com	Zhang, Zuohui/AAQ-6728-2021	Zhang, Zuohui/0000-0002-8486-4767	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201025, 81271344, 81571155]; National Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20131118, BL2014031]; Summit of Six Top Talents Program of Jiangsu Province [2013-WSN-081]; Mayor Program of Public Health of Jiangsu Province [Z201208]	This work was supported by the National Natural Science Foundation of China (Nos. 81201025, 81271344 and 81571155), the National Natural Science Foundation of Jiangsu Province (Nos. BK20131118 and BL2014031), the Summit of Six Top Talents Program of Jiangsu Province (No. 2013-WSN-081), and the Mayor Program of Public Health of Jiangsu Province (No. Z201208).	Barcelos LS, 2009, CIRC RES, V104, P1095, DOI 10.1161/CIRCRESAHA.108.192138; Cai LY, 2009, STEM CELLS, V27, P230, DOI 10.1634/stemcells.2008-0273; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Chen JL, 2011, STROKE, V42, P3551, DOI 10.1161/STROKEAHA.111.627174; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Cho YJ, 2012, J NEUROSCI RES, V90, P1794, DOI 10.1002/jnr.23063; Cui GY, 2013, NEUROSCI LETT, V554, P82, DOI 10.1016/j.neulet.2013.08.065; Cui GY, 2013, NEUROSCI LETT, V548, P101, DOI 10.1016/j.neulet.2013.02.072; Cui X, 2011, NEUROBIOL DIS, V43, P285, DOI 10.1016/j.nbd.2011.04.005; Di Santo S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005643; Hang Y, 2012, J MOL NEUROSCI, V46, P236, DOI 10.1007/s12031-011-9584-5; Hori S, 2004, J NEUROCHEM, V89, P503, DOI 10.1111/j.1471-4159.2004.02343.x; Inoue T, 2013, TISSUE ENG PT A, V19, P24, DOI [10.1089/ten.tea.2011.0385, 10.1089/ten.TEA.2011.0385]; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Li Y, 1998, STROKE, V29, P1972, DOI 10.1161/01.STR.29.9.1972; Lin YC, 2011, STROKE, V42, P2045, DOI 10.1161/STROKEAHA.110.603621; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Nourhaghighi N, 2003, LAB INVEST, V83, P1211, DOI 10.1097/01.LAB.0000082383.40635.FE; Perin EC, 2009, CATHETER CARDIO INTE, V73, P281, DOI 10.1002/ccd.21807; Sandhu R, 2004, CARDIOVASC RES, V64, P115, DOI 10.1016/j.cardiores.2004.05.013; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sell S, 2010, AM J PATHOL, V176, P2584, DOI 10.2353/ajpath.2010.091064; Stagg J, 2008, STEM CELL REV, V4, P119, DOI 10.1007/s12015-008-9030-4; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Ye X, 2011, NEUROSCIENCE, V190, P339, DOI 10.1016/j.neuroscience.2011.06.004; Ye XC, 2011, EXP NEUROL, V232, P299, DOI 10.1016/j.expneurol.2011.09.022; Yoon BS, 2010, STEM CELLS DEV, V19, P887, DOI 10.1089/scd.2009.0138; Zacharek A, 2010, STROKE, V41, P524, DOI 10.1161/STROKEAHA.109.568881; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhu JH, 2012, HISTOL HISTOPATHOL, V27, P537, DOI 10.14670/HH-27.537; Zhu SF, 2013, NEUROSCI LETT, V541, P77, DOI 10.1016/j.neulet.2013.03.018	39	33	36	1	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 22	2015	1624						489	496		10.1016/j.brainres.2015.08.003			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW5PY	WOS:000365050100049	26279113				2022-02-06	
J	Ying, CJ; Zhang, F; Zhou, XY; Hu, XT; Chen, J; Wen, XR; Sun, Y; Zheng, KY; Tang, RX; Song, YJ				Ying, Chang-jiang; Zhang, Fang; Zhou, Xiao-yan; Hu, Xiao-tong; Chen, Jing; Wen, Xiang-ru; Sun, Ying; Zheng, Kui-yang; Tang, Ren-xian; Song, Yuan-jian			Anti-inflammatory Effect of Astaxanthin on the Sickness Behavior Induced by Diabetes Mellitus	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Astaxanthin; Diabetes; Inflammation; Cystathionine beta-synthase	CYSTATHIONINE-BETA-SYNTHASE; TRAUMATIC BRAIN-INJURY; HYDROGEN-SULFIDE; FRONTAL-CORTEX; OXIDATIVE STRESS; IN-VIVO; MICE; RATS; ACTIVATION; DEPRESSION	Chronic inflammation appears to play a critical role in sickness behavior caused by diabetes mellitus. Astaxanthin has been used in treating diabetes mellitus and diabetic complications because of its neuroprotective and anti-inflammatory actions. However, whether astaxanthin can improve sickness behavior induced by diabetes and its potential mechanisms are still unknown. The aim of this study was to investigate the effects of astaxanthin on diabetes-elicited abnormal behavior in mice and its corresponding mechanisms. An experimental diabetic model was induced by streptozotocin (150 mg/kg) and astaxanthin (25 mg/kg/day) was provided orally for 10 weeks. Body weight and water consumption were measured, and the sickness behavior was evaluated by the open field test (OFT) and closed field test (CFT). The expression of glial fibrillary acidic protein (GFAP) was measured, and the frontal cortical cleaved caspase-3 positive cells, interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) expression levels were also investigated. Furthermore, cystathionine beta-synthase (CBS) in the frontal cortex was detected to determine whether the protective effect of astaxanthin on sickness behavior in diabetic mice is closely related to CBS. As expected, we observed that astaxanthin improved general symptoms and significantly increase horizontal distance and the number of crossings in the OFT and CFT. Furthermore, data showed that astaxanthin could decrease GFAP-positive cells in the brain and down-regulate the cleaved caspase-3, IL-6, and IL-1 beta, and up-regulate CBS in the frontal cortex. These results suggest that astaxanthin provides neuroprotection against diabetes-induced sickness behavior through inhibiting inflammation, and the protective effects may involve CBS expression in the brain.	[Ying, Chang-jiang] Xuzhou Med Coll, Dept Endocrinol, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China; [Zhang, Fang; Zhou, Xiao-yan; Hu, Xiao-tong; Chen, Jing; Tang, Ren-xian] Xuzhou Med Coll, Lab Morphol, Xuzhou 221004, Jiangsu, Peoples R China; [Wen, Xiang-ru; Song, Yuan-jian] Xuzhou Med Coll, Jiangsu Key Lab Brain Dis Bioinformat, Xuzhou 221004, Jiangsu, Peoples R China; [Sun, Ying] Xuzhou Med Coll, Dept Neurol, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China; [Song, Yuan-jian] Xuzhou Med Coll, Dept Genet, Neurobiol Res Ctr, Jiangsu 221004, Jiangsu, Peoples R China; [Zheng, Kui-yang; Tang, Ren-xian] Xuzhou Med Coll, Dept Pathogen Biol & Immunol, Lab Infect & Immun, Xuzhou 221004, Jiangsu, Peoples R China		Tang, RX (corresponding author), Xuzhou Med Coll, Lab Morphol, Xuzhou 221004, Jiangsu, Peoples R China.	tangrenxian-t@163.com; biosongyuanjian@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371300]; Education Departmental Natural Science Research Funds of Jiangsu Provincial Higher School of China [13KJB310021, 13KJD310003]; Project of Xuzhou science and technology plan [KC14SH076]; Foundation of President of Xuzhou Medical College [2012KJZ06]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Qing Lan Project of Jiangsu Province	This work was supported by the National Natural Science Foundation of China (81371300), the Education Departmental Natural Science Research Funds of Jiangsu Provincial Higher School of China (13KJB310021, 13KJD310003), the Project of Xuzhou science and technology plan (KC14SH076), the Foundation of President of Xuzhou Medical College (2012KJZ06), a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the Qing Lan Project of Jiangsu Province. Thanks to Hongyan Dong, Hongli Yu, Meng Wang, Baole Zhang and Xuebin Qu for their support and help during the experiments.	Aksu I, 2012, NEUROSCI LETT, V531, P176, DOI 10.1016/j.neulet.2012.10.045; Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Aminzadeh MA, 2012, NEPHROL DIAL TRANSPL, V27, P498, DOI 10.1093/ndt/gfr560; Bae SK, 2013, J AM CHEM SOC, V135, P9915, DOI 10.1021/ja404004v; Chen C, 2014, DIS MODEL MECH, V7, P723, DOI 10.1242/dmm.016162; Chen ML, 2007, J PSYCHIATR RES, V41, P57, DOI 10.1016/j.jpsychires.2005.03.005; Choi K, 2012, J PSYCHIATR RES, V46, P882, DOI 10.1016/j.jpsychires.2012.03.021; Chourbaji S, 2006, NEUROBIOL DIS, V23, P587, DOI 10.1016/j.nbd.2006.05.001; Damian JP, 2014, EXP ANIM TOKYO, V63, P277, DOI 10.1538/expanim.63.277; Dong LY, 2013, MAR DRUGS, V11, P960, DOI 10.3390/md11030960; El-Akabawy G, 2014, ANN ANAT, V196, P119, DOI 10.1016/j.aanat.2014.01.003; Enhamre-Brolin E, 2013, BEHAV BRAIN RES, V238, P273, DOI 10.1016/j.bbr.2012.10.036; Fu YY, 2014, CELL MOL NEUROBIOL, V34, P651, DOI 10.1007/s10571-014-0039-8; Gibney SM, 2013, BRAIN BEHAV IMMUN, V28, P170, DOI 10.1016/j.bbi.2012.11.010; Giuliani D, 2013, NEUROBIOL LEARN MEM, V104, P82, DOI 10.1016/j.nlm.2013.05.006; Gong QH, 2011, J ALZHEIMERS DIS, V24, P173, DOI 10.3233/JAD-2011-110128; Harden LM, 2011, PSYCHONEUROENDOCRINO, V36, P608, DOI 10.1016/j.psyneuen.2010.09.003; Holmes C, 2011, NEUROLOGY, V77, P212, DOI 10.1212/WNL.0b013e318225ae07; Ishigami M, 2009, ANTIOXID REDOX SIGN, V11, P205, DOI 10.1089/ARS.2008.2132; Ishiki M, 2013, ENDOCRINOLOGY, V154, P2600, DOI 10.1210/en.2012-2198; Jing YH, 2013, NEUROENDOCRINOLOGY, V98, P116, DOI 10.1159/000350435; Katon W, 2010, DEPRESS ANXIETY, V27, P323, DOI 10.1002/da.20683; Katon WJ, 2013, ANN FAM MED, V11, P245, DOI 10.1370/afm.1501; Keleshian VL, 2013, J NEUROCHEM, V125, P63, DOI 10.1111/jnc.12153; Kidd P, 2011, ALTERN MED REV, V16, P355; Kim YJ, 2009, J AGR FOOD CHEM, V57, P8793, DOI 10.1021/jf9019745; Kimura Y, 2006, ANTIOXID REDOX SIGN, V8, P661, DOI 10.1089/ars.2006.8.661; Kleinridders A, 2014, DIABETES, V63, P2232, DOI 10.2337/db14-0568; Lindahl B, 2008, INT J BEHAV MED, V15, P165, DOI 10.1080/10705500802222311; Liu YW, 2014, PHARMACOL BIOCHEM BE, V117, P128, DOI 10.1016/j.pbb.2013.11.027; Liu YW, 2013, PSYCHOPHARMACOLOGY, V228, P585, DOI 10.1007/s00213-013-3061-5; Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016; Marin DP, 2011, INT IMMUNOPHARMACOL, V11, P103, DOI 10.1016/j.intimp.2010.10.013; Marrero D, 2014, QUAL LIFE RES, V23, P75, DOI 10.1007/s11136-013-0436-3; Meng XF, 2014, MOL NEUROBIOL, V49, P673, DOI 10.1007/s12035-013-8551-2; O'Connor JC, 2005, J IMMUNOL, V174, P4991, DOI 10.4049/jimmunol.174.8.4991; Ola MS, 2014, NEUROL SCI, V35, P1003, DOI 10.1007/s10072-014-1628-5; Patel SS, 2014, METAB BRAIN DIS, V29, P121, DOI 10.1007/s11011-014-9480-0; Petrak F, 2013, DIABETES TECHNOL THE, V15, P702, DOI 10.1089/dia.2012.0257; Qu K, 2008, NEUROCHEM INT, V52, P155, DOI 10.1016/j.neuint.2007.05.016; Rajashree R, 2011, MALAYS J MED SCI, V18, P26; Renner NA, 2013, J CELL PHYSIOL, V228, P1284, DOI 10.1002/jcp.24283; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Saavedra JM, 2012, CELL MOL NEUROBIOL, V32, P667, DOI 10.1007/s10571-011-9754-6; Sajatovic M, 2011, PSYCHIAT SERV, V62, P1001, DOI 10.1176/appi.ps.62.9.1001; Sharma AN, 2010, PHYSIOL BEHAV, V101, P381, DOI 10.1016/j.physbeh.2010.07.002; Shelton RC, 2011, MOL PSYCHIATR, V16, P751, DOI 10.1038/mp.2010.52; Silverman MN, 2013, MOL PSYCHIATR, V18, P1006, DOI 10.1038/mp.2012.131; Sima AAF, 2010, ACTA DIABETOL, V47, P279, DOI 10.1007/s00592-010-0218-0; Sima Anders A F, 2009, Rev Diabet Stud, V6, P37, DOI 10.1900/RDS.2009.6.37; Singh S, 2009, J BIOL CHEM, V284, P22457, DOI 10.1074/jbc.M109.010868; Speranza L, 2012, MAR DRUGS, V10, P890, DOI 10.3390/md10040890; Spulber S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042078; Takao K, 2013, NEUROPSYCHOPHARMACOL, V38, P1409, DOI 10.1038/npp.2013.38; Talaei F, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-1; Tezuka T, 2013, NEUROBIOL DIS, V59, P63, DOI 10.1016/j.nbd.2013.07.003; Tomassoni D, 2013, NEUROSCI LETT, V543, P136, DOI 10.1016/j.neulet.2013.03.025; Tripathi DN, 2008, TOXICOLOGY, V248, P96, DOI 10.1016/j.tox.2008.03.015; Wang HN, 2014, J PSYCHIATR RES, V51, P79, DOI 10.1016/j.jpsychires.2014.01.004; Wilinski B, 2013, PHARMACOL REP, V65, P737, DOI 10.1016/S1734-1140(13)71053-3; Wu TH, 2008, BEHAV BRAIN RES, V193, P183, DOI 10.1016/j.bbr.2008.05.009; Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5; Zhang MY, 2013, NEUROCHEM RES, V38, P714, DOI 10.1007/s11064-013-0969-4; Zhang Q, 2014, PHARMACOL RES, V84, P32, DOI 10.1016/j.phrs.2014.04.009; Zhang XZ, 2014, ACS CHEM NEUROSCI, V5, P876, DOI 10.1021/cn500185g	66	33	36	4	38	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	OCT	2015	35	7					1027	1037		10.1007/s10571-015-0197-3			11	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	CR6VP	WOS:000361486300012	25971983				2022-02-06	
J	Taylor, HG; Orchinik, LJ; Minich, N; Dietrich, A; Nuss, K; Wright, M; Bangert, B; Rusin, J; Yeates, KO				Taylor, H. Gerry; Orchinik, Leah J.; Minich, Nori; Dietrich, Ann; Nuss, Kathryn; Wright, Martha; Bangert, Barbara; Rusin, Jerome; Yeates, Keith Owen			Symptoms of Persistent Behavior Problems in Children With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						child; brain; injury; neurobehavioral manifestations; traumatic mild	POST-CONCUSSIVE SYNDROME; CLOSED-HEAD-INJURY; 1ST 6 MONTHS; POSTCONCUSSIVE SYMPTOMS; YOUNG-CHILDREN; ADOLESCENTS; OUTCOMES; TERM	Objective: To investigate the effects of mild traumatic brain injury (mTBI) in children on symptom ratings of behavior problems across the first-year postinjury. Setting: Emergency departments of 2 regional children's hospitals. Participants: Parents of 176 children with mTBI and 90 children with orthopedic injury aged 8 to 15 years. Design: Group comparisons of postinjury parent and teacher ratings of child behavior problems controlling for background factors. Main Measures: Child Behavior Checklist and Teacher's Report Form. Results: For younger but not older children in the sample, children with mTBI compared with children with orthopedic injury had higher postinjury ratings on the Child Behavior Checklist Total Behavior Problem scale (t(264)=3.34, P<.001) and higher rates of T-scores of 60 or more on this scale (odds ratio=3.00; 95% confidence interval, 1.33-6.77; P=.008). For children with mTBI, hospitalization, motor vehicle accidents, loss of consciousness, and magnetic resonance imaging abnormality were associated with higher parent or teacher ratings. Conclusions: School-aged children with mTBI are at risk for persistent symptoms of behavior problems, especially if mTBI is more severe or occurs at a younger age. The findings justify monitoring of behavior long after injury and further research to identify risk factors for these symptoms and their association with clinical disorders.	[Taylor, H. Gerry; Minich, Nori; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Orchinik, Leah J.] Case Western Reserve Univ, Dept Psychol Sci, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, WO Walker Bldg,Ste 3150,10524 Euclid Ave, Cleveland, OH 44106 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA; [Yeates, Keith Owen] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA		Taylor, HG (corresponding author), Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, WO Walker Bldg,Ste 3150,10524 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@case.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD39834, K02HD44099]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	This research was funded by project grants R01HD39834 and K02HD44099 from the National Institute of Child Health and Human Development to Dr Yeates. The authors thank Lauren Ayr, Anne Birnbaum, Amy Clemens, Taryn Fay, Amanda Lininger, Katie Pestro, Elizabeth Roth, Elizabeth Shaver, and Heidi Walker for their assistance in carrying out this project.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Faul M, 2002, TRAUMATIC BRAIN INJU; Fidell L.S., 1983, USING MULTIVARIATE S; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hawkins DM, 2004, J CHEM INF COMP SCI, V44, P1, DOI 10.1021/ci0342472; Keightley ML, 2014, ARCH PHYS MED REHAB, V93, P5192; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Petty CR, 2008, J ANXIETY DISORD, V22, P532, DOI 10.1016/j.janxdis.2007.04.003; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wechsler D., 2011, WECHSLER ABBREVIATED; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	45	33	33	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					302	310		10.1097/HTR.0000000000000106			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400008	25629259	Green Accepted			2022-02-06	
J	Mitchell, LA; Hirdes, J; Poss, JW; Slegers-Boyd, C; Caldarelli, H; Martin, L				Mitchell, Lori A.; Hirdes, John; Poss, Jeff W.; Slegers-Boyd, Caroline; Caldarelli, Hilary; Martin, Lynn			Informal caregivers of clients with neurological conditions: profiles, patterns and risk factors for distress from a home care prevalence study	BMC HEALTH SERVICES RESEARCH			English	Article							PARKINSONS-DISEASE; FAMILY CAREGIVERS; BRAIN-INJURY; BURDEN; DEMENTIA; DEPRESSION; SUPPORT; PEOPLE; INTERVENTION; EXPERIENCES	Background: Individuals living in the community with neurological conditions receive the majority of their care from informal caregivers. The purpose of this project was to provide a profile of caregivers of home care clients with neurological conditions. The study also examined prevalence of caregiver distress and the association between neurological conditions and other client and caregiver characteristics with distress. Methods: The study population included Canadian home care clients in the Winnipeg Regional Health Authority in Manitoba and in the province of Ontario. Clients with RAI-Home Care (RAI-HC) assessment data from 2003 to 2010 were examined. Neurological conditions of interest included Alzheimer's disease and related dementias, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington disease, epilepsy, muscular dystrophy, cerebral palsy, traumatic brain injury, spinal cord injury, and stroke. Descriptive statistics were analyzed to describe home care client characteristics and caregiver characteristics for each neurological condition. Logistic regression analysis was used to identify risk factors associated with caregiver distress. Results: A substantial proportion of home care clients were found to have one or more of the neurological conditions (38.8 % to 41.9 %). Caregiver distress was twice as prevalent among caregivers of clients with neurological conditions (28.0 %). The largest associations with caregiver distress were the amount of informal care hours provided in a week and the MAPLe algorithm, an indicator of a client's level of priority for care. After adjustment for client characteristics, Huntington disease was the neurological condition most strongly associated with caregiver distress. However, clients' clinical characteristics and informal care hours had a stronger association with caregiver distress than the presence of a neurological condition. Provision of formal home care services provided a protective effect from caregiver distress. Conclusions: Neurological conditions are common among home care clients and a significant proportion of informal caregivers providing care to these clients experience distress. The complexity of clients with neurological conditions suggests the need for multicomponent support strategies for informal caregivers.	[Mitchell, Lori A.; Slegers-Boyd, Caroline] Winnipeg Reg Hlth Author, Home Care Program, Winnipeg, MB, Canada; [Hirdes, John; Poss, Jeff W.; Caldarelli, Hilary] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada; [Martin, Lynn] Lakehead Univ, Dept Hlth Sci, Thunder Bay, ON P7B 5E1, Canada		Mitchell, LA (corresponding author), Winnipeg Reg Hlth Author, Home Care Program, Winnipeg, MB, Canada.	lmitchell3@wrha.mb.ca			Public Health Agency of Canada; Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario	Funding for the study was provided by the Public Health Agency of Canada. The opinions expressed in this publication are those of the authors/researchers, and do not necessarily reflect the official views of the Public Health Agency of Canada. In addition, JPH holds the Ontario Home Care Research and Knowledge Exchange Chair funded by the Ontario Ministry of Health and Long-Term Care. The authors would like to thank Hal Loewen, Medical Rehabilitation Librarian at the University of Manitoba's Neil John Maclean Health Sciences Library in Winnipeg Manitoba for his literature search services.	Aarsland D, 2007, J NEUROL NEUROSUR PS, V78, P36, DOI 10.1136/jnnp.2005.083113; Alshubaili AF, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-206; Aubeeluck A, 2007, CLIN GENET, V71, P434, DOI 10.1111/j.1399-0004.2007.00784.x; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bogard CL, 2010, THESIS U MINNESOTA M; Bostrom Katrin, 2006, Clin Nurs Res, V15, P86, DOI 10.1177/1054773805285706; Bowes A, 2003, HEALTH SOC CARE COMM, V11, P387, DOI 10.1046/j.1365-2524.2003.00440.x; Buchanan R, 2010, DISABIL REHABIL, V32, P500, DOI 10.3109/09638280903171485; Burrows AB, 2000, AGE AGEING, V29, P165, DOI 10.1093/ageing/29.2.165; Chappell NL, 2002, GERONTOLOGIST, V42, P772, DOI 10.1093/geront/42.6.772; Cifu DX, 2006, J REHABIL RES DEV, V43, P499, DOI 10.1682/JRRD.2005.08.1365; Etters L, 2008, J AM ACAD NURSE PRAC, V20, P423, DOI 10.1111/j.1745-7599.2008.00342.x; Finlayson M, 2008, DISABIL REHABIL, V30, P1848, DOI 10.1080/09638280701707324; Garity J, 2006, J GERONTOL NURS, V32, P39, DOI 10.3928/00989134-20060601-07; Grant I, 2003, AM J GERIAT PSYCHIAT, V11, P62, DOI 10.1176/appi.ajgp.11.1.62; Health Council of Canada, 2012, SEN NEED CAR DISTR W; Hirdes JP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-9; Hirdes JP, 2003, J AM GERIATR SOC, V51, P96, DOI 10.1034/j.1601-5215.2002.51017.x; Ho Samuel M. Y., 2008, Hong Kong Medical Journal, V14, P286; Isaksson G, 2008, SCAND J OCCUP THER, V15, P236, DOI 10.1080/11038120802194265; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Kenneson A, 2010, HEALTH SOC CARE COMM, V18, P520, DOI 10.1111/j.1365-2524.2010.00930.x; Kramer BJ, 2000, HEALTH SOC WORK, V25, P97, DOI 10.1093/hsw/25.2.97; Kumamoto K, 2006, INT J GERIATR PSYCH, V21, P163, DOI 10.1002/gps.1445; Martinez-Martin P, 2008, MOVEMENT DISORD, V23, P1673, DOI 10.1002/mds.22106; McConaghy Ronelle, 2005, Nurs Health Sci, V7, P81, DOI 10.1111/j.1442-2018.2005.00213.x; McEwan L, 2007, EPILEPSY BEHAV, V11, P13, DOI 10.1016/j.yebeh.2007.02.019; Morris JN, 2000, CAN J AGING, V19, P87, DOI 10.1017/S071498080001391X; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Morris JN, 2002, RAI HOME CARE RAI HC; O'Connor EJ, 2011, QUAL LIFE RES, V20, P703, DOI 10.1007/s11136-010-9804-4; Pagnini F, 2010, PSYCHOL HEALTH MED, V15, P685, DOI 10.1080/13548506.2010.507773; Post MWM, 2005, SPINAL CORD, V43, P311, DOI 10.1038/sj.sc.3101704; Rabkin JG, 2009, AMYOTROPH LATERAL SC, V10, P448, DOI 10.1080/17482960802459889; Roscoe LA, 2009, HEALTH COMMUN, V24, P239, DOI 10.1080/10410230902804133; Shaw WS, 2003, J PSYCHOSOM RES, V54, P293, DOI 10.1016/S0022-3999(02)00412-9; Van doorne-huiskes A., 2003, COMMUNITY WORK FAM, V6, P223, DOI [10.1080/1366880032000143438, DOI 10.1080/136688003200014343810.1080/1366880032000143438]; W.H. Organization, 2006, NEUR DIS PUBL HLTH C	40	33	34	0	30	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1472-6963		BMC HEALTH SERV RES	BMC Health Serv. Res.	AUG 28	2015	15								350	10.1186/s12913-015-1010-1			12	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	CP7YS	WOS:000360106700005	26315104	gold, Green Published			2022-02-06	
J	O'Neill, BR; Handler, MH; Tong, SH; Chapman, KE				O'Neill, Brent R.; Handler, Michael H.; Tong, Suhong; Chapman, Kevin E.			Incidence of seizures on continuous EEG monitoring following traumatic brain injury in children	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						continuous EEG; traumatic brain injury; abusive head trauma; subclinical seizure; early posttraumatic seizure	ABUSIVE HEAD TRAUMA; EARLY POSTTRAUMATIC SEIZURES; NONCONVULSIVE ELECTROGRAPHIC SEIZURES; RADIOLOGICAL ASPECTS; NEUROPATHOLOGY; EPILEPSY; SCALE; COMA	OBJECT Seizures may cause diagnostic confusion and be a source of metabolic stress after traumatic brain injury (TBI) in children. The incidence of electroencephalography (EEG)-confirmed seizures and of subclinical seizures in the pediatric population with TBI is not well known. METHODS A routine protocol for continuous EEG (cEEG) monitoring was initiated for all patients with moderate or severe TBI at a Level 1 pediatric trauma center. Over a 3.5-year period, all patients with TBI who underwent cEEG monitoring, both according to protocol and those with mild head injuries who underwent cEEG monitoring at the discretion of the treating team, were identified prospectively. Clinical data were collected and analyzed. RESULTS Over the study period, 594 children were admitted with TBI, and 144 of these children underwent cEEG monitoring. One hundred two (71%) of these 144 children had moderate or severe TBI. Abusive head trauma (AHT) was the most common mechanism of injury (65 patients, 45%) in children with cEEG monitoring. Seizures were identified on cEEG in 43 patients (30%). Forty (93%) of these 43 patients had subclinical seizures, including 17 (40%) with only subclinical seizures and 23 (53%) with both clinical and subclinical seizures. Fifty-three percent of patients with seizures experienced status epilepticus. Age less than 2.4 years and AHT mechanism were strongly correlated with presence of seizures (odds ratios 8.7 and 6.0, respectively). Those patients with only subclinical seizures had the same risk factors as the other groups. The presence of seizures did not correlate with discharge disposition but was correlated with longer hospital stay and intensive care unit stay. CONCLUSIONS Continuous EEG monitoring identifies a significant number of subclinical seizures acutely after TBI. Children younger than 2.4 years of age and victims of AHT are particularly vulnerable to subclinical seizures, and Seizures in general. Continuous EEG monitoring allows for accurate diagnosis and timely treatment of posttraumatic seizures, and may mitigate secondary injury to the traumatized brain.	[O'Neill, Brent R.; Handler, Michael H.] Univ Colorado, Childrens Hosp Colorado, Dept Neurosurg, Aurora, CO 80045 USA; [Chapman, Kevin E.] Univ Colorado, Childrens Hosp Colorado, Dept Neurol, Aurora, CO 80045 USA; [Tong, Suhong; Chapman, Kevin E.] Univ Colorado, Childrens Hosp Colorado, Dept Pediat, Aurora, CO 80045 USA		O'Neill, BR (corresponding author), Univ Colorado, Childrens Hosp Colorado, Dept Neurosurg, 13123 E 16th Ave,B-330, Aurora, CO 80045 USA.	brent.oneill@childrenscolorado.org					Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bourgeois M, 2008, CHILD NERV SYST, V24, P169, DOI 10.1007/s00381-007-0493-4; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Faul M, 2010, TRAUMATIC BRAIN INJU; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Goldstein JL, 2011, NEUROCRIT CARE, V15, P63, DOI 10.1007/s12028-010-9468-5; Hasbani DM, 2013, PEDIATR CRIT CARE ME, V14, P709, DOI 10.1097/PCC.0b013e3182917b83; HENDRICK EB, 1968, J TRAUM, V8, P547; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maguire S, 2009, ARCH DIS CHILD, V94, P860, DOI 10.1136/adc.2008.150110; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Rakhade SN, 2009, NAT REV NEUROL, V5, P380, DOI 10.1038/nrneurol.2009.80; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Schreiber JM, 2012, NEUROCRIT CARE, V17, P31, DOI 10.1007/s12028-012-9715-z; Sieswerda-Hoogendoorn T, 2012, EUR J PEDIATR, V171, P617, DOI 10.1007/s00431-011-1611-6; Sieswerda-Hoogendoorn T, 2012, EUR J PEDIATR, V171, P415, DOI 10.1007/s00431-011-1598-z; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Welker KM, 2012, SEMIN NEUROL, V32, P15, DOI 10.1055/s-0032-1306382; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	30	33	34	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2015	16	2					167	176		10.3171/2014.12.PEDS14263			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CN8PB	WOS:000358702000009	25955809	Bronze			2022-02-06	
J	Scholten, AC; Polinder, S; Panneman, MJM; van Beeck, EF; Haagsma, JA				Scholten, Annemieke C.; Polinder, Suzanne; Panneman, Martien J. M.; van Beeck, Ed F.; Haagsma, Juanita A.			Incidence and costs of bicycle-related traumatic brain injuries in the Netherlands	ACCIDENT ANALYSIS AND PREVENTION			English	Article; Proceedings Paper	2nd International Conference on Transportation Information and Safety (ICTIS)	JUN 29-JUL 02, 2013	Wuhan, PEOPLES R CHINA			Bicycle; Bicycle-related injury; Traumatic brain injury; Risk groups; Prevention	QUALITY-OF-LIFE; HELMET LEGISLATION; NEW-ZEALAND; POPULATION; EPIDEMIOLOGY; EUROPE; TRENDS; RETURN; WORK	The main cause of death and serious disability in bicycle accidents is traumatic brain injury (TBI). The aim of this population-based study was to assess the incidence and costs of bicycle-related TBI across various age groups, and in comparison to all bicycle-related injuries, to identify main risk groups for the development of preventive strategies. Data from the National Injury Surveillance System and National Medical Registration were used for all patients with bicycle-related injuries and TBI who visited a Dutch emergency department (ED) between 1998 and 2012. Demographics and national, weighted estimates of injury mechanism, injury severity and costs were analysed per age group. Direct healthcare costs and indirect costs were determined using the incidence-based Dutch Burden of Injury Model. Between 1998 and 2012, the incidence of ED treatments due to bicycle-related TBI strongly increased with 54%, to 43 per 100,000 persons in 2012. However, the incidence of all bicycle-related injuries remained stable, from 444 in 1998 to 4561100,000 in 2012. Incidence of hospital admission increased in both TBI (92%) and all injuries from cycling (71%). Highest increase in incidence of both ED treatments and hospital admissions was seen in adults aged 55+. The injury rate of TBI per kilometre travelled increased (44%) except in children, but decreased (-4%) for all injuries, showing a strong decrease in children (-36%) but an increase in men aged 25+, and women aged 15+. Total costs of bicycle-related TBI were (sic)74.5 million annually. Although bicycle-related TBI accounted for 9% of the incidence of all ED treatments due to cycling, it accounted for 18% of the total costs due to all bicycle-related injuries ((sic)410.7 million). Children and adolescents (aged 0-24) had highest incidence of ED treatments due to bicycle-related injuries. Men in the working population (aged 15-64) had highest indirect costs following injuries from cycling, including TBI. Older cyclists (aged 55+) were identified as main risk group for TBI, as they had highest ED attendance, injury rate, injury severity, admission to hospital or intensive care unit, and costs. Incidence of ED treatments due to cycling are high and often involve TBI, imposing a high burden on individuals and society. Older cyclists aged 55+ were identified as main risk group for TBI to be targeted in preventive strategies, due to their high risk for (serious) injuries and ever-increasing share of ED visits and hospital admissions. (C) 2015 Elsevier Ltd. All rights reserved.	[Scholten, Annemieke C.; Polinder, Suzanne; van Beeck, Ed F.; Haagsma, Juanita A.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Panneman, Martien J. M.] Consumer & Safety Inst, Res Dept, Amsterdam, Netherlands		Scholten, AC (corresponding author), Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.	a.scholten@erasmusmc.nl					Aertsens J, 2010, ACCIDENT ANAL PREV, V42, P2149, DOI 10.1016/j.aap.2010.07.008; Airaksinen N., 2010, ANN ADV AUTOMOTIVE M, V54, P267; Amoros Emmanuelle, 2011, BMC Public Health, V11, P653, DOI 10.1186/1471-2458-11-653; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; BOVAG RAI Foundation, 2013, MOBILITY IN FIGURES; Chen WS, 2013, ACAD EMERG MED, V20, P570, DOI 10.1111/acem.12146; Consumer and Safety Institute, 2011, FACT SHEET BICYCLE A; Consumer and Safety Institute, 2005, THE DUTCH BURDEN OF; Consumer and Safety Institute, 2013, FACT SHEET NATIONAL; Consumer and Safety Institute and Institute for Road Safety Research (SWOV), 2012, FACTSH COOL KOP HELM; de Putter CE, 2012, J BONE JOINT SURG AM, V94A, DOI 10.2106/JBJS.K.00561; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; EilertPetersson E, 1997, ACCIDENT ANAL PREV, V29, P363, DOI 10.1016/S0001-4575(97)00002-X; Godefrooij T., 1997, GREENING URBAN TRANS, P229; Goldenbeld C., 2003, TIJDSCHRIFT VOOR GEZ, V81, P18; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-1; Hansen P, 1995, AUST J PUBLIC HEALTH, V19, P450; Hefny AF, 2012, INJURY, V43, P1547, DOI 10.1016/j.injury.2011.05.016; Hendriksen I., 2008, ELECTRIC BICYCLES MA; Holtslag HR, 2007, CLIN REHABIL, V21, P373, DOI 10.1177/0269215507072084; Institute for Health Metrics and Evaluation, 2013, GBD COMPARE FROM INS; Karkhaneh M, 2008, ACCIDENT ANAL PREV, V40, P192, DOI 10.1016/j.aap.2007.05.006; Karkhaneh M, 2013, ACCIDENT ANAL PREV, V59, P206, DOI 10.1016/j.aap.2013.05.027; Konkin DE, 2006, AM J SURG, V191, P615, DOI 10.1016/j.amjsurg.2006.02.012; Kopjar B, 2000, PREV MED, V30, P401, DOI 10.1006/pmed.2000.0645; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; Kuhn M., 2012, SAFETY ASPECTS OF HI; Meerding WJ, 2006, EUR J PUBLIC HEALTH, V16, P271, DOI 10.1093/eurpub/ckl006; Meerding WJ, 2010, INT J INJ CONTROL SA, V17, P13, DOI 10.1080/17457300903523237; Ministry of Transport and Fietsberaad, 2009, CYCLING IN THE NETHE; Mulder S, 2002, INJURY PREV, V8, P74, DOI 10.1136/ip.8.1.74; OECD, 2012, CLOSING THE GENDER G; Olivier J, 2013, ACCIDENT ANAL PREV, V50, P1128, DOI 10.1016/j.aap.2012.09.003; Oostenbrink JB, 2002, PHARMACOECONOMICS, V20, P443, DOI 10.2165/00019053-200220070-00002; Papoutsi S, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/850236; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Pucher J., 2012, TRANSPORT RES NEWS, V280, P34; Pucher J, 2008, TRANSPORT RES REC, P58, DOI 10.3141/2074-08; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Rivara FP, 2015, INJURY PREV, V21, P47, DOI 10.1136/injprev-00002-0038rep; Scheiman S, 2010, ACCIDENT ANAL PREV, V42, P758, DOI 10.1016/j.aap.2009.11.005; Schepers JP, 2014, ACCIDENT ANAL PREV, V73, P174, DOI 10.1016/j.aap.2014.09.010; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Statistics Netherlands (CBS), 2013, POPULATION DATA; Stone M, 2003, ACCIDENT ANAL PREV, V35, P549, DOI 10.1016/S0001-4575(02)00032-5; SWOV Institute for Road Safety Research, 2014, MOBILITY OF PERSONS; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Taylor M, 2002, INJ PREV, V8, P317, DOI 10.1136/ip.8.4.317; Thompson D. C., 2000, COCHRANE DATABASE SY, V2; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1388, DOI 10.2105/AJPH.80.11.1388; Van der Stegen R.H.M., 2009, DISCRIPTION OF METHO; Veisten K, 2007, ACCIDENT ANAL PREV, V39, P1162, DOI 10.1016/j.aap.2007.03.002; Villamor E, 2008, CHILD CARE HLTH DEV, V34, P743, DOI 10.1111/j.1365-2214.2008.00882.x; Zimmerman K, 2012, ACCIDENT ANAL PREV, V45, P204, DOI 10.1016/j.aap.2011.06.018	55	33	33	1	25	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	AUG	2015	81						51	60		10.1016/j.aap.2015.04.022			10	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	CM2YR	WOS:000357548800006	25939135				2022-02-06	
J	Reneker, JC; Moughiman, MC; Cook, CE				Reneker, Jennifer C.; Moughiman, M. Clay; Cook, Chad E.			The diagnostic utility of clinical tests for differentiating between cervicogenic and other causes of dizziness after a sports-related concussion: An international Delphi study	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Sports-related concussion; Cervical dizziness differential diagnosis; Delphi method	PROFESSIONAL FOOTBALL; WHIPLASH INJURY; PEOPLE; PAIN; DISTURBANCES; UNSTEADINESS; BIOMECHANICS; DISORDERS; STATEMENT; SEVERITY	Objectives: Dizziness after a sports-related concussion is very common and is associated with prolonged recovery. The events in sports that cause concussion include strong mechanical forces exerted to the head and neck, potentially injuring the cervical region, the peripheral vestibular and central nervous system, all of which can contribute to a sensation of dizziness. The purpose of this study was to identify proper clinically administered tests and measures that are useful in differentiating between cervicogenic and other causes of dizziness after a sports-related concussion. Design: The Delphi method. Methods: The workgroup identified the initial list of suggested clinical tests and the initial list of content experts on dizziness and/or concussion through a search of peer-reviewed and grey literature. The respondent group included all invited experts who opted to participate. A sequential three-round process was used for elicitation of consensus opinions from the targeted content experts. Results: The respondent group included 25 members from several medical disciplines who were experts in concussion and dizziness. At the conclusion of the study, ten clinical tests achieved the designation of strong clinical utility, six were determined to have weak clinical utility and seven achieved no consensus among the experts. Conclusions: The majority of clinical tests identified as having strong clinical utility are tests used to identify dizziness originating from the vestibular or central nervous system. No clinical tests specific for the cervical region achieved consensus. Expert opinion from different medical professions and even within professions was widely divergent regarding the utility of clinical tests to assess cervical dysfunction. Published by Elsevier Ltd on behalf of Sports Medicine Australia.	[Reneker, Jennifer C.; Cook, Chad E.] Walsh Univ, Div Phys Therapy, North Canton, OH USA; [Reneker, Jennifer C.; Moughiman, M. Clay] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Community Based Outpatient Therapy, Akron, OH USA		Reneker, JC (corresponding author), 2020 East Maple St NE, North Canton, OH 44720 USA.	JReneker@Walsh.edu	Reneker, Jennifer/N-2038-2016	Reneker, Jennifer/0000-0003-3617-5681			Al-Saif A, 2012, J AM SCI, V8, P483; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Ardic FN, 2006, OTOL NEUROTOL, V27, P676; Bossuyt PMM, 2012, CLIN CHEM, V58, P1636, DOI 10.1373/clinchem.2012.182576; Colledge NR, 1996, BMJ-BRIT MED J, V313, P788; DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Hansson EE, 2006, J REHABIL MED, V38, P387, DOI 10.1080/16501970600768992; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Malmstrom EM, 2007, DISABIL REHABIL, V29, P1193, DOI 10.1080/09638280600948383; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Nacci A, 2011, ACTA OTORHINOLARYNGO, V31, P378; Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x; Reid SA, 2008, MANUAL THER, V13, P357, DOI 10.1016/j.math.2007.03.006; Reid SA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-201; Schneider K, 2009, CLIN J SPORT MED, V19, P265; Schneider K, 2012, CLIN J SPORT MED, V22, P295; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2008, MANUAL THER, V13, P2, DOI 10.1016/j.math.2007.06.003; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Tuo Kwo-Shieng, 2006, J Chin Med Assoc, V69, P591; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Wells C, 2014, PHYS THER, V94, P792, DOI 10.2522/ptj.20130030; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755	28	33	35	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUL	2015	18	4					366	372		10.1016/j.jsams.2014.05.002			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CL3HL	WOS:000356840900002	24933505				2022-02-06	
J	Yue, JK; Pronger, AM; Ferguson, AR; Temkin, NR; Sharma, S; Rosand, J; Sorani, MD; McAllister, TW; Barber, J; Winkler, EA; Burchard, EG; Hu, DL; Lingsma, HF; Cooper, SR; Puccio, AM; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT				Yue, John K.; Pronger, Angela M.; Ferguson, Adam R.; Temkin, Nancy R.; Sharma, Sourabh; Rosand, Jonathan; Sorani, Marco D.; McAllister, Thomas W.; Barber, Jason; Winkler, Ethan A.; Burchard, Esteban G.; Hu, Donglei; Lingsma, Hester F.; Cooper, Shelly R.; Puccio, Ava M.; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.		COBRIT Investigators; TRACK-TBI Investigators	Association of a common genetic variant within ANKK1 with six-month cognitive performance after traumatic brain injury	NEUROGENETICS			English	Article						Traumatic brain injury; Genetic factors; Cognition; Outcome measures; Human studies	GENOME-WIDE ASSOCIATION; D2 RECEPTOR GENE; WORKING-MEMORY; DATA ELEMENTS; TAQ1A POLYMORPHISM; OUTCOME PREDICTION; ALZHEIMERS-DISEASE; MOLECULAR-GENETICS; PREFRONTAL CORTEX; CLINICAL-TRIALS	Genetic association analyses suggest that certain common single nucleotide polymorphisms (SNPs) may adversely impact recovery from traumatic brain injury (TBI). Delineating their causal relationship may aid in development of novel interventions and in identifying patients likely to respond to targeted therapies. We examined the influence of the (C/T) SNP rs1800497 of ANKK1 on post-TBI outcome using data from two prospective multicenter studies: the Citicoline Brain Injury Treatment (COBRIT) trial and Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot). We included patients with ANKK1 genotyping results and cognitive outcomes at six months post-TBI (n = 492: COBRIT n = 272, TRACK-TBI Pilot n = 220). Using the California Verbal Learning Test Second Edition (CVLT-II) Trial 1-5 Standard Score, we found a dose-dependent effect for the T allele, with T/T homozygotes scoring lowest on the CVLT-II Trial 1-5 Standard Score (T/T 45.1, C/T 51.1, C/C 52.1, ANOVA, p = 0.008). Post hoc testing with multiple comparison-correction indicated that T/T patients performed significantly worse than C/T and C/C patients. Similar effects were observed in a test of non-verbal processing (Wechsler Adult Intelligence Scale, Processing Speed Index). Our findings extend those of previous studies reporting a negative relationship of the ANKK1 T allele with cognitive performance after TBI. In this study, we demonstrate the value of pooling shared clinical, biomarker, and outcome variables from two large datasets applying the NIH TBI Common Data Elements. The results have implications for future multicenter investigations to further elucidate the role of ANKK1 in post-TBI outcome.	[Yue, John K.; Ferguson, Adam R.; Sharma, Sourabh; Sorani, Marco D.; Winkler, Ethan A.; Cooper, Shelly R.; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yue, John K.; Ferguson, Adam R.; Sharma, Sourabh; Sorani, Marco D.; Winkler, Ethan A.; Cooper, Shelly R.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Pronger, Angela M.; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Pronger, Angela M.; Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Rosand, Jonathan] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA; [McAllister, Thomas W.] Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA; [Burchard, Esteban G.; Hu, Donglei] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Cooper, Shelly R.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Ferguson, Adam/0000-0001-7102-1608; Cooper, Shelly/0000-0003-0026-6688	 [NIH U01 HD42652];  [NIH R01 HD48179];  [NIH RC2 NS0694909];  [DOD USAMRAAW81XWH-13-1-0441]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, U01NS086090] Funding Source: NIH RePORTER	The authors would like to thank the COBRIT and TRACK-TBI Investigators, without whom this work would not have been possible. The authors would like to thank the following contributors to the development of the TRACK-TBI database and repositories by organization and alphabetical order by last name - QuesGen Systems, Inc.: Vibeke Brinck, MS, and Michael Jarrett, MBA; One Mind: General Peter Chiarelli, U.S. Army (Ret.), and Garen Staglin; and Thomson Reuters: Sirimon O'Charoen, PhD. This work was supported by the following Grant Numbers: NIH U01 HD42652, NIH R01 HD48179 (to R.D.-A.), and NIH RC2 NS0694909, DOD USAMRAAW81XWH-13-1-0441 (to G.T.M.).	[Anonymous], 2014, TRAUM BRAIN INJ STAN; Baier B, 2010, J NEUROSCI, V30, P9788, DOI 10.1523/JNEUROSCI.1513-10.2010; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bettens K, 2013, LANCET NEUROL, V12, P92, DOI 10.1016/S1474-4422(12)70259-4; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brunetti A, 2014, WORLD J DIABETES, V5, P128, DOI 10.4239/wjd.v5.i2.128; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; Cresci Sharon, 2008, V448, P379, DOI 10.1007/978-1-59745-205-2_12; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; David SP, 2007, NICOTINE TOB RES, V9, P1251, DOI 10.1080/14622200701705027; Delis D.C., 2000, CALIFORNIA VERBAL LE; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Doris PA, 2012, CELL MOL LIFE SCI, V69, P3751, DOI 10.1007/s00018-012-0996-3; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M, 2010, TRAUMATIC BRAIN INJU; Fisher RA, 1936, J R ANTHROPOL INST G, V66, P57, DOI 10.2307/2844116; Gershon ES, 2011, AM J PSYCHIAT, V168, P253, DOI 10.1176/appi.ajp.2010.10091340; Gulcher JR, 2005, TRENDS MOL MED, V11, P217, DOI 10.1016/j.molmed.2005.03.001; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hirvonen M, 2004, MOL PSYCHIATR, V9, P1060, DOI 10.1038/sj.mp.4001561; Hoenicka J, 2010, BIOL PSYCHIAT, V67, P3, DOI 10.1016/j.biopsych.2009.08.012; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Klein TA, 2007, SCIENCE, V318, P1642, DOI 10.1126/science.1145044; Ku CS, 2010, J HUM GENET, V55, P195, DOI 10.1038/jhg.2010.19; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Malykhin N, 2008, PSYCHIAT RES-NEUROIM, V164, P132, DOI 10.1016/j.pscychresns.2007.11.007; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moraes CF, 2012, PSYCHOGERIATRICS, V12, P62, DOI 10.1111/j.1479-8301.2011.00378.x; Munafo MR, 2007, MOL PSYCHIATR, V12, P454, DOI 10.1038/sj.mp.4001938; National Center for Biotechnology Information, 2014, RS1800497 NAT CTR BI; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005; Norris J, 2013, TRAUMATIC BRAIN INJU; Ponce G, 2003, EUR PSYCHIAT, V18, P356, DOI 10.1016/j.eurpsy.2003.06.006; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rose SE, 2006, NEUROIMAGE, V32, P16, DOI 10.1016/j.neuroimage.2006.03.003; Ross OA, 2007, CURR DRUG TARGETS, V8, P850; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Smith L, 2008, AM J EPIDEMIOL, V167, P125, DOI 10.1093/aje/kwm281; Sorani MD, 2010, DRUG DISCOV TODAY, V15, P741, DOI 10.1016/j.drudis.2010.06.005; Takahashi E, 2013, NEUROIMAGE, V65, P488, DOI 10.1016/j.neuroimage.2012.10.002; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toga AW, 2012, NEUROSURGERY, V71, P1, DOI 10.1227/NEU.0b013e318258e9ff; Tosto G, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0381-0; Tsai CT, 2008, J AM COLL CARDIOL, V52, P241, DOI 10.1016/j.jacc.2008.02.072; van de Bunt M, 2010, CURR DIABETES REP, V10, P452, DOI 10.1007/s11892-010-0150-2; van der Sijde M. R., 2014, BIOCH BIOPHYS ACTA; Van Hecke J, 2010, BIOL PSYCHOL, V85, P143, DOI 10.1016/j.biopsycho.2010.06.005; Wang Q, 2005, CURR OPIN CARDIOL, V20, P182, DOI 10.1097/01.hco.0000160373.77190.f1; Wang Qing, 2005, Curr Atheroscler Rep, V7, P235, DOI 10.1007/s11883-005-0012-6; Wechsler D., 2008, WECHSLER ADULT INTEL; Wheeler E, 2011, BRIEF FUNCT GENOMICS, V10, P52, DOI 10.1093/bfgp/elr008; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue JK, J NEUROTRAUMA, V30, P1831; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	72	33	34	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1364-6745	1364-6753		NEUROGENETICS	Neurogenetics	JUL	2015	16	3					169	180		10.1007/s10048-015-0437-1			12	Genetics & Heredity; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity; Neurosciences & Neurology	CK9AS	WOS:000356532700003	25633559	Green Accepted			2022-02-06	
J	Mazza, M; Tempesta, D; Pino, MC; Nigri, A; Catalucci, A; Guadagni, V; Gallucci, M; Iaria, G; Ferrara, M				Mazza, Monica; Tempesta, Daniela; Pino, Maria Chiara; Nigri, Anna; Catalucci, Alessia; Guadagni, Veronica; Gallucci, Massimo; Iaria, Giuseppe; Ferrara, Michele			Neural activity related to cognitive and emotional empathy in post-traumatic stress disorder	BEHAVIOURAL BRAIN RESEARCH			English	Article						Explicit emotional empathy; Implicit emotional empathy; Cognitive empathy; Post-traumatic stress disorder	BORDERLINE PERSONALITY-DISORDER; TRAUMATIC BRAIN-INJURY; SOCIAL COGNITION; FUNCTIONING AUTISM; ASPERGER-SYNDROME; PTSD; FMRI; MIND; ALEXITHYMIA; QUOTIENT	The aim of this study is to evaluate the empathic ability and its functional brain correlates in posttraumatic stress disorder subjects (PTSD). Seven PTSD subjects and ten healthy controls, all present in the L'Aquila area during the earthquake of the April 2009, underwent fMRI during which they performed a modified version of the Multifaceted Empathy Test. PTSD patients showed impairments in implicit and explicit emotional empathy, but not in cognitive empathy. Brain responses during cognitive empathy showed an increased activation in patients compared to controls in the right medial frontal gyrus and the left inferior frontal gyrus. During implicit emotional empathy responses patients with PTSD, compared to controls, exhibited greater neural activity in the left pallidum and right insula; instead the control group showed an increased activation in right inferior frontal gyrus. Finally, in the explicit emotional empathy responses the PTSD group showed a reduced neural activity in the left insula and the left inferior frontal gyrus. The behavioral deficit limited to the emotional empathy dimension, accompanied by different patterns of activation in empathy related brain structures, represent a first piece of evidence of a dissociation between emotional and cognitive empathy in PTSD patients. The present findings support the idea that empathy is a multidimensional process, with different facets depending on distinct anatomical substrates. (C) 2014 Elsevier B.V. All rights reserved.	[Mazza, Monica; Tempesta, Daniela; Pino, Maria Chiara; Ferrara, Michele] Univ Aquila, Dept Life Hlth & Environm Sci, I-67100 Laquila, Italy; [Nigri, Anna] Fdn IRCCS Neurol Inst Carlo Besta, Dept Neuroradiol, Milan, Italy; [Catalucci, Alessia; Gallucci, Massimo] San Salvatore Hosp, Dept Neuroradiol, Laquila, Italy; [Guadagni, Veronica; Iaria, Giuseppe] Univ Calgary, Dept Psychol, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada; [Guadagni, Veronica; Iaria, Giuseppe] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada; [Guadagni, Veronica; Iaria, Giuseppe] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada		Mazza, M (corresponding author), Univ Aquila, Dept Life Hlth & Environm Sci, Via Vetoio, I-67100 Laquila, Italy.	monica.mazza@cc.univaq.it	Ferrara, Michele/AAB-7574-2022; Nigri, Anna/AAM-9827-2021; Guadagni, Veronica/AAY-6449-2021; Tempesta, Daniela/AAB-7539-2022	Ferrara, Michele/0000-0003-2304-7576; Nigri, Anna/0000-0002-1197-5458; Guadagni, Veronica/0000-0002-9309-0652; Tempesta, Daniela/0000-0002-6942-5336; Pino, Maria Chiara/0000-0003-2657-2122; Iaria, Giuseppe/0000-0002-5987-6491; Mazza, Monica/0000-0003-4050-2243			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Bandelow B, 2012, EUR ARCH PSY CLIN N, V262, P459, DOI 10.1007/s00406-012-0289-8; Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; Baron-Cohen S, 2005, ESSAY AUTISM THEORY; Beck JG, 2009, J ANXIETY DISORD, V23, P443, DOI 10.1016/j.janxdis.2008.09.001; Bernhardt BC, 2012, ANNU REV NEUROSCI, V35, P1, DOI 10.1146/annurev-neuro-062111-150536; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Chapman E, 2006, SOC NEUROSCI-UK, V1, P135, DOI 10.1080/17470910600992239; Craig AD, 2005, TRENDS COGN SCI, V9, P566, DOI 10.1016/j.tics.2005.10.005; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; DAVIS MH, 1994, J PERS, V62, P369, DOI 10.1111/j.1467-6494.1994.tb00302.x; Decety J, 2013, FRONT HUM NEUROSCI, P7; Decety J, 2008, DEV PSYCHOPATHOL, V20, P1053, DOI 10.1017/S0954579408000503; Decety J, 2011, NEUROPSYCHOLOGIA, V49, P2994, DOI 10.1016/j.neuropsychologia.2011.06.024; Devinsky O, 2000, EPILEPSY BEHAV, V1, P60, DOI 10.1006/ebeh.2000.0025; Driessen M, 2004, BIOL PSYCHIAT, V55, P603, DOI 10.1016/j.biopsych.2003.08.018; Duerden EG, 2013, NEUROIMAGE, V78, P159, DOI 10.1016/j.neuroimage.2013.04.014; Dziobek I, 2008, J AUTISM DEV DISORD, V38, P464, DOI 10.1007/s10803-007-0486-x; Dziobek I, 2011, NEUROIMAGE, V57, P539, DOI 10.1016/j.neuroimage.2011.05.005; Elliot TJ, 2006, COST CARING EXAMINAT; Fan Y, 2011, NEUROSCI BIOBEHAV R, V35, P903, DOI 10.1016/j.neubiorev.2010.10.009; Farrow TFD, 2005, PSYCHIAT RES-NEUROIM, V140, P45, DOI 10.1016/j.pscychresns.2005.05.012; Frewen PA, 2008, J ABNORM PSYCHOL, V117, P171, DOI 10.1037/0021-843X.117.1.171; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gallese V, 2007, PHILOS T R SOC B, V362, P659, DOI 10.1098/rstb.2006.2002; Gazzaniga M. S., 1985, THE SOCIAL BRAIN; Gelhaus P, 2012, MED HEALTH CARE PHIL, V15, P103, DOI 10.1007/s11019-011-9366-4; Germain A, 2013, AM J PSYCHIAT, V170, P372, DOI 10.1176/appi.ajp.2012.12040432; Guadagni V, 2014, J SLEEP RES, V23, P657, DOI 10.1111/jsr.12192; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hooker CI, 2010, BRAIN RES, V1308, P100, DOI 10.1016/j.brainres.2009.10.006; HOPPE KD, 1977, PSYCHOTHER PSYCHOSOM, V28, P148, DOI 10.1159/000287057; Kashdan TB, 2007, PERS INDIV DIFFER, V43, P725, DOI 10.1016/j.paid.2007.01.013; Klimecki OM, 2013, CEREB CORTEX, V23, P1552, DOI 10.1093/cercor/bhs142; Kraus A, 2009, PAIN, V143, P179, DOI 10.1016/j.pain.2008.12.018; Lanius RA, 2010, AM J PSYCHIAT, V167, P640, DOI 10.1176/appi.ajp.2009.09081168; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Lui S, 2009, P NATL ACAD SCI USA, V106, P15412, DOI 10.1073/pnas.0812751106; Mazza M, 2013, EUR ARCH PSY CLIN N, V263, P575, DOI 10.1007/s00406-013-0394-3; Mazza M, 2012, PSYCHIAT RES, V198, P248, DOI 10.1016/j.psychres.2011.11.027; Moroni L, 2006, Monaldi Arch Chest Dis, V66, P255; Nietlisbach G, 2010, PSYCHOL REP, V106, P832, DOI 10.2466/PR0.106.3.832-844; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Porto PR, 2009, J NEUROPSYCH CLIN N, V21, P114, DOI 10.1176/appi.neuropsych.21.2.114; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Seitz RJ, 2008, NEUROSCIENCE, V152, P713, DOI 10.1016/j.neuroscience.2007.10.066; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Singer T, 2006, NEUROSCI BIOBEHAV R, V30, P855, DOI 10.1016/j.neubiorev.2006.06.011; SPIELBERGER CD, 1984, J PERS ASSESS, V48, P95; Talairach J., 1988, COPLANAR STEREOTAXIC; Thirioux B, 2014, NEUROSCIENCE; Wellman HM, 1990, MIT PRESS SERIES LEA; Whiten A., 1991, NATURAL THEORIES MIN	64	33	34	5	64	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	APR	2015	282						37	45		10.1016/j.bbr.2014.12.049			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	CC2PB	WOS:000350186000005	25555525				2022-02-06	
J	Moor, HM; Eisenhauer, RC; Killian, KD; Proudfoot, N; Henriques, AA; Congeni, JA; Reneker, JC				Moor, Heather M.; Eisenhauer, Rita C.; Killian, Kathleen D.; Proudfoot, Nick; Henriques, Ashley A.; Congeni, Joseph A.; Reneker, Jennifer C.			THE RELATIONSHIP BETWEEN ADHERENCE BEHAVIORS AND RECOVERY TIME IN ADOLESCENTS AFTER A SPORTS-RELATED CONCUSSION: AN OBSERVATIONAL STUDY	INTERNATIONAL JOURNAL OF SPORTS PHYSICAL THERAPY			English	Article						Adherence; adolescent; concussion; recovery; rest	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; REHABILITATION; SYMPTOMS; EXERCISE; REST; MANAGEMENT; CHILDREN; ZURICH	Background: Adherence to rehabilitation is widely accepted as vital for recovery and return to play following sports injuries. Medical management of concussion is centered around physical and cognitive rest, a theory largely based on expert opinion, not empirical evidence. Current research on this topic focuses on factors that are predictive of adherence to rehabilitation, but fails to examine if patient adherence leads to a better outcome. The purpose of this study was to determine the adherence tendencies of adolescents to treatment recommendations provided by a sports-medicine physician after a concussion and to determine if adherence to each recommendation was a predictor of treatment duration. Study Design: Observational. Methods: Participants were enrolled in the study at their initial visit to the Sports-Medicine Center for medical care after a sports-related concussion. Individual treatment recommendations provided by a sports-medicine physician for concussion were recorded over the course of each participant's care. Once released from medical care, each participant was contacted to complete an online questionnaire to measure self-reported adherence tendencies to each treatment recommendation. Adherence was measured by two constructs: 1) the reported receptivity to the recommendation and 2) the frequency of following the recommendation. Exploratory univariate Poisson regression analyses were used to describe the relationship between adherence behaviors and the number of days of treatment required before the participant was returned to play. Results: Fifty-six questionnaires were completed, by 30 male and 26 female adolescent athletes. The self-reported adherence tendencies were very high. None of the measures of adherence to the treatment recommendations were significant predictors of the number of days of treatment; however, there was a clear tendency in five of the six rest parameters (physical rest, cognitive rest with restrictions from electronics, and cognitive rest with restrictions from school), where high levels of adherence to rest resulted in an increased average number of days of treatment (slower recovery) and those who reported being less adherent recovered faster. Conclusions: Adolescents were generally adherent to the physician recommendations. Those participants who reported being less adherent to physical and cognitive rest generally recovered faster than those who reported higher levels of adherence to these recommendations. As time progresses after the initial injury, physical and mental rest may be less effective to hasten recovery than more active treatment recommendations.	[Moor, Heather M.; Eisenhauer, Rita C.; Killian, Kathleen D.; Proudfoot, Nick; Henriques, Ashley A.; Reneker, Jennifer C.] Walsh Univ, Dept Phys Therapy, 2020 E Maple St, North Canton, OH 44720 USA; [Reneker, Jennifer C.] Kent State Univ, Coll Publ Hlth, Dept Biostat Epidemiol & Environm Hlth Sci, Kent, OH 44242 USA; [Congeni, Joseph A.] Akron Childrens Hosp, Ctr Orthoped & Sports Med, Akron, OH 44308 USA		Reneker, JC (corresponding author), Walsh Univ, Dept Phys Therapy, 2020 E Maple St, North Canton, OH 44720 USA.		Reneker, Jennifer/N-2038-2016	Reneker, Jennifer/0000-0003-3617-5681			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Balasundaram AP, 2013, PHYS THER SPORT, V14, P253, DOI 10.1016/j.ptsp.2013.06.002; Brewer BW, 2013, REHABIL PSYCHOL, V58, P64, DOI 10.1037/a0031297; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Byerly P N, 1994, J Athl Train, V29, P352; Cameron AC., 2009, MICROECONOMETRICS US; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; Gaetz MB, 2009, BRIT J SPORT MED, V43, P508, DOI 10.1136/bjsm.2008.051748; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gagnon I, 2009, J HEAD TRAUMA REHAB, V24, P355, DOI 10.1097/HTR.0b013e3181b97a4e; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marshall A, 2012, J SPORT REHABIL, V21, P18, DOI 10.1123/jsr.21.1.18; May KH, 2014, INT J SPORTS PHYS TH, V9, P242; McAbee GN, 2015, J CHILD NEUROL, V30, P1378, DOI 10.1177/0883073814551794; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56; Reneker JC, 2015, BRIT J SPORT MED, V49, P491, DOI 10.1136/bjsports-2014-093634; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	30	33	33	0	3	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	2159-2896			INT J SPORTS PHYS TH	Int. J. Sports Phys. Ther.	APR	2015	10	2					225	233					9	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	VA1WM	WOS:000409699200011	25883871				2022-02-06	
J	Kutcher, ME; Howard, BM; Sperry, JL; Hubbard, AE; Decker, AL; Cuschieri, J; Minei, JP; Moore, EE; Brownstein, BH; Maier, RV; Cohen, MJ				Kutcher, Matthew E.; Howard, Benjamin M.; Sperry, Jason L.; Hubbard, Alan E.; Decker, Anna L.; Cuschieri, Joseph; Minei, Joseph P.; Moore, Ernest E.; Brownstein, Bernard H.; Maier, Ronald V.; Cohen, Mitchell Jay			Evolving beyond the vicious triad: Differential mediation of traumatic coagulopathy by injury, shock, and resuscitation	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Coagulopathy; acute traumatic coagulopathy; vicious triad	STANDARD OPERATING PROCEDURES; DAMAGE CONTROL RESUSCITATION; SCALE COLLABORATIVE PROJECT; PROTEIN-C; INCREASED MORTALITY; CLINICAL CARE; HOST RESPONSE; ORGAN FAILURE; BRAIN-INJURY; COAGULATION	BACKGROUND: A subset of trauma patients with critical injury present with coagulopathy, portending markedly worse outcomes. Clinical practice is evolving to treat the classical risk factors of hypothermia, hemodilution, and acidosis; however, coagulopathy persists even in the absence of these factors. We sought to determine the relative importance of injury- and shock-specific factors compared with resuscitation-associated factors in coagulopathy after trauma. METHODS: Comprehensive demographic data, laboratory data, and outcomes data were prospectively collected from seven trauma centers over 8 years (November 2003 to August 2011) as part of the Inflammation and the Host Response to Injury Large-Scale Collaborative Program. A total of 1,537 critically injured patients with blunt trauma and hemorrhagic shock were analyzed to evaluate predictors of admission coagulopathy (international normalized ratio [INR] >= 1.3), multiorgan failure, and mortality. RESULTS: Of 1,537 patients, 578 (37.6%) had admission INR of 1.3 or greater. Coagulopathic patients had more severe injury, more severe base deficit and lactate levels, as well as lower admission temperature, lower pH, and higher prehospital crystalloid volume (all p < 0.001). Coagulopathic patients required more blood products and mechanical ventilation and had higher rates of nosocomial infection, multiorgan failure, and mortality (all p < 0.02). Injury severity, temperature, and acidosis (all p < 0.02) independently predicted coagulopathy in multivariate analysis, with a significant interaction between lactate and prehospital crystalloid. In Cox regression models, however, coagulopathy itself remained an independent predictor of both multiorgan failure and mortality (p < 0.02) even when adjusted for injury severity, shock, and elements of the vicious triad. CONCLUSION: Most patients with coagulopathy after trauma have mixed risk factors; however, coagulopathy has deleterious effects independent of injury severity, shock, and the vicious triad. Better understanding of the biochemical mechanisms of acute traumatic coagulopathy may facilitate biochemically targeted resuscitation strategies and improve outcomes. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)	[Kutcher, Matthew E.; Howard, Benjamin M.; Cohen, Mitchell Jay] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA; [Kutcher, Matthew E.; Howard, Benjamin M.; Cohen, Mitchell Jay] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Hubbard, Alan E.; Decker, Anna L.] Univ Calif Berkeley, Div Biostat, Berkeley, CA 94720 USA; [Hubbard, Alan E.; Decker, Anna L.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Sperry, Jason L.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA; [Sperry, Jason L.] Presbyterian Univ Hosp, Pittsburgh, PA 15213 USA; [Cuschieri, Joseph; Maier, Ronald V.] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA; [Cuschieri, Joseph; Maier, Ronald V.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Minei, Joseph P.] Parkland Hlth & Hosp Syst, Dallas, TX USA; [Moore, Ernest E.] Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80262 USA; [Moore, Ernest E.] Denver Hlth Med Ctr, Denver, CO USA; [Brownstein, Bernard H.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA		Cohen, MJ (corresponding author), San Francisco Gen Hosp, Dept Surg, Ward 3A,1001 Potrero Ave,Room 3C-38, San Francisco, CA 94110 USA.	mcohen@sfghsurg.ucsf.edu		Kutcher, Matthew/0000-0003-4566-5359	Inflammation and the Host Response to Injury Large-Scale Collaborative Research Grant from the National Institute of General Medical Sciences [2-U54-GM062119]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119] Funding Source: NIH RePORTER	This study was supported by the Inflammation and the Host Response to Injury Large-Scale Collaborative Research Grant from the National Institute of General Medical Sciences, 2-U54-GM062119.	Alam HB, 2007, SURG CLIN N AM, V87, P55, DOI 10.1016/j.suc.2006.09.015; Aras O, 2004, BLOOD, V103, P4545, DOI 10.1182/blood-2003-03-0713; Biffl WL, 2001, ANN SURG, V233, P843, DOI 10.1097/00000658-200106000-00015; Brandt C A, 2003, AMIA Annu Symp Proc, P794; Brazil EV, 2000, J ROY SOC MED, V93, P507, DOI 10.1177/014107680009301003; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Brown JB, 2013, J TRAUMA ACUTE CARE, V74, P1207, DOI 10.1097/TA.0b013e31828c44fd; Coats TJ, 2006, EMERG MED J, V23, P546, DOI 10.1136/emj.2005.032334; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; Duchesne JC, 2010, J TRAUMA, V69, P46, DOI 10.1097/TA.0b013e3181df91fa; Duchesne JC, 2009, BRIT J HOSP MED, V70, P22, DOI 10.12968/hmed.2009.70.1.37690; Evans HL, 2009, J TRAUMA, V67, P384, DOI 10.1097/TA.0b013e3181ad66a7; Gando S, 2001, SEMIN THROMB HEMOST, V27, P585, DOI 10.1055/s-2001-18864; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Hirshberg A, 2003, J TRAUMA, V54, P454, DOI 10.1097/01.TA.0000053245.08642.1F; Holcomb JB, 2015, PREHOSP EMERG CARE, V19, P1, DOI 10.3109/10903127.2014.923077; Hook EB, 1997, AM J EPIDEMIOL, V145, P1138; Johansson PI, 2012, J THROMB HAEMOST, V10, P207, DOI 10.1111/j.1538-7836.2011.04589.x; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; KASHUK JL, 1982, J TRAUMA, V22, P672, DOI 10.1097/00005373-198208000-00004; Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Maier RV, 2005, J TRAUMA, V59, P762, DOI 10.1097/01.ta.0000177656.85206.cd; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; Moore EE, 2014, SHOCK, V41, P35, DOI 10.1097/SHK.0000000000000110; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; Shafi S, 2005, J TRAUMA, V59, P1081, DOI 10.1097/01.ta.0000188647.03665.fd; STONE HH, 1983, ANN SURG, V197, P532, DOI 10.1097/00000658-198305000-00005; Subramanian J, 2011, STAT MED, V30, P642, DOI 10.1002/sim.4106; Trentzsch H, 2012, SHOCK, V37, P131, DOI 10.1097/SHK.0b013e318245f6b2; West MA, 2006, J TRAUMA, V61, P436, DOI 10.1097/01.ta.0000232517.83039.c4; Whittaker B, 2013, SHOCK, V39, P421, DOI 10.1097/SHK.0b013e31828e08cb; WILSON RF, 1987, AM SURGEON, V53, P410; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC	45	33	37	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2015	78	3					516	523		10.1097/TA.0000000000000545			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	CE8DQ	WOS:000352072000016	25710421				2022-02-06	
J	Sigurdardottir, S; Andelic, N; Wehling, E; Roe, C; Anke, A; Skandsen, T; Holthe, OO; Jerstad, T; Aslaksen, PM; Schanke, AK				Sigurdardottir, Solrun; Andelic, Nada; Wehling, Eike; Roe, Cecilie; Anke, Audny; Skandsen, Toril; Holthe, Oyvor O.; Jerstad, Tone; Aslaksen, Per M.; Schanke, Anne-Kristine			Neuropsychological Functioning in a National Cohort of Severe Traumatic Brain Injury: Demographic and Acute Injury-Related Predictors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive impairment; executive functions; memory; outcome prediction; traumatic brain injury	SEVERE HEAD-INJURY; PROGNOSTIC VALUE; MODERATE; REHABILITATION; PRODUCTIVITY; PERFORMANCE; RECOVERY; OUTCOMES; SCORE; CLASSIFICATION	Objectives: To determine the rates of cognitive impairment 1 year after severe traumatic brain injury (TBI) and to examine the influence of demographic, injury severity, rehabilitation, and subacute functional outcomes on cognitive outcomes 1 year after severe TBI. Setting: National multicenter cohort study over 2 years. Participants: Patients (N = 105), aged 16 years or older, with Glasgow Coma Scale score of 3 to 8 and Galveston Orientation and Amnesia Test score of more than 75. Main Measures : Neuropsychological tests representing cognitive domains of Executive Functions, Processing Speed, and Memory. Injury severity included Rotterdam computed tomography score, Glasgow Coma Scale score, and posttraumatic amnesia (PTA) duration, together with length of rehabilitation and Glasgow Outcome Scale-Extended score. Results: In total, 67% of patients with severe TBI had cognitive impairment. Executive Functions, Processing Speed, and Memory were impaired in 41%, 58%, and 57% of patients, respectively. Using multiple regression analysis, Processing Speed was significantly related to PTA duration, Glasgow Outcome Scale-Extended score, and length of inpatient rehabilitation (R-2 = 0.30); Memory was significantly related to Glasgow Outcome Scale-Extended score (R-2 = 0.15); and Executive Functions to PTA duration (R-2 = 0.10). Rotterdam computed tomography and Glasgow Coma Scale scores were not associated with cognitive functioning at 1 year postinjury. Conclusion: Findings highlight cognitive consequences of severe TBI, with nearly two-thirds of patients showing cognitive impairments in at least 1 of 3 cognitive domains. Regarding injury severity predictors, only PTA duration was related to cognitive functioning.	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, Dept Res, N-1450 Nesoddtangen, Norway; [Sigurdardottir, Solrun; Andelic, Nada] Univ Oslo, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Schanke, Anne-Kristine] Univ Oslo, Dept Psychol, Fac Social Sci, Oslo, Norway; [Andelic, Nada; Roe, Cecilie; Holthe, Oyvor O.] Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway; [Jerstad, Tone] Oslo Univ Hosp, Dept Neuroradiol, Oslo, Norway; [Wehling, Eike] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Wehling, Eike] Univ Bergen, Dept Biol & Med Psychol, Bergen, Norway; [Anke, Audny; Aslaksen, Per M.] Univ Hosp North Norway, Dept Rehabil, Tromso, Norway; [Anke, Audny] Univ Tromso, Fac Hlth Sci, Dept Clin Med, Tromso, Norway; [Aslaksen, Per M.] Univ Tromso, Fac Hlth Sci, Dept Psychol, Tromso, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, Trondheim, Norway		Sigurdardottir, S (corresponding author), Sunnaas Rehabil Hosp, Dept Res, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no	Aslaksen, Per/J-6589-2019	Aslaksen, Per/0000-0002-9299-7260; Andelic, Nada/0000-0002-3719-4406; Anke, Audny/0000-0002-2491-2560			Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Arango-Lasprilla JC, 2010, ARCH PHYS MED REHAB, V91, P1495, DOI 10.1016/j.apmr.2010.07.010; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL REV 19; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; De Guise E, 2005, BRAIN INJURY, V19, P1087, DOI 10.1080/02699050500149882; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P923, DOI 10.1007/978-0-387-76978-3_32; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Konigs M, 2012, J NEUROL NEUROSUR PS, V83, P1048, DOI 10.1136/jnnp-2012-302635; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacCallum RC, 1999, PSYCHOL METHODS, V4, P84, DOI 10.1037/1082-989x.4.1.84; Meyers JE., 1995, REY COMPLEX FIGURE T; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Thais MERD, 2014, J NEUROPSYCHOL, V8, P125, DOI 10.1111/jnp.12000; Roe C, 2012, J NEUROL RES, V2, P134, DOI DOI 10.4021/JNR133W; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Williams MW, 2013, CLIN NEUROPSYCHOL, V27, P356, DOI 10.1080/13854046.2013.765507; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	55	33	34	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2015	30	2					E1	E12		10.1097/HTR.0000000000000039			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CF1MG	WOS:000352309300001	24695265	Green Accepted, Green Submitted			2022-02-06	
J	Skopin, MD; Kabadi, SV; Viechweg, SS; Mong, JA; Faden, AI				Skopin, Mark D.; Kabadi, Shruti V.; Viechweg, Shaun S.; Mong, Jessica A.; Faden, Alan I.			Chronic Decrease in Wakefulness and Disruption of Sleep-Wake Behavior after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; lateral fluid percussion; sleep-wake disturbances; orexin; electroencephalography	LIMITS MICROGLIAL ACTIVATION; DAYTIME SLEEPINESS; OREXIN; DISTURBANCES; PATTERNS; IMPACT; MEMORY; MODEL; RATS; MICE	Traumatic brain injury (TBI) can cause sleep-wake disturbances and excessive daytime sleepiness. The pathobiology of sleep disorders in TBI, however, is not well understood, and animal models have been underused in studying such changes and potential underlying mechanisms. We used the rat lateral fluid percussion (LFP) model to analyze sleep-wake patterns as a function of time after injury. Rapid-eye movement (REM) sleep, non-REM (NREM) sleep, and wake bouts during light and dark phases were measured with electroencephalography and electromyography at an early as well as chronic time points after LFP. Moderate TBI caused disturbances in the ability to maintain consolidated wake bouts during the active phase and chronic loss of wakefulness. Further, TBI resulted in cognitive impairments and depressive-like symptoms, and reduced the number of orexin-A-positive neurons in the lateral hypothalamus.	[Skopin, Mark D.; Kabadi, Shruti V.; Viechweg, Shaun S.; Mong, Jessica A.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Organized Res, 20 Penn St Suite 247,Hlth Sci Facil HSF 2, Baltimore, MD 21201 USA.	afaden@anes.umm.edu		Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5 T32 GM 75767-5]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075767] Funding Source: NIH RePORTER	We thank Michael Makley, Adam Puche, and Cecilia Diniz Behn for their help with the sleep-wake analysis and the National Institutes of Health (5 T32 GM 75767-5) for their support.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Clauset A, 2009, SIAM REV, V51, P661, DOI 10.1137/070710111; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Fujiki Nobuhiro, 2007, CNS & Neurological Disorders-Drug Targets, V6, P45, DOI 10.2174/187152707779940781; Gerashchenko D, 2003, NEUROSCIENCE, V116, P223, DOI 10.1016/S0306-4522(02)00575-4; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hazra A, 2014, J NEUROSCI RES, V92, P1434, DOI 10.1002/jnr.23430; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Lu J, 2006, NATURE, V441, P589, DOI 10.1038/nature04767; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; Marr A., 2004, CENTRAL NERVOUS SYST; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Mihara Y, 2011, J MOL NEUROSCI, V43, P162, DOI 10.1007/s12031-010-9438-6; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rauchs G, 2004, SLEEP, V27, P395, DOI 10.1093/sleep/27.3.395; Rowe RK, 2014, SLEEP, V37, P743, DOI 10.5665/sleep.3582; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Sakurai T, 2005, SLEEP MED REV, V9, P231, DOI 10.1016/j.smrv.2004.07.007; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Schonberger M, 2014, J HEAD TRAUMA REHAB, V29, P427, DOI 10.1097/HTR.0b013e31829ddd08; Slattery DA, 2012, NAT PROTOC, V7, P1009, DOI 10.1038/nprot.2012.044; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Walker MP, 2005, NEUROSCIENCE, V133, P911, DOI 10.1016/j.neuroscience.2005.04.007; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Wiseman-Hakes C, 2011, BRAIN INJURY, V25, P1256, DOI 10.3109/02699052.2011.608215; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	45	33	35	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					289	296		10.1089/neu.2014.3664			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700001	25242371	Green Published			2022-02-06	
J	Su, CY; Wuang, YP; Lin, YH; Su, JH				Su, Chwen-Yng; Wuang, Yee-Pay; Lin, Yueh-Hsien; Su, Jui-Hsing			The Role of Processing Speed in Post-Stroke Cognitive Dysfunction	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Stroke; Processing speed; Cognitive impairment	MINI-MENTAL-STATE; TRAUMATIC BRAIN-INJURY; ISCHEMIC-STROKE; SUBARACHNOID HEMORRHAGE; NEUROPSYCHOLOGICAL PROFILES; CLINICAL DETERMINANTS; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; AGE-DIFFERENCES	The association between speed of information processing and cognition has been extensively validated in normal aging and other neurocognitive disorders. Our aim was to determine whether such a relationship exists in stroke. Thirty patients and 30 age-and education-matched healthy individuals were administered a comprehensive battery of neuropsychological tests divided into the following six cognitive domains: processing speed (PS), verbal memory, visual memory, visuoperceptual function, language, and cognitive flexibility. The results demonstrate that stroke patients were characterized by cognitive deficits in almost all of these domains, but have the most pronounced deficits in PS. After adjusting for symbol digit modalities test score, all significant group differences in cognitive functioning disappeared. However, group differences remained significant after controlling for the influence of other cognitive factors. These findings suggest that decreased PS appears to underlie post-stroke cognitive dysfunction and may serve as a potential target for intervention.	[Su, Chwen-Yng; Wuang, Yee-Pay] Kaohsiung Med Univ, Coll Hlth Sci, Dept Occupat Therapy, Kaohsiung, Taiwan; [Lin, Yueh-Hsien] Natl Taiwan Normal Univ, Special Educ Ctr, Taipei, Taiwan; [Su, Jui-Hsing] Kaohsiung Municipal Hsiaokang Hosp, Dept Rehabil Med, Kaohsiung 812, Taiwan		Su, JH (corresponding author), Kaohsiung Municipal Hsiaokang Hosp, Dept Rehabil Med, 482 Shanming Rd, Kaohsiung 812, Taiwan.	cysu@cc.kmu.edu.tw			National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC 97-2314-B-037-046-MY3]	This study was supported by the National Science Council of Taiwan under grant NSC 97-2314-B-037-046-MY3.	Allan LM, 2011, BRAIN, V134, P3713, DOI 10.1093/brain/awr273; [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105, DOI 10.1016/0895-4356(88)90084-4; Apostolova LG, 2006, ALZ DIS ASSOC DIS, V20, P224, DOI 10.1097/01.wad.0000213857.89613.10; Ballard C, 2003, DEMENT GERIATR COGN, V16, P52, DOI 10.1159/000069994; Barker-Collo S, 2010, NEUROLOGY, V75, P1608, DOI 10.1212/WNL.0b013e3181fb44c8; Barker-Collo S, 2013, INT J STROKE, V8, pE14, DOI 10.1111/j.1747-4949.2012.00959.x; Barker-Collo S, 2012, STROKE, V43, P50, DOI 10.1161/STROKEAHA.111.627182; Batista S, 2012, J NEUROL, V259, P139, DOI 10.1007/s00415-011-6147-1; Brand C, 2014, BRIT J NEUROSURG, V28, P68, DOI 10.3109/02688697.2013.815314; Bronnick K, 2010, COGNITIVE IMPAIRMENT, P27; Bugg JM, 2006, BRAIN COGNITION, V62, P9, DOI 10.1016/j.bandc.2006.02.006; Butters MA, 2004, ARCH GEN PSYCHIAT, V61, P587, DOI 10.1001/archpsyc.61.6.587; Cepeda NJ, 2013, DEVELOPMENTAL SCI, V16, P269, DOI 10.1111/desc.12024; Cohen J., 2013, STAT POWER ANAL BEHA; Cumming TB, 2013, INT J STROKE, V8, P38, DOI 10.1111/j.1747-4949.2012.00972.x; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P263, DOI 10.1001/archneur.1985.04060030081013; Diamond BJ, 2008, ARCH CLIN NEUROPSYCH, V23, P189, DOI 10.1016/j.acn.2007.10.002; Douiri A, 2013, STROKE, V44, P138, DOI 10.1161/STROKEAHA.112.670844; Duering M, 2011, BRAIN, V134, P2366, DOI 10.1093/brain/awr169; Elgamal SA, 2011, CAN GERIATR J, V14, P66, DOI 10.5770/cgj.v14i3.17; Ferrer E, 2013, DEVELOPMENTAL SCI, V16, P941, DOI 10.1111/desc.12088; Fjell AM, 2009, DEMENT GERIATR COGN, V28, P252, DOI 10.1159/000241878; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gerritsen MJJ, 2003, J CLIN EXP NEUROPSYC, V25, P1, DOI 10.1076/jcen.25.1.1.13622; Gillespie DC, 2006, CLIN NEUROPSYCHOL, V20, P59, DOI 10.1080/13854040500203308; Gold J. M., 2007, INFORM PROCESSING SP, P125; GOLDEN CJ, 1985, MANUAL LURIA NEBRASK; Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Gottesman RF, 2010, LANCET NEUROL, V9, P895, DOI 10.1016/S1474-4422(10)70164-2; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; Hannay H. J., 2004, NEUROPSYCHOLOGICAL A; Heaton R., 2000, WISCONSIN CARD SORTI; Hochstenbach J, 1998, J CLIN EXP NEUROPSYC, V20, P503, DOI 10.1076/jcen.20.4.503.1471; Hurford R, 2013, J NEUROL, V260, P237, DOI 10.1007/s00415-012-6625-0; Jaillard A, 2010, CEREBROVASC DIS, V29, P415, DOI 10.1159/000289344; Jokinen H, 2006, J NEUROL NEUROSUR PS, V77, P28, DOI 10.1136/jnnp.2005.069120; Joy S, 2004, ARCH CLIN NEUROPSYCH, V19, P759, DOI 10.1016/j.acn.2003.09.009; KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5; Kaplan E., 2001, BOSTON NAMING TEST; Kauhanen ML, 1999, STROKE, V30, P1875, DOI 10.1161/01.STR.30.9.1875; Kilander L, 1998, HYPERTENSION, V31, P780, DOI 10.1161/01.HYP.31.3.780; Knowles EEM, 2010, SCHIZOPHR RES, V117, P324, DOI 10.1016/j.schres.2010.02.552; Lee T, 2012, NEUROPSYCHOLOGY, V26, P776, DOI 10.1037/a0030053; Leeson VC, 2010, SCHIZOPHRENIA BULL, V36, P400, DOI 10.1093/schbul/sbn100; Lesniak M, 2008, DEMENT GERIATR COGN, V26, P356, DOI 10.1159/000162262; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovell M. R., 1997, HDB NEUROPSYCHOLOGY; Lyden PD, 2001, STROKE, V32, P1310, DOI 10.1161/01.STR.32.6.1310; Madureira S, 2001, EUR J NEUROL, V8, P621, DOI 10.1046/j.1468-1331.2001.00332.x; Mantyla R, 1999, STROKE, V30, P2053, DOI 10.1161/01.STR.30.10.2053; Rodriguez-Sanchez JM, 2007, BRIT J PSYCHIAT, V191, pS107, DOI 10.1192/bjp.191.51.s107; McGrath LM, 2011, J CHILD PSYCHOL PSYC, V52, P547, DOI 10.1111/j.1469-7610.2010.02346.x; McKinlay A, 2009, EUR J COGN PSYCHOL, V21, P330, DOI 10.1080/09541440802281266; Meyers JE., 1995, REY COMPLEX FIGURE T; Mok VCT, 2004, J NEUROL NEUROSUR PS, V75, P560, DOI 10.1136/jnnp.2003.015107; Moroney JT, 1997, NEUROLOGY, V48, P1317, DOI 10.1212/WNL.48.5.1317; Narasimhalu K, 2011, STROKE, V42, P883, DOI 10.1161/STROKEAHA.110.594671; NINDS Common Data Elements, MULTIPLE SCLEROSIS; Nys GMS, 2007, CEREBROVASC DIS, V23, P408, DOI 10.1159/000101464; Penke L, 2010, J NEUROSCI, V30, P7569, DOI 10.1523/JNEUROSCI.1553-10.2010; Rao S. M., 2014, MULT SCLER INT, V2014, DOI [10.1155/2014/975803, DOI 10.1155/2014/975803]; Rasquin S, 2005, CEREBROVASC DIS, V19, P309, DOI 10.1159/000084499; Ravnik J, 2006, CROAT MED J, V47, P253; Reed BR, 2007, BRAIN, V130, P731, DOI 10.1093/brain/awl385; Rypma B, 2006, NEUROIMAGE, V33, P969, DOI 10.1016/j.neuroimage.2006.05.065; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith EE, 2012, LANCET NEUROL, V11, P272, DOI 10.1016/S1474-4422(11)70307-6; SWIRSKYSACCHETTI T, 1992, J CLIN PSYCHOL, V48, P779, DOI 10.1002/1097-4679(199211)48:6<779::AID-JCLP2270480612>3.0.CO;2-B; TATEMICHI TK, 1993, ANN NEUROL, V33, P568, DOI 10.1002/ana.410330603; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Turken AU, 2008, NEUROIMAGE, V42, P1032, DOI 10.1016/j.neuroimage.2008.03.057; van der Ham IJM, 2011, NEUROPSYCHOLOGIA, V49, P999, DOI 10.1016/j.neuropsychologia.2011.02.024; Vermeer SE, 2003, STROKE, V34, P1126, DOI 10.1161/01.STR.0000068408.82115.D2; VERNON PA, 1986, INTELLIGENCE, V10, P315, DOI 10.1016/0160-2896(86)90002-4; Vernooij MW, 2009, ARCH GEN PSYCHIAT, V66, P545, DOI 10.1001/archgenpsychiatry.2009.5; Wechsler D., 1997, WECHSLER MEMORY SCAL; *WEST PSYCH SERV, 1983, HOOP VIS ORG TEST VO; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Winkens I, 2006, CLIN REHABIL, V20, P827, DOI 10.1177/0269215506070813; Zhu YC, 2012, J NEUROL, V259, P530, DOI 10.1007/s00415-011-6218-3; Zinn S, 2007, ARCH PHYS MED REHAB, V88, P173, DOI 10.1016/j.apmr.2006.11.015	84	33	33	1	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2015	30	2					148	160		10.1093/arclin/acu057			13	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	CF0JP	WOS:000352230000007	25618135	Bronze			2022-02-06	
J	Lange, RT; Panenka, WJ; Shewchuk, JR; Heran, MKS; Brubacher, JR; Bioux, S; Eckbo, R; Shenton, ME; Iverson, GL				Lange, Rael T.; Panenka, William J.; Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.; Bioux, Sylvain; Eckbo, Ryan; Shenton, Martha E.; Iverson, Grant L.			Diffusion Tensor Imaging Findings and Postconcussion Symptom Reporting Six Weeks Following Mild Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Diffusion tensor imaging; Postconcussion symptoms; Neurocognitive; Biomarkers	POST-CONCUSSION SYNDROME; POSTTRAUMATIC-STRESS-DISORDER; GOOD OLD DAYS; WHITE-MATTER; AXONAL INJURY; CORPUS-CALLOSUM; HEAD-INJURY; BASE RATES; MODERATE; DTI	The purpose of this study is to examine the relation between the microstructural architecture of white matter, as measured by diffusion tensor imaging (DTI), and postconcussion symptom reporting 6-8 weeks following mild traumatic brain injury (MTBI). Participants were 108 patients prospectively recruited from a Level 1 Trauma Center (Vancouver, BC, Canada) following an orthopedic injury [i.e., 36 trauma controls (TCs)] or MTBI (n = 72). DTI of the whole brain was undertaken using a Phillips 3T scanner at 6-8 weeks postinjury. Participants also completed a 5 h neurocognitive test battery and a brief battery of self-report measures (e.g., depression, anxiety, and postconcussion symptoms). The MTBI sample was divided into two groups based on ICD-10 criteria for postconcussional syndrome (PCS): first, PCS-present (n = 20) and second, PCS-absent (n = 52). There were no significant differences across the three groups (i.e., TC, PCS-present, and PCS-absent) for any of the neurocognitive measures (p = .138-.810). For the self-report measures, the PCS-present group reported significantly more anxiety and depression symptoms compared with the PCS-absent and TC groups (p < .001, d = 1.63-1.89, very large effect sizes). For the DTI measures, there were no significant differences in fractional anisotropy, axial diffusivity, radial diffusivity, or mean diffusivity when comparing the PCS-present and PCS-absent groups. However, there were significant differences (p < .05) in MD and RD when comparing the PCS-present and TC groups. There were significant differences in white matter between TC subjects and the PCS-present MTBI group, but not the PCS-absent MTBI group. Within the MTBI group, white-matter changes were not a significant predictor of ICD-10 PCS.	[Lange, Rael T.; Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [Lange, Rael T.; Panenka, William J.; Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.] Vancouver Gen Hosp, Vancouver, BC, Canada; [Bioux, Sylvain; Eckbo, Ryan; Shenton, Martha E.] Brigham Womens Hosp, Boston, MA USA; [Bioux, Sylvain; Eckbo, Ryan; Shenton, Martha E.; Iverson, Grant L.] Harvard Univ, Sch Med, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 8,Room 2264,8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.lange@gmail.com	Shenton, Martha/V-8780-2019	Panenka, William/0000-0001-7143-6512; Brubacher, Jeffrey/0000-0002-4866-4231; Iverson, Grant/0000-0001-7348-9570	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP-200377-BSB-CAAA-161276] Funding Source: Medline		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beck AT, 1993, BECK ANXIETY INVENTO; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cohen J., 2013, STAT POWER ANAL BEHA; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Deepika A, 2013, J HEAD TRAUMA REHAB, V28, P442, DOI 10.1097/HTR.0b013e31825e19e5; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gaetz M, 2000, BRAIN INJURY, V14, P815; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gering DT, 2001, J MAGN RESON IMAGING, V13, P967, DOI 10.1002/jmri.1139; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kamphaus, 2003, REYNOLDS INTELLECTUA; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lange RT, 2014, J NEUROTRAUM, V31, P198, DOI 10.1089/neu.2013.2866; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lannsjo M, 2013, EUR J NEUROL, V20, P124, DOI 10.1111/j.1468-1331.2012.03813.x; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mori A., 2005, MRI ATLAS HUMAN WHIT; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.3.CO;2-J; *PSYCH CORP, 2001, WECHSL TEST AD READ; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sexton CE, 2009, BIOL PSYCHIAT, V66, P814, DOI 10.1016/j.biopsych.2009.05.024; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	85	33	33	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2015	30	1					7	25		10.1093/arclin/acu060			19	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	CE6BA	WOS:000351919400002	25416729	Bronze			2022-02-06	
J	Papa, L; Robertson, CS; Wang, KKW; Brophy, GM; Hannay, HJ; Heaton, S; Schmalfuss, I; Gabrielli, A; Hayes, R; Robicsek, SA				Papa, Linda; Robertson, Claudia S.; Wang, Kevin K. W.; Brophy, Gretchen M.; Hannay, H. Julia; Heaton, Shelley; Schmalfuss, Ilona; Gabrielli, Andrea; Hayes, Ronald L.; Robicsek, Steven A.			Biomarkers Improve Clinical Outcome Predictors of Mortality Following Non-Penetrating Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Biomarkers; Severe traumatic brain injury; Mortality; Microtubual associated protein (MAP-2); S100B; Alpha-spectrin breakdown products (SBDPs); Ubiquitin C-terminal hydrolase (UCH-L1)	NEURON-SPECIFIC-ENOLASE; MICROTUBULE-ASSOCIATED PROTEIN-2; SPECTRIN BREAKDOWN PRODUCTS; C-TERMINAL HYDROLASE-L1; II-SPECTRIN; CEREBROSPINAL-FLUID; S-100B PROTEIN; SERUM S100B; HEAD-INJURY; DAMAGE	This study assessed whether early levels of biomarkers measured in CSF within 24-h of severe TBI would improve the clinical prediction of 6-months mortality. This prospective study conducted at two Level 1 Trauma Centers enrolled adults with severe TBI (GCS a parts per thousand currency sign8) requiring a ventriculostomy as well as control subjects. Ventricular CSF was sampled within 24-h of injury and analyzed for seven candidate biomarkers (UCH-L1, MAP-2, SBDP150, SBDP145, SBDP120, MBP, and S100B). The International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) scores (Core, Extended, and Lab) were calculated for each patient to determine risk of 6-months mortality. The IMPACT models and biomarkers were assessed alone and in combination. There were 152 patients enrolled, 131 TBI patients and 21 control patients. Thirty six (27 %) patients did not survive to 6 months. Biomarkers were all significantly elevated in TBI versus controls (p < 0.001). Peak levels of UCH-L1, SBDP145, MAP-2, and MBP were significantly higher in non-survivors (p < 0.05). Of the seven biomarkers measured at 12-h post-injury MAP-2 (p = 0.004), UCH-L1 (p = 0.024), and MBP (p = 0.037) had significant unadjusted hazard ratios. Of the seven biomarkers measured at the earliest time within 24-h, MAP-2 (p = 0.002), UCH-L1 (p = 0.016), MBP (p = 0.021), and SBDP145 (0.029) had the most significant elevations. When the IMPACT Extended Model was combined with the biomarkers, MAP-2 contributed most significantly to the survival models with sensitivities of 97-100 %. These data suggest that early levels of MAP-2 in combination with clinical data provide enhanced prognostic capabilities for mortality at 6 months.	[Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci & Neurosurg, Richmond, VA USA; [Hannay, H. Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Heaton, Shelley] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Schmalfuss, Ilona] Univ Florida, Dept Radiol, Gainesville, FL 32610 USA; [Schmalfuss, Ilona] NF SG Vet Adm, Gainesville, FL USA; [Gabrielli, Andrea; Robicsek, Steven A.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA		Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood S-200, Orlando, FL 32806 USA.	lpstat@aol.com; claudiar@bcm.edu; kawangwang17@gmail.com; gbrophy@vcu.edu; psycqs@central.uh.edu; sheaton@phhp.ufl.edu; schmai@radiology.ufl.edu; agabrielli@anest.ufl.edu; rhayes@banyanbio.com; robicsek@me.com		Wang, Kevin/0000-0002-9343-6473; Brophy, Gretchen/0000-0002-4749-2693; Hannay, H. Julia/0000-0001-7023-912X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS052831]	This study was funded by NIH RO1 NS052831 "Biochemical Markers of Severe Traumatic Brain Injury''. Drs. Brophy and Papa are consultants of Banyan Biomarkers, Inc. but receive no stocks or royalties from the company and will not benefit financially from this publication. Dr. Hayes and Wang own stock, receive royalties from Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication.	Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DIEZGUERRA FJ, 1993, EUR J BIOCHEM, V215, P181, DOI 10.1111/j.1432-1033.1993.tb18021.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Faul M, 2010, EMERGENCY DEP VISITS; Ferguson I, 2011, ANN EMERG MED, V58, pS213, DOI 10.1016/j.annemergmed.2011.06.133; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HAIMOTO H, 1987, LAB INVEST, V57, P489; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hunter CL, 2013, AM J EMERG MED, V31, P64, DOI 10.1016/j.ajem.2012.05.034; IBERTI TJ, 1990, CRIT CARE MED, V18, P275, DOI 10.1097/00003246-199003000-00005; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Khan SH, 1998, ACT NEUR S, V71, P50; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Papa L., 2012, PROTEOMICS HUMAN DIS; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; USUI A, 1989, CLIN CHEM, V35, P1942; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Xiong H, 2000, Sheng Li Ke Xue Jin Zhan, V31, P217; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6	61	33	35	1	14	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2015	22	1					52	64		10.1007/s12028-014-0028-2			13	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CA3FH	WOS:000348791300008	25052159				2022-02-06	
J	Shultz, SR; Aziz, NAB; Yang, L; Sun, MJ; MacFabe, DF; O'Brien, TJ				Shultz, Sandy R.; Aziz, Noor A. B.; Yang, Li; Sun, Mujun; MacFabe, Derrick F.; O'Brien, Terence J.			Intracerebroventricular injection of propionic acid, an enteric metabolite implicated in autism, induces social abnormalities that do not differ between seizure-prone (FAST) and seizure-resistant (SLOW) rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Autism; Animal model; Short chain fatty acid; Astrogliosis; Attention deficit hyperactivity disorder	TRAUMATIC BRAIN-INJURY; KINDLING-PRONE; SPECTRUM DISORDERS; RODENT MODEL; EPILEPSY; NEUROINFLAMMATION; PROFILES; BEHAVIOR; PRODUCT; ACTIVATION	Autism is a complex neurodevelopmental disorder that is characterized by social abnormalities. Genetic, dietary and gut-related factors are implicated in autism, however the causal properties of these factors and how they may interact are unclear. Propionic acid (PPA) is a product of gut microbiota and a food preservative. PPA has been linked to autism, and PPA administration to rats is an animal model of the condition. Seizure-prone (FAST) and seizure-resistant (SLOW) rats were initially developed to investigate differential vulnerability to developing epilepsy. However, FAST rats also display autistic-like features, and have been proposed as a genetic model of autism. Here we examined the effects of PPA on social behavior in FAST and SLOW rats. A single intracerebroventricular injection of PPA, or phosphate-buffered saline (PBS), was administered to young-adult male FAST and SLOW rats. Immediately after treatment, rats were placed in same-treatment and same-strain pairs, and underwent social behavior testing. PPA induced social abnormalities in both FAST and SLOW rat strains. While there was no evidence of social impairment in FAST rats that were not treated with PPA, these rats were hyperactive relative to SLOW rats. Post-mortem immunofluorescence analysis of brain tissue indicated that PPA treatment resulted in increased astrogliosis in the corpus callosum and cortex compared to PBS treatment. FAST rats had increased astrogliosis in the cortex compared to SLOW rats. Together these findings support the use of PPA as a rat model of autism, but indicate there are no interactive effects between the PPA and FAST models. (C) 2014 Elsevier B.V. All rights reserved.	[Shultz, Sandy R.; Aziz, Noor A. B.; Yang, Li; Sun, Mujun; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne Brain Ctr, Parkville, Vic, Australia; [Yang, Li] Kunming Med Univ, Dept Histol & Embryol, Kunming, Yunnan, Peoples R China; [MacFabe, Derrick F.] Univ Western Ontario, Kilee Patchell Evans Autism Res Grp, Dept Psychiat & Psychol, London, ON, Canada		Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne Brain Ctr, Parkville, Vic, Australia.	sshultz@unimelb.edu.au	O'Brien, Terence/AAU-5525-2021; O'Brien, Terence/L-8102-2013	Shultz, Sandy/0000-0002-2525-8775; O'Brien, Terence/0000-0002-7198-8621; Sun, Mujun/0000-0002-9923-9913	University of MelbourneUniversity of Melbourne; Royal Melbourne Hospital Neuroscience Foundation; Canadian Institute of Health Research fellowshipCanadian Institutes of Health Research (CIHR)	The authors thank Dr. Krista Gilby for providing access to the FAST and SLOW rat strains used in this study. This study was funded by grants from the University of Melbourne to SRS, a Royal Melbourne Hospital Neuroscience Foundation grant to TOB, and a Canadian Institute of Health Research fellowship to SRS.	Al-Lahham SH, 2010, BBA-MOL CELL BIOL L, V1801, P1175, DOI 10.1016/j.bbalip.2010.07.007; Argyropoulos A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00417; Azarbar A, 2010, BEHAV NEUROSCI, V124, P106, DOI 10.1037/a0018307; Baio Jon, 2012, Morbidity and Mortality Weekly Report, V61, P1; Bonnet U, 2000, EUR NEUROPSYCHOPHARM, V10, P97, DOI 10.1016/S0924-977X(99)00063-2; Cannizzaro C, 2003, NEUROCHEM INT, V43, P9, DOI 10.1016/S0197-0186(02)00211-5; Choi J, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-38; Crunelli V., 2014, NEUROSCIENTIST; Edmonson C, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-3; Foley KA, 2014, BEHAV BRAIN RES; Foley KA, 2014, INT J DEV NEUROSCI, V39, P68, DOI 10.1016/j.ijdevneu.2014.04.001; Foley KA, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087072, 10.1371/journal.pone.0108413]; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.143; Gilby KL, 2009, NEUROSCIENCE, V163, P750, DOI 10.1016/j.neuroscience.2009.07.013; Gilby KL, 2008, EPILEPSIA, V49, P108, DOI 10.1111/j.1528-1167.2008.01851.x; Gilby KL, 2013, EPILEPSY BEHAV, V26, P370, DOI 10.1016/j.yebeh.2012.11.002; Hamoda HM, 2009, EXPERT REV NEUROTHER, V9, P1747, DOI [10.1586/ern.09.128, 10.1586/ERN.09.128]; Herbert MR, 2010, CURR OPIN NEUROL, V23, P103, DOI 10.1097/WCO.0b013e328336a01f; Jeste SS, 2014, NAT REV NEUROL, V10, P74, DOI 10.1038/nrneurol.2013.278; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; KARURI AR, 1993, BRIT J CANCER, V68, P1080, DOI 10.1038/bjc.1993.485; Macfabe Derrick, 2013, Glob Adv Health Med, V2, P52, DOI 10.7453/gahmj.2013.089; MacFabe DF, 2007, BEHAV BRAIN RES, V176, P149, DOI 10.1016/j.bbr.2006.07.025; MacFabe Derrick F., 2012, Microbial Ecology in Health and Disease, V23, P19260, DOI 10.3402/mehd.v23i0.19260; MacFabe DF, 2011, BEHAV BRAIN RES, V217, P47, DOI 10.1016/j.bbr.2010.10.005; McIntyre DC, 2007, EPILEPSIA, V48, P30, DOI 10.1111/j.1528-1167.2007.01398.x; Mitsui R, 2005, NEUROGASTROENT MOTIL, V17, P585, DOI 10.1111/j.1365-2982.2005.00669.x; Pardo CA, 2014, NEUROTHERAPEUTICS, V11, P297, DOI 10.1007/s13311-014-0265-2; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Racine RJ, 1999, EPILEPSY RES, V35, P183, DOI 10.1016/S0920-1211(99)00013-3; Reiersen Angela M, 2008, Expert Rev Neurother, V8, P657, DOI 10.1586/14737175.8.4.657; Reinhart CJ, 2006, J COMP PSYCHOL, V120, P19, DOI 10.1037/0735-7036.120.1.19; Reinhart CJ, 2004, DEV PSYCHOBIOL, V45, P83, DOI 10.1002/dev.20016; Rossignol DA, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.4; Russell Vivienne A, 2006, Behav Brain Funct, V2, P30, DOI 10.1186/1744-9081-2-30; Severson CA, 2003, NAT NEUROSCI, V6, P1139, DOI 10.1038/nn1130; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Shultz SR., 2014, COMPREHENSIVE GUIDE, DOI [10.1007/978-1-4614-4788-7_106, DOI 10.1007/978-1-4614-4788-7_106]; Strickland AD, 2014, MED HYPOTHESES, V82, P522, DOI 10.1016/j.mehy.2014.02.003; Thomas RH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-153; Thomas RH, 2010, J NEUROCHEM, V113, P515, DOI 10.1111/j.1471-4159.2010.06614.x; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Vitaliti G, 2014, HUM VACC IMMUNOTHER, V10, P868, DOI 10.4161/hv.28400; Wang L, 2014, BIOMARK MED, V8, P331, DOI 10.2217/bmm.14.12; Zeidan-Chulia F, 2014, NEUROSCI BIOBEHAV R, V38, P160, DOI 10.1016/j.neubiorev.2013.11.008	50	33	35	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 1	2015	278						542	548		10.1016/j.bbr.2014.10.050			7	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	AY5AQ	WOS:000347586300067	25446754				2022-02-06	
J	Zaleski, A; Bogle, J; Starling, A; Zapala, DA; Davis, L; Wester, M; Cevette, M				Zaleski, Ashley; Bogle, Jamie; Starling, Amaal; Zapala, David A.; Davis, Laurie; Wester, Matthew; Cevette, Michael			Vestibular Evoked Myogenic Potentials in Patients With Vestibular Migraine	OTOLOGY & NEUROTOLOGY			English	Article						Migraine; Otolith; oVEMP; cVEMP	BONE-CONDUCTED VIBRATION; MENIERES-DISEASE; COLLIC REFLEX; FOLLOW-UP; VERTIGO; DIZZINESS; HEADACHE; RECOVERY; CLASSIFICATION; DISORDERS	Objective Literature investigating otolith reflexes in patients with vestibular migraine (VM) is variable and primarily describes the descending saccular pathway. This research aimed to study ocular vestibular evoked myogenic potential (oVEMP) and cervical vestibular evoked myogenic potential (cVEMP) prevalence and response characteristics in patients with suspected VM and in control patients. The purpose is to assess vulnerabilities within the ascending utricular and descending saccular pathways in the VM population. Study Design Retrospective study Setting Tertiary academic referral center Patients 39 adults with VM, 29 control patients Main Outcome Measure(s) Air conducted oVEMPs and cVEMPs measured with 500 Hz tone burst stimuli Results Age of headache onset was most often in childhood or adolescence, with dizziness onset occurring later. The rate of bilaterally absent oVEMPs was significantly higher (28%, p < 0.01) in the VM group compared with the control group (0%). oVEMP amplitude asymmetry ratios were significantly higher for the definite VM (p < 0.01) and probable VM (p = 0.023) groups than the control group. Eleven patients also had history of concussion; they were significantly more likely to demonstrate bilaterally absent oVEMPs (p < 0.01) in comparison to the control patients. When VM patients with a history of concussion were omitted from analysis, differences in oVEMP amplitude asymmetry (p < 0.01) and bilateral oVEMP absence remained significant (p = 0.015). There were no differences in the rate of bilateral cVEMP presence or response parameters between VM and control groups. Conclusion VEMP presentation differs for some patients diagnosed with VM. The higher rates of abnormal oVEMPs may suggest greater vulnerability within the ascending utricular-ocular pathway in patients with VM.	[Zaleski, Ashley; Bogle, Jamie; Davis, Laurie; Wester, Matthew; Cevette, Michael] Mayo Clin Arizona, Audiol Sect, Scottsdale, AZ USA; [Starling, Amaal] Mayo Clin Arizona, Neurol Sect, Scottsdale, AZ USA; [Zapala, David A.] Mayo Clin Florida, Audiol Sect, Jacksonville, FL USA		Bogle, J (corresponding author), Mayo Clin Scottsdale, Audiol Sect, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA.	bogle.jamie@mayo.edu					Allena M, 2007, CEPHALALGIA, V27, P1150, DOI 10.1111/j.1468-2982.2007.01414.x; Bahmad F, 2009, ANN OTO RHINOL LARYN, V118, P670, DOI 10.1177/000348940911800912; Baier B, 2009, J NEUROL, V256, P1447, DOI 10.1007/s00415-009-5132-4; Balabann CD, 2011, EXPERT REV NEUROTHER, V11, P379, DOI [10.1586/ern.11.19, 10.1586/ERN.11.19]; Baloh RW, 1997, HEADACHE, V37, P615, DOI 10.1046/j.1526-4610.1997.3710615.x; BARABAS G, 1983, PEDIATRICS, V72, P188; Bergenius J, 1999, ACTA OTO-LARYNGOL, V119, P895; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Boldingh MI, 2011, CEPHALALGIA, P31; Cass SP, 1997, ANN OTO RHINOL LARYN, V106, P182, DOI 10.1177/000348949710600302; Celebisoy N, 2008, CEPHALALGIA, V28, P72, DOI 10.1111/j.1468-2982.2007.01474.x; Cha YH, 2013, CEPHALALGIA, V33, P1160, DOI 10.1177/0333102413487999; Chihara Y, 2007, CLIN NEUROPHYSIOL, V118, P2745, DOI 10.1016/j.clinph.2007.08.005; Curthoys IS, 2012, ACTA OTORHINOLARYNGO, V32, P41; CUTRER FM, 1992, HEADACHE, V32, P300, DOI 10.1111/j.1526-4610.1992.hed3206300.x; Dieterich M, 1999, J NEUROL, V246, P883, DOI 10.1007/s004150050478; Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8; Furman JM, 2003, CURR OPIN NEUROL, V16, P5, DOI 10.1097/00019052-200302000-00002; Zuniga MG, 2012, OTOLARYNG HEAD NECK, V146, P788, DOI 10.1177/0194599811434073; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Hamel E, 2007, CEPHALALGIA, V27, P1295; Iwasaki S, 2009, CLIN NEUROPHYSIOL, V120, P588, DOI 10.1016/j.clinph.2008.12.036; Johnson GD, 1998, LARYNGOSCOPE, V108, P1, DOI 10.1097/00005537-199801001-00001; KAYAN A, 1984, BRAIN, V107, P1123, DOI 10.1093/brain/107.4.1123; Kim HA, 2008, NEUROLOGY, V70, P449, DOI 10.1212/01.wnl.0000297554.21221.a0; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; KURITZKY A, 1981, HEADACHE, V21, P227, DOI 10.1111/j.1526-4610.1981.hed2105227.x; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lee H, 2002, NEUROL RES, V24, P663, DOI 10.1179/016164102101200726; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Manzari L, 2012, J LARYNGOL OTOL, V126, P683, DOI 10.1017/S0022215112000692; Marano E, 2005, HEADACHE, V45, P325, DOI 10.1111/j.1526-4610.2005.05069.x; Marcelli V, 2010, HEADACHE, V50, P71, DOI 10.1111/j.1526-4610.2009.01454.x; Murofushi T, 2009, CEPHALALGIA, V29, P1259, DOI 10.1111/j.1468-2982.2009.01860.x; Murofushi T, 1997, ACTA OTO-LARYNGOL, V117, P66, DOI 10.3109/00016489709117994; Neff BA, 2012, OTOL NEUROTOL, V33, P1235, DOI 10.1097/MAO.0b013e31825d644a; Neuhauser H, 2001, NEUROLOGY, V56, P436, DOI 10.1212/WNL.56.4.436; Obermann M, 2012, NEUROLOGY, V78; Oh SY, 2015, CLIN NEUROPHYSIOL, V126, P180, DOI 10.1016/j.clinph.2014.03.030; Olesen J, 2005, REV NEUROL-FRANCE, V161, P689; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Piker EG, 2011, J AM ACAD AUDIOL, V22, P222, DOI 10.3766/jaaa.22.4.5; Polensek SH, 2010, AUDIOL NEURO-OTOL, V15, P241, DOI 10.1159/000255440; Radtke A, 2012, NEUROLOGY, V79, P1607, DOI 10.1212/WNL.0b013e31826e264f; Radtke A, 2011, CEPHALALGIA, V31, P906, DOI 10.1177/0333102411405228; Roceanu A, 2008, CEPHALALGIA, V28, P988, DOI 10.1111/j.1468-2982.2008.01641.x; Sharon JD, 2014, LARYNGOSCOPE, V124, P969, DOI 10.1002/lary.24285; Shin JE, 2013, ACTA OTO-LARYNGOL, V133, P154, DOI 10.3109/00016489.2012.727469; Taylor RL, 2012, CEPHALALGIA, V32, P213, DOI 10.1177/0333102411434166; Thakar A, 2001, J LARYNGOL OTOL, V115, P782; Vass Z, 2004, NEUROSCIENCE, V124, P919, DOI 10.1016/j.neuroscience.2003.12.030; von Brevern M, 2005, BRAIN, V128, P365, DOI 10.1093/brain/awh351; Vukovic V, 2007, HEADACHE, V47, P1427, DOI 10.1111/j.1526-4610.2007.00939.x; Young YH, 2003, ARCH OTOLARYNGOL, V129, P815, DOI 10.1001/archotol.129.8.815; Zapala David A, 2004, J Am Acad Audiol, V15, P198, DOI 10.3766/jaaa.15.3.3	55	33	35	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1531-7129	1537-4505		OTOL NEUROTOL	Otol. Neurotol.	FEB	2015	36	2					295	302		10.1097/MAO.0000000000000665			8	Clinical Neurology; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Otorhinolaryngology	AZ8IQ	WOS:000348459300028	25415464				2022-02-06	
J	Kim, N; Kim, JY; Yenari, MA				Kim, N.; Kim, J. Y.; Yenari, M. A.			PHARMACOLOGICAL INDUCTION OF THE 70-kDa HEAT SHOCK PROTEIN PROTECTS AGAINST BRAIN INJURY	NEUROSCIENCE			English	Article						animal studies; traumatic brain injury; therapeutic approaches	LEUKEMIA CELLS; INHIBITORS; HEAT-SHOCK-PROTEIN-70; OVEREXPRESSION; INFLAMMATION; MECHANISMS; APOPTOSIS; ISCHEMIA; SURVIVAL; NEURONS	The 70-kDa heat shock protein (HSP70) is known to protect the brain from injury through multiple mechanisms. We investigated the effect of pharmacological HSP70 induction in experimental traumatic brain injury (TBI). 3-month-old male C57/B6 mice were given 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) intraperitoneally (IP, 2 mg/kg) or intracerebroventricularly (ICV, 1 mu g/kg) to determine whether HSP70 could be induced in the brain. Mice were subjected to TBI via cortical controlled impact, and were treated with 17-AAG (or vehicle) IP according to one of two treatment regimens: (1) 2 mg/kg at the time of injury, (2) a total of three doses (4 mg/kg) at 2 and 1 d prior to TBI and again at the time of injury. Brains were assessed for HSP70 induction, hemorrhage volume at 3 d, and lesion size at 14 d post-injury. Immunohistochemistry showed that both IP and ICV administration of 17-AAG increased HSP70 expression primarily in microglia and in a few neurons by 24 h but not in astrocytes. 17-AAG induced HSP70 in injured brain tissue as early as 6 h, peaking at 48 h and largely subsiding by 72 h after IP injection. Both treatment groups showed decreased hemorrhage volume relative to untreated mice as well as improved neurobehavioral outcomes. These observations indicate that pharmacologic HSP70 induction may prove to be a promising treatment for TBI. Published by Elsevier Ltd. on behalf of IBRO.	[Yenari, M. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA		Yenari, MA (corresponding author), Neurol 127,VAMC 4150 Clement St, San Francisco, CA 94121 USA.	nuri@berkeley.edu; jongyoul74@gmail.com; yenari@alum.mit.edu		Hegelmeyer, Nuri/0000-0003-3606-0155	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS40516]; Department of DefenseUnited States Department of Defense; Veteran's Merit Award; American Heart Association Western States Affiliate Postdoctoral FellowshipAmerican Heart Association [13POST14810019]; Northern California Institute for Research and Education; resources of the Veterans Affairs Medical Center, San Francisco, California; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040516] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (NS40516), Department of Defense and the Veteran's Merit Award to MY, an American Heart Association Western States Affiliate Postdoctoral Fellowship (13POST14810019) to JYK. Grants to MY and JYK were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California. The authors wish to thank Dr. Linda Noble-Haeusslein for helpful discussion and advice.	Adachi M, 2009, PLOS ONE, V4, pA57, DOI 10.1371/journal.pone.0007719; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Chakraborty PK, 2008, CANCER SCI, V99, P1109, DOI 10.1111/j.1349-7006.2008.00809.x; Chatterjee A, 2008, AM J PHYSIOL-LUNG C, V294, pL755, DOI 10.1152/ajplung.00350.2007; Chatterjee A, 2007, AM J RESP CRIT CARE, V176, P667, DOI 10.1164/rccm.200702-291OC; Faul M, 2010, TRAUMATIC BRAIN INJU; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; Giffard RG, 2008, ANESTHESIOLOGY, V109, P339, DOI 10.1097/ALN.0b013e31817f4ce0; Henderson B, 2010, CELL BIOCHEM FUNCT, V28, P1, DOI 10.1002/cbf.1609; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Kelly S, 2002, ANN NEUROL, V52, P160, DOI 10.1002/ana.10264; Kelly Stephen, 2002, Curr Med Res Opin, V18 Suppl 2, ps55, DOI 10.1185/030079902125000732; Kim JY, 2013, NEUROBIOL DIS, V58, P289, DOI 10.1016/j.nbd.2013.06.012; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Komotar RJ, 2007, NAT PROTOC, V2, P2345, DOI 10.1038/nprot.2007.359; Kwon HM, 2008, NEUROL RES, V30, P740, DOI 10.1179/174313208X289615; Lee JE, 2004, NEUROREPORT, V15, P499, DOI 10.1097/00001756-200403010-00023; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Madrigal-Matute J, 2010, CARDIOVASC RES, V86, P330, DOI 10.1093/cvr/cvq046; Manaenko A, 2010, NEUROCHEM INT, V57, P844, DOI 10.1016/j.neuint.2010.09.001; Porter JR, 2009, CURR TOP MED CHEM, V9, P1386, DOI 10.2174/156802609789895719; Poulaki V, 2007, FASEB J, V21, P2113, DOI 10.1096/fj.06-7637com; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.3.CO;2-V; Sausville EA, 2003, CURR CANCER DRUG TAR, V3, P377, DOI 10.2174/1568009033481831; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Tavernier E, 2012, J CANCER RES CLIN, V138, P1753, DOI 10.1007/s00432-012-1247-6; Turturici G, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/618127; Vaishampayan UN, 2010, CLIN CANCER RES, V16, P3795, DOI 10.1158/1078-0432.CCR-10-0503; Wang GH, 2011, J NEUROCHEM, V117, P703, DOI 10.1111/j.1471-4159.2011.07239.x; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007; Zhang JJ, 2013, CLIN EXP MED, V13, P323, DOI 10.1007/s10238-012-0208-3	34	33	36	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 22	2015	284						912	919		10.1016/j.neuroscience.2014.11.010			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AW4HZ	WOS:000346243100081	25446362	Green Accepted, Green Submitted			2022-02-06	
J	Newell, EA; Exo, JL; Verrier, JD; Jackson, TC; Gillespie, DG; Janesko-Feldman, K; Kochanek, PM; Jackson, EK				Newell, Elizabeth A.; Exo, Jennifer L.; Verrier, Jonathan D.; Jackson, Travis C.; Gillespie, Delbert G.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Jackson, Edwin K.			2 ',3 '-cAMPI, 3 '-AMP, 2 '-AMP and adenosine inhibit TNF-alpha and CXCL10 production from activated primary murine microglia via A(2A) receptors	BRAIN RESEARCH			English	Article						Primary microglia; CXCL10; TNF; 2',3'-cAMP; 2'-AMP; 3'-AMP; Adenosine; Adenosine receptors; A(2A) receptors	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; SMOOTH-MUSCLE-CELL; BONE-MARROW-CELLS; CYCLIC-AMP; DIFFERENTIAL EXPRESSION; A2A RECEPTORS; PATHWAY; RAT	Background: Some cells, tissues and organs release 2',3'-cAMP (a positional isomer of 3',5'-cAMP) and convert extracellular 2',3'-cAMP to 2'-AMP plus 3'-AMP and convert these AMPs to adenosine (called the extracellular 2',3'-cAMP-adenosine pathway). Recent studies show that microglia have an extracellular 2',3'-cAMP-adenosine pathway. The goal of the present study was to investigate whether the extracellular 2',3'-cAMP-adenosine pathway could have functional consequences on the production of cytokines/chemokines by activated microglia. Methods: Experiments were conducted in cultures of primary murine microglia. In the first experiment, the effect of 2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine on LPS-induced TNF-alpha and CXCL10 production was determined. In the next experiment, the first protocol was replicated but with the addition of 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX) (0.1 mu M; antagonist of adenosine receptors). The last experiment compared the ability of 2-chloro-N-6-cyclopentyladenosine (CCPA) (10 mu M; selective A(1) agonist), 5'-N-ethylcarboxamide adenosine (NECA) (10 mu M; agonist for all adenosine receptor subtypes) and CGS21680 (10 mu M; selective A(2A) agonist) to inhibit LPS-induced TNF-alpha and CXCL10 production. Results: (1) 2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine similarly inhibited LPS-induced TNF-alpha and CXCL10 production; (2) DPSPX nearly eliminated the inhibitory effects of 2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine on LPS-induced TNF-alpha and CXCL10 production; (3) CCPA did not affect LPS-induced TNF-alpha and CXCL10; (4) NECA and CGS21680 similarly inhibited LPS-induced TNF-alpha and CXCL10 production. Conclusions: 2',3'-cAMP and its metabolites (3'-AMP, 2'-AMP and adenosine) inhibit LPS-induced TNF-alpha and CXCL10 production via A(2A)-receptor activation. Adenosine and its precursors, via A(2A) receptors, likely suppress TNF-alpha and CXCL10 production by activated microglia in brain diseases. (C) 2014 Elsevier B.V. All rights reserved.	[Newell, Elizabeth A.; Exo, Jennifer L.; Jackson, Travis C.; Janesko-Feldman, Keri; Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Safar Ctr Resuscitat Res,Dept Crit Care Med, Pittsburgh, PA USA; [Verrier, Jonathan D.; Gillespie, Delbert G.; Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA		Jackson, EK (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	elizabeth-newell@uiowa.edu; jnnfrx0@gmail.com; jdv17@pitt.edu; tcj10@pitt.edu; dgg3@pitt.edu; JaneskoKL@anes.upmc.edu; kochanekpm@ccm.upmc.edu; edj@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Newell, Elizabeth/0000-0002-1476-033X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS087978, HD040686, HL109002, DK091190, HL069846, DK068575, DK079307]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL109002, R01HL069846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575, P30DK079307, R01DK091190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS087978] Funding Source: NIH RePORTER	Supported by grants from the National Institutes of Health [NS087978 (PMK/EKJ); HD040686 (JLE); HL109002, DK091190, HL069846, DK068575 and DK079307 (EKJ)].	Aden U, 2003, STROKE, V34, P739, DOI 10.1161/01.STR.0000060204.67672.8B; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Biber K, 2002, NEUROSCIENCE, V112, P487, DOI 10.1016/S0306-4522(02)00114-8; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Dai SS, 2011, REV NEUROSCIENCE, V22, P231, DOI 10.1515/RNS.2011.020; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Dare E, 2007, PHYSIOL BEHAV, V92, P15, DOI 10.1016/j.physbeh.2007.05.031; Duan RS, 2008, NEUROCHEM RES, V33, P1085, DOI 10.1007/s11064-007-9554-z; Dubey RK, 2001, HYPERTENSION, V37, P1095, DOI 10.1161/01.HYP.37.4.1095; Dubey RK, 1998, HYPERTENSION, V31, P296, DOI 10.1161/01.HYP.31.1.296; Dubey RK, 1996, HYPERTENSION, V28, P765, DOI 10.1161/01.HYP.28.5.765; Dubey RK, 2000, HYPERTENSION, V36, P337, DOI 10.1161/01.HYP.36.3.337; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Eltzschig HK, 2009, ANESTHESIOLOGY, V111, P904, DOI 10.1097/ALN.0b013e3181b060f2; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Galimberti D, 2006, ARCH NEUROL-CHICAGO, V63, P538, DOI 10.1001/archneur.63.4.538; Giunti D, 2003, J LEUKOCYTE BIOL, V73, P584, DOI 10.1189/jlb.1202598; Grip O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005263; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Jackson EK, 2012, AM J PHYSIOL-RENAL, V303, pF954, DOI 10.1152/ajprenal.00335.2012; Jackson EK, 2011, J PHARMACOL EXP THER, V337, P444, DOI 10.1124/jpet.110.178137; Jackson EK, 2010, HYPERTENSION, V56, P151, DOI 10.1161/HYPERTENSIONAHA.110.152454; Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kochanek PM, 2005, J CEREBR BLOOD F MET, V25, P1596, DOI 10.1038/sj.jcbfm.9600154; Kolb SA, 1999, J NEUROIMMUNOL, V93, P172, DOI 10.1016/S0165-5728(98)00223-9; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Lee JY, 2006, NEUROSCI LETT, V396, P1, DOI 10.1016/j.neulet.2005.11.004; Link AA, 2000, J IMMUNOL, V164, P436, DOI 10.4049/jimmunol.164.1.436; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; MI ZC, 1994, LIFE SCI, V54, pPL277, DOI 10.1016/0024-3205(94)00846-9; Mi ZC, 1998, J PHARMACOL EXP THER, V287, P926; MI ZC, 1995, J PHARMACOL EXP THER, V273, P728; Muller M, 2010, NEUROPATH APPL NEURO, V36, P368, DOI 10.1111/j.1365-2990.2010.01089.x; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; van der Putten C, 2009, J IMMUNOL, V182, P7603, DOI 10.4049/jimmunol.0803383; van Weering HRJ, 2011, HIPPOCAMPUS, V21, P220, DOI 10.1002/hipo.20742; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Verrier JD, 2011, J NEUROCHEM, V118, P979, DOI 10.1111/j.1471-4159.2011.07392.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Wilson NO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060898; Wilson NO, 2011, DIS MARKERS, V30, P39, DOI [10.1155/2011/828256, 10.3233/DMA-2011-0763]; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	59	33	33	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 12	2015	1594						27	35		10.1016/j.brainres.2014.10.059			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY5CE	WOS:000347590100003	25451117	Green Accepted			2022-02-06	
J	Rousseau, P; Hoshizaki, TB				Rousseau, Philippe; Hoshizaki, Thomas B.			Defining the effective impact mass of elbow and shoulder strikes in ice hockey	SPORTS BIOMECHANICS			English	Article						sports biomechanics; impact reconstruction; Head injury	PROFESSIONAL FOOTBALL; HEAD IMPACTS; CONCUSSION; BIOMECHANICS; INJURIES; PLAYERS; RECONSTRUCTION; SPORTS; TRAUMA; BRAIN	Reconstruction of real-life events can be used to investigate the relationship between the mechanical parameters of the impact and concussion risk. Striking mass has typically been approximated as being the mass of the body part coming into contact with the head without accounting for the force applied by the striking athlete. Thus, the purpose of this study was to measure the effective impact mass of three common striking techniques in ice hockey. Fifteen participants were instructed to strike a suspended 50th percentile Hybrid III headform at least three times with their elbow or shoulder. Effective impact mass was calculated by measuring the change in velocity of the player and the headform. Mean effective impact mass for the extended elbow, tucked-in elbow, and shoulder check conditions were 4.8, 3.0, and 12.9kg, respectively. Peak linear accelerations were lower than the values associated with concussion in American football which could be a reflection of the methodology used in this study as well as inherent differences between both sports.	[Rousseau, Philippe; Hoshizaki, Thomas B.] Univ Ottawa, Neurotrauma Impact Sci Lab, Fac Hlth Sci, Ottawa, ON K1N 6N5, Canada		Rousseau, P (corresponding author), Univ Ottawa, Neurotrauma Impact Sci Lab, Fac Hlth Sci, A106-200 Lees Ave, Ottawa, ON K1N 6N5, Canada.	philippe.rousseau@uottawa.ca					Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Budescu E. I., 2008, P INT C COMP EXP ENG; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Foster J., 1974, HYBRID, P49; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hubbard R., 1974, HYBRID 3 1 HUMAN CRA, P95; Hutchison M. H., 2011, THESIS U TORONTO CAN; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Jorgensen U, 1986, Br J Sports Med, V20, P7; Karton C., 2012, THESIS U OTTAWA CANA; Karton CM, 2014, AM SOC TEST MATER, V1552, P23, DOI 10.1520/STP155220120175; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Mao H., 2010, INT J NUMERICAL METH, V27, P357; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mertz H. J., 1985, P 29 STAPP CAR CRASH; Morrison III B., 2003, P 47 STAPP CAR CRASH; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; Smith MS, 2000, J SPORT SCI, V18, P445, DOI 10.1080/02640410050074377; Society of Automotive Engineer International, 2007, J2111 SAE INT; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; Thibault L, 1999, P INT RES COUNC BIOM; USA Hockey, 2009, CHECK RIGHT WAY YOUT; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; WHITING WC, 1988, AM J SPORT MED, V16, P130, DOI 10.1177/036354658801600207; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Yu Z., 2009, BIOM SCI ENG C 1 ANN; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	49	33	33	1	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1476-3141	1752-6116		SPORT BIOMECH	Sport. Biomech.	JAN 2	2015	14	1					57	67		10.1080/14763141.2015.1025236			11	Engineering, Biomedical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	CH4YD	WOS:000354039000005	25895554				2022-02-06	
J	Dahm, J; Ponsford, J				Dahm, Jane; Ponsford, Jennie			Comparison of long-term outcomes following traumatic injury: What is the unique experience for those with brain injury compared with orthopaedic injury?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Outcomes; Orthopaedic trauma; Comparative study	QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; FATIGUE SEVERITY SCALE; HEAD-INJURY; PSYCHIATRIC-DISORDERS; MULTIPLE INJURIES; DEPRESSION SCALE; HOSPITAL ANXIETY; MAJOR TRAUMA; PSYCHOMETRIC PROPERTIES	Objective: Whilst it has been well-demonstrated that traumatic brain injury (TBI) results in long-term cognitive, behavioural and emotional difficulties, less is understood about how these outcomes differ from those following traumatic orthopaedic injury (TOI). The aim of this study was to compare self-reported outcomes at 5-10 years post-injury for those with TBI, TOI, and uninjured controls. It was hypothesised that participants with TBI would have greater cognitive difficulties; participants with TOI and TBI would have similar functional and physical outcomes, both being poorer than controls; and participants with TBI would have poorer psychosocial outcomes than those with TOI. Participants and methods: Eighty-eight individuals with complicated mild to severe TBI and 96 with TOI recruited during inpatient rehabilitation were followed up 5-10 years post-injury, together with 48 controls followed over a similar period. Self-report measures of global functioning (GOS-E), quality of life (SF-36), psychological wellbeing (SCL-90-R, HADS, PCL-S), psychosocial difficulties (SIP), cognitive difficulties (SF-36 COG), pain (BPI), and fatigue (FSS) were administered. Results: Outcomes for individuals with TBI and TOI differed significantly from controls, with poorer global functioning, and greater psychological distress and interference from pain. Only participants with TBI reported greater cognitive difficulties and anxiety than controls, and were less likely to be employed or in a relationship. Participants with TBI reported greater anxiety, PTSD, psychological distress and psychosocial difficulties than those with TOI. Conclusions: Both TOI and TBI cause long-term disability, interference from pain, and psychological distress. However, cognitive impairments, unemployment, lack of long-term relationships, anxiety and PTSD are more substantial long-term problems following TBI. Findings from this study have implications for managing risks associated with these injury groups and tailoring rehabilitation to improve long-term outcomes. (C) 2014 Elsevier Ltd. All rights reserved.	[Dahm, Jane; Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia; [Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia		Dahm, J (corresponding author), Monash Univ, Sch Psychol Sci, Bldg 17,Wellington Rd, Clayton, Vic 3800, Australia.	jane.dahm@monash.edu			Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR)	Information for individuals with traumatic brain injury was accessed from data collected for the Longitudinal Head Injury Study funded by the Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR).	Adkins JW, 2008, J ANXIETY DISORD, V22, P1393, DOI 10.1016/j.janxdis.2008.02.002; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ardolino A, 2012, INJURY, V43, P1662, DOI 10.1016/j.injury.2012.05.008; Australian Bureau of Statistics, 2008, NAT SURV MENT HLTH W; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bhandari M, 2008, CAN J SURG, V51, P15; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Braden CA, 2012, BRAIN INJURY, V26, P1315, DOI 10.3109/02699052.2012.706351; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cameron PA, 2006, INJURY, V37, P1178, DOI 10.1016/j.injury.2006.07.015; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Faul M, 2010, TRAUMATIC BRAIN INJU; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gabbe BJ, 2013, ANN SURG, V257, P166, DOI 10.1097/SLA.0b013e31825d7422; Ghinassi C. W., 2010, ANXIETY; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Gross T, 2012, ACTA ANAESTH SCAND, V56, P1163, DOI 10.1111/j.1399-6576.2012.02724.x; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-236; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Helps Y., 2008, INJURY RES STAT SERI; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hills A.M., 2011, FOOLPROOF GUIDE STAT; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Hoofien D, 2005, APPL NEUROPSYCHOL, V12, P30, DOI 10.1207/s15324826an1201_6; Hoofien D, 2001, BRAIN INJURY, V15, P189; Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; McCarthy ML, 2003, J BONE JOINT SURG AM, V85A, P1689, DOI 10.2106/00004623-200309000-00006; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2009, J REHABIL MED, V41, P179, DOI 10.2340/16501977-0306; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ponsford J., 2013, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Raichle KA, 2006, J PAIN, V7, P179, DOI 10.1016/j.jpain.2005.10.007; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Tan G, 2004, J PAIN, V5, P133, DOI 10.1016/j.jpain.2003.12.005; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; The Management of Concussion/mTBl Working Group, 2009, VA DOD CLIN PRACT GU; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Weathers F. W., 1993, ANN M INT SOC TRAUMA; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zeckey C, 2011, BRAIN INJURY, V25, P551, DOI 10.3109/02699052.2011.568036; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	85	33	34	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2015	46	1					142	149		10.1016/j.injury.2014.07.012			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AX1YJ	WOS:000346739600027	25123975				2022-02-06	
J	Finnanger, TG; Olsen, A; Skandsen, T; Lydersen, S; Vik, A; Evensen, KAI; Catroppa, C; Haberg, AK; Andersson, S; Indredavik, MS				Finnanger, Torun Gangaune; Olsen, Alexander; Skandsen, Toril; Lydersen, Stian; Vik, Anne; Evensen, Kari Anne I.; Catroppa, Cathy; Haberg, Asta K.; Andersson, Stein; Indredavik, Marit S.			Life after Adolescent and Adult Moderate and Severe Traumatic Brain Injury: Self-Reported Executive, Emotional, and Behavioural Function 2-5 Years after Injury	BEHAVIOURAL NEUROLOGY			English	Article							QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE IMPAIRMENT; HEAD-INJURY; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC-DISORDERS; SUBJECTIVE COMPLAINTS; MAJOR DEPRESSION; RATING INVENTORY; MOOD DISORDERS	Survivors of moderate-severe Traumatic Brain Injury (TBI) are at risk for long-term cognitive, emotional, and behavioural problems. This prospective cohort study investigated self-reported executive, emotional, and behavioural problems in the late chronic phase of moderate and severe TBI, if demographic characteristics (i.e., age, years of education), injury characteristics (Glasgow Coma Scale score, MRI findings such as traumatic axonal injury (TAI), or duration of posttraumatic amnesia), symptoms of depression, or neuropsychological variables in the first year after injury predicted long-term self-reported function. Self-reported executive, emotional, and behavioural functioning were assessed among individuals with moderate and severe TBI (N = 67, age range 15-65 years at time of injury) 2-5 years after TBI, compared to a healthy matched control group (N = 72). Results revealed significantly more attentional, emotional regulation, and psychological difficulties in the TBI group than controls. Demographic and early clinical variables were associated with poorer cognitive and emotional outcome. Fewer years of education and depressive symptoms predicted greater executive dysfunction. Younger age at injury predicted more aggressive and rule-breaking behaviour. TAI and depressive symptoms predicted Internalizing problems and greater executive dysfunction. In conclusion, age, education, TAI, and depression appear to elevate risk for poor long-term outcome, emphasising the need for long-term follow-up of patients presenting with risk factors.	[Finnanger, Torun Gangaune; Lydersen, Stian; Indredavik, Marit S.] Norwegian Univ Sci & Technol NTNU, Fac Med, Reg Ctr Child & Youth Mental Hlth & Child Welf Ce, N-7491 Trondheim, Norway; [Finnanger, Torun Gangaune; Indredavik, Marit S.] Univ Trondheim Hosp, St Olavs Hosp, Dept Child & Adolescent Psychiat, Div Mental Healthcare, N-7006 Trondheim, Norway; [Finnanger, Torun Gangaune] Univ Trondheim Hosp, St Olavs Hosp, Childrens Clin, N-7006 Trondheim, Norway; [Olsen, Alexander; Haberg, Asta K.] Norwegian Univ Sci & Technol, MI Lab, N-7491 Trondheim, Norway; [Olsen, Alexander; Haberg, Asta K.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Olsen, Alexander; Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway; [Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, Fac Med, N-7491 Trondheim, Norway; [Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Neuroclin, N-7006 Trondheim, Norway; [Evensen, Kari Anne I.] Norwegian Univ Sci & Technol, Dept Lab Med Children & Womens Hlth, Dept Publ Hlth & Gen Practice, N-7491 Trondheim, Norway; [Evensen, Kari Anne I.] Trondheim Municipal, Dept Physiotherapy, Trondheim, Norway; [Catroppa, Cathy] Murdoch Childrens Res Inst, Child Neuropsychol, Melbourne, Vic 3052, Australia; [Catroppa, Cathy] Univ Melbourne, Dept Pediat, Melbourne, Vic 3010, Australia; [Catroppa, Cathy] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic 3010, Australia; [Andersson, Stein] Oslo Univ Hosp, Dept Psychosomat Med, N-0424 Oslo, Norway; [Andersson, Stein] Univ Oslo, Dept Psychol, N-0373 Oslo, Norway		Finnanger, TG (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med, Reg Ctr Child & Youth Mental Hlth & Child Welf Ce, N-7491 Trondheim, Norway.	torun.g.finnanger@ntnu.no	Catroppa, Cathy/AAX-9458-2021; Olsen, Alexander/P-5235-2019	Catroppa, Cathy/0000-0002-9750-0436; Olsen, Alexander/0000-0001-8691-3860; Evensen, Kari Anne I./0000-0002-0129-0164	Norwegian Extra Foundation for Health and Rehabilitation [2010/2/0105]; Liaison Committee [47063700]; SINTEF Unimed Innovation Research FundSINTEF [09/9603]; Norwegian research Council, through MI Lab at the Norwegian University of Science and Technology; National Center of Competence Services for functional MRI, Department of Medical imaging, Trondheim University Hospital	The authors thank Brit Bjorklimo and neuropsychologists at the Department of Physical Medicine and Rehabilitation, St. Olavs Hospital, for assistance with collection and preparation of the neuropsychological data and Beate Holmqvist Karlsen, Stine B. Lund, and Otto Aarhaug for research assistance and outcome assessment. The authors would also like to thank Alexandra Maria Costache and Gunnar Gotaas for their contribution in data collection and assistance in the process of preprocessing self-report data in the follow-up phase of the project. This work was supported by the Norwegian Extra Foundation for Health and Rehabilitation (first author, Grant no. 2010/2/0105); the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU) (first author, Grant no. 47063700); and SINTEF Unimed Innovation Research Fund (first author, Grant no. 09/9603). The Norwegian research Council, through MI Lab at the Norwegian University of Science and Technology, and the National Center of Competence Services for functional MRI, Department of Medical imaging, Trondheim University Hospital, also contributed financially to this project.	Achenbach TM., 2003, MANUAL ASEBA ADULT F; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beck AT., 1979, COGNITIVE THERAPY DE; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cohen J., 2013, STAT POWER ANAL BEHA; Conners C. K., 2000, CONNERS CONTINUOUS P; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Di Battista A, 2015, BRAIN INJURY, V29, P573, DOI 10.3109/02699052.2014.989905; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Donders J., 2015, J HEAD TRAUMA REHABI; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fagerland MW, 2015, STAT METHODS MED RES, V24, P224, DOI 10.1177/0962280211415469; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Funderud I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048504; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Gardner M.J, 2000, STAT CONFIDENCE; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Green L, 2012, DEV NEUROREHABIL, V15, P105, DOI 10.3109/17518423.2011.638331; Grissom Robert J, 2005, EFFECT SIZES RES BRO; Haberg A. K., 2015, J NEUROSCI RES, V93, P1109; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; JOHNSTON MV, 1995, BRAIN DEV-JPN, V17, P301, DOI 10.1016/0387-7604(95)00079-Q; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Lengenfelder J, 2015, APPL NEUROPSYCH-ADUL, V22, P7, DOI 10.1080/23279095.2013.816703; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Meyers JE., 1995, REY COMPLEX FIGURE T; Misic-Pavkov G, 2012, EUR REV MED PHARMACO, V16, P1806; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Olsen A, 2015, CEREB CORTEX, V25, P2170, DOI 10.1093/cercor/bhu023; Olsen A, 2013, J COGNITIVE NEUROSCI, V25, P903, DOI 10.1162/jocn_a_00358; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Prigatano GP, 2005, ACT NEUR S, V93, P39; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Ragsdale KA, 2013, J ANXIETY DISORD, V27, P420, DOI 10.1016/j.janxdis.2013.04.003; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosema S, 2015, J NEUROTRAUM, V32, P976, DOI 10.1089/neu.2014.3567; Rotenberg-Shpigelman S., 2008, ISRAELI J OCCUPATION, V17, P77; Roth RM, 2013, ARCH CLIN NEUROPSYCH, V28, P425, DOI 10.1093/arclin/act031; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Sigurdardottir S, 2013, J REHABIL MED, V45, P808, DOI 10.2340/16501977-1156; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith A., 1982, SYMBOL DIGIT MODALIT; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stuss DT, 2013, ARCH CLIN NEUROPSYCH, V28, P1, DOI 10.1093/arclin/acs107; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Trahan D. E., 1988, CONTINOUS VISUALMEMO; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Velikonja D, 2010, J CLIN EXP NEUROPSYC, V32, P610, DOI 10.1080/13803390903401302; Waid-Ebbs JK, 2012, BRAIN INJURY, V26, P1646, DOI 10.3109/02699052.2012.700087; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wechsler D., 2011, WECHSLER ABBREVIATED; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	93	33	33	0	9	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0953-4180	1875-8584		BEHAV NEUROL	Behav. Neurol.		2015	2015								329241	10.1155/2015/329241			19	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CU5MV	WOS:000363577200001	26549936	Green Published, Green Submitted, gold			2022-02-06	
J	Lange, RT; Brickell, TA; Lippa, SM; French, LM				Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.			Clinical utility of the Neurobehavioral Symptom Inventory validity scales to screen for symptom exaggeration following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Validity-10; NIM5; LOW6; Military; Traumatic brain injury; Symptom exaggeration	PERSONALITY-ASSESSMENT INVENTORY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; POSTTRAUMATIC-STRESS-DISORDER; SERVICE MEMBERS; INDICATORS; SPECIFICITY; SENSITIVITY; VALIDATION; COMPLAINTS	The purpose of this study was to examine the clinical utility of three recently developed validity scales (Validity-10, NIM5, and LOW6) designed to screen for symptom exaggeration using the Neurobehavioral Symptom Inventory (NSI). Participants were 272 U. S. military service members who sustained a mild, moderate, severe, or penetrating traumatic brain injury (TBI) and who were evaluated by the neuropsychology service at Walter Reed Army Medical Center within 199 weeks post injury. Participants were divided into two groups based on the Negative Impression Management scale of the Personality Assessment Inventory: (a) those who failed symptom validity testing (SVT-fail; n = 27) and (b) those who passed symptom validity testing (SVT-pass; n = 245). Participants in the SVT-fail group had significantly higher scores (p<.001) on the Validity-10, NIM5, LOW6, NSI total, and Personality Assessment Inventory (PAI) clinical scales (range: d = 0.76 to 2.34). Similarly high sensitivity, specificity, positive predictive power (PPP), and negative predictive (NPP) values were found when using all three validity scales to differentiate SVT-fail versus SVT-pass groups. However, the Validity-10 scale consistently had the highest overall values. The optimal cutoff score for the Validity-10 scale to identify possible symptom exaggeration was = 19 (sensitivity =.59, specificity =.89, PPP =.74, NPP =.80). For the majority of people, these findings provide support for the use of the Validity-10 scale as a screening tool for possible symptom exaggeration. When scores on the Validity-10 exceed the cutoff score, it is recommended that (a) researchers and clinicians do not interpret responses on the NSI, and (b) clinicians follow up with a more detailed evaluation, using well-validated symptom validity measures (e. g., Minnesota Multiphasic Personality Inventory-2 Restructured Form, MMPI-2-RF, validity scales), to seek confirmatory evidence to support an hypothesis of symptom exaggeration.	[Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Dept Rehabil, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; Lippa, Sara M.; French, Louis M.] Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA		Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 8,Room 2264,8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.lange@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Calhoun PS, 2000, J PERS ASSESS, V75, P338, DOI 10.1207/S15327752JPA7502_11; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 2013, STAT POWER ANAL BEHA; Cooper DB, 2011, ARCH CLIN NEUROPSYCH, V26, P718, DOI 10.1093/arclin/acr070; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P325, DOI 10.1080/13803395.2015.1013021; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lees-Haley PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Liljequist L, 1998, J PERS ASSESS, V71, P322, DOI 10.1207/s15327752jpa7103_3; Morey, 1991, PERSONALITY ASSESSME; ROGERS R, 1993, J PERS ASSESS, V60, P554, DOI 10.1207/s15327752jpa6003_12; Rogers R, 1996, J PERS ASSESS, V67, P629, DOI 10.1207/s15327752jpa6703_15; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SILVERTON L, 1998, MALINGERING PROBABIL; Slick DJ, 2006, COMPENDIUM NEUROPSYC, P3; Smith GP, 1997, J AM ACAD PSYCHIATRY, V25, P183; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; [No title captured]	22	33	34	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2015	37	8					853	862		10.1080/13803395.2015.1064864			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	DD3FP	WOS:000369807800007	26245293				2022-02-06	
J	Liu, SG; Ren, PY; Wang, GY; Yao, SX; He, XJ				Liu, Shu-Guang; Ren, Peng-Yu; Wang, Guo-Yu; Yao, Shu-Xin; He, Xi-Jing			Allicin protects spinal cord neurons from glutamate-induced oxidative stress through regulating the heat shock protein 70/inducible nitric oxide synthase pathway	FOOD & FUNCTION			English	Article							RAT CORTICAL-NEURONS; ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; KAPPA-B ACTIVATION; LIPID-PEROXIDATION; PARKINSONS-DISEASE; SECONDARY INJURY; CONTUSION INJURY; IN-VITRO; EXPRESSION	Allicin, the main biologically active compound derived from garlic, exerts a broad spectrum of pharmacological activities and is considered to have therapeutic potential in many neurological disorders. Using an in vitro spinal cord injury model induced by glutamate treatment, we sought to investigate the neuroprotective effects of allicin in primary cultured spinal cord neurons. We found that allicin treatment significantly attenuated glutamate-induced lactate dehydrogenase (LDH) release, loss of cell viability and apoptotic neuronal death. This protection was associated with reduced oxidative stress, as evidenced by decreased reactive oxygen species (ROS) generation, reduced lipid peroxidation and preservation of antioxidant enzyme activities. The results of western blot analysis showed that allicin decreased the expression of inducible nitric oxide synthase (iNOS), but had no effects on the expression of neuronal NOS (nNOS) following glutamate exposure. Moreover, allicin treatment significantly increased the expression of heat shock protein 70 (HSP70) at both mRNA and protein levels. Knockdown of HSP70 by specific targeted small interfere RNA (siRNA) not only mitigated allicin-induced protective activity, but also partially nullified its effects on the regulation of iNOS. Collectively, these data demonstrate that allicin treatment may be an effective therapeutic strategy for spinal cord injury, and that the potential underlying mechanism involves HSP70/iNOS pathway-mediated inhibition of oxidative stress.	[Liu, Shu-Guang; Wang, Guo-Yu; He, Xi-Jing] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed, Xian 710004, Shaanxi, Peoples R China; [Ren, Peng-Yu] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 3, Dept Neurosurg, Xian 710068, Shaanxi, Peoples R China; [Liu, Shu-Guang; Yao, Shu-Xin] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp, Dept Orthopaed,Hong Hui Hosp, Xian 710004, Shaanxi, Peoples R China		He, XJ (corresponding author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed, Xian 710004, Shaanxi, Peoples R China.	hexijing_xjtu@163.com	He, Xijing/AAE-7424-2021	He, Xijing/0000-0002-0465-5376			Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Ayala GX, 2008, NEUROPHARMACOLOGY, V55, P1383, DOI 10.1016/j.neuropharm.2008.08.035; Bayan L, 2014, AVICENNA J PHYTOMEDI, V4, P1; Bruck R, 2005, LIVER INT, V25, P613, DOI 10.1111/j.1478-3231.2005.01050.x; Cao HQ, 2013, NEUROSCI BULL, V29, P94, DOI 10.1007/s12264-012-1277-8; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI 10.1089/neu.2008-0870; Chan JYY, 2013, PHYTOTHER RES, V27, P637, DOI 10.1002/ptr.4796; Chan JYH, 2004, CIRCULATION, V110, P3560, DOI 10.1161/01.CIR.0000143082.63063.33; Chang CC, 2014, NEUROBIOL DIS, V62, P241, DOI 10.1016/j.nbd.2013.10.012; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2013, CELL SIGNAL, V25, P2863, DOI 10.1016/j.cellsig.2013.09.004; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chen W, 2014, NEUROCHEM INT, V68, P28, DOI 10.1016/j.neuint.2014.01.015; Chiesa R, 2004, ANN VASC SURG, V18, P514, DOI 10.1007/s10016-004-0072-z; CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; Die J, 2010, BRAIN RES, V1346, P251, DOI 10.1016/j.brainres.2010.05.068; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Evans CG, 2010, J MED CHEM, V53, P4585, DOI 10.1021/jm100054f; Fujisawa H, 2008, J AGR FOOD CHEM, V56, P4229, DOI 10.1021/jf8000907; Garcia Y, 2013, ANIMAL, V7, P1651, DOI 10.1017/S1751731113001134; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; Hamaishi M, 2009, ANN VASC SURG, V23, P128, DOI 10.1016/j.avsg.2008.05.010; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Heneka MT, 2001, J NEUROIMMUNOL, V114, P8, DOI 10.1016/S0165-5728(01)00246-6; Horev-Azaria L, 2009, EUR J NUTR, V48, P67, DOI 10.1007/s00394-008-0762-3; Hunter R, 2005, ANN NY ACAD SCI, V1056, P234, DOI 10.1196/annals.1352.011; In JH, 2003, MOL CELLS, V15, P406; Isaka M, 2006, J VASC SURG, V43, P1257, DOI 10.1016/j.jvs.2006.02.017; Izigov N, 2011, FREE RADICAL BIO MED, V50, P1131, DOI 10.1016/j.freeradbiomed.2011.01.028; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Kakinohana M, 2011, STROKE, V42, P2302, DOI 10.1161/STROKEAHA.110.600429; Kao MC, 2004, ANESTH ANALG, V99, P580, DOI 10.1213/01.ANE.0000130391.62612.3E; Kiyoshima T, 2003, ANESTH ANALG, V96, P839, DOI 10.1213/01.ANE.0000047268.41102.D4; Lam T, 2013, SPINAL CORD, V51, P656, DOI 10.1038/sc.2013.71; Lawson LD, 2005, J AGR FOOD CHEM, V53, P6254, DOI 10.1021/jf050536+; Lawson LD, 2005, J AGR FOOD CHEM, V53, P1974, DOI 10.1021/jf048323s; Liu CL, 2002, CHINESE MED J-PEKING, V115, P740; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Liu Philip K., 2001, Current Topics in Medicinal Chemistry, V1, P483, DOI 10.2174/1568026013394688; Miron T, 2000, BBA-BIOMEMBRANES, V1463, P20, DOI 10.1016/S0005-2736(99)00174-1; Okada Y, 2005, REDOX REP, V10, P96, DOI 10.1179/135100005X38851; Patury S, 2009, CURR TOP MED CHEM, V9, P1337, DOI 10.2174/156802609789895674; Ross ME, 1996, METHOD ENZYMOL, V269, P408; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Santoscopy C, 2002, NEUROSCI LETT, V330, P94, DOI 10.1016/S0304-3940(02)00716-4; Sela U, 2008, NUTR CANCER, V60, P412, DOI 10.1080/01635580701733083; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Staba EJ, 2001, J NUTR, V131, p1118S, DOI 10.1093/jn/131.3.1118S; Tabayashi K, 2005, SURG TODAY, V35, P1, DOI 10.1007/s00595-004-2889-z; Temiz C, 2013, TURK NEUROSURG, V23, P67, DOI 10.5137/1019-5149.JTN.6825-12.1; van Duijnhoven N, 2010, EUR J APPL PHYSIOL, V109, P1059, DOI 10.1007/s00421-010-1398-6; Witt SN, 2010, BIOPOLYMERS, V93, P218, DOI 10.1002/bip.21302; Yang JY, 2007, SPINAL CORD, V45, P731, DOI 10.1038/sj.sc.3102036; Yune TY, 2009, J NEUROCHEM, V110, P1276, DOI 10.1111/j.1471-4159.2009.06214.x; Yune TY, 2004, J NEUROTRAUM, V21, P1778, DOI 10.1089/neu.2004.21.1778; Zhou LS, 2013, BRAIN RES, V1517, P150, DOI 10.1016/j.brainres.2013.04.007; Zhou YF, 2014, BRAIN RES BULL, V100, P14, DOI 10.1016/j.brainresbull.2013.10.013; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	63	33	34	2	21	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2042-6496	2042-650X		FOOD FUNCT	Food Funct.		2015	6	1					321	330		10.1039/c4fo00761a			10	Biochemistry & Molecular Biology; Food Science & Technology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Food Science & Technology	AX9QB	WOS:000347235900032	25473931				2022-02-06	
J	Chen, CC; Hung, TH; Lee, CY; Wang, LF; Wu, CH; Ke, CH; Chen, SF				Chen, Chien-Cheng; Hung, Tai-Ho; Lee, Chao Yu; Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu			Berberine Protects against Neuronal Damage via Suppression of Glia-Mediated Inflammation in Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; COPTIDIS-RHIZOMA EXTRACT; CEREBRAL-ISCHEMIA; INTESTINAL INJURY; TYROSINE KINASE; NERVOUS-SYSTEM; NITRIC-OXIDE; IN-VITRO; MICROGLIA; MICE	Traumatic brain injury (TBI) triggers a series of neuroinflammatory processes that contribute to evolution of neuronal injury. The present study investigated the neuroprotective effects and anti-inflammatory actions of berberine, an isoquinoline alkaloid, in both in vitro and in vivo TBI models. Mice subjected to controlled cortical impact injury were injected with berberine (10 mg.kg(-1)) or vehicle 10 min after injury. In addition to behavioral studies and histology analysis, blood-brain barrier (BBB) permeability and brain water content were determined. Expression of PI3K/Akt and Erk signaling and inflammatory mediators were also analyzed. The protective effect of berberine was also investigated in cultured neurons either subjected to stretch injury or exposed to conditioned media with activated microglia. Berberine significantly attenuated functional deficits and brain damage associated with TBI up to day 28 post-injury. Berberine also reduced neuronal death, apoptosis, BBB permeability, and brain edema at day 1 post-injury. These changes coincided with a marked reduction in leukocyte infiltration, microglial activation, matrix metalloproteinase-9 activity, and expression of inflammatory mediators. Berberine had no effect on Akt or Erk 1/2 phosphorylation. In mixed glial cultures, berberine reduced TLR4/MyD88/NF-kappa B signaling. Berberine also attenuated neuronal death induced by microglial conditioned media; however, it did not directly protect cultured neurons subjected to stretch injury. Moreover, administration of berberine at 3 h post-injury also reduced TBI-induced neuronal damage, apoptosis and inflammation in vivo. Berberine reduces TBI-induced brain damage by limiting the production of inflammatory mediators by glial cells, rather than by a direct neuroprotective effect.	[Chen, Chien-Cheng; Lee, Chao Yu; Ke, Chia-Hua; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan; [Wang, Liang-Fei; Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan		Chen, SF (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Hung, Tai-Ho/C-7584-2011; Hung, Tai-Ho/ABD-1800-2020; WU, CHUN-HU/P-3958-2018	WU, CHUN-HU/0000-0001-6851-7936; Hung, Tai-Ho/0000-0003-2354-7060	National Science Council of Taiwan, R.O.C. (NSC)Ministry of Science and Technology, Taiwan [101-2314-B-350-001-MY3]; Cheng Hsin General Hospital	This work was supported by 1. SFC: Grants from the National Science Council of Taiwan, R.O.C. (NSC 101-2314-B-350-001-MY3); 2. SFC and CCC: Cheng Hsin General Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Amasheh M, 2010, J CELL SCI, V123, P4145, DOI 10.1242/jcs.070896; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Chai YS, 2013, EUR J PHARMACOL, V708, P44, DOI 10.1016/j.ejphar.2013.02.041; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Durairajan SSK, 2012, NEUROBIOL AGING, V33, P2903, DOI 10.1016/j.neurobiolaging.2012.02.016; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hu J, 2012, EUR J PHARMACOL, V674, P132, DOI 10.1016/j.ejphar.2011.11.014; Jara JH, 2007, J NEUROCHEM, V100, P1407, DOI 10.1111/j.1471-4159.2006.04330.x; Jia LY, 2012, J PHARM PHARMACOL, V64, P1510, DOI 10.1111/j.2042-7158.2012.01529.x; Jiang-Shieh YF, 2005, J NEUROSCI RES, V82, P515, DOI 10.1002/jnr.20663; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/S0006-8993(96)00417-9; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Kulkarni SK, 2010, PHYTOTHER RES, V24, P317, DOI 10.1002/ptr.2968; Li HM, 2011, ACTA PHARMACOL SIN, V32, P1364, DOI 10.1038/aps.2011.102; Liao YJ, 2013, NEW ENGL J MED, V368, P2014, DOI 10.1056/NEJMicm1205007; Lu DY, 2010, J CELL BIOCHEM, V110, P697, DOI 10.1002/jcb.22580; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Ma YY, 2004, NAT IMMUNOL, V5, P380, DOI 10.1038/ni1054; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Song B, 2012, CELL IMMUNOL, V276, P91, DOI 10.1016/j.cellimm.2012.04.006; Tan XS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077969; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Wang XL, 2005, AM J CHINESE MED, V33, P935, DOI 10.1142/S0192415X05003557; Wang XL, 2005, LIFE SCI, V77, P3058, DOI 10.1016/j.lfs.2005.02.033; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang YQ, 2009, CARDIOVASC RES, V82, P484, DOI 10.1093/cvr/cvp078; Zhang QA, 2011, FOOD CHEM TOXICOL, V49, P61, DOI 10.1016/j.fct.2010.09.032; Zhang XL, 2012, BRAIN RES, V1459, P61, DOI 10.1016/j.brainres.2012.03.065; Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008; Zhou XQ, 2008, NEUROSCI LETT, V447, P31, DOI 10.1016/j.neulet.2008.09.064; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	54	33	39	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e115694	10.1371/journal.pone.0115694			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UN	WOS:000347120200055	25546475	Green Published, Green Submitted, gold			2022-02-06	
J	Bao, TH; Miao, W; Han, JH; Yin, M; Yan, Y; Wang, WW; Zhu, YH				Bao, Tian-hao; Miao, Wei; Han, Jian-hong; Yin, Mei; Yan, Yong; Wang, Wei-wei; Zhu, Yu-hong			Spontaneous Running Wheel Improves Cognitive Functions of Mouse Associated with miRNA Expressional Alteration in Hippocampus Following Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Spontaneous running wheel; Cognitive functions; miRNA	EXERCISE; MICRORNAS; TARGETS; GENE	Traumatic brain injury (TBI) is an insult to the brain that results in impairments of cognitive and physical functioning. Both of human research and animal studies demonstrate that spontaneous exercise can facilitate neuronal plasticity and improve cognitive function in normal or TBI rodent models. However, the possible mechanisms underlying are still not well known. We postulated that spontaneous running wheel (RW) altered microRNA (miRNA) expressions in hippocampus of mice following TBI, which might be associated with the improvement in cognitive functions. In the present study, acquisition of spatial learning and memory retention was assessed by using the Morris water maze (MWM) test on days 15 post RW exercise. Then, microarray analyses in miRNA files were employed, and the expressional changes of miRNAs in the hippocampus of mice were detected. The results showed that spontaneous RW exercise (i) recovered the hippocampus-related cognitive deficits induced by TBI, (ii) altered hippocampal expressions of miRNAs in both of sham and TBI mice, and (iii) miR-21 or miR-34a was associated with the recovery process. The present results indicated that an epigenetic mechanism might be involved in voluntary exercise-induced cognitive improvement of mice that suffered from TBI.	[Bao, Tian-hao; Miao, Wei; Han, Jian-hong; Yin, Mei; Yan, Yong; Zhu, Yu-hong] Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming 650031, Peoples R China; [Bao, Tian-hao] Psychiat Hosp Yunnan Prov, Kunming 650224, Peoples R China; [Wang, Wei-wei] Kunming Med Univ, Affiliated Hosp 2, Dept Cardiol, Kunming 650031, Peoples R China		Zhu, YH (corresponding author), Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming 650031, Peoples R China.	zhuyuhong2014@126.com					Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Koo HM, 2013, J PHYS THER SCI, V25, P1103, DOI 10.1589/jpts.25.1103; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Mooren FC, 2014, AM J PHYSIOL-HEART C, V306, pH557, DOI 10.1152/ajpheart.00711.2013; Ntanasis-Stathopoulos J, 2013, J MUSCULOSKEL NEURON, V13, P133; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Radom-Aizik S, 2014, BRAIN BEHAV IMMUN, V39, P121, DOI 10.1016/j.bbi.2014.01.003; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Roemer K, 2010, CELL CYCLE, V9, P3438, DOI 10.4161/cc.9.17.13001; Rosi S, 2012, HIPPOCAMPUS, V22, P544, DOI 10.1002/hipo.20920; Szabo Z, 2010, BRAIN RES, V1341, P25, DOI 10.1016/j.brainres.2009.01.035; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; VanLeeuwen JE, 2010, J NEUROSCI RES, V88, P650, DOI 10.1002/jnr.22216; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Zacharewicz E, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00266; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	29	33	33	1	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	DEC	2014	54	4					622	629		10.1007/s12031-014-0344-1			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AW0PP	WOS:000345995700004	24920273				2022-02-06	
J	Gaynor, JW; Kim, DS; Arrington, CB; Atz, AM; Bellinger, DC; Burt, AA; Ghanayem, NS; Jacobs, JP; Lee, TM; Lewis, AB; Mahle, WT; Marino, BS; Miller, SG; Newburger, JW; Pizarro, C; Ravishankar, C; Santani, AB; Wilder, NS; Jarvik, GP; Mital, S; Russell, MW				Gaynor, J. William; Kim, Daniel Seung; Arrington, Cammon B.; Atz, Andrew M.; Bellinger, David C.; Burt, Amber A.; Ghanayem, Nancy S.; Jacobs, Jeffery P.; Lee, Teresa M.; Lewis, Alan B.; Mahle, William T.; Marino, Bradley S.; Miller, Stephen G.; Newburger, Jane W.; Pizarro, Christian; Ravishankar, Chitra; Santani, Avni B.; Wilder, Nicole S.; Jarvik, Gail P.; Mital, Seema; Russell, Mark W.			Validation of association of the apolipoprotein E epsilon 2 allele with neurodevelopmental dysfunction after cardiac surgery in neonates and infants	JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY			English	Article							E GENOTYPE; CHILDREN; OUTCOMES; APOE; DISEASE; AGE; POPULATION	Objective: Apolipoprotein E (APOE) genotype is a determinant of neurologic recovery after brain ischemia and traumatic brain injury. The APOE epsilon 2 allele has been associated with worse neurodevelopmental (ND) outcome after repair of congenital heart defects (CHD) in infancy. Replication of this finding in an independent cohort is essential to validate the observed genotype- phenotype association. Methods: The association of APOE genotype with ND outcomes was assessed in a combined cohort of patients with single- ventricle CHD enrolled in the Single Ventricle Reconstruction and Infant Single Ventricle trials. ND outcome was assessed at 14 months using the Psychomotor Development Index (PDI) and Mental Development Index (MDI) of the Bayley Scales of Infant Development- II. Stepwise multivariable regression was performed to develop predictive models for PDI and MDI scores. Results: Complete data were available for 298 of 435 patients. After adjustment for preoperative and postoperative covariates, the APOE epsilon 2 allele was associated with a lower PDI score (P =038). Patients with the epsilon 2 allele had a PDI score approximately 6 points lower than those without the risk allele, explaining 1.04% of overall PDI variance, because the epsilon 2 allele was present in only 11% of the patients. There was a marginal effect of the epsilon 2 allele on MDI scores (P - .058). Conclusions: These data validate the association of the APOE epsilon 2 allele with adverse early ND outcomes after cardiac surgery in infants, independent of patient and operative factors. Genetic variants that decrease neuroresilience and impair neuronal repair after brain injury are important risk factors for ND dysfunction after surgery for CHD.	[Gaynor, J. William] Childrens Hosp Philadelphia, Div Cardiothorac Surg, Philadelphia, PA 19104 USA; [Kim, Daniel Seung; Jarvik, Gail P.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [Kim, Daniel Seung; Jarvik, Gail P.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA; [Arrington, Cammon B.] Primary Childrens Med Ctr, Salt Lake City, UT 84103 USA; [Atz, Andrew M.] Med Univ S Carolina, Div Pediat Cardiol, Charleston, SC 29425 USA; [Bellinger, David C.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Bellinger, David C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Burt, Amber A.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [Ghanayem, Nancy S.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Jacobs, Jeffery P.] Univ S Florida, All Childrens Hosp, Johns Hopkins Childrens Heart Inst, St Petersburg, FL 33701 USA; [Jacobs, Jeffery P.] Florida Hosp Children, St Petersburg, FL USA; [Lee, Teresa M.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY USA; [Lewis, Alan B.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; [Mahle, William T.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Marino, Bradley S.] Cincinnati Childrens Hosp Med Ctr, Ann & Robert F Lurie Childrens Hosp Chicago, Cincinnati, OH 45229 USA; [Miller, Stephen G.] Duke Univ, Med Ctr, Div Pediat Oncol, Durham, NC USA; [Newburger, Jane W.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA; [Pizarro, Christian] Alfred I Dupont Hosp Children, Nemours Cardiac Ctr, Wilmington, DE USA; [Ravishankar, Chitra] Childrens Hosp Philadelphia, Div Pediat Cardiol, Philadelphia, PA 19104 USA; [Santani, Avni B.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wilder, Nicole S.] Univ Michigan, Sch Med, Dept Anesthesia, Ann Arbor, MI USA; [Mital, Seema] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Russell, Mark W.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Div Pediat Cardiol, Ann Arbor, MI USA		Gaynor, JW (corresponding author), Childrens Hosp Philadelphia, Div Cardiothorac Surg, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	gaynor@email.chop.edu	Pizarro, Christian/AAO-9546-2021; Atz, Andrew/J-9196-2015	Atz, Andrew/0000-0002-4744-3832; Kim, Daniel/0000-0003-2971-1909	Daniel M. Tabas Endowed Chair in Pediatric Cardiothoracic Surgery at The Children's Hospital of Philadelphia; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1F31MH101905-01]; National Heart, Lung, and Blood Institute grants (NHLBI) [HL068269, HL068270, HL068279, HL068281, HL068285, HL068292, HL068290, HL068288, HL085057]; Food and Drug Administration's Office of Orphan Products Development; Harvard Catalyst/The Harvard Clinical and Translational Science Center (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 RR 025758]; Harvard Catalyst/The Harvard Clinical and Translational Science Center (Harvard University and its affiliated academic health care centers); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL068269, U01HL068288, U01HL068281, U10HL109778, U10HL109743, U01HL068279, U10HL109673, U01HL068285, U01HL085057, U01HL068290, U10HL109816, U10HL068270, U01HL068270, U01HL068292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH101905] Funding Source: NIH RePORTER	This study was supported by the Daniel M. Tabas Endowed Chair in Pediatric Cardiothoracic Surgery at The Children's Hospital of Philadelphia. D.S. Kim was funded by a grant from the National Institute of Mental Health (1F31MH101905-01).; The Infant Single Ventricle (ISV) trial was supported by the National Heart, Lung, and Blood Institute grants (NHLBI; HL068269, HL068270, HL068279, HL068281, HL068285, HL068292, HL068290, HL068288, and HL085057) and the Food and Drug Administration's Office of Orphan Products Development.; The Single Ventricle Reconstruction (SVR) trial was supported by grants HL068269, HL068270, HL068279, HL068281, HL068285, HL068288, HL068290, HL068292, and HL085057 from the National Heart, Lung, and Blood Institute; and with support from Harvard Catalyst/The Harvard Clinical and Translational Science Center (NIH Award UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers).	Aboud O, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-35; Ades AM, 2010, CARDIOL YOUNG, V20, P8, DOI 10.1017/S1047951109991909; Ballweg JA, 2006, PEDIAT CARDIOL, V28, P1450; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Braga LW, 2010, DEV MED CHILD NEUROL, V52, P666, DOI 10.1111/j.1469-8749.2009.03465.x; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Fuller S, 2009, EUR J CARDIO-THORAC, V36, P40, DOI 10.1016/j.ejcts.2009.02.047; Gaynor JW, 2007, J THORAC CARDIOV SUR, V133, P1344, DOI 10.1016/j.jtcvs.2006.10.087; Gaynor JW, 2003, J THORAC CARDIOV SUR, V126, P1736, DOI 10.1016/S0022-5223(03)01188-7; Gelfand AA, 2013, PEDIATR NEUROL, V48, P36, DOI 10.1016/j.pediatrneurol.2012.09.016; Hsu DT, 2010, CIRCULATION, V122, P333, DOI 10.1161/CIRCULATIONAHA.109.927988; Igl BW, 2009, HUM HERED, V67, P66, DOI 10.1159/000164400; Koch W, 2002, CLIN CHEM LAB MED, V40, P1123, DOI 10.1515/CCLM.2002.197; Konig IR, 2011, BRIEF BIOINFORM, V12, P253, DOI 10.1093/bib/bbq074; Kuroda MM, 2007, PEDIATRICS, V119, P306, DOI 10.1542/peds.2006-1083; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Marino BS, 2012, CIRCULATION, V126, P1143, DOI 10.1161/CIR.0b013e318265ee8a; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Mital S, 2011, CIRCULATION, V123, P2353, DOI 10.1161/CIRCULATIONAHA.110.004341; Newburger JW, 2012, CIRCULATION, V125, P2081, DOI 10.1161/CIRCULATIONAHA.111.064113; O'Callaghan ME, 2012, PEDIATRICS, V129, pE414, DOI 10.1542/peds.2011-0739; Ohye RG, 2010, NEW ENGL J MED, V362, P1980, DOI 10.1056/NEJMoa0912461; Oria RB, 2010, BRAZ J MED BIOL RES, V43, P249, DOI 10.1590/S0100-879X2010007500003; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Oria RB, 2007, MED HYPOTHESES, V68, P1099, DOI 10.1016/j.mehy.2006.09.036; Ravishankar C, 2013, J PEDIATR-US, V162, P250, DOI 10.1016/j.jpeds.2012.07.048; Roses AD, 1997, NEUROBIOL DIS, V4, P170, DOI 10.1006/nbdi.1997.0161; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; Shillingford AJ, 2008, PEDIATRICS, V121, pE759, DOI 10.1542/peds.2007-1066; Strittmatter WJ, 2002, CURR OPIN LIPIDOL, V13, P119, DOI 10.1097/00041433-200204000-00002; Tabbutt S, 2012, CURR OPIN CARDIOL, V27, P82, DOI 10.1097/HCO.0b013e328350197b; Trachtenberg AJ, 2012, NEUROIMAGE, V59, P565, DOI 10.1016/j.neuroimage.2011.07.059; Westlye LT, 2012, NEUROLOGY, V79, P1961, DOI 10.1212/WNL.0b013e3182735c9c; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Wu YW, 2011, PEDIATR RES, V70, P642, DOI 10.1203/PDR.0b013e31823240dd	35	33	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5223	1097-685X		J THORAC CARDIOV SUR	J. Thorac. Cardiovasc. Surg.	DEC	2014	148	6					2560	2566		10.1016/j.jtcvs.2014.07.052			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Respiratory System; Surgery	AU6BD	WOS:000345686100033	25282659	Green Accepted, Bronze			2022-02-06	
J	Joseph, B; Aziz, H; Pandit, V; Kulvatunyou, N; Sadoun, M; Tang, A; O'Keeffe, T; Gries, L; Green, DJ; Friese, RS; Lemole, MG; Rhee, P				Joseph, Bellal; Aziz, Hassan; Pandit, Viraj; Kulvatunyou, Narong; Sadoun, Moutamn; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Lemole, Michael G., Jr.; Rhee, Peter			Prospective validation of the brain injury guidelines: Managing traumatic brain injury without neurosurgical consultation	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	44th Annual Meeting of the Western-Trauma-Association	MAR 02-07, 2014	Steamboat Springs, CO	Western Trauma Assoc		Management of traumatic brain injury; neurosurgical consultation; brain injury guidelines; neurosurgical intervention; acute care surgeons	HEAD COMPUTED-TOMOGRAPHY; MANAGEMENT; MILD; CARE; COAGULOPATHY; UTILITY	BACKGROUND: To optimize neurosurgical resources, guidelines were developed at our institution, allowing the acute care surgeons to independently manage traumatic intracranial hemorrhage less than or equal to 4 mm. The aim of our study was to evaluate our established Brain Injury Guidelines (BIG 1 category) for managing patients with traumatic brain injury (TBI) without neurosurgical consultation. METHODS: We formulated the BIG based on a 4-year retrospective chart review of all TBI patients presenting at our Level 1 trauma center. We then prospectively implemented our BIG 1 category to identify TBI patients that were to be managed without neurosurgical consultation (No-NC). Propensity scoring matched patients with No-NC to a similar cohort of patients managed with NC before the implementation of our BIG in a 1:1 ratio for demographics, severity of injury, and type and size of intracranial hemorrhage. Primary outcome measure was need for neurosurgical intervention and 30-day readmission rates. RESULTS: A total of 254 TBI patients (127 of NC and 127 of No-NC patients) were included in the analysis. The mean (SD) age was 40.8 (22.7) years, 63.4% (n = 161) were male, median Glasgow Coma Scale (GCS) score was 15 (range, 13-15), and median head Abbreviated Injury Scale (AIS) score was 2 (range, 2-3). There was no neurosurgical intervention or 30-day readmission in both the groups. In the No-NC group, 3.9% of the patients had postdischarge emergency department visits compared with 4.7% of the NC group (p = 0.5). All patients were discharged home from the emergency department. CONCLUSION: We validated our BIG and demonstrated that acute care surgeons can effectively care for minimally injured TBI patients with good outcomes. Anational multi-institutional prospective evaluation is warranted. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Aziz, Hassan; Pandit, Viraj; Kulvatunyou, Narong; Sadoun, Moutamn; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Lemole, Michael G., Jr.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Med Ctr, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021	Aziz, Hassan/0000-0003-0406-1946			Aziz H, 2013, J TRAUMA ACUTE CARE, V75, P550, DOI 10.1097/TA.0b013e3182a53a77; Barker DE, 2006, AM SURGEON, V72, P1166; Borczuk P, 2013, J TRAUMA ACUTE CARE, V74, P1504, DOI 10.1097/TA.0b013e31829215cf; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Centers for Disease Control and Prevention, 2017, INJ PREV CONTR TRAUM; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Huynh T, 2006, AM SURGEON, V72, P1162; Joseph B, 2014, J AM COLL SURGEONS, V219, P45, DOI 10.1016/j.jamcollsurg.2013.12.062; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P965, DOI 10.1097/TA.0000000000000161; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P121, DOI 10.1097/TA.0b013e3182a9cc95; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Klein Y, 2010, J TRAUMA, V69, P544, DOI 10.1097/TA.0b013e3181c99936; Rhodes M, 1993, J TRAUMA, V35, P979; Wu C, 2012, J TRAUMA ACUTE CARE, V73, P1247, DOI 10.1097/TA.0b013e318265d24e	16	33	33	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2014	77	6					984	988		10.1097/TA.0000000000000428			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	AU8EE	WOS:000345828500043	25423541				2022-02-06	
J	Smith, PH; Potenza, MN; Mazure, CM; Mckee, SA; Park, CL; Hoff, RA				Smith, Philip H.; Potenza, Marc N.; Mazure, Carolyn M.; Mckee, Sherry A.; Park, Crystal L.; Hoff, Rani A.			Compulsive sexual behavior among male military veterans: Prevalence and associated clinical factors	JOURNAL OF BEHAVIORAL ADDICTIONS			English	Article						compulsive sexual behavior; military; PTSD; child abuse; veterans; trauma	IMPULSE-CONTROL DISORDERS; PSYCHIATRIC COMORBIDITY; BRAIN-INJURY; STRESS; CHILDHOOD; HISTORY; PTSD; MEN; PARAPHILIAS; EXPERIENCES	Background and aims: Compulsive sexual behavior (CSB) is highly prevalent among men, often co-occurring with psychiatric disorders and traumatic experiences. Psychiatric disorders and trauma are highly prevalent among military veterans, yet there is a paucity of research on CSB among military samples. The aim of this study was to examine the prevalence of and factors associated with CSB among male military veterans. Methods: Surveys were administered to veterans of Operations Iraqi Freedom, Enduring Freedom, or New Dawn at baseline (n = 258), 3 months (n= 194), and 6 months (n= 136). Bivariate analyses and Generalized Estimating Equations were utilized to estimate associations between CSB and the following variables: psychiatric co-morbidity, childhood physical or sexual trauma, pre- and post-deployment experiences, TV/ Internet usage, and sociodemographics. Associations between CSB and specific PTSD symptom clusters were also examined. Results: CSB was reported by 16.7% of the sample at baseline. Several variables were associated with CSB in bivariate analyses; however, only PTSD severity, childhood sexual trauma, and age remained significant in multivariable GEE models. The PTSD symptom cluster re-experiencing was most strongly associated with CSB. Discussion: This exploratory study suggests that CSB is prevalent amongst veterans returning from combat and is associated with childhood trauma and PTSD, particularly re-experiencing. Conclusions: Further study is needed to identify the mechanisms linking PTSD and CSB, define the context and severity of CSB in veterans, and examine the best ways to assess and treat CSB in VA clinical settings.	[Smith, Philip H.] Yale Univ, New Haven, CT 06520 USA; [Potenza, Marc N.; Mazure, Carolyn M.; Mckee, Sherry A.; Hoff, Rani A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; [Potenza, Marc N.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; [Potenza, Marc N.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA; [Park, Crystal L.] Univ Connecticut, Dept Psychol, Storrs, CT USA; [Hoff, Rani A.] VISN 1 Mental Illness Res Educ & Clin Care Ctr MI, Dept Psychol, Los Angeles, CA USA		Hoff, RA (corresponding author), NEPEC 182,950 Campbell Ave, West Haven, CT 06416 USA.	Rani.hoff@va.gov			U.S. Department of Veteran Affairs Office of Research and Development; Clinical Science Research and Development [ZDA1]; NIAAAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [RL1 AA017539]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH01423539]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [RL1AA017539] Funding Source: NIH RePORTER	This study was funded by the U.S. Department of Veteran Affairs Office of Research and Development, Clinical Science Research and Development (ZDA1, PI: Hoff), NIAAA (RL1 AA017539, PI: Potenza), and NIMH (T32MH01423539, PI: Zhang)	Bancroft J, 2004, J SEX RES, V41, P225, DOI 10.1080/00224490409552230; Bezeau SC, 2004, BRAIN INJURY, V18, P299, DOI 10.1080/02699050310001617398; Black DW, 1997, AM J PSYCHIAT, V154, P243; Blain LM, 2012, CHILD ABUSE NEGLECT, V36, P413, DOI 10.1016/j.chiabu.2012.03.003; Carnes P., 1991, DONT CALL IT LOVE RE; Carnes PJ, 1996, SEXUAL ADDICTION COM, DOI [DOI 10.1080/1072016, 10.1080/10720169608400116]; Carpenter BN, 2013, SEX ADDICT COMPULS, V20, P79, DOI 10.1080/10720162.2013.772873; Cloitre M, 2005, BEHAV THER, V36, P119, DOI 10.1016/S0005-7894(05)80060-7; COLEMAN E, 1992, PSYCHIAT ANN, V22, P320, DOI 10.3928/0048-5713-19920601-09; Dodge B, 2004, J SEX RES, V41, P343, DOI 10.1080/00224490409552241; Drummet AR, 2003, FAM RELAT, V52, P279, DOI 10.1111/j.1741-3729.2003.00279.x; Grant BF, 2003, DRUG ALCOHOL DEPEN, V71, P7, DOI 10.1016/S0376-8716(03)00070-X; GRANT BF, 2000, ALCOHOL USE DISORDER; Grant J. E., 2008, IMPULSE CONTROL DISO; Grant JE, 2005, AM J PSYCHIAT, V162, P2184, DOI 10.1176/appi.ajp.162.11.2184; Grant JE, 2007, J CLIN PSYCHIAT, V68, P1584, DOI 10.4088/JCP.v68n1018; Greenberg JB, 2012, PSYCHOL ADDICT BEHAV, V26, P89, DOI 10.1037/a0024328; Hansen NB, 2012, J TRAUMA DISSOCIATIO, V13, P345, DOI 10.1080/15299732.2011.641710; Howard MD, 2007, SEX ADDICT COMPULS, V14, P77, DOI 10.1080/10720160701310443; Kafka MP, 2010, ARCH SEX BEHAV, V39, P377, DOI 10.1007/s10508-009-9574-7; Kafka MP, 2003, INT J OFFENDER THER, V47, P439, DOI 10.1177/0306624X03253845; KAFKA MP, 1994, J CLIN PSYCHIAT, V55, P481; KAFKA MP, 1992, J CLIN PSYCHIAT, V53, P345; Katichman SC, 2004, J SEX RES, V41, P235, DOI 10.1080/00224490409552231; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kingston DA, 2013, SEX ADDICT COMPULS, V20, P91, DOI 10.1080/10720162.2013.768131; Kor A, 2013, SEX ADDICT COMPULS, V20, P27, DOI 10.1080/10720162.2013.768132; Kuzma JM, 2008, PSYCHIAT CLIN N AM, V31, P603, DOI 10.1016/j.psc.2008.06.005; McLaughlin KA, 2010, PSYCHOL MED, V40, P1647, DOI 10.1017/S0033291709992121; Miner MH, 2013, SEX ADDICT COMPULS, V20, P127, DOI 10.1080/10720162.2013.768133; Orsillo SM, 1996, J TRAUMA STRESS, V9, P235, DOI 10.1007/BF02110658; Pincus S. H., 2001, US ARMY MED DEP J, V4, P6; Raymond NC, 2003, COMPR PSYCHIAT, V44, P370, DOI 10.1016/S0010-440X(03)00110-X; Raymond NC, 2002, INT CLIN PSYCHOPHARM, V17, P201, DOI 10.1097/00004850-200207000-00008; Reid RC, 2010, J COUPLE RELATSH THE, V9, P203, DOI 10.1080/15332691.2010.491782; Reid RC, 2010, J SEX MARITAL THER, V37, P45, DOI 10.1080/0092623X.2011.533585; Reid RC, 2007, SEX ADDICT COMPULS, V14, P167, DOI 10.1080/10720160701480204; Schmied EA, 2013, MIL MED, V178, P1051, DOI 10.7205/MILMED-D-13-00135; Simms LJ, 2002, J ABNORM PSYCHOL, V111, P637, DOI 10.1037//0021-843X.111.4.637; Simpson JA, 2012, DEV PSYCHOL, V48, P674, DOI 10.1037/a0027293; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837	43	33	33	0	8	AKADEMIAI KIADO ZRT	BUDAPEST	BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY	2062-5871	2063-5303		J BEHAV ADDICT	J. Behav. Addict.	DEC	2014	3	4					214	222		10.1556/JBA.3.2014.4.2			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AY6FK	WOS:000347662500002	25592306	Green Published, Green Submitted, Green Accepted, gold			2022-02-06	
J	Wiggins-Dohlvik, K; Merriman, M; Shaji, CA; Alluri, H; Grimsley, M; Davis, ML; Smith, RW; Tharakan, B				Wiggins-Dohlvik, Katie; Merriman, Morgan; Shaji, Chinchusha A.; Alluri, Himakarnika; Grimsley, Marcene; Davis, Matthew L.; Smith, Randall W.; Tharakan, Binu			Tumor necrosis factor-alpha disruption of brain endothelial cell barrier is mediated through matrix metalloproteinase-9	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	66th Annual Meeting of the Southwestern-Surgical-Congress	APR 13-16, 2014	Scottsdale, AZ	SW Surg Congress		Traumatic brain injury; Blood brain barrier; Matrix metalloproteinase; Gelatinase B; Tumor necrosis factor; Caspase-3	INJURY; PATHOPHYSIOLOGY; INHIBITOR	Traumatic brain injuries cause vascular hyperpermeability. Tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-9 (MMP-9), and caspase-3 may be important in these processes but the relationship between them has not been investigated. We hypothesized that TNF-alpha regulates caspase-3-mediated hyperpermeability and blood brain barrier damage and hyperpermeability directly or indirectly via activation of MMP-9. To test this, rat brain microvascular endothelial cells were treated with TNF-alpha with or without inhibition of MMP-9. Monolayer permeability was measured, zonula occludens-1 and F-actin configuration were examined, and MMP-9 and caspase-3 activities were quantified. TNF-alpha increased monolayer permeability, damaged zonula occludens-1, induced filamentousactin stress fiber formation, and increased both MMP-9 and caspase-3 activities. Inhibition of MMP-9 attenuated these changes. These data highlight a novel link between TNF-alpha and MMP-9 and show that TNF-alpha regulated caspase-3-mediated hyperpermeability and vascular damage may be linked to MMP-9 in vitro. These findings augment the understanding of traumatic brain injury and pave the way for improved treatment. (C) 2014 Elsevier Inc. All rights reserved.	[Wiggins-Dohlvik, Katie; Merriman, Morgan; Shaji, Chinchusha A.; Alluri, Himakarnika; Grimsley, Marcene; Davis, Matthew L.; Smith, Randall W.; Tharakan, Binu] Baylor Scott & White Hlth, Dept Surg, Temple, TX 76508 USA; [Wiggins-Dohlvik, Katie; Merriman, Morgan; Shaji, Chinchusha A.; Alluri, Himakarnika; Grimsley, Marcene; Davis, Matthew L.; Smith, Randall W.; Tharakan, Binu] Texas A&M Univ Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX USA		Tharakan, B (corresponding author), Baylor Scott & White Hlth, Dept Surg, Temple, TX 76508 USA.	btharakan@sw.org					Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Centers for Disease Control and Prevention (CDC), 2010, NAT HOSP DISCH SURV; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, P1; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim J, 2011, KEDI J EDUC POLICY, V8, P3; Lee IT, 2010, J CELL PHYSIOL, V224, P454, DOI 10.1002/jcp.22142; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li W, 2010, BIOL REPROD, V83, P481, DOI 10.1095/biolreprod.109.082578; Lin Y, 2013, INT J MED SCI, V10, P515, DOI 10.7150/ijms.5423; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Qiu LB, 2011, TOXICOLOGY, V285, P31, DOI 10.1016/j.tox.2011.03.019; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tsai CL, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-12; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vermeer PD, 2009, AM J PHYSIOL-LUNG C, V296, pL751, DOI 10.1152/ajplung.90578.2008; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Yamada H, 2013, BIOCHEM PHARMACOL, V85, P1770, DOI 10.1016/j.bcp.2013.04.006; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375	28	33	34	0	2	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2014	208	6					954	960		10.1016/j.amjsurg.2014.08.014			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	AW2LU	WOS:000346120300023	25312844				2022-02-06	
J	Zemek, R; Eady, K; Moreau, K; Farion, KJ; Solomon, B; Weiser, M; Dematteo, C				Zemek, Roger; Eady, Kaylee; Moreau, Katherine; Farion, Ken J.; Solomon, Beverly; Weiser, Margaret; Dematteo, Carol			Knowledge of paediatric concussion among front-line primary care providers	PAEDIATRICS & CHILD HEALTH			English	Article						Adolescent; Concussion; Guidelines; Multidisciplinary; Practice variation; Youth	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SYMPTOM INVENTORY; CHILDREN; MANAGEMENT; SCALE; PHYSICIANS; CLINICIAN; CONSENSUS	Objective: To assess the knowledge of paediatric concussion diagnosis and management among front-line primary care providers. Methods: Experts from the Concussions Ontario Diagnosis and Early Education Working Group developed a 34-item survey incorporating case vignettes with the collaboration of experts in medical education. Electronic surveys were distributed via FluidSurveys using a modified version of Dillman's tailored design method. The survey was distributed to five Ontario professional associations. The target participants were front-line health care providers (family physicians, emergency medicine physicians, general paediatricians, nurse practitioners and physician assistants) in Ontario; only providers who diagnose and/or manage paediatric concussions were eligible to participate. Results: The survey was fully completed by 577 health care providers who treat paediatric concussion. Of the respondents, 78% (95% CI 74% to 81%) reported diagnosing >= 5 concussions annually. Physicians and nonphysicians equally recognized concussion (90% [95% CI 86% to 92%]; 85% [95% CI 77% to 90%], respectively). Only 37% (95% CI 32% to 41%) of physicians correctly applied graduated return to play guidelines. Return to learn recommendations were also insufficient: 53% (95% CI 49% to 58%) neglected to recommend school absence and 40% (95% CI (35% to 44%) did not recommend schoolwork accommodations. Only 26% (95% CI 22% to 30%) of physicians reported regular use of concussion scoring scales. Conclusions: Considerable gaps in knowledge exist in front-line primary care providers with inadequate application of graduated return to play and return to learn following concussion, as demonstrated by the present broad population-based survey. Consistent application of best evidence-based management using comprehensive guidelines may help to reduce the impact of concussion and persistent postconcussive problems in children and adolescents.	[Zemek, Roger; Moreau, Katherine; Farion, Ken J.] Univ Ottawa, Dept Paediat, Ottawa, ON, Canada; [Zemek, Roger; Farion, Ken J.] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Zemek, Roger; Eady, Kaylee; Moreau, Katherine; Farion, Ken J.] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; [Solomon, Beverly] Univ Toronto, Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada; [Weiser, Margaret] Western Univ, Acquired Brain Injury Rehabil Program, London, ON, Canada; [Dematteo, Carol] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada		Zemek, R (corresponding author), Childrens Hosp Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	rzemek@cheo.on.ca	Zemek, Roger/H-1039-2018		Ontario Neurotrauma Foundation, Toronto, Ontario	The authors thank Corinne Kagan from the Concussions Ontario/mTBI strategy for her assistance with this project, as well as Alia Busuttil and Hoang Pham for their assistance with manuscript editing. This project was funded by a grant from the Ontario Neurotrauma Foundation, Toronto, Ontario. This work originated at the Children's Hospital of Eastern Ontario (Ottawa, Ontario). The Research Ethics Board of the Children's Hospital of Eastern Ontario approved this study before initiation (file number: 12/88X).	[Anonymous], 2013, BR J SPORTS MED, V47, P259; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Carroll L J, 2011, CONCUSSION CRISIS AN; Dillman DA., 2000, MAIL INTERNET SURVEY; Forsyth R, 2012, CAN MED ASSOC J, V184, P1257, DOI 10.1503/cmaj.111045; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hill CA, 2006, WESTERN J NURS RES, V28, P322, DOI 10.1177/0193945905284723; IBM, 2012, SPSS SOFTW VERS 20 A; Inc C, 2012, FLUID SURV; Nguyen K, 2013, CAN FAM PHYSICIAN, V59, pE330; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P458, DOI 10.1097/PEC.0000000000000161; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; LECLERC S, 2004, ASSESSMENT CONCUSSIO; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Piland SG, 2003, J ATHL TRAINING, V38, P104; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Stoller J, 2014, CAN FAM PHYSICIAN, V60, P548; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Wiebe ER, 2012, CAN FAM PHYSICIAN, V58, pE225; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zemek R, 2014, GUIDELINES DIAGNOSIN; Zemek R, 2014, CJEM IN PRESS; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	41	33	34	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1205-7088	1918-1485		PAED CHILD HEALT-CAN	Paediatr. Child Health	NOV	2014	19	9					474	479		10.1093/pch/19.9.475			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AT0OQ	WOS:000344635600010	25414583	Green Published, Bronze			2022-02-06	
J	Stover, JF; Belli, A; Boret, H; Bulters, D; Sahuquillo, J; Schmutzhard, E; Zavala, E; Ungerstedt, U; Schinzel, R; Tegtmeier, F				Stover, John F.; Belli, Antonio; Boret, Henry; Bulters, Diederik; Sahuquillo, Juan; Schmutzhard, Erich; Zavala, Elisabeth; Ungerstedt, Urban; Schinzel, Reinhard; Tegtmeier, Frank		NOSTRA Investigators	Nitric Oxide Synthase Inhibition with the Antipterin VAS203 Improves Outcome in Moderate and Severe Traumatic Brain Injury: A Placebo-Controlled Randomized Phase IIa Trial (NOSTRA)	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; microdialysis; NO-synthase inhibition; traumatic brain injury	METABOLITES; FLUID; INOS	Traumatic brain injury (TBI) is an important cause of death and disability. Safety and pharmacodynamics of 4-amino-tetrahydrobiopterin (VAS203), a nitric oxide (NO)-synthase inhibitor, were assessed in TBI in an exploratory Phase IIa study (NOSynthase Inhibition in TRAumatic brain injury = NOSTRA). The study included 32 patients with TBI in six European centers. In a first open Cohort, eight patients received three 12-h intravenous infusions of VAS203 followed by a 12-h infusion-free interval over 3 days (total dose 15 mg/kg). Patients in Cohorts 2 and 3 (24) were randomized 2: 1 to receive either VAS203 or placebo as an infusion for 48 or 72 h, respectively (total dose 20 and 30 mg/kg). Effects of VAS203 on intracranial pressure (ICP), cerebral perfusion pressure (CPP), brain metabolism using microdialysis, and the therapy intensity level (TIL) were end points. In addition, exploratory analysis of the extended Glasgow Outcome Score (eGOS) after 6 months was performed. Metabolites of VAS203 were detected in cerebral microdialysates. No significant differences between treatment and placebo groups were observed for ICP, CPP, and brain metabolism. TIL on day 6 was significantly decreased (p < 0.04) in the VAS203 treated patients. The eGOS after 6 months was significantly higher in treated patients compared with placebo (p < 0.01). VAS203 was not associated with hepatic, hematologic, or cardiac toxic effects. At the highest dose administered, four of eight patients receiving VAS203 showed transitory acute kidney injury (stage 2-3). In conclusion, the significant improvement in clinical outcome indicates VAS203-mediated neuroprotection after TBI. At the highest dose, VAS203 is associated with a risk of acute kidney injury.	[Stover, John F.] Univ Hosp Zuerich, Zurich, Switzerland; [Belli, Antonio; Bulters, Diederik] Southampton Univ Hosp, Southampton, Hants, England; [Boret, Henry] HIA St Anne, Toulon, France; [Sahuquillo, Juan] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Schmutzhard, Erich] Med Univ Innsbruck, A-6020 Innsbruck, Austria; [Zavala, Elisabeth] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain; [Ungerstedt, Urban] Karolinska Inst, Stockholm, Sweden; [Schinzel, Reinhard; Tegtmeier, Frank] Vasopharm GmbH, D-97076 Wurzburg, Germany		Schinzel, R (corresponding author), Vasopharm GmbH, Friedrich Bergius Ring 15, D-97076 Wurzburg, Germany.	schinzel@vasopharm.de	Martinez-Ricarte, Fran/J-4729-2017; Shtaya, Anan/AAX-2494-2020; Torne, Ramon/ABI-3299-2020; Sahuquillo, Juan/B-3577-2008; Martinez-Ricarte, Fran/AAI-6846-2020; Poca, Maria A./B-8475-2008; Bulters, Diederik/ABH-3573-2020; Belli, Antonio/I-3799-2015	Martinez-Ricarte, Fran/0000-0003-4567-0828; Shtaya, Anan/0000-0001-7459-8437; Torne, Ramon/0000-0001-7932-2528; Sahuquillo, Juan/0000-0003-0713-5875; Martinez-Ricarte, Fran/0000-0003-4567-0828; Poca, Maria A./0000-0002-3831-0536; Belli, Antonio/0000-0002-3211-9933; Bulters, Diederik/0000-0001-9884-9050; Schmutzhard, Erich/0000-0003-3295-7491	EBIC	The study plan was developed with support from the EBIC.	Ahmed SB, 2007, CLIN J AM SOC NEPHRO, V2, P926, DOI 10.2215/CJN.00110107; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guzik TJ, 2002, HYPERTENSION, V39, P1088, DOI 10.1161/01.HYP.0000018041.48432.B5; Heemskerk S, 2009, NAT REV NEPHROL, V5, P629, DOI 10.1038/nrneph.2009.155; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Terpolilli NA, 2009, J NEUROTRAUM, V26, P1963, DOI 10.1089/neu.2008.0853; Tisdall MM, 2013, NEUROCRIT CARE, V19, P65, DOI 10.1007/s12028-011-9633-5; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Wang T, 2002, AM J PHYSIOL-RENAL, V283, pF658, DOI 10.1152/ajprenal.00243.2001; Weinstein JR, 2010, ADV CHRONIC KIDNEY D, V17, P302, DOI 10.1053/j.ackd.2010.05.002; Werner ER, 2000, HANDB EXP PHARMACOL, V143, P137; Werner ER, 1996, BIOCHEM J, V320, P93; Woitzik J, 2001, ANAL BIOCHEM, V289, P10, DOI 10.1006/abio.2000.4893	21	33	33	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1599	1606		10.1089/neu.2014.3344			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400001	24831445				2022-02-06	
J	Dohi, K; Kraemer, BC; Erickson, MA; McMillan, PJ; Kovac, A; Flachbartova, Z; Hansen, KM; Shah, GN; Sheibani, N; Salameh, T; Banks, WA				Dohi, Kenji; Kraemer, Brian C.; Erickson, Michelle A.; McMillan, Pamela J.; Kovac, Andrej; Flachbartova, Zuzana; Hansen, Kim M.; Shah, Gul N.; Sheibani, Nader; Salameh, Therese; Banks, William A.			Molecular Hydrogen in Drinking Water Protects against Neurodegenerative Changes Induced by Traumatic Brain Injury	PLOS ONE			English	Article							INDUCED OXIDATIVE DAMAGE; BARRIER; TRANSPORT; PERICYTES; MATRIX-METALLOPROTEINASE-9; PERMEABILITY; EXPRESSION; CYTOKINES; ALPHA	Traumatic brain injury (TBI) in its various forms has emerged as a major problem for modern society. Acute TBI can transform into a chronic condition and be a risk factor for neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, probably through induction of oxidative stress and neuroinflammation. Here, we examined the ability of the antioxidant molecular hydrogen given in drinking water (molecular hydrogen water; mHW) to alter the acute changes induced by controlled cortical impact (CCI), a commonly used experimental model of TBI. We found that mHW reversed CCI-induced edema by about half, completely blocked pathological tau expression, accentuated an early increase seen in several cytokines but attenuated that increase by day 7, reversed changes seen in the protein levels of aquaporin-4, HIF-1, MMP-2, and MMP-9, but not for amyloid beta peptide 1-40 or 1-42. Treatment with mHW also reversed the increase seen 4 h after CCI in gene expression related to oxidation/carbohydrate metabolism, cytokine release, leukocyte or cell migration, cytokine transport, ATP and nucleotide binding. Finally, we found that mHW preserved or increased ATP levels and propose a new mechanism for mHW, that of ATP production through the Jagendorf reaction. These results show that molecular hydrogen given in drinking water reverses many of the sequelae of CCI and suggests that it could be an easily administered, highly effective treatment for TBI.	[Dohi, Kenji; Kraemer, Brian C.; Erickson, Michelle A.; Kovac, Andrej; Hansen, Kim M.; Salameh, Therese; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA; [Dohi, Kenji] Jikei Univ, Sch Med, Dept Emergency Med, Tokyo, Japan; [Kraemer, Brian C.; Kovac, Andrej; Hansen, Kim M.; Salameh, Therese; Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA; [Kraemer, Brian C.; McMillan, Pamela J.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA; [McMillan, Pamela J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Flachbartova, Zuzana] Univ Vet Med & Pharm, Dept Microbiol & Immunol, Lab Biomed Microbiol & Immunol, Kosice, Slovakia; [Shah, Gul N.] St Louis Univ, Sch Med, Edward Doisy Res Ctr, Div Endocrinol,Dept Internal Med, St Louis, MO USA; [Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA		Banks, WA (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.	wabanks1@uw.edu	Banks, William A/K-1330-2017; Sheibani, Nader/AAG-2379-2020; Erickson, Michelle/U-7754-2019; Erickson, Michelle/AAR-8717-2021; Erickson, Michelle/G-4815-2014	Banks, William A/0000-0002-0496-3619; Sheibani, Nader/0000-0003-2723-9217; Erickson, Michelle/0000-0002-2575-1594; dohi, kenji/0000-0002-4451-0382	Kiban C grant [23592683]; VA Merit ReviewUS Department of Veterans Affairs [RO-1 AG029839, R0-1 NS064131];  [RO-1 DK083485]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK083485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES019851, P30ES013508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG029839] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002619] Funding Source: NIH RePORTER	KD was supported by Kiban C grant number 23592683. WAB was supported by VA Merit Review; RO-1 AG029839. WAB and GNS was supported by RO-1 DK083485. BCK was supported by VA Merit Review; R0-1 NS064131. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banks William A., 1997, V73, P353; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Erickson MA, 2012, J ALZHEIMERS DIS, V28, P951, DOI 10.3233/JAD-2011-111517; Guthrie CR, 2009, HUM MOL GENET, V18, P1825, DOI 10.1093/hmg/ddp099; Halliday MR, 2013, JAMA NEUROL, V70, P1198, DOI 10.1001/jamaneurol.2013.3841; Hawkins BE, 2013, J BIOL CHEM; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; JAGENDORF AT, 1966, P NATL ACAD SCI USA, V55, P170, DOI 10.1073/pnas.55.1.170; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Keep RF, 2012, TRANSL STROKE RES, V3, P263, DOI 10.1007/s12975-012-0152-2; Kovac A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-139; Miyamoto K, 2014, J MOL NEUROSCI; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Pan WH, 2006, J NEUROIMMUNOL, V174, P119, DOI 10.1016/j.jneuroim.2006.02.006; Pan WH, 1997, NEUROSCI BIOBEHAV R, V21, P603, DOI 10.1016/S0149-7634(96)00047-4; Pan WH, 1996, AM J PHYSIOL-ENDOC M, V271, pE636, DOI 10.1152/ajpendo.1996.271.4.E636; Pan WH, 2000, EXP NEUROL, V170, P357, DOI 10.1006/exnr.2001.7702; Pan WH, 1998, BRAIN RES, V788, P87, DOI 10.1016/S0006-8993(97)01525-4; Price TO, 2012, ENDOCRINOLOGY, V153, P362, DOI 10.1210/en.2011-1638; Reyes TM, 1999, BRAIN RES, V851, P215, DOI 10.1016/S0006-8993(99)02189-7; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Shah GN, 2013, J PHARMACOL EXP THER, V344, P637, DOI 10.1124/jpet.112.201400; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P1034, DOI 10.1097/NEN.0b013e3181f46e25; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Verma S, 2006, BRAIN BEHAV IMMUN, V20, P449, DOI 10.1016/j.bbi.2005.10.005; Wick Jeannette Y, 2012, Consult Pharm, V27, P392, DOI 10.4140/TCP.n.2012.392	33	33	35	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2014	9	9							e108034	10.1371/journal.pone.0108034			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AQ0SJ	WOS:000342492700070	25251220	Green Published, gold, Green Submitted			2022-02-06	
J	Eroglu, B; Kimbler, DE; Pang, JF; Choi, J; Moskophidis, D; Yanasak, N; Dhandapani, KM; Mivechi, NF				Eroglu, Binnur; Kimbler, Donald E.; Pang, Junfeng; Choi, Justin; Moskophidis, Demetrius; Yanasak, Nathan; Dhandapani, Krishnan M.; Mivechi, Nahid F.			Therapeutic inducers of the HSP70/HSP110 protect mice against traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						BGP-15; celastrol; closed cortical impact; Hsp110; Hsp70; knockout mice	GROWTH-HORMONE GH; HEAT-SHOCK; C-JUN; EXPRESSION; STRESS; HSP70; GENE; P53; ACCUMULATION; CHAPERONES	Traumatic brain injury (TBI) induces severe harm and disability in many accident victims and combat-related activities. The heat-shock proteins Hsp70/Hsp110 protect cells against death and ischemic damage. In this study, we used mice deficient in Hsp110 or Hsp70 to examine their potential requirement following TBI. Data indicate that loss of Hsp110 or Hsp70 increases brain injury and death of neurons. One of the mechanisms underlying the increased cell death observed in the absence of Hsp110 and Hsp70 following TBI is the increased expression of reactive oxygen species-induced p53 target genes Pig1, Pig8, and Pig12. To examine whether drugs that increase the levels of Hsp70/Hsp110 can protect cells against TBI, we subjected mice to TBI and administered Celastrol or BGP-15. In contrast to Hsp110- or Hsp70i-deficient mice that were not protected following TBI and Celastrol treatment, there was a significant improvement of wild-type mice following administration of these drugs during the first week following TBI. In addition, assessment of neurological injury shows significant improvement in contextual and cued fear conditioning tests and beam balance in wild- type mice that were treated with Celastrol or BGP-15 following TBI compared to TBI-treated mice. These studies indicate a significant role of Hsp70/Hsp110 in neuronal survival following TBI and the beneficial effects of Hsp70/Hsp110 inducers toward reducing the pathological consequences of TBI.	[Eroglu, Binnur; Mivechi, Nahid F.] CNVAMC, Augusta, GA 30904 USA; [Eroglu, Binnur; Kimbler, Donald E.; Pang, Junfeng; Choi, Justin; Moskophidis, Demetrius; Yanasak, Nathan; Dhandapani, Krishnan M.; Mivechi, Nahid F.] Georgia Regents Univ, Augusta, GA 30912 USA; [Eroglu, Binnur; Choi, Justin; Moskophidis, Demetrius; Mivechi, Nahid F.] Georgia Regents Univ, Ctr Canc, Augusta, GA 30912 USA; [Eroglu, Binnur; Kimbler, Donald E.; Pang, Junfeng; Choi, Justin; Moskophidis, Demetrius; Yanasak, Nathan; Dhandapani, Krishnan M.; Mivechi, Nahid F.] Med Coll Georgia, Augusta, GA 30912 USA; [Kimbler, Donald E.; Dhandapani, Krishnan M.] Georgia Regents Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Yanasak, Nathan; Mivechi, Nahid F.] Georgia Regents Univ, Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA		Mivechi, NF (corresponding author), CNVAMC, One Freedom Way, Augusta, GA 30904 USA.	nahid.mivechi@va.gov	Pang, Junfeng/I-9148-2014	Dhandapani, Krishnan/0000-0001-7044-1117; Pang, Junfeng/0000-0002-9982-8013	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA062130, R01CA121951, R01CA132640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000161] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA062130, CA132640, R01 CA121951, R01 CA132640, CA121951, R01 CA062130] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS065172, R01 NS065172] Funding Source: Medline; BLRD VA [I01 BX000161] Funding Source: Medline		Abbas HA, 2010, CELL STEM CELL, V7, P606, DOI 10.1016/j.stem.2010.09.013; Beck IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069115; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bonner HP, 2010, J NEUROCHEM, V114, P606, DOI 10.1111/j.1471-4159.2010.06790.x; Buschmann JP, 2012, J MOL NEUROSCI, V48, P66, DOI 10.1007/s12031-012-9773-x; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Covey MV, 2007, NEUROSCIENCE, V148, P501, DOI 10.1016/j.neuroscience.2007.06.015; Devesa J, 2013, HORM BEHAV, V63, P331, DOI 10.1016/j.yhbeh.2012.02.022; Engel T, 2012, FASEB J, V26, P1616, DOI 10.1096/fj.11-196089; Eroglu B, 2010, MOL CELL BIOL, V30, P4626, DOI 10.1128/MCB.01493-09; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; GARCIAARAGON J, 1992, DEVELOPMENT, V114, P869; Gehrig SM, 2012, NATURE, V484, P394, DOI 10.1038/nature10980; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gombos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028818; Haldimann P, 2011, J BIOL CHEM, V286, P18784, DOI 10.1074/jbc.M111.234773; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; Homma S, 2007, J NEUROSCI, V27, P7974, DOI 10.1523/JNEUROSCI.0006-07.2007; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang L, 2001, MOL CELL BIOL, V21, P8575, DOI 10.1128/MCB.21.24.8575-8591.2001; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P240, DOI 10.1016/j.biopha.2012.11.011; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kim JY, 2013, NEUROBIOL DIS, V58, P289, DOI 10.1016/j.nbd.2013.06.012; Kim MG, 2014, KIDNEY INT, V85, P62, DOI 10.1038/ki.2013.277; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lee H, 2013, HUM GENE THER, V24, P655, DOI 10.1089/hum.2013.001; Lee SH, 1999, BBA-GENE STRUCT EXPR, V1446, P389, DOI 10.1016/S0167-4781(99)00112-8; Lehar SM, 1996, ONCOGENE, V12, P1181; Li YH, 2012, BRAIN RES, V1464, P8, DOI 10.1016/j.brainres.2012.04.054; Literati-Nagy B, 2009, HORM METAB RES, V41, P374, DOI 10.1055/s-0028-1128142; LIU FT, 1995, AM J PATHOL, V147, P1016; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Narayan N, 2012, NATURE, V492, P199, DOI 10.1038/nature11700; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Polier S, 2008, CELL, V133, P1068, DOI 10.1016/j.cell.2008.05.022; Qi DS, 2012, J NEUROL SCI, V317, P123, DOI 10.1016/j.jns.2012.02.011; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Szabados E, 2000, BIOCHEM PHARMACOL, V59, P937, DOI 10.1016/S0006-2952(99)00418-9; Trott A, 2008, MOL BIOL CELL, V19, P1104, DOI 10.1091/mbc.E07-10-1004; TUPPER DE, 1980, ACTA NEUROBIOL EXP, V40, P999; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Wilson CA, 2013, PHARMACOL BIOCHEM BE, V104, P47, DOI 10.1016/j.pbb.2012.12.015; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu LJ, 2011, NEUROSCI LETT, V488, P279, DOI 10.1016/j.neulet.2010.11.047; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144	52	33	38	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2014	130	5					626	641		10.1111/jnc.12781			16	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN4EF	WOS:000340539700003	24903326	Green Accepted, Bronze			2022-02-06	
J	Sarmiento, K; Hoffman, R; Dmitrovsky, Z; Lee, R				Sarmiento, Kelly; Hoffman, Rosanne; Dmitrovsky, Zoe; Lee, Robin			A 10-year review of the Centers for Disease Control and Prevention's Heads Up initiatives: Bringing concussion awareness to the forefront	JOURNAL OF SAFETY RESEARCH			English	Article						CDC; Concussion; Heads Up	HIGH-SCHOOL; CDC HEADS; SPORTS; COACHES	TheJournal of Safety Research has partnered with the Office of the Associate Director for Science, Division of 16 Unintentional Injury Prevention in the National Center for Injury Prevention & Control at the Centers for Disease 17 Control and Prevention (CDC) in Atlanta, Georgia, USA, to briefly report on some of the latest findings in the re- 18 search and practice community. This report is the 32nd in a series of CDC articles.	[Sarmiento, Kelly; Lee, Robin] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30041 USA; [Hoffman, Rosanne; Dmitrovsky, Zoe] ICF Int, Strateg Commun & Mkt Div, Fairfax, VA USA		Sarmiento, K (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30041 USA.	KSarmiento@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline		Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; *CDCP, 2003, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, 2010, HEADS SCH KNOW YOUR; Centers for Disease Control and Prevention & CDC Foundation, 2013, HEADS PAR; Centers for Disease Control and Prevention National Center for Injury Prevention Control, 2010, HEADS ONL TRAIN COUR; Centers for Disease Control Prevention [CDC], 2007, HEADS CONC YOUTH SPO; Centers for Disease Control Prevention [CDC], 2005, HEADS CONC HIGH SCH; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Institute of Medicine (IOM) & National Research Council (NRC), 2013, SPORTS REL CONC YOUT; Library of Congress, 1999, BILL SUMM STAT 106 C; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Federation of State High School Associations, 2010, CONC SPORTS WHAT YOU; National Football League CDC Foundation and Centers for Disease Control and Prevention, 2011, HEADS CLIN ADDR CONC; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e	20	33	33	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4375	1879-1247		J SAFETY RES	J. Saf. Res.	SEP	2014	50						143	147		10.1016/j.jsr.2014.05.003			5	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	AO6QT	WOS:000341477300017	25142371	Green Accepted			2022-02-06	
J	McNett, M; Amato, S; Gianakis, A; Grimm, D; Philippbar, SA; Belle, J; Moran, C				McNett, Molly; Amato, Shelly; Gianakis, Anastasia; Grimm, Dawn; Philippbar, Sue Ann; Belle, Josie; Moran, Cristina			The FOUR Score and GCS as Predictors of Outcome After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Coma Scale; Outcome prediction; Traumatic brain injury	GLASGOW COMA SCALE; FUNCTIONAL INDEPENDENCE MEASURE; INTERRATER RELIABILITY; EMERGENCY-DEPARTMENT; IMPAIRED CONSCIOUSNESS; NATIONAL-SURVEY; HEAD-INJURY; VALIDATION; MEMORY	The Glasgow Coma Scale (GCS) is a routine component of a neurological exam for critically ill traumatic brain injury (TBI) patients, yet has been criticized for not accurately depicting verbal status among intubated patients or including brain stem reflexes. Preliminary research on the Full Outline of UnResponsiveness (FOUR) Scale suggests it overcomes these limitations. Research is needed to determine correlations with patient outcomes. The aims of this study were to: (1) examine correlations between 24 and 72 h FOUR and GCS scores and functional/cognitive outcomes; (2) determine relationship between 24 and 72 h FOUR scores and mortality. Prospective cohort study. Data gathered on adult TBI patients at a Level I trauma center. FOUR scores assigned at 24, 72 h. Functional outcome measured by functional independence measure scores at rehabilitation discharge; cognitive status measured by Weschler Memory Scale scores 3 months post-injury. n = 136. Mean age 53.1. 72 h FOUR and GCS scores correlated with functional outcome (r (s) = 0.34, p = 0.05; r (s) = 0.39, p = 0.02), but not cognitive status. Receiver operating characteristic curves were comparable for FOUR and GCS at 24 and 72 h for functional status (24 h FOUR, GCS = 0.625, 0.602, respectively; 72 h FOUR, GCS = 0.640, 0.688), cognitive status (24 h FOUR, GCS = 0.703, 0.731; 72 h FOUR, GCS = 0.837, 0.674), and mortality (24 h FOUR, GCS = 0.913, 0.935; 72 h FOUR, GCS = 0.837, 0.884). FOUR is comparable to GCS in terms of predictive ability for functional status, cognitive outcome 3 months post-injury, and in-hospital mortality.	[McNett, Molly] MetroHlth Syst, Dept Nursing Res, Cleveland, OH 44109 USA; [Amato, Shelly] MetroHlth Rehabil Inst Ohio, Dept Nursing, Cleveland, OH USA; [Gianakis, Anastasia; Grimm, Dawn] MetroHlth Syst, Dept Nursing, Trauma Crit Care Burns, Cleveland, OH USA; [Philippbar, Sue Ann] Case Western Reserve Univ, Dept Phys Med & Rehabil, MetroHlth Rehabil Inst Ohio, Cleveland, OH 44106 USA; [Belle, Josie; Moran, Cristina] MetroHlth Syst, Dept Nursing, Trauma Crit Care, Cleveland, OH USA		McNett, M (corresponding author), MetroHlth Syst, Dept Nursing Res, Cleveland, OH 44109 USA.	mmcnett@metrohealth.org			Sigma Theta Tau International	This study received partial funding from Sigma Theta Tau International.	BHATTY GB, 1993, ACTA NEUROCHIR, V120, P132, DOI 10.1007/BF02112031; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Chen BX, 2013, ACTA NEUROCHIR, V155, P2133, DOI 10.1007/s00701-013-1854-2; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Franzen M. D., 2000, RELIABILITY VALIDITY; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Hinkle JL, 2010, REHABIL NURS, V35, P23, DOI 10.1002/j.2048-7940.2010.tb00027.x; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; Iverson G, 1999, J COGNITIVE REHABILI, V17, P16; Juarez V J, 1995, J Neurosci Nurs, V27, P283; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; Kornbluth J, 2011, NEUROCRIT CARE, V14, P134, DOI 10.1007/s12028-010-9409-3; Ku┬nig N., 1996, CLIN REHABIL, V10, P309; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MCHORNEY CA, 1995, MED CARE, V33, P15, DOI 10.1097/00005650-199501000-00002; McNett Molly, 2007, J Neurosci Nurs, V39, P68; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; Roh DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; Sandhaug M, 2010, BRAIN INJURY, V24, P740, DOI 10.3109/02699051003652849; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; Stead LG, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-5; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	34	33	38	0	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2014	21	1					52	57		10.1007/s12028-013-9947-6			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AL7XP	WOS:000339350500008	24408147				2022-02-06	
J	Lama, S; Auer, RN; Tyson, R; Gallagher, CN; Tomanek, B; Sutherland, GR				Lama, Sanju; Auer, Roland N.; Tyson, Randy; Gallagher, Clare N.; Tomanek, Boguslaw; Sutherland, Garnette R.			Lactate Storm Marks Cerebral Metabolism following Brain Trauma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; OXIDATIVE STRESS; C-13 NMR; COGNITIVE DEFICITS; GLUCOSE-METABOLISM; SUBSTRATE DELIVERY; GLUTAMATE UPTAKE; INJURY; MICRODIALYSIS; ASTROCYTES	Brain metabolism is thought to be maintained by neuronalglial metabolic coupling. Glia take up glutamate from the synaptic cleft for conversion into glutamine, triggering glial glycolysis and lactate production. This lactate is shuttled into neurons and further metabolized. The origin and role of lactate in severe traumatic brain injury (TBI) remains controversial. Using a modified weight drop model of severe TBI and magnetic resonance (MR) spectroscopy with infusion of C-13-labeled glucose, lactate, and acetate, the present study investigated the possibility that neuronal-glial metabolism is uncoupled following severe TBI. Histopathology of the model showed severe brain injury with subarachnoid and hemorrhage together with glial cell activation and positive staining for Tau at 90 min post-trauma. High resolution MR spectroscopy of brain metabolites revealed significant labeling of lactate at C-3 and C-2 irrespective of the infused substrates. Increased C-13-labeled lactate in all study groups in the absence of ischemia implied activated astrocytic glycolysis and production of lactate with failure of neuronal uptake (i.e. a loss of glial sensing for glutamate). The early increase in extracellular lactate in severe TBI with the injured neurons rendered unable to pick it up probably contributes to a rapid progression toward irreversible injury and pan-necrosis. Hence, a method to detect and scavenge the excess extracellular lactate on site or early following severe TBI may be a potential primary therapeutic measure.	[Lama, Sanju; Tyson, Randy; Gallagher, Clare N.; Tomanek, Boguslaw; Sutherland, Garnette R.] Univ Calgary, Dept Clin Neurosci, Fac Med, Calgary, AB T2N 2T9, Canada; [Lama, Sanju; Tyson, Randy; Gallagher, Clare N.; Tomanek, Boguslaw; Sutherland, Garnette R.] Univ Calgary, Hotchkiss Brain Inst, Fac Med, Calgary, AB T2N 2T9, Canada; [Auer, Roland N.] Univ Montreal, Hop Ste Justine, Dept Pathol, Montreal, PQ H3T 1C5, Canada		Sutherland, GR (corresponding author), Univ Calgary, Hlth Res Innovat Ctr 1C60, 3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada.	garnette@ucalgary.ca	Tomanek, Boguslaw/AAD-7594-2019; Tomanek, Boguslaw/J-4720-2014; Auer, Roland/F-6661-2017	Tomanek, Boguslaw/0000-0003-2602-0280; Auer, Roland/0000-0001-9044-3419	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [RT733596]	This work was supported by the Canadian Institutes for Health Research grant entitled Cerebral Metabolism in Traumatic Brain Injury RT733596 (to G. R. S.).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; ALVES PM, 1995, NEUROREPORT, V6, P2201, DOI 10.1097/00001756-199511000-00024; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; BECKMANN N, 1991, BIOCHEMISTRY-US, V30, P6362, DOI 10.1021/bi00240a002; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi HB, 2012, NEURON, V75, P1094, DOI 10.1016/j.neuron.2012.08.032; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; Hassel B, 1997, J CEREBR BLOOD F MET, V17, P1230, DOI 10.1097/00004647-199711000-00012; HASSEL B, 1992, BRAIN RES, V576, P120, DOI 10.1016/0006-8993(92)90616-H; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KISHI K, 1994, BIOCHEMISTRY-US, V33, P8694, DOI 10.1021/bi00195a010; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Magistretti PJ, 2009, AM J CLIN NUTR, V90, p875S, DOI 10.3945/ajcn.2009.27462CC; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McKenna MC, 1995, NEUROCHEM RES, V20, P1491, DOI 10.1007/BF00970599; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Mondragon-Rodriguez S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/940603; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PEELING J, 1992, MAGNET RESON MED, V24, P123, DOI 10.1002/mrm.1910240113; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Peronnet F, 2006, RESP PHYSIOL NEUROBI, V150, P4, DOI 10.1016/j.resp.2005.04.005; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sanchez Jose J, 2013, Acta Neurochir Suppl, V118, P223, DOI 10.1007/978-3-7091-1434-6_42; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Tyson RL, 2000, NEUROREPORT, V11, P1845, DOI 10.1097/00001756-200006260-00009; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vogel R, 1998, NEUROSCI LETT, V247, P123, DOI 10.1016/S0304-3940(98)00290-0; Weinstein JS, 2010, J CEREBR BLOOD F MET, V30, P15, DOI 10.1038/jcbfm.2009.192; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	58	33	36	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2014	289	29					20200	20208		10.1074/jbc.M114.570978			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AL8NE	WOS:000339395200033	24849602	Green Published, hybrid			2022-02-06	
J	Barlow, KM; Brooks, BL; MacMaster, FP; Kirton, A; Seeger, T; Esser, M; Crawford, S; Nettel-Aguirre, A; Zemek, R; Angelo, M; Kirk, V; Emery, CA; Johnson, D; Hill, MD; Buchhalter, J; Turley, B; Richer, L; Platt, R; Hutchison, J; Dewey, D				Barlow, Karen M.; Brooks, Brian L.; MacMaster, Frank P.; Kirton, Adam; Seeger, Trevor; Esser, Michael; Crawford, Susan; Nettel-Aguirre, Alberto; Zemek, Roger; Angelo, Mikrogianakis; Kirk, Valerie; Emery, Carolyn A.; Johnson, David; Hill, Michael D.; Buchhalter, Jeff; Turley, Brenda; Richer, Lawrence; Platt, Robert; Hutchison, Jamie; Dewey, Deborah			A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial	TRIALS			English	Article						Concussion; Traumatic brain injury; Melatonin; Placebo; Pediatric; Randomized controlled trial	TRAUMATIC BRAIN-INJURY; IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; CENTRAL-NERVOUS-SYSTEM; SPORT-RELATED CONCUSSION; LONG-TERM POTENTIATION; ROUTINE FOLLOW-UP; OXIDATIVE STRESS; HEAD-INJURY; SLEEP DISORDERS	Background: By the age of sixteen, one in five children will sustain a mild traumatic brain injury also known as concussion. Our research found that one in seven school children with mild traumatic brain injury suffer post-concussion syndrome symptoms for three months or longer. Post-concussion syndrome is associated with significant disability in the child and his/her family and yet there are no evidence-based medical treatments available. Melatonin has several potential mechanisms of action that could be useful following mild traumatic brain injury, including neuroprotective effects. The aim of this study is to determine if treatment with melatonin improves post-concussion syndrome in youths following mild traumatic brain injury. Our hypothesis is that treatment of post-concussion syndrome following mild traumatic brain injury with 3 or 10 mg of sublingual melatonin for 28 days will result in a decrease in post-concussion syndrome symptoms compared with placebo. Methods/Design: Ninety-nine youths with mild traumatic brain injury, aged between 13 and 18 years, who are symptomatic at 30 days post-injury will be recruited. This study will be conducted as a randomized, double blind, placebo-controlled superiority trial of melatonin. Three parallel treatment groups will be examined with a 1:1:1 allocation: sublingual melatonin 3 mg, sublingual melatonin 10 mg, and sublingual placebo. Participants will receive treatment for 28 days. The primary outcome is a change on the Post-Concussion Symptom Inventory (Parent and Youth). The secondary outcomes will include neurobehavioral function, health-related quality of life and sleep. Neurophysiological and structural markers of change, using magnetic resonance imaging techniques and transcranial magnetic stimulation, will also be investigated. Discussion: Melatonin is a safe and well-tolerated agent that has many biological properties that may be useful following a traumatic brain injury. This study will determine whether it is a useful treatment for children with post-concussion syndrome. Recruitment commenced on 4 December 2014.	[Barlow, Karen M.; Brooks, Brian L.; MacMaster, Frank P.; Kirton, Adam; Seeger, Trevor; Esser, Michael; Crawford, Susan; Nettel-Aguirre, Alberto; Angelo, Mikrogianakis; Kirk, Valerie; Emery, Carolyn A.; Johnson, David; Buchhalter, Jeff; Turley, Brenda; Dewey, Deborah] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada; [Zemek, Roger] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; [Emery, Carolyn A.] Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Hill, Michael D.] Univ Calgary, Hlth Res Innovat Ctr, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; [Richer, Lawrence] Univ Alberta, Dept Pediat Neurol, Edmonton, AB T6G 2B7, Canada; [Platt, Robert] McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Stat, Montreal, PQ H3H 1P3, Canada; [Hutchison, Jamie] Hosp Sick Children, Dept Crit Care Med, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada		Barlow, KM (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Room 293,Heritage Med Res Bldg 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Karen.barlow@albertahealthservices.ca	Zemek, Roger/H-1039-2018; Richer, Lawrence/D-3622-2009; Barlow, Karen/C-1323-2014; Nettel-Aguirre, Alberto/ABB-9412-2021; Barlow, Karen/I-6492-2019; Kirton, Adam/L-8875-2016; Emery, Carolyn/AAI-2761-2020; Hill, Michael D/C-9073-2012	Richer, Lawrence/0000-0002-6897-8668; Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507; Hill, Michael D/0000-0002-6269-1543; Platt, Robert/0000-0002-5981-8443; Nettel-Aguirre, Alberto/0000-0001-6604-0652; MacMaster, Frank/0000-0002-7159-7583; Dewey, Deborah/0000-0002-1323-5832	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [293375]; Faculty of Medicine, University of Calgary	This study is funded by Canadian Institutes of Health Research (grant number: 293375) and Faculty of Medicine, University of Calgary. These funding sources had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. The design, management, analysis and reporting of the study are entirely independent of any manufacturers of melatonin. Pediatric Emergency Research Teams at Alberta Children's Hospital and Children's Hospital of Eastern Ontario, and Pediatric Emergency Research Consortium, Canada.	Acufla-Castroviejo D, 1995, J PINEAL RES, V19, P57; Castroviejo DA, 2011, CURR TOP MED CHEM, V11, P221; Acuna-Castroviejo D, 2003, ADV EXP MED BIOL, V527, P549; Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alstadhaug KB, 2010, NEUROLOGY, V75, P1527, DOI 10.1212/WNL.0b013e3181f9618c; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Antolin I, 2002, BRAIN RES, V943, P163, DOI 10.1016/S0006-8993(02)02551-9; Antonaci F, 2011, CURR NEUROL NEUROSCI, V11, P149, DOI 10.1007/s11910-010-0164-9; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Brooks BL, 2012, J CHILD NEUROL, V27, P982, DOI 10.1177/0883073811430863; Buscemi N, 2006, BMJ-BRIT MED J, V332, P385, DOI 10.1136/bmj.38731.532766.F6; Buscemi N, 2005, J GEN INTERN MED, V20, P1151, DOI 10.1111/j.1525-1497.2005.0243.x; Camins A, 2010, EXPERT OPIN INV DRUG, V19, P587, DOI 10.1517/13543781003781898; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Cardinali DP, 2013, HORM BEHAV, V63, P322, DOI 10.1016/j.yhbeh.2012.02.020; Carpentieri A, 2012, PHARMACOL RES, V65, P437, DOI 10.1016/j.phrs.2012.01.003; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Citera G, 2000, CLIN RHEUMATOL, V19, P9, DOI 10.1007/s100670050003; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dai X, 2007, BEHAV BRAIN RES, V182, P21, DOI 10.1016/j.bbr.2007.04.018; Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Dhanaraj E, 2004, PHARMACOL BIOCHEM BE, V79, P733, DOI 10.1016/j.pbb.2004.10.002; Dodge NN, 2001, J CHILD NEUROL, V16, P581, DOI 10.2310/7010.2001.16810; Donaldson CJ, 2010, OTOLARYNG HEAD NECK, V143, P820, DOI 10.1016/j.otohns.2010.09.024; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Doyle A, 1997, J CLIN CHILD PSYCHOL, V26, P276, DOI 10.1207/s15374424jccp2603_6; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Garcia J, 2001, Semin Pediatr Neurol, V8, P229, DOI 10.1053/spen.2001.29044; Gioia GA, 2011, MANUAL PEDIAT IMMEDI; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glass KL, 2005, 33 ANN M INT NEUR SO, V2005, P171; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Green LB, 2004, AM J PHYS MED REHAB, V83, P893, DOI 10.1097/01.PHM.0000143400.15346.C8; Green Robin, 2010, Neuropsychol Rehabil, V20, P471, DOI 10.1080/09602011003693298; Gurkanlar D, 2010, TURK NEUROSURG, V20, P442, DOI 10.5137/1019-5149.JTN.3176-10.1; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Herrera F, 2001, J PINEAL RES, V31, P356, DOI 10.1034/j.1600-079X.2001.310411.x; Hofstra WA, 2008, EPILEPSY BEHAV, V13, P438, DOI 10.1016/j.yebeh.2008.06.002; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Janusz JA, 2012, MILD TRAUMATIC BRAIN, DOI [10.1249/JSR.0b013-31819c7-87, DOI 10.1249/JSR.0B013-31819C7-87]; Koh JO, 2011, J SPORT MED PHYS FIT, V51, P625; Kotler M, 1998, J PINEAL RES, V24, P83, DOI 10.1111/j.1600-079X.1998.tb00371.x; Kuczynski A, 2011, CAN J NEUR SCI, V38; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kumar A, 2009, FUND CLIN PHARMACOL, V23, P439, DOI 10.1111/j.1472-8206.2009.00737.x; LABEL L S, 1991, Neurology, V41, P247; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Louzada PR, 2004, FASEB J, V18, P511, DOI 10.1096/fj.03-0739com; Lu WZ, 2005, ALIMENT PHARM THER, V22, P927, DOI 10.1111/j.1365-2036.2005.02673.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Maldonado MD, 2012, PHYSIOL BEHAV, V105, P1099, DOI 10.1016/j.physbeh.2011.12.015; Manda K, 2007, ACTA NEUROBIOL EXP, V67, P63; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Miano S, 2008, NEUROL SCI, V29, P285, DOI 10.1007/s10072-008-0983-5; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Mozaffari S, 2010, CURR PHARM DESIGN, V16, P3646, DOI 10.2174/138161210794079254; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Ochoa JJ, 2011, J PINEAL RES, V51, P373, DOI 10.1111/j.1600-079X.2011.00899.x; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Peres MFP, 2004, NEUROLOGY, V63, P757, DOI 10.1212/01.WNL.0000134653.35587.24; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; REDMAN JR, 1988, J PINEAL RES, V5, P203, DOI 10.1111/j.1600-079X.1988.tb00782.x; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Reiter Russel J, 2008, Interdiscip Toxicol, V1, P137, DOI 10.2478/v10102-010-0030-2; Reynolds CR, 2002, CLIN GUID BEHAV ASSE; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rosen J, 2006, J PINEAL RES, V41, P374, DOI 10.1111/j.1600-079X.2006.00379.x; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Saha L, 2007, J CLIN GASTROENTEROL, V41, P29, DOI 10.1097/MCG.0b013e31802df84c; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Solomon GS, 2011, CLIN SPORT MED, V30, P165, DOI 10.1016/j.csm.2010.09.002; Song GH, 2005, GUT, V54, P1402, DOI 10.1136/gut.2004.062034; Tal G, 2013, PEDIATR NEUROL, V48, P424, DOI 10.1016/j.pediatrneurol.2012.11.008; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Thiagarajan P, 2014, NEUROREHABILITATION, V34, P129, DOI 10.3233/NRE-131025; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tsai J, 2012, J CLIN PSYCHIAT, V73, P1110, DOI 10.4088/JCP.11m07587; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; UNDERWOOD H, 1987, Journal of Biological Rhythms, V2, P279, DOI 10.1177/074873048700200404; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Geijlswijk IM, 2010, PSYCHOPHARMACOLOGY, V212, P379, DOI 10.1007/s00213-010-1962-0; Rios ERV, 2010, INT J NEUROSCI, V120, P583, DOI 10.3109/00207454.2010.492921; Velkov ZA, 2009, EUR J MED CHEM, V44, P2834, DOI 10.1016/j.ejmech.2008.12.017; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wang WZ, 2006, J PINEAL RES, V41, P255, DOI 10.1111/j.1600-079X.2006.00361.x; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilhelmsen M, 2011, J PINEAL RES, V51, P270, DOI 10.1111/j.1600-079X.2011.00895.x; Wilhelmsen Michael, 2011, Ugeskr Laeger, V173, P1424; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yousaf F, 2010, ANESTHESIOLOGY, V113, P968, DOI 10.1097/ALN.0b013e3181e7d626; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	144	33	33	1	25	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	JUL 7	2014	15								271	10.1186/1745-6215-15-271			10	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	AM7SC	WOS:000340067500001	25001947	gold, Green Published			2022-02-06	
J	Hess, EP; Wyatt, KD; Kharbanda, AB; Louie, JP; Dayan, PS; Tzimenatos, L; Wootton-Gorges, SL; Homme, JL; Pencille, RNL; LeBlanc, A; Westphal, JJ; Shepel, K; Shah, ND; Branda, M; Herrin, J; Montori, VM; Kuppermann, N				Hess, Erik P.; Wyatt, Kirk D.; Kharbanda, Anupam B.; Louie, Jeffrey P.; Dayan, Peter S.; Tzimenatos, Leah; Wootton-Gorges, Sandra L.; Homme, James L.; Pencille, Laurie R. N.; LeBlanc, Annie; Westphal, Jessica J.; Shepel, Kathy; Shah, Nilay D.; Branda, Megan; Herrin, Jeph; Montori, Victor M.; Kuppermann, Nathan			Effectiveness of the head CT choice decision aid in parents of children with minor head trauma: study protocol for a multicenter randomized trial	TRIALS			English	Article							OPTION SCALE; VALIDATION; RISK; MEDICATIONS; CHILDHOOD; NUMERACY; TRUST; SCANS; CARE	Background: Blunt head trauma is a common cause of death and disability in children worldwide. Cranial computed tomography (CT), the reference standard for the diagnosis of traumatic brain injury (TBI), exposes children to ionizing radiation which has been linked to the development of brain tumors, leukemia, and other cancers. We describe the methods used to develop and test the effectiveness of a decision aid to facilitate shared decision-making with parents regarding whether to obtain a head CT scan or to further observe their child at home. Methods/Design: This is a protocol for a multicenter clinician-level parallel randomized trial to compare an intervention group receiving a decision aid, 'Head CT Choice', to a control group receiving usual care. The trial will be conducted at five diverse emergency departments (EDs) in Minnesota and California. Clinicians will be randomized to decision aid or usual care. Parents visiting the ED with children who are less than 18-years-old, have experienced blunt head trauma within 24 hours, and have one or two risk factors for clinically-important TBI (ciTBI) from the Pediatric Emergency Care Applied Research Network head injury clinical prediction rules will be eligible for enrollment. We will measure the effect of Head CT Choice on: (1) parent knowledge regarding their child's risk of ciTBI, the available diagnostic options, and the risks of radiation exposure associated with a cranial CT scan (primary outcome); (2) parent engagement in the decision-making process; (3) the degree of conflict parents experience related to feeling uninformed; (4) patient and clinician satisfaction with the decision made; (5) the rate of ciTBI at seven days; (6) the proportion of patients in whom a cranial CT scan is obtained; and (7) seven-day healthcare utilization. To capture these outcomes, we will administer parent and clinician surveys immediately after each clinical encounter, obtain video recordings of parent-clinician discussions, administer parent healthcare utilization diaries, analyze hospital billing records, review the electronic medical record, and conduct telephone follow-up. Discussion: This multicenter trial will robustly assess the effectiveness of a decision aid on patient-centered outcomes, safety, and healthcare utilization in parents of children with minor head trauma in five diverse EDs.	[Hess, Erik P.; Pencille, Laurie R. N.; LeBlanc, Annie; Shah, Nilay D.; Branda, Megan; Montori, Victor M.] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA; [Hess, Erik P.] Mayo Clin, Div Emergency Med Res, Dept Emergency Med, Rochester, MN 55905 USA; [Hess, Erik P.; LeBlanc, Annie; Shah, Nilay D.; Branda, Megan] Mayo Clin, Dept Hlth Sci Res, Div Hlth Care Policy & Res, Rochester, MN 55905 USA; [Hess, Erik P.; LeBlanc, Annie; Shah, Nilay D.; Branda, Megan] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Healthcare Del, Rochester, MN 55902 USA; [Wyatt, Kirk D.] Mayo Clin, Mayo Med Sch, Coll Med, Rochester, MN 55902 USA; [Kharbanda, Anupam B.] Childrens Hosp & Clin Minnesota, St Paul, MN 55102 USA; [Louie, Jeffrey P.] Univ Minnesota, Amplatz Childrens Hosp, Minneapolis, MN 55455 USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Emergency Med, New York, NY 10032 USA; [Louie, Jeffrey P.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Davis, CA 95817 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95817 USA; [Wootton-Gorges, Sandra L.] Univ Calif Davis, Sch Med, Dept Radiol, Davis, CA 95817 USA; [Homme, James L.] Mayo Clin, Dept Emergency Med, Div Pediat Emergency Med, Rochester, MN 55902 USA; [Homme, James L.] Mayo Clin, Dept Pediat, Div Pediat Emergency Med, Rochester, MN 55902 USA; [Westphal, Jessica J.] Parent Representat, Rochester, MN USA; [Shepel, Kathy] Mayo Clin, Sect Creat Media, Rochester, MN 55902 USA; [Herrin, Jeph] Yale Univ, Sch Med, Dept Cardiol, New Haven, CT 06520 USA; [Herrin, Jeph] Hlth Res & Educ Trust, Chicago, IL 60606 USA; [Montori, Victor M.] Mayo Clin, Dept Internal Med, Div Endocrinol & Metab, Rochester, MN 55902 USA		Hess, EP (corresponding author), Mayo Clin, Knowledge & Evaluat Res Unit, 200 First St SW, Rochester, MN 55905 USA.	hess.erik@mayo.edu	LeBlanc, Annie/AAZ-1381-2020	Montori, Victor/0000-0003-0595-2898; Kharbanda, Anupam/0000-0001-5231-9855	Patient Centered Outcomes Research Institute (PCORI)Patient-Centered Outcomes Research Institute - PCORI [CE-12-11-4435]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000135] Funding Source: NIH RePORTER	The trial was funded by the Patient Centered Outcomes Research Institute (PCORI) under contract number CE-12-11-4435.	ANDERSON LA, 1990, PSYCHOL REP, V67, P1091, DOI 10.2466/pr0.1990.67.3f.1091; Breslin M, 2008, PATIENT EDUC COUNS, V73, P465, DOI 10.1016/j.pec.2008.07.024; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Degner L F, 1997, Can J Nurs Res, V29, P21; Elwyn G, 2005, HEALTH EXPECT, V8, P34, DOI 10.1111/j.1369-7625.2004.00311.x; Elwyn G, 2003, QUAL SAF HEALTH CARE, V12, P93, DOI 10.1136/qhc.12.2.93; Fagerlin A, 2007, MED DECIS MAKING, V27, P672, DOI 10.1177/0272989x07304449; Faul M, 2010, TRAUMATIC BRAIN INJU; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hess EP, 2012, CIRC-CARDIOVASC QUAL, V5, P251, DOI 10.1161/CIRCOUTCOMES.111.964791; Karanicolas PJ, 2009, J CLIN EPIDEMIOL, V62, P479, DOI 10.1016/j.jclinepi.2008.02.009; Klar, 2000, DESIGN ANAL CLUSTER; Koedoot N, 2001, PATIENT EDUC COUNS, V45, P187, DOI 10.1016/S0738-3991(01)00120-3; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LeBlanc A, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-127; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Moher D, 2012, INT J SURG, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Montori VM, 2011, AM J MED, V124, P549, DOI 10.1016/j.amjmed.2011.01.013; Montori VM, 2007, PLOS MED, V4, P1303, DOI 10.1371/journal.pmed.0040233; Mullan RJ, 2009, ARCH INTERN MED, V169, P1560, DOI 10.1001/archinternmed.2009.293; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Snijders TAB., 2012, MULTILEVEL ANAL INTR; Stacey D, 2014, COCHRANE DATABASE SY, V1; Thom DH, 1999, MED CARE, V37, P510, DOI 10.1097/00005650-199905000-00010; Zikmund-Fisher BJ, 2007, MED DECIS MAKING, V27, P663, DOI 10.1177/0272989x07303824	32	33	34	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	JUN 25	2014	15								253	10.1186/1745-6215-15-253			11	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Research & Experimental Medicine	AK5KU	WOS:000338464300001	24965659	Green Published, gold			2022-02-06	
J	Badaut, J; Bix, GJ				Badaut, J.; Bix, G. J.			Vascular Neural Network Phenotypic Transformation After Traumatic Injury: Potential Role in Long-Term Sequelae	TRANSLATIONAL STROKE RESEARCH			English	Article						Traumatic brain injury; Juvenile traumatic injury; Blood-brain barrier; Neurovascular unit; Cerebral blood flow; Smooth muscle cells; Matrix	BLOOD-BRAIN-BARRIER; NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; IMPAIRED CEREBRAL AUTOREGULATION; ADVANCE TRANSLATIONAL RESEARCH; CENTRAL-NERVOUS-SYSTEM; P-GLYCOPROTEIN; HEAD-INJURY; EXTRACELLULAR-MATRIX; ALZHEIMERS-DISEASE	The classical neurovascular unit (NVU), composed primarily of endothelium, astrocytes, and neurons, could be expanded to include smooth muscle and perivascular nerves present in both the up- and downstream feeding blood vessels (arteries and veins). The extended NVU, which can be defined as the vascular neural network (VNN), may represent a new physiological unit to consider for therapeutic development in stroke, traumatic brain injury, and other brain disorders (Zhang et al., Nat Rev Neurol 8(12):711-716, 2012). This review is focused on traumatic brain injury and resultant post-traumatic changes in cerebral blood flow, smooth muscle cells, matrix, blood-brain barrier structures and function, and the association of these changes with cognitive outcomes as described in clinical and experimental reports. We suggest that studies characterizing TBI outcomes should increase their focus on changes to the VNN, as this may yield meaningful therapeutic targets to resolve posttraumatic dysfunction.	[Badaut, J.] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; [Badaut, J.] Loma Linda Univ, Sch Med, Dept Physiol, Loma Linda, CA 92354 USA; [Bix, G. J.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Bix, G. J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Bix, G. J.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA		Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD061946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	We thank Dane Sorensen for critical review of the manuscript and David Ajao for tissue staining of Cav-1. This study is supported in part by the NIH R01HD061946 (JB).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abrahamson EE, 2013, J CEREBR BLOOD F MET, V33, P826, DOI 10.1038/jcbfm.2013.24; Alexander MR, 2012, ANNU REV PHYSIOL, V74, P13, DOI 10.1146/annurev-physiol-012110-142315; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Armstead WM, 2011, NEUROL RES, V33, P127, DOI 10.1179/016164111X12881719352138; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Badaut J, 2000, J NEUROENDOCRINOL, V12, P960, DOI 10.1046/j.1365-2826.2000.00539.x; Badaut J, 1997, BRAIN RES, V778, P25, DOI 10.1016/S0006-8993(97)00999-2; Baeten KM, 2011, DEV NEUROBIOL, V71, P1018, DOI 10.1002/dneu.20954; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bauer PM, 2005, P NATL ACAD SCI USA, V102, P204, DOI 10.1073/pnas.0406092102; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Berardi N, 2004, NEURON, V44, P905, DOI 10.1016/j.neuron.2004.12.008; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brown AW, 2004, NEUROREHABILITATION, V19, P37; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Cauli Bruno, 2010, Front Neuroenergetics, V2, P9, DOI 10.3389/fnene.2010.00009; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cherian L, 2003, J PHARMACOL EXP THER, V304, P617, DOI 10.1124/JPET.102.043430; Cirrito JR, 2005, J CLIN INVEST, V115, P3285, DOI 10.1172/JCI25247; Cohen Z, 1996, PROG NEUROBIOL, V50, P335, DOI 10.1016/S0301-0082(96)00033-0; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; del Zoppo GJ, 2006, ARTERIOSCL THROM VAS, V26, P1966, DOI 10.1161/01.ATV.0000232525.65682.a2; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Dore-Duffy P, 2011, NEUROL RES, V33, P176, DOI 10.1179/016164111X12881719352372; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ge SJ, 2005, J NEUROSCI RES, V79, P421, DOI 10.1002/jnr.20313; Gu Y, 2012, J NEUROCHEM, V120, P147, DOI 10.1111/j.1471-4159.2011.07542.x; Guix FX, 2005, PROG NEUROBIOL, V76, P126, DOI 10.1016/j.pneurobio.2005.06.001; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hamel E, 2006, J APPL PHYSIOL, V100, P1059, DOI 10.1152/japplphysiol.00954.2005; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Himanen L, 2011, BRAIN INJURY, V25, P443, DOI 10.3109/02699052.2011.556580; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hubbell MC, 2012, AM J PHYSIOL-CELL PH, V303, pC1090, DOI 10.1152/ajpcell.00408.2011; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jodoin J, 2003, J NEUROCHEM, V87, P1010, DOI 10.1046/j.1471-4159.2003.02081.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; Kreipke CW, 2009, J CELL MOL MED, V13, P262, DOI 10.1111/j.1582-4934.2008.00508.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lajoie P, 2009, J CELL BIOL, V185, P381, DOI 10.1083/jcb.200811059; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lin JL, 2010, J CEREBR BLOOD F MET, V30, P1121, DOI 10.1038/jcbfm.2009.277; Lippert-Gruner M, 2006, BRAIN INJURY, V20, P569, DOI 10.1080/02699050600664467; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; McCaffrey G, 2007, J NEUROCHEM, V103, P2540, DOI 10.1111/j.1471-4159.2007.04943.x; McCaffrey G, 2012, J NEUROCHEM, V122, P962, DOI 10.1111/j.1471-4159.2012.07831.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mellergard P, 2010, BRIT J NEUROSURG, V24, P261, DOI 10.3109/02688690903521605; Milner R, 2002, MOL CELL NEUROSCI, V20, P616, DOI 10.1006/mcne.2002.1151; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1989, NEUROSURGERY, V25, P899; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; OWENS GK, 1995, PHYSIOL REV, V75, P487; Owens T, 2008, J NEUROPATH EXP NEUR, V67, P1113, DOI 10.1097/NEN.0b013e31818f9ca8; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Ragan DK, 2012, PEDIATR RES, V71, P199, DOI 10.1038/pr.2011.31; Rensen SSM, 2007, NETH HEART J, V15, P100, DOI 10.1007/BF03085963; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Ruderisch N, 2011, J CEREBR BLOOD F MET, V31, P1637, DOI 10.1038/jcbfm.2011.21; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Saubamea B, 2012, J CEREBR BLOOD F MET, V32, P81, DOI 10.1038/jcbfm.2011.109; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P1034, DOI 10.1097/NEN.0b013e3181f46e25; Silverberg GD, 2010, BRAIN RES, V1317, P286, DOI 10.1016/j.brainres.2009.12.065; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Virgintino D, 2002, NEUROSCIENCE, V115, P145, DOI 10.1016/S0306-4522(02)00374-3; Vogelgesang S, 2004, CURR ALZHEIMER RES, V1, P121, DOI 10.2174/1567205043332225; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wagenseil JE, 2009, PHYSIOL REV, V89, P957, DOI 10.1152/physrev.00041.2008; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830; Zhang JH, 2012, NAT REV NEUROL, V8, P711, DOI 10.1038/nrneurol.2012.210; Zlokovic BV, 2010, NAT MED, V16, P1370, DOI 10.1038/nm1210-1370; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	130	33	34	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	JUN	2014	5	3					394	406		10.1007/s12975-013-0304-z			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AH7TD	WOS:000336336200010	24323723	Green Accepted			2022-02-06	
J	Mannix, R; Iverson, GL; Maxwell, B; Atkins, JE; Zafonte, R; Berkner, PD				Mannix, Rebekah; Iverson, Grant L.; Maxwell, Bruce; Atkins, Joseph E.; Zafonte, Ross; Berkner, Paul D.			Multiple prior concussions are associated with symptoms in high school athletes	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article								Objectives: The purpose of this study was to evaluate the association of prior concussion on baseline computerized neurocognitive testing in a large cohort of high school athletes. Methods: This is a retrospective cohort study of student athletes from 49 Maine High Schools in 2010 who underwent baseline computerized neurocognitive evaluation with Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT (R)). As part of the ImPACT (R), subjects reported a prior history of concussion as well as demographic information and a symptom questionnaire. We used linear regression to evaluate the association of prior concussion with baseline: (1) ImPACT (R) composite scores; and (2) symptom scores. Results: Six thousand seventy-five subjects were included in the study, of whom 57% were boys. The majority of student athletes (85.3%) reported no prior history of concussion while 4.6% reported having sustained two or more prior concussions. On simple linear regression, increasing number of concussions was related to worse performance in verbal memory (P = 0.039) and greater symptoms scores (P < 0.001). On multivariate modeling, only the association with baseline symptoms remained (P < 0.001). Other factors associated with baseline symptom reporting in the multivariate model included mental health history, headache/migraine history, gender, developmental and/or learning problems, and number of prior concussions. Interpretation: In this large-scale, retrospective survey study, history of multiple prior concussions was associated with higher symptom burden but not baseline computerized neurocognitive testing. The association between baseline symptom reporting and clinical and demographic factors was greater than the association with a history of multiple concussions.	[Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA; [Mannix, Rebekah; Iverson, Grant L.; Zafonte, Ross] Harvard Med Sch, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.; Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA; [Maxwell, Bruce] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Atkins, Joseph E.] Colby Coll, Dept Psychol, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA		Mannix, R (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020	Iverson, Grant/0000-0001-7348-9570			Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Iverson GL, 2009, APPL NEUROPSYCHOL, V16, P254, DOI 10.1080/09084280903297594; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Rosenthal JA, 2014, AM J SPORTS MED; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	24	33	33	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	JUN	2014	1	6					433	438		10.1002/acn3.70			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V45KI	WOS:000209815100006	25356413	Green Published, gold			2022-02-06	
J	Griesbach, GS; Tio, DL; Nair, S; Hovda, DA				Griesbach, Grace S.; Tio, Delia L.; Nair, Shyama; Hovda, David A.			Recovery of Stress Response Coincides with Responsiveness to Voluntary Exercise after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain derived neurotrophic factor; corticosterone; exercise; temperature	HIPPOCAMPAL EXCITATORY SYNAPSES; NEUROTROPHIC FACTOR; DENTATE GYRUS; MILD; INCREASES; FATIGUE; CONCUSSION; EXPRESSION; DEPRESSION; SEVERITY	We have recently shown that there is a heightened stress response after a mild traumatic brain injury (TBI) during the first 2 post-injury weeks. This corresponds to the same post-injury period when exercise does not increase brain-derived neurotrophic factor (BDNF) and autonomic dysfunction becomes evident with exercise. Here we determined stress and autonomic responses to voluntary and forced exercise at a post-injury time window when exercise has been found to elicit beneficial effects. Rats underwent a mild fluid percussion injury and were exercised at post-injury days 28-32 and 35-39. Cardiac and temperature autonomic function were evaluated. Hippocampal tissue was obtained immediately after exercise for analysis of BDNF. In contrast to the sub-acute period, corticosterone and adrenocorticotropic hormone responses to exercise were normalized in the TBI group. Irrespective of injury, forced exercise markedly stimulated the corticotrophic axis and did not increase BDNF. BDNF levels were increased with voluntary exercise in all animals. Rats exposed to forced exercise had lower activity levels during periods of non-exercise. This effect was more pronounced in the TBI rats. Cardiac and temperature autonomic responses to delayed exercise also recuperated. Rats with TBI that underwent forced exercise, however, had higher core body temperatures during experimental manipulations, thus suggesting that exposure to a potent stressor facilitates responsiveness to environmental stimulations.	[Griesbach, Grace S.; Nair, Shyama; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Tio, Delia L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Griesbach, Grace S.; Nair, Shyama; Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957030, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS06190]; UCLA Brain Injury Research Center	We thank Ramin Rajai, Hans Sebastian, and Sam Kazemian for their excellent technical assistance. This research was supported by NIH grant NS06190 to GSG and the UCLA Brain Injury Research Center.	Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Griesbach GS, 2012, NEUROSCIENCE, V210, P393, DOI 10.1016/j.neuroscience.2012.03.005; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2013, J NEUROTRAUM, V30, P281, DOI 10.1089/neu.2012.2616; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; Tyler WJ, 2006, J PHYSIOL-LONDON, V574, P787, DOI 10.1113/jphysiol.2006.111310; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001	26	33	33	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					674	682		10.1089/neu.2013.3151			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000009	24151829	Green Published			2022-02-06	
J	Iaccarino, C; Schiavi, P; Picetti, E; Goldoni, M; Cerasti, D; Caspani, M; Servadei, F				Iaccarino, Corrado; Schiavi, Paolo; Picetti, Edoardo; Goldoni, Matteo; Cerasti, Davide; Caspani, Marialuisa; Servadei, Franco			Patients with brain contusions: predictors of outcome and relationship between radiological and clinical evolution	JOURNAL OF NEUROSURGERY			English	Article						cerebral contusion; radiological evolution; outcome; clinical deterioration; traumatic brain injury	HEAD-INJURY; RISK-FACTORS; PROGRESSION; HEMORRHAGE; LESIONS; DETERIORATION; MULTICENTER; MANAGEMENT; HEMATOMA; MODERATE	Object. Traumatic parenchymal mass lesions are common sequelae of traumatic brain injuries (TBIs). They occur in up to 8.2% of all TBI cases and 13%-35% of severe TBI cases, and they account for up to 20% of surgical intracranial lesions. Controversy exists concerning the association between radiological and clinical evolution of brain contusions. The aim of this study was to identify predictors of unfavorable outcome, analyze the evolution of brain contusions, and evaluate specific indications for surgery. Methods. In a retrospective, multicenter study, patients with brain contusions were identified in separate patient cohorts from 11 hospitals over a 4-year period (2008-2011). Data on clinical parameters and course of the contusion were collected. Radiological parameters were registered by using CT images taken at the time of hospital admission and at subsequent follow-up times. Patients who underwent surgical procedures were identified. Outcomes were evaluated 6 months after trauma by using the Glasgow Outcome Scale-Extended. Results. Multivariate analysis revealed the following reliable predictors of unfavorable outcome: 1) increased patient age, 2) lower Glasgow Coma Scale score at first evaluation, 3) clinical deterioration in the first hours after trauma, and 4) onset or increase of midline shift on follow-up CT images. Further multivariate analysis identified the following as statistically significant predictors of clinical deterioration during the first hours after trauma: 1) onset of or increase in midline shift on follow-up CT images (p < 0.001) and 2) increased effacement of basal cisterns on follow-up CT images (p < 0.001). Conclusions. In TBI patients with cerebral contusion, the onset of clinical deterioration is predictably associated with the onset or increase of midline shift and worsened status of basal cisterns but not with hematoma or edema volume increase. A combination of clinical deterioration and increased midline shift/basal cistern compression is the most reasonable indicator for surgery.	[Iaccarino, Corrado; Schiavi, Paolo; Servadei, Franco] Arcispedale Santa Maria Nuova Ist Ricovero & Cura, Reggio Emilia, Italy; [Iaccarino, Corrado; Schiavi, Paolo; Servadei, Franco] Univ Hosp Parma, Neurosurg Neurotraumatol Unit, I-43100 Parma, Italy; [Picetti, Edoardo; Caspani, Marialuisa] Univ Hosp Parma, Intens Care Unit, I-43100 Parma, Italy; [Goldoni, Matteo] Univ Hosp Parma, Dept Biostat, I-43100 Parma, Italy; [Cerasti, Davide] Univ Hosp Parma, Dept Neuroradiol, I-43100 Parma, Italy		Servadei, F (corresponding author), Univ Hosp Parma, Dept Emergency Med, Neurosurg Neurotraumatol Unit, Viale Gramsci 14, I-43100 Parma, Italy.	fservadei@ao.pr.it	Goldoni, Matteo/E-9153-2011; Iaccarino, Corrado/L-3190-2013; Schiavi, Paolo/AAB-9761-2022	Goldoni, Matteo/0000-0002-1342-3921; Iaccarino, Corrado/0000-0002-5133-6327; schiavi, paolo/0000-0002-8108-7747; Servadei, Franco/0000-0002-3595-3464			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; FABBRI A, 2006, APPROCCIO NEL DEA GE; Fabbri A, 2010, J NEUROL NEUROSUR PS, V81, P1275, DOI 10.1136/jnnp.2009.197467; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Iaccarino C, 2008, TELERADIOLOGY, P181; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Peterson EC, 2011, J TRAUMA, V71, P1588, DOI 10.1097/TA.0b013e31822b791d; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Snoek A, 2013, EUR J EMERG MED, V20, P167, DOI 10.1097/MEJ.0b013e328353d926; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	37	33	35	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					908	918		10.3171/2013.12.JNS131090			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800016	24506250				2022-02-06	
J	Park, J; Zheng, LX; Marquis, A; Walls, M; Duerstock, B; Pond, A; Vega-Alvarez, S; Wang, H; Ouyang, Z; Shi, RY				Park, Jonghyuck; Zheng, Lingxing; Marquis, Andrew; Walls, Michael; Duerstock, Brad; Pond, Amber; Vega-Alvarez, Sasha; Wang, He; Ouyang, Zheng; Shi, Riyi			Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage	JOURNAL OF NEUROCHEMISTRY			English	Article						acrolein scavenger; aldehyde; lipid peroxidation; oxidative stress	AXONAL MEMBRANE DISRUPTION; LIPID-PEROXIDATION; ALPHA,BETA-UNSATURATED ALDEHYDES; CYSTIC DEGENERATION; SECONDARY INJURY; CONDUCTION LOSS; PC12 CELLS; METHYLPREDNISOLONE; BRAIN; INFLAMMATION	Acrolein, an alpha,beta-unsaturated aldehyde and a reactive product of lipid peroxidation, has been suggested as a key factor in neural post-traumatic secondary injury in spinal cord injury (SCI), mainly based on in vitro and ex vivo evidence. Here, we demonstrate an increase of acrolein up to 300%; the elevation lasted at least 2 weeks in a rat SCI model. More importantly, hydralazine, a known acrolein scavenger can provide neuroprotection when applied systemically. Besides effectively reducing acrolein, hydralazine treatment also resulted in significant amelioration of tissue damage, motor deficits, and neuropathic pain. This effect was further supported by demonstrating the ability of hydralazine to reach spinal cord tissue at a therapeutic level following intraperitoneal application. This suggests that hydralazine is an effective neuroprotective agent not only in vitro, but in a live animal model of SCI as well. Finally, the role of acrolein in SCI was further validated by the fact that acrolein injection into the spinal cord caused significant SCI-like tissue damage and motor deficits. Taken together, available evidence strongly suggests a critical causal role of acrolein in the pathogenesis of spinal cord trauma. Since acrolein has been linked to a variety of illness and conditions, we believe that acrolein-scavenging measures have the potential to be expanded significantly ensuring a broad impact on human health.	[Park, Jonghyuck; Zheng, Lingxing; Marquis, Andrew; Walls, Michael; Duerstock, Brad; Pond, Amber; Vega-Alvarez, Sasha; Shi, Riyi] Purdue Univ, Coll Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Park, Jonghyuck; Zheng, Lingxing; Duerstock, Brad; Wang, He; Ouyang, Zheng; Shi, Riyi] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA		Shi, RY (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@purdue.edu		Pond, Amber/0000-0002-2836-889X	Indiana State Department of Health [204200]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073636]; Indiana CTSI Collaboration in Biomedical Translational Research (CBR/CTR) Pilot Program Grant [RR025761]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073636] Funding Source: NIH RePORTER	This study was supported by the Indiana State Department of Health (Grant # 204200 to RS), National Institutes of Health (Grant # NS073636 to RS), and Indiana CTSI Collaboration in Biomedical Translational Research (CBR/CTR) Pilot Program Grant (Grant # RR025761 to RS). The authors thank Melissa Tully and Jessica Page for critical reading of the manuscript and Michel Schweinsberg for illustration drawing. There is not a conflict of interest for any of the authors.	ANDERSON DK, 1994, BRAIN RES, V637, P119, DOI 10.1016/0006-8993(94)91224-6; Barger SW, 2007, J NEUROCHEM, V101, P1205, DOI 10.1111/j.1471-4159.2007.04487.x; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Burcham PC, 2000, REDOX REP, V5, P47, DOI 10.1179/rer.2000.5.1.47; Burcham PC, 2004, MOL PHARMACOL, V65, P655, DOI 10.1124/mol.65.3.655; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; COLE RA, 1960, AM J PSYCHIAT, V117, P361, DOI 10.1176/ajp.117.4.361; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMEDIUK P, 1989, J NEUROSCI RES, V23, P95, DOI 10.1002/jnr.490230113; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Facchinetti F, 2007, AM J RESP CELL MOL, V37, P617, DOI 10.1165/rcmb.2007-0130OC; Feng ZH, 2006, P NATL ACAD SCI USA, V103, P15404, DOI 10.1073/pnas.0607031103; Fitch MT, 1999, J NEUROSCI, V19, P8182; GEORGE ER, 1995, AM SURGEON, V61, P659; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2008, J NEUROCHEM, V104, P708, DOI 10.1111/j.1471-4159.2007.05002.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Hesterberg TW, 2008, ENVIRON SCI TECHNOL, V42, P6437, DOI 10.1021/es071718i; Hulsebosch CE, 2008, EXP NEUROL, V214, P6, DOI 10.1016/j.expneurol.2008.07.016; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Kaminskas LM, 2004, J PHARMACOL EXP THER, V310, P1003, DOI 10.1124/jpet.104.067330; Kehrer JP, 2000, TOXICOL SCI, V57, P6, DOI 10.1093/toxsci/57.1.6; KHAN MA, 1953, BMJ-BRIT MED J, V1, P27, DOI 10.1136/bmj.1.4800.27; Leung G, 2011, NEUROSCIENCE, V173, P150, DOI 10.1016/j.neuroscience.2010.11.018; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Lovell MA, 2000, FREE RADICAL BIO MED, V29, P714, DOI 10.1016/S0891-5849(00)00346-4; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; Montine TJ, 2002, FREE RADICAL BIO MED, V33, P620, DOI 10.1016/S0891-5849(02)00807-9; Moretto N, 2009, AM J PHYSIOL-LUNG C, V296, pL839, DOI 10.1152/ajplung.90570.2008; MUDGE K, 1984, SPINE, V9, P253, DOI 10.1097/00007632-198404000-00005; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; Newcomer JW, 1999, NEUROPSYCHOPHARMACOL, V20, P106, DOI 10.1016/S0893-133X(98)00067-0; NURICK S, 1970, BRAIN, V93, P211, DOI 10.1093/brain/93.1.211; Park YS, 2008, ANN NY ACAD SCI, V1126, P185, DOI 10.1196/annals.1433.034; Peasley MA, 2003, J NEUROL SCI, V216, P23, DOI 10.1016/S0022-510X(03)00201-6; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; REECE PA, 1981, MED RES REV, V1, P73, DOI 10.1002/med.2610010105; Reier P., 1983, SPINAL CORD RECONSTR, P163; Rooney GE, 2009, J NEUROSURG-SPINE, V11, P432, DOI 10.3171/2009.4.SPINE08784; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schurch B, 1996, J NEUROL NEUROSUR PS, V60, P61, DOI 10.1136/jnnp.60.1.61; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R., 2006, APPL NEUROL, V2, P22; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; Shi YZ, 2011, J NEUROCHEM, V117, P554, DOI 10.1111/j.1471-4159.2011.07226.x; Shibuta S, 2006, BRIT J ANAESTH, V97, P517, DOI 10.1093/bja/ael192; Smith KJ, 1999, BRAIN PATHOL, V9, P69; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Wang H, 2011, ANAL CHEM, V83, P1197, DOI 10.1021/ac103150a; White FA, 2005, NAT REV DRUG DISCOV, V4, P834, DOI 10.1038/nrd1852; White FA, 2007, P NATL ACAD SCI USA, V104, P20151, DOI 10.1073/pnas.0709250104; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Zheng LX, 2013, J NEUROTRAUM, V30, P1334, DOI 10.1089/neu.2013.2888	68	33	34	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2014	129	2					339	349		10.1111/jnc.12628			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AE1GE	WOS:000333716700033	24286176	Green Accepted			2022-02-06	
J	DiTommaso, C; Hoffman, JM; Lucas, S; Dikmen, S; Temkin, N; Bell, KR				DiTommaso, Craig; Hoffman, Jeanne M.; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.			Medication Usage Patterns for Headache Treatment After Mild Traumatic Brain Injury	HEADACHE			English	Article						post-traumatic headache; mild traumatic brain injury; headache; concussion; migraine	POSTTRAUMATIC HEADACHES	ObjectiveTo describe patient self-report of headache treatment in the first year following mild traumatic brain injury (TBI). BackgroundAn understanding of appropriate management of symptoms after mild TBI is crucial for improving acute care and long-term outcomes. This is particularly true for post-traumatic headaches as recent studies suggest that headaches after mild TBI are common with multiple phenotypes. In addition, symptoms such as headache after mild TBI are often managed by primary care providers without specialty training, and often in medically underserved areas. Outside of previous opinion papers, few studies have guided the treatment or examined the effectiveness of the interventions for post-traumatic headache. MethodsOne hundred sixty-seven participants admitted to a level 1 trauma hospital with mild TBI who were prospectively enrolled and reported new or worse headache at 3, 6, or 12 months after injury. ResultsParticipants were primarily male (75%), white (75%), injured in vehicle crashes (62%), and had completed high school (83%). The majority of headaches met International Classification of Headache Disorders - 2nd edition criteria for migraine/probable migraine, followed by tension-type headache. Despite the diverse nature of headaches, more than 70% of those with headache at each time period used acetaminophen or a nonsteroidal anti-inflammatory drug for headache control. Only 8% of those with the migraine/probable migraine phenotype used triptans. Of those individuals who used medication, 26% of those with migraine/probable migraine phenotype and 70% of those with tension headache phenotype endorsed complete relief (vs partial or no relief) because of medication use. The majority of individuals with tension headache reported never taking medication. ConclusionsHeadaches after mild TBI are frequent and are not optimally treated. Results suggest that many individuals with mild TBI may be self-treating their headaches by utilizing over-the-counter pain relief medications. These medications, however, are only providing effective treatment for a minority of this population. Further research must be conducted to develop evidence-guided treatment and educate providers.	[DiTommaso, Craig; Hoffman, Jeanne M.; Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Lucas, Sylvia] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Lucas, Sylvia; Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA		DiTommaso, C (corresponding author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.	craig.ditommaso@gmail.com		Bell, Kathleen/0000-0002-0928-2046	Department of Education, National Institute on Disability and Rehabilitation Research [H133G090022]; NIDRR; Department of DefenseUnited States Department of Defense; Wadsworth Foundation; St. Jude Medical Inc.St. Jude Medical; BiogenIdecBiogen; Zogenix; MAP; AllerganAbbVieAllergan; GenzymeSanofi-AventisGenzyme Corporation; NovartisNovartis; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Dr. DiTommaso has no conflicts of interest to disclose. Dr. Hoffman receives research funding from NIDRR and Department of Defense. Dr. Lucas receives funding from NIDRR, Department of Defense, the Wadsworth Foundation, St. Jude Medical Inc., and BiogenIdec. She has received consulting fees or honoraria from Zogenix, MAP, Allergan, BiogenIdec, Genzyme, and Novartis. Dr. Dikmen receives research funding from NIDRR, Department of Defense, and NIH. Dr. Temkin receives research funding from NIDRR, Department of Defense, and NIH. Dr. Bell receives research funding from NIDRR and Department of Defense.; This study was funded by the Department of Education, National Institute on Disability and Rehabilitation Research, grant number H133G090022. The Department of Education provided funding, but had no role in the study design, data collection, or writing of the paper.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bigal M, 2009, HEADACHE, V49, P1028, DOI 10.1111/j.1526-4610.2009.01410.x; D'Amico D, 2011, NEUROL SCI, V32, pS181, DOI 10.1007/s10072-011-0528-1; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Erickson Jay C, 2010, Continuum (Minneap Minn), V16, P55, DOI 10.1212/01.CON.0000391453.37923.83; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lainez MJA, 2011, CURR PAIN HEADACHE R, V15, P467, DOI 10.1007/s11916-011-0220-4; Lerman B, 2011, J NEUROTRAUM, V28, pA16; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Lipton RB, 2012, HEADACHE, V53, P81; Lucas S, 2013, CEPHALALGIA; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; National Center for Injury Prevention and Control, 2008, WHAT IS TRAUM BRAIN; Seng EK, 2013, HEADACHE, V53, P1312, DOI 10.1111/head.12155; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Theeler BJ, 2012, CEPHALALGIA, V32, P589, DOI 10.1177/0333102412445220; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003	22	33	34	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAR	2014	54	3					511	519		10.1111/head.12254			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC0AL	WOS:000332156900009	24741687				2022-02-06	
J	Graham, JE; Granger, CV; Karmarkar, AM; Deutsch, A; Niewczyk, P; DiVita, MA; Ottenbacher, KJ				Graham, James E.; Granger, Carl V.; Karmarkar, Amol M.; Deutsch, Anne; Niewczyk, Paulette; DiVita, Margaret A.; Ottenbacher, Kenneth J.			The Uniform Data System for Medical Rehabilitation Report of Follow-up Information on Patients Discharged from Inpatient Rehabilitation Programs in 2002-2010	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Benchmark; Evaluation; Quality Improvement	FUNCTIONAL INDEPENDENCE MEASURE; STROKE	Objective The aim of this study was to present yearly aggregated summaries of rehabilitation outcomes at admission, discharge, and follow-up from a national sample of patients receiving inpatient medical rehabilitation for stroke, traumatic brain injury, lower extremity fracture, lower extremity joint replacement, traumatic spinal cord injury, or debility. Design This is an analysis of secondary data from more than 300 inpatient rehabilitation facilities in the United States that contributed inpatient and follow-up data to the Uniform Data System for Medical Rehabilitation during the period January 2002 through December 2010. Aggregate variables reported include demographic information, social situation, and functional status (Functional Independence Measure instrument ratings at admission, discharge, and follow-up). Follow-up data were obtained 80-180 days after discharge through telephone interviews by trained clinical staff. Results The final sample included 287,104 patients with follow-up information. The median time to follow-up was 95 days. Overall, more than 90% of the patients within each impairment group were living in the community at follow-up. Follow-up Functional Independence Measure total ratings were stable to slightly increased over time. Change scores (discharge to follow-up) increased in all six groups. The mean Functional Independence Measure gains from discharge to follow-up, as a percentage of mean gains from admission to discharge, varied by impairment category: 46% for spinal cord injury to 71% for lower extremity fracture. Locomotion yielded the lowest ratings at all three assessments within each of the six impairment groups. Conclusions The follow-up data from the national sample of patients discharged from inpatient rehabilitation indicate that gains in mean functional independence scores from both admission to discharge and discharge to follow-up gradually increased from 2002 to 2010. At follow-up, more than nine of ten patients in all six groups are living in the community.	[Graham, James E.; Karmarkar, Amol M.; Ottenbacher, Kenneth J.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Granger, Carl V.; Niewczyk, Paulette; DiVita, Margaret A.] Uniform Data Syst Med Rehabil, Buffalo, NY USA; [Deutsch, Anne] Rehabil Inst Chicago, Chicago, IL USA; [Deutsch, Anne] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Deutsch, Anne] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Deutsch, Anne] RTI Int, Washington, DC USA		Ottenbacher, KJ (corresponding author), Univ Texas Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.		Deutsch, Anne/B-7530-2017	Deutsch, Anne/0000-0003-2290-7757; DiVita, Margaret/0000-0002-4878-2959; Ottenbacher, Kenneth/0000-0001-5990-3982	Department of EducationUS Department of Education; National Institute on Disability and Rehabilitation Research [H133G080163, H133N060014]; National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24 HD065702]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024832] Funding Source: NIH RePORTER	Supported by grants from the Department of Education; the National Institute on Disability and Rehabilitation Research (H133G080163 [to K.J.O.] and H133N060014 [to A. D.]); and the National Institutes of Health, National Center for Medical Rehabilitation Research (R24 HD065702 [to K.J.O., J.E.G., A.M.K.]).	CARTER GM, 2002, EXECUTIVE SUMMARY AN; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1297, DOI 10.1016/j.apmr.2008.12.029; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; Galloway RV, 2013, AM J PHYS MED REHAB, V92, P14, DOI 10.1097/PHM.0b013e31827441bc; Granger CV, 2012, AM J PHYS MED REHAB, V91, P289, DOI 10.1097/PHM.0b013e31824ad2fd; Granger CV, 2011, AM J PHYS MED REHAB, V90, P177, DOI 10.1097/PHM.0b013e31820b18d7; Granger CV, 2010, AM J PHYS MED REHAB, V89, P781, DOI 10.1097/PHM.0b013e3181f1c83a; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Stineman MG, 1997, STROKE, V28, P550, DOI 10.1161/01.STR.28.3.550; US Department of Health and Human Services, 2009, FED REG, VB74, P151; WALKER AJ, 1995, FAM RELAT, V44, P402, DOI 10.2307/584996	14	33	35	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR	2014	93	3					231	244		10.1097/PHM.0b013e3182a92c58			14	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	AB3RH	WOS:000331707400005	24088780	Green Accepted			2022-02-06	
J	Li, N; Yang, Y; Glover, DP; Zhang, JY; Saraswati, M; Robertson, C; Pelled, G				Li, Nan; Yang, Ya; Glover, David P.; Zhang, Jiangyang; Saraswati, Manda; Robertson, Courtney; Pelled, Galit			Evidence for Impaired Plasticity after Traumatic Brain Injury in the Developing Brain	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; development; magnetic resonance imaging; plasticity; somatosensory cortex; magnetic resonance imaging	IMMATURE RAT; CHRONIC STROKE; SOMATOSENSORY CORTEX; CONTRALATERAL HAND; CORPUS-CALLOSUM; MOTOR RECOVERY; NERVE INJURY; DEAFFERENTATION; REORGANIZATION; ANESTHESIA	The robustness of plasticity mechanisms during brain development is essential for synaptic formation and has a beneficial outcome after sensory deprivation. However, the role of plasticity in recovery after acute brain injury in children has not been well defined. Traumatic brain injury (TBI) is the leading cause of death and disability among children, and long-term disability from pediatric TBI can be particularly devastating. We investigated the altered cortical plasticity 2-3 weeks after injury in a pediatric rat model of TBI. Significant decreases in neurophysiological responses across the depth of the noninjured, primary somatosensory cortex (S1) in TBI rats, compared to age-matched controls, were detected with electrophysiological measurements of multi-unit activity (86.4% decrease), local field potential (75.3% decrease), and functional magnetic resonance imaging (77.6% decrease). Because the corpus callosum is a clinically important white matter tract that was shown to be consistently involved in post-traumatic axonal injury, we investigated its anatomical and functional characteristics after TBI. Indeed, corpus callosum abnormalities in TBI rats were detected with diffusion tensor imaging (9.3% decrease in fractional anisotropy) and histopathological analysis (14% myelination volume decreases). Whole-cell patch clamp recordings further revealed that TBI results in significant decreases in spontaneous firing rate (57% decrease) and the potential to induce long-term potentiation in neurons located in layer V of the noninjured S1 by stimulation of the corpus callosum (82% decrease). The results suggest that post-TBI plasticity can translate into inappropriate neuronal connections and dramatic changes in the function of neuronal networks.	[Li, Nan; Yang, Ya; Glover, David P.; Pelled, Galit] FM Kirby Res Ctr Funct Brain Imaging, Kennedy Krieger Inst, Baltimore, MD USA; [Li, Nan; Yang, Ya; Zhang, Jiangyang; Pelled, Galit] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Saraswati, Manda; Robertson, Courtney] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Robertson, Courtney] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA		Pelled, G (corresponding author), Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, FM Kirby Ctr Funct Brain Imaging, Sch Med,Kennedy Krieger Inst,Div MR Res, 707 N Broadway, Baltimore, MD 21205 USA.	Pelled@kennedykrieger.org	Li, Nan/K-7767-2015	Li, Nan/0000-0002-4751-2252; Zhang, Jiangyang/0000-0003-4146-8163; Zhang, Jiangyang/0000-0003-0740-2662	Johns Hopkins Brain Science InstituteJohns Hopkins University; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072171]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072171] Funding Source: NIH RePORTER	This work was supported by Johns Hopkins Brain Science Institute and the National Institutes of Health/National Institute of Neurological Disorders and Stroke (grant no. R01NS072171).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Aggarwal M, 2010, MAGN RESON MED, V64, P249, DOI 10.1002/mrm.22426; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bjorkman A, 2005, SCAND J PLAST RECONS, V39, P234, DOI 10.1080/0284431051006493; Bjorkman A, 2005, NEUROREPORT, V16, P517; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Card JP, 2005, J NEUROTRAUM, V22, P989, DOI 10.1089/neu.2005.22.989; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; DURHAM D, 1984, J COMP NEUROL, V223, P424, DOI 10.1002/cne.902230308; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Floel A, 2004, ANN NEUROL, V56, P206, DOI 10.1002/ana.20170; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Han Y, 2013, NEUROREHAB NEURAL RE, V27, P664, DOI 10.1177/1545968313484811; Isaac JTR, 1996, J PHYSIOLOGY-PARIS, V90, P299, DOI 10.1016/S0928-4257(97)87901-6; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618, DOI 10.1152/jn.1979.42.2.618; Karl A, 2001, J NEUROSCI, V21, P3609, DOI 10.1523/JNEUROSCI.21-10-03609.2001; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Li N, 2011, P NATL ACAD SCI USA, V108, P8838, DOI 10.1073/pnas.1100815108; Pelled G, 2007, NEUROIMAGE, V37, P262, DOI 10.1016/j.neuroimage.2007.03.069; Pelled G, 2009, P NATL ACAD SCI USA, V106, P14114, DOI 10.1073/pnas.0903153106; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Rosen B, 2006, J HAND SURG-BRIT EUR, V31B, P126, DOI 10.1016/j.jhsb.2005.10.017; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Schaechter JD, 2006, BRAIN, V129, P2722, DOI 10.1093/brain/awl214; Schaechter JD, 2012, NEUROREHAB NEURAL RE, V26, P325, DOI 10.1177/1545968311421613; SIMONS DJ, 1992, EXP BRAIN RES, V91, P259; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; Voller B, 2006, ANN NEUROL, V59, P385, DOI 10.1002/ana.20689; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Werhahn KJ, 2002, BRAIN, V125, P1402, DOI 10.1093/brain/awf140; Werhahn KJ, 2003, ANN NEUROL, V54, P464, DOI 10.1002/ana.10686; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zhao FQ, 2008, NEUROIMAGE, V39, P248, DOI 10.1016/j.neuroimage.2007.07.063	59	33	34	1	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					395	403		10.1089/neu.2013.3059			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600012	24050267	Green Published			2022-02-06	
J	Bulstrode, H; Nicoll, JAR; Hudson, G; Chinnery, PF; Di Pietro, V; Belli, A				Bulstrode, Harry; Nicoll, James A. R.; Hudson, Gavin; Chinnery, Patrick F.; Di Pietro, Valentina; Belli, Antonio			Mitochondrial DNA and traumatic brain injury	ANNALS OF NEUROLOGY			English	Article							TEMPORAL WINDOW; POLYMORPHISMS; IMPACT; LONGEVITY; ALLELE; RISK; CLASSIFICATION; VULNERABILITY; DYSFUNCTION; CONCUSSIONS	Objective Traumatic brain injury (TBI) is a multifactorial pathology with great interindividual variability in response to injury and outcome. Mitochondria contain their own DNA (mtDNA) with genomic variants that have different physiological and pathological characteristics, including susceptibility to neurodegeneration. Given the central role of mitochondria in the pathophysiology of neurological injury, we hypothesized that its genomic variants may account for the variability in outcome following TBI. Methods We undertook an analysis of mitochondrial haplogroups in a large, well-characterized cohort of 1,094 TBI patients. A proportional odds model including age, brain computed tomography characteristics, injury severity, pupillary reactivity, mitochondrial haplogroups, and APOE was applied to Glasgow Outcome Score (GOS) data. Results mtDNA had a significant association with 6-month GOS (p = 0.008). Haplogroup K was significantly associated with favorable outcome (odds ratio = 1.64, 95% confidence interval = 1.08-2.51, p = 0.02). There was also a significant interaction between mitochondrial genome and age (p = 0.002), with a strong protective effect of both haplogroups T (p = 0.015) and K (p = 0.017) with advancing age. We also found a strong interaction between APOE and mitochondrial haplogroups (p = 0.001), indicating a protective effect of haplogroup K in carriers of the APOE epsilon 4 allele. Interpretation These findings reveal an interplay between mitochondrial DNA, pathophysiology of TBI, and aging. Haplogroups K and T, which share a common maternal ancestor, are shown as protective in TBI. The data also suggest that the APOE pathways interact with genetically regulated mitochondrial functions in the response to acute injury, as previously reported in Alzheimer disease. Ann Neurol 2014;75:186-195	[Bulstrode, Harry] UCL, Inst Canc, London, England; [Nicoll, James A. R.] Univ Southampton, Div Clin & Expt Sci, Southampton, Hants, England; [Hudson, Gavin; Chinnery, Patrick F.] Newcastle Univ, Wellcome Ctr Mitochondrial Res, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Di Pietro, Valentina; Belli, Antonio] Univ Birmingham, Div Neurotrauma & Neurodegenerat, Birmingham B15 2TT, W Midlands, England; [Belli, Antonio] Univ Hosp Birmingham, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England		Belli, A (corresponding author), Univ Birmingham, Div Neurotrauma & Neurodegenerat, Sch Clin & Expt Med, Coll Med & Dent Sci,Inst Biomed Res West, Birmingham B15 2TT, W Midlands, England.	a.belli@bham.ac.uk	Belli, Antonio/I-3799-2015; Hudson, Gavin/E-7117-2017; Nicoll, James/I-9253-2017	Belli, Antonio/0000-0002-3211-9933; Chinnery, Patrick/0000-0002-7065-6617; Di Pietro, Valentina/0000-0001-9430-4723; Nicoll, James/0000-0002-9444-7246; Hudson, Gavin/0000-0001-7210-2733; Bulstrode, Harry/0000-0002-3480-108X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9601296N]; National Institute for Health ResearchNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/K000608/1] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K000608/1] Funding Source: researchfish; Parkinson&quot;s UKParkinson&apos;s UK [F-1202] Funding Source: researchfish	The APOE study was funded by the Medical Research Council (G9601296N). A.B. is funded by the National Institute for Health Research.	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463; Conley YP, 2014, J NEUROTRAUM, V31, P34, DOI 10.1089/neu.2013.2855; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gomez-Duran A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246; Jofre-Monseny L, 2008, MOL NUTR FOOD RES, V52, P131, DOI 10.1002/mnfr.200700322; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; McDonald RPA, 1999, NEUROREPORT, V10, P1875, DOI 10.1097/00001756-199906230-00014; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417; Rose G, 2001, EUR J HUM GENET, V9, P701, DOI 10.1038/sj.ejhg.5200703; Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Torroni A, 1996, GENETICS, V144, P1835; Tranah GJ, 2011, MITOCHONDRION, V11, P855, DOI 10.1016/j.mito.2011.04.005; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wallace DC, 2013, J CLIN INVEST, V123, P1405, DOI 10.1172/JCI61398; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	40	33	34	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	FEB	2014	75	2					186	195		10.1002/ana.24116			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AD1PD	WOS:000333005000006	24523223	Green Published, hybrid, Green Accepted			2022-02-06	
J	Kainerstorfer, JM; Sassaroli, A; Hallacoglu, B; Pierro, ML; Fantini, S				Kainerstorfer, Jana M.; Sassaroli, Angelo; Hallacoglu, Bertan; Pierro, Michele L.; Fantini, Sergio			Practical Steps for Applying a New Dynamic Model to Near-Infrared Spectroscopy Measurements of Hemodynamic Oscillations and Transient Changes: Implications for Cerebrovascular and Functional Brain Studies	ACADEMIC RADIOLOGY			English	Article						Hemodynamic model; near-infrared spectroscopy; cerebral autoregulation; cerebral blood flow; metabolic rate of oxygen	CONSUMPTION FOLLOWING ACTIVATION; BLOOD-FLOW; CEREBRAL AUTOREGULATION; CAPILLARY RECRUITMENT; BOLD SIGNAL; OXYGEN; VOLUME; CORTEX; TIME; DIFFUSION	Rationale and Objectives: Perturbations in cerebral blood volume (CBV), blood flow (CBF), and metabolic rate of oxygen (CMRO2) lead to associated changes in tissue concentrations of oxy- and deoxy-hemoglobin (Delta O and Delta D), which can be measured by near-infrared spectroscopy (NIRS). A novel hemodynamic model has been introduced to relate physiological perturbations and measured quantities. We seek to use this model to determine functional traces of cbv(t) and cbf(t) - cmro(2)(t) from time-varying NIRS data, and cerebrovascular physiological parameters from oscillatory NIRS data (lowercase letters denote the relative changes in CBV, CBF, and CMRO2 with respect to baseline). Such a practical implementation of a quantitative hemodynamic model is an important step toward the clinical translation of NIRS. Materials and Methods: In the time domain, we have simulated O(t) and D(t) traces induced by cerebral activation. In the frequency domain, we have performed a new analysis of frequency-resolved measurements of cerebral hemodynamic oscillations during a paced breathing paradigm. Results: We have demonstrated that cbv(t) and cbf(t) - cmro(2)(t) can be reliably obtained from O(t) and D(t) using the model, and that the functional NIRS signals are delayed with respect to cbf(t) - cmro(2)(t) as a result of the blood transit time in the microvasculature. In the frequency domain, we have identified physiological parameters (e.g., blood transit time, cutoff frequency of autoregulation) that can be measured by frequency-resolved measurements of hemodynamic oscillations. Conclusions: The ability to perform noninvasive measurements of cerebrovascular parameters has far-reaching clinical implications. Functional brain studies rely on measurements of CBV, CBF, and CMRO2, whereas the diagnosis and assessment of neurovascular disorders, traumatic brain injury, and stroke would benefit from measurements of local cerebral hemodynamics and autoregulation.	[Kainerstorfer, Jana M.; Sassaroli, Angelo; Hallacoglu, Bertan; Pierro, Michele L.; Fantini, Sergio] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA		Kainerstorfer, JM (corresponding author), Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA.	jana.kainerstorfer@tufts.edu			National Science FoundationNational Science Foundation (NSF) [IIS-1065154]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA154774]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA154774] Funding Source: NIH RePORTER	This research is supported by the National Science Foundation (Award No. IIS-1065154) and National Institutes of Health (Grant no. R01-CA154774). Drs. Kainstorfer and Sassaroli contributed equally to the work.	Aaslid R, 2007, STROKE, V38, P1465, DOI 10.1161/STROKEAHA.106.473462; Baumgartl H., 1983, POLAROGRAPHIC OXYGEN; Blaber AP, 1997, STROKE, V28, P1686, DOI 10.1161/01.STR.28.9.1686; Buxton RB, 2012, NEUROIMAGE, V62, P953, DOI 10.1016/j.neuroimage.2012.01.012; Cassot F, 2006, MICROCIRCULATION, V13, P1, DOI 10.1080/10739680500383407; CHEN JL, 1994, MICROVASC RES, V48, P190, DOI 10.1006/mvre.1994.1049; Cheng R, 2012, NEUROIMAGE, V62, P1445, DOI 10.1016/j.neuroimage.2012.05.069; Choi J, 2004, J BIOMED OPT, V9, P221, DOI 10.1117/1.1628242; Claassen JAHR, 2009, J APPL PHYSIOL, V106, P153, DOI 10.1152/japplphysiol.90822.2008; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Dunn AK, 2005, NEUROIMAGE, V27, P279, DOI 10.1016/j.neuroimage.2005.04.024; Fantini S, 2002, PHYS MED BIOL, V47, pN249, DOI 10.1088/0031-9155/47/18/402; Fantini S, 2014, PHYSIOL MEAS, P35; Fantini S, 2014, NEUROIMAGE, V85, P202, DOI 10.1016/j.neuroimage.2013.03.065; Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049; Friston KJ, 1998, MAGNET RESON MED, V39, P41, DOI 10.1002/mrm.1910390109; Gagnon L, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2982524; Gatto R, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2804705; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; GOBEL U, 1989, J CEREBR BLOOD F MET, V9, P491, DOI 10.1038/jcbfm.1989.72; Gommer ED, 2010, MED BIOL ENG COMPUT, V48, P1243, DOI 10.1007/s11517-010-0706-y; Goutte C, 2000, IEEE T MED IMAGING, V19, P1188, DOI 10.1109/42.897811; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; Hallacoglu B, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.8.081406; Hillman EMC, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2789693; Jones M, 2001, NEUROIMAGE, V13, P1002, DOI 10.1006/nimg.2001.0808; Kasischke KA, 2011, J CEREBR BLOOD F MET, V31, P68, DOI 10.1038/jcbfm.2010.158; Kida I, 2007, J CEREBR BLOOD F MET, V27, P690, DOI 10.1038/sj.jcbfm.9600409; KUSCHINSKY W, 1992, CEREBROVAS BRAIN MET, V4, P261; Leff DR, 2011, NEUROIMAGE, V54, P2922, DOI 10.1016/j.neuroimage.2010.10.058; Leung TS, 2009, PHYSIOL MEAS, V30, P1, DOI 10.1088/0967-3334/30/1/001; Lindquist MA, 2007, HUM BRAIN MAPP, V28, P764, DOI 10.1002/hbm.20310; Lindquist MA, 2009, NEUROIMAGE, V45, pS187, DOI 10.1016/j.neuroimage.2008.10.065; Mandeville JB, 1999, MAGN RESON MED, V42, P944, DOI 10.1002/(SICI)1522-2594(199911)42:5<944::AID-MRM15>3.0.CO;2-W; Masamoto K, 2004, BRAIN RES, V995, P66, DOI 10.1016/j.brainres.2003.09.055; Masamoto K, 2007, J APPL PHYSIOL, V103, P1352, DOI 10.1152/japplphysiol.01433.2006; Mayhew J, 2001, NEUROIMAGE, V13, P975, DOI 10.1006/nimg.2001.0807; Mayhew J, 2001, NEUROIMAGE, V13, P540, DOI 10.1006/nimg.2001.0753; Mayhew J, 2000, NEUROIMAGE, V12, P664, DOI 10.1006/nimg.2000.0656; Medvedev AV, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3533266; Mintun MA, 2001, P NATL ACAD SCI USA, V98, P6859, DOI 10.1073/pnas.111164398; Ohmae E, 2006, NEUROIMAGE, V29, P697, DOI 10.1016/j.neuroimage.2005.08.008; Pardridge WM, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-7; Pierro ML, 2014, NEUROIMAGE, V85, P222, DOI 10.1016/j.neuroimage.2013.03.037; Pierro ML, 2013, J BIOMED OPT; Pries AR, 2008, HANDBOOK OF PHYSIOLOGY: MICROCIRCULATION, 2ND EDITION, P3; Quaresima V, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1851512; Reinhard M, 2006, J NEUROL SCI, V250, P103, DOI 10.1016/j.jns.2006.07.011; Roche-Labarbe N, 2014, NEUROIMAGE, V85, P279, DOI 10.1016/j.neuroimage.2013.01.035; Sassaroli A, 2006, NEUROIMAGE, V33, P505, DOI 10.1016/j.neuroimage.2006.07.006; VILLRINGER A, 1994, CIRC RES, V75, P55, DOI 10.1161/01.RES.75.1.55; Villringer A, 2012, NEUROIMAGE, V62, P995, DOI 10.1016/j.neuroimage.2012.01.113; Yucel MA, 2012, NEUROIMAGE, V61, P1268, DOI 10.1016/j.neuroimage.2012.04.036; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zoccoli G, 1996, J CEREBR BLOOD F MET, V16, P1312, DOI 10.1097/00004647-199611000-00028	55	33	35	2	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	FEB	2014	21	2			SI		185	196		10.1016/j.acra.2013.10.012			12	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	298PH	WOS:000330336200008	24439332	Green Accepted			2022-02-06	
J	Liao, CC; Chou, YC; Yeh, CC; Hu, CJ; Chiu, WT; Chen, TL				Liao, Chien-Chang; Chou, Yi-Chun; Yeh, Chun-Chieh; Hu, Chaur-Jong; Chiu, Wen-Ta; Chen, Ta-Liang			Stroke Risk and Outcomes in Patients With Traumatic Brain Injury: 2 Nationwide Studies	MAYO CLINIC PROCEEDINGS			English	Article							POSTOPERATIVE ADVERSE OUTCOMES; HEAD-INJURY; SURGICAL-PATIENTS; POPULATION; SCHIZOPHRENIA; MORTALITY; SEVERITY; EPILEPSY; REHABILITATION; COUNTRIES	Objective: To investigate whether patients with traumatic brain injury (TBI) have an increased risk of stroke or poststroke mortality. Participants and Methods: Using Taiwan's National Health Insurance Research Database, we conducted a retrospective cohort study of 30,165 patients with new TBI and 120,660 personswithout TBI between January 1, 2000, and December 31, 2004. The risk of stroke was compared between 2 cohorts throughDecember 31, 2008. To investigate the association between in-hospital mortality after stroke and history of TBI, we conducted a casecontrol study of 7751 patients with newly diagnosed stroke between January 1, 2005, and December 31, 2008. Results: The TBI cohort had an increased stroke risk (hazard ratio [HR], 1.98; 95% CI, 1.86-2.11). Among patients with stroke, those with a history of TBI had a higher risk of poststroke mortality compared with those without TBI (odds ratio, 1.57; 95% CI, 1.13-2.19). In the TBI cohort, factors associated with stroke were history of TBI hospitalization (HR, 3.14; 95% CI, 2.77-3.56), emergency care for TBI (HR, 3.37; 95% CI, 2.88-3.95), brain hemorrhage (HR, 2.69; 95% CI, 2.43-2.99), skull fracture (HR, 3.00; 95% CI, 2.423.71), low income (HR, 2.65; 95% CI, 2.16-3.25), and high medical expenditure for TBI care (HR, 2.26; 95% CI, 2.09-2.43). The severity of TBI was also correlated with poststroke mortality. Conclusions: Traumatic brain injury was associated with risk of stroke and poststroke mortality. The relationship between TBI and poststrokemortality does not seem to transcend all age groups. This research shows the importance of prevention, early recognition, and treatment of stroke in this vulnerable population. (C) 2014 Mayo Foundation for Medical Education and Research	[Liao, Chien-Chang; Chen, Ta-Liang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei 11031, Taiwan; [Liao, Chien-Chang; Chen, Ta-Liang] Taipei Med Univ Hosp, Ctr Hlth Policy Res, Taipei 11031, Taiwan; [Liao, Chien-Chang; Hu, Chaur-Jong; Chen, Ta-Liang] Taipei Med Univ, Sch Med, Taipei, Taiwan; [Hu, Chaur-Jong] Taipei Med Univ, Dept Neurol, Shuang Ho Hosp, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan; [Chou, Yi-Chun] China Med Univ Hosp, Dept Phys Med & Rehabil, Taichung, Taiwan; [Yeh, Chun-Chieh] China Med Univ, Sch Med, Grad Inst Clin Med Sci, Taichung, Taiwan		Chen, TL (corresponding author), Taipei Med Univ Hosp, Dept Anesthesiol, 252 Wuxing St, Taipei 11031, Taiwan.	tlc@tmu.edu.tw	Yeh, Chun Chieh/Y-3304-2019; Yeh, Chun Chieh/I-4893-2019	Yeh, Chun Chieh/0000-0001-6753-7564			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Chang CC, 2012, EPILEPSIA, V53, P987, DOI 10.1111/j.1528-1167.2012.03448.x; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chou YC, 2012, J REHABIL MED, V44, P319, DOI 10.2340/16501977-0935; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Engberg AW, 2007, J HEAD TRAUMA REHAB, V22, P221, DOI 10.1097/01.HTR.0000281837.62226.54; Faul M, 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2007, LANCET NEUROL, V6, P94, DOI 10.1016/S1474-4422(07)70007-8; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hu CJ, 2012, WORLD J SURG, V36, P2051, DOI 10.1007/s00268-012-1609-x; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Kang JH, 2011, PSYCHOSOM MED, V73, P106, DOI 10.1097/PSY.0b013e3181fdc2c9; Kurth T, 2012, LANCET NEUROL, V11, P92, DOI 10.1016/S1474-4422(11)70266-6; Liao CC, 2012, J TRAUMA ACUTE CARE, V73, P1327, DOI 10.1097/TA.0b013e31826fc87f; Liao CC, 2012, J NEUROL NEUROSUR PS, V83, P1186, DOI 10.1136/jnnp-2012-302337; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Lin HC, 2008, SCHIZOPHR RES, V101, P234, DOI 10.1016/j.schres.2007.12.485; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Nishi N, 2007, SOC SCI MED, V65, P822, DOI 10.1016/j.socscimed.2007.04.013; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shih CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032540; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Tsai KY, 2012, SCHIZOPHR RES, V138, P41, DOI 10.1016/j.schres.2012.02.013; Wang IK, 2011, STROKE, V42, P716, DOI 10.1161/STROKEAHA.110.594523; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	42	33	34	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-6196	1942-5546		MAYO CLIN PROC	Mayo Clin. Proc.	FEB	2014	89	2					163	172		10.1016/j.mayocp.2013.09.019			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	302DJ	WOS:000330581500010	24485130				2022-02-06	
J	Park, KJ; Park, E; Liu, E; Baker, AJ				Park, Katya J.; Park, Eugene; Liu, Elaine; Baker, Andrew J.			Bone marrow-derived endothelial progenitor cells protect postischemic axons after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						endothelial progenitor cell; fluid percussion injury; ischemia; traumatic brain injury; vasculature; white matter injury	FOCAL CEREBRAL-ISCHEMIA; CYTOCHEMICAL EVIDENCE; CALCIUM INFLUX; CD34(+) CELLS; NERVE-FIBERS; OPTIC-NERVE; ANGIOGENESIS; STROKE; PROTEOGLYCANS; EXPRESSION	White matter sparing after traumatic brain injury (TBI) is an important predictor of survival and outcome. Blood vessels and axons are intimately associated anatomically and developmentally. Neural input is required for appropriate vascular patterning, and vascular signaling is important for neuron development and axon growth. Owing to this codependence between endothelial cells and axons during development and the contribution of endothelial progenitor cells (EPCs) in ischemic injury, we hypothesized that EPCs are important in axonal survival after TBI. We examined the effects of allogenic-cultured EPCs on white matter protection and microvascular maintenance after midline fluid percussion injury in adult Sprague-Dawley rats. We used two in vitro models of injury, mechanical stretch and oxygen-glucose deprivation (OGD), to examine the effects of EPCs on the mechanical and ischemic components of brain trauma, respectively. Our results indicate that EPCs improve the white matter integrity and decrease capillary breakdown after injury. Cultured cortical neurons exposed to OGD had less axon degeneration when treated with EPC-conditioned media, whereas no effect was seen in axons injured by mechanical stretch. The results indicate that EPCs are important for the protection of the white matter after trauma and represent a potential avenue for therapy.	[Park, Katya J.; Park, Eugene; Liu, Elaine; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] St Michaels Hosp, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Interdepartmental Div Crit Care, Toronto, ON, Canada		Park, E (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	parke@smh.ca			Ministry of Economic Development and Innovation, Government of Ontario	This study was funded by the Ministry of Economic Development and Innovation, Government of Ontario.	Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burlacu A, 2013, STEM CELLS DEV, V22, P643, DOI 10.1089/scd.2012.0273; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Chen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050105; Chen X, 2013, ACTA RADIOL, V54, P313, DOI 10.1258/ar.2012.120605; Di Santo S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005643; Fan Y, ANN NEUROL, V67, P488; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; He TR, 2004, STROKE, V35, P2378, DOI 10.1161/01.STR.0000141893.33677.5d; He XY, 2011, CYTOTHERAPY, V13, P46, DOI 10.3109/14653249.2010.510505; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; JOHANSSON S, 1985, BIOCHEM J, V232, P161, DOI 10.1042/bj2320161; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Joyce N, 2010, REGEN MED, V5, P933, DOI 10.2217/RME.10.72; KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x; Kuruvilla R, 2004, CELL, V118, P243, DOI 10.1016/j.cell.2004.06.021; Ladhoff J, 2010, CARDIOVASC RES, V88, P121, DOI 10.1093/cvr/cvq109; Lee AF, 2004, J NEUROSCI, V24, P9174, DOI 10.1523/JNEUROSCI.1588-04.2004; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mielke JG, 2005, J NEUROCHEM, V92, P103, DOI 10.1111/j.1471-4159.2004.02841.x; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Resch T, 2012, STEM CELL REV REP, V8, P926, DOI 10.1007/s12015-011-9332-9; Siddiq I, 2012, J NEUROTRAUM, V29, P2647, DOI 10.1089/neu.2012.2444; Siebert JR, 2011, J NEUROCHEM, V119, P176, DOI 10.1111/j.1471-4159.2011.07370.x; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Urbich C, 2004, TRENDS CARDIOVAS MED, V14, P318, DOI 10.1016/j.tcm.2004.10.001; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	40	33	33	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2014	34	2					357	366		10.1038/jcbfm.2013.216			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	304LK	WOS:000330748200022	24301295	Green Published, Bronze			2022-02-06	
J	Bruce, J; Echemendia, R; Meeuwisse, W; Comper, P; Sisco, A				Bruce, Jared; Echemendia, Ruben; Meeuwisse, Willem; Comper, Paul; Sisco, Amber			1 year test-retest reliability of ImPACT in professional ice hockey players	CLINICAL NEUROPSYCHOLOGIST			English	Article						Concussion; Neuropsychology; Mild traumatic brain injury; Hockey; Reliability	SPORTS-RELATED CONCUSSION; PERFORMANCE; MANAGEMENT; STATEMENT; UTILITY; INJURY	The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery is widely used to assess neurocognitive outcomes following sports-related concussion. The purpose of this study was to examine the 1 year test-retest reliability of ImPACT in a multilingual sample of professional hockey players. A total of 305 professional hockey players were tested 1 year apart using ImPACT. Reliable change confidence intervals were calculated and test-retest reliability was measured using Pearson and Intraclass correlation coefficients. Results indicated that the 1-year test-retest reliabilities for the Visual Motor and Reaction Time Composites ranged from low to high (.52 to .81). In contrast, 1-year test-retest reliabilities for the Verbal and Visual Memory Composites were low (.22 to .58). The 1-year test-retest results provided mixed support for the use of Visual Motor and Reaction Time Composites in select samples; in contrast, the Verbal and Visual Memory Composites may not be sensitive to clinical change.	[Bruce, Jared; Echemendia, Ruben; Sisco, Amber] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Meeuwisse, Willem] Univ Calgary, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Comper, Paul] Univ Toronto, Dept Kinesiol & Phys Educ, Toronto, ON, Canada; [Echemendia, Ruben] Psychol & Neurobehav Associates, State Coll, PA 16801 USA		Echemendia, R (corresponding author), Psychol & Neurobehav Associates, 204 East Calder Way,Ste 205, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Andrews G, 1994, MEASUREMENT CONSUMER; Baumgatner T., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; BURLINGAME GM, 1995, J MENT HEALTH ADMIN, V22, P226, DOI 10.1007/BF02521118; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Spreen O., 2006, COMPENDIUM NEUROPSYC; Yi JY, 2013, CURR SPORT MED REP, V12, P28, DOI 10.1249/JSR.0b013e31827ec9e3; Ziegler M, 2009, PSYCHOL SPORT EXERC, V10, P344, DOI 10.1016/j.psychsport.2008.12.004	38	33	33	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					14	25		10.1080/13854046.2013.866272			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800002	24345194				2022-02-06	
J	Bashem, JR; Rapport, LJ; Miller, JB; Hanks, RA; Axelrod, BN; Millis, SR				Bashem, Jesse R.; Rapport, Lisa J.; Miller, Justin B.; Hanks, Robin A.; Axelrod, Bradley N.; Millis, Scott R.			Comparisons of Five Performance Validity Indices in Bona Fide and Simulated Traumatic Brain Injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Assessment; Performance validity; Traumatic brain injury; Malingering; Sensitivity; Specificity; Diagnostic classification accuracy; ROC curve; Bayesian information criterion	SYMPTOM VALIDITY; NEUROPSYCHOLOGICAL TESTS; HEAD-INJURY; SCORES; EXAGGERATION; INDICATORS; SEVERITY; FAILURE; NUMBER; INTACT	A number of performance validity tests (PVTs) are used to assess memory complaints associated with traumatic brain injury (TBI); however, few studies examine the concordance and predictive accuracy of multiple PVTs, specifically in the context of combined models in known-group designs. The present study compared five widely used PVTs: the Test of Memory Malingering (TOMM), Medical Symptom Validity Test (MSVT), Reliable Digit Span (RDS), Word Choice Test (WCT), and California Verbal Learning Test - Forced Choice (CVLT-FC). Participants were 51 adults with bona fide moderate to severe TBI and 58 demographically comparable healthy adults coached to simulate memory impairment. Classification accuracy of individual PVTs was evaluated using logistic regression and receiver operating characteristic (ROC) curves, examining both the dichotomous cutting scores as recommended by the test publishers and continuous scores for the measures. Results demonstrated nearly equivalent discrimination ability of the TOMM, MSVT, and CVLT-FC as individual predictors, all of which markedly outperformed the WCT and RDS. Models of combined PVTs were examined using Bayesian information criterion statistics, with results demonstrating that diagnostic accuracy showed only small to modest growth when the number of tests was increased beyond two. Considering the clinical and pragmatic issues in deriving a parsimonious assessment battery, these findings suggest that using the TOMM and CVLT in conjunction or the MSVT and CVLT in conjunction maximized predictive accuracy as compared to a single index or an assortment of these widely used measures.	[Bashem, Jesse R.; Rapport, Lisa J.; Miller, Justin B.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Sch Med, Detroit, MI 48202 USA; [Axelrod, Bradley N.] John D Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	rapport@wayne.edu		Miller, Justin B./0000-0002-4439-6604; Rapport, Lisa/0000-0001-8014-9523	Wayne State University; Del Harder Foundation; National Institute on Disability and Rehabilitation Research [H133A080044]	This study was supported by grants from Wayne State University (Thesis and Dissertation Grants to Bashem and Miller under the direction of Rapport), the Del Harder Foundation (Miller, Rapport & Hanks), and the National Institute on Disability and Rehabilitation Research (H133A080044).	Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; BINDER LM, 1994, ARCH CLIN NEUROPSYCH, V9, P111; Boone K.B., 2007, ASSESSMENT FEIGNED C; Brennan A, 2009, CLIN NEUROPSYCHOL, V23, P314, DOI 10.1080/13854040802054151; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis D.C., 2000, CALIFORNIA VERBAL LE; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Green P., 2005, MED SYMPTOM VALIDITY; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hunsley J, 2003, PSYCHOL ASSESSMENT, V15, P446, DOI 10.1037/1040-3590.15.4.446; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Larrabee, 2007, ASSESSMENT MALINGERE, P334; Larrabee G. J., 2014, ARCH CLIN NEUROPSYCH; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Lemeshow S, 2000, APPL LOGISTIC REGRES; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Millis SR, 2009, J NEUROTRAUM, V26, P2409, DOI 10.1089/neu.2008.0530; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Pearson Education Inc., 2008, WECHSL MEM SCAL; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; ROGERS R, 1988, CLIN ASSESSMENT MALI; Russeler J, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-37; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J.A., 2007, ASSESSMENT MALINGERE, P287; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; The Psychological Corporation, 2001, WECHSLER TEST ADULT; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682	63	33	33	1	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	5					851	875		10.1080/13854046.2014.927927			25	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AP4MM	WOS:000342051100011	24983387				2022-02-06	
J	Forslund, MV; Arango-Lasprilla, JC; Roe, C; Perrin, PB; Sigurdardottir, S; Andelic, N				Forslund, Marit V.; Arango-Lasprilla, Juan C.; Roe, Cecilie; Perrin, Paul B.; Sigurdardottir, Solrun; Andelic, Nada			Multi-level modelling of employment probability trajectories and employment stability at 1, 2 and 5 years after traumatic brain injury	BRAIN INJURY			English	Article						Employment trajectories; job stability; prospective study; return to work; traumatic brain injury	RETURN; WORK; PREDICTION; DISABILITY; MODERATE	Primary objectives: To examine trajectories of employment probability and stability over the first 5 years after traumatic brain injury (TBI) by using multi-level modelling and multinomial logistic regressions. Research design: A longitudinal cohort study. Methods and procedures: One hundred and five individuals with moderate-to-severe TBI who had been admitted to the Trauma Referral Centre for the Southeast region of Norway were followed up at 1, 2 and 5 years after the injury. Main outcomes and results: Employment status was dichotomized into employed and unemployed, while employment stability was categorized into stably employed, unstably employed and unemployed at 1, 2 and 5 years after injury. Being single, unemployment prior to injury, blue collar occupation, lower Glasgow Coma Scale (GCS) score at hospital admission and greater length of post-traumatic amnesia (PTA) were significantly associated with being unemployed at 1, 2 and 5 years post-injury. Further, younger patients, those with a lower GCS, greater length of PTA and greater length of hospital stay were negatively associated with employment stability. Conclusions: It could be wise to target patient population with these demographic and injury characteristics for more extensive follow-ups and vocational rehabilitation to help improve employment outcomes following injury.	[Forslund, Marit V.; Roe, Cecilie; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Forslund, Marit V.; Roe, Cecilie] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Arango-Lasprilla, Juan C.] Univ Deusto, IKERBASQUE Basque Fdn Sci, Bilbao, Spain; [Perrin, Paul B.] Virginia Commonwealth Univ, Richmond, VA USA; [Sigurdardottir, Solrun; Andelic, Nada] Univ Oslo, Fac Med, CHARM Res Ctr Habilitat & Rehabil Models & Serv, Inst Hlth & Soc, Oslo, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp Trust, Akershus, Norway		Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway.	nadand@ous-hf.no	Perrin, Paul/L-5373-2015	Perrin, Paul/0000-0003-2070-215X; Andelic, Nada/0000-0002-3719-4406			Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Bjorkdahl A, 2010, BRAIN INJURY, V24, P1061, DOI 10.3109/02699052.2010.494588; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Fleming J, 1999, BRAIN INJURY, V13, P417; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Johnson R, 1987, Int Disabil Stud, V9, P49; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; TEASDALE G, 1974, LANCET, V2, P81; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335	28	33	33	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					980	986		10.3109/02699052.2014.888770			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600013	24655118				2022-02-06	
J	Gouello, G; Hamel, O; Asehnoune, K; Bord, E; Robert, R; Buffenoir, K				Gouello, Gaetane; Hamel, Olivier; Asehnoune, Karim; Bord, Eric; Robert, Roger; Buffenoir, Kevin			Study of the Long-Term Results of Decompressive Craniectomy after Severe Traumatic Brain Injury Based on a Series of 60 Consecutive Cases	SCIENTIFIC WORLD JOURNAL			English	Article							SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; COMPLICATIONS; CRANIOTOMY; EXPERIENCE; ICP	Background. Decompressive craniectomy can be proposed in the management of severe traumatic brain injury. Current studies report mixed results, preventing any clear conclusions on the place of decompressive craniectomy in traumatology. Methods. The objective of this retrospective study was to evaluate the results of all decompressive craniectomies performed between 2005 and 2011 for refractory intracranial hypertension after severe traumatic brain injury. Sixty patients were included. Clinical parameters (Glasgow scale, pupillary examination) and radiological findings (Marshall CT scale) were analysed. Complications, clinical outcome, and early and long-term Glasgow Outcome Scale (GOS) were evaluated after surgery. Finally, the predictive value of preoperative parameters to guide the clinician's decision to perform craniectomy was studied. Results. Craniectomy was unilateral in 58 cases and the mean bone flap area was 100 cm(2). Surgical complications were observed in 6.7% of cases. Mean followup was 30 months and a favourable outcome was obtained in 50% of cases. The initial Glasgow Scale was the only statistically significant predictive factor for long-term outcome. Conclusion. Despite the discordant results in the literature, this study demonstrates that decompressive craniectomy is useful for the management of refractory intracranial hypertension after severe traumatic brain injury.	[Gouello, Gaetane; Hamel, Olivier; Bord, Eric; Robert, Roger; Buffenoir, Kevin] CHU Nantes, Serv Neurotraumatol & Neurochirurg, F-44093 Nantes, France; [Asehnoune, Karim] CHU Nantes, Serv Anesthesie Reanimat Chirurg, F-44093 Nantes, France; [Buffenoir, Kevin] CHU Nantes, INSERM EA3826, F-44093 Nantes, France		Buffenoir, K (corresponding author), CHU Nantes, Serv Neurotraumatol & Neurochirurg, F-44093 Nantes, France.	kevin.buffenoirbillet@chu-nantes.fr	Buffenoir, Kevin/ABD-9003-2020				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bao YH, 2010, J NEUROTRAUM, V27, P341, DOI 10.1089/neu.2009.1040; Bouvier D, 2012, ANN BIOL CLIN-PARIS, V70, P269, DOI 10.1684/abc.2012.0701; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1996, J NEUROTRAUM, V13, P685; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Ecker RD, 2011, J NEUROSURG, V115, P124, DOI 10.3171/2011.2.JNS101490; Faleiro RM, 2008, ARQ NEURO-PSIQUIAT, V66, P369, DOI 10.1590/S0004-282X2008000300017; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kocher T., 1901, HIRNERSCHUTTERUNG HI, V3, P262; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schneider GH, 2002, ACT NEUR S, V81, P77; Tayfur V, 2010, J CRANIOFAC SURG, V21, P1945, DOI 10.1097/SCS.0b013e3181f4ee6a; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timmons SD, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Voelbel GT, 2012, NEUROREHABILITATION, V31, P281, DOI 10.3233/NRE-2012-0796; Wen L, 2011, BRAIN INJURY, V25, P1318, DOI 10.3109/02699052.2011.608214; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	32	33	33	0	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1537-744X			SCI WORLD J	Sci. World J.		2014									207585	10.1155/2014/207585			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC5ER	WOS:000332544300001	24719566	gold, Green Published, Green Submitted			2022-02-06	
J	Shaklai, S; Peretz, R; Spasser, R; Simantov, M; Groswasser, Z				Shaklai, Sharon; Peretz, Relly; Spasser, Raluca; Simantov, Maya; Groswasser, Zeev			Long-term functional outcome after moderate-to-severe paediatric traumatic brain injury	BRAIN INJURY			English	Article						Childhood; educational system; moderate traumatic brain injury (TBI); prognostic factors; severe TBI; work	CLOSED-HEAD-INJURY; CHILDREN; RECOVERY; REHABILITATION; RETURN; WORK; PREDICTORS; AGE	Background: Long-term follow-up studies after severe and moderate pediatric traumatic brain injury (TBI) are not common and inconclusive. Most studies focused on neurobehavioural sequelae, less data is reported about age appropriate function. Different prognostic factors were noted over past decades. Methods: A prospective historical study describing the functional long-term outcome after childhood moderate and severe TBI was conducted. Seventy-seven children who suffered either severe or moderate TBI were followed for an average of ten years and clinical functional outcome was recorded. Factors influencing prognosis were investigated. Results: All children but six were integrated into educational systems after discharge from rehabilitation settings (department and day-care); 61% of children who suffered severe-moderate TBI were able to function within their normative age peers. Positive outcome predictors were Glasgow Coma Scale (GCS) >5, length of unconsciousness (LOC) <11 days, Functional Independence Measure (FIM) and Intelligence Quotient (IQ) at discharge from rehabilitation, length of acute hospitalization and rehabilitation. Negative outcome predictors were vegetative state at admission to rehabilitation and associated anoxic brain injury. Conclusions: Guarded optimistic functional outcome can be expected after severe or moderate childhood TBI.	[Shaklai, Sharon; Peretz, Relly; Spasser, Raluca; Groswasser, Zeev] Loewenstein Hosp & Rehabil Ctr, Pediat Unit, IL-43100 Raanana, Israel; [Shaklai, Sharon; Simantov, Maya; Groswasser, Zeev] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel		Shaklai, S (corresponding author), Loewenstein Hosp & Rehabil Ctr, Pediat Unit, 278 Ahuza St,POB 3, IL-43100 Raanana, Israel.	sharons5@clalit.org.il					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Bedell Gary M, 2002, Pediatr Rehabil, V5, P107, DOI 10.1080/1363849021000013540; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Brooks N, 1993, BRAIN INJURY, V1, P5; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chang W C, 1997, J Outcome Meas, V1, P192; Chang W C, 1997, J Outcome Meas, V1, P259; Cohen S, 1996, ACQUIRED BRAIN INJUR, P149; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; De Oliveira Thais MER, 2012, J NEUROPSYCHOL, V7, P1; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; FACCO E, 1986, CHILD NERV SYST, V2, P67; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Formisano R, 2004, BRAIN INJURY, V18, P103, DOI 10.1080/0269905031000149470; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; GENSEMER IB, 1989, J TRAUMA, V29, P1616, DOI 10.1097/00005373-198912000-00003; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; JENNETT B, 1975, LANCET, V1, P480; Jensen MP, 2005, ARCH PHYS MED REHAB, V86, P116, DOI 10.1016/j.apmr.2004.01.040; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kothari S., 2007, BRAIN INJURY MED PRI, P169; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Petrella RJ, 2002, AM J PHYS MED REHAB, V81, P639, DOI 10.1097/00002060-200209000-00001; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Rice SA, 2004, AM J PHYS MED REHAB, V83, P27, DOI 10.1097/01.PHM.0000104667.81620.FA; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Weschsler D, 1991, WESCHLER INTELLIGENC; Wright J., 2000, CTR OUTCOME MEASUREM	57	33	34	1	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					915	921		10.3109/02699052.2013.862739			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600005	24826955				2022-02-06	
J	Varotto, G; Fazio, P; Sebastiano, DR; Duran, D; D'Incerti, L; Parati, E; Sattin, D; Leonardi, M; Franceschetti, S; Panzica, F				Varotto, Giulia; Fazio, Patrik; Sebastiano, Davide Rossi; Duran, Dunja; D'Incerti, Ludovico; Parati, Eugenio; Sattin, Davide; Leonardi, Matilde; Franceschetti, Silvana; Panzica, Ferruccio			Altered resting state effective connectivity in long-standing vegetative state patients: An EEG study	CLINICAL NEUROPHYSIOLOGY			English	Article						Effective connectivity; Partial directed coherence; Disorders of consciousness; EEG; Vegetative state	MINIMALLY CONSCIOUS STATES; PARTIAL DIRECTED COHERENCE; FUNCTIONAL CONNECTIVITY; BRAIN-INJURY; COMA; DYNAMICS; RECOVERY; MODULATION; DISORDERS; MODEL	Objective: Recent evidence mainly based on hemodynamic measures suggests that the impairment of functional connections between different brain areas may help to clarify the neuronal dysfunction occurring in patients with disorders of consciousness (DOC). Objective: The aim of this study was to evaluate effective EEG connectivity in a cohort of 18 patients in a chronic vegetative state (VS) observed years after the occurrence of hypoxic (eight) and traumatic or hemorrhagic brain insult. Methods: we analysed the EEG signals recorded under resting conditions using a frequency domain linear index of connectivity (partial directed coherence: PDC) estimated from a multivariate autoregressive model. The results were compared with those obtained in ten healthy controls. Results: Our findings indicated significant connectivity changes in EEG activities in delta and alpha bands. The VS patients showed a significant and widespread decrease in delta band connectivity, whereas the alpha activity was hyper-connected in the central and posterior cortical regions. Conclusion: These changes suggest the occurrence of severe circuitry derangements probably due to the loose control of the subcortical connections. The alpha hyper-synchronisation may be due to simplified networks mainly involving the short-range connections between intrinsically oscillatory cortical neurons that generate aberrant EEG alpha sources. This increased connectivity may be interpreted as a reduction in information capacity, implying an increasing prevalence of stereotypic activity patterns. Significance: Our observations suggest a remarkable rearrangement of connectivity in patients with long-standing VS. We hypothesize that in persistent VS, after a first period characterized by a breakdown of cortical connectivity, neurodegenerative processes, largely independent from the type of initial insult, lead to cortex de-afferentation and to a severe reduction of possible cortical activity patterns and states. (C) 2013 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Varotto, Giulia; Fazio, Patrik; Sebastiano, Davide Rossi; Duran, Dunja; Franceschetti, Silvana; Panzica, Ferruccio] IRCCS Fdn Carlo Besta Neurol Inst, Dept Neurophysiol & Diagnost Epileptol, Milan, Italy; [D'Incerti, Ludovico] IRCCS Fdn Carlo Besta Neurol Inst, Dept Neuroradiol, Milan, Italy; [Sattin, Davide; Leonardi, Matilde] IRCCS Fdn Carlo Besta Neurol Inst, Disabil Unit, Neurol Unit, Milan, Italy; [Fazio, Patrik] Univ Ferrara, Neurol Sect, Dept Med & Surg Sci Commun & Behav, I-44100 Ferrara, Italy; [Sattin, Davide; Leonardi, Matilde] IRCCS Fdn Carlo Besta Neurol Inst, Coma Res Ctr, Milan, Italy; [Parati, Eugenio] IRCCS Fdn Carlo Besta Neurol Inst, Dept Cerebrovasc Dis, Milan, Italy		Panzica, F (corresponding author), C Besta Fdn Neurol Inst, Dept Neurophysiol & Diagnost Epileptol, Via Celoria 11, I-20133 Milan, Italy.	panzica@istituto-besta.it	Parati, Eugenio Agostino/AAN-5893-2021; Franceschetti, Silvana/K-3438-2016; Sattin, Davide/K-5963-2016; Duran, Dunja/K-5844-2016; Rossi Sebastiano, Davide/G-8541-2016; Varotto, Giulia/K-5352-2016; leonardi, matilde/J-9997-2018; Panzica, Ferruccio/K-6711-2016	Parati, Eugenio Agostino/0000-0001-5020-6523; Franceschetti, Silvana/0000-0002-1921-6755; Sattin, Davide/0000-0001-7736-4337; Duran, Dunja/0000-0002-7232-4018; Rossi Sebastiano, Davide/0000-0003-3698-8615; Varotto, Giulia/0000-0001-8849-0398; leonardi, matilde/0000-0003-0552-8923; Panzica, Ferruccio/0000-0002-0105-943X; D'Incerti, Ludovico/0000-0002-4092-9290; Fazio, Patrik/0000-0002-1863-1922	Regione LombardiaRegione Lombardia [IX/000407, 05/08/20109]	The project 2CRC, "Coma Research Centre'' was supported by Grant No. No IX/000407 (05/08/20109 awarded by Regione Lombardia.	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AICARDI J, 1979, BRAIN, V102, P727, DOI 10.1093/brain/102.4.727; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Baccala LA, 2001, BIOL CYBERN, V84, P463, DOI 10.1007/PL00007990; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Boly M, 2011, CURR OPIN NEUROL, V24, P394, DOI 10.1097/WCO.0b013e328347da94; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Box G. E. P., 1970, TIME SERIES ANAL FOR; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; DASILVA FL, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI 10.1016/0013-4694(91)90044-5; Demertzi A, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2010.00245; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; Fingelkurts AA, 2012, CONSCIOUS COGN, V21, P149, DOI 10.1016/j.concog.2011.10.004; Friston K. J., 2001, BRAIN CONNECTIVITY, V1, P13; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Gosseries O, 2011, FUNCT NEUROL, V26, P25; Gugino LA, 2001, BRIT J ANAESTH, V87, P421, DOI 10.1093/bja/87.3.421; Hudetz AG, 2012, BRAIN CONNECT, V2, P291, DOI 10.1089/brain.2012.0107; Husain AM, 2006, J CLIN NEUROPHYSIOL, V23, P208, DOI 10.1097/01.wnp.0000220094.60482.b5; JENNETT B, 1972, LANCET, V1, P734; JOHNSEN SJ, 1978, GEOPHYSICS, V43, P681, DOI 10.1190/1.1440846; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Laureys S, 2008, NAT CLIN PRACT NEURO, V4, P544, DOI 10.1038/ncpneuro0887; Lehembre R, 2012, FUNCT NEUROL, V27, P41; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Moosmann M, 2003, NEUROIMAGE, V20, P145, DOI 10.1016/S1053-8119(03)00344-6; Niedermeyer E, 1997, INT J PSYCHOPHYSIOL, V26, P31, DOI 10.1016/S0167-8760(97)00754-X; Pollonini L, 2010, BRAIN TOPOGR, V23, P221, DOI 10.1007/s10548-010-0139-9; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Schlogl A., 2007, BRAIN COMPUTER INTER, P347; SHAUL Y, 1986, EMBO J, V5, P1967, DOI 10.1002/j.1460-2075.1986.tb04451.x; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Stam CJ, 2009, BRAIN, V132, P213, DOI 10.1093/brain/awn262; Steriade M, 2003, FRONT BIOSCI-LANDMRK, V8, pD878, DOI 10.2741/1043; Steriade M., 2000, NEURO CEREB CORTEX, V10, P1185; Supp GG, 2011, CURR BIOL, V21, P1988, DOI 10.1016/j.cub.2011.10.017; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Timofeev I, 2000, CEREB CORTEX, V10, P1185, DOI 10.1093/cercor/10.12.1185; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Varotto G, 2012, EPILEPSIA, V53, P359, DOI 10.1111/j.1528-1167.2011.03352.x; Wu DY, 2011, CLIN NEUROPHYSIOL, V122, P1956, DOI 10.1016/j.clinph.2011.03.018; Wu DY, 2011, CLIN NEUROPHYSIOL, V122, P490, DOI 10.1016/j.clinph.2010.05.036; ZETTERBERG LH, 1969, ELECTROEN CLIN NEURO, V26, P338; Zoubir AM, 2004, BOOTSTRAP TECHNIQUES	50	33	35	0	25	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2014	125	1					63	68		10.1016/j.clinph.2013.06.016			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	272ZD	WOS:000328501200010	23927942				2022-02-06	
J	Wood, RL; O'Hagan, G; Williams, C; McCabe, M; Chadwick, N				Wood, Rodger Ll.; O'Hagan, Geraldine; Williams, Claire; McCabe, Michael; Chadwick, Nicole			Anxiety Sensitivity and Alexithymia as Mediators of Postconcussion Syndrome Following Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						psychological distress; anxiety sensitivity; postconcussion symptoms; postconcussion syndrome; mild traumatic brain injury; alexithymia	DEPRESSION INVENTORY-II; MINOR HEAD-INJURY; POSTTRAUMATIC AMNESIA; STRESS-DISORDER; PANIC ATTACKS; PERCEPTION; SYMPTOMS; SCALE; PAIN; CONSCIOUSNESS	Objective: To examine the influence of anxiety sensitivity (AS) and alexithymia as potential mediators for the development of psychological distress and postconcussion syndrome after mild traumatic brain injury (mTBI). Participants: Sixty-one patients with mTBI assessed at a mean of 2.38 weeks after injury and demographically matched healthy controls (n = 61). Measures: Twenty-item Toronto Alexithymia Scale, Anxiety Sensitivity Index, State-Trait Anxiety Inventory, and Rivermead Post Concussion Questionnaire. Results: The mTBI group reported significantly higher levels of AS, alexithymia, psychological distress, and postconcussion (PC) symptom scores than controls. High AS and alexithymia in the mTBI group were associated with a greater number of PC symptoms and higher levels of psychological distress than patients scoring low on these measures and controls. In the mTBI group, a combination of AS and low mood explained 52.6% of the variance in PC symptom reporting. A combination of trait-anxiety, alexithymia, and PC symptoms explained 77.2% of the variance in levels of mood. Conclusion: A combination of low mood and high AS may act as a psychological diathesis for the development of persisting PC symptoms. Early identification could provide a focus for early intervention to prevent the development of postconcussion syndrome after mTBI.	[Wood, Rodger Ll.; O'Hagan, Geraldine; Williams, Claire; Chadwick, Nicole] Swansea Univ, Coll Human & Hlth Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales; [Wood, Rodger Ll.; McCabe, Michael] Morriston Hosp, Dept Accid & Emergency, Swansea, W Glam, Wales		Wood, RL (corresponding author), Swansea Univ, Coll Human & Hlth Sci, Dept Psychol, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X			Asmundson GJG, 2001, EUR J PAIN, V5, P23, DOI 10.1053/eujp.2000.0211; Asmundson GJG, 1999, BEHAV RES THER, V37, P703, DOI 10.1016/S0005-7967(98)00172-7; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Benton FA, 1996, J ANXIETY DISORD, V10, P267, DOI 10.1016/0887-6185(96)00011-4; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cochrane A, 2008, PSYCHOL REC, V58, P585, DOI 10.1007/BF03395639; Cohen J., 1998, STAT POWER ANAL BEHA, V2nd; COX BJ, 1994, J PSYCHOSOM RES, V38, P523, DOI 10.1016/0022-3999(94)90049-3; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deacon BJ, 2001, J PSYCHOPATHOL BEHAV, V23, P25, DOI 10.1023/A:1011087322899; DONNELL CD, 1990, BEHAV RES THER, V28, P83, DOI 10.1016/0005-7967(90)90058-Q; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; MALLER RG, 1992, J ANXIETY DISORD, V6, P241, DOI 10.1016/0887-6185(92)90036-7; Marchesi C, 2000, J PSYCHOSOM RES, V49, P43, DOI 10.1016/S0022-3999(00)00084-2; McCrea M., 2008, MILD TRAUMATIC BRAIN; McDonald S, 2011, BRAIN IMPAIR, V12, P165; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Mueller J, 2006, COMPR PSYCHIAT, V47, P489, DOI 10.1016/j.comppsych.2006.03.001; Nelson EA, 2006, J ANXIETY DISORD, V20, P1071, DOI 10.1016/j.janxdis.2006.02.001; Parker JDA, 2001, PERS INDIV DIFFER, V30, P107, DOI 10.1016/S0191-8869(00)00014-3; PASINI A, 1992, COMPR PSYCHIAT, V33, P42, DOI 10.1016/0010-440X(92)90078-5; Peterson R., 1992, ANXIETY SENSITIVITY; Pevalin D, 2002, SOC CONT, P75, DOI DOI 10.3917/SOCO.045.0075; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Poole H, 2006, CLIN J PAIN, V22, P790, DOI 10.1097/01.ajp.0000210930.20322.93; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; REISS S, 1986, BEHAV RES THER, V24, P1, DOI 10.1016/0005-7967(86)90143-9; Reiss S., 1985, THEORETICAL ISSUES B, P107; Richards JC, 2000, J ANXIETY DISORD, V14, P413, DOI 10.1016/S0887-6185(00)00031-1; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Schmidt NB, 1998, BEHAV RES THER, V36, P165, DOI 10.1016/S0005-7967(98)00011-4; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Spielberger C.D., 1989, STATE TRAIT ANXIETY; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Steer RA, 1998, J PSYCHOPATHOL BEHAV, V20, P127, DOI 10.1023/A:1023091529735; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Taylor G. J., 1997, DISORDERS AFFECT REG; Taylor GJ, 2003, J PSYCHOSOM RES, V55, P277, DOI 10.1016/S0022-3999(02)00601-3; Taylor S., 1999, ANXIETY SENSITIVITY; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 1999, BRAIN INJURY, V13, P463; Vanheule S, 2007, PSYCHOPATHOLOGY, V40, P14, DOI 10.1159/000096385; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Williams C, 2013, J HEAD TRAUMA REHAB, V28, pE21, DOI 10.1097/HTR.0b013e318267b0ab; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wood RL, 2007, J NEUROL NEUROSUR PS, V78, P552, DOI 10.1136/jnnp.2006.113845; Wood RLL, 2010, J INT NEUROPSYCH SOC, V16, P1108, DOI 10.1017/S1355617710001013; Wood RLL, 2009, BRAIN INJURY, V23, P649, DOI 10.1080/02699050902970786; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Wood RL, 2011, INJURY, V42, P1214, DOI 10.1016/j.injury.2010.07.245; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; Zahradnik M, 2009, J TRAUMA STRESS, V22, P131, DOI 10.1002/jts.20397; ZEITLIN SB, 1993, AM J PSYCHIAT, V150, P658	74	33	34	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					E9	E17		10.1097/HTR.0b013e31827eabba			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400003	23381020				2022-02-06	
J	Genovese, RF; Simmons, LP; Ahlers, ST; Maudlin-Jeronimo, E; Dave, JR; Boutte, AM				Genovese, R. F.; Simmons, L. P.; Ahlers, S. T.; Maudlin-Jeronimo, E.; Dave, J. R.; Boutte, A. M.			EFFECTS OF MILD TBI FROM REPEATED BLAST OVERPRESSURE ON THE EXPRESSION AND EXTINCTION OF CONDITIONED FEAR IN RATS	NEUROSCIENCE			English	Article						mTBI; blast overpressure; conditioned fear; PTSD; stress processes; operant conditioning	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; BATTLEFIELD INJURY; PAVLOVIAN FEAR; LONG-TERM; SUPPRESSION; BEHAVIOR; LESIONS; SYSTEM; MEMORY	Mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) are pressing medical issues for the War-lighter. Symptoms of mTBI can overlap with those of PTSD, suggesting the possibility of a causal or mediating role of mTBI in PTSD. To address whether mTBI can exacerbate the neurobiological processes associated with traumatic stress, we evaluated the impact of mTBI from a blast overpressure (BOP) on the expression of a conditioned fear. In the rat, conditioned fear models are used to evaluate the emotional conditioning processes that are known to become dysfunctional in PTSD. Rats were first trained on a variable interval (VI), food maintained, operant conditioning task that established a general measure of performance. Inescapable electric shock (IES) was paired with an audio-visual conditioned stimulus (CS) and followed 1 day later by three daily exposures to BOP (75 kPa). Subsequently, the CS alone was presented once every 7 days for 2 months, beginning 4 days following the last BOP. The CS was presented during the VI sessions allowing a concurrent measure of performance. Treatment groups (n = 10, each group) received IES + BOP, IES + sham-BOP, sham-IES + BOP or shamIES + sham-BOP. As expected, pairing the CS with IES produced a robust conditioned fear that was quantified by a suppression of responding on the VI. BOP significantly decreased the expression of the conditioned fear. No systematic short- or long-term performance deficits were observed on the VI from BOP. These results show that mTBI from BOP can affect the expression of a conditioned fear and suggests that BOP caused a decrease in inhibitory behavioral control. Continued presentation of the CS produced progressively less response suppression in both fear conditioned treatments, consistent with extinction of the conditioned fear. Taken together, these results show that mTBI from BOP can affect the expression of a conditioned fear but not necessarily in a manner that increases the conditioned fear or extends the extinction process. Published by Elsevier Ltd. on behalf of IBRO.	[Genovese, R. F.; Simmons, L. P.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Behav Biol Branch, Silver Spring, MD 20910 USA; [Ahlers, S. T.; Maudlin-Jeronimo, E.] Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, Silver Spring, MD USA; [Dave, J. R.; Boutte, A. M.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Neuroregenerat Branch, Silver Spring, MD USA		Genovese, RF (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Behav Biol Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Raymond.Genovese@US.Army.Mil	Dave, Jitendra R/A-8940-2011		Congressional Directed Medical Research Program [W81XWH-10-2-0091, W81XWH-10-2-0092]; Military Operational Medicine Research Program; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	This work was supported by the Congressional Directed Medical Research Program, (awards W81XWH-10-2-0091 and -0092) and by the Military Operational Medicine Research Program, U.S. Army Medical Research and Materiel Command. The funding sources had no role in the collection, analysis and interpretation of the data or in the decision to submit for publication.	Ahlers ST, 2012, FRONT NEUROL, V3, P1; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Amorapanth P, 1999, LEARN MEMORY, V6, P491, DOI 10.1101/lm.6.5.491; Blechert J, 2007, BEHAV RES THER, V45, P2019, DOI 10.1016/j.brat.2007.02.012; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Defense and Veterans Brain Injury Center Working Group on the Acute Management of Mild Traumatic Brain Injury in Military Operational Settings, 2006, CLIN PRACT GUID REC; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Dimoska-Di Marco A, 2011, J CLIN EXP NEUROPSYC, V33, P471, DOI 10.1080/13803395.2010.533158; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Eagle DM, 2010, NEUROSCI BIOBEHAV R, V34, P50, DOI 10.1016/j.neubiorev.2009.07.003; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Estes WK, 1941, J EXP PSYCHOL, V29, P390, DOI 10.1037/h0062283; Genovese RF, 2006, J TOXICOL ENV HEAL A, V69, P2167, DOI 10.1080/15287390600748153; GENOVESE RF, 1988, LIFE SCI, V43, P571, DOI 10.1016/0024-3205(88)90060-4; GENOVESE RF, 1994, BRAIN RES BULL, V34, P111, DOI 10.1016/0361-9230(94)90006-X; GENOVESE RF, 1992, PHYSIOL BEHAV, V52, P1025, DOI 10.1016/0031-9384(92)90386-G; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Lee JLC, 2005, BEHAV BRAIN RES, V159, P221, DOI 10.1016/j.bbr.2004.11.003; Long JB, 2010, IFMBE PROC, V32, P26, DOI 10.1007/978-3-642-14998-6_7; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; McDannald MA, 2011, BRAIN RES, V1374, P82, DOI 10.1016/j.brainres.2010.12.050; McDannald MA, 2010, BEHAV BRAIN RES, V211, P111, DOI 10.1016/j.bbr.2010.03.020; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Pickens CL, 2010, NEUROSCIENCE, V169, P1501, DOI 10.1016/j.neuroscience.2010.06.036; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wessa M, 2007, AM J PSYCHIAT, V164, P1684, DOI 10.1176/appi.ajp.2007.07030525	38	33	33	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 19	2013	254						120	129		10.1016/j.neuroscience.2013.09.021			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	255ZN	WOS:000327279400011	24056195				2022-02-06	
J	Campolo, M; Esposito, E; Ahmad, A; Di Paola, R; Wallace, JL; Cuzzocrea, S				Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Wallace, John L.; Cuzzocrea, Salvatore			A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury	FASEB JOURNAL			English	Article						inflammation; apoptosis; central nervous system; motor recovery; nonsteroidal anti-inflammatory drug	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; NITRIC-OXIDE; INFLAMMATORY RESPONSE; SIGNALING MOLECULE; OXIDATIVE STRESS; MOUSE MODEL; RAT; EXPRESSION; APOPTOSIS	Spinal cord trauma causes loss of motor function that is in part due to the ensuing inflammatory response. Hydrogen sulfide (H2S) is a potent, endogenous anti-inflammatory and neuroprotective substance that has been explored for use in the design of novel nonsteroidal anti-inflammatory drugs. In the current study, we evaluated the potential beneficial effects of ATB-346 [2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester], an H2S-releasing derivative of naproxen, in a murine model of spinal cord injury (SCI). SCI was induced in mice by spinal cord compression, produced through the application of vascular clips to the dura via a T5 to T8 laminectomy. ATB-346, naproxen (both at 30 mol/kg), or vehicle was orally administered to the mice 1 and 6 h after SCI and once daily thereafter for 10 d. Motor function [Basso Mouse Scale (BMS) of locomotion] improved gradually in the mice treated with naproxen. However, those treated with ATB-346 exhibited a significantly more rapid and sustained recovery of motor function, achieving greater than double the increase in locomotion score of the naproxen group by the 10th day of treatment. ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI. Again, the effects of ATB-346 were superior to those of naproxen for several parameters. These results showed marked beneficial effects of an H2S-releasing derivative of naproxen in an animal model of SCI, significantly enhancing recovery of motor function, possibly by reducing the secondary inflammation and tissue injury that characterizes this model. The combination of inhibition of cyclooxygenase and delivery of H2S may offer a promising alternative to existing therapies for traumatic injury.Campolo, M., Esposito, E., Ahmad, A., Di Paola, R., Wallace, J. L., Cuzzocrea, A. Hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury.	[Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, Messina, Italy; [Wallace, John L.] Univ Calgary, Inflammat Res Network, Calgary, AB T2N 4N1, Canada; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Sch Med, Manchester Biomed Res Ctr, Manchester M13 9WL, Lancs, England		Wallace, JL (corresponding author), Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada.	altapharm@hotmail.com	Campolo, Michela/K-6432-2016; Wallace, John/AAL-3763-2021; di paola, rosanna/U-4356-2019	di paola, rosanna/0000-0001-6725-8581; Ahmad, Akbar/0000-0003-1841-9670; Cuzzocrea, Salvatore/0000-0001-6131-3690	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	The authors thank Carmelo La Spada for excellent technical assistance during this study, Caterina Cutrona for secretarial assistance, and Valentina Malvagni for editorial assistance with the manuscript. This work was supported by a grant from the Canadian Institutes of Health Research (to J.L.W.). J.L.W. is a founder and shareholder of Antibe Therapeutics, Inc.	Abe K, 1996, J NEUROSCI, V16, P1066; Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blackler R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035196; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Chu QJ, 2013, J SURG RES, V183, P330, DOI 10.1016/j.jss.2012.12.003; Chvatal SA, 2008, BIOMATERIALS, V29, P1967, DOI 10.1016/j.biomaterials.2008.01.002; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Finnerup NB, 2001, SPINAL CORD, V39, P256, DOI 10.1038/sj.sc.3101161; Fiorucci S, 2007, BRIT J PHARMACOL, V150, P996, DOI 10.1038/sj.bjp.0707193; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Geng B, 2004, BIOCHEM BIOPH RES CO, V313, P362, DOI 10.1016/j.bbrc.2003.11.130; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2008, SHOCK, V30, P142, DOI 10.1097/SHK.0b013e31815dd381; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; Gong QH, 2010, PHARMACOL BIOCHEM BE, V96, P52, DOI 10.1016/j.pbb.2010.04.006; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Kimura H, 2005, ANTIOXID REDOX SIGN, V7, P778, DOI 10.1089/ars.2005.7.778; Kimura H, 2012, ANTIOXID REDOX SIGN, V17, P45, DOI 10.1089/ars.2011.4345; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014; Lin H, 2006, ANN NEUROL, V60, P399, DOI 10.1002/ana.20965; Liu KL, 2006, J AGR FOOD CHEM, V54, P3472, DOI 10.1021/jf060043k; Malaspina A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-500; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Pedersen MO, 2009, BIOFACTORS, V35, P315, DOI 10.1002/biof.44; Resnick DK, 2004, NEUROREPORT, V15, P837, DOI 10.1097/00001756-200404090-00020; Schmitt Caroline, 2006, Spine J, V6, P113, DOI 10.1016/j.spinee.2005.05.379; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tan BH, 2010, NEUROCHEM INT, V56, P3, DOI 10.1016/j.neuint.2009.08.008; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Wallace JL, 2008, Patent Application, Patent No. [WO/2008/009127, 2008009127]; Wallace JL, 2007, FASEB J, V21, P4070, DOI 10.1096/fj.07-8669com; Wallace JL, 2007, TRENDS PHARMACOL SCI, V28, P501, DOI 10.1016/j.tips.2007.09.003; Wallace JL, 2007, GASTROENTEROLOGY, V132, P261, DOI 10.1053/j.gastro.2006.11.042; Wallace JL, 2010, BRIT J PHARMACOL, V159, P1236, DOI 10.1111/j.1476-5381.2009.00611.x; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yip PK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-6; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	61	33	36	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4489	4499		10.1096/fj.13-234716			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	WOS:000329937500016	23901068				2022-02-06	
J	Glushakov, AV; Robbins, SW; Bracy, CL; Narumiya, S; Dore, S				Glushakov, Alexander V.; Robbins, Sean W.; Bracy, Connor L.; Narumiya, Shuh; Dore, Sylvain			Prostaglandin F-2 alpha FP receptor antagonist improves outcomes after experimental traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						AL-8810; Controlled cortical impact; Glial fibrillary astrocytic protein; G-protein-coupled receptors; Knockout mice; Prostaglandin F2a receptor; Traumatic brain injury	PGE(2) EP1 RECEPTOR; HUMAN CEREBROSPINAL-FLUID; ACID-INDUCED SEIZURE; FREE FATTY-ACIDS; CEREBRAL-ISCHEMIA; INTRACEREBRAL HEMORRHAGE; PATHOLOGICAL CONDITIONS; CORTICAL CONTUSION; STRAIN DIFFERENCES; BARRIER BREAKDOWN	Background: Injuries to the brain promote upregulation of prostaglandins, notably the proinflammatory PGF(2 alpha), and overactivation of their cognate G-protein-coupled FP receptor, which could exacerbate neuronal damage. Our study is focused on investigation of the FP receptor as a target for novel neuroprotective drugs in a preclinical animal traumatic brain injury (TBI) model. Methods: Accordingly, the effects of acute intraperitoneal post-treatment with selective FP antagonist AL-8810 were studied in wildtype (WT) and FP receptor knockout (FP-/-) mice after controlled cortical impact (CCI). Neurological impairments were evaluated using neurological deficit scores (NDS) and the grip strength test. Cortical lesions and overall brain pathology were assessed using immunohistochemistry. Results: Morphological analyses of cerebral vasculature and anastomoses revealed no differences between WT and FP-/- mice. CCI produced cortical lesions characterized by cavitation, neuronal loss, and hematoma with a volume of 20.0 +/- 1.0 mm(3) and significant hippocampal swelling (146.5 +/- 7.4% of contralateral) compared with sham (P < 0.05). Post-treatment with AL-8810 (1 to 10 mg/kg) had no significant effect on cortical lesions, which suggests the irreversible effect of primary CCI injury, but significantly reduced hippocampal swelling to a size not significantly different from the sham group. Post-treatment with AL-8810 at a dose of 10 mg/kg significantly improved NDS at 24 and 48 hours after CCI (P < 0.001 and P < 0.01, respectively). In the AL-8810 group, CCI-induced decrease in grip strength was three-fold (2.93 +/- 1.71) less and significantly different than in the saline-treated group. The FP-/- mice had significantly less hippocampal swelling, but not NDS, compared with WT mice. In addition, immunohistochemistry showed that pharmacologic blockade and genetic deletion of FP receptor led to attenuation of CCI-induced gliosis and microglial activation in selected brain regions. Conclusion: This study provides, for the first time, demonstration of the unique role of the FP receptor as a potential target for disease-modifying CNS drugs for treatment of acute traumatic injury.	[Glushakov, Alexander V.; Robbins, Sean W.; Bracy, Connor L.; Dore, Sylvain] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA; [Narumiya, Shuh] Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; [Dore, Sylvain] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; [Dore, Sylvain] Univ Florida, Coll Med, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32610 USA		Dore, S (corresponding author), Univ Florida, Coll Med, Dept Anesthesiol, POB 100159, Gainesville, FL 32610 USA.	sdore@ufl.edu	Glushakov, Alexander V/B-5452-2008; Dore, Sylvain/AAG-1470-2020	Glushakov, Alexander V/0000-0003-2872-8960; Dore, Sylvain/0000-0003-3771-5109	McKnight Brain Research Foundation; Brain and Spinal Cord Injury Research Trust Fund; National Institute of Heath [NS046400]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046400] Funding Source: NIH RePORTER	This work was supported by a grant from the McKnight Brain Research Foundation, Brain and Spinal Cord Injury Research Trust Fund, and the National Institute of Heath NS046400. Special thanks to Mr. Gerald R Boley, Jr. for technical assistance with immunohistochemistry, and to all Dorelab members for all their generous assistance.	Ahmad AS, 2008, NEUROTOX RES, V14, P343, DOI 10.1007/BF03033858; Ahmad AS, 2006, J NEUROTRAUM, V23, P1895, DOI 10.1089/neu.2006.23.1895; Ahmad AS, 2005, BRAIN RES, V1066, P71, DOI 10.1016/j.brainres.2005.10.068; Ahmad AS, 2006, TOXICOL SCI, V89, P265, DOI 10.1093/toxsci/kfj022; Ahmad Muzamil, 2010, Exp Transl Stroke Med, V2, P12, DOI 10.1186/2040-7378-2-12; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bazan NG, 1995, J NEUROTRAUM, V12, P814; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BHATTACHARYA SK, 1978, PSYCHOPHARMACOLOGY, V56, P235, DOI 10.1007/BF00431857; BHATTACHARYA SK, 1978, PROSTAG LEUKOTR ESS, V1, P159, DOI 10.1016/0161-4630(78)90042-3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carlson NG, 2003, J NEUROSCI RES, V71, P79, DOI 10.1002/jnr.10465; Cendes F, 2004, CURR OPIN NEUROL, V17, P161, DOI 10.1097/00019052-200404000-00013; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; CLIMAX J, 1981, ARCH INT PHARMACOD T, V250, P254; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Desjardins P, 2003, NEUROCHEM INT, V42, P299, DOI 10.1016/S0197-0186(02)00101-8; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Doi T, 2001, MOL BRAIN RES, V92, P107, DOI 10.1016/S0169-328X(01)00159-0; Dore S, 2006, TRENDS PHARMACOL SCI, V27, P458, DOI 10.1016/j.tips.2006.07.001; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; EGG D, 1980, J NEUROL, V222, P239, DOI 10.1007/BF00313153; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Golge M, 2004, ARCH PHYS MED REHAB, V85, P1435, DOI 10.1016/j.apmr.2003.11.029; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Griffin BW, 1999, J PHARMACOL EXP THER, V290, P1278; HADHAZY P, 1988, PROSTAG LEUKOTR ESS, V32, P175, DOI 10.1016/0952-3278(88)90169-X; HAGEN AA, 1977, STROKE, V8, P672, DOI 10.1161/01.STR.8.6.672; HAYASHI S, 1985, J PHARMACOL EXP THER, V233, P628; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Kim HJ, 2008, BRAIN RES, V1193, P153, DOI 10.1016/j.brainres.2007.12.017; Kim YT, 2012, NEUROBIOL DIS, V48, P58, DOI 10.1016/j.nbd.2012.06.003; KITANAKA J, 1991, BIOCHEM BIOPH RES CO, V178, P946, DOI 10.1016/0006-291X(91)90983-E; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; KOSTIC VS, 1984, EUR NEUROL, V23, P291, DOI 10.1159/000115744; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; LI DY, 1994, BRIT J PHARMACOL, V112, P59, DOI 10.1111/j.1476-5381.1994.tb13029.x; LI DY, 1995, J PHARMACOL EXP THER, V272, P15; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; LYNEHAM RC, 1973, LANCET, V2, P1003; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; Maeda K, 1999, NEUROBIOL DIS, V6, P101, DOI 10.1006/nbdi.1998.0235; Majid A, 2000, STROKE, V31, P2707, DOI 10.1161/01.STR.31.11.2707; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; McIntosh TK, 1996, LAB INVEST, V74, P315; Mohan Shekher, 2012, Front Neurol, V3, P145, DOI 10.3389/fneur.2012.00145; Moser VC, 2011, TOXICOL PATHOL, V39, P36, DOI 10.1177/0192623310385255; Muller K, 2000, CARCINOGENESIS, V21, P1063, DOI 10.1093/carcin/21.5.1063; Rantala H, 2001, EPILEPSY RES, V46, P251, DOI 10.1016/S0920-1211(01)00281-9; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saleem S, 2009, NEUROTOX RES, V15, P62, DOI 10.1007/s12640-009-9007-3; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SEDERBERGOLSEN J, 1983, ACTA OBSTET GYN SCAN, V62, P79, DOI 10.3109/00016348309155765; Sharma AK, 2007, TOXICOL PATHOL, V35, P984, DOI 10.1080/01926230701748305; SHEARMAN RP, 1975, BRIT J OBSTET GYNAEC, V82, P314, DOI 10.1111/j.1471-0528.1975.tb00641.x; Singh N, 2013, NEUROTOX RES, V24, P549, DOI 10.1007/s12640-013-9410-7; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAMAI I, 1983, BRAIN DEV-JPN, V5, P357, DOI 10.1016/S0387-7604(83)80039-4; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; Tomimoto H, 2000, ACTA NEUROPATHOL, V99, P26, DOI 10.1007/PL00007402; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Toti P., 2001, Journal of Submicroscopic Cytology and Pathology, V33, P245; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; WILLMORE LJ, 1991, INT J DEV NEUROSCI, V9, P175, DOI 10.1016/0736-5748(91)90009-B; WISLICKI L, 1982, INT J BIOL RES PREG, V3, P158; WOLFE LS, 1975, PROSTAGLANDINS, V9, P183, DOI 10.1016/0090-6980(75)90023-4; Woodward DF, 2011, PHARMACOL REV, V63, P471, DOI 10.1124/pr.110.003517; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	84	33	33	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 30	2013	10								132	10.1186/1742-2094-10-132			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	282XB	WOS:000329206700001	24172576	gold, Green Published			2022-02-06	
J	Kouvonen, A; Kivimaki, M; Oksanen, T; Pentti, J; De Vogli, R; Virtanen, M; Vahtera, J				Kouvonen, Anne; Kivimaki, Mika; Oksanen, Tuula; Pentti, Jaana; De Vogli, Roberto; Virtanen, Marianna; Vahtera, Jussi			Obesity and Occupational Injury: A Prospective Cohort Study of 69,515 Public Sector Employees	PLOS ONE			English	Article							BODY-MASS INDEX; HEALTH; RISK; WEIGHT; WORK; MORTALITY; HEIGHT	Background: Obesity and overweight are suggested to increase the risk of occupational injury but longitudinal evidence to confirm this is rare. We sought to evaluate obesity and overweight as risk factors for occupational injuries. Methodology/Principal Findings: A total of 69,515 public sector employees (80% women) responded to a survey in 20002002, 2004 or 2008. Body mass index (kg/m(2)) was derived from self-reported height and weight and was linked to records of subsequent occupational injuries obtained from national registers. Different injury types, locations and events or exposures (the manner in which the injury was produced or inflicted) were analyzed by body mass index category adjusting for baseline socio-demographic characteristics, work characteristics, health-risk behaviors, physical and mental health, insomnia symptoms, and sleep duration. During the mean follow-up of 7.8 years (SD = 3.2), 18% of the employees (N = 12,204) recorded at least one occupational injury. Obesity was associated with a higher overall risk of occupational injury; multivariable adjusted hazard ratio (HR) 1.21 (95% CI 1.14-1.27). A relationship was observed for bone fractures (HR = 1.37; 95% CI: 1.10-1.70), dislocations, sprains and strains (HR = 1.36; 95% CI: 1.25-1.49), concussions and internal injuries (HR = 1.26; 95% CI: 1.11-1.44), injuries to lower extremities (HR = 1.62; 95%: 1.46-1.79) and injuries to whole body or multiple sites (HR = 1.37; 95%: 1.10-1.70). Furthermore, obesity was associated with a higher risk of injuries caused by slipping, tripping, stumbling and falling (HR = 1.55; 95% CI: 1.40-1.73), sudden body movement with or without physical stress (HR = 1.24; 95% CI: 1.10-1.41) and shock, fright, violence, aggression, threat or unexpected presence (HR = 1.33; 95% CI: 1.03-1.72). The magnitude of the associations between overweight and injuries was smaller, but the associations were generally in the same direction as those of obesity. Conclusions/Significance: Obese employees record more occupational injuries than those with recommended healthy weight.	[Kouvonen, Anne] Queens Univ Belfast, Sch Sociol Social Policy & Social Work, Belfast, Antrim, North Ireland; [Kouvonen, Anne] Queens Univ Belfast, UKCRC Ctr Excellence Publ Hlth Northern Ireland, Belfast, Antrim, North Ireland; [Kivimaki, Mika; Oksanen, Tuula; Pentti, Jaana; Virtanen, Marianna; Vahtera, Jussi] Finnish Inst Occupat Hlth, Turku, Finland; [Kivimaki, Mika; Oksanen, Tuula; Pentti, Jaana; Virtanen, Marianna; Vahtera, Jussi] Finnish Inst Occupat Hlth, Helsinki, Finland; [Kivimaki, Mika; De Vogli, Roberto] UCL, Dept Epidemiol & Publ Hlth, London, England; [Kivimaki, Mika] Univ Helsinki, Inst Behav Sci, Helsinki, Finland; [De Vogli, Roberto] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Vahtera, Jussi] Univ Turku, Dept Publ Hlth, Turku, Finland; [Vahtera, Jussi] Turku Univ Hosp, FIN-20520 Turku, Finland		Kouvonen, A (corresponding author), Queens Univ Belfast, Sch Sociol Social Policy & Social Work, Belfast, Antrim, North Ireland.	a.kouvonen@qub.ac.uk	Oksanen, Tuula/AAK-5599-2021; Kivimaki, Mika/B-3607-2012	Kivimaki, Mika/0000-0002-4699-5627; Vahtera, Jussi/0000-0002-6036-061X; Kouvonen, Anne/0000-0001-6997-8312	Academy of FinlandAcademy of FinlandEuropean Commission [264944, 258598]; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [RES-590-28-001]; Academy of FinlandAcademy of FinlandEuropean Commission; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [K013351]; United States National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL036310, R01AG034454]; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); Economic and Social Research Council (ESRC)UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [RES-070-27-0034]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034454] Funding Source: NIH RePORTER; ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/J023299/1] Funding Source: UKRI; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/K013351/1] Funding Source: UKRI; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/J023299/1] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K013351/1] Funding Source: researchfish	The Finnish Public Sector Study is supported by the Academy of Finland (grant # 264944) and the participating organizations. A Kouvonen is supported by the Economic and Social Research Council funded United Kingdom Clinical Research Collaboration Centre of Excellence for Public Health (Northern Ireland) (RES-590-28-001). M Kivimaki is supported by the Academy of Finland, the Medical Research Council (K013351), the United States National Institutes of Health (R01HL036310; R01AG034454) and a professorial fellowship from the Economic and Social Research Council. R De Vogli is supported by a grant from the Economic and Social Research Council (ESRC) (RES-070-27-0034). M Virtanen is supported by the Academy of Finland (grant # 258598). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bes-Rastrollo M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-213; Cao JJ, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749-799X-6-30; Chau N, 2009, OCCUP MED-OXFORD, V59, P114, DOI 10.1093/occmed/kqp002; Cohen A, 2013, J CLIN ENDOCR METAB, V98, P2562, DOI 10.1210/jc.2013-1047; Dimitri P, 2012, BONE, V50, P457, DOI 10.1016/j.bone.2011.05.011; Gauchard GC, 2006, OCCUP MED-OXFORD, V56, P187, DOI 10.1093/occmed/kqj016; Goldberg D., 1988, USERS GUIDE GEN HLTH; HEINEMAN EF, 1989, AM J IND MED, V15, P267; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Janssen I, 2011, J OBES, V2011, DOI 10.1155/2011/531403; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Kivimaki M, 2010, DIABETES CARE, V33, P2611, DOI 10.2337/dc10-1187; Koritzky G, 2012, APPETITE, V59, P289, DOI 10.1016/j.appet.2012.05.020; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; Lombardi DA, 2012, CHRONOBIOL INT, V29, P556, DOI 10.3109/07420528.2012.675253; Morgan PJ, 2012, J OCCUP ENVIRON MED, V54, P122, DOI 10.1097/JOM.0b013e31824329ab; Myers AH, 1999, AM J PUBLIC HEALTH, V89, P1036, DOI 10.2105/AJPH.89.7.1036; Nyholm M, 2007, OBESITY, V15, P197, DOI 10.1038/oby.2007.536; OECD, 2012, OECD OB UPD 2012; Ostbye T, 2007, ARCH INTERN MED, V167, P766, DOI 10.1001/archinte.167.8.766; Pollack KM, 2007, INJURY PREV, V13, P297, DOI 10.1136/ip.2006.014787; Pollack KM, 2007, AM J EPIDEMIOL, V166, P204, DOI 10.1093/aje/kwm058; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; Salminen S, 2010, J SLEEP RES, V19, P207, DOI 10.1111/j.1365-2869.2009.00780.x; Statistics Finland, 1987, CLASS OCC, V14; Straker LM, 2009, ERGONOMICS, V52, P1215, DOI 10.1080/00140130903039101; Taylor AW, 2006, AUST NZ J PUBL HEAL, V30, P238, DOI 10.1111/j.1467-842X.2006.tb00864.x; U.S. Department of Labor Bureu of Labor Statistics, 2012, OCC INJ ILLN CLASS M; Virtanen M, 2011, OCCUPATIONAL ENV MED, V68, P1; Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3; WOHL AR, 1995, EPIDEMIOLOGY, V6, P110, DOI 10.1097/00001648-199503000-00004; World Health Organization, 2006, GLOB DAT BOD MASS IN	32	33	33	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e77178	10.1371/journal.pone.0077178			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	239JR	WOS:000326019400096	24146966	Green Published, gold			2022-02-06	
J	Bazarian, JJ; Blyth, BJ; He, H; Mookerjee, S; Jones, C; Kiechle, K; Moynihan, R; Wojcik, SM; Grant, WD; Secreti, LM; Triner, W; Moscati, R; Leinhart, A; Ellis, GL; Khan, J				Bazarian, Jeffrey J.; Blyth, Brian J.; He, Hua; Mookerjee, Sohug; Jones, Courtney; Kiechle, Karin; Moynihan, Ryan; Wojcik, Susan M.; Grant, William D.; Secreti, LaLainia M.; Triner, Wayne; Moscati, Ronald; Leinhart, August; Ellis, George L.; Khan, Jawwad			Classification Accuracy of Serum Apo A-I and S100B for the Diagnosis of Mild Traumatic Brain Injury and Prediction of Abnormal Initial Head Computed Tomography Scan	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; CT scanning; head trauma; human studies; traumatic brain injury	OPERATING CHARACTERISTIC CURVES; PROTEIN; MANAGEMENT; AREAS	The objective of the current study was to determine the classification accuracy of serum S100B and apolipoprotein (apoA-I) for mild traumatic brain injury (mTBI) and abnormal initial head computed tomography (CT) scan, and to identify ethnic, racial, age, and sex variation in classification accuracy. We performed a prospective, multi-centered study of 787 patients with mTBI who presented to the emergency department within 6h of injury and 467 controls who presented to the outpatient laboratory for routine blood work. Serum was analyzed for S100B and apoA-I. The outcomes were disease status (mTBI or control) and initial head CT scan. At cutoff values defined by 90% of controls, the specificity for mTBI using S100B (0.899 [95% confidence interval (CI): 0.78-0.92]) was similar to that using apoA-I (0.902 [0.87-0.93]), and the sensitivity using S100B (0.252 [0.22-0.28]) was similar to that using apoA-I (0.249 [0.22-0.28]). The area under the receiver operating characteristic curve (AUC) for the combination of S100B and apoA-I (0.738, 95% CI: 0.71, 0.77), however, was significantly higher than the AUC for S100B alone (0.709, 95% CI: 0.68, 0.74, p=0.001) and higher than the AUC for apoA-I alone (0.645, 95% CI: 0.61, 0.68, p<0.0001). The AUC for prediction of abnormal initial head CT scan using S100B was 0.694 (95%CI: 0.62, 0.77) and not significant for apoA-I. At a S100B cutoff of <0.060g/L, the sensitivity for abnormal head CT was 98%, and 22.9% of CT scans could have been avoided. There was significant age and race-related variation in the accuracy of S100B for the diagnosis of mTBI. The combined use of serum S100B and apoA-I maximizes classification accuracy for mTBI, but only S100B is needed to classify abnormal head CT scan. Because of significant subgroup variation in classification accuracy, age and race need to be considered when using S100B to classify subjects for mTBI.	[Bazarian, Jeffrey J.; Blyth, Brian J.; Jones, Courtney; Khan, Jawwad] Univ Rochester, Sch Med & Dent, Dept Emergency Med, Rochester, NY 14642 USA; [He, Hua] Univ Rochester, Sch Med & Dent, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.; Mookerjee, Sohug] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA; [Kiechle, Karin] Univ Munich, Chirurg Klin Innenstadt, Munich, Germany; [Moynihan, Ryan] SUNY Coll Geneseo, Geneseo, NY 14454 USA; [Wojcik, Susan M.; Grant, William D.; Secreti, LaLainia M.] SUNY Upstate Med Univ, Dept Emergency Med, Syracuse, NY 13210 USA; [Triner, Wayne] Albany Med Coll, Dept Emergency Med, Albany, NY 12208 USA; [Moscati, Ronald] SUNY Buffalo, Dept Emergency Med, Buffalo, NY 14260 USA; [Leinhart, August] Bassett Med Ctr, Dept Family Med, Cooperstown, NY USA; [Ellis, George L.] Guthrie Clin, Dept Emergency Med, Sayre, PA USA		Bazarian, JJ (corresponding author), Univ Rochester, Sch Med & Dent, 265 Crittenden Blvd,Box 655C, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			New York State Department of Health; Academic Health Center Consortium; Emergency Research Network of the Empire State (ERNIES); Pilot Research Collaborative Program of the Foundation for Healthy Living; University of Rochester's Clinical and Translational Science Award; Upstate New York Translational Research Network (UNYTRN); Upstate New York Consortium for Healthcare Research and Quality (UNYCHRQ)	This study was supported by funds from the New York State Department of Health, the Academic Health Center Consortium, and the Emergency Research Network of the Empire State (ERNIES). ERNIES is supported by the Pilot Research Collaborative Program of the Foundation for Healthy Living, the University of Rochester's Clinical and Translational Science Award, the Upstate New York Translational Research Network (UNYTRN), and the Upstate New York Consortium for Healthcare Research and Quality (UNYCHRQ).	ALLMAN RM, 1985, JAMA-J AM MED ASSOC, V254, P246, DOI 10.1001/jama.254.2.246; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Ben Abdesselam O, 2003, CLIN CHEM, V49, P836, DOI 10.1373/49.5.836; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blyth B. J., 2010, J NEUROTRAUM, V26, P25; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Bouvier D, 2009, ANN BIOL CLIN-PARIS, V67, P425, DOI 10.1684/abc.2009.0347; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Faul M, 2002, TRAUMATIC BRAIN INJU; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rader DJ, 2006, J CLIN INVEST, V116, P3090, DOI 10.1172/JCI30163; Rutland-Brown W, 2008, J HEAD TRAUMA REHAB, V23, P84, DOI 10.1097/01.HTR.0000314527.78134.70; Tang W, 2012, APPL CATEGORICAL COU; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TAPE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P295, DOI 10.1016/0005-2760(90)90030-2; Towend W, 2006, J NEUROTRAUM, V23, P149; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Van Lenten BJ, 2006, ARTERIOSCL THROM VAS, V26, P1687, DOI 10.1161/01.ATV.0000232522.47018.a6; Yu CJ, 2010, BBA-MOL CELL BIOL L, V1801, P819, DOI 10.1016/j.bbalip.2010.05.001; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	29	33	33	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1747	1754		10.1089/neu.2013.2853			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000007	23758329	Green Published			2022-02-06	
J	Mannix, R; Monuteaux, MC; Schutzman, SA; Meehan, WP; Nigrovic, LE; Neuman, MI				Mannix, Rebekah; Monuteaux, Michael C.; Schutzman, Sara A.; Meehan, William P., III; Nigrovic, Lise E.; Neuman, Mark I.			Isolated Skull Fractures: Trends in Management in US Pediatric Emergency Departments	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CHILDREN; INFANTS	Study objective: Previous studies have suggested that children with isolated skull fractures are at low risk of requiring neurosurgical intervention, suggesting that admission to the hospital may not be necessary in many instances. We seek to evaluate current practice for children presenting to the emergency department (ED) for isolated skull fractures in US children's hospitals. Methods: We conducted a retrospective multicenter cross-sectional study of children younger 19 years with a diagnosis of isolated skull fracture who were evaluated in the ED from 2005 to 2011, using the Pediatric Health Information System database. The primary outcome measure was the rate of hospital admission. Secondary outcomes were any neurosurgical procedure during hospitalization, repeated neuroimaging, duration of hospitalization, and cost of care. Results: We identified 3,915 patients with isolated skull fractures, of whom 60% were male patients; 78% were hospitalized. Of hospitalized children, 85% were discharged within 1 day and 95% were discharged within 2 days. During hospitalization, 47 patients received repeated computed tomography imaging and 1 child required a neurosurgical procedure. Hospital costs were more than triple for hospitalized patients compared with patients discharged from the ED ($2,064 versus $619). Conclusion: Most children treated in EDs of US children's hospitals with isolated skull fractures are hospitalized. The rate of neurosurgical intervention is very low. A better understanding of current practice is necessary to assess whether these admissions are warranted or not.	[Mannix, Rebekah; Monuteaux, Michael C.; Schutzman, Sara A.; Meehan, William P., III; Nigrovic, Lise E.; Neuman, Mark I.] Boston Childrens Hosp, Div Emergency Med, Dept Med, Boston, MA USA; [Mannix, Rebekah; Monuteaux, Michael C.; Schutzman, Sara A.; Meehan, William P., III; Nigrovic, Lise E.; Neuman, Mark I.] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Boston Childrens Hosp, Sports Concuss Clin, Div Sports Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA		Mannix, R (corresponding author), Boston Childrens Hosp, Div Emergency Med, Dept Med, Boston, MA USA.	rebekah.nnannix@childrens.harvard.edu	Monuteaux, Michael C/O-5032-2018; Mannix, Rebekah/AAD-8702-2020	Nigrovic, Lise/0000-0002-6369-3997			Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laskey AL, 2013, J PEDIATR-US, V162, P86, DOI 10.1016/j.jpeds.2012.06.038; Macy ML, 2012, J HOSP MED, V7, P287, DOI 10.1002/jhm.949; Narus Scott P, 2011, AMIA Annu Symp Proc, V2011, P994; Rollins MD, 2011, J PEDIATR SURG, V46, P1342, DOI 10.1016/j.jpedsurg.2010.12.019; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Tieder JS, 2011, PEDIATRICS, V128, P323, DOI 10.1542/peds.2010-2064	10	33	33	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	OCT	2013	62	4					327	331		10.1016/j.annemergmed.2013.02.027			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	229ZZ	WOS:000325307700011	23602429				2022-02-06	
J	Miller, LS; Colella, B; Mikulis, D; Maller, J; Green, REA				Miller, Lesley S.; Colella, Brenda; Mikulis, David; Maller, Jerome; Green, Robin E. A.			Environmental enrichment may protect against hippocampal atrophy in the chronic stages of traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						traumatic brain injury; environmental enrichment; subacute atrophy; adult; moderate to severe	DEFAULT MODE NETWORK; COGNITIVE RESERVE; LIFE-STYLE; AGED BRAIN; PLASTICITY; VOLUME; NEUROGENESIS; EXPERIENCE; DECLINE; NEURONS	Objective: To examine the relationship between environmental enrichment (EE) and hippocampal atrophy in the chronic stages of moderate to severe traumatic brain injury (TBI). Design: Retrospective analysis of prospectively collected data; obervational, within-subjects. Participants: Patients (N = 25) with moderate to severe TBI. Measures: Primary predictors: (1) An aggregate of self-report rating of EE (comprising hours of cognitive, physical, and social activities) at 5 months post-injury years of education as a proxy for pre-morbid EE (or cognitive reserve). Primary outcome: bilateral hippocampal volume change from 5 to 28 months post-injury. Results: As predicted, self-reported EE was significantly negatively correlated with bilateral hippocampal atrophy (p < 0.05), with greater EE associated with less atrophy from 5 to 28 months. Contrary to prediction, years of education (a proxy for cognitive reserve) was not significantly associated with atrophy. Conclusion: Post-injury EE may serve as a buffer against hippocampal atrophy in the chronic stages of moderate-severe TBI. Clinical application of EE should be considered for optimal maintenance of neurological functioning in the chronic stages of moderate-severe TBI.	[Miller, Lesley S.] Univ Toronto, Ontario Inst Studies Educ, Appl Psychol & Human Dev, Toronto, ON, Canada; [Colella, Brenda; Green, Robin E. A.] Toronto Rehab Univ Hlth Network, Res Dept, Cognit Neurorehabil Sci Lab, Toronto M5A 2G2, ON, Canada; [Mikulis, David] Univ Hlth Network, Toronto Western Res Inst, Div Appl & Intervent Res, fMRI Lab, Toronto, ON, Canada; [Mikulis, David] Univ Toronto, Fac Med, Dept Med Imaging, Toronto, ON, Canada; [Maller, Jerome] Alfred Hosp, Monash Alfred Psychiatry Res Ctr, Brain Stimulat & Neuroimaging Lab, Melbourne, Vic, Australia; [Green, Robin E. A.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada		Green, REA (corresponding author), Toronto Rehab Univ Hlth Network, Res Dept, Cognit Neurorehabil Sci Lab, 550 Univ Ave, Toronto M5A 2G2, ON, Canada.	robin.green@uhn.ca	Mikulis, David J/H-5167-2019; Maller, Jerome J/H-4963-2014	Maller, Jerome J/0000-0003-4685-1508; Green, Robin/0000-0001-9451-3963; Mikulis, David/0000-0003-3956-0892	Ontario Neurotrauma foundation; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Canada Research Chair and Physicians' Services Incorporated foundation	The study was supported by funding from the Ontario Neurotrauma foundation, Canadian Institutes for Health Research, Canada Research Chair and Physicians' Services Incorporated foundation.	Adnan A., BRAIN INJUR IN PRESS; Amaral David G., 1995, P443; Amato MP, 2013, NEUROLOGY, V80, P1728, DOI 10.1212/WNL.0b013e3182918c6f; Beck AT, 1990, BECK ANXIETY INVENTO; Beck AT, 1987, BECK DEPRESSION INVE; Berlucchi G, 2011, NEUROPSYCHOL REHABIL, V21, P560, DOI 10.1080/09602011.2011.573255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Blake DT, 2006, NEURON, V52, P371, DOI 10.1016/j.neuron.2006.08.009; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bosma H, 2002, Z GERONTOL GERIATR, V35, P575, DOI 10.1007/s00391-002-0080-y; CORKIN S, 1989, J NEUROSCI, V9, P3876; Corral M, 2006, DEV NEUROPSYCHOL, V29, P479, DOI 10.1207/s15326942dn2903_6; CSIKSZENTMIHALYI M, 1987, J NERV MENT DIS, V175, P526, DOI 10.1097/00005053-198709000-00004; Curlik DM, 2011, J COGNITIVE NEUROSCI, V23, P2159, DOI 10.1162/jocn.2010.21597; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Draganski B, 2006, J NEUROSCI, V26, P6314, DOI 10.1523/JNEUROSCI.4628-05.2006; Duvernoy HM., 2005, HUMAN HIPPOCAMPUS FU; Elkins JS, 2006, NEUROLOGY, V67, P435, DOI 10.1212/01.wnl.0000228246.89109.98; Evans J. J., 2008, NEUROPSYCHOL REHABIL, V18, P372, DOI [10.1080/09602010801909153, DOI 10.1080/09602010801909153]; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Fritsch T, 2007, GERONTOLOGIST, V47, P307, DOI 10.1093/geront/47.3.307; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; JACOBS B, 1993, J COMP NEUROL, V327, P97, DOI 10.1002/cne.903270108; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kasai H, 2010, TRENDS NEUROSCI, V33, P121, DOI 10.1016/j.tins.2010.01.001; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kempermann G, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00189; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kolb B, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00204; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lee T, 2009, NEUROREPORT, V20, P1554, DOI 10.1097/WNR.0b013e328332bb09; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mohammed AH, 2002, PROG BRAIN RES, V138, P109, DOI 10.1016/S0079-6123(02)38074-9; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Nithianantharajah J, 2009, PROG NEUROBIOL, V89, P369, DOI 10.1016/j.pneurobio.2009.10.001; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Petcu EB, 2008, GERONTOLOGY, V54, P6, DOI 10.1159/000112845; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Richards M, 2003, SOC SCI MED, V56, P785, DOI 10.1016/S0277-9536(02)00075-8; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; Salthouse TA, 2002, PSYCHOL AGING, V17, P548, DOI 10.1037//0882-7974.17.4.548; Sandrone S, 2012, J NEUROSCI, V32, P1915, DOI 10.1523/JNEUROSCI.5637-11.2012; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scarmeas N, 2003, J CLIN EXP NEUROPSYC, V25, P625, DOI 10.1076/jcen.25.5.625.14576; Shors TJ, 2012, BEHAV BRAIN RES, V227, P450, DOI 10.1016/j.bbr.2011.04.023; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, P112, DOI 10.1097/01.wad.0000213815.20177.19; Studenski S, 2006, SCI AGING KNOWLEDGE, V10, P21, DOI DOI 10.1126/SAGEKE.2006.10.PE21; Surget A, 2011, MOL PSYCHIATR, V16, P1177, DOI 10.1038/mp.2011.48; Tanti A, 2013, HIPPOCAMPUS, V23, P797, DOI 10.1002/hipo.22134; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Taub E, 2006, Eura Medicophys, V42, P241; Taylor VA, 2013, SOC COGN AFFECT NEUR, V8, P4, DOI 10.1093/scan/nsr087; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Watson C, 1997, ARCH NEUROL-CHICAGO, V54, P67, DOI 10.1001/archneur.1997.00550130049015; WechslerD, 2001, WECHSLER TEST ADULT; Willis KJ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00013; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	76	33	33	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	SEP 24	2013	7								506	10.3389/fnhum.2013.00506			8	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	223IM	WOS:000324797900001	24093011	Green Published, gold			2022-02-06	
J	Moler, FW; Silverstein, FS; Meert, KL; Clark, AE; Holubkov, R; Browning, B; Slomine, BS; Christensen, JR; Dean, JM				Moler, Frank W.; Silverstein, Faye S.; Meert, Kathleen L.; Clark, Amy E.; Holubkov, Richard; Browning, Brittan; Slomine, Beth S.; Christensen, James R.; Dean, J. Michael			Rationale, Timeline, Study Design, and Protocol Overview of the Therapeutic Hypothermia After Pediatric Cardiac Arrest Trials	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cardiac arrest; in hospital; mortality; multicenter; outcome; out of hospital; pediatric; randomized controlled trial; targeted temperature control; therapeutic hypothermia; therapeutic normothermia	TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CEREBRAL-ISCHEMIA; CRITICAL-CARE; RESUSCITATION; NEUROPROTECTION; CARDIOPULMONARY; HYPERTHERMIA	Objective: To describe the rationale, timeline, study design, and protocol overview of the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials. Design: Multicenter randomized controlled trials. Setting: Pediatric intensive care and cardiac ICUs in the United States and Canada. Patients: Children from 48 hours to 18 years old, who have return of circulation after cardiac arrest, who meet trial eligibility criteria, and whose guardians provide written consent. Interventions: Therapeutic hypothermia or therapeutic normothermia. Measurements and Main Results: From concept inception in 2002 until trial initiation in 2009, 7 years were required to plan and operationalize the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials. Two National Institute of Child Health and Human Development clinical trial planning grants (R21 and R34) supported feasibility assessment and protocol development. Two clinical research networks, Pediatric Emergency Care Applied Research Network and Collaborative Pediatric Critical Care Research Network, provided infrastructure resources. Two National Heart Lung Blood Institute U01 awards provided funding to conduct separate trials of in-hospital and out-of-hospital cardiac arrest. A pilot vanguard phase that included half the clinical sites began on March 9, 2009, and this was followed by full trial funding through 2015. Conclusions: Over a decade will have been required to plan, design, operationalize, and conduct the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials. Details described in this report, such as participation of clinical research networks and clinical trial planning grants utilization, may be of utility for individuals who are planning investigator-initiated, federally supported clinical trials.	[Moler, Frank W.; Silverstein, Faye S.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Meert, Kathleen L.] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Clark, Amy E.; Holubkov, Richard; Browning, Brittan; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Christensen, James R.] Kennedy Krieger Inst, Dept Pediat Rehabil Med, Baltimore, MD USA		Moler, FW (corresponding author), Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.	fmoler@umich.edu		Holubkov, Richard/0000-0003-0431-3381	Pediatric Emergency Care Applied Research Network (PECARN) [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]; Collaborative Pediatric Critical Care Research Network (CPCCRN) [U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, U01HD049934]; National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD044955]; NIH, NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD050531]; NIH, National Heart Lung Blood Institute (NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL094345]; NIH, NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL094339]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD050012, U10HD050096, U01HD049934, UG1HD050096, U10HD049981, U10HD049983] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R34HD050531, U10HD049945, R21HD044955] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094339, U01HL094345] Funding Source: NIH RePORTER	Supported, in part, by the Pediatric Emergency Care Applied Research Network (PECARN) from cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 and the Collaborative Pediatric Critical Care Research Network (CPCCRN) from cooperative agreements (U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, and U01HD049934).; Dr. Moler received federal grants HD044955 from the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); HD050531 from NIH, NICHD; and HL094345 from NIH, National Heart Lung Blood Institute (NHLBI). Dr. Dean received federal grant HL094339 from NIH, NHLBI. Drs. Silverstein, Meert, Clark, Holubkov, Browning, Slomine, and Christensen received funding from NIH.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Adelson PD, 2012, J NEUROTRAUM, V29, pA17; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Corbett D, 1997, STROKE, V28, P2238, DOI 10.1161/01.STR.28.11.2238; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dumas F, 2011, CIRCULATION, V123, P877, DOI 10.1161/CIRCULATIONAHA.110.987347; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Laptook AR, 1997, PEDIATR RES, V42, P17, DOI 10.1203/00006450-199707000-00004; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Meert KL, 2009, PEDIATR CRIT CARE ME, V10, P544, DOI 10.1097/PCC.0b013e3181a7045c; Moler FW, 2011, CRIT CARE MED, V39, P141, DOI 10.1097/CCM.0b013e3181fa3c17; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pediat Emergency Care Applied Res, 2003, ACAD EMERG MED, V10, P661; Pemberton VL, 2013, PEDIATR CRIT CARE ME, V14, P19, DOI 10.1097/PCC.0b013e31825b860b; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sparrow S.S., 2005, VINELAND ADAPTIVE BE; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; Willson DF, 2006, PEDIATR CRIT CARE ME, V7, P301, DOI 10.1097/01.PCC.0000227106.66902.4F; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	35	33	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2013	14	7					E304	E315		10.1097/PCC.0b013e31828a863a			12	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	235GN	WOS:000325705100001	23842585	Green Accepted			2022-02-06	
J	Dvorkin, AY; Ramaiya, M; Larson, EB; Zollman, FS; Hsu, N; Pacini, S; Shah, A; Patton, JL				Dvorkin, Assaf Y.; Ramaiya, Milan; Larson, Eric B.; Zollman, Felise S.; Hsu, Nancy; Pacini, Sonia; Shah, Amit; Patton, James L.			A "virtually minimal" visuo-haptic training of attention in severe traumatic brain injury	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Virtual reality; Robotics; Attention; Rehabilitation; TBI	COGNITIVE REHABILITATION; ONLINE CONTROL; MOTOR CONTROL; REALITY; INTERVENTION; REMEDIATION; ENVIRONMENT; PROGRAMS; BENEFITS; DEFICITS	Background: Although common during the early stages of recovery from severe traumatic brain injury (TBI), attention deficits have been scarcely investigated. Encouraging evidence suggests beneficial effects of attention training in more chronic and higher functioning patients. Interactive technology may provide new opportunities for rehabilitation in inpatients who are earlier in their recovery. Methods: We designed a "virtually minimal" approach using robot-rendered haptics in a virtual environment to train severely injured inpatients in the early stages of recovery to sustain attention to a visuo-motor task. 21 inpatients with severe TBI completed repetitive reaching toward targets that were both seen and felt. Patients were tested over two consecutive days, experiencing 3 conditions (no haptic feedback, a break-through force, and haptic nudge) in 12 successive, 4-minute blocks. Results: The interactive visuo-haptic environments were well-tolerated and engaging. Patients typically remained attentive to the task. However, patients exhibited attention loss both before (prolonged initiation) and during (pauses during motion) a movement. Compared to no haptic feedback, patients benefited from haptic nudge cues but not break-through forces. As training progressed, patients increased the number of targets acquired and spontaneously improved from one day to the next. Conclusions: Interactive visuo-haptic environments could be beneficial for attention training for severe TBI patients in the early stages of recovery and warrants further and more prolonged clinical testing.	[Dvorkin, Assaf Y.; Larson, Eric B.; Zollman, Felise S.; Hsu, Nancy; Pacini, Sonia; Patton, James L.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Dvorkin, Assaf Y.; Larson, Eric B.; Zollman, Felise S.; Patton, James L.] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Ramaiya, Milan; Shah, Amit; Patton, James L.] Univ Illinois, Chicago, IL USA		Dvorkin, AY (corresponding author), Rehabil Inst Chicago, 345 E Super St, Chicago, IL 60611 USA.	sasaf@vms.huji.ac.il	Larson, Eric/AAD-9567-2021		US Department of Education, National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133A080045A]	We gratefully acknowledge Kathleen Beck and Lindsay Davitt for assisting with initial study design and data collection. This work was supported by the US Department of Education, National Institute on Disability and Rehabilitation Research (Grant #H133A080045A). The opinions expressed here do not necessarily represent the policy of the Department of Education.	Ariff G, 2002, J NEUROSCI, V22, P7721; Bluteau J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001775; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Brewer BR, 2008, BRAIN RES BULL, V75, P804, DOI 10.1016/j.brainresbull.2008.01.006; Cantagallo, 2003, Z NEUROPSYCHOL, V14, P283, DOI [10.1024/1016-264X.14.4.283, DOI 10.1024/1016-264X.14.4.283]; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Dvorkin Assaf Y, 2009, 2009 IEEE International Conference on Rehabilitation Robotics: Reaching Users & the Community (ICORR), P962, DOI 10.1109/ICORR.2009.5209629; Dvorkin AY, 2013, BRAIN INJURY, V27, P957, DOI 10.3109/02699052.2013.793399; Dvorkin AY, 2009, EXP BRAIN RES, V193, P95, DOI 10.1007/s00221-008-1598-z; Galbiati S, 2009, NEUROPSYCHOLOGY, V23, P40, DOI 10.1037/a0013409; Gray R, 2002, EXP BRAIN RES, V145, P50, DOI 10.1007/s00221-002-1085-x; Hagen C, 1979, REHABILITATION HEAD, P87; Hart T, 2006, ARCH PHYS MED REHAB, V87, P647, DOI 10.1016/j.apmr.2006.01.016; Huang FC, 2007, J MOTOR BEHAV, V39, P179, DOI 10.3200/JMBR.39.3.179-193; Jones CM, 2008, EXP BRAIN RES, V186, P659, DOI 10.1007/s00221-008-1277-0; Larson EB, 2011, BRAIN INJURY, V25, P274, DOI 10.3109/02699052.2010.551648; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Merlo JL, 2010, AM J PSYCHOL, V123, P413, DOI 10.5406/amerjpsyc.123.4.0413; Michel J A, 2006, Eura Medicophys, V42, P59; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Palmese CA, 2000, BRAIN INJURY, V14, P535; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Patton J, 2006, ASSIST TECHNOL, V18, P181, DOI 10.1080/10400435.2006.10131917; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; Pittenger DJ, 2002, GENET SOC GEN PSYCH, V128, P237; Plotnik M, 1998, J NEUROL NEUROSUR PS, V65, P328, DOI 10.1136/jnnp.65.3.328; Potter GG, 2007, NEUROPSYCHOPHARMACOL, V32, P2135, DOI 10.1038/sj.npp.1301339; Rizzo A, 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI 10.1162/1054746053967094; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Spence C, 2004, CROSSMODAL SPACE CRO; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Weiss PL, 2003, CYBERPSYCHOL BEHAV, V6, P335, DOI 10.1089/109493103322011650; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zoccolotti P, 2011, EUR J PHYS REHAB MED, V47, P123	42	33	36	1	37	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1743-0003		J NEUROENG REHABIL	J. NeuroEng. Rehabil.	AUG 9	2013	10								92	10.1186/1743-0003-10-92			9	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering; Neurosciences & Neurology; Rehabilitation	199NE	WOS:000323000800001	23938101	Green Published, gold			2022-02-06	
J	Ahmed, FA; Kamnaksh, A; Kovesdi, E; Long, JB; Agoston, DV				Ahmed, Farid A.; Kamnaksh, Alaa; Kovesdi, Erzsebet; Long, Joseph B.; Agoston, Denes V.			Long-term consequences of single and multiple mild blast exposure on select physiological parameters and blood-based biomarkers	ELECTROPHORESIS			English	Article						Animal models; Brain trauma; Experimental; Physiology; Proteomics	TRAUMATIC BRAIN-INJURY; CONCUSSION; RATS	Mild traumatic brain injury (mTBI), especially when it is repeated (rmTBI), can lead to progressive degenerative diseases and lasting neuropsychiatric abnormalities. To better understand the long-term pathobiological changes in mTBI and rmTBI, we exposed rats to single or repeated (5 total; administered on consecutive days) mild blast overpressure, monitored changes in physiological parameters, and determined the plasma levels of select biomarkers at 42 days post injury by proteomics. We unexpectedly found comparable changes in arterial oxygen saturation levels and heart rates of single-injured (SI) and multiple-injured (MI) rats throughout the observation period. Our analyses indicated lasting oxidative stress, vascular abnormalities, and neuronal and glial cell loss in both injured groups. However, MI rats exhibited a relatively more pronounced increase in the plasma levels of most of the tested markers-particularly those associated with inflammation-albeit the differences between the two injured groups were not statistically significant. Our findings indicate that the frequency of blast exposures is an important determinant of the resulting cumulative damage in rmTBI.	[Ahmed, Farid A.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Ahmed, Farid A.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Long, Joseph B.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA		Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1703F]	We thank the Neurotrauma Team at the Walter Reed Army Institute of Research for their technical help during the exposures. This work was supported by the Center for Neuroscience and Regenerative Medicine grant number G1703F. The views, opinions, and/or findings contained herein are those of the authors and should not be construed as an official position, policy, or decision of the Department of the Army or the Department of Defense. The authors have no financial disclosures. Animal handling and treatments were conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations related to animals and experiments involving animals, and adhered to principles stated in the Guide to the Care and Use of Laboratory Animals, National Research Council. The facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.	Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Dash PK, 2010, J NEUROSCI RES, V88, P1719, DOI 10.1002/jnr.22336; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Schoknecht K, 2012, EPILEPSIA, V53, P7, DOI 10.1111/j.1528-1167.2012.03697.x; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Yeh SH, 2011, BRAIN PATHOL, V21, P249, DOI 10.1111/j.1750-3639.2010.00443.x	18	33	35	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	AUG	2013	34	15					2229	2233		10.1002/elps.201300077			5	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	261KJ	WOS:000327663600012	23712899				2022-02-06	
J	Labombarda, F; Ghoumari, AT; Liere, P; De Nicola, AE; Schumacher, M; Guennoun, R				Labombarda, Florencia; Ghoumari, Abdel Tvloumen; Liere, Philippe; De Nicola, Alejandro E.; Schumacher, Michael; Guennoun, Rachida			Neuroprotection by steroids after neurotrauma in organotypic spinal cord cultures: A key role for progesterone receptors and steroidal modulators of GABA(A) receptors	NEUROPHARMACOLOGY			English	Article						Progesterone; Allopregnanolone; Progesterone receptor; GABA(A) receptors; Organotypic slice cultures; Spinal cord	MYELIN BASIC-PROTEIN; NEUROACTIVE STEROIDS; COGNITIVE DEFICITS; SLICE CULTURES; CELL-DEATH; ALLOPREGNANOLONE; NEUROSTEROIDS; EXPRESSION; INJURY; NEUROPATHY	Progesterone is neuroprotective after spinal cord injury, however its mechanism of action remains unexplored. Here we used organotypic spinal cord slice cultures from 3 weeks-old mice to evaluate the mechanisms of neuroprotection by progesterone and its 5 alpha-reduced metabolites. In vitro spinal cord injury, using a weight drop model, induced a decrease in the number of motoneurons. This was correlated with an increase in the number of dying cells (PI+ cells) and in LDH release. Addition of 10 mu M of progesterone, 5 alpha-dihydroprogesterone (5 alpha-DHP) or allopregnanolone (3 alpha, 5 alpha-tetrahydroprogesterone) to the medium at the time of injury rescued the spinal cord slices from the effects of damage. Progesterone prevented membrane cell damage, motoneuron loss and cell death. These effects were not due to its bioconversion to 5 alpha-DHP nor to allopregnanolone, as supported by the finasteride, an inhibitor of 5 alpha-reductase enzymes, and by the absence of 5 alpha-reduced progesterone metabolites in the slices analyzed by gas chromatography mass spectrometry. The neuroprotective effects of progesterone required PR as they could not be observed in slices from homozygous knockout PR-/- mice. Allopregnanolone treatment was also neuroprotective. Its effects were not due to its bioconversion back to 5 alpha-DHP, which can activate gene transcription via PR, because they were still observed in slices from knockout PR-/- mice. Allopregnanolone effects involved GABA(A) receptors, as they were inhibited by the selective GABA(A) receptor antagonist Gabazine, in both PR+/+ and PR-/- mice. Altogether, these findings identify both PR and GABA(A) receptors as important targets for neuroprotection by progestagens after spinal cord injury. (C) 2013 Elsevier Ltd. All rights reserved.	[Labombarda, Florencia; Ghoumari, Abdel Tvloumen; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [Labombarda, Florencia; Ghoumari, Abdel Tvloumen; Liere, Philippe; Schumacher, Michael; Guennoun, Rachida] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Labombarda, Florencia; De Nicola, Alejandro E.] Univ Buenos Aires, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1053 Buenos Aires, DF, Argentina; [Labombarda, Florencia; De Nicola, Alejandro E.] Univ Buenos Aires, Dept Human Biochem, RA-1053 Buenos Aires, DF, Argentina		Guennoun, R (corresponding author), INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	flabo@dna.uba.ar; abdel.ghoumari@inserm.fr; philippe.liere@inserm.fr; alejandrodenicola@gmail.com; michael.schumacher@inserm.fr; rachida.guennoun@inserm.fr	Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371	AFMAssociation Francaise contre les Myopathies [RAE06031LLA]; Government of France (INSERM/CONICET); Government of Argentina (INSERM/CONICET); INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; "la Fondation pour la Recherche Medicale" (FRM)Fondation pour la Recherche Medicale	This work was partly supported by funds from AFM (RAE06031LLA) and a cooperative program between the Governments of France and Argentina (INSERM/CONICET). F.L. was supported by INSERM and by a post-doctoral research fellowship from "la Fondation pour la Recherche Medicale" (FRM). We are grateful to Dr J. Lydon for providing heterozygous breeder pairs of PRlacz mice to establish the colony in our animal facility. We thank the excellent technical assistance of B. Delespierre for mice genotyping; and B. Eychenne, A. Pianos and A. Cambourg for steroid measurements by GC/MS.	Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Ardeshiri A, 2006, EUR J NEUROSCI, V24, P2567, DOI 10.1111/j.1460-9568.2006.05142.x; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BURKE RE, 1977, J NEUROPHYSIOL, V40, P667, DOI 10.1152/jn.1977.40.3.667; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Diaz Brinton R., 2011, HORMONES NEURODEGENE, P287; Dingledine R, 1999, PHARMACOL REV, V51, P7; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Goletiani NV, 2007, EXP CLIN PSYCHOPHARM, V15, P427, DOI 10.1037/1064-1297.15.5.427; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Gwak YS, 2011, CURR PAIN HEADACHE R, V15, P215, DOI 10.1007/s11916-011-0186-2; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Ishihara Y, 2013, J STEROID BIOCHEM, V135, P1, DOI 10.1016/j.jsbmb.2012.12.013; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Keller AF, 2004, J NEUROSCI, V24, P907, DOI 10.1523/JNEUROSCI.4642-03.2004; KERKUT GA, 1995, PROG NEUROBIOL, V46, P1, DOI 10.1016/0301-0082(94)00055-M; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 2006, J MOL NEUROSCI, V28, P1, DOI 10.1385/JMN:28:1:1; Melcangi RC, 2010, HORM BEHAV, V57, P2, DOI 10.1016/j.yhbeh.2009.06.001; Patte-Mensah C, 2006, J MOL NEUROSCI, V28, P17, DOI 10.1385/JMN:28:1:17; Patte-Mensah C, 2008, BRAIN RES REV, V57, P454, DOI 10.1016/j.brainresrev.2007.05.007; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rupprecht R, 1996, EUR J PHARMACOL, V303, P227, DOI 10.1016/0014-2999(96)00036-2; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Singh C, 2012, NEUROBIOL AGING, V33, P1493, DOI 10.1016/j.neurobiolaging.2011.06.008; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; STEINER TJ, 1972, J PHYSIOL-LONDON, V222, pP123; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Ueno S, 1997, J NEUROSCI, V17, P625; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	63	33	37	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	AUG	2013	71						46	55		10.1016/j.neuropharm.2013.03.010			10	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	164QI	WOS:000320424200006	23542439				2022-02-06	
J	Cheadle, GA; Costantini, TW; Lopez, N; Bansal, V; Eliceiri, BP; Coimbra, R				Cheadle, Gerald A.; Costantini, Todd W.; Lopez, Nicole; Bansal, Vishal; Eliceiri, Brian P.; Coimbra, Raul			Enteric Glia Cells Attenuate Cytomix-Induced Intestinal Epithelial Barrier Breakdown	PLOS ONE			English	Article							NERVE-STIMULATION PROTECTS; TIGHT JUNCTION STRUCTURE; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; S-NITROSYLATION; BURN-INJURY; PERMEABILITY; GUT; KINASE; ACTIVATION	Background: Intestinal barrier failure may lead to systemic inflammation and distant organ injury in patients following severe injury. Enteric glia cells (EGCs) have been shown to play an important role in maintaining gut barrier integrity through secretion of S-Nitrosoglutathione (GSNO). We have recently shown than Vagal Nerve Stimulation (VNS) increases EGC activation, which was associated with improved gut barrier integrity. Thus, we sought to further study the mechanism by which EGCs prevent intestinal barrier breakdown utilizing an in vitro model. We postulated that EGCs, through the secretion of GSNO, would improve intestinal barrier function through improved expression and localization of intestinal tight junction proteins. Methods: Epithelial cells were co-cultured with EGCs or incubated with GSNO and exposed to Cytomix (TNF-alpha, INF-gamma, IL-1 beta) for 24 hours. Barrier function was assessed by permeability to 4kDa FITC-Dextran. Changes in tight junction proteins ZO-1, occludin, and phospho-MLC (P-MLC) were assessed by immunohistochemistry and immunoblot. Key Results: Co-culture of Cytomix-stimulated epithelial monolayers with EGCs prevented increases in permeability and improved expression and localization of occludin, ZO-1, and P-MLC. Further, treatment of epithelial monolayers with GSNO also prevented Cytomix-induced increases in permeability and exhibited a similar improvement in expression and localization of occludin, ZO-1, and P-MLC. Conclusions & Inferences: The addition of EGCs, or their secreted mediator GSNO, prevents epithelial barrier failure after injury and improved expression of tight junction proteins. Thus, therapies that increase EGC activation, such as VNS, may be a novel strategy to limit barrier failure in patients following severe injury.	[Cheadle, Gerald A.; Costantini, Todd W.; Lopez, Nicole; Bansal, Vishal; Eliceiri, Brian P.; Coimbra, Raul] Univ Calif San Diego Hlth Sci, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA USA		Coimbra, R (corresponding author), Univ Calif San Diego Hlth Sci, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Eliceiri, Brian/0000-0003-1811-1916; Lopez, Nicole/0000-0002-4807-7360; Costantini, Todd/0000-0002-0215-5327	American Association for the Surgery of Trauma (AAST) Research and Education Foundation Scholarship	This work was supported by the American Association for the Surgery of Trauma (AAST) Research and Education Foundation Scholarship (TWC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Sadi R, 2008, J IMMUNOL, V180, P5653, DOI 10.4049/jimmunol.180.8.5653; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Boivin MA, 2007, AM J PHYSIOL-GASTR L, V292, pG590, DOI 10.1152/ajpgi.00252.2006; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Chavez AM, 1999, CRIT CARE MED, V27, P2246, DOI 10.1097/00003246-199910000-00030; Conlin VS, 2009, AM J PHYSIOL-GASTR L, V297, pG735, DOI 10.1152/ajpgi.90551.2008; Costantini TW, 2012, AM J PATHOL, V181, P478, DOI 10.1016/j.ajpath.2012.04.005; Costantini TW, 2010, AM J PHYSIOL-GASTR L, V299, pG1308, DOI 10.1152/ajpgi.00156.2010; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Costantini TW, 2009, J TRAUMA, V67, P1162, DOI 10.1097/TA.0b013e3181ba3577; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Costantini TW, 2009, J TRAUMA, V66, P17, DOI 10.1097/TA.0b013e318191bb1f; Costantini TW, 2009, LIFE SCI, V84, P18, DOI 10.1016/j.lfs.2008.10.007; Deitch EA, 2004, CRIT CARE MED, V32, P533, DOI 10.1097/01.CCM.0000109773.00644.F4; Flamant M, 2011, GUT, V60, P473, DOI 10.1136/gut.2010.229237; Hollander D, 2003, J Physiol Pharmacol, V54 Suppl 4, P183; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Krzyzaniak M, 2011, J TRAUMA, V70, P1168, DOI 10.1097/TA.0b013e318216f754; Krzyzaniak MJ, 2011, SURGERY, V150, P379, DOI 10.1016/j.surg.2011.06.008; MacEachern SJ, 2011, J PHYSIOL-LONDON, V589, P3333, DOI 10.1113/jphysiol.2011.207902; MADARA JL, 1987, AM J PHYSIOL, V253, pC854, DOI 10.1152/ajpcell.1987.253.6.C854; Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101; Musch MW, 2006, AM J PHYSIOL-GASTR L, V290, pG222, DOI 10.1152/ajpgi.00301.2005; Neunlist M, 2008, J INTERN MED, V263, P577, DOI 10.1111/j.1365-2796.2008.01963.x; Neunlist M, 2007, AM J PHYSIOL-GASTR L, V292, pG231, DOI 10.1152/ajpgi.00276.2005; Neunlist M, 2003, AM J PHYSIOL-GASTR L, V285, pG1028, DOI 10.1152/ajpgi.00066.2003; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Ruhl A, 2004, NEUROGASTROENT MOTIL, V16, P44, DOI 10.1111/j.1743-3150.2004.00474.x; Samonte VA, 2004, CRIT CARE MED, V32, P2267, DOI 10.1097/01.CCM.0000145579.66001.05; Savidge TC, 2007, LAB INVEST, V87, P731, DOI 10.1038/labinvest.3700600; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; Shiou SR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.154625; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Van Landeghem L, 2011, AM J PHYSIOL-GASTR L, V300, pG976, DOI 10.1152/ajpgi.00427.2010; Van Landeghem L, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-507; Wang Q, 2008, SHOCK, V29, P531, DOI 10.1097/SHK.0b013e318150737f	40	33	34	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2013	8	7							e69042	10.1371/journal.pone.0069042			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175ZH	WOS:000321271900045	23840906	Green Published, Green Submitted, gold			2022-02-06	
J	Elterman, J; Brasel, K; Brown, S; Bulger, E; Christenson, J; Kerby, JD; Kannas, D; Lin, S; Minei, JP; Rizoli, S; Tisherman, S; Schreiber, MA				Elterman, Joel; Brasel, Karen; Brown, Siobhan; Bulger, Eileen; Christenson, Jim; Kerby, Jeffrey D.; Kannas, Delores; Lin, Steven; Minei, Joseph P.; Rizoli, Sandro; Tisherman, Samuel; Schreiber, Martin A.		Resuscitation Outcomes Consortium	Transfusion of red blood cells in patients with a prehospital Glasgow Coma Scale score of 8 or less and no evidence of shock is associated with worse outcomes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	26th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 15-19, 2013	Scottsdale, AZ	Eastern Assoc Surg Trauma		Traumatic brain injury; transfusion; resuscitation	TRAUMATIC BRAIN-INJURY; CEREBRAL OXYGENATION; SEVERITY SCORE; RISK; ADMISSION; INSULTS	BACKGROUND: Red blood cell transfusion practices vary, and the optimal hemoglobin for patients with traumatic brain injury has not been established. METHODS: A retrospective review of data collected prospectively as part of a randomized, controlled trial involving emergency medical service agencies within the Resuscitation Outcomes Consortium was conducted. In patients with a Glasgow Coma Scale (GCS) score of 8 or less without evidence of shock (defined by a systolic blood pressure [SBP] G 70 or SBP of 70 to 90 with a heart rate >= 108), the association of red blood cell transfusion with 28-day survival, adult respiratory distress syndrome-free survival, Multiple Organ Dysfunction Score (MODs), and 6-month Extended Glasgow Outcome Scale (GOSE) score was modeled using multivariable logistic regression with robust SEs adjusting for age, sex, injury severity (Injury Severity Score [ISS]), initial GCS score, initial SBP, highest field heart rate, penetrating injury, fluid use, study site, and hemoglobin (Hgb) level. RESULTS: A total of 1,158 patients had a mean age of 40, 76% were male, and 98% experienced blunt trauma. The initial mean GCS score was 5, and the initial mean SBP was 134. The mean head Abbreviated Injury Scale (AIS) score was 3.5. A categorical interaction of red blood cell transfusion stratified by initial Hgb showed that when the first Hgb was greater than 10 g/dL, volume of packed red blood cell was associated with a decreased 28-day survival (odds ratio, 0.83; 95% confidence interval [CI], 0.74-0.93; p < 0.01) and decreased adult respiratory distress syndrome-free survival (odds ratio, 0.82; 95% CI, 0.74-0.92; p < 0.01). When the initial Hgb was greater than 10, each unit of blood transfused increased the MODs by 0.45 (coefficient 95% CI, 0.19-0.70; p < 0.01). CONCLUSION: In patients with a suspected traumatic brain injury and no evidence of shock, transfusion of red blood cells was associated with worse outcomes when the initial Hgb was greater than 10. Copyright (C) 2013 by Lippincott Williams & Wilkins	[Elterman, Joel; Schreiber, Martin A.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA; [Brasel, Karen] Med Coll Wisconsin, Milwaukie, WI USA; [Brown, Siobhan; Bulger, Eileen; Kannas, Delores] Univ Washington, Seattle, WA 98195 USA; [Kerby, Jeffrey D.] Univ Alabama Birmingham, Birmingham, AL USA; [Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Tisherman, Samuel] Univ Pittsburgh, Pittsburgh, PA USA; [Christenson, Jim] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Lin, Steven] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Rizoli, Sandro] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada		Elterman, J (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code L611, Portland, OR 97239 USA.	joel.b.elterman.mil@mail.mil	Lin, Steve/H-3723-2013; Tisherman, Samuel A./AAK-9377-2020	Lin, Steve/0000-0002-8644-9719; Tisherman, Samuel A./0000-0003-3810-3729; Brown, Siobhan/0000-0002-4774-3122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077871, U01HL077867, U01HL077881, U01HL077873, U01HL077885, U01HL077866, U01HL077863, U01HL077887, U01HL077872] Funding Source: NIH RePORTER		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Carson JL, 1999, TRANSFUSION, V39, P694, DOI 10.1046/j.1537-2995.1999.39070694.x; Claridge JA, 2002, AM SURGEON, V68, P566; Committee on Trauma American College of Surgeons, 2008, ATLS ADV TRAUM LIF S, V8th; Dunne James R, 2004, Surg Infect (Larchmt), V5, P395, DOI 10.1089/sur.2004.5.395; Figaji AA, 2010, PEDIATR CRIT CARE ME, V11, P325, DOI 10.1097/PCC.0b013e3181b80a8e; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Langois JA, 2004, TRAUMATIC BRAIN INJU; Leal-Noval SR, 2008, CURR OPIN CRIT CARE, V14, P156, DOI 10.1097/MCC.0b013e3282f57577; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Malone DL, 2000, CRIT CARE MED, V28, pA138; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rubin D.B., 2004, MULTIPLE IMPUTATION; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; The Brain Trauma Foundation, GUID MAN SEV TRAUM B; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	26	33	34	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2013	75	1					8	14		10.1097/TA.0b013e318298492e			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	300EV	WOS:000330448100002	23778432	Green Accepted			2022-02-06	
J	Sonmez, E; Kabatas, S; Ozen, O; Karabay, G; Turkoglu, S; Ogus, E; Yilmaz, C; Caner, H; Altinors, N				Sonmez, Erkin; Kabatas, Serdar; Ozen, Ozlem; Karabay, Gulten; Turkoglu, Suna; Ogus, Ersin; Yilmaz, Cem; Caner, Hakan; Altinors, Nur			Minocycline Treatment Inhibits Lipid Peroxidation, Preserves Spinal Cord Ultrastructure, and Improves Functional Outcome After Traumatic Spinal Cord Injury in the Rat	SPINE			English	Article						apoptosis; behavioral assessment; lipid peroxidation; minocycline; neuroprotection; traumatic spinal cord injury	NEUROPROTECTIVE AGENT; RECOVERY; BRAIN; ACTIVATION; MEXILETINE	Study design. A prospective, randomized experimental research. Objective. To evaluate the short- and long-term neuroprotective effects of minocycline on the secondary injury process of an experimental traumatic spinal cord injury (SCI) model. Summary of Background Data. Traumatic SCI is a devastating problem of health that results in high morbidity and mortality rates. The loss of function after SCI results from both the primary mechanical insult and the subsequent, multifaceted secondary response. Methods. A total of 80 adult male Spraque-Dawley rats (breeded by the Baskent University Animal Research Center) were randomly divided into 4 groups. A T10 contusion injury was produced by using modified Allen technique in all groups except the control group. No medication was administered to the rats in the trauma group. Minocycline was administered intraperitoneally and intravenously to the treatment groups. Short-term and/or long-term neuroprotective effects of minocycline on the lipid peroxidation (malondialdehyde, glutathione), apoptosis (terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate-biotin nick end labeling), ultrastructure of spinal cord (tissue electron microscopy), and behavioral assessments (Basso-Beattie-Bresnahan) were evaluated. Results. As compared with the trauma group, tissue malondialdehyde and glutathione levels demonstrated that minocycline significantly diminishes lipid peroxidation. Electromicroscopic study showed that minocycline preserves the ultrastructure of spinal cord tissue in the early post-traumatic period. Minocycline treatment significantly reduced the number of terminal deoxynucleotidyl trans-ferase mediated deoxyuridine triphosphate-biotin nick end labeling positive cells both 1 day and 28 days after SCI. Behavioral assessments showed significant improvement in the hind limb functions of minocycline receiving rats starting 7 days after the SCI. Any statistically significant difference was not found between intraperitoneal or intravenous routes for minocycline injection. Conclusion. Minocycline is neuroprotective and contributes to functional improvement after traumatic SCI by eliminating the destructive process of secondary injury. Having both satisfying antiinfl ammatory and antiapoptotic effects in experimental models, it promises to be of therapeutic use in human SCI.	[Sonmez, Erkin; Yilmaz, Cem; Caner, Hakan; Altinors, Nur] Baskent Univ, Dept Neurosurg, Sch Med, TR-06490 Ankara, Turkey; [Ozen, Ozlem] Baskent Univ, Dept Pathol, Sch Med, TR-06490 Ankara, Turkey; [Karabay, Gulten] Baskent Univ, Dept Histol, Sch Med, TR-06490 Ankara, Turkey; [Turkoglu, Suna] Baskent Univ, Dept Biochem, Sch Med, TR-06490 Ankara, Turkey; [Ogus, Ersin] Baskent Univ, Dept Biostat, Sch Med, TR-06490 Ankara, Turkey; [Kabatas, Serdar] Baskent Univ, Istanbul Training & Res Hosp, Sch Med, Dept Neurosurg, Istanbul, Turkey		Sonmez, E (corresponding author), Baskent Univ, Dept Neurosurg, Sch Med, 10 Sokak,45, TR-06490 Ankara, Turkey.	erkinso@gmail.com	Kabatas, Serdar/AAA-3069-2020; Sonmez, Erkin/AAI-8820-2021; Ozen, Ozlem/AAK-4468-2021; Turkoglu, Suna/AAJ-2243-2021; Ogus, Ersin/AAJ-1058-2021; yilmaz, cem/AAK-2948-2021	Kabatas, Serdar/0000-0003-2691-6861; Sonmez, Erkin/0000-0002-5693-3542; Ozen, Ozlem/0000-0002-9082-1317; Turkoglu, Suna/0000-0003-4805-1918; Ogus, Ersin/0000-0002-9877-421X; yilmaz, cem/0000-0002-2353-8044	Baskent University Research FundsBaskent University	Baskent University Research Funds were received to support this work.	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Buege J A, 1978, Methods Enzymol, V52, P302; Colovic M, 2003, J CHROMATOGR B, V791, P337, DOI 10.1016/S1570-0232(03)00247-2; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Garrido-Mesa N, 2013, PHARMACOL RES, V67, P18, DOI 10.1016/j.phrs.2012.10.006; Kaptanoglu E, 2005, J NEUROSURG-SPINE, V3, P53, DOI 10.3171/spi.2005.3.1.0053; Kaptanoglu E, 2002, J NEUROSURG, V97, P49, DOI 10.3171/spi.2002.97.1.0049; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	19	33	37	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 1	2013	38	15					1253	1259		10.1097/BRS.0b013e3182895587			7	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	298XR	WOS:000330358500012	23370685				2022-02-06	
J	Choe, AS; Belegu, V; Yoshida, S; Joel, S; Sadowsky, CL; Smith, SA; van Zijl, PCM; Pekar, JJ; McDonald, JW				Choe, Ann S.; Belegu, Visar; Yoshida, Shoko; Joel, Suresh; Sadowsky, Cristina L.; Smith, Seth A.; van Zijl, Peter C. M.; Pekar, James J.; McDonald, John W.			Extensive neurological recovery from a complete spinal cord injury: a case report and hypothesis on the role of cortical plasticity	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						spinal cord injury; trauma; diffusion tensor imaging; magnetization transfer imaging; resting state fMRI; plasticity	PRINCIPAL EIGENVECTOR MEASUREMENTS; MAGNETIZATION-TRANSFER; MULTIPLE-SCLEROSIS; INDEPENDENT COMPONENTS; FRACTIONAL ANISOTROPY; RADIAL DIFFUSIVITY; MEAN DIFFUSIVITY; NERVOUS-SYSTEM; MOTOR CORTEX; WHITE-MATTER	Neurological recovery in patients with severe spinal cord injury (SCI) is extremely rare. We have identified a patient with chronic cervical traumatic SCI, who suffered a complete loss of motor and sensory function below the injury for 6 weeks after the injury, but experienced a progressive neurological recovery that continued for 17 years. The extent of the patient's recovery from the severe trauma-induced paralysis is rare and remarkable. A detailed study of this patient using diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), and resting state fMRI (rs-fMRI) revealed structural and functional changes in the central nervous system that may be associated with the neurological recovery. Sixty-two percent cervical cord white matter atrophy was observed. DTI-derived quantities, more sensitive to axons, demonstrated focal changes, while MTI-derived quantity, more sensitive to myelin, showed a diffuse change. No significant cortical structural changes were observed, while rs-fMRI revealed increased brain functional connectivity between sensorimotor and visual networks. The study provides comprehensive description of the structural and functional changes in the patient using advanced MR imaging technique. This multimodal MR imaging study also shows the potential of rs-fMRI to measure the extent of cortical plasticity	[Choe, Ann S.; Belegu, Visar; McDonald, John W.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Choe, Ann S.; Belegu, Visar; Sadowsky, Cristina L.; McDonald, John W.] Kennedy Krieger Inc, Hugo W Moser Res Inst, Int Ctr Spinal Cord Injury, Baltimore, MD USA; [Choe, Ann S.; Joel, Suresh; van Zijl, Peter C. M.; Pekar, James J.] Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD USA; [Yoshida, Shoko; Joel, Suresh; van Zijl, Peter C. M.; Pekar, James J.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Sadowsky, Cristina L.; McDonald, John W.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; [Smith, Seth A.] Vanderbilt Univ, Dept Radiol & Radiol Sci, Inst Imaging Sci, Nashville, TN 37235 USA		McDonald, JW (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	mcdonaldj@kennedykrieger.org	AS, Choe/I-2637-2019; Van Zijl, Peter C/ABF-3732-2020	AS, Choe/0000-0001-7352-1489; Belegu, Visar/0000-0002-1361-4517; Pekar, James/0000-0002-9830-0655	DODUnited States Department of Defense [W81XWH-08-1-0192]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 EB006120-01A2, P41 EB015909]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [K01EB009120, P41EB015909, R21EB006120] Funding Source: NIH RePORTER	The authors would like to thank Dr. Jeffrey D. Rothstein for helpful discussion and advice. This work was supported in part by grants from the DOD (W81XWH-08-1-0192) and NIH (R21 EB006120-01A2 and P41 EB015909).	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beg MF, 2005, INT J COMPUT VISION, V61, P139, DOI 10.1023/B:VISI.0000043755.93987.aa; Belegu V, 2007, NEUROSURG CLIN N AM, V18, P143, DOI 10.1016/j.nec.2006.10.012; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Choe AS, 2012, NMR BIOMED, V25, P900, DOI 10.1002/nbm.1810; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Cohen-Adad J, 2013, AMYOTROPH LAT SCL FR, V14, P30, DOI 10.3109/17482968.2012.701308; Crawley AP, 2004, BRAIN RES, V1028, P19, DOI 10.1016/j.brainres.2004.08.060; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Faria AV, 2011, NEUROIMAGE, V54, P1854, DOI 10.1016/j.neuroimage.2010.09.061; Faria AV, 2010, NEUROIMAGE, V52, P415, DOI 10.1016/j.neuroimage.2010.04.238; Farrell JAD, 2008, MAGN RESON MED, V59, P1079, DOI 10.1002/mrm.21563; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Farrell JAD, 2010, MAGN RESON MED, V63, P1323, DOI 10.1002/mrm.22389; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; Fountas KN, 1998, SPINE, V23, P1513, DOI 10.1097/00007632-199807150-00001; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Gilmore CP, 2005, ARCH NEUROL-CHICAGO, V62, P1859, DOI 10.1001/archneur.62.12.1859; Henderson LA, 2011, J NEUROSCI, V31, P2630, DOI 10.1523/JNEUROSCI.2717-10.2011; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Joel SE, 2011, MAGN RESON MED, V66, P644, DOI 10.1002/mrm.22818; Jurkiewicz MT, 2010, NEUROREHAB NEURAL RE, V24, P136, DOI 10.1177/1545968309347680; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Kameyama T, 1996, SPINE, V21, P1285, DOI 10.1097/00007632-199606010-00001; Kirshblum S, 2004, ARCH PHYS MED REHAB, V85, P1811, DOI 10.1016/j.apmr.2004.03.015; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Ko HY, 2004, SPINAL CORD, V42, P35, DOI 10.1038/sj.sc.3101538; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Landman BA, 2011, NEUROIMAGE, V54, P2854, DOI 10.1016/j.neuroimage.2010.11.047; Landman BA, 2010, NMR BIOMED, V23, P152, DOI 10.1002/nbm.1437; Levesque IR, 2010, MAGN RESON MED, V63, P633, DOI 10.1002/mrm.22244; Li YO, 2007, HUM BRAIN MAPP, V28, P1251, DOI 10.1002/hbm.20359; Loy DN, 2007, J NEUROTRAUM, V24, P979, DOI 10.1089/neu.2006.0253; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Maes F, 1999, Med Image Anal, V3, P373, DOI 10.1016/S1361-8415(99)80030-9; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Naismith RT, 2009, NEUROLOGY, V72, P589, DOI 10.1212/01.wnl.0000335766.22758.cd; NATHAN PW, 1994, BRAIN, V117, P337, DOI 10.1093/brain/117.2.337; Oishi K, 2011, NEUROIMAGE, V56, P8, DOI 10.1016/j.neuroimage.2011.01.051; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Schmithorst VJ, 2004, J MAGN RESON IMAGING, V19, P365, DOI 10.1002/jmri.20009; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seitz RJ, 1999, RESTOR NEUROL NEUROS, V14, P25; Sigmund EE, 2012, NMR BIOMED, V25, P891, DOI 10.1002/nbm.1809; Smith SA, 2005, MAGN RESON MED, V54, P201, DOI 10.1002/mrm.20553; Smith SA, 2010, NMR BIOMED, V23, P207, DOI 10.1002/nbm.1447; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stevens MC, 2009, BRAIN COGNITION, V70, P1, DOI 10.1016/j.bandc.2008.12.009; Vazquez Xoan Miguens, 2008, J Forensic Leg Med, V15, P20, DOI 10.1016/j.jflm.2007.06.003; White LE, 1997, CEREB CORTEX, V7, P31, DOI 10.1093/cercor/7.1.31; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Zackowski KM, 2009, BRAIN, V132, P1200, DOI 10.1093/brain/awp032	66	33	36	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JUN 25	2013	7								290	10.3389/fnhum.2013.00290			15	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	172FD	WOS:000320984500001	23805087	gold, Green Published			2022-02-06	
J	Graham, DP; Helmer, DA; Harding, MJ; Kosten, TR; Petersen, NJ; Nielsen, DA				Graham, David P.; Helmer, Drew A.; Harding, Mark J.; Kosten, Thomas R.; Petersen, Nancy J.; Nielsen, David A.			Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Genetic Factors; Polymorphism; Resilience; Serotonin Transporter; Traumatic Brain Injury; Veterans	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSION SYNDROME; COMMUNITY REINTEGRATION; PROMOTER POLYMORPHISM; 5-HTTLPR GENOTYPE; BIASED ATTENTION; FEMALE VETERANS; PTSD CHECKLIST; GENE; DEPRESSION	Evidence indicates that individuals with the 5-HTTLPR variant short/short genotype have increased sensitivity to both positive and negative perceptions of perceived social support. The aim of this study was to evaluate this association among Veterans in the context of mild traumatic brain injury (TBI). As part of a larger TBI center, we performed a cross-sectional study of 67 OEF/OIF/OND Veterans (41 with TBI and 26 controls without TBI) who completed the questionnaires and consented to genetic testing. The primary measures included the Connor-Davidson Resilience Scale (CDRISC) and the Perceived Limitations in community participation subscale of the Community Reintegration of Service Members Instrument (CRIS-PL). Both 5-HTTLPR genotype and TBI status were independently associated with the CRIS-PL (p = .009 for genotype, p = .001 for TBI) and the CDRISC (p = .015 for genotype, p = .003 for TBI) scores. This study suggests that both the 5-HTTLPR genotype and TBI status independently, in an almost equal but opposite direction, influence resilience and perceived limitations to social participation. Further, resilience appears more sensitive to perceived limitations in Veterans carrying an S'S' genotype than in L' carriers, but only in the context of having sustained a TBI. While having a TBI appeared to increase a Veteran's sensitivity to social stress, the Veteran's who were L' allele carriers with a TBI fared the worst, with lower resilience and more perceived limitations for community participation compared to L' carrier Veterans without a TBI or Veterans with the S'S' genotype regardless of TBI status. Published by Elsevier Ltd.	[Graham, David P.; Helmer, Drew A.; Harding, Mark J.; Kosten, Thomas R.; Petersen, Nancy J.; Nielsen, David A.] Michael E DeBakey Vet Affairs VA Med Ctr, Neurorehabil Neurons Networks Traumat Brain Injur, Houston, TX USA; [Graham, David P.; Harding, Mark J.; Nielsen, David A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Graham, David P.] South Cent Mental Illness Res Educ & Clin Ctr MIR, Dept Vet Affairs, Houston, TX USA; [Helmer, Drew A.] VA New Jersey Healthcare Syst, War Related Injury & Illness Ctr, E Orange, NJ USA; [Helmer, Drew A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Petersen, Nancy J.] Michael E DeBakey Vet Affairs VA Med Ctr, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA		Graham, DP (corresponding author), Michael E DeBakey VAMC, 2002 Holcombe Blvd 153 TBI,Bldg 100,STE 2B-126A, Houston, TX 77030 USA.	david.graham@va.gov	Graham, David/J-1158-2014; Kosten, Thomas/AAI-5998-2021; Nielsen, David A/B-4655-2009		Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; Neurons to Networks TBI Center of Excellence [B6812C]; Office of Research and Development, Rehabilitation Research and Development Service Career Development Award-2 [B7496W]; Houston VA HSR&D Center of Excellence [HFP90-020, DA026120 NIH/NIDA DA026120]; Toomim Family Fund; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R25DA026120] Funding Source: NIH RePORTER	This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service: the Neurorehabilitation: Neurons to Networks TBI Center of Excellence (Grant #B6812C), Office of Research and Development, Rehabilitation Research and Development Service Career Development Award-2 (Grant #B7496W), in part by the Houston VA HSR&D Center of Excellence (HFP90-020); through MD Anderson's Cancer Center Support Grant DA026120 NIH/NIDA DA026120, and the Toomim Family Fund. The funding sources had no role in the study design; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to submit the paper for publication.	Amstadter AB, 2012, J PSYCHIATR RES, V46, P87, DOI 10.1016/j.jpsychires.2011.09.017; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Brody GH, 2009, CHILD DEV, V80, P645, DOI 10.1111/j.1467-8624.2009.01288.x; Brody GH, 2009, J CONSULT CLIN PSYCH, V77, P1, DOI 10.1037/a0012996; Carli V, 2011, EUR PSYCHIAT, V26, P471, DOI 10.1016/j.eurpsy.2011.04.008; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Davidson J, 2008, INT CLIN PSYCHOPHARM, V23, P299, DOI 10.1097/YIC.0b013e32830c202d; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Fox E, 2011, BIOL PSYCHIAT, V70, P1049, DOI 10.1016/j.biopsych.2011.07.004; Fox E, 2009, P R SOC B, V276, P1747, DOI 10.1098/rspb.2008.1788; Haddley K, 2012, Curr Top Behav Neurosci, V12, P503; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hariri AR, 2009, ANNU REV NEUROSCI, V32, P225, DOI 10.1146/annurev.neuro.051508.135335; Hu XZ, 2006, AM J HUM GENET, V78, P815, DOI 10.1086/503850; Hu XZ, 2005, ALCOHOL CLIN EXP RES, V29, P8, DOI 10.1097/01.ALC.0000150008.68473.62; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kaufman J, 2004, P NATL ACAD SCI USA, V101, P17316, DOI 10.1073/pnas.0404376101; Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007; Kwang T, 2010, DEPRESS ANXIETY, V27, P746, DOI 10.1002/da.20708; Lang AJ, 2003, J TRAUMA STRESS, V16, P257, DOI 10.1023/A:1023796007788; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luthar SS, 2000, CHILD DEV, V71, P573, DOI 10.1111/1467-8624.00168; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Manuck SB, 2004, PSYCHONEUROENDOCRINO, V29, P651, DOI 10.1016/S0306-4530(03)00094-5; Markus CR, 2011, NEUROPSYCHOPHARMACOL, V36, P819, DOI 10.1038/npp.2010.221; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; O'Hara R, 2012, AM J GERIATRIC PSYCH, V00, P00; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Resnik L, 2011, J REHABIL RES DEV, V48, P89, DOI 10.1682/JRRD.2010.04.0070; Resnik L, 2009, J REHABIL RES DEV, V46, P469, DOI 10.1682/JRRD.2008.07.0082; Resnik LJ, 2007, J REHABIL RES DEV, V44, P991, DOI 10.1682/JRRD.2007.05.0071; ROBERTS RE, 1983, AM J PSYCHIAT, V140, P41; Roy A, 2007, NEUROPSYCHOPHARMACOL, V32, P2046, DOI 10.1038/sj.npp.1301331; Stein MB, 2008, NEUROPSYCHOPHARMACOL, V33, P312, DOI 10.1038/sj.npp.1301422; Stein MB, 2006, PSYCHOPHARMACOLOGY, V187, P68, DOI 10.1007/s00213-006-0349-8; Taylor SE, 2006, BIOL PSYCHIAT, V60, P671, DOI 10.1016/j.biopsych.2006.04.019; Uher R, 2010, MOL PSYCHIATR, V15, P18, DOI 10.1038/mp.2009.123; Uher R, 2009, MOL PSYCHIATR, V14, P1072, DOI 10.1038/mp.2009.85; Verschoor E, 2011, STRESS, V14, P407, DOI 10.3109/10253890.2010.548886; Walker EA, 2002, GEN HOSP PSYCHIAT, V24, P375, DOI 10.1016/S0163-8343(02)00203-7; Way BM, 2010, SOC COGN AFFECT NEUR, V5, P203, DOI 10.1093/scan/nsq059; Way BM, 2010, PSYCHOSOM MED, V72, P107, DOI 10.1097/PSY.0b013e3181ce6a7d; Weathers F.W., 1993, 9 ANN C ISTSS; Wermter AK, 2010, EUR CHILD ADOLES PSY, V19, P199, DOI 10.1007/s00787-009-0082-z; Windle G, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-8; Woltman H., 2012, TUTOR QUANT METHODS, V8, P52, DOI 10.20982/tqmp.08.1.p052; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153	54	33	35	0	25	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	JUN	2013	47	6					835	842		10.1016/j.jpsychires.2013.02.006			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	135ZH	WOS:000318328700019	23478049	Green Accepted			2022-02-06	
J	Zhang, D; Hu, Y; Sun, Q; Zhao, J; Cong, Z; Liu, H; Zhou, M; Li, K; Hang, C				Zhang, D.; Hu, Y.; Sun, Q.; Zhao, J.; Cong, Z.; Liu, H.; Zhou, M.; Li, K.; Hang, C.			INHIBITION OF TRANSFORMING GROWTH FACTOR BETA-ACTIVATED KINASE 1 CONFERS NEUROPROTECTION AFTER TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE			English	Article						TAK1; traumatic brain injury; 5Z-7-oxozeaenol; NF-kappa B; AP-1; inflammation	NF-KAPPA-B; CONTROLLED CORTICAL IMPACT; CEREBRAL-CORTEX; UP-REGULATION; TAK1; EXPRESSION; AP-1; INFLAMMATION; CONTUSION; SUPPRESSION	The transforming growth factor beta-activated kinase 1 (TAK1), a member of the Mitogen-activated protein kinase kinase kinase family, is characterized as a key regulator in inflammatory and apoptosis signaling pathways. The aim of the present study was to evaluate the role of the TAK1 pathway in experimental traumatic brain injury (TBI) in rats. Adult male Sprague Dawley rats were subjected to TBI using a modified Feeney's weight-drop model. The time course showed that a significant increase of TAK1 and p-TAK1 expression in the cortex after TBI. Moreover, TBI induced TAK1 redistribution both in neurons and astrocytes of the lesion boundary zone. The effects of specific inhibition of the TAK1 pathway by 5Z-7-oxozeaenol (OZ, intracerebroventricular injection at 10 min post-trauma) on histopathological and behavioral outcomes in rats were assessed at 24 h post injury. The number of TUNEL-positive stained cells was diminished and neuronal survival and neurological function were improved with OZ treatment. Biochemically, the high dose of OZ significantly reduced the levels of TAK1 and p-TAK1, further decreased nuclear factor-kappa B and activator protein 1 activities and the release of inflammatory cytokines. In addition, we found that both 10 min and 3 h post-trauma OZ therapies could markedly improve neurological function and neuronal survival after long-term survival. These results revealed that the TAK1 pathway is activated after experimental TBI and the inhibitor OZ affords significant neuro- protection and amelioration of neurobehavioral deficits after experimental TBI, suggesting a potential rationale for manipulating this pathway in clinical practice. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Zhang, D.; Hu, Y.; Sun, Q.; Zhao, J.; Cong, Z.; Zhou, M.; Hang, C.] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Li, K.] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210093, Jiangsu, Peoples R China; [Hang, C.] Southern Med Univ Guangzhou, Sch Med, Dept Neurosurg, Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China		Li, K (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	likuanyu@nju.edu.cn; hang_neurosurger-y@163.com	Li, Kuanyu/AAL-2051-2020	Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170]; Nature Science Foundation of the Jiangsu Province, China [BK2010459]	We would like to thank Dr. Zong Zhuang, Jiawei Wang and Lin Zhu for their technical assistance. This study was supported by the National Natural Science Foundation, China (No. 81171170) and the Nature Science Foundation of the Jiangsu Province, China (BK2010459).	Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bersudsky Y, 1997, J NEURAL TRANSM, V104, P943, DOI 10.1007/BF01285562; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; Dey N, 2011, VIROLOGY, V418, P93, DOI 10.1016/j.virol.2011.07.007; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hou DX, 2007, BIOCHEM PHARMACOL, V74, P742, DOI 10.1016/j.bcp.2007.06.006; Kajino-Sakamoto R, 2008, J IMMUNOL, V181, P1143, DOI 10.4049/jimmunol.181.2.1143; Lee AK, 2003, BRIT J PHARMACOL, V139, P11, DOI 10.1038/sj.bjp.0705231; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Ma FY, 2011, AM J PHYSIOL-RENAL, V300, pF1410, DOI 10.1152/ajprenal.00018.2011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Neubert M, 2011, CELL DEATH DIFFER, V18, P1521, DOI 10.1038/cdd.2011.29; Nijboer CH, 2009, STROKE, V40, P3362, DOI 10.1161/STROKEAHA.109.560250; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Safina A, 2008, ONCOGENE, V27, P1198, DOI 10.1038/sj.onc.1210768; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Serkkola E, 2005, EUR J BIOCHEM, V213, P243; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Wang JW, 2012, BRAIN RES, V1464, P73, DOI 10.1016/j.brainres.2012.05.014; White BJ, 2012, EXP NEUROL, V237, P238, DOI 10.1016/j.expneurol.2012.05.019; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	43	33	33	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 15	2013	238						209	217		10.1016/j.neuroscience.2013.02.022			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	141SH	WOS:000318746300019	23485590				2022-02-06	
J	Zhang, LJ; Hu, R; Li, M; Li, F; Meng, H; Zhu, G; Lin, JK; Feng, H				Zhang, Lijun; Hu, Rong; Li, Mei; Li, Fei; Meng, Hui; Zhu, Gang; Lin, Jiangkai; Feng, Hua			Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury	NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Deferoxamine; Iron; TRPC6; Spatial learning and memory	HEAD-INJURY; TRANSFERRIN; ERYTHROCYTES; EXPRESSION; THROMBIN; RECEPTOR; 1-YEAR; EDEMA; TRPC6; GENE	This study investigated whether deferoxamine (DFO), an iron chelator attenuates iron-induced toxicity in rats with traumatic brain injury. In this study, three groups of Sprague-Dawley rats (sham, injury and DFO groups) were examined. Rats were killed on day 28 after Morris water maze testing and brains perfused for either non-heme brain binding or hemosiderin staining. Western blotting was used to measure protein levels of ferritin, transferrin and transient receptor potential canonical channel 6 (TRPC6). In TBI rats, there was a significant increase in brain iron on day 28, ferritin L, ferritin H, transferrin and TRPC6 levels were all significantly elevated post-TB1. There were also deficits in spatial learning and memory; however, DFO administration attenuated these effects in TBI rats supporting the notion that DFO may reduce brain injury accentuated by iron overload.	[Zhang, Lijun; Hu, Rong; Li, Mei; Li, Fei; Meng, Hui; Zhu, Gang; Lin, Jiangkai; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China		Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Gaotanyan 30, Chongqing 400038, Peoples R China.	fenghua48@yahoo.com	Feng, Hua/AAX-4121-2021	Feng, Hua/0000-0003-4489-9217	National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872674, 30901545]	The authors thank Derong Chen of Third medical military Universty, Chongqing, P. R. China, and Youan Shan of Southwest hospital, Chongqing, P. R. China for technical assistance. This project is supported by grants from National Nature Science Foundation of China (No. 30872674, 30901545).	Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; [宫国旗 GONG Guoqi], 2008, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V30, P2172; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hanson LR, 2009, J PHARMACOL EXP THER, V330, P679, DOI 10.1124/jpet.108.149807; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Hua Y, 2006, J NEUROSURG, V104, P305, DOI 10.3171/jns.2006.104.2.305; Hua Y, 2003, J CEREBR BLOOD F MET, V23, P1448, DOI 10.1097/01.WCB.0000090621.86921.D5; IKEDA Y, 1990, ACT NEUR S, V51, P74; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Lee JY, 2011, ACTA NEUROCHIR SUPPL, V112, P101, DOI 10.1007/978-3-7091-0661-7_18; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Moos T, 1998, J COMP NEUROL, V398, P420; MORRIS CM, 1992, J INORG BIOCHEM, V47, P257, DOI 10.1016/0162-0134(92)84071-T; Mwanjewe J, 2004, BIOCHEM J, V378, P975, DOI 10.1042/BJ20031187; Nakamura T, 2005, BRAIN RES, V1039, P30, DOI 10.1016/j.brainres.2005.01.036; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Nilsson UA, 2002, FREE RADICAL RES, V36, P677, DOI 10.1080/10715760290029128; PALMER C, 1994, STROKE, V25, P1039, DOI 10.1161/01.STR.25.5.1039; Park UJ, 2011, ACTA NEUROPATHOL, V121, P459, DOI 10.1007/s00401-010-0785-8; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAYLOR EM, 1991, J NEUROCHEM, V57, P1584, DOI 10.1111/j.1471-4159.1991.tb06355.x; Testa U, 2002, FERRITIN PROTEINS IR, P449; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.bi.56.070187.001445; TU GF, 1991, J BIOL CHEM, V266, P6201; WEINFELD A, 1968, J CLIN PATHOL, V21, P35, DOI 10.1136/jcp.21.1.35; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; Xi G, 2005, STROKE, V36, P365; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhou J, 2008, NAT NEUROSCI, V11, P741, DOI 10.1038/nn.2127	39	33	34	3	16	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2013	34	5					639	645		10.1007/s10072-012-1090-1			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	163VA	WOS:000320363800004	22538758				2022-02-06	
J	Sajja, VSSS; Galloway, M; Ghoddoussi, F; Kepsel, A; VandeVord, P				Sajja, Venkata Siva Sai Sujith; Galloway, Matthew; Ghoddoussi, Farhad; Kepsel, Andrea; VandeVord, Pamela			Effects of blast-induced neurotrauma on the nucleus accumbens	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						nucleus accumbens; blast; neurotrauma; 1H-MRS; cognition; inflammation	TRAUMATIC BRAIN-INJURY; DOPAMINE; SEROTONIN; GLUTAMATE; BEHAVIOR; AMYGDALA; PRESSURE; IMPACT	Blast-induced neurotrauma (BINT) leads to deterioration at the cellular level, with adverse cognitive and behavioral outcomes. The nucleus accumbens (NAC) plays an important role in reward, addiction, aggression, and fear pathways. To identify the molecular changes and pathways affected at an acute stage in the NAC, this study focused on a time course analysis to determine the effects of blast on neurochemical and apoptotic pathways. By using a rodent model of BINT, acute damage to the NAC was assessed by proton magnetic resonance spectroscopy (1H-MRS), high-performance liquid chromatography, immunohistochemistry, and Western blotting. The results demonstrated ongoing neuroprotective effects from elevated levels of Bcl-2, an antiapoptotic marker, at 24 hr and N-acetyl aspartate glutamate at 48 hr following blast exposure. Selective loss of serotonin levels at 24 hr, increased levels of inflammation (elevated glycerophosphocholine at 48 and 72 hr), and increased levels of glial fibrillary acidic protein were also observed at 24 and 48 hr, leading to disruptive energy status. Furthermore, active cell death was indicated by the increased levels of the apoptotic marker Bax, decreased actin levels, and signs excitotoxicity (glutamate/creatine). In addition, increased evels of caspase-3, an apoptotic marker, confirm active cell death in NAC. It is hypothesized that blast overpressure causes inflammation and neurochemical changes that trigger apoptosis in NAC. This cascade of events may lead to stress-related behavioral outcomes and psychiatric sequelae. (c) 2013 Wiley Periodicals, Inc.	[Sajja, Venkata Siva Sai Sujith; VandeVord, Pamela] Virginia Polytech & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24060 USA; [Galloway, Matthew; Ghoddoussi, Farhad] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Galloway, Matthew; Ghoddoussi, Farhad] Wayne State Univ, Dept Anesthesiol, Detroit, MI USA; [Kepsel, Andrea; VandeVord, Pamela] John D Dingell VA Med Ctr, Detroit, MI USA		VandeVord, P (corresponding author), Virginia Polytech & State Univ, Sch Biomed Engn & Sci, 447 ICTAS Bldg,Stanger St, Blacksburg, VA 24060 USA.	pvord@vt.edu	Kepsel, Andrea/U-1596-2019; Sajja, Sujith/I-5289-2019	Kepsel, Andrea/0000-0002-9651-6700; Sajja, Sujith/0000-0002-1992-9501; Galloway, Matthew/0000-0002-7856-9606	Thomas C. Rumble Fellowship; National Institute of Drug Abuse (NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01-DA16736]; Joe Young Research Fund in Psychiatry; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA016736] Funding Source: NIH RePORTER	Contract grant sponsor: Thomas C. Rumble Fellowship; Contract grant sponsor: National Institute of Drug Abuse (NIDA); Contract grant number: R01-DA16736; Contract grant sponsor: Joe Young Research Fund in Psychiatry.	Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Belujon P, 2011, ANN NY ACAD SCI, V1216, P114, DOI 10.1111/j.1749-6632.2010.05896.x; Benarroch EE, 2008, NEUROLOGY, V70, P1353, DOI 10.1212/01.wnl.0000311267.63292.6c; Blum K, 2010, MED HYPOTHESES, V74, P513, DOI 10.1016/j.mehy.2009.10.008; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Commons KG, 2010, BRAIN RES, V1314, P175, DOI 10.1016/j.brainres.2009.11.014; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Edden RAE, 2007, MAGN RESON MED, V57, P977, DOI 10.1002/mrm.21234; Effie CR, 2012, J REHABIL RES DEV, V46, P851; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; GALLOWAY MP, 1990, SYNAPSE, V6, P63, DOI 10.1002/syn.890060108; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Haan C, 2007, J IMMUNOL METHODS, V318, P11, DOI 10.1016/j.jim.2006.07.027; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jessen F, 2011, SCHIZOPHRENIA B; Kim EM, 2004, BRAIN RES, V1029, P135, DOI 10.1016/j.brainres.2004.10.001; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Kosten TA, 2008, NEUROPSYCHOPHARMACOL, V33, P1545, DOI 10.1038/sj.npp.1301527; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacManus D, 2012, PSYCHOL MED, V42, P1663, DOI 10.1017/S0033291711002327; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; Moore Gregory J, 2002, Psychopharmacol Bull, V36, P5; Qi Z, 2011, PHARMACOPSYCHIATRY, V44, pS62, DOI 10.1055/s-0031-1273707; Quinlan JD, 2010, AM FAM PHYSICIAN, V82, P43; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ryding E, 2008, PROG BRAIN RES, V172, P307, DOI 10.1016/S0079-6123(08)00915-1; Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sesack SR, 2010, NEUROPSYCHOPHARMACOL, V35, P27, DOI 10.1038/npp.2009.93; Stetler RA, 2010, PROG NEUROBIOL, V92, P184, DOI 10.1016/j.pneurobio.2010.05.002; Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thomas AG, 2001, EUR J PHARMACOL, V426, P35, DOI 10.1016/S0014-2999(01)01198-0; Thompson JM, 2008, CAN FAM PHYSICIAN, V54, P1549; van Erp AMM, 2000, J NEUROSCI, V20, P9320; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Walter A, 2004, NEUROBIOL AGING, V25, P1299, DOI 10.1016/j.neurobiolaging.2004.02.016; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427	48	33	33	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2013	91	4					593	601		10.1002/jnr.23179			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	090IT	WOS:000314973400014	23335267				2022-02-06	
J	Siopi, E; Llufriu-Daben, G; Cho, AH; Vidal-Lletjos, S; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehranr, M				Siopi, Eleni; Llufriu-Daben, Gemma; Cho, Angelo H.; Vidal-Lletjos, Sandra; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehranr, Mehrnaz			Etazolate, an alpha-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice	NEUROPHARMACOLOGY			English	Article						Traumatic brain injury; sAPP alpha; Etazolate; Neuroprotection; Neuroinflammation; Functional outcome	AMYLOID-PRECURSOR-PROTEIN; SPINAL-CORD-INJURY; LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; MOUSE MODEL; COGNITIVE IMPAIRMENT; HIPPOCAMPAL-NEURONS; SAPP-ALPHA; CLINICAL NEUROPSYCHOLOGY; OLFACTORY DYSFUNCTION	Traumatic brain injury (TBI) evokes an intense neuroinflammatory reaction that is essentially mediated by activated microglia and that has been reported to act as a secondary injury mechanism that further promotes neuronal death. It involves the excessive production of inflammatory cytokines and the diminution of neuroprotective and neurotrophic factors, such as the soluble form alpha of the amyloid precursor protein (sAPP alpha), generated by the activity of alpha-secretases. Hence, the aim of this study was to examine the effects of etazolate, an alpha-secretase activator, on acute and belated post-TBI consequences. The mouse model of TBI by mechanical percussion was used and injured mice received either the vehicle or etazolate at the dose of 1, 3 or 10 mg/kg at 2 h post-TBI. Neurological score, cerebral edema, IL-1 beta and sAPP alpha levels, microglial activation and lesion size were evaluated from 6 to 24 h post-TBI. Spontaneous locomotor activity was evaluated from 48 h to 12 weeks post-TBI, memory function at 5 weeks and olfactory bulb lesions at 13 weeks post-TBI. A single administration of etazolate exerted a dose-dependent anti-inflammatory and anti-oedematous effect accompanied by lasting memory improvement, reduction of locomotor hyperactivity and olfactory bulb tissue protection, with a therapeutic window of at least 2 h. These effects were associated with the restoration of the levels of the sAPP alpha protein post-TBI. Taken together, these results highlight for the first time the therapeutic interest of an alpha-secretase activator in TBI. (C) 2012 Elsevier Ltd. All rights reserved.	[Siopi, Eleni; Llufriu-Daben, Gemma; Cho, Angelo H.; Vidal-Lletjos, Sandra; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehranr, Mehrnaz] Univ Paris 05, Lab Pharmacol Circulat Cerebrale EA 4475, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, F-75006 Paris, France		Jafarian-Tehranr, M (corresponding author), Univ Paris 05, CNRS UMR 8194, Sorbonne Paris Cite, UFR Biomed, 45 Rue St Peres, F-75006 Paris, France.	mehrnaz.jafarian@parisdescartes.fr	Vidal-Lletjos, Sandra/AAC-7312-2020; MARCHAND-LEROUX, Catherine/L-7453-2017	Vidal-Lletjos, Sandra/0000-0003-0629-9165; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856	Fondation des Gueules cassees	We would like to thank the non-profitable organisation "Fondation des Gueules cassees" for financially supporting this work (grants to ES and MJT).	Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; Anderson JJ, 1999, NEUROSCIENCE, V93, P1409, DOI 10.1016/S0306-4522(99)00244-4; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; BARNES DM, 1983, J NEUROSCI, V3, P762; Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; Drott J, 2010, EUR J PHARMACOL, V634, P95, DOI 10.1016/j.ejphar.2010.02.036; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; Fortin A, 2010, BRAIN INJURY, V24, P27, DOI 10.3109/02699050903446815; Frierl M.A., 2009, NAT PROTOC, V4, P1328; Fujii M, 2002, AURIS NASUS LARYNX, V29, P35, DOI 10.1016/S0385-8146(01)00118-3; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Girgis H., BRAIN RES IN PRESS; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hannila SS, 2008, EXP NEUROL, V209, P321, DOI 10.1016/j.expneurol.2007.06.020; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; Kang HM, 2010, NEUROREPORT, V21, P179, DOI 10.1097/WNR.0b013e328334884c; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kondo K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-147; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lesne S, 2005, J NEUROSCI, V25, P9367, DOI 10.1523/JNEUROSCI.0849-05.2005; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Marcade M, 2008, J NEUROCHEM, V106, P392, DOI 10.1111/j.1471-4159.2008.05396.x; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Mucignat-Caretta C, 2006, PHYSIOL BEHAV, V89, P637, DOI 10.1016/j.physbeh.2006.08.003; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Ohsawa I, 1997, BIOCHEM BIOPH RES CO, V236, P59, DOI 10.1006/bbrc.1997.6903; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Treiber C, 2004, J BIOL CHEM, V279, P51958, DOI 10.1074/jbc.M407410200; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vellas B, 2011, CURR ALZHEIMER RES, V8, P203, DOI 10.2174/156720511795256053; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang P, 1997, BIOCHEM BIOPH RES CO, V234, P320, DOI 10.1006/bbrc.1997.6636; Whitaker CM, 2008, NEUROSCI LETT, V438, P200, DOI 10.1016/j.neulet.2008.03.087; Whiting PJ, 1997, J NEUROSCI, V17, P5027; Wu AP, 2008, AM J RHINOL, V22, P606, DOI 10.2500/ajr.2008.22.3238; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; YAMAMOTO K, 1994, J NEUROBIOL, V25, P585, DOI 10.1002/neu.480250510; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zueger A, 2005, NEUROSCI LETT, V374, P142, DOI 10.1016/j.neulet.2004.10.040	85	33	36	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2013	67						183	192		10.1016/j.neuropharm.2012.11.009			10	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	097ME	WOS:000315477400021	23178198				2022-02-06	
J	Fitrolaki, DM; Dimitriou, H; Kalmanti, M; Briassoulis, G				Fitrolaki, Diana-Michaela; Dimitriou, Helen; Kalmanti, Maria; Briassoulis, George			CD64-Neutrophil expression and stress metabolic patterns in early sepsis and severe traumatic brain injury in children	BMC PEDIATRICS			English	Article						Metabolic pattern; Glucose; Lipoproteins; CD64; CD11b; Neutrophils; Sepsis; Traumatic brain injury	NEUTROPHIL CD64 EXPRESSION; HIGH-DENSITY-LIPOPROTEIN; CYTOKINE PRODUCTION; LIPIDS; RISK; HYPERGLYCEMIA; ACTIVATION; MORTALITY; MONOCYTES; INFECTION	Background: Critical illness constitutes a serious derangement of metabolism. The aim of our study was to compare acute phase metabolic patterns in children with sepsis (S) or severe sepsis/septic shock (SS) to those with severe traumatic brain injury (TBI) and healthy controls (C) and to evaluate their relations to neutrophil, lymphocyte and monocyte expressions of CD64 and CD11b. Methods: Sixty children were enrolled in the study. Forty-five children with systemic inflammatory response syndrome (SIRS) were classified into three groups: TBI (n = 15), S (n = 15), and SS (n = 15). C consisted of 15 non-SIRS patients undergoing screening tests for minor elective surgery. Blood samples were collected within 6 hours after admission for flow cytometry of neutrophil, lymphocyte and monocyte expression of CD64 and CD11b (n = 60). Procalcitonin (PCT), C-reactive protein (CRP), glucose, triglycerides (TG), total cholesterol (TC), high (HDL) or low-density-lipoproteins (LDL) were also determined in all groups, and repeated on day 2 and 3 in the 3 SIRS groups (n = 150). Results: CRP, PCT and TG (p < 0.01) were significantly increased in S and SS compared to TBI and C; glucose did not differ among critically ill groups. Significantly lower were the levels of TC, LDL, and HDL in septic groups compared to C and to moderate changes in TBI (p < 0.0001) but only LDL differed between S and SS (p < 0.02). Among septic patients, PCT levels declined significantly (p < 0.02) with time, followed by parallel decrease of HDL (p < 0.03) and increase of TG (p < 0.02) in the SS group. Neutrophil CD64 (nCD64) expression was higher in patients with SS (81.2%) and S (78.8%) as compared to those with TBI (5.5%) or C (0.9%, p < 0.0001). nCD64 was positively related with CRP, PCT, glucose, and TG (p < 0.01) and negatively with TC, LDL, and HDL (p < 0.0001), but not with severity of illness, hematologic indices, length of stay or mechanical ventilation duration. Conclusions: In sepsis, the early stress-metabolic pattern is characterized by a high (nCD64, glucose, TG) - low (TC, HDL, LDL) combination in contrast to the moderate pattern of TBI in which only glucose increases combined with a moderate cholesterol - lipoprotein decrease. These early metabolic patterns persist the first 3 days of acute illness and are associated with the acute phase CD64 expression on neutrophils.	[Fitrolaki, Diana-Michaela; Briassoulis, George] Univ Hosp Herakl, Pediat Intens Care Unit, Iraklion 71110, Crete, Greece; [Dimitriou, Helen; Kalmanti, Maria] Univ Crete, Sch Med, Dept Pediat Hematol Oncol, Iraklion, Greece		Briassoulis, G (corresponding author), Univ Hosp Herakl, Pediat Intens Care Unit, Iraklion 71110, Crete, Greece.	ggbriass@otenet.gr			European Union (European Social Fund (ESF))European Social Fund (ESF); Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES	This research has been co-financed by the European Union (European Social Fund (ESF)) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES. We thank all the nurses, doctors, and biologists who contributed to this study.	ALVAREZ C, 1986, CLIN CHEM, V32, P142; Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Barlage S, 2009, INTENS CARE MED, V35, P1877, DOI 10.1007/s00134-009-1609-y; Beekman JA, 2008, IMMUNOL LETT, V116, P149, DOI 10.1016/j.imlet.2007.12.003; Briassoulis G, 2005, INTENS CARE MED, V31, P851, DOI 10.1007/s00134-005-2631-3; Briassoulis G, 2006, PEDIATR CRIT CARE ME, V7, P56, DOI 10.1097/01.PCC.0000192339.44871.26; Briassoulis G, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/354047; Brunialti MKC, 2006, SHOCK, V25, P351, DOI 10.1097/01.shk.0000217815.57727.29; Cardelli P, 2008, INT J IMMUNOPATH PH, V21, P43, DOI 10.1177/039463200802100106; Davis BH, 2005, EXPERT REV MOL DIAGN, V5, P193, DOI 10.1586/14737159.5.2.193; Davis BH, 2006, ARCH PATHOL LAB MED, V130, P654; Dhar A, 2011, CURR OPIN PEDIATR, V23, P269, DOI 10.1097/MOP.0b013e3283464b3e; Dunham CM, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-42; Genel F, 2012, WORLD J PEDIATR, V8, P72, DOI 10.1007/s12519-011-0304-6; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Gordon BR, 2001, CRIT CARE MED, V29, P1563, DOI 10.1097/00003246-200108000-00011; Gros A, 2012, INTENS CARE MED, V38, P445, DOI 10.1007/s00134-012-2483-6; Groselj-Grenc M, 2009, INTENS CARE MED, V35, P1950, DOI 10.1007/s00134-009-1637-7; Groselj-Grenc M, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/202646; Gruher M, 2009, SWISS MED WKLY, V139, P166, DOI smw-12494; Gullo J. D., 2011, J CRIT CARE; Harris HW, 2002, CRIT CARE MED, V30, P23, DOI 10.1097/00003246-200201000-00004; Herra CM, 1996, J MED MICROBIOL, V44, P135, DOI 10.1099/00222615-44-2-135; Hsu KH, 2011, RESPIROLOGY, V16, P152, DOI 10.1111/j.1440-1843.2010.01876.x; HUBSCH AP, 1995, J LAB CLIN MED, V126, P548; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; Kosuge Masami, 2004, J Cardiol, V43, P251; Kumaraswamy SB, 2012, CRIT CARE, V16, DOI 10.1186/cc11305; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Li L, 2004, CIRC RES, V95, P877, DOI 10.1161/01.RES.0000147309.54227.42; Livaditi O, 2006, CYTOKINE, V36, P283, DOI 10.1016/j.cyto.2007.02.007; LopesVirella MF, 1997, ATHEROSCLEROSIS, V135, P161, DOI 10.1016/S0021-9150(97)00157-3; Luthold S, 2007, EUR J CLIN INVEST, V37, P573, DOI 10.1111/j.1365-2362.2007.01826.x; Mesotten D, 2004, J CLIN ENDOCR METAB, V89, P219, DOI 10.1210/jc.2003-030760; Nakae H, 1996, RES COMMUN MOL PATH, V91, P329; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Pussinen PJ, 2011, DIABETES CARE, V34, P392, DOI 10.2337/dc10-1676; Qureshi SS, 2001, CLIN EXP IMMUNOL, V125, P258, DOI 10.1046/j.1365-2249.2001.01596.x; RuchaudSparagano MH, 1997, BRIT J HAEMATOL, V98, P612, DOI 10.1046/j.1365-2141.1997.2523070.x; Russwurm S, 2002, SHOCK, V17, P263, DOI 10.1097/00024382-200204000-00004; Streimish I, 2012, PEDIATR INFECT DIS J, V31, P777, DOI 10.1097/INF.0b013e318256fb07; van Leeuwen HJ, 2003, CRIT CARE MED, V31, P1359, DOI 10.1097/01.CCM.0000059724.08290.51; Verhoeven JJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10006; Weinschenk NP, 2000, J PEDIATR-US, V137, P345, DOI 10.1067/mpd.2000.107846; Wolf Z, 2007, CYTOM PART A, V71A, P486, DOI 10.1002/cyto.a.20403; Wolfe RR, 2000, WORLD J SURG, V24, P639, DOI 10.1007/s002689910105; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; Zhang L, 2009, ATHEROSCLEROSIS, V206, P298, DOI 10.1016/j.atherosclerosis.2008.12.043	49	33	36	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	MAR 1	2013	13								31	10.1186/1471-2431-13-31			10	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	104KO	WOS:000315992000001	23452299	Green Published, gold			2022-02-06	
J	Singh, B; Murad, MH; Prokop, LJ; Erwin, PJ; Wang, Z; Mommer, SK; Mascarenhas, SS; Parsaik, AK				Singh, Balwinder; Murad, M. Hassan; Prokop, Larry J.; Erwin, Patricia J.; Wang, Zhen; Mommer, Shannon K.; Mascarenhas, Sonia S.; Parsaik, Ajay K.			Meta-analysis of Glasgow Coma Scale and Simplified Motor Score in predicting traumatic brain injury outcomes	BRAIN INJURY			English	Article						Emergency tracheal intubation; clinically significant brain injuries; neurosurgical intervention; mortality	INTERRATER RELIABILITY; IMPAIRED CONSCIOUSNESS; VALIDATION; CHILDREN; LEVEL	Objective: To perform a systematic review and meta-analysis to compare the Simplified Motor Score (SMS) and Glasgow Coma Scale (GCS) in predicting outcomes in patients with traumatic brain injury (TBI). Data sources and study selection: Ovid EMBASE, Ovid Medline, Ovid PsycInfo, evidence-based medicine reviews and Scopus and related conference proceedings were searched through 28 February 2012 for studies comparing SMS and GCS in predicting the outcomes [emergency tracheal intubation (ETI), clinically significant brain injuries (CSBI), neurosurgical intervention (NSI) and mortality] in patients with TBI. A random-effects model was used for meta-analysis. Data synthesis: Five retrospective studies were eligible, enrolling a total of 102 132 subjects with TBI (63.4% males), with 14 670 (14.4%) ETI, 16 201 (15.9%) CSBI, 4730 (4.6%) NSI and 6725 (6.6%) mortality. Pooled AUC of the GCS and SMS were as follows: CSBI 0.79 and 0.75 (p = 0.16), NSI 0.83 and 0.81 (p = 0.34), ETI 0.85 and 0.82 (p = 0.31) and mortality 0.90 and 0.87 (p = 0.01). The difference in AUC for mortality was 0.03. Large heterogeneity between the studies was observed in all analyses (I-2 > 50%). Conclusion: In patients with TBI, SMS predicts different outcomes with similar accuracy as GCS except mortality. However, due to heterogeneity and limited numbers of studies, further prospective studies are required.	[Singh, Balwinder] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; [Murad, M. Hassan] Mayo Clin, Dept Prevent Med, Rochester, MN 55905 USA; [Murad, M. Hassan; Prokop, Larry J.; Erwin, Patricia J.; Wang, Zhen] Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA; [Mommer, Shannon K.] Mayo Clin, Dept Gen Surg, Rochester, MN 55905 USA; [Mascarenhas, Sonia S.] London Training Coll, London, England; [Parsaik, Ajay K.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA		Parsaik, AK (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	parsaik.ajay@mayo.edu	Zhen, Wang/S-7244-2019; Singh, Balwinder/H-2016-2011; Wang, Zhen/D-5991-2013	Singh, Balwinder/0000-0001-7062-8192; Murad, Mohammad Hassan/0000-0001-5502-5975; Wang, Zhen/0000-0002-9368-6149			Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Bassi S, 1999, BRIT J NEUROSURG, V13, P526; Caterino JM, 2012, EMERG MED J, V29, P492, DOI 10.1136/emj.2010.110437; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Green SM, 2011, ANN EMERG MED, V58, P427, DOI 10.1016/j.annemergmed.2011.06.009; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Jackson D, 2010, STAT MED, V29, P1282, DOI 10.1002/sim.3602; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1977, LANCET, V1, P878; Kester ADM, 2000, MED DECIS MAKING, V20, P430, DOI 10.1177/0272989X0002000407; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; McNarry AF, 2004, ANAESTHESIA, V59, P34, DOI 10.1111/j.1365-2044.2004.03526.x; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; Thompson DO, 2011, ANN EMERG MED, V58, P417, DOI 10.1016/j.annemergmed.2011.05.033; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	34	33	37	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2013	27	3					293	300		10.3109/02699052.2012.743182			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	096OG	WOS:000315413400006	23252405				2022-02-06	
J	Kahalley, LS; Wilson, SJ; Tyc, VL; Conklin, HM; Hudson, MM; Wu, SJ; Xiong, XP; Stancel, HH; Hinds, PS				Kahalley, Lisa S.; Wilson, Stephanie J.; Tyc, Vida L.; Conklin, Heather M.; Hudson, Melissa M.; Wu, Shengjie; Xiong, Xiaoping; Stancel, Heather H.; Hinds, Pamela S.			Are the psychological needs of adolescent survivors of pediatric cancer adequately identified and treated?	PSYCHO-ONCOLOGY			English	Article						cancer; oncology; psychological; children	ACUTE LYMPHOBLASTIC-LEUKEMIA; LONG-TERM SURVIVORS; TRAUMATIC BRAIN-INJURY; CHILDHOOD-CANCER; EXECUTIVE FUNCTION; CRANIAL RADIATION; ADULT SURVIVORS; NEUROPSYCHOLOGICAL PERFORMANCE; YOUNG ADOLESCENT; SOCIAL OUTCOMES	Objectives To describe the psychological needs of adolescent survivors of acute lymphoblastic leukemia (ALL) or brain tumor (BT), we examined the following: (i) the occurrence of cognitive, behavioral, and emotional concerns identified during a comprehensive psychological evaluation and (ii) the frequency of referrals for psychological follow-up services to address identified concerns. Methods Psychological concerns were identified on measures according to predetermined criteria for 100 adolescent survivors. Referrals for psychological follow-up services were made for concerns previously unidentified in formal assessment or not adequately addressed by current services. Results Most survivors (82%) exhibited at least one concern across domains: behavioral (76%), cognitive (47%), and emotional (19%). Behavioral concerns emerged most often on scales associated with executive dysfunction, inattention, learning, and peer difficulties. Cranial radiation therapy was associated with cognitive concerns, 2(1, N=100)=5.63, p<0.05. Lower income was associated with more cognitive concerns for ALL survivors, t(47)=3.28, p<0.01, and more behavioral concerns for BT survivors, t(48)=2.93, p<0.01. Of the survivors with concerns, 38% were referred for psychological follow-up services. Lower-income ALL survivors received more referrals for follow-up, 2(1, N=41)=8.05, p<0.01. Referred survivors had more concerns across domains than non-referred survivors, ALL: t(39)=2.96, p<0.01; BT: t(39)=3.52, p<0.01. Trends suggest ALL survivors may be at risk for experiencing unaddressed cognitive needs. Conclusions Many adolescent survivors of cancer experience psychological difficulties that are not adequately managed by current services, underscoring the need for long-term surveillance. In addition to prescribing regular psychological evaluations, clinicians should closely monitor whether current support services appropriately meet survivors' needs, particularly for lower-income survivors and those treated with cranial radiation therapy. Copyright (c) 2012 John Wiley & Sons, Ltd.	[Kahalley, Lisa S.; Stancel, Heather H.] Baylor Coll Med, Dept Pediat, Psychol Sect, Houston, TX 77030 USA; [Wilson, Stephanie J.; Tyc, Vida L.; Conklin, Heather M.] St Jude Childrens Res Hosp, Dept Psychol, Memphis, TN 38105 USA; [Hudson, Melissa M.] St Jude Childrens Res Hosp, Div Oncol, Div Canc Survivorship, Memphis, TN 38105 USA; [Wu, Shengjie; Xiong, Xiaoping] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Hinds, Pamela S.] Childrens Natl Med Ctr, Dept Nursing Res & Qual Outcomes, Washington, DC 20010 USA; [Hinds, Pamela S.] George Washington Univ, Dept Pediat, Washington, DC 20052 USA		Kahalley, LS (corresponding author), Texas Childrens Hosp, 1102 Bates,Suite 730, Houston, TX 77030 USA.	lskahall@texaschildrens.org	Conklin, Heather M/N-2696-2018; Hudson, Melissa M/N-4441-2018; Hinds, Pamela/W-8115-2019	Hudson, Melissa M/0000-0001-6984-2407; 	National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F32DA024503]; NIH Cancer Center Support CORE Grant [CA21765]; American Lebanese Syrian Associated Charities (ALSAC)American Lebanese Syrian Associated Charities (ALSAC); NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R25CA023944, K07CA157923, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [F32DA024503] Funding Source: NIH RePORTER	This work was supported, in part, by the National Institute of Drug Abuse F32DA024503 (Lisa Schum [Kahalley], Principal Investigator), the NIH Cancer Center Support CORE Grant CA21765, and the American Lebanese Syrian Associated Charities (ALSAC).	ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; American Psychiatric Association, 2000, DIAGN STAT MENT DIS; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Armstrong GT, 2009, JNCI-J NATL CANCER I, V101, P946, DOI 10.1093/jnci/djp148; BROWN BB, 1993, CHILD DEV, V64, P467, DOI 10.1111/j.1467-8624.1993.tb02922.x; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P610, DOI 10.1097/00004583-199705000-00011; Children's Oncology Group, 2008, LONG TERM FOLL UP GU; Clinton-McHarg T, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-25; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Conners C. K., 2000, CONNERS CONTINUOUS P; Conners CK., 2008, CONNERS 3 EDITION MA; Dekovic M, 1997, J YOUTH ADOLESCENCE, V26, P253, DOI 10.1007/s10964-005-0001-7; Delis DC., 2001, DELIS KAPLAN EXECUTI; Eiser C, 2000, J PEDIATR PSYCHOL, V25, P449, DOI 10.1093/jpepsy/25.6.449; Fossen A, 1998, PEDIATR HEMAT ONCOL, V15, P479, DOI 10.3109/08880019809018309; Fuemmeler BF, 2002, CLIN PSYCHOL REV, V22, P547, DOI 10.1016/S0272-7358(01)00120-9; Gioia G.A., 2000, BRIEF BEHAV RATING I; Gurney JG, 2009, J CLIN ONCOL, V27, P2390, DOI 10.1200/JCO.2008.21.1458; Hill JM, 1998, CANCER-AM CANCER SOC, V82, P208; Holmquist LA, 2002, J CLIN PSYCHOL MED S, V9, P315, DOI 10.1023/A:1020791018897; Jones BL, 2008, FAM COMMUNITY HEALTH, V31, pS61, DOI 10.1097/01.FCH.0000304019.98007.ae; Kahalley LS, 2011, J CANCER SURVIV, V5, P123, DOI 10.1007/s11764-010-0149-3; Kirchhoff AC, 2010, MED CARE, V48, P1015, DOI 10.1097/MLR.0b013e3181eaf880; Krull KR, 2010, J CANCER SURVIV, V4, P210, DOI 10.1007/s11764-010-0123-0; Langer T, 2002, MED PEDIATR ONCOL, V38, P320, DOI 10.1002/mpo.10055; Lockwood KA, 1999, J PEDIATR PSYCHOL, V24, P55, DOI 10.1093/jpepsy/24.1.55; Lorenzi M, 2009, CANCER-AM CANCER SOC, V115, P2234, DOI 10.1002/cncr.24267; Lund LW, 2011, PEDIATR BLOOD CANCER, V56, P532, DOI 10.1002/pbc.22883; Mackie E, 2000, LANCET, V355, P1310, DOI 10.1016/S0140-6736(00)02112-7; Maddrey AM, 2005, J NEURO-ONCOL, V72, P245, DOI 10.1007/s11060-004-3009-z; Mattson SN, 1999, ALCOHOL CLIN EXP RES, V23, P1808, DOI 10.1111/j.1530-0277.1999.tb04077.x; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Meyer EA, 2002, PSYCHO-ONCOLOGY, V11, P74, DOI 10.1002/pon.553; Mody R, 2008, BLOOD, V111, P5515, DOI 10.1182/blood-2007-10-117150; Moleski M, 2000, ARCH CLIN NEUROPSYCH, V15, P603, DOI 10.1016/S0887-6177(99)00050-5; Mulhern Raymond K, 2004, Pediatr Rehabil, V7, P1, DOI 10.1080/13638490310001655528; National Cancer Institute, 2007, SEER CANC STAT REV 1 SEER CANC STAT REV 1; Nelson EE, 2005, PSYCHOL MED, V35, P163, DOI 10.1017/S0033291704003915; Newby WL, 2000, PSYCHO-ONCOL, V9, P113; Noll RB, 2007, J PEDIATR PSYCHOL, V32, P1089, DOI 10.1093/jpepsy/jsm049; Patenaude AF, 2005, J PEDIATR PSYCHOL, V30, P9, DOI 10.1093/jpepsy/jsi012; Peterson CC, 2008, PEDIATR BLOOD CANCER, V51, P99, DOI 10.1002/pbc.21544; Radcliffe J, 1996, J PEDIATR PSYCHOL, V21, P529, DOI 10.1093/jpepsy/21.4.529; Rapport MD, 2008, HDB CLIN PSYCHOL, V2, P386; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reich W, 1997, DIAGNOSTIC INTERVIEW; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; Rodgers J, 1999, ARCH DIS CHILD, V80, P318, DOI 10.1136/adc.80.4.318; Rogers R., 2001, HDB DIAGNOSTIC STRUC; RUTTER M, 1976, J CHILD PSYCHOL PSYC, V17, P35, DOI 10.1111/j.1469-7610.1976.tb00372.x; Ryan AM, 2001, CHILD DEV, V72, P1135, DOI 10.1111/1467-8624.00338; Schultz KAP, 2007, J CLIN ONCOL, V25, P3649, DOI 10.1200/JCO.2006.09.2486; Servitzoglou M, 2008, SUPPORT CARE CANCER, V16, P29, DOI 10.1007/s00520-007-0278-z; Sisk CL, 2005, FRONT NEUROENDOCRIN, V26, P163, DOI 10.1016/j.yfrne.2005.10.003; Sourander A, 1999, SOC PSYCH PSYCH EPID, V34, P657, DOI 10.1007/s001270050189; Spiegler BJ, 2006, J CLIN ONCOL, V24, P3858, DOI 10.1200/JCO.2006.05.9055; Stam H, 2001, SUPPORT CARE CANCER, V9, P489, DOI 10.1007/s005200100271; STEHBENS J A, 1991, Neuropsychology Review, V2, P147, DOI 10.1007/BF01109052; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; Wodka EL, 2008, ARCH CLIN NEUROPSYCH, V23, P283, DOI 10.1016/j.acn.2007.12.004; Zebrack BJ, 2004, J CLIN ONCOL, V22, P999, DOI 10.1200/JCO.2004.06.148; Zebrack BJ, 2002, PEDIATRICS, V110, P42, DOI 10.1542/peds.110.1.42	69	33	34	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1057-9249	1099-1611		PSYCHO-ONCOLOGY	Psycho-Oncol.	FEB	2013	22	2					447	458		10.1002/pon.3021			12	Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology; Psychology; Biomedical Social Sciences	083VQ	WOS:000314493700027	22278930	Green Accepted			2022-02-06	
J	Weckbach, S; Hohmann, C; Braumueller, S; Denk, S; Klohs, B; Stahel, PF; Gebhard, F; Huber-Lang, MS; Perl, M				Weckbach, Sebastian; Hohmann, Christoph; Braumueller, Sonja; Denk, Stephanie; Klohs, Bettina; Stahel, Philip F.; Gebhard, Florian; Huber-Lang, Markus S.; Perl, Mario			Inflammatory and apoptotic alterations in serum and injured tissue after experimental polytrauma in mice: Distinct early response compared with single trauma or "double-hit" injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Experimental polytrauma; inflammation; apoptosis; multiple injury; mice	ACUTE LUNG INJURY; BLUNT CHEST TRAUMA; ALVEOLAR MACROPHAGES; PULMONARY APOPTOSIS; FAS LIGAND; HEMORRHAGE; MORTALITY; DEATHS; NEUTROPHILS; FRACTURE	BACKGROUND: The exact alterations of the immune system after polytrauma leading to sepsis and multiple-organ failure are poorly understood. Thus, the early local and systemic inflammatory and apoptotic response was characterized in a new polytrauma model and compared with the alterations seen after single or combined injuries. METHODS: Anesthetized C57BL/6 mice were subjected to either blunt bilateral chest trauma (Tx), closed head injury, right femur fracture including contralateral soft tissue injury, or a combination of injuries (PTx). After 2 hours or 6 hours, animals were sacrificed, and the systemic as well as the local pulmonary immune response (bronchoalveolar lavage [BAL]/plasma cytokines, lung myeloperoxidase [MPO] activity, and alveolocapillary barrier dysfunction) were evaluated along with lung/brain apoptosis (lung caspase 3 Western blotting, immunohistochemistry, and polymorphonuclear leukocytes [PMN] Annexin V). RESULTS: Hemoglobin, Po-2 saturation, and pH did not differ between the experimental groups. Local BAL cytokines/chemokines were significantly increased in almost all groups, which included Tx. There was no further enhancement of this local inflammatory response in the lungs in case of PTx. At 2 hours, all groups except sham and closed head injury alone revealed an increased activity of lung MPO. However, 6 hours after injury, lung MPO remained increased only in the PTx group. Increased BAL protein levels were found, reflecting enhanced lung leakage in all groups with Tx 6 hours after trauma. Only after PTx was neutrophil apoptosis significantly decreased, whereas lung caspase 3 and plasma interleukin 6/keratinocyte chemoattractant (KC) were substantially increased. CONCLUSION: The combination of different injuries leads to an earlier systemic inflammatory response when compared with the single insults. Interestingly, only after PTx but not after single or double hits was lung apoptosis increased, and PMN apoptosis was decreased along with a prolonged presence of neutrophils in the lungs, which may therefore represent a possible pathomechanism for lung injury after polytrauma. (J Trauma Acute Care Surg. 2013; 74: 489-498. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Weckbach, Sebastian; Hohmann, Christoph; Braumueller, Sonja; Denk, Stephanie; Klohs, Bettina; Gebhard, Florian; Huber-Lang, Markus S.; Perl, Mario] Univ Ulm, Dept Trauma Hand Plast & Reconstruct Surg, D-89075 Ulm, Germany; [Stahel, Philip F.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed & Neurosurg, Denver, CO USA		Perl, M (corresponding author), Univ Ulm, Dept Trauma Hand Plast & Reconstruct Surg, Steinhoevelstr 9, D-89075 Ulm, Germany.	mario.perl@uniklinik-ulm.de	Huber-Lang, Markus/AAJ-2209-2020		Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [PE 908/2-1]; University of Ulm [LSPZ.0003.05, HU 823/3-2]	This study was supported by grants from the Deutsche Forschungsgemeinschaft PE 908/2-1 (to M.P.) and HU 823/3-2 (to M.S.H.-L. and M.P.) from the University of Ulm LSPZ.0003.05 (to M.P.)	Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0; [Anonymous], 2011, TRAUM REG DGU ANN RE; Ayala A, 2002, AM J PATHOL, V161, P2283, DOI 10.1016/S0002-9440(10)64504-X; Biffl WL, 1999, SURGERY, V126, P198, DOI 10.1067/msy.1999.98738; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Claes L, 2006, J ORTHOP RES, V24, P1178, DOI 10.1002/jor.20173; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frutos-Vivar Fernando, 2004, Curr Opin Crit Care, V10, P1, DOI 10.1097/00075198-200402000-00001; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Giannoudis PV, 2008, INJURY, V39, P705, DOI 10.1016/j.injury.2008.02.016; Hwang PF, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-92; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Knoferl MW, 2004, SHOCK, V22, P51, DOI 10.1097/01.shk.0000127684.64611.5c; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Lee KS, 2008, RESP MED, V102, P464, DOI 10.1016/j.rmed.2007.10.001; Liener UC, 2011, LANGENBECK ARCH SURG, V396, P251, DOI 10.1007/s00423-010-0645-y; Lomas-Neira J, 2006, AM J PHYSIOL-LUNG C, V290, pL51, DOI 10.1152/ajplung.00028.2005; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; Mommsen P, 2011, CYTOKINE, V53, P60, DOI 10.1016/j.cyto.2010.09.005; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Pang JM, 2008, INJURY, V39, P102, DOI 10.1016/j.injury.2007.05.022; Papa L, 2006, J TRAUMA, V61, P261, DOI 10.1097/01.ta.0000221789.53864.ba; Pape HC, 2000, CRIT CARE MED, V28, P3441, DOI 10.1097/00003246-200010000-00012; Perl M, 2005, AM J PATHOL, V167, P1545, DOI 10.1016/S0002-9440(10)61240-0; Perl M, 2007, AM J RESP CRIT CARE, V176, P591, DOI 10.1164/rccm.200611-1743OC; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054; Probst C, 2009, INJURY, V40, P77, DOI 10.1016/j.injury.2008.10.004; Qvick B, 2012, UNFALLCHIRURG, V115, P892, DOI 10.1007/s00113-010-1920-7; Ruchholtz S, 2008, DTSCH ARZTEBL INT, V105, P225, DOI 10.3238/arztebl.2008.0225; Seitz DH, 2011, SHOCK, V36, P621, DOI 10.1097/SHK.0b013e318234f8a0; STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; Tien HC, 2007, J TRAUMA, V62, P142, DOI 10.1097/01.ta.0000251558.38388.47; Trupka A, 1998, UNFALLCHIRURG, V101, P244, DOI 10.1007/s001130050265; Wafaisade A, 2011, CRIT CARE MED, V39, P621, DOI 10.1097/CCM.0b013e318206d3df; Wu JS, 2012, J EMERG MED, V43, P407, DOI 10.1016/j.jemermed.2009.05.024; Yang KY, 2003, AM J RESP CRIT CARE, V167, P1567, DOI 10.1164/rccm.200207-664OC	39	33	36	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					489	498		10.1097/TA.0b013e31827d5f1b			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	108UH	WOS:000316321200037	23354243				2022-02-06	
J	Kleindienst, A; Dunbar, JG; Glisson, R; Marmarou, A				Kleindienst, Andrea; Dunbar, Jana G.; Glisson, Renee; Marmarou, Anthony			The role of vasopressin V-1A receptors in cytotoxic brain edema formation following brain injury	ACTA NEUROCHIRURGICA			English	Article						AQP4 water channel; Vasopressin V-1A receptors; Brain edema; Experimental; Traumatic brain injury; Ischemic brain injury	CEREBRAL-ARTERY OCCLUSION; CORTICAL IMPACT INJURY; PHORBOL-MYRISTATE ACETATE; AQUAPORIN-4 MESSENGER-RNA; PROTEIN-KINASE-C; ANTAGONIST SR49059; AQP4 EXPRESSION; WATER TRANSPORT; V-2 RECEPTORS; GLIAL-CELLS	The hormone and neuropeptide arginine-vasopressin is designated to the maintenance of osmotic homoeostasis and blood pressure regulation. While experimental data show vasopressin V-1A receptors to regulate aquaporin (AQP)4 water channel dependent brain water movement, the specific role in vasogenic and cytotoxic edema formation remains unclear. The present study was designed to quantify the V-1A receptor mediated regional brain edema formation in two clinically relevant experimental models, brain injury combined with secondary insult and focal ischemia. Male Sprague-Dawley rats were randomly assigned to a continuous infusion of vehicle (1 % DMSO) or the selective non-peptide V-1A antagonist SR49059 (83nM = 1 mg/kg) starting before controlled cortical impact (CCI) injury plus hypoxia and hypotension (HH, 30 min), or middle cerebral artery (MCA) occlusion (2 h + 2 h reperfusion). A global analysis of brain water content by the wet/dry weight method allowed optimizing the SR49059 dosage, and demonstrated the down-regulation of brain AQP4 expression by immunoblotting. Microgravimetrical quantification in 64 one mm(3) samples per animal (n = 6 per group) from bregma +2.7 to -6.3 mm analysis demonstrated brain edema to be reduced at 4 h by SR49059 treatment in the injured and contralateral cortex following CCI + HH (p = 0.007, p < 0.001) and in the infarct area following MCA occlusion (p = 0.013, p = 0.002, p = 0.004). Our findings demonstrate that an early cytotoxic brain edema component following brain injury plus secondary insult or focal ischemia results from a vasopressin V-1A receptor mediated response, and occurs most likely through AQP4 up-regulation. The V-1A antagonist SR49059 offers a new avenue in brain edema treatment and prompts further study into the role of vasopressin following brain injury.	[Kleindienst, Andrea] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany; [Kleindienst, Andrea; Dunbar, Jana G.; Glisson, Renee; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA		Kleindienst, A (corresponding author), Univ Erlangen Nurnberg, Dept Neurosurg, Schwabachanlage 6, D-91054 Erlangen, Germany.	andrea.kleindienst@uk-erlangen.de; glissonre@gmail.com	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 12587, NS 19235]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, P01NS012587, R56NS019235, P50NS012587] Funding Source: NIH RePORTER	This research was supported by grant NS 12587 and grant NS 19235 from the National Institutes of Health. The experimental drug SR49059 was provided by Sanofi-Aventis France, and we thank specifically Dr. Claudine Serradeil Le Gal, Sanofi-Aventis Recherche Exploratoire, and Toulouse, France for providing information about the drug, dosage and safety issues.	Amedee T, 1997, GLIA, V21, P46, DOI 10.1002/(SICI)1098-1136(199709)21:1<46::AID-GLIA5>3.0.CO;2-#; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Ancellin N, 1997, FEBS LETT, V413, P323, DOI 10.1016/S0014-5793(97)00914-9; Badaut J, 2000, J NEUROENDOCRINOL, V12, P960, DOI 10.1046/j.1365-2826.2000.00539.x; Badaut J, 2000, NEUROSCI LETT, V292, P75, DOI 10.1016/S0304-3940(00)01364-1; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; de Vries GJ, 1998, PROG BRAIN RES, V119, P3; Dijkhuizen RM, 1999, J CEREBR BLOOD F MET, V19, P341, DOI 10.1097/00004647-199903000-00012; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fazzina G, 2009, J NEUROTRAUMA; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; GROEGER U, 1989, ACTA NEUROCHIR, V101, P134, DOI 10.1007/BF01410529; Hawtin SR, 2006, J BIOL CHEM, V281, P14604, DOI 10.1074/jbc.M511610200; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kempski O, 2001, SEMIN NEPHROL, V21, P303, DOI 10.1053/snep.2001.21665; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; LANDGRAF R, 1992, PROG BRAIN RES, V91, P29; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Liu X, 2009, NEUROCRIT CARE; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Lu H, 2003, CHINESE MED J-PEKING, V116, P1063; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1990, ACT NEUR S, V51, P123; Meinild AK, 1998, J BIOL CHEM, V273, P32446, DOI 10.1074/jbc.273.49.32446; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.0.CO;2-C; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Newman EA, 1995, NEUROGLIA, P717; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; PEREZPINON MA, 1995, J NEUROPHYSIOL, V74, P565, DOI 10.1152/jn.1995.74.2.565; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Schrier RW, 2007, CURR OPIN INVEST DR, V8, P304; Schrier RW, 2004, NEUROSCIENCE, V129, P897, DOI 10.1016/j.neuroscience.2004.06.043; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Somjen GG, 2002, NEUROSCIENTIST, V8, P254, DOI 10.1177/1073858402008003011; Stroop R, 1998, ACT NEUR S, V71, P303; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Thibonnier M, 1999, HYPERTENSION, V34, P1293, DOI 10.1161/01.HYP.34.6.1293; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Tribollet E, 1999, NEUROENDOCRINOLOGY, V69, P113, DOI 10.1159/000054409; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658	70	33	36	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2013	155	1					151	164		10.1007/s00701-012-1558-z			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	063QD	WOS:000313013900023	23188468				2022-02-06	
J	Olah, G; Heredi, J; Menyhart, A; Czinege, Z; Nagy, D; Fuzik, J; Kocsis, K; Knapp, L; Krucso, E; Gellert, L; Kis, Z; Farkas, T; Fulop, F; Pardutz, A; Tajti, J; Vecsei, L; Toldi, J				Olah, Gaspar; Heredi, Judit; Menyhart, Akos; Czinege, Zsolt; Nagy, David; Fuzik, Janos; Kocsis, Kitti; Knapp, Levente; Krucso, Erika; Gellert, Levente; Kis, Zsolt; Farkas, Tamas; Fueloep, Ferenc; Pardutz, Arpad; Tajti, Janos; Vecsei, Laszlo; Toldi, Jozsef			Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						blood-brain barrier; cortical spreading depression; glutamate receptors; kynurenic acid; kynurenines; NMDAR	STIMULATION-INDUCED INCREASE; ANOXIC DEPOLARIZATION; RAT NEOCORTEX; NITRIC-OXIDE; MIGRAINE; GLUTAMATE; EXPRESSION; RESPONSES; NUCLEUS; STROKE	Cortical spreading depression (CSD) involves a slowly-propagating depolarization wave in the cortex, which can appear in numerous pathophysiological conditions, such as migraine with aura, stroke, and traumatic brain injury. Neurons and glial cells are also depolarized transiently during the phenomena. CSD is followed by a massive increase in glutamate release and by changes in the brain microcirculation. The aim of this study was to investigate the effects of two N-methyl-D-aspartate receptor antagonists, endogenous kynurenic acid (KYNA) and dizocilpine, on CSD and the related blood-brain barrier (BBB) permeability in rats. In intact animals, KYNA hardly crosses the BBB but has some positive features as compared with its precursor L-Kynurenine, which is frequently used in animal studies (KYNA cannot be metabolized to excitotoxic agents such as 3-hydroxy-L-kynurenine and quinolinic acid). We therefore investigated the possible effects of peripherally administered KYNA. Repetitive CSD waves were elicited by the application of 1 M KCl solution to the cortex. Direct current-electrocorticograms were measured for 1 hour. Four parameters of the waves were compared. Evans blue dye and fluorescent microscopy were used to study the possible changes in the permeability of the BBB. The results demonstrated that N-methyl-D-aspartate receptor antagonists can reduce the number of CSD waves and decrease the permeability of the BBB during CSD. These results suggest that KYNA itself or its derivatives may offer a new approach in the therapy of migraines.	[Olah, Gaspar; Heredi, Judit; Menyhart, Akos; Nagy, David; Fuzik, Janos; Kocsis, Kitti; Knapp, Levente; Krucso, Erika; Gellert, Levente; Kis, Zsolt; Farkas, Tamas; Toldi, Jozsef] Univ Szeged, Dept Physiol Anat & Neurosci, H-6726 Szeged, Hungary; [Czinege, Zsolt] Univ Szeged, Dept Software Engn, H-6726 Szeged, Hungary; [Fueloep, Ferenc] Univ Szeged, Inst Pharmaceut Chem, H-6726 Szeged, Hungary; [Fueloep, Ferenc] Univ Szeged, MTA SZTE Res Grp Stereochem, H-6726 Szeged, Hungary; [Pardutz, Arpad; Tajti, Janos; Vecsei, Laszlo] Univ Szeged, Dept Neurol, H-6726 Szeged, Hungary; [Pardutz, Arpad; Tajti, Janos; Vecsei, Laszlo] Univ Szeged, MTA SZTE Neurosci Res Grp, H-6726 Szeged, Hungary		Toldi, J (corresponding author), Univ Szeged, Dept Physiol Anat & Neurosci, Kozep Fasor 52, H-6726 Szeged, Hungary.	toldi@bio.u-szeged.hu	Farkas, Tamas/B-7193-2008; Heredi, Judit/M-5044-2018; Toldi, Jozsef/M-4858-2018; Kis, Zsolt/A-4583-2009; Vecsei, Laszlo/ABA-6137-2021; Vecsei, Laszlo/B-2066-2010	Heredi, Judit/0000-0002-8248-3485; Toldi, Jozsef/0000-0001-7355-0503; Kis, Zsolt/0000-0002-6896-5883; Vecsei, Laszlo/0000-0001-8037-3672; Gellert, Levente/0000-0003-2254-2970; Menyhart, Akos/0000-0002-1355-3208	TAMOP [4.2.2-A-11/KONV-2012-0052, 4.2.4. A/2-11-1-2012-0001]; OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K105077]	This work was supported by TAMOP 4.2.2-A-11/KONV-2012-0052, OTKA K105077 and TAMOP 4.2.4. A/2-11-1-2012-0001 "National Excellence Program - Elaborating and operating an inland student and researcher personal support system".	Andras IE, 2007, J CEREBR BLOOD F MET, V27, P1431, DOI 10.1038/sj.jcbfm.9600445; Andreou AP, 2009, EXPERT OPIN INV DRUG, V18, P789, DOI [10.1517/13543780902913792, 10.1517/13543780902913792 ]; Brennan KC, 2007, J NEUROPHYSIOL, V97, P4143, DOI 10.1152/jn.00028.2007; Chauvel V, 2012, EXP NEUROL, V236, P207, DOI 10.1016/j.expneurol.2012.05.002; Chen Y, 2000, ACT NEUR S, V76, P131; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; Fejes A, 2011, CURR NEUROPHARMACOL, V9, P376, DOI 10.2174/157015911795596621; FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x; GARDNERMEDWIN AR, 1981, J EXP BIOL, V95, P111; Gniel HM, 2010, J NEUROPHYSIOL, V104, P3203, DOI 10.1152/jn.00922.2009; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; Hilmas C, 2001, J NEUROSCI, V21, P7463, DOI 10.1523/JNEUROSCI.21-19-07463.2001; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; Knyihar-Csillik E, 2007, J NEURAL TRANSM, V114, P417, DOI 10.1007/s00702-006-0545-z; Knyihar-Csillik E, 2007, NEUROSCI LETT, V418, P122, DOI 10.1016/j.neulet.2007.03.007; Konradsson-Geuken A, NEUROSCIENCE, V15, P1848; Koroleva VI, 2000, ZH VYSSH NERV DEYAT+, V50, P612; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Longoni M, 2006, NEUROL SCI, V27, pS107, DOI 10.1007/s10072-006-0582-2; Ramadan NM, 2003, CNS SPECTRUMS, V8, P446, DOI 10.1017/S1092852900018757; ROUSSEL S, 1990, BRAIN RES, V518, P353, DOI 10.1016/0006-8993(90)90997-P; Santos E, 2012, CEPHALALGIA, V32, P433, DOI 10.1177/0333102412441414; Scharfman HE, 1998, NEUROSCIENCE, V86, P751, DOI 10.1016/S0306-4522(98)00073-6; Schwarcz R, 2002, J PHARMACOL EXP THER, V303, P1, DOI 10.1124/jpet.102.034439; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Stone TW, 2007, METAB BRAIN DIS, V22, P337, DOI 10.1007/s11011-007-9064-3; Tajti J, 2012, J NEURAL TRANSM, V119, P557, DOI 10.1007/s00702-012-0788-9; Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223; TURSKI WA, 1988, EXP BRAIN RES, V71, P563, DOI 10.1007/BF00248748; Vamos E, 2009, NEUROPHARMACOLOGY, V57, P425, DOI 10.1016/j.neuropharm.2009.06.033; Zhang XC, 2010, J NEUROSCI, V30, P8807, DOI 10.1523/JNEUROSCI.0511-10.2010	34	33	33	0	7	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2013	7						981	987		10.2147/DDDT.S44496			7	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	216LX	WOS:000324286100001	24068867	Green Published, gold, Green Submitted			2022-02-06	
J	Rajaratnam, BS; Kaien, JG; JiaLin, KL; SweeSin, K; FenRu, SS; Enting, L; YiHsia, EA; KeatHwee, N; Su, YF; YingHowe, WW; SiaoTing, ST				Rajaratnam, B. S.; KaiEn, J. Gui; JiaLin, K. Lee; SweeSin, Kwek; FenRu, S. Sim; Enting, Lee; YiHsia, E. Ang; KeatHwee, Ng; Su Yunfeng; YingHowe, W. Woo; SiaoTing, S. Teo			Does the Inclusion of Virtual Reality Games within Conventional Rehabilitation Enhance Balance Retraining after a Recent Episode of Stroke?	REHABILITATION RESEARCH AND PRACTICE			English	Article							TRAUMATIC BRAIN-INJURY; ASSOCIATION; RELIABILITY; PERFORMANCE; PREVENTION; REDUCE; ADULTS; FALLS; TOOL	This randomised controlled and double-blinded pilot study evaluated if interactive virtual reality balance related games integrated within conventional rehabilitation sessions resulted in more superior retraining of dynamic balance compared to CR after stroke. 19 subjects diagnosed with a recent episode of stroke were recruited from a local rehabilitation hospital and randomly assigned to either a control or an experimental group. Subjects in the control groups underwent 60 minutes of conventional rehabilitation while those in the experimental groups underwent 40 minutes of convention rehabilitation and 20 minutes of self-directed virtual reality balanced rehabilitation. Functional Reach Test, Timed Up and Go, Modified Barthel Index, Berg Balance Scale, and Centre of Pressure of subjects in both groups were evaluated before and on completion of the rehabilitation sessions. Results indicate that the inclusion of interactive virtual reality balance related games within conventional rehabilitation can lead to improved functional mobility and balance after a recent episode of stroke without increasing treatment time that requires more health professional manpower.	[Rajaratnam, B. S.; KaiEn, J. Gui; JiaLin, K. Lee; SweeSin, Kwek; FenRu, S. Sim; Enting, Lee; YiHsia, E. Ang; KeatHwee, Ng; Su Yunfeng; YingHowe, W. Woo; SiaoTing, S. Teo] Nanyang Polytech, Sch Hlth Sci Allied Hlth, Singapore 569830, Singapore		Rajaratnam, BS (corresponding author), Nanyang Polytech, Sch Hlth Sci Allied Hlth, Singapore 569830, Singapore.	bala_s_rajaratnam@nyp.gov.sg			Ang Mo Kio Thye Hua Kuan Hospital	The authors thank the subjects and staff from Ang Mo Kio Thye Hua Kuan Hospital for their support and assistance to conduct this study. Special thanks also go to Tim Xu Tian Ma and Kishan Kumar for their contribution to this project. The authors sincerely appreciate Jerome-Christian NgZhilong contribution to presenting initial results at the 6th International Convention on Rehabilitation Engineering and Assistive Technology in 2012.	Betker AL, 2006, ARCH PHYS MED REHAB, V87, P1141, DOI 10.1016/j.apmr.2006.04.010; Bisson E, 2007, CYBERPSYCHOL BEHAV, V10, P16, DOI 10.1089/cpb.2006.9997; BOHANNON RW, 1995, ARCH PHYS MED REHAB, V76, P994, DOI 10.1016/S0003-9993(95)81035-8; Bomberger S, 2010, THESIS; Brumels KA, 2008, CLIN KINES, V62, P26; Burdea G., 2011, J PHYS THERAPY ED, V25, P19; Burdea G., 2002, 1 INT WORKSH VIRT RE; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; DeJong G, 2011, PHYS THER, V91, P1826, DOI 10.2522/ptj.20100424; Deutsch JE, 2009, 2009 VIRTUAL REHABILITATION INTERNATIONAL CONFERENCE, P117, DOI 10.1109/ICVR.2009.5174216; Di Monaco M, 2010, CLIN REHABIL, V24, P543, DOI 10.1177/0269215509353265; Emery CA, 2007, CLIN J SPORT MED, V17, P17, DOI 10.1097/JSM.0b013e31802e9c05; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Fong KNK, 2001, BRAIN INJURY, V15, P443, DOI 10.1080/02699050010005940; FORSTER A, 1995, BRIT MED J, V311, P83, DOI 10.1136/bmj.311.6997.83; Howe TE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004963.pub2; Lam YS, 2006, NEUROREHABILITATION, V21, P245; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4, 10.1002/14651858.CD008349.pub2]; Lin JH, 2001, DISABIL REHABIL, V23, P722; Meldrum D, 2012, DISABIL REHABIL-ASSI, V7, P205, DOI 10.3109/17483107.2011.616922; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; Moreira M. C., 2013, DISABILITY REHABILIT; Ng SS, 2005, ARCH PHYS MED REHAB, V86, P1641, DOI 10.1016/j.apmr.2005.01.011; Nitz JC, 2010, CLIMACTERIC, V13, P487, DOI 10.3109/13697130903395193; Okada S, 2001, EUR J APPL PHYSIOL, V85, P10, DOI 10.1007/s004210100423; Oujamaa L., 2009, Annals of Physical and Rehabilitation Medicine, V52, P269, DOI 10.1016/j.rehab.2008.10.003; Padala Kalpana P, 2012, J Aging Res, V2012, P597573, DOI 10.1155/2012/597573; Pigford T, 2010, J STUDENT PHYS THER, V2, P12; Rajaratnam BS, 2010, J SAINS KESIHAT MALA, V8, P21; Sainsbury A, 2005, AGE AGEING, V34, P228, DOI 10.1093/ageing/afi063; SANDIN KJ, 1990, STROKE, V21, P82, DOI 10.1161/01.STR.21.1.82; Shubert TE, 2011, J GERIATR PHYS THER, V34, P100, DOI 10.1519/JPT.0b013e31822938ac; Singh DKA, 2012, MATURITAS, V73, P239, DOI 10.1016/j.maturitas.2012.07.011; Sisto Sue Ann, 2002, Top Stroke Rehabil, V8, P11; Smith PS, 2004, CLIN REHABIL, V18, P811, DOI 10.1191/0269215504cr817oa; Sugarman H, 2009, 2009 VIRTUAL REHABILITATION INTERNATIONAL CONFERENCE, P111, DOI 10.1109/ICVR.2009.5174215; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Williams Marie A, 2010, BMC Res Notes, V3, P238, DOI 10.1186/1756-0500-3-238; World Health Organization, WORLD HLTH REP 2006; Zeltzer L., 2010, BARTHEL INDEX STORKE	41	33	35	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-2867	2090-2875		REHABIL RES PRACT	Rehabil. Res. Pract.		2013	2013								649561	10.1155/2013/649561			6	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V18OK	WOS:000214760500009		Green Submitted, Green Published, gold			2022-02-06	
J	Singleton, JAG; Gibb, IE; Hunt, NCA; Bull, AMJ; Clasper, JC				Singleton, James A. G.; Gibb, Iain E.; Hunt, Nicholas C. A.; Bull, Anthony M. J.; Clasper, Jonathan C.			Identifying future 'unexpected' survivors: a retrospective cohort study of fatal injury patterns in victims of improvised explosive devices	BMJ OPEN			English	Article							POSTMORTEM COMPUTED-TOMOGRAPHY; COMBAT CASUALTY CARE; TRAUMA VICTIMS; DEATH; AUTOPSY	Objectives: To identify potentially fatal injury patterns in explosive blast fatalities in order to focus research and mitigation strategies, to further improve survival rates from blast trauma. Design: Retrospective cohort study. Participants: UK military personnel killed by improvised explosive device (IED) blasts in Afghanistan, November 2007-August 2010. Setting: UK military deployment, through NATO, in support of the International Security Assistance Force (ISAF) mission in Afghanistan. Data sources: UK military postmortem CT records, UK Joint Theatre Trauma Registry and associated incident data. Main outcome measures: Potentially fatal injuries attributable to IEDs. Results: We identified 121 cases, 42 mounted (in-vehicle) and 79 dismounted (on foot), at a point of wounding. There were 354 potentially fatal injuries in total. Leading causes of death were traumatic brain injury (50%, 62/124 fatal injuries), followed by intracavity haemorrhage (20.2%, 25/124) in the mounted group, and extremity haemorrhage (42.6%, 98/230 fatal injuries), junctional haemorrhage (22.2%, 51/230 fatal injuries) and traumatic brain injury (18.7%, 43/230 fatal injuries) in the dismounted group. Conclusions: Head trauma severity in both mounted and dismounted IED fatalities indicated prevention and mitigation as the most effective strategies to decrease resultant mortality. Two-thirds of dismounted fatalities had haemorrhage implicated as a cause of death that may have been anatomically amenable to prehospital intervention. One-fifth of the mounted fatalities had haemorrhagic trauma which currently could only be addressed surgically. Maintaining the drive to improve all haemostatic techniques for blast casualties, from point of wounding to definitive surgical proximal vascular control, alongside the development and application of novel haemostatic interventions could yield a significant survival benefit. Prospective studies in this field are indicated.	[Singleton, James A. G.; Bull, Anthony M. J.; Clasper, Jonathan C.] Univ London Imperial Coll Sci Technol & Med, Ctr Blast Injury Studies, London, England; [Gibb, Iain E.] Ft Blockhouse, Def Ctr Imaging, Gosport, Hants, England; [Hunt, Nicholas C. A.] Forens Pathol Serv, Abingdon, Oxon, England; [Singleton, James A. G.; Clasper, Jonathan C.] Royal Ctr Def Med, Acad Dept Mil Surg & Trauma, Birmingham, W Midlands, England		Singleton, JAG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Blast Injury Studies, London, England.	j.singleton11@ic.ac.uk	Bull, Anthony M J/C-2317-2008	Bull, Anthony M J/0000-0002-4473-8264			BELLAMY RF, 1984, MIL MED, V149, P55; Bolliger SA, 2008, EUR RADIOL, V18, P273, DOI 10.1007/s00330-007-0737-4; Bosker AJ, 2012, IEDS WILL REMAIN WEA; Champion HR, 2010, J TRAUMA, V68, P1139, DOI 10.1097/TA.0b013e3181d86a0d; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; DCBI Task Force, 2011, REPORT OF THE ARMY D; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; DONCHIN Y, 1994, J TRAUMA, V37, P552, DOI 10.1097/00005373-199410000-00006; DONCHIN Y, 1994, J TRAUMA, V37, P555; Doyle GS, 2008, PREHOSP EMERG CARE, V12, P241, DOI 10.1080/10903120801907570; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b; Farkash U, 2000, J TRAUMA, V48, P303, DOI 10.1097/00005373-200002000-00018; Grabherr S, 2011, INT J LEGAL MED, V125, P791, DOI 10.1007/s00414-010-0526-5; Griffiths D, 2006, CURR ORTHOPAED, V20, P346, DOI 10.1016/j.cuor.2006.07.007; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Jeffery AJ, 2008, CLIN RADIOL, V63, P1160, DOI 10.1016/j.crad.2008.03.003; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Mazurek Michael T, 2006, J Am Acad Orthop Surg, V14, pS18; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; Morrison JJ, 2013, ANN SURG, V257, P330, DOI 10.1097/SLA.0b013e31827eefcf; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; O'Donnell C, 2008, CLIN RADIOL, V63, P1189, DOI 10.1016/j.crad.2008.05.008; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ramasamy A, 2009, J R Army Med Corps, V155, P265; Ramasamy A, 2008, J TRAUMA, V65, P910, DOI 10.1097/TA.0b013e3181848cf6; Russell RJ, 2011, PHILOS T R SOC B, V366, P171, DOI 10.1098/rstb.2010.0232; Scholing M, 2009, EUR RADIOL, V19, P2333, DOI 10.1007/s00330-009-1440-4; Shelton HH, 1998, PUB 3 07 2 JOINT TAC; Wullenweber R, 1977, Z RECHTSMED, V80, P277	30	33	33	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2013	3	8							e003130	10.1136/bmjopen-2013-003130			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301VX	WOS:000330561300084	23906957	gold, Green Published			2022-02-06	
J	Ersahin, M; Cevik, O; Akakin, D; Sener, A; Ozbay, L; Yegen, BC; Sener, G				Ersahin, Mehmet; Cevik, Ozge; Akakin, Dilek; Sener, Azize; Ozbay, Latif; Yegen, Berrak C.; Sener, Goksel			Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury	PROSTAGLANDINS & OTHER LIPID MEDIATORS			English	Article						Oxidative stress; Spinal cord injury; Caspase-3; Bladder; Leukotriene; Montelukast	RECEPTOR BLOCKER MONTELUKAST; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; NEUROLOGICAL DYSFUNCTION; SECONDARY INJURY; CELL-DEATH; INFILTRATION; INFLAMMATION; ANTAGONIST; APOPTOSIS	Spinal cord injury (SCI) leads to an inflammatory response that generates substantial secondary damage within the tissue besides the primary damage. Leukotrienes are biologically active 5-lipoxygenase products of arachidonic acid metabolism that are involved in the mediation of various inflammatory disorders including SCI. In this study, we investigated the possible protective effects of montelukast, a leukotriene receptor blocker, on SCI-induced oxidative damage. Wistar albino rats (n = 24) were divided randomly as control, vehicle- or montelukast (10 mg/kg, ip)-treated SCI groups. To induce SCI, a standard weight-drop method that induced a moderately severe injury at T10 was used. Vehicle or montelukast were administered to the injured animals 15 min after injury. At seven days post-injury, neurological examination was performed and rats were decapitated. Blood samples were taken to evaluate leukotriene 134 levels, and pro-inflmamatory cytokines (TNF-alpha, IL-1 beta) while in spinal cord and urinary bladder samples malondialdehyde (MDA), glutathione (GSH), luminol chemiluminescence (CL) levels and myeloperoxidase (MPO) and caspase-3 activities were determined. Tissues were also evaluated histologically. SCI caused significant decreases in tissue GSH, which were accompanied with significant increases in luminol CL and MDA levels and MPO and caspase-3 activities, while pro-inflammatory cytokines in the plasma were elevated. On the other hand. montelukast treatment reversed these parameters and improved histological findings. In conclusion, SCI caused oxidative tissue injury through the activation of pro-inflammatory mediators and by neutrophil infiltration into tissues, and the neuroprotective and antiapoptotic effects of montelukast are mediated by the inhibition of lipid peroxidation, neutrophil accumulation and proinflammatory cytokine release. Moreover, montelukast does not only exert antioxidant and antiapoptotic effects on the spinal cord, but it has a significant impact on the bladder tissue damage secondary to SCI. (C) 2012 Elsevier Inc. All rights reserved.	[Sener, Goksel] Marmara Univ, Sch Pharm, Dept Pharmacol, Istanbul, Turkey; [Yegen, Berrak C.] Marmara Univ, Sch Med, Dept Physiol, Istanbul, Turkey; [Ersahin, Mehmet] Istanbul Medeniyet Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey; [Cevik, Ozge] Cumhuriyet Univ, Sch Pharm, Dept Biochem, Sivas, Turkey; [Akakin, Dilek] Marmara Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkey; [Sener, Azize] Marmara Univ, Sch Pharm, Dept Biochem, Istanbul, Turkey; [Ozbay, Latif] Yeditepe Univ, Sch Pharm, Dept Pharmacol, Istanbul, Turkey		Sener, G (corresponding author), Marmara Univ, Sch Pharm, Dept Pharmacol, Istanbul, Turkey.	gsener@marmara.edu.tr	Yegen, Berrak/O-6652-2017; Sener, Goksel/AAN-4461-2021; Cevik, Ozge/Z-2790-2019; Yegen, Berrak C./ABA-1986-2020; Yegen, Berrak/ABA-3274-2020; Cevik, Ozge/F-1326-2014	Yegen, Berrak/0000-0003-0791-0165; Sener, Goksel/0000-0001-7444-6193; Yegen, Berrak C./0000-0003-0791-0165; Cevik, Ozge/0000-0002-9325-3757			Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BALENTINE JD, 1978, LAB INVEST, V39, P236; Ballatori N, 2009, BIOL CHEM, V390, P191, DOI 10.1515/BC.2009.033; Bao F, 2006, NEUROSCIENCE, V140, P1011, DOI 10.1016/j.neuroscience.2006.02.061; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Barut S, 2005, SURG NEUROL, V64, P213, DOI 10.1016/j.surneu.2005.03.042; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Beutler E., 1975, RED CELL METABOLISM; BISGAARD H, 1985, PROSTAGLANDINS, V30, P791, DOI 10.1016/0090-6980(85)90007-3; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buege J A, 1978, Methods Enzymol, V52, P302; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Chen J, 1998, J NEUROSCI, V18, P4914; Chu LS, 2006, ACTA PHARMACOL SIN, V27, P282, DOI 10.1111/j.1745-7254.2006.00290.x; Craggs MD, 2006, AUTON NEUROSCI-BASIC, V126, P355, DOI 10.1016/j.autneu.2006.03.010; DAMON M, 1983, BIOCHEM BIOPH RES CO, V111, P518, DOI 10.1016/0006-291X(83)90337-6; Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z; Ersahin M, 2012, J PINEAL RES, V52, P340, DOI 10.1111/j.1600-079X.2011.00948.x; Fehlings MG, 2010, J CLIN IMMUNOL, V30, pS109, DOI 10.1007/s10875-010-9404-7; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Genovese T, 2008, BRIT J PHARMACOL, V153, P568, DOI 10.1038/sj.bjp.0707577; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Han X, 2012, NEUROSCI LETT, V511, P28, DOI 10.1016/j.neulet.2012.01.030; Herrera JJ, 2010, J NEUROTRAUM, V27, P423, DOI 10.1089/neu.2009.0997; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Impellizzeri D, 2012, BIOCHEM PHARMACOL, V83, P1413, DOI 10.1016/j.bcp.2012.02.001; Jiang Q, 2003, FASEB J, V17, P816, DOI 10.1096/fj.02-0877com; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Kabasakal L, 2005, PROSTAG LEUKOTR ESS, V72, P431, DOI 10.1016/j.plefa.2005.02.008; Knoblach SM, 2005, J NEUROSCI RES, V80, P369, DOI 10.1002/jnr.20465; KROL W, 1990, BIOCHEM INT, V21, P593; Kyung KS, 2006, EUR J NEUROSCI, V24, P1042, DOI 10.1111/j.1460-9568.2006.04908.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; Mohamadin Ahmed M, 2011, Pathophysiology, V18, P235, DOI 10.1016/j.pathophys.2011.02.003; Moon YJ, 2012, J NEUROSCI RES, V90, P243, DOI 10.1002/jnr.22734; MORELAND DB, 1989, SURG NEUROL, V31, P277, DOI 10.1016/0090-3019(89)90052-9; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; Ozkan E, 2010, PANCREAS, V39, P1041, DOI 10.1097/MPA.0b013e3181db2dfd; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rong W, 2012, NEUROCHEM RES, V37, P1615, DOI 10.1007/s11064-012-0756-7; Saiwai H, 2010, AM J PATHOL, V176, P2352, DOI 10.2353/ajpath.2010.090839; Samson Gregory, 2007, Phys Med Rehabil Clin N Am, V18, P255; Sener G, 2005, PROSTAG LEUKOTR ESS, V73, P453, DOI 10.1016/j.plefa.2005.07.008; Sener G, 2007, PROSTAG OTH LIPID M, V83, P257, DOI 10.1016/j.prostaglandins.2007.01.013; Sener G, 2007, J PHARM PHARMACOL, V59, P837, DOI 10.1211/jpp.59.6.0009; Sener G, 2006, PHARMACOL RES, V54, P65, DOI 10.1016/j.phrs.2006.02.007; Taoka Y, 1998, J NEUROSCI, V18, P1393; Toklu HZ, 2010, J SPINAL CORD MED, V33, P401, DOI 10.1080/10790268.2010.11689719; Virchow JC, 2001, CLIN EXP ALLERGY, V31, P836, DOI 10.1046/j.1365-2222.2001.01051.x; WALLACE JL, 1989, GASTROENTEROLOGY, V96, P29, DOI 10.1016/0016-5085(89)90760-9; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yilmaz ER, 2012, ACTA NEUROCHIR, V154, P1037, DOI 10.1007/s00701-012-1298-0; Zhao R, 2011, J PHARM PHARMACOL, V63, P550, DOI 10.1111/j.2042-7158.2010.01238.x	64	33	38	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1098-8823	2212-196X		PROSTAG OTH LIPID M	Prostaglandins Other Lipid Mediat.	DEC	2012	99	3-4					131	139		10.1016/j.prostaglandins.2012.09.002			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	056SN	WOS:000312511800009	22986158				2022-02-06	
J	Raible, DJ; Frey, LC; Del Angel, YC; Russek, SJ; Brooks-Kayal, AR				Raible, Daniel J.; Frey, Lauren C.; Del Angel, Yasmin Cruz; Russek, Shelley J.; Brooks-Kayal, Amy R.			GABA(A) Receptor Regulation after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						Egr3 pathway; GABA(A) receptor; JaK/STAT pathway; traumatic brain injury	FLUID PERCUSSION INJURY; POSTTRAUMATIC EPILEPSY; SUBUNIT EXPRESSION; SIGNAL TRANSDUCER; TONIC INHIBITION; DELTA-SUBUNITS; UNITED-STATES; UP-REGULATION; ANIMAL-MODEL; MOUSE MODEL	The gamma-aminobutyric acid (GABA) type A receptor (GABA(A)R) is responsible for most fast synaptic inhibition in the adult brain. The GABA(A)R protein is composed of multiple subunits that determine the distribution, properties, and dynamics of the receptor. Several studies have shown that the Janus kinase/signal transducer and activator of transcription (JaK/STAT) and early growth response 3 (Egr3) signaling pathways can alter GABA(A)R subunit expression after status epilepticus (SE). In this study we investigated changes in these pathways after experimental TBI in the rat using a lateral fluid percussion injury (FPI) model. Our results demonstrated changes in the expression of several GABA(A)R subunit levels after injury, including GABA(A)R alpha 1 and alpha 4 subunits. This change appears to be transcriptional, and there is an associated increase in the phosphorylation of STAT3, and an increase in the expression of Egr3 and inducible cAMP element repressor (ICER) after FPI. These findings suggest that the activation of the JaK/STAT and Egr3 pathways after TBI may regulate injury-related changes in GABA(A)R subunit expression.	[Raible, Daniel J.; Brooks-Kayal, Amy R.] Univ Colorado, Neurosci Program, Aurora, CO USA; [Frey, Lauren C.; Brooks-Kayal, Amy R.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA; [Del Angel, Yasmin Cruz; Brooks-Kayal, Amy R.] Univ Colorado, Sch Med, Div Neurol, Dept Pediat, Aurora, CO USA; [Russek, Shelley J.] Boston Univ, Sch Med, Dept Pharmacol, Lab Translat Epilepsy, Boston, MA 02118 USA; [Brooks-Kayal, Amy R.] Childrens Hosp Colorado, Aurora, CO USA		Brooks-Kayal, AR (corresponding author), Univ Colorado AMC, Dept Pediat, Sch Pharm, 12850 E Montview Blvd C238,RM 3440D, Aurora, CO 80045 USA.	Amy.Brooks-Kayal@childrenscolorado.org		Russek, Shelley/0000-0001-7547-3089	Department of Defense (DoD)United States Department of Defense [W81XWH-11-1-0501]; NIH/NCRR Colorado CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [TL1 RR025778]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR001081] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR025778] Funding Source: NIH RePORTER	The funding for this research was provided by Department of Defense (DoD) award number W81XWH-11-1-0501, and by NIH/NCRR Colorado CTSI Grant no. TL1 RR025778. The contents are the authors' sole responsibility and do not necessarily represent official DoD or NIH views.	Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Choi JS, 2003, MOL BRAIN RES, V119, P10, DOI 10.1016/j.molbrainres.2003.08.010; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Gangisetty O, 2010, NEUROSCIENCE, V170, P865, DOI 10.1016/j.neuroscience.2010.07.037; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; Goodkin HP, 2008, J NEUROSCI, V28, P2527, DOI 10.1523/JNEUROSCI.3426-07.2008; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Jia F, 2005, J NEUROPHYSIOL, V94, P4491, DOI 10.1152/jn.00421.2005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kralic JE, 2006, J COMP NEUROL, V495, P408, DOI 10.1002/cne.20866; Liang J, 2006, J NEUROSCI, V26, P1749, DOI 10.1523/JNEUROSCI.4702-05.2006; Liang J, 2008, ALCOHOL CLIN EXP RES, V32, P19, DOI 10.1111/j.1530-0277.2007.00564.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lund IV, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162396; Marcikic M, 1998, INJURY, V29, P613, DOI 10.1016/S0020-1383(98)00146-6; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Nusser Z, 1998, J NEUROSCI, V18, P1693; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Planas AM, 1996, EUR J NEUROSCI, V8, P2612, DOI 10.1111/j.1460-9568.1996.tb01556.x; Raol YH, 2006, J NEUROSCI, V26, P11342, DOI 10.1523/JNEUROSCI.3329-06.2006; Roberts DS, 2006, J BIOL CHEM, V281, P29431, DOI 10.1074/jbc.C600167200; Roberts DS, 2005, P NATL ACAD SCI USA, V102, P11894, DOI 10.1073/pnas.0501434102; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sassoe-Pognetto M, 2000, J COMP NEUROL, V420, P481, DOI 10.1002/(SICI)1096-9861(20000515)420:4<481::AID-CNE6>3.0.CO;2-5; Schneider Gasser EM, 2007, EUR J NEUROSCI, V25, P3287, DOI 10.1111/j.1460-9568.2007.05558.x; Semyanov A, 2004, TRENDS NEUROSCI, V27, P262, DOI 10.1016/j.tins.2004.03.005; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sun CS, 2007, J NEUROSCI, V27, P12641, DOI 10.1523/JNEUROSCI.4141-07.2007; Sun CS, 2004, BRAIN RES, V1029, P207, DOI 10.1016/j.brainres.2004.09.056; Sur C, 1999, MOL PHARMACOL, V56, P110, DOI 10.1124/mol.56.1.110; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toth Z, 1997, J NEUROSCI, V17, P8106; Wei WZ, 2003, J NEUROSCI, V23, P10650; Zhang G, 2004, NEUROSCIENCE, V125, P299, DOI 10.1016/j.neuroscience.2004.01.040; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018	46	33	35	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	16					2548	2554		10.1089/neu.2012.2483			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	035CS	WOS:000310920900003	22827467	Green Published			2022-02-06	
J	Fernandez, E; Bringas, ML; Salazar, S; Rodriguez, D; Garcia, ME; Torres, M				Fernandez, Elizabeth; Luisa Bringas, Maria; Salazar, Sonia; Rodriguez, Daymi; Eugenia Garcia, Maria; Torres, Maydane			Clinical Impact of RehaCom Software for Cognitive Rehabilitation of Patients with Acquired Brain Injury	MEDICC REVIEW			English	Article						Acute brain injuries; traumatic brain injury; brain injury; vascular; rehabilitation; intellectual disability; neuropsychology; Cuba	IMPAIRMENT; EFFICACY	We describe the clinical impact of the RehaCom computerized cognitive training program instituted in the International Neurological Restoration Center for rehabilitation of brain injury patients. Fifty patients admitted from 2008 through 2010 were trained over 60 sessions. Attention and memory functions were assessed with a pre- and post-treatment design, using the Mini-Mental State Examination, Wechsler Memory Scale and Trail Making Test (Parts A and B). Negative effects were assessed, including mental fatigue, headache and eye irritation. The program's clinical usefulness was confirmed, with 100% of patients showing improved performance in trained functions.	[Fernandez, Elizabeth] Int Neurol Restorat Ctr CIREN, Havana, Cuba; [Luisa Bringas, Maria; Salazar, Sonia; Rodriguez, Daymi; Eugenia Garcia, Maria; Torres, Maydane] CIREN, Havana, Cuba		Fernandez, E (corresponding author), Int Neurol Restorat Ctr CIREN, Havana, Cuba.	efernandez@neuro.ciren.cu		Bringas, Maria L/0000-0003-2507-1959			Odriozola FA, 2009, MED INTENSIVA, V33, P171, DOI 10.1016/S0210-5691(09)71213-6; Ardila A, 2008, NEUROPSICOLOGIA CLIN; Boosman H, 2012, NEUROPSYCHOL REHABIL, V22, P26, DOI 10.1080/09602011.2011.632907; Bringas ML, 2009, REV NEUROPSICOLOGIA, V9, P53; Buller PI, 2008, CUAD NEUROPSICOL, V2, P10; Carvajal-Castrillon J, 2009, REV CHIL NEUROPSICOL, V4, P52; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; de Norena D, 2010, REV NEUROLOGIA, V51, P733, DOI 10.33588/rn.5112.2009653; de Norena D, 2010, REV NEUROLOGIA, V51, P687, DOI 10.33588/rn.5111.2009652; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Fernandez-Calvo B, 2011, PSICOTHEMA, V23, P44; Fernandez-Guinea S, 2001, REV NEUROLOGIA, V33, P373, DOI 10.33588/rn.3304.2000193; Ginarte Y, 2007, GEROINFO, V2, P1; Helmstaedter C, 2008, EPILEPSY BEHAV, V12, P402, DOI 10.1016/j.yebeh.2007.11.010; Junque C, 1999, REV NEUROLOGIA, V28, P423, DOI 10.33588/rn.2804.98420; O'Neil-Pirozzi TM, 2010, J HEAD TRAUMA REHAB, V25, P43, DOI 10.1097/HTR.0b013e3181bf24b1; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Perez Ortiz L, 2011, REV MED ELECT, V33; Rios-Lago M, 2007, REV NEUROLOGIA, V44, P291, DOI 10.33588/rn.4405.2006208; Schuhfried G, 2003, REHACOM VERSION 5 BA; Sentmanat A, 2003, SISTEMA NEURORREHABI; Tarraga L, 2006, J NEUROL NEUROSUR PS, V77, P1116, DOI 10.1136/jnnp.2005.086074; Wang YJ, 2011, REV MED CHILE, V139, P697, DOI /S0034-98872011000600001; Wilson BA, 2009, NEUROPSYCHOLOGICAL REHABILITATION: THEORY, MODELS, THERAPY AND OUTCOME, P1, DOI 10.1017/CBO9780511581083	24	33	34	0	15	MEDICC-MED EDUC COOPERATION CUBA	DECATUR	1902 CLAIRMONT RD, STE 250, DECATUR, GEORGIA 30033-3406 USA	1555-7960			MEDICC REV	MEDICC Rev.	OCT	2012	14	4					32	35		10.1590/S1555-79602012000400007			4	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	V33PX	WOS:000209031800007	23154316	Bronze			2022-02-06	
J	Giannakopoulos, GF; Saltzherr, TP; Beenen, LFM; Reitsma, JB; Bloemers, FW; Goslings, JC; Bakker, FC				Giannakopoulos, G. F.; Saltzherr, T. P.; Beenen, L. F. M.; Reitsma, J. B.; Bloemers, F. W.; Goslings, J. C.; Bakker, F. C.		REACT Study Grp	Missed injuries during the initial assessment in a cohort of 1124 level-1 trauma patients	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Missed injuries; Trauma; Diagnosis; Tertiary survey; Risk factors	MAJOR TRAUMA; BLUNT TRAUMA; TERTIARY	Introduction: Despite the presence of diagnostic guidelines for the initial evaluation in trauma, the reported incidence of missed injuries is considerable. The aim of this study was to assess the missed injuries in a large cohort of trauma patients originating from two European Level-1 trauma centres. Methods: We analysed the 1124 patients included in the randomised REACT trial. Missed injuries were defined as injuries not diagnosed or suspected during initial clinical and radiological evaluation in the trauma room. We assessed the frequency, type, consequences and the phase in which the missed injuries were diagnosed and used univariate analysis to identify potential contributing factors. Results: Eight hundred and three patients were male, median age was 38 years and 1079 patients sustained blunt trauma. Overall, 122 injuries were missed in 92 patients (8.2%). Most injuries concerned the extremities. Sixteen injuries had an AIS grade of >= 3. Patients with missed injuries had significantly higher injury severity scores (ISSs) (median of 15 versus 5, p < 0.001). Factors associated with missed injuries were severe traumatic brain injury (GCS <= 8) and multitrauma (ISS >= 16). Seventy-two missed injuries remained undetected during tertiary survey (59%). In total, 31 operations were required for 26 initially missed injuries. Conclusion: Despite guidelines to avoid missed injuries, this problem is hard to prevent, especially in the severely injured. The present study showed that the rate of missed injuries was comparable with the literature and their consequences not severe. A high index of suspicion remains warranted, especially in multitrauma patients. (C) 2011 Elsevier Ltd. All rights reserved.	[Giannakopoulos, G. F.; Bloemers, F. W.; Bakker, F. C.] Vrije Univ Amsterdam Med Ctr, Dept Trauma Surg, NL-1007 MB Amsterdam, Netherlands; [Saltzherr, T. P.; Goslings, J. C.] Univ Amsterdam, Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands; [Beenen, L. F. M.] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; [Reitsma, J. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands		Giannakopoulos, GF (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Trauma Surg, Room 7F-004,POB 7057, NL-1007 MB Amsterdam, Netherlands.	gf.giannakopoulos@gmail.com	Beenen, Ludo F/AAA-3114-2021; Bloemers, Frank/P-5436-2019	Beenen, Ludo F/0000-0001-9204-1026; Bloemers, Frank/0000-0002-8393-4946	ZonMw, the Netherlands Organization for Health Research and DevelopmentNetherlands Organization for Health Research and DevelopmentNetherlands Government [3920.0005]	This study was part of the REACT trial which was sponsored by an unrestricted grant from ZonMw, the Netherlands Organization for Health Research and Development (Grant number 3920.0005).	Agostini C, 2008, J RADIOL, V89, P325, DOI 10.1016/S0221-0363(08)93007-9; *AM ASS AUT MED, 1985, ABBR INJ SCAL 1985 R; American College of Surgeons Committee on Trauma, 1994, ADV TRAUM LIF SUPP R, P17; Biffl WL, 2003, J TRAUMA, V54, P38, DOI 10.1097/00005373-200301000-00005; Brink M, 2008, AM J ROENTGENOL, V190, P1591, DOI 10.2214/AJR.07.3277; Brooks A, 2004, INJURY, V35, P407, DOI 10.1016/S0020-1383(03)00219-5; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; ENDERSON BL, 1990, J TRAUMA, V30, P666, DOI 10.1097/00005373-199006000-00002; Goslings JC, 2006, J TRAUMA, V61, P111, DOI 10.1097/01.ta.0000222704.86560.ac; Hoff WS, 2004, J TRAUMA, V56, P291, DOI 10.1097/01.TA.0000105924.37441.31; Houshian S, 2002, J TRAUMA, V52, P715, DOI 10.1097/00005373-200204000-00018; Janjua KJ, 1998, J TRAUMA, V44, P1000, DOI 10.1097/00005373-199806000-00012; Jin PHFK, 2008, INJURY, V39, P83, DOI 10.1016/j.injury.2007.07.022; Kalemoglu M, 2006, MIL MED, V171, P598, DOI 10.7205/MILMED.171.7.598; Pfeifer R, 2008, PATIENT SAF SURG, V2, DOI 10.1186/1754-9493-2-20; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; RIZOLI SB, 1994, ACCIDENT ANAL PREV, V26, P681, DOI 10.1016/0001-4575(94)90030-2; Robertson R, 1996, AM J SURG, V172, P564, DOI 10.1016/S0002-9610(96)00247-4; Saltzherr TP, 2008, BMC EMERG MED, V22, P8; Vles WJ, 2003, J AM COLL SURGEONS, V197, P596, DOI 10.1016/S1072-7515(03)00601-X	21	33	33	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1517	1521		10.1016/j.injury.2011.07.012			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100034	21820114				2022-02-06	
J	Papa, L; Mendes, ME; Braga, CF				Papa, Linda; Mendes, Matthew E.; Braga, Carolina F.			Mild Traumatic Brain Injury Among the Geriatric Population	CURRENT GERIATRICS REPORTS			English	Article						Traumatic brain injury; Mild; TBI; Head injury; Concussion; Falls; Head trauma; Elderly; Octogenarians; Geriatrics; Outcomes; Function; Cognition; Prognosis; Diagnosis; Intracranial lesions; Healthcare; Depression; Neurodegenerative disorders	NEURON-SPECIFIC-ENOLASE; CLOSED-HEAD INJURY; NEUROBEHAVIORAL CONSEQUENCES; OUTCOME PREDICTION; ALZHEIMERS-DISEASE; ELDERLY-PATIENTS; S-100B PROTEIN; OLDER-ADULTS; SERUM; DEPRESSION	Mild traumatic brain injury (TBI) is an unfortunately common occurrence in the elderly. With the growing population of older adults in the United States and globally, strategies that reduce the risk of becoming injured need to be developed, and diagnostic tools and treatments that may benefit this group need to be explored. Particular attention needs to be given to polypharmacy, drug interactions, the use of anticoagulants, safety issues in the living environment, elder abuse, and alcohol consumption. Lowmechanism falls should prompt health care providers to consider the possibility of head injury in elderly patients. Early and tailored management of our seniors following a mild TBI can provide them with the best possible quality of life. This review will discuss the current literature on mild TBI in the older adult, address gaps in research, and discuss the implications for future care of the older TBI patient.	[Papa, Linda; Braga, Carolina F.] Orlando Reg Med Ctr Inc, Dept Emergency Med, Med Educ Bldg,86 West Underwood St,S-200, Orlando, FL 32806 USA; [Mendes, Matthew E.] Univ Cent Florida, Orlando, FL 32816 USA		Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, Med Educ Bldg,86 West Underwood St,S-200, Orlando, FL 32806 USA.	lpstat@aol.com			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS057676] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER		AharonPeretz J, 1997, BRAIN INJURY, V11, P871; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; [Anonymous], 2000, J Head Trauma Rehabil, V15, P750; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P101; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faul M, 2010, TRAUMATIC BRAIN INJU; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Jacoby SF, 2006, J NURS SCHOLARSHIP, V38, P133, DOI 10.1111/j.1547-5069.2006.00090.x; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Papa L, 2011, ANN EMERG MED; Papa L, 2012, POTEOMICS HUMAN DIS; Papa L, 2011, J NEUROTRAUM, V28, pA5; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson H, J NEUROTRAUMA; Thompson HJ, 2012, RES GERONTOL NURS, V5, P17, DOI 10.3928/19404921-20111206-02; Thurman DJ, 2001, EPIDEMIOLOGY EC HEAD, P327; Timmons T, 2010, CLIN GERIATR MED, V04, P20; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; YEALY D M, 1991, Emergency Medicine Clinics of North America, V9, P707	73	33	33	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	2196-7865			CURR GERIATR REP	Curr. Geriatr. Rep.	SEP	2012	1	3					135	142		10.1007/s13670-012-0019-0			8	Geriatrics & Gerontology	Emerging Sources Citation Index (ESCI)	Geriatrics & Gerontology	V3S8Y	WOS:000218556700002	23589783	Green Accepted, Bronze			2022-02-06	
J	Zhong, Q; Zhou, YF; Ye, WBA; Cai, T; Zhang, XQ; Deng, DYB				Zhong, Qian; Zhou, Yanfang; Ye, Weibiao; Cai, Tuo; Zhang, Xiuquan; Deng, David Y. B.			Hypoxia-Inducible Factor 1-alpha-AA-Modified Bone Marrow Stem Cells Protect PC12 Cells from Hypoxia-Induced Apoptosis, Partially Through VEGF/PI3K/Akt/FoxO1 Pathway	STEM CELLS AND DEVELOPMENT			English	Article							VASCULAR ENDOTHELIAL-CELLS; FOXO TRANSCRIPTION FACTORS; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; FUNCTIONAL RECOVERY; PROLYL HYDROXYLATION; TUMOR SUPPRESSION; MULTIPLE-MYELOMA; ISCHEMIC BRAIN	Bone marrow stem cells (BMSCs) have been shown to improve neurological function recovery in cerebral ischemia. Hypoxia-inducible factor-1 (HIF-1) alpha-AA is a more stable mutant form of HIF-1 alpha, which is a crucial oxygen- sensitive regulator. To investigate the protective effects of HIF-1 alpha-AA-modified BMSCs on neuron survival in cerebral ischemia models, we co-cultured HIF-1 alpha-AA-modified BMSCs with neuron-like cells (PC12 cells) and observed a significant increase in the release of vascular endothelial growth factor (VEGF) from BMSCs, the decreased PC12 cell apoptosis, and the upregulation of Survivin expression reduced by hypoxia in PC12 cells compared to enhanced green fluorescent protein (EGFP) BMSCs. In addition, to explore whether VEGF secreted by HIF-1 alpha-AA-modified BMSCs plays an important role in preventing hypoxia-induced apoptosis and the possible mechanism involved, exogenous VEGF were applied and the similar protective effects on PC12 cells were observed in vitro. Furthermore, hypoxia reduced the expression of phosphorylated Akt and phosphorylated FoxO1, whereas the administration of VEGF reversed these changes. Transfection of FoxO1 H215R, a DNA-binding mutant, abrogated the inhibitory ability on Survivin promoter activity, whereas FoxO1 AAA, the active form of FoxO1, presented further repression on Survivin promoter, indicating that FoxO1 directly binds on Survivin promoter as a transcriptional repressor and that phosphorylation status of FoxO1 affects its inhibition on the Survivin promoter. Transplantation of HIF-1a-AA-modified BMSCs after cerebral ischemia in vivo sufficiently reduced neurons apoptosis, decreased cerebral infarction volume, and induced a significant improvement on the modified neurological severity score compared to the EGFP BMSCs group. In conclusion, HIF-1 alpha-AA-modified MSCs showed an obvious protective effect on neuron-like cells or neuron after ischemia in vitro and in vivo, at least in part, through the VEGF/PI3K/Akt/FoxO1 pathway.	[Zhong, Qian; Zhou, Yanfang; Ye, Weibiao; Cai, Tuo; Deng, David Y. B.] Sun Yat Sen Univ, Dept Pathophysiol, Zhongshan Sch Med, Guangzhou 510089, Guangdong, Peoples R China; [Zhong, Qian] Sun Yat Sen Univ, Dept Res Lab, Ctr Canc, Guangzhou 510089, Guangdong, Peoples R China; [Zhou, Yanfang] Guangdong Med Coll, Dept Pathophysiol, Dongguan, Peoples R China; [Zhang, Xiuquan] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT USA; [Deng, David Y. B.] Sun Yat Sen Univ, Translat Med Lab, Affiliated Hosp 1, Guangzhou 510089, Guangdong, Peoples R China		Deng, DYB (corresponding author), Sun Yat Sen Univ, Dept Pathophysiol, Zhongshan Sch Med, Guangzhou 510089, Guangdong, Peoples R China.	dengyub@mail.sysu.edu.cn			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [30901547, 30973093, 81171711]; Doctoral Fund of Ministry of Education [20090171110048]; Guangdong Province Natural Science FundNational Natural Science Foundation of Guangdong Province [C030307, 2009B050200010]; Yixian Innovators' Training Project by Outstanding Mentor(s) at Sun Yat-sen University [50000-3126203]; Graduates' internationally cooperated research project of Sun Yatsen University	We are thankful to Helge Chrisopher Leukel for correcting the English of this article. This work was supported by the National Natural Science Foundation of China (NSFC) Grants (30901547, 30973093, and 81171711), Doctoral Fund of Ministry of Education 20090171110048, Guangdong Province Natural Science Fund (C030307 and 2009B050200010), Yixian Innovators' Training Project by Outstanding Mentor(s) at Sun Yat-sen University (50000-3126203), and the Graduates' internationally cooperated research project of Sun Yatsen University (2008-2009).	Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood-2006-07-035857; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Dai Y, 2007, J MOL CELL CARDIOL, V42, P1036, DOI 10.1016/j.yjmcc.2007.04.001; Deng YB, 2005, CHINESE MED J-PEKING, V118, P1533; Deng YB, 2008, NEUROL RES, V32, P148; Dharmasaroja P, 2009, J CLIN NEUROSCI, V16, P12, DOI 10.1016/j.jocn.2008.05.006; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Dormond O, 2007, J BIOL CHEM, V282, P23679, DOI 10.1074/jbc.M700563200; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ikeda N, 2005, STROKE, V36, P2725, DOI 10.1161/01.STR.0000190006.88896.d3; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Li Y, 2011, NEUROL RES, V33, P583, DOI 10.1179/1743132810Y.0000000013; Longa EZ, 1989, STROKE, V21, P89; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Perasso L, 2010, NEURAL PLAST, V2010, DOI 10.1155/2010/534925; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang XQ, 2005, BRAIN RES, V1057, P57, DOI 10.1016/j.brainres.2005.07.072; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Vangeison G, 2008, J NEUROSCI, V28, P1988, DOI 10.1523/JNEUROSCI.5323-07.2008; Wang XB, 2008, BIOCHEM BIOPH RES CO, V371, P283, DOI 10.1016/j.bbrc.2008.04.055; Wang Y, 2008, BRAIN RES, V1195, P104, DOI 10.1016/j.brainres.2007.11.068; Wang ZS, 2001, CANCER RES, V61, P7171; World Health Organization (WHO), 2004, ANN TABL 2 DEATHS CA; Yilmaz Gokhan, 2010, Exp Transl Stroke Med, V2, P11, DOI 10.1186/2040-7378-2-11; Zhao MZ, 2006, J CEREBR BLOOD F MET, V26, P1176, DOI 10.1038/sj.jcbfm.9600273	54	33	40	3	23	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287			STEM CELLS DEV	Stem Cells Dev.	SEP	2012	21	14					2703	2717		10.1089/scd.2011.0604			15	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	005JW	WOS:000308747700015	22468883	Green Published			2022-02-06	
J	Kirk, KA; Shoykhet, M; Jeong, JH; Tyler-Kabara, EC; Henderson, MJ; Bell, MJ; Fink, EL				Kirk, Katherine A.; Shoykhet, Michael; Jeong, Jong H.; Tyler-Kabara, Elizabeth C.; Henderson, Maryanne J.; Bell, Michael J.; Fink, Ericka L.			Dysautonomia after pediatric brain injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							PAROXYSMAL SYMPATHETIC HYPERACTIVITY; AUTONOMIC DYSFUNCTION; CHILDREN; REHABILITATION	Aim Dysautonomia after brain injury is a diagnosis based on fever, tachypnea, hypertension, tachycardia, diaphoresis, and/or dystonia. It occurs in 8 to 33% of adults with brain injury and is associated with poor outcome. We hypothesized that children with brain injury with dysautonomia have worse outcomes and prolonged rehabilitation, and sought to determine the prevalence of dysautonomia in children and to characterize its clinical features. Method We developed a database of children (n=249, 154 males, 95 females; mean [SD] age 11 years 10 months [5y 7mo]) with traumatic brain injury, cardiac arrest, stroke, infection of the central nervous system, or brain neoplasm admitted for rehabilitation to The Childrens Institute of Pittsburgh between 2002 and 2009. Dysautonomia diagnosis, injury type, clinical signs, length of stay, and Functional Independence Measure for Children (WeeFIM) testing were extracted from medical records, and analysed for differences between groups with and without dysautonomia. Results Dysautonomia occurred in 13% of children with brain injury (95% confidence interval 9.318.0%), occurring in 10% after traumatic brain injury and 31% after cardiac arrest. The combination of hypertension, diaphoresis, and dystonia best predicted a diagnosis of dysautonomia (area under the curve=0.92). Children with dysautonomia had longer stays, worse WeeFIM scores, and improved less on the scores motor component (all p=0.001). Interpretation Dysautonomia is common in children with brain injury and is associated with prolonged rehabilitation. Prospective study and standardized diagnostic approaches are needed to maximize outcomes.	[Kirk, Katherine A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Shoykhet, Michael] Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, Div Pediat Crit Care Med, St Louis, MO 63110 USA; [Jeong, Jong H.] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA; [Tyler-Kabara, Elizabeth C.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Henderson, Maryanne J.] Childrens Inst Pittsburgh, Pittsburgh, PA USA; [Bell, Michael J.; Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA; [Bell, Michael J.; Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Dept Pediat, Pittsburgh, PA USA; [Bell, Michael J.; Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Fink, EL (corresponding author), UPMC, Childrens Hosp Pittsburgh, 4401 Penn Ave,2nd Floor, Pittsburgh, PA 15224 USA.	finkel@ccm.upmc.edu	Fink, Ericka/AAU-9792-2021; Tyler-Kabara, Elizabeth/H-4930-2013	Jeong, Jong/0000-0003-0596-2201; Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Fink, Ericka/0000-0002-3683-4571; Hill, Katherine/0000-0002-9824-7268	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K23NS065132]; University of Pittsburgh School of MedicineUniversity of Pittsburgh; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS065132] Funding Source: NIH RePORTER	We thank Sharon Dorogy, Pat Wotherspoon, Ron Reeher, and Christopher Joseph from The Children's Institute for assistance in data collection and medical record access. We acknowledge our funding sources, National Institutes of Health grant 1K23NS065132 and University of Pittsburgh School of Medicine Dean's Summer Research Program.	Azaula M, 2000, ARCH PHYS MED REHAB, V81, P307, DOI 10.1016/S0003-9993(00)90076-5; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Faul M, 2010, TRAUMATIC BRAIN INJU; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Francois B, 2001, J TRAUMA, V50, P158, DOI 10.1097/00005373-200101000-00035; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Kim CT, 2010, PM&R, V2, pS3, DOI 10.1016/j.pmrj.2009.12.004; Kliegman R. M., 2007, NELSON TXB PEDIAT, V18th; Krach LE, 1997, J NEUROL REHABIL, V11, P41; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Mehta NM, 2008, JPEN-PARENTER ENTER, V32, P281, DOI 10.1177/0148607108316196; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Rodriguez N, 2006, REV NEUROLOGIA, V43, P143, DOI 10.33588/rn.4303.2004453	25	33	35	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	AUG	2012	54	8					759	764		10.1111/j.1469-8749.2012.04322.x			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	971TV	WOS:000306227700021	22712762	Green Accepted, Bronze			2022-02-06	
J	Bosco, FM; Angeleri, R; Zuffranieri, M; Bara, BG; Sacco, K				Bosco, Francesca M.; Angeleri, Romina; Zuffranieri, Marco; Bara, Bruno G.; Sacco, Katiuscia			Assessment Battery for Communication: Development of two equivalent forms	JOURNAL OF COMMUNICATION DISORDERS			English	Article							HEMISPHERE BRAIN-DAMAGE; CLOSED-HEAD INJURY; LANGUAGE DISORDERS; PRAGMATICS; SCHIZOPHRENIA; DISCOURSE; REQUESTS; NEUROPRAGMATICS; COMPREHENSION; SENSITIVITY	The aim of this paper was to develop and test two equivalent forms of the Assessment Battery for Communication (ABaCo), a tool for evaluating pragmatic abilities in patients with neuropsychological and psychiatric disorders. The equivalent forms were created using the data from a sample of 390 children, then tested in a sample of 30 patients with traumatic brain injury. Equivalent forms of the same test are useful in clinical practice and intervention research, when performance needs to be tested on two separate occasions, for example before and after a rehabilitation program. The present results provide additional evidence on the psychometric functioning of the equivalent forms of the ABaCo and their usability in a clinical context. Learning outcomes: The reader will be able to discuss the evidence of the psychometric propriety of the equivalent forms of the ABaCo and describe its potential usefulness. (C) 2012 Elsevier Inc. All rights reserved.	[Bosco, Francesca M.; Bara, Bruno G.] Univ Turin, Dept Psychol, Ctr Cognit Sci, Neurosci Inst Turin, I-10123 Turin, Italy; [Sacco, Katiuscia] Univ Turin, Dept Psychol, Ctr Cognit Sci, Neurosci Inst Turin,CCS fMRI Neuroradiol,Koellike, I-10123 Turin, Italy		Bosco, FM (corresponding author), Univ Turin, Dept Psychol, Ctr Cognit Sci, Neurosci Inst Turin, Via Po 14, I-10123 Turin, Italy.	francesca.bosco@unito.it	bosco, francesca marina/B-6746-2013; Sacco, Katiuscia/J-2133-2012	bosco, francesca marina/0000-0001-6101-8587; Sacco, Katiuscia/0000-0002-9660-5236	Regione PiemonteRegione Piemonte; project "Institutions, Behaviour and Markets in Local and Global Settings (IIINBEMA)"; project "The Invisible Grammar of Social Relations"	This research was supported by Regione Piemonte, in particular Francesca Bosco and Bruno Bara were supported by the project "Institutions, Behaviour and Markets in Local and Global Settings (IIINBEMA)", and Romina Angeleri and Katiuscia Sacco by the project "The Invisible Grammar of Social Relations". We thank Silvia Testa for her help with the revision of the manuscript. Special thanks go to Marco Del Giudice for his helpful suggestions and for his critical reading of the manuscript.	Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Bara BG, 1999, BRAIN LANG, V68, P507, DOI 10.1006/brln.1999.2125; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara Bruno, 2010, COGNITIVE PRAGMATICS; Bazin N, 2005, SCHIZOPHR RES, V77, P75, DOI 10.1016/j.schres.2005.01.020; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bosco FM, 2004, J PRAGMATICS, V36, P467, DOI 10.1016/S0378-2166(03)00055-9; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2006, J PRAGMATICS, V38, P1398, DOI 10.1016/j.pragma.2005.06.011; Bosco FM, 2012, J COGN PSYCHOL, V24, P525, DOI 10.1080/20445911.2012.658156; Bosco FM, 2009, J COGN SCI, V10, P245; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Brownell H, 1997, BRAIN LANG, V57, P60, DOI 10.1006/brln.1997.1834; Brownell H, 1999, BRAIN LANG, V68, P442, DOI 10.1006/brln.1999.2122; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; Bryan K., 1995, RIGHT HEMISPHERE LAN, V2nd ed.; Corcoran Rhiannon, 2003, Cogn Neuropsychiatry, V8, P223, DOI 10.1080/13546800244000319; Cummings Louise, 2007, Seminars in Speech and Language, V28, P96, DOI 10.1055/s-2007-970568; Davis G. Albyn, 2007, Seminars in Speech and Language, V28, P111, DOI 10.1055/s-2007-970569; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DeVellis R.F., 1991, SCALE DEV; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Dollaghan CA, 2004, J COMMUN DISORD, V37, P391, DOI 10.1016/j.jcomdis.2004.04.002; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frattali C. M., 1995, AM SPEECH LANGUAGE H; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gardner H, 1986, RIGHT HEMISPHERE COM; Grice P., 1989, STUDIES WAY WORDS; Holland A., 1998, COMMUNICATION ACTIVI; Holland A., 1980, COMMUNICATIVE ABILIT; Hollingshead A. B., 1975, 4 FACTORS INDEX INDE; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; Kasher Asa, 1991, CHOMSKYAN TURN, P122; Lakoff R. T., 1973, 9 REG M CHIC LING SO; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langdon R, 2002, PSYCHOL MED, V32, P1273, DOI 10.1017/S0033291702006396; Leroy F, 2005, PSYCHIAT RES, V133, P159, DOI 10.1016/j.psychres.2004.07.009; Levinson F. C., 1983, PRAGMATICS; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; Meilijson SR, 2004, J SPEECH LANG HEAR R, V47, P695, DOI 10.1044/1092-4388(2004/053); Nunnaly J.C., 1978, PSYCHOMETRIC THEORY; Pell MD, 2007, BRAIN LANG, V101, P64, DOI 10.1016/j.bandl.2006.10.003; Penn C, 1985, S Afr J Commun Disord, V32, P18; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Raykow T., 2009, INTRO PSYCHOMETRIC T; Rousseaux M, 2010, EUR J NEUROL, V17, P922, DOI 10.1111/j.1468-1331.2009.02945.x; Sacco K, 2008, J COGN SCI, V9, P111; Sarno M. T., 1969, FUNCTIONAL COMMUNICA; Sohlberg M., 2001, COGNITIVE REHABILITA; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; van der Meulen I, 2010, INT J LANG COMM DIS, V45, P424, DOI 10.3109/13682820903111952; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	57	33	33	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2012	45	4					290	303		10.1016/j.jcomdis.2012.03.002			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	966PA	WOS:000305848700004	22483360				2022-02-06	
J	Moore, MM; Pasquale, MD; Badellino, M				Moore, Margaret M.; Pasquale, Michael D.; Badellino, Michael			Impact of age and anticoagulation: Need for neurosurgical intervention in trauma patients with mild traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	Annual Scientific Meeting of the Keystone Chapter of the American-College-of-Surgeons	NOV 04, 2011	Allentown, PA	Amer Coll Surg		Anticoagulation; head injury; computed tomography; intervention	MINOR HEAD TRAUMA; PREINJURY WARFARIN; SUBDURAL-HEMATOMA; RISK	BACKGROUND: Of the 500,000 brain injuries in the United States annually, 80% are considered mild (mild traumatic brain injury). Unfortunately, 2% to 3% of them will subsequently deteriorate and result in severe neurologic dysfunction. Intracerebral changes in the elderly, chronic oral anticoagulation, and platelet inhibition may contribute to the development of intracranial bleeding after minor head injury. We sought to investigate the association of age and the use of anticoagulation and antiplatelet therapy with neurologic deterioration and the need for neurosurgical intervention in patients presenting with mild traumatic brain injury. METHODS: A retrospective review of all adult (>14 years) patients admitted to our Level I trauma service with a Glasgow Coma Scale (GCS) score of 14 to 15 who underwent neurosurgical intervention during their hospital stay was performed. Patients were stratified into two groups, age <65 years and age >= 65 years. Each group was then further stratified by the use of anticoagulants: warfarin, aspirin, clopidogrel, or a combination. Mechanism of injury, prehospital complaints, admission GCS, type of neurosurgical intervention, intensive care unit length of stay, hospital length of stay, and discharge disposition were evaluated. Z test and logistic regression were used to compare proportions or percentages from different groups. RESULTS: Of the 7,678 patients evaluated during the study period, 101 (1.3%) required neurosurgical intervention. The >= 65 years population underwent significantly more interventions as did those patients on anticoagulants. CONCLUSION: All patients aged 65 years or older who present with a GCS score of >13 after head trauma should undergo a screening computed tomography of the head regardless of prehospital use of anticoagulation. Patients younger than 65 years can be selectively screened based on presenting complaints and mechanism of injury provided they are not on anticoagulation. (J Trauma Acute Care Surg. 2012; 73: 126-130. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Moore, Margaret M.; Pasquale, Michael D.; Badellino, Michael] Lehigh Valley Hlth Network, Dept Surg, Allentown, PA 18103 USA		Moore, MM (corresponding author), Lehigh Valley Hlth Network, Dept Surg, 1240 S Cedar Crest Blvd,Suite 210, Allentown, PA 18103 USA.	Margaret_M.Moore@lvhn.org					Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; CDC, 1999, WISQARS LEAD CAUS DE; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch T, 2004, EMERGENCY MED COMPRE; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; PERLMUTTER I, 1961, JAMA-J AM MED ASSOC, V176, P212, DOI 10.1001/jama.1961.63040160001006; Ramenofsky ML., 2004, CURRENT SURG THERAPY; Schulman CI, 2008, TRAUMA; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026; Wahl WL, 2001, J TRAUMA, V51, P1151; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	20	33	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2012	73	1					126	130		10.1097/TA.0b013e31824b01af			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	979JU	WOS:000306814100018	22710784				2022-02-06	
J	Howells, T; Lewen, A; Skold, MK; Ronne-Engstrom, E; Enblad, P				Howells, Tim; Lewen, Anders; Skold, Mattias K.; Ronne-Engstrom, Elisabeth; Enblad, Per			An evaluation of three measures of intracranial compliance in traumatic brain injury patients	INTENSIVE CARE MEDICINE			English	Article						Intracranial compliance; Traumatic brain injury; Intracranial pressure; Cerebral hemodynamics	INTENSIVE-CARE; DECOMPRESSIVE CRANIECTOMY; SUBARACHNOID HEMORRHAGE; PULSE PRESSURE; VOLUME; HYDROCEPHALUS; MONITOR; COMPENSATION; ANESTHESIA; REACTIVITY	To compare intracranial pressure (ICP) amplitude, ICP slope, and the correlation of ICP amplitude and ICP mean (RAP index) as measures of compliance in a cohort of traumatic brain injury (TBI) patients. Mean values of the three measures were calculated in the 2-h periods before and after surgery (craniectomies and evacuations), and in the 12-h periods preceding and following thiopental treatment, and during periods of thiopental coma. The changes in the metrics were evaluated using the Wilcoxon test. The correlations of 10-day mean values for the three metrics with age, admission Glasgow Motor Score (GMS), and Extended Glasgow Outcome Score (GOSe) were evaluated. Patients under and over 60 years old were also compared using the Student test. The correlation of ICP amplitude with systemic pulse amplitude was analyzed. ICP amplitude was significantly correlated with GMS, and also with age for patients 35 years old and older. The correlations of ICP slope and the RAP index with GMS and with age were not significant. All three metrics indicated significant improvements in compliance following surgery and during thiopental coma. None of the metrics were significantly correlated with outcome, possibly due to confounding effects of treatment factors. The correlation of systemic pulse amplitude with ICP amplitude was low ( = 0.18), only explaining 3 % of the variance. This study provides further validation for all three of these features of the ICP waveform as measures of compliance. ICP amplitude had the best performance in these tests.	[Howells, Tim] Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; [Howells, Tim; Lewen, Anders; Skold, Mattias K.; Ronne-Engstrom, Elisabeth; Enblad, Per] Uppsala Univ, Dept Neurosci, Neurosurg Sect, Uppsala, Sweden		Howells, T (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden.	timothy.howells@lul.se	SkAld, Mattias/AAJ-8253-2020; Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			Abdullah J, 2005, ACT NEUR S, V95, P311; Asgari S, 2011, NEUROCRIT CARE, V15, P55, DOI 10.1007/s12028-010-9463-x; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bentsen G, 2008, CRIT CARE MED, V36, P2414, DOI 10.1097/CCM.0b013e318180fe04; Castellani G, 2009, NEUROCRIT CARE, V11, P143, DOI 10.1007/s12028-009-9235-7; Chestnut DE, 2000, J NEUROTRAUM, V17, P573; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Czosnyka M, 2001, J NEUROSURG, V94, P482, DOI 10.3171/jns.2001.94.3.0482; Eide PK, 2007, NEUROL RES, V29, P798, DOI 10.1179/016164107X224132; Eide PK, 2010, J NEUROSURG, V112, P616, DOI 10.3171/2009.7.JNS081593; Eide PK, 2011, NEUROSURGERY, V69, P1105, DOI 10.1227/NEU.0b013e318227e0e1; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Engelse WAH, 1979, IEEE COMPUT CARD, V6, P37; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Hoare SW, 2000, MED ENG PHYS, V22, P547, DOI 10.1016/S1350-4533(00)00071-0; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hu X, 2010, IEEE T BIO-MED ENG, V57, P1070, DOI 10.1109/TBME.2009.2037607; Jakob S, 2000, COMPUT METH PROG BIO, V63, P203, DOI 10.1016/S0169-2607(00)00110-3; Kiening KL, 2005, ACT NEUR S, V95, P293; Kiening KL, 2002, ACT NEUR S, V81, P177; Kim DJ, 2009, NEUROSURGERY, V64, P494, DOI 10.1227/01.NEU.0000338434.59141.89; MAKIVIRTA A, 1991, COMPUT METH PROG BIO, V34, P139, DOI 10.1016/0169-2607(91)90039-V; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MILLER JD, 1973, ARCH NEUROL-CHICAGO, V28, P265, DOI 10.1001/archneur.1973.00490220073011; PIERCE EC, 1962, J CLIN INVEST, V41, P1664, DOI 10.1172/JCI104623; Pino Esteban, 2005, AMIA Annu Symp Proc, P604; Piper I, 1999, BRIT J NEUROSURG, V13, P581, DOI 10.1080/02688699943097; PIPER IR, 1990, ACT NEUR S, V51, P387; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; Salci Kontsantin, 2006, J Clin Monit Comput, V20, P25, DOI 10.1007/s10877-006-2864-x; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, ACTA NEUROCHIR SUPPL, V102, P99, DOI 10.1007/978-3-211-85578-2_20; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; WILKINSON HA, 1979, J NEUROSURG, V50, P758, DOI 10.3171/jns.1979.50.6.0758; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yau Y, 2002, ACTA NEUROCHIR SUPPL, V81, P167	37	33	34	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2012	38	6					1061	1068		10.1007/s00134-012-2571-7			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	943RO	WOS:000304143100018	22527085				2022-02-06	
J	Davies, RC; Williams, WH; Hinder, D; Burgess, CNW; Mounce, LTA				Davies, Rebecca C.; Williams, W. H.; Hinder, Darren; Burgess, Cris N. W.; Mounce, Luke T. A.			Self-Reported Traumatic Brain Injury and Postconcussion Symptoms in Incarcerated Youth	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; crime; traumatic brain injury; youth	MILD HEAD-INJURY; CRIMINAL BEHAVIOR; PREVALENCE; POPULATION; QUESTIONNAIRE; PRISONERS; EMPATHY	Objectives: To determine the prevalence rate of traumatic brain injury (TBI) in incarcerated youth and whether frequency and severity of TBI are associated with postconcussion symptoms (PCS), violent offending behaviors, age of first conviction, and substance abuse. Participants: Sixty-one incarcerated male juvenile offenders with an average age of 16 years. Main Measures: Self-rated measures of head injury, TBI, PCS (Rivermead Post-concussion Symptoms Questionnaire), history of alcohol and drug use, and criminal history. Results: More than 70% reported at least 1 head injury at some point in their lives, and 41% reported experiencing a head injury with loss of consciousness. Postconcussion symptoms reliably increased with the frequency and severity of TBI. The relation between frequency and symptoms was mostly accounted for by severity of TBI. Alcohol use reliably increased with the severity of TBI and was associated with PCS. Alcohol use did not account for the dose-response relation between TBI and PCS. Conclusions: Findings indicate a need to account for TBI in offender populations in managing care needs, which may contribute to reduction in offending behaviors.	[Williams, W. H.] Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England		Williams, WH (corresponding author), Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England.	w.h.williams@exeter.ac.uk	Mounce, Luke/AAX-1911-2020	Mounce, Luke/0000-0002-6089-0661; Walesby, Rebecca/0000-0001-5004-8967; williams, huw/0000-0003-0670-2620			Benedek D.M., 1987, BEHAV SCI LAW, V5, P11, DOI DOI 10.1002/BSL.2370050103; Bjerregaard B, 2002, YOUTH SOC, V34, P31, DOI 10.1177/0044118X02034001002; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Fazel S, 2006, ADDICTION, V101, P181, DOI 10.1111/j.1360-0443.2006.01316.x; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Jolliffe D, 2007, LEGAL CRIMINOL PSYCH, V12, P265, DOI 10.1348/135532506X147413; Kenny DT, 2007, CONT ISSUES CRIME JU, V107, P1; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Marsden J, 1998, ADDICTION, V93, P1857, DOI 10.1046/j.1360-0443.1998.9312185711.x; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697	26	33	33	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					E21	E27		10.1097/HTR.0b013e31825360da			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500003	22573045				2022-02-06	
J	Terre, R; Mearin, F				Terre, R.; Mearin, F.			Effectiveness of chin-down posture to prevent tracheal aspiration in dysphagia secondary to acquired brain injury. A videofluoroscopy study	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						aspiration; chin-down posture; stroke; traumatic brain injury; videofluoroscopy	OROPHARYNGEAL DYSPHAGIA; INTERRATER RELIABILITY; ACUTE-PHASE; SWALLOW; STROKE; IMPACT	Background The chin-down posture is generally recommended in patients with neurogenic dysphagia to prevent tracheal aspiration; however, its effectiveness has not been demonstrated. Aim To videofluoroscopically (VDF) assess the effectiveness of chin-down posture to prevent aspiration in patients with neurogenic dysphagia secondary to acquired brain injury. Methods Randomized, alternating, cross-over study (with and without the chin-down posture) in 47 patients with a VDF diagnosis of aspiration [31 stroke, 16 traumatic brain injury (TBI)] and 25 controls without aspiration (14 stroke, 11 TBI). Key Results During the chin-down posture, 55% of patients avoided aspiration (40% preswallow aspiration and 60% aspiration during swallow). The percentage was similar in both etiologies (58% stroke and 50% TBI). Fifty-one percent of patients had silent aspiration; of these, 48% persisted with aspiration while in the chin-down posture. A statistically significant relationship was found between the existence of pharyngeal residue, cricopharyngeal dysfunction, pharyngeal delay time and bolus volume with the persistence of aspiration. The chin-down posture did not change swallow biomechanics in patients without aspiration. Conclusions & Inferences Only half the patients with acquired brain injury avoided aspiration during cervical flexion; 48% of silent aspirators continued to aspire during the maneuver. Several videofluoroscopic parameters were related to inefficiency of the maneuver. Therefore, the indication for chin-down posture should be evaluated by videofluoroscopic examination.	[Terre, R.; Mearin, F.] Autonomous Univ Barcelona, Funct Digest Rehabil Unit, Inst Guttmann, Neurorehabil Hosp,Univ Inst, Badalona 08916, Spain		Terre, R (corresponding author), Autonomous Univ Barcelona, Funct Digest Rehabil Unit, Inst Guttmann, Neurorehabil Hosp,Univ Inst, Cami de Can Ruti S-N, Badalona 08916, Spain.	rterre@guttmann.com					Ashford J, 2009, J REHABIL RES DEV, V46, P195, DOI 10.1682/JRRD.2008.08.0091; Bath P. M., 2000, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD000323, DOI 10.1002/14651858.CD000323]; Cook IJ, 1999, GASTROENTEROLOGY, V116, P455, DOI 10.1016/S0016-5085(99)70144-7; Ekberg O, 1988, Dysphagia, V3, P46, DOI 10.1007/BF02406279; Hagen C, 1999, REHABILITATION HEAD; Kendall K, 2008, DYSPHAGIA ASSESSMENT, P233; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; Leonard R, 2008, DYSPHAGIA ASSESSMENT, P295; Logemanin JA, 2008, J SPEECH LANG HEAR R, V51, P173, DOI 10.1044/1092-4388(2008/013); Logemann J., 1993, MANUAL VIDEOFLUOROGR, P115; Logemann JA, 2000, J SPEECH LANG HEAR R, V43, P1264, DOI 10.1044/jslhr.4305.1264; Logemann JA, 1998, EVALUATION TREATMENT, P307; Logemann JA, 1998, EVALUATION TREATMENT, P1; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Nagaya M, 2004, NAGOYA J MED SCI, V2, P17; Pena-Casanova J., 1991, PROGRAMA INTEGRADO E; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; Scott A, 1998, DYSPHAGIA, V13, P223, DOI 10.1007/PL00009576; SHANAHAN TK, 1993, ARCH PHYS MED REHAB, V74, P736, DOI 10.1016/0003-9993(93)90035-9; Singh S, 2006, POSTGRAD MED J, V82, P383, DOI 10.1136/pgmj.2005.043281; Stoeckli SJ, 2003, DYSPHAGIA, V18, P53, DOI 10.1007/s00455-002-0085-0; Terre R, 2006, NEUROGASTROENT MOTIL, V18, P200, DOI 10.1111/j.1365-2982.2005.00729.x; Terre R, 2009, NEUROGASTROENT MOTIL, V21, P361, DOI 10.1111/j.1365-2982.2008.01208.x; Terre R, 2009, AM J GASTROENTEROL, V104, P923, DOI 10.1038/ajg.2008.160; Terrte R, 2007, BRAIN INJURY, V21, P1411, DOI 10.1080/02699050701785096; WELCH MV, 1993, ARCH PHYS MED REHAB, V74, P178; Wheeler-Hegland K, 2009, J REHABIL RES DEV, V46, P185, DOI 10.1682/JRRD.2008.08.0094	29	33	38	0	14	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1350-1925			NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	MAY	2012	24	5					414	+		10.1111/j.1365-2982.2011.01869.x			7	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Neurosciences & Neurology	923IH	WOS:000302612500005	22309385				2022-02-06	
J	Salonia, R; Bell, MJ; Kochanek, PM; Berger, RP				Salonia, Rosanne; Bell, Michael J.; Kochanek, Patrick M.; Berger, Rachel P.			The Utility of Near Infrared Spectroscopy in Detecting Intracranial Hemorrhage in Children	JOURNAL OF NEUROTRAUMA			English	Article						abusive head trauma; children; intracranial hemorrhage; near infrared spectroscopy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BIOMARKERS; MANAGEMENT; HEMATOMAS; DIAGNOSIS; SERUM	A prospective case-control study was conducted in a tertiary care pediatric intensive care unit (PICU) to evaluate the use of near infrared spectroscopy (NIRS) for the detection of intracranial hemorrhage (ICH) in children. Subjects 0-14 years of age who had a computed tomography (CT) scan of the head performed as part of clinical care were eligible for enrollment. The children were stratified into two groups based on whether the CT was normal or abnormal. Children in the abnormal imaging cohort were further divided into those with ICH and those with other abnormalities of the brain parenchyma (contusions, diffuse axonal injury [DAI], or cerebral edema) or fractures. NIRS measurements were performed on all subjects within 24 h of head CT. The NIRS operator was blinded to the presence or absence of ICH. NIRS measurements were performed in eight different scalp locations (four bilaterally). A total of 103 measurements were made. The optical density (OD) was automatically calculated by comparing the reflected and diffused optical signal. A Delta OD>0.2 between hemispheres in any scalp location was considered abnormal. NIRS was performed in a total of 28 subjects: 7 had normal imaging and 21 had abnormal imaging. Of those with abnormal imaging, 12 had ICH. The sensitivity and specificity of NIRS at detecting ICH was 1.0 and 0.8, respectively. The positive and negative predictive values were 0.8 and 1.0, respectively. In conclusion, NIRS correctly identified all cases of ICH in this pilot study. Our preliminary results suggest that NIRS may be beneficial in the evaluation of a child with possible ICH.	[Salonia, Rosanne; Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15224 USA; [Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Pediat, Sch Med, Pittsburgh, PA 15224 USA; [Bell, Michael J.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Neurol Surg, Sch Med, Pittsburgh, PA 15224 USA; [Salonia, Rosanne; Bell, Michael J.; Kochanek, Patrick M.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15224 USA		Salonia, R (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Crit Care Med, Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	saloniar@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD040686-09, NS30318]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health 5T32HD040686-09 (to R.S. and P.M.K.), NS30318 (to P.M.K.), and the National Heart, Lung, and Blood Institute T32HL007820 (to R.S. and M.R.P.).	Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; *CDCP, 2000, NAT CTR INJ PREV CON; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Coren ME, 1998, PEDIATR PULM, V26, P389, DOI 10.1002/(SICI)1099-0496(199812)26:6<389::AID-PPUL3>3.0.CO;2-6; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Francis SV, 2005, J CLIN NEUROSCI, V12, P291, DOI 10.1016/j.jocn.2004.06.009; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Robertson C S, 1997, J Biomed Opt, V2, P31, DOI 10.1117/12.261680; Robertson CS, 2010, J NEUROTRAUM, V27, P1597, DOI 10.1089/neu.2010.1340; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P591, DOI 10.1089/neu.1995.12.591; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; VEYRAC C, 1990, PEDIATR RADIOL, V20, P236, DOI 10.1007/BF02019655; Zhang Q, 2000, J BIOMED OPT, V5, P206, DOI 10.1117/1.429988	24	33	33	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1047	1053		10.1089/neu.2011.1890			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100003	22098538	Green Published			2022-02-06	
J	Weckbach, S; Neher, M; Losacco, JT; Bolden, AL; Kulik, L; Flierl, MA; Bell, SE; Holers, VM; Stahel, PF				Weckbach, Sebastian; Neher, Miriam; Losacco, Justin T.; Bolden, Ashley L.; Kulik, Liudmila; Flierl, Michael A.; Bell, Scott E.; Holers, V. Michael; Stahel, Philip F.			Challenging the Role of Adaptive Immunity in Neurotrauma: Rag1(-/-) Mice Lacking Mature B and T Cells Do Not Show Neuroprotection after Closed Head Injury	JOURNAL OF NEUROTRAUMA			English	Article						adaptive immunity; closed head injury; complement system; natural antibodies; Rag1	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ISCHEMIA-REPERFUSION INJURY; NATURAL ANTIBODY REPERTOIRE; COMPLEMENT-SYSTEM; BARRIER DYSFUNCTION; INNATE IMMUNITY; TISSUE-INJURY; RAT-BRAIN; ACTIVATION	The role of adaptive immunity in contributing to post-traumatic neuroinflammation and neuropathology after head injury remains largely unexplored. The present study was designed to investigate the pathophysiological sequelae of closed head injury in Rag1(-/-) mice devoid of mature B and T lymphocytes. C57BL/6 wild-type and Rag1(-/-) mice were subjected to experimental closed head injury, using a standardized weight-drop device. Outcome parameters consisted of neurological scoring, quantification of blood-brain barrier (BBB) function, measurement of inflammatory markers and mediators of apoptosis in serum and brain tissue, and assessment of neuronal cell death, astrogliosis, and tissue destruction. There was no difference between wild-type and Rag1(-/-) mice with regard to injury severity and neurological impairment for up to 7 days after head injury. The extent of BBB dysfunction was in a similar range for both groups. Quantification of complement activation fragments in serum revealed significantly attenuated C3a levels in Rag1(-/-) mice compared to wild-type animals. In contrast, the levels of pro- and anti-inflammatory cytokines and pro-apoptotic and anti-apoptotic mediators remained in a similar range for both groups, and the histological analysis of brain sections did not reveal a difference in reactive astrogliosis, tissue destruction, and neuronal cell death in Rag1(-/-) compared to wild-type mice. These findings suggest that adaptive immunity is not of crucial importance for initiating and sustaining the inflammatory neuropathology after closed head injury. The attenuated extent of post-traumatic complement activation seen in Rag1(-/-) mice implies a cross-talk between innate and adaptive immune responses, which requires further investigation in future studies.	[Weckbach, Sebastian; Neher, Miriam; Losacco, Justin T.; Bolden, Ashley L.; Flierl, Michael A.; Stahel, Philip F.] Univ Colorado, Dept Orthopaed, Denver Hlth Med Ctr, Sch Med, Denver, CO 80204 USA; [Bell, Scott E.; Stahel, Philip F.] Univ Colorado, Dept Neurosurg, Sch Med, Denver, CO 80204 USA; [Kulik, Liudmila; Holers, V. Michael] Univ Colorado Denver, Dept Med, Aurora, CO USA; [Kulik, Liudmila; Holers, V. Michael] Univ Colorado Denver, Dept Immunol, Aurora, CO USA		Stahel, PF (corresponding author), Univ Colorado, Dept Orthopaed, Denver Hlth Med Ctr, Sch Med, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org		Losacco, Justin/0000-0001-7867-1152	Colorado TBI Trust Fund (COTBITF); German Research Foundation (DFG)German Research Foundation (DFG); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR051749]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051749] Funding Source: NIH RePORTER	This study was supported by a project grant from the Colorado TBI Trust Fund (COTBITF) to P.F.S. and M.A.F. S.W. was supported by a research fellowship from the German Research Foundation (DFG). V.M.H. was supported by an R01 grant from the NIH (no. AR051749).	Alexander JJ, 2008, J NEUROCHEM, V107, P1169, DOI 10.1111/j.1471-4159.2008.05668.x; Ankeny DP, 2009, J CLIN INVEST, V119, P2990, DOI 10.1172/JCI39780; Austen WG, 2004, SURGERY, V136, P401, DOI 10.1016/j.surg.2004.05.016; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Dimayuga PC, 2009, AM J PHYSIOL-REG I, V297, pR1593, DOI 10.1152/ajpregu.00114.2009; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Engelhardt B, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-4; Farkas IG, 2003, ACTA HISTOCHEM, V105, P115, DOI 10.1078/0065-1281-00696; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Finsen B., 2011, FEBS LETT; Fleming SD, 2004, J IMMUNOL, V173, P7055, DOI 10.4049/jimmunol.173.11.7055; Fleming SD, 2002, J IMMUNOL, V169, P2126, DOI 10.4049/jimmunol.169.4.2126; Fleming SD, 2006, AUTOIMMUNITY, V39, P379, DOI 10.1080/08916930600739381; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Francis Karen, 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403006252; Galea I, 2007, J EXP MED, V204, P2023, DOI 10.1084/jem.20070064; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; Gong N, 2011, J NEUROIMMUNOL, V230, P33, DOI 10.1016/j.jneuroim.2010.08.014; Griffiths MR, 2010, INT J INFLAMM, V2010, DOI 10.4061/2010/151097; Ha GK, 2006, J NEUROIMMUNOL, V172, P1, DOI 10.1016/j.jneuroim.2005.10.012; Harhausen D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-15; Hazlett LD, 2010, OCUL IMMUNOL INFLAMM, V18, P237, DOI 10.3109/09273948.2010.501946; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; Holers VM, 2007, MOL IMMUNOL, V44, P64, DOI 10.1016/j.molimm.2006.07.003; Holers VM, 2005, SPRINGER SEMIN IMMUN, V26, P405, DOI 10.1007/s00281-004-0186-y; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Kipnis J, 2003, J NEUROTRAUM, V20, P559, DOI 10.1089/089771503767168483; Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; LINDNER V, 1982, ATHEROSCLEROSIS, V43, P417, DOI 10.1016/0021-9150(82)90040-5; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mombaerts P, 1995, Int Rev Immunol, V13, P43, DOI 10.3109/08830189509061737; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morgan BP, 2005, IMMUNOL LETT, V97, P171, DOI 10.1016/j.imlet.2004.11.010; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pachter JS, 2003, J NEUROPATH EXP NEUR, V62, P593, DOI 10.1093/jnen/62.6.593; Perry VH, 1998, J NEUROIMMUNOL, V90, P113; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Ramlackhansingh A.F., 2011, ANN NEUROL; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Reid RR, 2002, J IMMUNOL, V169, P5433, DOI 10.4049/jimmunol.169.10.5433; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Sayed BA, 2010, J IMMUNOL, V184, P6891, DOI 10.4049/jimmunol.1000126; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Szmydynger-Chodobska J., 2011, J CEREB BLOOD FLOW M; Toapanta FR, 2006, IMMUNOL RES, V36, P197, DOI 10.1385/IR:36:1:197; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Volanakis JE, 2002, CURR TOP MICROBIOL, V266, P41; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Zhang M, 2006, J MOL CELL CARDIOL, V41, P62, DOI 10.1016/j.yjmcc.2006.02.006	72	33	35	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1233	1242		10.1089/neu.2011.2169			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100023	22335783	Green Published			2022-02-06	
J	Frugier, T; Conquest, A; McLean, C; Currie, P; Moses, D; Goldshmit, Y				Frugier, Tony; Conquest, Alison; McLean, Catriona; Currie, Peter; Moses, David; Goldshmit, Yona			Expression and Activation of EphA4 in the Human Brain After Traumatic Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Astrocytes; EphA4; Ephrin; Human brain; MAPK; Rho; Traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; RECEPTOR TYROSINE KINASES; UP-REGULATION; AXONAL REGENERATION; EPHA4-DEFICIENT MICE; ASTROCYTIC GLIOSIS; WHITE-MATTER; RHO KINASE; INHIBITION	Glial scars that consist predominantly of reactive astrocytes create a major barrier to neuronal regeneration after traumatic brain injury (TBI). In experimental TBI, Eph receptors and their ephrin ligands are upregulated on reactive astrocytes at injury sites and inhibit axonal regeneration, but very little is known about Eph receptors in the human brain after TBI. A better understanding of the functions of glial cells and their interactions with inflammatory cells and injured axons will allow the development of treatment strategies that may promote regeneration. We analyzed EphA4 expression and activation in postmortem brain tissue from 19 patients who died after acute closed head injury and had evidence of diffuse axonal injury and 8 controls. We also examined downstream pathways that are mediated by EphA4 in human astrocyte cell cultures. Our results indicate that, after TBI in humans, EphA4 expression is upregulated and is associated with reactive astrocytes. The expression was increased shortly after the injury and remained activated for several days. EphA4 activation induced under inflammatory conditions in vitro was inhibited using unclustered EphA4 ligand. These results suggest that blocking EphA4 activation may represent a therapeutic approach for TBI and other types of brain injuries in humans.	[Currie, Peter; Goldshmit, Yona] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia; [Moses, David] St Vincents Hosp, Ctr Neurosci & Neurol Res, Melbourne, Vic, Australia; [Frugier, Tony; Conquest, Alison] Monash Univ, Natl Trauma Res Inst, Alfred Hosp, Melbourne, Vic 3800, Australia; [McLean, Catriona] Monash Univ, Alfred Hosp, Dept Anat Pathol, Melbourne, Vic 3800, Australia; [Frugier, Tony; Conquest, Alison] Monash Univ, Dept Med, Melbourne, Vic 3800, Australia		Goldshmit, Y (corresponding author), Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia.	yona.goldshmit@monash.edu.au		Frugier, Tony/0000-0002-1275-5158; Currie, Peter/0000-0001-8874-8862	Victorian Neurotrauma Initiative; National Trauma Research Institute; University of MelbourneUniversity of Melbourne; Mental Health Research Institute of Victoria; Victorian Institute of Forensic Medicine; Victorian Neurotrauma Initiative, Neurosciences Australia; National Health & Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	This work was supported by the Victorian Neurotrauma Initiative. Tissues were received from the Victorian Brain Bank Network, supported by The National Trauma Research Institute, The University of Melbourne, The Mental Health Research Institute of Victoria, and The Victorian Institute of Forensic Medicine and were funded by the Victorian Neurotrauma Initiative, Neurosciences Australia, and the National Health & Medical Research Council of Australia.	Carpentier PA, 2005, GLIA, V49, P360, DOI 10.1002/glia.20117; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Ellezam B, 2002, PROG BRAIN RES, V137, P371; Fabes J, 2006, EUR J NEUROSCI, V23, P1721, DOI 10.1111/j.1460-9568.2006.04704.x; Fabes J, 2007, EUR J NEUROSCI, V26, P2496, DOI 10.1111/j.1460-9568.2007.05859.x; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Figueroa JD, 2006, J NEUROSCI RES, V84, P1438, DOI 10.1002/jnr.21048; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fu Q, 2007, J NEUROSCI, V27, P4154, DOI 10.1523/JNEUROSCI.4353-06.2007; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636; Goldshmit Y, 2010, J NEUROTRAUM, V27, P1321, DOI 10.1089/neu.2010.1294; Irizarry-Ramirez M, 2005, J NEUROTRAUM, V22, P929, DOI 10.1089/neu.2005.22.929; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Liebl DJ, 2003, J NEUROSCI RES, V71, P7, DOI 10.1002/jnr.10457; LIUZZI FJ, 1987, SCIENCE, V237, P642, DOI 10.1126/science.3603044; Martone ME, 1997, BRAIN RES, V771, P238, DOI 10.1016/S0006-8993(97)00792-0; Mor E, 2011, NUCLEIC ACIDS RES, V39, P3710, DOI 10.1093/nar/gkq1325; Moreno-Flores MT, 1999, NEUROSCIENCE, V91, P193, DOI 10.1016/S0306-4522(98)00568-5; Munoz JJ, 2006, J IMMUNOL, V177, P804, DOI 10.4049/jimmunol.177.2.804; Nakanishi M, 2007, EUR J NEUROSCI, V25, P649, DOI 10.1111/j.1460-9568.2007.05309.x; Ohta K, 1997, MECH DEVELOP, V64, P127, DOI 10.1016/S0925-4773(97)00056-7; Olivieri G, 1999, J HISTOCHEM CYTOCHEM, V47, P855, DOI 10.1177/002215549904700702; Parmentier-Batteur S, 2011, J NEUROCHEM, V118, P1016, DOI 10.1111/j.1471-4159.2011.07375.x; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sobel RA, 2005, BRAIN PATHOL, V15, P35; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang XX, 2009, J NEUROTRAUM, V26, P81, DOI 10.1089/neu.2007.0464; Willson CA, 2002, CELL TRANSPLANT, V11, P229	38	33	34	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2012	71	3					242	250		10.1097/NEN.0b013e3182496149			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	897EM	WOS:000300627500006	22318127	Bronze			2022-02-06	
J	van Bregt, DR; Thomas, TC; Hinzman, JM; Cao, TX; Liu, M; Bing, GY; Gerhardt, GA; Pauly, JR; Lifshitz, J				van Bregt, Daniel R.; Thomas, Theresa Currier; Hinzman, Jason M.; Cao, Tuoxin; Liu, Mei; Bing, Guoying; Gerhardt, Greg A.; Pauly, James R.; Lifshitz, Jonathan			Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						Substantia nigra; PCR; Concussion; Parkinsons; Brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; FOOTBALL-LEAGUE PLAYER; PARKINSONS-DISEASE; NEUROTROPHIC FACTOR; CELL-DEATH; HEAD-INJURY; DOPAMINERGIC-NEURONS; FISCHER-344 RATS; GENE DELIVERY; MICE	Dementia and parkinsonism are late-onset symptoms associated with repetitive head injury, as documented in multiple contact-sport athletes. Clinical symptomatology is the likely phenotype of chronic degeneration and circuit disruption in the substantia nigra (SN). To investigate the initiating neuropathology, we hypothesize that a single diffuse brain injury is sufficient to initiate SN neuropathology including neuronal loss, vascular disruption and microglial activation, contributing to neurodegeneration and altered dopamine regulation. Adult, male Sprague-Dawley rats were subjected to sham or moderate midline fluid percussion brain injury. Stereological estimates indicated a significant 44% loss of the estimated total neuron number in the SN at 28-days post-injury, without atrophy of neuronal nuclear volumes, including 25% loss of tyrosine hydroxylase positive neurons by 28-days post-injury. Multi-focal vascular compromise occurred 1-2 days post-injury, with ensuing microglial activation (significant 40% increase at 4-days). Neurodegeneration (silver-stain technique) encompassed on average 21% of the SN by 7-days post-injury and increased to 29% by 28-days compared to sham (1%). Whole tissue SN, but not striatum, dopamine metabolism was altered at 28-days post-injury, without appreciable gene or protein changes in dopamine synthesis or regulation elements. Together, single moderate diffuse brain injury resulted in SN neurovascular pathology potentially associated with neuroinflammation or dopamine dysregulation. Compensatory mechanisms may preserve dopamine signaling acutely, but subsequent SN damage with aging or additional injury may expose clinical symptomatology of motor ataxias and dementia. (C) 2011 Elsevier Inc. All rights reserved.	[Lifshitz, Jonathan] Univ Kentucky, Albert B Chandler Med Ctr, SCoBIRC, Off B463,Coll Med, Lexington, KY 40536 USA; [van Bregt, Daniel R.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; [Thomas, Theresa Currier; Hinzman, Jason M.; Liu, Mei; Bing, Guoying; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Hinzman, Jason M.; Gerhardt, Greg A.] Univ Kentucky, Coll Med, Morris K Udall Parkinsons Dis Res Ctr Excellence, Lexington, KY 40536 USA; [Hinzman, Jason M.; Gerhardt, Greg A.] Univ Kentucky, Coll Med, Ctr Microelectrode Technol, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Phys Med & Rehabil, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, SCoBIRC, Off B463,Coll Med, Biomed & Biol Sci Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.	JLifshitz@uky.edu	Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666; Bing, Guoying/0000-0003-0609-8152	University of Kentucky College of Medicine; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052, F31 NS067899, P30 NS051220]; NIH NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG000242]; Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) [7-11, 11-2a]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 NS039787]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS065052, P50NS039787, F31NS067899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242] Funding Source: NIH RePORTER	With generous thanks to Amanda Lisembee, Deanne Hopkins, Kelley Hall and Stewart Surgener without whose technical expertise and insightful support this study would not have been possible. Supported, in part, by University of Kentucky College of Medicine, NIH NINDS R01 NS065052, NIH NIA T32 AG000242, NIH NINDS F31 NS067899, Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) 7-11, KSCHIRT 11-2a, NIH P50 NS039787 and NIH NINDS P30 NS051220.	Anastasia A, 2009, J NEUROCHEM, V109, P755, DOI 10.1111/j.1471-4159.2009.06001.x; BERNHEIM.H, 1965, KLIN WOCHENSCHR, V43, P711, DOI 10.1007/BF01707066; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; Braak H, 2006, MOVEMENT DISORD, V21, P2042, DOI 10.1002/mds.21065; Breit S, 2007, EXP NEUROL, V205, P36, DOI 10.1016/j.expneurol.2006.12.016; Casson Ira R, 2006, Neurosurgery, V59, pE1152; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Di Monte DA, 2000, MOVEMENT DISORD, V15, P459, DOI 10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3; Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170; Duke DC, 2007, NEUROGENETICS, V8, P83, DOI 10.1007/s10048-006-0077-6; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Gash D M, 1998, Adv Pharmacol, V42, P911; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Greenamyre JT, 2004, SCIENCE, V304, P1120, DOI 10.1126/science.1098966; GUILARTE TR, 1995, NEUROTOXICOLOGY, V16, P441; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1988, J MICROSC-OXFORD, V151, P3, DOI 10.1111/j.1365-2818.1988.tb04609.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hall ED, 1996, BRAIN RES, V742, P80, DOI 10.1016/S0006-8993(96)00968-7; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hebert MA, 1998, BRAIN RES, V797, P42, DOI 10.1016/S0006-8993(98)00370-9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Hornykiewicz O, 1987, Adv Neurol, V45, P19; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HUDSON J, 1995, BRAIN RES BULL, V36, P425, DOI 10.1016/0361-9230(94)00224-O; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jellinger KA, 2009, J NEURAL TRANSM, V116, P1111, DOI 10.1007/s00702-009-0240-y; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; KOPIN IJ, 1994, J NEURAL TRANSM-SUPP, P57; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuhlmann AC, 1997, BRAIN RES, V751, P281, DOI 10.1016/S0006-8993(96)01409-6; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J., 2011, BRAIN STRUCT FUNCT; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Little KY, 1998, AM J PSYCHIAT, V155, P207; Litvan I, 2007, J NEUROPATH EXP NEUR, V66, P251, DOI 10.1097/nen.0b013e3180415e42; Liu M, 2008, J NEUROSCI RES, V86, P2792, DOI 10.1002/jnr.21725; Liu M, 2010, J NEUROCHEM, V112, P773, DOI 10.1111/j.1471-4159.2009.06497.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long-Smith CM, 2009, PROG NEUROBIOL, V89, P277, DOI 10.1016/j.pneurobio.2009.08.001; Lotharius J, 1999, J NEUROSCI, V19, P1284; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ JS, 1975, J NEUROSURG, V42, P166, DOI 10.3171/jns.1975.42.2.0166; Minnich JE, 2010, RESTOR NEUROL NEUROS, V28, P293, DOI 10.3233/RNN-2010-0528; MOKRY J, 1995, PHYSIOL RES, V44, P143; Nakajima H, 2010, SPINE, V35, P497, DOI 10.1097/BRS.0b013e3181b8e89b; NEDERGAARD S, 1993, J PHYSIOL-LONDON, V466, P727; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pedrosa R, 2002, BRIT J PHARMACOL, V137, P1305, DOI 10.1038/sj.bjp.0704982; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Przedborski S, 2010, MOVEMENT DISORD, V25, pS55, DOI 10.1002/mds.22638; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Salvatore MF, 2005, MOL BRAIN RES, V139, P341, DOI 10.1016/j.molbrainres.2005.06.002; Shih Ming Chi, 2006, Sao Paulo Med. J., V124, P168, DOI 10.1590/S1516-31802006000300014; Simunovic F, 2009, BRAIN, V132, P1795, DOI 10.1093/brain/awn323; Smith L, 2008, GENOME BIOL, V9, DOI [10.1186/gb-2008-9-s2-s2, 10.1186/gb-2008-9-S2-S2]; SMITH RD, 1993, NEUROSCIENCE, V52, P7, DOI 10.1016/0306-4522(93)90176-G; Stanford JA, 2003, NEUROBIOL AGING, V24, P259, DOI 10.1016/S0197-4580(02)00083-0; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Surmeier D.J., 2010, ANTIOXID REDOX SIGNA; Surmeier DJ, 2010, PROG BRAIN RES, V183, P59, DOI 10.1016/S0079-6123(10)83004-3; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thiffault C, 2000, BRAIN RES, V885, P283, DOI 10.1016/S0006-8993(00)02960-7; Thored P, 2009, GLIA, V57, P835, DOI 10.1002/glia.20810; Unterharnscheidt F, 1995, Rev Neurol, V23, P847; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F, 1995, Rev Neurol, V23, P1013; Unterharnscheidt F, 1995, Rev Neurol, V23, P833; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; West MJ, 1996, J COMP NEUROL, V370, P11; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zigmond MJ, 1997, NEUROBIOL DIS, V4, P247, DOI 10.1006/nbdi.1997.0157	104	33	33	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2012	234	1					8	19		10.1016/j.expneurol.2011.12.003			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910DN	WOS:000301617500003	22178300	Green Accepted			2022-02-06	
J	Johnson, B; Zhang, K; Gay, M; Neuberger, T; Horovitz, S; Hallett, M; Sebastianelli, W; Slobounov, S				Johnson, Brian; Zhang, Kai; Gay, Michael; Neuberger, Thomas; Horovitz, Silvina; Hallett, Mark; Sebastianelli, Wayne; Slobounov, Semyon			Metabolic alterations in corpus callosum may compromise brain functional connectivity in MTBI patients: An H-1-MRS study	NEUROSCIENCE LETTERS			English	Article						MTBI; Subacute; H-1-MRS; Functional connectivity	MILD; INJURY; SPECTROSCOPY; PERFORMANCE; RECOVERY; MODERATE; NETWORK	After clinical resolution of signs and symptoms of mild traumatic brain injury (MTBI) it is still not clear if there are residual abnormalities of structural or functional brain networks. We have previously documented disrupted interhemispheric functional connectivity in 'asymptomatic' concussed individuals during the sub-acute phase of injury. Testing of 15 normal volunteers (NV) and 15 subacute MTBI subjects was performed within 24 h of clinical symptoms resolution and medical clearance for the first stage of aerobic activity. In this MRS study we report: (a) both in the genu and splenium of the corpus callosum NAA/Cho and NAA/Cr ratios were significantly (p < 0.05) lower in MTBI subjects shortly after the injury compared to NVs, and (b) the metabolic ratio NAA/Cho in the splenium significantly correlated with the magnitude of inter-hippocampal functional connectivity in normal volunteers, but not in MTBI. This novel finding supports our hypothesis that the functional disruption of interhemispheric brain networks in MTBI subjects results from compromised metabolic integrity of the corpus callosum and that this persists despite apparent clinical return to baseline. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Johnson, Brian; Zhang, Kai; Gay, Michael; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Johnson, Brian; Neuberger, Thomas] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, HMC, Dept Orthoped & Med Rehabil, University Pk, PA 16802 USA; [Horovitz, Silvina; Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Neuberger, Thomas/ABE-3055-2021; Zhang, Kai/F-3261-2015	Horovitz, Silvina G./0000-0002-5501-5918; Zhang, Kai/0000-0002-5460-6150	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002667, R01NS056227] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 'Identification of Athletes at Risk for Traumatic Brain Injury'.	Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Gasparovic C., 2009, J NEUROTRAUM; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Henry L. C., 2011, J NEUROTRAUM; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Johnson B., 2011, NEUROIMAGE; Johnston JM, 2008, J NEUROSCI, V28, P6453, DOI 10.1523/JNEUROSCI.0573-08.2008; Kompus K., 2011, BRAIN RES; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mathew SJ, 2003, BIOL PSYCHIAT, V54, P727, DOI 10.1016/S0006-3223(03)00004-0; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Quigley M, 2003, AM J NEURORADIOL, V24, P208; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	33	33	33	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 10	2012	509	1					5	8		10.1016/j.neulet.2011.11.013			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	903DV	WOS:000301097100002	22108503	Green Accepted			2022-02-06	
J	Hoesch, RE; Lin, E; Young, M; Gottesman, RF; Altaweel, L; Nyquist, PA; Stevens, RD				Hoesch, Robert E.; Lin, Eric; Young, Mark; Gottesman, Rebecca F.; Altaweel, Laith; Nyquist, Paul A.; Stevens, Robert D.			Acute lung injury in critical neurological illness	CRITICAL CARE MEDICINE			English	Article						acute lung injury; acute respiratory distress syndrome; cough reflex; gag reflex; mechanical ventilation; pulmonary edema	RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; NEUROGENIC PULMONARY-EDEMA; SUBARACHNOID HEMORRHAGE; TIDAL VOLUME; CONSENSUS CONFERENCE; HEART-FAILURE; COUGH REFLEX; RISK-FACTORS; VENTILATION	Objective: Acute lung injury and acute respiratory distress syndrome have been reported in a significant proportion of patients with critical neurologic illness. Our aim was to identify risk factors for acute lung injury/acute respiratory distress syndrome in this population. Design: Prospective, observational study. Setting: A 22-bed, adult neurosciences critical care unit at a tertiary care hospital. Patients: Primary neurologic disorder, mechanical ventilation >48 hrs. Interventions: None. Measurements and Main Results: A total of 192 patients were enrolled with a range of neurologic disorders. Among these, 68 (35%) were diagnosed with acute lung injury/acute respiratory distress syndrome. In a multivariate logistic regression analysis, independent risk factors for acute lung injury/acute respiratory distress syndrome were pneumonia (odds ratio [95% confidence interval] 3.12 [1.5-6.0], p = .002), circulatory shock (2.2 [1.07-4.57], p = .03), and absence of a gag or cough reflex (3.41 [1.34-8.68], p = .01). Neither neurologic diagnosis nor neurologic severity, assessed with the Glasgow Coma Scale, was significantly associated with the development of acute lung injury/acute respiratory distress syndrome. Conclusion: Acute lung injury/acute respiratory distress syndrome occurred in more than one third of mechanically ventilated neurosciences critical care unit patients. Loss of the cough or gag reflex is strongly predictive of acute lung injury/acute respiratory distress syndrome, while neurologic diagnosis and Glasgow Coma Scale are not. Lower brainstem dysfunction, a clinical marker of neurologic injury not captured by the Glasgow Coma Scale, is a risk factor for acute lung injury/acute respiratory distress syndrome and could inform decisions regarding airway protection and mechanical ventilation. (Crit Care Med 2012; 40:587-593)	[Hoesch, Robert E.; Gottesman, Rebecca F.; Altaweel, Laith; Nyquist, Paul A.; Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Hoesch, Robert E.; Lin, Eric; Young, Mark; Nyquist, Paul A.; Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21205 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Neurol Surg, Baltimore, MD 21205 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA		Stevens, RD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	rstevens@jhmi.edu	Gottesman, Rebecca/ABA-8468-2020				Addington WR, 1999, STROKE, V30, P1203, DOI 10.1161/01.STR.30.6.1203; [Anonymous], 2000, N ENGL J MED, V342, P1301; Baumann A, 2007, ACTA ANAESTH SCAND, V51, P447, DOI 10.1111/j.1399-6576.2007.01276.x; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30; Garber BG, 1996, CRIT CARE MED, V24, P687, DOI 10.1097/00003246-199604000-00023; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Hammond CAS, 2001, NEUROLOGY, V56, P502, DOI 10.1212/WNL.56.4.502; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Kahn JM, 2006, CRIT CARE MED, V34, P196, DOI 10.1097/01.CCM.0000194540.44020.8E; Kahn JM, 2005, CRIT CARE MED, V33, P766, DOI 10.1097/01.CCM.0000157786.41506.24; Koenig MA, 2007, INTENS CARE MED, V33, P1587, DOI 10.1007/s00134-007-0704-1; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; Mandinov L, 2000, CARDIOVASC RES, V45, P813, DOI 10.1016/S0008-6363(99)00399-5; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158; MILNE ENC, 1984, RADIOLOGY, V152, P1; MOULTON C, 1994, LANCET, V343, P1261, DOI 10.1016/S0140-6736(94)92155-5; Pelosi P, 2011, CRIT CARE MED, V39, P1482, DOI 10.1097/CCM.0b013e31821209a8; Sedy J, 2008, PHYSIOL RES, V57, P499, DOI 10.33549/physiolres.931432; Sharshar T, 2011, CRIT CARE MED, V39, P1960, DOI 10.1097/CCM.0b013e31821b843b; Terrte R, 2007, BRAIN INJURY, V21, P1411, DOI 10.1080/02699050701785096; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; Widdicombe J, 2006, RESP PHYSIOL NEUROBI, V150, P105, DOI 10.1016/j.resp.2005.04.013	29	33	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	FEB	2012	40	2					587	593		10.1097/CCM.0b013e3182329617			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	879EW	WOS:000299313500030	21946655				2022-02-06	
J	Lyvers, M; Onuoha, R; Thorberg, FA; Samios, C				Lyvers, Michael; Onuoha, Roy; Thorberg, Fred Arne; Samios, Christina			Alexithymia in relation to parental alcoholism, everyday frontal lobe functioning and alcohol consumption in a non-clinical sample	ADDICTIVE BEHAVIORS			English	Article						Alcohol; Alexithymia; Frontal lobe	DISORDERS IDENTIFICATION TEST; TRAUMATIC BRAIN-INJURY; FACTORIAL VALIDITY; GENERAL-POPULATION; MAINTAINING ABSTINENCE; NEGATIVE FACTOR; DRUG-USE; SCALE; PSYCHOPATHOLOGY; RELIABILITY	Background: Recent studies have indicated that 45-67% of those in treatment for alcohol use disorders suffer from alexithymia, a multifaceted personality trait characterized by difficulties identifying and describing emotions and an externally oriented cognitive style. The high reported prevalence rates of alexithymia among those with alcohol dependence led to speculation that alexithymia is a personality dimension that may predispose to risky or problematic alcohol use. Methods: This notion was examined in 314 adult volunteers (54% female) aged 18-45 years (M = 27.6 years), all of whom reported at least occasional alcohol consumption, who completed online surveys assessing alexithymia (Toronto Alexithymia Scale, or TAS-20), parental alcoholism (Children of Alcoholics Screening Test, or CAST), everyday signs of frontal lobe dysfunction (Frontal Systems Behavior Scale, or FrSBe) and risky alcohol use (Alcohol Use Disorders Identification Test, or AUDIT). Results: TAS-20 scores were positively correlated with the index of parental alcoholism CAST, index of frontal lobe dysfunction FrSBe and measure of alcohol-related problems AUDIT. Chi-square test showed an association between TAS-20-defined alexithymia and being the offspring of an alcoholic parent as defined by CAST. Regression analysis showed that frontal lobe dysfunction (FrSBe) mediated the relationship between alexithymia (TAS-20 total score) and risky alcohol use (AUDIT). Conclusions: The findings suggest that alexithymia is related to deficiencies in frontal lobe functioning that may reflect a heritable predisposition to alcohol problems. (C) 2011 Elsevier Ltd. All rights reserved.	[Lyvers, Michael; Onuoha, Roy; Samios, Christina] Bond Univ, Dept Psychol, Gold Coast, Qld 4229, Australia; [Thorberg, Fred Arne] Queensland Univ Technol, Inst Hlth & Biomed Innovation, Brisbane, Qld 4059, Australia; [Thorberg, Fred Arne] Univ Queensland, Ctr Youth Substance Abuse Res, Fac Hlth, Brisbane, Qld 4072, Australia		Lyvers, M (corresponding author), Bond Univ, Dept Psychol, Gold Coast, Qld 4229, Australia.	mlyvers@bond.edu.au	Samios, Christina/AAF-7603-2021; Rodriguez, Lymarie/J-6382-2015	Samios, Christina/0000-0003-4661-8343; Thorberg, Fred Arne/0000-0002-8835-7631; Lyvers, Michael/0000-0002-8355-3182	internal Bond University Humanities & Social Sciences Research Grant	This study was funded by an internal Bond University Humanities & Social Sciences Research Grant. The funding sources had no further role in the study.	*AUSTR BUR STAT, 2006, APP CONS ALC AUSTR 2; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Bar-On R., 2000, B ON EMOTIONAL QUOTI; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Bergman H, 2002, ALCOHOL ALCOHOLISM, V37, P245, DOI 10.1093/alcalc/37.3.245; Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961; Chrikritzhs T., 1999, NATL ALCOHOL INDICAT; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; Collins DJ, 2008, COSTS TOBACCO ALCOHO; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; FINN PR, 1987, PSYCHOTHER PSYCHOSOM, V47, P18, DOI 10.1159/000287993; Franz M, 2008, SOC PSYCH PSYCH EPID, V43, P54, DOI 10.1007/s00127-007-0265-1; Gawin F., 2005, J PSYCHOSOM RES, V59, P85; Grabe HJ, 2006, PSYCHOTHER PSYCHOSOM, V75, P312, DOI 10.1159/000093954; Grant M., 1992, AUDIT ALCOHOL USE DI; Gunzelmann T, 2002, COMPR PSYCHIAT, V43, P74, DOI 10.1053/comp.2002.29855; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HILL SY, 1992, J AM ACAD CHILD PSY, V31, P1024, DOI 10.1097/00004583-199211000-00004; Honkalampi K, 2007, PSYCHOTHER PSYCHOSOM, V76, P312, DOI 10.1159/000104709; Iwamoto, 2007, PSYCHOL MEN MASCULIN, V8, P25, DOI [10.1037/1524-9220.8.1.25, DOI 10.1037/1524-9220.8.1.25]; Jones JW., 1983, CHILDREN ALCOHOLICS; Jorgensen MM, 2007, PSYCHOTHER PSYCHOSOM, V76, P369, DOI 10.1159/000107565; Kane TA, 2004, PERS INDIV DIFFER, V36, P83, DOI 10.1016/S0191-8869(03)00070-9; Karlsson H, 2008, BRIT J PSYCHIAT, V192, P32, DOI 10.1192/bjp.bp.106.034728; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Lane RD, 1998, COMPR PSYCHIAT, V39, P377, DOI 10.1016/S0010-440X(98)90051-7; Larson J. H., 1998, ALCOHOLISM TREATMENT, V16, P59; Loas G, 1997, COMPR PSYCHIAT, V38, P296, DOI 10.1016/S0010-440X(97)90063-8; Lowinson JH, 2005, SUBSTANCE ABUSE COMP; Lumley MA, 2000, COMPR PSYCHIAT, V41, P352, DOI 10.1053/comp.2000.9014; Lumley MA, 2008, EMOTION REGULATION C, P43; Lyvers M, 2000, EXP CLIN PSYCHOPHARM, V8, P225, DOI 10.1037/1064-1297.8.2.225; Lyvers M, 2010, PERS INDIV DIFFER, V48, P332, DOI 10.1016/j.paid.2009.10.030; Lyvers M, 2009, ADDICT RES THEORY, V17, P668, DOI 10.3109/16066350802404158; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; Mattila AK, 2006, J PSYCHOSOM RES, V61, P629, DOI 10.1016/j.jpsychores.2006.04.013; Moriguchi Y, 2009, HUM BRAIN MAPP, V30, P2063, DOI 10.1002/hbm.20653; Nemiah J. C., 1976, MODERN TRENDS PSYCHO, V3, P430; Pal HR, 2004, J STUD ALCOHOL, V65, P794, DOI 10.15288/jsa.2004.65.794; Parker JDA, 2003, J PSYCHOSOM RES, V55, P269, DOI 10.1016/S0022-3999(02)00578-0; PARKER JDA, 1993, EUR J PERSONALITY, V7, P221, DOI 10.1002/per.2410070403; Passingham R.E., 1993, FRONTAL LOBES VOLUNT; Petry NM, 1998, ADDICTION, V93, P729, DOI 10.1046/j.1360-0443.1998.9357298.x; Pilat J. M., 1985, ALCOHOL HEALTH RES W, V9, P27; Polce-Lynch M, 1998, SEX ROLES, V38, P1025, DOI 10.1023/A:1018830727244; REICH W, 1988, BRIT J ADDICT, V83, P831; Shields AL, 2004, SUBST USE MISUSE, V39, P1161, DOI 10.1081/JA-120038034; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; Spinella M, 2007, J GEN PSYCHOL, V134, P101, DOI 10.3200/GENP.134.1.101-111; Steinhausen H. C., 1986, ADV CLIN CHILD PSYCH, P217; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Taylor GJ, 2003, J PSYCHOSOM RES, V55, P277, DOI 10.1016/S0022-3999(02)00601-3; Thorberg FA, 2011, EUR PSYCHIAT, V26, P187, DOI 10.1016/j.eurpsy.2010.09.010; Thorberg FA, 2011, DRUG ALCOHOL DEPEN, V116, P238, DOI 10.1016/j.drugalcdep.2010.11.015; Thorberg FA, 2011, ADDICT BEHAV, V36, P427, DOI 10.1016/j.addbeh.2010.12.016; Thorberg FA, 2010, PERS INDIV DIFFER, V49, P119, DOI 10.1016/j.paid.2010.03.018; Thorberg FA, 2009, ADDICT BEHAV, V34, P237, DOI 10.1016/j.addbeh.2008.10.016; Verdejo-Garcia A, 2006, ADDICT BEHAV, V31, P1373, DOI 10.1016/j.addbeh.2005.11.003; Walter NT, 2011, PSYCHOSOM MED, V73, P23, DOI 10.1097/PSY.0b013e31820037c1; Wearden AJ, 2005, J PSYCHOSOM RES, V58, P279, DOI 10.1016/j.jpsychores.2004.09.010; Wester SR, 2002, COUNS PSYCHOL, V30, P630, DOI 10.1177/00100002030004008; Wilkinson D. A., 1991, SELF CONTROL ADDICTI, P107; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; ZIOLKOWSKI M, 1995, PSYCHOTHER PSYCHOSOM, V63, P169	70	33	33	1	23	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4603			ADDICT BEHAV	Addict. Behav.	FEB	2012	37	2					205	210		10.1016/j.addbeh.2011.10.012			6	Psychology, Clinical; Substance Abuse	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Substance Abuse	873VM	WOS:000298911100009	22075204	Green Submitted			2022-02-06	
J	Cekic, M; Johnson, SJ; Bhatt, VH; Stein, DG				Cekic, Milos; Johnson, Sarah J.; Bhatt, Vinay H.; Stein, Donald G.			Progesterone treatment alters neurotrophin/proneurotrophin balance and receptor expression in rats with traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Apoptosis; brain-derived growth factor (BDNF); frontal cortex; nerve growth factor (NGF); progesterone; proneurotrophins; recovery of function; traumatic brain injury; TrkA	NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; CELL-DEATH; SPINAL-CORD; FUNCTIONAL RECOVERY; UP-REGULATION; BDNF; ALLOPREGNANOLONE; NEUROPROTECTION; SORTILIN	Purpose: The neuroactive steroid progesterone (PROG) has been shown to be an effective treatment for traumatic brain injury (TBI) both in animal models and in humans, but the signaling pathways involved have not yet been fully described. Here we characterize the protein expression of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and their pro-proteins and receptors following PROG treatment for TBI. Methods: To evaluate whether PROG treatment given after TBI alters mature and proneurotrophin protein balance and the expression of receptors involved in apoptotic and cell survival signaling, we used Western blots in tissue obtained 24 h, 72 h, and 7 days after injury from rats with bilateral frontal cortical contusions. Results: Compared to controls, PROG reduced levels of pro-apoptotic NGF precursor (proNGF) at 24 h and 7 days post-injury, reduced levels of pro-apoptotic BDNF precursor (proBDNF) and the BDNF receptor TrkB at all time points, and increased levels of mature NGF at 72 h. Levels of mature BDNF were decreased at 24 and 72 h. These observations were associated with reduced markers of apoptosis and improved behavioral parameters in PROG-treated rats. Conclusions: Some of PROG's protective effects after TBI are mediated, in part, by simultaneous induction of pro-survival neurotrophin signaling and inhibition of apoptotic proneurotrophin signaling.	[Stein, Donald G.] Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Stein, Donald/AAJ-5139-2020; Cekic, Milos/AAR-8250-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1RO1N540825, 1RO1N538664]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [DP2AI112242] Funding Source: NIH RePORTER	This work was supported by funds from NIH grants 1RO1N540825 and 1RO1N538664.	Althaus HH, 2008, J MOL NEUROSCI, V35, P65, DOI 10.1007/s12031-008-9053-y; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; BJERRE B, 1973, BRAIN RES, V60, P161, DOI 10.1016/0006-8993(73)90855-X; Canudas AM, 2005, MOL BRAIN RES, V134, P147, DOI 10.1016/j.molbrainres.2004.11.012; Chandler B, 2012, NEURAL NETWORKS, V25, P21, DOI 10.1016/j.neunet.2011.07.009; Chen ZY, 2005, J NEUROSCI, V25, P6156, DOI 10.1523/JNEUROSCI.1017-05.2005; Cunha C, 2009, NEUROBIOL DIS, V33, P358, DOI 10.1016/j.nbd.2008.11.004; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; De Nicola AF, 2003, ANN NY ACAD SCI, V1007, P317, DOI 10.1196/annals.1286.030; Dixon KJ, 2006, EXP NEUROL, V202, P44, DOI 10.1016/j.expneurol.2006.05.010; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009; Grider MH, 2005, J NEUROSCI RES, V82, P404, DOI 10.1002/jnr.20635; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kim DH, 2004, J NEUROSURG, V100, P79, DOI 10.3171/jns.2004.100.1.0079; Koyama R, 2004, J NEUROSCI, V24, P7215, DOI 10.1523/JNEUROSCI.2045-04.2004; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Melcangi RC, 2003, J STEROID BIOCHEM, V85, P323, DOI 10.1016/S0960-0760(03)00228-0; Mohammad S, 1998, EPILEPSY RES, V30, P195, DOI 10.1016/S0920-1211(98)00004-7; National Research Counsil U.S., 2011, GUID CAR US LAB AN; Nygren J, 2006, J NEUROSCI RES, V84, P626, DOI 10.1002/jnr.20956; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pettigrew DB, 2007, EXP NEUROL, V203, P95, DOI 10.1016/j.expneurol.2006.07.026; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; SAUER H, 1994, NEUROREPORT, V5, P609, DOI 10.1097/00001756-199401000-00019; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Scharfman Helen E, 2005, Epilepsy Curr, V5, P83, DOI 10.1111/j.1535-7511.2005.05312.x; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Sobreviela T, 1996, J COMP NEUROL, V375, P417; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	62	33	36	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2012	30	2					115	126		10.3233/RNN-2011-0628			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	921DV	WOS:000302459100004	22232032				2022-02-06	
J	Franke, LM; Walker, WC; Cifu, DX; Ochs, AL; Lew, HL				Franke, Laura M.; Walker, William C.; Cifu, David X.; Ochs, Alfred L.; Lew, Henry L.			Sensorintegrative dysfunction underlying vestibular disorders after traumatic brain injury: A review	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						Afghanistan; anxiety; balance; blast injuries; brain injuries; central nervous system; Iraq; nonblast injuries; post-traumatic stress disorder; spatial perception; vestibular cortex; vestibular system	BLAST INJURY; POSTCONCUSSIVE SYMPTOMS; POSTURAL CONTROL; HEAD-INJURY; STIMULATION; MOTION; CORTEX; IMPAIRMENT; DIZZINESS; SPACE	Vestibular symptoms are persistent and problematic sequelae of blast exposure. Several lines of evidence suggest that these symptoms often stem from injury to the central nervous system. Current methods of assessing the vestibular system have described vestibular deficits that follow traumatic brain injury and differentiate blunt and blast trauma but have not examined the full range of vestibular functions that depend on the cerebral structures above the midbrain. Damage to the central vestibular circuits can lead to deficits in vital processes of spatial perception and navigation, in addition to dizziness and disequilibrium, and may also affect emotional functioning, particularly noradrenergically modulated states of anxiety. Perceptual functions can be assessed to determine the extent of central nervous system involvement in vestibular symptoms and to provide greater confidence when vestibular dysfunction is to be excluded. The ability to detect central vestibular dysfunction will significantly enhance our response to the dizziness and balance symptoms that are a common source of distress for Veterans.	[Franke, Laura M.; Walker, William C.; Lew, Henry L.] Def & Vet Brain Injury Ctr, Richmond, VA 23249 USA; [Franke, Laura M.; Walker, William C.; Cifu, David X.; Lew, Henry L.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA USA; [Cifu, David X.] Dept Vet Affairs VA, Dept Phys Med & Rehabil, Washington, DC USA; [Ochs, Alfred L.] Hunter Holmes McGuire VA Med Ctr, Neurol Serv, Richmond, VA USA; [Ochs, Alfred L.] Virginia Commonwealth Univ, Dept Biomed Engn, Sch Engn, Richmond, VA USA; [Lew, Henry L.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA		Franke, LM (corresponding author), Def & Vet Brain Injury Ctr, 1201 Broad Rock Blvd 151, Richmond, VA 23249 USA.	laura.manning3@va.gov	Walker, William C/N-3162-2014	Ochs, Alfred/0000-0003-3932-876X; Cifu, David/0000-0003-1600-9387	Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Henry M. Jackson Foundation; Hunter Holmes McGuire Depaitinent of Veterans Affairs Medical Center	This material is based on work supported in part by the Defense and Veterans Brain Injury Center, the Henry M. Jackson Foundation, and the Hunter Holmes McGuire Depaitinent of Veterans Affairs Medical Center.	Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Aldridge AJ, 2003, J NEURO-OPHTHALMOL, V23, P145, DOI 10.1097/00041327-200306000-00008; Balaban CD, 2001, J ANXIETY DISORD, V15, P53, DOI 10.1016/S0887-6185(00)00042-6; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Barra J, 2010, BRAIN, V133, P3552, DOI 10.1093/brain/awq311; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Bense S, 2001, J NEUROPHYSIOL, V85, P886, DOI 10.1152/jn.2001.85.2.886; Bent LR, 2002, EXP BRAIN RES, V146, P490, DOI 10.1007/s00221-002-1204-8; Brandt T, 1998, BRAIN, V121, P1749, DOI 10.1093/brain/121.9.1749; Brandt T, 1999, ANN NY ACAD SCI, V871, P293, DOI 10.1111/j.1749-6632.1999.tb09193.x; Brandt T, 2005, BRAIN, V128, P2732, DOI 10.1093/brain/awh617; BRANDT T, 1994, ANN NEUROL, V35, P403, DOI 10.1002/ana.410350406; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIETERICH M, 1993, NEUROLOGY, V43, P1732, DOI 10.1212/WNL.43.9.1732; Dieterich M, 2008, BRAIN, V131, P2538, DOI 10.1093/brain/awn042; FRIBERG L, 1985, BRAIN, V108, P609, DOI 10.1093/brain/108.3.609; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Gilbertson MW, 2007, BIOL PSYCHIAT, V62, P513, DOI 10.1016/j.biopsych.2006.12.023; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JACOB R, 1993, VESTIBULOOCULAR REFL; Jacob RG, 2009, J NEUROL NEUROSUR PS, V80, P74, DOI 10.1136/jnnp.2007.136432; JACOB RG, 1993, J PSYCHOPATHOL BEHAV, V15, P299, DOI 10.1007/BF00965035; Kapralos B, 2004, 116 AUD ENG SOC CONV; Karnath HO, 2000, P NATL ACAD SCI USA, V97, P13931, DOI 10.1073/pnas.240279997; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Miyai I, 1997, J NEUROL REHABIL, V11, P35; PENFIELD W, 1957, Ann Otol Rhinol Laryngol, V66, P691; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Ramachandran VS, 2007, NEUROCASE, V13, P185, DOI 10.1080/13554790701450446; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Scherer MR, 2011, EXP BRAIN RES, V208, P399, DOI 10.1007/s00221-010-2490-1; SCHWARZ DWF, 1971, SCIENCE, V172, P280, DOI 10.1126/science.172.3980.280; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Smith Paul F, 2010, Front Neurol, V1, P141, DOI 10.3389/fneur.2010.00141; Stackman RW, 2002, HIPPOCAMPUS, V12, P291, DOI 10.1002/hipo.1112; Suzuki M, 2001, COGNITIVE BRAIN RES, V12, P441, DOI 10.1016/S0926-6410(01)00080-5; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TAKEDA N, 1995, ACTA OTO-LARYNGOL, P110; Taube JS, 1996, BRAIN RES BULL, V40, P477, DOI 10.1016/0361-9230(96)00145-1; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thilo KV, 2003, J NEUROPHYSIOL, V90, P723, DOI 10.1152/jn.00880.2002; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; Vitte E, 1996, EXP BRAIN RES, V112, P523; WAESPE W, 1977, EXP BRAIN RES, V30, P323; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Welgampola MS, 2001, EXP BRAIN RES, V139, P345, DOI 10.1007/s002210100754	58	33	34	1	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					985	993		10.1682/JRRD.2011.12.0250			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	149EZ	WOS:000319303100004	23341274	Bronze			2022-02-06	
J	Kang, JH; Lin, HC				Kang, Jiunn-Horng; Lin, Herng-Ching			Increased Risk of Multiple Sclerosis after Traumatic Brain Injury: A Nationwide Population-Based Study	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; multiple sclerosis; trauma; traumatic brain injury	HEAD-INJURY; PATHOPHYSIOLOGY; COHORT; STROKE; MS	The etiology of multiple sclerosis (MS) is still not well known. Previous data show conflicting results regarding the association between MS and prior brain trauma. This study aims to investigate the risk for MS following a traumatic brain injury (TBI) using a large-scale cohort study design. This study used data from the National Health Insurance Research Database. A total of 72,765 patients with TBI were identified and included as the study cohort, and 218,295 randomly selected subjects were matched with the study cohort by sex and age as controls. We traced each patient individually for a 6-year period from their index health care utilization to identify those who received a subsequent diagnosis of MS. We used the Kaplan-Meier method and the log-rank test to compare the difference in 6-year MS-free survival rates between the two groups. Stratified Cox proportional hazard regressions were computed to compare the risk of developing MS for these two cohorts. Patients with TBI had a higher incidence of MS during the 6-year period than the comparison group (0.055% versus 0.037%). After excluding cases who died from non-MS causes, stratifying for hospitalization of cases as a proxy for severity, and adjusting for monthly income and geographic region of the community in which the patient resided, the hazard ratio (HR) of MS for patients with hospital-treated TBI injuries was 1.97 (95% CI 1.31,2.93, p<0.01) that of patients without TBI during the 6-year follow-up period after index health care use. Our study concludes that patients with TBI are at higher risk for subsequent MS over a 6-year follow-up period.	[Lin, Herng-Ching] Taipei Med Univ, Coll Med, Sch Hlth Care Adm, Taipei 110, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Dept Phys Med & Rehabil, Coll Med, Sch Med, Taipei 110, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Neurosci Res Ctr, Taipei 110, Taiwan		Lin, HC (corresponding author), Taipei Med Univ, Coll Med, Sch Hlth Care Adm, 250 Wu Hsing St, Taipei 110, Taiwan.	henry11111@tmu.edu.tw					ALTER M, 1968, NEUROLOGY, V18, P109, DOI 10.1212/WNL.18.2.109; Chen YH, 2011, LIVER INT, V31, P354, DOI 10.1111/j.1478-3231.2010.02350.x; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chung SD, 2011, J SEX MED, V8, P240, DOI 10.1111/j.1743-6109.2010.01973.x; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; EBERS GC, 1993, NEUROEPIDEMIOLOGY, V12, P1, DOI 10.1159/000110293; Goldacre MJ, 2006, J NEUROL NEUROSUR PS, V77, P351, DOI 10.1136/jnnp.2005.077693; Granieri E, 2000, J NEUROVIROL, V6, pS141; Gusev E, 1996, ACTA NEUROL SCAND, V94, P386, DOI 10.1111/j.1600-0404.1996.tb00050.x; Hernan MA, 2001, AM J EPIDEMIOL, V154, P69, DOI 10.1093/aje/154.1.69; JELLINEK EH, 1994, LANCET, V343, P1053, DOI 10.1016/S0140-6736(94)90178-3; KURLAND LT, 1994, ANN NEUROL, V36, pS33, DOI 10.1002/ana.410360711; LAUER K, 1994, NEUROLOGY, V44, P1360, DOI 10.1212/WNL.44.7.1360-a; Marmarou A, 2003, ACT NEUR S, V86, P7; Marrie RA, 2009, NEUROLOGY, V72, P117, DOI 10.1212/01.wnl.0000333252.78173.5f; Martinelli V., 2000, Neurological Sciences, V21, pS849, DOI 10.1007/s100720070024; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Pfleger CCH, 2009, MULT SCLER J, V15, P294, DOI 10.1177/1352458508099475; POSER CM, 1994, CLIN NEUROL NEUROSUR, V96, P103, DOI 10.1016/0303-8467(94)90042-6; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; SIVA A, 1993, NEUROLOGY, V43, P1878, DOI 10.1212/WNL.43.10.1878; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Welsh CJ, 2009, ANN NY ACAD SCI, V1153, P209, DOI 10.1111/j.1749-6632.2008.03984.x	25	33	33	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					90	95		10.1089/neu.2011.1936			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300010	22044110				2022-02-06	
J	Powell, T; Gilson, R; Collin, C				Powell, Trevor; Gilson, Rachael; Collin, Christine			TBI 13 years on: factors associated with post-traumatic growth	DISABILITY AND REHABILITATION			English	Article						Head injury; meaning; post-traumatic growth; purpose; social support; spirituality; TBI	TRAUMATIC BRAIN-INJURY; FOLLOW-UP; HEAD-INJURY; SCALE; DEPRESSION; OPTIMISM; REHABILITATION; PREDICTORS; COMMUNITY; ANXIETY	Purpose: To investigate factors associated with post-traumatic growth (PTG) 13 years after severe traumatic brain injury (TBI) and to see if PTG had remained consistent between 11 and 13 years after injury. Method: TBI survivors (n = 21), were interviewed and completed face-to face administration of questionnaires measuring PTG and factors potentially associated with PTG. The design was a longitudinal follow-up study. Results: Factors significantly associated with PTG included: having a sense of personal meaning (purpose and coherence), high life satisfaction now, social support, high-activity levels, a high number of life events, having paid work, new stable relationships after injury, milder disability, and having religious faith. Having a high level of "purpose" was the best predictor of PTG. There was no change in PTG between 11 and 13 years after injury suggesting PTG is a relatively stable phenomenon once established after the early years. Conclusion: Clinicians should be aware of PTG and how it is associated with factors such as "meaning" and "purpose" as well as demographic factors such as, social support, activity such as work, new and stable relationships, milder disability and a shift towards spiritual values. Clinicians can focus advice, resource and effort on supporting these developments.	[Powell, Trevor] Berkshire Healthcare NHS Fdn Trust, Erleigh Rd Clin, Reading RG1 5LR, Berks, England; [Collin, Christine] Fdn Trust, RBH, Reading, Berks, England		Powell, T (corresponding author), Berkshire Healthcare NHS Fdn Trust, Erleigh Rd Clin, 25 Erleigh Rd, Reading RG1 5LR, Berks, England.	trevor.powell@berkshire.nhs.uk					Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; [Anonymous], 2003, SPSS PC VERS 14 0 IB; Barskova T, 2009, DISABIL REHABIL, V31, P1709, DOI 10.1080/09638280902738441; Brooks N, 1981, J HEAD TRAUMA REHAB, V2, P1; Crown S, 1979, MANUAL CROWN CRISP E; Frankl V.E., 1963, MANS SEARCH MEANING; Fugl-Meyer, 1991, J REHABIL SCI, V4, P29; Hawley CA, 2008, BRAIN INJURY, V22, P427, DOI 10.1080/02699050802064607; Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; IDLER EL, 1992, AM J SOCIOL, V97, P1052, DOI 10.1086/229861; JENNETT B, 1975, LANCET, V1, P480; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lelorain S, 2010, J CLIN PSYCHOL MED S, V17, P14, DOI 10.1007/s10880-009-9183-6; Linge FR, 1997, INJURED BRAINS MED M; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; McGrath J, 2004, CLIN REHABIL, V18, P767, DOI 10.1191/0269215504cr802oa; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; Medical Disability Society, 1998, MAN TRAUM BRAIN INJ; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Peleg G, 2009, BRAIN INJURY, V23, P800, DOI 10.1080/02699050903196696; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Reker GT, 1997, GERONTOLOGIST, V37, P709, DOI 10.1093/geront/37.6.709; Reker GT, 2007, LIFE ATTITUDE PROFIL; ROTTER JB, 1966, PSYCHOL MONOGR, V80, P1, DOI 10.1037/h0092976; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schwarzer R., 1995, MEASURES HLTH PSYCHO; Sherer M, 2004, AWARENESS QUESTIONNA; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Stanton AL, 2002, J CLIN ONCOL, V20, P4160, DOI 10.1200/JCO.2002.08.521; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tedeschi R, 2006, HDB POSTTRAMATIC GRO; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; Tennen H., 2002, HDB POSITIVE PSYCHOL, P584; Wood RL, 2004, NEUROPSYCHOL REHABIL, V14, P329, DOI 10.1080/09602010343000255; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	38	33	35	0	28	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2012	34	17					1461	1467		10.3109/09638288.2011.644384			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	965VH	WOS:000305794900007	22233144				2022-02-06	
J	DeJong, G; Hsieh, CH; Putman, K; Smout, RJ; Horn, SD; Tian, WQ				DeJong, Gerben; Hsieh, Ching-Hui; Putman, Koen; Smout, Randall J.; Horn, Susan D.; Tian, Wenqiang			Physical Therapy Activities in Stroke, Knee Arthroplasty, and Traumatic Brain Injury Rehabilitation: Their Variation, Similarities, and Association With Functional Outcomes	PHYSICAL THERAPY			English	Article							SKILLED NURSING FACILITIES; INPATIENT REHABILITATION; BLACK-BOX; PATIENT CHARACTERISTICS; SEVERITY; ILLNESS; LENGTH; WHITE; STAY; INDEPENDENCE	Background. The mix of physical therapy services is thought to be different with different impairment groups. However, it is not clear how much variation there is across impairment groups. Furthermore, the extent to which the same physical therapy activities are associated with functional outcomes across different types of patients is unknown. Objective. The purposes of this study were: (1) to examine similarities and differences in the mix of physical therapy activities used in rehabilitation among patients from different impairment groups and (2) to examine whether the same physical therapy activities are associated with functional improvement across impairment groups. Design. This was a prospective observational cohort study. Methods. The study was conducted in inpatient rehabilitation facilities. The participants were 433 patients with stroke, 429 patients with total knee arthroplasty (TKA), and 207 patients with traumatic brain injury (TBI). Measures used in this study included: (1) the Comprehensive Severity Index to measure the severity of each patient's medical condition, (2) the Functional Independence Measure (FIM) to measure function, and (3) point-of-care instruments to measure time spent in specific physical therapy activities. Results. All 3 groups had similar admission motor FIM scores but varying cognitive FIM scores. Patients with TKA spent more time on exercise than the other 2 groups (average = 31.7 versus 6.2 minutes per day). Patients with TKA received the most physical therapy (average = 65.3 minutes per day), whereas the TBI group received the least physical therapy (average = 38.3 minutes per day). Multivariate analysis showed that only 2 physical therapy activities (gait training and community mobility) were both positively associated with discharge motor FIM outcomes across all 3 groups. Three physical therapy activities (assessment time, bed mobility, and transfers) were negatively associated with discharge motor FIM outcome. Limitations. The study focused primarily on physical therapy without concurrently considering other therapies such as occupational therapy, speech-language pathology, nursing care, and case management or the potential interaction of these inputs. This analysis did not consider the interventions that physical therapists used when patients participated in discrete physical therapy activities. Conclusions. All 3 patient groups spent a considerable portion of their physical therapy time in gait training relative to other activities. Both gait training and community mobility are higher-level activities that were positively associated with outcomes, although all 3 groups spent little time in community mobility activities. Further research studies, such as randomized clinical trials and predictive validity studies, are needed to investigate whether higher-level or more-integrated therapy activities are associated with better patient outcomes.	[DeJong, Gerben; Hsieh, Ching-Hui; Tian, Wenqiang] Natl Rehabil Hosp, Ctr Postacute Innovat & Res, Washington, DC 20010 USA; [Putman, Koen] Vrije Univ Brussel, Fac Med & Pharm, I CHER, Brussels, Belgium; [Smout, Randall J.; Horn, Susan D.] Inst Clin Outcomes Res, Salt Lake City, UT USA		DeJong, G (corresponding author), Natl Rehabil Hosp, Ctr Postacute Innovat & Res, 102 Irving St NW, Washington, DC 20010 USA.	gerben.dejong@medstar.net	Putman, Koen/ABG-6361-2021	Putman, Koen/0000-0002-7235-3759	National Institute of Disability and Rehabilitation Research, Department of Education [H133G050153]; National Center for Medical Rehabilitation Research (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 R01 HD050439]; National Institute of Disability and Rehabilitation Research [H133A080023]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	The stroke study was funded by National Institute of Disability and Rehabilitation Research, Department of Education grant H133G050153 (to Dr DeJong). The JOINTS study was privately and jointly funded by multiple institutions and organizations (to Dr DeJong). The TBI study was funded by National Center for Medical Rehabilitation Research (NIH) grant 1 R01 HD050439 (to Dr Horn and Dr Corrigan) and National Institute of Disability and Rehabilitation Research grant H133A080023 (to Dr Corrigan and Dr Horn).	[Anonymous], 2001, INP REH FAC PAT ASS; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Bode RK, 2004, ARCH PHYS MED REHAB, V85, P1901, DOI 10.1016/j.apmr.2004.02.023; Bode RK, 2004, STROKE, V35, P2537, DOI 10.1161/01.STR.0000145200.02380.a3; BUCKLE JM, 1992, ARCH INTERN MED, V152, P1596, DOI 10.1001/archinte.152.8.1596; Chodzko-Zajko WJ, 2009, MED SCI SPORT EXER, V41, P1510, DOI 10.1249/MSS.0b013e3181a0c95c; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1284, DOI 10.1016/j.apmr.2009.02.009; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; Deutscher D, 2010, ARCH PHYS MED REHAB, V91, P1722, DOI 10.1016/j.apmr.2010.08.007; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Grasel E, 2005, CLIN REHABIL, V19, P725, DOI 10.1191/0269215505cr900oa; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Horn SD, 2010, ARCH PHYS MED REHAB, V91, P1712, DOI 10.1016/j.apmr.2010.04.013; Horner RD, 2003, STROKE, V34, P1027, DOI 10.1161/01.STR.0000060028.60365.5D; Karges Joy, 2009, J Allied Health, V38, pE1; Koizumi D, 2009, J PHYS ACT HEALTH, V6, P467, DOI 10.1123/jpah.6.4.467; Rejeski WJ, 2009, J GERONTOL A-BIOL, V64, P462, DOI 10.1093/gerona/gln041; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, P1647, DOI 10.1053/S0003-9993(03)00317-4; STOSKOPF C, 1991, MED CARE, V29, P179, DOI 10.1097/00005650-199103000-00001; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007	27	33	34	0	35	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	DEC	2011	91	12					1826	1837		10.2522/ptj.20100424			12	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation	860DM	WOS:000297928700013	22003165	Bronze, Green Published			2022-02-06	
J	Radolovich, DK; Aries, MJH; Castellani, G; Corona, A; Lavinio, A; Smielewski, P; Pickard, JD; Czosnyka, M				Radolovich, D. K.; Aries, M. J. H.; Castellani, G.; Corona, A.; Lavinio, A.; Smielewski, P.; Pickard, J. D.; Czosnyka, M.			Pulsatile Intracranial Pressure and Cerebral Autoregulation After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Intracranial pressure amplitude; Flow velocity waveform analysis; Cerebrovascular autoregulation	WAVE-FORM ANALYSIS; HEAD-INJURY; PULSE PRESSURE; HYDROCEPHALUS; REACTIVITY; AMPLITUDE	Strong correlation between mean intracranial pressure (ICP) and its pulse wave amplitude (AMP) has been demonstrated in different clinical scenarios. We investigated the relationship between invasive mean arterial blood pressure (ABP) and AMP to explore its potential role as a descriptor of cerebrovascular pressure reactivity after traumatic brain injury (TBI). We retrospectively analyzed data of patients suffering from TBI with brain monitoring. Transcranial Doppler blood flow velocity, ABP, ICP were recorded digitally. Cerebral perfusion pressure (CPP) and AMP were derived. A new index-pressure-amplitude index (PAx)-was calculated as the Pearson correlation between (averaged over 10 s intervals) ABP and AMP with a 5 min long moving average window. The previously introduced transcranial Doppler-based autoregulation index Mx was evaluated in a similar way, as the moving correlation between blood flow velocity and CPP. The clinical outcome was assessed after 6 months using the Glasgow outcome score. 293 patients were studied. The mean PAx was -0.09 (standard deviation 0.21). This negative value indicates that, on average, an increase in ABP causes a decrease in AMP and vice versa. PAx correlated strong with Mx (R (2) = 0.46, P < 0.0002). PAx also correlated with age (R (2) = 0.18, P < 0.05). PAx was found to have as good predictive outcome value (area under curve 0.71, P < 0.001) as Mx (area under curve 0.69, P < 0.001). We demonstrated significant correlation between the known cerebral autoregulation index Mx and PAx. This new index of cerebrovascular pressure reactivity using ICP pulse wave information showed to have a strong association with outcome in TBI patients.	[Radolovich, D. K.; Aries, M. J. H.; Castellani, G.; Smielewski, P.; Pickard, J. D.; Czosnyka, M.] Univ Cambridge, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England; [Radolovich, D. K.] IRCCS Policlin San Matteo, Dept Intens Care, Pavia, Italy; [Aries, M. J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Castellani, G.] Inst Europeo Oncol, Dept Anaesthesia & Intens Care, Milan, Italy; [Corona, A.] Azienda Osped L Sacco, Dept Intens Care, Milan, Italy; [Lavinio, A.] Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; [Czosnyka, M.] Warsaw Univ Technol, ISE, Warsaw, Poland		Radolovich, DK (corresponding author), Univ Cambridge, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England.	iperdany@hotmail.com	Corona, Alberto/G-8914-2018; Lavinio, Andrea/M-1778-2016; Corona, Alberto/V-8684-2019; Corona, Alberto/B-3328-2013	Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation Trust - Neurosciences ThemeNational Institute for Health Research (NIHR); Senior Investigator Awards; European Federation of Neurological Societies (EFNS); Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	The project was supported by the National Institute of Health Research, Biomedical Research Centre, Cambridge University Hospital Foundation Trust - Neurosciences Theme (MC, PS) and Senior Investigator Awards (JDP). MJH Aries received a travel grant from the European Federation of Neurological Societies (EFNS) and is supported by the Netherlands Organisation for Health Research and Development. ICM+ is licensed by University of Cambridge, Cambridge Enterprise Ltd.	AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bentsen G, 2008, CRIT CARE MED, V36, P2414, DOI 10.1097/CCM.0b013e318180fe04; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Carrera E., 2009, J NEUROIMAGING; Carrera E, 2010, J NEUROTRAUM, V27, P317, DOI 10.1089/neu.2009.0951; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Eide PK, 2007, PEDIATR NEUROSURG, V43, P472, DOI 10.1159/000108790; Eide PK, 2006, ACTA NEUROCHIR, V148, P1267, DOI 10.1007/s00701-006-0908-0; Eide PK, 2006, ACTA NEUROCHIR, V148, P1151, DOI 10.1007/s00701-006-0896-0; Eide PK, 2010, ACTA NEUROL SCAND, V122, P262, DOI 10.1111/j.1600-0404.2009.01304.x; GUILLAUME J, 1951, REV NEUROL, V84, P131; Holm S, 2008, MED ENG PHYS, V30, P164, DOI 10.1016/j.medengphy.2007.03.003; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P557; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Madsen Joseph R, 2006, Clin Neurosurg, V53, P48; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002	25	33	33	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	DEC	2011	15	3					379	386		10.1007/s12028-011-9553-4			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	852NT	WOS:000297365400003	21805216				2022-02-06	
J	Long, B; Anderson, V; Jacobs, R; Mackay, M; Leventer, R; Barnes, C; Spencer-Smith, M				Long, Brian; Anderson, Vicki; Jacobs, Rani; Mackay, Mark; Leventer, Richard; Barnes, Chris; Spencer-Smith, Megan			Executive Function Following Child Stroke: The Impact of Lesion Size	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; PREFRONTAL CORTEX; ISCHEMIC-STROKE; FUTURE-RESEARCH; FRONTAL LOBES; MEMORY; ATTENTION; PERFORMANCE; NETWORKS	Childhood stroke is increasingly recognized as a major cause of childhood morbidity and mortality; however, limited information exists regarding neurobehavioral sequelae. Executive function (EF), important for problem solving, reasoning, social awareness, and adaptive behavior, may be particularly vulnerable to early brain lesions such as stroke, due to its protracted development. This study investigated: (i) the impact of childhood stroke on EF; and (ii) the impact of lesion size on EF outcome. Twenty-eight children diagnosed with stroke at least 12 months prior to assessment were recruited. Neurobehavioral assessment focused on cognitive and behavioral aspects of EF. Lesion volume was determined from standard ratings of brain pathology based on magnetic resonance imaging (MRI) scans. Deficits in cognitive aspects of EF were detected in attentional control, cognitive flexibility and information processing. Difficulties in behavioral aspects of EF were most striking, with problems identified across a wide range of behaviors. Lesion size impacted on EF, with large lesions (greater than 25% of brain volume) proving the most detrimental.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Long, Brian; Jacobs, Rani; Spencer-Smith, Megan] Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au		Spencer-Smith, Megan/0000-0002-1047-0829; Mackay, Mark/0000-0002-3787-1112			Abram HS, 1996, J CHILD NEUROL, V11, P276, DOI 10.1177/088307389601100403; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Aram DM, 1986, DEV NEUROPSYCHOL, V2, P155, DOI 10.1080/87565648609540339; Ballantyne AO, 2008, BRAIN, V131, P2975, DOI 10.1093/brain/awn176; BALLANTYNE AO, 1994, DEV NEUROPSYCHOL, V10, P39, DOI 10.1080/87565649409540565; Bava S, 2007, J CHILD NEUROL, V22, P841, DOI 10.1177/0883073807304700; Beauregard M, 1995, NEUROREPORT, V6, P2521, DOI 10.1097/00001756-199512150-00018; Beebe DW, 2002, J SLEEP RES, V11, P1, DOI 10.1046/j.1365-2869.2002.00289.x; Bertolino A, 1997, CEREB CORTEX, V7, P740, DOI 10.1093/cercor/7.8.740; Block GW, 1999, CHILD NEUROPSYCHOL, V5, P81, DOI 10.1076/chin.5.2.81.3169; Cohen J., 2013, STAT POWER ANAL BEHA; Daniel A, 1993, POWER PRIVILEGE PRES; Delis DC., 2001, DELIS KAPLAN EXECUTI; DELLAMALVA CL, 1993, NEUROPSYCHOLOGIA, V31, P363; DENNIS M, 1980, BRAIN LANG, V10, P287, DOI 10.1016/0093-934X(80)90058-9; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; deVeber GA, 2000, ANN NEUROL, V48, P514; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Everts R, 2008, CHILD NEUROPSYCHOL, V14, P323, DOI 10.1080/09297040701792383; Gioia G., 2000, BEHAV RATING EXECUTI; Goodman R, 1996, DEV MED CHILD NEUROL, V38, P881, DOI 10.1111/j.1469-8749.1996.tb15045.x; Gordon AL, 2002, J CHILD NEUROL, V17, P429, DOI 10.1177/088307380201700606; Hartel C, 2004, EUR J NEUROL, V11, P431, DOI 10.1111/j.1468-1331.2004.00861.x; Heyder K, 2004, ACTA PSYCHOL, V115, P271, DOI 10.1016/j.actpsy.2003.12.010; Hogan AM, 2000, J CHILD NEUROL, V15, P325, DOI 10.1177/088307380001500509; HUDSPETH WJ, 1992, INT J PSYCHOPHYSIOL, V12, P19, DOI 10.1016/0167-8760(92)90039-E; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Jacobs R., 2001, CLIN NEUROPSYCHOL, V2, P101; Klingberg T, 1997, CEREB CORTEX, V7, P465, DOI 10.1093/cercor/7.5.465; Knight RT, 1997, J COGNITIVE NEUROSCI, V9, P75, DOI 10.1162/jocn.1997.9.1.75; KOELFEN W, 1993, EUR J PEDIATR, V152, P1030, DOI 10.1007/BF01957231; Kolb B., 2002, PRINCIPLES FRONTAL L, P541; Lansing AE, 2004, J INT NEUROPSYCH SOC, V10, P742, DOI 10.1017/S1355617704105122; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; Leventer RJ, 1999, NEUROLOGY, V53, P715, DOI 10.1212/WNL.53.4.715; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine SC, 2005, BRAIN COGNITION, V59, P114, DOI 10.1016/j.bandc.2005.05.008; Luria A.R., 1973, WORKING BRAIN; Lynch JK, 2002, PEDIATRICS, V109, P116, DOI 10.1542/peds.109.1.116; Manly T., 1999, TEST EVERYDAY ATTENT; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; Max JE, 2004, J INT NEUROPSYCH SOC, V10, P698, DOI 10.1017/S1355617704105092; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; Reilly J, 2004, BRAIN LANG, V88, P229, DOI 10.1016/S0093-934X(03)00101-9; Semel E., 2003, CLIN EVALUATION LANG; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Steinlin M, 2004, EUR J PEDIATR, V163, P245, DOI 10.1007/s00431-003-1357-x; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Stiles J, 2008, NEUROPSYCHOLOGY, V22, P61, DOI 10.1037/0894-4105.22.1.61; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tabachnick B.G., 2001, USING MULTIVARIATE S; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Tullberg M, 2004, NEUROLOGY, V63, P246, DOI 10.1212/01.WNL.0000130530.55104.B5; VARGHAKHADEM F, 1992, BRAIN, V115, P315, DOI 10.1093/brain/115.1.315; Wechsler D., 1999, MANUAL WECHSLER ABBR; Wechsler D, 2003, MANUAL WECHSLER SCAL; Westmacott R, 2010, DEV MED CHILD NEUROL, V52, P386, DOI 10.1111/j.1469-8749.2009.03403.x	73	33	35	1	20	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	NOV-DEC	2011	36	8					971	987		10.1080/87565641.2011.581537			17	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	846VP	WOS:000296931600002	22004019				2022-02-06	
J	Potter, JL; Wade, SL; Walz, NC; Cassedy, A; Stevens, MH; Yeates, KO; Taylor, HG				Potter, Jennifer L.; Wade, Shari L.; Walz, Nicolay C.; Cassedy, Amy; Stevens, M. Hank; Yeates, Keith O.; Taylor, H. Gerry			Parenting Style Is Related to Executive Dysfunction After Brain Injury in Children	REHABILITATION PSYCHOLOGY			English	Article						traumatic; parenting; permissive; authoritarian; preschool	FAMILY ASSESSMENT DEVICE; YOUNG-CHILDREN; BEHAVIOR PROBLEMS; SHORT-TERM; FOLLOW-UP; OUTCOMES; RELIABILITY; VALIDITY; SKILLS; AUTHORITARIAN	Objective: The goal of this study was to examine how parenting style (authoritarian, authoritative, permissive) and family functioning are related to behavioral aspects of executive function following traumatic brain injury (TBI) in young children. Method: Participants included 75 children with TB! and 97 children with orthopedic injuries (OI), ages 3-7 years at injury. Pre-injury parenting behavior and family functioning were assessed shortly after injury, and postinjury executive functions were assessed using the Behavior Rating Inventory of Executive Functioning (BRIEF; Gioia & Isquith, 2004) at 6, 12, and 18 months postinjury. Mixed model analyses, using pre-injury executive functioning (assessed by the BRIEF at baseline) as a covariate, examined the relationship of parenting style and family characteristics to executive functioning in children with moderate and severe TBI compared to OI. Results: Among children with moderate TBI, higher levels of authoritarian parenting were associated with greater executive difficulties at 12 and 18 months following injury. Permissive and authoritative parenting styles were not significantly associated with postinjury executive skills. Finally, fewer family resources predicted more executive deficits across all of the groups, regardless of injury type. Conclusion: These findings provide additional evidence regarding the role of the social and familial environment in emerging behavior problems following childhood TBI.	[Potter, Jennifer L.] Cincinnati Childrens Hosp, Div Behav Med & Clin Psychol, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Stevens, M. Hank] Miami Univ, Dept Bot, Oxford, OH 45056 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA		Potter, JL (corresponding author), Cincinnati Childrens Hosp, Div Behav Med & Clin Psychol, Med Ctr, Dept Pediat, MLC 3015,3333 Burnet Ave, Cincinnati, OH 45229 USA.	jennifer.potter@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729] Funding Source: Medline		Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Arranz EB, 2010, J FAM STUD, V16, P130, DOI 10.5172/jfs.16.2.130; BAUMRIND D, 1966, CHILD DEV, V37, P887, DOI 10.1111/j.1467-8624.1966.tb05416.x; BAUMRIND D, 1971, DEV PSYCHOL, V4, P1, DOI 10.1037/h0030372; Baumrind D., 1967, GENETIC PSYCHOL MONO, V75, P89; Bernier A, 2010, CHILD DEV, V81, P326, DOI 10.1111/j.1467-8624.2009.01397.x; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Calkins SD, 1998, SOC DEV, V7, P350, DOI 10.1111/1467-9507.00072; CAMPOS JJ, 1989, DEV PSYCHOL, V25, P394, DOI 10.1037/0012-1649.25.3.394; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; DeGarmo S., 2004, PREV SCI, V5, P73, DOI DOI 10.1023/B:PREV.0000023078.30191.E0; DeVito C, 2001, DEV PSYCHOPATHOL, V13, P215, DOI 10.1017/S0954579401002024; DORNBUSCH SM, 1987, CHILD DEV, V58, P1244, DOI 10.2307/1130618; Eisenberg N, 2005, CHILD DEV, V76, P1055, DOI 10.1111/j.1467-8624.2005.00897.x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Garth J, 1997, Pediatr Rehabil, V1, P99; GAUVAIN M, 1989, DEV PSYCHOL, V25, P139, DOI 10.1037/0012-1649.25.1.139; GINSBURG GS, 1993, CHILD DEV, V64, P1461, DOI 10.1111/j.1467-8624.1993.tb02964.x; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Hess R. D., 1985, REV CHILD DEV RES, P179; LAMBORN SD, 1991, CHILD DEV, V62, P1049, DOI 10.1111/j.1467-8624.1991.tb01588.x; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS RH, 1988, SOC SCI MED, V27, P999, DOI 10.1016/0277-9536(88)90291-2; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Schroeder VM, 2009, J CHILD FAM STUD, V18, P227, DOI 10.1007/s10826-008-9223-0; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	44	33	34	0	30	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2011	56	4					351	358		10.1037/a0025445			8	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	862AQ	WOS:000298062600008	21928918	Green Accepted			2022-02-06	
J	Selassie, AW; Fakhry, SM; Ford, DW				Selassie, Anbesaw Wolde; Fakhry, Samir M.; Ford, Dee W.			Population-Based Study of the Risk of In-Hospital Death After Traumatic Brain Injury: The Role of Sepsis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Sepsis; Comorbidity; In-hospital death; Epidemiology	UNITED-STATES; EPIDEMIOLOGY; MORTALITY; TRENDS; SURVIVAL; IMPACT; RACE	Background: Traumatic brain injury (TBI) accounts for the largest proportion of injury-related deaths and disability in the United States. The proportion of TBI-related deaths that occur after admission in a hospital remains high despite improvement in medical technology. We provide findings on the risk factors of in-hospital death and demonstrate the risk associated with sepsis occurring in the hospital environment. Methods: Population-based retrospective cohort study of 41,395 patients with TBI from all nonfederal hospitals in South Carolina, 1998 to 2009. TBI was ascertained by International Classification of Diseases-9th Rev.-Clinical Modification codes of 800 to 801, 803 to 804, 850 to 854, and 959.01. Observation was censored at the 120th day. Days elapsing from the date of injury to date of death established the survival time (T). Cox regression was used to examine the risk of death, whereas Kaplan-Meier survival curves compared survival probabilities across time. Results: Sepsis was independently associated with risk of in-hospital death with hazard ratio of 1.34 (p < 0.001). Severity of TBI was the strongest risk factor with hazard ratio of 4.97 (p < 0.001). Nearly 90% of patients with sepsis were identified with one of the nosocomial etiologies included in the analyses compared with 7% of patients without sepsis (p < 0.001). The survival probabilities were significantly lower for persons with sepsis compared with those without (log-rank test p < 0.001). Conclusion: Sepsis occurring in the hospital environment and associated with nosocomial etiologies is a strong risk factor for in-hospital death after TBI. Reducing the risk of infections and subsequent sepsis through adherence with infection control measures is a critical step to reduce in-hospital deaths among patients with TBI.	[Selassie, Anbesaw Wolde] Med Univ S Carolina, Div Epidemiol & Biostat, Charleston, SC 29425 USA; [Fakhry, Samir M.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Ford, Dee W.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA		Selassie, AW (corresponding author), Med Univ S Carolina, Div Epidemiol & Biostat, 135 Cannon St, Charleston, SC 29425 USA.	selassie@musc.edu			National Institute of Health, Center for Minority and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC1MD004405-01]; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [RC1MD004405] Funding Source: NIH RePORTER	This study is supported by a grant from the National Institute of Health, Center for Minority and Health Disparities, Grant No. RC1MD004405-01 to a project entitled CRitical Care Excellence in Sepsis and Trauma (CREST) Medical University of South Carolina (MUSC) (to D.W.F. and S.M.F.).	Allison PD, 1995, SURVIVAL ANAL USING, P29; American Medical Association, 2009, INT CLASS DIS; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; [Anonymous], 2010, STAT AN SOFTW VERS 9; BABA H, 1995, PARAPLEGIA, V33, P281, DOI 10.1038/sc.1995.64; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Bateman BT, 2010, ANESTHESIOLOGY, V112, P917, DOI 10.1097/ALN.0b013e3181cea3d0; BOULANGER BR, 1994, CRIT CARE CLIN, V10, P537, DOI 10.1016/S0749-0704(18)30117-9; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; Centers for Disease Control and Prevention, 2006, TRAUM BRAIN INJ US C; Chotani R. A., 2007, Infectious disease epidemiology: theory and practice, P505; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Ekshyyan O, 2004, FRONT BIOSCI-LANDMRK, V9, P1567, DOI 10.2741/1357; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Ferraris VA, 2010, J TRAUMA, V69, P645, DOI 10.1097/TA.0b013e3181d8941d; Georgiou C, 2009, WORLD J SURG, V33, P1087, DOI 10.1007/s00268-009-9923-7; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Kao LS, 2006, AM J SURG, V192, P710, DOI 10.1016/j.amjsurg.2006.08.031; Kleinbaum DG, 2010, EVALUATING PROPORTIO, P130; Lorelli DR, 2001, AM SURGEON, V67, P693; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Plurad DS, 2010, AM SURGEON, V76, P43; Romano PS, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.2.154; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Thurman DJ., 1995, GUIDELINES SURVEILLA; Upperman Jeffrey S, 2005, Pediatr Crit Care Med, V6, pS108, DOI 10.1097/01.PCC.0000161578.11270.39; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wardle TD, 1999, BRIT MED BULL, V55, P744, DOI 10.1258/0007142991902754	38	33	34	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1226	1234		10.1097/TA.0b013e318226ecfc			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	849IG	WOS:000297118600029	22071924				2022-02-06	
J	Sukumari-Ramesh, S; Bentley, JN; Laird, MD; Singh, N; Vender, JR; Dhandapani, KM				Sukumari-Ramesh, Sangeetha; Bentley, J. Nicole; Laird, Melissa D.; Singh, Nagendra; Vender, John R.; Dhandapani, Krishnan M.			Dietary phytochemicals induce p53-and caspase-independent cell death in human neuroblastoma cells	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Ayurveda; Akt; Pediatric cancer; Nutrition; Chemotherapy	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; COMBINATION KAN-JANG; INDUCED APOPTOSIS; FERULIC ACID; CURCUMIN; PATHWAY; ACTIVATION; INHIBITION; EXPRESSION	Neuroblastoma (NB) is the most prevalent pediatric solid tumor and a leading cause of cancer-related death in children. In the present study, a novel cytotoxic role for the dietary compounds, curcumin, andrographolide, wedelolactone, dibenzoylmethane, and tanshinone IIA was identified in human S-type NB cells, SK-N-AS and SK-N-BE(2). Mechanistically, cell death appeared apoptotic by flow cytometry; however, these effects proceeded independently from both caspase-3 and p53 activation, as assessed by both genetic (shRNA) and pharmacological approaches. Notably, cell death induced by both curcumin and andrographolide was associated with decreased NF kappa B activity and a reduction in Bcl-2 and Bcl-xL expression. Finally, curcumin and andrographolide increased cytotoxicity following co-treatment with either cisplatin or doxorubicin, two chemotherapeutic agents widely used in the clinical management of NB. Coupled with the documented safety in humans, dietary compounds may represent a potential adjunct therapy for NB. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Sukumari-Ramesh, Sangeetha; Bentley, J. Nicole; Laird, Melissa D.; Vender, John R.; Dhandapani, Krishnan M.] Georgia Hlth Sci Univ, Dept Neurosurg, Augusta, GA 30912 USA; [Singh, Nagendra] Georgia Hlth Sci Univ, Dept Biochem, Augusta, GA 30912 USA		Dhandapani, KM (corresponding author), Georgia Hlth Sci Univ, Dept Neurosurg, 1120 15th St, Augusta, GA 30912 USA.	kdhandapani@georgiahealth.edu		Bentley, Nicole/0000-0002-8303-071X; Dhandapani, Krishnan/0000-0001-7044-1117	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065172]; American Heart AssociationAmerican Heart Association [BGIA2300135, 2250690]; A.R. Staulcup Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172] Funding Source: NIH RePORTER	The authors' research was supported in part by grants from the National Institutes of Health (NS065172) and the American Heart Association (BGIA2300135) to KMD, by a fellowship from the American Heart Association (2250690) to MDL, and by a grant from the A.R. Staulcup Foundation.	Alonso M, 2003, MOL CANCER THER, V2, P139; Aristotle L, 2004, ANTICANCER RES, V24, P987; Balachandran P, 2005, PHARMACOL RES, V51, P19, DOI 10.1016/j.phrs.2004.04.010; Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Biedler J L, 1988, Prog Clin Biol Res, V271, P265; BIEDLER JL, 1973, CANCER RES, V33, P2643; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893; Cui HJ, 2002, MOL CANCER THER, V1, P679; Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Gabrielian ES, 2002, PHYTOMEDICINE, V9, P589, DOI 10.1078/094471102321616391; HOLDER GM, 1978, XENOBIOTICA, V8, P761, DOI 10.3109/00498257809069589; HUMPL T, 1995, WORLD J UROL, V13, P233; Karacay B, 2004, CANCER GENE THER, V11, P681, DOI 10.1038/sj.cgt.7700749; Karmakar S, 2006, NEUROSCI LETT, V407, P53, DOI 10.1016/j.neulet.2006.08.013; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Kim NH, 2007, J CELL BIOCHEM, V102, P1160, DOI 10.1002/jcb.21344; KING MD, 2011, J NEUROSURG; Kobori M, 2004, CELL DEATH DIFFER, V11, P123, DOI 10.1038/sj.cdd.4401325; Kulichenko L. L., 2003, Journal of Herbal Pharmacotherapy, V3, P77, DOI 10.1080/J157v03n01_04; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lavoie S, 2009, J NEUROCHEM, V108, P1410, DOI 10.1111/j.1471-4159.2009.05908.x; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Mora J, 2001, CANCER RES, V61, P6892; Murakami Y, 2005, IN VIVO, V19, P1039; Negi AS, 2008, MED RES REV, V28, P746, DOI 10.1002/med.20115; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Ouyang W, 2006, CARCINOGENESIS, V27, P864, DOI 10.1093/carcin/bgi321; Panossian A, 2000, PHYTOMEDICINE, V7, P351, DOI 10.1016/S0944-7113(00)80054-9; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Ronchetti D, 2006, EUR J PHARMACOL, V532, P162, DOI 10.1016/j.ejphar.2005.12.034; ROSS RA, 1983, J NATL CANCER I, V71, P741; Scapagnini G, 2006, ANTIOXID REDOX SIGN, V8, P395, DOI 10.1089/ars.2006.8.395; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Singletary K, 1998, CARCINOGENESIS, V19, P1039, DOI 10.1093/carcin/19.6.1039; STILLER CA, 1992, INT J CANCER, V52, P538, DOI 10.1002/ijc.2910520407; Sukumari-Ramesh S, 2010, GLIA, V58, P1858, DOI 10.1002/glia.21055; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; Venkatesan N, 1998, BRIT J PHARMACOL, V124, P425, DOI 10.1038/sj.bjp.0701877; Venkatesan N, 2000, BRIT J PHARMACOL, V129, P231, DOI 10.1038/sj.bjp.0703067; Wakade C, 2009, ANTIOXID REDOX SIGN, V11, P35, DOI 10.1089/ars.2008.2056; Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004	47	33	34	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	NOV	2011	29	7					701	710		10.1016/j.ijdevneu.2011.06.002			10	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	837MR	WOS:000296208400004	21704149	Green Accepted			2022-02-06	
J	Ustinova, KI; Leonard, WA; Cassavaugh, ND; Ingersoll, CD				Ustinova, Ksenia I.; Leonard, Wesley A.; Cassavaugh, Nicholas D.; Ingersoll, Christopher D.			Development of a 3D immersive videogame to improve arm-postural coordination in patients with TBI	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						virtual reality; motor rehabilitation; postural control; brain injury	VIRTUAL-REALITY; BRAIN-INJURY; BALANCE; TRUNK; REHABILITATION; SYNERGIES; EXERCISE; STROKE; ENVIRONMENTS; RELIABILITY	Background: Traumatic brain injury (TBI) disrupts the central and executive mechanisms of arm(s) and postural (trunk and legs) coordination. To address these issues, we developed a 3D immersive videogame- Octopus. The game was developed using the basic principles of videogame design and previous experience of using videogames for rehabilitation of patients with acquired brain injuries. Unlike many other custom-designed virtual environments, Octopus included an actual gaming component with a system of multiple rewards, making the game challenging, competitive, motivating and fun. Effect of a short-term practice with the Octopus game on arm-postural coordination in patients with TBI was tested. Methods: The game was developed using WorldViz Vizard software, integrated with the Qualysis system for motion analysis. Avatars of the participant's hands precisely reproducing the real-time kinematic patterns were synchronized with the simulated environment, presented in the first person 3D view on an 82-inch DLP screen. 13 individuals with mild-to-moderate manifestations of TBI participated in the study. While standing in front of the screen, the participants interacted with a computer-generated environment by popping bubbles blown by the Octopus. The bubbles followed a specific trajectory. Interception of the bubbles with the left or right hand avatar allowed flexible use of the postural segments for balance maintenance and arm transport. All participants practiced ten 90-s gaming trials during a single session, followed by a retention test. Arm-postural coordination was analysed using principal component analysis. Results: As a result of the short-term practice, the participants improved in game performance, arm movement time, and precision. Improvements were achieved mostly by adapting efficient arm-postural coordination strategies. Of the 13 participants, 10 showed an immediate increase in arm forward reach and single-leg stance time. Conclusion: These results support the feasibility of using the custom-made 3D game for retraining of arm-postural coordination disrupted as a result of TBI.	[Ustinova, Ksenia I.; Leonard, Wesley A.; Ingersoll, Christopher D.] Cent Michigan Univ, Herbert H & Grace A Dow Coll Hlth Profess, Mt Pleasant, MI 48859 USA; [Cassavaugh, Nicholas D.] Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI USA; [Cassavaugh, Nicholas D.] Cent Michigan Univ, Ctr Driver Evaluat Educ & Res, Mt Pleasant, MI USA		Ustinova, KI (corresponding author), Cent Michigan Univ, Herbert H & Grace A Dow Coll Hlth Profess, Mt Pleasant, MI 48859 USA.	ustin1k@cmich.edu	Ustinova, Ksenia I/M-8250-2016; Ingersoll, Christopher/H-6474-2015	Ustinova, Ksenia I/0000-0002-1531-7591; Ingersoll, Christopher/0000-0001-9157-6846	US Department of DefenceUnited States Department of Defense	The authors acknowledge study participants, Lisette Tamkei for creating graphic design, Jessica Gardon-Rose and Christopher Hausbeck for patient recruitment and evaluation, and Amanda Schafer for help with data collection. The study was supported by the US Department of Defence.	Alexandrov A, 1998, EXP BRAIN RES, V118, P210, DOI 10.1007/s002210050274; Arce FI, 2004, HUM MOVEMENT SCI, V22, P749, DOI 10.1016/j.humov.2003.12.002; BERG K, 1989, Physiotherapy Canada, V41, P304; Bernstein NA., 1967, COORDINATION REGULAT; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Cirstea AC, 2007, NEUROREHAB NEURAL RE, V21, P398, DOI 10.1177/1545968306298414; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dault MC, 2002, BRAIN INJURY, V16, P231, DOI 10.1080/02699050110103300; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fredericks CM, 1996, PATHOPHYSIOLOGY MOTO; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gentile A., 1987, SKILL ACQUISITION AC; Gonzalez-Fernandez M, 2010, STUD HEALTH TECHNOL, V154, P61, DOI 10.3233/978-1-60750-561-7-61; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Holden M.K, 2002, NEUROLOGY REPORT, V26, P62, DOI [10.1097/01253086-200226020-00003, DOI 10.1097/01253086-200226020-00003]; Kaminski TR, 2007, GAIT POSTURE, V26, P256, DOI 10.1016/j.gaitpost.2006.09.006; KESHNER EA, 2004, J NEUROENG REHABIL, V3, P8; KLOCKGETHER T, 1990, J NEUROL NEUROSUR PS, V53, P297, DOI 10.1136/jnnp.53.4.297; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Levin MF, 1996, BRAIN, V119, P281, DOI 10.1093/brain/119.1.281; Levin MF, 2002, EXP BRAIN RES, V143, P171, DOI 10.1007/s00221-001-0976-6; Levin MF, 2009, STUD HEALTH TECHNOL, V145, P94, DOI 10.3233/978-1-60750-018-6-94; MAGDALON EC, 2011, ACTA PSYCHOL AMST; MAH CD, 1994, J MOTOR BEHAV, V26, P83, DOI 10.1080/00222895.1994.9941664; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Michaelsen SM, 2004, STROKE, V35, P1914, DOI 10.1161/01.STR.0000132569.33572.75; Mumford N, 2009, BRAIN INJURY, V23, P179, DOI 10.1080/02699050802695566; Newstead Ann H, 2005, J Neurol Phys Ther, V29, P18; Newton R., 2001, J GERONTOL A-BIOL, V56A, P248; Posner, 1967, HUM PERFORM; Qin H, 2009, INT J HUM-COMPUT INT, V25, P107, DOI 10.1080/10447310802546732; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SKINNER BF, 1938, BEHAV ORGANISM EXPT; SMITHWHEELOCK M, 1991, AM J OTOL, V12, P218; SUBRAMANIAN SK, 2011, J NEUROENG REHABIL, V30, P8; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Tyson SF, 2004, CLIN REHABIL, V18, P916, DOI 10.1191/0269215504cr821oa; Ustinova KI, 2004, MOTOR CONTROL, V8, P139, DOI 10.1123/mcj.8.2.139; USTINOVA KI, 2011, P VIRT REH C ZUR SWI, P27; WEISS PI, 2004, J NEUROENG REHABIL, V20, P1; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Yavuzer G, 2008, EUR J PHYS REHAB MED, V44, P237	44	33	36	2	32	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1743-0003		J NEUROENG REHABIL	J. NeuroEng. Rehabil.	OCT 31	2011	8								61	10.1186/1743-0003-8-61			11	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology; Rehabilitation	847NQ	WOS:000296980000001	22040301	gold, Green Published			2022-02-06	
J	Boulet, T; Kelso, ML; Othman, SF				Boulet, Thomas; Kelso, Matthew L.; Othman, Shadi F.			Microscopic magnetic resonance elastography of traumatic brain injury model	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury; Microscopic magnetic resonance; elastography; Inverse problem; Rat brain; In vivo mouse	MR ELASTOGRAPHY; VISCOELASTIC PROPERTIES; AXONAL INJURY; EDEMA; TIME; RECONSTRUCTION; IMPACT; SPECTROSCOPY; INVERSION; FIBROSIS	Traumatic brain injury (TB!) is a major cause of death and disability for which there is no cure. One of the issues inhibiting clinical trial success is the lack of targeting specific patient populations due to inconsistencies between clinical diagnostic tools and underlying pathophysiology. The development of reliable, noninvasive markers of TBI severity and injury mechanisms may better identify these populations, thereby improving clinical trial design. Magnetic resonance elastography (MRE), by assessing tissue mechanical properties, can potentially provide such marker. MRE synchronizes mechanical excitations with a phase contrast imaging pulse sequence to noninvasively register shear wave propagation, from which local values of tissue viscoelastic properties can be deduced. The working hypothesis of this study is that TBI involves a compression of brain tissue large enough to bring the material out of its elastic range, sufficiently altering mechanical properties to generate contrast on MRE measurements. To test this hypothesis, we combined microscopic MRE with brain tissue collected from adult male rats subjected to a controlled cortical impact injury. Measurements were made in different regions of interest (somatosensory cortex, hippocampus, and thalamus), and at different time points following the injury (immediate, 24 h, 7 days, 28 days). Values of stiffness in the somatosensory cortex were found to be 23-32% lower in the injured hemisphere than in the healthy one, when no significant difference was observed in the case of sham brains. A preliminary in vivo experiment is also presented, as well as alternatives to improve the faithfulness of stiffness recovery. (C) 2011 Elsevier B.V. All rights reserved.	[Othman, Shadi F.] Univ Nebraska, Dept Biol Syst Engn, Translat & Regenerat Med TREM Imaging Lab, Lincoln, NE 68583 USA; [Boulet, Thomas] Univ Nebraska, Dept Engn Mech, Lincoln, NE 68588 USA; [Kelso, Matthew L.] Univ Nebraska Med Ctr, Dept Pharm Practice, Coll Pharm, Omaha, NE 68198 USA		Othman, SF (corresponding author), Univ Nebraska, Dept Biol Syst Engn, Translat & Regenerat Med TREM Imaging Lab, 249 LW Chase Hall, Lincoln, NE 68583 USA.	thomas.boulet@huskers.unl.edu; mkelso@unmc.edu; sothman2@unl.edu			UNL/UNMC; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO3-EB007299-02]; NIH COBRE Nebraska Center for Nanomedicine [RR021937]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR021937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R03EB007299] Funding Source: NIH RePORTER	The authors wish to thank Mr. Evan Curtis and Mr. Simeng Zhang for their technical assistance. This research was supported in part by UNL/UNMC Engineering for Medicine Research Collaboration Seed Grant, NIH RO3-EB007299-02, and NIH COBRE grant RR021937 (Nebraska Center for Nanomedicine).	Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Basford JR, 2002, ARCH PHYS MED REHAB, V83, P1530, DOI 10.1053/apmr.2002.35472; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Chan RW, 2003, ANN BIOMED ENG, V31, P482, DOI 10.1114/1.1561287; Denic A, 2011, NEUROTHERAPEUTICS, V8, P3, DOI 10.1007/s13311-010-0002-4; Faria SC, 2009, RADIOGRAPHICS, V29, P1615, DOI 10.1148/rg.296095512; Faul M, 2010, HOSP DEATHS 2002 200; Finkelstein E., 2006, INCIDENCE EC BURDEN; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kuroiwa T, 2006, ACTA NEUROCHIR SUPPL, V96, P254; Kuroiwa T, 1997, ACT NEUR S, V70, P87; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Manduca A, 2003, MED IMAGE ANAL, V7, P465, DOI 10.1016/S1361-8415(03)00038-0; Mariappan YK, 2009, MAGN RESON MED, V61, P678, DOI 10.1002/mrm.21885; Meral FC, 2009, J ACOUST SOC AM, V126, P3278, DOI 10.1121/1.3242351; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; OHNISHI ST, 1995, CENTRAL NERVOUS SYST, P497; Oliphant TE, 2001, MAGNET RESON MED, V45, P299, DOI 10.1002/1522-2594(200102)45:2<299::AID-MRM1039>3.0.CO;2-O; Othman SF, 2005, MAGN RESON MED, V54, P605, DOI 10.1002/mrm.20584; Othman SF, 2012, NMR BIOMED, V25, P452, DOI 10.1002/nbm.1663; Park E, 2006, PHYS MED BIOL, V51, P3697, DOI 10.1088/0031-9155/51/15/007; Press WH., 1992, NUMERICAL RECIPES FO, V2; Romano AJ, 1998, IEEE T ULTRASON FERR, V45, P751, DOI 10.1109/58.677725; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sack I, 2009, NEUROIMAGE, V46, P652, DOI 10.1016/j.neuroimage.2009.02.040; Sadler TR, 2009, APPL IMMUNOHISTO M M, V17, P165, DOI 10.1097/PAI.0b013e3181853001; SCHREGEL K, 2011, P 2011 ANN ISMRM M E; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Houten EEW, 2001, MAGNET RESON MED, V45, P827, DOI 10.1002/mrm.1111; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Venkatesh SK, 2008, P INT SOC MAGN RES M, P2611; Watase K, 2003, NAT REV GENET, V4, P296, DOI 10.1038/nrg1045; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yin M, 2007, CLIN GASTROENTEROL H, V5, P1207, DOI 10.1016/j.cgh.2007.06.012	45	33	33	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2011	201	2					296	306		10.1016/j.jneumeth.2011.08.019			11	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	834XX	WOS:000295998900003	21871490				2022-02-06	
J	Kelava, T; Cavar, I; Culo, F				Kelava, Tomislav; Cavar, Ivan; Culo, Filip			Biological actions of drug solvents	PERIODICUM BIOLOGORUM			English	Article						dimethylsulfoxide; propylene glycol; ethanol	DIMETHYL-SULFOXIDE DMSO; NF-KAPPA-B; CHRONIC ETHANOL-CONSUMPTION; TRAUMATIC BRAIN-INJURY; INDUCED LIVER-INJURY; NATURAL-KILLER-CELL; K-ATP CHANNELS; PROPYLENE-GLYCOL; DIMETHYLSULFOXIDE DMSO; NITRIC-OXIDE	Many biologic agents are weakly soluble in water Therefore, they should be dissolved in organic lipophilic solvents (vehicles). A drug vehicle is a substance of no therapeutic value that is used to convey an active biological agent to the site of its action. Ideally, it should be biocompatible, 100% reliable, with no biological effect per se. However; presently used vehicles have pleiotropic effects, which are often unknown to researchers, and often cause misleading conclusions. In this review we summarize data on biological effects of the three most commonly used lipophilic drug vehicles dimethylsulfoxide (DMSO), propylene glycol (PG) and ethanol. Besides in experimental models, the data, where available, are shown on effects of solvents in therapeutic use in humans. In conclusion, some recommendations are given on the use of drug solvents in experiments.	[Kelava, Tomislav] Univ Zagreb, Dept Physiol, Sch Med, Zagreb 10000, Croatia; [Cavar, Ivan; Culo, Filip] Univ Mostar, Dept Physiol, Sch Med, Mostar 88000, Bosnia & Herceg; [Culo, Filip] Univ Osijek, Dept Physiol, Sch Med, Osijek 31000, Croatia		Kelava, T (corresponding author), Univ Zagreb, Dept Physiol, Sch Med, Salata 3B, Zagreb 10000, Croatia.	tkelava@mef.hr	Culo, Filip/E-7115-2018	Culo, Filip/0000-0001-9493-3407; Kelava, Tomislav/0000-0002-6665-116X			Aita K, 2005, EXP MOL PATHOL, V79, P265, DOI 10.1016/j.yexmp.2005.07.001; ALI BH, 1990, CLIN EXP PHARMACOL P, V17, P463, DOI 10.1111/j.1440-1681.1990.tb01345.x; Ali BH, 2001, HUM EXP TOXICOL, V20, P199, DOI 10.1191/096032701678766859; ALI BH, 1989, PHARMACOLOGY, V39, P98, DOI 10.1159/000138583; ALKHUDHAIRI D, 1986, BRIT J ANAESTH, V58, P897, DOI 10.1093/bja/58.8.897; ALTURA BM, 1981, BRIT J PHARMACOL, V73, P580, DOI 10.1111/j.1476-5381.1981.tb16789.x; Baraona E, 2002, LIFE SCI, V70, P2987, DOI 10.1016/S0024-3205(02)01572-2; Bardutzky J, 2005, J CEREBR BLOOD F MET, V25, P968, DOI 10.1038/sj.jcbfm.9600095; BARTSCH W, 1976, ARZNEIMITTEL-FORSCH, V26, P1581; BAUER MC, 1992, VET HUM TOXICOL, V34, P127; Bautista AP, 1996, ALCOHOL CLIN EXP RES, V20, P1395, DOI 10.1111/j.1530-0277.1996.tb01139.x; BEBAROVA M, ACTA PHYSL OXF, V200, P301; BECKMAN DL, 1981, P SOC EXP BIOL MED, V168, P45; BENTEL JM, 1990, INT J CANCER, V46, P251, DOI 10.1002/ijc.2910460218; Bini R, 2008, J TRAUMA, V64, P1048, DOI 10.1097/TA.0b013e318059362e; BLACK JL, 1198, BR J CLIN PHARM, V18, P349; BROWN FD, 1980, J NEUROSURG, V53, P58, DOI 10.3171/jns.1980.53.1.0058; CATANZARO JM, 1991, J AM ACAD DERMATOL, V24, P90, DOI 10.1016/0190-9622(91)70018-W; CATE JC, 1980, NEW ENGL J MED, V303, P1237; Cavaletti G, 2000, TOXICOL LETT, V118, P103, DOI 10.1016/S0378-4274(00)00269-1; Cavar I, 2010, HISTOL HISTOPATHOL, V25, P819, DOI 10.14670/HH-25.819; Cavar I, 2009, COLLEGIUM ANTROPOL, V33, P25; Chang CK, 1999, J SURG RES, V82, P294, DOI 10.1006/jsre.1998.5527; Chang CK, 2001, J SURG RES, V95, P181, DOI 10.1006/jsre.2000.6033; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; Choi H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013423; Choi S, 2009, XENOBIOTICA, V39, P205, DOI 10.1080/00498250802613620; Choudhury S. M., 2008, Al Ameen Journal of Medical Sciences, V1, P104; Churchill EN, 2009, J MOL CELL CARDIOL, V46, P278, DOI 10.1016/j.yjmcc.2008.09.713; CORNISH HH, 1977, ENVIRON HEALTH PERSP, V21, P149, DOI 10.2307/3428514; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; DENNING DW, 1987, J PHARM PHARMACOL, V39, P236, DOI 10.1111/j.2042-7158.1987.tb06258.x; Di Giorgio AM, 2008, RESTOR NEUROL NEUROS, V26, P501; DOEKEL RC, 1978, J APPL PHYSIOL, V44, P76, DOI 10.1152/jappl.1978.44.1.76; DRUMMOND WH, 1989, EXP LUNG RES, V15, P447, DOI 10.3109/01902148909087870; EICHBAUM FW, 1976, BASIC RES CARDIOL, V71, P355, DOI 10.1007/BF01910774; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; EVANS MH, 1973, BRIT J PHARMACOL, V49, P651, DOI 10.1111/j.1476-5381.1973.tb08540.x; Fischer SJ, 2008, NEUROTOXICOLOGY, V29, P444, DOI 10.1016/j.neuro.2008.02.010; FORREST P, 1988, ANAESTH INTENS CARE, V16, P158, DOI 10.1177/0310057X8801600205; Fossum EN, 2008, BRAIN RES, V1204, P53, DOI 10.1016/j.brainres.2008.02.022; Fujimura N, 2000, AM J RESP CRIT CARE, V162, P2159, DOI 10.1164/ajrccm.162.6.9912144; GOODNOUGH J, 1980, SURG NEUROL, V13, P273; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greenberg SS, 1999, ALCOHOL CLIN EXP RES, V23, P735, DOI 10.1111/j.1530-0277.1999.tb04177.x; Gross ER, 2001, ANESTH ANALG, V92, P299, DOI 10.1213/00000539-200102000-00003; HAIGLER HJ, 1981, LIFE SCI, V29, P1545, DOI 10.1016/0024-3205(81)90255-1; Hale S L, 2001, Heart Dis, V3, P293; HATTORI T, 1995, RES COMMUN MOL PATH, V88, P237; HATTORI T, 1993, FOOD CHEM TOXICOL, V31, P647, DOI 10.1016/0278-6915(93)90047-3; HAYES SN, 1988, CIRCULATION, V78, P165, DOI 10.1161/01.CIR.78.1.165; Hill DB, 2002, ALCOHOL CLIN EXP RES, V26, P74, DOI 10.1097/00000374-200201000-00011; HUDSON RD, 1970, ARCH INT PHARMACOD T, V186, P388; Iida C, 2007, J NUTR SCI VITAMINOL, V53, P160, DOI 10.3177/jnsv.53.160; Iida M, 2003, ALCOHOL, V30, P175, DOI 10.1016/j.alcohol.2003.05.001; Jaeschke H, 2006, LIFE SCI, V78, P1670, DOI 10.1016/j.lfs.2005.07.003; Jareo PW, 1996, ALCOHOL CLIN EXP RES, V20, P1646, DOI 10.1111/j.1530-0277.1996.tb01711.x; Jaruga B, 2004, AM J PHYSIOL-GASTR L, V287, pG471, DOI 10.1152/ajpgi.00018.2004; Jiang GS, 2006, INT IMMUNOPHARMACOL, V6, P1204, DOI 10.1016/j.intimp.2006.02.014; Jo SK, 2004, J AM SOC NEPHROL, V15, P2648, DOI 10.1097/01.ASN.0000139933.20109.CB; KANESKI CR, 1991, PROSTATE, V18, P47, DOI 10.1002/pros.2990180105; Karaca M, 2002, NEUROL RES, V24, P73, DOI 10.1179/016164102101199567; Kato H, 2005, ALCOHOL CLIN EXP RES, V29, p285S, DOI 10.1097/01.alc.0000191809.29775.41; Kelava T, 2010, CAN J PHYSIOL PHARM, V88, P960, DOI [10.1139/Y10-065, 10.1139/y10-065]; Kim SJ, 2007, J APPL TOXICOL, V27, P25, DOI 10.1002/jat.1180; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P258; Koteish A, 2002, J BIOL CHEM, V277, P13037, DOI 10.1074/jbc.M101632200; KUNZE M, 1975, ANN NY ACAD SCI, V243, P308, DOI 10.1111/j.1749-6632.1975.tb25370.x; LEVETT JM, 1987, CRIT CARE MED, V15, P656, DOI 10.1097/00003246-198707000-00006; Lin HQ, 1998, J PHARM PHARMACOL, V50, P1127, DOI 10.1111/j.2042-7158.1998.tb03323.x; Lind RC, 1997, TOXICOL APPL PHARM, V142, P201, DOI 10.1006/taap.1996.8009; Lind RC, 1999, EXP TOXICOL PATHOL, V51, P537, DOI 10.1016/S0940-2993(99)80134-1; Lind RC, 2000, TOXICOL APPL PHARM, V166, P145, DOI 10.1006/taap.2000.8949; Lu C Y, 1992, J Tongji Med Univ, V12, P253; Lu CB, 2001, EXP NEUROL, V170, P180, DOI 10.1006/exnr.2001.7686; Mandrekar P, 2009, J IMMUNOL, V183, P1320, DOI 10.4049/jimmunol.0803206; Marumo M, 2010, ALCOHOL, V44, P343, DOI 10.1016/j.alcohol.2010.02.002; Mason CM, 2000, ALCOHOL CLIN EXP RES, V24, P553, DOI 10.1097/00000374-200004000-00031; Masson MJ, 2008, HEPATOLOGY, V48, P889, DOI 10.1002/hep.22400; Matheus MG, 1997, BRAZ J MED BIOL RES, V30, P61, DOI 10.1590/S0100-879X1997000100009; Morshed KM, 1998, TOXICOL SCI, V46, P410, DOI 10.1006/toxs.1998.2521; MOURSI MM, 1983, STROKE, V14, P791, DOI 10.1161/01.STR.14.5.791; Mustafa S, 2007, CLIN PHYSIOL FUNCT I, V27, P185, DOI 10.1111/j.1475-097X.2007.00733.x; MUTHER RS, 1980, JAMA-J AM MED ASSOC, V244, P2081, DOI 10.1001/jama.244.18.2081; Nadruz W, 2004, AM J PHYSIOL-HEART C, V286, pH760, DOI 10.1152/ajpheart.00430.2003; Nishimura Y, 1999, RES COMMUN MOL PATH, V104, P229; Nishiyama D, 2002, HEPATOL RES, V23, P130, DOI 10.1016/S1386-6346(01)00168-1; Obregon ADC, 2005, NEUROCHEM RES, V30, P379, DOI 10.1007/s11064-005-2612-5; OSHIRO TT, 1990, GEN PHARMACOL, V21, P131, DOI 10.1016/0306-3623(90)90608-O; OWASOYO JO, 1981, TOXICOL LETT, V9, P267, DOI 10.1016/0378-4274(81)90159-4; Pagel PS, 2002, ANESTH ANALG, V94, P841, DOI 10.1097/00000539-200204000-00012; Pan HN, 2006, ALCOHOL CLIN EXP RES, V30, P1615, DOI 10.1111/j.1530-0277.2006.00194.x; Parisi A, 2010, J CARDIOVASC PHARM, V55, P106, DOI 10.1097/FJC.0b013e3181c87a65; Parkin J, 1997, UROLOGY, V49, P105, DOI 10.1016/S0090-4295(97)00181-7; PEARL RG, 1989, PHARMACOLOGY, V39, P383, DOI 10.1159/000138627; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PLUMMER JM, 1983, BIOCHEM PHARMACOL, V32, P151, DOI 10.1016/0006-2952(83)90668-8; Qi SH, 2010, NEUROSCIENCE, V167, P1125, DOI 10.1016/j.neuroscience.2010.02.018; Qi SH, 2009, BRAIN RES, V1276, P151, DOI 10.1016/j.brainres.2009.04.040; RANKIN GO, 1995, TOXICOLOGY, V100, P79, DOI 10.1016/0300-483X(95)93709-D; RAY SD, 1990, FUND APPL TOXICOL, V15, P429, DOI 10.1016/0272-0590(90)90029-J; Regoli F, 1999, TOXICOL APPL PHARM, V156, P96, DOI 10.1006/taap.1999.8637; Rosemberg DB, 2010, NEUROSCIENCE, V171, P683, DOI 10.1016/j.neuroscience.2010.09.030; Rubin R, 1999, ALCOHOL CLIN EXP RES, V23, P1114, DOI 10.1111/j.1530-0277.1999.tb04234.x; RUMBEIHA WK, 1992, VET HUM TOXICOL, V34, P21; Sahin M, 2004, TRANSPL P, V36, P2590, DOI 10.1016/j.transproceed.2004.09.057; Saini M, 2001, INDIAN J ANIM SCI, V71, P16; SALIM AS, 1992, J PHARM SCI, V81, P943, DOI 10.1002/jps.2600810921; SALIM AS, 1993, SURG GYNECOL OBSTET, V176, P484; Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006-2952(03)00002-9; Sapp DW, 1998, J PHARMACOL EXP THER, V284, P768; SATO C, 1981, GASTROENTEROLOGY, V80, P140; Shimizu S, 1997, NEUROSCI LETT, V239, P125, DOI 10.1016/S0304-3940(97)00915-4; SHIRLEY S W, 1978, Urology, V11, P215, DOI 10.1016/0090-4295(78)90118-8; SINGH PP, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1443; SMITH RS, 1992, MED HYPOTHESES, V39, P248, DOI 10.1016/0306-9877(92)90117-U; Sood R, 2007, J MAGN RESON IMAGING, V25, P39, DOI 10.1002/jmri.20802; SORBYE H, 1993, DIGEST DIS SCI, V38, P1243, DOI 10.1007/BF01296073; Steiner AA, 2007, J NEUROSCI, V27, P7459, DOI 10.1523/JNEUROSCI.1483-07.2007; SWANSON B N, 1985, Reviews in Clinical and Basic Pharmacology, V5, P1; Szabo G, 1996, ALCOHOL CLIN EXP RES, V20, P900, DOI 10.1111/j.1530-0277.1996.tb05269.x; TAMASHIRO H, 1986, J TOXICOL ENV HEALTH, V18, P595, DOI 10.1080/15287398609530897; Thirkill TL, 1997, J CELL BIOCHEM, V65, P460, DOI 10.1002/(SICI)1097-4644(19970615)65:4<460::AID-JCB2>3.0.CO;2-M; THOMSEN MS, 1995, PHARMACOL TOXICOL, V76, P395, DOI 10.1111/j.1600-0773.1995.tb00168.x; Titova E, 2007, CLIN EXP PHARMACOL P, V34, P845, DOI 10.1111/j.1440-1681.2007.04664.x; TOIVANEN J, 1984, THROMB RES, V33, P1, DOI 10.1016/0049-3848(84)90149-X; Trevisani M, 2004, J PHARMACOL EXP THER, V309, P1167, DOI 10.1124/jpet.103.064162; Valenzuela CF, 1997, ALCOHOL HEALTH RES W, V21, P144; Vasdev S, 2006, MOL CELL BIOCHEM, V287, P53, DOI 10.1007/s11010-005-9058-6; Vinson RB, 1998, AM J PHYSIOL-REG I, V275, pR1049, DOI 10.1152/ajpregu.1998.275.4.R1049; Vrsalovic M, 2007, J CARDIOVASC PHARM, V50, P462, DOI 10.1097/FJC.0b013e31812378fb; Wang Q, 2007, FREE RADICAL BIO MED, V43, P1048, DOI 10.1016/j.freeradbiomed.2007.06.018; Weber TP, 2003, ANESTH ANALG, V96, P665, DOI 10.1213/01.ANE.0000048712.95074.CD; WEETMAN DF, 1982, METHOD FIND EXP CLIN, V4, P99; Wieslander G, 2001, OCCUP ENVIRON MED, V58, P649, DOI 10.1136/oem.58.10.649; WILLMORE LJ, 1984, BRAIN RES, V296, P389, DOI 10.1016/0006-8993(84)90080-5; Wong CK, 2004, TOXICOL MECH METHOD, V14, P167, DOI 10.1080/15376520490429364; WONG LT, 1980, TOXICOLOGY, V17, P297, DOI 10.1016/0300-483X(80)90011-6; Yamagishi Y, 2002, AM J PHYSIOL-GASTR L, V282, pG640, DOI 10.1152/ajpgi.00171.2001; Yamaguchi T, 2003, FREE RADICAL BIO MED, V34, P365, DOI 10.1016/S0891-5849(02)01292-3; Yogi A, 2010, CLIN SCI, V118, P657, DOI 10.1042/CS20090352; Yoon MY, 2006, BIOL PHARM BULL, V29, P1618, DOI 10.1248/bpb.29.1618; Zar T, 2007, SEMIN DIALYSIS, V20, P217, DOI 10.1111/j.1525-139X.2007.00280.x; ZAROSLINSKI JF, 1971, TOXICOL APPL PHARM, V19, P573, DOI 10.1016/0041-008X(71)90289-4; Zhou HZ, 2002, AM J PHYSIOL-HEART C, V283, pH165, DOI 10.1152/ajpheart.00408.2001; Zink BJ, 2006, J NEUROSURG, V105, P884, DOI 10.3171/jns.2006.105.6.884; ZOREFSHANI E, 1994, J CANCER RES CLIN, V120, P717, DOI 10.1007/BF01194269	148	33	33	0	19	PERIODICUM BIOLOGORUM	ZAGREB	HRVATSKO PRIRODOSLOVNO DRUSTVO ILICA 16/111, 41000 ZAGREB, CROATIA	0031-5362			PERIOD BIOL	Period. Biol.	OCT	2011	113	3					311	320					10	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	864DD	WOS:000298216300005					2022-02-06	
J	Wagner, AK; Amin, KB; Niyonkuru, C; Postal, BA; McCullough, EH; Ozawa, H; Dixon, CE; Bayir, H; Clark, RS; Kochanek, PM; Fabio, A				Wagner, Amy K.; Amin, Krutika B.; Niyonkuru, Christian; Postal, Brett A.; McCullough, Emily H.; Ozawa, Haishin; Dixon, C. Edward; Bayir, Hulya; Clark, Robert S.; Kochanek, Patrick M.; Fabio, Anthony			CSF Bcl-2 and cytichrome C temporal profiles in outcome prediction for adults with severe TBI	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Bcl-2; biomarker; cerebral spinal fluid; cytochrome C; outcome; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CORTICAL IMPACT INJURY; SEVERE HEAD-INJURY; CYTOCHROME-C; CEREBROSPINAL-FLUID; TRANSGENIC MICE; CELL-DEATH; OXIDATIVE-STRESS; APOPTOSIS; PROTEIN	The biochemical cascades associated with cell death after traumatic brain injury (TBI) involve both pro-survival and pro-apoptotic proteins. We hypothesized that elevated cerebrospinal fluid (CSF) BcI-2 and cytochrome "C (CytoC) levels over time would reflect cellular injury response and predict long-term outcomes after TBI. Cerebrospinal fluid BcI-2.and CytoC levels were measured for 6 days after injury for adults with severe TBI (N=76 subjects; N=277 samples). Group-based trajectory analysis was used to generate distinct temporal biomarker profiles that were compared with Glasgow Outcome Scale (GOS) and Disability Rating Scale (DRS) scores at 6 and 12 months after TBI. Subjects with persistently elevated temporal BcI-2 and CytoC profiles compared with healthy controls had the worst outcomes at 6 and 12 months (P <= 0.027). Those with CytoC profiles near controls had better long-term outcomes, and those with declining CytoC levels over time had intermediate outcomes. Subjects with BcI-2 profiles that remained near controls had better outcomes than those with consistently elevated BcI-2 profiles. However, subjects with BcI-2 values that started near controls and steadily rose over time had 100% good outcomes by 12 months after TBI. These results show the prognostic value of BcI-2 and CytoC profiles and suggest a dynamic apoptotic and pro-survival response to TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1886-1896: doi:10.1038/jcbfm.2011.31; published online 30 March 2011	[Wagner, Amy K.; Amin, Krutika B.; Niyonkuru, Christian; Postal, Brett A.; McCullough, Emily H.; Ozawa, Haishin; Dixon, C. Edward; Fabio, Anthony] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Dixon, C. Edward; Bayir, Hulya; Clark, Robert S.; Kochanek, Patrick M.] Univ Pittsburgh, Safer Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Bayir, Hulya; Clark, Robert S.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Fabio, Anthony] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fabio, Anthony/0000-0002-6808-4939	DODUnited States Department of Defense [PT073914 W81XWH-08-1-0237, R49 CCR323155-03]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318-16];  [DODW81XWH-071-0701]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	This work was supported by DODW81XWH-071-0701 (AKW, AF), DOD PT073914 W81XWH-08-1-0237 (AKW, AF), R49 CCR323155-03 (AKW, AF, PMK, HB), NIH 5P01NS030318-16 (CED, PMK, RSB).	Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bayir H, 2009, J BIOL CHEM, V284, P15951, DOI 10.1074/jbc.M900418200; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Camlica H, 2008, AM J CLIN ONCOL-CANC, V31, P585, DOI 10.1097/COC.0b013e318174dbd2; Cardali S, 2006, J Neurosurg Sci, V50, P25; Clark RSB, 2005, CRIT CARE MED, V33, pS407, DOI 10.1097/01.CCM.0000191712.96336.51; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Comim CM, 2008, MITOCHONDRION, V8, P313, DOI 10.1016/j.mito.2008.07.002; Conti AC, 1998, J NEUROSCI, V18, P5663; d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b; Darwish RS, 2010, NEUROCRIT CARE, V12, P337, DOI 10.1007/s12028-009-9328-3; Fink EL, 2008, J CEREBR BLOOD F MET, V28, P1523, DOI 10.1038/jcbfm.2008.52; GOURIEROUX C, 1982, ECONOMETRICA, V50, P63, DOI 10.2307/1912529; Hoh NZ, 2010, J NEUROTRAUM, V27, P1413, DOI 10.1089/neu.2009.1256; JENNETT B, 1975, LANCET, V1, P480; Jones KE, 2001, J PHYSIOL-LONDON, V536, P635, DOI 10.1111/j.1469-7793.2001.0635c.xd; Kavathia N, 2009, AGING-US, V1, P652, DOI 10.18632/aging.100069; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Love S, 1999, BRAIN PATHOL, V9, P119; Nagin D.S., 2005, GROUP BASED MODELING; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Ozawa H, 2009, J NEUROTRAUM, V26, pA71; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Renz A, 2001, ADV EXP MED BIOL, V495, P331; RINK A, 1995, AM J PATHOL, V147, P1575; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	33	33	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2011	31	9					1886	1896		10.1038/jcbfm.2011.31			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	815KK	WOS:000294524300007	21448217	Green Published, Bronze			2022-02-06	
J	Tang, JF; Chen, PL; Tang, EJ; May, TA; Stiver, SI				Tang, Julin F.; Chen, Po-Liang; Tang, Eric J.; May, Todd A.; Stiver, Shirley I.			Dexmedetomidine Controls Agitation and Facilitates Reliable, Serial Neurological Examinations in a Non-Intubated Patient with Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Hypercarbia; Hypoxemia; Agitation; Alcohol withdrawal; Dexmedetomidine; Traumatic brain injury	ETHANOL WITHDRAWAL SYMPTOMS; CEREBRAL-BLOOD-FLOW; ALCOHOL-WITHDRAWAL; INTRACRANIAL-PRESSURE; PRACTICE GUIDELINE; METABOLIC-RATE; MANAGEMENT; DELIRIUM; SEDATION; HUMANS	Introduction We report the effective use of dexmedetomidine in the treatment of a patient with a history of chronic alcohol abuse and an acute traumatic brain injury who developed agitation that was unresolved if from traumatic brain injury, or alcohol withdrawal or the combination of both. Treatment with benzodiazepines failed; lorazepam therapy obscured our ability to do reliable neurological testing to follow his brain injury and nearly resulted in intubation of the patient secondary to respiratory suppression. Upon admission to hospital, the patient was first treated with intermittent, prophylactic doses of lorazepam for potential alcohol withdrawal based upon our institution's standard of care. His neurological examinations including a motor score of 6 (obeying commands) on his Glasgow Coma Scale testing, laboratory studies, and repeat CT head imaging remained stable. For lack of published literature in diagnosing symptoms of patients with a history of both alcohol withdrawal and traumatic brain injury, a diagnosis of agitation secondary to presumed alcohol withdrawal was made when the patient developed acute onset of tachycardia, confusion, and extreme anxiety with tremor and attempts to climb out of bed requiring him to be restrained. Additional lorazepam doses were administered following a hospital-approved protocol for titration of benzodiazepine therapy for alcohol withdrawal. The patient's mental status and respiratory function deteriorated with the frequent lorazepam dosing needed to control his agitation. Dexmedetomidine IV infusion at a rate of 0.5 mcg/kg/h was then administered and was titrated ultimately to 1.5 mcg/kg/h. After 8 days of therapy with dexmedetomidine, the patient was transferred from the ICU to a step-down unit with an intact neurological examination and no evidence of alcohol withdrawal. Airway intubation was avoided during the patient's entire hospitalization. This case report highlights the intricate balance between the side effects of benzodiazepine sedation for treatment of agitation and the difficulties of monitoring the neurological status of non-intubated patients with traumatic brain injury Conclusion Given the large numbers of alcohol-dependent patients who suffer a traumatic brain injury and subsequently develop agitation and alcohol withdrawal in hospital, dexmedetomidine offers a novel strategy to facilitate sedation without neurological or respiratory depression. As this case report demonstrates, dexmedetomidine is an emerging treatment option for agitation in patients who require reliable, serial neurological testing to monitor the course of their traumatic brain injury.	[Tang, Julin F.; Chen, Po-Liang; Tang, Eric J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia & Crit Care Med, San Francisco, CA 94110 USA; [May, Todd A.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, San Francisco, CA 94110 USA; [Stiver, Shirley I.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA		Tang, JF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia & Crit Care Med, 1001 Potrero Ave, San Francisco, CA 94110 USA.	tangj@anesthesia.ucsf.edu					Al-Sanouri I, 2005, SOUTH MED J, V98, P372, DOI 10.1097/01.SMJ.0000154769.33508.20; Aryan HE, 2006, BRAIN INJURY, V20, P791, DOI 10.1080/02699050600789447; Bekker A, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163476.42034.A1; BELLEVILLE JP, 1992, ANESTHESIOLOGY, V77, P1125, DOI 10.1097/00000542-199212000-00013; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cosar M, 2009, SURG NEUROL, V71, P54, DOI 10.1016/j.surneu.2007.08.020; Coursin D B, 2001, Curr Opin Crit Care, V7, P221, DOI 10.1097/00075198-200108000-00002; Darrouj J, 2008, ANN PHARMACOTHER, V42, P1703, DOI 10.1345/aph.1K678; DeCarolis DD, 2007, PHARMACOTHERAPY, V27, P510, DOI 10.1592/phco.27.4.510; Devlin JW, 2008, CURR OPIN CRIT CARE, V14, P403, DOI 10.1097/MCC.0b013e32830280b3; Drummond JC, 2008, ANESTHESIOLOGY, V108, P225, DOI 10.1097/01.anes.0000299576.00302.4c; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Hecksel KA, 2008, MAYO CLIN PROC, V83, P274, DOI 10.4065/83.3.274; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; KARLSSON BR, 1990, ANESTH ANALG, V71, P125; Lonergan E, 2009, COCHRANE DATABASE SY; Ma DQ, 2004, EUR J PHARMACOL, V502, P87, DOI 10.1016/j.ejphar.2004.08.044; Maccioli GA, 2003, ANESTHESIOLOGY, V98, P575, DOI 10.1097/00000542-200302000-00041; Mayo-Smith MF, 2004, ARCH INTERN MED, V164, P1405, DOI 10.1001/archinte.164.13.1405; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; Nakano T, 2009, J ANESTH, V23, P378, DOI 10.1007/s00540-009-0777-9; Pletcher MJ, 2005, JT COMM J QUAL PATIE, V31, P148, DOI 10.1016/S1553-7250(05)31020-8; Riihioja P, 1999, ALCOHOL CLIN EXP RES, V23, P432, DOI 10.1097/00000374-199903000-00008; Riihioja P, 1997, ALCOHOL, V14, P537, DOI 10.1016/S0741-8329(97)00044-X; Riihioja P, 1997, ALCOHOL CLIN EXP RES, V21, P804, DOI 10.1111/j.1530-0277.1997.tb03843.x; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rovasalo A, 2006, GEN HOSP PSYCHIAT, V28, P362, DOI 10.1016/j.genhosppsych.2006.03.002; Werner C, 1995, ANAESTHESIST, V44, pS566; Yost DA, 1996, AM FAM PHYSICIAN, V54, P657; ZORNOW MH, 1992, ANESTH ANALG, V75, P232	31	33	37	3	14	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					175	181		10.1007/s12028-009-9315-8			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100029	20198514				2022-02-06	
J	Kalayci, M; Unal, MM; Gul, S; Acikgoz, S; Kandemir, N; Hanci, V; Edebali, N; Acikgoz, B				Kalayci, Murat; Unal, Mufit M.; Gul, Sanser; Acikgoz, Serefden; Kandemir, Nilufer; Hanci, Volkan; Edebali, Nurullah; Acikgoz, Bektas			Effect of Coenzyme Q(10) on ischemia and neuronal damage in an experimental traumatic brain-injury model in rats	BMC NEUROSCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; SUPEROXIDE-PRODUCTION; CEREBRAL-ISCHEMIA; ANTIOXIDANT ROLE; FREE-RADICALS; PATHOPHYSIOLOGY; INVOLVEMENT; DECREASES; UBIQUINOL	Background: Head trauma is one of the most important clinical issues that not only can be fatal and disabling, requiring long-term treatment and care, but also can cause heavy financial burden. Formation or distribution of free oxygen radicals should be decreased to enable fixing of poor neurological outcomes and to prevent neuronal damage secondary to ischemia after trauma. Coenzyme Q(10) (CoQ(10)), a component of the mitochondrial electron transport chain, is a strong antioxidant that plays a role in membrane stabilization. In this study, the role of CoQ(10) in the treatment of head trauma is researched by analyzing the histopathological and biochemical effects of CoQ(10) administered after experimental traumatic brain injury in rats. A traumatic brain-injury model was created in all rats. Trauma was inflicted on rats by the free fall of an object of 450 g weight from a height of 70 cm on the frontoparietal midline onto a metal disc fixed between the coronal and the lambdoid sutures after a midline incision was carried out. Results: In the biochemical tests, tissue malondialdehyde (MDA) levels were significantly higher in the traumatic brain-injury group compared to the sham group (p < 0.05). Administration of CoQ(10) after trauma was shown to be protective because it significantly lowered the increased MDA levels (p < 0.05). Comparing the superoxide dismutase (SOD) levels of the four groups, trauma + CoQ(10) group had SOD levels ranging between those of sham group and traumatic brain-injury group, and no statistically significant increase was detected. Histopathological results showed a statistically significant difference between the CoQ(10) and the other trauma-subjected groups with reference to vascular congestion, neuronal loss, nuclear pyknosis, nuclear hyperchromasia, cytoplasmic eosinophilia, and axonal edema (p < 0.05). Conclusion: Neuronal degenerative findings and the secondary brain damage and ischemia caused by oxidative stress are decreased by CoQ(10) use in rats with traumatic brain injury.	[Kalayci, Murat; Unal, Mufit M.; Gul, Sanser; Edebali, Nurullah; Acikgoz, Bektas] Zonguldak Karaelmas Univ, Dept Neurosurg, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey; [Acikgoz, Serefden] Zonguldak Karaelmas Univ, Dept Biochem, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey; [Kandemir, Nilufer] Zonguldak Karaelmas Univ, Dept Pathol, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey; [Hanci, Volkan] Zonguldak Karaelmas Univ, Dept Anesthesiol, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey		Kalayci, M (corresponding author), Zonguldak Karaelmas Univ, Dept Neurosurg, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey.	drkalayci@yahoo.com	Hanci, Volkan/Q-1573-2019	Hanci, Volkan/0000-0002-2227-194X			Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bentinger M, 2007, MITOCHONDRION, V7, pS41, DOI 10.1016/j.mito.2007.02.006; ECKERSON HW, 1983, AM J HUM GENET, V35, P1126; Erol B, 2010, FERTIL STERIL, V93, P280, DOI 10.1016/j.fertnstert.2009.07.981; FOLKERS K, 1990, P NATL ACAD SCI USA, V87, P8931, DOI 10.1073/pnas.87.22.8931; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Kerimoglu A, 2007, ULUS TRAVMA ACIL CER, V13, P85; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEIBOVITZ BE, 1980, J GERONTOL, V35, P45, DOI 10.1093/geronj/35.1.45; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; Li H, 2000, BRAIN RES, V877, P7, DOI 10.1016/S0006-8993(00)02609-3; Littarru GP, 2005, CURR OPIN CLIN NUTR, V8, P641, DOI 10.1097/01.mco.0000171123.60665.16; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MASTERS SJ, 1980, AM J ROENTGENOL, V135, P539, DOI 10.2214/ajr.135.3.539; MELLORS A, 1966, J BIOL CHEM, V241, P4353; Nishio S, 1997, ACT NEUR S, V70, P84; Ostrowski RP, 2000, BRAIN RES BULL, V53, P399, DOI 10.1016/S0361-9230(00)00406-8; Ostrowski RP, 1999, FOLIA NEUROPATHOL, V37, P247; Piotrowski P, 1998, Neurol Neurochir Pol, V32, P1397; Portakal O, 1999, CLIN BIOCHEM, V32, P461, DOI 10.1016/S0009-9120(99)00041-7; Premkumar VG, 2008, VASC PHARMACOL, V48, P191, DOI 10.1016/j.vph.2008.02.003; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; SUN Y, 1988, CLIN CHEM, V34, P497; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Wang Zhipeng, 2007, Journal of Toxicological Sciences, V32, P505, DOI 10.2131/jts.32.505; Yokoyama K, 1999, SCAND J PLAST RECONS, V33, P1; YOKOYAMA K, 1992, PLAST RECONSTR SURG, V90, P890, DOI 10.1097/00006534-199211000-00026	33	33	34	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JUL 29	2011	12								75	10.1186/1471-2202-12-75			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	811ND	WOS:000294217100001	21801363	gold, Green Published			2022-02-06	
J	Cap, AP; Spinella, PC				Cap, Andrew Peter; Spinella, Philip C.			Severity of Head Injury Is Associated With Increased Risk of Coagulopathy in Combat Casualties	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Coagulopathy; Combat; Trauma; Mortality	TRAUMATIC BRAIN-INJURY; FIBRINOGEN CONCENTRATE; THROMBOELASTOMETRY; HYPOPERFUSION; MANAGEMENT	Background: Traumatic brain injury (TBI) is believed to cause more profound trauma-induced coagulopathy than other injuries of comparable severity. This has not been reported in a large series of combat casualties in which penetrating injuries predominate. Methods: Among US combat casualties severely injured in Iraq and Afghanistan who received transfused blood products, isolated TBI patients (head Abbreviated Injury Score [AIS] >= 3 and all other AIS <2) were compared with non-TBI patients (head AIS <= 2 and any other AIS >= 3) to determine the degree to which TBI is associated with coagulopathy as measured by International Normalized Ratio (INR) and to describe characteristics of this population. Stepwise multiple regression analysis was also performed on all US casualties who received transfused blood products to analyze independent predictors of coagulopathy. Results: We compared 117 patients with isolated TBI and 1,492 patients with non-TBI injuries. Admission INR was significantly higher in TBI patients. There were no differences in age, admission base deficit, systolic or diastolic blood pressure, or hemoglobin. On stepwise multiple regression, base deficit, Glasgow Coma Scale, and head AIS score were independently associated with increased coagulopathy as measured by INR. Conclusion: Patients with severe combat-related trauma and isolated TBI had worse coagulopathy than non-TBI patients. Base deficit, Glasgow Coma Scale, and severity of head injury, as reflected by head AIS, are independently associated with increased coagulopathy as measured by INR.	[Cap, Andrew Peter; Spinella, Philip C.] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA		Cap, AP (corresponding author), USA, Inst Surg Res, Bldg 3611, Ft Sam Houston, TX 78234 USA.	Andre.P.Cap@us.army.mil			US ArmyUnited States Department of Defense	Supported by the US Army.	Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Dunbar NM, 2009, TRANSFUSION, V49, P2652, DOI 10.1111/j.1537-2995.2009.02335.x; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Jeger V, 2010, EMERG MED J, V27, P551, DOI 10.1136/emj.2009.075994; Johansson PI, 2010, TRANSFUS APHER SCI, V43, P401, DOI 10.1016/j.transci.2010.09.002; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kitchen DP, 2010, SEMIN THROMB HEMOST, V36, P757, DOI 10.1055/s-0030-1265292; LUSTENBERGER T, 2010, INJURY          0512; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Nylund Cade M, 2009, Pediatr Crit Care Med, V10, pe22, DOI 10.1097/PCC.0b013e31819bb939; Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Schochl H, 2010, ANAESTHESIA, V65, P199, DOI 10.1111/j.1365-2044.2009.06188.x; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schreiber M, 2009, J TRAUMA, V67, P275; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0	21	33	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2011	71			1			S78	S81		10.1097/TA.0b013e3182218cd8			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	790RW	WOS:000292607900013	21795882				2022-02-06	
J	Luh, C; Gierth, K; Timaru-Kast, R; Engelhard, K; Werner, C; Thal, SC				Luh, Clara; Gierth, Katharina; Timaru-Kast, Ralph; Engelhard, Kristin; Werner, Christian; Thal, Serge C.			Influence of a Brief Episode of Anesthesia during the Induction of Experimental Brain Trauma on Secondary Brain Damage and Inflammation	PLOS ONE			English	Article							INCOMPLETE CEREBRAL-ISCHEMIA; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD TRAUMA; INTRACRANIAL-PRESSURE; ARTERIAL-HYPERTENSION; RATS; INJURY; ISOFLURANE; MICE; SEVOFLURANE	It is unclear whether a single, brief, 15-minute episode of background anesthesia already modulates delayed secondary processes after experimental brain injury. Therefore, this study was designed to characterize three anesthesia protocols for their effect on molecular and histological study endpoints. Mice were randomly separated into groups that received sevoflurane (sevo), isoflurane (iso) or an intraperitoneal anesthetic combination (midazolam, fentanyl and medetomidine; comb) prior to traumatic brain injury (controlled cortical impact, CCI; 8 m/s, 1 mm impact depth, 3 mm diameter). Twenty-four hours after insult, histological brain damage, neurological function (via neurological severity score), cerebral inflammation (via real-time RT-PCR for IL6, COX-2, iNOS) and microglia (via immunohistochemical staining for Iba1) were determined. Fifteen minutes after CCI, the brain contusion volume did not differ between the anesthetic regimens (sevo = 17.9 +/- 5.5 mm 3; iso = 20.5 +/- 3.7 mm(3); comb = 19.5 +/- 4.6 mm(3)). Within 24 hours after injury, lesion size increased in all groups (sevo = 45.3 +/- 9.0 mm(3); iso = 31.5 +/- 4.0 mm(3); comb = 44.2 +/- 6.2 mm(3)). Sevo and comb anesthesia resulted in a significantly larger contusion compared to iso, which was in line with the significantly better neurological function with iso (sevo = 4.6 +/- 1.3 pts.; iso = 3.9 +/- 0.8 pts.; comb = 5.1 +/- 1.6 pts.). The expression of inflammatory marker genes was not significantly different at 15 minutes and 24 hours after CCI. In contrast, significantly more Iba1-positive cells were present in the pericontusional region after sevo compared to comb anesthesia (sevo = 181 +/- 48/mm(3); iso = 150 +/- 36/mm(3); comb = 113 +/- 40/mm(3)). A brief episode of anesthesia, which is sufficient for surgical preparations of mice for procedures such as delivering traumatic brain injury, already has a significant impact on the extent of secondary brain damage.	[Luh, Clara; Gierth, Katharina; Timaru-Kast, Ralph; Engelhard, Kristin; Werner, Christian; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany; [Luh, Clara] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Med Ctr, D-6500 Mainz, Germany		Luh, C (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Brecht M, 2004, NATURE, V427, P704, DOI 10.1038/nature02266; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Engelhard K, 1999, BRIT J ANAESTH, V83, P415, DOI 10.1093/bja/83.3.415; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HATASHITA S, 1986, J NEUROSURG, V64, P643, DOI 10.3171/jns.1986.64.4.0643; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; JANSSEN BJ, 2004, AM J PHYSL HEART CIR; Khosrovani S, 2007, P NATL ACAD SCI USA, V104, P15911, DOI 10.1073/pnas.0702727104; Kongstad L, 2001, J TRAUMA, V51, P490, DOI 10.1097/00005373-200109000-00011; Li L, 2009, NEUROSCIENCE, V164, P497, DOI 10.1016/j.neuroscience.2009.08.011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matchett GA, 2009, NEUROL RES, V31, P128, DOI 10.1179/174313209X393546; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; Solt K, 2006, ANESTH ANALG, V102, P1407, DOI 10.1213/01.ane.0000204252.07406.9f; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wen YS, 2007, ENDOCRINOLOGY, V148, P1313, DOI 10.1210/en.2006-0665; WERNER C, 1995, BRIT J ANAESTH, V75, P756, DOI 10.1093/bja/75.6.756; Yurdakoc A, 2008, ACTA ANAESTH SCAND, V52, P658, DOI 10.1111/j.1399-6576.2008.01635.x; ZORNOW MH, 1992, ANESTH ANALG, V75, P232; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	31	33	34	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2011	6	5							e19948	10.1371/journal.pone.0019948			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766HI	WOS:000290771200032	21625505	Green Published, Green Submitted, gold			2022-02-06	
J	Ley, EJ; Srour, MK; Clond, MA; Barnajian, M; Tillou, A; Mirocha, J; Salim, A				Ley, Eric J.; Srour, Marissa K.; Clond, Morgan A.; Barnajian, Moshe; Tillou, Areti; Mirocha, James; Salim, Ali			Diabetic Patients With Traumatic Brain Injury: Insulin Deficiency Is Associated With Increased Mortality	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Diabetes mellitus; Hyperglycemia	CRITICALLY-ILL PATIENTS; GLUCOSE CONTROL; THERAPY	Background: Hyperglycemia after traumatic brain injury (TBI) is an independent predictor of mortality. Insulin deficiency, as opposed to elevated blood glucose, might be the reason for increased mortality. TBI patients with diabetes mellitus (DM) were analyzed to determine how insulin deficiency affects mortality after TBI. Methods: NTDB version 7 was queried for patients with isolated moderate to severe TBI (head abbreviated injury score [AIS] >= 3 with AIS <= 3 for other body regions). Demographics and outcomes were compared between TBI patients with insulin-dependent DM (IDDM), noninsulin-dependent DM (NIDDM), and those without DM. Logistic regression analysis was used to investigate the relationship between mortality and DM. Results: Overall, 51,585 patients with isolated moderate to severe TBI were analyzed. Mortality was 14.4% and 8.2% in patients with and without DM, respectively (p < 0.0001). Although head AIS scores were similar, patients with DM had a statistically higher Glasgow coma scale (GCS) at presentation compared with patients without DM (GCS score 12.4 vs. GCS score 10.9; p < 0.0001). After multivariable logistic regression analysis, DM was an independent predictor for mortality (odds ratio 1.5, confidence interval 1.29-1.74, p < 0.0001). When comparing TBI patients with IDDM to NIDDM, mortality was 17.1% for IDDM and 13.0% for NIDDM (p = 0.025). Conclusion: DM is a significant predictor for mortality after moderate to severe TBI. Insulin deficiency is a likely contributor to increased mortality after TBI as IDDM patients have higher mortality than NIDDM patients who have higher mortality than no-DM patients.	[Ley, Eric J.; Srour, Marissa K.; Clond, Morgan A.; Barnajian, Moshe; Mirocha, James; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Tillou, Areti] Univ Calif Los Angeles, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90024 USA		Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Clond, Morgan/0000-0002-3036-4193; Srour, Marissa/0000-0001-9206-2716	American Association for the Surgery of Trauma Research and Education Foundation	Supported, in part, by a grant from the American Association for the Surgery of Trauma Research and Education Foundation.	Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; Bingham EM, 2002, DIABETES, V51, P3384, DOI 10.2337/diabetes.51.12.3384; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Nov O, 2010, ENDOCRINOLOGY, V151, P4247, DOI 10.1210/en.2010-0340; Salim A, 2009, AM SURGEON, V75, P25; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	10	33	33	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2011	70	5					1141	1144		10.1097/TA.0b013e3182146d66			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	762LQ	WOS:000290480300034	21610428				2022-02-06	
J	Davis, DP; Koprowicz, KM; Newgard, CD; Daya, M; Bulger, EM; Stiell, I; Nichol, G; Stephens, S; Dreyer, J; Minei, J; Kerby, JD				Davis, Daniel P.; Koprowicz, Kent M.; Newgard, Craig D.; Daya, Mohamud; Bulger, Eileen M.; Stiell, Ian; Nichol, Graham; Stephens, Shannon; Dreyer, Jonathan; Minei, Joseph; Kerby, Jeffrey D.		ROC Investigators	THE RELATIONSHIP BETWEEN OUT-OF-HOSPITAL AIRWAY MANAGEMENT AND OUTCOME AMONG TRAUMA PATIENTS WITH GLASGOW COMA SCALE SCORES OF 8 OR LESS	PREHOSPITAL EMERGENCY CARE			English	Article						prehospital intubation; traumatic brain injury; airway management; paramedic; outcomes; major trauma victim; ventilation; mortality; Glasgow Coma Scale score	RAPID-SEQUENCE INTUBATION; INDUCED LUNG INJURY; ENDOTRACHEAL INTUBATION; MECHANICAL VENTILATION; BRAIN-INJURY; HYPERVENTILATION; IMPACT; CYTOKINES; SURVIVAL; MODEL	Background. Airway management remains a fundamental component of optimal care of the severely injured patient, with endotracheal intubation representing the definitive strategy for airway control. However, multiple studies document an association between out-of-hospital intubation and increased mortality for severe traumatic brain injury. Objectives. To explore the relationship between out-of-hospital intubation attempts and outcome among trauma patients with Glasgow Coma Scale (GCS) scores <= 8 across sites participating in the Resuscitation Outcomes Consortium (ROC). Methods. The ROC Epistry-Trauma, an epidemiologic database of prehospital encounters with critically injured trauma victims, was used to identify emergency medical services (EMS)-treated patients with GCS scores <= 8. Multiple logistic regression was used to explore the association between intubation attempts and vital status at discharge, adjusting for the following covariates: age, gender, GCS score, hypotension, mechanism of injury, and ROC site. Sites were then stratified by frequency of intubation attempts and chi-square test for trend was used to associate the frequency of intubation attempts with outcome. Results. A total of 1,555 patients were included in this analysis; intubation was attempted in 758 of these. Patients in whom intubation was attempted had higher mortality (adjusted odds ratio [OR] 2.91, 95% confidence interval [CI] 2.13-3.98, p < 0.01). However, sites with higher rates of attempted intubation had lower mortality across all trauma victims with GCS scores <= 8 (OR 1.40, 95% CI 1.15-1.72, p < 0.01). Conclusions. Patients in whom intubation is attempted have higher adjusted mortality. However, sites with a higher rate of attempted intubation have lower adjusted mortality across the entire cohort of trauma patients with GCS scores <= 8.	[Davis, Daniel P.] UCSD Ctr Resuscitat Sci, Dept Emergency Med, San Diego, CA USA; [Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Koprowicz, Kent M.] Axio Res Corp, Seattle, WA USA; [Newgard, Craig D.; Daya, Mohamud] Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA; [Stiell, Ian] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Nichol, Graham] Univ Washington, Clin Trials Ctr, Seattle, WA 98195 USA; [Stephens, Shannon; Kerby, Jeffrey D.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Dreyer, Jonathan] Univ Western Ontario, Div Emergency Med, London, ON, Canada; [Minei, Joseph] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dallas, TX 75390 USA		Davis, DP (corresponding author), Univ Calif San Diego, 200 W Arbor Dr, San Diego, CA 92103 USA.	davismd@cox.net	Nichol, Graham/Z-4996-2019; Daya, Mohamud R/A-9322-2012	Stiell, Ian/0000-0002-2583-6408; Stephens, Shannon/0000-0001-5898-5170	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077877, HL077873]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Army Medical Research & Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defence Research and Development CanadaCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; American Heart AssociationAmerican Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077873, U01HL077885, U01HL077881, U01HL077867, U01HL077908, U01HL077866, U01HL077871, U01HL077872, U01HL077863] Funding Source: NIH RePORTER	The Resuscitation Outcomes Consortium (ROC) was supported by a series of cooperative agreements to 10 regional clinical centers and one data coordinating center (5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077877, HL077873) from the National Heart, Lung and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, U.S. Army Medical Research & Material Command, The Canadian Institutes of Health Research (CIHR)-Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the Heart and Stroke Foundation of Canada, and the American Heart Association.	Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bao Yinghui, 2000, Chin J Traumatol, V3, P210; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Bozeman WP, 2005, J TRAUMA, V58, P278, DOI 10.1097/01.TA.0000152536.71932.85; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chiu EHH, 2006, ARCH NEUROL-CHICAGO, V63, P741, DOI 10.1001/archneur.63.5.741; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Cudnik MT, 2010, J EMERG MED, V38, P175, DOI 10.1016/j.jemermed.2008.01.022; Davis DP, 2008, CAN MED ASSOC J, V178, P1171, DOI 10.1503/cmaj.080234; Davis DP, 2007, PREHOSP EMERG CARE, V11, P369, DOI 10.1080/10903120701537147; Davis DP, 2006, PREHOSP EMERG CARE, V10, P356, DOI 10.1080/10903120600725751; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; DAVIS DP, 2005, PREHOSP EMERG CARE; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Klinger G, 2005, ARCH DIS CHILD-FETAL, V90, pF49, DOI 10.1136/adc.2003.048785; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; McDonald C C, 1998, Prehosp Emerg Care, V2, P29, DOI 10.1080/10903129808958836; McSwain NE, 2004, J TRAUMA, V57, P8; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Newgard CD, 2008, RESUSCITATION, V78, P170, DOI 10.1016/j.resuscitation.2008.01.029; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; Wang H E, 2001, Prehosp Emerg Care, V5, P10, DOI 10.1080/10903120190940254; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014	45	33	33	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	APR-JUN	2011	15	2					184	192		10.3109/10903127.2010.545473			9	Emergency Medicine; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Public, Environmental & Occupational Health	729FG	WOS:000287933400006	21309705	Green Accepted			2022-02-06	
J	Edut, S; Rubovitch, V; Schreiber, S; Pick, CG				Edut, Shahaf; Rubovitch, Vardit; Schreiber, Shaul; Pick, Chaim G.			The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI)	PSYCHOPHARMACOLOGY			English	Article						Mice; Minimal traumatic brain injury (MTBI); MDMA (3,4-methylenedioxymethamphetamine); Novel object recognition; Ecstasy; Spatial learning; Cognitive test; Behavioral assessment	ELEVATED PLUS-MAZE; CLOSED-HEAD-INJURY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; ADULT RATS; INDUCED NEUROTOXICITY; TYROSINE-HYDROXYLASE; CORTICAL-NEURONS; PATH-INTEGRATION; OXIDATIVE STRESS; MEMORY	The use of ecstasy (MDMA) among young adults has dramatically increased over the years. Since MDMA may impair the users' driving ability, the risk of being involved in a motor vehicle accident (MVA) is notably increased. Minimal traumatic brain injury (mTBI) a common consequence of MVAs-produces short- and long-term physical, cognitive, and emotional impairments. To investigate the effects of an acute dose of MDMA in mice subjected to closed head mTBI. Mice received 10 mg/kg MDMA 1 h prior to the induction of mTBI. Behavioral tests were conducted 7 and 30 days post-injury. In addition to the behavioral tests, phosphorylation of IGF-1R, ERK, and levels of tyrosine hydroxylase (TH) were measured. mTBI mice showed major cognitive impairments in all cognitive tests conducted. No additional impairments were seen if mTBI was preceded by one dose of MDMA. On the contrary, a beneficial effect was seen in these mice. The western blot analysis of TH revealed a significant decrease in the mTBI mice. These decreases were reversed in mice that were subjected to MDMA prior to the trauma. The presence of MDMA at the time of mTBI minimizes the alteration of visual and spatial memory of the injured mice. The IGF-1R pathway was activated due to mTBI and MDMA but was not the main contributor to the cognitive improvements. MDMA administration inverted the TH decreases seen after injury. We believe this may be the major cause of the cognitive improvements seen in these mice.	[Edut, Shahaf; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Schreiber, Shaul] Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	shahafed@post.tau.ac.il; rubovitc@post.tau.ac.il; shaulsch@tasmc.health.gov.il; pickc@post.tau.ac.il	Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693	Dr. Herman Schauder Endownment Fund for Research; The Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Tel Aviv University, Tel Aviv, Israel	This study was supported (in part) by a grant from the Dr. Herman Schauder Endownment Fund for Research and by a grant from The Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Tel Aviv University, Tel Aviv, Israel.	Able JA, 2006, BIOL PSYCHIAT, V59, P1219, DOI 10.1016/j.biopsych.2005.09.006; Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Bayir H, 2008, CRIT CARE, V12, DOI 10.1186/cc6779; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Brookhuis KA, 2004, PSYCHOPHARMACOLOGY, V173, P440, DOI 10.1007/s00213-003-1714-5; Brown PL, 2004, EUR J NEUROSCI, V20, P51, DOI 10.1111/j.0953-816X.2004.03453.x; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cadet JL, 2001, ANN MED INTERNE, V152, pS57; Camarasa J, 2008, EUR J PHARMACOL, V589, P132, DOI 10.1016/j.ejphar.2008.05.014; Camarero J, 2002, J NEUROCHEM, V81, P961, DOI 10.1046/j.1471-4159.2002.00879.x; Capela JP, 2007, NEUROTOXICOLOGY, V28, P868, DOI 10.1016/j.neuro.2007.04.005; Capela JP, 2009, MOL NEUROBIOL, V39, P210, DOI 10.1007/s12035-009-8064-1; Carvalho M, 2002, ARCH TOXICOL, V76, P166, DOI 10.1007/s00204-002-0324-z; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cheng CM, 2003, J NEUROSCI RES, V73, P1, DOI 10.1002/jnr.10634; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Colado MI, 2004, PSYCHOPHARMACOLOGY, V173, P249, DOI 10.1007/s00213-004-1788-8; Colado MI, 2001, BRIT J PHARMACOL, V134, P1711, DOI 10.1038/sj.bjp.0704435; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Darke S, 2004, ADDICTION, V99, P175, DOI 10.1046/j.1360-0443.2003.00604.x; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dhillon HS, 1998, BRAIN RES, V804, P231, DOI 10.1016/S0006-8993(98)00639-8; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Drummer OH, 2003, FORENSIC SCI INT, V134, P154, DOI 10.1016/S0379-0738(03)00134-8; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Fantegrossi WE, 2008, NEUROSCIENCE, V151, P533, DOI 10.1016/j.neuroscience.2007.11.007; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Granado N, 2008, SYNAPSE, V62, P80, DOI 10.1002/syn.20466; Green AR, 2009, PSYCHOPHARMACOLOGY, V204, P375, DOI 10.1007/s00213-008-1453-8; Green AR, 2003, PHARMACOL REV, V55, P463, DOI 10.1124/pr.55.3.3; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Gudelsky GA, 2008, PHARMACOL BIOCHEM BE, V90, P198, DOI 10.1016/j.pbb.2007.10.003; Haavik J, 1998, MOL NEUROBIOL, V16, P285, DOI 10.1007/BF02741387; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Henry JM, 1997, J INVEST SURG, V10, P281, DOI 10.3109/08941939709032167; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; HOOFT PJ, 1994, INT J LEGAL MED, V106, P328, DOI 10.1007/BF01224781; Kern CH, 2010, SYNAPSE, V64, P363, DOI 10.1002/syn.20736; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kumer SC, 1996, J NEUROCHEM, V67, P443; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Kuypers Kim P. C., 2009, P501, DOI 10.1007/978-3-7643-9923-8_30; Logan BK, 2001, J FORENSIC SCI, V46, P1426; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; McBeth BD, 2005, ACAD EMERG MED, V12, P483, DOI 10.1197/j.aem.2004.11.028; McGregor IS, 2003, NEUROPSYCHOPHARMACOL, V28, P1472, DOI 10.1038/sj.npp.1300185; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Milman A, 2006, BEHAV BRAIN RES, V170, P141, DOI 10.1016/j.bbr.2006.02.017; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morgan MJ, 2000, PSYCHOPHARMACOLOGY, V152, P230, DOI 10.1007/s002130000545; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Morton J, 2005, CURR OPIN PHARMACOL, V5, P79, DOI 10.1016/j.coph.2004.08.007; Movig KLL, 2004, ACCIDENT ANAL PREV, V36, P631, DOI 10.1016/S0001-4575(03)00084-8; Nochajski TH, 2006, CLIN PSYCHOL REV, V26, P179, DOI 10.1016/j.cpr.2005.11.006; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Petrasek T, 2009, PHYSIOL RES, V58, P299, DOI 10.33549/physiolres.931729; Pick CG, 1997, BRAIN RES, V744, P41, DOI 10.1016/S0006-8993(96)01069-4; PICK CG, 1991, BRAIN RES, V566, P295, DOI 10.1016/0006-8993(91)91712-A; Piper BJ, 2005, DEV PSYCHOBIOL, V47, P145, DOI 10.1002/dev.20085; Piper BJ, 2004, PHARMACOL BIOCHEM BE, V79, P723, DOI 10.1016/j.pbb.2004.10.001; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Simola N, 2009, NEUROSCIENCE, V158, P1625, DOI 10.1016/j.neuroscience.2008.11.009; Skelton MR, 2008, NEUROPHARMACOLOGY, V55, P1121, DOI 10.1016/j.neuropharm.2008.07.006; Smink BE, 2008, TRAFFIC INJ PREV, V9, P105, DOI 10.1080/15389580701824443; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Sprague JE, 2003, PHYSIOL BEHAV, V79, P281, DOI 10.1016/S0031-9384(03)00092-1; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Warren MW, 2007, ACTA NEUROPATHOL, V114, P277, DOI 10.1007/s00401-007-0259-9; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Weinbroum AA, 2003, EUR J EMERG MED, V10, P19, DOI 10.1097/00063110-200303000-00006; Weizman R, 2001, PHARMACOL BIOCHEM BE, V68, P491, DOI 10.1016/S0091-3057(01)00450-6; Whishaw IQ, 1996, PHYSIOL BEHAV, V60, P1191, DOI 10.1016/S0031-9384(96)00176-X; Yan H. Q., 2001, Society for Neuroscience Abstracts, V27, P567; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	95	33	33	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0033-3158	1432-2072		PSYCHOPHARMACOLOGY	Psychopharmacology	APR	2011	214	4					877	889		10.1007/s00213-010-2098-y			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	739XQ	WOS:000288755500009	21120456				2022-02-06	
J	Jiang, YF; Lv, HL; Huang, SS; Tan, HP; Zhang, YN; Li, H				Jiang, Yufeng; Lv, Hailong; Huang, Shanshan; Tan, Huiping; Zhang, Yinong; Li, He			Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model	NEUROLOGICAL RESEARCH			English	Article						Bone marrow mesenchymal stem cells; Huntington's disease; Quinolinic acid; Transplantation; Neurotrophic factor	TRAUMATIC BRAIN INJURY; STROMAL CELLS; RODENT MODEL; SPINAL-CORD; DIFFERENTIATE; DEFICITS; TRANSPLANTATION; RECOVERY; THERAPY; NEURONS	Objectives: The purpose of this study was to investigate the ability of bone marrow mesenchymal stem cells (BMSCs) to survive in the striatum and improve motor function in the quinolinic acid (QA) lesion rat model of Huntington's disease (HD). Methods: One week following QA lesioning of the striatum, rats were transplanted with BMSCs that had been expanded in culture and labeled with 4'-6-diamidino-2-phenylindole (DAPI) prior to transplantation. Results: BMSCs survived transplantation into the lesioned striatum and differentiated into both neurons. Moreover, transplantation of BMSCs significantly reduced motor dysfunction observed following striatal QA lesioning. Stereological striatal volume analyses performed on Nissl-stained sections revealed that rats transplanted with BMSCs had a greater striatal volume on the lesioned side compared with rats injected with vehicle. Cultured BMSCs expressed trophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF). In the striatum of BMSC-treated group, the expression levels of these genes were significantly elevated when compared with those of the control group. Conclusion: Our data suggested that striatal transplants of BMSCs elicit behavioral and anatomical recovery in the QA lesion model of HD.	[Jiang, Yufeng; Huang, Shanshan; Tan, Huiping; Zhang, Yinong; Li, He] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Anat, Div Histol & Embryol, Wuhan 430030, Peoples R China; [Jiang, Yufeng] Shihezi Univ, Coll Med, Dept Histol & Embryol, Xinjiang, Peoples R China; [Lv, Hailong] Shihezi Univ, Affiliated Hosp 1, Sch Med, Dept Gen Surg, Xinjiang, Peoples R China		Li, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Anat, Div Histol & Embryol, Wuhan 430030, Peoples R China.	lihe7541@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30430260]	This work was supported by the National Natural Science Foundation of China (30430260).	Akiyama Y, 2002, J NEUROSCI, V22, P6623; Armstrong RJE, 2000, CELL TRANSPLANT, V9, P55, DOI 10.1177/096368970000900108; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Chen GJ, 2002, J BIOMED SCI, V9, P303; Cuevas P, 2004, NEUROL RES, V26, P230, DOI 10.1179/016164104225013897; Emerich DF, 1996, J NEUROSCI, V16, P5168; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Humpel Christian, 1995, Journal of Neural Transplantation and Plasticity, V5, P257; Hurelbrink CB, 2000, CELL TRANSPLANT, V9, P743, DOI 10.1177/096368970000900601; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Song YN, 2006, NEUROSCIENCE, V140, P33, DOI 10.1016/j.neuroscience.2006.01.045; The Huntington's Disease Collaborative Research Group, 1993, CELL, V72, P971; Vazey EM, 2006, EXP NEUROL, V199, P384, DOI 10.1016/j.expneurol.2006.01.034; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	24	33	34	0	12	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	APR	2011	33	3					331	336		10.1179/016164110X12816242542571			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	751MW	WOS:000289623200016	21513650				2022-02-06	
J	Funk, JR; Cormier, JM; Bain, CE; Guzman, H; Bonugli, E; Manoogian, SJ				Funk, James R.; Cormier, Joseph M.; Bain, Charles E.; Guzman, Herb; Bonugli, Enrique; Manoogian, Sarah J.			Head and Neck Loading in Everyday and Vigorous Activities	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Injury criteria; Head; Brain; Concussion; Neck; Whiplash	FOOTBALL; WHIPLASH; ACCELERATIONS; IMPACT	The purpose of this study was to document head and neck loading in a group of ordinary people engaged in non-injurious everyday and more vigorous physical activities. Twenty (20) volunteers that were representative of the general population were subjected to seven test scenarios: a soccer ball impact to the forehead, a self-imposed hand strike to the forehead, vigorous head shaking, plopping down in a chair, jumping off a step, a seated drop onto the buttocks, and a vertical drop while seated supine in a chair. Some scenarios involved prescribed and well-controlled stimuli, while others allowed the volunteers to perform common activities at a self-selected level of intensity. Head accelerations up to 31 g and 2888 rad/s(2) and neck loads up to 268 N in posterior shear, 526 N in compression, and 36 Nm in extension were recorded. Most head and neck injury criteria predicted a low risk of injury in all activities. However, rotational head accelerations and Neck Injury Criterion (NIC) values were much higher than some proposed tolerance limits in a large number of tests, all of which were non-injurious. The data from this study help us to establish an envelope of head and neck loading that is commonly encountered and presents a minimal risk of injury.	[Funk, James R.; Cormier, Joseph M.; Bain, Charles E.; Guzman, Herb; Bonugli, Enrique; Manoogian, Sarah J.] Biodynam Res Corp, San Antonio, TX 78249 USA		Funk, JR (corresponding author), Biodynam Res Corp, 5711 Univ Hts Blvd,Suite 100, San Antonio, TX 78249 USA.	jfunk@brconline.com	Cormier, Joseph/L-7470-2019	Manoogian, Sarah/0000-0001-9822-5619			ALLEN ME, 1994, SPINE, V19, P1285, DOI 10.1097/00007632-199405310-00017; Beier G., 1980, IRCOBI C BIRM UK, P218; BUSSONE WR, 2009, 2009010383 SAE; Carragee E, 2006, SPINE, V31, P2942, DOI 10.1097/01.brs.0000248429.10963.13; Carvalho A. V. D., 2009, ACP MED, P11; Castro WHM, 2001, INT J LEGAL MED, V114, P316, DOI 10.1007/s004140000193; Clauser C. E., 1969, AMRLTR6970 WRIGHT PA; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Funk JR, 2009, 2009010251 SAE; FUNK JR, 2007, P INT IRCOBI C, P233; FUNK JR, 2007, P ASS ADV AUTOMOT ME, V51, P343; Haland Y., 1996, P IRCOBI C, P123; KULLGREN A, 2003, P 18 ENH SAF VEH C; Manoogian SJ, 2010, 2010010146 SAE; MERTZ HJ, 2000, P 44 STAPP CAR CRASH; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; ONO K, 1997, P 41 STAPP CAR CRASH, P339; Pincemaille Y, 1989, P 33 STAPP CAR CRASH, P177; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; SCHMITT KU, 2001, P 17 ENH SAF VEH C; SCHNEIDER LW, 1983, UMTRI83531 NAT HIGHW; VANDENKROONENBE.A, 1998, P 42 STAPP CAR CRASH, P207; Vorst MV, 2007, J TRAUMA, V62, P199, DOI 10.1097/01.ta.0000238665.09611.4b; VIJAYAKUMAR V, 2006, 2006010247 SAE, P49	27	33	33	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	FEB	2011	39	2					766	776		10.1007/s10439-010-0183-3			11	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	719OD	WOS:000287213300014	20960061				2022-02-06	
J	Hawthorne, G; Kaye, AH; Gruen, R; Houseman, D; Bauer, I				Hawthorne, G.; Kaye, A. H.; Gruen, R.; Houseman, D.; Bauer, I.			Traumatic brain injury and quality of life: Initial Australian validation of the QOLIBRI	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Clinical trials; Evaluation; Participant reported outcome; Quality of life; QOLIBRI; Traumatic brain injury	GLASGOW COMA SCALE; MINI-MENTAL-STATE; SUBJECTIVE EXPERIENCE; SOCIAL-ISOLATION; CLOSE RELATIVES; MULTIPLE TRAUMA; HEALTH; REHABILITATION; SATISFACTION; RELIABILITY	The Quality of Life after Brain Injury (QOLIBRI) is a new international instrument for assessing quality of life after traumatic brain injury (TBI). We report first use and validation. Patients previously admitted with TBI to the Royal Melbourne Hospital, Melbourne, Australia, were randomly sampled (n = 66, 61% response rate) and administered the QOLIBRI. Fifty-five re-completed it at 2-week follow-up. QOLIBRI scales (with two exceptions) met standard criteria for internal consistency, homogeneity and test-re-test reliability. Correlations with the Assessment of Quality of Life, Short Form-36 version 2 and the Satisfaction with Life Scale were moderate. The QOLIBRI was sensitive to the Glasgow Outcome Scale - Extended scores, Hospital Anxiety and Depression scale, and measures of social isolation (Friendship Scale). There was evidence that further refinement may improve the QOLIBRI. The QOLIBRI should be considered as an outcome measure by clinicians and researchers conducting treatment trials, rehabilitation studies or epidemiological surveys into the treatment or sequelae of trauma. (C) 2010 Elsevier Ltd. All rights reserved.	[Hawthorne, G.; Houseman, D.; Bauer, I.] Univ Melbourne, Royal Melbourne Hosp, Fac Med Dent & Hlth Sci, Dept Psychiat, Parkville, Vic 3050, Australia; [Kaye, A. H.] Univ Melbourne, Dept Surg, Parkville, Vic 3050, Australia; [Gruen, R.] Alfred Hosp, Natl Trauma Res Inst, Prahran, Vic 3181, Australia; [Gruen, R.] Monash Univ, Prahran, Vic, Australia		Hawthorne, G (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Fac Med Dent & Hlth Sci, Dept Psychiat, Level 1 N,Grattan St, Parkville, Vic 3050, Australia.	graemeeh@unimelb.edu.au	Bauer, Isabelle Esther/C-5839-2015	Bauer, Isabelle Esther/0000-0001-9613-9354; Kaye, Andrew Henry/0000-0001-5049-8861	Victorian Neurotrauma Initiative; Department of Psychiatry; Faculty of Medicine, Dentistry and Health Sciences at the University of MelbourneUniversity of Melbourne; Royal Melbourne Hospital (RMH)	This project was supported by the Victorian Neurotrauma Initiative, the Department of Psychiatry, and the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne, and the Royal Melbourne Hospital (RMH). We would like to thank those organisations for their support. We would also like to thank Professor Nicole von Steinbuechel for her encouragement and support, and the interviewers who collected the data, Ms Janifer Anderson and Ms Maritza Thompson. Finally we would like to thank the many former patients of the RMH who so willingly gave their time to participate in the study.	Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Beck AT, 1997, BEHAV RES THER, V35, P785, DOI 10.1016/S0005-7967(97)00025-9; Bjorkdahl Ann, 2004, J Stroke Cerebrovasc Dis, V13, P122, DOI 10.1016/j.jstrokecerebrovasdis.2004.04.004; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Burridge AC, 2007, NEUROPSYCHOL REHABIL, V17, P95, DOI 10.1080/09602010500505070; Coetzer R, 2005, INT J REHABIL RES, V28, P361, DOI 10.1097/00004356-200512000-00010; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; Collins R, 2000, J HEAD TRAUMA REHAB, V15, P1139, DOI 10.1097/00001199-200010000-00007; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; English TC, 1904, LANCET, V1, P485; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Hawthorne G, 2008, SOC PSYCH PSYCH EPID, V43, P140, DOI 10.1007/s00127-007-0279-8; Hawthorne G, 2007, QUAL LIFE RES, V16, P661, DOI 10.1007/s11136-006-9154-4; Hawthorne G, 2006, SOC INDIC RES, V77, P521, DOI 10.1007/s11205-005-7746-y; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HSU LM, 1994, MULTIVAR BEHAV RES, V29, P127, DOI 10.1207/s15327906mbr2902_1; Hutter BO, 2001, ZBL NEUROCHIR, V62, P37, DOI 10.1055/s-2002-19476; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; Mathiesen Birgit Bork, 2004, Cogn Neuropsychiatry, V9, P249, DOI 10.1080/13546800344000237; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Middelkamp W, 2007, CLIN REHABIL, V21, P425, DOI 10.1177/0269215507075307; MOKKEN RJ, 1982, APPL PSYCH MEAS, V6, P417, DOI 10.1177/014662168200600404; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P87; Nunnally J. C., 1994, PSYCHOMETRIC THOERY, V3rd; Olsson I, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-46; Pirente N, 2002, UNFALLCHIRURG, V105, P413; Pirente N, 2001, UNFALLCHIRURG, V104, P57, DOI 10.1007/s001130050688; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P561, DOI 10.1080/09602010500263084; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Sherwin E, 2006, BRAIN INJURY, V20, P383, DOI 10.1080/02699050600663097; Snaith R., 1994, HOSP ANXIETY DEPRESS; Sopena S, 2007, BRAIN INJURY, V21, P1063, DOI 10.1080/02699050701630342; STREINER D, 2006, HLTH MEASUREMENT SCA; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Tazopoulou E, 2005, ACTA NEUROPSYCHOL, V1, P13; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; TRUELLE JL, BRAIN INJUR IN PRESS; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P29, DOI 10.1076/jcen.21.1.29.939; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Ware J., 2000, SCORE VERSION 2 SF 3; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHOQOL Group, 1995, SOC SCI MED, V41, P1403, DOI DOI 10.1016/0277-9536(95)00112-K; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	71	33	35	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	FEB	2011	18	2					197	202		10.1016/j.jocn.2010.06.015			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	719BH	WOS:000287173700006	21163654				2022-02-06	
J	Donders, J; Strong, CAH				Donders, Jacobus; Strong, Carrie-Ann H.			Embedded Effort Indicators on the California Verbal Learning Test - Second Edition (CVLT-II): An Attempted Cross-Validation	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; assessment; validity; California Verbal Learning Test - Second edition; CVLT-II	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; VALIDITY; ISSUES; RATES; BIAS	This study determined whether the logistic regression method that was recently developed by Wolfe and colleagues (2010) for the detection of invalid effort on the California Verbal Learning Test - Second Edition (CVLT-II) could be cross-validated in an independent sample of 100 consecutively referred patients with traumatic brain injury. Although the CVLT-II logistic regression formula demonstrated a statistically significant level of agreement with results from the Word Memory Test, it was associated with an unacceptably high proportion of false positives. The component variables of the logistic regression were sensitive to length of coma but did not covary with psychosocial complicating factors (e. g., unresolved prior psychiatric history) that were associated with a higher relative risk of failure of WMT validity criteria. It is concluded that the Wolfe et al. logistic regression should be used only with great caution in the context of clinical neuropsychological evaluations.	[Donders, Jacobus; Strong, Carrie-Ann H.] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis D.C., 2000, CALIFORNIA VERBAL LE; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Horwitz JE, 2006, APPL NEUROPSYCHOL, V13, P175, DOI 10.1207/s15324826an1303_5; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; [No title captured]	22	33	33	1	4	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	1					173	184		10.1080/13854046.2010.536781			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	722FM	WOS:000287417100012	21181604				2022-02-06	
J	Kurczek, J; Duff, MC				Kurczek, Jake; Duff, Melissa C.			Cohesion, coherence, and declarative memory: Discourse patterns in individuals with hippocampal amnesia	APHASIOLOGY			English	Article; Proceedings Paper	40th Clinical Aphasiology Conference (CAC)	MAY 23-27, 2010	Isle of Palms, SC			Cohesion; Coherence; Declarative memory; Hippocampus; Discourse	CLOSED-HEAD INJURY; RELATIONAL MEMORY; ELICITATION TASK; WORKING-MEMORY; ADULTS; COMMUNICATION; NARRATIVES; DEMENTIA; LANGUAGE	Background: Discourse cohesion and coherence gives our communication continuity. Deficits in cohesion and coherence have been reported in patients with cognitive-communication disorders (e.g., TBI, dementia). However, the diffuse nature of pathology and widespread cognitive deficits of these disorders have made identification of specific neural substrates and cognitive systems critical for cohesion and coherence challenging. Aims: Taking advantage of a rare patient group with selective and severe declarative memory impairments, the current study attempts to isolate the contribution of declarative memory to the successful use of cohesion and coherence in discourse. Methods Procedures: Cohesion and coherence were examined in the discourse of six participants with hippocampal amnesia and six demographically matched comparison participants. Specifically, this study (1) documents the frequency, type, and completeness of cohesive ties; (2) evaluates discourse for local and global coherence; and (3) compares use of cohesive ties and coherence ratings in amnesia and healthy participants. Outcomes Results: Overall, amnesia participants produced fewer cohesive ties per T-unit, the adequacy of their ties were more often judged to be incomplete, and the ratings of their local coherence were consistently lower than comparison participants. Conclusions: These findings suggest that declarative memory may contribute to the discursive use of cohesion and coherence. Broader notions of cohesion, or interactional cohesion, i.e., cohesion across speakers (two or more people), time (days, weeks), and communicative resources (gesture), warrant further study as the experimental tasks used in the literature, and here, may actually underestimate or overestimate the extent of impairment.	[Duff, Melissa C.] Univ Iowa, Dept Commun Sci & Disorders, Iowa City, IA 52242 USA; [Kurczek, Jake; Duff, Melissa C.] Univ Iowa, Div Cognit Neurosci, Dept Neurol, Iowa City, IA USA; [Kurczek, Jake; Duff, Melissa C.] Univ Iowa, Neurosci Grad Programme, Iowa City, IA USA		Duff, MC (corresponding author), Univ Iowa, Dept Commun Sci & Disorders, 250 Hawkins Dr, Iowa City, IA 52242 USA.	melissa-duff@uiowa.edu	Kurczek, Jake/I-8619-2016	Kurczek, Jake/0000-0002-5965-2498	NIDCDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1F32DC008825];  [NINDS NS 19632]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F32DC008825] Funding Source: NIH RePORTER	We thank S. Shune for assistance in data coding and analysis and S. Shune, R. Gupta, and the Communication and Memory Laboratory for helpful comments on earlier versions of this manuscript. Funding from NIDCD grant 1F32DC008825, and Program Project Grant NINDS NS 19632 supported the study and manuscript preparation.	AGAR M, 1982, DISCOURSE PROCESS, V5, P1, DOI 10.1080/01638538209544529; ARBUCKLE TY, 1993, J GERONTOL, V48, pP225, DOI 10.1093/geronj/48.5.P225; Bourgeois M. S., 2009, DEMENTIA DIAGNOSIS M; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cohen, 2001, CONDITIONING CONSCIO; Cohen N. J., 2003, NEUROPSYCHOLOGY NEUR, P322; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Dijkstra K, 2004, J NEUROLINGUIST, V17, P263, DOI 10.1016/S0911-6044(03)00048-4; Dijkstra K, 2002, DISCOURSE PROCESS, V33, P53, DOI 10.1207/S15326950DP3301_03; Duff MC, 2006, NAT NEUROSCI, V9, P140, DOI 10.1038/nn1601; DUFF MC, 2005, LANGUAGE MEMORY ANAL; Duff MC, 2008, APHASIOLOGY, V22, P866, DOI 10.1080/02687030701844196; Duff MC, 2008, BRAIN LANG, V106, P41, DOI 10.1016/j.bandl.2007.10.004; Duff MC, 2007, APHASIOLOGY, V21, P702, DOI 10.1080/02687030701192265; Duff MC, 2009, APHASIOLOGY, V23, P926, DOI 10.1080/02687030802533748; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Glosser G., 1992, J CLIN EXPT NEUROPSY, V14, P40; Halliday M. K., 1976, COHESION ENGLISH; Hannula DE, 2006, J NEUROSCI, V26, P8352, DOI 10.1523/JNEUROSCI.5222-05.2006; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hengst JA, 2007, TOP LANG DISORD, V27, P37, DOI 10.1097/00011363-200701000-00005; Hengst JA, 2010, APHASIOLOGY, V24, P887, DOI 10.1080/02687030903478330; Hunt K., 1970, MONOGRAPHS SOC RES C, V35; Konkel A, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.015.2008; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Liles BZ, 1998, ANAL DISCOURSE COMMU, P65; Louwerse M. M., 2005, ENCY LINGUISTICS, P216; Murray Laura L., 2001, Seminars in Speech and Language, V22, P127; Ogden J.A., 1991, MEMORY MECH TRIBUTE; Olson IR, 2006, J COGNITIVE NEUROSCI, V18, P1087, DOI 10.1162/jocn.2006.18.7.1087; Richardson JTE., 2000, CLIN NEUROPSYCHOLOGI; Ripich DN, 2000, INT J LANG COMM DIS, V35, P49; Rogalski Y, 2010, J COMMUN DISORD, V43, P212, DOI 10.1016/j.jcomdis.2010.02.001; Ryan JD, 2004, J EXP PSYCHOL HUMAN, V30, P988, DOI 10.1037/0096-1523.30.5.988; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shadden B.B., 1991, CLIN APHASIOLOGY, V20, P327; Tannen D., 1989, TALKING VOICES REPET; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Warren DE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00035; WINTER P, 1976, BEAR FLY; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	44	33	34	2	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2011	25	6-7					700	712	PII 931812299	10.1080/02687038.2010.537345			13	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	775XO	WOS:000291497000004	23136461	Green Accepted			2022-02-06	
J	Schatz, P; Moser, RS				Schatz, Philip; Moser, Rosemarie Scolaro			Current Issues in Pediatric Sports Concussion	CLINICAL NEUROPSYCHOLOGIST			English	Article						Concussion; Mild traumatic brain injury; Long-term effects	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; STATES EMERGENCY-DEPARTMENTS; UNITED-STATES; ICE HOCKEY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; LACROSSE INJURIES; WOMENS LACROSSE; HEAD-INJURY	This article reviews current issues in the following areas of pediatric sports-related concussion: incidence of concussion, potential long-term effects, return to play, and the emergence of legislation regarding concussion education and management programs. Incidence of concussion is presented in context of emergency room visits, as well as under-reporting of concussions. The literature on history of concussion is reviewed, for high school, collegiate, and professional athletes, with respect to potential long-term effects of cerebral concussion. Specific discussions of effects include: decreased cognition and increased symptom reporting following multiple concussions, and recent diagnoses of chronic traumatic encephalopathy in non-professional and youth athletes. Recent legislative and advocacy efforts are reviewed, including mandated programs in specific states.	[Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Moser, Rosemarie Scolaro] RSM Psychol Ctr LLC, Sports Concuss Ctr New Jersey SM, Lawrenceville, NJ USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			2007-09 Official Rules of Ice Hockey, 2007, 2007 09 OFFICIAL RUL; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Aubry M, 2002, PHYSICIAN SPORTSMED, V30, P1; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; BRESLAU N, 1985, J AM ACAD CHILD PSY, V24, P87, DOI 10.1016/S0002-7138(09)60415-5; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P255; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Evans T., 2009, NY TIMES        1230; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fisher J, 2004, TOP EMERG MED, V26, P260; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Hohler B., 2009, BOSTON GLOBE    0127; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kraus JF, 1993, HEAD INJURY, P1; LOGAN K, 2009, ATHLETIC TRAINING SP, V1, P251; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2004, BRIT J SPORT MED, V29, P196; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; NATA, 2010, NAT ATHL TRAIN ASS I; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schwarz A., 2010, NY TIMES        0913; Schwarz A., 2010, NY TIMES        0916; Schwarz A., 2010, NY TIMES        0726; Shields BJ, 2009, J ATHL TRAINING, V44, P586, DOI 10.4085/1062-6050-44.6.586; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; [U.S.Census Bureau http://factfinder.census. gov/servlet/ Metadata BrowserServlet?type=program&id=PEP], 2009, 2009 POP EST PROJ; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wagner J., 2010, WASHINGTON POST 0924; Waicus KM, 2002, CLIN J SPORT MED, V12, P24, DOI 10.1097/00042752-200201000-00008; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yard EE, 2006, J ATHL TRAINING, V41, P441; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	81	33	34	0	28	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	6					1042	1057		10.1080/13854046.2011.556669			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	882JH	WOS:000299559400009	21391151				2022-02-06	
J	Serrano-Perez, MC; Martin, ED; Vaquero, CF; Azcoitia, I; Calvo, S; Cano, E; Tranque, P				Serrano-Perez, Maria C.; Martin, Eduardo D.; Vaquero, Cecilia F.; Azcoitia, Inigo; Calvo, Soledad; Cano, Eva; Tranque, Pedro			Response of Transcription Factor NFATc3 to Excitotoxic and Traumatic Brain Insults: Identification of a Subpopulation of Reactive Astrocytes	GLIA			English	Article						astrogliosis; glia; brain lesion; glial scar; neuroinflammation	NUCLEAR ACCUMULATION; GENE-EXPRESSION; GLIAL-CELLS; KAINIC ACID; CALCINEURIN; ACTIVATION; CYCLOOXYGENASE-2; INDUCTION; PROTEINS; CALCIUM	Astrocytes react to brain injury triggering neuroinflammatory processes that determine the degree of neuronal damage. However, the signaling events associated to astrocyte activation remain largely undefined. The nuclear factor of activated T-cells (NFAT) is a transcription factor family implicated in activation of immune cells. We previously characterized the expression of NFAT isoforms in cultured astrocytes, and NFAT activation in response to mechanical lesion. Here we analyze NFATc3 in two mouse models of inflammatory brain damage: hippocampal excitotoxicity induced by intracerebral kainic acid (KA) injection and cortical mechanical lesion. Immunofluorescence results demonstrated that NFATc3 is specifically induced in a subset of reactive astrocytes, and not in microglia or neurons. In KA-treated brains, NFATc3 expression is transient and NFATc3-positive astrocytes concentrate around damaged neurons in areas CA3 and CA1. Complementary Western blot and RT-PCR analysis revealed an NFAT-dependent induction of RCAN1-4 and COX-2 in hippocampus as soon as 6 h after KA exposure, indicating that NFAT activation precedes NFATc3 over-expression. Moreover, activation of NFAT by ATP increased NFATc3 mRNA levels in astrocyte cultures, suggesting that NFATc3 expression is controlled through an auto-regulatory loop. Meanwhile, stab wound enhanced NFATc3 expression specifically in a subclass of reactive astrocytes confined within the proximal layer of the glial scar, and GFAP immunoreactivity was attenuated in NFATc3-expressing astrocytes. In conclusion, our work establishes NFATc3 as a marker of activation for a specific population of astrocytes in response to brain damage, which may have consequences for neuronal survival. (C) 2010 Wiley-Liss, Inc.	[Tranque, Pedro] Univ Castilla La Mancha, Inst Invest Discapacidades Neurol IDINE, Fac Med, Albacete 02006, Spain; [Vaquero, Cecilia F.] Univ Castilla La Mancha, CRIB, Albacete 02006, Spain; [Azcoitia, Inigo] Univ Complutense, Fac Biol, Dept Biol Celular, Madrid, Spain; [Cano, Eva] Inst Salud Carlos III, Area Biol Celular & Desarrollo, Ctr Nacl Microbiol, Unidad Neuroinflamac, Madrid, Spain		Tranque, P (corresponding author), Univ Castilla La Mancha, Inst Invest Discapacidades Neurol IDINE, Fac Med, Av Almansa 14, Albacete 02006, Spain.	pedro.tranque@uclm.es	Azcoitia, Inigo/A-6208-2011; Cano, Eva/A-2049-2010; Romo, Jose A./J-3024-2012; Martin, Eduardo D./V-3344-2017	Azcoitia, Inigo/0000-0002-5791-9144; Cano, Eva/0000-0003-2750-6135; Romo, Jose A./0000-0003-2907-580X; Martin, Eduardo D./0000-0003-1768-3488; Tranque Gomez, Pedro Antonio/0000-0003-1072-7337; Fernandez Vaquero, Cecilia/0000-0002-7415-9060	MICINNSpanish GovernmentEuropean Commission [SAF2009-12869]; CEC-JCCM [PII1I09-0092-30]; FISInstituto de Salud Carlos III [PI09/218]	Grant sponsor: MICINN; Grant number: SAF2009-12869; Grant sponsor: CEC-JCCM; Grant number: PII1I09-0092-30; Grant sponsor: FIS; Grant number: PI09/218.	Abbracchio Maria P, 2006, Purinergic Signal, V2, P595, DOI 10.1007/s11302-006-9016-0; Abdul Hafiz Mohmmad, 2010, Mol Cell Pharmacol, V2, P7; Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; Blanco A, 2008, J IMMUNOL, V180, P530, DOI 10.4049/jimmunol.180.1.530; Blom MAA, 1997, BRAIN RES, V777, P210, DOI 10.1016/S0006-8993(97)01204-3; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Canellada A, 2008, GLIA, V56, P709, DOI 10.1002/glia.20647; Cano E, 2005, J BIOL CHEM, V280, P29435, DOI 10.1074/jbc.M506205200; Che YZ, 2001, MOL BRAIN RES, V94, P157, DOI 10.1016/S0169-328X(01)00233-9; Chen ZG, 2002, BRAIN RES, V931, P135, DOI 10.1016/S0006-8993(02)02268-0; Cho IH, 2003, J NEUROSCI RES, V74, P736, DOI 10.1002/jnr.10794; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Davies KJA, 2007, FASEB J, V21, P3023, DOI 10.1096/fj.06-7246com; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Dienz O, 2007, P NATL ACAD SCI USA, V104, P7175, DOI 10.1073/pnas.0610442104; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Filosa JA, 2007, AM J PHYSIOL-CELL PH, V293, pC1797, DOI 10.1152/ajpcell.00554.2006; FRANKLIN G, 2001, MOUSE BRAIN STEREOTA, P264; Friedman LK, 2006, MOL INTERV, V6, P315, DOI 10.1124/mi.6.6.5; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2006, TRANSCRIPTION FACTOR, P353; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hua LWL, 2002, J NEUROIMMUNOL, V126, P180, DOI 10.1016/S0165-5728(02)00055-3; Jones EA, 2003, J NEUROSCI RES, V72, P191, DOI 10.1002/jnr.10584; Kao SC, 2009, SCIENCE, V323, P651, DOI 10.1126/science.1166562; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Kyrkanides S, 2002, MOL BRAIN RES, V104, P159, DOI 10.1016/S0169-328X(02)00353-4; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lerma J, 2001, PHYSIOL REV, V81, P971, DOI 10.1152/physrev.2001.81.3.971; Liu QH, 2009, NAT CELL BIOL, V11, P154, DOI 10.1038/ncb1823; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nilsson LM, 2007, AM J PHYSIOL-CELL PH, V292, pC1167, DOI 10.1152/ajpcell.00590.2005; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Park HJ, 2008, EPILEPSIA, V49, P163, DOI 10.1111/j.1528-1167.2007.01308.x; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Perez-Ortiz JM, 2008, EUR J NEUROSCI, V27, P2453, DOI 10.1111/j.1460-9568.2008.06197.x; Renault-Mihara F, 2008, INT J BIOCHEM CELL B, V40, P1649, DOI 10.1016/j.biocel.2008.03.009; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwarcz R, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01487.x; Serfling E, 2006, TRENDS IMMUNOL, V27, P461, DOI 10.1016/j.it.2006.08.005; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Weigmann B, 2008, J EXP MED, V205, P2099, DOI 10.1084/jem.20072484; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	63	33	33	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN	2011	59	1					94	107		10.1002/glia.21079			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	693FL	WOS:000285209900009	20967884				2022-02-06	
J	Mao, HJ; Yang, KH; King, AI; Yang, K				Mao, Haojie; Yang, King H.; King, Albert I.; Yang, Kai			Computational neurotrauma-design, simulation, and analysis of controlled cortical impact model	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Brain injury; Controlled cortical impact; Finite element	TRAUMATIC BRAIN-INJURY; OLDER ADULTS; BIOMECHANICS; MILD; TBI; RAT	The controlled cortical impact (CCI) model is widely used in many laboratories to study traumatic brain injury (TBI). Although external impact parameters during CCI tests could be clearly defined, little is known about the internal tissue-level mechanical responses of the rat brain. Furthermore, the external impact parameters tend to vary considerably among different labs making the comparison of research findings difficult if not impossible. In this study, a design of computer experiments was performed with typical external impact parameters commonly found in the literature. An anatomically detailed finite element (FE) rat brain model was used to simulate the CCI experiments to correlate external mechanical parameters (impact depth, impact velocity, impactor shape, impactor size, and craniotomy pattern) with rat brain internal responses, as predicted by the FE model. Systematic analysis of the results revealed that impact depth was the leading factor affecting the predicted brain internal responses. Interestingly, impactor shape ranked as the second most important factor, surpassing impactor diameter and velocity which were commonly reported in the literature as indicators of injury severity along with impact depth. The differences in whole brain response due to a unilateral or a bilateral craniotomy were small, but those of regional intracranial tissue stretches were large. The interaction effects of any two external parameters were not significant. This study demonstrates the potential of using numerical FE modeling to engineer better experimental TBI models in the future.	[Mao, Haojie; Yang, King H.; King, Albert I.] Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA; [Yang, Kai] Wayne State Univ, Dept Ind & Mfg Engn, Detroit, MI 48201 USA		Mao, HJ (corresponding author), Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA.	hmao@wayne.edu	Mao, Haojie/Q-7514-2018	Mao, Haojie/0000-0002-7563-9234	Injury Control Research Center at University of Alabama at Birmingham	The authors would like to acknowledge Dr. Cheng-Tang Wu from LSTC for his help in post-processing of simulation results. The authors also acknowledge Chris Anderson for his help in preparing the manuscript. This study is partially supported by the Injury Control Research Center at University of Alabama at Birmingham.	Antony Jiju, 2003, DESIGN EXPT ENG SCI; Arbogast K., 1997, P 41 STAPP CAR CRASH; Bain A.C., 1999, 43 STAPP CAR CRASH C; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; FEARNSIDE MR, 1997, HEAD INJURY PATHOPHY, P3; Finkelstein E., 2006, INCIDENCE EC BURDEN; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Hoffmann B, 2002, ACT NEUR S, V79, P33; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kraus J, 1996, NEUROTRAUMA, P13; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LENTH RV, 1989, TECHNOMETRICS, V31, P469, DOI 10.2307/1269997; MAO H, 2009, BIOMEDICAL ENG; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Roy R.K., 2001, DESIGN EXPT USING TA; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Takhounts EG, 2008, STAPP CAR C, V52, P1; Vink R, 1990, Magnes Res, V3, P163; von Wild KRH, 2005, ACTA NEUROCHIR SUPPL, V93, P15	34	33	33	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	DEC	2010	9	6					763	772		10.1007/s10237-010-0212-z			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	684AA	WOS:000284518200009	20372960	hybrid			2022-02-06	
J	Petronilho, F; Feier, G; de Souza, B; Gughelmi, C; Constantino, LS; Walz, R; Quevedo, J; Dal-Pizzol, F				Petronilho, Fabricia; Feier, Gustavo; de Souza, Bruna; Gughelmi, Cecilia; Constantino, Larissa S.; Walz, Roger; Quevedo, Joao; Dal-Pizzol, Felipe			Oxidative Stress in Brain According to Traumatic Brain Injury Intensity	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; lipid peroxidation; protein carbonyls	NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; N-ACETYLCYSTEINE; HEAD-INJURY; PATHOPHYSIOLOGY; HIPPOCAMPUS; GLUTAMATE; STROKE; CORTEX; DAMAGE	Background The mechanisms of brain damage and neuroplasticity following traumatic brain injury (TB!) are complex and not completely understood Thus, we investigated markers of oxidative stress in the central nervous system after mild and severe TBI in rats Material and Methods Adult male wistar rats (five animals per group) submitted to mild (mTBI group) or severe TBI (sTBI Group) were sacrificed 30min, 3, 6, or 12 h after the injury to quantify markers of oxidative damage in different brain regions Levels of thiobarbituric acid reactive species and protein carbonyl in the cortex, hippocampus, striatum, and cerebellum of mTBI and sTBI groups were compared with the control group Results After mTBI, levels of protein oxidation were increased in all analyzed structures in several different times after injury The increase in TBARS levels was not so consistent in mTBI In contrast, sTBI did not induce a sustainable increase in oxidative damage markers in all analyzed structures Conclusions Oxidative damage seemed to be inversely proportional to severity of traumatic brain injury (C) 2010 Elsevier Inc All rights reserved	[Feier, Gustavo; Gughelmi, Cecilia; Quevedo, Joao] Univ Extremo Catarinense, Unidade Acad Ciencias Saude, Programa Pos Grad Ciencias Saude, Lab Neurociencias, BR-88806000 Criciuma, SC, Brazil; [Petronilho, Fabricia; de Souza, Bruna; Constantino, Larissa S.; Dal-Pizzol, Felipe] Univ Extremo Catarinense, Unidade Acad Ciencias Saude, Programa Pos Grad Ciencias Saude, Lab Fisiopatol Expt, BR-88806000 Criciuma, SC, Brazil; [Walz, Roger] Univ Fed Santa Catarina, Nucleo Pesquisas Neurol Expt & Clin NUPNEC, Florianopolis, SC, Brazil; [Walz, Roger] Hosp Governador Celso Ramos, Ctr Cirurgia Epilepsia Santa Catarina CEPESC, Florianopolis, SC, Brazil		Dal-Pizzol, F (corresponding author), Univ Extremo Catarinense, Lab Fisiopatol, BR-88806000 Criciuma, SC, Brazil.		de Quevedo, Joao Luciano/E-5491-2013; de Quevedo, Joao Luciano/N-1407-2019; Petronilho, Fabricia/D-8822-2013; Dal-Pizzol, Felipe/F-2756-2015; Constantino, Larissa/I-7062-2015; Walz, Roger/K-9096-2013	de Quevedo, Joao Luciano/0000-0003-3114-6611; de Quevedo, Joao Luciano/0000-0003-3114-6611; Dal-Pizzol, Felipe/0000-0003-3003-8977; Walz, Roger/0000-0002-9875-6687; Constantino, Larissa/0000-0002-5400-6331	CNPq/MCT BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); UNESC Brazil	The authors acknowledge support for this research by grants from CNPq/MCT Brazil and UNESC Brazil	Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feier G, 2006, NEUROCHEM RES, V31, P665, DOI 10.1007/s11064-006-9064-4; Fortunato JJ, 2006, NEUROCHEM RES, V31, P671, DOI 10.1007/s11064-006-9065-3; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Harukuni I, 2006, NEUROL CLIN, V24, P1, DOI 10.1016/j.ncl.2005.10.004; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jornada LK, 2007, NEUROCHEM RES, V32, P389, DOI 10.1007/s11064-006-9214-8; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; SHERKI YG, 2002, PHARMACOL REV, V54, P271; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x	39	33	34	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	DEC	2010	164	2					316	320		10.1016/j.jss.2009.04.031			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	690AO	WOS:000284972600022	19691993				2022-02-06	
J	Thompson, SN; Carrico, KM; Mustafa, AG; Bains, M; Hall, ED				Thompson, Stephanie N.; Carrico, Kimberly M.; Mustafa, Ayman G.; Bains, Mona; Hall, Edward D.			A Pharmacological Analysis of the Neuroprotective Efficacy of the Brain- and Cell-Permeable Calpain Inhibitor MDL-28170 in the Mouse Controlled Cortical Impact Traumatic Brain Injury Model	JOURNAL OF NEUROTRAUMA			English	Article						calpain; controlled cortical impact; cytoskeleton; neurodegeneration; traumatic brain injury	SPINAL-CORD-INJURY; INDUCED AXONAL INJURY; CYCLOSPORINE-A; HEAD-INJURY; SPECTRIN PROTEOLYSIS; CORPUS-CALLOSUM; DOSE-RESPONSE; RATS; NEURODEGENERATION; DEGRADATION	The cytoskeletal and neuronal protective effects of early treatment with the blood-brain barrier-and cell-permeable calpain inhibitor MDL-28170 was examined in the controlled cortical impact (CCI) traumatic brain injury (TBI) model in male CF-1 mice. This was preceded by a dose-response and pharmacodynamic evaluation of IV or IP doses of MDL-28170 with regard to ex vivo inhibition of calpain 2 activity in harvested brain homogenates. From these data, we tested the effects of an optimized MDL-28170 dosing regimen on calpain-mediated degradation of the neuronal cytoskeletal protein alpha-spectrin in cortical or hippocampal tissue of mice 24 h after CCI-TBI (1.0mm depth, 3.5 m/sec velocity). With treatment initiated at 15min post-TBI, alpha-spectrin degradation was significantly reduced by 40% in hippocampus and 44% in cortex. This effect was still observed with a 1-h but not a 3-h post-TBI delay. The cytoskeletal protection is most likely taking place in neurons surrounding the area of mainly necrotic degeneration, since MDL-28170 did not reduce hemispheric lesion volume as measured by the aminocupric silver staining method. This lack of effect on lesion volume has been seen with other calpain inhibitors, which suggests that pharmacological calpain inhibition by itself, while able to reduce axonal injury, may not be able to produce a measurable reduction in lesion volume. This is in contrast to certain other neuroprotective mechanistic approaches such as the mitochondrial protectant cyclosporine A, which produces at least a partial decrease in lesion volume in the same model. Accordingly, the combination of a calpain inhibitor with a compound such as cyclosporine A may be needed to achieve the optimal degree of post-TBI neuroprotection.	[Thompson, Stephanie N.; Carrico, Kimberly M.; Mustafa, Ayman G.; Bains, Mona; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Mustafa, Ayman G.] Jordan Univ Sci & Technol, Coll Med, Dept Anat & Cell Biol, Irbid, Jordan		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013; Thompson, Stephanie/AAB-8272-2020	Thompson, Stephanie/0000-0002-9128-7515; mustafa, ayman/0000-0002-0341-7149	Kentucky Spinal Cord & Head Injury Research Trust;  [1P01 NS058484];  [5P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058484, P30NS051220] Funding Source: NIH RePORTER	These studies were funded by grants 1P01 NS058484 and 5P30 NS051220 and the Kentucky Spinal Cord & Head Injury Research Trust.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Arataki S, 2005, J NEUROTRAUM, V22, P398, DOI 10.1089/neu.2005.22.398; Ayala-Grosso C, 2004, NEUROSCIENCE, V126, P927, DOI 10.1016/j.neuroscience.2004.04.048; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Czeiter E, 2009, MOLECULES, V14, P5115, DOI 10.3390/molecules14125115; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thompson VF, 2000, ANAL BIOCHEM, V279, P170, DOI 10.1006/abio.1999.4475; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; Yu CG, 2008, J NEUROTRAUM, V25, P833, DOI 10.1089/neu.2007.0490; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291	47	33	34	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2233	2243		10.1089/neu.2010.1474			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400012	20874056	Green Published			2022-02-06	
J	Hong, JH; Jang, SH				Hong, Ji Heon; Jang, Sung Ho			DEGENERATION OF CINGULUM AND FORNIX IN A PATIENT WITH TRAUMATIC BRAIN INJURY: DIFFUSE TENSOR TRACTOGRAPHY STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						cingulum; fornix; trauma; brain injury; memory; diffusion tensor image	AXONAL INJURY; RECOVERY; TRACKING; DAMAGE	Objectives: The cingulum and fornix are important structures for memory function. Using follow-up diffusion tensor tractography in a patient with traumatic brain injury we found degeneration of the cingulum and fornix. Case report: An 18-year-old male who had had a traffic accident underwent conservative management for diffuse axonal injury. Brain magnetic resonance imaging showed an encephalomalactic lesion in the posterior portion of the corpus callosum. The patient had severe cognitive problems at 3 months after onset. However, while his intelligence had improved, his memory impairment had been aggravated at 14 months from onset. Results: On the first diffusion tensor tractographies, the integrity of both corticospinal tracts, right cingulum, and left fornix were preserved; however, compared with controls, there were disruptions in both ends of the left cingulum and right fornical crus. On the second diffusion tensor tractographies, both the cingulum and fornix showed severe degeneration, although the integrities of both corticospinal tracts were well preserved. Conclusion: We conclude that patients with memory impairment following traumatic brain injury should be evaluated using diffusion tensor imaging. In addition, follow-up diffusion tensor imaging may be necessary in patients with sustained memory impairment.	[Hong, Ji Heon; Jang, Sung Ho] Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, Taegu 705717, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			Korean GovernmentKorean Government [KRF-2008-314-E00173]	This work was supported by National Research Foundation of Korea Grant funded by the Korean Government (KRF-2008-314-E00173)	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Ciccarelli O, 2003, NEUROIMAGE, V18, P348, DOI 10.1016/S1053-8119(02)00042-3; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Danielian LE, 2010, NEUROIMAGE, V49, P1572, DOI 10.1016/j.neuroimage.2009.08.062; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Jang SH, 2009, NEUROREHABILITATION, V24, P349, DOI 10.3233/NRE-2009-0489; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Malykhin N, 2008, PSYCHIAT RES-NEUROIM, V164, P132, DOI 10.1016/j.pscychresns.2007.11.007; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stieltjes B, 2001, NEUROIMAGE, V14, P723, DOI 10.1006/nimg.2001.0861; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler D, 1981, WECHSLER ADULT INTEL; Williams JM., 1991, MAS MEMORY ASSESSMEN; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zhang Y, 2009, BRAIN, V132, P2579, DOI 10.1093/brain/awp071	26	33	33	0	1	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV	2010	42	10					979	981		10.2340/16501977-0603			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	687BK	WOS:000284748600014	21031297	gold, Green Submitted			2022-02-06	
J	Sumowski, JF; Wood, HG; Chiaravalloti, N; Wylie, GR; Lengenfelder, J; Deluca, J				Sumowski, James F.; Wood, Hali G.; Chiaravalloti, Nancy; Wylie, Glenn R.; Lengenfelder, Jeannie; Deluca, John			Retrieval practice A simple strategy for improving memory after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Memory; Memory disorders; Cognition; Rehabilitation; Testing effect	COGNITIVE REHABILITATION; DIVIDED ATTENTION; EPISODIC MEMORY; HIPPOCAMPUS; BENEFITS; MULTIPLE; RECALL; TESTS	Memory impairment is common following traumatic brain injury (TBI) but interventions to improve memory in persons with TBI have been ineffective Retrieval practice is a robust memory strategy among healthy undergraduates whereby practice retrieving information shortly after it is presented leads to better delayed recall than simple restudy In a verbal paired associate paradigm we investigated the effect of retrieval practice relative to massed and spaced restudy on delayed recall in 14 persons with chronic memory impairment following a TBI and 14 age matched healthy controls A significant learning condition (massed restudy spaced restudy retrieval practice) by group (TBI healthy) interaction emerged whereby only healthy controls benefited from spaced restudy (i e distributed learning) over massed restudy but both groups greatly benefited from retrieval practice over massed and spaced restudy That is retrieval practice greatly Improves memory in persons with TBI, even when other mnemonic strategies (e g distributed learning) are less effective (JINS 2010 16 1147-1150)	[Sumowski, James F.] Kessler Fdn, Neuropsychol & Neurosci Lab, Res Ctr, W Orange, NJ 07052 USA; [Sumowski, James F.; Chiaravalloti, Nancy; Wylie, Glenn R.; Lengenfelder, Jeannie; Deluca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; [Deluca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA		Sumowski, JF (corresponding author), Kessler Fdn, Neuropsychol & Neurosci Lab, Res Ctr, 300 Execut Dr,Suite 10, W Orange, NJ 07052 USA.				National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD060765]; National Institute on Disability and Rehabilitation Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R00HD060765] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K99HD060765] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health (HD060765 to J FS) and National Institute on Disability and Rehabilitation Research (Research Grant to N C) The authors have no conflicts of interest to report	Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Balota DA, 2006, PSYCHOL AGING, V21, P19, DOI 10.1037/0882-7974.21.1.19; Carpenter SK, 2005, APPL COGNITIVE PSYCH, V19, P619, DOI 10.1002/acp.1101; Cepeda NJ, 2006, PSYCHOL BULL, V132, P354, DOI 10.1037/0033-2909.132.3.354; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cull WL, 2000, APPL COGNITIVE PSYCH, V14, P215, DOI 10.1002/(SICI)1099-0720(200005/06)14:3<215::AID-ACP640>3.0.CO;2-1; Delis D.C., 2000, CALIFORNIA VERBAL LE; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Ebbinghaus H., 1913, MEMORY CONTRIBUTION; Eldridge LL, 2000, NAT NEUROSCI, V3, P1149, DOI 10.1038/80671; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Karpicke JD, 2008, SCIENCE, V319, P966, DOI 10.1126/science.1152408; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; MORRIS CD, 1977, J VERB LEARN VERB BE, V16, P519, DOI 10.1016/S0022-5371(77)80016-9; Nelson D. L., 1998, U S FLORIDA WORD ASS; Prince SE, 2005, J NEUROSCI, V25, P1203, DOI 10.1523/JNEUROSCI.2540-04.2005; Roediger HL, 2006, PERSPECT PSYCHOL SCI, V1, P181, DOI 10.1111/j.1745-6916.2006.00012.x; Roediger HL, 2006, PSYCHOL SCI, V17, P249, DOI 10.1111/j.1467-9280.2006.01693.x; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Shrager Y, 2008, NEURON, V59, P547, DOI 10.1016/j.neuron.2008.07.022; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sumowski JF, 2010, NEUROPSYCHOLOGY, V24, P267, DOI 10.1037/a0017533; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	25	33	34	1	24	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2010	16	6					1147	1150		10.1017/S1355617710001128			4	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	690RL	WOS:000285023200022	20946709				2022-02-06	
J	Kahraman, S; Dutton, RP; Hu, P; Stansbury, L; Xiao, Y; Stein, DM; Scalea, TM				Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Stansbury, Lynn; Xiao, Yan; Stein, Deborah M.; Scalea, Thomas M.			Heart Rate and Pulse Pressure Variability are Associated With Intractable Intracranial Hypertension After Severe Traumatic Brain Injury	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						TBI; time-frequency analysis; cerebral pressure monitoring	SPECTRAL-ANALYSIS; BLOOD-PRESSURE; NOCICEPTION; MORTALITY; MECHANISM; DEATH	Calculation of integer heart rate variability (HRVi) permits monitoring over extended periods. We asked whether continuous monitoring of HRVi or integer pulse pressure (PP) variability (PPVi) could predict intracranial hypertension, defined as ICP > 20 mm Hg, cerebral hypoperfusion, defined as CPP < 60 mm Hg, mortality or functional outcome after severe traumatic brain injury. Dense integer data collected during continuous intensive care unit monitoring for periods of 1 to 11 days on 25 patients admitted to our Level I trauma center with Glasgow Coma Scale < 9 provided 1,715,000 data points over a mean 106 +/- 62 hours. PP, HRVi, and PPVi increased in response to increasing ICP when CPP > 60 mm Hg (P < 0.001), but HRVi and PPVi decreased when CPP < 60 mm Hg and P < 50 mm Hg, even with ICP < 20 mm Hg (P < 0.001). ICP up to 40 mm Hg still evoked an increase in HRVi and PPVi (P < 0.001), but both were suppressed with CPP < 50 mm Hg and ICP > 40 mm Hg (actual or impending brain death). Mean HRVi and PPVi predicted in-hospital mortality (sensitivity, 67%; specificity, 91% to 100%). Combining HRVi and PPVi as an "autonomic index" (AI) best predicted long-term functional outcome [Area Under the Curve: 0.84 +/- 0.08 for AI < 0.5]. Our data show that HRVi and PPVi can be monitored and calculated automatically and can provide useful prognostic information in patients with severe traumatic brain injury, particularly when combined into a single index.	[Kahraman, Sibel; Dutton, Richard P.; Hu, Peter; Stansbury, Lynn; Xiao, Yan; Stein, Deborah M.; Scalea, Thomas M.] Univ Maryland, Shock Trauma Anesthesia Res Organized Res Ctr, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA		Stansbury, L (corresponding author), Univ Maryland, Shock Trauma Anesthesia Res Organized Res Ctr, R Adams Cowley Shock Trauma Ctr, 220 Warren Ave, Baltimore, MD 21201 USA.	lynn.stansbury@gmail.com	Xiao, Yan/A-7506-2009	Xiao, Yan/0000-0003-2805-0619; Stein, Deborah/0000-0003-3683-3963			Ayres-de-Campos D, 2005, EUR J OBSTET GYN R B, V118, P52, DOI 10.1016/j.ejogrb.2004.04.013; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; BIGGER JT, 1992, CIRCULATION, V85, P164, DOI 10.1161/01.CIR.85.1.164; Biswas AK, 2004, J NEUROSURG ANESTH, V16, P62, DOI 10.1097/00008506-200401000-00011; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Camm AJ, 1996, EUR HEART J, V17, P354; CARTER MC, 1993, BRIT J OBSTET GYNAEC, V100, P21, DOI 10.1111/j.1471-0528.1993.tb10631.x; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; Cushing H, 1902, AM J MED SCI, V124, P375, DOI 10.1097/00000441-190209000-00001; Freitas J, 1996, CLIN AUTON RES, V6, P141, DOI 10.1007/BF02281900; Goldstein B, 1998, CRIT CARE MED, V26, P352, DOI 10.1097/00003246-199802000-00040; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; HON EH, 1963, AM J OBSTET GYNECOL, V87, P814; Jeanne M, 2009, AUTON NEUROSCI-BASIC, V147, P91, DOI 10.1016/j.autneu.2009.01.005; KAHRAMAN S, J TRAUMA IN PRESS; KJEIGER RE, 1987, AM J CARDIOL, V59, P256; Larma JD, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.06.053; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; MALIK M, 1989, EUR HEART J, V10, P1060, DOI 10.1093/oxfordjournals.eurheartj.a059428; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; PAUL RH, 1975, AM J OBSTET GYNECOL, V123, P206, DOI 10.1016/0002-9378(75)90528-1; Rantanen M, 2006, BRIT J ANAESTH, V96, P367, DOI 10.1093/bja/ael005; SCHIFRIN BS, 1972, J AMER MED ASSOC, V222, P196, DOI 10.1001/jama.222.2.196; Schifrin BS, 2004, BEST PRACT RES CL OB, V18, P437, DOI 10.1016/j.bpobgyn.2004.03.001; SCHMIDT EA, 2004, CLIN PHYSIOL FUNCT I, V24, P304; Toweill Daniel L, 2003, Pediatr Crit Care Med, V4, P308, DOI 10.1097/01.PCC.0000074260.93430.6A; Unoki T, 2009, AM J CRIT CARE, V18, P42, DOI 10.4037/ajcc2009509; VALLBONA C, 1965, AM J CARDIOL, V16, P379, DOI 10.1016/0002-9149(65)90729-0; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	34	33	37	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2010	22	4					296	302		10.1097/ANA.0b013e3181e25fc3			7	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	650ER	WOS:000281832500002	20622688				2022-02-06	
J	Klimek, M; Dammers, R				Klimek, Markus; Dammers, Ruben			Antiepileptic drug therapy in the perioperative course of neurosurgical patients	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						antiepileptic drugs; neurosurgery; perioperative; prophylaxis; side-effects	BRAIN-TUMORS; PHENYTOIN; LEVETIRACETAM; EPILEPSY; PROPHYLAXIS	Purpose of review Antiepileptic agents are widely used in the perioperative course of neurosurgical patients - for prophylactic and therapeutic reasons. However, the evidence supporting their use is extremely small and adverse events are common. This review highlights the current controversies. Recent findings Prophylactic use of antiepileptic agents is unfavorable for patients with subarachnoid hemorrhage. In patients with brain tumors, prophylactic use is not recommended. If the drugs are used nevertheless, stopping after the first postoperative week must be strongly recommended. After traumatic brain injury, early prophylactic use might prevent late post-traumatic seizures. The new antiepileptic drug levetiracetam seems to have a better safety profile, which makes it more suitable for prophylactic use. However, in all groups, evidence concerning the choice of drugs and duration of prophylaxis is lacking. Current research is focusing on prevention of epileptogenesis. Therapeutic use of antiepileptic drugs is supported by evidence. These drugs should be continued perioperatively. However, they might induce severe adverse events during adjuvant treatments like radiotherapy or chemotherapy in patients with brain tumors. Summary Despite lacking evidence, prophylactic antiepileptic drug use is common in the perioperative course of neurosurgical patients. More research is needed to deal better with epileptogenesis and to define the right drug for the right patient at the right time.	[Klimek, Markus] Erasmus MC, Univ Med Ctr, Dept Anesthesiol, Vice Head Residency Training Program, NL-3000 CA Rotterdam, Netherlands; [Dammers, Ruben] Erasmus MC, Univ Med Ctr, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands		Klimek, M (corresponding author), Erasmus MC, Univ Med Ctr, Dept Anesthesiol, Vice Head Residency Training Program, Off H-1279,POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.klimek@erasmusmc.nl	Klimek, Markus/I-6523-2013; Dammers, Ruben/AAL-8391-2021; Dammers, Ruben/AAD-9095-2021; Klimek, Markus/N-7047-2019	Dammers, Ruben/0000-0001-7033-0644; Klimek, Markus/0000-0002-0122-9929			Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Chaichana KL, 2009, J NEUROSURG, V111, P282, DOI 10.3171/2009.2.JNS081132; Chang EF, 2008, J NEUROSURG, V108, P227, DOI 10.3171/JNS/2008/108/2/0227; Fountain NB, 2009, EPILEPSY CURR, V9, P71, DOI 10.1111/j.1535-7511.2009.01297.x; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; Heros RC, 2007, J NEUROSURG, V107, P251, DOI 10.3171/JNS-07/08/0251; Jensen FE, 2009, EPILEPSIA S2, V50, pS1; Kofke WA, 2010, CURR OPIN ANESTHESIO, V23, P391, DOI 10.1097/ACO.0b013e328339250b; Lim DA, 2009, J NEURO-ONCOL, V93, P349, DOI 10.1007/s11060-008-9781-4; LOWENSTEIN D, 2009, EPILEPSIA S2, V50, pS4; Milligan TA, 2008, NEUROLOGY, V71, P665, DOI 10.1212/01.wnl.0000324624.52935.46; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Siomin V, 2005, J NEURO-ONCOL, V74, P211, DOI 10.1007/s11060-004-6912-4; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Tremont-Lukats IW, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004424.pub2; van Breemen MSM, 2007, LANCET NEUROL, V6, P421, DOI 10.1016/S1474-4422(07)70103-5	20	33	36	3	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2010	23	5					564	567		10.1097/ACO.0b013e32833e14f2			4	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	646RR	WOS:000281560500005	20689411				2022-02-06	
J	Zhang, Q; Hu, WZ; Meng, B; Tang, TS				Zhang, Qin; Hu, Wenzhi; Meng, Bin; Tang, Tiansi			PPAR gamma agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats	NEUROLOGICAL RESEARCH			English	Article						Spinal cord injury; rosiglitazone; inflammation; apoptosis	ACTIVATED-RECEPTOR-GAMMA; TRANSIENT FOCAL ISCHEMIA; HEAT-SHOCK PROTEINS; INFLAMMATION; EXPRESSION; MODEL; HEAT-SHOCK-PROTEIN-70; PIOGLITAZONE; DYSFUNCTION; PROTECTION	Spinal cord injury (SCI) results in the loss of function below the lesion. Secondary injury following the primary impact includes a number of biochemical and cellular alterations leading to tissue necrosis and cell death. Peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a ligand-activated transcription factor of nuclear hormone receptor superfamily. Thiazolidinedione rosiglitazone is a potent agonist of PPAR gamma which is shown to induce neuroprotection in animal models of focal ischemia and traumatic brain injury. SCI is induced by the application of vascular clips (force of 24 g) to the dura via a four-level T-5-T-8 laminectomy. To gain a better insight into the mechanism of action of the anti-inflammatory effects of rosiglitazone, the following end points of the inflammatory process were evaluated: (1) spinal cord inflammation and tissue injury (histological score); (2) neutrophil infiltration (myeloperoxidase activity); (3) apoptosis (terminal deoxynucleotidyl transferase-mediated UTP end labeling staining and electron microscopy); (4) proinflammatory cytokines TNF-alpha and IL-beta; (5) PPAR gamma, HSP70 and HSP27 expressions. To elucidate whether the protective effects of rosiglitazone were mediated via the estrogen receptors, we investigated the effect of a PPAR gamma antagonist, GW9662, on the protective effects of rosiglitazone. GW9662 significantly antagonized the effect of the rosiglitazone and abolished the protective effect against SCI. Taken together, our results clearly demonstrate that administration of rosiglitazone after SCI reduces the development of inflammation and tissue injury associated with spinal cord trauma.	[Zhang, Qin; Meng, Bin; Tang, Tiansi] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China; [Hu, Wenzhi] Nanjing Med Univ, Affiliated Hosp 2, Nanjing 210000, Peoples R China		Tang, TS (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Shizi St 96, Suzhou 215006, Peoples R China.	tiansitang19762@126.com					Bale TL, 2002, J NEUROSCI, V22, P193, DOI 10.1523/JNEUROSCI.22-01-00193.2002; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Chen Yu, 2007, Inflammation & Allergy Drug Targets, V6, P91; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Dehmer T, 2004, J NEUROCHEM, V88, P494, DOI 10.1046/j.1471-4159.2003.02210.x; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Genovese T, 2008, SHOCK, V30, P142, DOI 10.1097/SHK.0b013e31815dd381; Guay J, 1997, J CELL SCI, V110, P357; Guzman-Lenis MS, 2008, NEUROSCIENCE, V155, P104, DOI 10.1016/j.neuroscience.2008.04.078; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Imura T, 1999, J NEUROSCI, V19, P9768; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Liu XZ, 1997, J NEUROSCI, V17, P5395; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; McTigue DM, 2008, PPAR RES, V2008, DOI 10.1155/2008/517162; McTigue DM, 2000, PROG BRAIN RES, V128, P3; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Robinson MB, 2005, J NEUROSCI, V25, P9735, DOI 10.1523/JNEUROSCI.1912-05.2005; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0; Tolman Keith G, 2003, Clin Liver Dis, V7, P369, DOI 10.1016/S1089-3261(03)00020-5; Toumpoulis IK, 2003, J THORAC CARDIOV SUR, V125, P1030, DOI 10.1067/mtc.2003.174; Tureyen K, 2007, J NEUROCHEM, V101, P41, DOI 10.1111/j.1471-4159.2006.04376.x; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Watson GS, 2005, AM J GERIAT PSYCHIAT, V13, P950, DOI 10.1176/appi.ajgp.13.11.950; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233	37	33	37	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	2010	32	8					852	859		10.1179/016164110X12556180206112			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	647NU	WOS:000281626000012	20350367				2022-02-06	
J	Chen, LJ; Wang, YJ; Tseng, GF				Chen, Li-Jin; Wang, Yueh-Jan; Tseng, Guo-Fang			Compression Alters Kinase and Phosphatase Activity and Tau and MAP2 Phosphorylation Transiently while Inducing the Fast Adaptive Dendritic Remodeling of Underlying Cortical Neurons	JOURNAL OF NEUROTRAUMA			English	Article						in vivo studies; neuroplasticity; traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN-2; ALZHEIMER NEUROFIBRILLARY DEGENERATION; GLYCOGEN-SYNTHASE KINASE-3; CYCLIN-DEPENDENT KINASE-5; COLD-WATER STRESS; CEREBRAL-CORTEX; BRAIN-INJURY; EPIDURAL COMPRESSION; HIPPOCAMPAL-NEURONS; HYPERPHOSPHORYLATED-TAU	In traumatic brain injury (TBI) there is often compression of the cerebral cortex. Using a rat epidural bead implantation model we found that mechanical compression distorted the dendrites of underlying cortical pyramidal neurons, and that the deformed dendrites regained straight morphology in 3 days. This was accompanied by a transient increase in the phosphorylation of microtubule-associated proteins (MAPs) at sites known to destabilize microtubules, including MAP2 from 30 min to 1 h, and tau from 10 min to 12 h following compression. Immunostaining confirmed that phosphorylated MAPs were concentrated at the somata and dendrites of compressed cortical pyramidal neurons. Enzymes regulating MAP phosphorylation were found to be simultaneously altered, including downregulation of protein phosphatase 2A, but not 2B, activity from 10 min to 1 day, and transient excitatory phosphorylation of extracellular signal-regulated protein kinase 1/2 and p38/mitogen-activated protein kinase. The temporal coincidence of these events suggests that alterations of phosphatase and kinase activity underlie MAP2 and tau phosphorylation, thus causing the compressed cortical neurons to remodel their dendrites, including the proximal segments. The rapid onset of these molecular changes demonstrates that compression causes cortical neurons to undergo active changes much early than expected. The large-scale structural changes that result can alter cortical function for an extended period of time.	[Wang, Yueh-Jan; Tseng, Guo-Fang] Tzu Chi Univ, Coll Med, Dept Anat, Hualien 970, Taiwan; [Chen, Li-Jin] Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, Taipei 10764, Taiwan		Tseng, GF (corresponding author), Tzu Chi Univ, Coll Med, Dept Anat, 701,Sect 3,Jhongyang Rd, Hualien 970, Taiwan.	chris@mail.tcu.edu.tw; guofang@mail.tcu.edu.tw			National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC97-2320-B-320-006, NSC97-2320-B-007]; Tzu-Chi University [TCIRP-95003, TCIRP-98006]	This work was supported by grants from the National Science Council of Taiwan to G.-F.T. (NSC97-2320-B-320-006), and Y.-J.W. (NSC97-2320-B-007), and from Tzu-Chi University to G.-F.T. and Y.-J.W. (TCIRP-95003 and TCIRP-98006).	ABE T, 1984, SURG NEUROL, V22, P477, DOI 10.1016/0090-3019(84)90306-9; Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Arendt T, 2003, J NEUROSCI, V23, P6972, DOI 10.1523/JNEUROSCI.23-18-06972.2003; Baas PW, 2005, TRENDS CELL BIOL, V15, P183, DOI 10.1016/j.tcb.2005.02.001; Baas PW, 2005, TRENDS CELL BIOL, V15, P518, DOI 10.1016/j.tcb.2005.08.004; Bennecib M, 2001, FEBS LETT, V490, P15, DOI 10.1016/S0014-5793(01)02127-5; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; Braak E, 1997, ACTA NEUROPATHOL, V93, P323, DOI 10.1007/s004010050622; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CACERES A, 1986, J NEUROSCI, V6, P714; CACERES A, 1984, BRAIN RES, V315, P314; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Castejon O J, 1995, J Neurosurg Sci, V39, P47; Chen JR, 2010, NEUROSCIENCE, V167, P414, DOI 10.1016/j.neuroscience.2010.02.028; Chen JR, 2004, J NEUROTRAUM, V21, P1640, DOI 10.1089/0897715042441729; Chen JR, 2003, J NEUROTRAUM, V20, P767, DOI 10.1089/089771503767869999; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DIEZGUERRA FJ, 1993, NEUROREPORT, V4, P419, DOI 10.1097/00001756-199304000-00020; DIEZGUERRA FJ, 1995, EUR J BIOCHEM, V227, P68, DOI 10.1111/j.1432-1033.1995.tb20360.x; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Feng Q, 2005, NEUROSCI LETT, V388, P13, DOI 10.1016/j.neulet.2005.06.022; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gomez-Ramos A, 2006, J NEUROSCI RES, V83, P264, DOI 10.1002/jnr.20726; Gong CX, 2000, BRAIN RES, V853, P299, DOI 10.1016/S0006-8993(99)02294-5; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; Gotz J, 2001, NEUROREPORT, V12, P2007; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hernandez F, 2007, CELL MOL LIFE SCI, V64, P2219, DOI 10.1007/s00018-007-7220-x; Imahori K, 1997, J BIOCHEM, V121, P179; Iqbal K, 2008, J ALZHEIMERS DIS, V14, P365; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; KHATOON S, 1994, FEBS LETT, V351, P80, DOI 10.1016/0014-5793(94)00829-9; KORNEYEV A, 1995, NEUROSCI LETT, V191, P19, DOI 10.1016/0304-3940(95)11546-3; Kundrotiene J, 2004, J NEUROTRAUM, V21, P83, DOI 10.1089/089771504772695977; Kundrotiene J, 2002, J NEUROTRAUM, V19, P69, DOI 10.1089/089771502753460259; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lewthwaite JC, 2006, J BIOL CHEM, V281, P11011, DOI 10.1074/jbc.M510680200; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lin JL, 2010, J CEREBR BLOOD F MET, V30, P1121, DOI 10.1038/jcbfm.2009.277; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Liu F, 2006, PANMINERVA MED, V48, P97; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Papasozomenos SC, 1996, J NEUROCHEM, V66, P1140; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Qiang L, 2006, J NEUROSCI, V26, P3120, DOI 10.1523/JNEUROSCI.5392-05.2006; Quinlan EM, 1996, NEURON, V16, P357, DOI 10.1016/S0896-6273(00)80053-7; Quinlan EM, 1996, J NEUROSCI, V16, P7627; Rauch C, 2008, CELL BIOCHEM FUNCT, V26, P866, DOI 10.1002/cbf.1518; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Sanchez C, 1996, EUR J BIOCHEM, V241, P765, DOI 10.1111/j.1432-1033.1996.00765.x; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SPACEK J, 1987, ACTA NEUROPATHOL, V73, P77; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; Tashiro K, 1997, NEUROREPORT, V8, P2797, DOI 10.1097/00001756-199708180-00029; Toyota S, 2001, J NEUROTRAUM, V18, P1349, DOI 10.1089/08977150152725641; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wang JZ, 2008, PROG NEUROBIOL, V85, P148, DOI 10.1016/j.pneurobio.2008.03.002; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Yanagisawa M, 1999, FEBS LETT, V461, P329, DOI 10.1016/S0014-5793(99)01480-5; Yang HY, 2006, J NEUROTRAUM, V23, P721, DOI 10.1089/neu.2006.23.721	74	33	34	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1657	1669		10.1089/neu.2010.1308			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500012	20568963				2022-02-06	
J	Wu, HT; Mahmood, A; Lu, DY; Jiang, H; Xiong, Y; Zhou, D; Chopp, M				Wu, Hongtao; Mahmood, Asim; Lu, Dunyue; Jiang, Hao; Xiong, Ye; Zhou, Dong; Chopp, Michael			Attenuation of astrogliosis and modulation of endothelial growth factor receptor in lipid rafts by simvastatin after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						simvastatin; epidermal growth factor receptor; lipid raft; astrocyte; traumatic brain injury	PROSTATE-CANCER CELLS; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; NEURAL INJURY; ACTIVATION; RATS; ATORVASTATIN; NEUROPROTECTION; NEUROGENESIS; MICRODOMAINS	Object. The authors' previous studies have demonstrated that simvastatin treatment promotes neuronal survival and reduces inflammatory cytokine release from astrocytes after traumatic brain injury (TBI) in rats. Since reactive astrocytes produce inflammation mediators, in the current study the authors investigated the effect of simvastatin on astrocyte activation after TBI and its underlying signaling mechanisms. Methods. Saline or simvastatin (1 mg/kg) was orally administered to rats starting at Day 1 after TBI and then daily for 14 days. Rats were killed at 1, 3, 7, and 14 days after treatment. Brain sections and tissues were prepared for immunohistochemical staining and Western blot analysis, respectively. Cultured astrocytes were subjected to oxygen-glucose deprivation (OGD) and followed by immunocytochemical staining with glial fibrillary acidic protein/caveolin-1 and Western blot analysis. Lipid rafts were isolated from the cell lysate and Western blotting was carried out to detect the changes in epidermal growth factor receptor (EGFR) expression and phosphorylation in the lipid rafts. Results. Simvastatin significantly promoted neuronal survival after TBI and attenuated activation of astrocytes. Simvastatin modified the caveolin-1 expression in lipid rafts in astrocyte cell membrane, suppressed the phosphorylation of EGFR in lipid rafts of astrocytes after OGD, and inhibited the OGD-induced interleukin-1 production. Conclusions. These data suggest that simvastatin reduces reactive astrogliosis and rescues neuronal cells after TBI. These beneficial effects of simvastatin may be mediated by inhibiting astrocyte activation after TBI through modifying the caveolin-1 expression in lipid rafts and the subsequent modulation of EGFR phosphorylation in lipid rafts. (DOI: 10.3171/2009.9.JNS09859)	[Jiang, Hao; Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Wu, Hongtao; Mahmood, Asim; Lu, Dunyue; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Wu, Hongtao; Zhou, Dong] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, E&R Bldg 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	Wu, Hongtao/A-8602-2011	Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052280-01A1, PO1NS23345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280, R01NS023345] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant Nos. R01NS052280-01A1 (to Asim Mahmood, M.D., primary investigator) and PO1NS23345 (to Michael Chopp, Ph.D., primary investigator).	Arnbrosini A, 2005, J NEUROSCI METH, V144, P183, DOI 10.1016/j.jbeumeth.2004.11.002; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Freeman MR, 2007, STEROIDS, V72, P210, DOI 10.1016/j.steroids.2006.11.012; Jin KL, 2002, J NEUROSCI, V22, P5365; JUNIER MP, 1993, J NEUROSCI, V13, P703; Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liu B, 2004, GLIA, V46, P153, DOI 10.1002/glia.10358; Liu B, 2007, J NEUROSCI RES, V85, P3523, DOI 10.1002/jnr.21364; Liu B, 2006, J NEUROSCI, V26, P7532, DOI 10.1523/JNEUROSCI.1004-06.2006; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Oh HY, 2007, PROSTATE, V67, P1061, DOI 10.1002/pros.20593; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zhuang LY, 2005, J CLIN INVEST, V115, P959	29	33	34	1	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					591	597		10.3171/2009.9.JNS09859			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100024	19895202	Green Accepted			2022-02-06	
J	Jantzen, KJ				Jantzen, Kelly J.			Functional Magnetic Resonance Imaging of Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blood oxygen level-dependent; concussion; functional magnetic resonance imaging; literature review; mild brain injury; recovery of function; working memory	LONG-TERM POTENTIATION; VERBAL WORKING-MEMORY; HEAD-INJURY; PARAMETRIC MANIPULATION; POSTCONCUSSION SYNDROME; POSTURAL STABILITY; LONGITUDINAL FMRI; MOTOR RECOVERY; AXONAL INJURY; BOLD SIGNAL	Mild traumatic brain injury (MTBI) is a serious health problem that has been difficult to study because of the relative insensitivity of established anatomical imaging techniques for detecting the associated neural damage and dysfunction. Functional magnetic resonance imaging (fMRI) offers potential for understanding the neural and functional basis of MTBI and the relationship to behavioral and somatic symptoms. This article reviews the recent fMRI literature relevant to the study of MTBI. The pathophysiology of MTBI and the neural basis of the blood oxygen level-dependent fMRI response are also considered with particular focus on important issues for using fMRI to investigate MTBI.	Western Washington Univ, Bellingham, WA 98225 USA		Jantzen, KJ (corresponding author), Western Washington Univ, 516 High St, Bellingham, WA 98225 USA.	Kelly.jantzen@wwu.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS48229]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048229] Funding Source: NIH RePORTER	Western Washington University, Bellingham. A portion of this work was supported by a grant from the National Institute of Neurological Disorders and Stroke (NS48229).	Aguirre GK, 1998, NEUROIMAGE, V8, P360, DOI 10.1006/nimg.1998.0369; Arthurs OJ, 2002, TRENDS NEUROSCI, V25, P27, DOI 10.1016/S0166-2236(00)01995-0; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; BANDETTINI PA, 2000, FUNCTIONAL MRI; Barth JT, 1989, MILD HEAD INJURY; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Brookes MJ, 2005, NEUROIMAGE, V26, P302, DOI 10.1016/j.neuroimage.2005.01.050; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chun MM, 2007, CURR OPIN NEUROBIOL, V17, P177, DOI 10.1016/j.conb.2007.03.005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Connor LT, 2004, BRAIN LANG, V91, P82, DOI 10.1016/j.bandl.2004.06.044; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Fockert JW, 2001, SCIENCE, V291, P1803, DOI 10.1126/science.1056496; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Douglas EA, 2006, CURR MED IMAGING, V2, P105, DOI 10.2174/157340506775541712; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Ekstrom A, 2009, J NEUROPHYSIOL, V101, P2668, DOI 10.1152/jn.91252.2008; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Fox MD, 2007, NEURON, V56, P171, DOI 10.1016/j.neuron.2007.08.023; FREEMAN JR, 2005, TXB TRAUMATIC BRAIN; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GENNARELLI TA, 1993, HEAD INJURY, P127; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goense JBM, 2008, CURR BIOL, V18, P631, DOI 10.1016/j.cub.2008.03.054; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huettel S. A., 2004, FUNCTIONAL MAGNETIC; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jantzen KJ, 2006, J HEAD TRAUMA REHAB, V21, P427, DOI 10.1097/00001199-200609000-00046; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kim DS, 2004, NEUROIMAGE, V21, P876, DOI 10.1016/j.neuroimage.2003.10.018; Kim SG, 2000, MED RAD DIA IMG, P195; Krakauer JW, 2007, EXP NEUROL, V204, P491, DOI 10.1016/j.expneurol.2006.12.026; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Mayer A, 2009, J NEUROTRAUM, V26, pA85; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCALLISTER TW, 2005, TXB TRAUMATIC BRAIN; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGonigle DJ, 2000, NEUROIMAGE, V11, P708, DOI 10.1006/nimg.2000.0562; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Moonen CTW, 2000, MED RAD DIA IMG, P161; Murphy K, 2004, NEUROIMAGE, V21, P219, DOI 10.1016/j.neuroimage.2003.09.016; Muthukumaraswamy SD, 2009, HUM BRAIN MAPP, V30, P2000, DOI 10.1002/hbm.20644; Nair DG, 2005, BRAIN RES REV, V50, P229, DOI 10.1016/j.brainresrev.2005.07.001; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Niessing J, 2005, SCIENCE, V309, P948, DOI 10.1126/science.1110948; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; Pearce JMS, 2008, EUR NEUROL, V59, P113, DOI 10.1159/000111872; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1989, MILD HEAD INJURY; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Singh KD, 2002, NEUROIMAGE, V16, P103, DOI 10.1006/nimg.2001.1050; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Smith SM, 2005, HUM BRAIN MAPP, V24, P248, DOI 10.1002/hbm.20080; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P434, DOI 10.1016/j.neuropsychologia.2003.09.001; Tegeler C, 1999, HUM BRAIN MAPP, V7, P267, DOI 10.1002/(SICI)1097-0193(1999)7:4<267::AID-HBM5>3.0.CO;2-3; Thomason ME, 2005, NEUROIMAGE, V25, P824, DOI 10.1016/j.neuroimage.2004.12.026; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tomasi D, 2006, HUM BRAIN MAPP, V27, P694, DOI 10.1002/hbm.20211; Tombari D, 2004, NEUROIMAGE, V23, P827, DOI 10.1016/j.neuroimage.2004.07.058; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Ward NS, 2003, BRAIN, V126, P2476, DOI 10.1093/brain/awg245; Wei XC, 2004, NEUROIMAGE, V21, P1000, DOI 10.1016/j.neuroimage.2003.10.039; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Winterer G, 2007, HUM BRAIN MAPP, V28, P805, DOI 10.1002/hbm.20322; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	118	33	33	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					256	266		10.1097/HTR.0b013e3181e5477c			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900004	20611044				2022-02-06	
J	Goodrich-Hunsaker, NJ; Hopkins, RO				Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.			Spatial Memory Deficits in a Virtual Radial Arm Maze in Amnesic Participants With Hippocampal Damage	BEHAVIORAL NEUROSCIENCE			English	Article						amnesia; hippocampus; radial arm maze; spatial memory	TRAUMATIC BRAIN INJURY; SHORT-TERM-MEMORY; HUMAN NAVIGATION; CAUDATE-NUCLEUS; WATER-MAZE; PERFORMANCE; FMRI; ROUTE; ACTIVATION; HUMANS	Extensive research with laboratory animals indicates that the hippocampus is crucial for the formation and use of spatial memory. Hippocampal lesions in rodents impair spatial memory on radial arm maze tasks. It is unknown whether amnesic patients with hippocampal damage would exhibit similar impairments on a virtual version of a radial arm maze. To evaluate the importance of the hippocampus in spatial learning and memory, we tested amnesic participants with hippocampal damage in a virtual radial arm maze environment. The virtual radial arm maze required participants to learn and remember 4 rewarded arms of 8 total arms. Spatial learning and memory were assessed using the participants' ability to use salient distal cues in the virtual room to remember the 4 rewarded arms. Amnesic participants' latencies were longer and distance traveled was greater to the rewarded arms compared with nonamnesic participants. Amnesic participants made more errors than nonamnesic participants by either entering nonrewarded arms or by revisiting previously entered arms. These data are analogous to previous animal research. Overall, the human hippocampus is necessary for spatial memory and navigation in a virtual radial arm maze task.	[Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Dept Physiol & Dev Biol, Sacramento, CA USA; [Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Ctr Neurosci, Sacramento, CA USA; [Goodrich-Hunsaker, Naomi J.] Univ Calif Davis, Med Ctr, NeuroTherapeut Res Inst, Sacramento, CA 95817 USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Murray, UT USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Murray, UT USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Med, Div Pulm & Crit Care, Murray, UT USA		Goodrich-Hunsaker, NJ (corresponding author), MIND Inst, 2825 50th St,Room 1362, Sacramento, CA 95817 USA.	naomihunsaker@me.com					Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Astur R, 2005, APPL PSYCHOPHYS BIOF, V30, P307, DOI 10.1007/s10484-005-6385-z; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Buffalo EA, 1998, BEHAV NEUROSCI, V112, P3, DOI 10.1037/0735-7044.112.1.3; CAVE CB, 1992, HIPPOCAMPUS, V2, P151, DOI 10.1002/hipo.450020207; Cornwell BR, 2008, J NEUROSCI, V28, P5983, DOI 10.1523/JNEUROSCI.5001-07.2008; Etchamendy N, 2007, HIPPOCAMPUS, V17, P595, DOI 10.1002/hipo.20303; Goodrich-Hunsaker NJ, 2009, CHEM SENSES, V34, P513, DOI 10.1093/chemse/bjp026; GOODRICHHUNSAKE.NJ, 2009, HIPPOCAMPUS, DOI DOI 10.1002/HIPO.20651; Gron G, 2000, NAT NEUROSCI, V3, P404, DOI 10.1038/73980; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hartley T, 2003, NEURON, V37, P877, DOI 10.1016/S0896-6273(03)00095-3; Holdstock JS, 1995, NEUROPSYCHOLOGIA, V33, P1583, DOI 10.1016/0028-3932(95)00145-X; Hopkins RO, 2004, NEUROPSYCHOLOGIA, V42, P524, DOI 10.1016/j.neuropsychologia.2003.09.005; Iaria G, 2003, J NEUROSCI, V23, P5945; Jarrard L E, 1991, Hippocampus, V1, P236, DOI 10.1002/hipo.450010304; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Jonides J, 2008, ANNU REV PSYCHOL, V59, P193, DOI 10.1146/annurev.psych.59.103006.093615; Kandel E. R., 1995, ESSENTIALS NEURAL SC; Kesner RP, 2006, BIOL PSYCHOL, V73, P3, DOI 10.1016/j.biopsycho.2006.01.004; Kesner RP, 2010, NEUROPSYCHOLOGIA, V48, P2290, DOI 10.1016/j.neuropsychologia.2009.10.027; Kumaran D, 2005, J NEUROSCI, V25, P7254, DOI 10.1523/JNEUROSCI.1103-05.2005; Lauritzen M, 2001, J CEREBR BLOOD F MET, V21, P1367, DOI 10.1097/00004647-200112000-00001; Lee I, 2003, J NEUROSCI, V23, P1517, DOI 10.1523/JNEUROSCI.23-04-01517.2003; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1997, J NEUROSCI, V17, P7103; Mellet E, 2000, NEUROIMAGE, V12, P588, DOI 10.1006/nimg.2000.0648; Meyers JE., 1995, REY COMPLEX FIGURE T; MILNER B, 1966, AMNESIA, P109; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; OKAICHI H, 1990, PSYCHOBIOLOGY, V18, P416; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Parslow DM, 2004, NEUROPSYCHOLOGY, V18, P450, DOI 10.1037/0894-4105.18.3.450; Rosenbaum RS, 2004, HIPPOCAMPUS, V14, P826, DOI 10.1002/hipo.10218; ROSS ED, 1980, ARCH NEUROL-CHICAGO, V37, P193, DOI 10.1001/archneur.1980.00500530031001; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shrager Y, 2007, P NATL ACAD SCI USA, V104, P2961, DOI 10.1073/pnas.0611233104; Spiers HJ, 2007, NEUROSCIENCE, V149, P7, DOI 10.1016/j.neuroscience.2007.06.056; Spiers HJ, 2006, NEUROPSYCHOLOGIA, V44, P1674, DOI 10.1016/j.neuropsychologia.2006.03.028; Squire LR, 1997, PHILOS T R SOC B, V352, P1663, DOI 10.1098/rstb.1997.0148; Voermans NC, 2004, NEURON, V43, P427, DOI 10.1016/j.neuron.2004.07.009; Wais PE, 2006, NEURON, V49, P459, DOI 10.1016/j.neuron.2005.12.020; WALKER JA, 1979, PHYSIOL BEHAV, V23, P11, DOI 10.1016/0031-9384(79)90114-8; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 1997, WECHSLER MEMORY SCAL	52	33	33	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7044			BEHAV NEUROSCI	Behav. Neurosci.	JUN	2010	124	3					405	413		10.1037/a0019193			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	606YV	WOS:000278466000012	20528085				2022-02-06	
J	Mellergard, P; Sjogren, F; Hillman, J				Mellergard, Pekka; Sjogren, Florence; Hillman, Jan			Release of VEGF and FGF in the extracellular space following severe subarachnoidal haemorrhage or traumatic head injury in humans	BRITISH JOURNAL OF NEUROSURGERY			English	Article						Intensive care; microdialysis; monitoring; VEGF; FGF2; subarachnoidal hemorrhage; traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; NEUROSURGICAL INTENSIVE-CARE; BRAIN-INJURY; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; INTRACEREBRAL MICRODIALYSIS; CYTOKINE EXPRESSION; INFLAMMATION; RECOVERY; ANGIOGENESIS	Microdialysate fluid from 145 severely injured NSICU-patients, 88 with subarachnoidal haemorrage (SAH), and 57 with traumatic brain injury (TBI), was collected by microdialysis during the first 7 days following impact, and levels of the neurotrophins fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor (VEGF) were analysed. The study illustrates both similarities and differences in the reaction patterns of the 2 inflammatory proteins. The highest concentrations of both FGF2 and VEGF were measured on Day 2 (mean (+/- SE) values being 47.1 +/- 15.33 and 116.9 +/- 41.85 pg/ml, respectively, in the pooled patient material). The VEGF concentration was significantly higher in TBI-patients, while the FGF2 showed a tendency to be higher in SAH-patients. This is the first report presenting in some detail the human cerebral response of FGF2 and VEGF following SAH and TBI. Apart from increasing the understanding of the post-impact inflammatory response of the human brain, the study identifies potential threshold values for these chemokines that may serve as monitoring indicators in the NSICU.	[Mellergard, Pekka; Hillman, Jan] Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; [Sjogren, Florence] Linkoping Univ Hosp, Dept Dermatol, S-58185 Linkoping, Sweden		Mellergard, P (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	pekka.mellergard@lio.se					Alzheimer C, 2002, ADV EXP MED BIOL, V513, P335; Ao XP, 2006, METHODS, V38, P331, DOI 10.1016/j.ymeth.2005.11.012; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Croll SD, 2004, ADV EXP MED BIOL, V548, P57; Fulwyler M J, 1990, Methods Cell Biol, V33, P613; GONZALEZ AM, 1995, BRAIN RES, V701, P201, DOI 10.1016/0006-8993(95)01002-X; Gora-Kupilas K, 2005, FOLIA NEUROPATHOL, V43, P31; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Grothe C, 2001, ANAT EMBRYOL, V204, P171, DOI 10.1007/s004290100205; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Johansson A, 2003, NEUROREPORT, V14, P1867, DOI 10.1097/00001756-200310060-00022; KEMENY DM, 1992, J IMMUNOL METHODS, V150, P57, DOI 10.1016/0022-1759(92)90065-2; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Kusaka G, 2004, J CEREBR BLOOD F MET, V24, P916, DOI 10.1097/01.WCB.0000125886.48838.7E; Lafuente JV, 2006, J NEURAL TRANSM, V113, P487, DOI 10.1007/s00702-005-0407-0; Malek AM, 1997, PEDIATR NEUROSURG, V27, P182, DOI 10.1159/000121249; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Minami M, 2006, J PHARMACOL SCI, V100, P461, DOI 10.1254/jphs.CRJ06005X; Monfils MH, 2005, NEUROSCIENCE, V134, P1, DOI 10.1016/j.neuroscience.2005.04.006; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ornitz DM, 2001, GENOME BIOL, V2; Peles E, 2004, NEUROSURGERY, V55, P562, DOI 10.1227/01.NEU.0000134383.27713.9A; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Skold MK, 2008, CURR NEUROVASC RES, V5, P246, DOI 10.2174/156720208786413451; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sturnegk P, 2007, BRIT J NEUROSURG, V21, P332, DOI 10.1080/02688690701411574; Suzuki R, 2003, ACTA NEUROCHIR SUPPL, V86, P277; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Weickert CS, 2005, NEUROSCIENCE, V131, P219, DOI 10.1016/j.neuroscience.2004.09.070; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	41	33	33	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2010	24	3					261	267		10.3109/02688690903521605			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	625OR	WOS:000279905200007	20465454				2022-02-06	
J	Anderson, V; Brown, S; Newitt, H				Anderson, Vicki; Brown, Sandra; Newitt, Heidi			What Contributes to Quality of Life in Adult Survivors of Childhood Traumatic Brain Injury?	JOURNAL OF NEUROTRAUMA			English	Article						child; long-term outcome; quality of life; traumatic brain injury	OUTCOME 30 MONTHS; FUNCTIONAL RECOVERY; HEAD-INJURY; SHORT-TERM; FOLLOW-UP; PREDICTORS; SEVERITY; CHILDREN; TBI	Adult outcome from childhood brain injury is largely unknown, and health professionals have minimal evidence available to inform families about their child's long-term prognosis. This study aimed to investigate long-term outcomes in this group, focusing on quality of life (QOL) and the injury, developmental, and environmental factors that influence this domain, using a retrospective and cross-sectional design. The sample was ascertained via medical record audit at the Royal Children's Hospital, Melbourne, Australia, and included 130 adult survivors of child traumatic brain injury (TBI) (84 men). Participants were 18-42 years at evaluation (mean=23.2, SD=3.3) and completed questionnaires regarding QOL and educational, employment, and psychological status. Analysis of variance, chi-square, and regression were employed to assess group differences and predictors of outcome. While most adult survivors of childhood TBI rated their QOL as intact, 17% of the sample reported poor QOL. Poor QOL was more likely with low levels of perceived independence, severe TBI, younger age at injury, failure to complete high school, and psychological problems. In conclusion, QOL in adult survivors of childhood TBI is better than expected and closely associated with both injury and noninjury factors, most consistently with the individual's perception of their level of independence.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Anderson, Vicki; Brown, Sandra] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Newitt, Heidi] Univ Melbourne, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au					Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; *AUSTR BUR STAT, 2006, DIS LONG TERM HLTH C; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Daniel A., 1983, POWER PRIVILEGE PRES; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Nybo T, 1999, BRAIN INJURY, V13, P759; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; VIGNOLO G, 1980, ITAL J NEUROL, V2, P65; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	28	33	33	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					863	870		10.1089/neu.2009.1169			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400008	20144003				2022-02-06	
J	Figaji, AA; Zwane, E; Kogels, M; Fieggen, AG; Argent, AC; Le Roux, PD; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Kogels, M.; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Peter, Jonathan C.			The effect of blood transfusion on brain oxygenation in children with severe traumatic brain injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						blood transfusion; brain tissue oxygen tension; children; traumatic brain injury; head injury	CEREBRAL OXYGENATION; CRITICALLY-ILL; TISSUE OXYGENATION; CELL TRANSFUSION; ANEMIA; METABOLISM; MECHANISMS; DIFFUSION; DELIVERY; TENSION	Objective: The indications for blood transfusion in traumatic brain injury are controversial. In particular, little is known about the effect of blood transfusion in childhood traumatic brain injury. This study aimed to examine the influence of blood transfusion on brain tissue oxygen tension in children with severe traumatic brain injury. Design: A retrospective analysis of a prospective observational database of children with severe traumatic brain injury who received brain tissue oxygen tension monitoring and a blood transfusion. Setting: University-affiliated pediatric hospital. Patients: Children with severe traumatic brain injury and blood transfusion. Interventions: None. Measurments and Main Results: Brain tissue oxygen tension was measured in normal-appearing white matter with a commercially available polarographic Clarke-type electrode. Brain tissue oxygen tension values after blood transfusion were compared with pre-transfusion values in hemodynamically stable patients. Limited interventions were allowed during the studied period. Brain tissue oxygen tension values were examined for early (1-4 hrs) and late (24 hrs) changes after blood transfusion, controlling for multiple clinical and physiologic variables with regression techniques. Further comparison was made with matched non-transfused controls to examine the influence of time after injury. Nineteen blood transfusions in 17 patients were evaluated. Brain tissue oxygen tension increased significantly in the early period after blood transfusion (p = .0018; 79% increased, 21% decreased) in comparison with baseline values and matched controls, but the overall changes were small and, in part, influenced by accompanying cerebral perfusion pressure changes. Also, this effect was limited to the early period after blood transfusion and was not significant after 24 hrs. In general, the brain tissue oxygen tension increase was larger in patients with higher baseline brain tissue oxygen tension and lower initial hemoglobin; however, no factors associated with the magnitude of the brain tissue oxygen tension change were significant in multivariate analysis. Increased age of blood did not appear to impair brain tissue oxygen tension changes, but most blood transfusion were < 14 days old. Conclusions: Brain tissue oxygen tension increased transiently in 79% of blood transfusion in pediatric traumatic brain injury patients, and decreased transiently in 21%. Brain tissue oxygen tension returned to baseline within 24 hrs. Reliable predictors of this brain tissue oxygen tension response to blood transfusion, however, remain elusive. (Pediatr Crit Care Med 2010; 11: 325-331)	[Figaji, Anthony A.; Kogels, M.; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa; [Argent, Andrew C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Pediat Crit Care, ZA-7925 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit Biostat, ZA-7925 Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Figaji, AA (corresponding author), Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Argent, Andrew/J-1605-2019; Fieggen, Anthony Graham/AAT-6510-2021	Argent, Andrew/0000-0001-9333-2036; Fieggen, Anthony Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490	Integra Foundation	Dr. Figaji and Dr. Le Roux have received a grant from the Integra Foundation for the study of cerebral perfusion pressure thresholds in children but no funds were used for the purposes of this study. The remaining authors have not disclosed any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Armano R, 2005, CRIT CARE MED, V33, P2637, DOI 10.1097/01.CCM.0000185645.84802.73; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; Desmet L, 2004, CRIT CARE CLIN, V20, P299, DOI 10.1016/S0749-0704(03)00113-1; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; Hare GMT, 2008, ANESTH ANALG, V107, P1356, DOI 10.1213/ane.0b013e318184cfe9; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Netzer G, 2008, CRIT CARE MED, V36, P1383, DOI 10.1097/CCM.0b013e31816a10a3; Raat NJH, 2007, VOX SANG, V93, P12, DOI 10.1111/j.1423-0410.2007.00909.x; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vincent JL, 2006, CRIT CARE MED, V34, pS96, DOI 10.1097/01.CCM.0000214314.57109.CD; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	30	33	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2010	11	3					325	331		10.1097/PCC.0b013e3181b80a8e			7	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	593WO	WOS:000277493200001	19794323				2022-02-06	
J	Lu, J; Marmarou, A; Lapane, K; Turf, E; Wilson, L				Lu, Juan; Marmarou, Anthony; Lapane, Kate; Turf, Elizabeth; Wilson, Lindsay		IMPACT Grp Ctr; Amer Brain Injury Consortium Study	A Method for Reducing Misclassification in the Extended Glasgow Outcome Score	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; extended Glasgow Outcome Scale; inter-rater variation; misclassification; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CLINICAL-TRIALS; AGREEMENT; SCALE; MULTICENTER; EXPERIENCE; DISABILITY; EFFICACY; KAPPA	The eight-point extended Glasgow Outcome Scale (GOSE) is commonly used as the primary outcome measure in traumatic brain injury (TBI) clinical trials. The outcome is conventionally collected through a structured interview with the patient alone or together with a caretaker. Despite the fact that using the structured interview questionnaires helps reach agreement in GOSE assessment between raters, significant variation remains among different raters. We introduce an alternate GOSE rating system as an aid in determining GOSE scores, with the objective of reducing inter-rater variation in the primary outcome assessment in TBI trials. Forty-five trauma centers were randomly assigned to three groups to assess GOSE scores on sample cases, using the alternative GOSE rating system coupled with central quality control (Group 1), the alternative system alone (Group 2), or conventional structured interviews (Group 3). The inter-rater variation between an expert and untrained raters was assessed for each group and reported through raw agreement and with weighted kappa (kappa) statistics. Groups 2 and 3 without central review yielded inter-rater agreements of 83% (weighted kappa=0.81; 95% CI 0.69, 0.92) and 83% (weighted kappa=0.76, 95% CI 0.63, 0.89), respectively, in GOS scores. In GOSE, the groups had an agreement of 76% (weighted kappa=0.79; 95% CI 0.69, 0.89), and 63% (weighted kappa=0.70; 95% CI 0.60, 0.81), respectively. The group using the alternative rating system coupled with central monitoring yielded the highest inter-rater agreement among the three groups in rating GOS (97%; weighted kappa=0.95; 95% CI 0.89, 1.00), and GOSE (97%; weighted kappa=0.97; 95% CI 0.91, 1.00). The alternate system is an improved GOSE rating method that reduces inter-rater variations and provides for the first time, source documentation and structured narratives that allow a thorough central review of information. The data suggest that a collective effort can be made to minimize inter-rater variation.	[Lu, Juan; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Lapane, Kate; Turf, Elizabeth] Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth, Richmond, VA 23298 USA; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland		Lu, J (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980508, Richmond, VA 23298 USA.	jlu1@vcu.edu	Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Lu, Juan/0000-0002-5389-7603	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 42691]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	Support for this work was provided by National Institutes of Health grant NS 42691.	BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marmarou A., 2001, HEAD TRAUMA BASIC PR, P15; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	19	33	33	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					843	852		10.1089/neu.2010.1293			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400006	20334503	Green Submitted, Green Published			2022-02-06	
J	Mossberg, KA; Amonette, WE; Masel, BE				Mossberg, Kurt A.; Amonette, William E.; Masel, Brent E.			Endurance Training and Cardiorespiratory Conditioning After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						disability; fitness; head injury; oxygen consumption; rehabilitation	PHYSICAL-ACTIVITY; AEROBIC EXERCISE; HEAD-INJURY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; AMERICAN-COLLEGE; CHRONIC STROKE; PUBLIC-HEALTH; OLDER-ADULTS; FITNESS	Objective: To examine the importance of cardiorespiratory conditioning after traumatic brain injury (TBI) and provide recommendations for patients recovering from TBI. Method: Review of literature assessing the effectiveness of endurance training programs. Main outcomes and results: A sedentary lifestyle and lack of endurance are common characteristics of individuals with TBI who have a reduction in peak aerobic capacity of 25% to 30% compared with healthy sedentary persons. Increased physical activity and exercise training improves cardiorespiratory fitness in many populations with physical and cognitive impairments. Therefore, increasing the endurance and cardiorespiratory fitness of persons with TBI would seem to have important health implications. However, review of the TBI literature reveals that there have been few well-designed, well-controlled studies of physiologic and psychological adaptations of fitness training. Also lacking are long-term follow-up studies of persons with TBI. Conclusions: Assessing endurance capacity and cardiorespiratory fitness early in the TBI rehabilitation process merits consideration as a standard of care by professional rehabilitation societies. Also, providing effective, safe, and accessible training modalities would seem to be an important consideration for persons with TBI, given the mobility impairments many possess. Long-term follow-up studies are needed to assess the effectiveness of cardiorespiratory training programs on overall morbidity and mortality.	[Mossberg, Kurt A.; Amonette, William E.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA		Mossberg, KA (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossberg@utmb.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD046570, T32 HD007539]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046570, T32HD007539] Funding Source: NIH RePORTER	This work was partially supported by the National Institutes of Health R01 HD046570 to Dr Mossberg and T32 HD007539 to Mr Amonette. The authors thank Paula Skinkis for editorial assistance.	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Acosta AMD, 2001, J PHYSIOL BIOCHEM, V57, P313, DOI 10.1007/BF03179825; Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Bell K, 2007, BRAIN INJURY MED, P605; Bhambhani Y, 2005, ARCH PHYS MED REHAB, V86, P268, DOI 10.1016/j.apmr.2004.04.022; Bhambhani Y, 2003, ARCH PHYS MED REHAB, V84, P1629, DOI 10.1053/S0003-9993(03)00343-5; Booth F, 2000, Exerc Sport Sci Rev, V28, P145; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bussmann JBJ, 1998, CLIN REHABIL, V12, P455, DOI 10.1191/026921598674267844; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Chakravarthy MV, 2003, EXERCISE; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; Colditz GA, 1999, MED SCI SPORT EXER, V31, pS663, DOI 10.1097/00005768-199911001-00026; COOPER KH, 1968, JAMA-J AM MED ASSOC, V203, P135; Cooper RA, 1999, J REHABIL RES DEV, V36, P142; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; COWELL LL, 1986, MED SCI SPORT EXER, V18, P501; Crouter SE, 2006, J APPL PHYSIOL, V100, P1324, DOI 10.1152/japplphysiol.00818.2005; CURTIS KA, 1986, ARCH PHYS MED REHAB, V67, P862; de Vries WR, 2000, PSYCHOSOM MED, V62, P866, DOI 10.1097/00006842-200011000-00017; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; Gonzalez-Alonso J, 2004, J PHYSIOL-LONDON, V557, P331, DOI 10.1113/jphysiol.2004.060574; Goodwin RD, 2003, PREV MED, V36, P698, DOI 10.1016/S0091-7435(03)00042-2; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gordon WA, 2008, J HEAD TRAUMA REHAB, V23, P2, DOI 10.1097/01.HTR.0000308715.03462.dd; Grealy M A, 2000, Pediatr Rehabil, V4, P41; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greenleaf J E, 1982, Exerc Sport Sci Rev, V10, P84; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Harrison TR, 1944, J AMER MED ASSOC, V125, P1075, DOI 10.1001/jama.1944.02850340001001; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; HASKELL WL, 2007, CIRCULATION, V116, P1081, DOI DOI 10.1161/CIRCULATIONAHA.107.185649; Hassmen P, 2000, PREV MED, V30, P17, DOI 10.1006/pmed.1999.0597; Heath G W, 1997, Exerc Sport Sci Rev, V25, P195; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31, DOI 10.1152/jappl.1969.26.1.31; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Institute of Medicine, 2009, GULF WAR HLTH LONG T, V7; Ivey FM, 2008, J CARDIOPULM REHABIL, V28, P2, DOI 10.1097/01.HCR.0000311501.57022.a8; Jacobs PL, 2004, SPORTS MED, V34, P727, DOI 10.2165/00007256-200434110-00003; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; Kiraly MA, 2005, INT J PSYCHIAT MED, V35, P75, DOI 10.2190/HX7L-4B40-PQNY-2A4P; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Macko RF, 2005, STROKE, V36, P2206, DOI 10.1161/01.STR.0000181076.91805.89; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; MAZZEO RS, 1991, MED SCI SPORT EXER, V23, P839, DOI 10.1249/00005768-199107000-00012; McArdle WD., 2001, EXERCISE PHYSL ENERG; McTiernan A, 2004, CANCER INVEST, V22, P68, DOI 10.1081/CNV-120027581; *MERR WEBST, FAT; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Mossberg KA, 2008, PHYS THER, V88, P77, DOI 10.2522/ptj.20070022; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Mostert S, 2002, MULT SCLER J, V8, P161, DOI 10.1191/1352458502ms779oa; NOREAU L, 1992, PARAPLEGIA, V30, P563, DOI 10.1038/sc.1992.116; NORTON KI, 1995, EUR J APPL PHYSIOL O, V70, P115, DOI 10.1007/BF00361538; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Petajan JH, 1996, ANN NEUROL, V39, P432, DOI 10.1002/ana.410390405; PITETTI KH, 1993, SPORTS MED, V16, P23, DOI 10.2165/00007256-199316010-00004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; SANTIAGO MC, 1993, ARCH PHYS MED REHAB, V74, P1192; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SEGAL SS, 2006, ACSMS ADV EXERCISE P, P343; SHAPIRO CM, 1984, EUR J APPL PHYSIOL O, V53, P1, DOI 10.1007/BF00964680; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Stuart M, 2008, J REHABIL RES DEV, V45, P329, DOI 10.1682/JRRD.2007.02.0027; SULLIVAN K, 2007, BRAIN INJURY MED, P929; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Thompson W R, 2010, ACSMS GUIDELINES EXE; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; WINDER WW, 1979, J APPL PHYSIOL, V46, P766, DOI 10.1152/jappl.1979.46.4.766; Winsley RJ, 2005, INT J SPORTS MED, V26, P768, DOI 10.1055/s-2004-830560; Yamada K, 2003, J PHARMACOL SCI, V91, P267; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	95	33	33	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2010	25	3					173	183		10.1097/HTR.0b013e3181dc98ff			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	606KG	WOS:000278423300004	20473091	Green Accepted			2022-02-06	
J	Weightman, MM; Bolgla, R; McCulloch, KL; Peterson, MD				Weightman, Margaret M.; Bolgla, Robyn; McCulloch, Karen L.; Peterson, Michelle D.			Physical Therapy Recommendations for Service Members With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; military personnel; physical therapy; practice guidelines	HIGH-LEVEL MOBILITY; HEAD-INJURY; INTERRATER RELIABILITY; CONCURRENT VALIDITY; RETEST RELIABILITY; BALANCE DISORDERS; ASSESSMENT-TOOL; CONCUSSION; MANAGEMENT; EXERCISE	Mild traumatic brain injuries (MTBIs) are of increasing concern in both the military and civilian populations as the potential long-term effects and costs of such injuries are being further recognized. Injuries from conflicts in Afghanistan and Iraq have increased public awareness and concern for TBI. The Proponency Office for Rehabilitation and Reintegration, Office of the Surgeon General, US Army tasked a team of physical and occupational therapists to assemble evidence-informed guidelines for assessment and intervention specific to MTBI. Given the paucity of specific guidelines for physical therapy related to MTBI, we focused on literature that dealt with the specific problem area or complaint of the Service member following MTBI. Recommendations, characterized as practice standards or practice options based on strength of evidence, are provided relative to patient/client education, activity intolerance, vestibular dysfunction, high-level balance dysfunction, posttraumatic headache, temporomandibular disorder, attention and dual-task performance deficits, and participation in exercise. While highlighting the need for additional research, this work can be considered a starting point and impetus for the development of evidence-based practice in physical therapy for our deserving Service members.	[Weightman, Margaret M.] Abbott NW Hosp, Sister Kenny Res Ctr, Minneapolis, MN 55407 USA; [Weightman, Margaret M.] Proponency Off Rehabil & Reintegrat, Falls Church, VA USA; Dept Vet Affairs Miami & Broward Cty OPC, Sunrise, FL USA; [Bolgla, Robyn] USAH Army Prof Management Command, Forest Pk, GA USA; [McCulloch, Karen L.] Univ N Carolina, Div Phys Therapy, Chapel Hill, NC 27515 USA; [Peterson, Michelle D.] Minneapolis VA Med Ctr, Polytrauma Rehabil Ctr, Minneapolis, MN USA		Weightman, MM (corresponding author), Abbott NW Hosp, Sister Kenny Res Ctr, 800 E 28th St & Chicago, Minneapolis, MN 55407 USA.	margaret.weightman@allina.com			US Army Center for Health Promotion and Preventative Medicine (USACHPPM)	This project was supported in part by Margaret M. Weightman's appointment to the Internship/Research Participation Program for the US Army Center for Health Promotion and Preventative Medicine (USACHPPM) administered by the Oak Ridge Institute for Science and Education through an agreement with the US Department of Energy and the USACHPPM.	Bell KR, 1999, J HEAD TRAUMA REHAB, V14, P34, DOI 10.1097/00001199-199902000-00006; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Biondi DM, 2005, HEADACHE, V45, P738, DOI 10.1111/j.1526-4610.2005.05141.x; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; *DEF VET BRAIN INJ, 2006, DVBIC WORK GROUP AC; *DEF VET BRAIN INJ, 2008, CLIN GUID EV MAN CON; Dehail P, 2007, J REHABIL MED, V39, P531, DOI 10.2340/16501977-0096; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dworkin SF, 2002, J OROFAC PAIN, V16, P259; Evans JJ, 2009, J INT NEUROPSYCH SOC, V15, P112, DOI 10.1017/S1355617708090152; Goldberg Michael B., 1996, Journal of Orofacial Pain, V10, P126; Gordon CR, 2004, ARCH NEUROL-CHICAGO, V61, P1590, DOI 10.1001/archneur.61.10.1590; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gottshall Kim R, 2005, Int Tinnitus J, V11, P81; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Haskell WL, 2007, CIRCULATION, V116, P1081, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; HERDMAN SJ, 2007, VESTIBULAR REHABILIT, V3; Hillier SL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub2; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horak FB, 2009, PHYS THER, V89, P484, DOI 10.2522/ptj.20080071; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; INVERSON GL, 2007, BRAIN INJURY MED PRI, V1, P373; IVERSON GL, 2007, BRAIN INJURY MED PRI, P338; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; JACOBSON GP, 1995, HEADACHE, V35, P534, DOI 10.1111/j.1526-4610.1995.hed3509534.x; JACOBSON GP, 1994, NEUROLOGY, V44, P837, DOI 10.1212/WNL.44.5.837; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; MacDermid JC, 2009, J ORTHOP SPORT PHYS, V39, P400, DOI 10.2519/jospt.2009.2930; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCCULLOCH K, 2007, J NEUROL PHYS THER, V31, P104; McCulloch KL, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932010-00002; McNeely ML, 2006, PHYS THER, V86, P710, DOI 10.1093/ptj/86.5.710; Medlicott MS, 2006, PHYS THER, V86, P955, DOI 10.1093/ptj/86.7.955; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Ohrbach R, 2008, J OROFAC PAIN, V22, P219; Ohrbach R, 2008, COMMUNITY DENT ORAL, V36, P228, DOI 10.1111/j.1600-0528.2007.00397.x; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 2008, CURR PAIN HEADACHE R, V12, P67, DOI 10.1007/s11916-008-0013-6; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pehling J, 2002, J OROFAC PAIN, V16, P296; Pho C, 2004, J ORTHOP SPORT PHYS, V34, P521; Pho C, 2004, J ORTHOP SPORT PHYS, V34, P511; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Radomski MV, 2009, AM J OCCUP THER, V63, P646, DOI 10.5014/ajot.63.5.646; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scrivani SJ, 2008, NEW ENGL J MED, V359, P2693, DOI 10.1056/NEJMra0802472; SHEPARD NT, 2007, BRAIN INJURY MED PRI, V1, P491; Silsupadol P, 2006, PHYS THER, V86, P269, DOI 10.1093/ptj/86.2.269; Springer Barbara A, 2007, J Geriatr Phys Ther, V30, P8; Stratford P., 1995, PHYSIOTHER CAN, V47, P258, DOI DOI 10.3138/PTC.47.4.258; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *TRAUM BRAIN INJ T, 2007, REP ARM SURG GEN TRA; Truelove E, 2006, J AM DENT ASSOC, V137, P1099, DOI 10.14219/jada.archive.2006.0348; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whitney SL, 2005, PHYS THER, V85, P1034, DOI 10.1093/ptj/85.10.1034; Whitney SL, 2005, OTOL NEUROTOL, V26, P1027, DOI 10.1097/01.mao.0000185066.04834.4e; Whitney SL, 2000, LARYNGOSCOPE, V110, P1528, DOI 10.1097/00005537-200009000-00022; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Williams GP, 2006, PHYS THER, V86, P395, DOI 10.1093/ptj/86.3.395; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Wrisley DM, 2002, OTOL NEUROTOL, V23, P483, DOI 10.1097/00129492-200207000-00016	94	33	33	0	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2010	25	3					206	218		10.1097/HTR.0b013e3181dc82d3			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	606KG	WOS:000278423300007	20473094	Green Submitted			2022-02-06	
J	Israelsson, C; Bengtsson, H; Lobell, A; Nilsson, LNG; Kylberg, A; Isaksson, M; Wootz, H; Lannfelt, L; Kullander, K; Hillered, L; Ebendal, T				Israelsson, Charlotte; Bengtsson, Henrik; Lobell, Anna; Nilsson, Lars N. G.; Kylberg, Annika; Isaksson, Magnus; Wootz, Hanna; Lannfelt, Lars; Kullander, Klas; Hillered, Lars; Ebendal, Ted			Appearance of Cxcl10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; chemokines; dendritic cells; experimental autoimmune encephalomyelitis; inflammation; mouse	CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; CHEMOKINE RECEPTORS; DENDRITIC CELLS; BLOOD MONOCYTES; CEREBRAL-CORTEX; T-CELLS; IN-VIVO; EXPRESSION; MODEL	Traumatic brain injury (TBI) in the mouse results in the rapid appearance of scattered clusters of cells expressing the chemokine Cxcl10 in cortical and subcortical areas. To extend the observation of this unique pattern, we used neuropathological mouse models using quantitative reverse transcriptase-polymerase chain reaction, gene array analysis, in-situ hybridization and flow cytometry. As for TBI, cell clusters of 150-200 mu m expressing Cxcl10 characterize the cerebral cortex of mice carrying a transgene encoding the Swedish mutation of amyloid precursor protein, a model of amyloid Alzheimer pathology. The same pattern was found in experimental autoimmune encephalomyelitis in mice modelling multiple sclerosis. In contrast, mice carrying a SOD1G93A mutant mimicking amyotrophic lateral sclerosis pathology lacked such cell clusters in the cerebral cortex, whereas clusters appeared in the brainstem and spinal cord. Mice homozygous for a null mutation of the Cxcl10 gene did not show detectable levels of Cxcl10 transcript after TBI, confirming the quantitative reverse transcriptase-polymerase chain reaction and in-situ hybridization signals. Moreover, unbiased microarray expression analysis showed that Cxcl10 was among 112 transcripts in the neocortex upregulated at least threefold in both TBI and ageing TgSwe mice, many of them involved in inflammation. The identity of the Cxcl10+ cells remains unclear but flow cytometry showed increased numbers of activated microglia/macrophages as well as myeloid dendritic cells in the TBI and experimental autoimmune encephalomyelitis models. It is concluded that the Cxcl10+ cells appear in the inflamed central nervous system and may represent a novel population of cells that it may be possible to target pharmacologically in a broad range of neurodegenerative conditions.	[Israelsson, Charlotte; Bengtsson, Henrik; Kylberg, Annika; Wootz, Hanna; Kullander, Klas; Ebendal, Ted] Uppsala Univ, Biomed Ctr, Dept Neurosci, SE-75124 Uppsala, Sweden; [Lobell, Anna; Isaksson, Magnus] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden; [Nilsson, Lars N. G.; Lannfelt, Lars] Uppsala Univ, Rudbeck Lab, Dept Publ Hlth & Caring Sci Mol Geriatr, SE-75124 Uppsala, Sweden; [Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden		Ebendal, T (corresponding author), Uppsala Univ, Biomed Ctr, Dept Neurosci, POB 593, SE-75124 Uppsala, Sweden.	ted.ebendal@neuro.uu.se		nilsson, lars/0000-0002-8362-1042; Kullander, Klas/0000-0001-6418-5460; Hillered, Lars/0000-0002-2808-9292	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Research Foundation	This work was supported by the Swedish Research Council and the Swedish Brain Research Foundation. Hanna Goransson and Maria Rydaker carried out the GeneChip procedures.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Byrne FR, 2009, AUTOIMMUNITY, V42, P171, DOI 10.1080/08916930802629547; Carson MJ, 1999, J NEUROSCI RES, V55, P127, DOI 10.1002/(SICI)1097-4547(19990101)55:1<127::AID-JNR14>3.3.CO;2-U; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Chiu IM, 2008, P NATL ACAD SCI USA, V105, P17913, DOI 10.1073/pnas.0804610105; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; Fife BT, 2001, J NEUROSCI RES, V66, P705, DOI 10.1002/jnr.10037; Furtado GC, 2006, J IMMUNOL, V177, P6871, DOI 10.4049/jimmunol.177.10.6871; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; Karman J, 2006, J IMMUNOL, V177, P7750, DOI 10.4049/jimmunol.177.11.7750; Kieseier BC, 2002, BRAIN, V125, P823, DOI 10.1093/brain/awf070; Klein RS, 2004, J CELL BIOCHEM, V92, P213, DOI 10.1002/jcb.20052; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Marta M, 2008, EUR J IMMUNOL, V38, P565, DOI 10.1002/eji.200737187; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Muller M, 2007, J IMMUNOL, V179, P2774, DOI 10.4049/jimmunol.179.5.2774; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Philipson O, 2009, NEUROBIOL AGING, V30, P1393, DOI 10.1016/j.neurobiolaging.2007.11.022; Potts Mathew B, 2006, NeuroRx, V3, P143; Reichmann G, 2002, J NEUROIMMUNOL, V129, P125, DOI 10.1016/S0165-5728(02)00184-4; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Stalder AK, 2005, J NEUROSCI, V25, P11125, DOI 10.1523/JNEUROSCI.2545-05.2005; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Trifilo MJ, 2004, VIROLOGY, V327, P8, DOI 10.1016/j.virol.2004.06.027; Trifilo MJ, 2003, J NEUROVIROL, V9, P315, DOI 10.1080/13550280390201029; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Xu HP, 2005, J IMMUNOL, V175, P6915, DOI 10.4049/jimmunol.175.10.6915	42	33	33	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAR	2010	31	5					852	863		10.1111/j.1460-9568.2010.07105.x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	563AC	WOS:000275096500008	20374285				2022-02-06	
J	Nagamoto-Combs, K; Morecraft, RJ; Darling, WG; Combs, CK				Nagamoto-Combs, Kumi; Morecraft, Robert J.; Darling, Warren G.; Combs, Colin K.			Long-Term Gliosis and Molecular Changes in the Cervical Spinal Cord of the Rhesus Monkey after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						injury; microglia; motor recovery; spinal cord; synapse	GLUTAMATE TRANSPORTER GLT-1; PROTEIN-KINASE PATHWAYS; CORTICAL IMPACT INJURY; NOGO RECEPTOR; ARM REPRESENTATION; CEREBRAL-ISCHEMIA; IMMUNE-RESPONSE; CELL-DEATH; EXPRESSION; RECOVERY	Recovery of fine motor skills after traumatic brain injury (TBI) is variable, with some patients showing progressive improvements over time while others show poor recovery. We therefore studied possible cellular mechanisms accompanying the recovery process in a non-human primate model system, in which the lateral frontal motor cortex areas controlling the preferred upper limb were unilaterally lesioned, and the animals eventually regained fine hand motor function. Immunohistochemical staining of the cervical spinal cord, the site of compensatory sprouting and degeneration of corticospinal axons, showed profound increases in immunoreactivities for major histocompatibility complex class II molecule (MHC-II) and extracellular signal-regulated kinases (ERK1/2) up to 12 months post lesion, particularly within the lateral corticospinal tract (LCST). Double immunostaining demonstrated that phosphorylated ERK1/2 colocalized within the MCH-II+ microglia, suggesting a trophic role of long-term microglia activation after TBI at the site of compensatory sprouting. Active sprouting was observed in the LCST as well as in the spinal gray matter of the lesioned animals, as illustrated by increases in growth associated protein 43. Upregulation of Nogo receptor and glutamate transporter expression was also observed in this region after TBI, suggesting possible mechanisms for controlling aberrant sprouting and/or synaptic formation en route and interstitial glutamate concentration changes at the site of axon degeneration, respectively. Taken together, these changes in the non-human primate spinal cord support a long-term trophic/tropic role for reactive microglia, in particular, during functional and structural recovery after TBI.	[Combs, Colin K.] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA; [Nagamoto-Combs, Kumi] Univ N Dakota, Sch Med & Hlth Sci, Dept Anat & Cell Biol, Grand Forks, ND 58202 USA; [Morecraft, Robert J.] Univ S Dakota, Sch Med, Div Basic Biomed Sci, Vermillion, SD 57069 USA; [Darling, Warren G.] Univ Iowa, Dept Integrat Physiol, Iowa City, IA USA		Combs, CK (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 504 Hamline St,Neurosci Bldg, Grand Forks, ND 58202 USA.	ccombs@medicine.nodak.edu	Nagamoto-Combs, Kumi/AAN-6697-2021		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS046367, 5P20RR017699-08]; South Dakota Spinal Cord and Traumatic Brain Injury Research Council; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR017699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046367, R56NS046367] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health grants, NS046367 and 5P20RR017699-08, and The South Dakota Spinal Cord and Traumatic Brain Injury Research Council.	Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Agrawal SK, 1997, J NEUROSCI, V17, P1055; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Batchelor PE, 2000, EUR J NEUROSCI, V12, P3462, DOI 10.1046/j.1460-9568.2000.00239.x; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 2008, BRAIN RES, V1209, P49, DOI 10.1016/j.brainres.2008.02.098; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Butefisch CM, 2006, NEUROL SCI, V27, pS18, DOI 10.1007/s10072-006-0540-z; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Conti AC, 1998, J NEUROSCI, V18, P5663; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Darling WG, 2009, EXP NEUROL, V220, P90, DOI 10.1016/j.expneurol.2009.07.034; Darling WG, 2006, J NEUROSCI METH, V154, P38, DOI 10.1016/j.jneumeth.2005.11.013; David S, 2008, TRENDS NEUROSCI, V31, P221, DOI 10.1016/j.tins.2008.02.002; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Fukuda S, 2003, ILAR J, V44, P96, DOI 10.1093/ilar.44.2.96; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hamo L, 2007, GLIA, V55, P1169, DOI 10.1002/glia.20538; HODGE CW, 2008, NEW ENGL J MED, V358, P453; Jara JH, 2007, J NEUROCHEM, V100, P1407, DOI 10.1111/j.1471-4159.2006.04330.x; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Koura SS, 1998, ACT NEUR S, V71, P244; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Li SX, 2003, J NEUROSCI, V23, P4219; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Mark V W, 2006, Eura Medicophys, V42, P269; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; McNeal DW, 2010, J COMP NEUROL, V518, P586, DOI 10.1002/cne.22218; Morecraft RJ, 2004, J COMP NEUROL, V469, P37, DOI 10.1002/cne.10980; Morecraft RJ, 2001, BRAIN, V124, P176, DOI 10.1093/brain/124.1.176; Morecraft RJ, 2002, BRAIN, V125, P176, DOI 10.1093/brain/awf011; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; Morecraft RJ, 2007, J COMP NEUROL, V504, P149, DOI 10.1002/cne.21438; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Ouardouz M, 2009, ANN NEUROL, V65, P160, DOI 10.1002/ana.21539; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; Pizzimenti MA, 2007, J NEUROPHYSIOL, V98, P1015, DOI 10.1152/jn.00354.2007; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Redwine JM, 2001, AM J PATHOL, V159, P1219, DOI 10.1016/S0002-9440(10)62507-2; RINK A, 1995, AM J PATHOL, V147, P1575; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Satoh JI, 2005, J NEUROPATH EXP NEUR, V64, P129, DOI 10.1093/jnen/64.2.129; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; Stoll M, 2006, NEUROPATH APPL NEURO, V32, P650, DOI 10.1111/j.1365-2990.2006.00774.x; Straub RH, 1998, IMMUNOL TODAY, V19, P409, DOI 10.1016/S0167-5699(98)01297-3; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Yaguchi M, 2008, J NEUROSCI RES, V86, P1972, DOI 10.1002/jnr.21658; Yamamoto T, 1999, ACT NEUR S, V75, P17	87	33	34	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					565	585		10.1089/neu.2009.0966			21	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100010	20030560	Green Published			2022-02-06	
J	Tudor, M; Jandric, I; Marovic, A; Gjurasin, M; Perovic, D; Radic, B; Blagaic, AB; Kolenc, D; Brcic, L; Zarkovic, K; Seiwerth, S; Sikiric, P				Tudor, Mario; Jandric, Ivan; Marovic, Anton; Gjurasin, Miroslav; Perovic, Darko; Radic, Bozo; Blagaic, Alenka Boban; Kolenc, Danijela; Brcic, Luka; Zarkovic, Kamelija; Seiwerth, Sven; Sikiric, Predrag			Traumatic brain injury in mice and pentadecapeptide BPC 157 effect	REGULATORY PEPTIDES			English	Article						Traumatic brain injury; Pentadecapeptide BPC 157; Mice	GASTRIC PENTADECAPEPTIDE; RESTRAINT STRESS; CLINICAL-TRIALS; ACHILLES-TENDON; BPC-157; RAT; ETHANOL; PL-14736; PEPTIDE; WOUNDS	Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide, efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported, improved muscle crush injury. After an induced traumatic brain injury (TBI) in mice by a falling weight, BPC 157 regimens (10.0 mu g, 10.0 ng/kg i.p.) demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24 h post-injury period. Ultimately, the traumatic lesions (subarachnoidal and intraventricular haemorrhage, brain laceration, haemorrhagic laceration) were less intense and consecutive brain edema had considerably improved. Given prophylactically (30 min before TBI) the improved conscious/unconscious/death ratio in TBI-mice was after force impulses of 0.068 N s, 0.093 N s, 0.113 N s, 0.130 N s, 0.145 N s, and 0.159 N s. Counteraction (with a reduction of unconsciousness, lower mortality) with both mu g- and ng-regimens included the force impulses of 0.068-0.145 N s. A higher regimen presented effectiveness also against the maximal force impulse (0.159 N s). Furthermore, BPC 157 application immediately prior to injury was beneficial in mice subjected to force impulses of 0.093 N s-TBI. For a more severe force impulse (0.130 N s, 0.145 N s, or 0159 N s), the time-relation to improve the conscious/unconscious/death ratio was: 5 min (0.130 N s-TBI), 20 min (0.145 N s-TBI) or 30 min (0.159 N s-TBI). (C) 2009 Elsevier B.V. All rights reserved.	[Sikiric, Predrag] Univ Zagreb, Dept Pharmacol, Fac Med, Zagreb 10000, Croatia; Univ Zagreb, Dept Pathol, Fac Med, Zagreb 10000, Croatia		Sikiric, P (corresponding author), Univ Zagreb, Dept Pharmacol, Fac Med, Salata 11,POB 916, Zagreb 10000, Croatia.	sikiric@mef.hr	Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			Andresen J, 2006, J APPL PHYSIOL, V100, P318, DOI 10.1152/japplphysiol.00937.2005; Aziz Q, 1998, GASTROENTEROLOGY, V114, P559, DOI 10.1016/S0016-5085(98)70540-2; Blagaic AB, 2005, EUR J PHARMACOL, V512, P173, DOI 10.1016/j.ejphar.2005.02.033; Blagaic AB, 2004, EUR J PHARMACOL, V499, P285, DOI 10.1016/j.ejphar.2004.07.112; Boban-Blagaic A, 2006, MED SCI MONITOR, V12, pBR36; Boyd JG, 2002, EUR J NEUROSCI, V15, P613, DOI 10.1046/j.1460-9568.2002.01891.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Dobric I, 2007, J PHARMACOL SCI, V104, P7, DOI 10.1254/jphs.FP0061322; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jelovac N, 1999, EUR J PHARMACOL, V379, P19, DOI 10.1016/S0014-2999(99)00486-0; Jelovac N, 1998, BIOL PSYCHIAT, V43, P511, DOI 10.1016/S0006-3223(97)00277-1; Jubran M, 2003, EXP NEUROL, V181, P204, DOI 10.1016/S0014-4886(03)00041-4; Klicek R, 2008, J PHARMACOL SCI, V108, P7, DOI 10.1254/jphs.FP0072161; Krivic A, 2008, INFLAMM RES, V57, P205, DOI 10.1007/s00011-007-7056-8; Krivic A, 2006, J ORTHOP RES, V24, P982, DOI 10.1002/jor.20096; Lovric-Bencic M, 2004, J PHARMACOL SCI, V95, P19, DOI 10.1254/jphs.95.19; MAAS AI, 2005, HEAD INJURY, P406; Maier B, 2007, SHOCK, V27, P610, DOI 10.1097/shk.0b013e31802f9eaf; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; Park CO, 1998, YONSEI MED J, V39, P395, DOI 10.3349/ymj.1998.39.5.395; PEVEC D, 2009, MED SCI MON IN PRESS; Prkacin I, 2001, J PHYSIOL-PARIS, V95, P295, DOI 10.1016/S0928-4257(01)00041-9; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Ruenzi M, 2005, GASTROENTEROLOGY, V128, pA584; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sebecic B, 1999, BONE, V24, P195, DOI 10.1016/S8756-3282(98)00180-X; SEBECIC B, 2008, SURG TODAY, V38, P716; Seiwerth S, 1997, J PHYSIOLOGY-PARIS, V91, P173, DOI 10.1016/S0928-4257(97)89480-6; Seveljevic-Jaran D, 2006, SKIN PHARMACOL PHYS, V19, P266, DOI 10.1159/000093982; Sikiric P., 2006, Inflammopharmacology, V14, P214, DOI 10.1007/s10787-006-1531-7; Sikiric P, 2003, BURNS, V29, P323, DOI 10.1016/S0305-4179(03)00004-4; Sikiric P, 1999, EUR J PHARMACOL, V364, P23, DOI 10.1016/S0014-2999(98)00818-8; SIKIRIC P, 1993, LIFE SCI, V53, pPL291, DOI 10.1016/0024-3205(93)90589-U; Sikiric P, 1999, J PHYSIOL-PARIS, V93, P479, DOI 10.1016/S0928-4257(99)00123-0; SIKIRIC P, 1994, LIFE SCI, V54, pPL63, DOI 10.1016/0024-3205(94)00796-9; Sikiric P, 1996, DIGEST DIS SCI, V41, P1604, DOI 10.1007/BF02087908; Sikiric P, 1997, EUR J PHARMACOL, V332, P23, DOI 10.1016/S0014-2999(97)01033-9; Sikiric P, 1999, J PHYSIOL-PARIS, V93, P505, DOI 10.1016/S0928-4257(99)00119-9; SIKIRIC P, 1993, J PHYSIOL-PARIS, V87, P313, DOI 10.1016/0928-4257(93)90038-U; Skorjanec S, 2009, DIGEST DIS SCI, V54, P46, DOI 10.1007/s10620-008-0332-9; Soares HD, 1995, J NEUROSCI, V15, P8223; Staresinic M, 2006, J ORTHOP RES, V24, P1109, DOI 10.1002/jor.20089; Staresinic M, 2003, J ORTHOP RES, V21, P976, DOI 10.1016/S0736-0266(03)00110-4; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tkalcevic VI, 2007, EUR J PHARMACOL, V570, P212, DOI 10.1016/j.ejphar.2007.05.072; Tohyama Y, 2004, LIFE SCI, V76, P345, DOI 10.1016/j.lfs.2004.08.010; Urist M.R., 1996, OSTEOLOGIE, V4, P207; VELJACA M, 1995, J PHARMACOL EXP THER, V272, P417; VELJACA M, 1995, GASTROENTEROLOGY, V108, pA761; Veljaca M., 2003, GUT, V51, pA309; Wood JD, 2004, PHYSIOLOGY, V19, P326, DOI 10.1152/physiol.00034.2004; XUE XC, 2004, CHIN NEW DRUGS J, V12, P602; Xue XC, 2004, WORLD J GASTROENTERO, V10, P1032; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	59	33	33	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-0115	1873-1686		REGUL PEPTIDES	Regul. Pept.	FEB 25	2010	160	1-3					26	32		10.1016/j.regpep.2009.11.012			7	Endocrinology & Metabolism; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Physiology	560GL	WOS:000274890000004	19931318				2022-02-06	
J	Elkin, BS; Shaik, MA; Morrison, B				Elkin, Benjamin S.; Shaik, Mohammed A.; Morrison, Barclay, III			Fixed negative charge and the Donnan effect: a description of the driving forces associated with brain tissue swelling and oedema	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES			English	Article						oedema; brain injury; Donnan effect	ARTICULAR-CARTILAGE; CEREBRAL CONTUSION; RAT-BRAIN; INTRACRANIAL HYPERTENSION; MECHANICAL-PROPERTIES; CHONDROITIN SULFATE; VOLUME REGULATION; OSMOTIC-PRESSURE; CELLULAR EDEMA; INJURY	Cerebral oedema or brain tissue swelling is a significant complication following traumatic brain injury or stroke that can increase the intracranial pressure (ICP) and impair blood flow. Here, we have identified a potential driver of oedema: the negatively charged molecules fixed within cells. This fixed charge density (FCD), once exposed, could increase ICP through the Donnan effect. We have shown that metabolic processes and membrane integrity are required for concealing this FCD as slices of rat cortex swelled immediately (within 30 min) following dissection if treated with 2 deoxyglucose + cyanide (2DG+CN) or Triton X-100. Slices given ample oxygen and glucose, however, did not swell significantly. We also found that dead brain tissue swells and shrinks in response to changes in ionic strength of the bathing medium, which suggests that the Donnan effect is capable of pressurizing and swelling brain tissue. As predicted, a non-ionic osmolyte, 1,2 propanediol, elicited no volume change at 2000 x 10(-3) osmoles l(-1) (Osm). Swelling data were well described by triphasic mixture theory with the calculated reference state FCD similar to that measured with a 1,9 dimethylmethylene blue assay. Taken together, these data suggest that intracellular fixed charges may contribute to the driving forces responsible for brain swelling.	[Elkin, Benjamin S.; Shaik, Mohammed A.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA		Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	The authors would like to thank Gerard A. Ateshian for help with constitutive modelling and useful discussions, Vikrum A. Thimmappa for help with tissue-slice imaging and Michael B. Albro for useful discussions. This work was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) postgraduate scholarship (BSE).	Albro MB, 2007, J BIOMECH ENG-T ASME, V129, P503, DOI 10.1115/1.2746371; ALVARADO MV, 1984, J NEUROSCI RES, V11, P13, DOI 10.1002/jnr.490110103; Amorini AM, 2003, ACT NEUR S, V86, P261; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; ARNAUD FG, 1990, CRYOBIOLOGY, V27, P107, DOI 10.1016/0011-2240(90)90002-L; Asher RA, 2000, J NEUROSCI, V20, P2427; Ateshian GA, 2009, J BIOMECH, V42, P781, DOI 10.1016/j.jbiomech.2009.01.015; Azeloglu EU, 2008, AM J PHYSIOL-HEART C, V294, pH1197, DOI 10.1152/ajpheart.01027.2007; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bhardwaj A, 2007, CURR NEUROL NEUROSCI, V7, P513, DOI 10.1007/s11910-007-0079-2; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chahine NO, 2005, BIOPHYS J, V89, P1543, DOI 10.1529/biophysj.104.057315; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Costa C, 2007, J CHEM NEUROANAT, V33, P111, DOI 10.1016/j.jchemneu.2007.01.006; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FISHMAN RA, 1977, J NEUROCHEM, V28, P1061, DOI 10.1111/j.1471-4159.1977.tb10669.x; Goodacre S, 2008, EMERG MED J, V25, P556, DOI 10.1136/emj.2007.055723; Goodman JA, 2005, MAGN RESON MED, V53, P1040, DOI 10.1002/mrm.20444; Hatashita S, 1990, Adv Neurol, V52, P85; Hoffmann EK, 2009, PHYSIOL REV, V89, P193, DOI 10.1152/physrev.00037.2007; Hrabetova S, 2002, J CEREBR BLOOD F MET, V22, P80, DOI 10.1097/00004647-200201000-00010; Hutchinson Peter, 1800, Neurosurg Focus, V22, pE14; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; JENKINS HG, 1988, J NEUROCHEM, V51, P1634, DOI 10.1111/j.1471-4159.1988.tb01134.x; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawamata T, 2006, ACTA NEUROCHIR SUPPL, V96, P3; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Koppe G, 1997, CELL TISSUE RES, V288, P33, DOI 10.1007/s004410050790; Kurbel S, 2008, J THEOR BIOL, V252, P769, DOI 10.1016/j.jtbi.2008.02.022; Kuroiwa Toshihiko, 2007, Neurosurg Focus, V22, pE11, DOI 10.3171/foc.2007.22.5.12; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Lu XL, 2007, J BIOMECH, V40, P2434, DOI 10.1016/j.jbiomech.2006.11.015; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Maeda T, 2003, ACT NEUR S, V86, P329; Marchi N, 2009, EPILEPSIA, V50, P664, DOI 10.1111/j.1528-1167.2008.01989.x; MARGOLIS RK, 1979, P NATL ACAD SCI USA, V76, P1711, DOI 10.1073/pnas.76.4.1711; MARGOLIS RK, 1976, BRAIN RES, V112, P363, DOI 10.1016/0006-8993(76)90290-0; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mongin Alexander A, 2007, Pathophysiology, V14, P183, DOI 10.1016/j.pathophys.2007.09.009; MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202; Neprasova H, 2007, PFLUG ARCH EUR J PHY, V453, P839, DOI 10.1007/s00424-006-0151-9; Nguyen MK, 2006, J APPL PHYSIOL, V100, P1293, DOI 10.1152/japplphysiol.01274.2005; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Osada T, 2006, CLIN HEMORHEOL MICRO, V34, P223; OVERBEEK JTG, 1956, PROG BIOPHYS MOL BIO, V6, P58; Papadopoulos MC, 2004, FASEB J, V18, P425, DOI 10.1096/fj.04-2834fje; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raslan A., 2007, NEUROSURG FOCUS, V22, P1; SAMES K, 1992, ARCH GERONTOL GERIAT, V14, P75, DOI 10.1016/0167-4943(92)90008-R; Sherman LS, 2008, TRENDS NEUROSCI, V31, P44, DOI 10.1016/j.tins.2007.11.001; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sun DD, 2004, J BIOMECH ENG-T ASME, V126, P6, DOI 10.1115/1.1644562; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; TOMITA M, 1979, EXP NEUROL, V65, P66, DOI 10.1016/0014-4886(79)90248-6; TOMITA M, 1988, BRAIN RES, V474, P165, DOI 10.1016/0006-8993(88)90679-8; TOMITA M, 1992, AM J PHYSIOL, V262, pH603, DOI 10.1152/ajpheart.1992.262.2.H603; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Pul C, 2005, MAGNET RESON MED, V53, P348, DOI 10.1002/mrm.20353; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Wang Q, 2008, PHYS MED BIOL, V53, P2537, DOI 10.1088/0031-9155/53/10/006; Wang Q, 2007, J BIOMECH ENG-T ASME, V129, P413, DOI 10.1115/1.2720919; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YATES AJ, 1975, AM J PATHOL, V79, P555; Young W, 1986, Cent Nerv Syst Trauma, V3, P215; YOUNG W, 1987, STROKE, V18, P751, DOI 10.1161/01.STR.18.4.751	81	33	33	0	10	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1364-503X	1471-2962		PHILOS T R SOC A	Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci.	FEB 13	2010	368	1912					585	603		10.1098/rsta.2009.0223			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	539DJ	WOS:000273233400004	20047940	Green Published			2022-02-06	
J	Berg, C; Oeffner, A; Schumm-Draeger, PM; Badorrek, F; Brabant, G; Gerbert, B; Bornstein, S; Zimmermann, A; Weber, M; Broecker-Preuss, M; Mann, K; Herrmann, BL				Berg, C.; Oeffner, A.; Schumm-Draeger, P. -M.; Badorrek, F.; Brabant, G.; Gerbert, B.; Bornstein, S.; Zimmermann, A.; Weber, M.; Broecker-Preuss, M.; Mann, K.; Herrmann, B. L.			Prevalence of Anterior Pituitary Dysfunction in Patients following Traumatic Brain Injury in a German Multi-centre Screening Program	EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES			English	Article						hypopituitarism; insufficiencies; GH adrenal gland; hormones; cerebrovascular disease; neuropathy	ANEURYSMAL SUBARACHNOID HEMORRHAGE; GROWTH-HORMONE DEFICIENCY; POSTTRAUMATIC HYPOPITUITARISM; NEUROENDOCRINE DYSFUNCTION; GH DEFICIENCY; TSH RESPONSE; IGF-I; DIAGNOSIS; REHABILITATION; INVOLVEMENT	Introduction: We determined the prevalence of anterior pituitary dysfunction in a multi-centre screening program across five German endocrine centres in patients rehabilitating from TBI (GCS < 13). Patients & Methods: 246 patients (39 +/- 14 yrs; 133 males, 12 +/- 8 months after TBI) underwent a series of baseline endocrine tests with central assessment of TSH, free T4, prolactin, LH, FSH, testosterone (m), estradiol (f), cortisol, GH, and IGF-I. If IGF-I was < - 2 SDS dynamic testing was performed. GHD was defined according to BMI-dependent cut-off values for GH response to GHRH + arginine of < 4.2, < 8.0 and < 11.5 ng/ml in obese, overweight and lean subjects, respectively, or < 3 micro g/l in ITT. Hypocortisolism was suggested when basal cortisol was < 200 nmol/l and confirmed by ITT (peak < 500 nmol/l). Results: In TBI patients some degree of impaired pituitary function was shown in 21 % (n = 52/246). Total, multiple and isolated deficits were present in 1 %, 2 % and 18 %, respectively. 19 % had an IGF- I of < - 1 SDS, 9 % of < - 2 SDS. In 5 % GHD was confirmed. 9 % had hypogonadism. 4 % had hypocortisolism and 1 % of patients had confirmed ACTH-deficiency. 12 % had TSH-deficiency. Summary: In summary, in this large series carried out on an unselected group of TBI survivors we have found hypopituitarism in every fifth patient with predominantly secondary hypogonadism and hypothyreosis. Regarding somatotrope insufficiency IGF-I is decreased in 50 % of GHD patients. Conclusion: These findings strongly suggest that patients who suffer head trauma should routinely undergo endocrine evaluation.	[Berg, C.; Broecker-Preuss, M.; Mann, K.; Herrmann, B. L.] Univ Hosp Essen, Clin Endocrinol, Essen, Germany; [Oeffner, A.; Schumm-Draeger, P. -M.] Hosp Bogenhausen, Med Clin 3, Munich, Germany; [Badorrek, F.; Brabant, G.] Univ Hosp Hannover, Dept Endocrinol, Hannover, Germany; [Brabant, G.] Christie Hosp, Dept Endocrinol, Manchester, Lancs, England; [Gerbert, B.; Bornstein, S.] Univ Hosp Dresden, Dept Endocrinol, Dresden, Germany; [Zimmermann, A.; Weber, M.] Univ Hosp Mainz, Dept Endocrinol, Mainz, Germany; [Herrmann, B. L.] Technol Ctr Bochum, Bochum, Germany		Berg, C (corresponding author), Univ Duisburg Essen, Univ Clin Essen, Clin Endocrinol, Duisburg, Germany.	christian.berg@uni-essen.de			NovoNordisk GmbH, Mainz, GermanyNovo Nordisk	The study was supported by a grant from NovoNordisk GmbH, Mainz, Germany. (Responsibility T. Knittel) Moreover, we gratefully acknowledge the excellent support of the personnel at the Metabolic Laboratory, Division of Endocrinology, University Hospital of Essen, Germany.	Abs R, 2003, EUR J ENDOCRINOL, V148, pS3, DOI 10.1530/eje.0.148S003; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 1998, J ENDOCRINOL INVEST, V21, P506, DOI 10.1007/BF03347336; Aimaretti G, 2004, HORM RES, V62, P26, DOI 10.1159/000080755; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BENGTSSON BA, 1990, HORM RES, V33, P19, DOI 10.1159/000181579; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Coiro V, 2000, J INVEST MED, V48, P133; EDWARDS OM, 1986, MEDICINE, V65, P281; Elmlinger MW, 2004, CLIN CHEM LAB MED, V42, P654, DOI 10.1515/CCLM.2004.112; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Goni MJ, 1997, METABOLISM, V46, P1305, DOI 10.1016/S0026-0495(97)90235-3; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Herrmann BL, 2004, HORM METAB RES, V36, P54, DOI 10.1055/s-2004-814199; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P727, DOI 10.1210/jc.82.3.727; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MULLER EE, 1987, PHYSIOL REV, V67, P962, DOI 10.1152/physrev.1987.67.3.962; Radetti G, 2000, J ENDOCRINOL INVEST, V23, P744, DOI 10.1007/BF03345064; Rees P, 2001, LANCET, V358, P1812, DOI 10.1016/S0140-6736(01)06814-3; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Seidell JC, 2000, EUR J CLIN NUTR, V54, pS33, DOI 10.1038/sj.ejcn.1601023; TEASDALE G, 1974, LANCET, V2, P81; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; Webster JB, 1997, ARCH PHYS MED REHAB, V78, P314, DOI 10.1016/S0003-9993(97)90040-X; WEEKE J, 1974, SCAND J CLIN LAB INV, V33, P101, DOI 10.3109/00365517409082475	41	33	36	0	4	JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH	STUTTGART	RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY	0947-7349	1439-3646		EXP CLIN ENDOCR DIAB	Exp. Clin. Endocrinol. Diabet.	FEB	2010	118	2					139	144		10.1055/s-0029-1225611			6	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	563NE	WOS:000275138500014	19691014				2022-02-06	
J	Batti, L; O'Connor, JJ				Batti, Laura; O'Connor, John J.			Tumor necrosis factor-alpha impairs the recovery of synaptic transmission from hypoxia in rat hippocampal slices	JOURNAL OF NEUROIMMUNOLOGY			English	Article						Hypoxia; Adenosine A(1) receptor; TNF-alpha; LTP; Hippocampus; p38 MAP kinase	LONG-TERM POTENTIATION; ADENOSINE RECEPTOR ANTAGONISTS; PROTEIN-KINASE INHIBITOR; TNF-ALPHA; BRAIN-INJURY; IN-VITRO; AREA CA1; PROINFLAMMATORY CYTOKINES; INDUCED EXCITOTOXICITY; PRESYNAPTIC CALCIUM	Cerebral ischaemia is a common occurrence in a range of pathological conditions, including stroke and traumatic brain injury. Two of the components in ischaemia are tissue hypoxia and the release of pro-inflammatory agents such as TNF-alpha. The role of TNF-alpha in an ischaemic/hypoxic episode is still controversial, although deleterious effects of pro-inflammatory cytokines in the area of injury are well documented. One of the prime adaptive mechanisms in response to hypoxia is the cellular activation of adenosine 1 receptors (A1Rs), which inhibits excitatory synaptic transmission. In the present study we have examined the effect of TNF-alpha application on synaptic transmission during hypoxic exposure and re-oxygenation using extrarcellular recordings in the CA1 region of the rat hippocampal slice. Hypoxia caused a reversible depression of the field EPSP (29.6 +/- 9.7% of control, n = 5), which was adenosine A(1) receptor-dependent (85.7 +/- 4.3%, in the presence of DPCPX (200 nM), the adenosine A(1) receptor antagonist). DPCPX inhibited the maintenance of long-term potentiation obtained 30 min post hypoxia (143.8 +/- 8.2% versus 96.4 +/- 10.6% respectively, 1 h post tetanus; n = 5; p<0.005). In TNF-alpha (150 pM) treated slices hypoxic depression was similar to controls but a reduction in fEPSP slope was observed during re-oxygenation (66.8 +/- 1.4%, n = 5). This effect was reversed by pre-treatment with SB 203580 (1 mu M). a p38 MAP kinase inhibitor (91.8 +/- 6.9%, n = 5). These results demonstrate a novel p38 MAPK dependent role for TNF-alpha in attenuating synaptic transmission after a hypoxic episode. (C) 2009 Elsevier B.V. All rights reserved.	[Batti, Laura; O'Connor, John J.] UCD Conway Inst Biomol & Biomed Res, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland		O'Connor, JJ (corresponding author), UCD Conway Inst Biomol & Biomed Res, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	john.oconnor@ucd.ie		Batti, Laura/0000-0003-3717-8470; O'Connor, John/0000-0001-8229-8602	Marie Curie ActionsEuropean Commission	We would like to thank Marie Curie Actions for financial support and Professor Cormac Taylor for comments on the manuscript.	Arrigoni E, 2005, NEUROSCIENCE, V132, P575, DOI 10.1016/j.neuroscience.2004.12.009; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; BLOMQVIST P, 1985, J CEREBR BLOOD F MET, V5, P420, DOI 10.1038/jcbfm.1985.57; Bon CLM, 2002, J NEUROPHYSIOL, V87, P1781, DOI 10.1152/jn.00630.2001; Brust TB, 2006, J NEUROSCI, V26, P12427, DOI 10.1523/JNEUROSCI.4052-06.2006; Butler MP, 2004, NEUROSCIENCE, V124, P319, DOI 10.1016/j.neuroscience.2003.11.040; Centonze D, 2001, BRAIN, V124, P1855, DOI 10.1093/brain/124.9.1855; Chaparro-Huerta V, 2005, J NEUROIMMUNOL, V165, P53, DOI 10.1016/j.jneuroim.2005.04.025; Chavez-Valdez R, 2009, PEDIATR RES, V65, P203, DOI 10.1203/PDR.0b013e31818d66b1; Chen ZF, 1996, BRAIN RES, V708, P82, DOI 10.1016/0006-8993(95)01269-9; Coppi E, 2007, PURINERG SIGNAL, V3, P203, DOI 10.1007/s11302-006-9049-4; Cumiskey D, 2007, BRAIN RES, V1136, P13, DOI 10.1016/j.brainres.2006.12.019; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; de Mendonca A, 2000, NEUROSCI LETT, V291, P81, DOI 10.1016/S0304-3940(00)01391-4; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; DOOLETTE DJ, 1995, BRAIN RES, V677, P127, DOI 10.1016/0006-8993(95)00139-H; Feng YZ, 2003, ANN NY ACAD SCI, V1009, P152, DOI 10.1196/annals.1304.017; FUJIWARA N, 1987, J PHYSIOL-LONDON, V384, P131, DOI 10.1113/jphysiol.1987.sp016447; Gervitz LM, 2001, AM J PHYSIOL-REG I, V280, pR639, DOI 10.1152/ajpregu.2001.280.3.R639; Hsu KS, 2000, J NEUROPHYSIOL, V84, P1279, DOI 10.1152/jn.2000.84.3.1279; Izumi Y, 1998, J CEREBR BLOOD F MET, V18, P97, DOI 10.1097/00004647-199801000-00010; Kim JH, 2006, NEUROSCI LETT, V400, P1, DOI 10.1016/j.neulet.2006.01.035; Lee HT, 2004, AM J PHYSIOL-RENAL, V286, pF298, DOI 10.1152/ajprenal.00185.2003; Liang YC, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-13; LIPTON P, 1982, J PHYSIOL-LONDON, V325, P51, DOI 10.1113/jphysiol.1982.sp014135; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Markus T, 2009, J CEREBR BLOOD F MET, V29, P73, DOI 10.1038/jcbfm.2008.90; Mayne M, 1999, ANN NEUROL, V45, P633, DOI 10.1002/1531-8249(199905)45:5<633::AID-ANA12>3.0.CO;2-X; Murakami Y, 2005, J NEUROCHEM, V93, P1616, DOI 10.1111/j.1471-4159.2005.03163.x; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Pincheira R, 2008, J IMMUNOL, V181, P1288, DOI 10.4049/jimmunol.181.2.1288; Pugliese AM, 2006, BRIT J PHARMACOL, V147, P524, DOI 10.1038/sj.bjp.0706646; Renauld AE, 2002, J NEUROSCI RES, V67, P264, DOI 10.1002/jnr.10101; Rex CS, 2005, J NEUROSCI, V25, P5956, DOI 10.1523/JNEUROSCI.0880-05.2005; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; Saleshando G, 2000, NEUROSCI LETT, V288, P119, DOI 10.1016/S0304-3940(00)01210-6; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Scholz KP, 1996, J NEUROPHYSIOL, V76, P39, DOI 10.1152/jn.1996.76.1.39; Sebastiao AM, 2001, J NEUROSCI, V21, P8564, DOI 10.1523/JNEUROSCI.21-21-08564.2001; Seta K, 2002, ANN NY ACAD SCI, V971, P379, DOI 10.1111/j.1749-6632.2002.tb04500.x; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Souza LF, 2005, LIFE SCI, V77, P3117, DOI 10.1016/j.lfs.2005.05.049; Sperlagh B, 2007, NEUROSCIENCE, V149, P99, DOI 10.1016/j.neuroscience.2007.07.035; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Sun XC, 2006, BRAIN RES, V1084, P165, DOI 10.1016/j.brainres.2006.02.041; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Taylor CP, 1999, J NEUROSCI, V19, P619; Tha KK, 2000, BRAIN RES, V885, P25, DOI 10.1016/S0006-8993(00)02883-3; Walton KM, 1998, J NEUROCHEM, V70, P1764; Wang QW, 2005, EUR J NEUROSCI, V22, P2827, DOI 10.1111/j.1460-9568.2005.04457.x; WU LG, 1994, J NEUROSCI, V14, P645; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; ZHU PJ, 1993, NEUROSCI LETT, V155, P128, DOI 10.1016/0304-3940(93)90689-I; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	63	33	37	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	JAN 25	2010	218	1-2					21	27		10.1016/j.jneuroim.2009.11.002			7	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	557MH	WOS:000274672700004	19942300				2022-02-06	
B	Anderson, V; Anderson, PJ; Jacobs, R; Smith, MS		Anderson, V; Jacobs, R; Anderson, PJ		Anderson, Vicki; Anderson, Peter J.; Jacobs, Rani; Smith, Megan Spencer			Development and assessment of executive function: From preschool to adolescence	EXECUTIVE FUNCTIONS AND THE FRONTAL LOBES: A LIFESPAN PERSPECTIVE	Studies on Neuropsychology Neurology and Cognition		English	Article; Book Chapter							TRAUMATIC BRAIN-INJURY; HUMAN PREFRONTAL CORTEX; PROBLEM-SOLVING SKILLS; CLOSED HEAD-INJURY; COGNITIVE-DEVELOPMENT; FRONTAL LOBES; CONCEPT GENERATION; CEREBRAL-CORTEX; EARLY-CHILDHOOD; WORKING-MEMORY		[Anderson, Vicki; Smith, Megan Spencer] Univ Melbourne, Dept Psychol, Royal Childrens Hosp, Sch Behav Sci, Melbourne, Vic, Australia; [Jacobs, Rani] Univ Melbourne, Dept Psychol, Royal Childrens Hosp, Sch Psychol, Melbourne, Vic, Australia		Anderson, V (corresponding author), Univ Melbourne, Dept Psychol, Royal Childrens Hosp, Sch Behav Sci, Melbourne, Vic, Australia.		Anderson, Peter John/O-5302-2019; Anderson, Peter J/B-6839-2015	Anderson, Peter John/0000-0001-7430-868X; Anderson, Peter J/0000-0001-7430-868X			Albert M., 1980, NEW DIRECTIONS MEMOR, P403; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson P, 2001, CLIN NEUROPSYCHOL, V15, P81, DOI 10.1076/clin.15.1.81.1905; Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Anderson PJ., 2000, CLIN NEUROPSYCHOL AS, V1, P247; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2002, CHILD NEUROPSYCHOL, V8, P69, DOI 10.1076/chin.8.2.69.8725; ANDERSON V, 1988, P 13 ANN BRAIN IMP C, P223; Anderson V., 1995, NEUROPSYCHOLOGICAL A; Anderson V., 2002, PRINCIPLES FRONTAL L; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Anderson V A, 1996, Appl Neuropsychol, V3, P128, DOI 10.1207/s15324826an0303&4_5; Anderson VA, 2004, J CLIN EXP NEUROPSYC, V26, P684, DOI 10.1080/13803390490504344; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Baddeley A.D., 1986, WORKING MEMORY; Barbas H, 1992, Adv Neurol, V57, P91; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Baron I. S., 2004, NEUROPSYCHOLOGICAL E; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; BARTSCH K, 1989, CHILD DEV, V60, P946, DOI 10.1111/j.1467-8624.1989.tb03526.x; BECKER MG, 1987, DEV NEUROPSYCHOL, V3, P275, DOI 10.1080/87565648709540381; BELL MA, 1992, CHILD DEV, V63, P1142, DOI 10.1111/j.1467-8624.1992.tb01685.x; Benson D.F., 1986, FRONTAL LOBES; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BJORKLAND DV, 1989, CHILDRENS THINKING D; BLAKEMORE C, 1974, BRIT MED BULL, V30, P152, DOI 10.1093/oxfordjournals.bmb.a071186; BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; CAESER P, 1993, J CHILD PSYCHOL PSYC, V34, P101; Case R., 1985, INTELLECTUAL DEV BIR; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; CHUGANI HT, 1987, ANN NEUROL, V22, P287; CONDOR A, 1996, DEV NEUROPSYCHOL, V11, P485; Couper E., 2002, BRAIN IMPAIR, V3, P105, DOI [DOI 10.1375/BRIM.3.2.105, 10.1375/brim.3.2.105]; D'Esposito M., 2002, PRINCIPLES FRONTAL L, P168, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0011; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; De Luca CR, 2003, J CLIN EXP NEUROPSYC, V25, P242, DOI 10.1076/jcen.25.2.242.13639; DELIS DC, 2001, DELISKAPLAN EXECUTIV; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; DIAMOND A, 1985, NEUR ABSTR 2, V11, P832; DIDUS E, 2000, PEDIAT REHABILITATIO, V3, P177; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Emslie H., 2003, BEHAV ASSESSMENT DYS; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P379, DOI 10.1207/s15326942dn2601_1; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; Fuster J.M., 2002, PRINCIPLES FRONTAL L, P96, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0006; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; Garth J, 1997, Pediatr Rehabil, V1, P99; Gibbs J.C., 1992, MORAL MATURITY MEASU; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; Gioia GA IP, 2000, BEHAV RATING INVENTO; GLOSSER G, 1990, J CLIN EXP NEUROPSYC, V12, P485, DOI 10.1080/01688639008400995; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Golden C. J., 1981, NEUROPSYCHOLOGICAL A, P277; Goldman-Rakic P. S., 2002, PRINCIPLES FRONTAL L, P85, DOI DOI 10.1093/ACPR0F:0S0/9780195134971.003.0005; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.2307/1130201; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Hale S, 1997, DEV PSYCHOL, V33, P364, DOI 10.1037/0012-1649.33.2.364; HALFORD GS, 1980, COGNITIVE PSYCHOL, V12, P356, DOI 10.1016/0010-0285(80)90014-6; HALPERIN JM, 1989, J CLIN EXP NEUROPSYC, V11, P518, DOI 10.1080/01688638908400910; Heaton R.K., 1981, WISCONSIN CARD SORTI; HOWARD L, 1985, DEV PSYCHOL, V21, P283, DOI 10.1037/0012-1649.21.2.283; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Jacobs R, 2001, J DEV PHYS DISABIL, V13, P389, DOI 10.1023/A:1012289513829; Jacobs R., 2001, CLIN NEUROPSYCHOL, V2, P101; Jacques S, 2001, DEV NEUROPSYCHOL, V20, P573, DOI 10.1207/S15326942DN2003_2; JERNIGAN TL, 1990, DEV MED CHILD NEUROL, V32, P379; Johnson MH, 2003, BIOL PSYCHIAT, V54, P1312, DOI 10.1016/S0006-3223(03)00426-8; Johnson MH, 2000, CHILD DEV, V71, P75, DOI 10.1111/1467-8624.00120; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; KAIN W, 2001, SOCIAL BRAIN EVOLUTI, P197; Kirk U, 1985, HEMISPHERIC FUNCTION, P193; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; KOENDERINK MJT, 1994, BRAIN RES, V653, P173, DOI 10.1016/0006-8993(94)90387-5; Korkman M., 1998, MANUAL NEPSY; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; LANDRY SH, 1994, ADV CH NEUR, V2, P85; Lennenberg E. H., 1967, BIOL FDN LANGUAGE; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LIDOW MS, 1991, P NATL ACAD SCI USA, V88, P10218, DOI 10.1073/pnas.88.22.10218; Logan Gordon D., 1994, P189; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Luria A.R., 1973, WORKING BRAIN; Manly T., 1999, TEST EVERYDAY ATTENT; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P69; MATTHEWS L, 2001, CLIN NEUROPSYCHOL, V2, P85; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MELTZOFF A, 1997, DEV THEORIES INTENTI, P17; Mesulam MM, 2002, PRINCIPLES FRONTAL L, P8, DOI [10.1093/acprof:oso/9780195134971.003.0002, DOI 10.1093/ACPROF:OSO/9780195134971.003.0002]; MILLER PH, 1981, CHILD DEV, V52, P1183, DOI 10.1111/j.1467-8624.1981.tb03165.x; Neisser U., 1967, COGNITIVE PSYCHOL; Orzhekhovskaya N S, 1981, Neurosci Behav Physiol, V11, P379, DOI 10.1007/BF01184205; PARKER DM, 1992, HDB NEUROPSYCHOLOGIC, P267; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; Piaget J, 1963, ORIGINS INTELLIGENCE; Porteus SD., 1950, PORTEUS MAZE TEST IN; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; Reitan R, 1969, MANUAL ADM NEUROPSYC; Reitan RM, 1985, HALSTEADREITAN NEURO; Rey A., 1964, EXAMEN CLIN PSYCHOL; ROLLS ET, 2002, PRINCIPLES FRONTAL L, P354; Romine CB, 2005, APPL NEUROPSYCHOL, V12, P190, DOI 10.1207/s15324826an1204_2; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T, 1990, NEUROPSYCHOLOGY MENT; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; SODIAN B, 1991, CHILD DEV, V62, P468, DOI 10.1111/j.1467-8624.1991.tb01545.x; Sowell ER, 1999, NEUROIMAGE, V9, P587, DOI 10.1006/nimg.1999.0436; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; STEHBENS J A, 1991, Neuropsychology Review, V2, P147, DOI 10.1007/BF01109052; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Taylor H. G., 1990, HDB PSYCHOL ASSESSME, P228; THATCHER RW, 1992, BRAIN COGNITION, V20, P24, DOI 10.1016/0278-2626(92)90060-Y; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Tranel D., 2002, PRINCIPLES FRONTAL L, P338, DOI DOI 10.1093/ACPROF:OSO/9780195134971.001.0001; WABER DP, 1985, J CLIN EXP NEUROPSYC, V7, P264, DOI 10.1080/01688638508401259; Walsh K. W., 1985, UNDERSTANDING BRAIN; Walsh K. W., 1978, NEUROPSYCHOLOGY CLIN; WANSART WL, 1990, J LEARN DISABIL, V23, P164, DOI 10.1177/002221949002300306; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; YAKOVLEV P I, 1962, Res Publ Assoc Res Nerv Ment Dis, V39, P3; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3; Zelazo PD, 2004, ACTA PSYCHOL, V115, P167, DOI 10.1016/j.actpsy.2003.12.005; [No title captured]	156	33	34	1	8	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND			978-1-13687-354-6	STUD NEUROPSYCHOL NE			2010							123	154					32	Psychology, Biological; Psychology, Developmental; Psychology; Psychology, Experimental	Book Citation Index – Social Sciences & Humanities (BKCI-SSH); Book Citation Index – Science (BKCI-S)	Psychology	BVE09	WOS:000291249500008					2022-02-06	
J	Hofgren, C; Esbjornsson, E; Sunnerhagen, KS				Hofgren, C.; Esbjornsson, E.; Sunnerhagen, K. S.			Return to work after acquired brain injury: Facilitators and hindrances observed in a sub-acute rehabilitation setting	WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION			English	Article						Stroke; TBI; cognition; ADL; vocational; outcome	NEUROLOGICAL-INSTITUTE SCREEN; HIGHER CEREBRAL FUNCTIONS; REACTION LEVEL SCALE; ISCHEMIC-STROKE; YOUNG-ADULTS; FOLLOW-UP; ACUTE PREDICTORS; OUTCOMES; EMPLOYMENT; NEUROREHABILITATION	Objectives: There is great variability in the rate of return to work for persons who have suffered from brain injury. The aims of this study was: 1) to describe employment status of persons with stroke or traumatic brain injury, one year after the incident and 2) to investigate the impact of injury/stroke severity, length of stay, the ability to perform activities of daily living and cognitive function on return to work. Participants and Methods: Information was collected from 72 persons; 48 with a diagnosis of stroke and 24 with a traumatic brain injury. All patients had attended to a Rehabilitation Centre with inpatient and outpatient facilities. Data of the above mentioned variables was gathered retrospectively and information about employment status was retrieved from the medical records. Results: After one year, 13 persons (approximate to 18%), 5 with a stroke and 8 with a traumatic brain injury (one with mild brain injury, 9 with moderate and 3 persons with severe injuries) had returned to work. They had significantly shorter length of stay at the rehabilitation hospital and were younger than those that did not return to work. Somewhat better results at the neuropsychological screening were seen among those that returned to work, although with a significant difference only in the subscale assessing affect. Some persons with severe injury returned to work, while a majority of those with mild brain injury did not. Conclusion: Traumatic brain injury, younger age and less need of rehabilitation were associated with a higher rate of returning to work. Patients with stroke were older and seem to need more support in order to be successful in work return. It is of importance to reach primary rehabilitation goals, such as being ADL independent, as this was also favourable for work return. The impact of injury severity seemed complex and should to be further explored. Persons with mild brain injury should be followed-up with respect to work return. An important cognitive factor was ability to perceive and express affective responses, reflecting the need of social skills in today's work-life.	[Hofgren, C.; Esbjornsson, E.; Sunnerhagen, K. S.] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, S-41345 Gothenburg, Sweden; [Sunnerhagen, K. S.] Univ Oslo, Fac Med, N-0316 Oslo, Norway		Hofgren, C (corresponding author), Univ Gothenburg, HSahlgrenska Acad, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, Guldhedsgatan 19, S-41345 Gothenburg, Sweden.	caisa.hofgren@rehab.gu.se	Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400			Alaszewski A, 2007, DISABIL REHABIL, V29, P1858, DOI 10.1080/09638280601143356; Appelros Peter, 2004, J Stroke Cerebrovasc Dis, V13, P52, DOI 10.1016/j.jstrokecerebrovasdis.2004.02.005; BARNES MP, 2000, TXB REHABILITATION M, P257; BERGMANN H, 1991, J NEURAL TRANSM-GEN, P157; BLACKSCHAFFER RM, 1990, ARCH PHYS MED REHAB, V71, P285; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Dafer RM, 2008, TOP STROKE REHABIL, V15, P13, DOI 10.1310/tsr1501-13; Denvall V, 2002, J REHABIL MED, V34, P153, DOI 10.1080/16501970213231; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; FERRO JM, 1994, STROKE, V25, P1611, DOI 10.1161/01.STR.25.8.1611; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hinckley JJ, 2002, J COMMUN DISORD, V35, P543, DOI 10.1016/S0021-9924(02)00119-3; Hofgren C, 2007, ACTA NEUROL SCAND, V115, P73, DOI 10.1111/j.1600-0404.2006.00768.x; Hofgren C, 2007, J REHABIL MED, V39, P547, DOI 10.2340/16501977-0085; Hsieh CL, 1997, SCAND J REHABIL MED, V29, P113; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039; Malm J, 1998, NEUROLOGY, V51, P433, DOI 10.1212/WNL.51.2.433; Neau JP, 1998, CEREBROVASC DIS, V8, P296, DOI 10.1159/000015869; Perk J, 2004, SCAND J PUBLIC HEALT, V32, P181, DOI 10.1080/14034950410021880; Prigatano G., 1991, BNI Q, V7, P2; Prigatano GP, 1993, BNI Q, V9, P2; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; Saeki Satoru, 2004, J Stroke Cerebrovasc Dis, V13, P160, DOI 10.1016/j.jstrokecerebrovasdis.2004.06.006; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Treger I, 2007, DISABIL REHABIL, V29, P1397, DOI 10.1080/09638280701314923; Vestling Monika, 2005, Scand J Occup Ther, V12, P89, DOI 10.1080/11038120510031770; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Walther SM, 2003, INTENS CARE MED, V29, P933, DOI 10.1007/s00134-003-1757-4; Wozniak MA, 1999, STROKE, V30, P2568, DOI 10.1161/01.STR.30.12.2568; Wozniak MA, 2002, NEUROEPIDEMIOLOGY, V21, P159, DOI 10.1159/000059516	42	33	36	0	21	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1051-9815	1875-9270		WORK	Work		2010	36	4					431	439		10.3233/WOR-2010-1039			9	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	639IY	WOS:000280969700009	20714099				2022-02-06	
J	Komuta, Y; Teng, X; Yanagisawa, H; Sango, K; Kawamura, K; Kawano, H				Komuta, Yukari; Teng, Xichuan; Yanagisawa, Hiroko; Sango, Kazunori; Kawamura, Koki; Kawano, Hitoshi			Expression of Transforming Growth Factor-beta Receptors in Meningeal Fibroblasts of the Injured Mouse Brain	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Transforming growth factor-beta; Receptor; Fibrotic scar; Astrocyte; Immunohistochemistry; In situ hybridization	SPINAL-CORD-INJURY; NIGROSTRIATAL DOPAMINERGIC AXONS; MESSENGER-RNA; RAT-BRAIN; EXTRACELLULAR-MATRIX; CEREBRAL HEMISPHERE; ENHANCED EXPRESSION; GENE-EXPRESSION; NERVOUS-SYSTEM; SCAR FORMATION	The fibrotic scar which is formed after traumatic damage of the central nervous system (CNS) is considered as a major impediment for axonal regeneration. In the process of the fibrotic scar formation, meningeal fibroblasts invade and proliferate in the lesion site to secrete extracellular matrix proteins, such as collagen and laminin. Thereafter, end feet of reactive astrocytes elaborate a glia limitans surrounding the fibrotic scar. Transforming growth factor-beta 1 (TGF-beta 1), a potent scar-inducing factor, which is upregulated after CNS injury, has been implicated in the formation of the fibrotic scar and glia limitans. In the present study, expression of receptors to TGF-beta 1 was examined by in situ hybridization histochemistry in transcortical knife lesions of the striatum in the mouse brain in combination with immunofluorescent staining for fibroblasts and astrocytes. Type I and type II TGF-beta receptor mRNAs were barely detected in the intact brain and first found in meningeal cells near the lesion 1 day postinjury. Many cells expressing TGF-beta receptors were found around the lesion site 3 days postinjury, and some of them were immunoreactive for fibronectin. After 5 days postinjury, many fibroblasts migrated from the meninges to the lesion site formed the fibrotic scar, and most of them expressed TGF-beta receptors. In contrast, few of reactive astrocytes expressed the receptors throughout the postinjury period examined. These results indicate that meningeal fibroblasts not reactive astrocytes are a major target of TGF-beta 1 that is upregulated after CNS injury.	[Komuta, Yukari; Teng, Xichuan; Yanagisawa, Hiroko; Sango, Kazunori; Kawamura, Koki; Kawano, Hitoshi] Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, Tokyo 1838526, Japan; [Teng, Xichuan] Eastern Liaoning Univ, Dept Pathol, Coll Med, Dandong 118000, Peoples R China		Kawano, H (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, 2-6 Musashidai, Tokyo 1838526, Japan.	kawano-ht@igakuken.or.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20500318]	The authors would like to thank Dr. Geoffrey Raisman, UCL Institute of Neurology, Queen Square, London for reviewing the manuscript and valuable advice. This work was supported by the Ministry of Education, Science, Sports and Culture of Japan (20500318).	BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; De Groot CJA, 1999, J NEUROPATH EXP NEUR, V58, P174, DOI 10.1097/00005072-199902000-00007; Fee DB, 2004, BRAIN RES, V1012, P52, DOI 10.1016/j.brainres.2004.03.028; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Gold LI, 1997, AM J PATHOL, V150, P209; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Homma A, 2006, J COMP NEUROL, V499, P120, DOI 10.1002/cne.21097; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; Kawano H, 2007, NEURAL PROTEOGLYCANS, P215; Klapka N, 2006, J NEUROTRAUM, V23, P422, DOI 10.1089/neu.2006.23.422; Klapka N, 2005, EUR J NEUROSCI, V22, P3047, DOI 10.1111/j.1460-9568.2005.04495.x; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Li HP, 2007, J NEUROSCI RES, V85, P536, DOI 10.1002/jnr.21141; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; MOSES HL, 1987, J CELL PHYSIOL, P1, DOI 10.1002/jcp.1041330403; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; RIBOTTA MGY, 2001, PROG BRAIN RES, V132, P587; Schmid P, 1998, AM J PATHOL, V152, P485; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; Shearer MC, 2001, CELL TISSUE RES, V305, P267, DOI 10.1007/s004410100384; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Unsicker K, 2000, EUR J BIOCHEM, V267, P6972, DOI 10.1046/j.1432-1327.2000.01824.x; Vivien D, 1998, J NEUROCHEM, V70, P2296; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	40	33	42	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2010	30	1					101	111		10.1007/s10571-009-9435-x			11	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	549XI	WOS:000274087400011	19653094				2022-02-06	
J	Kreutzer, JS; Stejskal, TM; Godwin, EE; Powell, VD; Arango-Lasprilla, JC				Kreutzer, Jeffrey S.; Stejskal, Taryn M.; Godwin, Emilie E.; Powell, Victoria D.; Arango-Lasprilla, Juan Carlos			A mixed methods evaluation of the Brain Injury Family Intervention	NEUROREHABILITATION			English	Article						Traumatic brain injury; caregivers; family intervention; family therapy	SEVERE HEAD-INJURY; CAREGIVER BURDEN; PSYCHOLOGICAL DISTRESS; MARITAL STABILITY; CARERS; NEEDS; PROGRAM; REHABILITATION; IMPACT; INDIVIDUALS	Objective: To describe and compare caregivers' and patients' helpfulness and goal attainment ratings of the Brain Injury Family Intervention (BIFI), and qualitatively evaluate their perceptions of most important things learned. Methods: 76 caregivers and 76 patients with acquired brain injury participated in the BIFI, a structured family intervention program which includes educational, skill building, and psychological support components. Outcome measures were obtained following each of the five intervention sessions and following completion of the entire program. Results: Session helpfulness ratings for caregivers and patients were uniformly high as were ratings of the extent to which session goals were met. Between group comparisons did not indicate differences for individual session helpfulness or goal attainment ratings. Qualitative analysis of most important things learned provided corroboratory evidence that BIFI topics were relevant and consistent with program goals. Conclusions: The present investigation provides evidence that the BIFI is perceived as helpful and that treatment methods facilitate achievement of goals. The investigation also suggests that investigators may benefit from using mixed methods to evaluate outcomes, complementing traditional quantitative methods with qualitative approaches.	[Kreutzer, Jeffrey S.; Stejskal, Taryn M.; Godwin, Emilie E.; Powell, Victoria D.; Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA		Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	jskreutz@vcu.edu					ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; [Anonymous], 1997, GUID UN DAT SET MED; Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Bouwens SFM, 2009, CLIN REHABIL, V23, P310, DOI 10.1177/0269215508101744; Broderick CB., 1993, UNDERSTANDING FAMILY; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Creswell J.W., 2017, RES DESIGN QUALITATI; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ellis A., 1975, NEW GUIDE RATIONAL L; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HODGSON J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Kim JW, 2007, SOC WORK HEALTH CARE, V45, P81, DOI 10.1300/J010v45n01_06; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Maxwell J., 2005, QUALITATIVE RES DESI; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Murray HM, 2006, BRAIN INJURY, V20, P575, DOI 10.1080/02699050600664590; Nichols M. P., 2004, FAMILY THERAPY CONCE; Panting A, 1972, REHABILITATION, V38, P33; Patton MQ., 2015, QUALITATIVE RES EVAL, V4; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Pinquart M, 2006, J GERONTOL B-PSYCHOL, V61, pP33, DOI 10.1093/geronb/61.1.P33; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rossman G. B., 2003, LEARNING FIELD INTRO; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Schlosser RW, 2004, J COMMUN DISORD, V37, P217, DOI 10.1016/j.jcomdis.2003.09.003; Sinnakaruppan I, 2005, BRAIN INJURY, V19, P283, DOI 10.1080/02699050400003924; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turner-Stokes L, 2009, J REHABIL MED, V41, P528, DOI 10.2340/16501977-0383; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	54	33	34	1	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2010	27	1					19	29		10.3233/NRE-2010-0578			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000003	20634598				2022-02-06	
J	Malinauskas, R				Malinauskas, Romualdas			THE ASSOCIATIONS AMONG SOCIAL SUPPORT, STRESS, AND LIFE SATISFACTION AS PERCEIVED BY INJURED COLLEGE ATHLETES	SOCIAL BEHAVIOR AND PERSONALITY			English	Article						perceived stress; perceived social support; life satisfaction; sports injury; college athletes	TRAUMATIC BRAIN-INJURY; MULTIDIMENSIONAL SCALE; BUFFERING HYPOTHESIS; COPING RESPONSES; SELF-ESTEEM; PERCEPTIONS; REHABILITATION; ADJUSTMENT; PREINJURY; PEOPLE	The relationships were examined among severity of injury, and participants' perceptions of stress, social support, and life satisfaction. Participants were 123 college athletes (male, n = 69, female n = 54) with minor (69) or severe (54) injuries, who ranged in age from 18 to 25 years. Participants completed measures of perceived social support, stress, and satisfaction with life. Greater perceived stress was associated with diminished life satisfaction for athletes with a major injury more than for those with a minor injury. The interaction between perceived stress and perceived social support was associated most with diminished life satisfaction for participants with a major injury.	Lithuanian Acad Phys Educ, Dept Psychol, LT-44221 Kaunas, Lithuania		Malinauskas, R (corresponding author), Lithuanian Acad Phys Educ, Dept Psychol, Sporto 6, LT-44221 Kaunas, Lithuania.	r.malinauskas@lkka.lt	Malinauskas, Romualdas/E-6589-2018	Malinauskas, Romualdas/0000-0001-5578-3100			Adam M.U., 2004, J DANCE MED SCI, V8, P43; Affleck G, 1988, ARTHRIT CARE RES, V1, P71; Ahern DK, 1997, CLIN SPORT MED, V16, P755, DOI 10.1016/S0278-5919(05)70052-1; Albinson CB, 2003, J SPORT REHABIL, V12, P306, DOI 10.1123/jsr.12.4.306; Andrews F. M., 1976, SOCIAL INDICATORS WE; Bone JB, 2006, J SPORT REHABIL, V15, P156, DOI 10.1123/jsr.15.2.156; BREWER BW, 1995, CLIN J SPORT MED, V5, P241, DOI 10.1097/00042752-199510000-00006; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1988, CLAR SYMP, P31; Cohen S., 2000, SOCIAL SUPPORT MEASU; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Feldman PJ, 2000, PSYCHOSOM MED, V62, P715, DOI 10.1097/00006842-200009000-00016; FORDYCE MW, 1977, J COUNS PSYCHOL, V24, P511, DOI 10.1037/0022-0167.24.6.511; G Tenenbaum, 2007, HDB SPORT PSYCHOL, P404, DOI DOI 10.1002/9781118270011.CH18; Hamarat E., 2002, COLL STUDENT J, V36, P129; Hampton NZ, 2004, REHABIL COUNS BULL, V48, P31, DOI 10.1177/00343552040480010401; KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J; Krause JS, 1998, REHABIL PSYCHOL, V43, P282, DOI 10.1037/0090-5550.43.4.282; Malinauskas R, 2008, J SPORT MED PHYS FIT, V48, P107; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Park JK, 2000, SPORT PSYCHOL, V14, P63, DOI 10.1123/tsp.14.1.63; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PETRIE TA, 1992, BEHAV MED, V18, P127, DOI 10.1080/08964289.1992.9936963; Petrie TA, 1993, J APPL SPORT PSYCHOL, V5, P1, DOI DOI 10.1080/10413209308411301; POWELL JW, 1991, PREVENTION ATHLETIC, P11; Quackenbush N., 1994, Journal of Sport Behavior, V17, P178; Reed S, 2004, J ATHL TRAINING, V39, P193; Rees T, 2007, J SPORT SCI, V25, P1057, DOI 10.1080/02640410600982279; Robbins J, 2001, J SPORT BEHAV, V24, P277; Ryska TA, 1999, CURR PSYCHOL, V18, P381, DOI 10.1007/s12144-999-1011-5; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; SMITH RE, 1990, J PERS SOC PSYCHOL, V58, P360, DOI 10.1037/0022-3514.58.2.360; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Trieschmann R, 1988, SPINAL CORD INJURIES; Udry E, 1997, J SPORT EXERCISE PSY, V19, P368, DOI 10.1123/jsep.19.4.368; Wan C.K., 1990, INTERACTION EFFECTS; Warren L, 1996, J REHABIL RES DEV, V33, P404; Wasley D, 1998, PERCEPT MOTOR SKILL, V86, P1402, DOI 10.2466/pms.1998.86.3c.1402; ZIMET GD, 1990, J PERS ASSESS, V55, P610, DOI 10.1207/s15327752jpa5503&4_17; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2; [No title captured]; [No title captured]	46	33	33	2	21	SOC PERSONALITY RES INC	PALMERSTON NORTH	P O BOX 1539, PALMERSTON NORTH 5330, NEW ZEALAND	0301-2212			SOC BEHAV PERSONAL	Soc. Behav. Pers.		2010	38	6					741	752		10.2224/sbp.2010.38.6.741			12	Psychology, Social	Social Science Citation Index (SSCI)	Psychology	632NL	WOS:000280431300003					2022-02-06	
J	Ord, JS; Greve, KW; Bianchini, KJ; Aguerrevere, LE				Ord, Jonathan S.; Greve, Kevin W.; Bianchini, Kevin J.; Aguerrevere, Luis E.			Executive dysfunction in traumatic brain injury: The effects of injury severity and effort on the Wisconsin Card Sorting Test	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Wisconsin Card Sorting Test; Executive function; Outcome; Performance validity; Effort; Malingering	DIGIT RECOGNITION TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; CLOSED-HEAD INJURY; CLASSIFICATION ACCURACY; NEUROPSYCHOLOGICAL ASSESSMENT; LATENT STRUCTURE; PERFORMANCE; COMPENSATION; INDICATORS; EXAGGERATION	This study examined the persistent effects of traumatic brain injury (TBI) on Wisconsin Card Sorting Test (WCST) performance. Since poor effort can contaminate results in populations with incentive to perform poorly, performance validity was explicitly assessed and controlled for using multiple well-validated cognitive malingering indicators. Participants were 109 patients with mild TBI and 67 patients with moderate-to-severe TBI seen for neuropsychological evaluation at least one year post injury. Patients with diffuse neurological impairment and healthy controls were included for comparison. Results suggested a dose-response effect of TBI severity on WCST performance in patients providing good effort; the mild TBI group did not differ from controls while increased levels of impairment were observed in the moderate-to-severe TBI group. Effort during testing had a larger impact on WCST performance than mild or moderate-to-severe TBI. Clinical implications of these findings are discussed.	[Ord, Jonathan S.; Greve, Kevin W.; Bianchini, Kevin J.; Aguerrevere, Luis E.] Univ New Orleans, New Orleans, LA 70148 USA; [Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu	Aguerrevere, Luis/P-5684-2019	Aguerrevere, Luis/0000-0001-9160-1044			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1993, PORTLAND DIGIT RECOG; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Doane BM, 2005, CLIN NEUROPSYCHOL, V19, P99, DOI 10.1080/13854040490524100; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1996, MANUAL COMPUTERIZED; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2005, ARCH CLIN NEUROPSYCH, V20, P355, DOI 10.1016/j.acn.2004.09.004; Greve KW, 1997, BRIT J CLIN PSYCHOL, V36, P283, DOI 10.1111/j.2044-8260.1997.tb01414.x; Greve KW, 2002, ASSESSMENT, V9, P271, DOI 10.1177/1073191102009003006; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Greve KW, 1998, ARCH CLIN NEUROPSYCH, V13, P597; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1981, WISCONSIN CARD SORTI; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Iverson G L, 2000, Appl Neuropsychol, V7, P247, DOI 10.1207/S15324826AN0704_7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Love JM, 2003, APPL NEUROPSYCHOL, V10, P246, DOI 10.1207/s15324826an1004_7; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2003, J CLIN EXP NEUROPSYC, V25, P512, DOI 10.1076/jcen.25.4.512.13877; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	64	33	33	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	2					132	140		10.1080/13803390902858874			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	550YX	WOS:000274172300003	19484646				2022-02-06	
J	Talving, P; Lustenberger, T; Kobayashi, L; Inaba, K; Barmparas, G; Schnuriger, B; Lam, L; Chan, LS; Demetriades, D				Talving, Peep; Lustenberger, Thomas; Kobayashi, Leslie; Inaba, Kenji; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Chan, Linda S.; Demetriades, Demetrios			Erythropoiesis Stimulating Agent Administration Improves Survival After Severe Traumatic Brain Injury A Matched Case Control Study	ANNALS OF SURGERY			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; HUMAN ERYTHROPOLETIN; ANEMIA; NEUROPROTECTION; INFANTS; SAFETY	Objective: Erythropoiesis stimulating agent (ESA) administration may reduce mortality in severe traumatic brain injury (sTBI). Summary Background Data: It has been established that the administration of ESA in critically ill trauma victims has been associated with improved outcomes. Recent experimental and clinical data showed neuroprotective effects of ESA, however, the literature regarding impact on outcome in sTBI is lacking. Methods: A retrospective matched case control study in patients with sTBI [head Abbreviated Injury Scale (AIS), >= 3] receiving ESA while in the surgical intensive care unit from January 1, 1996 to December 31, 2007 (n = 89). were matched I to 2 (n = 178) by age, gender, mechanism of injury, Glasgow Coma Scale, presence of hypotension on admission, Injury Severity Score, AIS for all body regions, and presence of anemia with patients who did not receive the agent. Each case's controls were chosen to have surgical intensive care unit length of stay more than or equal to the time from admission to first dose of ESA. The primary outcome measure in this study was mortality. Results: Cases and controls had similar age, gender, mechanisms of injury, incidence of hypotension, Glasgow Coma Scale on admission, Injury Severity Score, and AIS for all body regions. Although the ESA+ patients experienced protracted hospital length of stay and comparable surgical intensive care unit free days, they demonstrated a significantly lower in-hospital mortality in comparison to controls at 7.9% versus 24.2%, respectively (OR: 0.27; 95% CI = 0.12-0.62; P = 0.001). Conclusions: Erythropoiesis stimulating agent administration in sTBI is associated with a significant in-hospital survival advantage without increase in morbidity. Prospective validation of our findings is warranted.	[Talving, Peep; Lustenberger, Thomas; Kobayashi, Leslie; Inaba, Kenji; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Chan, Linda S.; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Div Acute Care Surg Emergency Surg Trauma & Surg, Los Angeles, CA 90033 USA		Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Div Acute Care Surg Emergency Surg Trauma & Surg, Los Angeles Cty Gen Hosp,Dept Surg, 1200 N State St,C4E100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Talving, Peep/E-6015-2013; Talving, Peep/G-8621-2015; Barmparas, Galinos/L-6530-2019	Talving, Peep/0000-0002-9741-2073; 			*AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS7; Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Caucio L, 2008, J TRAUMA, V65, P297; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203; Fauchere JC, 2008, PEDIATRICS, V122, P375, DOI 10.1542/peds.2007-2591; Fliser D, 2007, SEMIN HEMATOL, V44, P212, DOI 10.1053/j.seminhematol.2007.04.008; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Juul SE, 2008, PEDIATRICS, V122, P383, DOI 10.1542/peds.2007-2711; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Napolitano LM, 2008, J TRAUMA, V65, P285, DOI 10.1097/TA.0b013e31817f2c6e; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Pacary E, 2006, NEURODEGENER DIS, V3, P87, DOI 10.1159/000092098; Robinson Y, 2008, ACTA ANAESTH SCAND, V52, P587, DOI 10.1111/j.1399-6576.2008.01617.x; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510	24	33	35	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	JAN	2010	251	1					1	4		10.1097/SLA.0b013e3181b844fa			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	538SF	WOS:000273203600001	19779323				2022-02-06	
J	Lo, TYM; Jones, PA; Minns, RA				Lo, Tsz-Yan M.; Jones, Patricia A.; Minns, Robert A.			Pediatric Brain Trauma Outcome Prediction Using Paired Serum Levels of Inflammatory Mediators and Brain-Specific Proteins	JOURNAL OF NEUROTRAUMA			English	Article						adhesion molecules; brain-specific proteins; interleukins; outcome prediction; pediatric traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; GLASGOW COMA SCALE; CEREBROSPINAL-FLUID; YOUNG-CHILDREN; BIOMARKER CONCENTRATIONS; MULTIPLEX ASSESSMENT; INTERLEUKIN-6; SEVERITY; DAMAGE	Many potential brain trauma biomarkers have been reported, but no previous study has described outcome prediction using combinations of biomarker levels. We aimed to investigate the outcome predictive values of multiple biomarkers from different mediator families and to determine whether combinations of two serum biomarkers may achieve higher outcome predictive values than individual biomarker levels. A prospective observational study was conducted involving 28 children requiring intensive care management following brain trauma. Day 1 post-injury serum concentrations of eight different biomarkers-S100b protein (S100b), neuron-specific enolase (NSE), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), soluble intracellular adhesion molecule (SICAM), L-selectin, and endothelin-were quantified using enzyme-linked immunosorbent assay (ELISA). Global outcome was assessed at 6 months post-injury using the Glasgow Outcome Score (GOS). Receiver operator characteristic curve (ROC) analysis and its multivariate extension, Multivariate ROC (MultiROC), were used to assess the outcome predictive values of the individual and the paired biomarkers. None of the eight biomarkers assessed individually achieved an area under the ROC curve (AUC) of more than 0.95 for predicting unfavorable outcome, but five of the 20 biomarker pairs assessed had this high degree of outcome predictability. Two combinations using S100b as the "screening marker'' and either L-selectin or IL-6 as the "varying marker'' achieved an AUC of 0.98, and their specificity and sensitivity for unfavorable outcome prediction were 96% and 100%, respectively. Prognostic pairs combining serum levels of two biomarkers (inflammatory mediators and brain-specific proteins) offer better outcome predictive values for unfavorable outcome after childhood brain trauma than may be achieved using individual marker levels.	[Lo, Tsz-Yan M.; Jones, Patricia A.; Minns, Robert A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland		Lo, TYM (corresponding author), 218 Queens Quay W,Suite 2504, Toronto, ON M5J 2Y6, Canada.	mils.lo@doctors.org.uk					Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Ergun R, 1998, NEUROL RES, V20, P418; FACCO E, 1986, CHILD NERV SYST, V2, P67; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SHULTZ EK, 1995, CLIN CHEM, V41, P1248; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Suominen P, 1998, INJURY, V29, P425; Takahashi H, 1989, Neurol Med Chir (Tokyo), V29, P192, DOI 10.2176/nmc.29.192; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WALKER PJ, 1987, AUST NZ J SURG, V57, P715, DOI 10.1111/j.1445-2197.1987.tb01249.x; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yang Yunmei, 2002, Chin J Traumatol, V5, P259	53	33	39	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1479	1487		10.1089/neu.2008.0753			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200005	19275469				2022-02-06	
J	Campbell, TA; Nelson, LA; Lumpkin, R; Yoash-Gantz, RE; Pickett, TC; McCormick, CL				Campbell, Thomas A.; Nelson, Lonnie A.; Lumpkin, Robin; Yoash-Gantz, Ruth E.; Pickett, Treven C.; McCormick, Cortney L.			Neuropsychological Measures of Processing Speed and Executive Functioning in Combat Veterans with PTSD, TBI, and Comorbid TBI/PTSD	PSYCHIATRIC ANNALS			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; MILD; REHABILITATION; PERFORMANCE; VIOLENCE; VICTIMS; MEMORY		[Campbell, Thomas A.; Pickett, Treven C.] Vet Affairs Med Ctr, Hunter Holmes McGuire Dept, Mental Hlth Serv, Richmond, VA USA; [Nelson, Lonnie A.] Primary TBI Operat Component Def Ctr Psychol Hlth, Def & Vet Brain Injury Ctr, Rosslyn, VA USA; [Nelson, Lonnie A.] Primary TBI Operat Component Def Ctr Excellence T, Def & Vet Brain Injury Ctr, Rosslyn, VA USA; [Lumpkin, Robin; McCormick, Cortney L.] MIRECC, VISN6, Durham, NC USA; [Yoash-Gantz, Ruth E.] MIRECC, Salisbury, NC USA; [Yoash-Gantz, Ruth E.] Hefner Vet Affairs Med Ctr, Salisbury, NC USA; [Yoash-Gantz, Ruth E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA; [Pickett, Treven C.] MIRECC, Richmond, VA USA; [Pickett, Treven C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA 23284 USA		Campbell, TA (corresponding author), McGuire VA Med Ctr, Psychol Sect 116B, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.	Thomas.Campbell4@va.gov					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Barrett DH, 1996, AM J PSYCHIAT, V153, P1492; Beckham JC, 1998, J TRAUMA STRESS, V11, P811, DOI 10.1023/A:1024409903617; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bremner J D, 1999, Semin Clin Neuropsychiatry, V4, P249; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Foa EB, 2004, J CONSULT CLIN PSYCH, V72, P879, DOI 10.1037/0022-006X.72.5.879; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Golden CJ, 1978, STROOP COLOR WORD TE; Green P., 1996, WORD MEMORY TEST USE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Jaycox, 2008, INVISIBLE WOUNDS WAR, P3; Kanagaratnam P, 2007, J ANXIETY DISORD, V21, P510, DOI 10.1016/j.janxdis.2006.06.008; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lanius RA, 2001, AM J PSYCHIAT, V158, P1920, DOI 10.1176/appi.ajp.158.11.1920; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; REITAN RM, 1985, HALLSTEAD REITAN NEU; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2	30	33	33	0	12	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0048-5713			PSYCHIAT ANN	Psychiatr. Ann.	AUG	2009	39	8					796	803		10.3928/00485713-20090728-01			8	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	483EP	WOS:000268945500005					2022-02-06	
J	Cribier, A; Litzler, PY; Eltchaninoff, H; Godin, M; Tron, C; Bauer, F; Bessou, JP				Cribier, Alain; Litzler, Pierre-Yves; Eltchaninoff, Helene; Godin, Matthieu; Tron, Christophe; Bauer, Fabrice; Bessou, Jean-Paul			Technique of Transcatheter Aortic Valve Implantation with the Edwards-Sapien (R) Heart Valve Using the Transfemoral Approach	HERZ			English	Article						Aortic valve stenosis; Valve replacement; Valve implantation; Prosthetic valves	STENOSIS; REPLACEMENT; PROSTHESIS	Transcatheter aortic valve implantation (TAVI) using a balloon-expandable valve has been developed by the authors' group 7 years ago to offer a therapeutic solution to nonoperable or surgical high-risk patients with degenerative aortic stenosis. The technique and the devices used have rapidly evolved thereafter and TAVI has become a clinical reality with more than 3,500 patients implanted worldwide with this device. The currently used Edwards-Sapien (R) Transcatheter Heart Valve (THV) consists of a balloon-expandable stent with an integrated bovine pericardial valve. It can be implanted within the diseased native aortic valve using either the retrograde transfemoral or antegrade transapical routes. This article is aimed at describing the updated transfemoral technique. Appropriate patient selection is crucial for a successful procedure including close evaluation of the arterial characteristics. After predilatation of the native valve with a balloon catheter, the THV with its delivery system is introduced within the femoral artery, advanced to the native aortic valve under X-ray control, positioned across the aortic annulus, and delivered by balloon inflation under rapid heart pacing. The acute procedural success is 96% and the technique leads to an immediate and lasting improvement of hemodynamics and clinical status. Complications are rare and the mortality rate is 6.3% at 1 month in this cohort of very sick patients. Procedural complications are headed by vascular injury related to the large size of the arterial introducers. An upcoming lower-profile Edwards THV should improve this issue and increase the indication for this less invasive approach in the near future. At the present time, the indications should be restricted to nonoperable or surgical high-risk patients and the procedure performed by experienced and formally trained physicians working in an optimal multidisciplinary environment.	[Cribier, Alain; Eltchaninoff, Helene; Godin, Matthieu; Tron, Christophe; Bauer, Fabrice] Univ Rouen, Dept Cardiol, Hosp Charles Nicolle, F-76000 Rouen, France; [Cribier, Alain; Eltchaninoff, Helene; Godin, Matthieu; Tron, Christophe; Bauer, Fabrice] INSERM 144, F-76000 Rouen, France; [Litzler, Pierre-Yves; Bessou, Jean-Paul] INSERM 644, Paris, France; [Litzler, Pierre-Yves; Bessou, Jean-Paul] Univ Rouen, Dept Cardiothorac Surg, Hosp Charles Nicolle, F-76000 Rouen, France		Cribier, A (corresponding author), Univ Rouen, Dept Cardiol, 1 Rue Germont, F-76000 Rouen, France.	Alain.Cribier@chu-rouen.fr					Agatiello C, 2006, ARCH MAL COEUR VAISS, V99, P195; Chiam PTL, 2009, AM HEART J, V157, P229, DOI 10.1016/j.ahj.2008.10.003; Cribier A, 2004, J AM COLL CARDIOL, V43, P698, DOI 10.1016/j.jacc.2003.11.026; Cribier A, 2002, CIRCULATION, V106, P3006, DOI 10.1161/01.CIR.0000047200.36165.B8; Cribier A, 2006, J AM COLL CARDIOL, V47, P1214, DOI 10.1016/j.jacc.2006.01.049; Solomon L W, 2001, J Invasive Cardiol, V13, P592; *TASKF MAN VALV HE, 2007, EUR HEART J, V428, P1; Vahanian A, 2008, EUR J CARDIO-THORAC, V34, P1, DOI 10.1016/j.ejcts.2008.04.039; Walther T, 2007, CIRCULATION, V116, pI240, DOI 10.1161/CIRCULATIONAHA.106.677237; Walther T, 2009, ANN THORAC SURG, V87, P276, DOI 10.1016/j.athoracsur.2008.08.017; Webb JG, 2006, CIRCULATION, V113, P842, DOI 10.1161/CIRCULATIONAHA.105.582882; Webb JG, 2008, JACC-CARDIOVASC INTE, V1, P122, DOI 10.1016/j.jcin.2007.11.010; Webb JG, 2007, CIRCULATION, V116, P755, DOI 10.1161/CIRCULATIONAHA.107.698258; Webb JG, 2006, CATHETER CARDIO INTE, V68, P199, DOI 10.1002/ccd.20829	14	33	33	0	3	URBAN & VOGEL	MUNICH	NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY	0340-9937	1615-6692		HERZ	Herz	AUG	2009	34	5					347	356		10.1007/s00059-009-3264-z			10	Cardiac & Cardiovascular Systems	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	487XZ	WOS:000269313200003	19711030				2022-02-06	
J	Hunt, TN; Ferrara, MS				Hunt, Tamerah N.; Ferrara, Michael S.			Age-Related Differences in Neuropsychological Testing Among High School Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; mild traumatic brain injuries; adolescents; cognitive maturity	FOOTBALL PLAYERS; NORMATIVE DATA; HEAD TRAUMA; CONCUSSION; COLLEGIATE; RECOVERY; STATEMENT; INJURY; SPORT	Context: Clinicians have questioned the need to obtain annual baseline neuropsychological tests in high school athletes. If no difference among academic grades exists, annual baseline testing may not be necessary. Objective: To examine differences at baseline testing on pencil-and-paper neuropsychological tests among grade levels in high school athletes. Design: Cross-sectional, between-groups design. Setting: Schools participating in a Georgia high school athletics association. Patients or Other Participants: High school football players (n = 198) in the 9th through 12th grades, with a mean age of 15.78 +/- 1.16 years. Main Outcome Measure(s): Participants were divided into 4 groups by grade and were administered a symptom checklist and brief neuropsychological test battery. Grade level served as the independent variable. Symptom and individual test scores within the neuropsychological test battery served as dependent variables. Results: Differences were noted among grades on the Trail Making Test A (F-3.194 = 3.23, P = .024, eta(2) = 0.048), Trail Making Test B (F-3,F-194 = 3.93, P = .009, eta(2) = 0.057), Symbol Digit Modalities Test (F-3,F-194 = 4.38, P = .005, eta(2) = 0.064), dominant tap (F-3,F-194 = 3.14, P = .026, eta(2) = 0.046), and nondominant tap (F-3,F-194 = 4.902, P = .003, eta(2) = 0.070). Using the Bonferroni correction (P <= .00625), we found differences between the 9th grade and 11th and 12th grades. Conclusions: Baseline neuropsychological test scores in high school athletes improved as a function of age, with differences between the 9th grade and 11th and 12th grades. Because the differences were driven by 9th-grade test scores, baseline testing should be completed, at minimum, upon entrance into 9th and 10th grades; however, annual testing is still recommended until additional research is conducted.	[Hunt, Tamerah N.] Ohio State Univ, Sports Med Ctr, Columbus, OH 43221 USA; [Ferrara, Michael S.] Univ Georgia, Athens, GA 30602 USA		Hunt, TN (corresponding author), Ohio State Univ, Sports Med Ctr, 2050 Kenny Rd,Suite 3100, Columbus, OH 43221 USA.	tamerah.hunt@osumc.edu	Hunt, Tamerah/E-3281-2011				Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; BAUMGARTNER TA, 2003, MEASUREMENT EVALUATI, P42; Benes FM, 2001, DEV COGN NEUROSCI, P79; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FINLAYSON MAJ, 1976, PERCEPT MOTOR SKILL, V43, P475, DOI 10.2466/pms.1976.43.2.475; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; *IMPACT, NORM DAT HIGH SCH ST; KEPPEL G, 1991, DESIGN ANAL RES HDB, P62; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; LURIA AR, 1980, HIGHER CORTICAL FUNC, P42; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MCCREA M, 2001, JAMA-J AM MED ASSOC, V290, P2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; OBRZUT JE, 1986, CHILD NEUROPSYCHOL, P18; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Piland SG, 2003, J ATHL TRAINING, V38, P104; RASMUSSON DX, 1995, ARCH CLIN NEUROPSYCH, V10, P21, DOI 10.1016/0887-6177(94)E0001-6; RUFF RM, 1993, PERCEPT MOTOR SKILL, V76, P1219, DOI 10.2466/pms.1993.76.3c.1219; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; SMITH A, 1991, SEMINAR ON PUBLISHING FOR AN OPTIMAL PRODUCT : MEETING THE NEEDS OF READERS AND ADVERTISERS IN TODAYS MARKET, P1; SPREEN O, 1995, DEV NEUROPSYCHOL, P37; Theye Fred, 2004, Clin Med Res, V2, P165; Valovich TC, 2003, J ATHL TRAINING, V38, P51; YEUDALL LT, 1987, J CLIN PSYCHOL, V43, P346, DOI 10.1002/1097-4679(198705)43:3<346::AID-JCLP2270430308>3.0.CO;2-Q	36	33	33	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2009	44	4					405	409		10.4085/1062-6050-44.4.405			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	474EZ	WOS:000268266600010	19593423	Green Published, Green Submitted			2022-02-06	
J	Lenhardt, R; Orhan-Sungur, M; Komatsu, R; Govinda, R; Kasuya, Y; Sessler, DI; Wadhwa, A				Lenhardt, Rainer; Orhan-Sungur, Mukadder; Komatsu, Ryu; Govinda, Raghavendra; Kasuya, Yusuke; Sessler, Daniel I.; Wadhwa, Anupama			Suppression of Shivering during Hypothermia Using a Novel Drug Combination in Healthy Volunteers	ANESTHESIOLOGY			English	Article							COMPUTER-CONTROLLED INFUSION; TRAUMATIC BRAIN-INJURY; ADULT HUMAN VOLUNTEERS; DEXMEDETOMIDINE HYDROCHLORIDE; ISOFLURANE ANESTHESIA; SWEATING THRESHOLD; ADDITIVELY REDUCE; SHORT-TERM; VASOCONSTRICTION; MEPERIDINE	Background: Hypothermia may be beneficial in stroke victims; however, it provokes vigorous shivering. Buspirone and dexmedetomidine each linearly reduce the shivering threshold with minimal sedation and no respiratory depression. This study tested the hypotheses that the combination of buspirone and dexmedetomidine would (1) synergistically reduce the shivering threshold, (2) synergistically reduce die gain and maximum intensity of shivering, and (3) produce sufficient inhibition to permit cooling to 34 degrees C without excessive hypotension or sedation. Methods: Eight healthy men were randomly assigned on 4 days to (1) no drug, (2) buspirone (60 mg orally), (3) dexmedetomidine (intravenous infusion to target plasma concentration of 0.6 ng/ml), or (4) combination of buspirone and dexmedetomidine at same doses. lactated Ringer's solution (approximately 3 degrees C) was infused intravenously to decrease tympanic membrane temperature by 1.5 degrees C/h. Shivering threshold was defined as an increase in oxygen consumption greater than 20%. Sedation was evaluated using the Observer's Assessment of Sedation/Alertness scale. Results: Mean arterial pressure and heart rate were slightly lower on dexmedetomidine and combination days. Likewise, the level of sedation was statistically different on these 2 days but clinically unimportant. Buspirone reduced the shivering threshold from 36.6 degrees C +/- 0.4 degrees C to 35.9 degrees C +/- 0.4 degrees C, dexmedetomidine reduced it to 34.7 degrees C +/- 0.5 degrees C, and the combination to 34.1 +/- 0.4 degrees C. The interaction effect of 0.04 degrees C was not significant. The gain of shivering and maximum shivering intensity were similar on each day. Conclusions: The combination of buspirone and dexmedetomidine additively reduced the shivering threshold. Thus, supplementing dexmedetomidine with buspirone blocks shivering and causes only minimal sedation.	Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA; Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA		Lenhardt, R (corresponding author), Univ Hosp, Dept Anesthesiol, 530 S Jackson St, Louisville, KY 40202 USA.	lenhardt@louisville.edu	Sungur, Mukadder Orhan/A-6574-2017; Sessler, Daniel/D-3504-2011; wadhwa, Anupama/AAO-2571-2020	Sungur, Mukadder Orhan/0000-0002-0770-8904; Sessler, Daniel/0000-0001-9932-3077; wadhwa, Anupama/0000-0002-4655-0169; Komatsu, Ryu/0000-0002-3824-8680	Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, Kentucky; Department of Outcomes Research, The Cleveland Clinic, Cleveland, Ohio; National Institutes of Health, Bethesda, MarylandUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [061655]; Joseph Drown Foundation, Los Angeles, California; Gheen's Foundation, Louisville, Kentucky; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM061655] Funding Source: NIH RePORTER	Received from the Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, Kentucky, and the Department of Outcomes Research, The Cleveland Clinic, Cleveland, Ohio. Submitted for publication July 9, 2008. Accepted for publication December 17, 2008. Dr. Orhan-Sungur's current position: Attending Physician, Department of Anesthesia, Istanbul University, Istanbul, Turkey; Dr. Komatsu's current position: Clinical Instructor, Department of Anesthesiology, Tokyo Women's Medical University, Tokyo, Japan. Funded by GM 061655 from the National Institutes of Health, Bethesda, Maryland (to Dr. Sessler), the Joseph Drown Foundation, Los Angeles, California, and the Gheen's Foundation, Louisville, Kentucky. Mallinckrodt Anesthesiology Products, Inc., St. Louis, Missouri, donated the thermocouples we used.	ARMSTRONG PJ, 1986, ANESTH ANALG, V65, P536; BARNARD MS, 1973, S AFR MED J, V47, P469; Campbell K, 2008, BRAIN RES, V1230, P258, DOI 10.1016/j.brainres.2008.06.110; Chenzbraun A, 1995, J Am Soc Echocardiogr, V8, P1, DOI 10.1016/S0894-7317(05)80351-7; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; DYCK JB, 1993, ANESTHESIOLOGY, V78, P813, DOI 10.1097/00000542-199305000-00002; DYCK JB, 1993, ANESTHESIOLOGY, V78, P821, DOI 10.1097/00000542-199305000-00003; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; Hoehn T, 2008, RESUSCITATION, V78, P7, DOI 10.1016/j.resuscitation.2008.04.027; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs S, 2007, COCHRANE DB SYST REV, P4, DOI DOI 10.1002/14651858.CD003311.PUB2; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; KURZ A, 1995, ANESTHESIOLOGY, V83, P293, DOI 10.1097/00000542-199508000-00009; Lamberg TS, 1998, CLIN PHARMACOL THER, V63, P640, DOI 10.1016/S0009-9236(98)90087-X; Lee SH, 2008, J NEUROL SCI, V275, P18, DOI 10.1016/j.jns.2008.05.024; LESLIE K, 1994, ANESTHESIOLOGY, V81, P353, DOI 10.1097/00000542-199408000-00013; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; LOPEZ M, 1994, ANESTHESIOLOGY, V80, P780, DOI 10.1097/00000542-199404000-00009; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; MERILAINEN PT, 1987, INT J CLIN MONIT COM, V4, P167, DOI 10.1007/BF02915904; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P985, DOI 10.1097/00000542-199112000-00010; SESSLER DI, 1992, ANESTHESIOLOGY, V76, P670, DOI 10.1097/00000542-199205000-00002; SHAFER SL, 1992, J PHARMACOKINET BIOP, V20, P147, DOI 10.1007/BF01070999; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Slinker BK, 1998, J MOL CELL CARDIOL, V30, P723, DOI 10.1006/jmcc.1998.0655; Sterz Fritz, 2006, Acute Card Care, V8, P25, DOI 10.1080/14628840600621371; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; TALLARIDA RJ, 1989, LIFE SCI, V45, P947, DOI 10.1016/0024-3205(89)90148-3; Tayefeh F, 1998, PFLUG ARCH EUR J PHY, V435, P402, DOI 10.1007/s004240050530; TISSOT S, 1995, INTENS CARE MED, V21, P149, DOI 10.1007/BF01726538; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; WEYLAND A, 1994, ANAESTHESIST, V43, P658; Wilson TE, 2007, J APPL PHYSIOL, V103, P1257, DOI 10.1152/japplphysiol.00401.2007; Xiong JY, 1996, ANESTHESIOLOGY, V85, P240, DOI 10.1097/00000542-199608000-00003; ZEISBERGER E, 1996, HDB PHYSL 4, P579	40	33	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	2009	111	1					110	115		10.1097/ALN.0b013e3181a979a3			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	462IY	WOS:000267346200019	19512867	Bronze			2022-02-06	
J	Hamberger, A; Viano, DC; Saljo, A; Bolouri, H				Hamberger, Anders; Viano, David C.; Saljo, Annette; Bolouri, Hayde			CONCUSSION IN PROFESSIONAL FOOTBALL: MORPHOLOGY OF BRAIN INJURIES IN THE NFL CONCUSSION MODEL-PART 16	NEUROSURGERY			English	Article						Animal model; Brain edema; Brain injury; Diffuse axonal injury; Glial fibrillary acidic protein; Hemorrhage; NF-200	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; ROTATIONAL ACCELERATION; BLOOD-FLOW; RAT-BRAIN; SEQUELAE; REDISTRIBUTION; BIOMECHANICS; HIPPOCAMPUS; IMPACTS	OBJECTIVE: An animal model of concussions in National Football League players has been described in a previous study. It involves a freely moving 300-g Wistar rat impacted on the side of the head at velocities of 7.4 to 11.2 m/s with a 50-g impactor. The impact causes a 6% to 28% incidence of meningeal hemorrhages and 0.1- to 0.3-mm focal petechiae depending on the impact velocity. This study addresses the immunohistochemical responses of the brain. METHODS: Twenty-seven tests were conducted with a 50-g impactor and velocities of 7.4, 9.3, or 11.2 m/s. The left temporal region of the helmet-protected head was hit I or 3 times. Thirty-one additional tests were conducted with a 100-g impactor. Diffuse axonal injury in distant regions of the brain was assessed with immunohistochemistry for NF-200, the heaviest neurofilament subunit, and glial fibrillary acidic protein, an intermediate filament protein in astrocytes. Hemorrhages were analyzed by unspecific peroxidase. There were 10 controls. RESULTS: A single impact at 7.4 and 9.3 m/s velocity with the 50-g impactor causes minimal neuronal injury and astrocytosis. Repeat impacts with 11.2 m/s velocity and more than 9.3-m/s impacts with 100 g cause diffuse axonal injury and distant injury bilaterally in the cerebral cortex, the subcortical, the white matter, the hippocampus CA1, the corpus callosum, and the striatum, as indicated by NF-200 accumulation in neuronal perikarya 10 days after impact. It also causes reactive astrocytosis in the midline regions of the cerebral cortex and periventricularly. Regions with erythrocyte-loaded blood capillaries indicated brain edema in regions of the cerebral cortex, the brainstem, and the cerebellum. CONCLUSION: When the immunohistochemical results are extrapolated to professional football players, concussions result in no or minimal brain injury. Repeat impacts at higher velocity or with a heavier mass impactor cause extensive and distant diffuse axonal injury. Based on this model, the threshold for diffuse axonal injury is above even the most severe conditions for National Football League concussion.	[Saljo, Annette; Bolouri, Hayde] Univ Gothenburg, Sect Anat & Cell Biol, Inst Biomed, SE-40530 Gothenburg, Sweden; [Viano, David C.] Mild Traumat Brain Injury Comm, New York, NY USA; [Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI USA		Hamberger, A (corresponding author), Univ Gothenburg, Sect Anat & Cell Biol, Inst Biomed, Box 440, SE-40530 Gothenburg, Sweden.	anders.hamberger@anatcell.gu.se					Adams JH, 1992, GREENFIELDS NEUROPAT, P106; AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Assaf Y, 1999, NMR BIOMED, V12, P335, DOI 10.1002/(SICI)1099-1492(199910)12:6<335::AID-NBM581>3.0.CO;2-A; Bodjarian N, 1997, NEUROREPORT, V8, P3951, DOI 10.1097/00001756-199712220-00020; BOLOURI H, NEUROSURGERY UNPUB; BULLOCK R, 2004, INT NEUR S AD S AUST; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P407, DOI 10.1111/j.1365-2990.1991.tb00740.x; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McIntosh TK, 1996, LAB INVEST, V74, P315; Mertz H. J., 1996, 960099 SAE; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; VIANO DC, NEUROSURGERY, V64, P1162; Vink R, 2003, ACT NEUR S, V86, P257; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	41	33	33	1	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	2009	64	6					1174	1182		10.1227/01.NEU.0000316855.40986.2A			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	452YE	WOS:000266576300037	19487898				2022-02-06	
J	Wartella, JE; Auerbach, SM; Ward, KR				Wartella, Jennifer E.; Auerbach, Stephen M.; Ward, Kevin R.			Emotional distress, coping and adjustment in family members of neuroscience intensive care unit patients	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						Emotional distress; Coping; Family members; Neuroscience intensive care unit; Caregiver adjustment	TRAUMATIC BRAIN-INJURY; CAREGIVING APPRAISAL; STRESS; PREDICTORS; DEPRESSION; SYMPTOMS; ANXIETY; HEALTH; ADOLESCENTS; RESPONSES	Objective: We evaluated emotional distress, coping strategy use, caregiver adjustment, and the relationship among these variables in family members (FMs) of patients hospitalized in a neuroscience intensive care unit (NSICU). Methods: Fifty-one primary relatives of NSICU patients were administered the Brief Symptom Inventory (BSI) and an abbreviated version of the COPE within 2 days of admission to the NSICU, just prior to patient discharge from the unit, and approximately 30 days after patient discharge (follow-Lip). FMs' adjustment to the role of caregiver was also evaluated at follow-up with the Caregiver Appraisal Scale (CAS). Results: BSI emotional distress levels were higher than those of the nonpatient normative sample at patient admission, but, except for anxiety, were within a standard deviation of the mean of the said group;, with the exception of anxiety they declined to below nonpatient non-native levels at follow-up. Females' distress levels were higher than those of males'. FMs' use of both problem-focused and emotion-focused coping strategies increased from admission through follow-up. Emotional distress was unrelated to problem-focused coping but was associated with emotion-focused coping at admission and discharge, with use of denial as a coping strategy primarily accounting for this relationship. Extent of use of both problem-focused and emotion-focused coping at admission was associated with better caregiver adjustment at follow-up, but over time only increases in problem-focused coping were associated with better subsequent caregiver adjustment. Conclusions: Findings suggest that interventions fostering increased use of problem-focused coping and sense of control will be effective in lowering FM distress level and enhancing subsequent adjustment in the role of caregiver. (C) 2009 Elsevier Inc. All rights reserved.	[Wartella, Jennifer E.; Auerbach, Stephen M.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Auerbach, Stephen M.; Ward, Kevin R.] Virginia Commonwealth Univ, Reanimat Engn Shock Ctr, Richmond, VA 23284 USA; [Ward, Kevin R.] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA 23284 USA		Auerbach, SM (corresponding author), Virginia Commonwealth Univ, Dept Psychol, 806 W Franklin St,Box 842018, Richmond, VA 23284 USA.	sauerbac@vcu.edu					Auerbach SM, 2005, AM J CRIT CARE, V14, P202, DOI 10.4037/ajcc2005.14.3.202; AUERBACH SM, 1989, J CONSULT CLIN PSYCH, V57, P388, DOI 10.1037/0022-006X.57.3.388; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS DN, 1985, J NEURO NEUROPSYCHIA, V49, P764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; DEROGATIS L, 1979, BRIEF SYMPTOM INVENT; FLORIAN V, 1991, NEUROPSYCHOLOGIA, V5, P478; Folkman S., 1984, STRESS; Frye B A, 1982, Rehabil Nurs, V7, P27; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HALM MA, 1990, HEART LUNG, V19, P62; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Johansson I, 2006, J ADV NURS, V56, P463, DOI 10.1111/j.1365-2648.2006.04040.x; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P221; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; McAdam JL, 2008, INTENS CARE MED, V34, P1097, DOI 10.1007/s00134-008-1066-z; McKinley Sharon, 2002, Intensive Crit Care Nurs, V18, P27, DOI 10.1054/iccn.2002.1611; Minnes P, 2000, BRAIN INJURY, V14, P737; Moskowitz JT, 1996, ANN BEHAV MED, V18, P49, DOI 10.1007/BF02903939; NARSAVAGE GL, 1994, NURS RES, V43, P90; Paparrigopoulos T, 2006, J PSYCHOSOM RES, V61, P719, DOI 10.1016/j.jpsychores.2006.05.013; Perez-San Gregorio M A, 1992, Intensive Care Med, V18, P278, DOI 10.1007/BF01706473; Pochard F, 2005, J CRIT CARE, V20, P90, DOI 10.1016/j.jcrc.2004.11.004; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Rivera P, 2007, NEUROREHABILITATION, V22, P3; ROBERTS JG, 1987, NURS RES, V36, P94; Rodriguez AM, 2005, J PSYCHOSOM RES, V58, P447, DOI 10.1016/j.jpsychores.2004.11.011; RUCKHOLM E, 1992, CAN J CARDIO NURS, V2, P15; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2007, NEUROREHABILITATION, V22, P1; STRENTZ T, 1988, J PERS SOC PSYCHOL, V55, P652, DOI 10.1037/0022-3514.55.4.652; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406	43	33	35	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999	1879-1360		J PSYCHOSOM RES	J. Psychosomat. Res.	JUN	2009	66	6					503	509		10.1016/j.jpsychores.2008.12.005			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	452BR	WOS:000266515100004	19446709				2022-02-06	
J	Kim, J; Kim, TY; Hwang, JJ; Lee, JY; Shin, JH; Gwag, BJ; Koh, JY				Kim, Jean; Kim, Tae-Youn; Hwang, Jung Jin; Lee, Joo-Yong; Shin, Jin-Hee; Gwag, Byung Joo; Koh, Jae-Young			Accumulation of labile zinc in neurons and astrocytes in the spinal cords of G93A SOD-1 transgenic mice	NEUROBIOLOGY OF DISEASE			English	Article						Excitotoxicity; Motoneurons; HNE; Zinc chelator; ALS	AMYOTROPHIC-LATERAL-SCLEROSIS; GLIAL GLUTAMATE TRANSPORTER; TRAUMATIC BRAIN-INJURY; ALS-LINKED SOD1; HIPPOCAMPAL-NEURONS; MOUSE MODEL; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; OXIDATIVE STRESS; MOTOR-NEURONS	Zinc dyshomeostasis may trigger oxidative stress, which is likely the key mechanism of neuronal death in amyotrophic lateral sclerosis (AILS), including familial forms such as G93A SOD-1 ALS. Since zinc binding by G93A SOD-1 is weaker than by normal SOD-1, we assessed whether labile zinc levels are altered in the spinal cords of G93A SOD-1 transgenic (Tg) mice. Whereas no zinc-containing cells were found in wild-type (WT) mice, neurons and astrocytes with high levels of labile zinc appeared in G93A SOD-1 Tg mice, in correlation with motoneuron degeneration. The level of HNE, an endogenous neurotoxic molecule, was increased around zinc-accumulating cells and mSOD-1 positive cells, suggesting a link between HNE, SOD-1 mutation and zinc accumulation. Moreover. exposure of cultured spinal neurons and astrocytes from G93A SOD-1 Tg mice to HNE increased labile zinc levels, and exposure to zinc increased 4-hydroxynonenal (HNE) levels, to a greater degree than in WT neurons and astrocytes. Administration of the zinc chelator TPEN extended survival in G93A SOD-1 Tg mice. These results indicate that zinc dyshomeostasis occurs in the spinal cords of Tg mice, and that this dyshomeostasis may contribute to motoneuron degeneration. (C) 2009 Elsevier Inc. All rights reserved.	[Kim, Jean; Kim, Tae-Youn; Koh, Jae-Young] Univ Ulsan, Coll Med, Neural Injury Res Lab, Seoul, South Korea; [Hwang, Jung Jin; Lee, Joo-Yong; Koh, Jae-Young] Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul, South Korea; [Shin, Jin-Hee; Gwag, Byung Joo] Ajou Univ, Coll Med, Suwon 441749, South Korea		Koh, JY (corresponding author), Univ Ulsan, Coll Med, Neural Injury Res Lab, Seoul, South Korea.	jkko@amc.seoul.kr	Hwang, Jung Jin/F-3424-2014; Lee, Joo-Yong/F-4545-2014; Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X	Korea Science and Engineering FoundationKorea Science and Engineering Foundation [M10600000181-06J0000-18110]; Korean Ministry of Science and TechnologyMinistry of Science and Technology (MOST) Korea [M103KV010020-06K2201-02010]; Korean Ministry of Education and Human Resources DevelopmentMinistry of Education & Human Resources Development (MOEHRD), Republic of Korea [KRF-2005-084-C00026]	This work was supported by the Korea Science and Engineering Foundation through the National Research Laboratory Program (M10600000181-06J0000-18110), by the Brain Research Center of 21st Century Frontier Research Program (M103KV010020-06K2201-02010) funded by Korean Ministry of Science and Technology, and by the Korea Research Foundation (Grant MOEHRD, KRF-2005-084-C00026) funded by the Korean Ministry of Education and Human Resources Development.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bishop GM, 2007, FREE RADICAL BIO MED, V42, P1222, DOI 10.1016/j.freeradbiomed.2007.01.022; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Chang I, 2003, DIABETOLOGIA, V46, P1220, DOI 10.1007/s00125-003-1171-z; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Crow JP, 1997, J NEUROCHEM, V69, P1936; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Gong YH, 2000, EXP NEUROL, V162, P27, DOI 10.1006/exnr.2000.7323; Groeneveld GJ, 2003, NEUROSCI LETT, V352, P175, DOI 10.1016/j.neulet.2003.08.062; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Hwang JJ, 2008, J NEUROSCI, V28, P3114, DOI 10.1523/JNEUROSCI.0199-08.2008; Jia YS, 2002, J PHYSIOL-LONDON, V543, P35, DOI 10.1113/jphysiol.2002.020172; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kelland EE, 2004, EUR J NEUROSCI, V19, P287, DOI 10.1111/j.0953-816X.2003.03134.x; Kim TY, 2007, EXP NEUROL, V208, P159, DOI 10.1016/j.expneurol.2007.08.013; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Lee JY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0002.2001; Lee JY, 2000, J NEUROSCI, V20; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Malecki A, 2000, J NEUROCHEM, V74, P2278, DOI 10.1046/j.1471-4159.2000.0742278.x; Matyja E, 2006, FOLIA NEUROPATHOL, V44, P183; Menzies FM, 2002, NEUROCHEM INT, V40, P543, DOI 10.1016/S0197-0186(01)00125-5; Mocchegiani E, 2007, J ALZHEIMERS DIS, V12, P101; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Noh KM, 2000, J NEUROSCI, V20; Park JA, 2000, J NEUROSCI, V20, P9096; Park JH, 2007, NEUROSCI LETT, V413, P265, DOI 10.1016/j.neulet.2006.11.058; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Petri S, 2007, J NEUROCHEM, V102, P991, DOI 10.1111/j.1471-4159.2007.04604.x; Post JI, 2008, AMYOTROPH LATERAL SC, V9, P149, DOI 10.1080/17482960801934015; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Puttaparthi K, 2002, J NEUROSCI, V22, P8790; Rao SD, 2004, TRENDS NEUROSCI, V27, P17, DOI 10.1016/j.tins.2003.11.001; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Robberecht W, 2000, J NEUROL, V247, P1; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Sillevis Smitt Peter A. E., 1994, Biological Signals, V3, P193; Simpson EP, 2004, NEUROLOGY, V62, P1758, DOI 10.1212/WNL.62.10.1758; Smith AP, 2007, AMYOTROPH LATERAL SC, V8, P131, DOI 10.1080/17482960701249241; Suh SW, 2007, MOL MED, V13, P344, DOI 10.2119/2007-00043.Suh; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tokuda E, 2007, TOXICOLOGY, V229, P33, DOI 10.1016/j.tox.2006.09.011; Tortarolo M, 2006, J NEUROSCI RES, V83, P134, DOI 10.1002/jnr.20715; Vanoni C, 2004, J CELL SCI, V117, P5417, DOI 10.1242/jcs.01411; Vigh L, 2005, ACTA NEUROPATHOL, V109, P567, DOI 10.1007/s00401-004-0977-1; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315; Zarkovic Kamelija, 2003, Molecular Aspects of Medicine, V24, P293, DOI 10.1016/S0098-2997(03)00024-4	60	33	34	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAY	2009	34	2					221	229		10.1016/j.nbd.2009.01.004			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	442VT	WOS:000265869400004	19344646				2022-02-06	
J	Yan, W; Wang, HD; Feng, XM; Ding, YS; Jin, W; Tang, K				Yan, Wei; Wang, Han-Dong; Feng, Xiao-Mei; Ding, Ya-Suo; Jin, Wei; Tang, Ke			The Expression of NF-E2-Related Factor 2 in the Rat Brain After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						NF-E2-related factor 2; Traumatic brain injury; Expression; Brain	RESPONSIVE ELEMENT; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; HEME OXYGENASE-1; IN-VIVO; NRF2; INDUCTION; PROTECTS; NEUROPROTECTION; PATHWAY	Background: Secondary brain damage plays a critical role in the outcome of patients with traumatic brain injury (TBI). The mechanisms underlying secondary brain damage are complex. A target that can interrupt multiple mechanisms underlying secondary brain damage may represent a promising new therapeutic approach for TBI. NF-E2-related factor 2 (Nrf2) is the key regulator in reducing oxidative stress, inflammatory damage, and the accumulation of toxic metabolites, which are all involved in secondary brain damage after TBI. Therefore, Nrf2 might represent a new direction for the treatment of TBI. However, the expression pattern of Nrf2 after TBI has not yet been studied. Methods: This study involved the detection of Nrf2 mRNA levels by reverse-transcriptase polymerase chain reaction, and its nuclear protein levels by Western blot from 3 hour to 72 hour after TBI. Nrf2 distribution in the brain after TBI was also investigated by immunohistochemistry. Results: After TBI, the nuclear Nrf2 protein level is significantly increased, whereas its mRNA level remains unchanged. Increased Nrf2 immunostaining was detected not only in the vulnerable regions but also in the brain barrier system. Conclusion: Nrf2 might play a protective role in the brain after TBI, possibly by reducing oxidative stress and brain edema.	[Wang, Han-Dong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; Nanjing Univ, Sch Med, Jinling Hosp, Dept Anesthesiol, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.	njwanghd@gmail.com		Yan, Wei/0000-0002-1123-0835			Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen J, 2005, CURR NEUROVASC RES, V2, P189, DOI 10.2174/1567202054368344; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; STEARDO L, 1987, SCIENCE, V235, P470, DOI 10.1126/science.2879355; Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; TREVISANI GT, 1994, J TRAUMA, V37, P452, DOI 10.1097/00005373-199409000-00021; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	26	33	35	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2009	66	5					1431	1435		10.1097/TA.0b013e318180f5c7			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	445AJ	WOS:000266021700031	19430250				2022-02-06	
J	Simon, CM; Sharif, S; Tan, RP; LaPlaca, MC				Simon, Crystal M.; Sharif, Shan; Tan, Richard P.; LaPlaca, Michelle C.			Spinal Cord Contusion Causes Acute Plasma Membrane Damage	JOURNAL OF NEUROTRAUMA			English	Article						bleb; mechanoporation; permeability; plasma membrane; spinal cord injury	TRAUMATIC BRAIN-INJURY; BLEB FORMATION; AXOLEMMAL PERMEABILITY; NEURONAL INJURY; CORTICAL ACTIN; CELL-SURFACE; REPAIR; DISRUPTION; AXONS; MECHANISMS	Spinal cord injury (SCI) launches a complex cascade of events that leads to progressive damage and loss of function. Compromise of plasma membrane integrity due to the mechanical impact is an acute event that may contribute to cellular dysfunction. Therefore, the objective of this study was to better understand the extent of acute plasma membrane damage associated with SCI as a function of injury severity and membrane defect size. Fluorescent cell-impermeant dyes were injected into the cerebrospinal fluid of adult male rats prior to contusion injury, and the anatomical location of cell bodies and axons taking up the dye within 10 min following SCI was quantified. Lucifer yellow uptake was assessed as a function of impact force (experimental groups: sham, 100 kdyn, 150 kdyn, and 200 kdyn force). In a separate group of animals, FITC-conjugated dextran molecules of various sizes (3 kDa and 10 kDa with a 1.6-nm and 2.7-nm radius, respectively) were used to approximate the size of membrane defects following moderate injury (150 kdyn force). Quantification revealed that cellular uptake of lucifer yellow was positively correlated with the force of the mechanical impact, indicating that the severity of injury is related to the degree of acute membrane failure. In addition, after moderate injury, cell bodies and axons (located up to 2 mm and 3 mm from the epicenter, respectively) took up significantly more of the 3-kDa and 10-kDa dextran permeability marker compared to sham controls. Permeable neuronal cell bodies exhibited a morphological appearance characterized by pericellular blebbing, suggesting that plasma membrane compromise is associated with pathophysiological cellular alterations. Collectively, these results enhance our understanding of acute SCI and provide targets for developing novel treatment strategies.	Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Univ, Lab Neuroengn, Atlanta, GA 30322 USA; Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Georgia Inst Technol, Emory Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			National Science FoundationNational Science Foundation (NSF) [EEC-9731643]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS061153] Funding Source: NIH RePORTER	The authors would like to acknowledge Sha'Aqua Asberry, Andres Garcia, Chris Lessing, Darren Miller, Gustavo Prado, Robyn Schlicher, and Akshay Shetty for their assistance with the technical aspects of experiments and data interpretation. Funding was provided by National Science Foundation grant EEC-9731643.	Baptiste DC, 2007, PROG BRAIN RES, V161, P217, DOI 10.1016/S0079-6123(06)61015-7; Barbee KA, 2005, ANN NY ACAD SCI, V1066, P67, DOI 10.1196/annals.1363.006; Barros LF, 2003, CELL DEATH DIFFER, V10, P687, DOI 10.1038/sj.cdd.4401236; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Charras GT, 2008, BIOPHYS J, V94, P1836, DOI 10.1529/biophysj.107.113605; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Guzman HR, 2001, J ACOUST SOC AM, V110, P588, DOI 10.1121/1.1376131; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hiruma H, 2007, J PHOTOCH PHOTOBIO B, V86, P1, DOI 10.1016/j.jphotobiol.2006.08.003; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Keller H, 1998, CELL MOTIL CYTOSKEL, V41, P181, DOI 10.1002/(SICI)1097-0169(1998)41:2<181::AID-CM8>3.3.CO;2-M; Keller H, 2002, EXP CELL RES, V277, P161, DOI 10.1006/excr.2002.5552; KILINC D, 2007, C P IEEE ENG MED BIO, V1, P5395; Kloos AD, 2005, EXP NEUROL, V191, P251, DOI 10.1016/j.expneurol.2004.09.016; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Laster SM, 1996, MICROSC RES TECHNIQ, V34, P272, DOI 10.1002/(SICI)1097-0029(19960615)34:3<272::AID-JEMT10>3.0.CO;2-J; Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224; McNeil PL, 2000, J CELL SCI, V113, P1891; McNeil PL, 2002, J CELL SCI, V115, P873; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Miyake K, 2001, J CELL SCI, V114, P3487; OLIVER JD, 1992, J AM SOC NEPHROL, V3, P214; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Rentsch PS, 2000, EUR J CELL BIOL, V79, P975, DOI 10.1078/0171-9335-00124; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SCHEIRER CJ, 1976, BIOMETRICS, V32, P429, DOI 10.2307/2529511; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Shi RY, 2004, J NEUROCYTOL, V33, P203, DOI 10.1023/B:NEUR.0000030695.76840.19; Shi XR, 2005, AM J PHYSIOL-CELL PH, V288, pC1332, DOI 10.1152/ajpcell.00522.2004; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Sokal RR., 1995, STAT TABLES, V3rd ed; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stroetz RW, 2001, J APPL PHYSIOL, V90, P2361, DOI 10.1152/jappl.2001.90.6.2361; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Togo T, 1999, J CELL SCI, V112, P719; Tomiyoshi G, 2004, GENES CELLS, V9, P591, DOI 10.1111/j.1356-9597.2004.00745.x; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Yoo S, 2003, J NEUROSCI RES, V74, P541, DOI 10.1002/jnr.10771	58	33	34	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					563	574		10.1089/neu.2008.0523			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300008	19260780	Green Published			2022-02-06	
J	Williams, G; Morris, ME; Schache, A; McCrory, P				Williams, Gavin; Morris, Meg E.; Schache, Anthony; McCrory, Paul			Observational gait analysis in traumatic brain injury: Accuracy of clinical judgment	GAIT & POSTURE			English	Article						Gait; Brain injury; Observational gait analysis; Motion analysis; Validity	BOTULINUM-TOXIN-A; CEREBRAL-PALSY; ALCOHOL NEUROLYSIS; RELIABILITY; OUTCOMES; SCALE; RECOMMENDATIONS; MANAGEMENT; SPASTICITY; CHILDREN	Objective: To determine the accuracy of clinicians' visual observations of gait disorders following traumatic brain injury (TBI). Methods: 30 ambulant participants (sample of convenience) receiving physiotherapy for mobility limitations following TBI and 25 age, height, weight and sex matched healthy unimpaired controls (HQ were recruited. Kinematic and ground reaction force data during gait were captured and video recordings were concurrently collected. Participants with TBI walked at self-selected speed whilst HCs walked at preferred speed as well as the mean TBI speed for comparison. 40 doctors, experienced physiotherapists, new graduate physiotherapists and novices were observers. Each viewed and rated 36 gait variables for a randomized sub-sample of 10 participants with TBI. Observer inaccuracy was calculated for each gait variable. Results: Overall the accuracy of observational gait analysis was low and there was considerable variability in observations between clinicians. For most kinematic variables, observer inaccuracy ranged from 30% to 50%. Although experienced observers were generally more accurate, average inter-item correlations were low, indicating that experience did not consistently improve the accuracy of visual observations. Observational plane, gait variable type, the joint or the segment had little effect on accuracy of observations. Conclusions: Observational gait analysis for adults with TBI has relatively low accuracy. Some of the gait abnormalities evident from quantitative gait analysis were not detected by observational gait analysis. (C) 2008 Elsevier B.V. All rights reserved.	[Williams, Gavin] Epworth Med Fdn, Melbourne, Vic 3121, Australia; [Williams, Gavin; McCrory, Paul] Univ Melbourne, Sch Physiotherapy, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia; [Schache, Anthony] Univ Melbourne, Sch Mech Engn, Melbourne, Vic 3010, Australia		Williams, G (corresponding author), Epworth Med Fdn, 89 Bridge Rd, Melbourne, Vic 3121, Australia.	gavin.williams@epworth.org.au	Schache, Anthony G/F-4482-2016; McCrory, Paul/Q-8688-2019	Schache, Anthony G/0000-0002-1041-5213; Williams, Gavin/0000-0003-2758-7473; Morris, Meg/0000-0002-0114-4175; McCrory, Paul/0000-0003-4850-0568			BOENIG DD, 1977, PHYS THER, V57, P795, DOI 10.1093/ptj/57.7.795; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Cappello A, 2005, IEEE T BIO-MED ENG, V52, P992, DOI 10.1109/TBME.2005.846728; Chang FM, 2006, J PEDIATR ORTHOPED, V26, P612, DOI 10.1097/01.bpo.0000229970.55694.5c; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chua KSG, 2000, ARCH PHYS MED REHAB, V81, P1432, DOI 10.1053/apmr.2000.9395; Chua KSG, 2001, BRAIN INJURY, V15, P733, DOI 10.1080/02699050010009775; Cioni M, 2006, AM J PHYS MED REHAB, V85, P600, DOI 10.1097/01.phm.0000223216.50068.bc; de Morais MC, 2008, GAIT POSTURE, V28, P316, DOI 10.1016/j.gaitpost.2008.01.013; EASTLACK ME, 1991, PHYS THER, V71, P465, DOI 10.1093/ptj/71.6.465; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Kawamura CM, 2007, GAIT POSTURE, V25, P18, DOI 10.1016/j.gaitpost.2005.12.005; Keenan AM, 1996, ARCH PHYS MED REHAB, V77, P651, DOI 10.1016/S0003-9993(96)90003-9; KOMAN LA, 1994, J PEDIATR ORTHOPED, V14, P299, DOI 10.1097/01241398-199405000-00005; KREBS DE, 1985, PHYS THER, V65, P1027, DOI 10.1093/ptj/65.7.1027; LEE EH, 1992, ARCH PHYS MED REHAB, V73, P642; Lelas JL, 2003, GAIT POSTURE, V17, P106, DOI 10.1016/S0966-6362(02)00060-7; Lord SE, 1998, CLIN REHABIL, V12, P107, DOI 10.1191/026921598666182531; Mackey AH, 2003, DEV MED CHILD NEUROL, V45, P4, DOI 10.1017/S0012162203000021; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; McGinley JL, 2003, PHYS THER, V83, P146, DOI 10.1093/ptj/83.2.146; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; OCONNOR P, 2002, HOSP DUE TRAUMATIC B; Perry J, 1999, J HEAD TRAUMA REHAB, V14, P116, DOI 10.1097/00001199-199904000-00003; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Read HS, 1999, GAIT POSTURE, V10, P63; Riley PO, 2001, J BIOMECH, V34, P197, DOI 10.1016/S0021-9290(00)00174-3; ROBINSON JL, 1981, PHYS THER, V61, P351, DOI 10.1093/ptj/61.3.351; Schache AG, 2007, GAIT POSTURE, V25, P440, DOI 10.1016/j.gaitpost.2006.05.018; Toro B, 2003, ARCH PHYS MED REHAB, V84, P1878, DOI 10.1016/S0003-9993(03)00482-9; Turani N, 2004, SCAND J CARING SCI, V18, P103, DOI 10.1111/j.1471-6712.2004.00262.x	33	33	33	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	APR	2009	29	3					454	459		10.1016/j.gaitpost.2008.11.005			6	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics; Sport Sciences	423AR	WOS:000264469300018	19109020				2022-02-06	
J	Korenov, M; Zilk, N; Stozicka, Z; Bugos, O; Vanicky, I; Novak, M				Korenov, Miroslava; Zilk, Norbert; Stozicka, Zuzana; Bugos, Ondrej; Vanicky, Ivo; Novak, Michal			NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Neurobehavioural assessment; Sensorimotor impairment; Scoring system; Transgenic rat; Misfolded tau protein	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; MARROW STROMAL CELLS; TRUNCATED TAU; MOTOR; MICE; ISCHEMIA; RECOVERY; IMPAIRMENT; MOUSE	We have previously shown that transgenic rats expressing misfolded tau protein developed neurofibrillary tangles and axonal degeneration in the brain and spinal cord, which led to impairment of sensorimotor and neuromuscular functions. To quantify neurobehavioral phenotype of the transgenic rats we have designed a testing protocol and a novel scoring system - NeuroScale - that reliably reflects progression of functional impairment of transgenic rats. NeuroScale consists of three variants of beam walking test with different sensitivity and a rapid neuromuscular and neurological examination, where animal performance is evaluated and scored according to a pre-defined rating scale. The range of the rating scale was developed to increase homogeneity of the collected behavioral data without lowering sensitivity of the testing methods. Finally, all awarded points were summed up to obtain a complete quantitative behavioral readout, the NeuroScale score, from animals under investigation. Increase in the NeuroScale score faithfully mirrored disease progression and allowed statistically significant discrimination (p < 0.001) between behavioral responses of transgenic and control animals during the whole disease process. The method was suitable for a high-throughput test whereby an experienced operator can examine up to 60 rats per day. We show that this multi-test battery with novel sensitive scoring system - NeuroScale - represents a rapid, simple to perform, high throughput method for quantitative evaluation of behavioral phenotype of transgenic rats that could serve as a valuable primary read-out for in vivo validation of therapeutic agents. (C) 2008 Elsevier B.V. All rights reserved.	[Korenov, Miroslava; Zilk, Norbert; Stozicka, Zuzana; Bugos, Ondrej; Novak, Michal] Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Bratislava 84510, Slovakia; [Korenov, Miroslava; Zilk, Norbert; Novak, Michal] Axon Neurosci GmbH, A-1030 Vienna, Austria; [Vanicky, Ivo] Slovak Acad Sci, Inst Neurobiol, Kosice 04001, Slovakia		Novak, M (corresponding author), Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Dubravska 9, Bratislava 84510, Slovakia.	Michal.Novak@savba.sk	Vanicky, Ivo/ABB-2298-2021	Stozicka, Zuzana/0000-0001-6888-9254	 [VEGA 210144/08];  [2/6183/26];  [2/5101/27];  [APVV 0603-06];  [APVV 0631-07];  [LPP-032606];  [LPP-0353-06];  [LPP-0354-06];  [LPP-0363-06]	This work was supported by research Grants VEGA 210144/08; 2/6183/26 and 2/5101/27, APVV 0603-06, APVV 0631-07, LPP-032606, LPP-0353-06, LPP-0354-06 and LPP-0363-06.	Abel A, 2001, HUM MOL GENET, V10, P107, DOI 10.1093/hmg/10.2.107; Alexis NE, 1996, BRAIN RES, V706, P273, DOI 10.1016/0006-8993(95)01180-3; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; BURES J, 1983, TECHNIQUES BASIC EXP, P77; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goettl VM, 2001, BRAIN RES, V906, P92, DOI 10.1016/S0006-8993(01)02559-8; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; Hrnkova M, 2007, BRAIN RES, V1130, P206, DOI 10.1016/j.brainres.2006.10.085; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Katsuoka F, 2003, MOL CELL BIOL, V23, P1163, DOI 10.1128/MCB.23.4.1163-1174.2003; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Lalonde R, 2004, BRAIN RES BULL, V64, P251, DOI 10.1016/j.brainresbull.2004.07.011; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McManamny P, 2002, HUM MOL GENET, V11, P2103, DOI 10.1093/hmg/11.18.2103; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Ulrich PT, 1998, STROKE, V29, P2412, DOI 10.1161/01.STR.29.11.2412; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; Zilka N, 2006, FEBS LETT, V580, P3582, DOI 10.1016/j.febslet.2006.05.029	34	33	33	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	FEB 15	2009	177	1					108	114		10.1016/j.jneumeth.2008.09.027			7	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	398BM	WOS:000262706300013	18977247				2022-02-06	
J	Bergwerf, I; De Vocht, N; Tambuyzer, B; Verschueren, J; Reekmans, K; Daans, J; Ibrahimi, A; Van Tendeloo, V; Chatterjee, S; Goossens, H; Jorens, PG; Baekelandt, V; Ysebaert, D; Van Marck, E; Berneman, ZN; Van Der Linden, A; Ponsaerts, P				Bergwerf, Irene; De Vocht, Nathalie; Tambuyzer, Bart; Verschueren, Jacob; Reekmans, Kristien; Daans, Jasmijn; Ibrahimi, Abdelilah; Van Tendeloo, Viggo; Chatterjee, Shyama; Goossens, Herman; Jorens, Philippe G.; Baekelandt, Veerle; Ysebaert, Dirk; Van Marck, Eric; Berneman, Zwi N.; Van Der Linden, Annemie; Ponsaerts, Peter			Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice	BMC BIOTECHNOLOGY			English	Article							MESSENGER-RNA ELECTROPORATION; LENTIVIRAL VECTOR PRODUCTION; GREEN FLUORESCENT PROTEIN; ADULT STEM-CELLS; HIGHLY EFFICIENT; FUNCTIONAL RECOVERY; IN-VIVO; DIFFERENTIATION; TRANSPLANTATION; BRAIN	Background: Cell transplantation is likely to become an important therapeutic tool for the treatment of various traumatic and ischemic injuries to the central nervous system (CNS). However, in many pre-clinical cell therapy studies, reporter gene-assisted imaging of cellular implants in the CNS and potential reporter gene and/or cell-based immunogenicity, still remain challenging research topics. Results: In this study, we performed cell implantation experiments in the CNS of immunocompetent mice using autologous (syngeneic) luciferase-expressing bone marrow-derived stromal cells (BMSC-Luc) cultured from ROSA26-L-S-L-Luciferase transgenic mice, and BMSC-Luc genetically modified using a lentivirus encoding the enhanced green fluorescence protein (eGFP) and the puromycin resistance gene (Pac) (BMSC-Luc/eGFP/Pac). Both reporter gene-modified BMSC populations displayed high engraftment capacity in the CNS of immunocompetent mice, despite potential immunogenicity of introduced reporter proteins, as demonstrated by real-time bioluminescence imaging (BLI) and histological analysis at different time-points post-implantation. In contrast, both BMSC-Luc and BMSC-Luc/eGFP/Pac did not survive upon intramuscular cell implantation, as demonstrated by real-time BLI at different time-points post-implantation. In addition, ELISPOT analysis demonstrated the induction of IFN-gamma-producing CD8+ T-cells upon intramuscular cell implantation, but not upon intracerebral cell implantation, indicating that BMSCLuc and BMSC-Luc/eGFP/Pac are immune-tolerated in the CNS. However, in our experimental transplantation model, results also indicated that reporter gene-specific immune-reactive T-cell responses were not the main contributors to the immunological rejection of BMSC-Luc or BMSCLuc/eGFP/Pac upon intramuscular cell implantation. Conclusion: We here demonstrate that reporter gene-modified BMSC derived from ROSA26-LSL- Luciferase transgenic mice are immune-tolerated upon implantation in the CNS of syngeneic immunocompetent mice, providing a research model for studying survival and localisation of autologous BMSC implants in the CNS by real-time BLI and/or histological analysis in the absence of immunosuppressive therapy.	[Bergwerf, Irene; De Vocht, Nathalie; Tambuyzer, Bart; Reekmans, Kristien; Daans, Jasmijn; Van Tendeloo, Viggo; Berneman, Zwi N.; Ponsaerts, Peter] Univ Antwerp, Lab Expt Hematol, B-2020 Antwerp, Belgium; [Bergwerf, Irene; De Vocht, Nathalie; Tambuyzer, Bart; Reekmans, Kristien; Daans, Jasmijn; Van Tendeloo, Viggo; Goossens, Herman; Berneman, Zwi N.; Ponsaerts, Peter] Univ Antwerp, Vaccine & Infect Dis Inst, B-2020 Antwerp, Belgium; [De Vocht, Nathalie; Verschueren, Jacob; Van Der Linden, Annemie] Univ Antwerp, Bioimaging Lab, B-2020 Antwerp, Belgium; [Ibrahimi, Abdelilah] Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, Louvain, Belgium; [Chatterjee, Shyama; Van Marck, Eric] Univ Antwerp, Pathol Lab, B-2020 Antwerp, Belgium; [Baekelandt, Veerle] Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, Louvain, Belgium; [Ysebaert, Dirk] Univ Antwerp, Expt Surg Lab, B-2020 Antwerp, Belgium; [Van Tendeloo, Viggo; Jorens, Philippe G.; Ysebaert, Dirk; Berneman, Zwi N.; Ponsaerts, Peter] Univ Antwerp Hosp, Ctr Cellular Therapy & Regenerat Med CCRG, Antwerp, Belgium; [Ibrahimi, Abdelilah; Baekelandt, Veerle] Katholieke Univ Leuven, Mol Small Anim Imaging Ctr Mosaic, Louvain, Belgium		Ponsaerts, P (corresponding author), Univ Antwerp, Lab Expt Hematol, B-2020 Antwerp, Belgium.	irene.bergwerf@ua.ac.be; nathalie.devocht@ua.ac.be; bart.tambuyzer@ua.ac.be; jacob.verschueren@ua.ac.be; kristien.reekmans@ua.ac.be; jasmijn.daans@ua.ac.be; abdelilah.ibrahimi@med.kuleuven.be; viggo.van.tendeloo@uza.be; shyama.chatterjee@ua.ac.be; herman.goossens@ua.ac.be; philippe.jorens@uza.be; veerle.baekelandt@med.kuleuven.be; dirk.ysebaert@uza.be; eric.van.marck@uza.be; zwi.berneman@uza.be; annemie.vanderlinden@ua.ac.be; peter.ponsaerts@ua.ac.be	Ponsaerts, Peter/B-6213-2017; Baekelandt, Veerle/ABB-9736-2020; Van der Linden, Annemie/L-7855-2017; Ghosh, Shyama/AAK-1173-2020; Ysebaert, Dirk/J-6800-2013; Van Tendeloo, Viggo FI/A-1233-2010	Ponsaerts, Peter/0000-0002-1892-6499; Baekelandt, Veerle/0000-0001-8966-2921; Van der Linden, Annemie/0000-0003-2941-6520; Ghosh, Shyama/0000-0003-4550-7780; Ysebaert, Dirk/0000-0002-3350-6994; Van Tendeloo, Viggo FI/0000-0003-3217-9917			Arbab Ali Syed, 2004, Mol Imaging, V3, P24, DOI 10.1162/153535004773861697; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Baekelandt V, 2003, GENE THER, V10, P1933, DOI 10.1038/sj.gt.3302094; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Bradbury MS, 2007, J NEUROCHEM, V102, P2029, DOI 10.1111/j.1471-4159.2007.04681.x; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Di Ianni M, 1999, GENE THER, V6, P703; Gambotto A, 2000, GENE THER, V7, P2036, DOI 10.1038/sj.gt.3301335; Geraerts M, 2005, J GENE MED, V7, P1299, DOI 10.1002/jgm.778; Hakamata Y, 2006, TRANSPLANTATION, V81, P1179, DOI 10.1097/01.tp.0000203137.06587.4a; Keyaerts M, 2008, EUR J NUCL MED MOL I, V35, P999, DOI 10.1007/s00259-007-0664-2; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Li J, 2007, BIOMED ENVIRON SCI, V20, P242; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Magnitsky S, 2005, NEUROIMAGE, V26, P744, DOI 10.1016/j.neuroimage.2005.02.029; Ormerod BK, 2008, PHILOS T R SOC B, V363, P153, DOI 10.1098/rstb.2006.2018; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Ponsaerts P, 2006, LEUKEMIA, V20, P767, DOI 10.1038/sj.leu.2404219; Ponsaerts P, 2004, GENE THER, V11, P1606, DOI 10.1038/sj.gt.3302342; Ponsaerts P, 2002, J IMMUNOL, V169, P1669, DOI 10.4049/jimmunol.169.4.1669; Ronsyn MW, 2008, SPINAL CORD, V46, P532, DOI 10.1038/sc.2008.13; Ronsyn MW, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-90; Rosser AE, 2007, CURR OPIN NEUROL, V20, P688, DOI 10.1097/WCO.0b013e3282f132fc; Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476-9255-2-8; Safran Michal, 2003, Mol Imaging, V2, P297, DOI 10.1162/153535003322750637; Smits E, 2004, LEUKEMIA, V18, P1898, DOI 10.1038/sj.leu.2403463; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; Van den Plas D, 2003, BIOCHEM BIOPH RES CO, V305, P10, DOI 10.1016/S0006-291X(03)00669-7; Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49; Van Tendeloo VF, 2007, CURR OPIN MOL THER, V9, P423; Vandermeulen G, 2007, J CONTROL RELEASE, V124, P81, DOI 10.1016/j.jconrel.2007.08.010; Webber DJ, 2007, REGEN MED, V2, P929, DOI 10.2217/17460751.2.6.929; Wiehe JM, 2007, J CELL MOL MED, V11, P521, DOI 10.1111/j.1582-4934.2007.00038.x	34	33	34	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1472-6750		BMC BIOTECHNOL	BMC Biotechnol.	JAN 7	2009	9								1	10.1186/1472-6750-9-1			14	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	397YO	WOS:000262698500001	19128466	Green Published, gold			2022-02-06	
J	Anderson, MI; Simpson, GK; Morey, PJ; Mok, MMC; Gosling, TJ; Gillett, LE				Anderson, Malcolm I.; Simpson, Grahame K.; Morey, Peter J.; Mok, Magdalena M. C.; Gosling, Tamera J.; Gillett, Lauren E.			Differential pathways of psychological distress in spouses vs. parents of people with severe traumatic brain injury (TBI): Multi-group analysis	BRAIN INJURY			English	Article						Family; neurobehavioral; psychological; stress; traumatic brain injury	CAREGIVER BURDEN; LIFE SATISFACTION; FAMILY CAREGIVERS; PREDICTORS; RELATIVES; STRESS; MODEL; REHABILITATION; INDIVIDUALS; INDICATORS	Primary objective: A contemporary model of psychological stress based on an amalgamation of Conservation of Resources theory and the McMaster Model of Family Functioning was devised to compare the effects of neurobehavioural impairments on family functioning and psychological distress in spouses and parents caring for relatives with TBI. Method: Participants were 64 spouses and 58 parents. They completed the Neurobehavioral Problem Checklist, Family Assessment Device and the Brief Symptom Inventory. Structural equation modelling (SEM) was used to test the model for the combined (spouses and parents) sample. Multi-group analysis was then employed for examining differences in structural weights for spouses and parents. Main results: SEM supported the model for the combined sample. Multi-group analysis showed for spouses cognitive and behavioural impairments significantly disrupted family functioning, which in turn increased psychological distress. In contrast, cognitive and behavioural impairments did not significantly disrupt family functioning in parents. For parents, however, cognitive impairments increased psychological distress. Furthermore, parents who reported disrupted family functioning also experienced higher levels of psychological distress. The effect of cognitive impairments was statistically more influential on the level of distress in parents when compared to spouses. Conclusions: Understanding these differences can assist in better targeting family support interventions.	[Anderson, Malcolm I.; Gosling, Tamera J.] Avondale Coll, Fac Nursing & Hlth, Wahroonga, NSW 2076, Australia; [Simpson, Grahame K.; Gillett, Lauren E.] Liverpool Hlth Serv, Brain Injury Unit, Liverpool, NSW, Australia; [Morey, Peter J.] Avondale Coll, Fac Business & Informat Technol, Cooranbong, NSW, Australia; [Mok, Magdalena M. C.] Hong Kong Inst Educ, Ctr Assessment Res & Dev, Hong Kong, Hong Kong, Peoples R China		Anderson, MI (corresponding author), Avondale Coll, Fac Nursing & Hlth, Sydney Campus,185 Fox Valley Rd, Wahroonga, NSW 2076, Australia.	malcolm.anderson@avondale.edu.au	Mok, Magdalena M. C./G-1713-2017; Simpson, Grahame K/W-1074-2019	Mok, Magdalena M. C./0000-0002-6503-8152; Simpson, Grahame K/0000-0001-8156-9060; Anderson, Malcolm/0000-0003-2963-7497			AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Anderson M. I., 2006, STRESS ITS IMPACT SO, P23; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; ARBUCKLE JL, 2006, AMOS 7 COMPUTER SOFT; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1980, PSYCHOL BULL, V107, P238; BISHOP DS, 1988, J HEAD TRAUMA REHAB, V3, P6; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; CAMPLAIR PS, 1989, THESIS VIRGINIA COMM; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; Ding L, 1995, STRUCT EQU MODELING, V2, P119, DOI 10.1080/10705519509540000; ELLIOTT GR, 1982, STRESS HUMAN HLTH AN; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Flanagan DAJ, 1998, BRIT J CLIN PSYCHOL, V37, P431, DOI 10.1111/j.2044-8260.1998.tb01400.x; Frosch S, 1997, BRAIN INJURY, V11, P891; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Ho R., 2006, HDB UNIVARIATE MULTI; HOBFOLL SE, 1989, AM PSYCHOL, V44, P513, DOI 10.1037/0003-066X.44.3.513; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoyle R.H., 1995, STRUCTURAL EQUATION; Joreskog K. G., 1993, LISREL 8 USERS REFER; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kosciulek JF, 1997, BRAIN INJURY, V11, P821, DOI 10.1080/026990597123034; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Laroi F, 2003, BRAIN INJURY, V17, P175, DOI 10.1080/0269905021000010140; Lazarus RS, 1987, EUR J PERSONAL, V1, P141, DOI [10.1002/per.2410010304, DOI 10.1002/PER.2410010304]; LEATHAM J, 1996, BRAIN INJURY, V10, P543; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MacCallum RC, 1997, MULTIVAR BEHAV RES, V32, P193, DOI 10.1207/s15327906mbr3202_5; Man DWK, 2002, BRAIN INJURY, V16, P1025, DOI 10.1080/0269905021000010087; Man DWK, 1998, BRAIN INJURY, V12, P245, DOI 10.1080/026990598122728; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Panting A, 1972, REHABILITATION, V38, P33; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RICE VH, 2000, HDB STRESS COPING IM; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2007, NEUROREHABILITATION, V22, P9; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Spielberger C.D., 1992, J FAMILY PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; TATE R, BRAIN INJURY OUTCOME; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; ZEIGLER EA, 1990, COGNITIVE REHABILITA, V8, P14	71	33	33	1	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	12					931	943		10.3109/02699050903302336			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	529YL	WOS:000272555200001	19831490				2022-02-06	
J	Cook, NL; Vink, R; Donkin, JJ; van den Heuvel, C				Cook, Naomi L.; Vink, Robert; Donkin, James J.; van den Heuvel, Corinna			Validation of Reference Genes for Normalization of Real-Time Quantitative RT-PCR Data in Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						real-time PCR; substance P; quantitation; rats; neurotrauma	POLYMERASE CHAIN-REACTION; MESSENGER-RNA; HOUSEKEEPING GENES; REVERSE TRANSCRIPTION; EDEMA FORMATION; RIBOSOMAL-RNA; BETA-ACTIN; INTERNAL CONTROL; SUBSTANCE-P; EXPRESSION	Careful validation of reference genes used for the normalization of real-time RT-PCR data is required to obtain accurate results regarding gene expression. We evaluated the stability of seven commonly used reference genes in the cerebral cortex and hippocampus of rats 3 days following traumatic brain injury (TBI). HPRT, SDHA, and GUSB were found to be the most stable reference genes in the cerebral cortex, whereas B2MG, TBP, and GAPDH were the most stable in the hippocampus. The use of three reference genes was determined to be the optimal number for accurate normalization of data. To illustrate this point, when our gene of interest, substance P (SP), was normalized against the three most stable reference genes in both brain areas, we found no significant difference between injured and uninjured rats at the 3-day time point. However, when our SP data were normalized to each reference gene individually, SP mRNA level was highly variable depending on the reference gene chosen. The results of the present study highlight the importance of validating reference genes to be used for real-time RT-PCR analysis. The use of the most stable reference genes presented here will allow more accurate normalization of gene expression data in TBI. (C) 2008 Wiley-Liss, Inc.	[van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia		van den Heuvel, C (corresponding author), Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	Cook, Naomi L/B-2536-2012; Cook, Naomi L/P-1223-2019; Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Cook, Naomi L/0000-0002-1830-2432; Cook, Naomi L/0000-0002-1830-2432; Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935	Neurosurgical Research Foundation of Australia; NHMRC Dora Lush Biomedical Postgraduate ScholarshipNational Health and Medical Research Council of Australia	Neurosurgical Research Foundation of Australia; Contract grant sponsor: NHMRC Dora Lush Biomedical Postgraduate Scholarship (to N.L.C.).	Aerts JL, 2004, BIOTECHNIQUES, V36, P84, DOI 10.2144/04361ST04; Backman CM, 2006, MOL CELL ENDOCRINOL, V252, P160, DOI 10.1016/j.mce.2006.03.013; Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x; Boutros PC, 2004, BIOINFORMATICS, V20, P2399, DOI 10.1093/bioinformatics/bth257; Brown R, 2008, NEUROSCI LETT, V432, P73, DOI 10.1016/j.neulet.2007.12.008; Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; BUSTIN SA, 2005, ENCY DIAGNOSTIC GENO; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01; Glare EM, 2002, THORAX, V57, P765, DOI 10.1136/thorax.57.9.765; Haller F, 2004, ANAL BIOCHEM, V335, P1, DOI 10.1016/j.ab.2004.08.024; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Jain M, 2006, BIOCHEM BIOPH RES CO, V345, P646, DOI 10.1016/j.bbrc.2006.04.140; Ke LD, 2000, MOL CELL PROBE, V14, P127, DOI 10.1006/mcpr.2000.0288; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Klein D, 2002, TRENDS MOL MED, V8, P257, DOI 10.1016/S1471-4914(02)02355-9; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Li Q, 2003, MOL BRAIN RES, V114, P46, DOI 10.1016/S0169-328X(03)00131-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meldgaard M, 2006, J NEUROSCI METH, V156, P101, DOI 10.1016/j.jneumeth.2006.02.008; Moriya Y, 2006, BIOL PHARM BULL, V29, P535, DOI 10.1248/bpb.29.535; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pohjanvirta R, 2006, CHEM-BIOL INTERACT, V160, P134, DOI 10.1016/j.cbi.2006.01.001; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Smith RD, 2003, BIOTECHNIQUES, V34, P88, DOI 10.2144/03341st05; Sturzenbaum SR, 2001, COMP BIOCHEM PHYS B, V130, P281, DOI 10.1016/S1096-4959(01)00440-7; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; Turner RJ, 2006, ACTA NEUROCHIR SUPPL, V96, P263; Turner RJ, 2004, J AM COLL NUTR, V23, p534S, DOI 10.1080/07315724.2004.10719397; Ullmannova V, 2003, FOLIA BIOL-PRAGUE, V49, P211; UNTERGASSER A, 2007, NUCL ACIDS IN PRESS; van Wijngaarden P, 2007, MOL VIS, V13, P1508; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vink R, 2003, ACT NEUR S, V86, P257; Wilhelm J, 2003, CHEMBIOCHEM, V4, P1120, DOI 10.1002/cbic.200300662; Wong ML, 2005, BIOTECHNIQUES, V39, P484, DOI 10.2144/000112064; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815; Zhu LJ, 2005, ANAL BIOCHEM, V345, P102, DOI 10.1016/j.ab.2005.07.028	56	33	33	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN	2009	87	1					34	41		10.1002/jnr.21846			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	397QX	WOS:000262678300004	18711751				2022-02-06	
J	Ettenhofer, ML; Abeles, N				Ettenhofer, Mark L.; Abeles, Norman			The significance of mild traumatic brain injury to cognition and self-reported symptoms in long-term recovery from injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Mild head injury; Neurocognition; Postconcussive symptoms; Postconcussion syndrome	HEAD-INJURY; POSTCONCUSSION SYNDROME; DIAGNOSTIC-CRITERIA; DISABILITY; DEPRESSION; AWARENESS; ANXIETY; UTILITY; ADULTS	The aim of this study was to evaluate neurocognition and self-reported symptoms in long-term recovery from mild traumatic brain injury (mild TBI). Participants' time since injury ranged from 3 to 72 (M = 36.75) months. Relative to orthopedic injury controls (n = 63), mild TBI participants (n = 63) did not demonstrate cognitive impairment in any domains examined, or differences in self-report of postconcussive or psychiatric symptoms. However, postconcussive and psychiatric symptoms were strongly related (r = .50, p .05). Results provide additional evidence that neurological injury in single-incident mild TBI is of little clinical significance to long-term cognitive and symptom outcome.	[Ettenhofer, Mark L.] Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Abeles, Norman] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA		Ettenhofer, ML (corresponding author), Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA.	MEttenhofer@mednet.ucla.edu	Ettenhofer, Mark L./J-7171-2019	Ettenhofer, Mark L./0000-0001-9381-7578			Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Bigler ED, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P63; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Derogatis LR., 1982, BRIEF SYMPTOM INVENT; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; FEE CRA, 1987, ARCH EMERG MED, V4, P159; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jeyakumar SLE, 2004, EDUC PSYCHOL MEAS, V64, P71, DOI 10.1177/0013164403258407; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P327; Lees-Haley PR, 2003, ARCH CLIN NEUROPSYCH, V18, P585; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Marschark M, 2000, J HEAD TRAUMA REHAB, V15, P1227, DOI 10.1097/00001199-200012000-00004; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilcox RR, 1998, BRIT J MATH STAT PSY, V51, P123, DOI 10.1111/j.2044-8317.1998.tb00670.x; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	58	33	33	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	3					363	372	PII 794907397	10.1080/13803390802175270			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	423QF	WOS:000264510100010	18618356				2022-02-06	
J	Gunning, M; O'Loughlin, E; Fletcher, M; Crilly, J; Hooper, M; Ellis, DY				Gunning, M.; O'Loughlin, E.; Fletcher, M.; Crilly, J.; Hooper, M.; Ellis, D. Y.			Emergency intubation: a prospective multicentre descriptive audit in an Australian helicopter emergency medical service	EMERGENCY MEDICINE JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; RAPID-SEQUENCE INDUCTION; HOSPITAL ENDOTRACHEAL INTUBATION; MANAGEMENT; ANESTHESIA; AIRWAY; IMPACT; SCORE	Objective: To describe the safety profile of emergency airway management when performed by a prehospital team consisting of a doctor and a paramedic. Success rates, the incidence of difficult airways and the ability of prehospital doctors to determine a difficult airway are reported. Methods: A prospective audit and descriptive study of three Australian helicopter emergency medical service (HEMS) bases, over a 9-month period. Doctors completed questionnaires regarding the number of endotracheal intubation (ETI) attempts on patients transported intubated and ventilated, Cormack and Lehane view of the cords during laryngoscopy and the anticipated and actual ease of ETI. Results: A total of 114 (11.4%) patients transported by the HEMS was intubated and ventilated. Study questionnaires were completed on 89 of the 114 cases (78.1%), of which 32 (36%) were trauma related. HEMS were involved with 43 (48.3%) of the 89 intubations and performed 12.4% (n = 11) out of hospital. The HEMS ETI success rate was 97.6%. No surgical airways were performed. The actual incidence of difficult airways was higher (n = 4, 9.3%) than the anticipated incidence (n = 1, 2.3%). Six patients (14.0%) were successfully intubated by the doctor after the paramedic failed. Conclusions: Well-trained doctor paramedic teams, utilising standardised operating procedures, can safely perform rapid sequence induction and ETI in the prehospital and emergency environment. However, prehospital doctors are not always able to anticipate a difficult airway. The complication rate was similar to that in hospital emergency departments and to that of other physician-led HEMS.	[Gunning, M.; O'Loughlin, E.; Fletcher, M.; Hooper, M.; Ellis, D. Y.] CareFlight Med Serv, Brisbane, Qld 4000, Australia; [Crilly, J.] Gold Coast Hosp, So Area Hlth Serv, Emergency Dept Clin Network, Southport, Qld, Australia		Gunning, M (corresponding author), CareFlight Med Serv, Level 3,172 Edward St, Brisbane, Qld 4000, Australia.	MattGunning@rcsed.ac.uk		Crilly, Julia/0000-0002-1455-8983			Adnet F, 1997, ANESTHESIOLOGY, V87, P1290, DOI 10.1097/00000542-199712000-00005; *AM COLL SURG COMM, 2005, ADV TRAUM LIF SUPP A; Bernard Stephen, 2002, Emerg Med (Fremantle), V14, P406, DOI 10.1046/j.1442-2026.2002.00382.x; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Chesnut RM, 1997, J TRAUMA, V42, pS19, DOI 10.1097/00005373-199705001-00004; Combes X, 2006, ACAD EMERG MED, V13, P828, DOI 10.1197/j.aem.2006.02.016; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Cudnik MT, 2007, PREHOSP EMERG CARE, V11, P224, DOI 10.1080/10903120701205208; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis MJ, 2002, CHEM VAPOR DEPOS, V8, P7, DOI 10.1002/1521-3862(20020116)8:1<7::AID-CVDE7>3.0.CO;2-A; Ellis DY, 2007, EMERG MED J, V24, P139, DOI 10.1136/emj.2006.040428; Graham CA, 1997, J ACCID EMERG MED, V14, P219; Helm M, 2006, BRIT J ANAESTH, V96, P67, DOI 10.1093/bja/aei275; Lockey D, 2007, EMERG MED J, V24, P606, DOI 10.1136/emj.2007.047258; Mackay CA, 2001, EMERG MED J, V18, P20, DOI 10.1136/emj.18.1.20; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Polit DF, 2004, ESSENTIALS NURSING R; SAKLES JC, 1998, ANN EMERG MED; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Swanson Eric R, 2005, Air Med J, V24, P40, DOI 10.1016/j.amj.2004.10.008; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; Timmermann A, 2007, ANAESTHESIST, V56, P328, DOI 10.1007/s00101-007-1153-5; Wang HE, 2006, ACAD EMERG MED, V13, P372, DOI 10.1197/j.aem.2005.11.001; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	25	33	33	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	JAN	2009	26	1					65	69		10.1136/emj.2008.059345			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	393SX	WOS:000262394300026	19104110				2022-02-06	
J	Jang, SH				Jang, Sung Ho			Review of motor recovery in patients with traumatic brain injury	NEUROREHABILITATION			English	Article						Brain injury; motor recovery; rehabilitation; hemiparesis	DIFFUSE AXONAL INJURY; CLOSED-HEAD TRAUMA; TRANSCRANIAL MAGNETIC STIMULATION; BASAL GANGLIA HEMORRHAGE; CORTICOSPINAL TRACT; FUNCTIONAL MRI; TRANSTENTORIAL HERNIATION; FOLLOW-UP; STROKE; CHILDREN	Detailed information about motor recovery is essential for brain rehabilitation because it enables us to establish scientific rehabilitative strategies and predict motor outcome. For this review, we summarized the literature on motor recovery of patients with traumatic brain injury (TBI) in relation to the following: epidemiology of motor weakness, mechanisms of injury that cause motor weakness, course of motor recovery, and mechanisms underlying motor recovery. The motor weakness in patients with TBI is characterized by a low incidence, decreased severity, long recovery time, and good motor outcome when comparing with cognitive or behavior problems following TBI or the motor weakness affecting stroke patients. However, there are few studies describing the course of motor recovery and the underlying mechanisms of motor recovery. Knowledge in the course of recovery and the mechanisms of recovery can alert clinicians to obtain the salient information about the critical period for rehabilitation and the rehabilitative strategies respectively. Therefore, we suggest that further research should focus on these topics.	Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Binder DK, 2004, NEUROSURGERY, V54, P999, DOI 10.1227/01.NEU.0000115674.15497.09; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; Boto GR, 2001, J NEUROSURG, V94, P224, DOI 10.3171/jns.2001.94.2.0224; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUNNSTROM S, 1966, MOVEMENT THERAPY HEM, P34; DELISA JA, 1993, REHABILITATION MED P, P825; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; FAHY TJ, 1967, LANCET, V2, P475; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Han BS, 2007, NEUROREHABILITATION, V22, P151; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Jang SH, 2002, AM J PHYS MED REHAB, V81, P844, DOI 10.1097/00002060-200211000-00007; Jang SH, 2007, J COMPUT ASSIST TOMO, V31, P901, DOI 10.1097/rct.0b013e31804089a6; Jang SH, 2007, NEUROREHABILITATION, V22, P253; JAYAKUMAR PN, 1989, ACTA NEUROCHIR, V97, P114, DOI 10.1007/BF01772820; JENNETT B, 1975, LANCET, V7905, P480; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; Kernohan JW, 1929, ARCH NEURO PSYCHIATR, V21, P274, DOI 10.1001/archneurpsyc.1929.02210200030004; Kim DG, 2007, NEUROREHABILITATION, V22, P273; KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039; LEE JP, 1991, J TRAUMA, V31, P376, DOI 10.1097/00005373-199103000-00011; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073	43	33	38	0	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2009	24	4					349	353		10.3233/NRE-2009-0489			5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	481VH	WOS:000268839800008	19597273				2022-02-06	
J	Lane-Brown, AT; Tate, RL				Lane-Brown, A. T.; Tate, R. L.			Apathy after acquired brain impairment: A systematic review of non-pharmacological interventions	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Apathy; Traumatic brain injury; Dementia; Cerebrovascular accident; Hydrocephalus	MULTISENSORY STIMULATION; DAY-CARE; DEMENTIA; PEOPLE; REHABILITATION; RELIABILITY; DEPRESSION; STRATEGIES; MANAGEMENT; DISORDERS	Apathy commonly occurs after acquired brain impairment. It is characterised by impaired initiative, diminished activity, and lack of concern; formally delineated as a decrease in cognitive, behavioural and emotional components of goal-directed activity. The impact is widespread, hampering rehabilitation and outcome. This systematic review identifies and assesses the efficacy of non-pharmacological treatments for apathy following four types of acquired brain impairment (traumatic brain injury, dementia, cerebrovascular accident, encephalitis). Nine databases were searched. Studies were reviewed according to the following criteria: age over 16 years, acquired brain impairment, non-pharmacological intervention for apathy, and data reported on treatment efficacy. The methodological quality of the studies was assessed. Searches yielded 1754 articles, with 28 meeting criteria. Methodological quality ranged greatly. The majority of trials involved the dementia population. Cognitive interventions were the most frequent mode of treatment. For those with severe impairments, the strongest evidence suggested music therapy and for milder impairment, the strongest evidence was for cognitive rehabilitation. This review reveals a need for more high quality, methodologically rigorous treatment studies for apathy, particularly within the milder ranges of impairment. Initially, however, a uniform operational definition needs to be utilised in all research studies to minimise variability. Additionally, employing a standardised outcome measure specific to apathy would greatly enhance comparison among treatments.	Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia		Lane-Brown, AT (corresponding author), Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	amandal@med.usyd.edu.au			Rehabilitation Studies Unit, University of SydneyUniversity of Sydney; Northern Medical Research Foundation; Northern Clinical School, University of SydneyUniversity of Sydney; Australian Government through an Australian Postgraduate AwardAustralian Government	This study was supported by the University of Sydney and funding has been provided by the Rehabilitation Studies Unit, University of Sydney; the Northern Medical Research Foundation and the Northern Clinical School, University of Sydney; and the Australian Government through an Australian Postgraduate Award.	Adam S, 2000, NEUROPSYCHOL REHABIL, V10, P485, DOI 10.1080/09602010050143568; Altus Deborah E, 2002, J Gerontol Nurs, V28, P47; Baker R, 2003, J ADV NURS, V43, P465, DOI 10.1046/j.1365-2648.2003.02744.x; Baker R, 2001, BRIT J CLIN PSYCHOL, V40, P81, DOI 10.1348/014466501163508; Baker R., 1997, BRIT J OCCUP THER, V60, P213; Boyle PA, 2004, DEMENT GERIATR COGN, V17, P91, DOI 10.1159/000074280; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Campbell JJ, 1997, PSYCHIAT ANN, V27, P44, DOI 10.3928/0048-5713-19970101-11; Chapman SB, 2004, J SPEECH LANG HEAR R, V47, P1149, DOI 10.1044/1092-4388(2004/085); Chatterjee A, 2002, J NEUROPSYCH CLIN N, V14, P461, DOI 10.1176/appi.neuropsych.14.4.461; Cohen J., 2013, STAT POWER ANAL BEHA; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DEPOY E, 1990, Occupational Therapy in Health Care, V7, P101, DOI 10.1080/J003v07n01_09; Droes RM, 2004, INT J GERIATR PSYCH, V19, P673, DOI 10.1002/gps.1142; DUFFY JD, 2006, GUIDE NEUROPSYCHIATR; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Finnema E, 2005, INT J GERIATR PSYCH, V20, P330, DOI 10.1002/gps.1286; Finset A, 2000, BRAIN INJURY, V14, P887; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Gigliotti C.M., 2004, DEMENTIA, V3, P161, DOI [10.1177/1471301204042335, DOI 10.1177/1471301204042335]; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; Graff MJ, 2006, DEMENTIA, V5, P503, DOI DOI 10.1177/1471301206069918; Harvey Lisa, 2002, Physiother Res Int, V7, P1, DOI 10.1002/pri.236; Holmes C, 2006, INT PSYCHOGERIATR, V18, P623, DOI 10.1017/S1041610206003887; Hope K W, 1998, J Psychiatr Ment Health Nurs, V5, P377; Hozumi S, 1996, INT J NEUROSCI, V88, P1; Johnson JR, 1997, PHYS OCCUPATIONAL TH, V15, P15; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kirsch-Darrow L, 2006, NEUROLOGY, V67, P33, DOI 10.1212/01.wnl.0000230572.07791.22; LaGory M., 2003, CITY COMMUNITY, V2, P33, DOI DOI 10.1111/1540-6040.00037; Lane-Brown A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006341.pub2; Macauley BL, 2006, J REHABIL RES DEV, V43, P357, DOI 10.1682/JRRD.2005.01.0027; Maher CG, 2003, PHYS THER REHABIL J, V83, P713, DOI 10.1093/ptj/83.8.713; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Marin RA, 2005, TXB TRAUMATIC BRAIN, P337; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; Marit RS, 2005, J HEAD TRAUMA REHAB, V20, P377, DOI 10.1097/00001199-200507000-00009; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McAllister T W, 2000, Semin Clin Neuropsychiatry, V5, P275, DOI 10.1053/scnp.2000.9557; Mickus MA., 2002, J MENTAL HLTH AGING, V8, P37; MILLARD KAO, 1989, J MUSIC THER, V26, P58; Murphy KJ., 2000, NEUROPSYCHOLOGY EMOT, P340; Newburn G, 2005, BRAIN INJURY, V19, P149, DOI 10.1080/02699050410001719989; Perdices M., 2006, BRAIN IMPAIR, V7, P119, DOI DOI 10.1375/BRIM.7.2.119; PERDICES M, NEUROPSYCHO IN PRESS; Politis AM, 2004, INT J GERIATR PSYCH, V19, P1087, DOI 10.1002/gps.1215; Roth Robert M, 2007, Curr Treat Options Neurol, V9, P363, DOI 10.1007/s11940-007-0022-5; Rusted J, 2006, GROUP ANAL, V39, P517, DOI DOI 10.1177/0533316406071447; Sherratt K, 2004, AGING MENT HEALTH, V8, P233, DOI 10.1080/13607860410001669769; SMITH RB, 1994, BRAIN INJURY, V8, P357, DOI 10.3109/02699059409150986; Sohlberg McK. M., 1988, COGNITIVE REHABILITA, V6, P36; Spaull D., 1998, BEHAV COGN PSYCHOTH, V26, P77, DOI DOI 10.1017/S1352465898000083; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; van Reekum R, 2005, J NEUROPSYCH CLIN N, V17, P7, DOI 10.1176/appi.neuropsych.17.1.7; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767; WONGPAKARAN N, 2007, DIRECTIONS PSYCHIAT, V27, P261	62	33	37	0	20	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	4					481	516		10.1080/09602010902949207			36	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	539EJ	WOS:000273236100001	19533496				2022-02-06	
J	Li, CY; Wu, PM; Jung, W; Ahn, CH; Shutter, LA; Narayan, RK				Li, Chunyan; Wu, Pei-Ming; Jung, WooSeok; Ahn, Chong H.; Shutter, Lori A.; Narayan, Raj K.			A novel lab-on-a-tube for multimodality neuromonitoring of patients with traumatic brain injury (TBI)	LAB ON A CHIP			English	Article							IRIDIUM OXIDE; MICRODIALYSIS; ELECTRODE	A novel lab-on-a-tube integrated with spirally-rolled pressure, temperature, oxygen and glucose microsensors is described for multimodal neuromonitoring of patients with traumatic brain injury. In addition to measuring various crucial parameters in real-time continuous formats, the newly developed device also works as an intraventricular catheter to lower the elevated intracranial pressure by draining cerebrospinal fluid.	[Li, Chunyan; Shutter, Lori A.; Narayan, Raj K.] Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Cincinnati, OH 45267 USA; [Li, Chunyan; Wu, Pei-Ming; Jung, WooSeok; Ahn, Chong H.] Univ Cincinnati, Microsyst & BioMEMS Lab, Dept Elect & Comp Engn, Cincinnati, OH 45221 USA		Li, CY (corresponding author), Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Cincinnati, OH 45267 USA.	lic2@email.uc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628	Integra Lifesciences Foundation	The work was supported from the Integra Lifesciences Foundation. The authors thank Mr Ron Flenniken and Mr Jeff Simkins in the Nano/Micro Fabrication Engineering Research Center at the University of Cincinnati for their technical support, and also thank Mr Michael Rust and Mr Andrew Browne for valuable discussion.	Chu X, 2007, TALANTA, V71, P2040, DOI 10.1016/j.talanta.2006.09.013; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Lee IS, 2005, THIN SOLID FILMS, V475, P332, DOI 10.1016/j.tsf.2004.08.076; LI C, 2008, P 12 INT C MICR TOT, P1916; Li CY, 2008, J MICROELECTROMECH S, V17, P334, DOI 10.1109/JMEMS.2007.911375; Li CY, 2008, BIOMED MICRODEVICES, V10, P671, DOI 10.1007/s10544-008-9178-3; Li CY, 2007, BIOSENS BIOELECTRON, V22, P1988, DOI 10.1016/j.bios.2006.08.043; Li J, 2007, BIOSENS BIOELECTRON, V22, P2898, DOI 10.1016/j.bios.2006.12.004; Lu Y, 2008, ELECTROCHEM COMMUN, V10, P778, DOI 10.1016/j.elecom.2008.02.013; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Yang YX, 2004, PROG COMPUT FLUID DY, V4, P46, DOI 10.1504/PCFD.2004.003785	13	33	34	0	12	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1473-0197			LAB CHIP	Lab Chip		2009	9	14					1988	1990		10.1039/b900651f			3	Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry, Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics; Instruments & Instrumentation	465GY	WOS:000267572000002	19568663				2022-02-06	
J	Nguyen, R; Zenteno, JFT				Rita Nguyen; Zenteno, Jose F. Tellez			Injuries in epilepsy: a review of its prevalence, risk factors, type of injuries and prevention	NEUROLOGY INTERNATIONAL			English	Article						injuries; epilepsy	SEIZURE-RELATED INJURIES; FRACTURE RISK; ACCIDENTS; CHILDREN; BURNS; SHOULDER; PEOPLE; DEATH; RESPONSIBILITY; DISLOCATION	Currently, there is intense clinical research into various aspects of the medical risks relating to epilepsy, including total and cause-specific mortality, accidents and injuries in patients with epilepsy and mortality related with seizures. Seizures occurring in precarious situations and resulting in injuries are still an important concern for patients with epilepsy, their employers and their caregivers. Submersion injuries, motor vehicle accidents, burns, and head injuries are among the most feared epilepsy-related injuries. These concerns seem valid because the hallmark of epilepsy, episodic impairment of consciousness and motor control, may occur during interictal EEC epileptiform discharges, even in the absence of a clinical seizure. In addition, psychomotor comorbidity and side effects of antiepileptic drugs may contribute to the risk of injuries in patients with epilepsy. Published risk factors for injuries include the number of antiepileptic drugs. history of generalized seizures, and seizure frequency In general, epidemiological information about incidence of injuries has been conflicting and sparse. In general, studies focusing on populations with more severe forms of epilepsy tend to report substantially higher risks of injuries than those involving less selected populations. On the other hand, studies based on non-selected populations of people with epilepsy have not shown an increased frequency of injuries in people with epilepsy compared with the general population. Some studies have shown that patients with epilepsy are more frequently admitted to the hospital following an injury. Possible explanations include: more cautious attitude of clinicians toward injuries occurring in the setting of seizures; hospitalization required because of seizures and not to the injuries themselves; and hospitalization driven by other issues, such as comorbidities, which are highly prevalent in patients with epilepsy. Potentially, the high rate of hospitalizations could be related with the severity of the injury. This article reviews the best available epidemiological information about injuries, including incidence and risk factors. Also this article reviews information about specific types of injuries such as fractures. burns, concussions, dislocations. etc. Information about accidents in people with epilepsy is also discussed.	[Rita Nguyen] Univ Saskatchewan, Dept Med, Div Neurol, Saskatoon, SK, Canada		Zenteno, JFT (corresponding author), Royal Univ Hosp, Div Neurol, Dept Med, 103 Hosp Dr,Box 26,Room 1622, Saskatoon, SK S7N 0W8, Canada.	jft084@mail.usask.ca	Tellez-Zenteno, Jose F./AAM-3096-2020				Aboukasm AG, 1997, ARCH FAM MED, V6, P185, DOI 10.1001/archfami.6.2.185; Aldenkamp T, 2004, EPILEPSIA, V45, P54, DOI 10.1111/j.0013-9580.2004.33403.x; ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; Appleton RE, 2002, EPILEPSIA, V43, P764, DOI 10.1046/j.1528-1157.2002.41101.x; Bautista RED, 2008, EPILEPSY RES, V79, P120, DOI 10.1016/j.eplepsyres.2008.01.003; Beghi E, 2005, BMJ-BRIT MED J, V331, P60, DOI 10.1136/bmj.331.7508.60; Beghi E, 2005, LANCET NEUROL, V4, P71, DOI 10.1016/S1474-4422(05)00971-3; Beghi E, 2002, EPILEPSIA, V43, P1076, DOI 10.1046/j.1528-1157.2002.18701.x; Bird S., 2005, AUST FAM PHYSICIAN, V34, P1057; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; Buhler M, 2002, J SHOULDER ELB SURG, V11, P339, DOI 10.1067/mse.2002.124524; BULL JP, 1964, BRIT MED J, V2, P1421, DOI 10.1136/bmj.2.5422.1421; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P818; COCKERELL OC, 1995, LANCET, V346, P1228, DOI 10.1016/S0140-6736(95)92933-9; Currie CJ, 1998, EPILEPSIA, V39, P537, DOI 10.1111/j.1528-1157.1998.tb01417.x; Davidson DLW, 2002, SEIZURE-EUR J EPILEP, V11, P344, DOI 10.1053/seiz.2001.0620; Dulac O, 1997, EPILEPSIA, V38, P1054; Gosens T, 2000, SEIZURE-EUR J EPILEP, V9, P446, DOI 10.1053/seiz.2000.0418; HAMPTON KK, 1988, BRIT MED J, V296, P1659, DOI 10.1136/bmj.296.6637.1659; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Jones MW, 1998, CAN J NEUROL SCI, V25, pS24, DOI 10.1017/S0317167100034934; Josty IC, 2000, EPILEPSIA, V41, P453, DOI 10.1111/j.1528-1157.2000.tb00188.x; KIRBY S, 1995, EPILEPSIA, V36, P25, DOI 10.1111/j.1528-1157.1995.tb01660.x; Kirsch R, 2001, J CHILD NEUROL, V16, P100, DOI 10.2310/7010.2001.6916; Krauss GL, 2001, NEUROLOGY, V57, P1780, DOI 10.1212/WNL.57.10.1780; Krauss GL, 1999, NEUROLOGY, V52, P1324, DOI 10.1212/WNL.52.7.1324; KRISTIANSEN B, 1984, INJURY, V16, P108, DOI 10.1016/S0020-1383(84)80009-1; Lawn ND, 2004, NEUROLOGY, V63, P1565, DOI 10.1212/01.WNL.0000142991.14507.B5; Lings S, 2001, NEUROLOGY, V57, P435, DOI 10.1212/WNL.57.3.435; MAISELS DO, 1964, LANCET, V1, P1298; MASLAND RL, 1978, ANN NEUROL, V4, P485, DOI 10.1002/ana.410040602; McLachlan RS, 2007, EPILEPSIA, V48, P1500, DOI 10.1111/j.1528-1167.2007.01051.x; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x; Nei M, 2007, CURR NEUROL NEUROSCI, V7, P335, DOI 10.1007/s11910-007-0051-1; Neufeld MY, 1999, EPILEPSY RES, V34, P123, DOI 10.1016/S0920-1211(98)00105-3; Persson HBI, 2002, EPILEPSIA, V43, P768, DOI 10.1046/j.1528-1157.2002.15801.x; RICHARDS EH, 1968, EPILEPSIA, V9, P127, DOI 10.1111/j.1528-1157.1968.tb05134.x; Rimmer RB, 2007, J BURN CARE RES, V28, P318, DOI 10.1097/BCR.0B013E318031A161; SHAW JL, 1971, J BONE JOINT SURG AM, VA 53, P1437, DOI 10.2106/00004623-197153070-00023; SHETH RD, 1995, J PEDIATR-US, V127, P256, DOI 10.1016/S0022-3476(95)70304-7; Sheth SG, 2004, NEUROLOGY, V63, P1002, DOI 10.1212/01.WNL.0000138590.00074.9A; SILBERGELD D L, 1991, Journal of the Royal College of Surgeons of Edinburgh, V36, P139; Souverein PC, 2005, EPILEPSIA, V46, P304, DOI 10.1111/j.0013-9580.2005.23804.x; SPITZ MC, 1994, EPILEPSIA, V35, P764, DOI 10.1111/j.1528-1157.1994.tb02508.x; Spitz MC, 1998, EPILEPSIA, V39, P904, DOI 10.1111/j.1528-1157.1998.tb01189.x; Stephen LJ, 1999, SEIZURE-EUR J EPILEP, V8, P339, DOI 10.1053/seiz.1999.0301; Taylor J, 1996, J NEUROL NEUROSUR PS, V60, P621, DOI 10.1136/jnnp.60.6.621; Tellez-Zenteno JF, 2008, EPILEPSIA, V49, P954, DOI 10.1111/j.1528-1167.2007.01499.x; TEMPEST MN, 1956, BMJ-BRIT MED J, V1, P1387, DOI 10.1136/bmj.1.4980.1387; van den Broek M, 2004, EPILEPSIA, V45, P667, DOI 10.1111/j.0013-9580.2004.33903.x; VANDERLUGT PJM, 1975, EPILEPSIA, V16, P747, DOI 10.1111/j.1528-1157.1975.tb04760.x; Vestergaard P, 2005, ACTA NEUROL SCAND, V112, P277, DOI 10.1111/j.1600-0404.2005.00474.x; Vestergaard P, 1999, ACTA NEUROL SCAND, V99, P269, DOI 10.1111/j.1600-0404.1999.tb00675.x; WALLER JA, 1965, NEW ENGL J MED, V273, P1413, DOI 10.1056/NEJM196512232732605; Wirrell EC, 1996, ARCH NEUROL-CHICAGO, V53, P929, DOI 10.1001/archneur.1996.00550090141020; ZIEGLER AL, 1994, ARCH PEDIATRIE, V1, P801; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	57	33	34	0	0	PAGEPRESS PUBL	PAVIA	MEDITGROUP, VIA G BELLI, 4, PAVIA, 27100, ITALY	2035-8385	2035-8377		NEUROL INT	Neurol. Int.		2009	1	1					72	78		10.4081/ni.2009.e20			7	Clinical Neurology	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V0T0L	WOS:000216532600020	21577358	Green Submitted, Green Published, gold			2022-02-06	
J	Warner, KJ; Cuschieri, J; Garland, B; Carlbom, D; Baker, D; Copass, MK; Jurkovich, GJ; Bidger, EM				Warner, Keir J.; Cuschieri, Joseph; Garland, Brandon; Carlbom, David; Baker, David; Copass, Michael K.; Jurkovich, Gregory J.; Bidger, Eileen M.			The Utility of Early End-Tidal Capnography in Monitoring Ventilation Status After Severe Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						End-tidal capnography; Trauma; Ventilation; Prehospital; Emergency department; Intubation	TRAUMATIC BRAIN-INJURY; CARBON-DIOXIDE; TENSION DIFFERENCE; ARTERIAL PCO2; HYPERVENTILATION; ANESTHESIA; IMPACT	Background: An arterial CO2 (Paco(2)) of 30 mm Hg to 39 mm Fig has been shown to be the ideal target range for early ventilation in trauma patients; however, this requires serial arterial blood gases. The use of end-tidal capnography (Etco(2)) has been recommended as a surrogate measure of ventilation in the prehospital arena. This is based on the observation of close Etco(2) Paco(2) correlation in healthy patients, yet trauma patients frequently suffer from impaired pulmonary ventilation/perfusion. Thus, we hypothesize that Etco(2) will demonstrate a poor reflection of actual ventilation status after severe injury. Methods. Prospective observational study on consecutive intubated trauma patients treated in our emergency department (ED) during 9 months. Arterial blood gas values and concomitant Etco(2) levels were recorded. Regression was used to determine the strength of correlation among all trauma patients and subgroups based on injury severity (Abbreviated Injury Score and Injury Severity Score) and physiologic markers of perfusion status (lactate, shock index, and arterial base deficit). Results. During 9 months, 180 patients, were evaluated. The Etco(2) Paco(2) correlation was poor at R-2 = 0.277. Patients ventilated in the recommended Etco(2) (range, 35 to 40) were likely to be under ventilated (Paco(2) > 44) mm Hg) 80% of the time, and severely under ventilated (Paco(2) > 50 mm Hg) 30% of the time. Correlation was best for patients with isolated traumatic brain injury and worst for those with evidence of poor tissue perfusion. Conclusion: Etco(2) has low correlation with Paco(2), and therefore should not be used to guide ventilation in intubated trauma patients in the ED. Better strategies for guiding prehospital and ED ventilation are needed.	[Warner, Keir J.; Cuschieri, Joseph; Jurkovich, Gregory J.; Bidger, Eileen M.] Univ Washington, Harborview Med Ctr, Dept Trauma Surg, Seattle, WA 98104 USA; [Carlbom, David; Baker, David; Copass, Michael K.] Univ Washington, Harborview Med Ctr, Dept Emergency Med, Seattle, WA 98104 USA; [Garland, Brandon] Univ Washington, Sch Med, Seattle, WA 98104 USA		Warner, KJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Trauma Surg, 325 9Th Ave, Seattle, WA 98104 USA.	keirw@u.washington.edu					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belpomme V, 2005, AM J EMERG MED, V23, P852, DOI 10.1016/j.ajem.2005.04.011; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; *BRAIN TRAUM FDN, 2008, GUID PREH MAN TRAUM; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Committee on Medical Aspect of Automotive Safety, 1971, JAMA-J AM MED ASSOC, V215, P277; Davis D, 2008, RESUSCITATION, V77, P418, DOI 10.1016/j.resuscitation.2008.01.014; Davis D, 2004, ARCHAEOLOGY, V57, P8; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; FLETCHER R, 1984, BRIT J ANAESTH, V56, P109, DOI 10.1093/bja/56.2.109; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; *NAEMT, 2006, PHTLS PREH TRAUM LIF; NUNN JF, 1960, J APPL PHYSIOL, V15, P383, DOI 10.1152/jappl.1960.15.3.383; Pepe Paul E, 2004, Crit Care Med, V32, pS414, DOI 10.1097/01.CCM.0000134264.88332.37; Prause G, 1997, RESUSCITATION, V35, P145, DOI 10.1016/S0300-9572(97)00043-9; SHANKAR KB, 1989, CAN J ANAESTH, V36, P124, DOI 10.1007/BF03011432; TEASDALE G, 1974, LANCET, V2, P81; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Warner KJ, 2008, J TRAUMA, V64, P341, DOI 10.1097/TA.0b013e318160dfb3; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Yosefy C, 2004, EMERG MED J, V21, P557, DOI 10.1136/emj.2003.005819; [No title captured]	23	33	36	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					26	31		10.1097/TA.0b013e3181957a25			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	395SJ	WOS:000262543500003	19131802				2022-02-06	
J	Choi, JH; Jakob, M; Stapf, C; Marshall, RS; Hartmann, A; Mast, H				Choi, Jae H.; Jakob, Michael; Stapf, Christian; Marshall, Randolph S.; Hartmann, Andreas; Mast, Henning			Multimodal Early Rehabilitation and Predictors of Outcome in Survivors of Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	130th Annual Meeting of the American-Neurological-Association	SEP 25-28, 2005	San Diego, CA	Amer Neurol Assoc, AstraZeneca		Severe traumatic brain injury; Outcome; Early rehabilitation; Multimodal rehabilitation	SEVERE HEAD-INJURY	Background: To determine the effect of brain lesion pattern on early recovery after severe traumatic brain injury (TBI). Methods: In a setting of a multimodal early rehabilitation unit at a level I trauma center, 135 consecutive survivors of severe TBI (mean age, 40 years, 25% women) were studied prospectively. Assessment of disability was performed weekly using an extended Barthel Index (eBI) ranging from -325 to +100 points. Clinical and brain morphologic variables were tested in multivariate logistic regression models to determine predictors of outcome. Results: Imaging revealed cerebral contusion in 115 patients (85%) affecting the frontal (n = 80), temporal (n = 62), parieto-occipital (n = 17), brain stern (n = 13), and cerebellar (n = 5) regions. In addition, 80 patients (59%) showed diffuse brain edema, 75 (55%) subarachnoid, 37 (28%) subdural, and 18 (13%) epidural hemorrhage. After a mean stay of 72 +/- 51 days in the early rehabilitation unit, one patient died, 40 (30%) revealed good outcome (median eBI, +55), and a further 43 patients (32%) showed excellent outcomes (eBI, 90-100). Temporal (odds ratio 2.6; 95% confidence interval 1.1-6.5) and brain stem contusions (odds ratio 13.8; 95% confidence interval 3.0-64.1) were independent predictors of poor outcome. Conclusions: Temporal and brain stern contusions constitute independent risk factors for poor outcome in survivors of severe TBI. The results further suggest a high potential for multimodal early rehabilitation after severe TBI.	[Choi, Jae H.; Jakob, Michael; Mast, Henning] BG Kliniken Bergmannstrost, Dept Neurol, D-06112 Halle, Germany; [Choi, Jae H.; Stapf, Christian; Marshall, Randolph S.; Hartmann, Andreas; Mast, Henning] Columbia Univ, Med Ctr, Neurol Inst, New York, NY USA; [Choi, Jae H.] Columbia Univ, Med Ctr, Dept Radiol, New York, NY USA; [Stapf, Christian] Hop Lariboisiere, AP HP, Dept Neurol, F-75475 Paris, France; [Hartmann, Andreas; Mast, Henning] Charite Campus Benjamin Franklin, Dept Neurol, Berlin, Germany		Choi, JH (corresponding author), BG Kliniken Bergmannstrost, Dept Neurol, Merseburger Str 165, D-06112 Halle, Germany.	jchoi@neuro.columbia.edu		Stapf, Christian/0000-0002-3193-1006			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Collin C, 1988, Int Disabil Stud, V10, P61; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; *DEP HLTH SOC SEC, FED HLTH REP; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FIRSCHING R, 2003, DTSCH ARZEBL, V100, P1868; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NAT CTR INJ PREV, 2006, TRAUM INJ US EM DEP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REGEL G, 1993, UNFALLCHIRURG, V96, P350; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; [No title captured]; 1994, N ENG J MED, V330, P1572	28	33	34	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2008	65	5					1028	1035		10.1097/TA.0b013e31815eba9b			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	372DD	WOS:000260881000011	19001970				2022-02-06	
J	VanLandingham, JW; Cekic, M; Cutler, SM; Hoffman, SW; Washington, ER; Johnson, SJ; Miller, D; Stein, DG				VanLandingham, Jacob W.; Cekic, Milos; Cutler, Sarah M.; Hoffman, Stuart W.; Washington, Ebony R.; Johnson, Sarah J.; Miller, Darren; Stein, Donald G.			Progesterone and its metabolite allopregnanolone differentially regulate hemostatic proteins after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						allopregnanolone; coagulation; hemostasis; progesterone; traumatic brain injury	TISSUE-PLASMINOGEN ACTIVATOR; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; PROCOAGULANT ACTIVITY; CATAMENIAL EPILEPSY; NEUROPROTECTION; RATS; THROMBIN; RECEPTOR; COAGULOPATHY	Our laboratory has shown in numerous experiments that the neurosteroids progesterone (PROG) and allopregnanolone ( ALLO) improve molecular and functional outcomes after traumatic brain injury (TBI). As coagulopathy is an important contributor to the secondary destruction of nervous tissue, we hypothesized that PROG and ALLO administration may also have a beneficial effect on coagulation protein expression after TBI. Adult male Sprague-Dawley rats were given bilateral contusions of the medial frontal cortex followed by treatments with PROG ( 16 mg/kg), ALLO ( 8 mg/kg), or vehicle (22.5% hydroxypropyl-beta-cyclodextrin). Controls received no injury or injections. Progesterone generally maintained procoagulant (thrombin, fibrinogen, and coagulation factor XIII), whereas ALLO increased anticoagulant protein expression (tissue-type plasminogen activator, tPA). In addition, PROG significantly increased the ratio of tPA bound to neuroserpin, a serine protease inhibitor that can reduce the activity of tPA. Our findings suggest that in a model of TBI, where blood loss may exacerbate injury, it may be preferable to treat patients with PROG, whereas it might be more appropriate to use ALLO as a treatment for thrombotic stroke, where a reduction in coagulation would be more beneficial.	[Stein, Donald G.] Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Cekic, Milos/AAR-8250-2020; Stein, Donald/AAJ-5139-2020		NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1N540825, 1RO1N538664]; Department of Emergency Medicine at Emory University; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008169] Funding Source: NIH RePORTER	The funding for this study was provided by the NINDS Grants 1RO1N540825 and 1RO1N538664 and the Department of Emergency Medicine at Emory University.	Bulens F, 1997, J BIOL CHEM, V272, P663; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Herkert O, 2001, CIRCULATION, V104, P2826, DOI 10.1161/hc4801.099737; Herzog AG, 2008, SEIZURE-EUR J EPILEP, V17, P151, DOI 10.1016/j.seizure.2007.11.014; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Kato S, 2005, J CLIN ENDOCR METAB, V90, P1181, DOI 10.1210/jc.2004-0857; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Melchor JP, 2005, THROMB HAEMOSTASIS, V93, P655, DOI 10.1160/TH04-12-0838; Miranda E, 2006, CELL MOL LIFE SCI, V63, P709, DOI 10.1007/s00018-005-5077-4; Monsonego A, 1998, FASEB J, V12, P1163, DOI 10.1096/fasebj.12.12.1163; MOSESSON MW, 1992, NOUV REV FR HEMATOL, V34, P11; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Reddy DS, 2004, METHOD FIND EXP CLIN, V26, P547, DOI 10.1358/mf.2004.26.7.863737; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Savitz SI, 2005, STROKE, V36, P1447, DOI 10.1161/01.STR.0000170647.42126.a8; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Schindler AE, 2003, MATURITAS, V46, pS31, DOI 10.1016/j.maturitas.2003.09.016; Schreiber MA, 2005, CURR OPIN CRIT CARE, V11, P590, DOI 10.1097/01.ccx.0000186374.49320.ab; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sheehan JJ, 2005, GLIA, V50, P340, DOI 10.1002/glia.20150; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; WILLIAMS JE, 1981, BIOCHEM J, V197, P661, DOI 10.1042/bj1970661; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yepes M, 2004, THROMB HAEMOSTASIS, V91, P457, DOI 10.1160/TH03-12-0766	40	33	38	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2008	28	11					1786	1794		10.1038/jcbfm.2008.73			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	366IB	WOS:000260472900003	18628783	Bronze			2022-02-06	
J	Liu, WL; Lee, YH; Tsai, SY; Hsu, CY; Yu-Yo, S; Yang, LY; Tsai, SH; Yang, WCV				Liu, Wei-Lin; Lee, Yi-Hsuan; Tsai, Shih-Ying; Hsu, Chung Yi; Yu-Yo, Sun; Yang, Liang-Yo; Tsai, Shing-Han; Yang, Wei-Chung Vivian			Methylprednisolone inhibits the expression of glial fibrillary acidic protein and chondroitin sulfate proteoglycans in reactivated astrocytes	GLIA			English	Article						central nervous system; chondroitin sulfate proteoglycans; gliosis; glucocorticoid; spinal cord injury	SPINAL-CORD-INJURY; AMPA RECEPTOR ACTIVATION; GLUCOCORTICOID-RECEPTOR; CNS INJURY; BRAIN; NEUROCAN; INFLAMMATION; OUTGROWTH; RESPONSES; CULTURE	Reactive gliosis caused by post-traumatic injury often results in marked expression of chondroitin sulfate proteoglycan (CSPG), which inhibits neurite outgrowth and regeneration. Methylprednisolone (MP), a synthetic glucocorticoid, has been shown to have neuroprotective and anti-inflammatory effects for the treatment of acute spinal cord injury (SCI). However, the effect of MP on CSPG expression in reactive glial cells remains unclear. In our study, we induced astrocyte reactivation using alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and cyclothiazide to mimic the excitotoxic stimuli of SCI. The expression of glial fibrillary acidic protein (GFAP), a marker of astrocyte reactivation, and CSPG neurocan and phosphacan were significantly elevated by AMPA treatment. The conditioned media from AMPA-treated astrocytes strongly inhibited neurite outgrowth of rat dorsal root ganglion neurons, and this effect was reversed by pretreatment with MR Furthermore, MR downregulated GFAP and CSPG expression in adult rats with SCI. Additionally, both the glucocorticoid receptor (GR) antagonist RU486 and GR siRNA reversed the inhibitory effects of MR on GFAP and neurocan expression. Taken together, these results suggest that MR may improve neuronal repair and promote neurite outgrowth after excitotoxic insult via GR-mediated downregulation of astrocyte reactivation and inhibition of CSPG expression. (c) 2008 Wiley-Liss, Inc.	[Liu, Wei-Lin; Yang, Wei-Chung Vivian] Taipei Med Univ, Grad Inst Biomed Mat & Engn, Taipei 110, Taiwan; [Liu, Wei-Lin; Lee, Yi-Hsuan; Hsu, Chung Yi; Yang, Liang-Yo] Taipei Med Univ, Coll Med, Grad Inst Neurosci, Taipei 110, Taiwan; [Lee, Yi-Hsuan; Yu-Yo, Sun; Yang, Liang-Yo] Taipei Med Univ, Coll Med, Sch Med, Dept Physiol, Taipei 110, Taiwan; [Lee, Yi-Hsuan; Tsai, Shih-Ying; Yu-Yo, Sun; Yang, Liang-Yo] Taipei Med Univ, Grad Inst Med Sci, Div Physiol & Neurosci, Coll Med, Taipei 110, Taiwan; [Tsai, Shing-Han] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei 110, Taiwan; [Tsai, Shing-Han] Taipei Municipal WanFang Hosp, Dept Neurosurg, Taipei, Taiwan		Yang, WCV (corresponding author), Taipei Med Univ, Grad Inst Biomed Mat & Engn, 250 Wu Hsing St, Taipei 110, Taiwan.	vyang@tmu.edu.tw		Sun, Yu-Yo/0000-0002-6608-1347; Hsu, Chung Y./0000-0002-5632-2733	National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC93-3112-B-038-003, NSC93-3112-B-038-004, NSC94-2314-B-038-017, NSC95-2745-B-038-005]; Ministry of Education, TaiwanMinistry of Education, Taiwan	National Science Council of Taiwan; Grant numbers: NSC93-3112-B-038-003, NSC93-3112-B-038-004 NSC94-2314-B-038-017, NSC95-2745-B-038-005. Grant sponsor: The Topnotch Stroke Research Center Grant, Ministry of Education, Taiwan.	Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; Asher RA, 2000, J NEUROSCI, V20, P2427; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; Bracken M B, 1991, J Neurotrauma, V8 Suppl 1, pS47; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; BRACKEN MB, 1991, J NEUROTRAUMA S1, V8, pS51; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CANNING DR, 1993, EXP NEUROL, V124, P289, DOI 10.1006/exnr.1993.1199; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DAHL D, 1976, BRAIN RES, V116, P150, DOI 10.1016/0006-8993(76)90257-2; DAHL D, 1974, J NEUROL SCI, V23, P551, DOI 10.1016/0022-510X(74)90027-6; David JC, 1996, J NEUROSCI, V16, P200; Deupree DL, 1996, NEUROCHEM INT, V29, P255, DOI 10.1016/0197-0186(96)00003-4; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Haas CA, 1999, J NEUROSCI, V19, P9953; HALL ED, 1981, EXP NEUROL, V73, P321, DOI 10.1016/0014-4886(81)90067-4; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Honer C, 2003, MOL PHARMACOL, V63, P1012, DOI 10.1124/mol.63.5.1012; HOSLI E, 1993, PROG NEUROBIOL, V40, P477, DOI 10.1016/0301-0082(93)90019-O; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Levison S., 1991, CULTURING NERVE CELL, P309; Mace K, 2002, J NEUROSCI RES, V70, P46, DOI 10.1002/jnr.10381; Magnus T, 2001, J IMMUNOL, V167, P5004, DOI 10.4049/jimmunol.167.9.5004; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Powell EM, 1999, GLIA, V26, P73, DOI 10.1002/(SICI)1098-1136(199903)26:1<73::AID-GLIA8>3.0.CO;2-S; Ransom B, 2003, TRENDS NEUROSCI, V26, P520, DOI 10.1016/j.tins.2003.08.006; ROZOVSKY I, 1995, ENDOCRINOLOGY, V136, P2066, DOI 10.1210/en.136.5.2066; SARID J, 1991, J NEUROSCI RES, V28, P217, DOI 10.1002/jnr.490280209; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Shank SS, 2003, AM J PHYSIOL-HEART C, V284, pH1751, DOI 10.1152/ajpheart.01033.2002; Shirakawa H, 2005, EUR J NEUROSCI, V21, P2329, DOI 10.1111/j.1460-9568.2005.04079.x; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Snow DM, 2003, EXP NEUROL, V182, P310, DOI 10.1016/S0014-4886(03)00034-7; SNOWDON AL, 1990, COLOUR ATLAS POSTHAR, V1, P11; SORRELL JM, 1993, MATRIX, V13, P351, DOI 10.1016/S0934-8832(11)80040-5; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3; YOUNG W, 1992, J NEUROTRAUM, V9, pS397	58	33	35	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	OCT	2008	56	13					1390	1400		10.1002/glia.20706			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345KL	WOS:000258995300003	18618653				2022-02-06	
J	Dudkiewicz, M; Proctor, KG				Dudkiewicz, Michael; Proctor, Kenneth G.			Tissue oxygenation during management of cerebral perfusion pressure with phenylephrine or vasopressin	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; blast; pulmonary contusion; mannitol; swine; combat casualty care	ARGININE-VASOPRESSIN; BRAIN EDEMA; BLOOD-FLOW; HEMORRHAGIC-SHOCK; DOSE VASOPRESSIN; LIVER TRAUMA; RESUSCITATION; RAT; HYPOTENSION; ANTAGONIST	Objective: Phenylephrine is often used for management of cerebral perfusion pressure after traumatic brain injury, but can have undesirable actions. Few studies have evaluated alternatives. The hypothesis was that arginine vasopressin was as effective as pherylephrine for maintaining tissue oxygenation during cerebral perfusion pressure management. Design: Prospective randomized, blinded animal study, Setting: University laboratory. Subjects: Thirty-five anesthetized swine (46 +/- 1 kg). Interventions: Blunt trauma to the head and bilateral chests (estimated injury severity score was 25-32) was followed by hypoventilation. Resuscitation was divided into phases to simulate treatment in a typical prehospital, emergency room, and intensive care unit. For 30-45 mins postinjury, 1 L of normal saline was administered. For 45-120 mins, normal saline maintained systolic blood pressure >100 mm Hg plus-mannitol for intracranial hypertension. After 120 mins, phenylephrine or arginine vasopressin was titrated to cerebral perfusion pressure >70 mm Hg (randomized and blinded) plus normal saline to maintain filling pressure >12 mm Hg plus glucose to maintain normoglycemia. Measurements and Main Results: Mortality rate was 37% (13 of 35) within 2 hrs. Before resuscitation, mean arterial pressure was 61 +/- 5 mm Hg, heart rate was 110 +/- 6 beats/min, Pa0(2) was 46 +/- 2 mm Hg, and lactate was 5.0 +/- 0.4 mM. Intracranial pressure increased from 8 +/- 1 mm Hg to 20 +/- 1 mm Hg and brain tissue P0(2) decreased from 19 +/- 1 mm Hg to 8 +/- 1 mm Hg. Resuscitation corrected most variables, as well as mixed venous, renal, portal, and muscle oxygen saturations, but 90% (20 of 22) required pressor support. After 6 hrs with either pressor, hemodynamics were stable. However, with phenylephrine vs. arginine vasopressin, intracranial pressure averaged >10 mm Hg higher and brain tissue P0(2) was 6 mm Hg lower, whereas tissue oxygen saturations were >10% higher in the shoulder and hindlimb muscles (all p < 0.05). Conclusions: Arginine vasopressin was as effective as phenylephrine for maintaining cerebral perfusion pressure, but intracranial pressure and brain tissue oxygenation were improved at the expense of the periphery.	[Proctor, Kenneth G.] Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Deiv Surg Crit Care, Miami, FL 33136 USA		Proctor, KG (corresponding author), Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Trauma, Miami, FL 33136 USA.	kproctor@miami.edu	Proctor, Kenneth/AAA-2199-2022	Proctor, Kenneth/0000-0003-1326-6628	Office of Naval ResearchOffice of Naval Research [N140610670]	Supported by grant# N140610670 from the Office of Naval Research.	Argenziano M, 1997, CIRCULATION, V96, P286; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; Bilski TR, 2003, J TRAUMA, V54, P814, DOI 10.1097/01.TA.0000046627.87250.1D; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CACH R, 1989, BRAIN RES, V483, P221, DOI 10.1016/0006-8993(89)90166-2; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cornwell E, 1999, J TRAUMA, V47, P703; DELGADO TJ, 1988, J NEUROSURG, V68, P266, DOI 10.3171/jns.1988.68.2.0266; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desselle WJ, 2001, J TRAUMA, V51, P239, DOI 10.1097/00005373-200108000-00005; DeWitt DS, 2000, CRIT CARE MED, V28, P3933, DOI 10.1097/00003246-200012000-00036; DOCZI T, 1984, NEUROSURGERY, V14, P436, DOI 10.1227/00006123-198404000-00008; Earle SA, 2007, J AM COLL SURGEONS, V204, P261, DOI 10.1016/j.jamcollsurg.2006.11.014; Feinstein AJ, 2005, J TRAUMA, V59, P876, DOI 10.1097/01.ta.0000187654.24146.22; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Holmes Cheryl L, 2004, Curr Opin Crit Care, V10, P442, DOI 10.1097/01.ccx.0000144769.19213.0c; Holtzer S, 2001, CRIT CARE MED, V29, P1609, DOI 10.1097/00003246-200108000-00018; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KATUSIC ZS, 1984, CIRC RES, V55, P575, DOI 10.1161/01.RES.55.5.575; Kelly ME, 2003, J TRAUMA, V55, P94, DOI 10.1097/01.TA.0000029042.37577.A6; Krismer Anette C, 2004, Crit Care Med, V32, pS432, DOI 10.1097/01.CCM.0000134267.91520.C0; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Landry DW, 1997, CIRCULATION, V95, P1122; Malay MB, 1999, J TRAUMA, V47, P699, DOI 10.1097/00005373-199910000-00014; Malay MB, 2004, CRIT CARE MED, V32, P1327, DOI 10.1097/01.CCM.0000128578.37822.F1; Maxwell RA, 2001, J TRAUMA, V51, P849, DOI 10.1097/00005373-200111000-00005; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; ONOUE H, 1988, STROKE, V19, P1388, DOI 10.1161/01.STR.19.11.1388; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; PROCTOR KG, 1987, CIRC RES, V61, P42, DOI 10.1161/01.RES.61.1.42; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robin JK, 2003, J TRAUMA, V54, pS149, DOI 10.1097/01.TA.0000064523.93060.60; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; SUZUKI Y, 1994, J AUTONOM NERV SYST, V49, pS129; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Trandafir CC, 2004, CLIN EXP PHARMACOL P, V31, P261, DOI 10.1111/j.1440-1681.2004.03986.x; TSUGANE S, 1994, J AUTONOM NERV SYST, V49, pS133; *US TOD, US TOD SPEC REP; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Wenzel V, 2005, RESUSCITATION, V64, P219, DOI 10.1016/j.resuscitation.2004.07.013; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Yeh CC, 2003, ANESTH ANALG, V97, P577, DOI 10.1213/01.ANE.0000070231.16378.A6	49	33	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2008	36	9					2641	2650		10.1097/CCM.0b013e3181847af3			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	345TV	WOS:000259020800022	18679110				2022-02-06	
J	Engel, DC; Mies, G; Terpolilli, NA; Trabold, R; Loch, A; De Zeeuw, CI; Weber, JT; Maas, AIR; Plesnila, N				Engel, Doortje C.; Mies, Guenter; Terpolilli, Nicole A.; Trabold, Raimund; Loch, Alexander; De Zeeuw, Chris I.; Weber, John T.; Maas, Andrew I. R.; Plesnila, Nikolaus			Changes of cerebral blood flow during the secondary expansion of a cortical contusion assessed by C-14-iodoantipyrine autoradiography in mice using a non-invasive protocol	JOURNAL OF NEUROTRAUMA			English	Article						autoradiography; brain contusion; brain edema; cerebral blood flow; controlled cortical impact; mice; secondary brain damage; traumatic brain injury	TRAUMATIC BRAIN-INJURY; IMPACT INJURY; HEAD-INJURY; OXYGEN-CONSUMPTION; NEURONAL DEATH; RATS; ISCHEMIA; EDEMA; PERFUSION; MOUSE	Although changes of cerebral blood flow (CBF) in and around traumatic contusions are well documented, the role of CBF for the delayed death of neuronal cells in the traumatic penumbra ultimately resulting in secondary contusion expansion remains unclear. The aim of the current study was therefore to investigate the relationship between changes of CBF and progressive peri-contusional cell death following traumatic brain injury (TBI). CBF and contusion size were measured in C57Bl6 mice under continuous on-line monitoring of ETpCO2 before, and at 15 min and 24 h following controlled cortical impact by C-14-iodoantipyrine autoradiography (IAP-AR; n = 5-6 per group) and by Nissl staining, respectively. Contused and ischemic (CBF < 10%) tissue volumes were calculated and compared over time. Cortical CBF in not injured mice varied between 69 and 93 mL/100mg/min depending on the anatomical location. Fifteen minutes after trauma, CBF decreased in the whole brain by similar to 50% (39 +/- 18 mL/100mg/min; p < 0.05), except in contused tissue where it fell by more than 90% (3 +/- 2 mL/100mg/min; p < 0.001). Within 24 h after TBI, CBF recovered to normal values in all brain areas except the contusion where it remained reduced by more than 90% (p < 0.001). Contusion volume expanded from 24.9 to 35.5 mm3 (p < 0.01) from 15 min to 24 h after trauma (+43%), whereas the area of severe ischemia (CBF < 10%) showed only a minimal (+13%) and not significant increase (22.3 to 25.1 mm(3)). The current data therefore suggest that the delayed secondary expansion of a cortical contusion following traumatic brain injury may not be caused by a reduction of CBF alone.	[Engel, Doortje C.; Terpolilli, Nicole A.; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Med Ctr, Dept Neurosurg, Munich, Germany; [Engel, Doortje C.; Terpolilli, Nicole A.; Loch, Alexander; Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Surg Res, Munich, Germany; [Engel, Doortje C.; De Zeeuw, Chris I.; Weber, John T.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; [Maas, Andrew I. R.] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Mies, Guenter] Max Planck Inst Neurol Res, Cologne, Germany		Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St Stevens Green, Dublin 2, Ireland.	nikolausplesnila@rcsi.ie	Maas, Andrew IR/C-5584-2013; Terpolilli, Nicole/AAG-3598-2021; Plesnila, Nikolaus/T-7522-2019	Maas, Andrew IR/0000-0003-1612-1264; 			ALEXANDER MJ, 1994, ACTA NEUROCHIR, P479; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Holmstrom A, 2005, ACTA ANAESTH SCAND, V49, P16, DOI 10.1111/j.1399-6576.2004.00576.x; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JAY TM, 1988, J CEREBR BLOOD F MET, V8, P121, DOI 10.1038/jcbfm.1988.16; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; Katayama Y, 1998, ACT NEUR S, V71, P289; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MADSEN FF, 1990, ACTA NEUROCHIR, V105, P150, DOI 10.1007/BF01670000; Maeda K, 2000, J CEREBR BLOOD F MET, V20, P10, DOI 10.1097/00004647-200001000-00003; Maeda T, 1997, ACT NEUR S, V70, P102; MARTINS AN, 1978, STROKE, V9, P509, DOI 10.1161/01.STR.9.5.509; MARTINS AN, 1977, J NEUROSURG, V47, P346, DOI 10.3171/jns.1977.47.3.0346; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Pollay M, 1980, Adv Exp Med Biol, V131, P321; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SCHWARZMAIER S, 2007, J NEUROTRAUM, V23, P769; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; SUTTON RL, 1994, ACTA NEUROCHIR, P446; TANAKA H, 1994, ACTA NEUROCHIR, P524; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Tornheim P A, 1990, Adv Neurol, V52, P377; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Wellons JC, 2000, BRAIN RES, V868, P14, DOI 10.1016/S0006-8993(00)02216-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	62	33	34	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					739	753		10.1089/neu.2007.0480			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000003	18627253				2022-02-06	
J	Duane, TM; Mayglothling, J; Grandhi, R; Warrier, N; Aboutanos, MB; Wolfe, LG; Malhotra, AK; Ivatury, RR				Duane, Therese M.; Mayglothling, Julie; Grandhi, Ramesh; Warrier, Nisha; Aboutanos, Michel B.; Wolfe, Luke G.; Malhotra, Ajai K.; Ivatury, Rao R.			The effect of anemia and blood transfusions on mortality in closed head injury patients	JOURNAL OF SURGICAL RESEARCH			English	Article						trauma; closed head injury; anemia; transfusion; outcome; mortality	POSTOPERATIVE BACTERIAL-INFECTION; INDEPENDENT RISK-FACTOR; TRAUMA PATIENTS; CRITICAL-CARE; REQUIREMENTS; INCREASES; STRATEGY	Background. The purpose of this study was to determine if anemia in isolated head trauma patients results in a higher mortality rate that would justify a more liberal use of blood transfusions. Methods. A retrospective review of isolated blunt head trauma patients was performed between January 2001 and December 2006. Comparisons were made between survivors and nonsurvivors regarding demographics, laboratory values, transfusions received, and lengths of stay. Results. There were 788 patients with 735 survivors who were significantly younger (46.3 y +/- 21.5 survivors versus 68.9 y +/- 18.8 nonsurvivors, P < 0.0001) and less injured [(ISS: 14.7 +/- 5.2 survivors versus 23.2 +/- 4.7 nonsurvivors, P < 0.0001), (head abbreviated injury severity: 3.7 +/- 0.7 survivors versus 4.7 +/- 0.5 nonsurvivors, P < 0.0001)] than those who died (n = 53). The survivors also had shorter lengths of stay (days) [(ICU: 2.4 +/- 4.2 versus 5.6 +/- 11.7, P = 0.03), (hospital: 6.3 +/- 9.8 versus 7.8 +/- 14.89 P = 0.02)]. Multivariate logistic regression showed age (OR 1.063, CI 1.042-1.084), ISS (OR 1.376, Cl 1.270-1.491), minimum hemoglobin (OR 0.855, Cl 0.732-1.000), and total blood products transfused (OR 1.073, Cl 1.008-1.142) to be independent predictors of mortality with an ROC of 0.942. Outcome was independent of the operative procedures, hematocrit and packed red blood cells transfused at 24, 48, and 72 h. Hemoglobin levels of <8 mg/dL were more predictive of death than >8 mg/dL (P = 0.01). Conclusions. This study supports the need to balance mild anemia with judicious blood product use in the head trauma patient. Given the risk with blood product use, each transfusion should be carefully considered and the patient re-evaluated regularly to determine the need for further intervention. (C) 2008 Elsevier Inc. All rights reserved.	[Duane, Therese M.; Mayglothling, Julie; Grandhi, Ramesh; Warrier, Nisha; Aboutanos, Michel B.; Wolfe, Luke G.; Malhotra, Ajai K.; Ivatury, Rao R.] Virginia Commonwealth Univ, Med Ctr, Div Trauma Crit Care & Emergency Gen Surg, Richmond, VA 23298 USA		Duane, TM (corresponding author), Virginia Commonwealth Univ, Med Ctr, W Hosp, 1200 E Broad St,15th Floor,POB 980454, Richmond, VA 23298 USA.	tmduane@vcu.edu	Ivatury, Rao R./H-2922-2019				Avall A, 1997, ANESTHESIOLOGY, V87, P511, DOI 10.1097/00000542-199709000-00009; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Carson JL, 1999, TRANSFUSION, V39, P694, DOI 10.1046/j.1537-2995.1999.39070694.x; Chang H, 2000, VOX SANG, V78, P13, DOI 10.1046/j.1423-0410.2000.7810013.x; Claridge JA, 2002, AM SURGEON, V68, P566; Dunne James R, 2004, Surg Infect (Larchmt), V5, P395, DOI 10.1089/sur.2004.5.395; EDNA TH, 1992, J TRAUMA, V33, P659, DOI 10.1097/00005373-199211000-00010; Fransen E, 1999, CHEST, V116, P1233, DOI 10.1378/chest.116.5.1233; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Hill GE, 2003, J TRAUMA, V54, P908, DOI 10.1097/01.TA.0000022460.21283.53; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; May AK, 1997, AM SURGEON, V63, P233; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49	17	33	34	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	JUN 15	2008	147	2					163	167		10.1016/j.jss.2008.02.044			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	306JP	WOS:000256244500001	18498864				2022-02-06	
J	Mihalik, JP; Guskiewicz, KM; Jeffries, JA; Greenwald, RM; Marshall, SW				Mihalik, J. P.; Guskiewicz, K. M.; Jeffries, J. A.; Greenwald, R. M.; Marshall, S. W.			Characteristics of head impacts sustained by youth ice hockey players	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART P-JOURNAL OF SPORTS ENGINEERING AND TECHNOLOGY			English	Article						accelerometers; biomechanics; concussion; head impact; sports injury		This study aimed to measure the magnitude of head impacts sustained by 14 male, youth (13 years old) ice hockey players wearing instrumented helmets, and to compare impacts across event type (practice, game), player position, and location. Head impact magnitudes were captured during 58 games and 51 practices. Mixed linear models were utilized to analyze differences by event type, player position, and location of impact. Game impact magnitudes were significantly greater than practice impacts. Impacts sustained by forwards were similar in magnitude to those sustained by defensemen. Significant differences between head impact locations across all player positions were observed. Impacts to the top of the head were significantly greater than impacts to the back, front, left, and right sides. Youth ice hockey players sustain helmet impacts nearing 20 g on average, similar to measured values in collegiate American football players, and of potential concern because this sample involves younger athletes. Future biomechanical studies are needed to better interpret the finding that there is an increased likelihood of higher magnitude head impacts to the top of the head. The authors' long-term goal is to improve the understanding of impacts that may lead to concussions in young athletes.	[Mihalik, J. P.; Guskiewicz, K. M.; Jeffries, J. A.] Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Mihalik, J. P.; Guskiewicz, K. M.] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Chapel Hill, NC 27599 USA; [Guskiewicz, K. M.; Marshall, S. W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Greenwald, R. M.] Simbex LLC, Lebanon, NH USA; [Greenwald, R. M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Marshall, S. W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, 204 Fetzer Gymnasium,South Rd, Chapel Hill, NC 27599 USA.		Mihalik, Jason P/E-7059-2010		Ontario Neurotrauma Foundation (Toronto, ON, Canada) [2005-PREV-BANT-387]	This study was supported in part by a grant from the Ontario Neurotrauma Foundation (Toronto, ON, Canada) to the University of North Carolina at Chapel Hill Injury Prevention Research Center (grant number 2005-PREV-BANT-387). Additional thanks are offered to William Montelpare, Ph.D. (Lakehead University; Thunder Bay, Ontario, Canada), and his colleagues for their assistance with this project. We would also like to thank the engineering team at Simbex (Lebanon, New Hampshire, USA) for their continued support of this project.	ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CHU JJ, 2006 WORLD C BIOM MU; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duhaime AC, 2006, J NEUROSURG, V104, P259, DOI 10.3171/ped.2006.104.4.259; Duval J, 2002, BRAIN COGNITION, V48, P337, DOI 10.1006/brcg.2001.1373; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555	27	33	33	1	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1754-3371	1754-338X		P I MECH ENG P-J SPO	Proc. Inst. Mech. Eng. Part P-J. Sport. Eng. Technol.	JUN	2008	222	P1					45	52		10.1243/17543371JSET4			8	Engineering, Mechanical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	V13KB	WOS:000207664600006					2022-02-06	
J	Ozturk, A; Sasson, AD; Farrell, JAD; Landman, BA; da Motta, ACBS; Aralasmak, A; Yousem, DM				Ozturk, A.; Sasson, A. D.; Farrell, J. A. D.; Landman, B. A.; da Motta, A. C. B. S.; Aralasmak, A.; Yousem, D. M.			Regional differences in diffusion tensor imaging measurements: Assessment of intrarater and interrater variability	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							WHITE-MATTER; MULTIPLE-SCLEROSIS; FRACTIONAL ANISOTROPY; HUMAN BRAIN; NOISE; MRI; ADRENOLEUKODYSTROPHY; REPRODUCIBILITY; TRACTOGRAPHY; ADOLESCENCE	BACKGROUND AND PURPOSE: Diffusion tensor imaging (DTI) has become a valuable tool in both the research and clinical evaluation of subjects, We sought to quantify interobserver and intraobserver variability of diffusivity and diffusion anisotropy measurements with regard to specific regions of interest (ROIs). MATERIALS AND METHODS: The subject group consisted of 5 healthy control subjects and 7 study subjects (all males; 16-19 years old; mean age = 17.5 years), as part of a protocol for closed head injury. Two whole-brain DTI scans were acquired on a 3T scanner for each subject. Analysis was performed using a ROI approach. Two independent observers analyzed the apparent diffusion coefficient (ADC) and fractional anisotropy (FA) indices in the corpus callosum, cortical spinal tract, internal capsules (ICs), basal ganglia, and centrum semiovale (CSO). Intraobserver and interobserver variability were calculated for the mean ADC, FA, and ordered eigenvalues of the diffusion tenser (lambda(1), lambda(2), and lambda(3)). RESULTS: The overall kappa statistic for intraobserver variability for both observers showed slight-to-substantial agreement (kappa = 0.02-0.69), however FA values in the CSO showed only slight agreement. Interobserver agreement was also slight to substantial for these DTI measurements with high variability in FA values in the IC and CSO. CONCLUSIONS: When one is comparing 2 DTI measurements, it is important to assess intraobserver and interobserver variability. We recommend caution in the analysis of DTI contrasts in the IC and CSO, because we have found the widest range of variability in measurements within these structures.	[Ozturk, A.; Sasson, A. D.; Farrell, J. A. D.; da Motta, A. C. B. S.; Yousem, D. M.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, FM Kirby Res Ctr Funct Brain Imaging, Kennedy Krieger Inst, Baltimore, MD 21287 USA; [Farrell, J. A. D.] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; [Landman, B. A.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; [Aralasmak, A.] Akdeniz Univ, Dept Radiol, TR-07058 Antalya, Turkey		Yousem, DM (corresponding author), Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, FM Kirby Res Ctr Funct Brain Imaging, Kennedy Krieger Inst, 600 N Wolfe St,Phipps B112, Baltimore, MD 21287 USA.	dyousem1@jhu.edu	Landman, Bennett A/A-2343-2009	Landman, Bennett A/0000-0001-5733-2127			Alexopoulos GS, 2002, AM J PSYCHIAT, V159, P1929, DOI 10.1176/appi.ajp.159.11.1929; Anderson AW, 2001, MAGNET RESON MED, V46, P1174, DOI 10.1002/mrm.1315; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 2000, MAGNET RESON MED, V44, P41, DOI 10.1002/1522-2594(200007)44:1<41::AID-MRM8>3.0.CO;2-O; Bastianetto S, 1998, ADV GINKGO, V7, P85; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Ciccarelli O, 2001, NEUROLOGY, V56, P926, DOI 10.1212/WNL.56.7.926; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; Heim S, 2004, MAGN RESON MED, V52, P582, DOI 10.1002/mrm.20169; Holtmannspotter M, 2005, STROKE, V36, P2559, DOI 10.1161/01.STR.0000189696.70989.a4; Horsfield MA, 2002, NMR BIOMED, V15, P570, DOI 10.1002/nbm.787; Huang H, 2004, MAGN RESON MED, V52, P559, DOI 10.1002/mrm.20147; Ito R, 2001, NEUROLOGY, V56, P544, DOI 10.1212/WNL.56.4.544; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kubicki M, 2002, HARVARD REV PSYCHIAT, V10, P324, DOI 10.1080/10673220216231; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Lee SK, 2005, RADIOGRAPHICS, V25, P68; Lee SK, 2005, RADIOGRAPHICS, V25, P53, DOI 10.1148/rg.251045085; Marenco S, 2006, PSYCHIAT RES-NEUROIM, V147, P69, DOI 10.1016/j.pscychresns.2006.01.008; Neil JJ, 1998, RADIOLOGY, V209, P57, DOI 10.1148/radiology.209.1.9769812; Ni H, 2006, AM J NEURORADIOL, V27, P1776; Nusbaum AO, 2001, AM J NEURORADIOL, V22, P136; Pfefferbaum A, 2003, J MAGN RESON IMAGING, V18, P427, DOI 10.1002/jmri.10377; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Price SJ, 2003, CLIN RADIOL, V58, P455, DOI 10.1016/S0009-9260(03)00115-6; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schneider JFL, 2003, AM J NEURORADIOL, V24, P819; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Sigmund EE, 2006, MAGN RESON IMAGING, V24, P7, DOI 10.1016/j.mri.2005.10.015; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Tievsky AL, 1999, AM J NEURORADIOL, V20, P1491; Vrenken H, 2006, J MAGN RESON IMAGING, V23, P628, DOI 10.1002/jmri.20564; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626	37	33	34	0	3	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JUN-JUL	2008	29	6					1124	1127		10.3174/ajnr.A0998			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	315QI	WOS:000256894100018	18356471	Green Published, hybrid			2022-02-06	
J	Rossiter, K; Gray, J; Kontos, P; Keightley, M; Colantonio, A; Gilbert, J				Rossiter, Kate; Gray, Julia; Kontos, Pia; Keightley, Michelle; Colantonio, Angela; Gilbert, Julie			From page to stage - Dramaturgy and the art of interdisciplinary translation	JOURNAL OF HEALTH PSYCHOLOGY			English	Article						dramaturgy; health research; interdisciplinary collaboration; theatre; traumatic brain injury		In recent years, interdisciplinary collaboration between artists and social scientists has received sustained interest from many members of the academic community. However, cross-disciplinary work is often more difficult than presumed. Epistemological and methodological differences between disciplines create barriers that may impede collaborative projects. This article explores some of the unique tensions and challenges that arose from the creation of 'After the Crash', a research-based theatre production about traumatic brain injury. Through the narrative lens of the project's dramaturg, we explore moments of interdisciplinary tension, and the possibility for the role of the dramaturg to build bridges between disparate methods of knowledge generation and translation.	[Rossiter, Kate] Univ Toronto, Dept Publ Hlth, Toronto, ON M5T 3M7, Canada; [Gray, Julia] York Univ, N York, ON M3J 1P3, Canada; [Kontos, Pia; Colantonio, Angela] Toronto Rehabil Inst, Toronto, ON, Canada; [Kontos, Pia; Keightley, Michelle; Gilbert, Julie] Univ Toronto, Toronto, ON M5S 1A1, Canada		Rossiter, K (corresponding author), Univ Toronto, Dept Publ Hlth, 6th Floor,Hlth Sci Bldg,155 Coll St, Toronto, ON M5T 3M7, Canada.	kate.rossiter@utoronto.ca		Kontos, Pia/0000-0002-8893-2544			Cardullo Bert, 1995, WHAT IS DRAMATURGY, P3; COLANTONIO A, 2006, WORLD FED OCC THER C; Cole A.L., 2008, HDB ARTS QUALITATIVE; Copelin D., 1995, WHAT IS DRAMATURGY, P17; Deavere Smith A., 1993, FIRES MIRROR; Denzin N. K., 1997, INTERPRETIVE ETHNOGR; Gray Ross, 2000, Health Expect, V3, P137, DOI 10.1046/j.1369-6513.2000.00071.x; Gray Ross, 2003, QUALITATIVE RES, V3, P284; HEARN A, 1996, OUTSIDE LINES ISSUES; Katz Leon, 1995, WHAT IS DRAMATURGY, P13; Martin Carol, 1993, DRAMA REV, V37, P45; MCCALL H, 2000, HDB QUALITATIVE RES, P112; Naglie G., 2006, QUALITATIVE RES, V6, P301, DOI [10.1177/1468794106065005, DOI 10.1177/1468794106065005]; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Palmer C.L., 2001, WORK BOUNDARIES SCI; Rowe J.W., 2003, EXPANDING BOUNDARIES, P3; RUDAKOFF JB, 2002, LINES PROCESS DRAMAT, pR3; Saldana J, 2003, QUAL INQ, V9, P218, DOI 10.1177/1077800402250932; Schechner Richard, 1993, DRAMA REV, V37, P63; SMITH AD, 2000, TALK ME LISTENING LI; SMITH AD, 1994, TWILIGHT LOS ANGELES; Stehr N., 2000, PRACTISING INTERDISC	22	33	33	0	13	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1359-1053			J HEALTH PSYCHOL	J. Health Psychol.	MAR	2008	13	2					277	286		10.1177/1359105307086707			10	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	291BL	WOS:000255167200012	18375632				2022-02-06	
J	Weiss, N; Galanaud, D; Carpentier, A; de Montcel, ST; Naccache, L; Coriat, P; Puybasset, L				Weiss, Nicolas; Galanaud, Damien; Carpentier, Alexandre; de Montcel, Sophie Tezenas; Naccache, Lionel; Coriat, Pierre; Puybasset, Louis			A combined clinical and MRI approach for outcome assessment of traumatic head injured comatose patients	JOURNAL OF NEUROLOGY			English	Article						coma; MRI; TBI; brainstem; outcome	PERSISTENT VEGETATIVE STATE; MAGNETIC-RESONANCE; BRAIN-STEM; PATHOLOGY; LESION; VOLUME; DAMAGE	Traumatic brain injury (TBI) is associated with substantial consumption of health care resources. No clinical or paraclinical examination can reliably predict neurological evolution. In this study, we evaluated the ability of a combined clinical and MRI approach to predict outcome. Methods This prospective study took place between June 2001 and March 2005 in a Neurosurgical Intensive Care Unit in Paris, France. Inclusion criteria were TBI patients still mechanically ventilated and without clinical signs of awareness after 2 weeks. Four clinical signs were assessed after cessation of sedation: grasping, yawning, chewing and paroxysmal sympathetic storm. FLAIR and T2* acquisitions on MRI were used in order to localize brain lesions. Statistically linked regions (clusters) were defined. Outcome was assessed at one year by Glasgow Outcome Scale (GOS). Findings 73 patients were included: 41 had poor outcome (GOS 1-3) and 32 had good outcome (GOS 4-5). Lesions in the clusters "right upper pons and right lower midbrain"," hypothalamus and basal forebrain","left parietal, left temporal, left occipital lobes and left insula" and the presence of grasping or chewing were associated with poor outcome in multivariate analysis. This combined clinical and MRI approach gives a much better prediction than MRI approach only (P < 0.009), with an area under the ROC curve of 0.94 (95 % CI, 0.89-1.00). Interpretation These data suggest that MRI associated with clinical assessment improves outcome prediction in severe TBI patients.	[Weiss, Nicolas; Coriat, Pierre; Puybasset, Louis] Hop La Pitie Salpetriere, Dept Anesthesie Reanimat, Unite NeuroAnesthesie Renanimat, F-75013 Paris, France; [Galanaud, Damien; Carpentier, Alexandre; de Montcel, Sophie Tezenas; Naccache, Lionel] Univ Paris 06, Paris, France; [Galanaud, Damien; Carpentier, Alexandre] Hop La Pitie Salpetriere, AP HP, Dept Neuroradiol, Paris, France; [de Montcel, Sophie Tezenas] Hop La Pitie Salpetriere, AP HP, Biostat & Med Informat Dept, Paris, France; [Naccache, Lionel] Hop La Pitie Salpetriere, AP HP, Dept Neurophysiol, Paris, France		Puybasset, L (corresponding author), Hop La Pitie Salpetriere, Dept Anesthesie Reanimat, Unite NeuroAnesthesie Renanimat, 47-83 Bd Hop, F-75013 Paris, France.	louis.puybasset@psl.aphp.fr	Weiss, Nicolas/E-7345-2011	Weiss, Nicolas/0000-0001-5155-196X; naccache, lionel/0000-0002-2874-1009			Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; DENNYBROWN D, 1958, J NERV MENT DIS, V126, P9, DOI 10.1097/00005053-195801000-00003; DERENZI E, 1992, BRAIN, V115, P293, DOI 10.1093/brain/115.1.293; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; Jordan L M, 1992, Curr Opin Neurobiol, V2, P794, DOI 10.1016/0959-4388(92)90136-9; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Laowattana S, 2006, NEUROLOGY, V66, P477, DOI 10.1212/01.wnl.0000202684.29640.60; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Lavigne GJ, 2003, CRIT REV ORAL BIOL M, V14, P30, DOI 10.1177/154411130301400104; Lescot T, 2005, INTENS CARE MED, V31, P1042, DOI 10.1007/s00134-005-2709-y; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1997, NEUROSURGERY, V40, P440; Mascia MM, 2005, MOVEMENT DISORD, V20, P26, DOI 10.1002/mds.20272; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249	25	33	35	0	4	DR DIETRICH STEINKOPFF VERLAG	DARMSTADT	PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY	0340-5354			J NEUROL	J. Neurol.	FEB	2008	255	2					217	223		10.1007/s00415-008-0658-4			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	269HV	WOS:000253641000010	18283406				2022-02-06	
J	Sakellaris, G; Nasis, G; Kotsiou, M; Tamiolaki, M; Charissis, G; Evangeliou, A				Sakellaris, George; Nasis, George; Kotsiou, Maria; Tamiolaki, Maria; Charissis, Giorgos; Evangeliou, Athanasios			Prevention of traumatic headache, dizziness and fatigue with creatine administration. A pilot study	ACTA PAEDIATRICA			English	Article							BRAIN-INJURY; RAT; SUPPLEMENTATION; MITOCHONDRIA; DEFICIENCY; PROTECTS; RECOVERY; MUSCLE; DAMAGE; ADULT	Aim: The complex pathobiology of traumatic brain injury (TBI) offers numerous targets for potential neuroprotective agents. We evaluate the clinical benefit after creatine (Cr) administration in children and adolescents Methods: A prospective, randomized, comparative, open- labelled pilot study of the possible neuroprotective effect of Cr was carried out on 39 children and adolescents, aged between 1 and 18 years of age, with TBI. The Cr was administered for 6 months, at a dose of 0.4 g/kg in an oral suspension form every day. For categorical variables, we used the Chi-square test to identify differences between controls and cases. Statistical significance was defined as a p-value < 0.05 and not statistically significant if p-value > 0.1. Results: The administration of Cr to children and adolescents with TBI improved results in several parameters, including duration of post traumatic amnesia (PTA), duration of intubation, intensive care unit stay. Significant improvement was recorded in the categories of headache (p < 0.001), dizziness (p = 0.005) and fatigue (p < 0.001), aspects in all patients. No side effects were seen due to Cr administration. Conclusion: More specific examinations including brain spectroscopy for in vivo evaluation of Cr can be done, in order to draw conclusions for the optimal duration and manner of Cr supply, as well as its possible role for the prevention of TBI complications, in double blind studies.	[Sakellaris, George; Charissis, Giorgos] Univ Hosp Heraklio, Dept Paediat Surg, Iraklion, Greece; [Nasis, George] 417 Army Share Fund Hosp, Dept Neurol, Athens, Greece; [Kotsiou, Maria; Tamiolaki, Maria] Hippocratio Hosp Thessaloniki, Paediat Intens Care Unit, Thessaloniki, Greece; [Evangeliou, Athanasios] Univ Hosp Heraklio, Dept Paediat, Iraklion, Greece		Sakellaris, G (corresponding author), EL Venizelou 105, GR-70014 P Hersonissou, Greece.	gsakell@mycosmos.gr					Balestrino M, 1999, BRAIN RES, V816, P124, DOI 10.1016/S0006-8993(98)01131-7; BERGER R, 1999, BRAIN RES, V816, P124; Borges N, 2004, INT J NEUROSCI, V114, P217, DOI 10.1080/00207450490249419; EPPENBERGEREBERHARDT M, 1991, J CELL BIOL, V113, P289, DOI 10.1083/jcb.113.2.289; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Eviatar L, 1986, Pediatr Neurol, V2, P61, DOI 10.1016/0887-8994(86)90058-5; Felber S, 2000, NEUROL RES, V22, P145, DOI 10.1080/01616412.2000.11741051; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; GORDON A, 1995, CARDIOVASC RES, V30, P413, DOI 10.1016/0008-6363(95)00062-3; Holtzman D, 1998, PEDIATR RES, V44, P410, DOI 10.1203/00006450-199809000-00024; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Lane Judy C., 2002, Curr Treat Options Neurol, V4, P89, DOI 10.1007/s11940-002-0007-3; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Schulze A, 2003, ANN NEUROL, V53, P248, DOI 10.1002/ana.10455; Stockler S, 1997, METABOLISM, V46, P1189, DOI 10.1016/S0026-0495(97)90215-8; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C; TEGAS JJ, 1990, J PEDIATR SURG, V25, P92; Wilson Maria-Carmen B, 2006, Curr Pain Headache Rep, V10, P387, DOI 10.1007/s11916-006-0065-4; YLIKOSKI J, 1982, AM J OTOL, V3, P343	24	33	33	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	JAN	2008	97	1					31	34		10.1111/j.1651-2227.2007.00529.x			4	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	251RX	WOS:000252392700007	18053002	Bronze, Green Published			2022-02-06	
J	Droll, KP; Broekhuyse, H; O'Brien, P				Droll, Kurt P.; Broekhuyse, Henry; O'Brien, Peter			Fracture of the femoral head	JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS			English	Article							TRAUMATIC POSTERIOR DISLOCATION; TERM-FOLLOW-UP; HIP DISLOCATIONS; INJURY	Fracture of the femoral head is a severe, relatively uncommon injury; typically, it occurs following traumatic posterior dislocation of the hip joint. The Pipkin classification is the most commonly used classification system. Diagnosis is aided by a complete history, physical examination, and imaging, including computed tomography. Treatment consists of urgent closed reduction of the dislocated hip followed by nonsurgical or surgical management of any associated fractures. Controversies include the preferred surgical approach (anterior versus posterior) and whether to perform femoral head fragment excision or internal fixation. Complications associated with fracture of the femoral head and subsequent treatment include osteonecrosis, posttraumatic osteoarthritis, and heterotopic ossification. Fracture of the femoral head has been associated with a relatively poor functional outcome.	Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Orthopaed Surg, Div Orthopaed Trauma, Vancouver, BC V5Z 1M9, Canada		O'Brien, P (corresponding author), Univ British Columbia, Vancouver Gen Hosp, 2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.						Asghar FA, 2004, ORTHOP CLIN N AM, V35, P463, DOI 10.1016/S0030-5898(04)00042-2; Birkett J, 1869, Med Chir Trans, V52, P133; Brumback R J, 1987, Hip, P181; BUTLER JE, 1981, J BONE JOINT SURG AM, V63, P1292, DOI 10.2106/00004623-198163080-00011; Cornwall R, 2000, CLIN ORTHOP RELAT R, P84; DAVIS JB, 1950, AM J SURG, V80, P893, DOI 10.1016/0002-9610(50)90473-9; DELEE JC, 1980, J BONE JOINT SURG AM, V62, P960, DOI 10.2106/00004623-198062060-00012; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; EPSTEIN HC, 1961, J BONE JOINT SURG AM, V43, P1079, DOI 10.2106/00004623-196143080-00002; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, V201, P9; Funsten RV, 1938, J BONE JOINT SURG, V20, P124; Ganz R, 2001, J BONE JOINT SURG BR, V83B, P1119, DOI 10.1302/0301-620X.83B8.11964; Gautier E, 2000, J BONE JOINT SURG BR, V82B, P679, DOI 10.1302/0301-620X.82B5.10426; GOULET JA, 2003, SKELETAL TRAUMA BASI, V3, P1657; HOUGAARD K, 1988, J BONE JOINT SURG AM, V70A, P233, DOI 10.2106/00004623-198870020-00011; HOUGAARD K, 1987, J BONE JOINT SURG AM, V69A, P679, DOI 10.2106/00004623-198769050-00007; HOWE WW, 1950, J BONE JOINT SURG AM, V32-A, P856, DOI 10.2106/00004623-195032040-00015; Kloen P., 2002, EUR J TRAUMA EMERG S, V28, P221, DOI [10.1007/s00068-002-1173-4, DOI 10.1007/S00068-002-1173-4]; LANGSTEVENSON A, 1987, INJURY, V18, P264, DOI 10.1016/0020-1383(87)90011-8; Marchetti ME, 1996, J ORTHOP TRAUMA, V10, P455, DOI 10.1097/00005131-199610000-00002; McKee MD, 1998, J ORTHOP TRAUMA, V12, P223, DOI 10.1097/00005131-199805000-00001; MOED BR, 1993, CLIN ORTHOP RELAT R, P161; PIPKIN G, 1957, J BONE JOINT SURG AM, V39, P1027, DOI 10.2106/00004623-195739050-00004; ROEDER LF, 1980, CLIN ORTHOP RELAT R, V147, P121; ROSENTHAL RE, 1979, J TRAUMA, V19, P572, DOI 10.1097/00005373-197908000-00005; Sahin V, 2003, J TRAUMA, V54, P520, DOI 10.1097/01.TA.0000020394.32496.52; SEVITT S, 1965, J Bone Joint Surg Br, V47, P560; Stannard JP, 2000, CLIN ORTHOP RELAT R, P44; Swiontkowski M F, 1992, J Orthop Trauma, V6, P437, DOI 10.1097/00005131-199212000-00008; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; TRUETA J, 1953, J BONE JOINT SURG BR, V35, P442, DOI 10.1302/0301-620X.35B3.442; UPADHYAY SS, 1985, J BONE JOINT SURG BR, V67, P232, DOI 10.1302/0301-620X.67B2.3884614	32	33	44	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1067-151X	1940-5480		J AM ACAD ORTHOP SUR	J. Am. Acad. Orthop. Surg.	DEC	2007	15	12					716	727		10.5435/00124635-200712000-00005			12	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	238RU	WOS:000251466100005	18063712				2022-02-06	
J	Lew, HL; Gray, M; Poole, JH				Lew, Henry L.; Gray, Max; Poole, John H.			Temporal stability of auditory event-related potentials in healthy individuals and patients with traumatic brain injury	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						brain injury; event-related potentials; reliability	TEST-RETEST RELIABILITY; SOMATOSENSORY-EVOKED POTENTIALS; MISMATCH NEGATIVITY; ODDBALL TASK; P300; RESPONSES; SCHIZOPHRENIA; RECOGNITION; VARIABILITY; ALCOHOLICS	Historically, cognitive event-related potentials (ERPs) have received limited acceptance for clinical use due to lack of evidence for their reliability. However, recent advances in computer technology and artifact rejection methods have greatly enhanced the fidelity of ERP measurements. The present study examined the test-retest reliability of ERP measurement by using current data processing methods. We assessed the temporal stability of the most commonly used ERP paradigm, auditory pure-tone "odd ball" detection, and compared it with other commonly used clinical measures reported in the literature. Auditory ERPs were collected in 19 healthy subjects and 7 patients with traumatic brain injury at two time points, 2 days to 2 months apart. Test-retest reliability was calculated for four ERP components: N1, MMN (mismatch negativity), P3, and N4. In healthy subjects, temporal stabilities of these four commonly studied ERP components' amplitude measurements were moderate to high, with intraclass correlations ranging from 0.6 to 0.8. In contrast, in patients with traumatic brain injury, ERPs were stable only for the NI component (intraclass correlation = 0.7).	VA Palo Alto Hlth Care Syst, Palo Alto, CA USA		Lew, HL (corresponding author), PM&R, 3801 Miranda Ave,MS-117B, Palo Alto, CA 94304 USA.	henrylew@stanford.edu					Barnes VA, 2004, BLOOD PRESS MONIT, V9, P173, DOI 10.1097/00126097-200408000-00001; Comas A, 1998, Aten Primaria, V22, P142; Debener S, 2002, INT J PSYCHOPHYSIOL, V46, P77, DOI 10.1016/S0167-8760(02)00072-7; Duzel E, 2001, P NATL ACAD SCI USA, V98, P8101, DOI 10.1073/pnas.131205798; Fallgatter AJ, 2001, J NEURAL TRANSM, V108, P679, DOI 10.1007/s007020170045; Ford JM, 2004, ARCH GEN PSYCHIAT, V61, P119, DOI 10.1001/archpsyc.61.2.119; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; Giaquinto S, 2004, FUNCT NEUROL, V19, P219; GLENN S, 1994, BIOL PSYCHIAT, V36, P443, DOI 10.1016/0006-3223(94)90639-4; Hummel T, 2002, PULM PHARMACOL THER, V15, P321, DOI 10.1006/pupt.2002.0356; Kiehl KA, 1999, BIOL PSYCHIAT, V45, P1498, DOI 10.1016/S0006-3223(98)00193-0; KILENY PR, 1987, EAR HEARING, V8, P110, DOI 10.1097/00003446-198704000-00008; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; LEW HL, 2004, PHYS MED REHABILITAT, V15, pR13; Mathalon DH, 2000, BIOL PSYCHIAT, V47, P434, DOI 10.1016/S0006-3223(99)00277-2; Naatanen R, 2003, INT J PSYCHOPHYSIOL, V48, P179, DOI 10.1016/S0167-8760(03)00053-9; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Nieuwenhuis S, 2004, PSYCHOPHYSIOLOGY, V41, P157, DOI 10.1046/j.1469-8986.2003.00128.x; Nuwer MR, 1998, ELECTROEN CLIN NEURO, V106, P142, DOI 10.1016/S0013-4694(97)00117-X; OADES RD, 1995, INT J NEUROSCI, V81, P265, DOI 10.3109/00207459509004891; PEKKONEN E, 1995, EVOKED POTENTIAL, V96, P546, DOI 10.1016/0013-4694(95)00148-R; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1111/1469-8986.3720127; Polich J, 1997, INT J PSYCHOPHYSIOL, V25, P169, DOI 10.1016/S0167-8760(96)00742-8; Raikkonen K, 2003, NEUROREPORT, V14, P2121, DOI 10.1097/01.wnr.0000095493.09138.31; Ramchandani VA, 1999, ALCOHOL CLIN EXP RES, V23, P1320, DOI 10.1097/00000374-199908000-00005; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SINHA R, 1992, BIOL PSYCHIAT, V32, P992; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; Swerdlow NR, 2005, BIOL PSYCHOL, V69, P133, DOI 10.1016/j.biopsycho.2004.07.002; Thesen T, 2002, PSYCHOPHYSIOLOGY, V39, P733, DOI 10.1111/1469-8986.3960733; Walhovd KB, 2002, INT J PSYCHOPHYSIOL, V46, P29, DOI 10.1016/S0167-8760(02)00039-9; Wambacq I, 2004, EPILEPSY BEHAV, V5, P503, DOI 10.1016/j.yebeh.2004.03.012; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475; WOODS DL, 1986, ELECTROEN CLIN NEURO, V65, P447, DOI 10.1016/0168-5597(86)90024-9	38	33	36	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	OCT	2007	24	5					392	397		10.1097/WNP.0b013e31814a56e3			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	221FS	WOS:000250213400004	17912063				2022-02-06	
J	Maurer, MH; Haux, D; Sakowitz, OW; Unterberg, AW; Kuschinsky, W				Maurer, Martin H.; Haux, Daniel; Sakowitz, Oliver W.; Unterberg, Andreas W.; Kuschinsky, Wolfgang			Identification of early markers for symptomatic vasospasm in human cerebral microdialysate after subarachnoid hemorrhage: Preliminary results of a proteome-wide screening	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aneurysmal or aneurismal subarachnoid hemorrhage; cardiac arrest; cerebral blood flow; cerebral hemodynamics and metabolism; CPR; gender differences; head injury; injury; microdialysis; neurogenesis; neurosurgery; proteomics; stroke; subarachnoid hemorrhage; traumatic brain injury; vasospasm	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; NEUROLOGICAL DEFICITS; BEDSIDE MICRODIALYSIS; NUCLEAR TRANSLOCATION; STEM-CELLS; METABOLITES; PREDICTION; ISCHEMIA; EVENTS; OXYGEN	A major complication of aneurysmal subarachnoid hemorrhage (SAH) is symptomatic vasospasm, a complex syndrome consisting of neurological deterioration and exclusion of other sources of ischemia. Approximately 30% of SAH patients are affected. Although symptomatic vasospasm is associated with high mortality and poor clinical outcome, it is not possible to identify the individual risk on a molecular level for patients before symptoms have developed. In this study, we hypothesize that protein changes occur in the cerebral microdialysate of patients who later develop symptomatic vasospasm which are not found in matched-pairs control subjects. We searched for changes in protein concentrations in microdialysate sampled from the fronto- temporal brain tissue of five vasospastic and five nonvasospastic SAH patients using proteomics technology based on two-dimensional gel electrophoresis and mass spectrometry. Microdialysate samples were taken at least 1.5 days before the onset of symptomatic vasospasm. Comparing protein expression profiles, we found that the protein concentrations of several isoforms of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 1.79-fold +/- 1.29 ( N= 5, P < 0.05) higher in the group which later developed symptomatic vasospasm, whereas heat-shock cognate 71 kDa protein (HSP7C) isoforms were decreased to 0.50-fold +/- 0.19 ( N= 5, P < 0.05; all expression data means +/- s. d.). The changes in protein concentrations were detected 3.861.7 days ( N= 5, P < 0.05) before symptomatic vasospasm developed. We conclude that GAPDH and HSP7C may be used as early markers indicating the later development of symptomatic vasospasm after SAH, enabling selective early therapeutic intervention in this high-risk group of patients.	Univ Heidelberg, Dept Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany		Maurer, MH (corresponding author), Univ Heidelberg, Dept Physiol & Pathophysiol, Neuenheimer Feld 326, D-69120 Heidelberg, Germany.	maurer@physiologie.uni-heidelberg.de	Maurer, Martin/AAF-1337-2019	Maurer, Martin/0000-0001-7551-3415; Sakowitz, Oliver/0000-0003-3248-6335			Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Borderie D, 2000, CELL BIOL INT, V24, P285, DOI 10.1006/cbir.2000.0498; Brookes PS, 1997, FEBS LETT, V416, P90, DOI 10.1016/S0014-5793(97)01181-2; Brune B, 1995, Adv Pharmacol, V34, P351; Bulliard C, 1997, BIOCHEM J, V324, P555, DOI 10.1042/bj3240555; Dastoor Z, 2000, J CELL SCI, V113, P2845; DRAKE CG, 1988, J NEUROSURG, V68, P985; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; Feldmann RE, 2005, ELECTROPHORESIS, V26, P2749, DOI 10.1002/elps.200410406; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B; Graven KK, 1998, AM J PHYSIOL-CELL PH, V274, pC347, DOI 10.1152/ajpcell.1998.274.2.C347; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Harrod CG, 2005, NEUROSURGERY, V56, P633, DOI 10.1227/01.NEU.0000156644.45384.92; HIJDRA A, 1987, STROKE, V18, P1061, DOI 10.1161/01.STR.18.6.1061; Janjua Nazli, 2003, Curr Opin Crit Care, V9, P113, DOI 10.1097/00075198-200304000-00006; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Macdonald RL, 2003, J NEUROSURG, V99, P644, DOI 10.3171/jns.2003.99.4.0644; Maurer MH, 2006, CURR BIOINFORM, V1, P255, DOI 10.2174/157489306777011969; Maurer Martin H., 2005, Current Proteomics, V2, P179, DOI 10.2174/157016405774641165; Maurer Martin H, 2003, Proteome Sci, V1, P7, DOI 10.1186/1477-5956-1-7; Maurer MH, 2005, J PROTEOME RES, V4, P96, DOI 10.1021/pr049841l; Nakamura T, 2002, BIOCHEM BIOPH RES CO, V290, P858, DOI 10.1006/bbrc.2001.6271; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Peerdeman SM, 2003, J NEUROL, V250, P797, DOI 10.1007/s00415-003-1079-z; Pyne-Geithman GJ, 2005, J CEREBR BLOOD F MET, V25, P1070, DOI 10.1038/sj.jcbfm.9600101; Qureshi AI, 2001, NEUROSURGERY, V49, P607, DOI 10.1097/00006123-200109000-00014; Sakowitz OW, 2001, J CEREBR BLOOD F MET, V21, P1067, DOI 10.1097/00004647-200109000-00004; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Sickman A, 2002, J CHROMATOGR B, V771, P167, DOI 10.1016/S1570-0232(01)00626-2; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vilo J., 2003, ANAL GENE EXPRESSION	38	33	34	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2007	27	10					1675	1683		10.1038/sj.jcbfm.9600466			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	212GV	WOS:000249583200003	17327882	Bronze			2022-02-06	
J	Heegaard, W; Biros, M				Heegaard, William; Biros, Michelle			Traumatic brain injury	EMERGENCY MEDICINE CLINICS OF NORTH AMERICA			English	Article							RECOMBINANT-FACTOR-VIIA; ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; COMA SCALE SCORE; ENDOTRACHEAL INTUBATION; INTRACRANIAL HYPERTENSION; HYPERTONIC SALINE; SODIUM-CHLORIDE; IMPACT; CONCUSSION	Traumatic brain injury (TBI) refers to the potential for significant injury to the brain parenchyma following head trauma. This article covers pertinent principles, management approaches, and current controversies in severe, moderate, and minor TBI. Controversies covered include hypertonic saline (HTS) for increased intracranial pressure (ICP), prehospital intubation of patients who have experienced TBI, and the use of recombinant factor VIIa (rFVIIa). Traumatic head injury has plagued humankind since the beginning of civilization. The writings of Hippocrates refer to trephination [1], and early writings on the practice of neurosurgery describe the management of head trauma. Although the most common mechanism for TBI has changed since antiquity from assaults to motor vehicle-associated injuries, TBI remains the single largest cause of trauma morbidity and accounts for nearly one third of all trauma deaths (Fig. 1) [2-4]. An estimated 1.1 million patients are evaluated each year in emergency departments for acute TBI [3]. TBI occurs most. often in young people, with a peak incidence at 15 to 24 years of age [4]. Smaller peaks occur in children younger than 5 years of age and in individuals older than 85 years [4]. Child abuse is common in children younger than 4 years of age who present with severe to moderate TBI (Fig. 2) [5]. TBI is commonly categorized by means of the Glasgow Coma Scale (GCS) [6] as severe (GCS <= 8), moderate (GCS 9-13), and minor (GCS 14-15). Severe TBI accounts for approximately 10% of all cases, whereas moderate TBI accounts for another 10%; the remaining 80% are classified as minor [4].	Univ Minnesota, Sch Med, Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA		Heegaard, W (corresponding author), Univ Minnesota, Sch Med, Hennepin Cty Med Ctr, Dept Emergency Med, 701 Pk Ave S, Minneapolis, MN 55415 USA.	emdoc@yahoo.com					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; Bell Scott E, 2006, Curr Treat Options Neurol, V8, P167, DOI 10.1007/s11940-006-0007-9; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; BRITT P, 2000, HEAD INJURY, P27; Bullock M Ross, 2006, Neurosurgery, V58, pS7; BULLOCK MR, 2000, J NEUROTRAUM, V17, P471; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHILES B, 1994, NEUROSURGICAL EMERGE, P73; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; CRUZ J, 1998, NEUROLOGIC NEUROSURG, P405; Davies B, 2003, J EXP BOT, V54, P3; Davis D P, 2001, Prehosp Emerg Care, V5, P163, DOI 10.1080/10903120190940065; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Dutton RP, 2003, J CLIN ANESTH, V15, P184, DOI 10.1016/S0952-8180(03)00034-5; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Gaab M R, 1990, Adv Neurol, V52, P391; GAAB MR, 1990, ACT NEUR S, V51, P320; Graham D.I., 2000, HEAD INJ, P133; GREENBERG M, 1997, GREEBERG GRAPHICS; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HEEGAARD WG, 2006, ROSENS EMERGENCY MED, P349; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Kraus J, 2000, HEAD INJURY, P1; Laffey JG, 2002, NEW ENGL J MED, V347, P43, DOI 10.1056/NEJMra012457; Levi M, 2005, CRIT CARE MED, V33, P883, DOI 10.1097/01.CCM.0000159087.85970.38; Lloyd G. E. R., 1978, HIPPOCRATIC WRITINGS; MACLAREN RE, 1993, ARCH EMERG MED, V10, P138; MAHONEY BD, 1981, NEUROSURGERY, V8, P551, DOI 10.1227/00006123-198105000-00006; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Mayer SA, 2007, STROKE, V38, P763, DOI 10.1161/01.STR.0000254499.46122.22; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; Monro A, 1783, OBSERVATION STRUCTUR; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN R, 1994, PRINCIPLES NEUROSURG, P235; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; REIVICH M, 1964, AM J PHYSIOL, V206, P25, DOI 10.1152/ajplegacy.1964.206.1.25; ROCKSWOLD G, 1996, EMERGEN MED, P913; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; Schierhout G, 2001, COCHRANE DB SYST REV, V4; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHAW N, 2002, NEUROPHYSIOLOGY CONC; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stein DM, 2005, J TRAUMA, V59, P609, DOI 10.1097/01.ta.0000177655.67763.df; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; Weiner H. L., 2000, HEAD INJURY, P419; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WILBERGER J, 2000, HEAD INJURY, P63; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Zwienenberg M, 2001, HEAD TRAUMA, P303; 1997, MMWR MORB MORTAL WKL, V46, P224	83	33	37	3	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8627	1558-0539		EMERG MED CLIN N AM	Emerg. Med. Clin. N. Am.	AUG	2007	25	3					655	+		10.1016/j.emc.2007.07.001			25	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	216OF	WOS:000249886900006	17826211				2022-02-06	
J	Lu, KT; Wu, CY; Yen, HH; Peng, JHF; Wang, CL; Yang, YL				Lu, Kwok-Tung; Wu, Chang-Yen; Yen, Hao-Han; Peng, Jeng-Hsiung F.; Wang, Chi-Ling; Yang, Yi-Ling			Bumetanide administration attenuated traumatic brain injury through IL-1 overexpression	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; Na+-K+-2Cl(-) -cotransporter; IL-1	K-CL COTRANSPORTER; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; REACTIVE ASTROCYTES; EDEMA; EXPRESSION; RAT; INFLAMMATION; MODEL	Objective: To examine the effects of administration of bumetanide, a specific NKCC1 inhibitor, on traumatic brain injury (TBI)-induced interleukin-1 (IL-1) expression. Methods: TBI model was induced by the calibrated weight drop device (450 g in weight, 2.0 m in height) in adult rats based on procedures previously reported. One hundred and sixty Wistar rats were divided into sham-control group and experimental group for time course works of TBI. The expression of IL-1b brain edema and neuronal damage were determined in these animals after TBI. Results: We found that both mRNA and protein of IL-1b were up-regulated in the hippocampus 3-24 hours after TBI. Animals displayed severe brain edema and neuron damage after TBI. Bumetanide (15 mg/kg), a specific Na+- K+- 2Cl(-) cotransporter inhibitor, significantly attenuated the TBI-induced neuronal damage by IL-1b overexpression. The present study suggests that administration of bumetanide could significantly decreased TBI-induced inflammatory response and neuronal damage.	Natl Chiayi Univ, Inst Biotechnol, Dept Mol Biol & Biochem, Chiayi, Taiwan; Natl Chiayi Univ, Gen Educ Ctr, Chiayi, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan		Yang, YL (corresponding author), Natl Chiayi Univ, Inst Biotechnol, Dept Mol Biol & Biochem, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw					Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Busse S, 2005, BRAIN RES, V1046, P116, DOI 10.1016/j.brainres.2005.03.055; Chen CA, 2002, MOL PHYLOGENET EVOL, V23, P137, DOI 10.1016/S1055-7903(02)00008-8; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GOSS JR, 1995, J NEUROCHEM, V64, P1351; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; JAVAHERI S, 1991, J APPL PHYSIOL, V71, P795, DOI 10.1152/jappl.1991.71.3.795; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; Obermuller N, 1996, J CLIN INVEST, V98, P635, DOI 10.1172/JCI118834; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; ODONNELL ME, 1995, AM J PHYSIOL-CELL PH, V268, pC747, DOI 10.1152/ajpcell.1995.268.3.C747; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Ringel F, 2000, J NEUROCHEM, V75, P125, DOI 10.1046/j.1471-4159.2000.0750125.x; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x	35	33	36	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2007	29	4					404	409		10.1179/016164107X204738			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	192PM	WOS:000248214200011	17626737				2022-02-06	
J	Truettner, JS; Hu, BR; Alonso, OF; Bramlett, HM; Kokame, K; Dietrich, WD				Truettner, Jessie S.; Hu, Bingren; Alonso, Ofelia F.; Bramlett, Helen M.; Kokame, Koichi; Dietrich, W. Dalton			Subcellular stress response after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						hypoxia; stress genes; subcellular; traumatic brain injury; unfolded protein response	UNFOLDED-PROTEIN-RESPONSE; ENDOPLASMIC-RETICULUM STRESS; CORTICAL SPREADING DEPRESSION; CEREBRAL BLOOD-FLOW; CIS-ACTING ELEMENT; CELL-DEATH PROGRAM; ER STRESS; TRANSCRIPTION FACTOR; NEUROTROPHIC FACTOR; GENE-EXPRESSION	Traumatic brain injury (TBI) initiates a complex genetic response that may include the expression of organelle specific stress genes. We investigated the effects of brain trauma on the expression of a number of stress genes by in situ hybridization and Western blot analysis including the endoplasmic reticulum (ER) stress gene grp78, ER protein processing enzymes calnexin and protein disulphide isomerase (PDI), the mitochondrial stress gene hsp60, and the cytoplasmic stress gene hsp70. Male Sprague-Dawley rats were subjected either to sham-surgery or moderate (1.8-2.2 atm) parasagittal fluid-percussion (F-P) brain injury followed by 30 min of either normoxic or hypoxic (30-40 mm Hg) gas levels. Expression of grp78 was increased in the ipsilateral cerebral cortex and dentate gyrus beginning 4 h after trauma plus hypoxia. Similarly, mRNA encoding the mitochondrial hsp60 was induced in the ipsilateral outer cortical layers at 4-24 h after TBI plus hypoxia. Calnexin and PDI mRNAs were not significantly altered following TBI with or without secondary hypoxia. In contrast, mRNA of the cytoplasmic hsp70 was strongly induced at 4 h after brain injury in multiple brain regions within the injured hemisphere, and this expression was greatly enhanced by secondary hypoxia. Because subcellular stress gene expression may reflect where unfolded or damaged proteins are abundant, these findings suggest that abnormal proteins are localized mainly in the cytoplasm, and to a lesser degree in the ER lumen and mitochondria after brain trauma. Thus, distinct parts of the cellular machinery respond to traumatic and metabolic stresses in specific ways.	Univ Miami, Miami Project Cure Paralysis, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Univ Miami, Miami Project Cure Paralysis, Sch Med, Dept Neurol, Miami, FL 33101 USA; Univ Miami, Miami Project Cure Paralysis, Sch Med, Neurotrauma Res Ctr, Miami, FL 33101 USA; Natl Cardiovasc Ctr, Inst Res, Osaka, Japan		Dietrich, WD (corresponding author), Univ Miami, Miami Project Cure Paralysis, Sch Med, Dept Neurol Surg, POB 016960,R-48, Miami, FL 33101 USA.	ddietrich@miami.edu		Kokame, Koichi/0000-0002-9654-6299	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NINDS 30291, NINDS 42133] Funding Source: Medline		Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chesnut R M, 1995, New Horiz, V3, P366; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Corydon TJ, 2005, MOL GENET METAB, V85, P260, DOI 10.1016/j.ymgme.2005.04.003; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Dietrich WD, 2000, J CEREBR BLOOD F MET, V20, P103, DOI 10.1097/00004647-200001000-00014; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; HOVDA DA, 1990, ACT NEUR S, V51, P331; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Hu BR, 2001, J CEREBR BLOOD F MET, V21, P865, DOI 10.1097/00004647-200107000-00012; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KADA T, 2002, BIOCHEM J, V366, P585; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim BH, 2002, J EXP BOT, V53, P371, DOI 10.1093/jexbot/53.367.371; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Knowlton AA, 2001, AM J PHYSIOL-HEART C, V280, pH455, DOI 10.1152/ajpheart.2001.280.1.H455; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lee KH, 2002, BIOCHEM BIOPH RES CO, V298, P216, DOI 10.1016/S0006-291X(02)02423-3; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; LONGO FM, 1993, J NEUROSCI RES, V36, P325, DOI 10.1002/jnr.490360310; LOWENSTEIN DH, 1994, BRAIN RES MOL BRAIN, V22, P229; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin J, 1997, J BIOENERG BIOMEMBR, V29, P35, DOI 10.1023/A:1022407705182; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Motoyama S, 2004, SHOCK, V22, P234, DOI 10.1097/01.shk.0000132459.68561.f4; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Pan YX, 2004, J CARDIOVASC PHARM, V44, pS117, DOI 10.1097/01.fjc.0000166234.11336.a9; Paschen W, 2004, J NEUROCHEM, V88, P983, DOI 10.1046/j.1471-4159.2003.02218.x; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 2002, CANCER RES, V62, P7207; Rissanen A, 2006, BRAIN RES, V1087, P60, DOI 10.1016/j.brainres.2006.02.095; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Romano CC, 2004, INT IMMUNOPHARMACOL, V4, P1067, DOI 10.1016/j.intimp.2004.04.013; Schneeloch E, 2004, NEUROSCI LETT, V368, P37, DOI 10.1016/j.neulet.2004.06.061; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Szegezdi E, 2006, BIOCHEM BIOPH RES CO, V349, P1406, DOI 10.1016/j.bbrc.2006.09.009; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Xu XH, 2006, BRAIN RES, V1102, P154, DOI 10.1016/j.brainres.2006.04.111; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; ZILLES L, 1985, STEREOTAXIC ATLAS	80	33	39	1	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					599	612		10.1089/neu.2006.0186			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000003	17439344				2022-02-06	
J	Barber, RC; Aragaki, CC; Chang, LYE; Purdue, GF; Hunt, JL; Arnoldo, BD; Horton, JW				Barber, Robert C.; Aragaki, Corinne C.; Chang, Ling-Yu E.; Purdue, Gary F.; Hunt, John L.; Arnoldo, Brett D.; Horton, Jureta W.			CD14-159 C allele is associated with increased risk of mortality after burn injury	SHOCK			English	Article						mortality; burn injury; innate immunity; polymorphism; SNP; CD14	TOLL-LIKE RECEPTOR-4; INTERLEUKIN-6 PROMOTER POLYMORPHISM; LIPOPOLYSACCHARIDE-BINDING PROTEIN; SINGLE NUCLEOTIDE POLYMORPHISM; ACUTE MYOCARDIAL-INFARCTION; SEVERE SEPSIS; SIGNAL-TRANSDUCTION; SOLUBLE CD14; GENE-EXPRESSION; INNATE IMMUNITY	Although comprehension of postburn pathophysiology has grown in recent years, we are still unable to accurately identify burn patients who are at an increased risk of infectious complications and death. This unexplained variation is likely influenced by heritable factors; the genetic predisposition for death from infection has been estimated as greater than that for cardiovascular disease or cancer. Identify genetic variants associated with increased mortality after burn injury. A total of 233 patients with burns of 15% of total body surface area or greater or smoke inhalation injury who survived more than 48 h after admission and were without significant nonburn-related trauma (injury severity score >= 16), traumatic or anoxic brain injury, or spinal cord injury. We examined the influence of genotype at five candidate loci (interleukin [IL]-1 beta, IL-6, tumor necrosis factor-a, toll-like receptor 4, CD14) on mortality risk after burn injury. DNA was isolated from residual blood from laboratory draws and candidate genotypes were determined by real-time polymerase chain reaction using TaqMan probes. Clinical data were prospectively collected into a local, curated database. Allelic associations were analyzed by multivariate logistic regression. After adjustment for age, full-thickness burn size, inhalation injury, ethnicity, and sex, carriage of the CD14-159 C allele imparted at least a 1.3-fold increased risk for death after burn injury, relative to TT homozygotes (adjusted odds ratio, 2.9; 95% confidence interval, 1.3 - 6.8; P= 0.01). This association was stronger (adjusted odds ratio, 3.3; 95% confidence interval, 1.3 - 8.4; P = 0.01) when the analysis was conducted only on deaths accompanied by severe sepsis. In addition, a gene dosage effect for increased mortality was apparent for carriage of the CD14-159 C allele (P = 0.006). The gene dosage effect remained when white, Hispanic, or African American patients were analyzed independently, although statistical significance was not achieved in the subgroup analysis. None of the other single nucleotide polymorphisms examined were significantly associated with mortality. These data provide strong evidence that a CD14 promoter allele that is known to impart lower baseline and induced CD14 transcription also affects mortality risk after burn injury. A potential (although untested) mechanism for our observation is that reduced signaling through CD14/toll-like receptor 4 in response to challenge by gram-negative bacteria after burns results in a blunted innate immune response and subsequent increased likelihood for systemic infection and death.	Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75390 USA; Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Div Epidemiol, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Div Biostat, Houston, TX USA		Barber, RC (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	robert.barber@utsouthwesternm.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5P50GM021681-40] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM021681] Funding Source: NIH RePORTER		Abel B, 2002, J IMMUNOL, V169, P3155, DOI 10.4049/jimmunol.169.6.3155; Abraham LJ, 1999, J LEUKOCYTE BIOL, V66, P562, DOI 10.1002/jlb.66.4.562; Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Arnalich F, 2002, CLIN EXP IMMUNOL, V127, P331, DOI 10.1046/j.1365-2249.2002.01743.x; Barber RC, 2003, CRIT CARE MED, V31, pA50; Barber RC, 2004, J MED GENET, V41, P808, DOI 10.1136/jmg.2004.021600; Barber RC, 2006, CLIN MED RES, V4, P250, DOI 10.3121/cmr.4.4.250; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Brull DJ, 2001, ARTERIOSCL THROM VAS, V21, P1458, DOI 10.1161/hq0901.094280; Burgmann H, 1996, CLIN IMMUNOL IMMUNOP, V80, P307, DOI 10.1006/clin.1996.0128; Carrillo EH, 2001, J TRAUMA, V50, P810, DOI 10.1097/00005373-200105000-00006; Comstock KL, 1998, J MOL CELL CARDIOL, V30, P2761, DOI 10.1006/jmcc.1998.0851; Diks SH, 2004, CURR TOP MED CHEM, V4, P1115, DOI 10.2174/1568026043388141; Ebong SJ, 2001, INFECT IMMUN, V69, P2099, DOI 10.1128/IAI.69.4.2099-2106.2001; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fang CWH, 2002, J TRAUMA, V53, P957, DOI 10.1097/00005373-200211000-00024; Fishman D, 1998, EUR CYTOKINE NETW, V9, P364; Gibot S, 2002, CRIT CARE MED, V30, P969, DOI 10.1097/00003246-200205000-00003; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Henneke P, 2001, J IMMUNOL, V167, P7069, DOI 10.4049/jimmunol.167.12.7069; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; Hubacek JA, 1999, CIRCULATION, V99, P3218, DOI 10.1161/01.CIR.99.25.3218; Hubacek JA, 2000, GENES IMMUN, V1, P405, DOI 10.1038/sj.gene.6363691; Kitchens RL, 2001, J CLIN INVEST, V108, P485, DOI 10.1172/JCI200113139; Koch W, 2002, AM HEART J, V143, P971, DOI 10.1067/mhj.2002.122512; Kondo T, 2003, HEART, V89, P931, DOI 10.1136/heart.89.8.931; Kroeger KM, 2000, CYTOKINE, V12, P110, DOI 10.1006/cyto.1999.0529; LANDMANN R, 1995, J INFECT DIS, V171, P639, DOI 10.1093/infdis/171.3.639; Le Roy D, 2001, J IMMUNOL, V167, P2759, DOI 10.4049/jimmunol.167.5.2759; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Lin Jing, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P271; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nwariaku F, 1996, J TRAUMA, V40, P564, DOI 10.1097/00005373-199604000-00007; O'Keefe GE, 2002, J TRAUMA, V52, P817, DOI 10.1097/00005373-200205000-00001; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Power CP, 2004, J IMMUNOL, V173, P5229, DOI 10.4049/jimmunol.173.8.5229; PUGIN J, 1993, J EXP MED, V178, P2193, DOI 10.1084/jem.178.6.2193; Pugin J, 1995, Prog Clin Biol Res, V392, P369; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; Schluter B, 2002, CRIT CARE MED, V30, P32, DOI 10.1097/00003246-200201000-00005; Schwartz DA, 2002, INT J HYG ENVIR HEAL, V205, P221, DOI 10.1078/1438-4639-00117; Shimada K, 2000, AM J CARDIOL, V86, P682, DOI 10.1016/S0002-9149(00)01054-7; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; STEINEMANN S, 1994, ARTERIOSCLER THROMB, V14, P1202, DOI 10.1161/01.ATV.14.7.1202; Ulevitch RJ, 2001, CRIT CARE MED, V29, pS8, DOI 10.1097/00003246-200107001-00004; ULEVITCH RJ, 1990, J TRAUMA, V30, pS189; Wang Y, 2003, HEPATOLOGY, V37, P65, DOI 10.1053/jhep.2003.50017	52	33	34	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	MAR	2007	27	3					232	237		10.1097/01.shk.0000239770.10528.9a			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	140AV	WOS:000244475300003	17304102				2022-02-06	
J	Lienhart, HG; Wenzel, V; Braun, J; Dorges, V; Dunser, M; Gries, A; Hasibeder, WR; Helm, M; Lefering, R; Schlechtriemen, T; Trimmel, H; Ulmer, H; Ummenhofer, W; Voelckel, WG; Waydhas, C; Lindner, K				Lienhart, H. G.; Wenzel, V.; Braun, J.; Doerges, V.; Duenser, M.; Gries, A.; Hasibeder, W. R.; Helm, M.; Lefering, R.; Schlechtriemen, T.; Trimmel, H.; Ulmer, H.; Ummenhofer, W.; Voelckel, W. G.; Waydhas, C.; Lindner, K.			Vasopressin for therapy of persistent traumatic hemorrhagic shock. The VITRIS at study	ANAESTHESIST			German	Article						VITRIS study; traumatic hemorrhagic shock; shock therapy; helicopter; emergency medical service; air rescue service; vasopressin	CARDIAC-ARREST; BRAIN-INJURY; FLUID RESUSCITATION; BLOOD-PRESSURE; LIFE-SUPPORT; HYPOTENSION; SURVIVAL; MODEL	While fluid management is established in controlled hemorrhagic shock, its use in uncontrolled hemorrhagic shock is being controversially discussed, because it may worsen bleeding. In the irreversible phase of hemorrhagic shock that was unresponsive to volume replacement, airway management and catecholamines, vasopressin was beneficial due to an increase in arterial blood pressure, shift of blood away from a subdiaphragmatic bleeding site towards the heart and brain and decrease of fluid resuscitation requirements. The purpose of this multicenter, randomized, controlled, international trial is to assess the effects of vasopressin (10 IU IV) vs. saline placebo IV (up to 3 injections at least 5 min apart) in patients with prehospital traumatic hemorrhagic shock that persists despite standard shock treatment. The study will be carried out by helicopter emergency medical service teams in Austria, Germany, Czech Republic, Portugal, the Netherlands and Switzerland. Inclusion criteria are adult trauma patients with presumed traumatic hemorrhagic shock (systolic arterial blood pressure < 90 mmHg) that does not respond to the first 10 min of standard shock treatment (endotracheal intubation, fluid resuscitation and use of vasopressors) after arrival of the first emergency physician at the scene. The time window for randomization will close after 30 min of shock treatment. Exclusion criteria are terminal illness, no intravenous access, age < 18 years, injury > 60 min before randomization, cardiac arrest before randomization, presence of a do-not-resuscitate order, untreated tension pneumothorax, untreated cardiac tamponade, or known pregnancy. Primary study end-point is the hospital admission rate, secondary end-points are hemodynamic variables, fluid resuscitation requirements and hospital discharge rate.	Med Univ Innsbruck, Klin Anasthesie & Allg Intens Med, A-6020 Innsbruck, Austria; Univ Kiel, Klin Anasthesie & Operat Intens Med, Kiel, Germany; Deutsch Rettungsflugwacht, Stuttgart, Germany; Univ Kliniken Bern, Inselspital, Klin Intens Med, Bern, Switzerland; Heidelberg Univ, Klin Anasthesie & Intens Med, Heidelberg, Germany; Allg Krankenhaus, Klin Anasthesie & Intens Med, Ried Im Innkreis, Germany; Bundeswehrkrankenhaus, Abt Anasthesie & Intens Med, Ulm, Germany; Bundeswehr, Luftrettungsdienst, Ulm, Germany; Krankenhaus Merheim, Abt Unfallchirurg, Cologne, Germany; Deutsch Gesellschaft Unfallchirurg, Cologne, Germany; Stadt Klinikum, Abt Anasthesie & Intens Med, Saarbrucken, Germany; ADAC, Luftrettung, Munich, Germany; Allg Krankenhaus, Abt Anasthesie Intens & Notfallmed, Wiener Neustadt, Germany; OAMTC, Flugrettung, Vienna, Austria; Med Univ, Dept Med Stat Informat & Gesundheitsokonomie, Innsbruck, Austria; Univ Klinikum Basel, Klin Anasthesie & Intens Med, Basel, Switzerland; REGA, Zurich, Switzerland; Univ Klinikum Essen, Unfallchirurg Klin, Essen, Germany		Wenzel, V (corresponding author), Med Univ Innsbruck, Klin Anasthesie & Allg Intens Med, Anichstr 35, A-6020 Innsbruck, Austria.	volker.wenzel@UKI.AT	Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002			BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Chan L, 1997, ACAD EMERG MED, V4, P785, DOI 10.1111/j.1553-2712.1997.tb03785.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coats TJ, 2001, LANCET, V357, P2070, DOI 10.1016/S0140-6736(00)05225-9; DEAKIN CD, 1994, J ACCID EMERG MED, V11, P154; Dick W F, 2000, Acta Anaesthesiol Belg, V51, P18; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Ericsson B F, 1971, Acta Chir Scand Suppl, V414, P1; ERICSSON BF, 1971, ACTA CHIR SCAND, V137, P729; Feinstein AJ, 2005, J TRAUMA, V59, P876, DOI 10.1097/01.ta.0000187654.24146.22; Fialka C, 2004, J TRAUMA, V57, P809, DOI 10.1097/01.TA.0000124266.39529.6E; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Krausz MM, 2003, J TRAUMA, V54, pS39, DOI 10.1097/01.TA.0000064506.47688.51; Kreimeier U, 2002, ANAESTHESIST, V51, P787, DOI 10.1007/s00101-002-0398-2; Krismer AC, 2005, ANAESTHESIST, V54, P220, DOI 10.1007/s00101-004-0793-y; Kwan I, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002245; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Roberts I, 2001, LANCET, V357, P385, DOI 10.1016/S0140-6736(00)03653-9; Ruchholtz S, 2000, UNFALLCHIRURG, V103, P30, DOI 10.1007/s001130050005; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; Schummer W, 2005, ANAESTHESIST, V54, P707, DOI 10.1007/s00101-005-0854-x; Sharma RM, 2005, ANESTH ANALG, V101, P833, DOI 10.1213/01.ANE.0000175209.61051.7F; SHELLY MP, 1988, INTENS CARE MED, V14, P526, DOI 10.1007/BF00263525; Shoemaker WC, 1996, CRIT CARE MED, V24, pS12; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Stadlbauer KH, 2005, ANESTH ANALG, V101, P830, DOI 10.1213/01.ANE.0000175217.55775.1C; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; Thomas A, 2000, ANASTH INTENSIV NOTF, V35, P91, DOI 10.1055/s-2000-13006; Tsuneyoshi Isao, 2005, J Anesth, V19, P170, DOI 10.1007/s00540-004-0299-4; Voelckel WG, 2000, ANESTH ANALG, V91, P627, DOI 10.1213/00000539-200009000-00024; Yeh CC, 2003, ANESTH ANALG, V97, P577, DOI 10.1213/01.ANE.0000070231.16378.A6; Zenati MS, 2002, J TRAUMA, V53, P232, DOI 10.1097/00005373-200208000-00007	38	33	34	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	FEB	2007	56	2					145	+		10.1007/s00101-006-1114-4			5	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	139SN	WOS:000244453000006	17265038				2022-02-06	
J	Rosso, A; Brazinova, A; Janciak, I; Wilbacher, I; Rusnak, M; Mauritz, W				Rosso, Annalisa; Brazinova, Alexandra; Janciak, Ivan; Wilbacher, Ingrid; Rusnak, Martin; Mauritz, Walter		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria II: Epidemiology of hospital admissions	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; epidemiology; Austria	HEAD-INJURY; POPULATION; CARE	OBJECTIVES: The goal of this paper is to describe the hospital-based epidemiology of severe TBI in Austria. PATIENTS AND METHODS: Data sets from 492 patients included in the study by 5 Austrian hospitals were available. Age and gender distribution, education, occupation, location of trauma, mechanism of injury, alcohol use, type and severity of injury, associated injuries, length of intensive care unit stay, and intensive care unit outcome were evaluated for each of the 5 centers. RESULTS: The sample represents roughly 13% of all cases with severe TBI which were treated in Austrian hospitals during the study period. Mean age was 48 +/- 21 years, and most patients were male (72%). The most important trauma locations were roads (50%), home (24%), outdoors (10%), and workplace (7%). Transportrelated trauma was the most important mechanism (44%) followed by falls < 3 m (30%), falls > 3 m (11%), and sports injuries (5%). Detailed analysis of transport-related trauma showed that car accidents (45%) were most common, followed by pedestrian (20%), motorbike (19%), and bicycle (16%) accidents. Significant differences between the centers were found for most of the variables analyzed. The severe traumatic brain injury was associated with spinal cord injury in 10%, and with severe multiple trauma in 38% of cases. Intensive care mortality was 31.7%. There were no significant correlations between mechanisms of injury and severity of trauma, nor between mechanisms and ICU outcome. CONCLUSIONS: Epidemiology of severe traumatic brain injuries in Austria is not much different from other industrialized countries. Traffic accidents are responsible for the majority of traumas, stressing the importance of road injury prevention. Attention should also be paid to the specific risks of older people and to prevent injuries at home.	INRO, Med Advisory Board, A-1080 Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anesthesia & Crit Care Med, Vienna, Austria		Mauritz, W (corresponding author), INRO, Med Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Brazinova, Alexandra/C-4265-2016; Rusnak, Martin/K-9349-2016	Brazinova, Alexandra/0000-0003-0625-256X; Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			ADEKOYA N, 2002, MMWR SURVEILL SUMM, V6, P1; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Drobetz H, 2000, ANASTH INTENSIV NOTF, V35, P630, DOI 10.1055/s-2000-7365; Elesha S O, 2002, Niger Postgrad Med J, V9, P38; Firsching R, 2001, WORLD J SURG, V25, P1221; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; LANGLOIS JA, 2003, MMWR SURVEILL SUMM, V27, P1; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MEERHOFF SR, 2000, NED TIJDSCHR GENEES, V30, P1915; Nakamura N, 2002, NEUROL RES, V24, P45, DOI 10.1179/016164102101199530; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Raja IA, 2001, WORLD J SURG, V25, P1230; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; *STAT AUSTR, 2004, JB GES I002; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; *WHO, 2002, INJ CHARTB GRAPH OV	27	33	34	1	15	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					29	34		10.1007/s00508-006-0761-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	142GQ	WOS:000244637800008	17318748				2022-02-06	
J	Agha, A; Phillips, J; Thompson, CJ				Agha, Amar; Phillips, Jack; Thompson, C. J.			Hypopituitarism following traumatic brain injury (TBI)	BRITISH JOURNAL OF NEUROSURGERY			English	Article						hypopituitarism; pituitary; traumatic brain injury	GROWTH-HORMONE DEFICIENCY; ANTERIOR-PITUITARY INSUFFICIENCY; ANTI-DIURETIC HORMONE; SEVERE HEAD-INJURY; POSTTRAUMATIC HYPOPITUITARISM; INAPPROPRIATE SECRETION; BODY-COMPOSITION; HYPOGONADOTROPIC HYPOGONADISM; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE	Traumatic brain injury ( TBI) is the commonest cause of death and disability in young adults living in industrialised countries. Recently, several studies have shown that hypopituitarism is a common complication of head trauma, with a prevalence of at least 25% among patients who were studied months or years following injury. This remarkably high frequency has changed the traditional concept of hypopituitarism being a rare complication of TBI, and suggests that most cases of posttraumatic hypopituitarism remain undiagnosed and untreated in clinical practice. It is therefore reasonable to infer that posttraumatic hypopituitarism may have an important contribution to the high physical and neuropsychiatric morbidity seen in patients with head injury. This article discusses the published reports on neuroendocrine dysfunction in TBI patients and the natural history of this disorder. The potential impact of posttraumatic hypopituitarism on recovery and rehabilitation after injury will also be examined, as well as the need for the identification, and appropriate and timely management of hormone deficiencies in order to reduce morbidity, aid recovery, and avoid the long-term complications of pituitary failure.	Beaumont Hosp, Div Endocrinol, Dublin 9, Ireland; Beaumont Hosp, Div Neurosurg, Dublin 9, Ireland; RCSI Med Sch, Dublin, Ireland		Agha, A (corresponding author), Beaumont Hosp, Dept Endocrinol, Beaumont Rd, Dublin 9, Ireland.	amaragha@beaumont.ie					Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918, DOI 10.1093/ajcn/55.5.918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Boughey JC, 2004, AM SURGEON, V70, P500; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219, DOI 10.1152/ajpendo.1994.267.2.E219; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; DANIEL PM, 1959, LANCET, V2, P927; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jcem.77.6.8263155; Monson JP, 2003, EUR J ENDOCRINOL, V148, pS9, DOI 10.1530/eje.0.148S009; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; VIGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; World Health Organization, 1980, INT CLASS IMP DIS HA; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; 1998, NIH             1026, P1	70	33	37	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		2007	21	2					210	216		10.1080/02688690701253331			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	167UC	WOS:000246476900009	17453791				2022-02-06	
J	Gautschi, OP; Toffoli, AM; Joesbury, KA; Skirving, AP; Filgueira, L; Zellweger, R				Gautschi, Oliver P.; Toffoli, Andrew M.; Joesbury, Karen A.; Skirving, Allan P.; Filgueira, Luis; Zellweger, Rene			Osteoinductive effect of cerebrospinal fluid from brain-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						BMP; cerebrospinal fluid; osteoinductive factor; S100B; traumatic brain injury	SEVERE HEAD-INJURY; HETEROTOPIC OSSIFICATION; BONE-FORMATION; S100B; PROTEIN; OSTEOGENESIS; TRAUMA; MARKER; DAMAGE; CELLS	Patients with traumatic brain injury (TBI) are predisposed to heterotopic ossification, which is believed to be due to osteoinductive factors released at the site of the brain injury. To date, little is known about the presence of such factors in human cerebrospinal fluid (CSF). This study investigated whether CSF of TBI patients is osteoinductive. In addition, known osteoinductive factors-such as bone morphogenetic protein (BMP)-2, BMP-4, and BMP-7, and S100B-were measured in CSF. Eighty-four consecutive patients were classified according to brain pathology: TBI (n = 11), non-traumatic brain pathology (NTBP) (n = 26), and no brain pathology (control group) (n = 47). The osteoinductive effect of CSF was measured repeatedly in proliferation assays using a fetal human osteoblast cell line. The mean proliferation rate (normalized to the internal negative control) of the TBI, NTBP, and control groups was 138.2% (SD 13.1), 110.0% (SD 22.1), and 118.8% (SD 16.9), respectively. The potentially confounding effect of age was investigated further by restricting the selection of patients for analysis to that of the oldest patient in the TBI group and use of multiple regression analysis. After implementation of both, it was shown that age is highly unlikely to account for the higher rates of proliferation observed among the TBI patients in this study. Of note, the TBI group had a significantly higher mean proliferation rate than the NTBP (P < 0.001) and the control group (p = 0.006). S100B and BMP-2, -4, or -7 concentrations were measured using enzyme-linked immunosorbent assay (ELISA). There was no correlation between proliferation rates and S100B (r = 0.023). Only three of 36 CSF samples had measurable levels of BMP-2 and -7, and none had detectable concentrations of BMP-4. Consequently, it is unlikely that S100B or BMP-2, -4, or -7 are the putative osteoinductive factors. The results indicate that CSF from TBI patients has an osteoinductive effect in vitro. However, the osteoinductive factor has still to be characterized.	Royal Perth Hosp, Dept Orthopaed & Trauma Surg, Perth, WA 6000, Australia; Univ Western Australia, Sch Anat & Human Biol, Perth, WA 6009, Australia		Gautschi, OP (corresponding author), Royal Perth Hosp, Dept Orthopaed & Trauma Surg, North Block,Level 5,Wellington St, Perth, WA 6000, Australia.	ogautschi@datacomm.ch	Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650			Baltzer AWA, 1999, ZBL CHIR, V124, P1011; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bottiger BW, 2001, CIRCULATION, V103, P2694; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; CRAVEN PL, 1971, CLIN ORTHOP RELAT R, P231; Dattatreyamurty B, 2001, EXP NEUROL, V172, P273, DOI 10.1006/exnr.2001.7728; HARRIS SA, 1995, J BONE MINER RES, V10, P178; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KNUDSEN L, 1982, SCAND J RHEUMATOL, V11, P27, DOI 10.3109/03009748209098110; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; MATHURIYA SN, 1989, CLIN NEUROL NEUROSUR, V91, P269, DOI 10.1016/0303-8467(89)90124-8; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pittenger D E, 1991, Orthop Rev, V20, P33; PUZAS JE, 1989, CLIN ORTHOP RELAT R, P269; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Scher A T, 1976, Paraplegia, V14, P202; Shehab D, 2002, J NUCL MED, V43, P346; STOVER SL, 1975, ARCH PHYS MED REHAB, V56, P199; Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x	32	33	37	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					154	162		10.1089/neu.2006.0166			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100015	17263679				2022-02-06	
J	Moyle, JJ; Fox, AM; Bynevelt, M; Arthur, M; Burnett, JR				Moyle, J. J.; Fox, A. M.; Bynevelt, M.; Arthur, M.; Burnett, J. R.			A neuropsychological profile of off-diet adults with phenylketonuria	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TREATED PHENYLKETONURIA; SUSTAINED ATTENTION; MULTIPLE-SCLEROSIS; TYROSINE DEPLETION; DOPAMINE SYNTHESIS; PHENYLALANINE; TRAIL; PKU; PERFORMANCE	The metabolic disorder phenylketonuria (PKU) is treated early by a low-phenylalanine diet. While this prevents global cognitive impairment, some patients still experience cognitive and neurophysiological abnormalities. Neuropsychological testing of early treated, currently off-diet, PKU patients attending an adult PKU clinic showed a reduction in the Perceptual Organization Index (POI), Processing Speed Index ( PSI) from the Wechsler Adult Intelligence Scale Third Edition (WAIS-III), and Part A of the Trail Making Test for the PKU group relative to controls. Taken together, these results supported a profile of reduced information-processing speed.	Univ Western Australia, Sch Psychol, Crawley, WA 6009, Australia; Royal Perth Hosp, Dept Radiol, Perth, WA, Australia; Royal Perth Hosp, Dept Nutr & Dietet, Perth, WA, Australia; Royal Perth Hosp, PathWest Lab Med WA, Dept Core Clin Pathol & Biochem, Perth, WA, Australia; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia		Moyle, JJ (corresponding author), Univ Western Australia, Sch Psychol M304, 35 Stirling Highway, Crawley, WA 6009, Australia.	jmoyle@student.uwa.edu.au; afox@psy.uwa.edu.au	Fox, Allison M/H-9218-2014	Fox, Allison M/0000-0001-5189-6271			Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Brumm VL, 2004, J INHERIT METAB DIS, V27, P549, DOI 10.1023/B:BOLI.0000042985.02049.ff; Burgard P, 1997, PEDIATR RES, V41, P368, DOI 10.1203/00006450-199703000-00011; Channon S, 2005, NEUROPSYCHOLOGY, V19, P679, DOI 10.1037/0894-4105.19.5.679; Channon S, 2004, NEUROPSYCHOLOGY, V18, P613, DOI 10.1037/0894-4105.18.4.613; CHOI TB, 1986, J BIOL CHEM, V261, P6536; CLARKE JTR, 1987, AM J MENT RETARD, V92, P255; De Sonneville LMJ, 2002, NEUROPSYCHOLOGIA, V40, P1751, DOI 10.1016/S0028-3932(02)00041-6; DIAMOND A, 1987, MONOGRAPHS SOC RES C, V62, P1; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Grevet EH, 2002, J PSYCHOPHARMACOL, V16, P51, DOI 10.1177/026988110201600103; Harmer CJ, 2001, PSYCHOPHARMACOLOGY, V154, P105, DOI 10.1007/s002130000613; Hedges L.V., 1985, STAT METHODS META AN; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Huijbregts SCJ, 2002, NEUROPSYCHOLOGIA, V40, P7, DOI 10.1016/S0028-3932(01)00078-1; Huijbregts SCJ, 2003, NEUROPSYCHOLOGY, V17, P369, DOI 10.1037/0894-4105.17.3.369; Huttenlocher PR, 2000, EUR J PEDIATR, V159, pS102, DOI 10.1007/PL00014371; Joseph B, 2003, J NEUROCHEM, V86, P615, DOI 10.1046/j.1471-4159.2003.01887.x; Koch R, 2002, J INHERIT METAB DIS, V25, P333, DOI 10.1023/A:1020158631102; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Luciana M, 2004, PSYCHOPHARMACOLOGY, V175, P18, DOI 10.1007/s00213-004-1775-0; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Miner T, 1998, BRAIN COGNITION, V38, P246, DOI 10.1006/brcg.1998.1034; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; PIETZ J, 1993, DEV MED CHILD NEUROL, V35, P54; Pietz J, 1998, EUR J PEDIATR, V157, P824, DOI 10.1007/s004310050945; *PSYCH CORP, 1997, WECHSL MEM SCAL 3 ED; Robertson I., 1994, TEST EVERYDAY ATTENT; SCHMIDT E, 1994, J CLIN EXP NEUROPSYC, V16, P681, DOI 10.1080/01688639408402681; Scriber C, 2001, METABOLIC MOL BASES, P1667; Sumerall SW, 1997, J CLIN PSYCHOL, V53, P517, DOI 10.1002/(SICI)1097-4679(199708)53:5<517::AID-JCLP14>3.0.CO;2-H; TAM SY, 1990, J NEURAL TRANSM-GEN, V81, P97, DOI 10.1007/BF01245830; [No title captured]	35	33	35	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2007	29	4					436	441		10.1080/13803390600745829			6	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	177EP	WOS:000247136700010	17497567				2022-02-06	
J	Sander, AM; Davis, LC; Struchen, MA; Atchison, T; Sherer, M; Malec, JF; Nakase-Richardson, R				Sander, Angelle M.; Davis, Lynne Cole; Struchen, Margaret A.; Atchison, Timothy; Sherer, Mark; Malec, James F.; Nakase-Richardson, Risa			Relationship of race/ethnicity to caregivers' coping, appraisals, and distress after traumatic brain injury	NEUROREHABILITATION			English	Article						traumatic brain injury; caregiving; race/ethnicity	SEVERE HEAD-INJURY; FAMILY CAREGIVERS; SOCIAL SUPPORT; BURDEN; DEMENTIA; PREDICTORS; IMPACT; RACE; HEALTH	The objective of the current study was to determine the relationship between race/ethnicity and caregivers' coping, appraisals of the caregiving role, and distress after traumatic brain injury (TBI). Participants were 195 caregivers (75% white; 25% black/Hispanic) of persons with TBI who were admitted to comprehensive inpatient rehabilitation at one of three participating centers and were followed up at 1 year after injury. Caregivers completed interview and self-report questionnaires, including the Ways of Coping Questionnaire, Caregiver Appraisal Scale, and Brief Symptom Inventory. Compared to whites, blacks/Hispanics reported lower levels of education, lower annual household income, and were more likely to be caring for an extended family member. After adjusting for relationship to the person with injury, age, education and income, race/ethnicity significantly predicted caregivers' use of the coping strategies distancing and accepting responsibility. Blacks/Hispanics made greater use of these strategies compared to whites. Blacks/Hispanics also showed more traditional beliefs regarding the caregiving role. Race/ethnicity was not predictive of distress. However, an interaction was noted between race/ethnicity and caregiver ideology. For Blacks/Hispanics, more traditional ideology was associated with increased distress. Future research using a larger sample of non-whites and including measures of acculturation is warranted.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Inst Rehabil & Res, Houston, TX USA; W Texas A&M Univ, Dept Behav Sci, Canyon, TX USA; Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS USA; Mayo Clin & Mayo Fdn, Med Ctr, Rochester, MN USA; Mayo Clin & Mayo Fdn, Sch Med, Rochester, MN USA		Sander, AM (corresponding author), Brain Injury Res Ctr, 2455 S Braeswood, Houston, TX 77030 USA.	asander@bcm.tmc.edu					Braun KL, 1998, HEALTH SOC WORK, V23, P262, DOI 10.1093/hsw/23.4.262; Calderon V, 1998, J GERONTOL SOC WORK, V30, P159, DOI 10.1300/J083v30n01_10; Connell CM, 1997, GERONTOLOGIST, V37, P355, DOI 10.1093/geront/37.3.355; COX C, 1995, SOC WORK, V40, P343; COX C, 1990, J APPLIED GERONTOLOG, V9, P340, DOI DOI 10.1177/073346489000900308; COX C, 1993, AM J ALZHEIMERS CARE, V8, P33; Derogatis LR., 1982, BRIEF SYMPTOM INVENT; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Farran CJ, 1997, J AGING HEALTH, V9, P316, DOI 10.1177/089826439700900303; Folkman S., 1984, STRESS; Folkman S., 1988, MANUAL WAYS COPING Q; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; Haley WE, 1995, PSYCHOL AGING, V10, P540, DOI 10.1037/0882-7974.10.4.540; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HINRICHSEN GA, 1992, GERONTOLOGIST, V32, P375, DOI 10.1093/geront/32.3.375; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Knight BG, 2000, J GERONTOL B-PSYCHOL, V55, pP142, DOI 10.1093/geronb/55.3.P142; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; LAWTON MP, 1992, J GERONTOL, V47, pS156, DOI 10.1093/geronj/47.4.S156; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MACERA CA, 1992, AM J ALZHEIMERS  SEP, P4; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MILLER B, 1995, J GERONTOL B-PSYCHOL, V50, pS374, DOI 10.1093/geronb/50B.6.S374; Minnes P, 2000, BRAIN INJURY, V14, P737; MORYCZ RK, 1987, J GERONTOL SOC WORK, V10, P133, DOI 10.1300/J083V10N01_10; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Panting A, 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander A. M., 2005, REHABILITATION TRAUM, P156; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WOOD JB, 1990, J APPL GERONTOL, V0009, P00325, DOI DOI 10.1177/073346489000900307; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Wykle M, 1991, J Natl Black Nurses Assoc, V5, P29	47	33	33	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	1					9	17					9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600003	17379945				2022-02-06	
J	Stulemeijer, M; Andriessen, TMJC; Brauer, JMP; Vos, PE; Van Der Werf, S				Stulemeijer, Maja; Andriessen, Teuntje M. J. C.; Brauer, Jolanda M. P.; Vos, Pieter E.; Van Der Werf, Sieberen			Cognitive performance after Mild Traumatic Brain Injury: The impact of poor effort on test results and its relation to distress, personality and litigation	BRAIN INJURY			English	Article						cognition; outcome; mild brain injury; neuropsychological; effort tests	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; CLOSED-HEAD INJURY; SOCIAL INHIBITION; MEMORY TEST; COMPENSATION; IMPAIRMENT; DEFICITS; FATIGUE; DISTURBANCE; PREDICTORS	Primary objective: To compare consecutive Mild Traumatic Brain Injury ( MTBI) patients with and without adequate effort on cognitive performance, litigation status, fatigue, distress and personality. Research design: ( Neuro) psychological assessment was done 6 months post- injury in 110 patients from a cohort of 618 consecutive MTBI patients aged 18 - 60, who attended the emergency department of our level I trauma centre. Effort was tested with the Amsterdam Short Term Memory test. Main outcome and results: Thirty patients ( 27%) failed the effort test. Poor effort was associated with significantly poorer scores on seven out of eleven measures, covering all tested domains. Poor effort was associated with lower educational level and changes in work status, but not litigation. Furthermore, poor effort was related to high levels of distress, Type- D personality and fatigue. Conclusions: Even in a sample of non- referred MTBI patients, poor effort was common and was strongly associated with inferior test performance. These findings imply that effort testing should be part of all cognitive assessments, also outside mediolegal settings. Behavioural factors like distress and personality should be considered as potential threats to the validity of neuropsychological testing after MTBI.	Radboud Univ Nijmegen, Nijemegen Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Nijemegen Med Ctr, Dept Neurol, Nijmegen, Netherlands		Stulemeijer, M (corresponding author), Radboud Univ Nijmegen, Nijemegen Med Ctr, Dept Med Psychol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	M.Stulemeijer@neuro.umcn.nl	Vos, Pieter/A-6043-2012				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Beck AT, 1997, BEHAV RES THER, V35, P785, DOI 10.1016/S0005-7967(97)00025-9; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; BREHM JW, 1983, J EXP SOC PSYCHOL, V19, P21, DOI 10.1016/0022-1031(83)90003-3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; DEGORATIS LR, 1994, SCL90; Delis DC, 1987, CALIFORNIA VERBAL LE; Denollet J, 2006, EUR HEART J, V27, P171, DOI 10.1093/eurheartj/ehi616; Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Efklides A., 2006, METACOGN LEARN, V1, P33, DOI [10.1007/s11409-006-6581-0, DOI 10.1007/S11409-006-6581-0]; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Kahneman D., 1973, ATTENTION EFFORT; Keller M, 2000, J NEUROL NEUROSUR PS, V68, P761, DOI 10.1136/jnnp.68.6.761; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lindeboom J, 1999, AMSTERDAM SHORT TERM; Lindem K, 2003, J PSYCHOPATHOL BEHAV, V25, P129, DOI 10.1023/A:1023399100404; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; MULDER JL, 1996, HANDLEIDING VERBALE; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; REVELLE W, 1993, NONCOGNITIVE DETERMI, P346; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Rose CL, 2002, EUR J PERSONALITY, V16, P185, DOI 10.1002/per.451; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; Sanderman R., 1995, METEN PERSOONLIJKHEI; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schmand B, 1998, J NEUROL NEUROSUR PS, V64, P339, DOI 10.1136/jnnp.64.3.339; Schmand B, 1991, Tijdschr Gerontol Geriatr, V22, P15; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; ZIMMERMANN P, 1996, MANUAL TESTBATTERY A	52	33	34	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	3					309	318		10.1080/02699050701209980			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400006	17453759				2022-02-06	
J	Tombaugh, TN; Rees, L; Stormer, P; Harrison, AG; Smith, A				Tombaugh, Tom N.; Rees, Laura; Stormer, Peter; Harrison, Allyson G.; Smith, Andra			The effects of mild and severe traumatic brain injury on speed of information processing as measured by the computerized tests of information processing (CTIP)	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						computerized tests of information processing; CTIP; TBI	CLOSED-HEAD-INJURY; VISUAL REACTION-TIME; NEUROPSYCHOLOGICAL ASSESSMENT; ATTENTION DEFICITS; DIVIDED ATTENTION; CONCUSSION; MEMORY; PERFORMANCE; RECOVERY; CONSISTENCY	In spite of the fact that reaction time (RT) measures are sensitive to the effects of traumatic brain injury (TBI), few RT procedures have been developed for use in standard clinical evaluations. The computerized test of information processing (CTIP) [Tombaugh, T.N., & Rees, L. (2000). Manual for the computerized tests of information processing (CTIP). Ottawa, Ont.: Carleton University] was designed to measure the degree to which TBI decreases the speed at which information is processed. The CTIP consists of three computerized programs that progressively increase the amount of information that is processed. Results of the current study demonstrated that RT increased as the difficulty of the CTIP tests increased (known as the complexity effect), and as severity of injury increased (from mild to severe TBI). The current study also demonstrated the importance of selecting a non-biased measure of variability. Overall, findings suggest that the CTIP is an easy to administer and sensitive measure of information processing speed. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Carleton Univ, Dept Psychol, Ottawa, ON K1S 5B6, Canada; Rehabil Ctr, Ottawa, ON, Canada; Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada; Hawkes Bay Dist Hlth Board, Rehabil Unit, Hastings, New Zealand; Univ Ottawa, Ottawa, ON K1N 6N5, Canada		Tombaugh, TN (corresponding author), Carleton Univ, Dept Psychol, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada.	tom_tombaugh@carleton.ca					BAIRD B, IN PRESS J APPL NEUR; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BRUHN P, 1971, CORTEX, V7, P279; CHANG TM, 1986, PSYCHOL BULL, V99, P199, DOI 10.1037/0033-2909.99.2.199; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; ELSASS P, 1985, ACTA NEUROL SCAND, V71, P11; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; GODEFROY O, 1994, J NEUROL SCI, V126, P168, DOI 10.1016/0022-510X(94)90268-2; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LOFTUS EF, 1973, J EXP PSYCHOL, V97, P70, DOI 10.1037/h0033782; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MARING W, 1984, INS B, V24; Miller E, 1970, Cortex, V6, P121; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Patton J.H., 1991, CLIN NEUROPSYCHOL, V5, P33, DOI [10.1080/13854049108401840, DOI 10.1080/13854049108401840]; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RABBITT P, 1989, J EXP PSYCHOL GEN, V118, P338; REEVES D, 1989, 891 US NAV AER MED R; Reitan RM, 1985, HALSTEADREITAN NEURO; Sarno S, 2003, BRAIN INJURY, V17, P413, DOI 10.1080/0269905031000070161; Schmidt J. P., 1995, LEARNING MEMORY BATT; Smith A., 1982, SYMBOL DIGIT MODALIT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 2000, MANUAL COMPUTERIZED; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler, 1997, WECHSLER ADULT INTEL; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	53	33	34	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					25	36		10.1016/j.acn.2006.06.013			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	144RV	WOS:000244814700003	17071052	Bronze			2022-02-06	
J	Hewett, SJ; Silakova, JM; Hewett, JA				Hewett, Sandra J.; Silakova, Janna M.; Hewett, James A.			Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; CULTURED CORTICAL-NEURONS; INDUCED OXIDATIVE DAMAGE; TRANSGENIC MOUSE MODEL; CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; H SYNTHASE-1; CELL-DEATH	The purpose of this study was to determine whether the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib [ 4-[ 4-(methylsulfonyl) phenyl]-3-phenyl-2(5H)-furanone] could effectively prevent hippocampal neuronal injury in an animal model of excitotoxic neurodegeneration. COX-2 protein levels increased between 3 and 6 h, peaked at 12 h, and declined to near baseline levels 24 h after injection of N-methyl-D-aspartate (NMDA; 18 nmol) into the CA1 region of the left hippocampus. Mice that were fed ad libitum a control rodent diet for 4 days before and 3 days after injection of NMDA demonstrated marked neuronal loss in the primary cell layers of the ipsilateral CA1, CA3, and dentate gyrus (50, 30, and 20% cell loss, respectively). This injury was potently and dose-dependently reduced by feeding animals a diet standardized to deliver 15 or 30 mg/ kg rofecoxib per day. Neurodegeneration in the CA1 region was reduced by 30.1 +/- 5.6 and 51.5 +/- 9.0%, respectively; in the CA3 by 64.6 +/- 12.4 and 69.0 +/- 14.1%, respectively; and in the dentate gyrus by 47.8 +/- 15.2 and 58.0 +/- 18.2%, respectively. Moreover, rofecoxib chow slightly but significantly reduced injury-induced brain edema. These findings demonstrate that rofecoxib can ameliorate excitotoxic neuronal injury in vivo and, as such, may be a particularly promising pharmaceutical for the treatment of neurological diseases associated with overactivation of NMDA receptors.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Program Cellular & Mol Pharmacol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Neurosci, Program Neurosci, Farmington, CT 06030 USA		Hewett, SJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, Program Cellular & Mol Pharmacol, MC-3401,263 Farmington Ave, Farmington, CT 06030 USA.	shewett@neuron.uchc.edu		Hewett, Sandra/0000-0002-2987-3791	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS036812, R01NS036812] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36812, R01 NS036812] Funding Source: Medline		Adams J, 1996, J NEUROCHEM, V66, P6; AKAIKE A, 1994, BRAIN RES, V663, P237, DOI 10.1016/0006-8993(94)91268-8; Azari MF, 2005, EUR J NEUROL, V12, P357, DOI 10.1111/j.1468-1331.2004.00987.x; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Candelario-Jalil E, 2000, EUR J PHARMACOL, V390, P295, DOI 10.1016/S0014-2999(99)00908-5; Candelario-Jalil E, 2003, NEUROSCI RES, V47, P245, DOI 10.1016/S0168-0102(03)00184-6; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Carlson NG, 2003, J NEUROSCI RES, V71, P79, DOI 10.1002/jnr.10465; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CAZEVIEILLE C, 1994, NEUROCHEM INT, V24, P395, DOI 10.1016/0197-0186(94)90118-X; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chan CC, 1999, J PHARMACOL EXP THER, V290, P551; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dembo G, 2005, ANESTHESIOLOGY, V102, P409, DOI 10.1097/00000542-200502000-00026; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Depre M, 2000, EUR J CLIN PHARMACOL, V56, P167, DOI 10.1007/s002280050736; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Halpin RA, 2000, DRUG METAB DISPOS, V28, P1244; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Jiang JF, 2004, J NEUROCHEM, V90, P1036, DOI 10.1111/j.1471-4159.2004.02577.x; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Klivenyi P, 2004, J NEUROCHEM, V88, P576, DOI 10.1046/j.1471-4159.2003.02160.x; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nogawa S, 1997, J NEUROSCI, V17, P2746; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; POWERS MM, 1955, STAIN TECHNOL, V30, P83, DOI 10.3109/10520295509113749; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Sandhya TL, 1998, BRAIN RES, V788, P223, DOI 10.1016/S0006-8993(97)01552-7; Sanz O, 1997, NEUROSCIENCE, V80, P221, DOI 10.1016/S0306-4522(97)00089-4; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Silakova JM, 2004, J PHARMACOL EXP THER, V309, P1060, DOI 10.1124/jpet.103.063867; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Torrie JG., 1980, PRINCIPLES PROCEDURE, V1; Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; Yokota O, 2004, ACTA NEUROPATHOL, V107, P399, DOI 10.1007/s00401-004-0826-2	67	33	34	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	DEC	2006	319	3					1219	1224		10.1124/jpet.106.109876			6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	105QX	WOS:000242048500025	16963621				2022-02-06	
J	Egan, J; Chenoweth, L; McAuliffe, D				Egan, Jennifer; Chenoweth, Lesley; McAuliffe, Donna			Email-facilitated qualitative interviews with traumatic brain injury survivors: A new and accessible method	BRAIN INJURY			English	Article						email interviewing; traumatic brain injury; disability; qualitative research; Internet	COMPUTER-MEDIATED COMMUNICATION; HEAD-INJURY; PEOPLE; INTERNET; ISSUES; EMOTION	Primary objective: To trial the method of email-facilitated qualitative interviewing with people with traumatic brain injury (TBI). Research design: Qualitative semi-structured email-facilitated interviews. Procedures: Nineteen people (17 severe diagnosis) with a TBI participated in email interviews. Main outcomes and results: Findings indicate that this method facilitates the participation of people with TBI in qualitative interviews. Advantages include increased time for reflection, composing answers and greater control of the interview setting. In addition, the data indicates that people with a TBI are capable of greater insight, reflection and humour than indicated by previous research. Conclusion: Findings indicate that new technologies may advance data collection methods for people with cognitive-linguistic impairments who face participation barriers in face-to-face interviews.	Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia; Griffith Univ, Sch Human Serv, Nathan, Qld 4111, Australia		Egan, J (corresponding author), Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia.	j.egan@social.uq.edu.au	McAuliffe, Donna A/F-1853-2011	McAuliffe, Donna/0000-0002-6584-0540			Association of Internet Researchers, 2002, ETH DEC MAK INT RES; BAMPTON R, 2002, E INTERVIEW FORUM QU, V19, P3; BENNETT C, 1998, MEN ONLINE DISCUSSIN; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Bowker N, 2002, DISABIL SOC, V17, P327, DOI 10.1080/09687590220139883; COELHO C, 1996, J SPEECH HEAR RES, V39, P5; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; Dunne G. A., 1999, DIFFERENT DIMENSIONS; Egan J, 2005, BRAIN INJURY, V19, P555, DOI 10.1080/02699050400013659; Egan J, 2004, APHASIOLOGY, V18, P265, DOI 10.1080/02687030344000562; FONTANA A, 1994, HDB QUALITATIVE RES; Galinsky MJ, 1997, HEALTH SOC WORK, V22, P181, DOI 10.1093/hsw/22.3.181; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; HUTCHINSON S, 1992, NURS RES, V41, P117; KARPMAN T, 1985, J APPL REHABILITATIO, V0017, P00028; Kendall L., 1999, DOING INTERNET RES C, P57, DOI DOI 10.4135/9781452231471.N3; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Mann C., 2000, INTERNET COMMUNICATI; Mantovani G, 2001, CYBERPSYCHOL BEHAV, V4, P47, DOI 10.1089/10949310151088370; MARKHAM AN, 1998, ETHNOGRAPHICS ALTERN, V6, P246; MCAULIFFE D, 2000, HYPOTHETICAL PRACTIT, P371; MCAULIFFE D, 2003, QUALITATIVE REPORT, V8, P8; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MCDONALD S, 2005, BRAIN IMPAIRMENT, V6, P55; *NAT HLTH MRC, 1999, NAT STAT ETH COND RE; *NHMRC, 2004, HUM RES ETH HDB; *NHMRC, JOINT NHMRC AVCC STA; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Parks MR, 1996, J COMMUN, V46, P80, DOI 10.1111/j.1460-2466.1996.tb01462.x; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Patton M. Q., 2014, QUALITATIVE RES EVAL, V4th; *QSR INT PTY LTD, 2002, NVIVO QUAL DAT AN PR; RICE RE, 1987, J COMMUN, V37, P65, DOI 10.1111/j.1460-2466.1987.tb01009.x; RICE RE, 1987, COMMUN RES, V14, P85, DOI 10.1177/009365087014001005; Sproull L., 1991, CONNECTIONS NEW WAYS; STEWART F, 2004, ADV SPEECH LANGUAGE, V6, P209; TEASDALE G, 1974, LANCET, V2, P81; THORNE SE, 1998, ANN REV NURSING RES, V18, P3; Togher L., 2000, BRAIN DAM B, P1; TREMBLAY MA, 1957, AM ANTHROPOL, V59, P688, DOI 10.1525/aa.1957.59.4.02a00100; Williams CC, 1999, PSYCHIATRY, V62, P61, DOI 10.1080/00332747.1999.11024853	44	33	34	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2006	20	12					1283	1294		10.1080/02699050601049692			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DF	WOS:000242357800007	17132551				2022-02-06	
J	Fujiki, M; Hikawa, T; Ishii, TAK; Kobayashi, H				Fujiki, Minoru; Hikawa, Takarnitsu; Ishii, Tatsuya Abe Keisuke; Kobayashi, Hidenori			Reduced short latency afferent inhibition in diffuse axonal injury patients with memory impairment	NEUROSCIENCE LETTERS			English	Article						diffuse axonal injury; traumatic brain injury; transcranial magnetic stimulation; short latency afferent inhibition; cholinergic inhibition	TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; EXCITABILITY; DONEPEZIL; FACILITATION; CIRCUITS	The present study used short interval intracortical inhibition (SICI), intracortical facilitation (ICF), and short latency afferent inhibition (SAI) to evaluate motor cortex excitability in 16 diffuse axonal injury (DAI) patients with memory impairment and compared the data with those of 16 healthy controls. SAI was reduced in patients compared with controls (92 +/- 12 versus 39 +/- 11% of the test size; p < 0.0001, unpaired t-test). DAI patients tended to have a high resting motor threshold (RMT) and less pronounced SICI and ICF than controls, but these differences were not significant. A single oral dose (3 mg) of donepezil, an acetylcholinesterase inhibitor that is commonly used to treat Alzheimer's disease (AD), improved SAI in DAI patients with wide individual variations that ranged from an increase of 77-18% of test size. These findings suggest that measuring SAI may provide a means of probing the integrity of cholinergic networks in an injured human brain. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Oita Univ, Sch Med, Dept Neurosurg, Oita 8795593, Japan		Fujiki, M (corresponding author), Oita Univ, Sch Med, Dept Neurosurg, 1-1 Idaigaoka, Oita 8795593, Japan.	fujilci@med.oita-u.ac.jp					Alagona G, 2001, NEUROSCI LETT, V314, P57, DOI 10.1016/S0304-3940(01)02288-1; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Di Lazzaro V, 2005, J NEUROL NEUROSUR PS, V76, P1064, DOI 10.1136/jnnp.2004.051334; Di Lazzaro V, 2004, J NEUROL NEUROSUR PS, V75, P555, DOI 10.1136/jnnp.2003.018127; Di Lazzaro V, 2002, NEUROLOGY, V59, P392, DOI 10.1212/WNL.59.3.392; Di Lazzaro V, 2000, EXP BRAIN RES, V135, P455, DOI 10.1007/s002210000543; Kessler KR, 2005, MOVEMENT DISORD, V20, P238, DOI 10.1002/mds.20295; Kosasa T, 2000, EUR J PHARMACOL, V389, P173, DOI 10.1016/S0014-2999(99)00876-6; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Pennisi G, 2002, NEUROSCI LETT, V329, P293, DOI 10.1016/S0304-3940(02)00701-2; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	17	33	34	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 25	2006	405	3					226	230		10.1016/j.neulet.2006.07.005			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	083PL	WOS:000240470600015	16901641				2022-02-06	
J	Thelandersson, A; Cider, A; Nellgard, B				Thelandersson, A.; Cider, A.; Nellgard, B.			Prone position in mechanically ventilated patients with reduced intracranial compliance	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						prone position; neurosurgery; intracranial pressure; cerebral perfusion pressure; acute lung insufficiency	RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE-UNIT; OXYGENATION; MANAGEMENT; PRESSURE; INJURY; LUNG	Background: Prone position has been used for several years to treat acute lung insufficiency, but in previous studies patients with unstable intracranial pressure (ICP) are mostly excluded. The aim of this study was to investigate if prone position is a safe and useful treatment in patients with reduced intracranial compliance. Methods: A consecutive, prospective pilot study of 11 patients admitted to the neuro intensive care unit (NICU) due to traumatic brain injury or intracerebral haemorrhage. ICP, cerebral perfusion pressure (CPP), heart rate (HR), mean arterial blood pressure (MABP), arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), arterial oxygen saturation (SaO(2)) and respiratory system compliance were measured before, three times during and two times after the patients were placed in the prone position. Results: No significant changes were demonstrated in ICP, CPP or MABP. PaO2 and SaO(2) were significantly increased in the prone position. HR was significantly increased in the prone position and after 10 min in the supine post-prone position and the respiratory system compliance was increased after 1 h in the supine post-prone position. Conclusion: Turning NICU patients from the supine to the prone position did not influence ICP, CPP or MABP, but significantly improved patient PaO2, SaO(2) and respiratory system compliance.	Sahlgrens Univ Hosp, Dept Phys Therapy, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41345 Gothenburg, Sweden		Thelandersson, A (corresponding author), Sahlgrens Univ Hosp, Dept Phys Therapy, S-41345 Gothenburg, Sweden.	anneli.thelandersson@vgregion.se		Cider, Asa/0000-0003-2140-8569			Blanch L, 1997, INTENS CARE MED, V23, P1033, DOI 10.1007/s001340050453; Dettenkofer M, 2001, J NEUROL, V248, P959, DOI 10.1007/s004150170048; Fletcher SJ, 2003, BRIT J ANAESTH, V90, P238, DOI 10.1093/bja/aeg026; HEDENSTIERNA G, 1986, ACTA ANAESTH SCAND, V30, P183, DOI 10.1111/j.1399-6576.1986.tb02393.x; Johannigman JA, 2000, SURGERY, V128, P708, DOI 10.1067/msy.2000.108225; Mure M, 1997, CRIT CARE MED, V25, P1539, DOI 10.1097/00003246-199709000-00022; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; Sofianou DC, 2000, EUR J CLIN MICROBIOL, V19, P460, DOI 10.1007/s100960000236; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Takahashi N, 2004, CHEST, V125, P935, DOI 10.1378/chest.125.3.935; Williams A, 1993, Am J Crit Care, V2, P68	13	33	34	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2006	50	8					937	941		10.1111/j.1399-6576.2006.01037.x			5	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	076EF	WOS:000239939100005	16923087				2022-02-06	
J	Tasker, RC; Morris, KP; Forsyth, RJ; Hawley, CA; Parslow, RC				Tasker, RC; Morris, KP; Forsyth, RJ; Hawley, CA; Parslow, RC		UK Paediat Brain Injury Study G; Paediat Intens Care Soc Grp	Severe head injury in children: emergency access to neurosurgery in the United Kingdom	EMERGENCY MEDICINE JOURNAL			English	Article							INTENSIVE-CARE; UK	Objective: To determine the scale of acute neurosurgery for severe traumatic brain injury (TBI) in childhood, and whether surgical evacuation for haematoma is achieved within four hours of presentation to an emergency department. Methods: A 12 month audit of emergency access to all specialist neurosurgical and intensive care services in the UK. Severe TBI in a child was defined as that necessitating admission to intensive care. Results: Of 448 children with severe head injuries, 91 (20.3%) underwent emergency neurosurgery, and 37% of these surgical patients had at least one non-reactive and dilated pupil. An acute subdural or epidural haematoma was present in 143/448 (31.9%) children, of whom 66 (46.2%) underwent surgery. Children needing surgical evacuation of haematoma were at a median distance of 29 km (interquartile range (IQR) 11.8-45.7) from their neurosurgical centre. One in four children took longer than one hour to reach hospital after injury. Once in an accident and emergency department, 41% took longer than fours hours to arrive at the regional centre. The median interval between time of accident and arrival at the surgical centre was 4.5 hours ( IQR 2.23-7.73), and 79% of inter-hospital transfers were undertaken by the referring hospital rather than the regional centre. In cases where the regional centre undertook the transfer, none were completed within four hours of presentation-the median interval was 6.3 hours (IQR 5.1-8.12). Conclusions: The system of care for severely head injured children in the UK does not achieve surgical evacuation of a significant haematoma within four hours. The recommendation to use specialist regional paediatric transfer teams delays rather than expedites the emergency service.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge CB2 2QQ, England; Diana Princess Wales Childrens Hosp, Birmingham, W Midlands, England; Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Sch Clin Med Sci Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Warwick, Warwick Med Sch, Div Hlth Community, Coventry CV4 7AL, W Midlands, England; Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Ctr Biostat & Epidemiol, Paediat Epidemiol Grp, Leeds, W Yorkshire, England		Tasker, RC (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Hills Rd, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Forsyth, Rob/H-9193-2019; Forsyth, Rob J/I-9226-2012; Parslow, Roger/AAV-1477-2020; Tasker, Robert C/R-5837-2019; Hawley, Carol/AAG-3830-2019	Forsyth, Rob/0000-0002-5657-4180; Forsyth, Rob J/0000-0002-5657-4180; Tasker, Robert/0000-0003-3647-8113; Parslow, Roger/0000-0002-3945-5294			Abdalla IM, 1997, ACCIDENT ANAL PREV, V29, P583, DOI 10.1016/S0001-4575(97)00011-0; Atkins DJ, 1995, STUDIES MED POPULATI, V58; *DEP HLTH, 1977, PAED INT CAR FRAM FU; *GEN REG OFF SCOTL, 2001 CENS STAND AR S; Hewson P, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-15; *NAT COLL CTR AC C, 2003, HEAD INJ TRIAG ASS I, P74; Office for National Statistics, 2001, CENS STAND AR STAT E; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; *ROYAL COLL PAED C, 2001, CLIN APPR SIGN HEAD; *ROYAL COLL SURG E, 1999, REP WORK PART MAN PA; Royal College of Surgeons of England and the British Orthopaedic Society, 2000, BETT CAR SEV INJ; *SCOTT INT GUID NE, 2000, EARL MAN PAT HEAD IN, P36; Seeley HM, 2001, EMERG MED J, V18, P358, DOI 10.1136/emj.18.5.358; SHANN F, 1993, LANCET, V342, P68, DOI 10.1016/0140-6736(93)91282-Q; *SOC BRIT NEUR SUR, 1999, SAF NEUR 2000; Tasker RC, 2004, EMERG MED J, V21, P433, DOI 10.1136/emj.2002.004069	16	33	33	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	JUL	2006	23	7					519	522		10.1136/emj.2005.028779			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	055UV	WOS:000238477000006	16794092	Green Published			2022-02-06	
J	Ponsford, J; Harrington, H; Olver, J; Roper, M				Ponsford, J; Harrington, H; Olver, J; Roper, M			Evaluation of a community-based model of rehabilitation following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article								In recent years there has been a growing trend towards community-based post-acute rehabilitation for individuals with traumatic brain injury (TBI), as opposed to the traditional centre-based model, based on the premise that these individuals will learn more effectively in settings where they usually have to perform. In the present study, outcomes at two years post-injury in 77 individuals with TBI, treated within the community were compared on measures of activities of daily living (ADL), vocational status, and emotional adjustment with those of 77 TBI patients individually matched for gender, age, education, occupation, post-traumatic amnesia ( PTA) duration, Glasgow Coma Scale (GCS) score and time in inpatient rehabilitation, who had attended the hospital for outpatient therapy. There were no significant differences between groups in terms of employment outcomes or independence in personal or domestic ADL. However those treated in the community were less likely to be independent in shopping and financial management and reported more changes in communication and social behaviour. Due to constraints of time and resources, these patients had received fewer one-on-one therapy sessions and thus treatment costs were somewhat lower. Attendant care costs were also lower in the community treatment group. Strengths and weaknesses of community-based post-acute rehabilitation are discussed.	Epworth Med Fdn, Epworth Rehabil Ctr, Dept Psychol, Richmond, Vic 3121, Australia; Monash Univ, Clayton, Vic 3168, Australia; Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic 3121, Australia; Epworth Hosp Melbourne, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Epworth Med Fdn, Epworth Rehabil Ctr, Dept Psychol, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au		Olver, John/0000-0001-7069-1191			Bowen A, 1999, NEUROREHABILITATION, V13, P147; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519	8	33	33	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN	2006	16	3					315	328		10.1080/09602010500176534			14	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	054XR	WOS:000238412400005	16835154				2022-02-06	
J	Wang, H; Olivero, W; Wang, D; Lanzino, G				Wang, H; Olivero, W; Wang, D; Lanzino, G			Cold as a therapeutic agent	ACTA NEUROCHIRURGICA			English	Article						hypothermia; cold; history of medicine	EXTRACORPOREAL CIRCULATION; INDUCED HYPOTHERMIA; CEREBRAL-ISCHEMIA; CARDIAC-ARREST; BRAIN; RESUSCITATION; POTENTIALS; INDUCTION; ANEURYSMS; ARTERY	The use of cold as a therapeutic agent has a long and colorful history. The Edwin Smith Papyrus, the most ancient medical text known, dated 3500 B.C., made numerous references to the use of cold as therapy. Baron de Larrey, a French army surgeon during Napoleon's Russian campaign, packed the limbs in ice prior to amputations to render the procedures painless. In the early twentieth century, a neurosurgeon, Temple Fay, pioneered "human refrigeration" as a treatment for malignancies and head injuries. In 1961, Irving Cooper developed the first closed cryoprobe system and ushered in the modern era of cryogenic surgery with his imperturbable convictions. Fay's early work fell victim to the disruptive sequel of the World War II. The Nazis confiscated his data (presented before the Third International Cancer Congress in 1939) forwarded to Belgium for publication and brutally applied his refrigeration techniques experimentally without any benefit of anesthesia in the concentration camps, especially Dachau. Hypothermia became associated in the public mind with the atrocities exposed at the war trials in Nurnberg. After lying dormant for decades, the interest was rekindled in the late 80s when mild hypothermia was shown to confer dramatic neuroprotection in a number of experimental models of brain injury. With several large multi-center clinical studies currently under way, hypothermia is receiving unprecedented attention from the medical and scientific communities.	Univ Illinois, Coll Med, Dept Neurosurg, Illinois Neurol Inst, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Illinois Neurol Inst, Dept Neurol, Peoria, IL USA		Lanzino, G (corresponding author), UNICOMP, POB 1649, Peoria, IL 61656 USA.	lanzino@uic.edu					ADAMS F, 1929, GENUINE WORKS HIPPOC, P741; Baiping Lei, 1994, Stroke, V25, P147; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BIGLOW EG, 1950, ANN SURG, V132, P849; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; COOPER IS, 1961, J NERV MENT DIS, V133, P259, DOI 10.1097/00005053-196109000-00013; DRAKE CG, 1964, J NEUROSURG, V21, P575, DOI 10.3171/jns.1964.21.7.0575; FAY T, 1959, J NEUROSURG, V16, P239, DOI 10.3171/jns.1959.16.3.0239; FLOYER J, 1715, HIST COLD BATHING BO, P92; Gage AA, 1998, SEMIN SURG ONCOL, V14, P99, DOI 10.1002/(SICI)1098-2388(199803)14:2<99::AID-SSU2>3.0.CO;2-1; HENDERSON A R, 1971, Medical Annals of the District of Columbia, V40, P583; Holzer M, 2002, NEW ENGL J MED, V346, P549; HOSSMANN KA, 1988, CRIT CARE MED, V16, P964, DOI 10.1097/00003246-198810000-00007; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kumar K, 1995, METAB BRAIN DIS, V10, P283, DOI 10.1007/BF02109359; PENEL P, 1791, TRAITE MED PHILOS AL, P180; ROSOMOFF HL, 1956, J NEUROSURG, V13, P332; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; SEALY WC, 1958, ANN SURG, V147, P603, DOI 10.1097/00000658-195805000-00004; SHAVER EG, 1995, STROKE, V26, P1273, DOI 10.1161/01.STR.26.7.1273; Solomon R A, 1994, Clin Neurosurg, V41, P351; SOLOMON RA, 1991, NEUROSURGERY, V29, P732, DOI 10.1227/00006123-199111000-00015; SPETZLER RF, 1988, J NEUROSURG, V68, P868, DOI 10.3171/jns.1988.68.6.0868; Stellar S, 1993, Surg Neurol, V39, P331, DOI 10.1016/0090-3019(93)90016-T; WESTIN B, 1971, AM J OBSTET GYNECOL, V110, P1134, DOI 10.1016/0002-9378(71)90313-9; WONG KC, 1936, HIST CHINESE MED, P54	29	33	38	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAY	2006	148	5					565	570		10.1007/s00701-006-0747-z			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	034GG	WOS:000236916400022	16489500				2022-02-06	
J	Pinto, FCG; Capone-Neto, A; Prist, R; Silva, MRE; Poli-de-Figueiredo, LF				Pinto, FCG; Capone-Neto, A; Prist, R; Silva, MRE; Poli-de-Figueiredo, LF			Volume replacement with lactated ringer's or 3% hypertonic saline solution during combined experimental hemorrhagic shock and traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Japanese-Association-for-Acute-Medicine	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma, Japanese Assoc Acute Med		hemorrhagic shock; traumatic brain injury; hypertonic saline solution; lactated Ringer's solution	HEAD-INJURY; INTRACRANIAL-PRESSURE; RESUSCITATION; FLUID; MODEL; DEXTRAN-40; WATER	Background. The devastating effects of hypotension on head-trauma-related mortality are well known. This study evaluates the systemic and cerebral hemodynamic responses to volume replacement with 3% hypertonic saline (HSS) or lactated Ringer's solution (LR), during the acute phase of hemorrhagic shock (HS) associated with traumatic brain injury (TBI). Methods: Fifteen dogs were assigned to one of three groups (n = 5, each) according to the volume replacement protocol, infused after TBI (brain fluid percussion, 4 atm) and epidural balloon to an intracranial pressure (ICP) higher than 20 mm Hg and HS, induced by blood removal to a mean arterial pressure (MAP) of 40 rum Hg in 5 minutes: Group HS+TBI+HSS (8 mL/kg of 3% HSS), HS+TBI+LR (16 mL/kg LR), and Group HS+TBI (controls, no fluids). We simulated treatment during prehospital and early hospital admission. Groups HS+ TBI and HS+TBI+LR received shed blood infusion to a target hematocrit of 30%. Measurements included shed blood volume, fluid volume infused to restore MAP, MAP, cardiac output, cerebral perfusion pressure, cerebral and systemic lactate, and oxygen extraction ratios. Results: Fluid replacement with HSS 3% or LR promoted major hemodynamic benefits over control animals without luids. Cerebral perfusion pressure was higher than controls and similar between treated groups; however, HSS 3% infusion was associated with lower ICP during the "early hospital phase" and a higher serum sodium and osmolarity. Conclusion: In the event of severe head trauma and hemorrhagic shock, the use of HSS 3% and larger volumes of LR promote similar systemic and cerebral hemodynamic benefits. However, a lower ICP was observed after HSS 3% than after LR.	Univ Sao Paulo, Div Appl Physiol, Inst Heart, Sch Med,InCor, BR-05403000 Sao Paulo, Brazil		Pinto, FCG (corresponding author), Univ Sao Paulo, Div Appl Physiol, Inst Heart, Sch Med,InCor, Av Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.	acapuano@terra.com.br	Pinto, Fernando Gomes/F-6094-2012	PINTO, FERNANDO/0000-0003-2384-2190; Namias, Nicholas/0000-0001-7021-2250			American College of Surgeons, 1996, ADV TRAUM LIF SUPP I; Anderson JT, 1997, J TRAUMA, V42, P592, DOI 10.1097/00005373-199704000-00003; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; Bhardwaj, 1999, Curr Treat Options Neurol, V1, P179, DOI 10.1007/s11940-999-0002-z; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DeWitt DS, 1996, CRIT CARE MED, V24, P109, DOI 10.1097/00003246-199601000-00019; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; ELIASTAM M, 1984, ANN EMERG MED, V13, P874, DOI 10.1016/S0196-0644(84)80464-3; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GUNNAR W, 1989, BRAZ J MED BIOL RES, V22, P287; GUNNAR W, 1988, SURGERY, V103, P398; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; KIRKEBY OJ, 1995, J NEUROSURG, V83, P1067, DOI 10.3171/jns.1995.83.6.1067; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Rocha-e-Silva Mauricio, 2005, Clinics, V60, P159, DOI 10.1590/S1807-59322005000200013; ROPPER A, 1993, NEUROLOGICAL NEUROSU; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SHACKFORD SR, 1988, SURGERY, V104, P553; Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; VELANOVICH V, 1989, SURGERY, V105, P65; VELASCO IT, 1980, AM J PHYSIOL, V239, P664; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021; 2002, J NEUROTRAUMA, V19, P149	36	33	43	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2006	60	4					758	763		10.1097/01.ta.0000214581.89316.73			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	033RY	WOS:000236868100014	16612295				2022-02-06	
J	Shojo, H; Kibayashi, K				Shojo, H; Kibayashi, K			Changes in localization of synaptophysin following fluid percussion injury in the rat brain	BRAIN RESEARCH			English	Article						synaptophysin; traumatic brain injury; fluid percussion injury; axonal transport	SPINAL-CORD; TRANSMITTER SECRETION; AXONAL-TRANSPORT; TRANSECTION; MECHANISM; NEURONS; KINESIN; PROTEIN; MARKER	Traumatic brain injuries damage neurons and cause progressing dysfunctions of the brain. Synaptophysin (SYP), a major integral transmembrane protein of synaptic vesicles, provides a molecular marker for the synapse and serves as a functional marker of the brain. This study examined magnitude -dependent changes of SYP in the rat brain 2 days following low, moderate or high fluid percussion injuries and investigated time-dependent changes of SYP in the rat brain with moderate fluid percussion injury 2, 15 and 30days after trauma using immunohistochemistry and Western blotting. SYP immunoreactivity increased in the lateral cortex and in the subcortical white matter, with increasing magnitude of injury and time after trauma. Increased SYP immunoreactivity was accompanied with degeneration of neuronal cell bodies, their processes and terminals as well as glial cell proliferations. Amounts of SYP measured by Western blotting remained unchanged in brains with moderate fluid percussion within 30days after trauma. These findings indicate that trauma accumulates SYP at injured sites of neurons without changing SYP contents and that increased SYP immunoreactivity in the cerebral cortex following traumatic injury reflects an inhibition of synaptic vesicle transportation and dysfunction of synapses, thus providing a histological substrate for brain dysfunctions. (c) 2006 Elsevier B.V. All rights reserved.	Saga Univ, Fac Med, Dept Forens Med, Saga 8498501, Japan		Shojo, H (corresponding author), Saga Univ, Fac Med, Dept Forens Med, 5-1-1 Nabeshima, Saga 8498501, Japan.	shojo@med.saga-u.ac.jp	Kazuhiko, Kibayashi/F-5173-2013	Kazuhiko, Kibayashi/0000-0001-6510-5215			ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; BRUCE A, 2002, INTRACELLULAR VES 4, P711; Callahan LM, 2002, J NEUROPATH EXP NEUR, V61, P384, DOI 10.1093/jnen/61.5.384; Chou AK, 2002, NEUROSCI LETT, V333, P155, DOI 10.1016/S0304-3940(02)00575-X; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Duchen L. W., 1992, GREENFIELDS NEUROPAT, P1; Eastwood SL, 2001, BRAIN RES BULL, V55, P569, DOI 10.1016/S0361-9230(01)00530-5; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; LI JY, 1992, J NEUROBIOL, V23, P1094, DOI 10.1002/neu.480230813; Li JY, 2000, J NEUROSCI RES, V61, P151, DOI 10.1002/1097-4547(20000715)61:2<151::AID-JNR6>3.0.CO;2-N; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moran LB, 2004, BRAIN RES REV, V44, P154, DOI 10.1016/j.brainresrev.2003.11.004; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; RINK A, 1995, AM J PATHOL, V147, P1575; SANES JR, 2000, DEV NERVOUS SYSTEM P, P1087; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STROEMER RP, 1992, NEUROSCI LETT, V147, P21, DOI 10.1016/0304-3940(92)90765-Y; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Tiraihi T, 2004, DEV BRAIN RES, V148, P97, DOI 10.1016/j.devbrainres.2003.11.002; Valtorta F, 2004, BIOESSAYS, V26, P445, DOI 10.1002/bies.20012; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	37	33	35	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 17	2006	1078						198	211		10.1016/j.brainres.2006.01.063			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	035CO	WOS:000236977800020	16497279				2022-02-06	
J	Avesani, R; Gambini, MG; Albertini, G				Avesani, R; Gambini, MG; Albertini, G			The vegetative state: A report of two cases with a long-term follow-up	BRAIN INJURY			English	Article						persistent vegetative state; outcome; follow-up; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; RECOVERY; PROGNOSIS	Objectives: To demonstrate that patients with Prolonged Vegetative State (PVS) can show signs of improvements and important changes and, consequently, to strengthen the necessity to evaluate them with long-term serial follow-ups. Setting: Rehabilitation of patients with severe traumatic brain injury (TBI). Participants: Two people with severe TBI discharged after a long period of inpatient rehabilitation in a condition of PVS. Results: After 5 years some important changes happened and the initial prognosis was proved to be wrong. Conclusion: Sometimes patients declared to be in PVS have the possibility to recover, especially when initial clinical conditions are particularly severe and do not allow the emergence of the state of consciousness. It is important to conduct regular follow-ups to better evaluate changes and, if it is necessary, to re-adjust the rehabilitation accordingly.	Rehabil Dept Sacro Cuore Don Calabria, Verona, Italy		Avesani, R (corresponding author), Osped Sacro Cuore Don Calabria, I-37024 Verona, Italy.	renato.avesani@sacrocuore.it	Gambini, Maria grazia/ABA-3969-2021	Gambini, Maria Grazia/0000-0002-6211-2169			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Avesani R, 2002, ACT NEUR S, V79, P45; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BROOKS DN, 1995, DOCUMENT EUROPEENNE; Childs NL, 1996, BRIT MED J, V313, P944; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gostin L, 1989, Law Med Health Care, V17, P295; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; *I SUP SAN PROGR L, 2000, C NAZ CONS MOD TRATT; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	21	33	33	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					333	338		10.1080/02699050500487605			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400013	16537275				2022-02-06	
J	Esper, DH; Coplin, WM; Carhuapoma, JR				Esper, Dema Halasa; Coplin, William M.; Carhuapoma, J. Ricardo			Energy expenditure in patients with nontraumatic intracranial hemorrhage	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article; Proceedings Paper	2nd Annual Nutrition Week Conference	JAN 20, 2003	SAN ANTONIO, TX				SPONTANEOUS INTRACEREBRAL HEMORRHAGE; INDIRECT CALORIMETRY; ACUTE STROKE; INJURY	Background: Patients with intracerebral (ICH), intraventricular (IVH) and subarachnoid hemorrhage (SAH) have increased morbidity and mortality compared with other forms of stroke. We postulate that the systemic inflammatory state triggered by these forms of nontraumatic intracranial hemorrhage (IH) translates into higher nutrition requirements than traditionally assumed. In order to test this hypothesis,, we performed a retrospective study comparing the resting energy expenditure (REE) of 14 mechanically ventilated IH patients with the REE of 6 severe traumatic brain injury (sTBI) patients (a disease known to induce an increased metabolic state). Methods: Using nonparametric analysis, we compared 2 contemporary cohorts of patients-IH and sTBI-who required mechanical ventilation and who underwent indirect calorimetry (IC) within 7 days after the ictus. Results: Fourteen patients with nontraumatic IH (IVH, 2; SAH, 9; SAH/ICH, 1; ICI/SAH/IVH, 2) who underwent IC within 7 days from injury were identified; median age: 59 (28-84) years, median admission Glasgow Coma Scale (GCS): 6 (4-9), and median APACHE 11: 19.5 (15-28). A control cohort of 6 patients with sTBI was identified; median age: 57.5 (18-80) years, admission GCS: 6.5 (4-8), and APACHE 11: 16 (11-31). Sedation was used in 11/14 patients with IH and in 5/6 severe TBI patients. No patient was pharmacologically paralyzed. Median REE was 1810 (1124-2806) and 2238 (1860-2780) kcal/d for the IH and for the sTBI patient cohorts, respectively. Using Wilcoxon signed ranks test, the 2 patient groups were found comparable in regard to baseline clinical variables and disease severity (APACHE II). We did not identify a statistically significant difference in the REE between these 2 cohorts of patients (p =.25). Conclusions: Patients with severe TBI and patients with IH have similar increments in metabolic rate during the initial phase (1 week from onset) of their disease. This information needs to be confirmed in a larger cohort of patients. If reproduced, our results suggest that nontraumatic IH patients are at high risk of inadequate nutrition if their metabolic rate is estimated after conventional nutrition practice.	Detroit Receiving Hosp & Univ Hlth Ctr, Dept Nutr, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA		Carhuapoma, JR (corresponding author), Johns Hopkins Univ Hosp, Div Neurosci Crit Care, 600 N Wolfe St,Meyer 8-140, Baltimore, MD 21287 USA.	jcarhua1@jhmi.edu	Carhuapoma, Juan/AAC-5279-2019; Carhuapoma, Juan/X-9195-2018	Carhuapoma, Juan/0000-0002-5868-7701; 			Blackburn G L, 1977, JPEN J Parenter Enteral Nutr, V1, P11, DOI 10.1177/014860717700100111; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chalela JA, 2004, NEUROCRIT CARE, V1, P331, DOI 10.1385/NCC:1:3:331; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; DAVERAT P, 1991, STROKE, V22, P1, DOI 10.1161/01.STR.22.1.1; Frankenfield DC, 1998, J AM DIET ASSOC, V98, P439, DOI 10.1016/S0002-8223(98)00100-X; Kasuya H, 1998, NEUROSURGERY, V42, P1268, DOI 10.1097/00006123-199806000-00038; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; McClave SA, 2003, JPEN-PARENTER ENTER, V27, P16, DOI 10.1177/014860710302700116; McClave SA, 2001, J CLIN GASTROENTEROL, V33, P14, DOI 10.1097/00004836-200107000-00005; McClave SA, 1998, JPEN-PARENTER ENTER, V22, P375, DOI 10.1177/0148607198022006375; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Rhoney DH, 2002, NEUROL RES, V24, P613, DOI 10.1179/016164102101200456; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; Silva Y, 2005, STROKE, V36, P86, DOI 10.1161/01.STR.0000149615.51204.0b; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363	22	33	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-6071	1941-2444		JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	MAR-APR	2006	30	2					71	75		10.1177/014860710603000271			5	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Nutrition & Dietetics	195WT	WOS:000248443700001	16517949				2022-02-06	
J	Pleacher, MD; Dexter, WW				Pleacher, MD; Dexter, WW			Concussion management by primary care providers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS; GUIDELINES; PERFORMANCE	Objective: To assess current concussion management practices of primary care providers. Methods: An 11 item questionnaire was mailed to primary care providers in the state of Maine, with serial mailings to non-respondents. Results: Over 50% of the questionnaires were completed, with nearly 70% of primary care providers indicating that they routinely use published guidelines as a tool in managing patients with concussion. Nearly two thirds of providers were aware that neuropsychological tests could be used, but only 16% had access to such tests within a week of injury. Conclusions: Primary care providers are using published concussion management guidelines with high frequency, but many are unable to access neuropsychological testing when it is required.	Maine Med Ctr, Portland, ME 04102 USA		Pleacher, MD (corresponding author), Maine Med Ctr, Portland, ME 04102 USA.	pleacherm@hotmail.com					Barth JT, 1989, MILD HEAD INJURY, P257; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; *CONC SPORT GROUP, 2002, PHYSICIAN SPORTSMED, V30, P57; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	16	33	33	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2006	40	1							e2	10.1136/bjsm.2005.019067			2	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	995YG	WOS:000234140600022	16371479	Green Published, Bronze			2022-02-06	
J	Zhang, ZR; Artelt, M; Bernet, M; Trautmann, K; Schluesener, HJ				Zhang, ZR; Artelt, M; Bernet, M; Trautmann, K; Schluesener, HJ			Lesional accumulation of P2X(4) receptor(+) monocytes following experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						P2X(4) receptor; traumatic brain injury; microglia/macrophages	SPINAL MICROGLIA; UP-REGULATION; CELL-DEATH; ATP; ACTIVATION; MACROPHAGES; MECHANISMS; EXPRESSION; STRIATUM; RELEASE	P2X(4) receptor (P2X(4)R) is an ATP-gated ion channel. ATP is an important messenger in traumatic brain injury. Here, we report expression of P2X(4)R in rat traumatic brain injury with focus on the early phase, most amenable to therapy. Accumulation of P2X(4)R(+) cells was observed as early as 6 h after injury and continued to increase 4 days post-injury at the lesion and remote areas. Double staining revealed that most P2X(4)R(+) cells coexpressed ED-1, a marker for reactive microglia/macrophages, but not nestin or W3/13. Our data suggest that P2X(4)R expression defines a Subtype of activated microglia/macrophages involved in the early processes following traumatic brain injury. (c) 2005 Elsevier Inc. All rights reserved.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Synovo GmbH, D-72076 Tubingen, Germany		Zhang, ZR (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	zhangzhiren@yahoo.com	zhang, zhiren/I-1046-2014; Zhang, Zhiren/O-1012-2019	zhang, zhiren/0000-0002-5238-2835; Zhang, Zhiren/0000-0002-5238-2835			BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Braun N, 1998, J NEUROSCI, V18, P4891; Brough D, 2002, MOL CELL NEUROSCI, V19, P272, DOI 10.1006/mcne.2001.1054; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Burnstock G, 2003, CURR TOP MEMBR, V54, P307, DOI 10.1016/S1063-5823(03)01010-X; BURNSTOCK G, 2004, INT REV CYTOL, V240, P304; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; EDWARDS FA, 1993, FEBS LETT, V325, P86, DOI 10.1016/0014-5793(93)81419-Z; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Gendron FP, 2003, J NEUROCHEM, V87, P344, DOI 10.1046/j.1471-4159.2003.01995.x; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; GREGERSEN R, 2002, J CEREB BLOOD FLOW M, V20, P53; Guo LH, 2005, NEUROSCIENCE, V134, P199, DOI 10.1016/j.neuroscience.2005.04.026; Guo LH, 2005, J NEUROIMMUNOL, V163, P120, DOI 10.1016/j.jneuroim.2005.03.007; Guo LH, 2004, J NEUROIMMUNOL, V152, P67, DOI 10.1016/j.jneuroim.2004.04.005; Kennedy C, 2000, J AUTONOM NERV SYST, V81, P158, DOI 10.1016/S0165-1838(00)00133-8; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Lehrmann E, 1997, J COMP NEUROL, V386, P461; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nieber K, 1999, PROG BRAIN RES, V120, P287; Norenberg W, 1999, PROG BRAIN RES, V120, P209; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Rothermel Annette L., 2004, BMC Immunology, V5, P1; Ryu JK, 2002, NEUROREPORT, V13, P1611, DOI 10.1097/00001756-200209160-00008; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; Yamamoto K, 2000, AM J PHYSIOL-HEART C, V279, pH285, DOI 10.1152/ajpheart.2000.279.1.H285; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	38	33	35	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2006	197	1					252	257		10.1016/j.expneurol.2005.09.015			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	001LI	WOS:000234534200026	16259982				2022-02-06	
J	Hayashi, Y; Shumsky, JS; Connors, T; Otsuka, T; Fischer, I; Tessler, A; Murray, M				Hayashi, Y; Shumsky, JS; Connors, T; Otsuka, T; Fischer, I; Tessler, A; Murray, M			Immunosuppression with either cyclosporine A or FK506 supports survival of transplanted fibroblasts and promotes growth of host axons into the transplant after spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						allograft survival; axonal growth; cyclosporine A; FK506; immunophilin ligands; spinal cord injury; transplantation	TRAUMATIC BRAIN-INJURY; BDNF-PRODUCING FIBROBLASTS; IMMUNOPHILIN LIGAND FK506; RAT SCIATIC-NERVE; ADULT RATS; FUNCTIONAL RECOVERY; LIPID-PEROXIDATION; IMMUNE SUPPRESSION; SCHWANN-CELLS; IN-VIVO	Fibroblasts that have been genetically modified to secrete neurotrophins can stimulate axonal regeneration, rescue injured neurons, and improve function when grafted into a spinal cord injury site. These grafts are usually allografts that require immunosuppression to prevent rejection. In this study, we compared the effects of two immunophilin-ligands (cyclosporine A [CsA] and FK506) that are used clinically to prevent transplant rejection on protection of grafted fibroblasts. As there are risks associated with prolonged immunosuppression, we compared the effects of 2 or 8 weeks of administration of these drugs, in combination with our standard methylprednisolone protocol, in animals that survived for 8 weeks, to determine whether a shorter course of immunosuppression would be effective. Outcome measures included fibroblast survival, infiltration of activated macrophages and microglia into the graft, final lesion size, and growth of host axons into the graft. The graft consisted of a Vitrogen matrix into which fibroblasts were suspended; the graft was placed into a C3/C4 lateral funiculus lesion. The fibroblasts were isolated from a transgenic strain of Fischer rats that produce the marker alkaline phosphatase (Fb/AP). This enabled us to track the grafted fibroblasts and to evaluate the extent of their survival. The grafted matrix filled the lesion cavity. The density of fibroblasts within the matrix differed according to treatment. Fibroblast survival was most robust in animals that received 8 weeks of immunophilin-ligand treatment. FK506 supported greater Fb/AP survival than CsA. ED-1 immunostaining for activated microglia and macrophages showed an inverse correlation between AP immunoreactivity and the density of immune cells within the graft. Thus, prolonged administration of either FK506 or CsA was necessary for maximal fibroblast survival and for limiting the macrophage invasion of the graft. None of the FK506 or CsA protocols modified the size of the lesion, indicating that these immunophilin-ligands had little effect on secondary enlargement of the lesion and therefore little neuroprotective effect. Because immunophilin-ligands have been shown to be neurotrophic, we used RT-97 immunostaining for neurofilaments and calcitonin gene related protein (CGRP) staining for dorsal root axons to visualize axons that grew into the graft. Some axons grew into the matrix even in the absence of immunophilin-ligand treatment, suggesting that the Vitrogen matrix itself is permissive, but all of the immunophilin-ligand protocols were much more effective in eliciting axonal growth. Growth of axons into the transplants was equally increased by drug treatment for 2 or 8 weeks. Thus, both treatments improved fibroblast survival, diminished immune cell invasion, and promoted axonal growth, and a 2-week course of treatment with either immunophilin-ligand was as effective as 8 weeks in stimulating axonal growth.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; Nagoya City Univ, Sch Med, Dept Orthoped Surg, Nagoya, Aichi 467, Japan; Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA		Murray, M (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 299 Queen Lane, Philadelphia, PA 19129 USA.	mm72@drexel.edu	Fischer, Itzhak/D-1080-2012	Fischer, Itzhak/0000-0003-3187-8740	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS024707, P01NS024707] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24707] Funding Source: Medline		ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FINBERG R, 2004, INFECT TRANSPLANT RE; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; Hadley MN, 2002, NEUROSURGERY, V50, pS63; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Ibarra A, 2003, BRAIN RES, V979, P165, DOI 10.1016/S0006-8993(03)02898-1; Ibarra A, 1996, J NEUROTRAUM, V13, P569, DOI 10.1089/neu.1996.13.569; Jost SC, 2000, RESTOR NEUROL NEUROS, V17, P39; Katsube K, 1998, TRANSPLANTATION, V66, P772, DOI 10.1097/00007890-199809270-00012; Kaymaz M, 2005, SPINAL CORD, V43, P22, DOI 10.1038/sj.sc.3101621; Kim D, 2001, NEUROREHAB NEURAL RE, V15, P141, DOI 10.1177/154596830101500207; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Lee M, 2000, MUSCLE NERVE, V23, P633, DOI 10.1002/(SICI)1097-4598(200004)23:4<633::AID-MUS24>3.0.CO;2-Q; Liu Y, 1999, J NEUROSCI, V19, P4370; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Mabon PJ, 1999, J NEUROVIROL, V5, P268, DOI 10.3109/13550289909015813; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; MCCARTHY PW, 1990, NEUROSCIENCE, V34, P623, DOI 10.1016/0306-4522(90)90169-5; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Pan YA, 2003, J NEUROSCI, V23, P11479; Pearse DD, 2004, J NEUROTRAUM, V21, P1223, DOI 10.1089/0897715041953876; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Rosenstiel P, 2003, J NEUROTRAUM, V20, P297, DOI 10.1089/089771503321532888; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Springer JE, 2000, J NEUROSCI, V20, P7246; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Sugawara T, 1999, NEUROREPORT, V10, P3949, DOI 10.1097/00001756-199912160-00041; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; Tanaka KI, 2003, BRAIN RES, V970, P250, DOI 10.1016/S0006-8993(03)02434-X; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Teichner A, 1993, J Hirnforsch, V34, P343; Tobias CA, 2001, J NEUROTRAUM, V18, P287, DOI 10.1089/08977150151070937; Tobias CA, 2005, J NEUROTRAUM, V22, P138, DOI 10.1089/neu.2005.22.138; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Udina E, 2004, GLIA, V47, P120, DOI 10.1002/glia.20025; Udina E, 2004, MUSCLE NERVE, V29, P812, DOI 10.1002/mus.20029; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang M S, 1999, J Spinal Cord Med, V22, P287; Wang MS, 1997, J PHARMACOL EXP THER, V282, P1084; Winter C, 2000, NEUROSCIENCE, V95, P753	55	33	39	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2005	22	11					1267	1281		10.1089/neu.2005.22.1267			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	989OI	WOS:000233683000001	16305315				2022-02-06	
J	Messori, A; Polonara, G; Carle, F; Gesuita, R; Salvolini, U				Messori, A; Polonara, G; Carle, F; Gesuita, R; Salvolini, U			Predicting posttraumatic epilepsy with MRI: Prospective longitudinal morphologic study in adults	EPILEPSIA			English	Article						posttraumatic epilepsy; brain MRI; hemosiderin; gliosis	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; HEAD-INJURY; SEIZURES; FEATURES; MODEL	Purpose: Evaluation of morphologic risk factors for posttraumatic epilepsy (PTE) by using brain magnetic resonance imaging (MRI) in serial assessments <= 2 years after traumatic brain injury (TBI). Methods: Brain MRI hyperintense (gliosis) or hypointense (hemosiderin) areas or both were assessed in the images of 135 adult TBI inpatients who completed a 2-year clinical, EEG, and MRI study protocol. Overall clinical follow-up for the development of PTE was 5-10 years (median, 102 months). Morphologic risk factors for PTE were evaluated by using Kaplan-Meier curves and Cox regression analysis. Results: In 20 patients, PTE developed. Kaplan-Meier curves showed that gliomesenchymal sequelae of focal brain lesions (subdural hematomas/contusions) that required surgical treatment (sSDH-C) were a PTE risk factor (p < 0.001), as were sequelae of nonsurgical hemorrhagic contusions with gliosis wall incompletely surrounding hemosiderin dregs (IW) (p = 0.039) and mainly those with time-related changes from incomplete to complete gliosis wall around hemosiderin (I/CW) (p = 0.005); those with early hemosiderin completely surrounded by gliosis (CW) were not (p = 0.821). Cox regression analysis showed that for patients with sequelae of sSDH-C, the PTE risk was 4.38 (p = 0.023) times higher than for those who did not require surgical treatment or underwent surgery because of purely extradural hematoma; for those with IW and I/CW lesions, considered pooled, it was 6.61 times higher (p = 0.014) than for those with CW lesions. Conclusions: MRI follow-up examination in the early chronic stage can differentiate among low-, intermediate-, and high-risk sequelae of TBI. These findings yield new evidence for, but do not resolve, the debate on posttraumatic epileptogenesis.	Univ Hosp Umberto 1, Dept Neuroradiol, I-60020 Ancona, Italy; Univ Ancona, Dept Epidemiol & Biostat, Ancona, Italy		Salvolini, U (corresponding author), Univ Hosp Umberto 1, Dept Neuroradiol, Via Conca Torrette, I-60020 Ancona, Italy.	u.salvolini@univpm.it	Messori, Andrea/U-6903-2019; Gesuita, Rosaria/AAU-8863-2020	POLONARA, GABRIELE/0000-0002-2866-2749			Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COX DR, 1972, J R STAT SOC B, V34, P187; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DALESSANDRO R, 1983, ARCH NEUROL-CHICAGO, V40, P831, DOI 10.1001/archneur.1983.04050120081022; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; JACKSON GD, 1993, AM J NEURORADIOL, V14, P753; Jacobs KM, 2000, EPILEPSIA, V41, pS153, DOI 10.1111/j.1528-1157.2000.tb01574.x; JENNETT B, 1975, EPILEPSY NONMISSILE; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kumar R, 2003, AM J NEURORADIOL, V24, P218; KUZNIECKI RI, 1995, MAGNETIC RESONANCE E; LEE TE, 1990, STAT METHODS SURVIVA; Leone M, 2002, NEUROL SCI, V23, P99, DOI 10.1007/s100720200034; Lowenstein D, 2001, ANN NEUROL, V50, P696, DOI 10.1002/ana.10090; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; PAGNI CA, 1990, ACT NEUR S, V50, P38; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Samuelsson C, 2003, EPILEPSY RES, V56, P165, DOI 10.1016/j.eplepsyres.2003.09.004; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408	42	33	33	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	SEP	2005	46	9					1472	1481		10.1111/j.1528-1167.2005.34004.x			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	959GV	WOS:000231507100015	16146443	Bronze			2022-02-06	
J	Fritz, HG; Walter, B; Holzmayr, M; Brodhun, M; Patt, S; Bauer, R				Fritz, HG; Walter, B; Holzmayr, M; Brodhun, M; Patt, S; Bauer, R			A pig model with secondary increase of intracranial pressure after severe traumatic brain injury and temporary blood loss	JOURNAL OF NEUROTRAUMA			English	Article						fluid-percussion injury; hemorrhagic hypotension; intracranial pressure; piglets; secondary injury	CEREBRAL PERFUSION-PRESSURE; COLORED MICROSPHERE TECHNIQUE; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; NEWBORN PIGLETS; IMPACT INJURY; AXONAL INJURY; FLOW; METABOLISM; RAT	There is a lack of animal models of traumatic brain injury (TBI) that adequately simulate the long-term changes in intracranial pressure (ICP) increase following clinical TBI. We therefore reproduced the clinical scenario in an animal model of TBI and studied long-term postinjury changes in ICP and indices of brain injury. After induction of anesthesia, juvenile piglets were randomly traumatized using fluid-percussion injury (FPI) to induce either moderate (mTBI = 6 pigs: 3.2 +/- 0.6 atm) or severe (sTBI = 7 pigs: 4.1 +/- 1.0 atm) TBI. Injury was followed by a 30% withdrawal of blood volume. ICP and systemic hemodynamic were monitored continuously. Repeated measurements of global cerebral blood flow (CBF) and cerebral metabolic rate of oxygen (CMRO2) were performed at baseline, at the end of blood withdrawal, after volume replacement, and at 8 and 24 h postinjury. Histological and immunocytochemical studies have also performed. ICP peaked immediately following FPI (mTBI: 33 +/- 16 mm Hg; sTBI: 47 +/- 14 mm Hg, p < 0.05) in both groups. In the sTBI group, we noted a second peak at 5 +/- 1.5 h postinjury. This second ICP peak was accompanied by a 50% reduction in CBF (44 +/- 31 mL center dot min center dot 100 g(-1)) and CMRO2 (2.5 +/- 2.0 mL center dot min center dot 100 g(-1)). Moderate TBI typically resulted in focal pathological change whereas sTBI caused more diffuse change, particularly in terms of the ensuing axonal damage. We thus describe an animal model of severe TBI with a reproducible secondary ICP increase accompanied by patterns of diffuse brain damage. This model may be helpful in the study of pathogenetic relevance of concomitant affections and verify new therapeutic approaches in severe TBI.	Dept Anesthesiol & Intens Care Med, Halle An Der Saale, Germany; Matha Maria Hosp, Halle An Der Saale, Germany; Univ Jena, Univ Klinikum Jena, Dept Neurosurg, D-07740 Jena, Germany; Univ Jena, Univ Klinikum Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany; Univ Jena, Univ Klinikum Jena, Inst Pathol, D-07740 Jena, Germany		Bauer, R (corresponding author), Univ Jena, Inst Pathophysiol & Pathobiochem, D-07740 Jena, Germany.	Reinhard.Bauer@mti.uni-jena.de					Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; Bauer R, 2001, PEDIATR RES, V49, P474, DOI 10.1203/00006450-200104000-00007; Bauer R, 1996, EXP TOXICOL PATHOL, V48, P415; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Buki A, 2000, J NEUROSCI, V20, P2825; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CIRICILLO SF, 1992, J TRAUMA, V33, P899, DOI 10.1097/00005373-199212000-00018; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COYLE MG, 1993, AM J PHYSIOL, V264, pH141, DOI 10.1152/ajpheart.1993.264.1.H141; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Felix B, 1999, BRAIN RES BULL, V49, P1, DOI 10.1016/S0361-9230(99)00012-X; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LEFFLER CW, 1989, AM J PHYSIOL, V257, pH1917, DOI 10.1152/ajpheart.1989.257.6.H1917; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; Lundberg N., 1960, ACTA PSYCHIAT NEUROL, V149, P158; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Marmarou A, 1990, Adv Neurol, V52, P233; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P827, DOI 10.1111/j.1399-6576.1995.tb04179.x; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POWNALL R, 1973, BRIT VET J, V129, P583, DOI 10.1016/S0007-1935(17)36340-6; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Walter B, 1997, BASIC RES CARDIOL, V92, P191, DOI 10.1007/s003950050037; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784	50	33	33	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					807	821		10.1089/neu.2005.22.807			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800008	16004583				2022-02-06	
J	Kotchoubey, B				Kotchoubey, B			Apallic syndrome is not apallic: Is vegetative state vegetative?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the International-Neuropsychological-Society/German-Society-for-Neuropsychology	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc, German Soc Neuropsychol			EVENT-RELATED POTENTIALS; CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; LOCKED-IN SYNDROME; MISMATCH NEGATIVITY; EVOKED-POTENTIALS; TEMPORAL-LOBE; GLUCOSE-METABOLISM; NOVELTY DETECTION; DEVIANT STIMULI	Initial conceptualisation about the nature of vegetative state (VS) assumed at least temporary loss of the entire cortical functioning. Since a broad range of stimulus-related cortical activations was demonstrated in VS patients, this simplified idea is not tenable any longer, but no alternative concept emerges instead. Two recent hypotheses, empirically testable and well grounded, could fill this vacuum: (1) In VS, isolated cortical areas may work, but their integration into a distributed network is lacking. (2) In VS, complex stimulus processing is limited to primary sensory and motor areas; the co-ordination between them and the secondary and tertiary areas is lacking. To test these hypotheses, we estimated the frequency of occurrence of late event-related potential components P3 and N400, presumably indicating activity of complex distributed networks including high-level sensory and associative areas. Both components occurred in VS with above-chance frequencies, but less frequently than in two control groups. Besides these frequent normal brain activations, some VS patients exhibit highly significant but abnormal activations, whose functional meaning remains unclear. A methodological analysis leads to the conclusion that any neurophysiological assessment of VS patients is biased toward under-, rather than over-estimation, of their remaining information processing abilities.	Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72074 Tubingen, Germany		Kotchoubey, B (corresponding author), Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Gartenstr 29, D-72074 Tubingen, Germany.	boris.kotchoubey@uni-tuebingen.de					Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; AGARDH CD, 1983, ANN NEUROL, V14, P482, DOI 10.1002/ana.410140414; Agresti A., 1992, STAT SCI, V7, P131, DOI [DOI 10.1214/SS/1177011454, https://doi.org/10.1214/ss/1177011454]; Alkire MT, 2004, ANESTHESIOLOGY, V100, P939, DOI 10.1097/00000542-200404000-00026; Anderer P, 1998, NEUROPSYCHOBIOLOGY, V37, P20, DOI 10.1159/000026472; ARCENI S, 1981, ACTA NEUROCHIRURGIAE, V59, P45; Atienza M, 2001, CLIN NEUROPHYSIOL, V112, P2031, DOI 10.1016/S1388-2457(01)00650-2; BENTIN S, 1993, PSYCHOPHYSIOLOGY, V30, P161, DOI 10.1111/j.1469-8986.1993.tb01729.x; Bingel U, 2003, NEUROIMAGE, V18, P740, DOI 10.1016/S1053-8119(02)00033-2; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bostanov V, 2004, IEEE T BIO-MED ENG, V51, P1057, DOI 10.1109/TBME.2004.826702; Bostanov V, 2004, PSYCHOPHYSIOLOGY, V41, P259, DOI 10.1111/j.1469-8986.2003.00142.x; Casey K L, 2000, Prog Brain Res, V129, P277; Coghill RC, 2003, P NATL ACAD SCI USA, V100, P8538, DOI 10.1073/pnas.1430684100; COLES MGH, 1990, TUTORIALS PSYCHOPHYS, P413; deJong BM, 1997, CLIN NEUROL NEUROSUR, V99, P213, DOI 10.1016/S0303-8467(97)00024-3; DEVOLDER AG, 1990, ARCH NEUROL-CHICAGO, V47, P197, DOI 10.1001/archneur.1990.00530020103022; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; FALK RH, 1990, POSTGRAD MED J, V66, P384, DOI 10.1136/pgmj.66.775.384; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Garcia-Larrea L, 2003, NEUROPHYSIOL CLIN, V33, P279, DOI 10.1016/j.neucli.2003.10.008; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Halgren E, 2002, NEUROIMAGE, V17, P1101, DOI 10.1006/nimg.2002.1268; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P229, DOI 10.1016/0013-4694(95)98475-N; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B., 2002, VEGETATIVE STATE; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; KANEKO S, 2000, KINO ZAIRYO, V3, P5; Kiehl KA, 2002, NEUROIMAGE, V17, P842, DOI 10.1006/nimg.2002.1244; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Klein M, 1997, Eur J Pain, V1, P165, DOI 10.1016/S1090-3801(97)90075-6; Knight RT, 1998, J CLIN NEUROPHYSIOL, V15, P3, DOI 10.1097/00004691-199801000-00003; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; Kotchoubey B, 2003, J NEUROL, V250, P1121, DOI 10.1007/s00415-003-0132-2; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2003, NEUROPHYSIOL CLIN, V33, P23, DOI 10.1016/S0987-7053(03)00003-0; Kotchoubey B, 2001, NEUROSCI LETT, V301, P37, DOI 10.1016/S0304-3940(01)01600-7; Kretschmer E, 1940, Z GESAMTE NEUROL PSY, V169, P576, DOI 10.1007/BF02871384; Kuperberg GR, 2003, J COGNITIVE NEUROSCI, V15, P272, DOI 10.1162/089892903321208204; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Kutas M, 1997, PSYCHOPHYSIOLOGY, V34, P383, DOI 10.1111/j.1469-8986.1997.tb02382.x; Lakatos I., 1976, PROOFS REFUTATIONS; Laureys S, 2002, ACTA NEUROL BELG, V102, P176; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Llinas R, 1998, PHILOS T ROY SOC B, V353, P1841, DOI 10.1098/rstb.1998.0336; Loewy DH, 2000, CLIN NEUROPHYSIOL, V111, P863, DOI 10.1016/S1388-2457(00)00256-X; Lotze M, 2001, BRAIN, V124, P2268, DOI 10.1093/brain/124.11.2268; Makela AM, 2001, NEUROREPORT, V12, P249; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; MOLNAR M, 1994, INT J PSYCHOPHYSIOL, V17, P129, DOI 10.1016/0167-8760(94)90028-0; Mutschler V, 1996, NEUROPHYSIOL CLIN, V26, P158, DOI 10.1016/0987-7053(96)89626-2; Naatanen R, 2000, INT J PSYCHOPHYSIOL, V37, P3, DOI 10.1016/S0167-8760(00)00091-X; Neumann N, 2004, BRAIN RES PROTOC, V14, P25, DOI 10.1016/j.brainresprot.2004.09.001; Niddam DM, 2002, NEUROIMAGE, V17, P1437, DOI 10.1006/nimg.2002.1270; Onofrj M, 1997, J NEUROL NEUROSUR PS, V63, P759, DOI 10.1136/jnnp.63.6.759; Onofrj M, 1996, COGNITIVE BRAIN RES, V4, P95; ORE GD, 1987, APALLIC SYNDROME; Owen AM, 2002, NEUROCASE, V8, P394, DOI 10.1076/neur.8.4.394.16184; Perrin F, 2002, NEUROREPORT, V13, P1345, DOI 10.1097/00001756-200207190-00026; Perrin F, 2000, NEUROREPORT, V11, P1637, DOI 10.1097/00001756-200006050-00008; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Peyron R, 2002, NEUROIMAGE, V17, P1336, DOI 10.1006/nimg.2002.1315; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; PLATT JR, 1964, SCIENCE, V146, P347, DOI 10.1126/science.146.3642.347; Plum F, 1998, PHILOS T ROY SOC B, V353, P1929, DOI 10.1098/rstb.1998.0345; POLICH J, 1993, ELECTROEN CLIN NEURO, V86, P408, DOI 10.1016/0013-4694(93)90136-J; POLICH J, 1991, American Journal of EEG Technology, V31, P201; Polich J, 2003, BRAIN TOPOGR, V15, P141, DOI 10.1023/A:1022637732495; Popper K, 2014, CONJECTURES REFUTATI; Portas CM, 2000, NEURON, V28, P991, DOI 10.1016/S0896-6273(00)00169-0; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; PUCE A, 1991, EPILEPSIA, V32, P629, DOI 10.1111/j.1528-1157.1991.tb04701.x; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Rossell SL, 2003, NEUROPSYCHOLOGIA, V41, P550, DOI 10.1016/S0028-3932(02)00181-1; Rudolf J, 1999, J NEUROSURG ANESTH, V11, P17, DOI 10.1097/00008506-199901000-00004; Rudolf J, 2000, FORTSCHR NEUROL PSYC, V68, P344, DOI 10.1055/s-2000-11800; SALISBURY D, 1993, J SLEEP RES, V2, P232, DOI 10.1111/j.1365-2869.1993.tb00094.x; Sallinen M, 1997, ELECTROEN CLIN NEURO, V102, P363, DOI 10.1016/S0013-4694(96)96614-6; SAZBON L, 1990, J NEUROL NEUROSUR PS, V56, P407; SCHEFFERS MK, 1991, PSYCHOPHYSIOLOGY, V28, P274, DOI 10.1111/j.1469-8986.1991.tb02194.x; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Shah MK, 2004, BRAIN INJURY, V18, P111, DOI 10.1080/0269905031000149551; Signorino M, 1997, J PSYCHOPHYSIOL, V11, P59; Spencer KM, 2001, PSYCHOPHYSIOLOGY, V38, P343, DOI 10.1017/S0048577201000324; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P409, DOI 10.1017/S0048577299981180; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; Tarkka IM, 1998, BRAIN TOPOGR, V11, P141, DOI 10.1023/A:1022258606418; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Tononi G, 2000, BRAIN RES REV, V31, P391, DOI 10.1016/S0165-0173(99)00056-9; VANPETTEN C, 1995, PSYCHOPHYSIOLOGY, V32, P511; VERLEGER R, 1994, PSYCHOPHYSIOLOGY, V31, P359, DOI 10.1111/j.1469-8986.1994.tb02444.x; Walter GF, 1999, CRIT REV NEUROSURG, V9, P367, DOI 10.1007/s003290050157; WINTER O, 1995, EVOKED POTENTIAL, V96, P398, DOI 10.1016/0168-5597(95)00030-V; Witzke W, 1996, NEUROL REHAB, V2, P68; YAMAGUCHI S, 1991, J NEUROSCI, V11, P2039; Ypparila H, 2002, CLIN NEUROPHYSIOL, V113, P1357, DOI 10.1016/S1388-2457(02)00158-X; Zhang WT, 2003, BRAIN RES, V982, P168, DOI 10.1016/S0006-8993(03)02983-4	111	33	34	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					333	356		10.1080/09602010443000416			24	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900020	16350976				2022-02-06	
J	Larner, SF; McKinsey, DM; Hayes, RL; Wang, KKW				Larner, SF; McKinsey, DM; Hayes, RL; Wang, KKW			Caspase 7: increased expression and activation after traumatic brain injury in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; caspase; caspase 7; cell death; traumatic brain injury	ENDOPLASMIC-RETICULUM STRESS; CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; NERVOUS-SYSTEM; NEURONAL DEATH; SPECTRIN BREAKDOWN; PROTEASE FAMILIES; CONVERTING-ENZYME; ALPHA-SPECTRIN; PC12 CELLS	Caspases, a cysteine proteinase family, are required for the initiation and execution phases of apoptosis. It has been suggested that caspase 7, an apoptosis executioner implicated in cell death proteolysis, is redundant to the main executioner caspase 3 and it is generally believed that it is not present in the brain or present in only minute amounts with highly restricted activity. Here we report evidence that caspase 7 is up-regulated and activated after traumatic brain injury (TBI) in rats. TBI disrupts homeostasis resulting in pathological apoptotic activation. After controlled cortical impact TBI of adult male rats we observed, by semiquantitative real-time PCR, increased mRNA levels within the traumatized cortex and hippocampus peaking in the former about 5 days post-injury and in the latter within 6-24 h of trauma. The activation of caspase 7 protein after TBI, demonstrated by immunoblot by the increase of the active form of caspase 7 peaking 5 days post-injury in the cortex and hippocampus, was found to be up-regulated in both neurons and astrocytes by immunohistochemistry. These findings, the first to document the up-regulation of caspase 7 in the brain after acute brain injury in rats, suggest that caspase 7 activation could contribute to neuronal cell death on a scale not previously recognized.	Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32610 USA		Larner, SF (corresponding author), Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, 100 S Newell Dr,Box 100244, Gainesville, FL 32610 USA.	sflarner@ufl.edu		Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS40182, R01-NS39091] Funding Source: Medline		Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Ethell DW, 2001, BBA-MOL CELL RES, V1541, P231, DOI 10.1016/S0167-4889(01)00159-8; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Henshall DC, 2002, NEUROBIOL DIS, V10, P71, DOI 10.1006/nbdi.2002.0505; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Juan TSC, 1997, GENOMICS, V40, P86, DOI 10.1006/geno.1996.4548; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Korfali N, 2004, J BIOL CHEM, V279, P1030, DOI 10.1074/jbc.M306277200; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Meller R, 2002, NEUROSCI LETT, V324, P33, DOI 10.1016/S0304-3940(02)00166-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pompl PN, 2003, ARCH NEUROL-CHICAGO, V60, P369, DOI 10.1001/archneur.60.3.369; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RAY N, 2002, APOPTOSIS MOL BIOL P, P117; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Repici M, 2003, NEUROSCIENCE, V117, P859, DOI 10.1016/S0306-4522(02)00968-5; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; RINK A, 1995, AM J PATHOL, V147, P1575; Rozen S., 1998, PRIMER3; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soung YH, 2003, ONCOGENE, V22, P8048, DOI 10.1038/sj.onc.1206727; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang Y, 2000, J NEUROSCI, V20, P8384, DOI 10.1523/JNEUROSCI.20-22-08384.2000	56	33	33	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2005	94	1					97	108		10.1111/j.1471-4159.2005.03172.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	934JO	WOS:000229705300010	15953353	Bronze			2022-02-06	
J	German, JW; Hart, BL; Benzel, EC				German, JW; Hart, BL; Benzel, EC			Nonoperative management of vertical C2 body fractures	NEUROSURGERY			English	Article						axis; C2 vertebra; cervical spine; odontoid; spondylolisthesis; trauma	AXIS; CLASSIFICATION	OBJECTIVE: To estimate the incidence and to describe the clinical results of the nonoperative management of vertical C2 body fractures. METHODS: An 8-year retrospective review of upper cervical spine injuries from the registry of a level I trauma center identified 21 patients with a vertical C2 body fracture. RESULTS: Sixteen coronally oriented Type 1 vertical C2 body fractures and 5 sagittally oriented Type 2 vertical C2 body fractures were identified. These fractures account for approximately 10% of the upper cervical spine fractures identified over this period of time. One elderly patient with a Type 1 fracture died as a result of pneumonia, and two patients with Type 2 fractures died from severe closed-head injuries. One patient had evidence of spinal cord injury. This was not related to the C2 body fracture but rather to a subaxial cervical spine injury. Of the surviving 18 patients, all were managed nonoperatively (with external orthoses) and showed evidence of fusion (union of fracture fragments) at the time of the last follow-up. CONCLUSION: Vertical C2 body fractures are not rare injuries and can account for up to 10% of upper cervical spine injuries. In general, vertical C2 body fractures are amenable to nonoperative treatment with external orthoses.	Univ New Mexico, Div Neurosurg, Albuquerque, NM 87131 USA; Cleveland Clin Fdn, Spine Inst, Albuquerque, NM USA; Univ New Mexico, Dept Radiol, Albuquerque, NM 87131 USA		German, JW (corresponding author), Albany Med Coll, Div Neurosurg, 47 New Scotland,MC 61-NE, Albany, NY 12208 USA.	jwgerman@hotmail.com					ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017; BENZEL EC, 1994, J NEUROSURG, V81, P206, DOI 10.3171/jns.1994.81.2.0206; Bohay D, 1992, J Orthop Trauma, V6, P416, DOI 10.1097/00005131-199212000-00004; BURKE JT, 1989, SKELETAL RADIOL, V18, P335, DOI 10.1007/BF00361422; EFFENDI B, 1981, J BONE JOINT SURG BR, V63, P319, DOI 10.1302/0301-620X.63B3.7263741; Fujimura Y, 1996, J ORTHOP TRAUMA, V10, P536, DOI 10.1097/00005131-199611000-00005; Greene KA, 1997, SPINE, V22, P1843, DOI 10.1097/00007632-199708150-00009; Hadley MN, 2002, NEUROSURGERY, V50, pS125; Iizuka H, 2001, SPINE, V26, P2220, DOI 10.1097/00007632-200110150-00013; Korres D S, 1994, Eur Spine J, V3, P151, DOI 10.1007/BF02190577; LEVINE AM, 1985, J BONE JOINT SURG AM, V67A, P217, DOI 10.2106/00004623-198567020-00007; LOZANOREQUENA JA, 1994, INT ORTHOP, V18, P114, DOI 10.1007/BF02484421; MAROTTA TR, 1990, NEUROSURGERY, V26, P848, DOI 10.1227/00006123-199005000-00017; RAINOV NG, 2004, MINIM INVAS NEUROSUR, V41, P93; SMOKER WRK, 1987, AM J ROENTGENOL, V148, P609, DOI 10.2214/ajr.148.3.609; STARR JK, 1993, SPINE, V18, P1954, DOI 10.1097/00007632-199310001-00005; Vialle R, 2004, REV CHIR ORTHOP, V90, P152	17	33	36	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2005	56	3					516	520		10.1227/01.NEU.0000153908.53579.E4			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	905IP	WOS:000227562100033	15730577				2022-02-06	
J	Leblanc, N; Chen, S; Swank, PR; Ewing-Cobbs, L; Barnes, M; Dennis, M; Max, J; Levin, H; Schachar, R				Leblanc, N; Chen, S; Swank, PR; Ewing-Cobbs, L; Barnes, M; Dennis, M; Max, J; Levin, H; Schachar, R			Response inhibition after traumatic brain injury (TBI) in children: Impairment and recovery	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; WORKING-MEMORY; PRESCHOOL-CHILDREN; LIFE-SPAN; MILD; SEVERITY; AGE; CHILDHOOD	Children who experience traumatic brain injury (TBI) often show cognitive impairments postinjury, some of which recover over time. We examined the recovery of motor response inhibition immediately following TBI and over 2 years. We assessed the role of injury severity, age at injury, and lesion characteristics on initial impairment and recovery while considering the role of pre-injury psychiatric disorder. Participants were 136 children with TBI aged 5-16 years. Latency of motor response inhibition was measured with the stop-signal task within 1 month of the injury and again at 3, 6, 12, and 24 months. The performance of the TBI participants at each measurement occasion was standardized with 117 children of similar age, but without injury. Residualized latency scores were calculated. Growth curve analyses showed an initial impairment in response inhibition and improvement over the 2 years following injury. Younger TBI patients were initially more impaired although they exhibited greater recovery of response inhibition than did older TBI patients. Longer duration of coma, but not reactivity of pupils or Glasgow Coma Scale score, predicted initial deficit. Lesion characteristics or pre-injury attention deficit hyperactivity disorder did not predict initial impairment or recovery. Replication with longitudinal testing of a comparison group of children sustaining extracranial injury is necessary to confirm our findings.	Univ Toronto, Hosp Sick Children, Dept Psychiat, Brain & Behav Programme, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Univ Toronto, Hosp Sick Children, Dept Psychol, Brain & Behav Program, Toronto, ON M5G 1X8, Canada; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA		Schachar, R (corresponding author), Univ Toronto, Hosp Sick Children, Dept Psychiat, Brain & Behav Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	russell.schachar@sickkids.ca		Schachar, Russell/0000-0002-2015-4395; Leblanc, Nancy/0000-0002-7403-3441	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2000, BRAIN INJURY, V14, P679; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Bakker K, 1999, Pediatr Rehabil, V3, P149; Band GPH, 2000, J EXP CHILD PSYCHOL, V75, P263, DOI 10.1006/jecp.1999.2538; Band GPH, 1999, ACTA PSYCHOL, V101, P179, DOI 10.1016/S0001-6918(99)00005-0; Bedard AC, 2002, DEV NEUROPSYCHOL, V21, P93, DOI 10.1207/S15326942DN2101_5; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Duval J, 2002, BRAIN COGNITION, V48, P337, DOI 10.1006/brcg.2001.1373; ERIKSEN CW, 1979, PERCEPT PSYCHOPHYS, V25, P249, DOI 10.3758/BF03198804; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Houghton George, 1994, P53; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jennings JR, 1997, DEV PSYCHOL, V33, P308, DOI 10.1037/0012-1649.33.2.308; JENNINGS JR, 1992, J EXP PSYCHOL HUMAN, V18, P422, DOI 10.1037/0096-1523.18.2.422; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; KINDLON D, 1995, J CHILD PSYCHOL PSYC, V36, P645, DOI 10.1111/j.1469-7610.1995.tb01316.x; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kolb Bryan, 2003, Phys Med Rehabil Clin N Am, V14, pS7, DOI 10.1016/S1047-9651(02)00056-6; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan Gordon D., 1994, P189; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Moses P, 2002, DEV PSYCHOBIOL, V40, P266, DOI 10.1002/dev.10031; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; OSMAN A, 1986, J EXP PSYCHOL HUMAN, V12, P243, DOI 10.1037/0096-1523.12.3.243; Pascual-Leone J, 2000, J EXP CHILD PSYCHOL, V77, P138, DOI 10.1006/jecp.2000.2593; Perner J, 2002, CHILD DEV, V73, P752, DOI 10.1111/1467-8624.00436; RAUDENBUSH SW, 2000, HLM 5 HIERARCHICAL L; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rubia K, 2001, BRIT J PSYCHIAT, V179, P138, DOI 10.1192/bjp.179.2.138; Russell J., 1998, AUTISM EXECUTIVE DIS, P256; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Sosin DM, 1996, BRAIN INJURY, V10, P47; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; TEASDALE G, 1974, LANCET, V2, P81; Temple CM, 1997, J CHILD PSYCHOL PSYC, V38, P27, DOI 10.1111/j.1469-7610.1997.tb01504.x; Thompson Matthew D, 2003, Semin Pediatr Neurol, V10, P130, DOI 10.1016/S1071-9091(03)00021-4; Tranel D, 2000, DEV NEUROPSYCHOL, V18, P273, DOI 10.1207/S1532694201Tranel; Vicari S, 2000, CORTEX, V36, P31, DOI 10.1016/S0010-9452(08)70834-7; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; [No title captured]; [No title captured]	79	33	33	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2005	28	3					829	848		10.1207/s15326942dn2803_5			20	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	987UC	WOS:000233541800005	16266251				2022-02-06	
J	Dow, C; Seidenberg, M; Hermann, B				Dow, C; Seidenberg, M; Hermann, B			Relationship between information processing speed in temporal lobe epilepsy and white matter volume	EPILEPSY & BEHAVIOR			English	Article						temporal lobe epilepsy; magnetic resonance volumetrics; white matter; Sternberg task	WORKING-MEMORY; ABNORMALITIES; MRI	Abnormalities in white matter have been linked to processing speed impairment in clinical populations (e.g., multiple sclerosis, closed head injury). Recent studies indicate the presence of significant reduction in cerebral white matter volume in some patients with chronic temporal lobe epilepsy (TLE). The objective of this study was to examine the relationship between white matter volume and processing speed and performance efficiency on the Sternberg Memory Scanning Test (SMST). The study groups included TLE subjects with white matter volume reduction (n = 13), TLE subjects with normal white matter volume (n = 14), and healthy controls (n = 18). The groups did not differ in total cerebral gray matter volume. Compared with the controls, the reduced white matter volume TLE group exhibited a significantly steeper slope on the SMST. This was characterized by a disproportionate increase in reaction time with increased processing demands (set size), particularly for negative probe trials. In contrast, no significant differences on the SMST were evident between controls and the normal white matter volume TLE group. These findings suggest the presence of information processing speed and efficiency impairment in TLE and its relationship with white matter volume integrity. (C) 2004 Elsevier Inc. All rights reserved.	Rosalind Franklin Univ Sci & Med, Dept Psychol, N Chicago, IL 60064 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA		Seidenberg, M (corresponding author), Rosalind Franklin Univ Sci & Med, Dept Psychol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	michael.seidenberg@rosalindfranklin.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR003186] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1 RR03186] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [2R01-37738] Funding Source: Medline		ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Becker J T, 1995, J Int Neuropsychol Soc, V1, P3; FILLEY CM, 2001, BEHAV NEUROLOGY WHIT; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; GRIPPO A, 1994, BEHAV NEUROL, V7, P143, DOI 10.3233/BEN-1994-73-406; Gron G, 1996, J CLIN EXP NEUROPSYC, V18, P406, DOI 10.1080/01688639608408997; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Harris G, 1999, J COMPUT ASSIST TOMO, V23, P144, DOI 10.1097/00004728-199901000-00030; Hermann B, 2003, J INT NEUROPSYCH SOC, V9, P353, DOI 10.1017/S1355617703930013; Hermann BP, 1997, ARCH NEUROL-CHICAGO, V54, P369, DOI 10.1001/archneur.1997.00550160019010; Hermann BP, 2002, PROG BRAIN RES, V135, P429; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; Magnotta VA, 1999, RADIOLOGY, V211, P781, DOI 10.1148/radiology.211.3.r99ma07781; Marsh L, 1997, EPILEPSIA, V38, P576, DOI 10.1111/j.1528-1157.1997.tb01143.x; PAULESU E, 1993, NATURE, V331, P68; Pelosi L, 2000, CLIN NEUROPHYSIOL, V111, P1531, DOI 10.1016/S1388-2457(00)00354-0; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; SININGER YS, 1989, J SPEECH HEAR RES, V32, P289, DOI 10.1044/jshr.3202.289; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; STERNBERG S, 1969, AM SCI, V57, P421; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STUSS DT, 1987, J CLIN EXP NEUROPSYC, V9, P131, DOI 10.1080/01688638708405353; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; Verger K, 2001, BRAIN INJURY, V15, P211; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M	28	33	33	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	DEC	2004	5	6					919	925		10.1016/j.yebeh.2004.08.007			7	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	881NL	WOS:000225874100018	15582841				2022-02-06	
J	Oermann, E; Bidmon, HJ; Witte, OW; Zilles, K				Oermann, E; Bidmon, HJ; Witte, OW; Zilles, K			Effects of 1 alpha,25 dihydroxyvitamin D-3 on the expression of HO-1 and GFAP in glial cells of the photothrombotically lesioned cerebral cortex	JOURNAL OF CHEMICAL NEUROANATOMY			English	Article						1.25 dihydroxycholecalciferol; brain; ischemia; heme oxygenase; glial fibrillary acidic proteins; oxidative stress; rat	NITRIC-OXIDE SYNTHASE; FOCAL CORTICAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; HEME OXYGENASE-1 HO-1; NECROSIS-FACTOR-ALPHA; D ENDOCRINE SYSTEM; GROWTH-FACTOR-BETA; NF-KAPPA-B; 1,25-DIHYDROXYVITAMIN D-3	In ischemic cerebral injuries a cascade of degenerative mechanisms, all participating in the development of oxidative stress, influence the condition of the tissue. The survival of viable tissue affected by secondary injury largely depends on the balance between endogenous protective mechanisms and the ongoing degenerative processes. The inducible enzyme, heme oxygenase-1 metabolizes and thus detoxifies free heme to the powerful endogenous antioxidants biliverdin and bilirubin therefore enhancing neuroprotection. The secosteroid 1alpha,25-dihydroxyvitamin D-3 (1,25-D-3) is a modulator of the immune system and also exhibits a strong potential for neuroprotection as recently shown in the MCAO model of cerebral ischemia. We studied the effects of 1,25-D-3 treatment on heme oxygenase-1 expression following focal cortical ischemia elicited by photo-thrombosis. Postlesional treatment with 1,25-D-3 (4 mug/kg body weight) resulted in a transient, but significant upregulation of glial heme oxygenase-1 immunoreactivity concomitant with a reduction in glial fibrillary acidic protein immunoreactivity in remote cortical regions affected by a secondary spread of injury, whereas the size of the lesion's core remained unaffected. 1,25-D-3 did not produce a temporal shift or extension of injury-related heme oxygenase-1 responses, indicating that 1,25-D-3 did not prolong ischemia-related heme oxygenase-1 expression. In contrast to glial heme oxygenase-1 upregulation, glial fibrillary acidic protein, a sensitive marker for reactive gliosis, was significantly reduced. These findings support an additional protective action of 1,25-D-3 at the cellular level in regions affected by secondary injury-related responses. (C) 2004 Elsevier B.V. All rights reserved.	Univ Dusseldorf, C&O Vogt Inst Brain Res, D-40225 Dusseldorf, Germany; Univ Jena, Neurol Clin, D-07743 Jena, Germany; Inst Med, Res Ctr, D-52425 Julich, Germany		Oermann, E (corresponding author), Univ Dusseldorf, C&O Vogt Inst Brain Res, Moorenstr 5, D-40225 Dusseldorf, Germany.	oermann@uni-duesseldorf.de	Zilles, Karl/J-9704-2013; Zilles, Karl/Y-3784-2019; Witte, Otto/P-4127-2018	Zilles, Karl/0000-0001-9296-9959; Zilles, Karl/0000-0002-4705-4175; Witte, Otto/0000-0003-2101-4105			Baas D, 2000, GLIA, V31, P59, DOI 10.1002/(SICI)1098-1136(200007)31:1<59::AID-GLIA60>3.0.CO;2-Y; BAN EM, 1993, NEUROSCIENCE, V52, P725, DOI 10.1016/0306-4522(93)90421-B; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Bidmon HJ, 1998, NEUROSCIENCE, V82, P397; Bidmon HJ, 2001, EXP NEUROL, V168, P1, DOI 10.1006/exnr.2000.7456; Bidmon HJ, 2000, J CHEM NEUROANAT, V20, P163, DOI 10.1016/S0891-0618(00)00081-8; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Buisson A, 2003, CELL MOL NEUROBIOL, V23, P539, DOI 10.1023/A:1025072013107; Calabrese V, 2003, AMINO ACIDS, V25, P437, DOI 10.1007/s00726-003-0048-2; Chen KB, 2003, ANN NY ACAD SCI, V993, P313, DOI 10.1111/j.1749-6632.2003.tb07539.x; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; d'Hellencourt CL, 2003, J NEUROSCI RES, V71, P575, DOI 10.1002/jnr.10491; DERYCK M, 1990, EUR NEUROL, V30, P21; DIETRICH WD, 1987, ACTA NEUROPATHOL, V72, P326, DOI 10.1007/BF00687263; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Elias J, 2003, RECENT RESULTS CANC, V164, P319; FORSTING M, 1994, NEURORADIOLOGY, V36, P264, DOI 10.1007/BF00593255; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Garcion E, 1999, J NEUROCHEM, V73, P859, DOI 10.1046/j.1471-4159.1999.0730859.x; Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1; Garcion E, 2003, ACTA NEUROPATHOL, V105, P438, DOI 10.1007/s00401-002-0663-0; Garcion E, 1997, MOL BRAIN RES, V45, P255, DOI 10.1016/S0169-328X(96)00260-4; Garcion E, 1998, GLIA, V22, P282, DOI 10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Gladilin S, 2000, ARCH BIOCHEM BIOPHYS, V380, P237, DOI 10.1006/abbi.2000.1943; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; Hahn M, 1997, J NEUROCHEM, V69, P102; Hamann GF, 1997, RADIOLOGE, V37, P843, DOI 10.1007/s001170050292; Harant H, 1997, EUR J BIOCHEM, V250, P63, DOI 10.1111/j.1432-1033.1997.00063.x; Hayes CE, 2003, CELL MOL BIOL, V49, P277; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Horvath B, 2003, J CEREBR BLOOD F MET, V23, P653, DOI 10.1097/01.WCB.0000071890.63724.C9; Isenmann S, 1998, BRAIN PATHOL, V8, P49; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Kitamura Y, 1998, GLIA, V22, P138; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Lemire J, 2000, Z RHEUMATOL, V59, P24; Lin AMY, 2003, FREE RADICAL BIO MED, V34, P1416, DOI 10.1016/S0891-5849(03)00105-9; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI [10.1016/S0091-6749(03)01855-4, 10.1037/mai.2003.1703]; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MCAULEY MA, 1995, CEREBROVAS BRAIN MET, V7, P153; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Mennel HD, 2000, EXP TOXICOL PATHOL, V52, P395, DOI 10.1016/S0940-2993(00)80070-6; NEVEU I, 1994, J NEUROSCI RES, V38, P214, DOI 10.1002/jnr.490380212; NEVEU I, 1994, MOL BRAIN RES, V24, P70, DOI 10.1016/0169-328X(94)90119-8; Pettigrew LC, 2003, NEUROL RES, V25, P201; Riachy R, 2002, ENDOCRINOLOGY, V143, P4809, DOI 10.1210/en.2002-220449; RICCHETTI GA, 2004, J LEUKOC BIOL, V7; Rostworowski M, 1997, J NEUROSCI, V17, P3664; SAGGESE G, 1993, ACTA PAEDIATR, V82, P54, DOI 10.1111/j.1651-2227.1993.tb12930.x; Sanchez B, 2002, MOL BRAIN RES, V108, P143, DOI 10.1016/S0169-328X(02)00545-4; Satoh T, 2003, EUR J NEUROSCI, V17, P2249, DOI 10.1046/j.1460-9568.2003.02688.x; Schroeter M, 2002, J NEUROSCI METH, V117, P43, DOI 10.1016/S0165-0270(02)00072-9; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; STUMPF WE, 1995, HISTOCHEM CELL BIOL, V104, P417, DOI 10.1007/BF01464331; Stumpf WE, 2003, DRUG TARGETING DELIV; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Sweeney MI, 1995, CAN J PHYSIOL PHARM, V73, P1525, DOI 10.1139/y95-211; TAOKA T, 1993, MOL CELL ENDOCRINOL, V95, P51, DOI 10.1016/0303-7207(93)90028-I; Timms PM, 2002, QJM-INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wang JY, 2001, BRAIN RES, V904, P67, DOI 10.1016/S0006-8993(01)02450-7; Wang Y, 2000, NEUROPHARMACOLOGY, V39, P873, DOI 10.1016/S0028-3908(99)00255-5; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Witte OW, 2000, J CEREBR BLOOD F MET, V20, P1149, DOI 10.1097/00004647-200008000-00001; Yacobi R, 1996, J ENDOCRINOL, V149, P327, DOI 10.1677/joe.0.1490327; Yu ACH, 2000, NEUROCHEM INT, V36, P369, DOI 10.1016/S0197-0186(99)00145-X; YU XP, 1995, P NATL ACAD SCI USA, V92, P10990, DOI 10.1073/pnas.92.24.10990; Zhai QH, 1997, J NEUROL SCI, V152, P119, DOI 10.1016/S0022-510X(97)00154-8; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x; Zhuang H, 2003, ANN NY ACAD SCI, V993, P208, DOI 10.1111/j.1749-6632.2003.tb07531.x; ZILLES K, 1985, STEREOTAXIC ATLAS; Zittermann A, 2003, BRIT J NUTR, V89, P552, DOI 10.1079/BJN2003837; Zittermann A, 2004, PEDIAT ALLERG IMM-UK, V15, P242, DOI 10.1111/j.1399-3038.2004.00140.x	82	33	35	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0891-0618	1873-6300		J CHEM NEUROANAT	J. Chem. Neuroanat.	DEC	2004	28	4					225	238		10.1016/j.jchemneu.2004.07.003			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	874EW	WOS:000225334700003	15531134				2022-02-06	
J	Dumont, C; Gervais, M; Fougeyrollas, P; Bertrand, R				Dumont, C; Gervais, M; Fougeyrollas, P; Bertrand, R			Toward an explanatory model of social participation for adults with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						determination; fatigue; self-efficacy; social participation; traumatic brain injury	COMMUNITY INTEGRATION; COGNITIVE REHABILITATION; LIFE SATISFACTION; DISABILITY; RESILIENCY; EFFICACY; OUTCOMES; RETURN; WORK; CONSEQUENCES	To identify resiliency factors that could improve social participation for adults with traumatic brain injury. Design: Cross-sectional single measurement, correlational and exploratory study, including quantitative and qualitative data. Participants: Fifty-three community-dwelling people with sequelae of traumatic brain injury, individually interviewed, which included filling out questionnaires and answering open-ended questions. Main Measures: Social participation, self-efficacy, and positive mental states. Results: Dynamism, self-efficacy, and will account for 51% of the variance in social participation and are the main resiliency factors. Fatigue is one of the sequelae that pose the greatest challenge to self-efficacy and limit social participation. Conclusion: Resiliency factors constitute a target for research and intervention for this population.	Univ Laval, Fac Med, Dept Readaptat, Quebec City, PQ G1K 7P4, Canada; Univ Laval, CRIRES, Quebec City, PQ G1K 7P4, Canada		Dumont, C (corresponding author), Univ Laval, Fac Med, Dept Readaptat, Pavillon Ferdinand Vandry, Quebec City, PQ G1K 7P4, Canada.	Claire.Dumont@rea.ulaval.ca					AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; BANDURA A, 2001, IN PRESS GUIDE CONST; Bandura A, 1986, SOCIAL FDN THOUGHT A; Bent N, 2001, CLIN REHABIL, V15, P552, DOI 10.1191/026921501680425270; Bond T, 2001, APPL RASCH MODEL FUN; Bowen A, 1999, NEUROREHABILITATION, V13, P147; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Christensen AL, 1998, J HEAD TRAUMA REHAB, V13, P79, DOI 10.1097/00001199-199810000-00009; Christiansen CH, 1999, AM J OCCUP THER, V53, P547, DOI 10.5014/ajot.53.6.547; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Condeluci A., 1995, INTERDEPENDENCE ROUT; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; CRISP R, 1992, J REHABIL, V58, P27; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DeHope E, 1999, NEUROREHABILITATION, V13, P3; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; DUMONT C, 2001, CAN J OCCUP THER, V68, P239; Dumont Claire, 2003, J Appl Meas, V4, P309; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Fougeyrollas P., 1999, QUEBEC CLASSIFICATIO; FRASER D, 1999, QSRNUD IST VIVO REFE; Fraser MW, 1999, SOC WORK RES, V23, P131, DOI 10.1093/swr/23.3.131; Gillham JE, 1999, BEHAV RES THER, V37, pS163, DOI 10.1016/S0005-7967(99)00055-8; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GUTMAN SA, 2000, OCCUPATIONAL THERAPY, V15, P1; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HELFRICH C, 1994, AM J OCCUP THER, V48, P311, DOI 10.5014/ajot.48.4.311; HINDS P, 1992, QUALITATIVE HLTH RES, V2, P61, DOI DOI 10.1177/104973239200200105; HOWELL DC, 1997, METHODES STAT SCI HU; Huberman AM, 1991, ANAL DONNEES QUALITA; Jerusalem M., 1997, SELF EFFICACY CHANGI, P177; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; KIELHOFNER G, 1996, MODEL HUMAN OCCUPATI; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; KREFTING L, 1991, AM J OCCUP THER, V45, P214, DOI 10.5014/ajot.45.3.214; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levy AJ, 2000, FAM SOC-J CONTEMP H, V81, P402, DOI 10.1606/1044-3894.1083; LINACRE JM, 1999, WINSTEPS BIGSTEPS RA; LUBRUSCO AA, 1994, BRAIN INJURY, V8, P65; Markstrom CA, 2000, J ADOLESCENCE, V23, P693, DOI 10.1006/jado.2000.0353; Marshall C., 1995, DESIGNING QUALITATIV; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Meyerson MD, 2001, CLEFT PALATE-CRAN J, V38, P231, DOI 10.1597/1545-1569(2001)038<0231:RASIAW>2.0.CO;2; Moon DG, 2000, J DRUG EDUC, V30, P373, DOI 10.2190/4AEC-BV03-5KDE-FUMW; Noreau L, 2000, DISABIL REHABIL, V22, P170; NOREAU L, 1996, CANADIAN J REHABILIT, V10, P81; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PAJARES F, 2003, OVERVIEW SOCIAL COGN; Paradiso S, 1999, J NEUROL NEUROSUR PS, V67, P664, DOI 10.1136/jnnp.67.5.664; PEPIN M, 1999, TEST PERSONALITE PER; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Resnick M D, 2000, Adolesc Med, V11, P157; Richards L., 1999, USING NVIVO QUALITAT; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schootman M, 1999, BRAIN INJURY, V13, P995; SCHWARZER R, 1994, PSYCHOL HEALTH, V9, P161, DOI 10.1080/08870449408407475; Schwarzer R., 1992, SELF EFFICACY THOUGH; SHERER M, 1982, PSYCHOL REP, V51, P663, DOI 10.2466/pr0.1982.51.2.663; SHERER M, 1983, PSYCHOL REP, V53, P899, DOI 10.2466/pr0.1983.53.3.899; Sherman SE, 2000, J GEN INTERN MED, V15, P2; SMITH RM, 1997, PHYS MED REHABIL STA, P261; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WARR P, 1978, BRIT J PSYCHOL, V69, P111, DOI 10.1111/j.2044-8295.1978.tb01638.x; WEISS DM, 1999, J COGN REHABIL, V17, P6; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; WOODRUFF SL, 1993, PSYCHOL REP, V72, P423, DOI 10.2466/pr0.1993.72.2.423; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Ylvisaker M., 2003, BRAIN IMPAIR, V4, P1, DOI [DOI 10.1375/brim.4.1.1.27031, https://doi.org/10.1375/brim.4.1.1.27031, DOI 10.1375/BRIM.4.1.1.27031]	80	33	34	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2004	19	6					431	444		10.1097/00001199-200411000-00002			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	873LZ	WOS:000225283100002	15602307				2022-02-06	
J	Krimchansky, BZ; Keren, O; Sazbon, L; Groswasser, Z				Krimchansky, BZ; Keren, O; Sazbon, L; Groswasser, Z			Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment	BRAIN INJURY			English	Article							CONNECTIVITY; AMANTADINE; RECOVERY; SCAN	Objective: The goal of the study was to look for the response of treatment with increasing doses of dopaminergic medication on the recovery of vegetative state patients post-TBI. Design: A prospective study of eight patients aged 25-50 years in vegetative state (VS) of mean duration of 104 days following traumatic brain injury (TBI) was performed by investigating changes of their state of consciousness while they were treated with levodopa/carbidopa. Results: Initial improvement was observed in all patients within a mean of 13 days after onset of treatment. Seven patients recovered consciousness after a mean time of 31 days of treatment. The remaining patient showed only slight improvement to minimally conscious state. The sequence of symptoms leading to recovery was the same in all patients; the first to appear was moving a limb on a request, which appeared at a mean time of 13 days. Gradual increase of dose leads to the appearance of better-organized responses like reacting to more than one command, than opening the mouth and appearance of a reciprocal contact. The orgy side effect was visual hallucinations in one patient, which disappeared after decreasing the dosage. Conclusions: Clinical awareness to the structured order of responses and to the effect of dosage can help clinicians in early assessment of response to dopaminergic treatment in VS patients.	Loewenstein Hosp & Rehabil Ctr, Rehabil Intens Care Unit Comatose Patients, IL-43100 Raanana, Israel; Loewenstein Hosp & Rehabil Ctr, Dept TBI Rehabil, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel		Groswasser, Z (corresponding author), Loewenstein Hosp & Rehabil Ctr, Rehabil Intens Care Unit Comatose Patients, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.	zeevgros@post.tau.ac.il					Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Forsyth R., 2003, COCHRANE DB SYST REV, V1; GOMORI JM, 1984, NEURORADIOLOGY, V26, P21, DOI 10.1007/BF00328197; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; NOLTE J, 1998, HUMAN BRAIN INTRO IT, P171; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rapp B, 2002, NEUROREPORT, V13, P207, DOI 10.1097/00001756-200202110-00007; ReiderGroswasser I, 1997, BRAIN INJURY, V11, P865, DOI 10.1080/026990597122936; STAFFORD JL, 1988, ARCH NEUROL-CHICAGO, V45, P409, DOI 10.1001/archneur.1988.00520280055016; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; Zafonte RD, 1998, BRAIN INJURY, V12, P617	16	33	38	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2004	18	11					1099	1105		10.1080/02699050310001646206			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	863JW	WOS:000224558900003	15545207				2022-02-06	
J	McMillan, TM; Herbert, CM				McMillan, TM; Herbert, CM			Further recovery in a potential treatment withdrawal case 10 years after brain injury	BRAIN INJURY			English	Article							LIFE	A young woman was rendered tetraplegic and anarthric as a result of a traumatic brain injury in 1993. Two years later, she was considered to be in a minimally conscious state and became the subject of legal debate in the UK with regard to withdrawal of artificial feeding and hydration. Before injury, she made a verbal advanced directive that she would not wish to continue living if ever becoming severely disabled. Neuropsychological assessment found statistically significant evidence for sentience and expression of a wish to live and the application to Court was withdrawn. Further meaningful recovery occurred between 7-10 years after injury. She now lives in the community with 24 hour care. She speaks, initiates conversation and actions, expresses clear and consistent preferences and has a spontaneous sense of humour. She uses an electric wheelchair, eats solid food and drinks through a straw. Her mood is variable and sometimes low. This case demonstrates the need for careful consideration of advanced directives and for specialist neuropsychological assessment in people with severe cognitive and communication difficulties. It supports the view that routine assessment and follow-up of people thought to be in minimally conscious states is important. In addition, it shows that recovery with reduction in disability and significant implications for quality of life can continue for at least 10 years after extremely severe traumatic brain injury.	Brain Injury Rehabil Trust, Dept Clin Psychol, Burgess Hill, W Sussex, England		McMillan, TM (corresponding author), Univ Glasgow, Fac Med, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					ANDERSON C, 1993, LANCET, V342, P867, DOI 10.1016/0140-6736(93)92728-C; Andrew K, 1993, NEUROPSYCHOL REHABIL, V3, P109; DYER C, 1993, BRIT MED J, V306, P413; Jennett B., 2002, VEGETATIVE STATE; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; McMillan T, 2003, STUD NEUROPSYCHOL DE, P271; McMillan TM, 1997, BRAIN INJURY, V11, P483, DOI 10.1080/713802184; McMillan TM, 2000, BRAIN INJURY, V14, P197, DOI 10.1080/026990500120853; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; Pickl GB, 2002, FOLIA PHONIATR LOGO, V54, P26, DOI 10.1159/000048594; *ROYAL COLL PHYS, 2003, VEG STAT GUID DIAGN; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; *SCOTT EX, 2000, AD INC SCOTL ACT; Shiel A, 1998, BRAIN INJURY, V12, P809, DOI 10.1080/026990598122043	14	33	35	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2004	18	9					935	940		10.1080/02699050410001675915			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700008	15223745				2022-02-06	
J	Rath, JF; Langenbahn, DM; Simon, D; Sherr, RL; Fletcher, J; Diller, L				Rath, JF; Langenbahn, DM; Simon, D; Sherr, RL; Fletcher, J; Diller, L			The construct of problem solving in higher level neuropsychological assessment and rehabilitation	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	109th Annual Convention of the American-Psychological-Association	AUG 24-28, 2001	SAN FRANCISCO, CA	Amer Psychol Assoc		neuropsychological assessment; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; COMMUNITY INTEGRATION; DEPRESSION; ATTENTION; VALIDITY; DEFICITS; PERFORMANCE; OUTPATIENTS; DISABILITY; COMPLAINTS	Three inter-related studies examine the construct of problem solving as it relates to the assessment of deficits in higher level outpatients with traumatic brain injury (TBI). Sixty-one persons with TBI and 58 uninjured participants completed measures of problem solving and conceptually related constructs, which included neuropsychological tests, self-report inventories, and roleplayed scenarios. In Study I, TBI and control groups performed with no significant differences on measures of memory, reasoning, and executive function, but medium to large between-group differences were found on timed attention tasks. The largest between-group differences were found on psychosocial and problem-solving self-report inventories. In Study II, significant-other (SO) ratings of patient functioning were consistent with patient self-report, and for both self-report and SO ratings of patient problem solving, there was a theoretically meaningful pattern of correlations with timed attention tasks. In Study III, a combination of self-report inventories that accurately distinguished between participants with and without TBI, even when cognitive tests scores were in the normal range, was determined. The findings reflect intrinsic differences in measurement approaches to the construct of problem solving and suggest the importance of using a multidimensional approach to assessment. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	NYU, Sch Med, Rusk Inst Rehabil Med, Dept Rehabil Med, New York, NY 10016 USA		Rath, JF (corresponding author), NYU, Sch Med, Rusk Inst Rehabil Med, Dept Rehabil Med, 400 E 34th St, New York, NY 10016 USA.	joseph.rath@med.nyu.edu	Rath, Joseph F./C-4823-2008	Rath, Joseph F./0000-0003-2933-6299; Diller, Leonard/0000-0001-7295-7846	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD032943] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01-HD32943] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Babin PR, 2002, J REHABIL, V68, P4; BENTON AL, 1994, ANNU REV PSYCHOL, V45, P1, DOI 10.1146/annurev.ps.45.020194.000245; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; Bruner J.S., 1956, STUDY THINKING; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen J., 2013, STAT POWER ANAL BEHA; D'Zurilla TJ, 2001, HANDBOOK OF COGNITIVE-BEHAVIORAL THERAPIES, SECOND EDITION, P211; D'Zurilla TJ., 1982, ADV COGNITIVE BEHAV, P201, DOI [10.1016/B978-0-12-010601-1.50010-3, DOI 10.1016/B978-0-12-010601-1.50010-3]; DANIEL M, 1986, BEHAV THERAPIST, V4, P71; DEROGATIS LR, 1990, BRIEF SYMPTOM INVENT; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DILLER L, 1993, ADV STROKE REHABILIT; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DOWNEY J, 1923, WILL TEMPERAMENT ITS; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; DZURILLA TJ, 1995, BEHAV THER, V26, P409, DOI 10.1016/S0005-7894(05)80091-7; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GOLDSTEIN FC, 1987, NEUROPSYCHOL REHABIL, P327; HANIG BS, 1993, ADJUNCT SKILLS QUEST; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HART T, 1986, CLIN NEUROPSYCHOLOGY; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1981, WISCONSIN CARD SORTI; HEPPNER PP, 1988, PROBLEM SOLVING INVE; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; KING MC, 1981, J CLIN PSYCHOL, V37, P400, DOI 10.1002/1097-4679(198104)37:2<400::AID-JCLP2270370233>3.0.CO;2-B; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langenbahn DM, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P167; Levin H.S., 1989, MILD HEAD INJURY; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lovejoy DW, 2001, ARCH CLIN NEUROPSYCH, V16, P743; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria AR, 1963, RESTORATION FUNCTION; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Montgomery GK, 1999, ARCH CLIN NEUROPSYCH, V14, P794, DOI 10.1016/S0887-6177(99)80337-0; NEZU AM, 1989, J CONSULT CLIN PSYCH, V57, P408, DOI 10.1037/0022-006X.57.3.408; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; Paul RH, 1998, APPL NEUROPSYCHOL, V5, P143, DOI 10.1207/s15324826an0503_5; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RABIN LA, 2001, DISS ABSTR INT, V68, pB3934; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; RONAN GF, 1993, J PERS ASSESS, V61, P28, DOI 10.1207/s15327752jpa6101_3; Rosenblatt J. S., 1979, Advances in the Study of Behavior, V10, P225, DOI 10.1016/S0065-3454(08)60096-0; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sherr RL, 1998, REHABIL PSYCHOL, V43, P184; SHERR RL, 1996, PROBLEM SOLVING ROLE; SHERR RL, 1992, NEUROPSYCHOLOGY, V6, P417, DOI DOI 10.1037/0894-4105.6.4.417; SHERR RL, 1996, PROBLEM SOLVING QUES; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spreen O., 1977, NEUROSENSORY CTR COM, VRev; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Watson G., 1980, WATSON GLASER CRITIC; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; Zasler ND, 2003, NEUROPSYCHOL REHABIL, V13, P31, DOI 10.1080/09602010; [No title captured]	85	33	33	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2004	19	5					613	635		10.1016/j.acn.2003.08.006			23	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	845PT	WOS:000223257500002	15271407				2022-02-06	
J	Rosenfeld, JV				Rosenfeld, JV			Damage control neurosurgery	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						damage control; neurosurgery; traumatic brain injury; rural surgery; military surgery	ACUTE SUBDURAL HEMATOMAS; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; NEW-SOUTH-WALES; EXTRADURAL HEMORRHAGE; LEBANESE CONFLICT; COMATOSE PATIENTS; MANAGEMENT; EXPERIENCE; CRANIOTOMY	Damage control neurosurgery (DCNS) is abbreviated urgent neurosurgery performed on the injured patient which helps to prevent secondary brain injury, assists in stabilising the patient and improves survival and outcome. It may be urgent surgery done by the neurosurgeon in a trauma centre, but it has particular application in the remote, rural or military environment where the surgery can be performed by a generalist. This surgery should always be done in collaboration with the trauma team caring for the overall needs of the patient. The Definitive Surgery Trauma Course (DSTC) is an ideal educational vehicle to disseminate the principles of DCNS. (C) 2004 Elsevier Ltd. All rights reserved.	Monash Univ, Alfred Hosp, Dept Neurosurg & Surg, Prahran, Vic 3181, Australia		Rosenfeld, JV (corresponding author), Monash Univ, Alfred Hosp, Dept Neurosurg & Surg, Commercial Rd, Prahran, Vic 3181, Australia.	j.rosenfeld@alfred.org.au	Rosenfeld, Jeffrey V/B-7249-2011				Alam HB, 2003, J TRAUMA, V54, P1077, DOI 10.1097/01.TA.0000068258.99048.70; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Connolly E, 2002, FUNDAMENTALS OPERATI; Coutts A, 1998, BRIT MED J, V317, P1687, DOI 10.1136/bmj.317.7174.1687; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 2001, NEUROSURGERY, V49, P864; DAN NG, 1986, AUST NZ J SURG, V56, P535, DOI 10.1111/j.1445-2197.1986.tb07096.x; DUFOUR D, 1990, SURG VICTIMS WAR; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Harding JN, 1996, ANAESTH INTENS CARE, V24, P500, DOI 10.1177/0310057X9602400417; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; McDermott FT, 2004, J TRAUMA, V56, P137, DOI 10.1097/01.TA.0000056163.58047.74; Moore EE, 1998, WORLD J SURG, V22, P1184, DOI 10.1007/s002689900542; Newcombe R, 1999, J CLIN NEUROSCI, V6, P85, DOI 10.1016/S0967-5868(99)90619-7; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Rosenfeld JV, 2002, J CLIN NEUROSCI, V9, P9, DOI 10.1054/jocn.2001.0949; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; ROTONDO MF, 1997, SURG CLIN N AM, V77, P12; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SIMPSON DA, 1988, INJURY, V19, P307, DOI 10.1016/0020-1383(88)90100-3; STENING WA, 1986, AUST NZ J SURG, V56, P549, DOI 10.1111/j.1445-2197.1986.tb07098.x; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Watters DA, 2001, NEUROSURGERY TROPICS; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; Woodman T, 1996, NEUROTRAUMA, P519	30	33	43	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JUL	2004	35	7					655	660		10.1016/j.injury.2004.03.006			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	834WL	WOS:000222441500004	15203305				2022-02-06	
J	Dash, PK; Kobori, N; Moore, AN				Dash, PK; Kobori, N; Moore, AN			A molecular description of brain trauma pathophysiology using microarray technology: An overview	NEUROCHEMICAL RESEARCH			English	Article						brain derived neurotrophic factor (BDNF); hypoxia inducible factor (HIF); transtheritin urokinase plasminogen activator receptor-1 (uPAR-1); urokinase plasminogen activator (uPA)	ENDOTHELIAL GROWTH-FACTOR; SPATIAL MEMORY DEFICITS; CORTICAL IMPACT INJURY; GENE-EXPRESSION; NEUROTROPHIC FACTOR; RAT-BRAIN; ALTERED EXPRESSION; DNA MICROARRAY; MESSENGER-RNA; UP-REGULATION	It has been estimated that 50% of human transcriptome, the collection of mRNA in a cell, is expressed in the brain, making it one of the most complex organs to understand in terms of genomic responses to injury ( 1). The availability of genome sequences for several organisms coupled with the increasing affordability of microarray technologies makes it feasible to monitor the mRNA levels of thousands of genes simultaneously. In this paper, we provide an overview of findings using both cDNA-and oligonucleotide-based microarray analyses after experimental traumatic brain injury (TBI). Specifically, the utility of this methodology as a means of cataloging the biochemical sequelae of brain trauma and elucidating novel genes or pathways for further study is discussed. Furthermore, we offer future directions for the continued evaluation of microarray results and discuss the usefulness of microarray techniques as a testing format for determining the efficacy of mechanism-based therapies.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Beschorner R, 2000, NEUROPATH APPL NEURO, V26, P522, DOI 10.1046/j.0305-1846.2000.287.x; Birnbaum SG, 2000, PHARMACOL BIOCHEM BE, V67, P397, DOI 10.1016/S0091-3057(00)00306-3; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; BOLL TJ, 1982, HEAD INJURY, P363; Cao YX, 2001, CURR OPIN NEUROBIOL, V11, P615, DOI 10.1016/S0959-4388(00)00258-0; Chaki S, 2003, EUR J PHARMACOL, V464, P49, DOI 10.1016/S0014-2999(03)01368-2; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Dabrowski M, 2003, J NEUROCHEM, V85, P1279, DOI 10.1046/j.1471-4159.2003.01753.x; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dobrogowska DH, 1998, J NEUROCYTOL, V27, P163, DOI 10.1023/A:1006907608230; DomanskaJanik K, 1996, ACTA NEUROBIOL EXP, V56, P579; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; Gorski JA, 2003, J NEUROSCI, V23, P6856; GRAHAM DL, 1996, TRAUMA, P1386; Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hertel P, 1999, SCIENCE, V286, P105, DOI 10.1126/science.286.5437.105; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1992, J CEREBR BLOOD F MET, V12, P697, DOI 10.1038/jcbfm.1992.95; Merched A, 1998, FEBS LETT, V425, P225, DOI 10.1016/S0014-5793(98)00234-8; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mirnics K, 2001, NAT REV NEUROSCI, V2, P444, DOI 10.1038/35077587; Murphy D, 2002, ADV PHYSIOL EDUC, V26, P256, DOI 10.1152/advan.00043.2002; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Nisenbaum LK, 2002, GENES BRAIN BEHAV, V1, P27, DOI 10.1046/j.1601-1848.2001.00013.x; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Palha JA, 1996, NEUROSCI LETT, V204, P212, DOI 10.1016/0304-3940(96)12334-X; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; POLSKYCYNKIN R, 1985, CLIN CHEM, V31, P1438; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Rothman RB, 2003, PEPTIDES, V24, P413, DOI 10.1016/S0196-9781(03)00056-1; Saito M, 2002, NEUROCHEM RES, V27, P1221, DOI 10.1023/A:1020937728506; Sendera TJ, 2002, NEUROCHEM RES, V27, P1005, DOI 10.1023/A:1020948603490; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Waxham MN, 1996, J CEREBR BLOOD F MET, V16, P1, DOI 10.1097/00004647-199601000-00001; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198	65	33	36	0	2	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	JUN	2004	29	6					1275	1286		10.1023/B:NERE.0000023614.30084.eb			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	812CB	WOS:000220816500025	15176484				2022-02-06	
J	Tolentino, PJ; Waghray, A; Wang, KKW; Hayes, RL				Tolentino, PJ; Waghray, A; Wang, KKW; Hayes, RL			Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; cross-linking; ischemia; transglutaminase	GTP-BINDING PROTEIN; ALZHEIMERS-DISEASE; RETINOIC ACID; CROSS-LINKING; CELL-DEATH; DIFFERENTIAL EXPRESSION; BRAIN-INJURY; SPINAL-CORD; APOPTOSIS; CALCIUM	Tissue-type transglutaminase (TG-2) has been implicated in neurodegenerative diseases. In this study, induction of TG-2 was studied in rats following transient middle cerebral artery occlusion. Alterations in 2,3,5-triphenylterazolium chloride staining revealed maximum infarction 3 days after injury. Measurement of mRNA transcript levels by real-time PCR analysis showed both forms of TG-2 mRNA peaking on day 5 after injury in ipsilateral cortex, with greater induction of the full-length TG-2 (TG-L) transcript than the truncated form of the TG-2 (TG-S) transcript. However, in the ipsilateral hippocampus, peak induction of both forms of TG-2 mRNA peaked 1 day after injury and to a lesser extent than observed in the ipsilateral cortex. Western blot analysis demonstrated that TG-L protein expression progressively increased from 1 to 7 days after ischemia, with greater expression in cortex than hippocampus (525+/-10% vs. 196+/-8% of control, respectively). However, expression of TG-S was not detected. These results demonstrate that increased TG-2 mRNA and protein expression occurs in a delayed fashion following ischemic injury. The temporal profile of TG-2 induction after ischemia was similar to that observed after traumatic brain injury (previously described), suggesting a similar role of TG-2 in both pathological conditions.	Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32610 USA		Hayes, RL (corresponding author), Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, 100 S Newell Dr,Box 100244, Gainesville, FL 32610 USA.	hayes@ufbi.ufl.edu		Wang, Kevin/0000-0002-9343-6473			ANDO M, 1993, BRAIN RES, V604, P64, DOI 10.1016/0006-8993(93)90352-N; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Blass JP, 2003, NEW ENGL J MED, V348, P1277, DOI 10.1056/NEJMe030017; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Buki A, 2000, J NEUROSCI, V20, P2825; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; Chu D, 2002, NEUROCHEM RES, V27, P97, DOI 10.1023/A:1014858707218; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Elkind MS, 1998, SEMIN NEUROL, V18, P429, DOI 10.1055/s-2008-1040896; Facchiano F, 2001, EXP CELL RES, V271, P118, DOI 10.1006/excr.2001.5356; Ferrari N, 1998, MOL CELL BIOL, V18, P6482, DOI 10.1128/MCB.18.11.6482; Festoff BW, 2002, J NEUROCHEM, V81, P708, DOI 10.1046/j.1471-4159.2002.00850.x; Fujita K, 1995, NEUROCHEM RES, V20, P1195, DOI 10.1007/BF00995383; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; Gill LS, 1998, BRAIN RES, V788, P95, DOI 10.1016/S0006-8993(97)01526-6; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hayes RL, 2001, HEAD TRAUMA, P219; He Z, 2000, J NEUROL SCI, V182, P16, DOI 10.1016/S0022-510X(00)00434-2; IKURA K, 1994, BIOSCI BIOTECH BIOCH, V58, P1540, DOI 10.1271/bbb.58.1540; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; Lefebvre O, 1999, CELL DEATH DIFFER, V6, P433, DOI 10.1038/sj.cdd.4400510; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; MADDOX AM, 1988, EXP CELL BIOL, V56, P49; Mattson MP, 2000, BRAIN PATHOL, V10, P300, DOI 10.1111/j.1750-3639.2000.tb00264.x; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; Pennypacker KR, 1999, BRAIN RES BULL, V48, P539, DOI 10.1016/S0361-9230(99)00031-3; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; Pluta R, 2000, ANN NY ACAD SCI, V903, P324, DOI 10.1111/j.1749-6632.2000.tb06383.x; SUEDHOFF T, 1990, CANCER RES, V50, P7830; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	44	33	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2004	89	5					1301	1307		10.1111/j.1471-4159.2004.02436.x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	821CK	WOS:000221437200024	15147523				2022-02-06	
J	Willer, B; Dumas, J; Hutson, A; Leddy, J				Willer, B; Dumas, J; Hutson, A; Leddy, J			A population based investigation of head injuries and symptoms of concussion of children and adolescents in schools	INJURY PREVENTION			English	Article							SPORTS-RELATED CONCUSSION; EPIDEMIOLOGY; EXPERIENCE	Objective: To examine the incidence of head injury and symptoms of concussion among children at school and to determine the relationship of age, gender, and cause to incidence rates. Design: Incident reports involving head injury for schools in the Province of Ontario, Canada during the year 2000 were evaluated. Participants: The population base for the schools represented was 1 372 979 children aged 6 to 16. Setting: 95% of schools in the province of Ontario, Canada participated in the injury reporting system. Main outcome measures: A head injury was defined as any injury to the head that came to the attention of a school official. Head injuries accompanied by symptoms of concussion became a secondary outcome measure. Results: There were 11 068 unduplicated head injury reports for the year 2000 of which 1861 qualified as producing signs or symptoms of concussion. Young children were more likely to have a head injury than older children, but slightly less likely to experience concussive symptoms. The primary cause of injury to young children was falls. Older children were more likely to receive head injuries and symptoms of concussion from sports activities. Conclusions: Overall rate of injury (3.98 per 100 children) was consistent with previous studies using prospective injury reporting systems. Probability of a head injury with symptoms of concussion among schoolchildren was only 1.9% for boys and <1% for girls during the course of their school years. There is ample justification for prevention efforts in schools.	SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA; Brock Univ, St Catharines, ON L2S 3A1, Canada; Ontario Brain Injury Assoc, St Catharines, ON, Canada; SUNY Buffalo, Inst Sports Med, Buffalo, NY USA		Willer, B (corresponding author), SUNY Buffalo, Dept Psychiat, G96 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	willer@vaxxine.com					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; BOYCE WT, 1984, PEDIATRICS, V74, P342; BOYCE WT, 1989, AM J DIS CHILD, V143, P338, DOI 10.1001/archpedi.1989.02150150096024; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GLOR ED, 1989, CAN J PUBLIC HEALTH, V80, P435; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAMMARSTROM A, 1994, SCAND J SOC MED, V22, P120, DOI 10.1177/140349489402200207; Iverson GL, 2004, BRAIN INJURY, V18, P1; Junkins EP, 1999, J SCHOOL HEALTH, V69, P409, DOI 10.1111/j.1746-1561.1999.tb06360.x; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LENAWAY DD, 1992, AM J PREV MED, V8, P193, DOI 10.1016/S0749-3797(18)30831-6; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McKeag DB, 2003, JAMA-J AM MED ASSOC, V290, P2604, DOI 10.1001/jama.290.19.2604; Schuller A A, 2000, Tidsskr Nor Laegeforen, V120, P301; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; SHEPS SB, 1987, PEDIATRICS, V79, P69; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	21	33	33	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	JUN	2004	10	3					144	148		10.1136/ip.2003.005017			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	844YY	WOS:000223203300004	15178669	Green Published, Bronze			2022-02-06	
J	Daugherty, WP; Levasseur, JE; Sun, D; Spiess, BD; Bullock, MR				Daugherty, WP; Levasseur, JE; Sun, D; Spiess, BD; Bullock, MR			Perfluorocarbon emulsion improves cerebral oxygenation and mitochondrial function after fluid percussion brain injury in rats	NEUROSURGERY			English	Article						cerebral oxygenation; mitochondrial function; perfluorocarbon; traumatic brain injury	ARTIFICIAL BLOOD SUBSTITUTES; HUMAN HEAD-INJURY; FLUOSOL-DA; TISSUE OXYGENATION; TRANSPORT; ISCHEMIA; METABOLISM; MODEL; DOGS; PERFLUOROCHEMICALS	OBJECTIVE: Cerebral ischemia is a common secondary sequela of traumatic brain injury (TBI). Experimental models of stroke have demonstrated reductions in ischemia after perfluorocarbon (PFC) administration; however, there are no published reports of PFC efficacy after TBI. The current study analyzed the effect of the PFC emulsion Oxygent (AF0144; Alliance Pharmaceutical Corp., San Diego, CA) on cerebral oxygenation, mitochondrial redox potential, and free radical formation after lateral fluid percussion injury. METHODS: After fluid percussion injury, five 2.25 ml/kg doses of PFC or saline were administered to rats breathing 100% O-2, and oxygen tension was recorded. In a second experiment, a single bolus (11.25 ml/kg) of PFC or saline was given after injury, and redox potential and free radical formation were measured at I or 4 hours with Alamar blue dye and dihydrorhodamine 123, respectively. RESULTS: Cerebral oxygen tension was significantly increased in both injured and sham animals treated with 11.25 ml/kg of PFC as compared with saline (P < 0.05). Likewise, PFC significantly increased mitochondrial redox potential as compared with saline at 4 hours after injury (P < 0.01). Mitochondrial peroxynitrite and peroxide production also increased with the administration of PFC (P < 0.05). CONCLUSION: The current study demonstrates that a PFC emulsion can significantly increase cerebral oxygenation after TBI and enhance mitochondrial function at 4 hours after injury as compared with saline. This study demonstrates a new therapeutic potential for PFC to enhance cerebral oxygenation and aerobic metabolism after TBI. However, the increased free radical formation with high-dose PFCs suggests the need for further studies combining PFCs with free radical scavengers.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anesthesiol, Richmond, VA 23298 USA		Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, POB 980631,1200 E Marshall St, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Alessandri B, 1999, ACT NEUR S, V75, P21; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; COKELET GR, 1987, HDB BIOENGINEERING, P1; DAUGHERTY WP, 2002, J NEUROTRAUM, V19, P1357; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EYER CL, 1991, BIOMAT ARTIF CELL IM, V19, P719, DOI 10.3109/10731199109117850; FAITHFULL NS, 1988, J CRIT CARE, V3, P14; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; GEYER RP, 1988, BIOMATER ARTIF CELL, V16, P31; GEYER RP, 1982, NEW ENGL J MED, V307, P304, DOI 10.1056/NEJM198207293070509; GEYER RP, 1975, FED PROC, V34, P1499; GEYER RP, 1973, NEW ENGL J MED, V289, P1077; GLOGAR DH, 1981, SCIENCE, V211, P1439, DOI 10.1126/science.7466402; GUO J, 1995, NEUROSURGERY, V36, P350, DOI 10.1227/00006123-199502000-00015; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; JOHNSON EC, 1995, J APPL PHYSIOL, V79, P1777, DOI 10.1152/jappl.1995.79.5.1777; KAUFMAN RJ, 1995, BLOOD SUBSTITUTES, P53; KAUFMAN RJ, 1996, BLOOD SUBSTITUTES NE, P60; KLINE RA, 1991, AM J SURG, V162, P103, DOI 10.1016/0002-9610(91)90168-D; KOLODGIE FD, 1985, VIRCHOWS ARCH B, V50, P119; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P435; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Matthews OA, 1998, PROG POLYM SCI, V23, P1, DOI 10.1016/S0079-6700(97)00025-7; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MITSUNO T, 1982, ANN SURG, V195, P60, DOI 10.1097/00000658-198201001-00010; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, P1; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; OSTERHOLM JL, 1983, NEUROSURGERY, V13, P381, DOI 10.1227/00006123-198310000-00006; Padnick LB, 1999, J APPL PHYSIOL, V86, P1497, DOI 10.1152/jappl.1999.86.5.1497; Patel S, 1998, ASAIO J, V44, P157, DOI 10.1097/00002480-199805000-00007; Patel S, 1998, ASAIO J, V44, P144, DOI 10.1097/00002480-199805000-00006; PEERLESS SJ, 1985, STROKE, V16, P38, DOI 10.1161/01.STR.16.1.38; PEERLESS SJ, 1981, STROKE, V12, P558, DOI 10.1161/01.STR.12.5.558; RIESS JG, 1991, VOX SANG, V61, P225, DOI 10.1111/j.1423-0410.1991.tb00952.x; SATTERFIELD R, 1993, INVEST RADIOL, V28, P325, DOI 10.1097/00004424-199304000-00013; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; Stowell CP, 2001, TRANSFUSION, V41, P287, DOI 10.1046/j.1537-2995.2001.41020287.x; SUZUKI J, 1984, STROKE, V15, P672, DOI 10.1161/01.STR.15.4.672; Taguchi Y, 1986, No To Shinkei, V38, P177; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoles E, 2000, NEUROL RES, V22, P404, DOI 10.1080/01616412.2000.11740691; ZUCK TF, 1994, CRIT REV CL LAB SCI, V31, P295, DOI 10.3109/10408369409084678	51	33	34	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2004	54	5					1223	1230		10.1227/01.NEU.0000119238.68938.5D			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	819JA	WOS:000221310000054	15113478				2022-02-06	
J	Breed, ST; Flanagan, SR; Watson, KR				Breed, ST; Flanagan, SR; Watson, KR			The relationship between age and the self-report of health symptoms in persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	age of onset; brain injuries; health status; rehabilitation	HEAD-INJURY; CONSEQUENCES; INDIVIDUALS; COMMUNITY	Objective: To examine the impact of age on health problems related to traumatic brain injury (TBI). Design: Case-control study using a survey instrument. Setting: Outpatient setting of a large urban tertiary care hospital. Participants: Young and old community dwellers with histories of TBI and control subjects matched for age. Intervention: Structured interview using the Living Life After TBI assessment tool. Main Outcome Measure: Symptom reporting on 52 potential health problems. Results: Individuals with TBI reported significantly more overall health problems than those without TBI. Younger subjects with TBI reported more problems than their nondisabled, age-matched peers with their patterns of sleep as well as with their metabolic/endocrine, neurologic, and musculoskeletal systems. Conclusions: Older people with TBI were more likely than nondisabled, age-matched peers to report problems with their metabolic/endocrine and neurologic systems. Younger people with TBI were more likely than older people with TBI to report difficulty falling asleep.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Breed, ST (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl, New York, NY 10029 USA.	Sabrina.Breed@msnyuhealth.org		Flanagan, Steven/0000-0001-9005-5897			AMACHER AL, 1987, NEUROSURGERY, V20, P954; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FIELDS RB, 1994, TXB GERIATRIC NEUROP, P479; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOODMAN H, 1992, PHYS MED REH CLIN N, V3, P441; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; *MED COLL VIRG DEP, TBI SYMPT CHECKL; *MED OUTC TRUST, 1992, MED OUTC TRUST SF 36; *MOUNT SIN SCH MED, 1998, BRAIN INJ SCREEN QUE; *MOUNT SIN SCH MED, 1995, QUAL LIF INT HLTH IN; *MOUNT SIN SCH MED, 1998, LIV LIF TBI LLATBI; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Picard M., 1991, HELPS; Ross A M, 1992, J Neurosci Nurs, V24, P88; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; THURMAN DJ, 1999, J HEAD TRAUMA REHAB, V46, P8; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	25	33	33	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S61	S67		10.1016/j.apmr.2003.08.115			7	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	812FL	WOS:000220825300008	15083423				2022-02-06	
J	Shanmuganathan, K; Gullapalli, RP; Mirvis, SE; Roys, S; Murthy, P				Shanmuganathan, K; Gullapalli, RP; Mirvis, SE; Roys, S; Murthy, P			Whole-brain apparent diffusion coefficient in traumatic brain injury: Correlation with Glasgow coma scale score	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							WEIGHTED MR; AXONAL INJURY; ACUTE STROKE; HEAD-INJURY; EDEMA	BACKGROUND AND PURPOSE: Patients with traumatic brain injury (TBI) and low Glasgow coma scale (GCS) scores may have severe injury associated with cellular disruption that can be studied with whole-brain apparent diffusion coefficient (ADC) histograms. We retrospectively studied this hypothesis and correlated ADC with GCS. METHODS: Twenty-one patients (37.81 +/- 41.3 years) with TBI were enrolled: Group A had normal MR imaging findings but low GCS scores (n = 6). Group B had brain stem injury with low GCS scores (n = 6). Group C had cortical lesions with normal GCS scores (n = 5), and group D had cortical lesions with low GCS scores (n = 4). Eleven control subjects were enrolled (32.7 +/- 19.2 years). Whole-brain ADC maps and histograms were generated and normalized for each subject. Mean and peak ADCs were determined. A one-sided t test was performed for each parameter. Average GCS scores and corresponding peak and mean ADCs were correlated. RESULTS: Peak histogram values significantly differed between controls and groups A, B, and D (P < .0019, P < .00129, and P < .0148, respectively). In groups A and D, values were significantly skewed compared with control values. Mean ADC was significantly different between the control ADC and group A (P < .013) but not group C. In each group, peak ADC and GCS score were strongly correlated (R-2 = 0.67). CONCLUSION. Whole-brain peak ADCs and GCS scores are significantly correlated in patients with TBI. Although conventional MR images were normal, ADC independently indicated TBI and better represents the degree of neurologic dysfunction.	Univ Maryland, Ctr Med, Dept Diagnost Radiol, Baltimore, MD 21201 USA; Univ Maryland, Ctr Med, Maryland Shock Trauma Ctr, Baltimore, MD 21201 USA		Shanmuganathan, K (corresponding author), Univ Maryland, Ctr Med, Dept Radiol, 22 S Greene St, Baltimore, MD 21201 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Bartnik BL, 2001, BRAIN RES, V915, P133, DOI 10.1016/S0006-8993(01)02805-0; Carhuapoma JR, 2002, AM J NEURORADIOL, V23, P1322; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; ENGELTER ST, 2000, AM J ROENTGENOL, V175, P2; FISHER M, 1995, SURG NEUROL, V43, P606, DOI 10.1016/0090-3019(95)00015-1; GEAN DA, 1994, IMAGING HEAD TRAUMA, P1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JENNETT B, 1976, LANCET, V1, P1031; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1080/028418501127346990; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Sunshine JL, 1999, RADIOLOGY, V212, P325, DOI 10.1148/radiology.212.2.r99au52325; TEASDALE G, 1974, LANCET, V2, P81; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Wittsack HJ, 2002, RADIOLOGY, V222, P397, DOI 10.1148/radiol.2222001731; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	24	33	35	0	0	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2004	25	4					539	544					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	815LD	WOS:000221042900005	15090338				2022-02-06	
J	Yildirim, E; Kaptanoglu, E; Ozisik, K; Beskonakli, E; Okutan, O; Sargon, MF; Kilinc, K; Sakinci, U				Yildirim, E; Kaptanoglu, E; Ozisik, K; Beskonakli, E; Okutan, O; Sargon, MF; Kilinc, K; Sakinci, U			Ultrastructural changes in pneumocyte type II cells following traumatic brain injury in rats	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article; Proceedings Paper	17th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery/11th Annual Meeting of the European-Society-of-Thoracic-Surgeons	OCT 12-15, 2003	VIENNA, AUSTRIA	European Assoc Cardio Thorac Surg, European Soc Thorac Surg		brain; trauma; animal model; electron microscopy; lung; pneumocyte type II cells	NEUROGENIC PULMONARY-EDEMA; SPINAL-CORD-INJURY; LUNG; METHYLPREDNISOLONE	Objective: We aimed to demonstrate the time-dependent ultrastructural changes in pneumocyte type II cells following brain injury, and to propose an electron microscopic scoring model for the damage. Methods: Forty Wistar-Albino female rats weighing 170-200 g were used. The rats were allocated into five groups. The first group was the control and the second was the craniotomy without trauma. The others were trauma groups. Weight-drop method was used for achieving head trauma. Samples were obtained from the right and left pulmonary lobes at 2-, 8-, and 24-h intervals after transcardiac perfusion. An electron microscopic scoring model was used to reveal the changes. Results: There were no ultrastructural pathological findings pointing to lung injury in any rat of the control groups. There was intense intracellular oedema in type II pneumocyte and interstitial oedema in the adjacent tissue in trauma groups. Oedema in mitochondria and dilatation in both smooth endoplasmic reticulum and Golgi apparatus was more evident in the 8- and 24-h trauma groups. The chromatin dispersion was disintegrated in the nucleus in all trauma groups. Scores of all trauma groups were significantly different from the controls (P < 0.05). All trauma groups were different from each other at significant levels (P < 0.05 for each trauma groups). Conclusions: The data suggested that ultrastructural damage is obvious at 2 h and deteriorates with time. The electron microscopic scoring model worked well in depicting the traumatic changes, which were supported by lipid peroxidation. Further experiments are needed to determine the exact outcome after brain death model. (C) 2004 Elsevier B.V. All rights reserved.	Ankara Numune Educ & Res Hosp, Dept Thorac Surg, Ankara, Turkey; Ankara Numune Educ & Res Hosp, Dept Neurosurg, Ankara, Turkey; Hacettepe Univ, Fac Med, Dept Anat, TR-06100 Ankara, Turkey; Hacettepe Univ, Fac Med, Dept Biochem, TR-06100 Ankara, Turkey		Yildirim, E (corresponding author), Asagiovecler Mh,79-Sk,8-3 Dikmen,Cankaya, Ankara, Turkey.	erseyda@yahoo.com	YILDIRIM, Erkan/AAO-6961-2020; Sargon, Mustafa F./AAZ-5470-2021	Sargon, Mustafa F./0000-0001-6360-6008			Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; CORMAN J, 1991, ANN CHIR, V45, P791; COTTRELL TS, 1967, CIRC RES, V21, P783, DOI 10.1161/01.RES.21.6.783; DETTBARN CL, 1989, HEART LUNG, V18, P583; EDMONDS HL, 1986, NEUROSURGERY, V19, P36, DOI 10.1227/00006123-198607000-00005; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall SRR, 2002, ANESTH ANALG, V94, P948; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kaptanoglu E, 2002, J NEUROSURG ANESTH, V14, P114, DOI 10.1097/00008506-200204000-00005; MARON MB, 1989, J APPL PHYSIOL, V67, P305, DOI 10.1152/jappl.1989.67.1.305; MIHARA M, 1981, YAKUGAKU ZASSHI, V101, P221, DOI 10.1248/yakushi1947.101.3_221; Novick RJ, 1996, ANN THORAC SURG, V62, P302, DOI 10.1016/0003-4975(96)00333-5; Pyeron A M, 2001, J Neurosci Nurs, V33, P203; Schwarz S, 1997, NERVENARZT, V68, P956, DOI 10.1007/s001150050222; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SINGBARTL G, 1989, ANAESTHESIST, V38, P360; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; WANG NS, 1971, AM J PATHOL, V62, P237; West JB, 2000, J APPL PHYSIOL, V89, P2483, DOI 10.1152/jappl.2000.89.6.2483	21	33	34	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	APR	2004	25	4					523	529		10.1016/j.ejcts.2003.12.021			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cardiovascular System & Cardiology; Respiratory System; Surgery	811IL	WOS:000220765500010	15037266	Bronze, Green Published			2022-02-06	
J	Kao, CQ; Goforth, PB; Ellis, EF; Satin, LS				Kao, CQ; Goforth, PB; Ellis, EF; Satin, LS			Potentiation of GABA(A) currents after mechanical injury of cortical neurons	JOURNAL OF NEUROTRAUMA			English	Article						cortex; GABA; GABA(A) receptor; NMDA antagonist; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; INTRACELLULAR FREE CALCIUM; FLUID-PERCUSSION INJURY; STRETCH-INDUCED INJURY; AMINO-ACIDS; AMPA RECEPTORS; NEGATIVE MODULATION; SILENT SYNAPSES; HEAD TRAUMA	Numerous studies have implicated glutamate receptors, glutamate neurotoxicity, and hyperexcitation in the pathobiology of traumatic brain injury, yet much less is known about the effects of neurotrauma on inhibitory GABA channels of the brain. Using an in vitro cell injury model, we tested whether mild stretch injury altered the GABA(A) Currents of cultured rat cortical neurons. The application of 1-100 muM GABA to single pyramidal neurons voltage clamped to -60 mV activated an inward current that reversed near 0 mV in solutions containing symmetrical [Cl-]. This current was inhibited by bicuculline, consistent with mediation by GABAA receptor channels. In injured neurons, 50 muM GABA elicited a peak current density of 41.2 +/- 2.6 pA/pF (n = 82), which was significantly larger than in uninjured control neurons, 20.2 +/- 1.7 pA/pF (n = 69,p < 0.01). The GABAA currents of injured neurons did not differ from those of control neurons in their sensitivity to GABA or their reversal potentials, suggesting that GABA current potentiation did not result from changes in the agonist affinity or ionic selectivity of the channels. GABA current potentiation was prevented by injuring neurons in the presence of the NMDA antagonist APV, or the CaMKII inhibitor KN93. These results thus suggest that NMDA receptor activation following neuronal injury may potentiate GABAA channels through the activation of CaMKII. The increase in GABAA receptor function observed following injury could potentially contribute to dysfunctional synaptic function and information processing as well as unconsciousness and coma following human brain trauma.	Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Dept Med Endocrinol, Richmond, VA 23298 USA; Vanderbilt Univ, Ctr Med, Dept Neurol Surg, Nashville, TN 37232 USA		Satin, LS (corresponding author), Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, Box 980524, Richmond, VA 23298 USA.	lsatin@hsc.vcu.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [521084, 5T32N50 7288-13] Funding Source: Medline		Aguayo LG, 1998, PFLUG ARCH EUR J PHY, V435, P382, DOI 10.1007/s004240050527; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; ANDINE P, 1991, DEV BRAIN RES, V64, P115, DOI 10.1016/0165-3806(91)90214-4; BEDFORD FK, 2000, SOC NEUR M ABST, P1657; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BULLOCK R, 1997, HEAD INJURY PATHOPHY, P120; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CELENTANO JJ, 1991, MOL PHARMACOL, V40, P766; CHOI DW, 1987, J NEUROSCI, V7, P369; Churn SB, 2000, P NATL ACAD SCI USA, V97, P5604, DOI 10.1073/pnas.080071697; CHURN SB, 2000, SOC NEUR M ABST, P1657; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GOFORTH PB, 2000, SOC NEUR ABST, V26; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KAO CQ, 1999, SOC NEUR M ABST, V29, P314; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; LEGENDRE P, 1991, MOL PHARMACOL, V39, P267; LIAO D, 2000, NATURE, V405, P955; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Lissin DV, 1999, J NEUROSCI, V19, P1263; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pickard L, 2001, NEUROPHARMACOLOGY, V41, P700, DOI 10.1016/S0028-3908(01)00127-7; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Toth Z, 1997, J NEUROSCI, V17, P8106; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; Weber JT, 2002, J NEUROTRAUM, V19, P1433, DOI 10.1089/089771502320914660; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whiting PJ, 1999, NEUROCHEM INT, V34, P387, DOI 10.1016/S0197-0186(99)00048-0; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	63	33	34	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					259	270		10.1089/089771504322972059			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600004	15115601				2022-02-06	
J	Cassidy, JD; Carroll, L; Cote, P; Holm, L; Nygren, A				Cassidy, JD; Carroll, L; Cote, P; Holm, L; Nygren, A			Mild traumatic brain injury after traffic collisions: A population-based inception cohort study	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; epidemiology; prognosis; compensation	WHIPLASH INJURY; PAIN INTENSITY; HEAD-INJURY; BACK-PAIN; COMPENSATION; OUTCOMES; WORKERS; CARE; NECK	Objective: To study the incidence and claim closure of traffic-related mild traumatic brain injury and the effect of insurance factors. Design: Population-based, cohort study of mild traumatic brain injury caused by traffic collisions in Saskatchewan, Canada, between July 1, 1994 and December 31, 1995. On January 1, 1995 the insurance law changed from tort to no fault. Subjects: 657 adults, 18 years or older, who hit their head and indicated loss of consciousness or uncertain loss of consciousness and were not hospitalized for more than 2 days. Methods: Subjects entered the cohort on the injury date and exited on the day the insurance claim closed, or on November 1, 1997, when remaining open claims were censored. All 657 subjects answered a baseline questionnaire, and 479 who did not reopen their claim were included in the follow-up. The relationship between claim closure and health was studied in 225 (47%) of these claimants. Results: The 6-month incidence dropped from 36/100,000 to 27/100,000 after the insurance change. The median time-to-claim closure dropped from 408 days to 233 days. Prolonged claim closure was associated with both injury and insurance-related factors. Claim closure occurred faster when claimants' health improved. Conclusions: Mild traumatic brain injury incidence and claim closure is affected by both health and insurance-related factors.	Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Toronto, Inst Work & Hlth, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada		Cassidy, JD (corresponding author), Univ Hlth Network, Toronto Western Hosp, Div Outcomes & Populat Hlth, Res Inst, 399 Bathurst St,MP 10-328A, Toronto, ON M5T 2S8, Canada.	dcassidy@uhnres.utoronto.ca	Cote, Pierre/AAG-5358-2021	Cote, Pierre/0000-0002-6986-6676; Carroll, Linda/0000-0003-0876-2336			ABENHAIM L, 1987, J OCCUP ENVIRON MED, V29, P670; Allison PD, 1995, SURVIVAL ANAL USING; Beaton DE, 2001, ARTHRIT RHEUM-ARTHR, V45, P270, DOI 10.1002/1529-0131(200106)45:3<270::AID-ART260>3.3.CO;2-K; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cassidy JD, 2000, NEW ENGL J MED, V342, P1179, DOI 10.1056/NEJM200004203421606; Cote P, 2001, J CLIN EPIDEMIOL, V54, P275, DOI 10.1016/S0895-4356(00)00319-X; Greenland S., 1998, MODERN EPIDEMIOLOGY, P253; Hadler NM, 1996, SPINE, V21, P2397, DOI 10.1097/00007632-199610150-00021; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Kessels RPC, 2000, J INT NEUROPSYCH SOC, V6, P271, DOI 10.1017/S1355617700633027; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANSKY D, 1992, MED CARE, V30, pMS57, DOI 10.1097/00005650-199205001-00006; LOESER JD, 1995, MED CARE RES REV, V52, P34, DOI 10.1177/107755879505200104; MARGOLIS RB, 1986, PAIN, V24, P57, DOI 10.1016/0304-3959(86)90026-6; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Mercado AC, 2000, HEALTH PSYCHOL, V19, P333, DOI 10.1037/0278-6133.19.4.333; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Phillips R C, 1992, J Heart Valve Dis, V1, P42; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Radanov BP, 1996, SPINE, V21, P392, DOI 10.1097/00007632-199602010-00029; Ruff RM, 1999, BRAIN INJURY, V13, P943; *SAS I, 1996, SAS COMP PROGR VERS; *SASK GOV INS, 1996, SASK TRAFF ACC FACTS; *SASK HLTH, 1995, HLTH INS REG COV POP; Sinclair SJ, 1997, SPINE, V22, P2919, DOI 10.1097/00007632-199712150-00015; *SPSS, 1999, SPSS COMP PROGRAM VE; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298	34	33	33	0	3	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			15	21		10.1080/16501960410023688			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	800QR	WOS:000220043300005	15083868	gold			2022-02-06	
J	Eriksson, PO; Zafar, H; Haggman-Henrikson, B				Eriksson, PO; Zafar, H; Haggman-Henrikson, B			Deranged jaw-neck motor control in whiplash-associated disorders	EUROPEAN JOURNAL OF ORAL SCIENCES			English	Article						human; jaw; neck; movement; whiplash	OPENING-CLOSING TASKS; HUMAN MASSETER MUSCLE; TEMPOROMANDIBULAR DISORDERS; INTRAMUSCULAR CONCENTRATION; CRANIOFACIAL PAIN; FUSIMOTOR DRIVE; HEAD; MOVEMENTS; BRADYKININ; SPINDLES	Recent findings of simultaneous and well coordinated head-neck movements during single as well as rhythmic jaw opening-closing tasks has led to the conclusion that 'functional jaw movements' are the result of activation of jaw as well as neck muscles, leading to simultaneous movements in the temporomandibular, atlanto-occipital and cervical spine joints. It can therefore be assumed that disease or injury to any of these joint systems would disturb natural jaw function. To test this hypothesis, amplitudes, temporal coordination, and spatiotemporal consistency of concomitant mandibular and head-neck movements during single maximal jaw opening-closing tasks were analysed in 25 individuals suffering from whiplash-associated disorders (WAD) using optoelectronic movement recording technique. In addition, the relative durations for which the head position was equal to, leading ahead of, or lagging behind the mandibular position during the entire jaw opening-closing cycle were determined. Compared with healthy individuals, the WAD group showed smaller amplitudes, and changed temporal coordination between mandibular and head-neck movements. No divergence from healthy individuals was found for the spatiotemporal consistency or for the analysis during the entire jaw opening-closing cycle. These findings in the WAD group of a 'faulty', but yet consistent, jaw-neck behavior may reflect a basic importance of linked control of the jaw and neck sensory-motor systems. In conclusion, the present results suggest that neck injury is associated with deranged control of mandibular and head-neck movements during jaw opening-closing tasks, and therefore might compromise natural jaw function.	Umea Univ, Dept Odontol Clin Oral Physiol, S-90187 Umea, Sweden; Gavle Univ, Ctr Musculoskeletal Res, Gavle, Sweden		Eriksson, PO (corresponding author), Umea Univ, Dept Clin Oral Physiol, S-90187 Umea, Sweden.	per-olof.eriksson@odont.umu.se	Haggman-Henrikson, Birgitta/C-6998-2008	Haggman-Henrikson, Birgitta/0000-0001-6088-3739; Zafar, Hamayun/0000-0001-9318-3691			Browne PA, 1998, ORAL SURG ORAL MED O, V86, P633, DOI 10.1016/S1079-2104(98)90195-0; Capra NF, 2000, PAIN, V86, P151, DOI 10.1016/S0304-3959(00)00231-1; De Laat A, 1998, Clin Oral Investig, V2, P54, DOI 10.1007/s007840050045; Dessem D, 1999, EXP BRAIN RES, V128, P451, DOI 10.1007/s002210050868; DJUPSJOBACKA M, 1995, NEUROSCI RES, V22, P325, DOI 10.1016/0168-0102(95)00906-A; Eriksson PO, 2000, J DENT RES, V79, P1378, DOI 10.1177/00220345000790060501; Eriksson PO, 1998, J ORAL REHABIL, V25, P859, DOI 10.1046/j.1365-2842.1998.00333.x; ERIKSSON PO, 1987, ARCH ORAL BIOL, V32, P483, DOI 10.1016/S0003-9969(87)80009-2; ERIKSSON PO, 1994, MUSCLE NERVE, V17, P31, DOI 10.1002/mus.880170105; Ferrari R, 1998, J AM DENT ASSOC, V129, P1739, DOI 10.14219/jada.archive.1998.0144; Freeman MD, 1999, SPINE, V24, P86, DOI 10.1097/00007632-199901010-00022; Goldberg MB, 1999, J OROFAC PAIN, V13, P291; Haggman-Henrikson B, 2002, J DENT RES, V81, P747, DOI 10.1177/154405910208101105; Helkimo M, 1974, Sven Tandlak Tidskr, V67, P165; Hellstrom F, 2000, J DENT RES, V79, P1815, DOI 10.1177/00220345000790101401; HELLSTROM F, 2002, THESIS UMEA U UMEA; HU JW, 1993, PAIN, V55, P243, DOI 10.1016/0304-3959(93)90153-G; Johansson H, 1999, AM J IND MED, P104; Josefsson T, 1996, COMPUT METH PROG BIO, V49, P119, DOI 10.1016/0169-2607(96)01715-4; Karppinen K, 1999, J ORAL REHABIL, V26, P715, DOI 10.1046/j.1365-2842.1999.00448.x; Kasch H, 2002, J OROFAC PAIN, V16, P118; KIRVESKARI P, 1984, COMMUNITY DENT ORAL, V12, P78, DOI 10.1111/j.1600-0528.1984.tb01417.x; Kirveskari P, 1984, Proc Finn Dent Soc, V80, P227; KIRVESKARI P, 1988, ACTA ODONTOL SCAND, V46, P281, DOI 10.3109/00016358809004778; Kohno S, 2001, J ORAL REHABIL, V28, P740, DOI 10.1046/j.1365-2842.2001.00707.x; Kolbinson Dean A., 1996, Journal of Orofacial Pain, V10, P101; LUND JP, 1991, CAN J PHYSIOL PHARM, V69, P683, DOI 10.1139/y91-102; McKay DC, 1998, J ORAL REHABIL, V25, P731, DOI 10.1046/j.1365-2842.1998.00321.x; OKESON JP, 1996, OROFACIAL PAIN GUIDE, P19; Pedersen J, 1997, PAIN, V70, P83, DOI 10.1016/S0304-3959(96)03305-2; Ro JY, 2001, PAIN, V92, P117, DOI 10.1016/S0304-3959(00)00477-2; SPITZER WO, 1995, SPINE, V20, pS1; Stohler CS, 1999, CRIT REV ORAL BIOL M, V10, P504, DOI 10.1177/10454411990100040601; Svensson P, 2001, J OROFAC PAIN, V15, P117; VISSCHER CM, 2000, THESIS ACAD CTR DENT; Wenngren BI, 1998, NEUROSCI RES, V32, P119, DOI 10.1016/S0168-0102(98)00074-1; Zafar H, 2000, ARCH ORAL BIOL, V45, P675, DOI 10.1016/S0003-9969(00)00032-7; Zafar H, 2000, J ORAL REHABIL, V27, P227, DOI 10.1046/j.1365-2842.2000.00505.x; Zafar H, 2002, EXP BRAIN RES, V146, P70, DOI 10.1007/s00221-002-1157-y; ZAFAR H, 2000, SWED DENT J S, V143, P1	40	33	34	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0909-8836	1600-0722		EUR J ORAL SCI	Eur. J. Oral Sci.	FEB	2004	112	1					25	32		10.1111/j.0909-8836.2004.00098.x			8	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	772WF	WOS:000188864400006	14871190				2022-02-06	
J	Kuipers, P; Kendall, M; Fleming, J; Tate, R				Kuipers, P; Kendall, M; Fleming, J; Tate, R			Comparison of the Sydney Psychosocial Reintegration Scale (SPRS) with the Community Integration Questionnaire (CIQ): psychometric properties	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; REHABILITATION; OUTCOMES; RELATIVES; VALIDITY; NEEDS	Primary objective: This study compared the psychometric properties of two community integration measures used with people with acquired brain injury (ABI) in the community. Research design: Questionnaires were mailed-out to people with ABI and nominated proxies. Methods and procedures: Responses were obtained from 96 people with ABI and 121 proxies on the Community Integration Questionnaire (CIQ) and the Sydney Psychosocial Reintegration Scale ( SPRS). Main outcomes and results: Matched client-proxy scores were not significantly different. The SPRS had greater internal consistency and more normal distributions than the CIQ. Correlations between the three pairs of theoretically parallel sub-scales were modest (0.41 - 0.60). Multi-dimensional scaling did not support the theoretical structure of the sub-scales, but found two dimensions underpinning the measurement of community integration. Conclusions: Mail-out administration is associated with poor completion rates. The SPRS has sound psychometric properties when compared to the CIQ. Further research investigating the theoretical structure of community integration in ABI is recommended.	Univ Queensland, CONROD, Herston, Qld 4006, Australia; Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia; Univ Queensland, St Lucia, Qld 4072, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Royal Rehabil Ctr Sydney, Ryde, NSW 1680, Australia		Kuipers, P (corresponding author), Univ Queensland, CONROD, Herston, Qld 4006, Australia.		Fleming, Jennifer M/B-4436-2011	Kuipers, Pim/0000-0003-0340-2286			BERKOWITZ S, 1996, NEEDS ASSESSMENT CRE, P33; Coakes S., 1999, SPSS ANAL ANGUISH; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; *CTR OUTC MEAS BRA, 2001, COMBI; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers M., 1998, TOP SPINAL CORD INJ, V4, P1, DOI DOI 10.1310/BJJA-2018-45KL-0VTL; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Hellawell DJ, 2000, DISABIL REHABIL, V22, P446, DOI 10.1080/09638280050045910; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Kruskal J. B., 1978, MULTIDIMENSIONAL SCA, V11; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, ICIDH INT CLASS IMP; World Health Organization, 2001, ICF INT CLASS FUNCT	26	33	33	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2004	18	2					161	177		10.1080/0269905031000149524			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000005	14660228				2022-02-06	
J	Funk, M; Endler, G; Schillinger, M; Mustafa, S; Hsieh, K; Exner, M; Lalouschek, W; Mannhalter, C; Wagner, O				Funk, M; Endler, G; Schillinger, M; Mustafa, S; Hsieh, K; Exner, M; Lalouschek, W; Mannhalter, C; Wagner, O			The effect of a promoter polymorphism in the heme oxygenase-1 gene on the risk of ischaemic cerebrovascular events - The influence of other vascular risk factors	THROMBOSIS RESEARCH			English	Article						heme oxygenase 1; GT dinucleotide repeats; ischaemic stroke; cerebrovascular disease	CORONARY-ARTERY-DISEASE; TRAUMATIC BRAIN-INJURY; MICROSATELLITE POLYMORPHISM; OXIDATIVE STRESS; RAT-BRAIN; CEREBRAL-ISCHEMIA; FOCAL ISCHEMIA; PROTEIN; EXPRESSION; BILIRUBIN	Heme oxygenase-1 (HO-1) has been demonstrated to exert potent anti-oxidant and anti-inflammatory effects in the context of atherosclerotic vascular disease, and therefore was referred to as a potential vascular protective factor. A (GT)n dinucteotide repeat polymorphism in the HO-1 promoter has been shown to modulate HO-1 gene expression. Short (< 25) GT repeats were associated with HO1 up-regulation, and therefore may influence susceptibility to ischaemic vascular events. We investigated the association of HO-1 repeat length with the risk of cerebrovascular events in a case control study and assessed possible interrelations with vascular risk factors. We determined the number of GT repeats in the HO-1 promoter in 399 patients with ischaemic cerebrovascular events and 398 healthy controls and compared the frequencies of short (<25) repeat (class S) and long (greater than or equal to 25) repeat (class L) alleles after adjustment for potentially confounding factors. Genotype distributions of S/S, S/L and L/L in patients were 9.8% (n = 39), 45.1% (n = 180) and 45.1% (n = 180), which was similar to the distribution in controls with 11.5% (n = 46), 44.5% (n = 177) and 44.0% (n = 175). In the presence of vascular risk factors, the HO-1 genotype became functionally relevant: in patients without hyperlipidemia the S/S genotype exerted a protective effect on the development of ischaemic cerebrovascular events (OR 0.2; 95% CI 0.1-0.6), while this effect was no longer present in hyperlipidemic patients. Short (<25 GT) repeats in the HO-1 gene promoter confer a reduced risk for cerebrovascular events in individuals with normal plasma lipid levels. This may explain controversial findings in different populations. (C) 2004 Elsevier Ltd. All rights reserved.	Med Univ Vienna, Klin Inst Med & Chem Labordiagnost, A-1090 Vienna, Austria; Med Univ Vienna, Div Angiol, Dept Internal Med 2, A-1090 Vienna, Austria; Med Univ Vienna, Dept Neurol, A-1090 Vienna, Austria		Mannhalter, C (corresponding author), Med Univ Vienna, Klin Inst Med & Chem Labordiagnost, Waehringerguertel 18-20, A-1090 Vienna, Austria.	Christine.Mannhalter@univie.ac.at; Oswald.Wagner@univie.ac.at		Mannhalter, Christine/0000-0001-7667-8078; Funk, Marion/0000-0002-4099-6995			Alf C, 2001, WIEN KLIN WOCHENSCHR, V113, P141; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; Endler G, 2004, THROMB HAEMOSTASIS, V91, P155, DOI 10.1160/TH03-05-0291; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; Hu FB, 2000, AM J CLIN NUTR, V72, P912; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Kaneda H, 2002, ARTERIOSCL THROM VAS, V22, P1680, DOI 10.1161/01.ATV.0000033515.96747.6F; Kitamura Y, 2003, J NEUROSCI RES, V71, P544, DOI 10.1002/jnr.10514; Le W, 1999, J NEUROSCI RES, V56, P652; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; NEUZIL J, 1994, J BIOL CHEM, V269, P16712; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; Panahian N, 1999, J NEUROCHEM, V72, P1187; Satoh T, 2003, EUR J NEUROSCI, V17, P2249, DOI 10.1046/j.1460-9568.2003.02688.x; Schillinger M, 2002, THROMB RES, V106, P131, DOI 10.1016/S0049-3848(02)00100-7; Schillinger M, 2002, J ENDOVASC THER, V9, P385, DOI 10.1583/1545-1550(2002)009<0385:HOGIAV>2.0.CO;2; Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; YAMAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V214, P11, DOI 10.1006/bbrc.1995.2250	30	33	39	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0049-3848			THROMB RES	Thromb. Res.		2004	113	3-4					217	223		10.1016/j.thromres.2004.03.003			7	Hematology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Hematology; Cardiovascular System & Cardiology	824ME	WOS:000221689900006	15140586				2022-02-06	
J	Harker, KT; Whishaw, IQ				Harker, KT; Whishaw, IQ			Impaired place navigation in place and matching-to-place swimming pool tasks follows both retrosplenial cortex lesions and cingulum bundle lesions in rats	HIPPOCAMPUS			English	Article						learning and memory; posterior cingulate; place learning; spatial behavior; hippocampal formation	HEAD-DIRECTION CELLS; SPATIAL MEMORY; HIPPOCAMPAL-FORMATION; BEHAVIORAL-ANALYSIS; POSTERIOR CORTEX; PERFORMANCE; DEFICITS; CONNECTIONS; TESTS; DARK	The retrosplenial (RS) cortex (area 29) and the adjacent cingulum bundle (CG) are components of neural circuits that include the hippocampus. Given the evidence suggesting that the hippocampus plays a central role in spatial navigation, several lines of investigation have examined the possible contributions of these structures to spatial navigation. The combined and/or separate contributions of these structures have been difficult to establish because their close proximity usually results in combined injury after lesions and because there have been conflicting results related to lesion type and the strain of rat subjects. The purpose of the present study was to compare the effects of selective CG damage with selective RS damage in Long-Evans rats, a domestic rat strain that displays superior spatial skills, and by using spatial behavior assessment procedures that are sensitive to CC damage. Rats with cytotoxic N-methyl-D-aspartate (NMDA) RS lesions or surgical CG transection were tested on two spatial tasks in the Morris water task; a place learning task, sensitive to nonspatial and spatial behavior, and a matching-to-place task, sensitive to spatial behavior. Both the RS and CG groups were impaired on most measures relative to the control group on both the place task and the matching-to-place task. The results are discussed in relation to the anatomical organization of CG and RG projections to the hippocampus and with respect to their possible separate/conjoint contributions to spatial behavior. (C) 2004 Wiley-Liss, Inc.	Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada		Harker, KT (corresponding author), Dalhousie Univ, Dept Psychol & Neurosci, 1355 Oxford St, Halifax, NS B3J 4J1, Canada.	kharker@dal.ca					AGGLETON JP, 1995, J NEUROSCI, V15, P7270; Brown RW, 2000, BEHAV BRAIN RES, V114, P135, DOI 10.1016/S0166-4328(00)00225-4; CHEN LL, 1994, EXP BRAIN RES, V101, P8, DOI 10.1007/BF00243212; CHEN LL, 1994, EXP BRAIN RES, V101, P24, DOI 10.1007/BF00243213; Cho JW, 2001, BEHAV NEUROSCI, V115, P3, DOI 10.1037//0735-7044.115.1.3; Cooper BG, 2001, J NEUROSCI, V21, P3986, DOI 10.1523/JNEUROSCI.21-11-03986.2001; Cooper BG, 2001, BEHAV NEUROSCI, V115, P1012, DOI 10.1037//0735-7044.115.5.1012; DOMESICK VB, 1969, BRAIN RES, V12, P296, DOI 10.1016/0006-8993(69)90002-X; Harker KT, 2002, J NEUROSCI, V22, P1155, DOI 10.1523/JNEUROSCI.22-03-01155.2002; Harker KT, 2002, BEHAV BRAIN RES, V134, P467; JELTSCH H, 1994, BEHAV NEURAL BIOL, V62, P121, DOI 10.1016/S0163-1047(05)80033-0; KOLB B, 1991, Brain Dysfunction, V4, P75; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MUFSON EJ, 1984, J COMP NEUROL, V225, P31, DOI 10.1002/cne.902250105; NEAVE N, 1994, BEHAV BRAIN RES, V65, P89, DOI 10.1016/0166-4328(94)90077-9; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; PAKHOMOVA A S, 1985, Neirofiziologiya, V17, P102; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Prusky GT, 2002, BEHAV BRAIN RES, V136, P339, DOI 10.1016/S0166-4328(02)00126-2; Saucier D, 1996, BEHAV NEUROSCI, V110, P103, DOI 10.1037/0735-7044.110.1.103; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; SUTHERLAND RJ, 1993, NEUROBIOLOGY CINGULA, P461; VANDERWOLF CH, 1985, ELECTRICAL ACTIVITY, P47; Vann SD, 2002, BEHAV NEUROSCI, V116, P85, DOI 10.1037//0735-7044.116.1.85; VOGT BA, 1983, J COMP NEUROL, V216, P192, DOI 10.1002/cne.902160207; Warburton EC, 1998, EUR J NEUROSCI, V10, P622, DOI 10.1046/j.1460-9568.1998.00074.x; Whishaw IQ, 1997, CURR OPIN NEUROBIOL, V7, P228, DOI 10.1016/S0959-4388(97)80011-6; WHISHAW IQ, 1985, BEHAV NEUROSCI, V99, P979, DOI 10.1037/0735-7044.99.5.979; WHISHAW IQ, 1985, PHYSIOL BEHAV, V35, P139, DOI 10.1016/0031-9384(85)90186-6; Whishaw IQ, 2001, BEHAV BRAIN RES, V118, P67, DOI 10.1016/S0166-4328(00)00312-0; Winer BJ, 1962, STAT PRINCIPLES EXPT; WYSS JM, 1992, HIPPOCAMPUS, V2, P1	35	33	34	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	1050-9631			HIPPOCAMPUS	Hippocampus		2004	14	2					224	231		10.1002/hipo.10159			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	805TF	WOS:000220387900010	15098727				2022-02-06	
J	Alessandri, B; Heimann, A; Filippi, R; Kopacz, L; Kempski, O				Alessandri, B; Heimann, A; Filippi, R; Kopacz, L; Kempski, O			Moderate controlled cortical contusion in pigs: Effects on multi-parametric neuromonitoring and clinical relevance	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; microdialysis; monitoring; pig; ptiO(2)	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; FLUID-PERCUSSION INJURY; INTRACRANIAL-PRESSURE; EXTRACELLULAR POTASSIUM; SUBSTRATE DELIVERY; OXYGEN-TENSION; INTENSIVE-CARE; TISSUE OXYGEN	Over the last decade, routine neuromonitoring of ICP and CPP has been extended with new on-line techniques such as microdialysis, tissue oxygen (ptiO(2)), acid-base balance (ptiCO(2), pH) and CBF measurements, which so far have not lead to clear-cut therapy approaches in the neurointensive care unit. This is partially due to the complex pathophysiology following a wide-range of brain injuries, and the lack of suitable animal models allowing simultaneous, clinically relevant neuromonitoring under controlled conditions. Therefore, a controlled cortical impact (CCI) model in large animals (pig) has been developed. After placement of microdialysis, ptiO(2), temperature and ICP catheters, an unilateral CCI injury (2.6-2.8 m/sec velocity, 9 mm depth, 400 ms dwell time) was applied and neuromonitoring continued for 10 h. CCI caused a rapid drop in CPP, ptiO(2) and glucose, whereas ICP, glutamate and lactate increased significantly. Most parameters returned to baseline values within hours. Lactate stayed elevated significantly throughout the experiment, but the lactate-to-pyruvate ratio (LPR) changed only slightly, indicating no severely ischemic CBF. Contralateral parameters were not affected significantly. Evaluation of brain water content and histology (12 h post-CCI) showed ipsilateral brain swelling by 5% and massive cell damage underneath the injury site which correlated with changes of ICP, CPP, glutamate, lactate, and ptiO(2) within the first hours post-CCI. Moderate controlled cortical contusion in pigs induced a complex pattern of pathophysiological processes which led to `early' histological damage. Thus, this new large animal model will enable us to investigate the effect of therapeutic interventions on multi-parametric neuromonitoring and histological outcome, and to translate the data into clinical practice.	Johannes Gutenberg Univ Mainz, Inst Neurosurg Pathophysiol, D-6500 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Neurosurg, D-6500 Mainz, Germany		Alessandri, B (corresponding author), Johannes Gutenberg Univ Mainz, Inst Neurosurg Pathophysiol, D-6500 Mainz, Germany.	beat.alessandri@uni-mainz.de		Heimann, Axel/0000-0003-2510-3228			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Alessandri B, 1996, ACT NEUR S, V67, P6; Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; Alessandri B, 1999, ACT NEUR S, V75, P21; Alessandri B, 1999, ACT NEUR S, V75, P25; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Barbiro-Micahely E, 2001, J NEUROTRAUM, V18, P711, DOI 10.1089/089771501750357654; Bardt TF, 1998, ACT NEUR S, V71, P153; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Felix B, 1999, BRAIN RES BULL, V49, P1, DOI 10.1016/S0361-9230(99)00012-X; Fray AE, 1996, J PHYSIOL-LONDON, V496, P49, DOI 10.1113/jphysiol.1996.sp021664; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Goodman JC, 1996, ACT NEUR S, V67, P37; Goodman JC, 1999, ACT NEUR S, V75, P35; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempski O, 1990, Adv Neurol, V52, P219; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LANDOLT H, 1994, ACTA NEUROCHIR, P475; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vath A, 2000, ZBL NEUROCHIR, V61, P2, DOI 10.1055/s-2000-8258; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	58	33	33	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1293	1305		10.1089/089771503322686094			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700002	14748978				2022-02-06	
J	Hashiguchi, N; Shiozaki, T; Ogura, H; Tanaka, H; Koh, T; Noborio, M; Fugita, K; Akimau, P; Kuwagata, Y; Shimazu, T; Sugimoto, H				Hashiguchi, N; Shiozaki, T; Ogura, H; Tanaka, H; Koh, T; Noborio, M; Fugita, K; Akimau, P; Kuwagata, Y; Shimazu, T; Sugimoto, H			Mild hypothermia reduces expression of heat shock protein 60 in leukocytes from severely head-injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						heat shock protein 60; head injury; mild hypothermia; infectious complication; polymorphonuclear leukocyte; flow cytometry	LOW INTRACRANIAL-PRESSURE; TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; ENHANCED EXPRESSION; SHOCK PROTEINS; THERAPY; CELLS; MYCOBACTERIAL; INFECTIONS; INVITRO	Background. Infectious complications are among the most serious problems that occur in severely head-injured patients treated with mild hypothermia. The mechanism underlying the susceptibility to infection has not been clarified. Heat shock protein (HSP) 60 has been reported to play an essential role in innate immunity. Thus, we conducted a study to clarify the impact of mild hypothermia on the expression of HSPs in polymorphonuclear leukocytes (PMNLs) in severely head-injured patients. Methods. Between September 1997 and November 1999, 17 severely head-injured patients with a Glasgow Coma Scale score of 8 or less at admission in whom intracranial pressure could be maintained below 20 mm Hg by conventional therapy were randomly assigned to two treatment groups: a mild hypothermia group (HT group, nine patients) and a normothermia group (NT group, eight patients). The HT group was subjected to mild hypothermia (intracranial temperature, 34degreesC) for 48 hours followed by rewarming at a rate of VC per day for 3 days, whereas the NT group was subjected to normothermia (intracranial temperature, 37degreesC) for 5 days. Blood samples were serially obtained at three time points; days 0 to 1, days 2 to 5, and days 6 to 14 after head injury. We measured the expression of HSP27, HSP60, HSP70, and HSP90 by flow cytometry. Results. The two groups were similar with respect to prognostic factors, and there was no difference in clinical outcome. The expression of PMNL HSP60 in the HT group was significantly lower in all three time periods compared with that in the NT group (p < 0.05), whereas expression of the other HSPs did not differ significantly between the groups. The incidence of infectious complications was significantly increased in the HT group over that in the NT group (p < 0.05). In in vitro studies, PMNLs from 10 healthy volunteers were incubated at 37degreesC, 34degreesC, or 26degreesC for 1 hour with sodium arsenite (100,mumol/L), an HSP inducer. The expression of HSP60 at 26degreesC and 34degreesC was significantly lower than that at 37degreesC (p < 0.05), whereas expression of the other HSPs did not differ significantly at 26degreesC, 34degreesC, or 37degreesC. Conclusion: Mild hypothermia reduces the expression of HSP60 in PMNLs from severely head-injured patients. Thus, mild hypothermia may suppress innate immunity.	Osaka Univ, Dept Traumatol D 8, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Clin Invest, Grad Sch Med, Suita, Osaka 5650871, Japan; Tottori Prefectual Cent Hosp, Dept Traumatol & Crit Care Med, Tottori, Japan		Hashiguchi, N (corresponding author), Osaka Univ, Dept Traumatol D 8, Grad Sch Med, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan.	hashiguchi@mx51.tiki.ne.jp					AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51, DOI 10.1002/jlb.37.1.51; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; CHANT ID, 1995, BRIT J HAEMATOL, V90, P163, DOI 10.1111/j.1365-2141.1995.tb03395.x; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; FERRICK DA, 1992, CHEM IMMUNOL, V53, P17; Hashiguchi N, 2001, J TRAUMA, V51, P1104, DOI 10.1097/00005373-200112000-00015; Hashiguchi N, 2001, J TRAUMA, V50, P102, DOI 10.1097/00005373-200101000-00018; Jason J, 2000, J INFECT DIS, V182, P474, DOI 10.1086/315740; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KAUFMANN SHE, 1991, IMMUNOL REV, V121, P67, DOI 10.1111/j.1600-065X.1991.tb00823.x; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; LEE KJ, 1998, J CELL PHYSL, V136, P411; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; OBRIEN RL, 1991, IMMUNOL REV, V121, P155, DOI 10.1111/j.1600-065X.1991.tb00827.x; PEETERMANS WE, 1994, SCAND J IMMUNOL, V39, P613, DOI 10.1111/j.1365-3083.1994.tb03421.x; SHINNICK TM, 1991, CURR TOP MICROBIOL, V167, P145; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; THOMAS G, 1986, J PHARM PHARMACOL, V38, P936, DOI 10.1111/j.2042-7158.1986.tb03390.x; Wiegant FAC, 1996, J CELL PHYSIOL, V169, P364, DOI 10.1002/(SICI)1097-4652(199611)169:2<364::AID-JCP16>3.0.CO;2-9	24	33	36	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1054	1060		10.1097/01.TA.0000033252.43742.8B			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	758TL	WOS:000187666200009	14676650				2022-02-06	
J	Messori, A; Polonara, G; Mabiglia, C; Salvolini, U				Messori, A; Polonara, G; Mabiglia, C; Salvolini, U			Is haemosiderin visible indefinitely on gradient-echo MRI following traumatic intracerebral haemorrhage?	NEURORADIOLOGY			English	Article						head injury; cerebral haemorrhage; haemosiderin; magnetic resonance imaging	DIFFUSE AXONAL INJURY; HIGH-FIELD MR; HEAD-INJURY; MAGNETIC-RESONANCE; CEREBRAL MICROBLEEDS; BRAIN; FERRITIN; HEMATOMAS; IRON; CT	Gradient-echo (GE) MRI has been demonstrated to be the most sensitive current technique for detection of intracerebral haemosiderin, especially in the chronic stage of haemorrhage. Our purpose was to see whether GE MRI shows old haemorrhage indefinitely. We reviewed serial GE images of 105 adults with imaging features consistent with post-traumatic intracerebral haemorrhage, who had serial MRI at 1, 4-6, 12, and 24 months after trauma. Of 1235 scattered low-signal foci consistent with isolated intracerebral haemosiderin deposits on images at 4-6 months, 248 (20.1%) were not seen at 24-month assessment. Reviewing individual patients, we saw that in 71.8% of those with scattered haemosiderin deposits and 46.4% of those with haemosiderin surrounded by gliosis, the low-signal foci appeared less conspicuous with time. Even given certain limitations to the interpretation of these findings, it would appear that, even with the use of GE MRI, time affects the visibility of haemorrhagic intracerebral lesions. We therefore conclude that a time of 4-6 months to 1 year or slightly more should be recommended for most precise detection of haemosiderin deposits on MRI of head-injured patients, should this be thought desirable. Normal GE images may not exclude old haemorrhage.	Umberto I Hosp & Univ Ancona, Dept Neuroradiol, I-60020 Ancona, Italy		Salvolini, U (corresponding author), Umberto I Hosp & Univ Ancona, Dept Neuroradiol, Via Conca, I-60020 Ancona, Italy.		Messori, Andrea/U-6903-2019	POLONARA, GABRIELE/0000-0002-2866-2749			Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; CAMPEAU NG, 2001, NEURORADIOLOGY, V43, pS89; Chan S, 1996, AM J NEURORADIOL, V17, P1821; CHEN JC, 1989, RADIOLOGY, V173, P521, DOI 10.1148/radiology.173.2.2798884; CHEN JC, 1993, AM J NEURORADIOL, V14, P275; DARROW VC, 1988, AM J PATHOL, V130, P44; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; FOBBEN ES, 1989, AM J NEURORADIOL, V10, P687; GENTRY LR, 1994, RADIOLOGY, V191, P1; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; Greenberg SM, 1999, NEUROLOGY, V53, P1135, DOI 10.1212/WNL.53.5.1135; Greenberg SM, 1996, NEUROLOGY, V46, P1751, DOI 10.1212/WNL.46.6.1751; Grossman R I, 1988, Radiographics, V8, P441; HESSELINK JR, 1988, AM J NEURORADIOL, V9, P269; Kuzma BB, 2000, SURG NEUROL, V53, P400; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Patel MR, 1996, STROKE, V27, P2321, DOI 10.1161/01.STR.27.12.2321; PELLICANO G, 1997, NEURORADIOLOGY, V39, pS82; Roob G, 1999, NEUROLOGY, V52, P991, DOI 10.1212/WNL.52.5.991; Roob G, 2000, CURR OPIN NEUROL, V13, P69, DOI 10.1097/00019052-200002000-00013; SCHARF J, 1994, NEURORADIOLOGY, V36, P504, DOI 10.1007/BF00593508; THULBORN KR, 1990, AM J NEURORADIOL, V11, P291; Tsushima Y, 2002, NEURORADIOLOGY, V44, P31, DOI 10.1007/s002340100649; Tsushima Y, 2000, NEURORADIOLOGY, V42, P499, DOI 10.1007/s002340000326; UNGER EC, 1989, MAGN RESON IMAGING, V7, P163, DOI 10.1016/0730-725X(89)90700-5; Vymazal J, 2000, CELL MOL BIOL, V46, P835; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757; ZYED A, 1991, AM J NEURORADIOL, V12, P469	34	33	33	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	DEC	2003	45	12					881	886		10.1007/s00234-003-1048-3			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	749XY	WOS:000186956400007	14579110				2022-02-06	
J	Zygun, DA; Doig, CJ; Gupta, AK; Whiting, G; Nicholas, C; Shepherd, E; Conway-Smith, C; Menon, DK				Zygun, DA; Doig, CJ; Gupta, AK; Whiting, G; Nicholas, C; Shepherd, E; Conway-Smith, C; Menon, DK			Non-neurological organ dysfunction in neurocritical care	JOURNAL OF CRITICAL CARE			English	Article							CEREBRAL-BLOOD-FLOW; SOFA SCORE; BRAIN-INJURY; METABOLISM; CIRCULATION	Purpose: To determine the incidence of non-neurological organ dysfunction in patients with severe neurological injury. Materials and Methods: Modified daily SOFA (mSOFA) scores were retrospectively calculated for 55 consecutive patients with severe head injury or subarachnoid hemorrhage. mSOFA was defined as the sum of the 5 non-neurological component SOFA scores, maximum mSOFA as the sum of the most abnormal non-neurological SOFA component scores and delta mSOFA as the difference between maximum mSOFA and admission mSOFA. Organ failure was defined as a SOFA component score greater than or equal to3. Results: Median (IQR) admission, maximum and delta mSOFA scores were 4 (3-6),8 (6-9), and 2 (1-5), respectively. Respiratory and cardiac failure developed in 80% and 82% of patients, respectively. No patient developed renal or hepatic failure. Three patients developed hematological failure. There was no difference between survivors and nonsurvivors with respect to admission mSOFA (P = .45), maximum mSOFA (P = .54), or delta mSOFA (P = .19). There was no difference between those patients with favorable or unfavorable neurological outcome with respect to admission mSOFA (P = .24), maximum mSOFA (P = .84), or delta mSOFA (P = .20). Conclusions: Cardiopulmonary failure, as defined by SOFA, is common in intensive care unit patients with severe head injury and subarachnoid hemorrhage. In contrast to other intensive care unit patient populations, the mortality of patients with closed head injury or subarachnoid hemorrhage was not related to the severity of organ dysfunction on admission or its development during the intensive care unit stay. (C) 2003 Elsevier Inc. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Anesthesia, Cambridge, England; Addenbrookes Hosp, Cambridge, England; Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada		Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Neurosci Crit Care Unit, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Doig, Christopher/AAC-7949-2020	Doig, Christopher/0000-0002-8576-9139			Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026; Bota DP, 2002, INTENS CARE MED, V28, P1619, DOI 10.1007/s00134-002-1491-3; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; DEVLIN EG, 1994, BRIT J ANAESTH, V73, P315, DOI 10.1093/bja/73.3.315; Dujardin KS, 2001, J HEART LUNG TRANSPL, V20, P350, DOI 10.1016/S1053-2498(00)00193-5; GADKARY CS, 2002, COCHRANE DATABASE SY; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Hayashi T, 2000, J NEUROSURG, V93, P1014, DOI 10.3171/jns.2000.93.6.1014; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Loop T, 2002, ANESTHESIOLOGY, V96, P1202, DOI 10.1097/00000542-200205000-00025; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	21	33	36	2	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	DEC	2003	18	4					238	244		10.1016/j.jcrc.2003.10.007			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	759BG	WOS:000187717500006	14691897				2022-02-06	
J	Borgaro, SR; Prigatano, GP				Borgaro, SR; Prigatano, GP			Modification of the Patient Competency Rating Scale for use on an acute neurorehabilitation unit: the PCRS-NR	BRAIN INJURY			English	Article							AWARENESS; DEFICITS; INJURY	Objective: The Patient Competency Rating Scale (PCRS) is a 30-item self-report questionnaire that was developed to assess awareness of deficits in post-acute patients following traumatic brain injury (TBI). The purpose of this study was to develop a modified and psychometrically sound version of the PCRS for use on an acute, inpatient neurorehabilitation unit. Research design: Prospective cohort of patients seen for inpatient rehabilitation following brain injury. Procedures: Nineteen items from the original PCRS were retained for their applicability to an inpatient neurorehabilitation unit and administered to 108 acute neurological inpatients. Results: Principle components factor analyses with varimax rotation yielded a three factor solution. Acceptable internal consistencies were calculated for each factor and the total PCRS score. Conclusions: These findings document the psychometric properties of a briefer version of the PCRS for use on an inpatient rehabilitation unit. This modified version has been labelled the PCRS for neurorehabilitation (i.e. PCRS-NR).	St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA		Borgaro, SR (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	sborgar@chw.edu					BAER DM, 1983, NEUROLOGICAL REV, V40, P195; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; DILLER L, 1981, J CONSULT CLIN PSYCH, V49, P822, DOI 10.1037/0022-006X.49.6.822; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, 1975, AWARENESS DEFICIT BR; PRIGATANO GP, 1983, REHABIL PSYCHOL, V34, P135; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SHERER M, IN PRESS ARCH PHYSIC; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; [No title captured]	22	33	36	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2003	17	10					847	853		10.1080/0269905031000089350			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	719CR	WOS:000185186500003	12963551				2022-02-06	
J	Huh, JW; Raghupathi, R; Laurer, HL; Helfaer, MA; Saatman, KE				Huh, JW; Raghupathi, R; Laurer, HL; Helfaer, MA; Saatman, KE			Transient loss of microtubule-associated protein 2 immunoreactivity after moderate brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						cytoskeleton; head injury; immunohistochemistry; microtubule-associated protein 2 (MAP2); plasticity; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT; CYTOSKELETAL ALTERATIONS; MAP2 IMMUNOREACTIVITY; MOLECULAR MECHANISMS; RAT; CALPAIN; PROTEOLYSIS; DEGRADATION; HIPPOCAMPUS	Microtubule-associated protein 2 (MAP2) is important for microtubule stability and neural plasticity and appears to be among the most vulnerable of the cytoskeletal proteins under conditions of neuronal injury. To evaluate the acute effects of moderate severity traumatic brain injury on MAP2, anesthetized, adult male C57BL/6 mice were subjected to controlled cortical impact brain injury. At 5 min, 15 min, 90 min, 4 h, and 24 h following brain injury (n = 4 injured and n = 1 sham-injured per time point), mice were sacrificed and immunohistochemistry was performed on coronal brain sections. Profound decreases in MAP2 immunolabeling were observed in the ipsilateral cortex and hippocampal dentate hilus at 5 min postinjury and in the ipsilateral hippocampal CA3 area by 4 h postinjury. Decreases in MAP2 labeling occurred prior to notable neuronal cell loss. Interestingly, cortical MAP2 immunoreactivity returned by 90 min postinjury, but the recovery was short-lived within the core in comparison to the periphery of the impact site. Partial restoration of MAP2 immunoreactivity was also observed in the ipsilateral CA3 and dentate hilus by 24 h postinjury. Our data corroborate that MAP2 is an early and sensitive marker for neuronal damage following traumatic brain injury. Acute MAP2 loss, however, may not necessarily presage neuronal death, even following moderate severity traumatic brain injury. Rather, to the best of our knowledge, our data are the first to suggest an intrinsic ability of the traumatized brain for MAP2 recovery after injury of moderate severity.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA USA; Drexel Univ, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA		Saatman, KE (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 113 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS41561, P50-NS08803] Funding Source: Medline		Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; AVILA J, 1992, LIFE SCI, V50, P327, DOI 10.1016/0024-3205(92)90433-P; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KITAGAWA K, 1989, NEUROSCIENCE, V2, P401; KWAK S, 1988, J NEUROCYTOL, V17, P189, DOI 10.1007/BF01674206; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li Y, 1998, STROKE, V29, P1972, DOI 10.1161/01.STR.29.9.1972; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.ne.11.030188.000333; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; *NAT RES COUNC, 1996, GUID CAR US LAB; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Popa-Wagner A, 1999, J CEREBR BLOOD F MET, V19, P425, DOI 10.1097/00004647-199904000-00008; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SAATMAN KE, 1999, J NEUROTRAUM, V16, P1002; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281	37	33	37	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					975	984		10.1089/089771503770195821			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300006	14588114				2022-02-06	
J	von Gertten, C; Holmin, S; Mathiesen, T; Nordqvist, ACS				von Gertten, C; Holmin, S; Mathiesen, T; Nordqvist, ACS			Increases in matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 mRNA after cerebral contusion and depolarisation	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						rat; traumatic brain injury (TBI); in situ hybridisation; RT-PCR	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CORTICAL SPREADING DEPRESSION; GENE KNOCK-OUT; RAT-BRAIN; C-FOS; CYTOKINE EXPRESSION; FOCAL ISCHEMIA; GELATINASE-B; BARRIER	Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) play major roles in physiological extracellular matrix turnover during normal development and in pathological processes. In brain, increases in MMP activity occur, for example, in multiple sclerosis, Alzheimer's disease, and after head trauma. We examined MMP-9 and TIMP-1, -2, and -3 in events after head trauma. A time-course study was carried out using two different rat injury models, cerebral contusion and depolarisation. Brains were analysed by RT-PCR and in situ hybridisation. We observed a distinct and time-dependent upregulation of MMP-9 and TIMP-1 mRNA in ipsilateral cortical areas. MMP-9 mRNA levels were upregulated 1 day after cerebral contusion with a peak at Day 4. Depolarisation per se, which also occurs after traumatic brain injury, lead to delayed increase of MMP-9 mRNA, 4 days post application. At Day 14, MMP-9 mRNA levels were indistinguishable from controls in both models. TIMP-1 mRNA increases were observed in both models 4 hr after injury, and increased further at Days 1 and 4. At Day 14, mRNA levels declined and were no higher than control levels. No alterations in mRNA levels were noted for TIMP-2 or -3. Our results support earlier reports on MMP-9 involvement in brain injury. It also shows a role for TIMP-1 in the mechanisms of trauma, where depolarisation could be the mechanism responsible for this upregulation. (C) 2003 Wiley-Liss, Inc.	Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden		Nordqvist, ACS (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden.		mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Bode W, 2001, Methods Mol Biol, V151, P45; Bugno M, 1999, FEBS LETT, V448, P9, DOI 10.1016/S0014-5793(99)00323-3; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; COUSSENS LM, 2001, METHOD MOL BIOL, V151, P149; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FED EUR BIOCH SOC, V1, P29; Hermann DM, 1999, NEUROSCIENCE, V88, P599, DOI 10.1016/S0306-4522(98)00249-8; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jaworski DM, 2000, J NEUROSCI RES, V61, P396, DOI 10.1002/1097-4547(20000815)61:4<396::AID-JNR6>3.0.CO;2-S; Jaworski J, 1999, J BIOL CHEM, V274, P28106, DOI 10.1074/jbc.274.40.28106; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Kariko K, 1998, J CEREBR BLOOD F MET, V18, P1308, DOI 10.1097/00004647-199812000-00005; Kawahara N, 1999, EXP NEUROL, V158, P27, DOI 10.1006/exnr.1999.7091; Khuth ST, 2001, J VIROL, V75, P8268, DOI 10.1128/JVI.75.17.8268-8282.2001; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Parsons AA, 1998, CURR OPIN NEUROL, V11, P227, DOI 10.1097/00019052-199806000-00006; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Rangel YM, 2001, MOL BRAIN RES, V88, P103, DOI 10.1016/S0169-328X(01)00037-7; Rathke-Hartlieb S, 2000, FEBS LETT, V481, P227, DOI 10.1016/S0014-5793(00)02011-1; Rivera S, 1997, J NEUROSCI, V17, P4223; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; ROSENBERG GA, 1992, BRAIN RES, V576, P203, DOI 10.1016/0006-8993(92)90681-X; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vincenti M P, 2001, Methods Mol Biol, V151, P121; Wang XK, 1998, J CEREBR BLOOD F MET, V18, P1173, DOI 10.1097/00004647-199811000-00002; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	52	33	33	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	SEP 15	2003	73	6					803	810		10.1002/jnr.10729			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	718MK	WOS:000185150400007	12949906				2022-02-06	
J	Alvarez, XA; Sampedro, C; Perez, P; Laredo, M; Couceiro, V; Hernandez, A; Figueroa, J; Varela, M; Arias, D; Corzo, L; Zas, R; Lombardi, V; Fernandez-Novoa, L; Pichel, V; Cacabelos, R; Windisch, M; Aleixandre, M; Moessler, H				Alvarez, XA; Sampedro, C; Perez, P; Laredo, M; Couceiro, V; Hernandez, A; Figueroa, J; Varela, M; Arias, D; Corzo, L; Zas, R; Lombardi, V; Fernandez-Novoa, L; Pichel, V; Cacabelos, R; Windisch, M; Aleixandre, M; Moessler, H			Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: An exploratory study	INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY			English	Article						cerebrolysin; clinical outcome; cognition; quantitative EEG; traumatic brain injury	DOUBLE-BLIND; ALZHEIMERS-DISEASE; PERFORMANCE; SEVERITY; DAMAGE	The potential effects of Cerebrolysin (EBEWE Pharma, Unterach, Austria), a peptide preparation with neurotrophic activity, on brain bioelectrical activity, cognitive performance and clinical outcome in postacute traumatic brain injury (TBI) patients, were investigated in an exploratory study. A decrease in slow electroencephalogram (EEG) activity and an increase in fast frequencies were observed after the administration of Cerebrolysin. This EEG-activating effect was not influenced by TBI time course or severity, nor by the chronic treatment with nootropic compounds. Cognitive performance, evaluated with the Syndrome Kurztest test, improved in TBI patients after Cerebrolysin treatment, independent of disease severity, time course or disability. A significant improvement in the patients' clinical outcome, only evident during the first year after brain trauma, was also found following Cerebrolysin infusions. No relevant changes in biological parameters nor drug-related adverse events were observed. These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials. (C) 2003 Lippincott Williams Wilkins.	EuroEspes Biomed Res Ctr, Dept Neuropharmacol, La Coruna 15166, Spain; JSW Res Inc, Graz, Austria; Univ Granada, Fac Psicol, Granada, Spain; EBEWE Pharma, Unterach, Austria		Alvarez, XA (corresponding author), EuroEspes Biomed Res Ctr, Dept Neuropharmacol, La Coruna 15166, Spain.	me-direccion@euroespes.com					AKAI F, 1992, HISTOL HISTOPATHOL, V7, P213; ALBRECHT E, 1993, ADV BIOSCI, V87, P341; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281; Alvarez XA, 1999, METHOD FIND EXP CLIN, V21, P633; Alvarez XA, 1999, 1ST INTERNATIONAL CONGRESS ON VASCULAR DEMENTIA, P233; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P315; ALVAREZ XA, 2001, RES PRACTICE ALZHEIM, V5, P179; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Bae CY, 2000, J AM GERIATR SOC, V48, P1566, DOI 10.1111/j.1532-5415.2000.tb03865.x; Cacabelos R, 1996, ANN NY ACAD SCI, V777, P399, DOI 10.1111/j.1749-6632.1996.tb34452.x; CACABELOS R, 1996, ALZHEIMER DIS MOL BI, P469; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; FrancisTurner L, 1996, NEUROSCI LETT, V202, P193, DOI 10.1016/0304-3940(95)12240-0; Funke M, 1998, J NEURAL TRANSM-SUPP, P385; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Hutter-Paier B, 1998, J NEURAL TRANSM-SUPP, P351; HutterPaier B, 1996, J NEURAL TRANSM-SUPP, P267; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lombardi VRM, 1999, METHOD FIND EXP CLIN, V21, P331, DOI 10.1358/mf.1999.21.5.541910; Masliah E, 1999, PHARMACOL BIOCHEM BE, V62, P239, DOI 10.1016/S0091-3057(98)00144-0; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Muller SV, 2002, ARCH PHYS MED REHAB, V83, P115, DOI 10.1053/apmr.2002.27472; Overall J E, 1992, J Geriatr Psychiatry Neurol, V5, P220; Panisset M, 2002, J NEURAL TRANSM, V109, P1089, DOI 10.1007/s007020200092; PEREZ P, 1999, ANN PSYCHIAT, V7, P77; RAINER M, 2002, RES PRACTICE ALZHEIM, V6, P244; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rockenstein E, 2002, J NEURAL TRANSM-SUPP, P327; Ruether E, 2002, J NEURAL TRANSM-SUPP, P265; Ruether E, 2001, INT CLIN PSYCHOPHARM, V16, P253, DOI 10.1097/00004850-200109000-00002; RUTHER E, 1994, PHARMACOPSYCHIATRY, V27, P32, DOI 10.1055/s-2007-1014271; SALETU B, 1995, INT J CLIN PHARM TH, V33, P249; Satou T., 1994, JPN PHARMACOL THER, V22, P205; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Silvestrini MC, 1997, NAT MED, V3, P521, DOI 10.1038/nm0597-521; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Wallace BE, 2001, J HEAD TRAUMA REHAB, V16, P165, DOI 10.1097/00001199-200104000-00006; Windisch M, 1998, J NEURAL TRANSM-SUPP, P289	47	33	36	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0268-1315	1473-5857		INT CLIN PSYCHOPHARM	Int. Clin. Psychopharmacol.	SEP	2003	18	5					271	278		10.1097/07.yic.0000085765.24936.9a			8	Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pharmacology & Pharmacy; Psychiatry	715WA	WOS:000184994700003	12920387				2022-02-06	
J	Penkowa, M; Camats, J; Giralt, M; Molinero, A; Hernandez, J; Carrasco, J; Campbell, IL; Hidalgo, J				Penkowa, M; Camats, J; Giralt, M; Molinero, A; Hernandez, J; Carrasco, J; Campbell, IL; Hidalgo, J			Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression	GLIA			English	Article						metallothionein-I; overexpression; transgenic mice; interleukin-6	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INCREASED OXIDATIVE STRESS; FOCAL CEREBRAL-ISCHEMIA; ACID-INDUCED SEIZURES; DEFICIENT MICE; GENE-EXPRESSION; NEURODEGENERATIVE DISEASES; CYTOKINE ACTIONS; IMMUNE FUNCTION	Transgenic expression of IL-6 in the CNS under the control of the GFAP gene promoter, glial fibrillary acidic protein-interleukin-6 (GFAP-IL-6) mice, raises an inflammatory response and causes significant brain damage. However, the results obtained in the GFAP-IL-6 mice after a traumatic brain injury, such as a cryolesion, demonstrate a neuroprotective role of IL-6. Thus, the GFAP-IL-6 mice showed faster tissue repair and decreased oxidative stress and apoptosis compared with control litter-mate mice. The neuroprotective factors metallothionein-I + II (MT-I+II) were upregulated by the cryolesion to a higher extent in the GFAP-IL-6 mice, suggesting that they could be related to the neuroprotection afforded by the transgenic expression of IL-6. To examine this possibility, we have crossed GFAP-IL-6 mice with transgenic mice overexpressing MT-I (TgMT), producing double transgenic GFAP-IL-6 TgMT mice. The results obtained after cryolesion in GFAP-IL-6 TgMT mice, as well as in TgMT mice, consistently supported the idea that the increased MT-I+II levels observed in GFAP-IL-6 mice are a fundamental and important mechanism for coping with brain damage. Accordingly, MT-I overexpression regulated the inflammatory response, decreased oxidative stress and apoptosis significantly, and increased brain tissue repair in comparison with either GFAP-IL-6 or control litter-mate mice. Overall, the results demonstrate that brain MT-I+II proteins are fundamental neuroprotective factors.	Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Univ Autonoma Barcelona, Fac Ciencias, Inst Neurosci, E-08193 Barcelona, Spain; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA USA		Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain.		Giralt, Mercedes/K-1626-2014; Hernandez, Joaquim/E-1298-2011; Hidalgo, Juan/C-9082-2011; Carrasco, Javier/C-9732-2011; molinero, amalia/K-2147-2014	Giralt, Mercedes/0000-0002-1806-1528; Hernandez, Joaquim/0000-0003-1409-5568; Hidalgo, Juan/0000-0003-0921-1122; Carrasco, Javier/0000-0001-6436-0863; molinero, amalia/0000-0001-8661-8570	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA12444] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH50426] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH050426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA012444] Funding Source: NIH RePORTER		Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Borghesi LA, 1996, TOXICOLOGY, V108, P129, DOI 10.1016/S0300-483X(95)03243-9; Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carrasco J, 1998, EXP NEUROL, V153, P184, DOI 10.1006/exnr.1998.6861; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Chen Y, 2002, BIOCHEMISTRY-US, V41, P8360, DOI 10.1021/bi020030+; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Crowthers KC, 2000, TOXICOL APPL PHARM, V166, P161, DOI 10.1006/taap.2000.8961; Dalton T, 1996, ENVIRON HEALTH PERSP, V104, P68, DOI 10.2307/3432762; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851; GASULL T, 1994, AM J PHYSIOL, V266, pE760, DOI 10.1152/ajpendo.1994.266.5.E760; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Hernandez J, 1997, MOL BRAIN RES, V48, P125, DOI 10.1016/S0169-328X(97)00087-9; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Hidalgo J, 2002, METHOD ENZYMOL, V348, P238, DOI 10.1016/S0076-6879(02)48642-9; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee YS, 1999, J AM ASSOC GYN LAP, V6, P59, DOI 10.1016/S1074-3804(99)80042-5; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168; Nagano S, 2001, EUR J NEUROSCI, V13, P1363, DOI 10.1046/j.0953-816x.2001.01512.x; Okuda Y, 1999, J NEUROIMMUNOL, V101, P188, DOI 10.1016/S0165-5728(99)00139-3; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Penkowa M, 2000, EXP NEUROL, V163, P72, DOI 10.1006/exnr.2000.7383; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; Sugiura S, 2000, EUR J NEUROSCI, V12, P457, DOI 10.1046/j.1460-9568.2000.00922.x; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Wang GW, 2001, J PHARMACOL EXP THER, V298, P461; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; YOUN J, 1995, J TOXICOL ENV HEALTH, V45, P397, DOI 10.1080/15287399509532004; Youn J, 1999, TOXICOL SCI, V52, P199, DOI 10.1093/toxsci/52.2.199	73	33	36	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	MAY	2003	42	3					287	306		10.1002/glia.10208			20	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	671TT	WOS:000182480700007	12673834				2022-02-06	
J	Stendel, R; Heidenreich, J; Schilling, A; Akhavan-Sigari, R; Kurth, R; Picht, T; Pietila, T; Suess, O; Kern, C; Meisel, J; Brock, M				Stendel, R; Heidenreich, J; Schilling, A; Akhavan-Sigari, R; Kurth, R; Picht, T; Pietila, T; Suess, O; Kern, C; Meisel, J; Brock, M			Clinical evaluation of a new intracranial pressure monitoring device	ACTA NEUROCHIRURGICA			English	Article							FIBEROPTIC DEVICE; COMPLICATIONS; INFECTIONS; PROBES; RISK	Background. Continuous monitoring of intracranial pressure (ICP) still plays a key role in the management of patients at risk from intracranial hypertension. Numerous ICP-measuring devices are available. The aim of the present study was to investigate the clinical characteristics and the magnetic resonance imaging (MRI) compatibility of the recently developed Neurovent-P(R) (REHAU AG+CO, REHAU, Germany) ICP monitoring device. Method. In a prospective two-center study, a total of 98 patients with severe head injury, subarachnoid haemorrhage, intracerebral haemorrhage, and non-traumatic brain edema underwent intraparenchymal monitoring of ICP using the Neurovent-P(R). A control group comprising 50 patients underwent implantation of the Camino(R)-OLM-110-4B ICP monitor. The zero drift of the probes was determined before and after the ICP recording period. Technical and medical complications were documented. The MRI compatibility of the Neurovent-P(R) ICP probe was investigated by evaluating artifacts caused by the probe, probe function and temperature changes during MRI, and probe movement caused by the magnetic field. Findings. The mean zero drift was 0.2 +/- 0.41 mmHg (maximum 3 rnmHg) for the Neurovent-P(R) ICP probes and 0.4 +/- 0.57 mmHg (maximum 12 mmHg) for the Caminol(R)-OLM-110-4B ICP probes. No significant correlation was identified between the extent of zero drift following the removal of the probes and the length of monitoring. Intraparenchymal haemorrhage spatially related to the probe occurred in 1 out of 50 (2%) patients with a Camino(R)-OLM-110-4B probe and in 1 out of 98 (1%) with a Neurovent-P(R). Damage of the probe due to kinking or overextension of the cable or glass fiber occurred in 4 of the 50 (8%) Camino(R)-OLM-110-4B ICP probes and in 5 of the 98 (5%) Neurovent-P(R) probes. On T2-weighted MR images, the Neurovent-P(R) ICP probe induced only small artifacts with very good discrimination of the surrounding tissue. On T1-weighted MR images, there was a good imaging quality but artifact-related local disturbances in signal occurred. There was no temperature change in the Neurovent-P(R) probe and in the surrounding brain tissue during MR imaging. Interpretation. The Neurovent-P(R) ICP measuring system is a safe and reliable tool for ICP monitoring. Handling of the Neurovent-P(R) system is safe when performed properly.	Free Univ Berlin, Dept Neurosurg, Benjamin Franklin Med Ctr, D-12203 Berlin, Germany; Free Univ Berlin, Dept Radiol & Nucl Med, Benjamin Franklin Med Ctr, D-12203 Berlin, Germany; BG Hosp Bergmannstrost, Dept Neurosurg, Halle Saale, Germany		Stendel, R (corresponding author), Free Univ Berlin, Dept Neurosurg, Benjamin Franklin Med Ctr, Hindenburgdamm 30, D-12203 Berlin, Germany.			Picht, Thomas/0000-0002-8630-1466			AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; Bavetta S, 1997, J NEUROSURG, V86, P927, DOI 10.3171/jns.1997.86.6.0927; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Ghajar J, 1995, New Horiz, V3, P395; Holzschuh M, 1998, BRAIN INJURY, V12, P191, DOI 10.1080/026990598122665; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Miller JD, 1989, INTRACRANIAL PRESSUR, P5; MOLLMAN HD, 1988, J NEUROSURG, V68, P737, DOI 10.3171/jns.1988.68.5.0737; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; PIPER IR, 1999, BRIT J NEUROSURG, V13, P114; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Schurer L, 1997, ACT NEUR S, V70, P296; SYMON L, 1974, J NEUROL NEUROSUR PS, V37, P617, DOI 10.1136/jnnp.37.6.617; TASKER RC, 1991, NEUROPEDIATRICS, V22, P47, DOI 10.1055/s-2008-1071416; WEINSTABL C, 1992, J CLIN MONITOR, V8, P116, DOI 10.1007/BF01617429; WILKINSON HA, 1989, NEUROSURGERY, V24, P348, DOI 10.1227/00006123-198903000-00007; Williams EJ, 1999, J NEUROSURG, V91, P706, DOI 10.3171/jns.1999.91.4.0706; WINFIELD JA, 1993, NEUROSURGERY, V33, P424; YABLON JS, 1993, J CLIN MONITOR, V9, P171, DOI 10.1007/BF01617024; YAU YH, 2000, NEUROSURG FOCUS, V9, P1	22	33	36	0	2	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAR	2003	145	3					185	193		10.1007/s00701-002-1052-0			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	658GZ	WOS:000181714400005	12632114				2022-02-06	
J	Furuya, Y; Hlatky, R; Valadka, AR; Diaz, P; Robertson, CS				Furuya, Y; Hlatky, R; Valadka, AR; Diaz, P; Robertson, CS			Comparison of cerebral blood flow in computed tomographic hypodense areas of the brain in head-injured patients	NEUROSURGERY			English	Article						brain contusion; brain ischemia; cerebral blood flow; computed tomography; head injury; xenon-enhanced computed tomography	ISCHEMIC STROKE; FOCAL ISCHEMIA; TISSUE; CT; OXYGENATION; CONTUSIONS; PTIO(2)	OBJECTIVE: Hypodense lesions identified on computed tomographic (CT) scans are often assumed to indicate ischemia. The purpose of this study was to investigate regional cerebral blood flow, (rCBF) in hypodense areas of the brain after severe traumatic brain injury. METHODS: CBF was measured by stable xenon-enhanced CT scans. Hypodense areas were identified, and rCBF values as well as CT density were averaged for the region. RESULTS: Thirty (60%) of the 50 patients had a total of 45 hypodense regions; which were associated with either contusion (n = 30) or areas of infarction (n = 15). rCBF in the hypodense regions was variable, ranging from a low of 3.3 to a high of 72.5 ml/100 g/min. The cause of the lesion was the major factor associated with the. level of rCBF. Although the average decrease-in CT density was similar for the two types of lesions, the average rCBF was significantly lower and the difference in rCBF between the lesion and the contralateral side was greater when the,hypodense lesion was associated with a contusion. A critical reduction in rCBF (<20 ml/100 g/min) was found in 19 (63%) of the hypodense regions associated with contusions but in only 4 (27%) of those from areas of infarction. CONCLUSION: Hypodensity on plain CT scans does not always indicate reduction in CBF. This association was found more commonly when the low-density area was associated with a contusion. In hypodense areas associated with infarction, rCBF was variable and not commonly in the ischemic range at the time the CBF measurement was obtained.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic; St Marianna Univ, Sch Med, Dept Neurosurg, Kawasaki, Kanagawa 213, Japan		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin,Suite 944, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		BARON JC, 1983, AM J NEURORADIOL, V4, P536; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1985, J NEUROSURG, V63, P64, DOI 10.3171/jns.1985.63.1.0064; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Krieger DW, 1999, STROKE, V30, P287, DOI 10.1161/01.STR.30.2.287; Marks MP, 1999, STROKE, V30, P389, DOI 10.1161/01.STR.30.2.389; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Scott JN, 1999, CAN J NEUROL SCI, V26, P182, DOI 10.1017/S0317167100000226; Stocchetti N, 1998, ACT NEUR S, V71, P162; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; YONAS H, 1988, STROKE, V19, P228, DOI 10.1161/01.STR.19.2.228	13	33	34	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	FEB	2003	52	2					340	345		10.1227/01.NEU.0000043931.83041.AA			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	644DA	WOS:000180901600017	12535362				2022-02-06	
S	Ford, J; Farid, H; Makedon, F; Flashman, LA; McAllister, TW; Megalooikonomou, V; Saykin, AJ		Ellis, RE; Peters, TM		Ford, J; Farid, H; Makedon, F; Flashman, LA; McAllister, TW; Megalooikonomou, V; Saykin, AJ			Patient classification of fMRI activation maps	MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2003, PT 2	Lecture Notes in Computer Science		English	Article; Proceedings Paper	6th International Conference on Medical Image Computing and Computer-Assisted Intervention	NOV 15-18, 2003	MONTREAL, CANADA	Robarts Res Inst, No Digital Inc			FUNCTIONAL MRI ACTIVATION; PATTERNS; REPRODUCIBILITY; SCHIZOPHRENIA; TASK	The analysis of brain activations using functional magnetic resonance imaging (fMRI) is an active area of neuropsychological research. Standard techniques for analysis have traditionally focused on finding the most significant areas of brain activation, and have only recently begun to explore the importance of their spatial characteristics. We compare fMRI contrast images and significance maps to training sets of similar maps using the spatial distribution of activation values. We demonstrate that a Fisher linear discriminant (FLD) classifier for either type of map can differentiate patients from controls accurately for Alzheimer's disease, schizophrenia, and mild traumatic brain injury (MTBI).	Dartmouth Coll, Dept Comp Sci, Hanover, NH 03755 USA; Dartmouth Coll, Ctr Cognit Neurosci, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat,Brain Imaging Lab, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Radiol, Hanover, NH 03756 USA; Temple Univ, Dept Comp & Informat Sci, Philadelphia, PA 19122 USA		Ford, J (corresponding author), Dartmouth Coll, Dept Comp Sci, Hanover, NH 03755 USA.	jford@cs.dartmouth.edu; farid@cs.dartmouth.edu; makedon@cs.dartmouth.edu	Ford, James/AAF-7039-2020; Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532			Aguirre GK, 1998, NEUROIMAGE, V8, P302, DOI 10.1006/nimg.1998.0367; Casey BJ, 1998, NEUROIMAGE, V8, P249, DOI 10.1006/nimg.1998.0360; Cohen MS, 1999, JMRI-J MAGN RESON IM, V10, P33, DOI 10.1002/(SICI)1522-2586(199907)10:1<33::AID-JMRI5>3.0.CO;2-N; Coulon O, 1999, LECT NOTES COMPUT SC, V1613, P448; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastie T., 2008, RANDOM FORESTS, DOI DOI 10.1007/978-0-387-84858-7_15; HUGHES GF, 1968, IEEE T INFORM THEORY, V14, P55, DOI 10.1109/TIT.1968.1054102; Hutchinson M, 1999, MAGN RESON IMAGING, V17, P1427, DOI 10.1016/S0730-725X(99)00093-4; Liow JS, 2000, J NUCL MED, V41, P612; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MOELLER JR, 1987, J CEREBR BLOOD F MET, V7, P649, DOI 10.1038/jcbfm.1987.118; RAUDYS SJ, 1991, IEEE T PATTERN ANAL, V13, P252, DOI 10.1109/34.75512; Rubia K, 2001, SCHIZOPHR RES, V52, P47, DOI 10.1016/S0920-9964(00)00173-0; Saykin AJ, 1999, SCHIZOPHR RES, V36, P233; Saykin AJ, 1999, J INT NEUROPSYCH SOC, V5, P377, DOI 10.1017/S135561779955501X; Skurichina M., 1996, P 13 INT C PATT REC, V2, P891; Tegeler C, 1999, HUM BRAIN MAPP, V7, P267, DOI 10.1002/(SICI)1097-0193(1999)7:4<267::AID-HBM5>3.0.CO;2-3	18	33	34	1	8	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0302-9743		3-540-20464-4	LECT NOTES COMPUT SC			2003	2879						58	65					8	Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging	BY19R	WOS:000188180400008		Bronze			2022-02-06	
S	Gilchrist, MD		DulieuBarton, JM; Brennan, MJ; Holford, KM; Worden, K		Gilchrist, MD			Modelling and accident reconstruction of head impact injuries	DAMAGE ASSESSMENT OF STRUCTURES, PROCEEDINGS	Key Engineering Materials		English	Article; Proceedings Paper	5th International Conference on Damage Assessment of Structures	JUL 01-03, 2003	SOUTHAMPTON, ENGLAND			accident reconstruction; head injury; impact; neurotrauma	BIOMECHANICS; EPIDEMIOLOGY; PRESSURE	This paper describes a computational mechanics framework within which the physiological consequences of an accidental head impact injury can be. simulated. This method relies on a combined use of multibody dynamics and finite element analyses. Such a procedure could ultimately be used to assist in the clinical diagnosis of neurotrauma and in the design of optimised safety helmets.	Univ Coll Dublin, Dept Mech Engn, Dublin 4, Ireland		Gilchrist, MD (corresponding author), Univ Coll Dublin, Dept Mech Engn, Dublin 4, Ireland.	Michael.Gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X			Allsop D. L., 1991, P 35 STAPP CAR CRASH, P269; AUER C, 2001, P INT SOC BIOM 18 C; Dassios G, 1998, COMPUT MECH, V21, P382, DOI 10.1007/s004660050315; DIMASI F, 1991, P 13 INT TECHN C EXP; EDBERG S, 1963, LAB INVEST, V12, P1305; *EEVC WORK GROUP, 1994, 10 EEVC WORK GROUP; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; GOLDSMITH W, 1972, BIOMECHANICS HEAD IN; Gurdjian E S, 1972, Clin Neurosurg, V19, P1; Holbourn AHS, 1943, LANCET, V2, P438; HORGAN TJ, 2003, IN PRESS INT J CRASH; HOSEY RR, 1982, HOMEOMORPHIC FINITE, P379; HU H, 1998, P 5 INT LS DYNA US C; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jones SE, 1998, COMPUT MECH, V22, P413, DOI 10.1007/s004660050373; Kang HS, 1997, P 41 STAPP CAR CRASH, P329; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; LEE ES, 1990, THESIS GEORGIA I TEC; LJUNG C, 1978, SCALING HEAD INJURY; LORENSON B, VTK OPEN SOURCE SOFT; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; MENDIS KK, 1995, ASME, V117, P279; MISRA JC, 1984, J BIOMECH, V17, P459, DOI 10.1016/0021-9290(84)90014-9; MOHAN D, 1979, ASME, V101, P250; Mortensen K., 1999, Tidsskrift for den Norske Laegeforening, V119, P1870; Nahum AM, 1977, P 21 STAPP CAR CRASH; *NIH, VIS HUM DAT; Nisitani H, 1997, COMPUT MECH, V19, P470, DOI 10.1007/s004660050195; North JB, 1991, P INT RES COUNC BIOK, P77; O'Donoghue D., 1998, IRISH J MED SCI, V167, P263; ODONOGHUE D, 1999, THESIS U COLL DUBLIN; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; ONO K, 1980, P 24 STAPP CAR CRASH, P101; ORIORDAIN K, 2003, IN PRESS CLIN BIOMEC; ORIORDAIN K, 2002, THESIS U COLL DUBLIN; Ruan J. S., 1994, THESIS WAYNE STATE U; Sauren A. A. H. J., 1993, P INT IRCOBI C BIOM, P241; SCALLAN E, 2001, INJURY IRELAND; SHUGAR TA, 1975, ASCE J ENG MECH, V173, P223; SMYTH A, 2002, P IR NEUR GROUP ANN; SPEYER H, 1997, 970088 SAE; TURQUIER F, 1996, P 40 STAPP CAR CRASH; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; Ward C, 1975, P 19 STAPP CAR CRASH; Watson WL, 2000, ACCIDENT ANAL PREV, V32, P277, DOI 10.1016/S0001-4575(99)00121-9; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R., 1992, P INT RES COUNC BIOK, P283; Willinger R., 1992, P INT IRCOBI C BIOM, P179; Wismans, 1997, P 41 STAPP CAR CRASH, V41, P315, DOI DOI 10.4271/973338; YANAGIDA Y, 1989, FORENSIC SCI INT, V41, P135, DOI 10.1016/0379-0738(89)90245-4; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; ZHOU C, 1996, P 1996 INT IRCOBI C, P35; 2000, ABAQUS STANDARD USER; 1999, MADYMO VERSION 5 4 1; 2002, MSC PATRAN USERS MAN	58	33	33	1	7	TRANS TECH PUBLICATIONS LTD	DURNTEN-ZURICH	KREUZSTRASSE 10, 8635 DURNTEN-ZURICH, SWITZERLAND	1013-9826		0-87849-922-9	KEY ENG MATER			2003	245-2						417	429		10.4028/www.scientific.net/KEM.245-246.417			13	Materials Science, Ceramics; Materials Science, Composites	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	BW97Q	WOS:000183830800047		Green Submitted			2022-02-06	
J	Lippert-Gruner, M; Wedekind, C; Klug, N				Lippert-Gruner, M; Wedekind, C; Klug, N			Outcome of prolonged coma following severe traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; REHABILITATION	Primary objective : To assess the outcome of severe traumatic brain injury 1 year after trauma. Research design : Prospective study conducted at the neurosurgical department of a university hospital. Methods and procedures : A total of 24 patients were included. Outcome was assessed by means of Glasgow outcome scale, Barthel index, Functional independence measure (FIM) and Disability rating scale (DRS). Need of care and job ability were also evaluated. Experimental interventions : Patients received multimodal early-onset stimulation and continuous inpatient and outpatient rehabilitation therapy. Main outcomes and results : Six patients died, three remained in a vegetative state, six were severely disabled, six were moderately disabled and three achieved a good recovery 1 year after injury. Mean Barthel index was 68.9, mean FIM was 88.3 and mean DRS 27.7. The majority of patients still were at least intermittently dependent on care. Most of the trauma survivors were unable to work. Conclusions : Despite intensive rehabilitation treatment, severe traumatic brain injury is still burdened with significant mortality and morbidity.	Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany		Lippert-Gruner, M (corresponding author), Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany.	drchrwedekind@web.de					Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DAVIS CHH, 1997, AM J PHYSICAL MED RE, V76, P20; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Grossman P, 1996, DISABIL REHABIL, V18, P57, DOI 10.3109/09638289609166019; Gruner ML, 2000, BRAIN INJURY, V14, P585; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V41, P661; MAHONEY F I, 1965, Md State Med J, V14, P61; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; TALBOT LR, 1994, BRAIN INJURY, V8, P689, DOI 10.3109/02699059409151023; TEASDALE G, 1974, LANCET, V2, P81	20	33	35	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	1					49	54		10.1080/0269905021000010230			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600004	12519647				2022-02-06	
J	Kentner, R; Rollwagen, FM; Prueckner, S; Behringer, W; Wu, XR; Stezoski, J; Safar, P; Tisherman, SA				Kentner, R; Rollwagen, FM; Prueckner, S; Behringer, W; Wu, XR; Stezoski, J; Safar, P; Tisherman, SA			Effects of mild hypothermia on survival and serum cytokines in uncontrolled hemorrhagic shock in rats	SHOCK			English	Article						hemorrhage; fluid resuscitation; outcome; inflammatory response	TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; MODERATE HYPOTHERMIA; RESUSCITATION; SUPPRESSION; DYSFUNCTION; TEMPERATURE; IMPROVES; IL-10	Previous studies have suggested benefit of mild hypothermia during hemorrhagic shock (HS). This finding needs additional confirmation and investigation into possible mechanisms. Proinflammatory cytokines are mediators of multiple organ failure following traumatic hemorrhagic shock and resuscitation. We hypothesized that mild hypothermia would improve survival from HIS and may affect the pro- and anti-inflammatory cytokine response in a rat model of uncontrolled HS. Under light halothane anesthesia, uncontrolled HS was induced by blood withdrawal of 3 mL/1 00 g over 15 min followed by tail amputation. Hypotensive (limited) fluid resuscitation (to prevent mean arterial pressure [MAP] from decreasing below 40 mmHg) with blood was started at 30 min and continued to 90 min. After hemostasis and resuscitation with initially shed blood and Ringer's solution, the rats were observed for 72 h. The animals were randomized into two HS groups (n = 10 each): normothermia (38degreesC 0.5degreesC) and mild hypothermia (34degreesC 0.5degreesC) from HS 30 min until resuscitation time (RT) 60 min; and a sham group (n = 3). Venous blood samples were taken at baseline, RT 60 min, and days 1, 2, and 3. Serum interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor (TNF)-alpha concentrations were quantified by ELISA. Values are expressed as median and interquartile range. Survival time by life table analysis was greater in the hypothermia group (P = 0.04). Survival rates to 72 h were 1 of 10 vs. 6 of 10 in the normothermia vs. hypothermia groups, respectively (P = 0.057). All cytokine concentrations were significantly increased from baseline at RT 60 min in both HS groups, but not in the shams. At RT 60 min, in the normothermia vs. hypothermia groups, respectively, IL-1beta levels were 185 (119-252) vs. 96 (57-135) pg/mL (P = 0.15); IL-6 levels were 2242 (1903-3777) vs. 1746 (585-2480) pg/mL (P = 0.20); TNF-alpha levels were 97 (81-156) vs. 394 (280-406) pg/mL (P = 0.02); and IL-10 levels were 1.7 (0-13.3) vs. 15.8 (1.9-23.0) pg/mL (P = 0.09). IL-10 remained increased until day 3 in the hypothermia group. High IL-1 p levels (>100 pg/mL) at RT 60 min were associated with death before 72 h (odds ratio 66, C.I. 3.5-1255). We conclude that mild hypothermia improves survival time after uncontrolled HS. Uncontrolled HS induces a robust proinflammatory cytokine response. The unexpected increase in TNF-a with hypothermia deserves further investigation.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol, CCM, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA		Tisherman, SA (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Tisherman, Samuel A./AAK-9377-2020	Tisherman, Samuel A./0000-0003-3810-3729; Behringer, Wilhelm/0000-0003-2261-3193			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; BarrosoAranda J, 1995, J CARDIOVASC PHARM, V25, pS23, DOI 10.1097/00005344-199500252-00006; Beilin B, 1998, ANESTHESIOLOGY, V89, P1133, DOI 10.1097/00000542-199811000-00013; BELLAMY RF, 1984, MIL MED, V149, P55; Bull DA, 2000, J THORAC CARDIOV SUR, V119, P242, DOI 10.1016/S0022-5223(00)70179-6; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; Foex BA, 1997, SHOCK, V8, P276, DOI 10.1097/00024382-199710000-00007; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; GIROIR BP, 1994, AM J PHYSIOL, V267, pH118, DOI 10.1152/ajpheart.1994.267.1.H118; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hasko G, 1998, EUR J IMMUNOL, V28, P1417, DOI 10.1002/(SICI)1521-4141(199804)28:04<1417::AID-IMMU1417>3.0.CO;2-L; HEGNAUER AH, 1954, AM J PHYSIOL, V178, P138, DOI 10.1152/ajplegacy.1954.178.1.138; HOOPARIS R, 1991, AM J PHYSIOL, V260, pR480, DOI 10.1152/ajpregu.1991.260.3.R480; Jarrar D, 1999, INT J MOL MED, V4, P575; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kim SH, 1997, J TRAUMA, V42, P213, DOI 10.1097/00005373-199702000-00006; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; Mizushima Y, 2000, ARCH SURG-CHICAGO, V135, P175, DOI 10.1001/archsurg.135.2.175; Palo M, 2000, EUR J APPL PHYSIOL, V81, P391, DOI 10.1007/s004210050059; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; Prueckner S, 2001, J TRAUMA, V50, P253, DOI 10.1097/00005373-200102000-00010; RHEE P, 1993, RESUSCITATION, V25, P249, DOI 10.1016/0300-9572(93)90122-7; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Rozenfeld RA, 1996, J APPL PHYSIOL, V81, P1834, DOI 10.1152/jappl.1996.81.4.1834; SAFAR P, 1997, TXB NEUROANESTHESIA, P557; Seekamp A, 1999, J TRAUMA, V47, P673, DOI 10.1097/00005373-199910000-00011; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Takasu A, 2000, CRIT CARE MED, V28, P2465, DOI 10.1097/00003246-200007000-00047; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; ZAGER RA, 1991, CIRC RES, V68, P185, DOI 10.1161/01.RES.68.1.185	35	33	39	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2002	17	6					521	526		10.1097/00024382-200206000-00014			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	626MT	WOS:000179877200014	12069191				2022-02-06	
J	Garcia, LJ; Laroche, C; Barrette, J				Garcia, LJ; Laroche, C; Barrette, J			Work integration issues go beyond the nature of the communication disorder	JOURNAL OF COMMUNICATION DISORDERS			English	Article						work integration; quality of life; communication disorders; disability process model	TRAUMATIC BRAIN INJURY; QUALITY-OF-LIFE; DISABILITY MANAGEMENT; VOICE PROBLEMS; RETURN; OUTCOMES; STROKE; REINTEGRATION; PERCEPTIONS; PREDICTORS	The ability to obtain and maintain employment is one of society's most valued life participation events and is often considered in measurements of quality of life (QOL). Many work-places now require good communication skills and this may jeopardize the opportunity for persons with communication disorders (CD) to access interesting jobs. Sarno, Silverman, and Levita (1970) have long emphasized that functioning is a result of the interaction of psychosocial factors as well as conununication disorder characteristics. The current study gathered perceptions from different groups of persons with CID, from service providers and employers on the barriers towork integration. The results show that many barriers are corturion across types of CD. Such examples are noise, tasks requiring speed, having to speak to groups of persons and the attitudes of others. Although some common barriers were identified between the service providers and the persons with CID, service providers placed more emphasis on psychological adaptation aspects than did persons with CD. Employers generated an equivalently long list of barriers but were also very concerned about job market issues. Learning outcomes: As a result of this activity, the following learning outcomes will be realized: participants will be able to (1) identify barriers that service providers and persons with CD each perceive; (2) identify differences in the perceptions of each group concerning barriers; (3) learn ways to modify or eliminate barriers that interfere with successful employment among individuals with CD. (C) 2002 Elsevier Science Inc. All rights reserved.	Univ Ottawa, Inst Hlth Elderly, Ottawa, ON K1N 5C8, Canada; Univ Ottawa, Audiol & Speech Language Pathol Program, Ottawa, ON, Canada; Univ Ottawa, Fac Adm, Ottawa, ON K1N 6N5, Canada		Garcia, LJ (corresponding author), Univ Ottawa, Inst Hlth Elderly, 43 Bruyere St, Ottawa, ON K1N 5C8, Canada.	lgarcia@scohs.on.ca					ALGELERI R, 1993, STROKE, V10, P1478; BACKENROTH GAM, 1995, INT J REHABIL RES, V18, P76, DOI 10.1097/00004356-199501000-00012; BLACKSCHAFFER RM, 1990, ARCH PHYS MED REHAB, V71, P285; BROTHERSON MJ, 1994, TOP EARLY CHILD SPEC, V14, P101, DOI 10.1177/027112149401400110; BRUNELLE J, 1988, SUPERVISION INTERVEN, P179; CANELON MF, 1995, AM J OCCUP THER, V49, P461, DOI 10.5014/ajot.49.5.461; CAREY ML, 1992, BLS B, V2404; CARRIERO MR, 1987, CORTEX, V23, P667, DOI 10.1016/S0010-9452(87)80056-4; CASSAR MC, 1997, SEMINARS SPEECH LANG, V4, P371; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CRAIG AR, 1991, J SPEECH HEAR RES, V34, P279, DOI 10.1044/jshr.3402.279; DESANTO LW, 1995, ANN OTO RHINOL LARYN, V104, P763, DOI 10.1177/000348949510401003; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fougeyrollas P, 1997, ICIDH ENV FACTORS IN, V9, P32; FOUGEYROLLAS P, 1997, QUEBEC CLASSIFICATIO; FRITH C, 1985, J COMMUN DISORD, V18, P475, DOI 10.1016/0021-9924(85)90034-6; Garcia LJ, 2000, APHASIOLOGY, V14, P269, DOI 10.1080/026870300401478; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Isaki E, 2000, BRAIN INJURY, V14, P441; Jensen K., 1999, INT J DISABIL DEV ED, V46, P453, DOI DOI 10.1080/103491299100434; Kalina CM, 1999, ANN NY ACAD SCI, V888, P343, DOI 10.1111/j.1749-6632.1999.tb07969.x; Laroche C, 2000, J ACAD REHABIL AUDIO, V23, P63; Lunday AM, 1996, TOP LANG DISORD, V16, P23, DOI 10.1097/00011363-199605000-00004; MALMSBORG T, 1995, INT J TECHNOL ASSESS, V11, P235, DOI 10.1017/S0266462300006851; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MOHIDE EA, 1992, AM J SURG, V164, P619, DOI 10.1016/S0002-9610(05)80720-2; PARVING A, 1993, SCAND AUDIOL, V22, P133, DOI 10.3109/01050399309046029; RICE M, 1995, WORLD C INT FLUENC A; ROLLAND J, 1991, APHASIQUE, P195; Ruben RJ, 2000, LARYNGOSCOPE, V110, P241, DOI 10.1097/00005537-200002010-00010; RUMRILL PG, 1994, J LONG TERM CARE ADM, P7; Saeki S, 2000, DISABIL REHABIL, V22, P578, DOI 10.1080/09638280050138241; Sarno M. T., 1969, FUNCTIONAL COMMUNICA; SARNO MT, 1970, J AM GERIATR SOC, V18, P405, DOI 10.1111/j.1532-5415.1970.tb03673.x; SARNO MT, 1983, SCAND J REHABIL MED, P75; Sarno MT, 1997, APHASIOLOGY, V11, P665, DOI 10.1080/02687039708249414; SARNO MT, 1993, LIVING APHASIA PSYCH, P269; SCHLOSS PJ, 1987, J SPEECH HEAR DISORD, V52, P30, DOI 10.1044/jshd.5201.30; Shrey DE, 2000, OCCUP MED-STATE ART, V15, P789; Smith E, 1998, J VOICE, V12, P223, DOI 10.1016/S0892-1997(98)80042-8; Smith E, 1998, J VOICE, V12, P328, DOI 10.1016/S0892-1997(98)80022-2; Smith E, 1997, J VOICE, V11, P81, DOI 10.1016/S0892-1997(97)80027-6; Stewart MG, 1998, ARCH OTOLARYNGOL, V124, P143, DOI 10.1001/archotol.124.2.143; Target P, 1998, INT J REHABIL RES, V21, P41, DOI 10.1097/00004356-199803000-00004; THORNBURG L, 1994, J LONG TERM CARE ADM, P14; Titze IR, 1997, J VOICE, V11, P254, DOI 10.1016/S0892-1997(97)80002-1; World Health Organization, 2001, ICF INT CLASS FUNCT; World Health Organization, 1980, INT CLASS IMP DIS HA; Wozniak MA, 1999, STROKE, V30, P2568, DOI 10.1161/01.STR.30.12.2568; Zwerling C, 1998, J OCCUP ENVIRON MED, V40, P720, DOI 10.1097/00043764-199808000-00010; [No title captured]	51	33	34	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	MAR-APR	2002	35	2					187	211	PII S0021-9924(02)00064-3	10.1016/S0021-9924(02)00064-3			25	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	553BE	WOS:000175655000007	12036151				2022-02-06	
J	Wells, RG; Vetter, C; Laud, P				Wells, RG; Vetter, C; Laud, P			Intracranial Hemorrhage in children younger than 3 years - Prediction of intent	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; SHAKEN-BABY SYNDROME; HEAD-INJURY; SUBDURAL-HEMATOMA; INFANTS; ABUSE	Objective: To determine whether certain computed tomographic imaging patterns in infants and young children with intracranial hemorrhage help predict intentional compared with unintentional injuries. Design: Retrospective consecutive case series over a 10-year period. Patients: Two hundred ninety-three children younger than 3 years with intracranial hemorrhage. Main Outcome Measures: The sensitivity and specificity of computed tomographic imaging patterns for intentional head injury. Setting: Regional pediatric medical center. Results: Four variables used in the multiple logistic regression analysis for predicting intentional head injury were statistically significant (P<.05): subdural hematoma located over the cerebral convexities, hematoma within the interhemispheric subdural space, hygroma (nonhemic subdural fluid) with intracranial hemorrhage, and absence of a skull fracture with intracranial hemorrhage. The prediction model for the diagnosis of intentional head trauma using combinations of these 4 variables and a 45 probability cutoff point indicated a sensitivity of 84% (95% confidence interval, 78%-90%) and a specificity of 83% (95% confidence interval, 74%-89%). Conclusion: Computed tomographic imaging patterns of intracranial hemorrhage in children younger than 3 years help predict whether the injury was intentional.	Childrens Hosp Wisconsin, Dept Radiol, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA		Wells, RG (corresponding author), Childrens Hosp Wisconsin, Dept Radiol, MS 721,9000 W Wisconsin Ave,POB 1997, Milwaukee, WI 53201 USA.	rwells@chw.org					AOKI N, 1990, J NEUROSURG, V73, P201, DOI 10.3171/jns.1990.73.2.0201; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; *NAT CTR CHILD AB, 1988, STUD NAT INC PREV CH; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; TSAI FY, 1980, CT-J COMPUT TOMOGR, V4, P277, DOI 10.1016/0149-936X(80)90020-X; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	17	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAR	2002	156	3					252	257		10.1001/archpedi.156.3.252			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	528XK	WOS:000174270000009	11876669	Bronze			2022-02-06	
J	Fragala, MA; Haley, SM; Dumas, HM; Rabin, JP				Fragala, MA; Haley, SM; Dumas, HM; Rabin, JP			Classifying mobility recovery in children and youth with brain injury during hospital-based rehabilitation	BRAIN INJURY			English	Article							HEAD-INJURY; CHILDHOOD; SEVERITY; STROKE; PERFORMANCE; OUTCOMES; SYSTEM; COHORT	Primary objective: This article describes mobility recovery for children and youth with traumatic and non-traumatic brain injury during hospital-based rehabilitation. Research design: A retrospective, descriptive pre-test/post-test design was used. Methods and procedures: One hundred and fifty-seven individuals with brain injury who were admitted for rehabilitation over a 5-year period were enrolled in this study. The Paediatric Evaluation of Disability Inventory (PEDI) was used to document functional mobility at admission and discharge from the rehabilitation programme. The PEDI mobility classification system consisting of seven discrete levels of mobility was developed to provide clinically relevant and succinct outcome information. Main outcomes and results: The majority of children with brain injury (69%) improved one or more mobility classification levels. Children in the traumatic brain injury group made greater changes (p = 0.001) in mobility recovery than children in the non-traumatic group. Conclusions: Information about recovery using a well-defined functional classification system may assist with programme evaluation and facilitate optimal service delivery.	Franciscan Childrens Hosp & Rehabil Ctr, Res Ctr Children Special Hlth Care Needs, Boston, MA 02135 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Ctr Rehabil Effectiveness, Boston, MA 02215 USA; Franciscan Childrens Hosp & Rehabil Ctr, Inpatient Rehabil Program, Boston, MA USA		Fragala, MA (corresponding author), Franciscan Childrens Hosp & Rehabil Ctr, Res Ctr Children Special Hlth Care Needs, 30 Warren St, Boston, MA 02135 USA.	mfragala@tiac.net					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; CAMPBELL NN, 1994, J ROY SOC MED, V87, P73; CARNEY N, 1999, AHCPR PUBLICATION; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EWINGCOBBS I, 1997, J INT NEUROPSYCHOLOG, V3; Ganesan V, 2000, DEV MED CHILD NEUROL, V42, P455, DOI 10.1017/S0012162200000852; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; HALEY S, 1992, PEDIAT EVALUATION IN; HALEY SM, 1997, J REHABILITATION OUT, V1, P61; HAMILITON BB, 1994, PHYS THER, V74, P494, DOI 10.1093/ptj/74.5.494; Hurvitz E A, 1999, Pediatr Rehabil, V3, P43; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LANSKA MJ, 1991, PEDIATR NEUROL, V7, P333, DOI 10.1016/0887-8994(91)90062-P; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Montgomery PC, 1998, PEDIATR PHYS THER, V10, P148; Moorthi S, 1999, BRAIN INJURY, V13, P139, DOI 10.1080/026990599121809; Nichols DS., 1996, PEDIATR PHYS THER, V8, P15, DOI DOI 10.1097/00001577-199600810-00004; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Peacock WJ, 1996, CHILD NERV SYST, V12, P376, DOI 10.1007/BF00395089; PHILIP PA, 1994, ARCH PHYS MED REHAB, V75, P36; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; *WHO, 2000, ICIDH2 INT CLASS FUN; WOLFEN W, 1998, DEV MED CHILD NEUROL, V40, P667; Wright FV, 1993, CAN J REHABIL, V7, P41	33	33	33	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2002	16	2					149	160		10.1080/02699050110103328			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	518TG	WOS:000173683500004	11839109				2022-02-06	
S	Logan, A; Berry, M		Alzheimer, C		Logan, A; Berry, M			Cellular and molecular determinants of glial scar formation	MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS	Advances in Experimental Medicine and Biology		English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; GROWTH-FACTOR-BETA; TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; CHONDROITIN-SULFATE PROTEOGLYCAN; CEREBRAL-ARTERY OCCLUSION; MESSENGER-RNA EXPRESSION; RAT OPTIC-NERVE; FIBRILLARY ACIDIC PROTEIN		Queen Elizabeth Hosp, Wolfson Res Labs, Dept Med, Birmingham B15 2TH, W Midlands, England; Ctr Neurosci, GKT Sch Biomed Res, London SE1 1UL, England		Logan, A (corresponding author), Queen Elizabeth Hosp, Wolfson Res Labs, Dept Med, Birmingham B15 2TH, W Midlands, England.			Logan, Ann/0000-0003-3215-5042			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Acarin L, 1999, J NEUROPATH EXP NEUR, V58, P389, DOI 10.1097/00005072-199904000-00009; ADZICK NS, 1994, ANN SURG, V220, P10, DOI 10.1097/00000658-199407000-00003; AJEMIAN A, 1994, J COMP NEUROL, V340, P233, DOI 10.1002/cne.903400208; Ajtai BM, 2000, ANAT EMBRYOL, V202, P313, DOI 10.1007/s004290000117; Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Aldskogius H, 1999, J NEUROSCI RES, V58, P33, DOI 10.1002/(SICI)1097-4547(19991001)58:1<33::AID-JNR5>3.3.CO;2-D; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Andjelkovic AV, 2000, J LEUKOCYTE BIOL, V68, P545; ANTONIADES HN, 1991, P NATL ACAD SCI USA, V88, P565, DOI 10.1073/pnas.88.2.565; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; Bagley C, 1928, ARCH SURG-CHICAGO, V17, P18, DOI 10.1001/archsurg.1928.01140070021002; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; Balasingam V, 1996, J NEUROSCI, V16, P2945; BALENTINE JD, 1978, LAB INVEST, V39, P236; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BARDAKDJIAN J, 1979, NEUROCHEM RES, V4, P517, DOI 10.1007/BF00964645; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BARTSCH U, 1992, EUR J NEUROSCI, V4, P338, DOI 10.1111/j.1460-9568.1992.tb00881.x; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bell MD, 1996, EUR J NEUROSCI, V8, P1803, DOI 10.1111/j.1460-9568.1996.tb01324.x; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Benjelloun N, 1999, STROKE, V30, P1916, DOI 10.1161/01.STR.30.9.1916; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; BERRY M, 1979, J ANAT, V128, P859; Berry M, 2001, MOL CELL NEUROSCI, V17, P706, DOI 10.1006/mcne.2001.0975; Berry M, 1982, Bibl Anat, P1; BERRY M, 1989, J NEUROCYTOL, V18, P141, DOI 10.1007/BF01206658; Berry M, 1999, J NEUROCYTOL, V28, P721, DOI 10.1023/A:1007086004022; Berry M, 1998, J NEUROCYTOL, V27, P915, DOI 10.1023/A:1006953107636; BERRY M, 1992, J NEUROCYTOL, V21, P426, DOI 10.1007/BF01191507; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Bolton SJ, 1998, EXP NEUROL, V154, P231, DOI 10.1006/exnr.1998.6927; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Bresjanac M, 2000, EXP NEUROL, V164, P53, DOI 10.1006/exnr.2000.7416; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brook GA, 2000, EUR J NEUROSCI, V12, P3224, DOI 10.1046/j.1460-9568.2000.00228.x; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Bruni JE, 1998, MICROSC RES TECHNIQ, V41, P2, DOI 10.1002/(SICI)1097-0029(19980401)41:1<2::AID-JEMT2>3.3.CO;2-T; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butt AM, 2000, J NEUROSCI RES, V59, P477, DOI 10.1002/(SICI)1097-4547(20000215)59:4<477::AID-JNR2>3.0.CO;2-J; Butt AM, 1999, GLIA, V26, P84, DOI 10.1002/(SICI)1098-1136(199903)26:1<84::AID-GLIA9>3.0.CO;2-L; Buytaert KA, 2001, BRAIN RES, V894, P121, DOI 10.1016/S0006-8993(01)01987-4; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal R., 1928, DEGENERATION REGENER; CARBONELL AL, 1991, HISTOL HISTOPATHOL, V6, P443; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Cartmell T, 2001, J PHYSIOL-LONDON, V531, P171, DOI 10.1111/j.1469-7793.2001.0171j.x; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Cerutti SM, 2000, CELL BIOL INT, V24, P35, DOI 10.1006/cbir.1999.0451; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clarke WE, 2001, MOL CELL NEUROSCI, V17, P17, DOI 10.1006/mcne.2000.0920; CLEMENTE CD, 1958, J COMP NEUROL, V109, P123, DOI 10.1002/cne.901090107; CLEMENTE CD, 1954, J COMP NEUROL, V101, P691, DOI 10.1002/cne.901010304; CLEMENTE CD, 1964, INT REV NEUROBIOL, V6, P257, DOI 10.1016/S0074-7742(08)60771-0; Cohen IR, 1999, J NEUROIMMUNOL, V100, P111, DOI 10.1016/S0165-5728(99)00190-3; COLLINS P, 1990, NEUROPATH APPL NEURO, V16, P45, DOI 10.1111/j.1365-2990.1990.tb00931.x; Condorelli DF, 1999, NEUROCHEM RES, V24, P709, DOI 10.1023/A:1021016828704; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Cui W., 1996, GROW FACT CYTOK  A&B, P319; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; DAVIES SJA, 1993, EUR J NEUROSCI, V5, P95, DOI 10.1111/j.1460-9568.1993.tb00474.x; DAVIES SJA, 1994, J NEUROSCI, V14, P1596, DOI 10.1523/JNEUROSCI.14-03-01596.1994; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; de Castro R, 2000, NEUROREPORT, V11, P3551, DOI 10.1097/00001756-200011090-00029; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; DEROUICHE A, 1994, J COMP NEUROL, V341, P340, DOI 10.1002/cne.903410305; Di Bello IC, 1999, J NEUROCYTOL, V28, P365, DOI 10.1023/A:1007069815302; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Dijkstra S, 2000, J COMP NEUROL, V428, P266, DOI 10.1002/1096-9861(20001211)428:2<266::AID-CNE6>3.0.CO;2-0; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Dreyfus CF, 1999, J NEUROSCI RES, V56, P1, DOI 10.1002/(SICI)1097-4547(19990401)56:1<1::AID-JNR1>3.0.CO;2-3; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Dusart I, 1999, J COMP NEUROL, V408, P399; ECLANCHER F, 1990, GLIA, V3, P502, DOI 10.1002/glia.440030609; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; FAGAN AM, 1990, EXP NEUROL, V110, P105, DOI 10.1016/0014-4886(90)90055-W; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FERTIG A, 1971, EXP NEUROL, V33, P372, DOI 10.1016/0014-4886(71)90029-X; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; Fischer D, 2000, INVEST OPHTH VIS SCI, V41, P3943; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLINT G, 1973, EXPERIENTIA, V29, P566, DOI 10.1007/BF01926668; Flood C, 2001, J CEREBR BLOOD F MET, V21, P157, DOI 10.1097/00004647-200102000-00007; Flugel A, 2001, J CEREBR BLOOD F MET, V21, P69; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Friedman WJ, 2001, EXP NEUROL, V168, P23, DOI 10.1006/exnr.2000.7595; Fukui N, 2001, J ORTHOPAED RES, V19, P456, DOI 10.1016/S0736-0266(00)90016-0; FULTON BP, 1992, J NEUROSCI, V12, P4816; Gabellec MM, 1999, NEUROSCI RES, V33, P251, DOI 10.1016/S0168-0102(99)00014-0; Galasso JM, 2000, NEUROSCIENCE, V101, P737, DOI 10.1016/S0306-4522(00)00399-7; GARDNER WJ, 1950, J NEUROSURG, V7, P199, DOI 10.3171/jns.1950.7.3.0199; Gates MA, 1996, NEUROSCIENCE, V74, P579, DOI 10.1016/0306-4522(96)00146-7; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Ghirnikar RS, 2000, J NEUROSCI RES, V59, P63, DOI 10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.3.CO;2-N; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; Giovannoni G, 1998, J NEUROL SCI, V156, P53, DOI 10.1016/S0022-510X(98)00021-5; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; Gomide VC, 1999, BRAIN RES, V835, P162, DOI 10.1016/S0006-8993(99)01557-7; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GRABHAM P, 1995, J NEUROCHEM, V64, P583; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; GRAFFRADFORD NR, 1989, ARCH NEUROL-CHICAGO, V46, P744, DOI 10.1001/archneur.1989.00520430038014; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Guh JY, 1996, J AM SOC NEPHROL, V7, P1207; Haas CA, 1999, J NEUROSCI, V19, P9953; HALL S, 1989, J NEUROCYTOL, V18, P171, DOI 10.1007/BF01206660; HALL SM, 1992, J NEUROCYTOL, V21, P402, DOI 10.1007/BF01191505; Hallscheidt P, 2001, TRANSPLANT P, V33, P2157, DOI 10.1016/S0041-1345(01)01926-1; Hammes EM, 1944, ARCH NEURO PSYCHIATR, V52, P505, DOI 10.1001/archneurpsyc.1944.02290360077006; Hashizume H, 2000, SPINE, V25, P1206, DOI 10.1097/00007632-200005150-00003; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hauss-Wegrzyniak B, 1999, BRAIN RES, V815, P36, DOI 10.1016/S0006-8993(98)01081-6; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hill C, 2001, DIABETOLOGIA, V44, P495, DOI 10.1007/s001250051648; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Igarashi Atsuyuki, 1992, Journal of Dermatology (Tokyo), V19, P642; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; JACKOWSKI A, 1990, J CEREBR BLOOD F MET, V10, P835, DOI 10.1038/jcbfm.1990.140; James G, 1999, NEUROSCI LETT, V268, P53, DOI 10.1016/S0304-3940(99)00370-5; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jensen MB, 1999, NEUROSCIENCE, V93, P507, DOI 10.1016/S0306-4522(99)00139-6; Jiang Y, 2000, NEUROSCIENCE, V97, P735, DOI 10.1016/S0306-4522(00)00084-1; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; Kalman M, 2000, BRAIN RES, V857, P291, DOI 10.1016/S0006-8993(99)02399-9; Kalman Mihaly, 2000, Neural Plasticity, V7, P147, DOI 10.1155/NP.2000.147; Kamei H, 2000, J SURG RES, V89, P20, DOI 10.1006/jsre.1999.5802; KANEKO R, 1994, P NATL ACAD SCI USA, V91, P4529, DOI 10.1073/pnas.91.10.4529; KAO CC, 1977, EXP NEUROL, V54, P591, DOI 10.1016/0014-4886(77)90259-X; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; King VR, 2000, EXP NEUROL, V165, P327, DOI 10.1006/exnr.2000.7480; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KITAZAWA K, 1994, STROKE, V25, P1400, DOI 10.1161/01.STR.25.7.1400; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; KNOWLES JF, 1978, EXP NEUROL, V62, P1, DOI 10.1016/0014-4886(78)90037-7; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Kondo Y, 1999, BRAIN RES, V834, P146, DOI 10.1016/S0006-8993(99)01517-6; KORSCHING S, 1993, J NEUROSCI, V13, P2739; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 2000, J CELL PHYSIOL, V182, P119, DOI 10.1002/(SICI)1097-4652(200001)182:1<119::AID-JCP13>3.0.CO;2-4; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kozlova EN, 1999, GLIA, V27, P249, DOI 10.1002/(SICI)1098-1136(199909)27:3<249::AID-GLIA6>3.3.CO;2-5; Krenz NR, 2000, J NEUROCHEM, V74, P730, DOI 10.1046/j.1471-4159.2000.740730.x; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KREUTZBERG GW, 1978, J NEUROCYTOL, V7, P601, DOI 10.1007/BF01260892; KRUGER S, 1986, J COMP NEUROL, V249, P103, DOI 10.1002/cne.902490108; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Krupinski J, 1998, NITRIC OXIDE-BIOL CH, V2, P442, DOI 10.1006/niox.1998.0204; Kudo A, 2000, CEREBROVASC DIS, V10, P424, DOI 10.1159/000016102; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; Lee YL, 2000, NEUROCHEM INT, V36, P417, DOI 10.1016/S0197-0186(99)00133-3; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; LEPRINCE G, 1990, DEV BRAIN RES, V51, P295, DOI 10.1016/0165-3806(90)90290-F; LEPRINCE G, 1991, GLIA, V4, P322, DOI 10.1002/glia.440040310; Leskovar A, 2000, J EXP BIOL, V203, P1783; LEVINE JM, 1987, J NEUROSCI, V7, P2711; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; LEVINE JM, 1987, J NEUROSCI, V7, P2721; Lew SM, 1999, BRAIN RES BULL, V48, P325, DOI 10.1016/S0361-9230(99)00004-0; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li Y, 1999, J NEUROCYTOL, V28, P417, DOI 10.1023/A:1007026001189; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; LINDA H, 1992, J COMP NEUROL, V318, P188, DOI 10.1002/cne.903180205; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; LIPPOLDT A, 1994, BRAIN RES, V668, P144, DOI 10.1016/0006-8993(94)90520-7; LIPS K, 1995, J NEUROCYTOL, V24, P449, DOI 10.1007/BF01181606; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; Liu L, 1999, EXP NEUROL, V157, P69, DOI 10.1006/exnr.1999.7046; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; Lucius R, 1998, J EXP MED, V188, P661, DOI 10.1084/jem.188.4.661; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; Maclennan KM, 1996, PROG NEUROBIOL, V50, P585, DOI 10.1016/S0301-0082(96)00047-0; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MARTIN P, 1994, EYE, V8, P155, DOI 10.1038/eye.1994.39; MARTIN P, 1993, DEV GENET, V14, P225, DOI 10.1002/dvg.1020140309; Martinez G, 2001, BRAIN RES, V894, P1, DOI 10.1016/S0006-8993(00)03140-1; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MAXWELL WL, 1984, HISTOCHEM J, V16, P1219, DOI 10.1007/BF01003445; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148, DOI 10.1152/ajpcell.1999.276.5.C1148; MCCONNELL P, 1984, BRAIN RES, V323, P257, DOI 10.1016/0006-8993(84)90296-8; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCMASTER RE, 1962, J COMP NEUROL, V119, P113, DOI 10.1002/cne.901190110; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Michael GJ, 1999, EUR J NEUROSCI, V11, P3539, DOI 10.1046/j.1460-9568.1999.00767.x; MILHORAT TH, 1995, J NEUROSURG, V82, P802, DOI 10.3171/jns.1995.82.5.0802; Mita T, 1998, GRAEF ARCH CLIN EXP, V236, P834, DOI 10.1007/s004170050168; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; Monzon-Mayor M, 2000, BRAIN RES, V865, P245, DOI 10.1016/S0006-8993(00)02231-9; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; MORSHEAD CM, 1990, BRAIN RES, V535, P237, DOI 10.1016/0006-8993(90)91606-H; Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x; MOTOHASHI O, 1995, NEUROSCI LETT, V190, P105, DOI 10.1016/0304-3940(95)11513-V; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; Nadal A, 1997, GLIA, V19, P343, DOI 10.1002/(SICI)1098-1136(199704)19:4<343::AID-GLIA7>3.0.CO;2-Y; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; Ng YK, 2001, HISTOL HISTOPATHOL, V16, P167, DOI 10.14670/HH-16.167; Nieto-Sampedro M, 1999, ADV EXP MED BIOL, V468, P207; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nishiyama A, 1997, J NEUROSCI RES, V48, P299, DOI 10.1002/(SICI)1097-4547(19970515)48:4<299::AID-JNR2>3.0.CO;2-6; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Nomoto Y, 2001, NEUROSURGERY, V48, P158, DOI 10.1097/00006123-200101000-00027; Norton WT, 1999, NEUROCHEM RES, V24, P213, DOI 10.1023/A:1022505903312; Nouel D, 1999, NEUROSCIENCE, V94, P1189, DOI 10.1016/S0306-4522(99)00354-1; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; Otten U, 2000, ANN NY ACAD SCI, V917, P322; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Pan WH, 1999, J NEUROSCI, V19, P3649; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Park KI, 2000, YONSEI MED J, V41, P825, DOI 10.3349/ymj.2000.41.6.825; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 2001, BRAIN RES REV, V35, P36, DOI 10.1016/S0165-0173(00)00050-3; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Penkowa M, 1999, GLIA, V25, P343; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; Phillips AO, 1997, LAB INVEST, V76, P591; Pindon A, 2000, J NEUROSCI, V20, P2543; POBER JS, 1990, HUM IMMUNOL, V28, P258, DOI 10.1016/0198-8859(90)90027-M; Pratt Bruce M., 1997, Cytokine and Growth Factor Reviews, V8, P267, DOI 10.1016/S1359-6101(97)00018-X; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Probstmeier R, 2000, J NEUROSCI RES, V60, P21, DOI 10.1002/(SICI)1097-4547(20000401)60:1<21::AID-JNR3>3.0.CO;2-H; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RAMSAY SC, 1992, LANCET, V339, P1054, DOI 10.1016/0140-6736(92)90576-O; Rathke-Hartlieb S, 2000, FEBS LETT, V481, P227, DOI 10.1016/S0014-5793(00)02011-1; RAYMOND AA, 1994, J NEUROL NEUROSUR PS, V57, P1195, DOI 10.1136/jnnp.57.10.1195; Redwine JM, 1998, J NEUROBIOL, V37, P413, DOI 10.1002/(SICI)1097-4695(19981115)37:3<413::AID-NEU7>3.0.CO;2-8; Reier P J, 1988, Adv Neurol, V47, P87; Reier P.J., 1986, ASTROCYTES, V3, P263; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; RISLING M, 1983, BRAIN RES, V280, P15, DOI 10.1016/0006-8993(83)91169-1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; Roitbak T, 1999, GLIA, V28, P40, DOI 10.1002/(SICI)1098-1136(199910)28:1<40::AID-GLIA5>3.0.CO;2-6; ROMANIC AM, 1994, BRAIN PATHOL, V4, P145, DOI 10.1111/j.1750-3639.1994.tb00825.x; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Saito N, 2000, J NEUROTRAUM, V17, P173, DOI 10.1089/neu.2000.17.173; Saliba E, 2001, BIOL NEONATE, V79, P224; Sanderson MJ, 1996, NEWS PHYSIOL SCI, V11, P262, DOI 10.1152/physiologyonline.1996.11.6.262; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; SARNAT HB, 1995, J NEUROPATH EXP NEUR, V54, P1, DOI 10.1097/00005072-199501000-00001; Sasamura H, 2001, HYPERTENS RES, V24, P165, DOI 10.1291/hypres.24.165; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Schiefer J, 1998, J NEUROIMMUNOL, V89, P168, DOI 10.1016/S0165-5728(98)00133-7; Schlomann U, 2000, J NEUROSCI, V20, P7964; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab JM, 2000, NEUROPATH APPL NEURO, V26, P434, DOI 10.1046/j.1365-2990.2000.00271.x; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHEWAN D, 1995, J NEUROSCI, V15, P2057, DOI 10.1523/JNEUROSCI.15-03-02057.1995; SHEWAN D, 1993, EUR J NEUROSCI, V5, P809, DOI 10.1111/j.1460-9568.1993.tb00932.x; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; Silverstein FS, 1997, NEUROCHEM INT, V30, P375, DOI 10.1016/S0197-0186(96)00072-1; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Slevin M, 2000, STROKE, V31, P1863, DOI 10.1161/01.STR.31.8.1863; Smith C, 2001, EUR J NEUROSCI, V13, P443, DOI 10.1046/j.1460-9568.2001.01400.x; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; STICHEL CC, 1995, EUR J NEUROSCI, V7, P401, DOI 10.1111/j.1460-9568.1995.tb00336.x; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STRUCKHOFF G, 1995, NEUROSCI LETT, V189, P117, DOI 10.1016/0304-3940(95)11468-C; Sugiura S, 2000, EUR J NEUROSCI, V12, P457, DOI 10.1046/j.1460-9568.2000.00922.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; SUNG JH, 1981, J NEUROPATH EXP NEUR, V40, P645, DOI 10.1097/00005072-198111000-00006; Suzuki H, 1999, NEUROL RES, V21, P269, DOI 10.1080/01616412.1999.11740930; SUZUKI S, 1977, ACTA NEUROCHIR, V39, P1, DOI 10.1007/BF01405236; Szczepanik AM, 1996, NEUROSCIENCE, V70, P57, DOI 10.1016/0306-4522(95)00296-U; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; TAKAYAMA S, 1994, BRAIN RES, V653, P131, DOI 10.1016/0006-8993(94)90381-6; Tallant EA, 1997, GLIA, V19, P333; Tang HB, 2000, NEUROSCI LETT, V285, P143, DOI 10.1016/S0304-3940(00)00998-8; Taoka Y, 2001, J NEUROTRAUM, V18, P533, DOI 10.1089/089771501300227332; TAPANINAHO A, 1993, ACTA NEUROCHIR, V123, P118, DOI 10.1007/BF01401866; TARDY M, 1991, ANN NY ACAD SCI, V633, P630; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; Tokita Y, 2001, J NEUROSCI, V21, P1257; Tonai T, 1999, J NEUROCHEM, V72, P302, DOI 10.1046/j.1471-4159.1999.0720302.x; Tretter YP, 2000, NAT MED, V6, P812, DOI 10.1038/77548; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; Tsao MN, 1999, J NEUROPATH EXP NEUR, V58, P1051, DOI 10.1097/00005072-199910000-00003; Tzeng SF, 2001, LIFE SCI, V68, P1005, DOI 10.1016/S0024-3205(00)01003-1; Uhl E, 1999, STROKE, V30, P880, DOI 10.1161/01.STR.30.4.880; Vale FL, 1997, J NEUROSURG, V86, P462, DOI 10.3171/jns.1997.86.3.0462; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WAHL SM, 1989, J CELL BIOCHEM, V40, P193, DOI 10.1002/jcb.240400208; WALLACE MC, 1987, SURG NEUROL, V27, P209, DOI 10.1016/0090-3019(87)90031-0; Walter HJ, 1999, ENDOCRINOLOGY, V140, P520, DOI 10.1210/en.140.1.520; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WANG L, 1994, CELL IMMUNOL, V159, P152, DOI 10.1006/cimm.1994.1304; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1998, ACT NEUR S, V71, P212; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; WILLIAMS B, 1981, PARAPLEGIA, V19, P67, DOI 10.1038/sc.1981.18; WILLIAMS B, 1980, J ROY SOC MED, V73, P798, DOI 10.1177/014107688007301109; WINDLE WF, 1952, T AM NEUROL ASSOC, P164; WINDLE WF, 1956, PHYSIOL REV, V36, P427, DOI 10.1152/physrev.1956.36.4.427; WINDLE WF, 1952, J COMP NEUROL, V96, P359, DOI 10.1002/cne.900960207; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Yang GY, 1999, BRAIN RES, V817, P123, DOI 10.1016/S0006-8993(98)01236-0; Yick LW, 1998, NEUROSCI LETT, V241, P155; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; YONG VW, 1992, GLIA, V6, P269, DOI 10.1002/glia.440060405; Yoon DH, 1999, YONSEI MED J, V40, P313, DOI 10.3349/ymj.1999.40.4.313; Yoshimoto T, 1997, ACTA NEUROPATHOL, V93, P154, DOI 10.1007/s004010050596; Young KA, 1999, GLIA, V26, P333, DOI 10.1002/(SICI)1098-1136(199906)26:4<333::AID-GLIA7>3.0.CO;2-S; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang LZ, 2001, AM J PHYSIOL-GASTR L, V280, pG1247, DOI 10.1152/ajpgi.2001.280.6.G1247; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; Zhang Y, 2001, MOL CELL NEUROSCI, V17, P444, DOI 10.1006/mcne.2000.0952; Zhang Y, 1997, J NEUROSCI RES, V49, P433; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	456	33	35	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598	2214-8019	0-306-47414-X	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2002	513						115	158					44	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	BW92A	WOS:000183600500004	12575819				2022-02-06	
J	Vitaz, TW; McIlvoy, L; Raque, GH; Spain, D; Shields, CB				Vitaz, TW; McIlvoy, L; Raque, GH; Spain, D; Shields, CB			Development and implementation of a clinical pathway for severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						clinical pathway; severe traumatic brain injury	TRACHEOSTOMY; GASTROSTOMY; CARE	Background. Clinical pathways (CPs) have been shown to be beneficial in optimizing patient care and resource use. Methods. A multidisciplinary CP for the treatment of severe traumatic brain injury (Glasgow Coma Scale score of 3-7) was developed. Data from these patients (group I) were collected prospectively and compared with a retrospective database (group II). Results. There were a total of 119 patients managed in conjunction with the CP and 43 patients in the control group. No statistical differences were found between the groups in age, Glasgow Coma Scale score at 24 hours, or Injury Severity Scores. There was a significant decrease in the length of hospital stay, intensive care unit stay, and length of ventilator support in the study group (group I: 22.5, 16.8, and 11.5 days, respectively; group II: 31.0, 21.2, and 14.4 days, respectively; p < 0.03). Conclusion: The use of this CP helped to standardize and improve patient care with fewer complications and a potential cost savings of approximately $14,000 per patient.	Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Gen Surg, Louisville, KY 40292 USA; Univ Hlth Care, Louisville, KY USA		Vitaz, TW (corresponding author), 210 E Gray St,Suite 1102, Louisville, KY 40202 USA.						*AM COLL SURG COMM, 1998, ADV TRAUM LIF SUPP C; Armstrong PA, 1998, SURGERY, V124, P763, DOI 10.1067/msy.1998.91224; Aronson B, 1996, J Contin Educ Nurs, V27, P215; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; DAMELIO LF, 1994, AM SURGEON, V60, P180; FLORIN R, 1995, GUIDELINES MANAGEMEN; Ibarra VL, 1997, SPINE, V22, P352, DOI 10.1097/00007632-199702010-00022; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Kitchiner D, 1996, ARCH DIS CHILD, V75, P166, DOI 10.1136/adc.75.2.166; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; Ross BJ, 1996, AM SURGEON, V62, P19; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Zevola D R, 1997, Crit Care Nurse, V17, P20	14	33	33	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2001	51	2					369	375		10.1097/00005373-200108000-00025			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	463DW	WOS:000170462400024	11493802				2022-02-06	
J	Oliaro, S; Anderson, S; Hooker, D				Oliaro, S; Anderson, S; Hooker, D			Management of cerebral concussion in sports: The athletic trainer's perspective	JOURNAL OF ATHLETIC TRAINING			English	Article						mild head injury; neuropsychological testing; postural stability testing; grading scales	MILD HEAD-INJURY; POSTURAL STABILITY; FOOTBALL PLAYERS; EPIDEMIOLOGY; GUIDELINES; COLLEGIATE; SEQUELAE	Objective: To present a new approach in the evaluation and management of concussion from the athletic trainer's perspective. Background: The evaluation and management of concussion continues to be a controversial topic among sports medicine professionals. Inconsistent management, lack of objective data, and confusion concerning assessment techniques may lead to inappropriate decisions regarding when to return an athlete to competition after concussion. In this article, we provide recommendations and considerations for the certified athletic trainer in the management of concussion. We also present a quantifiable assessment technique that provides more information on which return-to-play decisions can be made; this technique can be used during the initial sideline examination as well as during subsequent follow-up examinations. Recommendations: Certified athletic trainers and team physicians should consistently use appropriate grading scales. Assessment of concussion should include a symptom checklist, the Balance Error Scoring System, and the Standardized Assessment of Concussion, and the results should be compared with the athlete's normal baseline scores. Follow-up neuropsychological and postural stability testing is recommended. Return-to-play decisions should be based on the grade of concussion, scores on objective tests, and presence of concussive symptoms during exertional activities.	Univ N Carolina, Chapel Hill, NC 27515 USA; Univ Oklahoma, Norman, OK 73019 USA		Oliaro, S (corresponding author), Univ N Carolina, POB 2126, Chapel Hill, NC 27515 USA.						ARNHEIM DD, 1997, PRINCIPLES ATHLETIC; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; *C NEUR SURG INC, 1966, CLIN NEUROSURG, V14, P424; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Ferrara Michael S., 2001, J Athl Train, V36, P145; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; GUSKIEWICZ KM, 1999, ATHLETIC TRAINING SP, P143; Jordan B, 1989, SPORTS NEUROLOGY; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Onate JA, 2000, J ATHL TRAINING, V35, P155; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Torg JS, 1991, ATHLETIC INJURIES HE, Vsecond	21	33	33	0	3	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					257	262					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	557NC	WOS:000175913800008	12937494				2022-02-06	
J	Tsushima, WT; Tsushima, VG				Tsushima, WT; Tsushima, VG			Comparison of the Fake Bad Scale and other MMPI-2 validity scales with personal injury litigants	ASSESSMENT			English	Article						MMPI-2; Fake Bad Scale; validity scales; personal injury; litigation; malingering	CLOSED-HEAD INJURY; FORENSIC ASSESSMENT; F(P) SCALE	Five MMPI-2 validity scales were evaluated with 120 personal injury litigation patients (LP) and 208 clinical patients (CP) along with 43 normal participants (NP). The validity measures included the Fake Bad Scale (FBS), Infrequency scale (F), Back Infrequency scale (Fb), Infrequency-Psychopathology scale (F-[p]), and the Dissimulation scale-2 (Ds(2)). Results showed that only the FBS significantly differentiated the LP and CP, whereas the LP and CP scored significantly higher than the NP on FBS, F, Fb, and Ds(2). The content of the FBS, with several items from the Hypochondriasis (Hs) and Hysteria (Hy) Scales, appears to enhance the FBS' ability to detect the somatic overreporting often observed with personal injury claimants. The authors suggest that the FBS may be a useful index of symptom magnification when employed within a comprehensive assessment of malingering in personal injury plaintiffs.	Straub Clin & Hosp, Dept Psychiat & Psychol, Honolulu, HI 96813 USA; Goodsill Anderson Quinn & Stifel, Honolulu, HI USA		Tsushima, WT (corresponding author), Straub Clin & Hosp, Dept Psychiat & Psychol, 888 S King St, Honolulu, HI 96813 USA.						Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 1998, PSYCHOL ASSESSMENT, V10, P221, DOI 10.1037/1040-3590.10.3.221; Arbisi PA, 1997, PSYCHOL ASSESSMENT, V9, P102, DOI 10.1037/1040-3590.9.2.102; BAGBY RM, 1995, PSYCHOL ASSESSMENT, V7, P84; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Butcher J, 1989, MANUAL ADM SCORING M; Butcher JN, 1995, PSYCHOL ASSESSMENT, V7, P320, DOI 10.1037/1040-3590.7.3.320; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; GRAHAM JR, 1991, J PERS ASSESS, V57, P264, DOI 10.1207/s15327752jpa5702_6; Hathaway SR, 1943, MANUAL MINNESOTA MUL; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; POPE KS, 2000, MMPI MMPI2 MMPIA COU; ROGERS R, 1994, LAW HUMAN BEHAV, V18, P543, DOI 10.1007/BF01499173; Rogers R., 1995, ASSESSMENT, V2, P81, DOI DOI 10.1177/1073191195002001008; Rogers R., 1997, CLIN ASSESSMENT MALI; Rothke SE, 2000, PSYCHOL ASSESSMENT, V12, P335, DOI 10.1037/1040-3590.12.3.335; Sivec, 1994, Assessment, V1, P69, DOI 10.1177/1073191194001001010; WETTER MW, 1992, PSYCHOL ASSESSMENT, V4, P369, DOI DOI 10.1037/1040-3590.4.3.369; Williams CW, 1999, PROF PSYCHOL-RES PR, V30, P361, DOI 10.1037/0735-7028.30.4.361; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177; Ziskin J, 1988, COPING PSYCHIAT PSYC, P481; [No title captured]	27	33	33	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911			ASSESSMENT	Assessment	JUN	2001	8	2					205	212		10.1177/107319110100800208			8	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	537LB	WOS:000174759100008	11428699				2022-02-06	
J	Brodhun, M; Fritz, H; Walter, B; Antonow-Schlorke, I; Reinhart, K; Zwiener, U; Bauer, R; Patt, S				Brodhun, M; Fritz, H; Walter, B; Antonow-Schlorke, I; Reinhart, K; Zwiener, U; Bauer, R; Patt, S			Immunomorphological sequelae of severe brain injury induced by fluid-percussion in juvenile pigs - effects of mild hypothermia	ACTA NEUROPATHOLOGICA			English	Article						trauma; fluid percussion brain injury; pig hypothermia; immunohistochemistry	MICROTUBULE-ASSOCIATED PROTEIN-2; DIFFUSE AXONAL INJURY; CEREBRAL BLOOD-FLOW; HEAD-INJURY; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; SYSTEMIC HYPOTHERMIA; RAT-BRAIN; BETA-APP	Severe traumatic brain injury (TBI) often leads to a bad outcome with considerable neurological deficits. Secondary brain injuries due to a rise of intracranial pressure (ICP) and global hypoxia-ischemia are critical and may be reduced in extent by mild hypothermia. A porcine animal model was used to study the effect of severe TBI, induced by fluid percussion (FP; 3.5 +/-0.3 atm) in combination with a secondary insult, i.e., temporary blood loss with hypovolemic hypotension. Six-week-old juvenile pigs were subjected to this kind of severe TBI; one group was then submitted to moderate hypothermia at 32 degreesC for 6 h, starting 1 h after brain injury. Animals were killed after 24 h. TBI and hypothermia-associated alterations in the brains were investigated by immunohistochemistry with antibodies against microtubule-associated protein 2 (MAP-2) and beta -amyloid precursor protein (beta APP). In addition, DNA fragmentation was investigated by the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) method. Seven of the 13 normothermic TBI animals developed a secondary increase in ICP (TBI-NT-ICP) after an interval of several hours. None of the animals in the hypothermic trauma (TBI-HT) group exhibited a secondary ICP increase, indicating a protective effect of the treatment. TBI-HT animals showed significantly higher levels of MAP-2 immunoreactivity, lower levels of beta APP immunoreactivity and less DNA fragmentation than the TBI-NT-ICP animals. Differences between the TBI-HT group and normothermic animals without an ICP increase (TBI-NT) were less marked. A considerable decrease in MAP-2 outside the site of TBI-FP administration was seen only in the TBI-NT-ICP animals. MAP-2 immunohistochemistry was thus a reliable marker of diffuse brain damage. Axonal injury was present in all TBI groups, indicating its special significance in neurotrauma. Thus, severe TBI caused by FP, combined with temporary blood loss, consistently produced traumatic axonal injury and focal brain damage. Mild hypothermia was able to prevent a secondary increase in ICP and its sequelae of diffuse hypoxic-ischemic brain injury. However, hypothermia did not afford protection from traumatic axonal injury.	Univ Jena, Inst Pathol Neuropathol, D-07740 Jena, Germany; Univ Jena, Clin Anesthesiol & Intens Care, D-07740 Jena, Germany; Univ Jena, Inst Pathophysiol, D-07740 Jena, Germany		Patt, S (corresponding author), Univ Jena, Inst Pathol Neuropathol, Bachstr 18, D-07740 Jena, Germany.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Arani R B, 1998, J Biopharm Stat, V8, P585, DOI 10.1080/10543409808835262; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentleman SM, 1999, NEUROPATH APPL NEURO, V25, P41; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P198; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Laptook AR, 1997, PEDIATR RES, V42, P17, DOI 10.1203/00006450-199707000-00004; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOMINAGA T, 1993, BRAIN RES, V608, P21, DOI 10.1016/0006-8993(93)90768-I; WALTER B, 1997, PFLUGERS ARCH S, V433, pR63; Wladis A, 1998, J TRAUMA, V45, P527, DOI 10.1097/00005373-199809000-00019; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610; Yoshikawa T., 1968, ATLAS BRAINS DOMESTI; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046	68	33	33	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2001	101	5					424	434					11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	446UU	WOS:000169533200002	11484813				2022-02-06	
J	Johnston, KM; Lassonde, M; Ptito, A				Johnston, KM; Lassonde, M; Ptito, A			A contemporary neurosurgical approach to sport-related head injury: The McGill concussion protocol	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							DIFFUSION-WEIGHTED MR; TRAUMATIC BRAIN-INJURY; STANDARDIZED ASSESSMENT; FOLLOW-UP; GUIDELINES; SPECT; RETURN; DYSFUNCTION; MANAGEMENT; SYMPTOMS		McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Dept Psychol & Neuropsychol, McGill Sport Med, Montreal, PQ, Canada		Johnston, KM (corresponding author), McGill Univ, Ctr Hlth, Dept Neurosurg, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.						Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; ANDERSON SD, 1995, CAN J DIAGN, V12, P77; BANICH MT, 1997, NEURAL BASES MENTAL; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; FICK DS, 1995, POSTGRAD MED, V97, P53, DOI 10.1080/00325481.1995.11945958; Fox W, 1984, DANDY J HOPKINS; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hofman PAM, 1999, MAGN RESON MED, V42, P803, DOI 10.1002/(SICI)1522-2594(199910)42:4<803::AID-MRM24>3.3.CO;2-6; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jacobs A, 1996, J NUCL MED, V37, P1605; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, IN PRESS CLIN J SPOR; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LEBIHAN D, 1997, BASICS PHYSICS MR IM, P131; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; LECLERC S, 2000, MED SCI SPORTS EXERC; LECLERC S, IN PRESS SPORTS MED; Li TQ, 1998, ACTA RADIOL, V39, P460; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makris N, 1997, ANN NEUROL, V42, P951, DOI 10.1002/ana.410420617; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCCRORY P, IN PRESS PHYS SPORTS; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Milner B., 1964, FRONTAL GRANULAR COR, P313; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; PETRIDES M, 1995, J NEUROSCI, V15, P359; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Shallice T, 1990, NEUROPSYCHOLOGY MENT; *SPORT MED COUNC A, 1999, HEADS UP; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TATOR CH, 1987, CLIN SPORT MED, V6, P101; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Umile EM, 1998, BRAIN INJURY, V12, P577; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	61	33	33	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	APR	2001	192	4					515	524		10.1016/S1072-7515(01)00797-9			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	416QX	WOS:000167792600015	11294409				2022-02-06	
J	Hauser, KF; Knapp, PE; Turbek, CS				Hauser, KF; Knapp, PE; Turbek, CS			Structure-activity analysis of dynorphin A toxicity in spinal cord neurons: Intrinsic neurotoxicity of dynorphin A and its carboxyl-terminal, nonopioid metabolites	EXPERIMENTAL NEUROLOGY			English	Article						kappa-opioid receptors; N-methyl-D-aspartate (NMDA) receptor complex; MK-801 (dizocilpine); nor-binaltorphimine; intracellular calcium; neurotoxicology; spinal cord injury; neurotrauma	EXCITATORY AMINO-ACIDS; NMDA-RECEPTOR CHANNELS; LONG-LASTING ALLODYNIA; KAPPA-OPIOID RECEPTOR; BRAIN-INJURY; IN-VITRO; EXPRESSION; PEPTIDES; ANTINOCICEPTION; INFLAMMATION	Dynorphin A [dynorphin A (1-17)] is an endogenous opioid peptide that is antinociceptive at physiological concentrations. Levels of dynorphin A increase markedly following spinal cord trauma and may contribute to secondary neurodegeneration. Both kappa opioid and N-methyl-D-aspartate (NMDA) receptor antagonists can modulate the effects of dynorphin, suggesting that dynorphin is acting through kappa opioid and/or NMDA receptor types. Despite these findings, few studies have critically examined the mechanisms of dynorphin A neurotoxicity at the cellular level. To better understand how dynorphin affects cell viability, structure-activity studies were performed examining the effects of dynorphin A and dynorphin A-derived peptide fragments on the survival of mouse spinal cord neurons coexpressing kappa opioid and NMDA receptors in vitro. Time-lapse photography was used to repeatedly follow the same neurons before and during experimental treatments. Dynorphin A caused significant neuronal losses that were dependent on concentration (greater than or equal to1 muM) and duration of exposure. Moreover, exposure to an equimolar concentration of dynorphin A fragments (100 muM) also caused a significant loss of neurons. The rank order of toxicity was dynorphin A (1-17) > dynorphin A (1-13) congruent to dynorphin A (2-13) congruent to dynorphin A (13-17) (least toxic) > dynorphin A (1-5) ([Leu(5)]-enkephalin) or dynorphin A (1-11). Dynorphin A (1-5) or dynorphin A (1-11) did not cause neuronal losses even following 96 h of continuous exposure, while dynorphin A (3-13), dynorphin A (6-17), and dynorphin A (13-17) were neurotoxic. The NMDA receptor antagonist MK-801 (dizocilpine) (10 muM) significantly attenuated the neurotoxic effects of dynorphin A and/or dynorphin-derived fragments except dynorphin A (13-17), suggesting that the neurotoxic effects of dynorphin were largely mediated by NMDA receptors. Thus, toxicity resides in the carboxyl-terminal portion of dynorphin A and this minimally includes dynorphin A (3-13) and (13-17). Our findings suggest that dynorphin A and/or its metabolites may contribute significantly to neurodegeneration during spinal cord injury and that alterations in dynorphin A biosynthesis, metabolism, and/or degradation may be important in determining injury outcome. (C) 2001 Academic Press.	Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Coll Med, Lexington, KY 40536 USA		Hauser, KF (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA.		Hauser, Kurt/AAX-8361-2020	Hauser, Kurt/0000-0001-7886-0332	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 06204] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA006204] Funding Source: NIH RePORTER		ARVIDSSON U, 1995, P NATL ACAD SCI USA, V92, P5062, DOI 10.1073/pnas.92.11.5062; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793, DOI 10.1523/JNEUROSCI.10-12-03793.1990; Boyce S, 1999, NEUROPHARMACOLOGY, V38, P611, DOI 10.1016/S0028-3908(98)00218-4; Brauneis U, 1996, J PHARMACOL EXP THER, V279, P1063; Caudle RM, 1998, NEUROPEPTIDES, V32, P87, DOI 10.1016/S0143-4179(98)90022-1; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1995, J PHYSIOL-LONDON, V482, P575, DOI 10.1113/jphysiol.1995.sp020541; Chen L, 1998, J PHARMACOL EXP THER, V284, P826; CHEN L, 1995, J NEUROSCI, V15, P4602; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Duggan AW, 1996, PROG BRAIN RES, V110, P137; EVANS CJ, 1988, OPIATE RECEPTORS, P23; Faden A I, 1996, NIDA Res Monogr, V163, P318; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1992, J NEUROSCI, V12, P425; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GOLDSTEIN A, 1979, P NATL ACAD SCI USA, V76, P6666, DOI 10.1073/pnas.76.12.6666; Gurwell JA, 1996, BRAIN RES, V737, P175, DOI 10.1016/0006-8993(96)00728-7; HAUSER KF, 1989, BRAIN RES, V485, P157, DOI 10.1016/0006-8993(89)90677-X; Hauser KF, 1999, EXP NEUROL, V160, P361, DOI 10.1006/exnr.1999.7235; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; Hu WH, 1998, EUR J PHARMACOL, V342, P325, DOI 10.1016/S0014-2999(97)01492-1; IADAROLA MJ, 1988, PAIN, V35, P313, DOI 10.1016/0304-3959(88)90141-8; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; Jarvis CR, 1997, J NEUROPHYSIOL, V78, P2363, DOI 10.1152/jn.1997.78.5.2363; KAKIDANI H, 1982, NATURE, V298, P245, DOI 10.1038/298245a0; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; KOLAJ M, 1995, BRAIN RES, V671, P227, DOI 10.1016/0006-8993(94)01333-D; Laughlin TM, 1997, PAIN, V72, P253, DOI 10.1016/S0304-3959(97)00046-8; Laughlin TM, 1999, PAIN, V80, P37, DOI 10.1016/S0304-3959(98)00191-2; Lipton SA, 1996, BRAIN PATHOL, V6, P507, DOI 10.1111/j.1750-3639.1996.tb00879.x; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; Long J B, 1986, NIDA Res Monogr, V75, P524; LONG JB, 1994, J PHARMACOL EXP THER, V269, P358; LONG JB, 1988, EUR J PHARMACOL, V153, P45, DOI 10.1016/0014-2999(88)90586-9; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1994, AM J PHYSIOL, V267, pR665, DOI 10.1152/ajpregu.1994.267.3.R665; Messersmith DJ, 1998, MOL BRAIN RES, V53, P259, DOI 10.1016/S0169-328X(97)00308-2; MILLAN MJ, 1988, PAIN, V35, P299, DOI 10.1016/0304-3959(88)90140-6; MORRIS BJ, 1995, TRENDS NEUROSCI, V18, P350, DOI 10.1016/0166-2236(95)93927-P; NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169-328X(91)90065-6; OLESHANSKY M A, 1991, Society for Neuroscience Abstracts, V17, P1268; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PORRECA F, 1998, INT NARC RES C, V29, P31; Prokai L, 1998, J CHROMATOGR A, V800, P59, DOI 10.1016/S0021-9673(97)01295-8; Shukla VK, 1997, J PHARMACOL EXP THER, V283, P604; SHUKLA VK, 1994, TRENDS PHARMACOL SCI, V15, P420, DOI 10.1016/0165-6147(94)90091-4; SHUKLA VK, 1992, J PSYCHIATR NEUROSCI, V17, P106; SKILLING SR, 1992, BRAIN RES, V575, P272, DOI 10.1016/0006-8993(92)90090-V; Sykova E, 1997, ADV NEUROL, V73, P121; Sykova E, 1999, GLIA, V25, P56, DOI 10.1002/(SICI)1098-1136(19990101)25:1<56::AID-GLIA6>3.0.CO;2-4; Tachibana T, 1998, J NEUROTRAUM, V15, P485, DOI 10.1089/neu.1998.15.485; Tang QB, 2000, J NEUROPHYSIOL, V83, P2610, DOI 10.1152/jn.2000.83.5.2610; Tang QB, 1999, J PHARMACOL EXP THER, V291, P760; TUCKER RP, 1988, J NEUROSCI, V8, P4503; Vanderah TW, 1996, PAIN, V68, P275, DOI 10.1016/S0304-3959(96)03225-3; WALKER JM, 1982, SCIENCE, V218, P1136, DOI 10.1126/science.6128791; WALKER JM, 1982, LIFE SCI, V31, P1821, DOI 10.1016/0024-3205(82)90219-3; WALKER JM, 1982, EUR J PHARMACOL, V85, P121, DOI 10.1016/0014-2999(82)90433-2; WEIHE E, 1989, NEUROSCIENCE, V31, P77, DOI 10.1016/0306-4522(89)90031-6; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Yaksh TL, 1999, P NATL ACAD SCI USA, V96, P7680, DOI 10.1073/pnas.96.14.7680; Ye ZC, 1998, GLIA, V22, P237, DOI 10.1002/(SICI)1098-1136(199803)22:3<237::AID-GLIA3>3.0.CO;2-2; YOUNG EA, 1987, PEPTIDES, V8, P701, DOI 10.1016/0196-9781(87)90046-5; Zhang L, 1997, J NEUROPHYSIOL, V78, P582, DOI 10.1152/jn.1997.78.2.582; Ziak D, 1998, PHYSIOL RES, V47, P365; Zoli M, 1999, TRENDS PHARMACOL SCI, V20, P142, DOI 10.1016/S0165-6147(99)01343-7	74	33	34	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2001	168	1					78	87		10.1006/exnr.2000.7580			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	406ER	WOS:000167202400006	11170722				2022-02-06	
J	Schellinger, PD; Schwab, S; Krieger, D; Fiebach, JB; Steiner, T; Hund, EF; Hacke, W; Meinck, HM				Schellinger, PD; Schwab, S; Krieger, D; Fiebach, JB; Steiner, T; Hund, EF; Hacke, W; Meinck, HM			Masking of vertebral artery dissection by severe trauma to the cervical spine	SPINE			English	Article						acute spinal injury; cervical spine; dissection; trauma; vertebral artery	CLINICAL-FEATURES; NECK PAIN; THERAPY; INJURY; SUBLUXATION; OCCLUSION; DIAGNOSIS; INFARCTS; HEADACHE	Study Design. A prospective case study was performed. Objectives. To illustrate the association of cervical trauma with vertebral artery dissection, and to propose a diagnostic and therapeutic algorithm for suspected traumatic vertebral artery dissection. Summary of Background Data. Vertebral artery dissection is a recognized but underdiagnosed complication of trauma to the cervical spine. Symptoms of spinal cord injury, however, may obscure those of vertebral artery dissection, presumably causing gross underdiagnosis of this complication. Methods. All patients with vertebral artery dissection admitted to the authors' facility between 1992 and 1997 were screened for cervical trauma. Results. This article presents four patients with severe trauma to the cervical spine, defined as luxation, subluxation, or fracture, in whom symptoms of vertebral artery dissection developed after a delay ranging from several hours to weeks. The traumatic vertebral artery dissection typically was located at the site of vertebral injury or cranial to it. One patient with fracture of the odontoid process survived symptom free without ischemic brain infarctions. Another patient survived with traumatic quadriplegia in addition to large cerebellar and posterior cerebral artery infarctions. Two patients died as a result of fulminant vertebrobasilar infarctions, both with only moderate impairment from the primary spinal cord injury. Conclusions. Early signs of vertebral artery dissection include head and neck pain, often localized to the site of intimal disruption, which may be disguised by the signs of the spinal injury. Early Doppler ultrasound and duplex sonography as a noninvasive screening method should be performed for patients with severe trauma to the cervical spine. In cases of vertebral artery dissection, immediate anticoagulation should be initiated. Traumatologists should be aware of this complication in evaluating patients with severe trauma of the cervical spine, and also for a variety of forensic reasons.	Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Neuroradiol, D-69120 Heidelberg, Germany; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA		Schellinger, PD (corresponding author), Univ Heidelberg, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Steiner, Thorsten/L-2868-2018; Steiner, Thorsten/A-7391-2014	Steiner, Thorsten/0000-0002-5080-8222; Fiebach, Jochen B./0000-0002-7936-6958			Adamek RJ, 1998, HELICOBACTER, V3, P206, DOI 10.1046/j.1523-5378.1998.08044.x; Bartels E, 1996, STROKE, V27, P290, DOI 10.1161/01.STR.27.2.290; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; BRANDT T, 1995, NERVENARZT, V66, P267; CARPENTER S, 1961, J NEUROSURG, V18, P849, DOI 10.3171/jns.1961.18.6.0849; Chiles BW, 1996, NEW ENGL J MED, V334, P514, DOI 10.1056/NEJM199602223340807; Hart R G, 1983, Neurol Clin, V1, P155; HINSE P, 1991, J NEUROL NEUROSUR PS, V54, P863, DOI 10.1136/jnnp.54.10.863; HINZ P, 1963, ARCH ORTHOP UNFALLCH, V64, P268; HOFFMANN M, 1993, STROKE, V24, P815, DOI 10.1161/01.STR.24.6.815; JABRE A, 1991, NEUROSURGERY, V29, P912, DOI 10.1227/00006123-199112000-00020; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Khurana DS, 1996, PEDIATR NEUROL, V14, P255, DOI 10.1016/0887-8994(96)00015-X; Krayenbuhl H, 1957, VASKULAREN ERKRANKUN, P13; KRIEGER D, 1990, DEUT MED WOCHENSCHR, V115, P580, DOI 10.1055/s-2008-1065050; LOUW JA, 1990, J BONE JOINT SURG BR, V72, P679, DOI 10.1302/0301-620X.72B4.2380226; MAS JL, 1987, STROKE, V18, P1037, DOI 10.1161/01.STR.18.6.1037; PARENT AD, 1992, NEUROSURGERY, V31, P501, DOI 10.1227/00006123-199209000-00012; PRATTTHOMAS HR, 1947, JAMA-J AM MED ASSOC, V133, P600, DOI 10.1001/jama.1947.02880090022005; Provenzale JM, 1996, J COMPUT ASSIST TOMO, V20, P185, DOI 10.1097/00004728-199603000-00004; PULLICINO P, 1994, STROKE, V25, P1870, DOI 10.1161/01.STR.25.9.1870; Schellinger PD, 1997, FORTSCHR NEUROL PSYC, V65, P425, DOI 10.1055/s-2007-996348; SILBERT PL, 1995, NEUROLOGY, V45, P1517, DOI 10.1212/WNL.45.8.1517; STURZENEGGER M, 1993, STROKE, V24, P1910, DOI 10.1161/01.STR.24.12.1910; Sturzenegger M, 1996, Ther Umsch, V53, P544; STURZENEGGER M, 1993, SCHWEIZ MED WSCHR, V123, P1389; STURZENEGGER M, 1994, HEADACHE, V34, P187, DOI 10.1111/j.1526-4610.1994.hed3404187.x; STURZENEGGER M, 1994, NERVENARZT, V65, P402; SUECHTING RL, 1955, J NEUROSURG, V12, P187, DOI 10.3171/jns.1955.12.2.0187; TULYAPRONCHOTE R, 1994, NEUROLOGY, V44, P1397, DOI 10.1212/WNL.44.8.1397; WILLIS BK, 1994, NEUROSURGERY, V34, P435, DOI 10.1227/00006123-199403000-00008; [No title captured]	32	33	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	FEB 1	2001	26	3					314	319		10.1097/00007632-200102010-00019			6	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	400TE	WOS:000166887100013	11224870				2022-02-06	
J	Nicholson, K; Martelli, MF; Zasler, ND				Nicholson, K; Martelli, MF; Zasler, ND			Does pain confound interpretation of neuropsychological test results?	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; POSTTRAUMATIC HEADACHE; COGNITIVE PERFORMANCE; ANXIETY DISORDERS; RISK-FACTORS; MEMORY; DEFICITS; METAANALYSIS; ATTENTION; MORPHINE	There is increasing evidence that pain and related problems (e.g., affective distress, sleep disturbance, medication use) can interfere with cognitive performance and confound the interpretation of neuropsychological test results. This maybe of particular concern incases of the persistent post-concussive syndrome where headache is the primary problem. Such effects can be pronounced, obscuring the effects associated with mild or even much more significant brain injury. However, it remains unclear what specific chronic or acute pain experiences, in what individuals, with or without which associated problems, will actually result in particular performance deficits. Whereas pain may disrupt brain function, this is likely to be temporary and not indicative of permanent impairment of neuropsychological function. Further study of this important topic is warranted.	Toronto Western Hosp, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada; Pinnacle Rehabil & Tree Life, Concuss Care Ctr Virginia, Glen Allen, VA USA; Virginia Commonwealth Univ, Richmond, VA 23298 USA; Virginia Commonwealth Univ Med Coll Virginia, Richmond, VA USA		Nicholson, K (corresponding author), Toronto Western Hosp, Comprehens Pain Program, 4BFell-150,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	keith@uhnres.utoronto.ca					Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOROD JC, 2000, NEUROPSYCHOL EMOTION; Branca B, 1996, HEADACHE, V36, P300, DOI 10.1046/j.1526-4610.1996.3605300.x; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Cleeland CS, 1996, NEUROPSYCHOPHARMACOL, V15, P252, DOI 10.1016/0893-133X(95)00205-R; Crombez G, 1997, PAIN, V70, P149, DOI 10.1016/S0304-3959(96)03304-0; Crombez G, 1996, BEHAV RES THER, V34, P911, DOI 10.1016/S0005-7967(96)00058-7; CROMBEZ G, 1994, BEHAV RES THER, V32, P611, DOI 10.1016/0005-7967(94)90015-9; DANDREA G, 1989, CEPHALALGIA, V9, P25, DOI 10.1046/j.1468-2982.1989.0901025.x; Davidson RJ, 1999, CURR OPIN NEUROBIOL, V9, P228, DOI 10.1016/S0959-4388(99)80032-4; Davis PJ, 2000, PAIN MED, V1, P238, DOI 10.1046/j.1526-4637.2000.00032.x; DUFTON BD, 1989, INT J PSYCHIAT MED, V19, P291, DOI 10.2190/JDJK-0795-5BFL-5N6K; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Eccleston C, 1997, PAIN, V72, P209, DOI 10.1016/S0304-3959(97)00030-4; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; FISHBAIN DA, 1999, INT ASS PAIN 9 WORLD; Francis Se, 2000, DISS ABSTR INT, V60, P3562; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Gonzales VA, 2000, NEUROREHABILITATION, V14, P69; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Iezzi T, 1999, J BEHAV MED, V22, P205, DOI 10.1023/A:1018791622441; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; Jorge RE, 1999, NEUROLOGY, V53, P543, DOI 10.1212/WNL.53.3.543; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kessels RPC, 2000, J INT NEUROPSYCH SOC, V6, P271, DOI 10.1017/S1355617700633027; KEWMAN DG, 1989, ARCH PHYSL MED REHAB; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lorenz J, 1997, PAIN, V73, P369, DOI 10.1016/S0304-3959(97)00123-1; Lorenz J, 1997, PSYCHOPHYSIOLOGY, V34, P436, DOI 10.1111/j.1469-8986.1997.tb02387.x; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MARTELLI MF, IN PRESS PAIN MANAGE; Menefee LA, 2000, PAIN MED, V1, P156, DOI 10.1046/j.1526-4637.2000.00022.x; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; Nicholson K, 2000, NEUROREHABILITATION, V14, P57; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; PATIL PG, 1995, PHYSIOL BEHAV, V58, P1281, DOI 10.1016/0031-9384(95)02071-3; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Pita G, 1998, HUM PSYCHOPHARM CLIN, V13, P315, DOI 10.1002/(SICI)1099-1077(199807)13:5<315::AID-HUP2>3.0.CO;2-B; Post RM, 2000, PSYCHIAT ANN, V30, P485, DOI 10.3928/0048-5713-20000701-09; ROBINSON ME, 1999, PSYCHOSOCIAL FACTORS, P74; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, MILD HEAD INJURY, P217; RUTTAN LA, 1998, SCI ENG 5B, V59, P2432; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SELTZER SF, 1991, PAIN, V47, P47, DOI 10.1016/0304-3959(91)90010-U; SHAPIRO AP, 1993, SPINE STATE ART REV, V7, P455; Sjogren P, 2000, PAIN, V86, P237, DOI 10.1016/S0304-3959(00)00248-7; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Toren P, 2000, J ANXIETY DISORD, V14, P239, DOI 10.1016/S0887-6185(99)00036-5; VERNONWILKINSON R, 1993 NAT AC NEUR ANN; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Zacny JP, 1995, EXP CLIN PSYCHOPHARM, V3, P432, DOI 10.1037/1064-1297.3.4.432; ZEITLIN C, 1984, BRIT J CLIN PSYCHOL, V23, P27, DOI 10.1111/j.2044-8260.1984.tb00623.x	62	33	33	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2001	16	4					225	230					6	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	521VC	WOS:000173861200006	11790908				2022-02-06	
J	Erlich, S; Shohami, E; Pinkas-Kramarski, R				Erlich, S; Shohami, E; Pinkas-Kramarski, R			Closed head injury induces up-regulation of ErbB-4 receptor at the site of injury	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						tyrosine kinase; ErbB-4; brain; closed head injury; microglia/macrophages	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; NECROSIS-FACTOR-ALPHA; RAT-BRAIN; NERVOUS-SYSTEM; EXPRESSION; MICROGLIA; CELLS; MEMBER; FAMILY	ErbB-4 receptor tyrosine kinase and its ligand neu differentiation factor (NDF/neuregulin) are widely expressed in the brain. The closed head injury model was used to investigate the possible role of ErbB-4 receptor in neurodegeneration. It is demonstrated that levels of ErbB-4 are dramatically increased at the site of injury. Activated microglia/macrophages constitute the major population of cells with the highest receptor levels at the site of injury. In addition ErbB-4 expression after injury is elevated also in neurons but not in astrocytes. Confocal microscopy analysis suggests that the high level of ErbB-4 protein in activated microglia/macrophages is probably due to phagocytosis of neuronal cells. These findings show for the first time that ErbB-4 receptors play a role in brain responses to head trauma. Overexpression of ErbB-4 receptors may be important for directing activated microglia/macrophages to the lesion site.	Tel Aviv Univ, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel		Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel.	lironit@post.tau.ac.il		Pinkas-Kramarski, Ronit/0000-0002-1000-369X			AKIYAMA H, 1994, BRAIN RES, V635, P257, DOI 10.1016/0006-8993(94)91447-8; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARPENTER G, 1991, PEPTIDE GROWTH FACTO; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CORFAS G, 1993, J NEUROSCI, V13, P2118; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DERYNCK R, 1985, CANCER CELL, V3, P79; Eilam R, 1998, P NATL ACAD SCI USA, V95, P1888, DOI 10.1073/pnas.95.4.1888; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KRISTT DA, 1993, NEUROSURGERY, V33, P106; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Mograbi B, 1997, EUR CYTOKINE NETW, V8, P73; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; Opanashuk LA, 1999, J NEUROSCI, V19, P133, DOI 10.1523/JNEUROSCI.19-01-00133.1999; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PINKASKRAMARSKI R, 1995, ENTRY HUMAN CYTOKINE, V2, P340; Planas AM, 1998, GLIA, V23, P120, DOI 10.1002/(SICI)1098-1136(199806)23:2<120::AID-GLIA3>3.0.CO;2-A; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; RAFF MC, 1978, CELL, V15, P813, DOI 10.1016/0092-8674(78)90266-0; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Tanaka N, 1999, BRAIN RES, V827, P130, DOI 10.1016/S0006-8993(99)01319-0; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; Yamamoto T, 1986, Horiz Biochem Biophys, V8, P571	53	33	35	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	NOV	2000	16	5					597	608		10.1006/mcne.2000.0894			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	378XT	WOS:000165611200006	11083921				2022-02-06	
J	Ringel, F; Chang, RCC; Staub, F; Baethmann, A; Plesnila, N				Ringel, F; Chang, RCC; Staub, F; Baethmann, A; Plesnila, N			Contribution of anion transporters to the acidosis-induced swelling and intracellular acidification of glial cells	JOURNAL OF NEUROCHEMISTRY			English	Article						brain edema; lactacidosis; Cl-/HCO3- exchanger; Na+-K+-Cl- cotransporter; C6 glioma cells	C6 GLIOMA-CELLS; RABBIT ESOPHAGEAL EPITHELIUM; BRAIN EDEMA; PH REGULATION; RAT ASTROCYTES; EXTRACELLULAR ACIDOSIS; CEREBRAL-ISCHEMIA; VOLUME REGULATION; NA+/H+ EXCHANGE; INVITRO MODEL	This study examines the contribution of anion transporters to the swelling and intracellular acidification of glial cells from an extracellular lactacidosis, a condition well-known to accompany cerebral ischemia and traumatic brain injury. Suspended C6 glioma cells were exposed to lactacidosis in physiological or anion-depleted media, and different anion transport inhibitors were applied, Changes in cell volume and intracellular pH (pH(i)) were simultaneously quantified by flow cytometry. Extracellular lactacidosis (pH 6.2) led to an increase in cell volume to 125.1 +/- 2.5% of baseline within 60 min, whereas the pH, dropped from the physiological value of 7.13 +/- 0.05 to 6.32 +/- 0.03, Suspension in Cl--free or HCO3-/CO2-free media or application of anion transport inhibitors 0.1 mM bumetanide or 0.5 mM 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS)I did not affect cell volume during baseline conditions but significantly reduced cell swelling from lactacidosis. In addition, the Cl--free or HCO3-/CO2-free media and DIDS attenuated intracellutar acidosis on extracellular acidification. From these findings it is concluded that besides the known activation of the Na+/H+ exchanger, activation of the Na+-independent Cl-/HCO3- exchanger and the Na+-K+-Cl- cotransporter contributes to acidosis-induced glial swelling and the intracellular acidification. Inhibition of these processes may be of interest for future strategies in the treatment of cytotoxic brain edema from cerebral ischemia or traumatic brain injury.	Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81366 Munich, Germany; Univ Cologne, Dept Neurosurg, Cologne, Germany		Plesnila, N (corresponding author), Univ Munich, Klinikum Grosshadern, Inst Surg Res, Marchioninistr 15, D-81366 Munich, Germany.		Ringel, Florian/E-4933-2014; Plesnila, Nikolaus/T-7522-2019; Chang, Raymond Chuen-Chung/C-1107-2009	Chang, Raymond Chuen-Chung/0000-0001-8538-7993			BAETHMAN A, 1978, NEUROSURG REV, V1, P85; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Bourke R S, 1980, Adv Neurol, V28, P99; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHASSANDE O, 1988, EUR J BIOCHEM, V171, P425, DOI 10.1111/j.1432-1033.1988.tb13807.x; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HOSSMANN KA, 1989, NEUROSURG REV, V12, P263, DOI 10.1007/BF01780838; JAKUBOVICZ DE, 1987, BRAIN RES, V435, P138, DOI 10.1016/0006-8993(87)91594-0; JAKUBOVICZ DE, 1989, BRAIN RES, V485, P215, DOI 10.1016/0006-8993(89)90564-7; JEAN T, 1986, EUR J BIOCHEM, V160, P211, DOI 10.1111/j.1432-1033.1986.tb09959.x; Jenkins L.W., 1984, RECENT PROGR STUDY T, P523; KACHEL V, 1976, J HISTOCHEM CYTOCHEM, V24, P2111; KEMPSKI O, 1988, STROKE, V19, P385, DOI 10.1161/01.STR.19.3.385; KEMPSKI O, 1983, BRAIN RES, V279, P217, DOI 10.1016/0006-8993(83)90180-4; KEMPSKI O, 1988, NEUROCHEM PATHOL, V9, P109; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LeBars E, 1996, NEUROSCI LETT, V213, P123; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MELLERGARD P, 1994, AM J PHYSIOL, V267, pC581, DOI 10.1152/ajpcell.1994.267.2.C581; MELLERGARD P, 1993, EXP BRAIN RES, V95, P371; MELLERGARD PE, 1991, NEUROREPORT, V2, P695, DOI 10.1097/00001756-199111000-00016; Mongin AA, 1996, BBA-BIOMEMBRANES, V1285, P229, DOI 10.1016/S0005-2736(96)00165-4; NAKAI H, 1988, STROKE, V19, P764, DOI 10.1161/01.STR.19.6.764; Plesnila N, 1998, ACT NEUR S, V71, P203; Plesnila N, 1999, J NEUROTRAUM, V16, P831, DOI 10.1089/neu.1999.16.831; RINGEL F, 1996, CEREBROVASC DIS S2, V6, P120; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SHRODE LD, 1994, GLIA, V12, P196, DOI 10.1002/glia.440120305; SIESJO BK, 1993, PROG BRAIN RES, V96, P23; STAUB F, 1994, J NEUROTRAUM, V11, P679, DOI 10.1089/neu.1994.11.679; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; STAUB F, 1990, J CEREBR BLOOD F MET, V10, P866, DOI 10.1038/jcbfm.1990.143; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOBEY NA, 1995, GASTROENTEROLOGY, V109, P414, DOI 10.1016/0016-5085(95)90328-3; Tobey NA, 1997, GASTROENTEROLOGY, V112, P847, DOI 10.1053/gast.1997.v112.pm9041246; Volk C, 1998, BBA-BIOMEMBRANES, V1372, P28, DOI 10.1016/S0005-2736(98)00044-3	39	33	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2000	75	1					125	132		10.1046/j.1471-4159.2000.0750125.x			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	325CP	WOS:000087659000016	10854255	Bronze			2022-02-06	
J	Donaldson, JW; Edwards-Brown, M; Luerssen, TG				Donaldson, JW; Edwards-Brown, M; Luerssen, TG			Arachnoid cyst rupture with concurrent subdural hygroma	PEDIATRIC NEUROSURGERY			English	Article						arachnoid cyst; subdural hygroma; head injury	FOSSA; SPACE; CT	Arachnoid cysts (ACs) are relatively common intracranial mass lesions, which occur most often in the middle cranial fossa, While these lesions can present as a mass lesion, many are asymptomatic, Rarely, posttraumatic or spontaneous rupture of ACs can result in intracystic hemorrhage, subdural hematoma or subdural hygroma, We have encountered two cases of ruptured arachnoid cysts that resulted in subdural hygromas. Both patients harbored middle cranial fossa cysts and suffered mild closed head injuries. The presentation, radiographic findings and surgical management of these patients as well as the association between ACs and subdural hygromas are described, Copyright (C) 2000 S.Karger AG, Basel.	Indiana Univ, Sch Med, Sect Neurol Surg, Dept Surg,Dept Radiol, Indianapolis, IN 46202 USA		Donaldson, JW (corresponding author), Indiana Univ, Sch Med, Sect Neurol Surg, Dept Surg,Dept Radiol, Emerson 139,545 Barnhill Dr, Indianapolis, IN 46202 USA.						Albuquerque FC, 1997, NEUROSURGERY, V41, P951, DOI 10.1097/00006123-199710000-00036; BECKER T, 1991, NEURORADIOLOGY, V33, P341, DOI 10.1007/BF00587820; Choong CT, 1998, BRAIN DEV-JPN, V20, P319, DOI 10.1016/S0387-7604(98)00039-4; CHOUX M, 1978, CHILD BRAIN, V4, P15; CULLIS PA, 1983, J NEUROL NEUROSUR PS, V46, P454, DOI 10.1136/jnnp.46.5.454; EUSTACE S, 1992, J COMPUT ASSIST TOMO, V16, P995, DOI 10.1097/00004728-199211000-00034; GALASSI E, 1980, SURG NEUROL, V14, P211; KULALI A, 1989, Neurosurgical Review, V12, P508, DOI 10.1007/BF01790696; OSBORN AG, 1994, DIAGNOSTIC NEURORADI, P639; RAKIER A, 1995, J NEUROSURG, V83, P1085, DOI 10.3171/jns.1995.83.6.1085; Sener RN, 1997, COMPUT MED IMAG GRAP, V21, P341; YAMANOUCHI Y, 1986, CHILD NERV SYST, V2, P40, DOI 10.1007/BF00274033	12	33	36	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	MAR	2000	32	3					137	139		10.1159/000028918			3	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	327ZK	WOS:000087824200006	10867560				2022-02-06	
J	Oehmichen, M; Meissner, C; Konig, HG				Oehmichen, M; Meissner, C; Konig, HG			Brain injury after gunshot wounding: Morphometric analysis of cell destruction caused by temporary cavitation	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; axonal injury; neuronal injury; permanent track; temporary cavitation	BALLISTICS; MECHANISMS; PROTEIN; HEAD	In addition to the primary destruction of brain tissue readily visible at autopsy (permanent track), gunshot wounding to the brain creates a pulsating temporary cavity due to radial expansion along the bullet's track. To determine the maximum extent of this temporary cavitation in brains of victims of gunshots from weapons with low muzzle velocity, we carried out morphometric studies on 20 cases of death from gunshot wounding to the head from bullets with a muzzle energy <500 J and a survival time of <90 min. The brains were fixed in formalin, examine macroscopically and microscopically, and subjected to morphometric analyses. Surrounding the permanent track, a narrow mantle-like zone of astrocyte destruction was found within an area of hemorrhagic extravasation, Axons near the permanent track had been broken into tiny fragments. The axonal damage lessened with increasing distance from the permanent track, although axons continued to be fragmented and to exhibit varicose changes and clumping until assuming their normal structure beyond 18 mm, Nerve cells were extremely shrunken close to the permanent track but gradually took on their normal shape with increasing distance. We also assessed the loss of glial fibrillary acid protein expression by astrocytes in the white matter, the extent of traumatic bleeding, and damage to axons and neurons as measured radially from the permanent track. Axonal and neuronal damage were found to extend about 18 mm radially from the permanent track, tapering gradually along the track from entry point to exit point. The destruction was probably produced by the temporary cavitation and accords with theoretical considerations and experimental observations.	Univ Lubeck, Inst Legal Med, D-23562 Lubeck, Germany; Univ Tubingen, Inst Legal Med, Tubingen, Germany		Oehmichen, M (corresponding author), Univ Lubeck, Inst Legal Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.						Baker JR., 1958, PRINCIPLES BIOL MICR; Bowen TE, 1988, EMERGENCY WAR SURG 2; BUTLER FG, 1945, J NEUROSURG, V2, P238; Callender GR, 1935, MIL SURG, V77, P177; CAMPBELL E, 1950, J NEUROPATH EXP NEUR, V9, P139, DOI 10.1097/00005072-195004000-00002; CAMPBELL E, 1958, SURG WORLD WAR 2 NEU, V1, P335; DEMUTH WE, 1966, J TRAUM, V6, P222, DOI 10.1097/00005373-196606020-00008; ENG LF, 1983, PROG NEUROPATH, V5, P19; Fackler M. L., 1991, WOUND BALLISTICS REV, V1, P38; FACKLER ML, 1985, J TRAUMA, V25, P522, DOI 10.1097/00005373-198506000-00009; FACKLER ML, 1988, J TRAUMA, V28, pS21, DOI 10.1097/00005373-198801001-00007; FACKLER ML, 1991, WOUND BALLISTICS REV, V1, P41; HARVEY EN, 1947, SURGERY, V21, P218; Harvey EN, 1945, WAR MED, V8, P91; HOLLERMAN JJ, 1990, AM J ROENTGENOL, V155, P685, DOI 10.2214/ajr.155.4.2119095; KARGER B, 1995, INT J LEGAL MED, V108, P53, DOI 10.1007/BF01369905; KARGER B, 1988, INT J LEGAL MED, V111, P314; KARGER B, 1996, INT LEG MED, V108, P117; KIRKPATRICK JB, 1988, FORENSIC NEUROPATHOL, P276; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; NAOUMENKO JULIA, 1963, ACTA NEUROPATHOL, V2, P402; Oehmichen M, 1985, Beitr Gerichtl Med, V43, P55; OEHMICHEN M, 2000, UNPUB BRAIN INJURY S; OEHMICHEN M, 1992, KOPFSCHUSS SPANNUNGS, P37; OTTOSON R, 1964, MIL MED, V129, P1017, DOI 10.1093/milmed/129.11.1017; Parkinson J, 1982, J Neurosurg Nurs, V14, P232; Ramon Y, 1928, DEGENERATION REGENER; Rand CW, 1934, ARCH NEURO PSYCHIATR, V31, P527, DOI 10.1001/archneurpsyc.1934.02250030067004; Sellier K, 1969, SCHUSSWAFFEN SCHUSSW; Sellier KG, 1994, WOUND BALLISTICS SCI; UNTERHARNSCHEID.F, 1993, PATHOLOGIE NERVENS A, V6	31	33	36	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					155	162		10.1089/neu.2000.17.155			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800005	10709873				2022-02-06	
J	Posmantur, RM; Newcomb, JK; Kampfl, A; Hayes, RL				Posmantur, RM; Newcomb, JK; Kampfl, A; Hayes, RL			Light and confocal microscopic studies of evolutionary changes in neurofilament proteins following cortical impact injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						axons; confocal microscopy; dendrites; immunofluorescence; neurofilament proteins; traumatic brain injury	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; INDUCED AXONAL INJURY; LEVELS DECREASE; CALPAIN; NEURONS; HIPPOCAMPUS; SPECTRIN; PHOSPHORYLATION; PERMEABILITY	Previous studies have shown that traumatic brain injury (TBI) produces progressive degradation of cytoskeletal proteins including neurofilaments (e,g,, neurofilament 68 [NF68] and neurofilament 200 [NF2001]) within the first 24 h after injury. Thus, we employed immunofluorescence (light and confocal microscopy) to study the histopathological correlates of progressive neurofilament protein loss observed at 15 min, 3 h, and 24 h following unilateral cortical injury in rats, TBI produced significant alterations in NF68 and NF200 immunolabeling in dendrites and cell bodies at contusion sites ipsilateral to injury, as well as in the noncontused contralateral cortex, Changes in immunolabeling were associated with, but not exclusively restricted to, regions previously shown to contain dark shrunken neurons labeled by hematoxylin and eosin staining, a morphopathological response to injury suggesting impending cell death. Immunofluorescence microscopic studies of neurofilament proteins in the ipsilateral cerebral cortex detected prominent fragmentation of apical dendrites of pyramidal neurons in layers 3-5 and loss of fine dendritic arborization within layer 1, While modest changes were observed 15 min follow-injury, more pronounced loss of dendritic neurofilament immunofluorescence was detected 3 and 24 h following injury. Confocal microscopy also revealed progressive alterations in NF68 immunoreactivity in dendrites following TBI, While some evidence of structural alterations was observed 15 min following TBI, dendritic breaks were readily detected in confocal micrographs from 3 to 24 h following injury. However, disturbances in axonal NF68 by immunofluorescence microscopy in the corpus callosum were not detected until 24 h after injury. These studies confirmed that derangements in dendritic neurofilament cytoskeletal proteins are not exclusively restricted to sites of impact contusion. Moreover, changes in dendritic cytoskeletal proteins are progressive and not fully expressed within the first 15 min following impact injury, These progressive dendritic disruptions are characterized by disturbances in the morphology of neurofilament proteins, resulting in fragmentation and focal loss of NF68 immunofluorescence within apical dendrites. In contrast, alterations in axonal cytoskeletal proteins are more restricted and delayed with no pronounced changes until 24 h after injury, (C) 2000 Academic Press.	Bristol Myers Squibb Co, Neurosci Drug Discovery, Dept 405, Wallingford, CT 06492 USA; Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; Univ Florida, Inst Brain, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA		Posmantur, RM (corresponding author), Bristol Myers Squibb Co, Neurosci Drug Discovery, Dept 405, POB 5100,5 Res Pkwy, Wallingford, CT 06492 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40182, R01-NS 21458] Funding Source: Medline		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BARINAGA M, 1995, SCIENCE, V268, P200, DOI 10.1126/science.7536341; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; ISOKAWA M, 1991, NEUROSCI LETT, V132, P212, DOI 10.1016/0304-3940(91)90304-C; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KARST H, 1993, NEUROSCI LETT, V164, P154, DOI 10.1016/0304-3940(93)90880-T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; Nixon RA, 1998, CURR OPIN CELL BIOL, V10, P87, DOI 10.1016/S0955-0674(98)80090-2; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHORMAIR C, 1993, BRAIN RES BULL, V32, P329, DOI 10.1016/0361-9230(93)90196-I; SHAW G, 1986, BIOESSAYS, V4, P161, DOI 10.1002/bies.950040406; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	50	33	33	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2000	161	1					15	26		10.1006/exnr.1999.7244			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	290FU	WOS:000085666300002	10683270				2022-02-06	
J	Stevens, H; Jansen, HML; De Reuck, J; Lemmerling, M; Strijckmans, K; Goethals, P; Lemahieu, I; de Jong, BM; Willemsen, ATM; Korf, J				Stevens, H; Jansen, HML; De Reuck, J; Lemmerling, M; Strijckmans, K; Goethals, P; Lemahieu, I; de Jong, BM; Willemsen, ATM; Korf, J			(55)Cobalt (Co) as a PET-tracer in stroke, compared with blood flow, oxygen metabolism, blood volume and gadolinium-MRI	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						cerebral ischemia; cobalt; cerebral blood flow; cerebral oxygen metabolic rate; tomography; emission-computed	POSITRON-EMISSION-TOMOGRAPHY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; COBALT-55; PATHOPHYSIOLOGY; NEURONS; DAMAGE; CO-57; VISUALIZATION; ACCUMULATION	Several studies have shown the feasibility of divalent cobalt (Co)-isotopes (Co-55 and Co-57) in imaging of neuronal damage in stroke, multiple sclerosis, cerebral tumors and traumatic brain injury. Little is known how regional Co uptake relates to other pathophysiological changes after stroke. Therefore, we compared Co-55-PET with functional parameters such as regional cerebral blood dow (rCBF) using (CO2)-O-15, regional oxygen metabolism (rCMRO(2)) using O-15(2), regional cerebral bloodvolume (rCBV) and post-gadolinium (Gd) T(1)w-MRI to assess the permeability of the blood-brain-barrier (BBB). Sixteen patients (10 female; six male) aged 43 to 84 (mean 69) years with first ever stroke, as shown by CT or MRI, were examined with Co-55-PET and (CO2)-O-15-, O-15(2)- and (CO)-O-15-PET in one single session, in a period varying from 0 to 30 days after stroke-onset. Regions of infarction on (CO2)-O-15- and O-15(2)-PET (defined by rCMRO(2) <65% or rCBF<45% of the contralateral value) were subsequently superimposed on the Co-55-PET scan. Clinical status was established using the Orgogozo stroke scale, which was assessed both at day 1 and at discharge (at least 6 weeks after day 1). Accumulation of Co-55 was Seen in eight out of 16 patients, occurring in areas showing a diminished oxygen metabolism, was only partially related to blood flow, and was located mainly outside the extent of the infarction or luxury perfusion as seen on post-Gd T(1)w-MRI. Statistical analysis showed a negative correlation between the Orgogozo score at discharge and the uptake of radioactive cobalt. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Groningen Hosp, Dept Biol Psychiat, Groningen, Netherlands; State Univ Ghent Hosp, PET Ctr, B-9000 Ghent, Belgium; State Univ Ghent, Dept Neurol, B-9000 Ghent, Belgium; State Univ Ghent, Dept Radiol, B-9000 Ghent, Belgium; State Univ Ghent, Inst Sci Nucl, Dept Analyt Chem, B-9000 Ghent, Belgium; State Univ Ghent, Dept Elect & Informat Sci, B-9000 Ghent, Belgium; Univ Groningen Hosp, Dept Neurol, Groningen, Netherlands; Univ Groningen Hosp, Natl PET Ctr, Groningen, Netherlands		Korf, J (corresponding author), Univ Groningen Hosp, Dept Biol Psychiat, Groningen, Netherlands.		Lemahieu, Ignace/G-8625-2012	Lemahieu, Ignace/0000-0002-0894-9988; de Jong, Bauke M./0000-0002-6568-5739			BARON JC, 1987, CLIN EFFICACY POSITR, P15; DEREUCK J, 1993, J NEUROL, V3, P416; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; GRAMSBERGEN JBP, 1988, J NEUROCHEM, V50, P1798, DOI 10.1111/j.1471-4159.1988.tb02481.x; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HEISS WD, 1994, EUR J NUCL MED, V21, P455; HEISS WD, 1993, STROKE, V24, P1784, DOI 10.1161/01.STR.24.12.1784; HEISS WD, 1993, STROKE S1, V24, P50; Jansen HM, 1997, NUCL MED COMMUN, V18, P734, DOI 10.1097/00006231-199708000-00007; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; Jansen HML, 1996, J NUCL MED, V37, P2082; JANSEN HML, 1995, J NEUROL SCI, V132, P139, DOI 10.1016/0022-510X(95)00139-S; Jansen HML, 1997, CLIN NEUROL NEUROSUR, V99, P6, DOI 10.1016/S0303-8467(96)00558-6; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Korf J, 1998, J NUCL MED, V39, P836; Linde R, 1996, ACT NEUR S, V66, P15; MARCHAL G, 1993, LANCET, V341, P925, DOI 10.1016/0140-6736(93)91214-7; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; ORGOGOZO JM, 1991, CEREBROVASC DIS, V1, P100, DOI 10.1159/000108904; Pagani M, 1997, EUR J NUCL MED, V24, P1301, DOI 10.1007/s002590050156; PRUSS RM, 1991, NEURON, V7, P509, DOI 10.1016/0896-6273(91)90302-G; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Stevens H, 1998, NEUROSCI LETT, V258, P183, DOI 10.1016/S0304-3940(98)00883-0; Stevens H, 1998, NUCL MED COMMUN, V19, P573, DOI 10.1097/00006231-199806000-00010; Stevens H, 1998, J NUCL MED, V39, P495; WANG PY, 1993, STROKE, V24, P236, DOI 10.1161/01.STR.24.2.236; WILLIAMS LR, 1992, BRAIN RES, V581, P181, DOI 10.1016/0006-8993(92)90707-G; [No title captured]	31	33	35	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	DEC 1	1999	171	1					11	18		10.1016/S0022-510X(99)00229-4			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	269PX	WOS:000084487700004	10567044				2022-02-06	
J	Lang, EW; Diehl, RR; Timmermann, L; Baron, R; Deuschl, G; Mehdorn, HM; Zunker, P				Lang, EW; Diehl, RR; Timmermann, L; Baron, R; Deuschl, G; Mehdorn, HM; Zunker, P			Spontaneous oscillations of arterial blood pressure, cerebral and peripheral blood flow in healthy and comatose subjects	NEUROLOGICAL RESEARCH			English	Article						cerebral autoregulation; peripheral autoregulation; coma; transcranial Doppler ultrasound; cerebral circulation; covariance analysis	TRANSCRANIAL DOPPLER RECORDINGS; ROSTRAL VENTROLATERAL MEDULLA; SEROTONERGIC INNERVATION; INTRACRANIAL-PRESSURE; RHYTHMIC OSCILLATIONS; AUTOREGULATION; HUMANS; STIMULATION; NEURONS; MUSCLE	Slow and rhythmic spontaneous oscillations of cerebral and peripheral blood flow occur within frequencies of 0.5-3 min(-1) (0.008-0.05 Hz, B-waves) and 3-9 min(-1) (0.05-0.15 Hz, M-waves). The generators and pathways of such oscillations are not fully understood. We compared the coefficient of variance (CoV), which serves as an indicator for the amplitude of oscillations and is calculated as the percent standard deviation of oscillations within a particular frequency band from the mean, to study the impairment of generators or pathways of such oscillations in normal subjects and comatose patients in a controlled fashion. With local ethic committee approval, data were collected from 19 healthy volunteers and nine comatose patients suffering from severe traumatic brain injury (n = 3), severe subarachnoid hemorrhage (n = 3), and intracerebral hemorrhage (n = 3). Cerebral blood flow velocities were measured by transcranial Doppler ultrasound (TCD), peripheral vasomotion by finger tip laser Doppler flowmetry (LDF), and ABP by either non-invasive continuous blood pressure recordings (Finapres method) in control subjects, or by direct radial artery recordings in comatose patients. Each recording session lasted similar to 20-30 min. Data were stored in the TCD device for offline analysis of CoV. For CoV in the cerebral B-wave frequency range there was no difference between coma patients and controls, however there was a highly significant reduction in the amplitude of peripheral B-wave LDF and ABP vasomotion (3.8 +/- 2.1 vs. 28.2 +/- 16.1 for LDF, p < 0.001; and 1.2 +/- 0.7 vs. 4.6 +/- 2.8 for ABP, p < 0.007) This observation was confirmed for spontaneous cerebral and peripheral oscillations in the M-wave frequency range. The CoV reduction in peripheral LDF and ABP oscillations suggest a severe impairment of the proposed sympathetic pathway in comatose patients. The preservation of central TCD oscillations argues in favor of different pathways and/or generators of cerebral and peripheral B- and M-waves.	Univ Kiel, Dept Neurosurg, D-24106 Kiel, Germany; Univ Kiel, Dept Neurol, D-2300 Kiel, Germany; Alfried Krupp Hosp, Dept Neurol, Essen, Germany		Lang, EW (corresponding author), Univ Kiel, Dept Neurosurg, Weimarer Str 8, D-24106 Kiel, Germany.		Deuschl, Guenther/A-7986-2010; Baron, Ralf/E-4298-2010; Mehdorn, Maximilian/D-2495-2010	Deuschl, Guenther/0000-0002-4176-9196; 			AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; ANDERSON EA, 1987, HYPERTENSION, V9, P114, DOI 10.1161/01.HYP.9.6_Pt_2.III114; ARBAB MAR, 1988, J CEREBR BLOOD F MET, V8, P54, DOI 10.1038/jcbfm.1988.8; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; BAKER CH, 1990, CIRC SHOCK, V32, P101; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; Blessing WW, 1997, LOWER BRAINSTEM BODI, P165; BONVENTO G, 1991, J NEUROCHEM, V56, P681, DOI 10.1111/j.1471-4159.1991.tb08203.x; BONVENTO G, 1991, BRAIN RES REV, V16, P257, DOI 10.1016/0165-0173(91)90009-W; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; DAMPNEY RAL, 1988, J PHYSIOL-LONDON, V395, P41, DOI 10.1113/jphysiol.1988.sp016907; Diehl B, 1997, STROKE, V28, P2457, DOI 10.1161/01.STR.28.12.2457; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; DROSTE DW, 1994, ACTA NEUROL SCAND, V90, P99; EINHAUPL KM, 1986, INTRACRANIAL PRESSUR, V6, P290; GOADSBY PJ, 1985, AM J PHYSIOL, V248, pR257, DOI 10.1152/ajpregu.1985.248.2.R257; GOADSBY PJ, 1986, BRAIN RES, V381, P63, DOI 10.1016/0006-8993(86)90690-6; GUYENET PG, 1990, AM J PHYSIOL, V259, pR1063, DOI 10.1152/ajpregu.1990.259.5.R1063; JANIG W, 1988, ANNU REV PHYSIOL, V50, P525, DOI 10.1146/annurev.ph.50.030188.002521; KANO T, 1993, J AUTONOM NERV SYST, V45, P191, DOI 10.1016/0165-1838(93)90051-U; LAL SKL, 1995, HYPERTENSION, V26, P307, DOI 10.1161/01.HYP.26.2.307; LIANG CS, 1987, CIRCULATION, V75, P443, DOI 10.1161/01.CIR.75.2.443; LUNDBERG N, 1960, ACTA PSYCHIATRICA  S, V149, P1; MAEDA M, 1986, INTRACRANIAL PRESSUR, V6, P151; Mayer, 1876, SBER AKAD WISS WIEN, V74, P281; MCALLEN RM, 1994, AM J PHYSIOL-REG I, V267, pR935, DOI 10.1152/ajpregu.1994.267.4.R935; Michaloudis D, 1998, ANAESTHESIA, V53, P446, DOI 10.1046/j.1365-2044.1998.00323.x; MORITATSUZUKI Y, 1992, ACTA PHYSIOL SCAND, V146, P431, DOI 10.1111/j.1748-1716.1992.tb09444.x; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; SUN MK, 1988, BRAIN RES, V442, P229, DOI 10.1016/0006-8993(88)91508-9; TSAI SH, 1985, NEUROSURGERY, V16, P463, DOI 10.1227/00006123-198504000-00005; vandenBerg F, 1996, PSYCHOPHARMACOLOGY, V128, P21, DOI 10.1007/s002130050105; WALLIN BG, 1975, PFLUG ARCH EUR J PHY, V358, P101, DOI 10.1007/BF00583921; WALLIN BG, 1994, NEWS PHYSIOL SCI, V9, P203; Yu YH, 1997, AM J PHYSIOL-REG I, V272, pR208, DOI 10.1152/ajpregu.1997.272.1.R208; Zunker P., 1997, NEW TRENDS CEREBRAL, P718	38	33	33	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	1999	21	7					665	669		10.1080/01616412.1999.11740995			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	246XT	WOS:000083190700010	10555189				2022-02-06	
J	Samii, A; Badie, H; Fu, K; Luther, RR; Hovda, DA				Samii, A; Badie, H; Fu, K; Luther, RR; Hovda, DA			Effects of an N-type calcium channel antagonist (SNX 111; ziconotide) on calcium-45 accumulation following fluid-percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						calcium; calcium-45 autoradiography; concussion; fluid percussion; omega conopeptide	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; METHYL-D-ASPARTATE; OMEGA-CONOTOXIN; SPINAL-CORD; CELL-DEATH; RAT-BRAIN; NEUROCHEMICAL SEQUELAE; GLUCOSE-UTILIZATION; CA-45 ACCUMULATION	Accumulation of calcium following experimental traumatic brain injury (TBI) has been demonstrated to be a prominent pathophysiological component that can compromise mitochondrial functioning and threaten cell survival. The omega-conopeptide SNX-111, also known as Ziconotide, is a potent antagonist of the voltage-gated N-type calcium channel and has demonstrated significant neuroprotective effects against ischemia-induced neuronal injury. To determine whether this compound would be effective in reducing calcium accumulation associated with TBI, SNX-111 was administered intravenously to rats 1 hour following a moderate (2.2 to 2.75 atm) lateral fluid-percussion injury (or sham) at doses of 1 (n = 30), 3 (n = 31), or 5 (n = 30) mg/kg; another group received 0.9% saline solution (n = 35). Brains were processed for calcium 45 (Ca-45) autoradiography at 6, 12, 24, 48, and 96 hours following insult. Optical density measurements of 20 cortical and subcortical regions were analyzed. Injured animals administered saline solution exhibited a significant increase in Ca-45 uptake within 12 regions ipsilateral to the site of injury. The most prominent increases were evident throughout the ipsilateral cerebral cortex. SNX-111 reduced the injury-induced calcium accumulation within the ipsilateral cortex in a dose-response fashion when measured at 6, 12, and 48 hours after insult. These drug-induced reductions in calcium accumulation were as high as 75% in the ipsilateral cerebral cortex, and up to 50% in other ipsilateral regions (including thalamus and hippocampus). Consequently, the results suggest that posttraumatic blocking of the voltage-gated N-type calcium channel after injury reduces prolonged, trauma-induced calcium accumulation.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA		Hovda, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA.	hovda@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS27544] Funding Source: Medline		ARAKI T, 1990, BRAIN RES, V528, P114, DOI 10.1016/0006-8993(90)90202-M; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BETZ AL, 1989, BASIC NEUROCHEMISTRY, P591; BIGNAMI A, 1987, BRAIN RES, V409, P143, DOI 10.1016/0006-8993(87)90750-5; Bowersox S, 1997, DRUG METAB DISPOS, V25, P379; BOWERSOX SS, 1992, J CARDIOVASC PHARM, V20, P756, DOI 10.1097/00005344-199220050-00011; Bowersox SS, 1997, BRAIN RES, V747, P343; BUCHAN AM, 1994, J CEREBR BLOOD F MET, V14, P903, DOI 10.1038/jcbfm.1994.121; CARTER CJ, 1987, J NEUROCHEM, V49, P195, DOI 10.1111/j.1471-4159.1987.tb03414.x; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DOOLEY DJ, 1987, N-S ARCH PHARMACOL, V336, P467, DOI 10.1007/BF00164885; FARBER JL, 1981, LIFE SCI, V29, P1289, DOI 10.1016/0024-3205(81)90670-6; FARBER JL, 1981, AM J PATHOL, V102, P271; FAROOQUI AA, 1991, BRAIN RES REV, V16, P171, DOI 10.1016/0165-0173(91)90004-R; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ghosh S, 1997, NEUROL RES, V19, P403, DOI 10.1080/01616412.1997.11740833; GRAMSBERGEN JBP, 1988, J NEUROCHEM, V50, P1798, DOI 10.1111/j.1471-4159.1988.tb02481.x; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1994, ACTA NEUROCHIR, P521; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATO H, 1989, BRAIN RES, V479, P366, DOI 10.1016/0006-8993(89)91642-9; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYER FB, 1989, BRAIN RES REV, V14, P227, DOI 10.1016/0165-0173(89)90002-7; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; OYAMA Y, 1987, BRAIN RES, V424, P58, DOI 10.1016/0006-8993(87)91192-9; POVLISHOCK JT, 1989, SOC NEUROSCI, V15; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROSENBERG C, 1984, ARCH NEUROL-CHICAGO, V41, P835, DOI 10.1001/archneur.1984.04050190041012; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1989, MAGNESIUM, V8, P223; STEIN DT, 1988, J CEREBR BLOOD F MET, V8, P834, DOI 10.1038/jcbfm.1988.140; STOEHR SJ, 1993, NEUROSCI LETT, V161, P113, DOI 10.1016/0304-3940(93)90153-C; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; TAKIZAWA S, 1995, J CEREBR BLOOD F MET, V15, P611, DOI 10.1038/jcbfm.1995.75; THOMAS S, 1991, Society for Neuroscience Abstracts, V17, P166; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Watanabe H, 1998, J CEREBR BLOOD F MET, V18, P686, DOI 10.1097/00004647-199806000-00011; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAUCHI Y, 1990, J CEREBR BLOOD F MET, V10, P207, DOI 10.1038/jcbfm.1990.36; Yenari MA, 1996, BRAIN RES, V739, P36, DOI 10.1016/S0006-8993(96)00808-6; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; YOUNG W, 1996, NEUROTRAUMA, P1421; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V150, P459, DOI 10.1111/j.1748-1716.1994.tb09713.x	70	33	34	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					879	892		10.1089/neu.1999.16.879			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900003	10547097				2022-02-06	
J	Perez-Pinzon, MA; Alonso, O; Kraydieh, S; Dietrich, WD				Perez-Pinzon, MA; Alonso, O; Kraydieh, S; Dietrich, WD			Induction of tolerance against traumatic brain injury by ischemic preconditioning	NEUROREPORT			English	Article						global ischemia; neuropathology; tolerance; trauma	HEAD-INJURY; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; PATHO-PHYSIOLOGY; DAMAGE; GERBIL; RATS; HYPOTHERMIA; GLUTAMATE; NEURONS	WE tested the hypothesis that a transient non-lethal ischemic insult lasting 2 min would protect against subsequent moderate traumatic brain injury. Sprague-Dawley rats were randomized into three experimental groups, including sham ischemia procedures and ischemic preconditioning (IPC) followed 48 h later by moderate traumatic brain injury (TBI) provoked by parasagittal fluid percussion injury (1.8-2.1 atm) and IPC followed by 48h sham TBI. Seven days after the secondary insult, animals were perfusion-fixed for quantitative histopathological analysis. The CA3 necrotic;cell count was decreased by 63% in TBI animals that-had undergone IPC as compared to TBI animals that:underwent sham IPC. TBI animals that had undergone IPC demonstrated significantly smaller contusion:volumes than the TBI alone group (6.44 +/- 1.51 vs 1.37 +/- 0.63 mm(3), mean +/- s.e.m.) These data indicate that IPC applied 2 days before moderate fluid percussion brain injury increases the brain resistance to traumatic brain: damage. (C) 1999 Lippincott Williams & Wilkins.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA		Perez-Pinzon, MA (corresponding author), Univ Miami, Sch Med, Dept Neurol, D4-5,POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034773, R55NS034773, P50NS030291, R29NS034773] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS 34773] Funding Source: Medline		BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1992, BRIT J CLIN PHARMACO, V34, P396, DOI 10.1111/j.1365-2125.1992.tb05648.x; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Das Dipak K., 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P739; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HOSHIDA S, 1993, HEART VESSELS, V8, P115, DOI 10.1007/BF01744795; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; Kawai K, 1998, J CEREBR BLOOD F MET, V18, P288, DOI 10.1097/00004647-199803000-00007; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; LIPTON SA, 1993, CURR OPIN NEUROL NEU, V6, P588; OHTSUKI T, 1992, BRAIN RES, V599, P246, DOI 10.1016/0006-8993(92)90398-S; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TOSAKI A, 1994, J CARDIOVASC PHARM, V23, P365, DOI 10.1097/00005344-199423030-00002	25	33	34	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	SEP 29	1999	10	14					2951	2954		10.1097/00001756-199909290-00014			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	241CV	WOS:000082865500017	10549803				2022-02-06	
